Text,CUIS
,
lipid,C0023779
characteristic,C1521970
gissi prevention $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0199176;C1706420;C2700409
placebo n $nmbr$,C0032042;C1696465;C1706408
p $nmbr$ vs no treatment $nmbr$,C0369773;C2603361;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
gemfibrozil n $nmbr$,C0017245
lips,C0023759
age yr,C0001779;C0439234
f $nmbr$ vs placebo,C0016327;C0032042;C1696465;C1706408
$nmbr$ $nmbr$,
hps,C0242994
age $nmbr$ yr,C0001779;C0439234
$nmbr$,
s $nmbr$ vs placebo,C0032042;C1696465;C1706408
race white,C0007457;C0043157;C0220938
prosper,
black,C0005680;C0027567;C0085756;C0439541
allhat llt,C2347090
other,
p $nmbr$ vs usual care,C0369773;C2603361;C3538928;C1947933
education $nmbr$ yr,C0013621;C0439234;C0013622;C0013658;C0039401
^ $nmbr$,
current smoker,C3173209;C3241966
ascot lla,C0718674
alcohol consumption $nmbr$ drink dav,C0556297
a $nmbr$ vs placebo,C0032042;C1696465;C1706408
alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
$nmbr$ $nmbr$ drinks dav,C0452428
cards,C2930619;C3275277
$nmbr$ drinks dav,C0452428
hypertension,C0020538;C1963138
diabetes,C0011847;C0011849
prior myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ s scandinavian simvastatin survival study $nmbr$ woscops west of scotland coronary prevention study $nmbr$ care cholesterol and recurrent events $nmbr$ post cabg post coronary artery bypass graft $nmbr$ afcaps texcaps air force texas coronary atherosclerosis prevention study $nmbr$ lipid long term intervention with pravastatin in ischaemic disease $nmbr$ gissi prevention gruppo italiano per lo studio della sopravvivenza nell infarto miocardico $nmbr$ lips lescol intervention prevention study $nmbr$ hps heart protection study $nmbr$ prosper prospective study of pravastatin in the elderly at risk $nmbr$ allhat llt antihypertensive and lipid lowering treatment to prevent heart attack trial $nmbr$ ascot lla anglo scandinavian cardiac outcomes trial lipid lowering arm $nmbr$ alert assessment of lescol in renal transplantation $nmbr$ cards collaborative atorvastatin diabetes study $nmbr$ s simvastatin l lovastatin p pravastatin f uvastatin a atorvastatin mean duration of follow up based on survival times within each trial overall mean is weighted by trial speci c variances of logrank o e for major vascular events all trials included dietary intervention woscops gissi prevention lipid $nmbr$ s lips and hps provided dietary advice afcaps texcaps post cabg care allhat alert cards and prosper used american heart association aha step $nmbr$ diet and care intensi ed to step $nmbr$ diet if ldl cholesterol $nmbr$ $nmbr$ mmol l $nmbr$ mg dl other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi as already counted in mi column other vascular includes history of intracerebral bleed transient ischaemic attack ischaemic stroke unknown stroke and peripheral artery disease none includes individuals without a history of mi symptomatic chd intracerebral bleed transient ischaemic attack ischaemic stroke unknown stroke or peripheral artery disease,C1705493;C1706420;C2347647;C0085542;C0679698;C1096775;C0033522;C1709709;C0001792;C0003364;C1999167;C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0309872;C0027051;C0441994;C2003888;C1261322;C1516048;C0846101;C0024027;C0016327;C0449238;C2926735;C1527178;C1705938;C0444504;C2347634;C2348143;C0005910;C0043100;C1305866;C0441471;C3541888;C0012171;C0023759;C0242994;C2930619;C3275277;C0012155;C0012159;C1519433;C2983588;C3668949;C3538926;C1532980;C0280604;C3542407;C0332257;C1552866;C2700399;C0679831;C0231220;C0332196;C2828389;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0750480;C1705566;C0005847;C1558950;C1801960;C0455536;C2937358;C1704436;C4025272;C0027361;C0237401
time since most recent myocardial,C0040223;C3541383
groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
infarction yr history of congestive heart failure,C0455531
events treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
cabg or ptca,C0010055;C2936173
control $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
medication use aspirin,C0240320;C0004057
rr cl,C4554402;C0596019
nitratesf,
heterogeneity trend test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
calcium channel blockers,C0006684;C2757014
previous disease,C0205156;C0012634;C1552607
ace inhibitors,C0003015
post mi,C0856742
beta blockers,C0001645
other chd,C0280604;C3542407
any antianginal drug,C0013227;C1254351
xho p o $nmbr$,C4050013
body mass index,C0005893;C0578022;C1305855
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$ o,C0483204
waist to hip ratio,C0205682
s $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$,
x $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,
blood pressure mm hg systolic,C0005823;C0039155;C1271104;C1272641
xi $nmbr$ $nmbr$ p $nmbr$,C1720296
diastolic,C0012000
treated hypertension,C0020538;C1963138
plasma lipids mg dl $nmbr$ total cholesterol mean,C0444504;C2347634;C2348143
x l $nmbr$ p $nmbr$ $nmbr$,
interquartile range,C1711350
x $nmbr$ l p $nmbr$ $nmbr$,
ldl cholesterol mean,C0444504;C2347634;C2348143
x $nmbr$ $nmbr$ l p $nmbr$ $nmbr$,
^ $nmbr$ $nmbr$,
hdl cholesterol mean,C0444504;C2347634;C2348143
triglycerides mean,C0444504;C2347634;C2348143
ldl cholesterol mmol l,C0023824;C1532563;C0202117
subgroupt,
xi o $nmbr$ p o $nmbr$,C1720296
placebo,C0032042;C1696465;C1706408
sso $nmbr$,
gemfibrozil,C0017245
o $nmbr$ ii,C1710602;C4082587
risk reduction $nmbr$ cl,C1137094;C0596019
$nmbr$ $nmbr$ o $nmbr$ o o $nmbr$,C0483204
p value,C1709380
triglycerides mmol l,C0041004;C1532563
no with event total no,C0439175;C0439810
$nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
age,C0001779
$nmbr$ io $nmbr$,C1046794;C3146236
$nmbr$ yr,C0439234
xi $nmbr$ $nmbr$ p $nmbr$ l,C1720296
$nmbr$ $nmbr$ $nmbr$,
xi $nmbr$ l p $nmbr$ $nmbr$,C1720296
$nmbr$ $nmbr$ to $nmbr$,
x $nmbr$ $nmbr$ p $nmbr$ $nmbr$,
race,C0034510;C1706779;C3853635
xi l $nmbr$ p $nmbr$ $nmbr$,C1720296
white,C0007457;C0043157;C0220938
xi $nmbr$ $nmbr$ p o l,C1720296
nonwhite,
s $nmbr$ $nmbr$,
family history^,C0241889
o $nmbr$ i i,C0021966;C0221138
yes,C1549445;C1705108;C1710701
xi $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C1720296
no,
ssi $nmbr$,
smoking,C0037369;C0453996;C1881674
xi oo p o $nmbr$,C1720296
current,C0521116;C1705970
pioglitazone n $nmbr$,C0071097
former or never diabetes,C0205156;C0750523;C0011847;C0011849
patients characteristics,C0815172
$nmbr$ $nmbr$ $nmbr$ to $nmbr$,
time since diagnosis of diabetes years median iqr,C0556970;C0011847;C0011849
aspirin use,C0042153;C0457083;C1947944
body mass index kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
no beta blocker use,C0042153;C0457083;C1947944
blood pressure systolic diastolic mm hg mean sd,C0428886;C2699239
hdl cholesterol,C0023822;C0392885
past smoker,C0337664
$nmbr$ $nmbr$ mg dl,C0439269
microvascular disease,C0443258;C0012634
$nmbr$ $nmbr$ mg dl triglycerides^,C0439269;C0041004
blood glucose lowering treatment,C0005802;C0441994;C2003888;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ mg dl,C0439269
metformin only,C0025598
$nmbr$ mg dl ldl cholesterol,C0023824;C0202117
sulphonylureas only,C0038766
stent plus placebo,C0038257;C0032042;C1696465;C1706408
metformin sulphonylureas,C0025598;C0038766
stent plus abciximab,C0038257;C0288672
insulin only,C0021641;C1533581;C1579433;C3714501
p,C0369773;C2603361
insulin metformin,C0021641;C0025598;C1533581;C1579433;C3714501
balloon angioplasty plus abciximab,C0002996;C0002997
insulin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
pt,C0032743;C0699718
insulin metformin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
diabetic patients,C0241863;C0030705
other combination,C0205195;C1947911;C3811910
total,C0439175;C0439810
diet only,C0012155;C0012159;C1519433;C2983588;C3668949
death,C0011065;C1306577;C4082313;C4552775
laboratory data,C1511726;C3245479;C3714741
death large mi,C0011065;C3810814;C1306577;C4082313;C4552775
hba $nmbr$ c median iqr,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
large mi,C0549177;C3810814
ldl cholesterol mmol l median iqr,C0023824;C0202117
tvr,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
non diabetic patients,C1829939;C0241863
hdl cholesterol mmol l median iqr,C0023822;C0392885
characteristics,C1521970
triglycerides mmol l median iqr,C0041004;C1532563
chlorthalidone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
creatinine ^mol l median iqr,C0010294;C0347982;C1561535
doxazosin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
micral test result,C0456984;C0587081
no of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
negative,C0205160;C1513916;C2825415;C2825491;C3853545
age y,C0001779
about $nmbr$ mg l,C0439268
women,C0043210
about $nmbr$ mg l or more,C0439268
race ethnicity white non hispanic,C1533020;C1533021
enact $nmbr$ trial,C0008976
black non hispanic,C1533017;C1533018
enact $nmbr$ trial rerandomization to natalizumab n $nmbr$,C0008976;C1172734
white hispanic,C1533020;C1533021
natalizumab n $nmbr$ f,C1172734;C0016327
black hispanic,C1533017;C1533018
rerandomization to placebo n $nmbr$ f,C0032042;C0016327;C1696465;C1706408
other races,C0034510;C3669213
$nmbr$ $nmbr$ j,
education y,C0013621;C0013622;C0013658;C0039401
duration of disease mo,C0872146;C0026544;C0332177
blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
intestinal area involved no,C0017446;C0205146;C1314939
treated for hypertension,C1522326;C0020538;C1963138
ileum,C0020885
eligibility risk factors t ascvo,C0035648;C1553898
ileum and colon,C0020885;C0009368;C3888384
st t wave changes,C0392747;C0443172
colon,C0009368;C3888384
type $nmbr$ diabetes,C1320657
data missing or no drug given,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0013227;C1254351
cigarette smoking,C0239059;C0700219
previous segmental resection no,C0205156;C2987624;C1552607
hdl c $nmbr$ mg dl,C3715113;C0439269
cdai score,C0449820;C4050231
lvh from electrocardiogram,C0149721;C0013798;C1547122;C1623258
c reactive protein,C0006560;C1413716;C4048285
lvh from echocardiogram,C0149721;C0013516;C2243117
elevated at wk $nmbr$ no,C0205250;C3163633
serum biochemistry potassium mmol l,C0302353;C1532563;C0543465
week $nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fasting glucose mg dl,C0015663;C0439269
mean,C0444504;C2347634;C2348143
creatinine mg dl,C0010294;C0439269;C1561535
week $nmbr$ mg liter^,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cholesterol mg dl,C0008377;C0439269
elevated at wk $nmbr$ no $nmbr$,C0205250;C3163633
ldl c mg dl,C0439269
concomitant medication no,C0013227;C3244316;C4284232
hdl c mg dl,C3715113;C0439269
corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
fasting triglycerides mg dl,C0015663;C0041004;C0439269
prednisone,C0032952
tirofiban n $nmbr$,C0247025
budesonide,C0054201
abciximab n $nmbr$,C0288672
immunosuppressants,C0021081
male sex,C0086582
azathioprine,C0004482
weight kg,C0022718;C0439209;C4054209
mercaptopurine,C0000618
smoker,C0337664
methotrexate,C0025677
medical history,C0262926;C1704706
antibiotics,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
coronary artery bypass grafting,C0010055
$nmbr$ aminosalicylates i i,C0021966;C0221138
percutaneous coronary revascularization,C1532338
$nmbr$ corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
cerebrovascular accident,C0038454
previous receipt of therapy against tnf a no,C0039798;C0087111;C1363945;C1448177;C1710304
primary target vessel,C0205225;C0449618;C0439612;C0439631
refractory to such therapy no,C0205269;C0039798;C0087111;C1363945
current smoker $nmbr$ cigarettes day no,C0332173;C0439228;C0439505
l eft anterior descending coronary artery,C0439394;C0226032;C1706495;C3642217
r ight coronar y artery,C0003842;C0226004
figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d,C0439165;C1549488;C1561533;C0008976;C1096775;C0441833;C1706365;C1999270;C0544452;C0687702;C0545082;C1512346;C2826704;C0332174;C0441837;C0439230
left circumflex artery,C0226037
a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown,C0871261;C1704632;C1706817;C2911692;C1704788;C3539106;C0168634;C1442488;C0011198;C0017480;C3541240;C0205232;C0687757;C0449820;C4050231;C0237881;C0750502;C1546944;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1547282
bypass graft,C0185098
clopidogrel n $nmbr$ $nmbr$,C0070166
restenotic vessel,C0005847
age at entry years,C1510829;C1705654
variable,C0439828;C4553760
time since onset h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
no of patients,C0030705
ecg abnormality at entry,C1623258;C1704258
irofiban,
st elevation,C0520886
abciximab,C0288672
bundle branch block,C0006384;C1879286
sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
st depression without st elevation,C0520887
male,C0086582;C1706180;C1706428;C1706429
ii or iii,C0439070;C1705160
female,C0043210;C0086287;C1705497;C1705498
previous disease and drug use,C0205156;C0012634;C1552607;C0242510
clopidogrel given before procedure,C0070166;C0184661;C2700391;C3274430;C3539779
previous hypertension,C0020538;C1963138
location of treatment center,C0450429;C1515974;C4284930;C4284931
aspirin before admission,C0004057;C0184666;C0809949
united states,C0041703
$nmbr$ blocker before admission,C0184666;C0809949
indication for stent,C0392360;C3146298
fibrinolytic agent before randomisation,C0016018;C0034656
acute coronary syndrome $nmbr$,C0948089
non trial treatment during hospital stay,C0019948;C3166479
nct $nmbr$,
non trial antiplatelet,C1518422;C0008976
clinical characteristics,C0683325
fibrinolytic agents before or after entry,C0016018;C1705654
hyperlipidemia,C0020473;C0428465;C4555212
anticoagulant,C0003280;C0848112;C3536711
history of hypertension,C0455527
antiarrhythmic,C0003195;C3537142
histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
nitrate oral or intravenous,C0442027;C4521986;C0348016
histor y of unstable angina,C0002965
calcium antagonist,C0006684
histor y of stable angina,C0340288
metoprolol n $nmbr$ $nmbr$,C0025859
histor y of heart failure,C0018801;C0018802;C4554158
ai $nmbr$,C0003504;C4551710
congestive heart failure,C0018802
p blocker before admission,C0369773;C0184666;C0809949;C2603361
cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901;C0034656
non trial p blocker,C1518422;C0008976
previous intervention,C0184661;C0886296;C1273869
score $nmbr$ $nmbr$,C0449820;C4050231
percutaneous transluminal coronary angioplasty,C2936173
mfns n $nmbr$,
coronar y artery bypass grafting,C0332835;C1527362;C1961139
mean age y range,C1514721;C2348147;C3542016
administration of study drug,C0150270;C0262754;C3469597
gender male,C0086582;C1706180;C1706428;C1706429
bolus,C1186706;C1511237;C1705509;C3812160
mean baseline nasal congestion score,C3533236;C0027424;C4554631
bolus and infusion,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
eze simva $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
infarct territory,C1301808;C2983136
atv $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ f,C0016327
number of females n,C0237753;C0449788
anterior,C0205094
race n,C0034510;C1706779;C3853635
inferior,C0542339;C0678975
body mass index mean sd kg m,C0022718;C0439209;C4054209
infarct related vessel,C0021308;C0005847
duration of hypercholesterolaemia mean sd year,C0449238;C2926735
l eft anterior descending,C0439394;C0205094;C1706495;C3642217;C0205386;C1547177
patient history of disease n,C0683519;C0730226;C0850708;C0944983
r ight coronary,C0205090;C0018787;C0684010;C2603358
concomitant therapies n,C1707479
circumflex,C1880089
drugs used in diabetes,C0013227;C3687832;C1273517;C0011847;C0011849
graft,C0181074;C0332835;C1961139
antithrombotic agents,C1704311
sr ii b $nmbr$ cjl $nmbr$,C0753208;C1709991;C3813610;C3890900;C3891546
age years,C1510829
antihypertensive agents,C0003364
cardiac therapy,C3654025
body mass index kg m $nmbr$,C0022718;C0439209;C4054209
peripheral vasodilators,C0724804
history of hypertension a c,C0455527
vasoprotectives,C0304533
history of high cholesterol a $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline lipids mean sd mmol l,C0023779;C1532563
history of diabetes a,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
tgt,C1421391;C1428265;C4321338
history of parental myocardial,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0027061;C1522564
apo bt,
infarction before age $nmbr$ a,C0021308;C0001779
smoking a,C0037369;C0453996;C1881674
never,C2003901
apo apolipoprotein dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol tc total cholesterol tg triglycerides includes agents acting on the renin angiotensin system beta blocking agents calcium channel blockers and diuretics median values [standard deviation for medians calculated by q $nmbr$ q $nmbr$ $nmbr$ $nmbr$ ] includes cardiac glycosides antiarrhythmics class i and iii vasodilators used in cardiac diseases and other cardiac preparations expressed as g l,C0062152;C0332257;C1552866;C2700399;C0006684;C0549183;C0042295;C0876920;C2347635;C2348144;C2939193;C0871420;C0444686;C1441506;C0441885;C1319793;C2698967;C0439070;C0042402;C1705160;C1273517;C0018799;C1521827;C3812761;C0439294;C0456615
past,
non white,C0007457;C0043157;C0220938
alcohol intake a,C0001948
$nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
rarely,C0522498
left ventricular ejection fraction mean sd,C0428772;C2699239;C0488728
monthly,C0332177
nyha functional class $nmbr$,C1882083;C0205245;C0542341;C2700217
weekly,C0332174
$nmbr$ $nmbr$ $nmbr$ q,
daily,C0332173
lll iv,C0022326;C4265176
exercise at least weekly a,C0015259;C0332174;C1522704
$nmbr$ $nmbr$ $nmbr$ j,
post menopausal a,C0232970
history congestive heart failure,C0019664;C0018802;C0019665;C0262512;C0262926;C1705255;C2004062
use of hormone replacement therapy a,C1524063;C0282402
chronic obstructive pulmonary disease,C0024117
randomized to active yitamin e,C0034656;C3815594
cerebrovascular accident tia,C0007787;C0917805;C1054154
number reporting migraine on $nmbr$ month questionnaire,C0149931;C0034394
preoperative use p blocker,C0445204;C0042153;C0457083;C1947944
aspirin asa $nmbr$ $nmbr$,C0004057;C3853627
angiotensin receptor blocker,C0034787;C1622222
placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
nsaid,C0003211;C3536840
odds ratio $nmbr$ ci,C0008107;C3259781
baseline characteristics,C4684572
all randomized women,C0034656;C0043210;C3815594
postoperative use of p blocker,C0032790;C1524063
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
operative procedure,C0543467;C0677612
hormonal status,C0458083;C0449438
cabg surgery by no of vessels $nmbr$,C0042381;C3714645
pre menopausal without hormone replacement therapy asa $nmbr$ placebo $nmbr$,C0282402
type no of valves repaired replaced mitral,C0332307;C1547052;C0396849;C0559956;C1299987
pre menopausal with hormone replacement therapy asa $nmbr$ placebo $nmbr$,C0282402
aortic,C0003483
post menopausal without hormone replacement therapy asa $nmbr$ $nmbr$ placebo $nmbr$,C0019930
multiple,C0439064
post menopausal with hormone replacement therapy asa $nmbr$ $nmbr$ placebo $nmbr$,C0019930
type of surgery cabg only,C0332307;C1547052
age yrs,C0001779
valve repair replacement with or without cabg,C0035139;C0559956;C1555302;C4553149;C0010055
digoxin,C0012265
valve repair replacement only,C0035139;C0559956;C1555302;C4553149
n,C0369718;C0441922
time mean sd min procedure,C0184661;C2700391;C3274430;C3539779
prior mi,C0332152;C3810814;C2826257
pump,C0182537
diabetes etiology,C0015127;C1314792;C1524003
cross clamp,C0175721;C1883710;C3810601
ischemic,C0475224
total no of patients,C0439175;C0439810;C0030705
nonischemic,
no of patients with atrial tachyarrhythmia,C0030705;C0018792;C0080203
heart rate min_ $nmbr$ mean,C0444504;C2347634;C2348143
hazard ratio $nmbr$ cl,C2985465;C0596019
systolic bp mm hg mean nyha class,C0488053;C1882083
absolute risk reduction $nmbr$ cl,C3179139;C0596019
ttf fv,C1332112;C1705840;C4087167
no needed to treat $nmbr$ cl,C0027552;C0686904
ct ratio $nmbr$ $nmbr$,C0456603;C1547037
amiodarone,C0002598
ejection fraction mean,C0444504;C2347634;C2348143
age years $nmbr$,C1510829
creatinine $nmbr$ $nmbr$ mg dl medications,C0013227;C0802604;C2598133;C4284232
diuretics,C0012798
type of surgery cabg coronary artery bypass graft,C0449494
stent group n $nmbr$,C0038257;C0441848
type of surgery valve replacement repair with or without cabg,C0449521;C0449533;C0010055
alteplase group n $nmbr$,C0032143;C0441848
preoperative beta blocker use yes,C1549445;C1705108;C1710701
demography,C0011298
preoperative beta blocker use no,C0042153;C0457083;C1947944
median iqr age years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
tenecteplase and pci n $nmbr$,C0872913;C4049621
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
pci alone n $nmbr$,C0205171;C0439044;C0679994
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
height cm,C0489786
m f,C0016327
ii iii,C0439070;C1705160
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
congestive heart failure at randomisation,C0018802;C0034656
history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
previous infarction,C0205156;C0021308;C1552607
receiving insulin therapy,C1514756;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
previous congestive heart failure,C0205156;C0018802;C1552607
median iqr cholesterol,C0549183;C0008377;C0876920;C2347635;C2348144;C2939193
previous pci,C0205156;C4049621;C1552607
mmol l,C1532563
previous coronary artery bypass graft,C2144990
previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
glucosamine n $nmbr$,C0017718
previous cabg,C0205156;C0010055;C1552607
chondroitin sulfate n $nmbr$,C0008466
infarct localisation,C0475264;C1744691
lateral,C0205093
glucosamine chondroitin sulfate n $nmbr$,C0017720
killip class,C1881332
celecoxib n $nmbr$,C0538927
i,C0021966;C0221138
hispanic no,C0086409
ii,
duration of osteoarthritis symptoms yr,C0436359;C0029408
iii,C0439070;C1705160
time since diagnosis of osteoarthritis yr,C0040223;C3541383
iv,C0022326;C4265176
no of $nmbr$ mg acetaminophen tablets day,C0439422;C1243102
median iqr admission data,C1511726;C3245479;C3714741
ara functional class no,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
systolic blood pressure,C0488055;C0871470;C1306620
unknown,C0439673;C3541433;C4050014
mm hg,C0439475
kellgren and lawrence radiographic reading grade $nmbr$ no,C0441800;C0919553;C3244287
diastolic blood pressure,C0428883;C1305849
global assessment of disease status score,C0281858;C3176928
heart rate beats min,C0439385
physician,C0031831;C0804815
time to admission min,C3854258;C3854259
patient,C0030705
time to balloon needle min,C0040223;C3541383
joint swelling effusion or both on clinical examination no,C1253936;C1963136;C4554335;C0031809
losartan n $nmbr$,C0126174
womac score,C0449820;C4050231
atenolol n $nmbr$,C0004147
pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
all with diabetes n $nmbr$,C0011847;C0011849
stiffness subscale,C0427008
all without diabetes n $nmbr$,C0011847;C0011849
function subscale,C0031843;C0542341;C0700205;C1705273
demographic and clinical characteristics,C0011298;C0683325
normalized,C1882115
ethnic origin white,C0007457;C0043157;C0220938
health assessment questionnaire score,C2960025
hispanic,C0086409
alternative disability,C1523987;C0231170
asian,C0078988
pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
heart rate bpm,C0018810
sf $nmbr$ score,C0449820;C4050231
bmi kg m $nmbr$,C0022718;C0439209;C4054209
physical component,C0449432;C1705248
cornell voltage duration product mmxmsec,C0598352;C0449238;C2926735
mental component,C0449432;C1705248
sokolow lyon mm,C4330985;C4554674
glucosamine,C0017718
framingham risk score,C0035647;C0449820;C4050231;C4552904
chondroitin sulfate,C0008466
current smokers,C3173209;C3241966
glucosamine chondroitin sulfate,C0017720
any vascular diasease,C0005847;C1558950;C1801960
celecoxib,C0538927
coronary heart disease,C0010054;C0010068;C1956346
all randomized patients,C0034656;C0030705;C3815594
cerebrovascular disease,C0007820
primary outcome $nmbr$ decrease in womac pain score,C0392756;C0547047
peripheral vascular disease,C0085096
at end of follow up no,C0444930;C2746065
atrial fibrillation,C0004238;C0344434;C1963067
secondary outcomes,C0027627;C1274040;C0175668;C0205436
isolated systolic hypertension^,C0745133
omeract oarsi response,C0871261;C1704632;C1706817;C2911692
clopidogrel n $nmbr$,C0070166
$nmbr$ decrease in womac pain score,C0392756;C0547047
ticlopidine n $nmbr$,C0040207
womac pain score,C0582148
women n,C0043210
change from baseline,C0392747;C0443172;C1705241;C4319952
diabetes n,C0011847;C0011849
at end of follow up,C0444930;C2746065
smoking habit n,C4505437
womac stiffness score,C0449820;C4050231
hypercholesterolemia n,C0020443;C1522133
womac function score,C0449820;C4050231
systemic arterial hypertension n,C0020538
normalized womac score,C0449820;C4050231
previous myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
haq alternative disability score,C0449820;C4050231
previous balloon angioplasty n,C0002996;C0002997
haq pain score,C0102923;C0582148;C0451208
previous bypass surgery n,C0205156;C1536078;C1552607
patient s global assessment of response to therapy score,C0030705;C0281858;C0871261;C1704632;C1706817;C2911692;C0449820;C4050231
unstable angina n,C0002965
patient s global assessment of disease status score,C0030705;C0281858;C3176928
platelet count x $nmbr$ mm $nmbr$,C4330985;C4554674
physician s global assessment of disease status score,C0031831;C0804815;C0281858;C3176928
baseline demographics,C0011298;C1704791
joint swelling effusion or both on clinical examination,C1253936;C1963136;C4554335;C0031809
simvastatin n $nmbr$,C0074554
at baseline no,C0168634;C1442488
women men [ ],C0043210;C0025266
at end of follow up no total no,C0444930;C2746065;C0439175;C0439810
disease duration yr,C0872146;C0439234
no of $nmbr$ mg tablets of acetaminophen,C0024671;C1243102;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mmse points,C1552961;C2347617;C3714763
patients with moderate to severe pain womac pain score $nmbr$ $nmbr$,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0582148
adas cog score,C0449820;C4050231
at baseline,C0168634;C1442488
points,C1552961;C2347617;C3714763
patients with mild pain womac pain score $nmbr$ $nmbr$,C0030705;C0278138;C4522280
serum ldl cholesterol,C0428474
figure $nmbr$ pairwise comparisons of the overall likelihood of a response,C1707455;C0871258
mg dl,C0439269
subgroups those with mild pain and those with moderate severe pain,C1079230;C0278138;C4522280;C0278140;C4050465;C4521229
csf a $nmbr$ pm,C3540512;C3889436;C0030266;C4049155
baseline characteristic,C0168634;C1521970;C1442488
csf lathosterol jlg cll,C0064673;C0023434
mtx plus placebo,C0025677;C1417487
csf cholesterol,C3540512;C0008377;C3889436
mtx plus infliximab,C0025677;C1417487
csf $nmbr$ s hydroxy,C3540512;C3889436;C0700307
coefficient,C1707429
cholesterol ng ml,C0008377;C0439275
swollen joint count $nmbr$ $nmbr$,C0451521
mmse mini mental state examination adas cog alzhei,C0451306
tender joint count $nmbr$ $nmbr$,C0451530
mer s disease assessment,C1261322;C1516048
rf mg dl,C0035448;C0439269;C0201660;C0748398;C1547111
scale cognitive portion ldl low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
crp mg dl,C3890735;C0439269;C4048285
density lipoprotein csf,C3540512;C3889436
esr mm hour,C0439227;C0564385
cerebrospinal fluid,C0007806;C0007807
baseline shs $nmbr$ $nmbr$,C0168634;C1442488
mmse $nmbr$ $nmbr$,C0451306
j $nmbr$ coefficient,C1707429
simvastatin,C0074554
or $nmbr$ ci,C0008107;C3259781
measures,C0079809;C1879489
age per $nmbr$ years,C1510829
n $nmbr$,C0369718;C0441922
sex male,C0086582
serum,C0229671;C1546774;C1550100
swollen joint count $nmbr$ $nmbr$ per swollen joint,C0451521;C0152031;C4554794;C4696257
aldl cholesterol,C0008377
tender joint count $nmbr$ $nmbr$ per tender joint,C0451530;C0240094;C4554549;C4696258
$nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
csf,C3540512;C3889436
rf mg dl per unit,C0439269
a a $nmbr$,
crp mg dl per unit,C0439269
aab $nmbr$,
esr mm hour per unit,C3811131;C0456685
alathosterol,
shs $nmbr$ $nmbr$ per $nmbr$ score,C0449820;C4050231
acholesterol,
baseline inflammation markers,C0021368;C0005516
a $nmbr$ s hydroxy cholesterol,C0700307;C0008377
changes in shs,C0392747;C0443172
table $nmbr$ characteristics of patients treated with losartan and atenolol,C0039224;C0815172;C1706074;C0332293;C0126174;C0004147
normal crp and esr,C3890735;C4048285;C3811131
women no,C0043210
high crp or esr,C3890735;C4048285;C3811131
ethnicity no,C0015031;C0243103
high crp and esr,C3890735;C4048285;C3811131
systolic,C0039155
figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231;C0332174;C0439230;C0681867;C1514756;C0666743;C3899278;C0008976
cornell voltage duration product mm x ms,C2349943;C3539704;C3713294
framingham risk score arbitrary units,C0035647;C0439183;C4552904
shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group,C1547282;C0168634;C0201657;C1442488;C1176468;C1619634;C0441837;C0032042;C1696465;C1706408;C0025677;C0666743;C0072053
current smoker no,C3173209;C3241966
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C0008976;C4706353
medical history no,C0262926;C1704706
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C3890735;C0441889;C4048285;C3811131;C0451521;C1510992;C2825518;C0008976
previously untreated isolated systolic hypertension,C0745133
diagnosed diabetes n $nmbr$,C0011847;C0011849
crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups,C3890735;C3811131;C4048285;C0451521;C1510992;C2825518;C0008976;C0750572;C0017446;C0205146;C0025663;C0021966;C0221138;C0449851;C0871511;C0025677;C1417487;C1550452;C1704788;C3539107;C3888054;C0681841;C0374505
undiagnosed diabetes n $nmbr$,C0011847;C0011849
$nmbr$ abciximab n $nmbr$,C0288672
impaired fasting giucose levei n $nmbr$,C0221099;C0015663
insulin treated diabetes,C0011847;C0011849
normai fasting giucose levei n $nmbr$,C0015663
prior aortocoronary bypass surgery,C0455610;C0010055
p vaiue,C0369773;C2603361
elevated troponin $nmbr$ $nmbr$ pg l,C0041199;C0439278
age mean sd y,C0001779;C0444504;C2347634;C2348143
elevated creatine kinase mb $nmbr$ u l,C0010290;C0439339;C0523584
race nonwhite,C0034510;C1706779;C3853635
hours from clopidogrel loading mean sd,C0439227;C0070166
smoking current,C0521116;C1705970
multivessel disease,C0012634
alcohol with $nmbr$ drink d,C0001948;C0556297
target vessel,C0449618
prior myocardial intarction,C0332152;C0027061;C1522564;C2826257
left main artery,C0205091;C0003842;C0226004;C0443246;C1552822
prior stroke,C0038454;C4554100
left anterior descending artery,C0226032
ptca cabg,C2936173;C0010055
ptca,C2936173
right coronary artery,C1261316
cabg,C0010055
complex lesions^,C0439855;C0221198;C1704241
medication use,C0240320
lesion length mean sd mm,C4330985;C4554674
aspirin,C0004057
vessel size mean sd mm,C4330985;C4554674
ace inhibitor,C0003015;C4541021
diameter stenosis mean sd,C0552409;C2699239
anyantianginal agent,C0450442;C1254351;C1521826
type of intervention,C3274412
calcium channel blocker,C0006684;C3536851;C4521885
drug eluting stent,C1322815
p blocker,C0369773;C2603361
bare metal stent,C2825200
bmi mean sd,C0444504;C2699239;C2347634;C2348143
balloon angioplasty,C0002996;C0002997
waist circumference mean sd in,C0455829;C2699239
concomitant drug therapy at discharge,C0013216;C0013217
blood pressure mean sd mm hg,C0428886;C0439475
calcium antagonists,C0006684
lipids mean sd mg dlf,C0023779;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
primary end point no of events total no,C2986535;C0439175;C0439810
hdl c,C3715113
all participants,C0679646
triglycerides,C0041004
troponin level,C0441889;C0456079;C1547707;C2946261
ldl c,
$nmbr$ $nmbr$ ug l,C0439275
total cholesterol,C0201950;C0543421
clopidogrel pretreatment duration,C0449238;C2926735
fpg mean sd mg dlf,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
fpi mean sd pu rnff,C0444504;C0018387;C2347634;C2348143
body mass indexj,C0518010
outcome,C1274040
measured at clinic visit with automated device,C0444706;C3541902;C0025080;C0699733
hr,
measured at clinic visit with usual device,C0444706;C3541902;C0025080;C0699733
subgroup_name_level,C0441889;C0456079;C1547707;C2946261
measured at home with automated device,C0442519;C0025080;C0699733
combined end poir,C0205195;C0444930;C2746065
lower than normal range ^,C0441994;C1548802;C2003888
it $nmbr$ $nmbr$,
glucose mg dl,C0017725;C0439269
p oo $nmbr$,C0369773;C2603361
insulin iu,C0049272;C0439453;C0694756
no diabetes,C0011847;C0011849
insulin glucose ratio,C0456603;C1547037
p $nmbr$,C0369773;C2603361
subgroups,C1079230
nonfatal myocardiail infarction,C0021308
relative risk $nmbr$ ci,C0008107;C3259781
chd death,C0011065;C1306577;C4082313;C4552775
at home systolic pressure $nmbr$ mm hg,C0871470;C0439475
p o $nmbr$,C0369773;C2603361
stroke,C0038454;C4554100
at home systolic pressure,C4534363;C0871470
subgroup_name,C0027365;C1547383;C4522128
at home diastolic pressure $nmbr$ mm hg,C0428883;C0439475
subgroup_level fpi gu ml pmol l,C1635169
at clinic systolic pressure $nmbr$ mm hg,C0871470;C0439475
hazard ratio,C2985465
at clinic systolic pressure,C0002424;C0871470;C0442592
fasting plasma insulin,C0015663;C0857690
at clinic diastolic pressure $nmbr$ mm hg,C0428883;C0439475
overall n $nmbr$,C0282416;C1561607
at clinic diastolic pressure,C0002424;C0428883;C0442592
rate control group n $nmbr$,C0441848
weight,C0005910;C0043100;C1305866;C1705104
$nmbr$ lb,
rhythm control group n $nmbr$,C0441848
enoxaparin n $nmbr$ $nmbr$,C0206460
female sex no,C0086287
fondaparinux n $nmbr$ $nmbr$,C1098510
ethnic minority group no,C0015031;C1879937
time from onset of pain to randomization hr,C0449244;C0034656
predominant cardiac diagnosis no,C0011900;C1704338;C1704656
diagnosis at study entry no,C1704656;C4068481
coronar y artery disease,C0852949
cardiomyopathy,C0878544
suspected myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
valvular disease,C3258293
current or former smoker,C0521116;C1705970;C0337671
any electrocardiographic abnormality no,C0522055
no apparent heart disease,C0750489;C0018799
histor y of congestive heart failure no,C0018802
st segment depression $nmbr$ mm no,C4330985;C4554674
duration of qualifying atrial fibrillation $nmbr$ days no,C0449238;C2926735;C1514624;C0004238;C0439228;C0344434;C1963067
medications at the time of randomization no,C0013227;C0802604;C2598133;C4284232
clopidogrel or ticlopidine,C0070166;C0040207
first episode of atrial fibrillation vs recurrent episode no f,C0332189;C0439615;C0443287;C0016327
ace inhibitor or arb,C0003015;C4541021;C3888198
any prerandomization failure of an antiarrhythmic drug no,C0231174;C0680095
lipid lowering agent,C0086440
size of left atrium normal no,C0225860;C0332506
medications in the hospital after randomization no,C0013227;C0802604;C2598133;C4284232;C0034656
left ventricular ejection fraction,C0428772;C0488728
procedures in the hospital no,C0025664;C0184661;C2700391;C3538935
coronary angiography,C0085532;C1548829
normal left ventricular ejection fraction no j,C0428772;C0488728
pci,C4049621
no of participants,C0679646
procedures after discharge no,C0012621;C0030685;C2926602
$nmbr$ chlorthalidone n $nmbr$,C0008294
panel a,C0441833;C1706365;C1999270
amlodipine n $nmbr$,C0051696
no of,
i lisinopril n $nmbr$,C0021966;C0065374;C0221138
percentage of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
age range y,C0001779;C1514721;C2348147;C3542016
interaction p value,C1704675;C1709380
a $nmbr$,
fondaparinux,C1098510
ethnicity,C0015031;C0243103
creatinine,C0010294;C1561535
white non hispanic,C1533020;C1533021
at or above median,C0549183;C0876920;C2347635;C2348144;C2939193
education mean sd y,C0013621;C0013622;C0013658;C0039401
less than median,C0549183;C0876920;C2347635;C2348144;C2939193
receiving antihypertensive,C1514756;C0003364
heparin at randomization,C0019134;C0770546
treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
revascularization in $nmbr$ days,C0581603;C0439228
treated at baseline,C1522326;C0168634;C1442488
catheterization laboratory in center,C0007430;C0022877;C3244292;C4283904
untreated at baseline,C0332155;C0168634;C1442488
panel b,C0441833;C1706365;C1999270
$nmbr$ $nmbr$ s $nmbr$ $nmbr$,
percentage of p,C0439165;C1549488;C1561533
eligibility risk factors,C0035648;C1553898
atients with event,C0441471;C4019010
cigarette smoker,C0337667
catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
atherosclerotic cvdj,C0333482
center,C0205099;C3810851
history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
unfractionated heparin n $nmbr$ $nmbr$,C0019134;C2825026
history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age $nmbr$ yr no,C0001779;C0439234
revascularization,C0581603
white race no total no f,C0007457;C0043157;C0439175;C0439810;C0016327
other atherosclerotic cvd,C0333482;C0007222
hypertension no total no,C0020538;C1963138;C0439175;C0439810
major st depression or,C0041696;C1269683
hyperlipidemia no total no,C0020473;C0428465;C4555212;C0439175;C0439810
t wave inversion,C0520888
current smoker no total no,C3173209;C3241966;C0439175;C0439810
lvh by electrocardiogram,C0149721;C0013798;C1547122;C1623258
diabetes mellitus no total no,C0011849;C0439175;C0439810
lvh by echocardiogram,C0149721;C0013516;C2243117
prior myocardial infarction no total no,C0027051;C0428953;C2926063;C3810814;C4552959;C0439175;C0439810
history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
prior angina pectoris no total no,C0332152;C0002962;C2826257;C0439175;C0439810
body mass index mean sd,C0005893;C2699239;C0578022;C1305855
prior percutaneous coronary intervention no total no,C0332152;C1532338;C2826257;C0439175;C0439810
current medication use,C0240320
estrogen supplementation,C0014939;C0242297;C2936882;C4542544
anterior myocardial infarction no total no,C0340293;C0439175;C0439810
women only,C0043210
long term treatment with aspirin no total no,C0023977;C0004057;C0439175;C0439810
lioid trial participants,C1997894;C2242969
unfractionated heparin within $nmbr$ hr before randomization no total no,C0019134;C2825026;C0034656;C0439175;C0439810
placebo group n $nmbr$,C0032042;C0441848;C1696465;C1706408
lmwh within $nmbr$ days before randomization no total no,C0019139;C3536766;C0034656;C0439175;C0439810
warfarin group n $nmbr$,C0043031;C0441848
creatinine clearance ml min,C0812399;C0439445
median,C0549183;C0876920;C2347635;C2348144;C2939193
killip class no i,C1881332;C0021966;C0221138
female sex,C0086287
data missing,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
race or ethnic group,C0034510;C1706779;C3853635;C0015031;C1879937
timi risk score no total no c,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810
non hispanic white,C0007457;C0043157;C0220938
time from symptom onset to start of fibrinolytic therapy hr,C0449244;C0439659;C0040044
non hispanic black,C0005680;C0027567;C0085756;C0439541
fibrinolytic therapy no,C0040044
history of diabetes,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
time from fibrinolytic therapy to study drug administration no total no,C0040223;C3541383;C0150270;C3469597;C0439175;C0439810
$nmbr$ previous venous thromboembolisms,C0205156;C1997614;C1552607
$nmbr$ min,C0702093;C1524029;C3813700
family history of venous thromboembolism,C0455533
$nmbr$ $nmbr$ min,C0702093;C1524029;C3813700
factor v leiden,C0380964;C0584960;C1414509;C3542419
ace inhibitors or angiotensin receptor blockers,C0003015;C0521942;C0815017
prothrombin mutation,C1610621
statin,C0360714
duration of full dose warfarin therapy before enrollment mo,C0444917;C0366686;C0026544;C0332177
statistics,C0038215;C0600673
time between cessation of full dose warfarin therapy and enrollment mo,C0682295;C0366686;C0026544;C0332177
w,
placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
ni,C0028075;C2348274;C3869926;C3869927
warfarin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mean s d,C0444504;C2347634;C2348143
hazard ratio $nmbr$ ci,C0008107;C3259781
dbp mmhg,C0536221;C0439475;C3813197;C4281799
p value for interaction^,C1709380;C1704675
sbp mmhg,C0085805;C0439475
no of events,C0441471;C3541888
hemoglobin gm dl,C0017480;C3642216;C3854019
no $nmbr$ person yr,C0027361;C0439234;C2347489
albuminuria g g,C0001925;C1319635
in,
factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419;C1610621
gm,C0017480;C3854019
present,C0150312;C0449450
absent,C0332197;C4285062
proteinuria $nmbr$ g day,C0033687;C0439417;C1962972;C4554346
$nmbr$ $nmbr$ yr,C0439234
bmi body mass index dbp diastolic blood pressure gm geometric mean sbp systolic blood pressure the analysis was based on observed data without imputation on missing values asubgroup of patients in whom $nmbr$ h urine was collected see materials and methods section,C0488055;C0871470;C1306620;C0002778;C0936012;C1524024;C1527178;C1705938;C2699638;C0030705;C0042036;C0042037;C2963137;C0042789;C0520510;C1947903;C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
no of previous venous thromboembolic events,C1861172;C1997614;C3160733
pre specified hr $nmbr$ cl,C2826245;C0596019
time since randomization,C0040223;C3541383
adjusted hr $nmbr$ cl,C0456081;C0596019
time since cessation of full dose warfarin therapy,C0682295;C0366686
n event rate,C0871208;C1521828
$nmbr$ mo,C0026544;C0332177
w event rate,C0871208;C1521828
hba $nmbr$ c strata,C0019016;C1825777;C3538758
rsg $nmbr$ mg day,C0439422
bp blood pressure ci confidence interval esrd end stage renal disease hr hazard ratio all patients except patients with other race were included with missing covariates imputed event no of patients with esrd rate event rate per $nmbr$ years of follow up pre specified a cox model with treatment group and region as covariates and baseline proteinuria level o or x $nmbr$ g g as strata adjusted a multivariate cox model with treatment group time varying systolic and diastolic bp as covariates pre specified analysis and adjusted for time varying bp,C1442095;C0030705;C0034510;C1706779;C3853635;C0332257;C0441471;C4019010;C0589120;C1522577;C1704685;C3274571;C2826245;C1565830;C0679845;C0017446;C0205147;C0168634;C0033687;C1962972;C4554346;C1442488;C1319635;C0456081;C0428883;C0037623;C1415692;C1708288;C4318478
patients n,C0030705
baseline to year $nmbr$,C0168634;C1442488
age years mean sd,C1510829;C2699239
relative risk $nmbr$ cl,C0242492;C0596019
gender male female,C0043210;C0086287;C1705497;C1705498
age $nmbr$,C0001779
white black other,C0005680;C0027567;C0085756;C0439541
age a $nmbr$,C0001779
bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
non black,C0005680;C0027567;C0085756;C0439541
hba $nmbr$ c,C0019016;C1825777;C3538758
diabetic,C0241863
baseline mean sd,C0168634;C2699239;C1442488
non diabetic,C1518422;C0241863
week $nmbr$ mean sd,C0332174;C2699239;C0439230
year $nmbr$,C0439234;C0439508
comparison with baseline,C1707455;C0168634;C1442488
gender n,C0079399;C1522384
mean change,C0392747;C0443172;C1705241;C4319952
age years mean range,C1514721;C2348147;C3542016
mean change $nmbr$ ci,C0008107;C3259781
diagnoses risk factors n,C0035648;C1553898
comparison with placebo,C1707455;C0032042;C1696465;C1706408
lipid and lipoprotein values mg dl,C0023779;C0023820;C0439269
mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
hs crp mg l,C3890735;C0439268;C4048285
mean difference $nmbr$ ci,C0008107;C3259781
c,
fpg mg dl,C0439269
non c,C1518422
baseline geometric mean cv,C3538987;C4048877;C4318503
known chd,C0280604;C3542407
week $nmbr$ geometric mean cv,C3538987;C4048877;C4318503
hyper tension,C0020538;C1963138
comparison with baseline mean,C1707455;C0168634;C1442488
baseline ldl c $nmbr$ mg dl,C0168634;C0439269;C1442488
change $nmbr$ ci,C0008107;C3259781
apo b,C0003593;C3252643
comparison with placebo mean,C1707455;C0032042;C1696465;C1706408
apo a i,C0085201;C1677784
difference $nmbr$ ci,C0008107;C3259781
entire cohort,C0009247;C0599755
comparison with baseline mean change $nmbr$ ci,C1707455;C0008107;C3259781
simva n $nmbr$,
comparison with placebo mean difference $nmbr$ ci,C1707455;C0008107;C3259781
eze simva n $nmbr$,
usual care n $nmbr$,C3538928;C1947933
female simva n $nmbr$,C0043210;C0086287;C1705497;C1705498
intervention n $nmbr$,C0184661;C0886296;C1273869
female eze simva n $nmbr$,C0043210;C0086287;C1705497;C1705498
demographics,C0011298;C1704791
male simva n $nmbr$,C0086582;C1706180;C1706428;C1706429
sex female,C0086287
male eze simva n $nmbr$,C0086582;C1706180;C1706428;C1706429
marital status married,C0024841;C0555047
caucasian simva n $nmbr$,C0007457;C0043157
education high school or higher,C0683862;C0205250
caucasian eze simva n $nmbr$,C0007457;C0043157
medical characteristics,C0199168;C1521970;C0205476
non caucasian simva n $nmbr$,C0007457;C0043157
smoking history,C1519384
$nmbr$ $nmbr$ io i,C0021966;C0221138
hypercholesterolemia,C0020443;C1522133
non caucasian eze simva n $nmbr$,C0007457;C0043157
renal insufficiency,C0035078;C1565489
$nmbr$ years simva n $nmbr$,C0439234
previous ml,C0439526;C1705224;C3887665
$nmbr$ years eze simva n $nmbr$,C0439234
previous cabg surgery,C0038894;C0038895;C0543467;C1274039
gender n ],C0079399;C1522384
previous ptca,C0205156;C2936173;C1552607
race n ],C0034510;C1706779;C3853635
chf history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
diagnoses risk factors n ],C0035648;C1553898
comorbidity score mean sd t,C0009488;C0444504;C2347634;C2348143
$nmbr$ mg dl simva n $nmbr$,C0439269
systolic blood pressure mean sd mm hg,C0428886;C0439475
$nmbr$ mg dl eze simva n $nmbr$,C0439269
body mass index mean sd t,C0005893;C0578022;C1305855
$nmbr$ mg dl simva $nmbr$,C0439269
characteristics of the index ml,C1521970;C0439526;C1705224;C3887665
$nmbr$ mg dl eze simva $nmbr$,C0439269
infarct type,C0332307;C1547052
chd status,C0280604;C0449438;C3542407
q wave,C0429089;C1305738
chd simva $nmbr$,C0280604;C3542407
non q wave,C0429089;C1305738
chd eze simva $nmbr$,C0280604;C3542407
indeterminate or unknown,C0205258;C0439673;C3541433;C4050014
no chd simva $nmbr$,C0280604;C3542407
infarct location,C0450429;C1515974;C4284930;C4284931
no chd eze simva n $nmbr$,C0280604;C3542407
ejection fraction category,C0683312;C3889287
simva,
severe dysfunction,C3274777
eze simva,
moderate dysfunction,C3274776
$nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mild dysfunction or normal,C3274775;C0205307;C0231683;C0439166;C2347086;C4553972
entire cohort gender,C0079399;C1522384
killip class lll iv,C2697847;C1261077
caucasian,C0007457;C0043157
treatment of the index ml,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
non caucasian,C0007457;C0043157
thrombolytic therapy,C0040044
$nmbr$ years baseline ldl c,C0439234;C0168634;C1442488
cabg surgery,C0038894;C0038895;C0543467;C1274039
$nmbr$ mg dl chd status,C0439269;C0449438
cardiac catheterization,C0018795
chd,C0280604;C3542407
current prescribed medications,C3166216;C3202967
no chd,C0280604;C3542407
anticoagulants,C0003280
p $nmbr$ $nmbr$ for between treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean standard error simva simvastatin eze ezetimibe chd coronary heart disease,C0369773;C2603361;C1705241;C1705242;C1511726;C3245479;C3714741;C0023189;C0010068
p blockers,C0369773;C2603361
select lipids and lipoproteins,C1707391;C0023779;C0023820
lipid lowering drugs,C0086440
eze simva gender,C0079399;C1522384
psychosocial risk factors,C0033963
female simva,C0043210;C0086287;C1705497;C1705498
depressed only,C0344315;C0549249
female eze simva,C0043210;C0086287;C1705497;C1705498
low perceived social support only,C0037438;C0748877;C1540833;C3669642
male simva,C0086582;C1706180;C1706428;C1706429
depressed and low perceived social support,C0344315;C0549249;C0037438;C0748877;C1540833;C3669642
male eze simva,C0086582;C1706180;C1706428;C1706429
abbreviations ace angiotensin converting enzyme cabg coronary artery bypass graft chf congestive heart failure ml myocardial infarction ptca percutaneous transluminal coronary angioplasty data are presented as no unless otherwise indicated denominator may vary due to missing values tbased on charlson comorbidity index range in sample $nmbr$ $nmbr$ recalculated as weight in kilograms divided by the square of height in meters,C1511726;C3245479;C3714741;C0449450;C1444656;C2825218;C0678226;C0042295;C4546361;C2348147;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074
caucasian simva,C0007457;C0043157
patients treated with losartan n $nmbr$,C0030705;C0332293;C0126174
caucasian eze simva,C0007457;C0043157
patients treated with atenoloi n $nmbr$,C0030705;C0332293
non caucasian simva,C0007457;C0043157
aii patients n $nmbr$,C1424250;C0030705;C2698414
non caucasian eze simva,C0007457;C0043157
age x,C0001779
$nmbr$ years simva,C0439234
ethnicity n,C0015031;C0243103
$nmbr$ years eze simva,C0439234
bmi kg m^,C0022718;C0439209;C4054209
$nmbr$ years eze simva baseline ldl c,C0439234;C0168634;C1442488
cornell voltage x duration product mm x ms,C2349943;C3539704;C3713294
$nmbr$ mg dl simva,C0439269
sokolow lyon voltage mm,C4330985;C4554674
$nmbr$ mg dl eze simva,C0439269
current smokers n,C3173209;C3241966
chd simva,C0280604;C3542407
atrial fibrillation n,C0004238;C0344434;C1963067
chd eze simva,C0280604;C3542407
isolated systolic hypertension n,C0745133
no chd simva,C0280604;C3542407
no chd eze simva,C0280604;C3542407
patients with clinically evident vascular disease,C0683521
patients without clinically evident vascular disease,C0683521
p $nmbr$ $nmbr$ for eze simva pooled across doses vs simva pooled across doses for the entire cohort data are presented as least squares mean standard error median se for tg for the entire cohort and also for each selected subgroup simva simvastatin eze ezetimibe tc total cholesterol tg triglycerides hdl c high density lipoprotein cholesterol non hdl c non high density lipoprotein cholesterol apo apolipoprotein,C0369773;C2603361;C1709595;C2349200;C4522255;C1511726;C3245479;C3714741;C0449450;C0023189;C0337445;C0009247;C0599755;C1079232;C0003591
treated with losartan n $nmbr$,C0332293;C0126174
clinical ae n,C0205210;C3887670
treated with atenolol n $nmbr$,C0332293;C0004147
laboratory ae n,C0022877;C3244292;C4283904
adjusted hazard ratio $nmbr$ cl,C2985465;C0596019
any clinical ae,C0205210;C3887670
unadjusted hazard ratio $nmbr$ cl,C2985465;C0596019
drug related ae,C0013227;C3887670;C1254351
unadjusted hazard ratio $nmbr$ ci,C0008107;C3259781
serious ae,C0205404;C3887670
patients,C0030705
discontinuations due to ae,C0457454;C0678226
ratet,
myopathyt,
primary composite end points,C0205199;C2349179;C1547335
deaths,C0011065;C1306577
$nmbr$ ^ $nmbr$,
alt and or ast $nmbr$ times uln consecutive,C1266129;C4553172;C0040223;C1519815;C1632851;C1707491
cardiovascular mortality,C0026565;C0026566
cpk $nmbr$ times uln,C0040223;C1519815;C1632851
\ $nmbr$ $nmbr$ $nmbr$,
simva $nmbr$,
total mortality,C0026565;C0026566
eze simva $nmbr$,
hospitalization,C0019993
female simva $nmbr$,C0043210;C0086287;C1705497;C1705498
angina pectoris,C0002962
$nmbr$ [ $nmbr$,
heart failure,C0018801;C0018802;C4554158
female eze simva $nmbr$,C0043210;C0086287;C1705497;C1705498
new onset diabetes,C0011847;C0011849
male simva $nmbr$,C0086582;C1706180;C1706428;C1706429
analysis,C0002778;C0936012;C1524024
$nmbr$ c $nmbr$,
doubling of baseline serum creatinine or esrd rr ci,C0205173;C1705764;C0008107;C3259781
male eze simva $nmbr$,C0086582;C1706180;C1706428;C1706429
esrd only rr ci,C0022661;C0035078;C2316810;C0008107;C3259781
caucasian simva $nmbr$,C0007457;C0043157
unadjusted,C1439367
caucasian eze simva $nmbr$,C0007457;C0043157
adjusted for all baseline variables $nmbr$,C0456081;C0168634;C1442488
non caucasian simva $nmbr$,C0007457;C0043157
adjusted for all baseline variables and interaction between acei and baseline upb,C0456081;C0168634;C1442488;C1704675
non caucasian eze simva $nmbr$,C0007457;C0043157
adjusted for all baseline variables interaction between acei and baseline up and declines in sbp and up,C0456081;C0168634;C1442488;C0085805
$nmbr$ years simva $nmbr$,C0439234
$nmbr$ years eze simva $nmbr$,C0439234
relative risk of outcome in acei group iw control group bbaseline variables for models included logarithm of age reciprocal of serum creatinine sbp up excretion treatment assignment and terms for studies $nmbr$ $nmbr$ $nmbr$ and $nmbr$ see footnotes of table $nmbr$ other baseline variables considered for analysis p $nmbr$ $nmbr$ in univariate analysis included dp mean arterial pressure type of antihypertensive regimen in the control group planned duration of follow up whether or not the investigators were blinded whether or not dietary advice was given and the year of publication,C0242492;C1274040;C0439828;C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0233324;C1515273;C1705313;C2826302;C2825232;C0039224;C1706074;C0168634;C1442488;C0750591;C0002778;C0936012;C1524024;C0332307;C1547052;C0009932;C4288391;C1518422;C0035173;C0150108;C0204932;C0439234;C0439508
$nmbr$ mg dl simva n $nmbr$ ],C0439269
$nmbr$ prolonged antithrombotic pretreatment n $nmbr$,C0439590;C1550147;C2709094;C3539075;C3539076
$nmbr$ $nmbr$ ],
$nmbr$ early intervention n $nmbr$,C0242687;C1964029
$nmbr$ mg dl simva $nmbr$ $nmbr$ ],C0439269
age median iqr y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ mg dl eze simva $nmbr$ $nmbr$,C0439269
active smoker,C0205177;C0337664;C3853793;C3888249
chd simva $nmbr$ $nmbr$ ],C0280604;C3542407
serum cholesterol median iqr mg dl,C0587184;C0439269
chd eze simva n $nmbr$ ],C0280604;C3542407
arterial hypertension,C0020538
no chd simva n $nmbr$ ],C0280604;C3542407
diabetes mellitus,C0011849
no chd eze simva $nmbr$ $nmbr$,C0280604;C3542407
insulin dependent,C0021641;C0429964;C0429986;C0851827;C1701901;C3244310;C4321395;C1533581;C1579433;C3714501
previous balloon angioplasty,C0002996;C0002997
determined by investigator to be possibly probably or definitely related to study drug tmyopathy defined as cpk $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^consecutive defined as two or more measurements at least one week apart or one measurement $nmbr$ days after the last dose of study drug presumed consecutive two patients had incomplete data to assess chd status simva simvastatin eze ezetimibe ae adverse event alt alanine aminotransferase ast aspartate aminotransferase cpk creatine phosphokinase uln upper limit of normal,C0521095;C0035173;C2362652;C0750492;C0439849;C0445223;C1704788;C3539106;C0521989;C0242485;C1442452;C3844320;C0678766;C3242203;C1516048;C1282910;C0439801;C1549649;C2349209;C0205307;C0231683;C0439166;C2347086;C4553972
entry criteria,C1705654;C0243161
aspirin dipyridamole n $nmbr$,C0732279
st segment depression,C0520887
aspirin alone n $nmbr$,C0004057;C0205171;C0439044;C0679994
cardiac troponin t level $nmbr$ $nmbr$ pg l,C3538889;C0439278
randomisation scheme,C0034656;C1519193
three arm,C0205449;C0446516;C3715044;C4553528
cardiac troponin t level median iqr pg l,C3538889;C0439278
two arm,C0446516;C3715044;C4553528
no of coronary vessels with $nmbr$ diameter stenosis,C0010075;C0678234;C1261287;C2632116
none,
transient monocular blindness,C0149793
transient ischaemic attack,C0007787;C0917805
left ventricular ejection fraction median iqr,C0428772;C0488728
minor ischaemic stroke,C0026193;C0948008;C0205165
calcium antagonist strategy n $nmbr$ $nmbr$,C0006684;C0679199
time from longest event to randomisation,C0040223;C3541383;C0034656
non calcium antagonist strategy n $nmbr$ $nmbr$,C0006684;C0679199
$nmbr$ week to $nmbr$ month,C0332174;C0439230
demographic $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0011298
$nmbr$ $nmbr$ months,C0439231
race ethnicity white,C0007457;C0043157;C0220938
rankin grade,C0441800;C0919553;C3244287
other multiracial,C1881928
$nmbr$ no symptoms,C0683368;C1457887
bmi mean sd kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ minor symptoms no limitations,C0683368;C1457887;C0449295
condition $nmbr$ $nmbr$ $nmbr$,C0012634;C0348080;C1705253;C3864998
$nmbr$ some restrictions no help needed,C0443288;C1269765;C1552861;C0027552;C0686904
abnormal angiogram,C0002978;C1548816;C3891555;C4255126
$nmbr$ help needed still independent,C0085862;C1290940;C1299583
prior ml or abnormal angiogram,C0439526;C1705224;C3887665;C0002978;C1548816;C3891555;C4255126
additional investigations,C2359834
concordant stress test abnormalities,C0000768;C0000769
ct or mr scan of the brain,C0007673;C3540513;C3813556;C3888140;C0596217;C0881827
cabg $nmbr$ month ago,C0332177;C0439231
any infarct,C0021308
pci $nmbr$ month ago,C0332177;C0439231
any relevant infarct,C2347946;C0021308
cabg or pci,C0010055;C4049621
ultrasound carotid arteries,C0948945
left ventricular hypertrophy,C0149721;C3484363
stenosis $nmbr$,C0678234;C1261287;C2632116
unstable angina $nmbr$ mo ago,C0026544;C0332177
intermittent claudication,C0021775
arrhythmia,C0003811
vascular intervention,C0184661;C0886296;C1273869
heart failure class l lll,C0018801;C1261077;C0018802;C4554158
hyperlipidaemia,C0020473;C0428465;C4555212
smoking past,C0037369;C0453996;C1881674
systolic mean sd,C0039155;C2699239
within last $nmbr$ d,
diastolic mean sd,C0012000;C2699239
diabetesf,
type of vessel involved,C1282017;C1314939
hypercholesterolemiat,
large vessel,C0225990
renal impairmentt,C0022646
small vessel,C0225988
cancer,C0006826;C0998265;C1306459
unspecified,C0205370;C1549663;C2983689;C4048188
aspirin or other antiplatelet agent,C0004057;C0085826
antithrombotic drug use at time of event,C0242510
medication $nmbr$ $nmbr$ $nmbr$,C0013227;C3244316;C4284232
oral anticoagulants,C0354604
other nsaids,C0003211
dose of aspirin,C4696290
antidiabetic medication,C0935929
any lipid lowering agent,C0086440
figure $nmbr$ subgroup analyses for primary outcome event,C2986480;C1624730
nitrates,C0028125
estimated gfr at baseline ml min $nmbr$,C0017654;C1424601
potassium supplement,C0304475
m $nmbr$,
hormone replacement,C0282402
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
abbreviations bmi body mass index cabg coronary artery bypass graft nsaids nonsteroidal anti inflammatory drugs pci percutaneous coronary interventions values expressed as number percentage unless otherwise indicated percentages may not equal $nmbr$ due to rounding fhistory of or currently taking antidiabetic or lipid lowering medications ^history of or currently have elevated serum creatinine level but less than $nmbr$ mg dl_,C1881192;C0237753;C0439165;C1549488;C1561533;C0449788;C0242503;C0332490;C0521116;C0935929;C0023779;C0441994;C2003888;C1553893;C0600061;C0700225;C0439269
female sex n of patients,C0086287
baseline subgroup,C1079230;C1515021
race white n of patients,C0007457;C0043157
calcium antagonist strategy cas events n,C0006684;C0441471;C3541888
medical history n of patients,C0262926
documented mi,C1301725;C3810814;C1609436
non calcium antagonist strategy ncas events n,C0006684;C0441471;C3541888
current cigarette n,C0521116;C0677453;C1704760;C3890423;C1705970
rr $nmbr$ cl,C4554402;C0596019
race ethnicity,C0015031;C0243103
mean blood pressure mm hg,C0428886;C0439475;C0488053
us resident,C4698406
laboratory determinations,C0022877;C0680730;C3244292;C4283904
candesartan group n $nmbr$,C0717550;C0441848
mean serum creatinine mg dl,C0201976;C0439269;C0600061
control group n $nmbr$,C0441848
lv ejection fraction $nmbr$ and,C0489482;C2700378
mean age y,C0444504;C0001779;C2347634;C2348143
n of patients,C0369718;C0441922
ejection fraction,C0489482;C2700378
lv ejection fraction n $nmbr$,C0489482;C2700378
history of,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
medications n of patients,C0013227;C0030705;C0802604;C2598133;C4284232
smoking status,C1519386
aspirin antiplatelet medication,C0085826
exsmoker,C0337671;C4555205
lipid lowering drug,C0086440
arterial hypertension no,C0020538
diuretic any,C0012798
type $nmbr$ diabetes no,C1320657
hrt use,C0042153;C0457083;C1947944
hypercholesterolemia no,C0020443;C1522133
egfr category,C0683312;C3889287
prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
trandolapril n $nmbr$,C0076891
prior aortocoronary bypass surgery no,C0455610;C0010055
multivariable adjusted hr $nmbr$ ci,C0008107;C3259781
angina class iii or iv no,C0264677;C0022326;C4265176
events n,C0441471;C3541888
multivessel disease no,C0012634
hr $nmbr$ ci,C0008107;C3259781
duration of clopidogrel pretreatment hr median,C0449238;C2926735
trandolapril,C0076891
$nmbr$ th $nmbr$ th percentiles,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
egfr $nmbr$,C1739039;C3811844;C3812682
drug therapy at admission no aspirin,C0013216;C0013217;C0004057
egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$,C1739039;C3811844;C3812682
calcium channel antagonists,C0006684;C2757014
reference,C1514811;C1706462
statins,C0360714
cardiovascular mortality or mi,C0026565;C0026566;C3810814
group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
cardiovascular mortality mi or revascularization,C0007226;C3810814;C3887460;C0581603
abciximab no total,C0288672;C0439175;C0439810
hope n $nmbr$,C0392347
placebo no total,C0032042;C1696465;C1706408;C0439175;C0439810
hope patients with coronary artery disease n $nmbr$,C0741926
all patients,C0030705
europa n $nmbr$ l $nmbr$,C0242751
angina class iii or iv prior myocardial infarction,C0264677;C0027051;C0428953;C2926063;C3810814;C4552959
peace n $nmbr$,C0680443
intervention in complex lesions,C1292781;C0221198
previous stroke ortransient ischaemic attack,C0038454;C0745413;C4554100
type of lipid lowering regimen,C0332307;C1547052;C0441994;C2003888;C0040808;C2945654
peripheral artery disease,C1704436;C4025272
i moderate $nmbr$ mg of pravastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum cholesterol mg l,C0587184;C0439268
i intensive $nmbr$ mg of atorvastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diastolic blood pressure mm hg medications,C0849164
mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0444504;C2699239;C2347634;C2348143
antiplatelet agents,C0085826
cholesterol mg dl total,C0201950;C0543421
lipid lowering agents,C0086440
low density lipoprotein,C0023823
pci percutaneous coronary intervention cabg coronary artery bypass graft for hope $nmbr$ mg l for europa $nmbr$ mg l or on a lipid lowering treatment for peace data are mean sd data are mean sd unless otherwise indicated,C0010055;C0242751;C0439268;C0023767;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C1444656
high density lipoprotein,C0023821
$nmbr$ year rates in placebo groups,C0871208;C1521828
triglycerides mg dl,C0041004;C0439269
interactior $nmbr$ p,
apolipoprotein b $nmbr$ mg dl,C0003593;C0439269
with antiplatelets,
c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
without antiplatelets,
men n $nmbr$,C0025266
with lipid lowering agents,C0086440
no $nmbr$ $nmbr$,
without lipid lowering agents,C0086440
white n $nmbr$,C0007457;C0043157;C0220938
with p blockers,C0369773;C2603361
smoking status current smoker n $nmbr$,C1519386;C3173209;C3241966
without p blockers,C0369773;C2603361
past or nonsmoker n $nmbr$,C0337672;C0425293;C4554605
all of the above,
history of hypertension n $nmbr$,C0455527
one of the above,C0205447
prior statin use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
two of the above,C0205448
history of diabetes mellitus n $nmbr$,C0455488
none of the above,
metabolic syndrome n $nmbr$,C0524620
with revascularisation,C0581603
subgroup,C1079230;C1515021
without revascularsation,
test for interaction p value,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
revascularisation antiplatelets lipid lowering agents p blockers,C0086440
gender,C0079399;C1522384
revascularisation but no antiplatelets lipid lowering agents or p blockers,C0581603;C0086440;C0369773;C2603361
country,C0454664;C1511538
no pretreatment,C1550147;C2709094;C3539075;C3539076
ethnic group,C0015031;C1879937
ufh only,
disease history,C0683519
enoxaparin only,C0206460
mi,C3810814
unadjusted p value,C1439367;C1709380
ihd,C0151744
region,C0017446;C0205147
angina,C0002962
australia new zealand,C0027978;C0324547
microalbuminuria,C0730345
latin america,C0023122
ish,
ecg at time of qualifying symptoms,C1623258;C0040223;C3541383;C1514624;C0683368;C1457887
alcohol intake,C0001948
st segment elevation,C0520886
exercise status,C0015259;C0449438;C1522704
inclusion criteria,C1512693
bmi,C0578022
age is $nmbr$ vrs significant ecg changes and no positive bi omark ers,C0001779;C0237881;C0855329;C0750502;C1546944;C1704489;C2931783
systolic bp,C0871470
age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes,C0001779;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269;C4050619;C0855329
diastolic bp,C0428883
si gni fi canr ecg changes positive biomarkers and age,C0855329;C0005516;C0001779
ecg lvh cornell,C0232306
age is $nmbr$ vrs significant ecg changes and positive biomarkers,C0001779;C0237881;C0855329;C0750502;C1546944;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269
ecg lvh sokolow lyon,C0232306
time to randomization h,C0040223;C3541383
adjusted hazard ratio $nmbr$ ci,C0008107;C3259781
hvpertension,
rate,C0871208;C1521828
hvpercholesterolemia,
worldwide black patients,C0005680;C0030705;C0027567;C0085756;C0439541
familv historv of cad,C1504769;C2239547;C3813548;C4284121
composite,C0205199;C1547335
medical historv,C0199168;C0205476
mi fatal nonfatal,C1302234;C1705232
chf,C0018802
stroke fatal nonfatal,C0038454;C1302234;C1705232;C4554100
transient ischemic attack,C0007787;C0917805
worldwide non black patients,C1829939;C0005680;C0027567;C0085756;C0439541
diet group n $nmbr$,C0012155;C0441848;C0012159;C1519433;C2983588;C3668949
u s black patients,C0041703;C0030705
diet plus pravastatin group n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
u s non black patients,C0041703;C1829939
current past smoker,C3173209;C3241966
monteiukast n $nmbr$,
lipid concentrations,C0023779;C0086045
sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
$nmbr$ ^ $nmbr$ $nmbr$,
race no,C0034510;C1706779;C3853635
triglyceride mmol l t,C0041004;C1532563
patients receiving immunotherapy no,C0030705;C1514756;C0005525;C0021083
lipoprotein a mmol l,C0065058;C1532563;C0125953;C1096202;C1439335
allergic rhinitis duration mean sd y,C1334103;C2607914;C4552864
medications,C0013227;C0802604;C2598133;C4284232
baseline daytime nasal symptoms score mean sd,C0231918;C2699239
antihypertensive drugs,C0003364
pollen exposure,C0274281;C0332157
ace inhibitors arb,C0003015;C3888198
patients included in analysis,C0030705;C0332257;C0002778;C0936012;C1524024
$nmbr$ blockers,
daytime nasal symptoms score change from baseline mean se,C0436315
reported by physicians tdata are median iqr all data are mean sd or number unless otherwise indicated,C1709908;C0031831;C0549183;C0876920;C2347635;C2348144;C2939193;C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0237753;C0449788;C1444656
ls mean difference $nmbr$ cl,C0023668;C0596019
ace angiotensin converting enzyme arb angiotensin receptor blockers,C0521942;C0815017
monteiukast,
p value for interaction,C1709380;C1704675
monteiukast vs placebo,C0032042;C1696465;C1706408
o $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0483204
pollen $nmbr$,C0032385;C0795585;C1320238
ldl cholesterol,C0023824;C0202117
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ t,C2603360
hdlcholesterol,
first recorded event no and of patients,C0441471;C4019010;C0030705
with t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
hemispheric tia n $nmbr$,C0205139;C0007787;C0917805;C1054154
without t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
hemispheric stroke n $nmbr$,C0205139;C0038454;C4554100
rosuva $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959;C0002962
duration of hypercholesterolemia yr,C0449238;C2926735
smoking in the past year,C0037369;C0453996;C1881674
current smoker n,C3173209;C3241966
$nmbr$ degree of ica stenosis,C0201519;C4034225
nob systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
irregular or ulcerated ica p laque [,C0205271;C0041582;C0201519;C3887532
history of hypertension n,C0455527
infarct on brain imaging,C0021308;C0203860
history of chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
intracranial disease of major artery,C0852949;C0752138
history of pvd n,C4534349
iduration of symptoms $nmbr$ min,C0683368;C0702093;C1524029;C3813700;C1457887
statin potency stratum n,C0360714
factor,C1521761;C2827422
low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
no of strokes no of patients in category and,C0038454;C0030705;C0683312;C3889287
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
hazard ratio and $nmbr$ ci,C2985465;C0008107;C3259781
concomitant medications,C0013227;C0802604;C2598133;C4284232
factor present,C0150312;C0449450
drugs used in diabetes n,C0013227;C3687832;C1273517;C0011847;C0011849
factor absent,C1521761;C2827422;C0332197;C4285062
antithrombotic agents n,C1704311
crude,
adjusted,C0456081
antihypertensive agents n,C0003364
ica stenosis $nmbr$ $nmbr$ f,C0201519;C0016327
cardiac therapy n d,C3654025
irregular or ulcerated ica plaquef,C0205271;C0041582;C0201519;C3887532
parameter statistics,C0038215;C0600673
infarct on brain imaging^,C0021308;C0203860
rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ez simva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
intracranial disease of major artery disease t,C0752138
all rosuva,
duration of symptoms $nmbr$ min,C0436359;C0702093;C1524029;C3813700
all ez simva,C0206578
alcohol consumption,C0001948
baseline mean mg dl],C0168634;C0439269;C1442488
none n $nmbr$,C0369718;C0441922
mmol l],C1532563
$nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
c $nmbr$ $nmbr$ ],
$nmbr$ $nmbr$ week n $nmbr$ $nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
se],C0036919
$nmbr$ week n $nmbr$,C0332174;C0439230
treatment difference,C1705241;C1705242
age years s d,C1510829
$nmbr$ y,
x $nmbr$ n,
$nmbr$ j $nmbr$,
female n,C0043210;C0086287;C1705497;C1705498
se]tf hdl c,C0036919;C4048299;C3715113;C4048587
white n,C0007457;C0043157;C0220938
baseline mean mg dl,C0168634;C0439269;C1442488
black n,C0005680;C0027567;C0085756;C0439541
cl $nmbr$ ],C0596019
hispanic n,C0086409
se]tf total c,C0036919;C0439175;C0439810
asian n,C0078988
se]t,C0036919;C2603360
other race n,C0034510;C1706779;C3853635
$nmbr$ q,
cigarette smoking n,C0239059;C0700219
se]tf,C0036919;C4048299;C4048587
previous smokers,C0337671
baseline median mg dl,C0168634;C0439269;C1442488
$nmbr$ $nmbr$ day,C0332173;C0439228;C0439505
$nmbr$ ell ll,C1427925;C3273466
$nmbr$ day,C0332173;C0439228;C0439505
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
exercise n,C0015259;C1522704
$nmbr$ ell ll non hdl c,C1427925;C3273466;C1518422;C3715113
p $nmbr$ min twice week,C0332174;C0439230
ldl c hdl c,C3715113
$nmbr$ min twice week,C0332174;C0439230
baseline mean,C0444504;C2347634;C2348143
enoxaparin n $nmbr$,C0206460
se t,C0036919
unfractionated heparin n $nmbr$,C0019134;C2825026
[ $nmbr$ $nmbr$ ],
female sex no total,C0086287;C0439175;C0439810
total c hdl c,C0439175;C3715113;C0439810
region no total,C0017446;C0205147;C0439175;C0439810
cse],
austral ia new zealand,C0027978;C0324547
$nmbr$ g,C0439267
europe,C0015176
cg ld,C0043444;C0694649;C1567075;C3540479
north america,C0028405
hscrp,
south america,C0037713
baseline median [mg l],C0549183;C0876920;C2347635;C2348144;C2939193;C0439268
race no total,C0034510;C1706779;C3853635;C0439175;C0439810
$nmbr$ ci] $nmbr$,C0008107;C3259781
american indian,C0002460
$nmbr$ ci]h,C0008107;C3259781;C0033727;C0369286;C0441932;C0564385;C4528284
pacific islander,C0242191
parameter,C0549193;C1704769;C2350001
clinical variables median iqr,C0205210;C0439828
diabetes mellitus n $nmbr$ $nmbr$,C0011849
medical history and risk factors no total,C0262926;C1704706;C0035648;C1553898;C0439175;C0439810
neither n $nmbr$ $nmbr$,C0369718;C0441922
killip class $nmbr$,C1881332
pbo statin n $nmbr$,C0031962;C0360714
prior angina,C0332152;C0002962;C2826257
eze statin n $nmbr$,C0360714
prior infarction,C0332152;C0021308;C2826257
age years mean _ sd sex n,C1510829;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
prior oabg surgery,C0455610
metabolic syndrome characteristics n,C0524620;C1521970
prior pci,C0332152;C4049621;C2826257
waist circumference women $nmbr$ in $nmbr$ cm men $nmbr$ in $nmbr$ cm tc $nmbr$ c $nmbr$ mg dl,C0455829;C0043210;C0025266;C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
g $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439267
_ $nmbr$ $nmbr$ mmol l hdl c women $nmbr$ mg dl $nmbr$ $nmbr$ mmol l men $nmbr$ mg dl,C3539687
prior congestive heart failure,C0332152;C0018802;C2826257
hypertension bp $nmbr$ $nmbr$ mmhg or using antihypertensive medication,C0020538;C0439475;C1963138;C1524063;C0003364
history of peripheral vascular disease,C1881056
fc $nmbr$ mg dl _ $nmbr$ $nmbr$ mmol l or history of diabetes,C0439268;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
previous,C0205156;C1552607
key fc fasting glucose bp this category did not include ar have $nmbr$ of the indicated charac,C0037623;C1415692;C1708288;C4318478;C0683312;C3889287;C1518422;C0332257;C1552866;C2700399;C1436327;C2986463;C3884535;C4521369;C1444656
family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
time from symptom onset to enrollment,C0449244;C1516879;C1696073;C3888021
blood pressure pbo y patients with diabe teristics ncep atp i,C0005823;C0030705;C1271104;C1272641
median iqr h,C0033727;C0369286;C0441932;C0564385;C4528284
placebo eze tes fc j $nmbr$ rr $nmbr$ definition,C1550452;C1704788;C3539107;C3888054
time from hospital admission to enrollment,C3854258;C3854259;C1516879;C1696073;C3888021
ezetimibe tc triglycerides hdl c lg dl l $nmbr$ $nmbr$ mmol l] to qualify as having,C0039411;C0023128;C0694651;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
placebo $nmbr$ mg d of simvastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0073187;C0074554;C0332173;C4484261
high density lipoprotein cholesterol metabolic syndrome patients were to,C0023822;C0030705
simvastatin $nmbr$ $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
lipid measure,C0079809;C0242485
age median $nmbr$ th $nmbr$ th percentiles y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
metabolic syndrome,C0524620
men,C0025266
neither pbo statin eze statin,C0031962;C0360714
prior cardiovascular history,C0332152;C1880008;C2826257
pbo statin $nmbr$,C0031962;C0360714
percutaneous coronary intervention,C1532338
ze statin,C0360714
prior to index event,C0441471;C4019010
pbo statin,C0031962;C0360714
for treatment of index event,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
eze statin,C0360714
peripheral arterial disease,C0085096;C1704436
ldl c mmol l mean,C0444504;C2347634;C2348143
risk factors,C0035648;C1553898
n $nmbr$ n $nmbr$,C0369718;C0441922
current smoking,C0037369;C0453996;C1881674
baseline,C0168634;C1442488
premature cad among family members,C1504769;C2239547;C3813548;C4284121
at six weeks,C0205452;C0439230
qualifying event,C1514624;C0441471;C4019010
change,C0392747;C0443172;C1705241;C4319952
tg mmol l median,C0549183;C0876920;C2347635;C2348144;C2939193
st segment elevation mi,C0520886;C3810814
hdl c mmol l mean,C0444504;C2347634;C2348143
non st segment elevation acs,C0520886;C0742343;C4318612
non hdl c mmol l mean,C0444504;C2347634;C2348143
participation in phase a,C0679823;C0205390;C1710475
total c mmol l mean,C0444504;C2347634;C2348143
concomitant therapies at hospital discharge,C1707479;C0586003
apo b apo a l ratio mean,C0444504;C2347634;C2348143
primary end point kaplan meier rate,C0871208;C1521828
hs crp mg l median,C0549183;C0876920;C2347635;C2348144;C2939193
simvastatin $nmbr$ $nmbr$ mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ mg d of simvastatin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0073187;C0074554;C0332173;C4484261
key tc triglyceride hs crp ldl c low density lipoprotein fc fasting glucose ncep atp this category did not include ar to have _ $nmbr$ of the indicated char least square means except tc an note all treatment by subgroup,C2744579;C4552600;C0683312;C3889287;C1518422;C0332257;C1552866;C2700399;C1436327;C2986463;C3884535;C4521369;C0023189;C1704970;C1316572;C1317574;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
risk reduction,C1137094
ldl cholesterol mg dl,C0023824;C0439269;C0202117
c reactive protein high sensitivity assay mitt modified intent to treat pbo cholesterol cl confidence intervals hdl c high density lipoprotein cholest national cholesterol education program adult treatment panel y patients with diabetes fc _ $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] to qualify as having acteristics described in methods ncep atp iii definition baseline values are rr d hs crr for which medians are presented p $nmbr$ $nmbr$,C0162425;C1283828;C1550453;C2699193;C3165426;C0439268;C1552738;C0456580;C0549183;C0449450
hdl cholesterol mg dl,C0023822;C0439269;C0392885
placebo eze ezetimibe erol apo apolipoprotein metabolic syndrome patients were eans and percentage changes are,C0524620;C0030705;C0392747;C0443172
index diagnosis,C0011900;C1704338;C1704656
age $nmbr$ y n $nmbr$,C0001779
pci for index event,C4049621;C0441471;C4019010
hypercholesterolemia $nmbr$ mg dl,C0020443;C0439269;C1522133
strategy,C0679199
prior coronary artery bypass surgery,C0010055
verapamil sr no $nmbr$,C1527129
interval from clopidogrel loading h,C1272706;C1552654;C1552713
atenolol no $nmbr$,C0004147
elevated troponin t $nmbr$ $nmbr$ xg l,C0077404;C1420827
mean age sd years,C0444504;C1510829;C2347634;C2348143
therapy at discharge,C0039798;C0087111;C1363945
age $nmbr$ years,C1510829
figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization,C0021149;C0220856;C0449618;C0001779;C0039798;C3810814;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0027051;C0428953;C2926063;C4552959;C0581603
mean bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
age dependent effect of abcixima,C1280500;C1518681;C2348382
previous ml or abnormal angiogram,C0439526;C1705224;C3887665;C0002978;C1548816;C3891555;C4255126
death or myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
cabg or angioplasty,C0010055;C0162577;C1548817
target vessel revascularization,C0449618;C0581603
stroke tia,C0007787;C0917805;C1054154
mace,C0349381;C0949745;C1445339
lvh,C0149721
major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
unstable angina,C0002965
hemorrhagic stroke,C0553692
pvd,C0085096;C4521226
minor bleeding,C0026193;C0019080;C0205165
renal impairmentf,C0022646
blood transfusion,C0005841;C0281867
cancert,
profound thrombocytopenia $nmbr$ x $nmbr$ l,C0040034;C0392386
heart rate sd bpm blood pressure mm hg,C0428876;C0439475
moderate thrombocytopenia $nmbr$ x $nmbr$ l,C0205081;C0040034;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
sbp sd,C0085805;C2699239
mild thrombocytopenia $nmbr$ x $nmbr$ l,C1856453
dbp sd,C0536221;C2699239;C3813197;C4281799
aged ^ $nmbr$ years,C0001779;C0439234;C0001792;C1999167
antihypertensive medication,C0003364
aged,C0001779;C0001792;C1999167
mean no agents sd other medications,C0444504;C2347634;C2348143;C0450442;C2699239;C1254351;C1521826;C0013227;C0802604;C2598133;C4284232
p value aged $nmbr$ vs,C1709380;C0001779;C0001792;C1999167
aspirin or other antiplatelet agents,C0004057;C0085826
z\tonastaiin,
antidiabetic medications,C0935929
all,
insulin,C0021641;C1533581;C1579433;C3714501
aiorvasiaiin,
oral hypoglycemics hormone replacement,C0359086;C0282402
while ethnic origin,C0015031
percentage of females,C0439165;C1549488;C1561533
l $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
systolic blood pressure mmhg,C0488055;C0439475;C0871470;C1306620
hl $nmbr$ $nmbr$,C1453952;C4085347
percentage unless otherwise noted cabg indicates coronary artery bypass graft lvh left ventricular hypertrophy nsaids nonsteroidal antiinflammatory drugs pvd peripheral vascular disease tia transient ischemic attack history of hypercholesterolemia or reporting use of lipid lowering medications at baseline thistory of or currently have elevated serum creatinine level,C0439165;C1549488;C1561533;C4288581;C0010055;C1553893;C0020443;C1522133;C1524063;C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232;C0521116;C0600061;C0700225
diastolic blood pressure mmhg,C0428883;C0439475;C1305849
verapamil sr n $nmbr$,C1527129
macroalbuminuria,
$nmbr$ cl,C0596019
retinopathy,C0035309;C1962966
primary outcome,C0205225;C1274040;C0439612;C0439631
duration diabetes years,C0011847;C0439234;C0011849
death all cause,C0011065;C1306577;C4082313;C4552775;C0015127;C1524003
hi ah,C0018619;C1836672;C0239849;C1412082;C1412316;C1431594;C4552857
nonfatal ml,C0439526;C1705224;C3887665
ldl cholesicrol minol l,
nonfatal stroke,C0038454;C4554100
kdl cholesterol mmol,C0008377;C0439190
cardiovascular death,C0011065;C1306577;C4082313;C4552775
i idl cholesterol mg dl,C0619865;C0439269
cardiovascular hospitalization,C0007226;C0019993;C3887460
total cholesterol mmo $nmbr$ $nmbr$,C0201950;C0543421
planned conservative therapy subgroup,C1079230;C1515021
toial cholcsierol mg dl,C0439269
overall a phase population,C0282416;C1561607;C0032659;C1257890
trigl yeerides m mol l,C0347982
male gender,C0086582;C1706180
apolipoproiein a $nmbr$ tng $nmbr$,
us site of enrollment,C0815353;C2945843;C3889164
apolipoproiein b mij $nmbr$,
angina past $nmbr$ weeks,C0002962;C0439230
$nmbr$ j $nmbr$ $nmbr$,
coronary revascularisation,C0877341
diabetes treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bypass surgery,C1536078
bi $nmbr$ $nmbr$,
percutaneous intervention,C0522523;C0184661;C0886296;C1273869
$nmbr$ h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
congestive heart failure chf in past $nmbr$ weeks,C0018802;C0439230
oral hypoglycemic drugs only,C0359086
left ventricular dysfunction,C0242698
$nmbr$ j $nmbr$ $nmbr$ $nmbr$,
prior medications,C0013227;C0802604;C2598133;C4284232
insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501;C0359086
angiotensin converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
blood pressure lowering treatment,C0596197
b blocker,
a blocker,
nitrate,C0028125;C0699857;C3848573
i blocker,C0021966;C0221138
diuretic,C0012798
calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
long term aspirin,C0443252;C0004057
$nmbr$ h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
unfractionated heparin before randomisation,C0019134;C2825026
ace inhibitor or angiotensin ii receptor,C0003015;C4541021;C0003011
low molecular weight lmw heparin before randomisation,C0019139;C3536766
aniagonisi,
diurciic,
neither uh or lmw heparin,C0019134;C0770546
atv n,C0210243;C0674679;C1145759;C1334862
investigator determined myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
pbo n,C0031962
st change $nmbr$ mm,C4330985;C4554674
rrr,
enoxaparin,C0206460
total population,C3258257
ufh,
k m n,C0369637;C0441923
acute coronary event,C0205178;C0741923
age ^ $nmbr$,C0001779
k m,C0369637;C0441923
coronary revascularization,C0877341
overall effect,C1280500;C1518681;C2348382
males,C0086582
fatal and nonfatal stroke,C1302234;C1705232;C0038454;C4554100
females,C0086287
infliximab $nmbr$ mg kg,C0666743;C0439272
$nmbr$ years,C0439234
patients randomized,C0030705;C0034656;C3815594
$nmbr$ yea s,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
non diabetics,C1518422;C0241863
psoriasis duration yrs,C0033860;C0449238;C2926735
diabetics,C0241863
psoriatic arthritis,C0003872
no prior aspirin,C0332152;C0004057;C2826257
bsa,
prior aspirin,C0332152;C0004057;C2826257
pasi score $nmbr$ $nmbr$,C0449820;C4050231
dlqi $nmbr$ $nmbr$,C3899393
normal troponin,C0205307;C0041199;C0231683;C0439166;C2347086;C4553972
prior therapy,C1514463
elevated troponin,C0205250;C0041199;C3163633
biologic agents,C0005515
no st depression or elevation,C0520887;C0439775;C0702240
topical therapy,C0039798;C0087111;C1363945
st depression or elevation,C0520887;C0439775;C0702240
uvb,C0454530;C0564461
timi risk score $nmbr$ $nmbr$,C0035647;C0449820;C4050231;C4552904
puva,C0853073;C1704892
niacin n $nmbr$,C0027996;C1142562
acitretin,C0050559
male gender n,C0086582;C1706180
cyclosporin,C0010592;C0010594
age mean sd,C0001779;C2699239
placebo n,C0032042;C1696465;C1706408
type $nmbr$ diabetes mellitus n,C1320657
infliximab combined $nmbr$ mg kg and $nmbr$ mg kg n,C0205195;C0439272
hypertension n,C0020538;C1963138
difference,C1705241;C1705242
tobacco use n,C0040335;C0543414;C0841002;C3853727
$nmbr$ ci for difference,C0008107;C3259781
family history ot chd n,C0241889;C0280604;C3542407
baseline pasi score,C0449820;C4050231
metabolic syndrome n,C0524620
baseline bsa involvement,C0168634;C1314939;C1442488
history ot chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
dissatisfied with stopped $nmbr$ prior systemic therapy because of side effects,C0870433;C4085546;C0001688;C0877248;C0879626
ml,C0439526;C1705224;C3887665
dissatisfied with stopped $nmbr$ prior systemic therapies because of side effects,C0870433;C4085546;C0001688;C0877248;C0879626
angina with documented ischemia,C0002962;C0022116;C4321499
prior use of $nmbr$ systemic therapies,C1524063;C1515119
medications n,C0013227;C0802604;C2598133;C4284232
prior use of biologic agents,C1524063;C0005515
$nmbr$ blocker,
etoricoxib n $nmbr$ $nmbr$,C0972314
vitamin e,C0042874;C3714803
diclofenac n $nmbr$ $nmbr$,C0012091
vitamin c,C0003968;C2349136;C3714687;C4522080
arthritis type,C0332307;C1547052
figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus,C0392747;C0443172;C1705241;C4319952;C0439231;C0030705;C0332293;C0032042;C1696465;C1706408;C0027996;C1142562;C0332197;C1689985;C1320657
osteoarthritis,C0029408
serum creatinine concentration and randomization to losartan,C0683149;C0034656;C0126174
rheumatoid arthritis,C0003873
or placebo treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
weight in kg mean sd,C0005910;C0043100;C1305866;C1705104
lowest tertile range $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C3539687
bmi in kg m $nmbr$ mean sd,C0578022;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
middle tertile range $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C3539687
hispanic american,C0019576
multiracial,C1881928
highest tertile range $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C3539687
othert,
losartan,C0126174
dyslipidaemiaj,
nkf stage,C0205390;C1300072;C1306673
current cigarette smoker,C3173209;C3241966
gfr ml min per $nmbr$ $nmbr$ nr,C0017654;C0439445;C1424601
established atherosclerotic cv disease,C0333482;C0007222
esrd on losartan,C0022661;C0035078;C2316810
$nmbr$ cv risk factors^ or established atherosclerotic cv disease,C0035648;C1553898;C0333482;C0007222
esrd on placebo,C0022661;C0035078;C2316810
low dose aspirin use,C0042153;C0457083;C1947944
risk reduction $nmbr$ ci,C0008107;C3259781
cardiac mediations,C0018787;C0680727;C1522601
p losartan versus placebo,C0369773;C0126174;C2603361;C0032042;C1696465;C1706408
anti arthritic medications,C0013227;C0802604;C2598133;C4284232
chf on losartan,C0018802;C0126174
cox $nmbr$ selective nsaid,C0003211;C3536840
chf on placebo,C0018802;C0032042;C1696465;C1706408
traditional nsaid,C0003211;C3536840
patients ft,C1881534;C3890579
paracetamol,C0000970
asian black white hispanic other clinical parameters,C1533017;C1533018;C0205210;C0449381
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
high dose aspirin,C0444956;C0004057
glucocorticoid,C0017710
stage i gfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ and stage v gfr,C0441766;C0439445;C0205390;C1300072;C1306673;C0017654;C1424601
dmard,C0242708
systolic bp mmhg,C0871470;C0439475
etoricoxib,C0972314
heart failure ci confidence interval,C0018801;C0009667;C0018802;C4554158
diclofenac,C0012091
diastolic bp mmhg,C0428883;C0439475
n pyr,C0369718;C0441922
mean bp mmhg,C0037623;C0439475;C1415692;C1708288;C4318478
established ascvd,C0443211;C3665365;C1272684
oral antidiabetic drugs insulin,C0021641;C1533581;C1579433;C3714501
established ascvd or $nmbr$ cv risk factors,C0443211;C3665365;C1272684;C0035648;C1553898
smoking laboratory parameters,C0022877;C0449381;C3244292;C4283904
low dose aspirin use at baseline,C0042153;C0457083;C1947944
hbalc,
disease,C0012634
total cholesterol mg dl,C0201950;C0439269;C0543421
etoricoxib dose,C0178602;C0869039;C1114758
potassium meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$,C0019134;C2825026;C0206460;C0016011
uric acid mg dl creatinine clearance ml min per $nmbr$ $nmbr$ m $nmbr$,C0151280
bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$,C0168273;C0016011
mean sd,C0444504;C2699239;C2347634;C2348143
bivalirudin alone n $nmbr$,C0168273;C0205171;C0439044;C0679994
range,C1514721;C2348147;C3542016
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
male sex no medical history no total no,C0086582;C0262926;C1704706;C0439175;C0439810
median albumin creatinine ratio g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
insulin requiring diabetes,C0011847;C0011849
elevation of cardiac biomarker levels no total no,C0439775;C0702240;C0439175;C0439810
beta carotene n $nmbr$ $nmbr$,C0053396;C0696105
elevation of troponin levels no total no,C0439775;C0702240;C0439175;C0439810
mean age yrs,C0444504;C0001779;C2347634;C2348143
reported hypertension,C0020538;C1963138
st segment deviation $nmbr$ mm no total no,C4330985;C4554674;C0439175;C0439810
reported high cholesterol,C0020443;C1522133
elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no,C0439775;C0702240;C4330985;C4554674;C0439175;C0439810
reported diabetes mellitus,C0684224;C0011849;C0700287;C4319718
timi risk score no total no f,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810;C0016327
mean body mass index kg m $nmbr$,C0022718;C0439209;C4054209
variable demographic characteristics,C0683970
parental history of mii,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
rosiglitazone n $nmbr$,C0289313
health habits,C0018684;C0018464
metformin n $nmbr$,C0025598
past only,
glyburide n $nmbr$,C0017628
alcohol use,C0001948
race or ethnic background no f,C0034510;C1706779;C3853635;C0015031;C0016327
rarely never,C4035880
region no,C0017446;C0205147
physical activity,C0015259;C0026606
time since diagnosis of diabetes no,C0040223;C3541383
multivitamin use current,C0521116;C1705970
anthropometric characteristics,C1521970
rr,
waist circumference cm,C0455829
$nmbr$ ci,C0008107;C3259781
hip circumference cm,C0562350
beta carotene,C0053396;C0696105
systolic mm hg,C0039155;C0439475
p interaction,C0369773;C1704675;C2603361
diastolic mm hg,C0012000;C0439475
cases,C0868928;C1533148
antihypertensive therapy no,C0585941
total cataract,C3665439
fasting plasma glucose mg dl,C0202042;C0439269;C0455280
current non smoker,C0425311
glycated hemoglobin,C0017853
total cataract extraction,C0007389
fasting insulin pmol liter,C0015663;C0021641;C0475211;C1533581;C1579433;C3714501
eze,
insulin sensitivity,C0920563;C4049919
pooled simva,C1709595;C2349200;C4522255
^ $nmbr$ cell function,C0007613
pooled eze simva,C1709595;C2349200;C4522255
gad positive no ^,C0439178;C1446409;C1514241;C2825490;C3812269
n ms,C2349943;C3539704;C3713294
lipids,C0023779
ri $nmbr$,C0035487;C1826843
lipid lowering therapy no,C0585943
$nmbr$ $nmbr$ i $nmbr$ s,C0021966;C0221138
the test for heterogeneity interaction indicates whether the treatment effect varied significantly among the sub groups the hochberg method was applied to each of the two comparisons of the treatment groups bmi denotes body mass index the weight in kilograms divided by the square of the height in meters,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C0025663;C0449851;C0871511;C4048755;C0374505;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074
patients aged $nmbr$ y no ss,C0001779;C0001792;C1999167;C2699257;C3891295;C4551874
p value for heterogeneity rosiglitazone versus metformin,C1709380;C0019409;C0242960;C0025598
pace no $nmbr$,C0287990;C1552930;C4048252
p value for heterogeneity rosiglitazone versus glyburide,C1709380;C0019409;C0242960;C0017628
b lack,C0332268
$nmbr$ $nmbr$ $nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
bmi mean sd kg rn $nmbr$,C2827110;C3540639;C4281819
$nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
baseline lipid lipoprotem values,C0023779;C0042295
waist circumference,C0455829
ldl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
$nmbr$ $nmbr$ cm,
tg median sdy rng cjl,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ cm,
tc mean sd rrig dl,C0039411;C3642216;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
baseline fasting plasma glucose,C0202042;C0455280
hdl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
i $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
non hdl c mean sd rng dl,C0444504;C3642216;C2347634;C2348143
$nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
ldl cihdl c mean sd,C0444504;C2699239;C2347634;C2348143
general health self reported,C0424575;C4018875;C0681906;C2700446
tchdl c mean sd,C0444504;C2699239;C2347634;C2348143
very good or excellent,C3641222;C1548784;C1961136
apo b mean sd mg dl,C0003593;C0439269;C3252643
good,C0205170
apo a $nmbr$ mean sd mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
fair or poor,C2911689;C0032854;C0542537;C2700379
crp median se rng l,C0549183;C0036919;C0876920;C2347635;C2348144;C2939193
walk for exercise,C0080331;C0015259;C1522704
plp c mean sd mg dl,C0034266;C0439269;C1175541;C1257874;C1705623
fall in last $nmbr$ mo,C0085639;C0238715;C4553726
$nmbr$ $nmbr$ i,C0021966;C0221138
baseline vertebral fracture,C0168634;C0080179;C1442488
history of clinical fracture $nmbr$ years old,C1272071;C0205210
eze ezetimibe $nmbr$ mg pooled sinva simvastatin pooled across doses pooled eze sinva ezetimibe simvastatin tablet pooled across doses bni body mass index ldl c low density lipoprotein cholesterol t g triglycerides t c total cholesterol hdl c high density lipoprotein cholesterol apo apolipoprotein c rp c neactive protein rlp c remnant like particle cholesterol,C1532737;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0039225;C1705223;C4319774;C1709595;C2349200;C4522255;C2612459
high fracture risk stratum,C0332167;C3272283;C4050568;C4319571
former,C0205156;C0750523
figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol,C1504308;C1742862;C2349179;C2826544;C1709595;C1532737;C2349200;C4522255;C0074554;C0449450;C2985777;C0237753;C0449788;C0552369
duration of alendronate use mean sd y,C1881378;C2826775
amiodarone n $nmbr$,C0002598
current alendronate use,C0042153;C0457083;C1947944
icd therapy n,C0021122;C0039798;C0087111;C1363945
current use of hormone therapy,C1524063;C0279025
nonwhite race no ejection fraction,C0034510;C1706779;C3853635;C0489482;C2700378
or raloxifene,C0244404
diabetes no,C0011847;C0011849
time since start of fit mean sd y,C1301880;C0036572;C2349186;C4048158;C4553125
pulmonary disease no,C0024115
time since end of fit mean sd y,C1522314;C0036572;C2349186;C4048158;C4553125
hypertension no,C0020538;C1963138
flex baseline bmd mean sd g cm $nmbr$,C0168634;C0439267;C1442488
atrial fibrillation or flutter no,C0004238;C0344434;C1963067;C0016385;C2242390
total hip,C0019552;C0022122;C1505163;C3538851;C4284725
nonsustained ventricular tachycardia no j,C0750194;C2919575
femoral neck,C0015815
syncope no,C0039070;C3541349;C4554644
lumbar spine,C0024091;C3887615
electrophysiological study no weight ibj,C0850293;C0005910;C0043100;C1305866;C1705104
forearm,C0016536
systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
total body,C0229960
flex baseline bmd t score,C0449820;C4050231
diastolic blood pressure mm hg,C0428883;C0439475;C1305849
at femoral neck mean sd,C0015815;C2699239
serum sodium meq liter,C0523891;C0475211
$nmbr$ $nmbr$ to,
serum creatinine mg dl,C0201976;C0439269;C0600061
serum bone specific alkaline,C0205369;C1552740;C1979842
medication use no ^,C0240320
phosphatase mean sd ng mlf,C0017887;C0066495;C0028074
ace inhibitor at enrollment,C0003015;C4541021
serum c terminal telopeptide of,C0229671;C1707271;C1546774;C1550100
ace inhibitor at last follow up,C0003015;C4541021
type $nmbr$ collagen mean sd ng ml,C0009325;C0439275
arb at enrollment,C3888198;C1516879;C1696073;C3888021
arb at last follow up,C3888198;C0589120;C1522577;C1704685;C3274571
serum n propeptide of type $nmbr$ collagen,C1709708;C1875696
ace inhibitor or arb at enrollment,C0003015;C4541021;C3888198;C1516879;C1696073;C3888021
mean sd ng ml,C0444504;C0439275;C2347634;C2348143
ace inhibitor or arb at last follow up,C0003015;C4541021;C3888198;C0589120;C1522577;C1704685;C3274571
dietary calcium intake mean sd mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
early routine,C1279919;C0205547
beta blocker at enrollment,C0001645;C1516879;C1696073;C3888021
post fibrinolysis angioplasty n $nmbr$,C0016017;C0162577;C1548817;C1305868
beta blocker at last follow up,C0001645;C0589120;C1522577;C1704685;C3274571
primary angioplasty n $nmbr$,C0205225;C0162577;C1548817;C0439612;C0439631
loop at enrollment,C0445022;C1516879;C1696073;C3888021
age year,C0439234;C0439508
loop at last follow up,C0445022;C0589120;C1522577;C1704685;C3274571
male sex n,C0086582
potassium sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C3714637;C1516879;C1696073;C3888021
current smoking n,C0037369;C0453996;C1881674
potassium sparing at last follow up,C0032821;C0202194;C0304475;C0597277;C3714637;C0589120;C1522577;C1704685;C3274571
cholesterol $nmbr$ $nmbr$ mmol l n,C0008377;C1532563
thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
family history n,C0241889
thiazide at last follow up,C0541746;C0589120;C1522577;C1704685;C3274571
previous angina n,C0205156;C0002962;C1552607
digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
previous angioplasty n,C0205156;C0162577;C1548817;C1552607
digoxin at last follow up,C0012265;C0589120;C1522577;C1704685;C3274571
heart rates beats minutes,C0439385
aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
medical treatment,C0679624
aspirin at last follow up,C0004057;C0589120;C1522577;C1704685;C3274571
aspirin n,C0004057
warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
warfarin at last follow up,C0043031;C0589120;C1522577;C1704685;C3274571
beta blockers n,C0001645
statin at enrollment,C0360714;C1516879;C1696073;C3888021
ace inhibitors n,C0003015
statin at last follow up,C0360714;C0589120;C1522577;C1704685;C3274571
calcium antagonists n,C0006684
time from symptoms to treatment,C0040223;C3541383;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hypercholesterolemia was defined as a low density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter $nmbr$ $nmbr$ mmol per liter after an overnight fast nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute to convert weight to kilograms divide by $nmbr$ $nmbr$ to convert values for creatinine to micromoles per liter multiply by $nmbr$ $nmbr$ data for follow up medication were available for $nmbr$ patients amiodarone $nmbr$ placebo $nmbr$ and icd $nmbr$ ace de notes angiotensin converting enzyme and arb angiotensin ii receptor blocker p,C0020443;C1522133;C1704788;C3539106;C1516879;C1696073;C3888021;C0439241;C0439190;C0750194;C2919575;C1883530;C0439232;C0700321;C0702093;C1282918;C2347166;C0439209;C0332849;C0042295;C0010294;C1561535;C0439300;C1719797;C2911648;C1511726;C3245479;C3714741;C0470187;C0002598;C0022709;C0011198;C0017480;C3541240;C0521942;C3536793
interval from onset of symptoms,C1272706;C1552654;C1552713
amiodarone vs placebo no hazard ratio $nmbr$ $nmbr$ cl,C0002598;C0032042;C1696465;C1706408;C2985465;C0596019
to randomization,C0034656
icd therapy vs placebo no hazard ratio $nmbr$ $nmbr$ cl,C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C2985465;C0596019
interval from randomization to angiography,C1272706;C1552654;C1552713;C0002978
white race,C0007457;C0043157
angiographic features,C1521970;C1706388;C2346469;C2348519
nonwhite race,C0034510;C1706779;C3853635
infarct related artery location,C0450429;C1515974;C4284930;C4284931
lvef,C0428772;C0488728
left anterior descending n,C0441998;C0205386;C1547177;C0369718;C0441922
lvef $nmbr$,C0428772;C0488728
left circumflex n,C0205091;C0443246;C1552822
qrs,
rca n,
qrs $nmbr$ msec $nmbr$ min walk test,C0439223;C4277740
number of vessels disease,C0237753;C0449788
$nmbr$ $nmbr$ ft,C1881534;C3890579
non stenotic vessels n,C0333181;C0005847;C4049883
$nmbr$ ft,C1881534;C3890579
single vessel disease n,C0037179;C0042373;C0087136;C0205171
beta blocker,C0001645
double vessel disease n,C0205173;C0042373;C1705764;C1705765
no beta blocker,C0001645
triple vessel disease n,C0856738
characteristic age,C1521970;C0001779
degree of stenosis of diameter,C4034225;C1301886
aspirin n $nmbr$ $nmbr$,C0004057
evidence or thombus n,C3887511
total n $nmbr$ $nmbr$,C0439175;C0439810
figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals,C1705117;C4035091;C0425043;C0581603;C0439231;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1707455;C0680395;C1707156;C3274014;C3541345;C1272706
mean sd yr,C0444504;C0439234;C2347634;C2348143
past or never,C2003901
vildagliptin $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ to $nmbr$ $nmbr$,
rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
menopausal status and use of hrt y,C1513126;C1524063;C0282402
hispanic or latino,C0086409;C0086528
all other,
premenopausal,C0279752
uncertain,C0087130;C4085655
bmi group kg m^,C0022718;C0439209;C4054209
alc,C1424945;C3811058
postmenopausal and current hrt,C0232970;C0521116;C0282402;C1705970
postmenopausal and no hrt,C0232970;C0282402
alc group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
hypertension t,C0020538;C1963138
fpg mmol $nmbr$,C0439190
disease duration years,C0872146;C0439234
blood pressure,C0005823;C1271104;C1272641
rosiglitazone $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm hg,C0439475
adjusted mean change kg,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ mm hg,C0439475
whole cohort,C0009247;C0599755
parental history of myocardial infarction before $nmbr$ yr of age,C0030551;C1275835;C0439234;C0001779
bmi $nmbr$,C0578022
$nmbr$ yr risk of coronary heart disease ^,C0439234;C1277690
etoricoxib group n $nmbr$ $nmbr$,C0972314;C0441848
no of risk factors,C0035648;C1553898
diclofenac group n $nmbr$ $nmbr$,C0012091;C0441848
total no,C0439175;C0439810
ppi use,C0042153;C0457083;C1947944
major cv event,C0441471;C4019010
traditional nsaid use,C3897349;C0003211;C3536840
ischemic stroke,C0948008
cox $nmbr$ selective inhibitor use,C0042153;C0457083;C1947944
asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
systemic corticosteroid use,C0239126
pla,C0456170
methotrexate use,C0042153;C0457083;C1947944
rr $nmbr$ ci,C0008107;C3259781
other dmard use,C0042153;C0457083;C1947944
body mass indexf,C0518010
history of upper,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
menopause and hrt,C0025320;C0567312;C0282402
gastrointestinal event,C0441471;C4019010
postmenopausal current hrt,C0232970;C0282402
regular ppi use,C0042153;C0457083;C1947944
postmenopausal no hrt,C0232970;C0282402
no regular ppi use,C0042153;C0457083;C1947944
male sex no,C0086582
regular aspirin use,C0042153;C0457083;C1947944
white race no f,C0007457;C0043157;C0016327
no regular aspirin use,C0042153;C0457083;C1947944
hyperlipidemia no,C0020473;C0428465;C4555212
etoricoxib n $nmbr$,C0972314
diabetes mellitus no,C0011849
diclofenac n $nmbr$,C0012091
prior percutaneous coronary intervention no,C0332152;C1532338;C2826257
history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
anterior myocardial infarction no,C0340293
corticosteroid use,C0239126
fibrinolytic agent no t,C0016018;C2603360
established atherosclerotic cardiovascular disease,C0443211;C0004153;C1272684
tenecteplase,C0872913
n n,C0369718;C0441922
reteplase,C0256103
patients with any clinical event,C0030705;C0205210
alteplase,C0032143
streptokinase,C0038418
aspirin use p $nmbr$ $nmbr$ t,C0004057;C0042153;C0457083;C1947944
initial aspirin no,C0205265;C0004057;C1279901;C1555582;C1705685
ppi use p $nmbr$ $nmbr$ t,C0358591;C0042153;C0457083;C1947944;C0871125;C3811894
initial heparin no,C0019134;C0770546
patients with complicated events,C0030705;C0231242
unfractionated heparin,C0019134;C2825026
patients with uncomplicated events,C0030705;C0441471;C3541888
low molecular weight heparin,C0019139;C3536766
patients with any clinical event p $nmbr$ $nmbr$ o,C0030705;C0205210
both,
no aspirin or ppi,C0004057;C0358591;C0871125;C3811894
neither,
ppi but no aspirin,C0358591;C0871125;C3811894
time from onset of symptoms to start of fibrinolytic therapy hr,C1320528;C0439659;C0040044
aspirin but no ppi,C0004057;C0358591;C0871125;C3811894
angiography no,C0002978
aspirin and ppi,C0004057;C0358591;C0871125;C3811894
time to angiography hr,C0040223;C3541383
patients with complicated events p $nmbr$ $nmbr$,C0030705;C0231242
cardiac medications during index hospitalization no,C0013227;C0802604;C2598133;C4284232
$nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
ace inhibitors or angiotensin receptor blockers^,C0003015;C0521942;C0815017
patients with uncomplicated events p o $nmbr$,C0030705;C0441471;C3541888
open label clopidogrel after completion of study drug,C1709323;C0070166
combinations of aspirin and ppi use p $nmbr$ $nmbr$ t,C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036;C0358591;C0042153;C0457083;C1947944;C0871125;C3811894
etoricoxib $nmbr$ mg n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ticlopidine after completion of study drug,C0040207;C0013175
diclofenac $nmbr$ mg n $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with end point,C0030705;C2349179;C2826544
age mean yrs sd,C0001779;C2699239
reduction in odds,C0301630;C0392756;C1293152;C4551656
clopidogrel,C0070166
sex n,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
overall,C0282416;C1561607
native american,C0282204;C1515945
nonanterior,
body mass index mean kg m^ sd,C0022718;C0439209;C4054209;C2699239
types of fibrinolytic agent,C0332307;C0016018
primary study joint n,C0205225;C0022417;C0392905;C1706309;C0439612;C0439631
fibrin specific,C0205369;C1552740
knee,C0022742;C0022745;C1963703
non fibrin specific,C0205370;C0015982
hand,C0018563;C1552914
predominant type of heparin,C0332307;C1547052
left shoulder,C0524469
low molecular weight,C0041667
acr functional class n,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
unfractionated,
class i,C0441885;C1319793;C2698967
variables $nmbr$,C0439828
class ii,C0441886;C2698968
eze $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
class $nmbr$,C0456387;C1518526;C1705943
feno $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior antiinflammatory antirheumatic products n,C0003209;C0003191;C1515999
feno $nmbr$ mg eze $nmbr$ mg n $nmbr$,C1319635
rofecoxib,C0762662
metabolic syndrome b,C0524620
valdecoxib,C0913246
ldl c mmol l,C1532563
ibuprofen,C0020740
naproxen,C0027396
tc mmol l,C0039411;C1532563;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
hdl c mmol l,C3715113;C1532563
prior analgesic products n,C0332152;C0002771;C2826257
acetaminophen,C0000970;C2917659
tg mmol l c,C0337445;C1532563
history of upper gl events perforations ulcers bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
non hdl c mmol l,C1518422;C1532563
apo b g l,C1447574;C4521365
low dose aspirin use strata n,C2608320;C0042153;C0457083;C1947944
user,C1548600;C1706077
apo a l g l,C0628062
nonuser,
hscrp mg l c,C0439268
fibrinogen pmol l c,C0016006;C0439284;C1167394;C2587184;C3540039
increased risk for thrombotic cardiovascular event^ n,C1273410
feno,
history of diagnosed hypertension prior to randomization n,C0455527;C0011900;C0034656
feno eze,
patient years,C0030705;C0439234
tg,C0337445
baseline aspirin use strata,C0004057;C0042153;C0457083;C1947944
tg $nmbr$ $nmbr$,C0337445
pt years $nmbr$,C0032743;C0439234;C0699718
normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0205307;C0231683;C0439166;C2347086;C4553972;C1417190;C3815103
continued use of gastroprotective agents gpa,C0549178;C1524063
mild decrease in gfr $nmbr$ $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0392756;C0547047
new use of gastroprotective agents gpa,C1518316;C1524063
moderate or severe decrease in gfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0392756;C0547047
parameters,C0449381
$nmbr$ chlorthalidone,C0008294
infliximab,C0666743
amlodipine,C0051696
$nmbr$ mg kg n $nmbr$,C0439272
ii lisinopril i,C0021966;C0221138
combined n $nmbr$,C0205195
chlorthalidone,C0008294
sex female n,C0086287
ii lisinopril,C1710602;C0065374;C4082587
race white n,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
$nmbr$ lisinopril,C0065374
disease characteristics,C0599878
no randomized,C0034656;C3815594
disease duration yr mean sd,C0872146;C2699239
age mean sd y ethnicity no,C0015031;C0243103
mayo score mean sd,C0444504;C2699239;C2347634;C2348143
biack non hispanic,C1518424
aminosalicylates,C0368663
biack hispanic,C0086409
immunomodulatory agents,C0005525
extent of disease n,C0449279;C4553144
baseline systolic blood pressure mean sd mm hg,C4274438;C0439475
left side only,C0205091
baseline diastolic blood pressure mean sd mm hg,C4274392;C0439475
extensive,C0205231
history of coronary heart disease no,C0683519;C0730226;C0850708;C0944983
health related quality of life,C4279947
estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^,C0017654;C0444504;C2347634;C2348143;C1424601
ibdq mean sd,C0444504;C2699239;C2347634;C2348143
eligibility risk factors no t,C0035648;C1553898;C2603360
sf $nmbr$ pcs mean sd,C0037712;C2699239
current cigarette smoking,C0239059;C0700219
sf $nmbr$ mcs mean sd,C0037712;C2699239
atherosclerotic cardiovascular disease,C0004153
no of individuals,C0027361;C0237401
history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
i rosuvastatin n $nmbr$,C0021966;C0221138
st segment depression or t wave inversion on ecg,C0520887;C0520888
i placebo n $nmbr$,C0021966;C0032042;C1696465;C1706408;C0221138
type $nmbr$ diabetes meiiitus,C1320657
blood pressure mean sd mm hgt,C0428886;C2699239
low hdl c,C0151691
fasting blood glucose mean sd mg dlt,C1413248;C3273706
lvh by ecg,C0232306
impaired renal function,C1565489
lvh by echocardiography,C0149721;C0013516
estimated glomerular filtration rate,C3811844
total no of events total no of participants,C0439175;C0439810;C0679646
normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
mean se $nmbr$ year rates per $nmbr$ population,C0871208;C1521828
mild decrease $nmbr$,C0392756;C0547047
rr $nmbr$ cl [ value],C4554402;C0596019;C1522609
moderate decrease $nmbr$,C0392756;C0547047
$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
concomitant medication use,C0521115;C0240320
lisinopril,C0065374
antihypertensive,C0003364
ii chiorthaiidone amiodipine,C1710602;C4082587
the metabolic syndrome^,C0524620
ii $nmbr$ amlodipine lisinopril chlorthalidone chlorthalidone,C0051696;C0008294
body mass index $nmbr$ t,C0005893;C0578022;C1305855
total by baseline diabetic status,C0439175;C0439810
triglycerides $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
diabetic participants,C0241863;C0679646
diastolic blood pressure $nmbr$ mm hg,C0428883;C0439475;C1305849
nondiabetic participants,C0679646
systolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620
by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
or taking antihypertensive medication,C1290952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
fasting blood glucose $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m,C0017654;C0241863;C1424601
$nmbr$ chd risk factors,C0035648;C1282512;C1553898
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
chd risk factors,C0035648;C1282512;C1553898
$nmbr$ amlodipine chlorthalidone,C0051696;C0008294
family history of premature chd,C0241889;C0151526;C0205252;C4018905
$nmbr$ lisinopril chlorthalidone,C0065374;C0008294
smoking during the previous month,C2114448;C0332177;C0439231
total no of events of participants total no of participants,C0439175;C0439810;C0679646
hypertension $nmbr$ $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
[p value],C1709380
[ $nmbr$ ],
$nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
by baseline diabetic status,C0168634;C0449438;C1442488
mean of maximum cimt mean sd mm,C0444504;C0806909;C1552615;C2826546;C2347634;C2348143
by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^,C0076836;C1199517;C1419603;C3539732;C0679646;C0439445
$nmbr$ carotid artery sites,C0007272;C0205145;C0162859
by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
common carotid artery sites,C0007272;C0205145;C0162859
vertebral fracture and or t score s $nmbr$ $nmbr$,C0080179;C0718146
carotid bulb sites,C0007281;C0205145
vertebral fracture and or t score $nmbr$ $nmbr$,C0080179;C3854607
internal carotid artery sites,C0007276;C0205145
alendronate n $nmbr$,C0102118
mean of mean cimt mean sd mm,C0444504;C2347634;C2348143
mean age years,C0444504;C1510829;C2347634;C2348143
tolvaptan n $nmbr$,C1176308
otherf,
mean years since menopause,C0439234;C0025320;C0567312
ejection fraction mean sd,C0489482;C2699239;C2700378
mean femoral neck t score,C3533236;C0015815
ischemic heart failure etiology,C0015127;C1314792;C1524003
mean lumbar spine t score,C3533236;C0024091;C3887615
$nmbr$ $nmbr$ q $nmbr$,
previous hospitalization for heart failure,C0205156;C3898876;C1552607
nyha class,C1882083
number of prevalent vertebral fractures,C0237753;C0449788
$nmbr$ or more,
chronic renal insufficiency,C0403447;C1561643
history of falls in year before randomization,C1561668;C2919132;C0439234;C0439508
valvular disease mitral,C3258293;C0746591
prior clinical fracture since age $nmbr$,C0016658;C0001779
baseline therapy,C0039798;C0087111;C1363945
hip,C0019552;C0022122;C1505163;C3538851;C4284725
ace inhibitors arbs,C0003015;C3888198
spine,C0037949;C2752558
aldosterone blockers,C0002006
wrist,C0043262;C1322271
baseline cardiovascular assessment,C4684571
hip wrist or spine,C0043262;C1322271;C0037949;C2752558
dyspnea frequent continuous,C0013404;C0549178;C1963100
alendronate,C0102118
orthopnea frequent continuous,C0085619;C0549178
age group,C0027362;C2348001
rales,C0034642;C0240859
$nmbr$ to $nmbr$,
pedal edema slight moderate marked,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0522501;C1706089
ezetimibe $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
jugular venous distention $nmbr$ cm,C0425687
number of patients $nmbr$ years,C2360800;C0439234
all cause mortality,C0015127;C0026565;C0026566;C1524003
number of females,C0237753;C0449788
cardiovascular death or heart failure hospitalization,C0011065;C1306577;C4082313;C4552775;C3898876
weight mean sd kg,C0022718;C0439209;C4054209
no of deaths,C0011065;C1306577
body mass index mean sd kg m $nmbr$,C0022718;C0439209;C4054209
tolvaptan,C1176308
duration of hypercholesterolemia mean sd years,C0449238;C2926735
$nmbr$ placebo,C0032042;C1696465;C1706408
western europe,C0043129
patient history of disease,C0683519;C0730226;C0850708;C0944983
eastern europe,C0015177
dm,C0011816;C3250443
etiology,C0015127;C1314792;C1524003
atorvastatin dose,C0178602;C0869039;C1114758
dyspnea,C0013404;C1963100
$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
frequent or continuous,C0332183;C0549178
baseline lipids mean sd mmol $nmbr$,C0023779;C0439190
none or seldom,C0522498
tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
congestion,C0700148;C2826600
non hdl c,C1518422;C3715113
not severe,C4316743
ldl c hdl c ratio,C0428621
severe,C0205082;C4050465;C4050466
tc hdl c ratio,C0456603;C1547037
systolic bp mm hg,C0871470;C0439475
apo apolipoprotein dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol tc total cholesterol,C0202069;C0369300
new york heart association class,C1882083
tg triglycerides median values standard deviation for medians,C0871420
serum sodium meq l,C0523891;C0439375
mean baseline ldl c mmol l,C0168634;C1532563;C1442488
serum urea nitrogen mg dl,C0600137;C0439269;C1291218;C3683557
population,C0032659;C1257890
avp pg ml,C1098706;C0439297;C1568204;C1708407
pbo,C0031962
b natriuretic peptide pg ml,C0070338;C0439297
eze $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p blocker use,C0042153;C0457083;C1947944
treatment stratum^,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ace inhibitor or arb use,C0003015;C4541021;C0042153;C0457083;C1947944
atv $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aldosterone use,C0042153;C0457083;C1947944
p $nmbr$ $nmbr$,C0369773;C2603361
younger subjects aged,C0681850;C1550501;C1706203;C2349001;C2697811;C0001779;C0001792;C1999167
atv $nmbr$ mg study protocol,C1507394;C2348563;C2599718
older subjects aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
$nmbr$ yrs sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
sertraline,C0074393;C0524265
$nmbr$ $nmbr$ kg m $nmbr$ hypertension,C0022718;C0439209;C4054209;C0020538;C1963138
married,C0024841;C0555047
baseline ldl c,C0168634;C1442488
education years,C0013621;C0439234;C0013622;C0013658;C0039401
$nmbr$ $nmbr$ mmol l,C1532563
controls n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
epa treatment n $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
atv atorvastatin ldl c low density lipoprotein cholesterol p values pertain to treatment by stratum interaction test for stratum or treatment by subgroup interaction test for subgroups multiplicity adjustments were not applied to this predefined subgroup analysis of ldl c goal attainment [expressed as number of patients reaching ldl c goal at week $nmbr$ number of patients above goal at baseline ^treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg,C0042295;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1079230;C0237455;C1515021;C0376209;C0456081;C2945673;C4048755;C0680230;C2360800;C2584321;C0018017;C1571704;C1704788;C3539106;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ to,
bmi kg m $nmbr$ cardiovascular history,C0022718;C0439209;C4054209;C1880008
cabgorptca,
alcohol use drinks wk,C0332174;C0439230
hypertension serum lipid values,C0428462;C0042295
physical activity kcal wk,C0332174;C0439230
menopausal status and use of ht,C1513126;C1524063;C0018510;C0677607
triglyceride mmol l blood pressure,C0005823;C1271104;C1272641
postmenopausal and current ht,C0232970;C0018510;C0677607
hmgcoa rl,C1419337;C3539667
pravastatin,C0085542
postmenopausal and no ht,C0232970;C0018510;C0677607
other statin,C0360714
family history of cancerf,C0241889
antiplatelet agent,C0085826
randomized to receive vitamin e,C0034656;C3815594;C1514756;C0042874;C3714803
other antihypertensive agents,C0003364
randomized to receive beta carotene,C0034656;C3815594;C1514756;C0053396;C0696105
hypoglycaemic agents,C0020616
relative risk $nmbr$ confidence interval,C0242492;C0009667
p for interaction,C0369773;C2603361
data are number of patients or mean sd unless otherwise indicated cabg coronary artery bypass grafting ptca percutaneous transluminal coronary angioplasty ldl low density lipoprotein hdl high density lipoprotein iqr i nterquarti le range hmg coa ri $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a reductase inhibitor bmi body mass index which is weight in kg divided by the square of height in metres median iqr,C1511726;C3245479;C3714741;C2360800;C0444504;C2699239;C2347634;C2348143;C0428776;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ aspirin n $nmbr$ $nmbr$,C0004057
control n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
$nmbr$ placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
epa n $nmbr$,
$nmbr$ vitamin e n $nmbr$ $nmbr$,C0042874;C3714803
interaction p,C1704675
never rarely,C2003901;C0522498
previous cad,C1504769;C2239547;C3813548;C4284121
at least $nmbr$ mo,C0026544;C0332177
non smoker,C0337672;C0425293;C4554605
multivitamin use,C0042153;C0457083;C1947944
triglyceride mm,C4330985;C4554674
menopausal status and hormone therapy use,C1513126;C0042153;C0457083;C1947944
ol l,
postmenopausal current hormone,C0019932;C4521914
ranolazine n $nmbr$,C0073633
therapy use,C0042153;C0457083;C1947944
age $nmbr$ y,C0001779
postmenopausal,C0232970
weight median iqr kg,C0022718;C0439209;C4054209
never or past,C2003901
body mass index median iqr,C0005893;C0578022;C1305855
hormone therapy use,C0042153;C0457083;C1947944
comorbidities,C0009488
hypertension^,C0020538;C1963138
cardiac history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
parental history of myocardial infarction before age $nmbr$ y,C0030551;C1275835;C0001779
prior ml,C0439526;C1705224;C3887665
major cardiovascular event,C0205082;C1320716;C0205164;C4318856;C4521762
prior coronary revascularization,C0332152;C0877341;C2826257
total invasive cancer,C0439175;C0677898;C0439810
prior heart failure,C0018801;C0018802;C4554158
postmenopausal current hormone therapy use,C0042153;C0457083;C1947944
estimated creatinine clearance,C0750572;C0812399
postmenopausal never or past hormone therapy use,C0232970;C2003901;C0279025;C0042153;C0457083;C1947944
index event,C0441471;C4019010
randomized to receive aspirin,C0034656;C3815594;C1514756;C0004057
non st elevation ml,C0439526;C1705224;C3887665
parental history of mi before age $nmbr$ y,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0001779
st segment depression $nmbr$ $nmbr$ mv,C1454484;C1705503;C4281602
$nmbr$ year risk of chd,C0439234;C1282512;C0439508
timi risk scoret,C0035647;C4552904
sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C1419891;C0439275;C3273112
time from onset of pain to randomization median iqr h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
race non white,C0007457;C0043157;C0220938
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
previous digoxin use,C0042153;C0457083;C1947944
coronary angiography during the index hospitalization,C0085532;C1548829
previous mi,C0205156;C3810814;C1552607
cardiac medications during index hospitalization,C0013227;C0802604;C2598133;C4284232
current angina,C0521116;C0002962;C1705970
and or discharge,C0012621;C0030685;C2926602
ischemic etiology,C0015127;C1314792;C1524003
heparin,C0019134;C0770546
nyha functional class,C1882083;C0205245;C0542341;C2700217
glycoprotein llb llla receptor inhibitor,C0017968;C1999216
vasodilator therapy,C0039798;C0087111;C1363945
thienopyridine,C1120149
lvef u,C0428772;C0439148;C0488728
ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021;C0521942;C3536793
duration of chf months,C0449238;C2926735
sbp mm hg,C0085805;C0439475
abbreviations ace angiotensin converting enzyme iqr interquartile range ml myocardial infarction si conversion to convert creatinine clearance to ml s multiply by $nmbr$ $nmbr$ data are expressed as no total unless otherwise specified festimated using cockroft gault equation tthe timi risk score was used to categorize patients at low $nmbr$ $nmbr$ intermediate $nmbr$ $nmbr$ and high $nmbr$ $nmbr$ risk $nmbr$,C0022709;C0439836;C0439390;C1511726;C3245479;C3714741;C0439175;C0439810;C0205369;C1524063;C0035647;C0449820;C4050231;C4552904;C1273517;C0871968;C0030705;C0205103;C1550465;C2827755;C3889971;C0332167;C3272283;C4050568;C4319571
dbp mm hg,C0536221;C0439475;C3813197;C4281799
no of events sample size i i,C0242618;C3811654
ct ratio,C0456603;C1547037
kaplan meier rates i i,C0021966;C0221138
chf score u,C0018802;C0439148
ranolazine,C0073633
egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
hr $nmbr$ cl,C0596019
sdc ng ml,C1419891;C0439275;C3273112
pfor interaction,C1151635;C1704675
na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
] $nmbr$,
time sample drawn h,C0033727;C0369286;C0441932;C0564385;C4528284
timi risk score,C0035647;C0449820;C4050231;C4552904
lrg,C1428862
] j $nmbr$,
hrg,C1437978;C1705020
st segment depression $nmbr$ mm,C4330985;C4554674
atenolol,C0004147
creatinine clearance,C0812399
ns,C0038944;C1112705;C1705982
$nmbr$ mlymin,
sex women n [ ],C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
early invasive,C0205281;C1334278
race white n [ ],C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
etanercept n $nmbr$,C0717758
demographic characteristics,C0683970
heart rate min $nmbr$,C0702093;C1524029;C3813700
cornell voltage duration mv ms,C2349943;C3539704;C3713294
female no,C0043210;C0086287;C1705497;C1705498
age mean min max yrs,C0001779;C0444504;C2347634;C2348143
sokolow lyon voltage mv,C1454484;C1705503;C4281602
duration of ra mean min max yrs,C0449238;C2926735
serum glucose mmol l,C0202041;C1532563;C3534430
comorbid diseasesa diabetesb,
total cholesterol mmol l,C0201950;C1532563;C0543421
insulin dependentc,C0021641;C1533581;C1579433;C3714501
hdl cholesterol mmol l,C0023822;C1532563;C0392885
oral hypoglycaemics only,C0359086
serum creatinine mmol l,C0201976;C1532563;C0600061
comorbidities other than diabetes,C0009488;C0011847;C0011849
urine albumin creatinine mg mmol,C0567349;C2348885
chronic pulmonary disease,C0746102
bp component mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
pneumonia in past year,C0032285;C0439234;C0439508
sbp baseline,C0168634;C1442488
recurrent infections $nmbr$ per year,C0239998;C0439234;C0439508
sbp last,C0085805
bronchitis,C0006277
sbp difference,C1705241;C1705242
sinusitis,C0037199;C4553555
difference in sbp between treatment,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
urinary tract infection,C0042029;C0262655;C4554638
mean arterial pressure baseline,C0443150
cardiovascular risk factors no,C0850624
mean arterial pressure last,C0428886
coronary artery disease,C0010054;C0010068;C1956346
mean arterial pressure difference,C0563547
congestive heart failure definite,C0018802;C0439544;C1704787
end point,C2349179;C2826544
at least two cardiovascular risk factors,C0035648;C0850624
higher risk n $nmbr$,C0332167;C3272283;C4050568;C4319571
medically important infectionsa,C3898777;C4084912
lower risk n $nmbr$,C3272281;C3538919
serious adverse events,C1519255
adjusted hr,C0456081
etanercept,C0717758
unadjusted hr,C1439367
events,C0441471;C3541888
primary composite end point,C2986535;C0205199;C1547335
patients with diabetes b,C0030705;C0011847;C0011849
components,C0449432
patients without diabetes b,C0030705;C0011847;C0011849
other prespecified end points,C2349179
patients with chronic pulmonary disease,C0683521
hospitalization for,C0019993
sudden cardiac death,C0085298
patients without chronic pulmonary disease,C0683521
new onset atrial fibrillation,C0741281
adalimumab group n $nmbr$ t,C0036669
endpoint,C2349179;C2826544
men n,C0025266
pvalue,
mean age sd y,C0444504;C0001779;C2347634;C2348143
primary composite endpoint,C2986535;C0205199;C1547335
mean weight sd kg,C0022718;C0439209;C4054209
losartan n $nmbr$ $nmbr$,C0126174
intestinal area involved n,C0021853;C0017446;C0205146
demographic and clinical,C0011298;C0205210
rectum,C0034896
cornell voltage duration product mm ms,C2349943;C3539704;C3713294
perianal or anus,C0442158;C0003461
gastroduodenal,C0450199
medical history n,C0262926;C1704706
jejunum,C0022378
any vascular disease,C0042373
abdominal or perianal fistula at baseline n,C0000726;C0267561;C0168634;C1442488
isolated systolic hypertension,C0745133
mean cdai score sd,C3533236;C2699239
with aspirin n $nmbr$ $nmbr$,C0004057
without aspirin n $nmbr$ $nmbr$,C0004057
mean baseline ibdq score sd crp concentration mg l,C3533236;C0439268
median range,C1514721;C2348147;C3542016
sys ns dia,C0038944;C1706546;C1112705;C1705982
atenolol n $nmbr$ $nmbr$,C0004147
crp concentration $nmbr$ mg l n \,C0086045;C0439268;C1446561;C3827302
dates of recruitment,C0011008;C2348077
previous loss of response to infliximab n,C0205156;C1517945;C1552607;C0666743
year of publication of primary results,C0439234;C0439508
previous intolerance of infliximab n,C0231199;C1744706;C2355652
acute reaction,C0205178;C0443286
mean duration offollow up years,C0444504;C0439234;C2347634;C2348143
delayed reaction,C0205421;C0443286;C1545665;C3272602
treatment comparison mg day t,C0039798;C0439422;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
acute and delayed reaction,C0205178;C0205421;C0443286;C1545665;C3272602
number of patients,C2360800
previous loss of response to and intolerance of infliximab n,C0205156;C1517945;C1552607;C0231199;C1744706;C2355652
age range years,C1510829;C1514721;C2348147;C3542016
antibodies to infliximab n,C3533054
baseline history of vascular disease,C0683519;C0730226;C0850708;C0944983
indeterminate,C0205258
ml c,C0439526;C1705224;C3887665
concomitant medication n,C0521115;C0013227;C3244316;C4284232
itherchdt,
steroids,C0038317
other vasculars,
any immunosuppressive agent,C0021081
noneh,
$nmbr$ aminosalicylates,C0368663
s $nmbr$ $nmbr$ vs placebo,C0032042;C1696465;C1706408
woscops,
placebo group n n,C0032042;C0441848;C1696465;C1706408
p $nmbr$ vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
adalimumab group n n,C1122087;C0441848
care,C1947933
primary analysis,C0002778;C0936012;C1524024
post cabg,C0687676;C0010055;C1704687;C3469826
remission in overall population,C0544452;C0687702
l $nmbr$ $nmbr$ vs l $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
prespecified subgroup analyses,C2986480
afcaps,
remission,C0544452;C0687702
l $nmbr$ $nmbr$ vs placebo,C0439394;C1706495;C3642217;C0032042;C1696465;C1706408
patients with previous loss of response to infliximab,C0030705;C0205156;C1552607;C0666743
$nmbr$ $nmbr$ men,C0025266
patients with previous intolerance of infliximab,C0030705;C0205156;C1552607
texcaps,
patients with baseline crp concentration $nmbr$ mg l,C0030705;C0439268
$nmbr$ $nmbr$ women,C0043210
additional subgroup analyses,C1524062;C2986480
lipid,C0023779
patients not receiving immunosuppressive agents at baseline,C0030705;C1518422;C1514756;C0021081;C0168634;C1442488
gissi prevention $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0199176;C1706420;C2700409
patients receiving immunosuppressive agents at baseline,C0030705;C1514756;C0021081;C0168634;C1442488
p $nmbr$ vs no treatment $nmbr$,C0369773;C2603361;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
patients not receiving corticosteroids at baseline,C0030705;C1518422;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
lips,C0023759
patients receiving corticosteroids at baseline,C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
f $nmbr$ vs placebo,C0016327;C0032042;C1696465;C1706408
patients with previous loss of response to and intolerance of infliximab,C0030705;C0205156;C1552607;C0231199;C1744706;C2355652
hps,C0242994
patients who received negative results on test for antibodies to infliximabt,C1334932;C0003241
s $nmbr$ vs placebo,C0032042;C1696465;C1706408
patients who received indeterminate results on test for antibodies to infliximabt,C0456984;C0003241
prosper,
allhat llt,C2347090
patients who received positive results on test for antibodies to infliximabt,C1335447;C0003241
p $nmbr$ vs usual care,C0369773;C2603361;C3538928;C1947933
pooled simvastatin factorial studies,C0074554;C2826344
^ $nmbr$,
atorvastatin factorial study,C0286651;C2826344
ascot lla,C0718674
simvastatin monotherapy n $nmbr$ $nmbr$,C0074554
a $nmbr$ vs placebo,C0032042;C1696465;C1706408
ezetimibe simvastatin n $nmbr$ $nmbr$,C1532737
alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
atorvastatin monotherapy n $nmbr$,C0286651
cards,C2930619;C3275277
ezetimibe simvastatin n $nmbr$,C1532737
body mass index kg nr,C0027496;C3844738
crp mg l median sd,C0439268;C2699239
tg mg dl median sd,C0439269;C2699239
$nmbr$ s scandinavian simvastatin survival study $nmbr$ woscops west of scotland coronary prevention study $nmbr$ care cholesterol and recurrent events $nmbr$ post cabg post coronary artery bypass graft $nmbr$ afcaps texcaps air force texas coronary atherosclerosis prevention study $nmbr$ lipid long term intervention with pravastatin in ischaemic disease $nmbr$ gissi prevention gruppo italiano per lo studio della sopravvivenza nell infarto miocardico $nmbr$ lips lescol intervention prevention study $nmbr$ hps heart protection study $nmbr$ prosper prospective study of pravastatin in the elderly at risk $nmbr$ allhat llt antihypertensive and lipid lowering treatment to prevent heart attack trial $nmbr$ ascot lla anglo scandinavian cardiac outcomes trial lipid lowering arm $nmbr$ alert assessment of lescol in renal transplantation $nmbr$ cards collaborative atorvastatin diabetes study $nmbr$ s simvastatin l lovastatin p pravastatin f uvastatin a atorvastatin mean duration of follow up based on survival times within each trial overall mean is weighted by trial speci c variances of logrank o e for major vascular events all trials included dietary intervention woscops gissi prevention lipid $nmbr$ s lips and hps provided dietary advice afcaps texcaps post cabg care allhat alert cards and prosper used american heart association aha step $nmbr$ diet and care intensi ed to step $nmbr$ diet if ldl cholesterol $nmbr$ $nmbr$ mmol l $nmbr$ mg dl other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi as already counted in mi column other vascular includes history of intracerebral bleed transient ischaemic attack ischaemic stroke unknown stroke and peripheral artery disease none includes individuals without a history of mi symptomatic chd intracerebral bleed transient ischaemic attack ischaemic stroke unknown stroke or peripheral artery disease,C1705493;C1706420;C2347647;C0085542;C0679698;C1096775;C0033522;C1709709;C0001792;C0003364;C1999167;C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0309872;C0027051;C0441994;C2003888;C1261322;C1516048;C0846101;C0024027;C0016327;C0449238;C2926735;C1527178;C1705938;C0444504;C2347634;C2348143;C0005910;C0043100;C1305866;C0441471;C3541888;C0012171;C0023759;C0242994;C2930619;C3275277;C0012155;C0012159;C1519433;C2983588;C3668949;C3538926;C1532980;C0280604;C3542407;C0332257;C1552866;C2700399;C0679831;C0231220;C0332196;C2828389;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0750480;C1705566;C0005847;C1558950;C1801960;C0455536;C2937358;C1704436;C4025272;C0027361;C0237401
apolipoprotein b mg dl,C0003593;C0439269
groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
hdl mg dl,C3715113;C0439269
events treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
control $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups,C1705241;C1705242;C3890735;C0441889;C4048285;C0030705;C0042295;C1882932;C2360800;C1709595;C0074554;C2349200;C4522255;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0369773;C2603361;C0332529;C1547017;C1079230
rr cl,C4554402;C0596019
tiotropium,C0213771
heterogeneity trend test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
total randomised n,C0439175;C0439810
previous disease,C0205156;C0012634;C1552607
male n,C0086582;C1706180;C1706428;C1706429
post mi,C0856742
smoking history pack years,C1519384;C1277691
other chd,C0280604;C3542407
screening visit $nmbr$,C0545082;C1512346;C2826704
xho p o $nmbr$,C4050013
fev $nmbr$ l pre bronchodilator,C3714541;C2599602
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$ o,C0483204
fev $nmbr$ predicted normal,C0520835;C0681842;C1882327
s $nmbr$,
fev $nmbr$ fvc,C3714541
x $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,
fvc l,C3714541
xi $nmbr$ $nmbr$ p $nmbr$,C1720296
nice classification of copd severity of obstruction n [ $nmbr$ ],C0008902;C0008903;C0678229
treated hypertension,C0020538;C1963138
mild fev $nmbr$ predicted,C0681842;C1882327
x l $nmbr$ p $nmbr$ $nmbr$,
moderate $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
x $nmbr$ l p $nmbr$ $nmbr$,
severe fev,C0205082;C3714541;C4050465;C4050466
x $nmbr$ $nmbr$ l p $nmbr$ $nmbr$,
pulmonary medication during baseline,C0013227;C3244316;C4284232
^ $nmbr$ $nmbr$,
laba n,
ldl cholesterol mmol l,C0023824;C1532563;C0202117
laba no ics n,C0815320;C4551720
xi o $nmbr$ p o $nmbr$,C1720296
ics n,C0815320;C4551720
sso $nmbr$,
ics no laba n,C0815320;C4551720
o $nmbr$ ii,C1710602;C4082587
laba plus ics n,C0815320;C4551720
$nmbr$ $nmbr$ o $nmbr$ o o $nmbr$,C0483204
no laba no ics n,C0815320;C4551720
triglycerides mmol l,C0041004;C1532563
saba use occasions weekt,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
trough fev response l,C0444506;C0871261;C1704632;C1706817;C2911692
$nmbr$ io $nmbr$,C1046794;C3146236
trough fvc response l,C0444506;C0871261;C1704632;C1706817;C2911692
xi $nmbr$ $nmbr$ p $nmbr$ l,C1720296
effect size^,C0814843
xi $nmbr$ l p $nmbr$ $nmbr$,C1720296
laba tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
x $nmbr$ $nmbr$ p $nmbr$ $nmbr$,
ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
xi l $nmbr$ p $nmbr$ $nmbr$,C1720296
ics no laba tiotropium n $nmbr$ placebo n $nmbr$,C0815320;C4551720;C0213771;C0032042;C1696465;C1706408
xi $nmbr$ $nmbr$ p o l,C1720296
s $nmbr$ $nmbr$,
laba plus ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
o $nmbr$ i i,C0021966;C0221138
no laba no ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
xi $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C1720296
trough fev response l i,C0021966;C0221138
ssi $nmbr$,
effect size,C0814843
xi oo p o $nmbr$,C1720296
fev $nmbr$ predicted,C0681842;C1882327
pioglitazone n $nmbr$,C0071097
tiotropium n $nmbr$ placebo n,C0213771;C0032042;C1696465;C1706408
patients characteristics,C0815172
fev,C3714541
time since diagnosis of diabetes years median iqr,C0556970;C0011847;C0011849
placebo group n $nmbr$ j,C0441844
body mass index kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
certolizumab group n $nmbr$,C1872109;C0441848
mean age yr range,C1514721;C2348147;C3542016
blood pressure systolic diastolic mm hg mean sd,C0428886;C2699239
mean body mass indexj,C0444504;C0518010;C2347634;C2348143
past smoker,C0337664
microvascular disease,C0443258;C0012634
duration of disease yr^ mean,C0872146;C0439234
geometric mean ofcrp mg liter range,C1514721;C2348147;C3542016
blood glucose lowering treatment,C0005802;C0441994;C2003888;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
metformin only,C0025598
disease site no ^,C0205145;C1515974;C2825164
sulphonylureas only,C0038766
terminal ileum,C0227327
metformin sulphonylureas,C0025598;C0038766
lleocolon,
insulin only,C0021641;C1533581;C1579433;C3714501
previous infliximab therapy,C0205156;C4076075;C1552607
any therapy no,C0039798;C0087111;C1363945
insulin metformin,C0021641;C0025598;C1533581;C1579433;C3714501
insulin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
median infusions no range,C0549183;C0574032;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
insulin metformin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
previous hypersensitivity reaction no,C0205156;C0020517;C1552607
other combination,C0205195;C1947911;C3811910
resection performed no,C0015252;C0728940;C0884358
diet only,C0012155;C0012159;C1519433;C2983588;C3668949
concurrent treatment at study entry no,C0679827;C1521826;C3161471
laboratory data,C1511726;C3245479;C3714741
glucocorticoids only,C0017710;C3540777;C3540778
hba $nmbr$ c median iqr,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
immunosuppressive agents only,C0021081
ldl cholesterol mmol l median iqr,C0023824;C0202117
glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778;C0205195;C0021081
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778;C0021081
hdl cholesterol mmol l median iqr,C0023822;C0392885
certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
triglycerides mmol l median iqr,C0041004;C1532563
no total,C0439175;C0439810
creatinine ^mol l median iqr,C0010294;C0347982;C1561535
a decrease of $nmbr$ points in the cdai score,C0392756;C0547047;C0449820;C4050231
micral test result,C0456984;C0587081
with baseline crp level of $nmbr$ mg liter,C0441889;C0456079;C1547707;C2946261
negative,C0205160;C1513916;C2825415;C2825491;C3853545
at week $nmbr$,C0332174;C0439230
about $nmbr$ mg l,C0439268
at weeks $nmbr$ and $nmbr$,C0439230
about $nmbr$ mg l or more,C0439268
no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
enact $nmbr$ trial,C0008976
immunosuppressive agents at baseline,C0021081;C0168634;C1442488
enact $nmbr$ trial rerandomization to natalizumab n $nmbr$,C0008976;C1172734
no glucocorticoids at baseline,C0017710;C3540777;C3540778
natalizumab n $nmbr$ f,C1172734;C0016327
glucocorticoids at baseline,C0017710;C3540777;C3540778
rerandomization to placebo n $nmbr$ f,C0032042;C0016327;C1696465;C1706408
previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ $nmbr$ j,
patients with remission,C1277626
duration of disease mo,C0872146;C0026544;C0332177
placebo group n $nmbr$ f,C0441840
intestinal area involved no,C0017446;C0205146;C1314939
male sex no of patients,C0086582;C0030705
ileum,C0020885
duration of disease yr,C0872146;C0439234
ileum and colon,C0020885;C0009368;C3888384
current smoker no of patients,C3173209;C3241966;C0030705
colon,C0009368;C3888384
crp mg liter^,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
data missing or no drug given,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0013227;C1254351
geometric mean,C2986759
previous segmental resection no,C0205156;C2987624;C1552607
disease site no of patients,C0205145;C1515974;C2825164;C0030705
cdai score,C0449820;C4050231
ileocolon,
c reactive protein,C0006560;C1413716;C4048285
previous infliximab therapy no of patients,C0205156;C4076075;C1552607;C0030705
elevated at wk $nmbr$ no,C0205250;C3163633
no of infusions,C0574032
week $nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous acute hypersensitivity reaction to infliximab no of patients,C0205156;C0413234;C1552607;C0030705
mean,C0444504;C2347634;C2348143
previous bowel resection performed no of patients,C0205156;C0741614;C1552607;C0884358;C0030705
week $nmbr$ mg liter^,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concurrent treatment of crohn s disease at study entry no of patients ff,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2985574;C1705654;C0030705;C4554348
elevated at wk $nmbr$ no $nmbr$,C0205250;C3163633
glucocorticoids plus immunosuppressive agents,C0017710;C3540777;C3540778
concomitant medication no,C0013227;C3244316;C4284232
corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter,C1280519;C1707887;C1872109;C0030705;C0871261;C1704632;C1706817;C2911692;C0441837;C1547282;C0034746;C0032659;C1257890;C0332174;C0439230;C0441889;C0456079;C1547707;C2946261;C0441833;C1706365;C1999270;C0439165;C1549488;C1561533;C0205210;C1704788;C3539106;C0087111;C1292734;C1522326;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0475211
prednisone,C0032952
fondaparinux n $nmbr$,C1098510
budesonide,C0054201
age median range years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
immunosuppressants,C0021081
risk factor for venous thromboembolism no,C3495424;C3496592
azathioprine,C0004482
obesity,C0028754;C1963185
mercaptopurine,C0000618
history of venous,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
methotrexate,C0025677
thromboembolism,C0040038
antibiotics,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
nyha grade iii or iv,C0205617;C0450094;C0475271;C0687697;C3889290;C4050000;C4283820;C4283821;C4283822;C0022326;C4265176
$nmbr$ aminosalicylates i i,C0021966;C0221138
chronic obstructive pulmonary,C0205191;C0549186;C0024109;C2707265;C2709248;C4522268
$nmbr$ corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
inflammatory bowel disease,C0021390
corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
cancer surgery,C0920424
previous receipt of therapy against tnf a no,C0039798;C0087111;C1363945;C1448177;C1710304
no of risk factors for venous thromboembolism no,C0035648;C1553898;C1861172
refractory to such therapy no,C0205269;C0039798;C0087111;C1363945
creatinine clearance no,C0812399
current smoker $nmbr$ cigarettes day no,C0332173;C0439228;C0439505
$nmbr$ $nmbr$ ml min $nmbr$,C0439445
figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d,C0439165;C1549488;C1561533;C0008976;C1096775;C0441833;C1706365;C1999270;C0544452;C0687702;C0545082;C1512346;C2826704;C0332174;C0441837;C0439230
$nmbr$ ml min $nmbr$,C0439445
a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown,C0871261;C1704632;C1706817;C2911692;C1704788;C3539106;C0168634;C1442488;C0011198;C0017480;C3541240;C0205232;C0687757;C0449820;C4050231;C0237881;C0750502;C1546944;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1547282
randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
clopidogrel n $nmbr$ $nmbr$,C0070166
active n $nmbr$,C0205177;C3853793;C3888249
age at entry years,C1510829;C1705654
age when diabetes first diagnosed years mean sd,C0001779;C0011847;C2699239;C0011849
time since onset h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
previous vascular disease,C0205156;C0042373;C1552607
ecg abnormality at entry,C1623258;C1704258
history of major macrovascular disease n,C0683519;C0730226;C0850708;C0944983
st elevation,C0520886
history of myocardial infarction n,C1275835
bundle branch block,C0006384;C1879286
history of stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
st depression without st elevation,C0520887
history of major microvascular disease n,C0683519;C0730226;C0850708;C0944983
ii or iii,C0439070;C1705160
history of macroalbuminuriat n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
previous disease and drug use,C0205156;C0012634;C1552607;C0242510
history of microvascular eye disease n,C0683519;C0730226;C0850708;C0944983
previous hypertension,C0020538;C1963138
blood pressure control,C0005823;C1271104;C1272641
aspirin before admission,C0004057;C0184666;C0809949
$nmbr$ blocker before admission,C0184666;C0809949
systolic blood pressure mm hg mean sd,C0428886;C2699239
fibrinolytic agent before randomisation,C0016018;C0034656
diastolic blood pressure mm hg mean sd,C0428886;C2699239
non trial treatment during hospital stay,C0019948;C3166479
history of currently treated hypertension n,C0455527;C0521116
non trial antiplatelet,C1518422;C0008976
other major risk factors,C0035648;C1553898
fibrinolytic agents before or after entry,C0016018;C1705654
serum total cholesterol mmol l mean sd,C0587184;C2699239;C1287371
anticoagulant,C0003280;C0848112;C3536711
serum hdl cholesterol mmol l mean sd,C0428472;C2699239
antiarrhythmic,C0003195;C3537142
urinary albumin creatinine ratio pg mg median iqr,C0486293;C1318293
nitrate oral or intravenous,C0442027;C4521986;C0348016
microalbuminuria n,C0730345
calcium antagonist,C0006684
serum creatinine pmol l mean sd,C0201976;C2699239;C0600061
metoprolol n $nmbr$ $nmbr$,C0025859
serum haemoglobin a $nmbr$ c concentration mean sd,C0683149;C2699239
ai $nmbr$,C0003504;C4551710
number of patients with event,C2360800;C0441471;C4019010
p blocker before admission,C0369773;C0184666;C0809949;C2603361
relative risk reduction $nmbr$ cl,C0242492;C0596019
non trial p blocker,C1518422;C0008976
pctindopnl indapamide n $nmbr$,C0021186
score $nmbr$ $nmbr$,C0449820;C4050231
$nmbr$ oto $nmbr$,
mfns n $nmbr$,
$nmbr$ ito $nmbr$,C0022283
mean age y range,C1514721;C2348147;C3542016
history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
gender male,C0086582;C1706180;C1706428;C1706429
history of microvascular disease,C0683519;C0730226;C0850708;C0944983
mean baseline nasal congestion score,C3533236;C0027424;C4554631
treatment with any bp lowering drugs,C3469597;C0037623;C1415692;C1708288;C4318478
eze simva $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment with open label perindopril,C3640652;C0136123
atv $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment with statins,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
number of females n,C0237753;C0449788
treatment with anti platelet drugs,C3469597
race n,C0034510;C1706779;C3853635
combined macro micro,C0085672;C1553035;C3811161;C4049106
body mass index mean sd kg m,C0022718;C0439209;C4054209
european trial,C0239307;C0008976;C1535514
duration of hypercholesterolaemia mean sd year,C0449238;C2926735
non european trial,C0239307;C0008976;C1535514
patient history of disease n,C0683519;C0730226;C0850708;C0944983
combined trials,C0205195;C0008976
concomitant therapies n,C1707479
dronedarone n $nmbr$,C0766326
drugs used in diabetes,C0013227;C3687832;C1273517;C0011847;C0011849
race no f,C0034510;C1706779;C3853635;C0016327
antithrombotic agents,C1704311
body mass index no,C0005893;C0578022;C1305855
antihypertensive agents,C0003364
cardiovascular history no,C1880008
cardiac therapy,C3654025
structural heart disease,C1290384
peripheral vasodilators,C0724804
coronary artery disease^,C0010054;C0010068;C1956346
vasoprotectives,C0304533
cardiac valvular disease,C0018824
baseline lipids mean sd mmol l,C0023779;C1532563
nonischemic cardiomyopathy,C0878544
tgt,C1421391;C1428265;C4321338
apo bt,
implanted pacemaker,C0848753
implanted cardioverter defibrillator,C0021102;C0810516;C2828363
rheumatic heart disease,C0035439
apo apolipoprotein dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol tc total cholesterol tg triglycerides includes agents acting on the renin angiotensin system beta blocking agents calcium channel blockers and diuretics median values [standard deviation for medians calculated by q $nmbr$ q $nmbr$ $nmbr$ $nmbr$ ] includes cardiac glycosides antiarrhythmics class i and iii vasodilators used in cardiac diseases and other cardiac preparations expressed as g l,C0062152;C0332257;C1552866;C2700399;C0006684;C0549183;C0042295;C0876920;C2347635;C2348144;C2939193;C0871420;C0444686;C1441506;C0441885;C1319793;C2698967;C0439070;C0042402;C1705160;C1273517;C0018799;C1521827;C3812761;C0439294;C0456615
hypertrophic cardiomyopathy,C0007194;C4551472
non white,C0007457;C0043157;C0220938
congenital heart disease,C0152021
$nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
left atrial anteroposterior diameter mm,C4330985;C4554674
left ventricular ejection fraction mean sd,C0428772;C2699239;C0488728
congestive heart failure no,C0018802
nyha functional class $nmbr$,C1882083;C0205245;C0542341;C2700217
any disease,C0012634
$nmbr$ $nmbr$ $nmbr$ q,
nyha class i,C1882084
lll iv,C0022326;C4265176
nyha class ii,C1882085
$nmbr$ $nmbr$ $nmbr$ j,
symptoms of atrial fibrillation in the $nmbr$ months before randomiza,C0683368;C1457887;C0439231
history congestive heart failure,C0019664;C0018802;C0019665;C0262512;C0262926;C1705255;C2004062
tion no,
chronic obstructive pulmonary disease,C0024117
recent cardioversion within $nmbr$ days before randomization,C0332185;C0013778;C0034656
cerebrovascular accident tia,C0007787;C0917805;C1054154
concomitant cardiovascular therapy no,C1707479
preoperative use p blocker,C0445204;C0042153;C0457083;C1947944
calcium channel blocker ratelowering,C0006684;C3536851;C4521885
angiotensin receptor blocker,C0034787;C1622222
beta blocker except sotalol,C0001645;C0037707
nsaid,C0003211;C3536840
oral anticoagulant,C0354604
baseline characteristics,C4684572
postoperative use of p blocker,C0032790;C1524063
long term antiplatelet therapy,C0443252;C1096021
operative procedure,C0543467;C0677612
previous antiarrhythmic treatment no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
cabg surgery by no of vessels $nmbr$,C0042381;C3714645
class ia,C0020980;C0694634;C1947960
type no of valves repaired replaced mitral,C0332307;C1547052;C0396849;C0559956;C1299987
class ib,C2744579;C3890035;C4283819
aortic,C0003483
class ic,C0020750;C4554818
multiple,C0439064
class iii,C0441887;C2698969
type of surgery cabg only,C0332307;C1547052
class iv,C0441888;C2698970
sotalol,C0037707
valve repair replacement with or without cabg,C0035139;C0559956;C1555302;C4553149;C0010055
valve repair replacement only,C0035139;C0559956;C1555302;C4553149
hazard ratio for event $nmbr$ ci,C2985465;C0008107;C3259781
time mean sd min procedure,C0184661;C2700391;C3274430;C3539779
left atrial diameter,C0225860;C0225861
pump,C0182537
$nmbr$ mm,C4330985;C4554674
cross clamp,C0175721;C1883710;C3810601
heart failure criteria met,C0428210;C1550543;C4317104
total no of patients,C0439175;C0439810;C0030705
conversion to sinus rhythm in,C1321500
no of patients with atrial tachyarrhythmia,C0030705;C0018792;C0080203
previous use of amiodarone,C1524063;C0002598
hazard ratio $nmbr$ cl,C2985465;C0596019
yes stopped for trial,C1549445;C1705108;C1710701;C1272691;C0008976
absolute risk reduction $nmbr$ cl,C3179139;C0596019
previous use of antiarrhythmic drugs,C1524063
no needed to treat $nmbr$ cl,C0027552;C0686904
sample size n,C0242618
amiodarone,C0002598
age in years mean,C1510829;C0444504;C2347634;C2348143
age years $nmbr$,C1510829
$nmbr$ to $nmbr$ y n,
type of surgery cabg coronary artery bypass graft,C0449494
$nmbr$ y n,
type of surgery valve replacement repair with or without cabg,C0449521;C0449533;C0010055
education in years mean,C0013621;C0013622;C0013658;C0039401
preoperative beta blocker use yes,C1549445;C1705108;C1710701
clinic research experience n,C0002424;C0035168;C0242481;C0442592
preoperative beta blocker use no,C0042153;C0457083;C1947944
on bp medication n,C0037623;C0013227;C3244316;C4284232;C1415692;C1708288;C4318478
hx of diabetes n,C0262926;C3814444
tenecteplase and pci n $nmbr$,C0872913;C4049621
chd n,C0280604;C3542407
pci alone n $nmbr$,C0205171;C0439044;C0679994
height cm,C0489786
baseline ecg with lvh n,C0168634;C0232306;C1442488
ii iii,C0439070;C1705160
ascvd n,C3665365
congestive heart failure at randomisation,C0018802;C0034656
bmi kg m $nmbr$ mean,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
previous infarction,C0205156;C0021308;C1552607
glucose mg dl mean,C0444504;C2347634;C2348143
previous congestive heart failure,C0205156;C0018802;C1552607
potassium meq dl mean,C0444504;C2347634;C2348143
previous pci,C0205156;C4049621;C1552607
creatinine mg dl mean,C0444504;C2347634;C2348143
previous coronary artery bypass graft,C2144990
geographic region,C0017446
glucosamine n $nmbr$,C0017718
south n,C1710133
chondroitin sulfate n $nmbr$,C0008466
pr virgin islands n,C0279759;C0042752;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
glucosamine chondroitin sulfate n $nmbr$,C0017720
others n,C1955473;C3539125
celecoxib n $nmbr$,C0538927
time in trial,C0040223;C3541383;C0150312;C0008976;C0332285;C1707101
hispanic no,C0086409
no with visit,C0545082;C1512346;C2826704
duration of osteoarthritis symptoms yr,C0436359;C0029408
sbp dbp mean,C0444504;C2347634;C2348143
time since diagnosis of osteoarthritis yr,C0040223;C3541383
no of drugs,C0013227;C3687832
on step $nmbr$ drug,C0013227;C1254351
no of $nmbr$ mg acetaminophen tablets day,C0439422;C1243102
sd,C2699239
ara functional class no,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
figure percentage of subgroup with bp controlled sbp,C0439165;C1549488;C1561533;C0037623;C0085805;C1415692;C1708288;C4318478
unknown,C0439673;C3541433;C4050014
aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
kellgren and lawrence radiographic reading grade $nmbr$ no,C0441800;C0919553;C3244287
diff_measure dm added this as table had multiple headings,C0011816;C3250443;C1524062;C0039224;C1706074;C0439064
global assessment of disease status score,C0281858;C3176928
bl,C0005918;C0006413;C1552663;C2827109
physician,C0031831;C0804815
diff_measure,C0079809;C0242485
patient,C0030705
am_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
joint swelling effusion or both on clinical examination no,C1253936;C1963136;C4554335;C0031809
$nmbr$ $nmbr$ o lt,C0023376;C0230426;C3887647;C4521399
womac score,C0449820;C4050231
$nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
body weight kg,C0022718;C0439209;C4054209
stiffness subscale,C0427008
$nmbr$ $nmbr$ l ot,C1318464;C1418208;C1705587
function subscale,C0031843;C0542341;C0700205;C1705273
responder analyses achieving alc $nmbr$ $nmbr$,C0002778;C0936012;C1524024;C1424945;C3811058
normalized,C1882115
n responders,C0369718;C0441922
health assessment questionnaire score,C2960025
$nmbr$ $nmbr$ $nmbr$ t,C2603360
alternative disability,C1523987;C0231170
baseline alc $nmbr$ $nmbr$,C1424945;C3811058
pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
fasting lipids mmol $nmbr$,C0015663;C0023779;C0439190
sf $nmbr$ score,C0449820;C4050231
am_ delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
physical component,C0449432;C1705248
ldl,
mental component,C0449432;C1705248
hdl,C3715113
glucosamine,C0017718
non hdl,C1518422;C3715113
chondroitin sulfate,C0008466
vldl,C0523560
glucosamine chondroitin sulfate,C0017720
blood pressure mmhg,C0005823;C0439475;C1271104;C1272641
celecoxib,C0538927
mean_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
all randomized patients,C0034656;C0030705;C3815594
subgroup analyses,C2986480
primary outcome $nmbr$ decrease in womac pain score,C0392756;C0547047
bl alc $nmbr$ $nmbr$,C1424945;C3811058
at end of follow up no,C0444930;C2746065
blaic $nmbr$ $nmbr$,
secondary outcomes,C0027627;C1274040;C0175668;C0205436
bl bmioo kg m^,C0022718;C0439209;C4054209
omeract oarsi response,C0871261;C1704632;C1706817;C2911692
bl bml $nmbr$ kg m^,C0022718;C0439209;C4054209
$nmbr$ decrease in womac pain score,C0392756;C0547047
bl bm $nmbr$ $nmbr$ kg m^,C0022718;C0439209;C4054209
womac pain score,C0582148
bl bml $nmbr$ ke m^,C0005918;C0022558;C0006413;C1552663;C2827109
change from baseline,C0392747;C0443172;C1705241;C4319952
e characteristic n,C1521970
at end of follow up,C0444930;C2746065
toricoxib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
womac stiffness score,C0449820;C4050231
age mean years sd,C1510829;C2699239
womac function score,C0449820;C4050231
female $nmbr$,C0043210;C0086287;C1705497;C1705498
normalized womac score,C0449820;C4050231
caucasian $nmbr$,C0007457;C0043157
haq alternative disability score,C0449820;C4050231
body mass index mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
haq pain score,C0102923;C0582148;C0451208
previous anti inflammatory antirheumatic products n,C0432633
patient s global assessment of response to therapy score,C0030705;C0281858;C0871261;C1704632;C1706817;C2911692;C0449820;C4050231
meloxicam,C0083381
patient s global assessment of disease status score,C0030705;C0281858;C3176928
piroxicam,C0031990
physician s global assessment of disease status score,C0031831;C0804815;C0281858;C3176928
indomethacin,C0021246
joint swelling effusion or both on clinical examination,C1253936;C1963136;C4554335;C0031809
previous analgesic products n,C0205156;C0002771;C1552607
at baseline no,C0168634;C1442488
history of upper gi events perforations ulcers and bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0019080
at end of follow up no total no,C0444930;C2746065;C0439175;C0439810
non user $nmbr$,C1518422;C1548600;C1706077
no of $nmbr$ mg tablets of acetaminophen,C0024671;C1243102;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
increased risk for thrombotic cardiovascular,C4699158;C0007226;C3887460
patients with moderate to severe pain womac pain score $nmbr$ $nmbr$,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0582148
event n,C0441471;C4019010
at baseline,C0168634;C1442488
history of diagnosed hypertension n,C0455527;C0011900
patients with mild pain womac pain score $nmbr$ $nmbr$,C0030705;C0278138;C4522280
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ pty $nmbr$,
figure $nmbr$ pairwise comparisons of the overall likelihood of a response,C1707455;C0871258
continued use of gpa,C0549178;C1524063
subgroups those with mild pain and those with moderate severe pain,C1079230;C0278138;C4522280;C0278140;C4050465;C4521229
new use of gpa,C0205314;C1524063
baseline characteristic,C0168634;C1521970;C1442488
treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mtx plus placebo,C0025677;C1417487
air n $nmbr$,C0001861;C3536832
mtx plus infliximab,C0025677;C1417487
ig n $nmbr$,C0021027;C0305052;C0360506
coefficient,C1707429
air ig n $nmbr$,C0001861;C0021027;C0305052;C0360506;C3536832
swollen joint count $nmbr$ $nmbr$,C0451521
$nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
tender joint count $nmbr$ $nmbr$,C0451530
gender [n ],C0079399;C1522384;C0369718;C0441922
rf mg dl,C0035448;C0439269;C0201660;C0748398;C1547111
origin [n ],C0079946;C0439659;C1550512;C0369718;C0441922
crp mg dl,C3890735;C0439269;C4048285
african,C0027567
esr mm hour,C0439227;C0564385
duration of diabetes years,C0449238;C2926735
baseline shs $nmbr$ $nmbr$,C0168634;C1442488
oam use [n ],C0042153;C0457083;C1947944;C0369718;C0441922
j $nmbr$ coefficient,C1707429
insulin secretagogue,C0021641;C4704833;C1533581;C1579433;C3714501
or $nmbr$ ci,C0008107;C3259781
biguanides,C0005382;C0360396;C3540012
age per $nmbr$ years,C1510829
tzd,
sex male,C0086582
baseline insulin dose u kg [lsm se ],C0366513;C1300561;C0036919
swollen joint count $nmbr$ $nmbr$ per swollen joint,C0451521;C0152031;C4554794;C4696257
baseline a $nmbr$ c [lsm se ],C0168634;C0036919;C1442488
tender joint count $nmbr$ $nmbr$ per tender joint,C0451530;C0240094;C4554549;C4696258
a $nmbr$ c [n ],C1272460
rf mg dl per unit,C0439269
prior insulin use years,C0240016;C0439234
crp mg dl per unit,C0439269
algorithm $nmbr$,C0002045;C1553907
esr mm hour per unit,C3811131;C0456685
number,C0237753;C0449788
shs $nmbr$ $nmbr$ per $nmbr$ score,C0449820;C4050231
female male,C0086582;C1706180;C1706428;C1706429
baseline inflammation markers,C0021368;C0005516
duration since diagnosis years,C0449238;C2926735
changes in shs,C0392747;C0443172
time since start insulin years,C1301880
normal crp and esr,C3890735;C4048285;C3811131
hba $nmbr$ c baseline,C0168634;C1442488
fbg baseline,C0168634;C1442488
high crp or esr,C3890735;C4048285;C3811131
premixed insulin only,C0021641;C1533581;C1579433;C3714501
high crp and esr,C3890735;C4048285;C3811131
premixed insulin with oads,C0021641;C1533581;C1579433;C3714501
figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231;C0332174;C0439230;C0681867;C1514756;C0666743;C3899278;C0008976
insulin glargine oad,C0907402
shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group,C1547282;C0168634;C0201657;C1442488;C1176468;C1619634;C0441837;C0032042;C1696465;C1706408;C0025677;C0666743;C0072053
insulin glargine oad od prandial,C0229089;C0439164;C1512019;C3273373;C3665488;C1998602;C4553624
insulin glargine oad bd prandial,C0005126;C2344255;C4050145;C1998602;C4553624
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C0008976;C4706353
fbg mg dl,C0439269
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C3890735;C0441889;C4048285;C3811131;C0451521;C1510992;C2825518;C0008976
fbg mmol l,C1532563
crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups,C3890735;C3811131;C4048285;C0451521;C1510992;C2825518;C0008976;C0750572;C0017446;C0205146;C0025663;C0021966;C0221138;C0449851;C0871511;C0025677;C1417487;C1550452;C1704788;C3539107;C3888054;C0681841;C0374505
rosuvastatin,C0965129
$nmbr$ abciximab n $nmbr$,C0288672
mean yr,C0444504;C0439234;C2347634;C2348143
insulin treated diabetes,C0011847;C0011849
$nmbr$ yr no,C0439234
prior aortocoronary bypass surgery,C0455610;C0010055
nyha class no,C1882083
elevated troponin $nmbr$ $nmbr$ pg l,C0041199;C0439278
past or current angina pectoris,C0521116;C0002962;C1705970
elevated creatine kinase mb $nmbr$ u l,C0010290;C0439339;C0523584
current atrial fibrillation or flutter on ecg,C0004238;C0344434;C1963067;C0016385;C2242390
hours from clopidogrel loading mean sd,C0439227;C0070166
pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
multivessel disease,C0012634
implantable cardioverter defibrillator,C0162589;C2825184
target vessel,C0449618
laboratory measurements,C0681902
cholesterol mmol liter,C0008377;C0475211
left main artery,C0205091;C0003842;C0226004;C0443246;C1552822
apob apoa l ratio,C0456603;C1547037
left anterior descending artery,C0226032
triglycerides mmol liter,C0041004;C0475211
right coronary artery,C1261316
serum creatinine,C0201976;C0600061
complex lesions^,C0439855;C0221198;C1704241
$nmbr$ tmol liter no,C0475211
lesion length mean sd mm,C4330985;C4554674
estimated gfr,C0017654;C1424601
vessel size mean sd mm,C4330985;C4554674
nt pro bnp pmol liter j,C0669479;C0754710
diameter stenosis mean sd,C0552409;C2699239
hscrp mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
type of intervention,C3274412
current medication no,C0746467
drug eluting stent,C1322815
loop diuretic,C0354100;C3536704
bare metal stent,C2825200
loop or thiazide diuretic,C0445022;C0012802;C3536861
balloon angioplasty,C0002996;C0002997
aldosterone antagonist,C0002007;C2757004;C3536833
digitalis glycoside,C0012253
concomitant drug therapy at discharge,C0013216;C0013217
antiarrhythmic therapy,C0039798;C0087111;C1363945
calcium antagonists,C0006684
antiplatelet therapy,C1096021
primary end point no of events total no,C2986535;C0439175;C0439810
anticoagulant therapy,C0150457
all participants,C0679646
antiplatelet or anticoagulant therapy,C0150457
troponin level,C0441889;C0456079;C1547707;C2946261
placebo no of events no,C0032042;C1696465;C1706408;C0441471;C3541888
$nmbr$ $nmbr$ ug l,C0439275
rosuvastatin of patients rate,C0965129;C0030705
clopidogrel pretreatment duration,C0449238;C2926735
iii and iv,C0439070;C1705160;C0022326;C4265176
$nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ mm hg,C0439475
body mass indexj,C0518010
heart rate,C0018810
measured at clinic visit with automated device,C0444706;C3541902;C0025080;C0699733
$nmbr$ $nmbr$ bpm,
measured at clinic visit with usual device,C0444706;C3541902;C0025080;C0699733
previous revascularization,C0205156;C0581603;C1552607
measured at home with automated device,C0442519;C0025080;C0699733
cardiac rhythm,C0232187
lower than normal range ^,C0441994;C1548802;C2003888
sinus rhythm,C0232201
glucose mg dl,C0017725;C0439269
ldl cholesterol level,C0023824;C0201950;C0202117;C0428466
insulin iu,C0049272;C0439453;C0694756
$nmbr$ $nmbr$ mmol liter,C0439190;C0475211
insulin glucose ratio,C0456603;C1547037
apob apoa i ratio,C0456603;C1547037
subgroups,C1079230
hdl cholesterol level,C0201950;C0428466
relative risk $nmbr$ ci,C0008107;C3259781
triglyceride level,C0428475
at home systolic pressure $nmbr$ mm hg,C0871470;C0439475
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
at home systolic pressure,C4534363;C0871470
nt pro bnp,C0669479;C0754710
at home diastolic pressure $nmbr$ mm hg,C0428883;C0439475
$nmbr$ $nmbr$ pmol liter,C0439192;C0475211
at clinic systolic pressure $nmbr$ mm hg,C0871470;C0439475
hscrp level,C0441889;C0456079;C1547707;C2946261
at clinic systolic pressure,C0002424;C0871470;C0442592
$nmbr$ $nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
at clinic diastolic pressure $nmbr$ mm hg,C0428883;C0439475
assigned to topiramate,C1516050;C1552601
at clinic diastolic pressure,C0002424;C0428883;C0442592
assigned to placebo,C1516050;C1552601
weight,C0005910;C0043100;C1305866;C1705104
migraine occurrence days month,C0149931;C0556971
$nmbr$ lb,
migraine duration h,C0033727;C0369286;C0441932;C0564385;C4528284
enoxaparin n $nmbr$ $nmbr$,C0206460
migraine severity score,C0149931;C0457451
fondaparinux n $nmbr$ $nmbr$,C1098510
acute medication intake days month,C0013227;C0556971;C3244316;C4284232
time from onset of pain to randomization hr,C0449244;C0034656
midas score,C0449820;C4050231
diagnosis at study entry no,C1704656;C4068481
patients assessed,C0030705;C1516048
suspected myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
hit $nmbr$ score,C0449820;C4050231
current or former smoker,C0521116;C1705970;C0337671
sf $nmbr$ mcs score,C0449820;C4050231
any electrocardiographic abnormality no,C0522055
sf $nmbr$ pcs score,C0449820;C4050231
st segment depression $nmbr$ mm no,C4330985;C4554674
participants with metabolic syndrome,C0679646;C0524620
medications at the time of randomization no,C0013227;C0802604;C2598133;C4284232
participants without metabolic syndrome,C0679646;C0524620
clopidogrel or ticlopidine,C0070166;C0040207
number randomized,C0237753;C0449788;C0034656;C3815594
ace inhibitor or arb,C0003015;C4541021;C3888198
womens,
lipid lowering agent,C0086440
years of education,C0439234;C0013621;C0013622;C0013658;C0039401
medications in the hospital after randomization no,C0013227;C0802604;C2598133;C4284232;C0034656
antihypertensive treatments,C0003364;C0087111
procedures in the hospital no,C0025664;C0184661;C2700391;C3538935
atherosclerotic cvd,C0333482;C0007222
coronary angiography,C0085532;C1548829
history ol mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
pci,C4049621
history ol coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
procedures after discharge no,C0012621;C0030685;C2926602
other ascvd,C3665365
panel a,C0441833;C1706365;C1999270
st t wave,C0036056;C0429103;C3272372
no of,
lelt ventricular hypertrophy,C0340279
percentage of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
history ol chd at baselines,C0280604;C3542407
interaction p value,C1704675;C1709380
bmi kg m,C0022718;C0439209;C4054209
fondaparinux,C1098510
fasting glucose,C0015663;C0017725
creatinine,C0010294;C1561535
cardiovascular metabolic syndrome risk lactors,C0007226;C0524620;C3887460
at or above median,C0549183;C0876920;C2347635;C2348144;C2939193
fasting glucose $nmbr$ mg dl,C0015663;C0439269
less than median,C0549183;C0876920;C2347635;C2348144;C2939193
bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
heparin at randomization,C0019134;C0770546
fasting triglycerides $nmbr$ mg dl,C0015663;C0041004;C0439269
revascularization in $nmbr$ days,C0581603;C0439228
low hdl cholesterol,C0151691
catheterization laboratory in center,C0007430;C0022877;C3244292;C4283904
panel b,C0441833;C1706365;C1999270
high blood pressure,C0020538;C2926615
percentage of p,C0439165;C1549488;C1561533
lipid trial participantss,C0023779;C0008976
atients with event,C0441471;C4019010
table_group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
comparison,C1707455
center,C0205099;C3810851
with metabolic syndrome,C0524620
unfractionated heparin n $nmbr$ $nmbr$,C0019134;C2825026
without metabolic syndrome,C0524620
age $nmbr$ yr no,C0001779;C0439234
a,
white race no total no f,C0007457;C0043157;C0439175;C0439810;C0016327
amlodipine chlorthalidone,C0051696;C0008294
hypertension no total no,C0020538;C1963138;C0439175;C0439810
combined cvd,C0205195;C0007222
esrd,C0022661;C0035078;C2316810
hyperlipidemia no total no,C0020473;C0428465;C4555212;C0439175;C0439810
b,
current smoker no total no,C3173209;C3241966;C0439175;C0439810
lisinopril chlorthalidone,C0065374;C0008294
diabetes mellitus no total no,C0011849;C0439175;C0439810
categories of urinary acr ^g mg,C0683312;C1300563
prior myocardial infarction no total no,C0027051;C0428953;C2926063;C3810814;C4552959;C0439175;C0439810
p for trend,C0369773;C2603361
prior angina pectoris no total no,C0332152;C0002962;C2826257;C0439175;C0439810
lowest normal n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
prior percutaneous coronary intervention no total no,C0332152;C1532338;C2826257;C0439175;C0439810
low normal n $nmbr$,C0205251;C0205307;C0231683;C0439166;C2347086;C4553972;C1550472;C3890211;C4048187;C4321351;C4522223
anterior myocardial infarction no total no,C0340293;C0439175;C0439810
medium normal n $nmbr$,C0009458;C0205307;C0231683;C0439166;C2347086;C4553972;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
long term treatment with aspirin no total no,C0023977;C0004057;C0439175;C0439810
high normal n $nmbr$,C0205250;C0205307;C0231683;C0439166;C2347086;C4553972;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
unfractionated heparin within $nmbr$ hr before randomization no total no,C0019134;C2825026;C0034656;C0439175;C0439810
low medium microalbuminuria n $nmbr$,C0205251;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C1550472;C3890211;C4048187;C4321351;C4522223
lmwh within $nmbr$ days before randomization no total no,C0019139;C3536766;C0034656;C0439175;C0439810
high microalbuminuria to macroalbuminuria n $nmbr$,C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
creatinine clearance ml min,C0812399;C0439445
male acr definition ^ g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
killip class no i,C1881332;C0021966;C0221138
female acr definition ^g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
data missing,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
female sex n,C0086287
timi risk score no total no c,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810
white n medical history n,C0262926;C1704706
time from symptom onset to start of fibrinolytic therapy hr,C0449244;C0439659;C0040044
prior angina pectoris,C0332152;C0002962;C2826257
fibrinolytic therapy no,C0040044
prior cabg,C0332152;C0010055;C2826257
time from fibrinolytic therapy to study drug administration no total no,C0040223;C3541383;C0150270;C3469597;C0439175;C0439810
prior ptca or cabg,C0332152;C2936173;C2826257;C0010055
$nmbr$ min,C0702093;C1524029;C3813700
current smoker n of patients,C3173209;C3241966
$nmbr$ $nmbr$ min,C0702093;C1524029;C3813700
dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799;C0439475;C0680730
ace inhibitors or angiotensin receptor blockers,C0003015;C0521942;C0815017
egfr ml mn $nmbr$ $nmbr$ m $nmbr$,C0026327;C0026405;C4285072
statin,C0360714
mean serum potassium mg dl,C0302353;C0439269;C0543465
statistics,C0038215;C0600673
mean serum cholesterol mg dl,C0587184;C0439269
w,
ni,C0028075;C2348274;C3869926;C3869927
lv function $nmbr$ $nmbr$ and,C0031843;C0542341;C0700205;C1705273
j $nmbr$ blocker,
mean s d,C0444504;C2347634;C2348143
dbp mmhg,C0536221;C0439475;C3813197;C4281799
potassium sparing diuretic,C0304490;C3536751
other diuretic,C0012798
sbp mmhg,C0085805;C0439475
digitalis,C0012252;C0304520
hemoglobin gm dl,C0017480;C3642216;C3854019
active treatment,C1704532
albuminuria g g,C0001925;C1319635
hr and $nmbr$ ci,C0008107;C3259781
in,
gm,C0017480;C3854019
low to medium microalbuminuria n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
proteinuria $nmbr$ g day,C0033687;C0439417;C1962972;C4554346
urinary acr,C1412134;C1515941
primary outcome n $nmbr$,C0205225;C0439612;C0439631
bmi body mass index dbp diastolic blood pressure gm geometric mean sbp systolic blood pressure the analysis was based on observed data without imputation on missing values asubgroup of patients in whom $nmbr$ h urine was collected see materials and methods section,C0488055;C0871470;C1306620;C0002778;C0936012;C1524024;C1527178;C1705938;C2699638;C0030705;C0042036;C0042037;C2963137;C0042789;C0520510;C1947903;C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
$nmbr$ $nmbr$ reference,C1514811;C1706462
pre specified hr $nmbr$ cl,C2826245;C0596019
cardiovascular death n $nmbr$,C0007226;C0011065;C1306577;C4082313;C4552775;C3887460
adjusted hr $nmbr$ cl,C0456081;C0596019
all cause mortality n $nmbr$,C0015127;C0026565;C0026566;C1524003
n event rate,C0871208;C1521828
primary,C0205225;C0439612;C0439631
w event rate,C0871208;C1521828
companion $nmbr$ $nmbr$ hours,C0031268;C0439227;C0335343;C0682323
companion wake up stroke,C0038454;C4554100
bp blood pressure ci confidence interval esrd end stage renal disease hr hazard ratio all patients except patients with other race were included with missing covariates imputed event no of patients with esrd rate event rate per $nmbr$ years of follow up pre specified a cox model with treatment group and region as covariates and baseline proteinuria level o or x $nmbr$ g g as strata adjusted a multivariate cox model with treatment group time varying systolic and diastolic bp as covariates pre specified analysis and adjusted for time varying bp,C1442095;C0030705;C0034510;C1706779;C3853635;C0332257;C0441471;C4019010;C0589120;C1522577;C1704685;C3274571;C2826245;C1565830;C0679845;C0017446;C0205147;C0168634;C0033687;C1962972;C4554346;C1442488;C1319635;C0456081;C0428883;C0037623;C1415692;C1708288;C4318478
mean age y mean sd,C0001779;C2699239
baseline to year $nmbr$,C0168634;C1442488
men women,C0025266;C0043210
relative risk $nmbr$ cl,C0242492;C0596019
mean weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
age $nmbr$,C0001779
location,C0450429;C1515974;C4284930;C4284931
age a $nmbr$,C0001779
south africa,C0037712
non black,C0005680;C0027567;C0085756;C0439541
australia,C0004340
diabetic,C0241863
ct findings,C2607943;C2926606;C3539655
non diabetic,C1518422;C0241863
$nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
year $nmbr$,C0439234;C0439508
$nmbr$ patients,C0030705
gender n,C0079399;C1522384
new stroke,C0038454;C4554100
age years mean range,C1514721;C2348147;C3542016
old stroke,C1536121
diagnoses risk factors n,C0035648;C1553898
previous tia,C0007787;C0917805;C1054154
previous stroke,C0038454;C4554100
lipid and lipoprotein values mg dl,C0023779;C0023820;C0439269
mean systolic bp mmhg mean sd,C0871470;C2699239
hs crp mg l,C3890735;C0439268;C4048285
c,
mean diastolic bp mmhg mean sd,C0428883;C2699239
non c,C1518422
mean serum glucose mg dl mean sd,C0202041;C2699239;C3534430
known chd,C0280604;C3542407
figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b,C0520511;C1704711;C1522706;C2349188;C3714939;C3854213;C1274040;C1546471;C2825142;C1524063;C0002778;C0030705;C0936012;C1524024;C4684790;C0009247;C0599755;C1522326;C0288672;C0032042;C1696465;C1706408;C0871208;C1521828;C0168634;C1442488;C0449820;C4050231;C1547282
hyper tension,C0020538;C1963138
subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes,C1079230;C1527178;C1705938;C0683970;C0235828;C0205225;C1274040;C0439612;C0439631
baseline ldl c $nmbr$ mg dl,C0168634;C0439269;C1442488
baseline hb $nmbr$ g $nmbr$ $nmbr$ n $nmbr$,C0062408
apo b,C0003593;C3252643
baseline hb $nmbr$ g i $nmbr$ n $nmbr$,C0062408;C0086706
apo a i,C0085201;C1677784
$nmbr$ placebo n $nmbr$,C0032042;C1696465;C1706408
entire cohort,C0009247;C0599755
race or ethnicity n,C0034510;C1706779;C3853635;C0015031;C0243103
simva n $nmbr$,
eze simva n $nmbr$,
diastolic bp mm hg,C0428883;C0439475
female simva n $nmbr$,C0043210;C0086287;C1705497;C1705498
uacr mgg $nmbr$ gm,C0017480;C3854019
female eze simva n $nmbr$,C0043210;C0086287;C1705497;C1705498
serum creatinine limo $nmbr$ $nmbr$,C0201976;C0600061
male simva n $nmbr$,C0086582;C1706180;C1706428;C1706429
egfr ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
male eze simva n $nmbr$,C0086582;C1706180;C1706428;C1706429
triglycerides mmolt $nmbr$ gm,C0017480;C3854019
caucasian simva n $nmbr$,C0007457;C0043157
serum albumin g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
caucasian eze simva n $nmbr$,C0007457;C0043157
hemoglobin g $nmbr$ $nmbr$,C1319312
non caucasian simva n $nmbr$,C0007457;C0043157
calcium mmol $nmbr$ $nmbr$,C0006675;C0439190;C0006726;C2936886;C3540037;C3714611
$nmbr$ $nmbr$ io i,C0021966;C0221138
phosphorus mmol $nmbr$ $nmbr$,C0031705;C0439190;C0080014;C3714498
p valuec,C0369773;C2603361
non caucasian eze simva n $nmbr$,C0007457;C0043157
$nmbr$ years simva n $nmbr$,C0439234
hemoglobin gl^ $nmbr$ for combined hemoglobin groups,C0018229;C1423073;C1427674
$nmbr$ years eze simva n $nmbr$,C0439234
hemoglobin gl^ $nmbr$ for baseline hemoglobin $nmbr$ gl^ $nmbr$,C0019046;C0018229;C1423073;C1427674
gender n ],C0079399;C1522384
hemoglobin gl^ $nmbr$ for baseline hemoglobin gt $nmbr$ gl^ $nmbr$,C0019046;C0018229;C1423073;C1427674
race n ],C0034510;C1706779;C3853635
gmr,C1522544;C1704695
diagnoses risk factors n ],C0035648;C1553898
reduction,C0301630;C0392756;C1293152;C4551656
$nmbr$ mg dl simva n $nmbr$,C0439269
uacr mgg^ $nmbr$,
$nmbr$ mg dl eze simva n $nmbr$,C0439269
bsl hb gl $nmbr$,C0018229;C1423073;C1427674
rrr $nmbr$ cl,C0596019
$nmbr$ mg dl simva $nmbr$,C0439269
p valuea,C0369773;C2603361
$nmbr$ mg dl eze simva $nmbr$,C0439269
interaction $nmbr$,C1704675
chd status,C0280604;C0449438;C3542407
k rate,C0871208;C1521828
chd simva $nmbr$,C0280604;C3542407
cox bsl only,C1565830;C1549954
chd eze simva $nmbr$,C0280604;C3542407
no chd simva $nmbr$,C0280604;C3542407
cox bsl yr $nmbr$ hbd,C1549954;C0439234
esrd or death,C0022661;C0035078;C2316810;C0011065;C1306577;C4082313;C4552775
no chd eze simva n $nmbr$,C0280604;C3542407
simva,
eze simva,
bsl baseline cl confidence interval esrd end stage renal disease hb hemoglobin k rate of events per $nmbr$ patient years of follow up rrr relative risk reduction yr year ^treatment effect of losartan versus placebo interaction test between treatment group and hemoglobin group $nmbr$ or $nmbr$ g i $nmbr$ cmultivariate cox model with baseline log urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin as covariates dmultivariate cox model with baseline log urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin and change in hemoglobin at year $nmbr$ as covariates,C0026538;C1554093;C3242279;C3242455;C0237455;C1626828;C1565830;C3161035;C3274659;C3714583;C3853906;C0019046;C0201976;C0600061;C0392747;C0443172;C1705241;C4319952;C0439234;C0439508
$nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hemoglobin category,C0683312;C3889287
entire cohort gender,C0079399;C1522384
no anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
caucasian,C0007457;C0043157
improving anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1272745;C1319635
non caucasian,C0007457;C0043157
new anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
$nmbr$ years baseline ldl c,C0439234;C0168634;C1442488
persistent anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
$nmbr$ mg dl chd status,C0439269;C0449438
missing hb at yr $nmbr$,C0019046;C0439234
chd,C0280604;C3542407
no chd,C0280604;C3542407
bsl baseline cl confidence interval esrd end stage renal disease hb hemoglobin hr hazard ratio k rate of events per $nmbr$ patient years of follow up yr year multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin as covariates,C0026538;C0030705;C0439234;C0683312;C3889287;C0201976;C0600061;C0019046
men total n $nmbr$,C0025266;C0439175;C0439810
p $nmbr$ $nmbr$ for between treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean standard error simva simvastatin eze ezetimibe chd coronary heart disease,C0369773;C2603361;C1705241;C1705242;C1511726;C3245479;C3714741;C0023189;C0010068
diet n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
select lipids and lipoproteins,C1707391;C0023779;C0023820
diet pravastatin n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
eze simva gender,C0079399;C1522384
total n $nmbr$,C0439175;C0439810
female simva,C0043210;C0086287;C1705497;C1705498
mean sd y,C0444504;C2347634;C2348143
female eze simva,C0043210;C0086287;C1705497;C1705498
sbp mean sd mm hg,C0085805;C0439475
male simva,C0086582;C1706180;C1706428;C1706429
dbp mean sd mm hg,C0444504;C0439475;C2347634;C2348143
male eze simva,C0086582;C1706180;C1706428;C1706429
smoker n,C0337664
caucasian simva,C0007457;C0043157
drinking n,C0001948;C0684271;C0369718;C0441922
caucasian eze simva,C0007457;C0043157
lipid values mmol l,C0023779;C1532563
non caucasian simva,C0007457;C0043157
tc mean sd,C0039411;C2699239;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
non caucasian eze simva,C0007457;C0043157
ldl c mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ years simva,C0439234
hdl c mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ years eze simva,C0439234
tg median interquartile range,C0337445;C1711350
$nmbr$ years eze simva baseline ldl c,C0439234;C0168634;C1442488
lp a mean sd,C0065058;C2699239;C1439335;C4553379
$nmbr$ mg dl simva,C0439269
incidence rate no $nmbr$ person years,C1708485;C0027361;C0439234;C2347489
$nmbr$ mg dl eze simva,C0439269
diet,C0012155;C0012159;C1519433;C2983588;C3668949
chd simva,C0280604;C3542407
diet pravastatin,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
chd eze simva,C0280604;C3542407
heterogeneity p value,C0019409;C1709380;C0242960
no chd simva,C0280604;C3542407
chd cerebrovascular disease,C0280604;C0007820;C3542407
no chd eze simva,C0280604;C3542407
hazard ratiof $nmbr$ ci,C0008107;C3259781
chd cerebral infarction,C0280604;C0007785;C3542407
p $nmbr$ $nmbr$ for eze simva pooled across doses vs simva pooled across doses for the entire cohort data are presented as least squares mean standard error median se for tg for the entire cohort and also for each selected subgroup simva simvastatin eze ezetimibe tc total cholesterol tg triglycerides hdl c high density lipoprotein cholesterol non hdl c non high density lipoprotein cholesterol apo apolipoprotein,C0369773;C2603361;C1709595;C2349200;C4522255;C1511726;C3245479;C3714741;C0449450;C0023189;C0337445;C0009247;C0599755;C1079232;C0003591
$nmbr$ years $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439234
clinical ae n,C0205210;C3887670
id genotype,C0009450;C0017431;C0600091;C1441613
laboratory ae n,C0022877;C3244292;C4283904
ii n $nmbr$,C1710602;C4082587
any clinical ae,C0205210;C3887670
id n $nmbr$,C0009450;C0600091;C1441613
drug related ae,C0013227;C3887670;C1254351
dd n $nmbr$,C3538867;C3814791
serious ae,C0205404;C3887670
race or ethnic group no,C0034510;C1706779;C3853635;C0015031;C1879937
discontinuations due to ae,C0457454;C0678226
myopathyt,
body mass index $nmbr$,C0005893;C0578022;C1305855
deaths,C0011065;C1306577
known duration of diabetes yr,C0449238;C2926735
alt and or ast $nmbr$ times uln consecutive,C1266129;C4553172;C0040223;C1519815;C1632851;C1707491
not available,C0686905
cpk $nmbr$ times uln,C0040223;C1519815;C1632851
use of antihypertensive drugs,C1524063
simva $nmbr$,
coronary revascularization procedure,C0877341
eze simva $nmbr$,
lipid disorder,C0154251
female simva $nmbr$,C0043210;C0086287;C1705497;C1705498
amputation,C0002688;C0332840;C1546539
$nmbr$ [ $nmbr$,
neuropathy,C0442874
female eze simva $nmbr$,C0043210;C0086287;C1705497;C1705498
laboratory variables,C0022877;C0439828;C3244292;C4283904
male simva $nmbr$,C0086582;C1706180;C1706428;C1706429
urinary albumin creatinine ratio median mg g range,C1514721;C2348147;C3542016
$nmbr$ c $nmbr$,
serum creatinine mg dlb,C0752347;C3890365
male eze simva $nmbr$,C0086582;C1706180;C1706428;C1706429
glomerular filtration rate $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1561549
caucasian simva $nmbr$,C0007457;C0043157
serum cholesterol mg dld,C1414063;C2826331
caucasian eze simva $nmbr$,C0007457;C0043157
serum triglycerides mg dle,C0024138;C3542918
non caucasian simva $nmbr$,C0007457;C0043157
hemoglobin g dlf,C1319312
non caucasian eze simva $nmbr$,C0007457;C0043157
glycosylated hemoglobin,C0017853
$nmbr$ years simva $nmbr$,C0439234
serum albumin g dl,C0036773;C0439267;C0728877
$nmbr$ years eze simva $nmbr$,C0439234
$nmbr$ mg dl simva n $nmbr$ ],C0439269
mean sd values are presented for all variables except medical history race or ethnic group and sex n and urinary albumin creatinine ratio median range abody mass index is the weight in kilograms divided by the square of the height in meters bto convert values to micromoles per liter multiply by $nmbr$ $nmbr$ estimated using the modified equation from the modification of diet in renal disease study dto convert values to millimoles per liter multiply by $nmbr$ $nmbr$ eto convert values to millimoles per liter multiply by $nmbr$ $nmbr$ ^to convert values to millimoles per liter multiply by $nmbr$ $nmbr$,C0444504;C0042295;C2347634;C2348143;C0449450;C0439828;C0034510;C1706779;C3853635;C0015031;C1879937;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0600653;C0918012;C1552854;C1637833;C2986546;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0439194;C0475211;C0750572;C1524063;C0552449;C0086153;C3671772;C0022658;C1532563;C1719797;C2911648;C0439190
$nmbr$ $nmbr$ ],
losartan n n,C0126174
$nmbr$ mg dl simva $nmbr$ $nmbr$ ],C0439269
placebo n n,C0032042;C1696465;C1706408
$nmbr$ mg dl eze simva $nmbr$ $nmbr$,C0439269
adjusted $nmbr$ risk reduction losartan vs placebo $nmbr$ cl,C1137094;C0126174;C0032042;C0596019;C1696465;C1706408
chd simva $nmbr$ $nmbr$ ],C0280604;C3542407
composite endpoint of doubling of serum creatinine esrd or death,C2349179;C2826544;C0011065;C1306577;C4082313;C4552775
chd eze simva n $nmbr$ ],C0280604;C3542407
id,C0009450;C0600091;C1441613
no chd simva n $nmbr$ ],C0280604;C3542407
dd,C3538867;C3814791
no chd eze simva $nmbr$ $nmbr$,C0280604;C3542407
doubling of serum creatinine,C0205173;C1705764
or esrd,C0022661;C0035078;C2316810
determined by investigator to be possibly probably or definitely related to study drug tmyopathy defined as cpk $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^consecutive defined as two or more measurements at least one week apart or one measurement $nmbr$ days after the last dose of study drug presumed consecutive two patients had incomplete data to assess chd status simva simvastatin eze ezetimibe ae adverse event alt alanine aminotransferase ast aspartate aminotransferase cpk creatine phosphokinase uln upper limit of normal,C0521095;C0035173;C2362652;C0750492;C0439849;C0445223;C1704788;C3539106;C0521989;C0242485;C1442452;C3844320;C0678766;C3242203;C1516048;C1282910;C0439801;C1549649;C2349209;C0205307;C0231683;C0439166;C2347086;C4553972
rosiglitazone,C0289313
aspirin dipyridamole n $nmbr$,C0732279
metformin,C0025598
aspirin alone n $nmbr$,C0004057;C0205171;C0439044;C0679994
glyburide,C0017628
randomisation scheme,C0034656;C1519193
time since diagnosis of diabetes,C0040223;C3541383
three arm,C0205449;C0446516;C3715044;C4553528
$nmbr$ $nmbr$ years,C0439234
two arm,C0446516;C3715044;C4553528
a $nmbr$ c,
transient monocular blindness,C0149793
fasting insulin pmol l,C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
transient ischaemic attack,C0007787;C0917805
estrogen containing hormones,C0014939;C0019932;C2936882;C4542544
minor ischaemic stroke,C0026193;C0948008;C0205165
calcium supplements,C3540037
time from longest event to randomisation,C0040223;C3541383;C0034656
bisphosphonates,C0012544;C3541401
$nmbr$ week to $nmbr$ month,C0332174;C0439230
glucocorticoids,C0017710;C3540777;C3540778
$nmbr$ $nmbr$ months,C0439231
thiazide diuretics,C0012802
rankin grade,C0441800;C0919553;C3244287
loop diuretics,C0354100
$nmbr$ no symptoms,C0683368;C1457887
py $nmbr$ $nmbr$,C0030428;C3538810
$nmbr$ minor symptoms no limitations,C0683368;C1457887;C0449295
py,C0030428;C3538810
$nmbr$ some restrictions no help needed,C0443288;C1269765;C1552861;C0027552;C0686904
number of patients with fractures,C2360800;C0016658
$nmbr$ help needed still independent,C0085862;C1290940;C1299583
fractures site not specified,C0449676;C1518422;C0205369
additional investigations,C2359834
lower limb fractures,C0596838
ct or mr scan of the brain,C0007673;C3540513;C3813556;C3888140;C0596217;C0881827
hip fracture,C0019557;C0149531;C4552776
any infarct,C0021308
others,C1955473;C3539125
any relevant infarct,C2347946;C0021308
ankle fracture,C0159877;C4552974
ultrasound carotid arteries,C0948945
femur fracture,C0015802
stenosis $nmbr$,C0678234;C1261287;C2632116
fibula fracture,C0149699
intermittent claudication,C0021775
foot fracture,C0272774
vascular intervention,C0184661;C0886296;C1273869
lower limb fracture,C0596838
hyperlipidaemia,C0020473;C0428465;C4555212
patella fracture,C0159849
systolic mean sd,C0039155;C2699239
tibia fracture,C0040185
diastolic mean sd,C0012000;C2699239
skull and facial bone fractures,C0037303;C2951888;C0743751
type of vessel involved,C1282017;C1314939
spinal fractures,C0080179;C0518450
large vessel,C0225990
thoracic cage fractures,C0222762;C0016658
small vessel,C0225988
upper limb fractures,C0178316
unspecified,C0205370;C1549663;C2983689;C4048188
clavicle fracture,C0159658
antithrombotic drug use at time of event,C0242510
hand fracture,C0435632
oral anticoagulants,C0354604
humerus fracture,C0020162
dose of aspirin,C4696290
radius fracture,C0034628
figure $nmbr$ subgroup analyses for primary outcome event,C2986480;C1624730
upper limb fracture,C0178316
estimated gfr at baseline ml min $nmbr$,C0017654;C1424601
wrist fracture,C0435630;C4553927
m $nmbr$,
py $nmbr$,C0030428;C3538810
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
pelvic fractures,C0149531
$nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
forearm fracture,C1305215
female sex n of patients,C0086287
black participants,C0005680;C0679646;C0027567;C0085756;C0439541
race white n of patients,C0007457;C0043157
nonblack participants,C0679646
medical history n of patients,C0262926
i with mets n $nmbr$,C0021966;C0221138
documented mi,C1301725;C3810814;C1609436
i without mets n $nmbr$,C0021966;C0221138
current cigarette n,C0521116;C0677453;C1704760;C3890423;C1705970
$nmbr$ $nmbr$ $nmbr$ b,
years of education mean sd,C0439234;C0013621;C0013622;C0013658;C0039401
mean blood pressure mm hg,C0428886;C0439475;C0488053
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
laboratory determinations,C0022877;C0680730;C3244292;C4283904
currentd,
mean serum creatinine mg dl,C0201976;C0439269;C0600061
antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lv ejection fraction $nmbr$ and,C0489482;C2700378
treated,C1522326
n of patients,C0369718;C0441922
untreated,C0332155
lv ejection fraction n $nmbr$,C0489482;C2700378
history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
medications n of patients,C0013227;C0030705;C0802604;C2598133;C4284232
history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
aspirin antiplatelet medication,C0085826
$nmbr$ $nmbr$ $nmbr$ c,
lipid lowering drug,C0086440
other atherosclerotic cvdd e,C0333482;C1859330
diuretic any,C0012798
st t wave abnormality d,C0036056;C1839341;C3272372
hrt use,C0042153;C0457083;C1947944
lvh by ecg or echocardiographyd,C0232306
egfr category,C0683312;C3889287
glycemic status f,C0449438;C0016327
trandolapril n $nmbr$,C0076891
impaired fasting glucose,C1272092
multivariable adjusted hr $nmbr$ ci,C0008107;C3259781
normoglycemic,C0580545
events n,C0441471;C3541888
history of chd at baseline d g,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488;C0439267
hr $nmbr$ ci,C0008107;C3259781
lipid trial participants,C1997894;C2242969
trandolapril,C0076891
systolic mean sd mm hg h,C0456680
egfr $nmbr$,C1739039;C3811844;C3812682
diastolic mean sd mm hg,C0012000;C0439475
egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$,C1739039;C3811844;C3812682
serum potassium level mean sd meq l,C0302353;C0439375;C0543465
reference,C1514811;C1706462
cardiovascular mortality or mi,C0026565;C0026566;C3810814
fasting serum glucose level mean sd mg dl,C0202045;C0439269
cardiovascular mortality mi or revascularization,C0007226;C3810814;C3887460;C0581603
serum creatinine level mean sd mg dl,C0600061;C0439269
hope n $nmbr$,C0392347
tc level mean sd mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
hope patients with coronary artery disease n $nmbr$,C0741926
ldl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
europa n $nmbr$ l $nmbr$,C0242751
hdl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
peace n $nmbr$,C0680443
hdl c level $nmbr$ mg dld,C1414063;C2826331
previous stroke ortransient ischaemic attack,C0038454;C0745413;C4554100
fasting triglyceride level mean sd mg dl,C0015663;C0428475;C0439269
peripheral artery disease,C1704436;C4025272
cv mortality,C0026565;C0026566
serum cholesterol mg l,C0587184;C0439268
combined chd,C0280604;C3542407
diastolic blood pressure mm hg medications,C0849164
non black participants,C0005680;C0679646;C0027567;C0085756;C0439541
antiplatelet agents,C0085826
i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
lipid lowering agents,C0086440
ii $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1710602;C4082587
doxazosin,C0114873
pci percutaneous coronary intervention cabg coronary artery bypass graft for hope $nmbr$ mg l for europa $nmbr$ mg l or on a lipid lowering treatment for peace data are mean sd data are mean sd unless otherwise indicated,C0010055;C0242751;C0439268;C0023767;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C1444656
$nmbr$ year rates in placebo groups,C0871208;C1521828
figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease,C1707455;C0077770;C1511726;C3245479;C3714741;C2985465;C0009667;C0871208;C1521828;C4330837;C0013227;C1254351;C0034510;C1706779;C3853635;C0280604;C3542407;C0010054;C0010068;C1956346;C0022661
interactior $nmbr$ p,
p women vs men,C0369773;C0043210;C2603361;C0025266
with antiplatelets,
overaii n $nmbr$,
without antiplatelets,
atenoioi n $nmbr$,
with lipid lowering agents,C0086440
biack,
without lipid lowering agents,C0086440
systoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
with p blockers,C0369773;C2603361
diastoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
without p blockers,C0369773;C2603361
body mass index kg m^,C0022718;C0439209;C4054209
all of the above,
corneii product mm ms,C2349943;C3539704;C3713294
one of the above,C0205447
sokoiow lyon voitage mv,C1454484;C1705503;C4281602
two of the above,C0205448
current smokers n medicai history n,C3173209;C3241966
none of the above,
isoiated systoiic hypertension,C0020538;C1963138
with revascularisation,C0581603
cerebrovascuiar disease,C0012634
without revascularsation,
peripherai arteriai disease,C0012634
revascularisation antiplatelets lipid lowering agents p blockers,C0086440
adjusted hr losartan vs atenolol,C0456081;C0126174;C0004147
revascularisation but no antiplatelets lipid lowering agents or p blockers,C0581603;C0086440;C0369773;C2603361
women n $nmbr$ events,C0441471;C3541888
no pretreatment,C1550147;C2709094;C3539075;C3539076
women n $nmbr$,C0043210
ufh only,
ratet n,
enoxaparin only,C0206460
primary composite^,C0205199;C1547335
unadjusted p value,C1439367;C1709380
cardiovascuiar mortaiity,
region,C0017446;C0205147
myocardiai infarction,C0021308
australia new zealand,C0027978;C0324547
totai mortaiity,
latin america,C0023122
hospitaiization for angina,C0002962
ecg at time of qualifying symptoms,C1623258;C0040223;C3541383;C1514624;C0683368;C1457887
hospitaiization for heart faiiure,C0018787
st segment elevation,C0520886
vildagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
inclusion criteria,C1512693
viidagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age is $nmbr$ vrs significant ecg changes and no positive bi omark ers,C0001779;C0237881;C0855329;C0750502;C1546944;C1704489;C2931783
placebo glimepiride,C0032042;C0061323;C1696465;C1706408
age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes,C0001779;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269;C4050619;C0855329
age years mean s d,C1510829;C0444504;C2347634;C2348143
hispanic latino,C0086409;C0086528
si gni fi canr ecg changes positive biomarkers and age,C0855329;C0005516;C0001779
bmi kg m^ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
age is $nmbr$ vrs significant ecg changes and positive biomarkers,C0001779;C0237881;C0855329;C0750502;C1546944;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269
hbaic mean s d,C0444504;C2347634;C2348143
time to randomization h,C0040223;C3541383
hvpertension,
hbaic group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
hvpercholesterolemia,
fpg mmol l mean s d,C0439433
familv historv of cad,C1504769;C2239547;C3813548;C4284121
disease duration years mean s d,C0872146;C0439234
medical historv,C0199168;C0205476
duration of sulphonylurea use months mean s d,C1881378;C2826775
chf,C0018802
fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged,C0349966;C1337208;C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C2349179;C2826544;C0001779;C0001792;C1999167
transient ischemic attack,C0007787;C0917805
amlodipine valsartan $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diet group n $nmbr$,C0012155;C0441848;C0012159;C1519433;C2983588;C3668949
amlodipine valsartan $nmbr$ $nmbr$ mg n $nmbr$ i,C0021966;C0221138
diet plus pravastatin group n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
total study population n $nmbr$,C3258257
current past smoker,C3173209;C3241966
age ya,C0001779
lipid concentrations,C0023779;C0086045
age category,C0683312;C3889287
$nmbr$ ^ $nmbr$ $nmbr$,
mssbp mm hga,C4330985;C4554674
triglyceride mmol l t,C0041004;C1532563
msdbp mm hga,C4330985;C4554674
lipoprotein a mmol l,C0065058;C1532563;C0125953;C1096202;C1439335
sitting pulse bpma,C0277814;C0232117;C0391850;C1947910;C2584297;C4050224
medications,C0013227;C0802604;C2598133;C4284232
prior treatment,C1514463
antihypertensive drugs,C0003364
arb,C3888198
ace inhibitors arb,C0003015;C3888198
acei,
$nmbr$ blockers,
ccb,C0006684
reported by physicians tdata are median iqr all data are mean sd or number unless otherwise indicated,C1709908;C0031831;C0549183;C0876920;C2347635;C2348144;C2939193;C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0237753;C0449788;C1444656
severity of hypertensionb,C0439793;C0522510
ace angiotensin converting enzyme arb angiotensin receptor blockers,C0521942;C0815017
more severe,C0205082;C4050465;C4050466
p value for interaction,C1709380;C1704675
less severe,C0205082;C4050465;C4050466
o $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0483204
diabetic status,C0241863;C0449438
ldl cholesterol,C0023824;C0202117
nondiabetic,
hdlcholesterol,
with t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
abbreviations acei angiotensin converting enzyme inhibitor arb angiotensin receptor blocker bpm beats per minute ccb calcium channel blocker msdbp mean sitting diastolic blood pressure mssbp mean sitting systolic blood pressure values are no unless otherwise indicated amean sd bmore severe $nmbr$ and $nmbr$ and $nmbr$ and $nmbr$ and,C0034787;C1622222;C1319893;C0042295;C1444656;C2699239;C0205082;C4050465;C4050466
without t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
amlodipine valsartan $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rosuva $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine wlsartan i $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of hypercholesterolemia yr,C0449238;C2926735
amlodipine valsartan $nmbr$ $nmbr$ vs $nmbr$ $nmbr$ mg,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current smoker n,C3173209;C3241966
mssbp msdbp,
change from,C0392747;C0443172;C1705241;C4319952
nob systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
week and,C0332174;C0439230
history of hypertension n,C0455527
baseline mm hg,C0168634;C0439475;C1442488
history of chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
difference in change,C1705241;C1705242
history of pvd n,C4534349
disease severity,C0521117
statin potency stratum n,C0360714
sem,
low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
$nmbr$ ci p value,C0008107;C1709380;C3259781
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
endpoint week $nmbr$,C0332174;C0439230
concomitant medications,C0013227;C0802604;C2598133;C4284232
intent to treatb,C0162425;C1283828;C1550453
drugs used in diabetes n,C0013227;C3687832;C1273517;C0011847;C0011849
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
antithrombotic agents n,C1704311
less severe hypertension,C4013784
antihypertensive agents n,C0003364
more severe hypertension,C4013784
cardiac therapy n d,C3654025
mean sd age years,C0444504;C1510829;C2347634;C2348143
parameter statistics,C0038215;C0600673
mean sd bmi kg m $nmbr$,C0022718;C0439209;C4054209
rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current $nmbr$ cigs day,C0332173;C0439228;C0439505
ez simva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
exercise,C0015259;C1522704
all rosuva,
$nmbr$ week,C0332174;C0439230
all ez simva,C0206578
$nmbr$ $nmbr$ week,C0332174;C0439230
baseline mean mg dl],C0168634;C0439269;C1442488
$nmbr$ $nmbr$ month,C0332177;C0439231
mmol l],C1532563
postmenopausal hormone use,C0042153;C0457083;C1947944
c $nmbr$ $nmbr$ ],
aspirin group n $nmbr$ $nmbr$ $nmbr$ $nmbr$ person years,C0027361;C0439234;C2347489
se],C0036919
placebo group n $nmbr$ $nmbr$ $nmbr$ $nmbr$ person years,C0027361;C0439234;C2347489
treatment difference,C1705241;C1705242
newly diagnosed asthma n,C0011900;C0004096;C2984299
$nmbr$ y,
active,C0205177;C3853793;C3888249
$nmbr$ j $nmbr$,
mets,C0812270;C1705694;C2939420
se]tf hdl c,C0036919;C4048299;C3715113;C4048587
non mets,C0812270;C1705694;C2939420
baseline mean mg dl,C0168634;C0439269;C1442488
placebo dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
cl $nmbr$ ],C0596019
eze simva $nmbr$ $nmbr$ mg dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
se]tf total c,C0036919;C0439175;C0439810
feno $nmbr$ dn $nmbr$,C1333964;C1707618
se]t,C0036919;C2603360
eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
$nmbr$ q,
placebo dn $nmbr$,C1333964;C1707618
se]tf,C0036919;C4048299;C4048587
eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline median mg dl,C0168634;C0439269;C1442488
feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
$nmbr$ ell ll,C1427925;C3273466
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
waist circumference cm mean sd,C0455829;C2699239
$nmbr$ ell ll non hdl c,C1427925;C3273466;C1518422;C3715113
diagnosis of diabetes n,C0011900;C1704338;C1704656
ldl c hdl c,C3715113
tg mg dl,C0337445;C0439269
baseline mean,C0444504;C2347634;C2348143
non hdl c mg dl,C1518422;C0439269
se t,C0036919
apo b mg dl,C0003593;C0439269;C3252643
[ $nmbr$ $nmbr$ ],
tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
total c hdl c,C0439175;C3715113;C0439810
apo a i mg dl,C0085201;C0439269;C1677784
cse],
data are expressed as median sd except,C1511726;C3245479;C3714741;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ g,C0439267
data are expr,C1511726;C3245479;C3714741
cg ld,C0043444;C0694649;C1567075;C3540479
ssed as ls means,C0023668;C1704970
hscrp,
by treatment arm,C1522541
baseline median [mg l],C0549183;C0876920;C2347635;C2348144;C2939193;C0439268
syncope,C0039070;C3541349;C4554644
$nmbr$ ci] $nmbr$,C0008107;C3259781
by cause of death,C0007465;C4050444
$nmbr$ ci]h,C0008107;C3259781;C0033727;C0369286;C0441932;C0564385;C4528284
sudden death,C0011071;C1964022;C4554103
parameter,C0549193;C1704769;C2350001
all patients $nmbr$ $nmbr$,C0030705
diabetes mellitus n $nmbr$ $nmbr$,C0011849
verapamil sr $nmbr$ $nmbr$,C1527129
neither n $nmbr$ $nmbr$,C0369718;C0441922
atenolol $nmbr$ $nmbr$,C0004147
pbo statin n $nmbr$,C0031962;C0360714
sbp mean sd mmhg,C0085805;C0439475
eze statin n $nmbr$,C0360714
dbp mean sd mmhg,C0444504;C0439475;C2347634;C2348143
age years mean _ sd sex n,C1510829;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
heart rate mean sd b p m,C0018810;C0444504;C2347634;C2348143
metabolic syndrome characteristics n,C0524620;C1521970
age mean sd year,C0439234;C0439508
waist circumference women $nmbr$ in $nmbr$ cm men $nmbr$ in $nmbr$ cm tc $nmbr$ c $nmbr$ mg dl,C0455829;C0043210;C0025266;C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
arrhythmias,C0003811
_ $nmbr$ $nmbr$ mmol l hdl c women $nmbr$ mg dl $nmbr$ $nmbr$ mmol l men $nmbr$ mg dl,C3539687
heart failure class i iii,C0441887;C2698969
hypertension bp $nmbr$ $nmbr$ mmhg or using antihypertensive medication,C0020538;C0439475;C1963138;C1524063;C0003364
renal impairment,C1565489
fc $nmbr$ mg dl _ $nmbr$ $nmbr$ mmol l or history of diabetes,C0439268;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
smoking ever,C0037369;C0453996;C1881674
key fc fasting glucose bp this category did not include ar have $nmbr$ of the indicated charac,C0037623;C1415692;C1708288;C4318478;C0683312;C3889287;C1518422;C0332257;C1552866;C2700399;C1436327;C2986463;C3884535;C4521369;C1444656
sbp systolic blood pressure sd standard deviation dbp diastolic blood pressure b p m beats per minute mi myocardial infarction tia transient ischaemic attack,C1305849;C0439385;C0007787
blood pressure pbo y patients with diabe teristics ncep atp i,C0005823;C0030705;C1271104;C1272641
verapamil sr strategy,C1527129;C0679199
placebo eze tes fc j $nmbr$ rr $nmbr$ definition,C1550452;C1704788;C3539107;C3888054
atenolol strategy,C0004147;C0679199
ezetimibe tc triglycerides hdl c lg dl l $nmbr$ $nmbr$ mmol l] to qualify as having,C0039411;C0023128;C0694651;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
adverse outcome,C1274040
high density lipoprotein cholesterol metabolic syndrome patients were to,C0023822;C0030705
non fatal mi,C1302234;C3810814;C1705232
lipid measure,C0079809;C0242485
non fatal stroke,C0038454;C4554100
metabolic syndrome,C0524620
no prior mi,C0332152;C3810814;C2826257
neither pbo statin eze statin,C0031962;C0360714
denosumab n $nmbr$,C1690432
pbo statin $nmbr$,C0031962;C0360714
all n $nmbr$,C0369718;C0441922
ze statin,C0360714
$nmbr$ yr since menopause,C0439234;C0025320;C0567312
pbo statin,C0031962;C0360714
years since menopause,C0439234;C0025320;C0567312
eze statin,C0360714
bodymass index kg m $nmbr$,C0022718;C0439209;C4054209
ldl c mmol l mean,C0444504;C2347634;C2348143
lumbar spine bmd t score,C0449820;C4050231
n $nmbr$ n $nmbr$,C0369718;C0441922
serum ctx ng ml,C0010377;C0439275;C0631180;C3539598
baseline,C0168634;C1442488
serum p $nmbr$ np ^g liter,C0065827;C0475211;C1706141;C3887659
at six weeks,C0205452;C0439230
serum trap $nmbr$ b u liter,C0184047;C0475211;C1336677;C1566918;C1706005;C1710330;C3887583
change,C0392747;C0443172;C1705241;C4319952
site,C0205145;C1515974;C2825164
tg mmol l median,C0549183;C0876920;C2347635;C2348144;C2939193
stratum,
hdl c mmol l mean,C0444504;C2347634;C2348143
difference from baselinea,C1705241;C1705242
non hdl c mmol l mean,C0444504;C2347634;C2348143
difference from placeboa,C1705241;C1705242
total c mmol l mean,C0444504;C2347634;C2348143
ls mean,C0444504;C2347634;C2348143
apo b apo a l ratio mean,C0444504;C2347634;C2348143
ci b,C0008107;C3259781
hs crp mg l median,C0549183;C0876920;C2347635;C2348144;C2939193
p value c,C1709380
denosumab,C1690432
key tc triglyceride hs crp ldl c low density lipoprotein fc fasting glucose ncep atp this category did not include ar to have _ $nmbr$ of the indicated char least square means except tc an note all treatment by subgroup,C2744579;C4552600;C0683312;C3889287;C1518422;C0332257;C1552866;C2700399;C1436327;C2986463;C3884535;C4521369;C0023189;C1704970;C1316572;C1317574;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
trochanter,C0162370
one third radius,C0034627;C1306504
c reactive protein high sensitivity assay mitt modified intent to treat pbo cholesterol cl confidence intervals hdl c high density lipoprotein cholest national cholesterol education program adult treatment panel y patients with diabetes fc _ $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] to qualify as having acteristics described in methods ncep atp iii definition baseline values are rr d hs crr for which medians are presented p $nmbr$ $nmbr$,C0162425;C1283828;C1550453;C2699193;C3165426;C0439268;C1552738;C0456580;C0549183;C0449450
total body without head,C0229960;C0018670;C1706305
placebo eze ezetimibe erol apo apolipoprotein metabolic syndrome patients were eans and percentage changes are,C0524620;C0030705;C0392747;C0443172
volumetric bmd by qct,C0445383;C0412669
age $nmbr$ y n $nmbr$,C0001779
aggressive n $nmbr$,C0001807;C0580822
hypercholesterolemia $nmbr$ mg dl,C0020443;C0439269;C1522133
standard n $nmbr$,C1442989;C2828392
prior coronary artery bypass surgery,C0010055
gender women n,C0079399;C0043210;C1522384
interval from clopidogrel loading h,C1272706;C1552654;C1552713
body mass index bmi kg m $nmbr$,C0022718;C0439209;C4054209
elevated troponin t $nmbr$ $nmbr$ xg l,C0077404;C1420827
waist cm,C0230097
therapy at discharge,C0039798;C0087111;C1363945
ale,C0678386;C2632076
figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization,C0021149;C0220856;C0449618;C0001779;C0039798;C3810814;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0027051;C0428953;C2926063;C4552959;C0581603
diabetes therapy,C3274787;C3539002
age dependent effect of abcixima,C1280500;C1518681;C2348382
lifestyle,C0023676
death or myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
oral hypoglycemics,C0359086
target vessel revascularization,C0449618;C0581603
insulin plus oral,C0021641;C1533581;C1579433;C3714501
mace,C0349381;C0949745;C1445339
egfr,C1739039;C3811844;C3812682
major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
aspirin use $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hemorrhagic stroke,C0553692
carotid,C0741968
minor bleeding,C0026193;C0019080;C0205165
imt mm,C4330985;C4554674
blood transfusion,C0005841;C0281867
arterial area mm $nmbr$,C4330985;C4554674
profound thrombocytopenia $nmbr$ x $nmbr$ l,C0040034;C0392386
plaque score $nmbr$ $nmbr$,C0429153
sk $nmbr$,
moderate thrombocytopenia $nmbr$ x $nmbr$ l,C0205081;C0040034;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
plaque n,C0011389;C0241148;C0332461;C0333463;C4316797
mild thrombocytopenia $nmbr$ x $nmbr$ l,C1856453
cardiac,C0018787;C1522601
aged ^ $nmbr$ years,C0001779;C0439234;C0001792;C1999167
lv mass,C0455825
aged,C0001779;C0001792;C1999167
lv mass index g m $nmbr$ $nmbr$,C0455825;C0439267
p value aged $nmbr$ vs,C1709380;C0001779;C0001792;C1999167
z\tonastaiin,
lv ejection fraction,C0489482;C2700378
all,
aiorvasiaiin,
abbreviations egfr estimated glomerular filtration rate imt intimal medial thickness lv left ventricular two sample comparison t tests were calculated based on log transformed variables geometric mean with $nmbr$ confidence interval in parenthesis,C3811844;C0871472;C1527178;C1705938;C0009667
imt $nmbr$,C0334121;C1704614;C4318736
while ethnic origin,C0015031
aggressive $nmbr$,C0001807;C0580822
l $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
standard $nmbr$,C1442989;C2828392
systolic blood pressure mmhg,C0488055;C0439475;C0871470;C1306620
group dif $nmbr$,C0812246;C1710304
hl $nmbr$ $nmbr$,C1453952;C4085347
p val $nmbr$,C0042285;C0523975
diastolic blood pressure mmhg,C0428883;C0439475;C1305849
lvmi $nmbr$,
macroalbuminuria,
inter,C0205103;C1548610
retinopathy,C0035309;C1962966
non hdl mg dl,C1518422;C0439269
duration diabetes years,C0011847;C0439234;C0011849
$nmbr$ l $nmbr$,C0439394;C1706495;C3642217
hi ah,C0018619;C1836672;C0239849;C1412082;C1412316;C1431594;C4552857
current smoker yes,C1549445;C1705108;C1710701
ldl cholesicrol minol l,
primary prevention subgroup,C1079230;C1515021
kdl cholesterol mmol,C0008377;C0439190
secondary prevention subgroup,C1079230;C1515021
i idl cholesterol mg dl,C0619865;C0439269
no epa group n $nmbr$,C0441848
total cholesterol mmo $nmbr$ $nmbr$,C0201950;C0543421
epa group n $nmbr$,C0441848
toial cholcsierol mg dl,C0439269
cerebral thrombosis,C0079102;C0151945;C0795687
trigl yeerides m mol l,C0347982
cerebral embolism,C0007780
apolipoproiein a $nmbr$ tng $nmbr$,
tia,C0007787;C0917805;C1054154
apolipoproiein b mij $nmbr$,
cerebral hemorrhage,C2937358
$nmbr$ j $nmbr$ $nmbr$,
subarachnoid hemorrhage,C0038525
diabetes treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
triglyceride mmol l,C0041004;C1532563
bi $nmbr$ $nmbr$,
aa mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
$nmbr$ h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
epa mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
oral hypoglycemic drugs only,C0359086
$nmbr$ j $nmbr$ $nmbr$ $nmbr$,
epa aa ratio,C0456603;C1547037
insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501;C0359086
sbp indicates systolic blood pressure dbp diastolic blood pressure aa arachidonic acid epa eicosapentaenoic acid values for age bmi total cholesterol ldl cholesterol hdl cholesterol sbp dbp aa epa and epa aa ratio represent the mean values represent the median interquartile range p values are for the differences between the no epa and epa groups,C0085805;C1305849;C0042295;C2699193;C0456603;C1547037;C1882932;C0444504;C2347634;C2348143;C1711350;C1709380;C1705241;C1705242;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
blood pressure lowering treatment,C0596197
standard deviation triglyceride,C0871420;C0041004
a blocker,
no epa group no of events,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0441471;C3541888
i blocker,C0021966;C0221138
epa group no of events,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0441471;C3541888
calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
metoprolol group n $nmbr$,C0025859;C0441848
$nmbr$ h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
preoperative heart rate beats per minute,C0439385
ace inhibitor or angiotensin ii receptor,C0003015;C4541021;C0003011
preoperative blood pressure mm hg patients fulfilling eligibility criteria,C0005823;C0030705;C1271104;C1272641;C1550543;C1512693
aniagonisi,
diurciic,
stroke thought due to atherothrombotic disease,C0039869;C4319827
atv n,C0210243;C0674679;C1145759;C1334862
hospitalisation for chf within $nmbr$ years of randomisation,C0019993;C0018802;C0439234;C0034656
pbo n,C0031962
undergoing major vascular surgery,C0679637
rrr,
three of seven risk factors,C0035648;C1553898
total population,C3258257
intrathoracic or intraperitoneal surgery,C0595836;C0038894;C0038895;C0543467;C1274039
acute coronary event,C0205178;C0741923
any history of congestive heart failure,C0455531
age ^ $nmbr$,C0001779
diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849;C0521116;C0359086
coronary revascularization,C0877341
preoperative serum creatinine $nmbr$ pmol l,C0201976;C0439284;C0600061
fatal and nonfatal stroke,C1302234;C1705232;C0038454;C4554100
history of a transient ischaemic attack,C0455536
infliximab $nmbr$ mg kg,C0666743;C0439272
emergent urgent surgery,C0750573;C2188405
patients randomized,C0030705;C0034656;C3815594
other cardiovascular risk factors,C0850624
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
pre operative cardiac medications,C2347660
psoriasis duration yrs,C0033860;C0449238;C2926735
low molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766;C0354566
psoriatic arthritis,C0003872
surgery,C0038894;C0038895;C0543467;C1274039
bsa,
vascular,C0005847;C1558950;C1801960
pasi score $nmbr$ $nmbr$,C0449820;C4050231
intraperitoneal,C0442120
dlqi $nmbr$ $nmbr$,C3899393
orthopaedic,C0029355
prior therapy,C1514463
anaesthesia analgesia,C0002905
biologic agents,C0005515
general,C0205246;C3812897;C3891294;C4521767
topical therapy,C0039798;C0087111;C1363945
spinal,C0521329
uvb,C0454530;C0564461
lumbar epidural,C0581283
puva,C0853073;C1704892
acitretin,C0050559
general andthoracic epidural,C0228134;C0812144
cyclosporin,C0010592;C0010594
general and lumbar epidural,C0205246;C3812897;C3891294;C4521767;C0581283
placebo n,C0032042;C1696465;C1706408
regional anaesthesia,C0002911
infliximab combined $nmbr$ mg kg and $nmbr$ mg kg n,C0205195;C0439272
data are mean sd or n ace angiotensin converting enzyme arb angiotensin receptor blocker chf congestive heart failure any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0034787;C0018802;C1622222;C0042153;C0457083;C1947944;C0038894;C0038895;C0543467;C1274039;C1514873
difference,C1705241;C1705242
figure $nmbr$ subgroup analyses for the primary outcome,C2986480;C0205225;C0439612;C0439631
$nmbr$ ci for difference,C0008107;C3259781
valsartan n $nmbr$,C0216784
baseline pasi score,C0449820;C4050231
valsartan hctz n $nmbr$,C0216784;C0020261
baseline bsa involvement,C0168634;C1314939;C1442488
age median interquartile range y,C0001779;C1711350
dissatisfied with stopped $nmbr$ prior systemic therapy because of side effects,C0870433;C4085546;C0001688;C0877248;C0879626
age group no y,C0027362;C2348001
dissatisfied with stopped $nmbr$ prior systemic therapies because of side effects,C0870433;C4085546;C0001688;C0877248;C0879626
body mass index category no l,C0683312;C3889287;C0439394;C1706495;C3642217
prior use of $nmbr$ systemic therapies,C1524063;C1515119
lean,
prior use of biologic agents,C1524063;C0005515
overweight $nmbr$ to,C0497406
etoricoxib n $nmbr$ $nmbr$,C0972314
obese $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
diclofenac n $nmbr$ $nmbr$,C0012091
weight median interquartile range kg,C0022718;C0439209;C4054209
arthritis type,C0332307;C1547052
smoking status no,C1519386
osteoarthritis,C0029408
concomitant therapy no,C1707479
rheumatoid arthritis,C0003873
hormone therapy,C0279025
weight in kg mean sd,C0005910;C0043100;C1305866;C1705104
oral contraceptives,C0009905
bmi in kg m $nmbr$ mean sd,C0578022;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
hctz hydrochlorothiazide based on wilcoxon $nmbr$ sample rank sum tests for age and body mass index t tests for systolic and diastolic blood and $nmbr$ tests for categorical variables t data were missing for some patients,C0020261;C1527178;C1705938;C0001779;C0005893;C0871472;C0578022;C1305855;C0005767;C0005768;C0229664;C0022885;C0392366;C1551393;C1705492;C3272743
hispanic american,C0019576
pressure,C0033095;C0460139;C1306345;C4284008
multiracial,C1881928
valsartan n n,C0216784
othert,
dyslipidaemiaj,
valsartan hctz n n,C0216784;C0020261
current cigarette smoker,C3173209;C3241966
entire evaluable cohort,C0009247;C0599755
established atherosclerotic cv disease,C0333482;C0007222
current nonsmokers,C0337672;C4554605
$nmbr$ cv risk factors^ or established atherosclerotic cv disease,C0035648;C1553898;C0333482;C0007222
hctz hydrochlorothiazide based on a _ $nmbr$ test t data were missing for some patients,C0020261;C1527178;C1705938;C1551393;C1705492;C3272743
low dose aspirin use,C0042153;C0457083;C1947944
valsartan,C0216784
cardiac mediations,C0018787;C0680727;C1522601
valsartan hctz,C0216784;C0020261
anti arthritic medications,C0013227;C0802604;C2598133;C4284232
current nonsmoker,C0337672;C0425293;C4554605
cox $nmbr$ selective nsaid,C0003211;C3536840
diabetes status,C1317301
traditional nsaid,C0003211;C3536840
hctz hydrochlorothiazide data were missing for some patients,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
paracetamol,C0000970
characteristic and treatment,C1521970;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
high dose aspirin,C0444956;C0004057
primary pci n $nmbr$,C0205225;C0439612;C0439631
glucocorticoid,C0017710
abciximab facilitated pci n $nmbr$,C0288672;C4049621
dmard,C0242708
combination facilitated pci n $nmbr$,C0205195;C1947911;C3811910
etoricoxib,C0972314
family history of cad diagnosed at,C0241889;C1504769;C2239547;C3813548;C4284121;C0011900
diclofenac,C0012091
past or current,C0521116;C1705970
n pyr,C0369718;C0441922
patients treated with insulin,C0030705;C0332293;C0021641;C1533581;C1579433;C3714501
established ascvd,C0443211;C3665365;C1272684
previous mi no,C0205156;C3810814;C1552607
established ascvd or $nmbr$ cv risk factors,C0443211;C3665365;C1272684;C0035648;C1553898
previous chf no,C0205156;C0018802;C1552607
low dose aspirin use at baseline,C0042153;C0457083;C1947944
hypertension no hypercholesterolemia no,C0020538;C1963138;C0020443;C1522133
disease,C0012634
patients treated,C0030705;C1522326
etoricoxib dose,C0178602;C0869039;C1114758
location of infarction no,C0450429;C1515974;C4284930;C4284931
unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$,C0019134;C2825026;C0206460;C0016011
inferior or posterior,C0542339;C0678975;C0205095
bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$,C0168273;C0016011
not localized,C1518422;C0392752
bivalirudin alone n $nmbr$,C0168273;C0205171;C0439044;C0679994
interval from symptom onset to qualifying ecg obtained in the er hr,C1272706;C1552654;C1552713;C1514624;C1623258;C1301820;C3810541;C3811131
male sex no medical history no total no,C0086582;C0262926;C1704706;C0439175;C0439810
door to balloon time hr,C4296144
insulin requiring diabetes,C0011847;C0011849
peak procedural act sec,C0079613;C0565930;C1704930;C1869853;C3890007;C4048375
elevation of cardiac biomarker levels no total no,C0439775;C0702240;C0439175;C0439810
ace inhibitors through hospital discharge or day $nmbr$,C0003015;C0586003;C0332173;C0439228;C0439505
elevation of troponin levels no total no,C0439775;C0702240;C0439175;C0439810
beta blockers through hospital discharge or day $nmbr$,C0001645;C0586003;C0332173;C0439228;C0439505
st segment deviation $nmbr$ mm no total no,C4330985;C4554674;C0439175;C0439810
primary pci no,C0205225;C0439612;C0439631
elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no,C0439775;C0702240;C4330985;C4554674;C0439175;C0439810
combination facilitated pci,C0205195;C4049621;C1947911;C3811910
timi risk score no total no f,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810;C0016327
hazard ratio $nmbr$ confidence interval,C2985465;C0009667
variable demographic characteristics,C0683970
baseline killip class,C0168634;C1881332;C1442488
rosiglitazone n $nmbr$,C0289313
history of diabetes mellitus,C0455488
metformin n $nmbr$,C0025598
no or unknown,C0439673;C3541433;C4050014
glyburide n $nmbr$,C0017628
not anterior,C1518422;C0205094
race or ethnic background no f,C0034510;C1706779;C3853635;C0015031;C0016327
geographic location,C0017446
region no,C0017446;C0205147
rest of the world,C0035253;C1622890
time since diagnosis of diabetes no,C0040223;C3541383
hub,C0063034;C1414372;C1708389
anthropometric characteristics,C1521970
spoke,
waist circumference cm,C0455829
time from symptom onset to randomization,C0449244;C0034656
hip circumference cm,C0562350
$nmbr$ hr,
systolic mm hg,C0039155;C0439475
time from qualifying ecg to balloon inflation,C0040223;C3541383;C1514624;C1623258;C0021398;C1318493
diastolic mm hg,C0012000;C0439475
slowest third,C0439834;C0205437
antihypertensive therapy no,C0585941
middle third,C0442050
fasting plasma glucose mg dl,C0202042;C0439269;C0455280
fastest third,C0015663;C0205437;C0456962;C2985769
glycated hemoglobin,C0017853
time from symptom onset to balloon inflation,C0449244;C0021398;C1318493
fasting insulin pmol liter,C0015663;C0021641;C0475211;C1533581;C1579433;C3714501
index pci performed,C0600653;C4049621;C0918012;C1552854;C1637833;C2986546;C0884358
insulin sensitivity,C0920563;C4049919
pci delay due to low risk,C0205421;C0678226
^ $nmbr$ cell function,C0007613
enrollment in lmwh substudy,C1516879;C1696073;C3888021
gad positive no ^,C0439178;C1446409;C1514241;C2825490;C3812269
high risk,C0332167;C3272283;C4050568;C4319571
lipids,C0023779
sal n $nmbr$ $nmbr$,C0036140;C0037494;C0206136
lipid lowering therapy no,C0585943
fp n $nmbr$ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
sfc n $nmbr$ $nmbr$,C4521536
the test for heterogeneity interaction indicates whether the treatment effect varied significantly among the sub groups the hochberg method was applied to each of the two comparisons of the treatment groups bmi denotes body mass index the weight in kilograms divided by the square of the height in meters,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C0025663;C0449851;C0871511;C4048755;C0374505;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074
mean age sd yr,C0001779;C0439234
p value for heterogeneity rosiglitazone versus metformin,C1709380;C0019409;C0242960;C0025598
mean body mass index sd kg m $nmbr$,C0022718;C0439209;C4054209
p value for heterogeneity rosiglitazone versus glyburide,C1709380;C0019409;C0242960;C0017628
baseline post bronchodilator fev $nmbr$ sd ml,C0439526;C1705224;C3887665
$nmbr$ $nmbr$ $nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
predicted post bronchodilator fev sd ml,C0439526;C1705224;C3887665
$nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
region n,C0017446;C0205147
waist circumference,C0455829
asia pacific,C0003980
$nmbr$ $nmbr$ cm,
$nmbr$ cm,
number of subjects in analysis,C0237753;C0449788;C0002778;C0936012;C1524024
baseline fasting plasma glucose,C0202042;C0455280
baseline mean fev $nmbr$ sd ml,C0439526;C1705224;C3887665
i $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
adjusted rate of fev $nmbr$ decline se ml yr,C0456081;C0871208;C1521828
$nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
effect of covariates on slopes,C1280500;C1518681;C2348382;C0807955
general health self reported,C0424575;C4018875;C0681906;C2700446
current n $nmbr$ $nmbr$,C0521116;C1705970
very good or excellent,C3641222;C1548784;C1961136
former n $nmbr$ $nmbr$,C0205156;C0750523
good,C0205170
female n $nmbr$ $nmbr$,C0043210;C0086287;C1705497;C1705498
fair or poor,C2911689;C0032854;C0542537;C2700379
male n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
walk for exercise,C0080331;C0015259;C1522704
$nmbr$ n $nmbr$,C0369718;C0441922
fall in last $nmbr$ mo,C0085639;C0238715;C4553726
$nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
baseline vertebral fracture,C0168634;C0080179;C1442488
predicted fev $nmbr$,C0681842;C3714541;C1882327
$nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
history of clinical fracture $nmbr$ years old,C1272071;C0205210
united states n $nmbr$ $nmbr$,C0041703
high fracture risk stratum,C0332167;C3272283;C4050568;C4319571
asia pacific n $nmbr$,C0003980
former,C0205156;C0750523
eastern europe n $nmbr$ $nmbr$,C0015177
duration of alendronate use mean sd y,C1881378;C2826775
western europe n $nmbr$ $nmbr$,C0043129
current alendronate use,C0042153;C0457083;C1947944
other n $nmbr$,C0369718;C0441922
current use of hormone therapy,C1524063;C0279025
ethnic origin,C0015031
or raloxifene,C0244404
white n $nmbr$ $nmbr$,C0007457;C0043157;C0220938
time since start of fit mean sd y,C1301880;C0036572;C2349186;C4048158;C4553125
black n $nmbr$,C0005680;C0027567;C0085756;C0439541
time since end of fit mean sd y,C1522314;C0036572;C2349186;C4048158;C4553125
asian n $nmbr$,C0078988
flex baseline bmd mean sd g cm $nmbr$,C0168634;C0439267;C1442488
american hispanic n $nmbr$,C0596070;C0086409
total hip,C0019552;C0022122;C1505163;C3538851;C4284725
$nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
femoral neck,C0015815
exacerbations in the year before study,C4086268;C0439234;C0439508;C0557651;C2603343
lumbar spine,C0024091;C3887615
baseline sgrq total score,C0168634;C2964552;C1442488
forearm,C0016536
with dm n proactive intervention n $nmbr$ a,C0011816;C0184661;C0886296;C1273869;C3250443
total body,C0229960
without dm n $nmbr$ i $nmbr$,C0021966;C0221138
flex baseline bmd t score,C0449820;C4050231
usual care n $nmbr$ a,C3538928;C1947933
at femoral neck mean sd,C0015815;C2699239
p value $nmbr$,C1709380
$nmbr$ $nmbr$ to,
proactive intervention n $nmbr$ a,C0184661;C0886296;C1273869
serum bone specific alkaline,C0205369;C1552740;C1979842
usual care n $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
phosphatase mean sd ng mlf,C0017887;C0066495;C0028074
sbp mm hg mean sdc,C1419891;C3273112
serum c terminal telopeptide of,C0229671;C1707271;C1546774;C1550100
i $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
type $nmbr$ collagen mean sd ng ml,C0009325;C0439275
dbp mm hg mean sdc,C1419891;C3273112
serum n propeptide of type $nmbr$ collagen,C1709708;C1875696
heart rate beats min mean sd,C0425583;C2699239
mean sd ng ml,C0444504;C0439275;C2347634;C2348143
tc mg dl mean sd,C0439269;C2699239
dietary calcium intake mean sd mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ldl c mg dl mean sd,C0439269;C2699239
early routine,C1279919;C0205547
hdl c mg dl mean sd,C0439269;C2699239
post fibrinolysis angioplasty n $nmbr$,C0016017;C0162577;C1548817;C1305868
tg mg dl mean sd,C0439269;C2699239
primary angioplasty n $nmbr$,C0205225;C0162577;C1548817;C0439612;C0439631
$nmbr$ year framingham chd risk,C0439234;C1282512;C0439508
age year,C0439234;C0439508
$nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
male sex n,C0086582
current smoking n,C0037369;C0453996;C1881674
cholesterol $nmbr$ $nmbr$ mmol l n,C0008377;C1532563
treated patients with baseline and $nmbr$ post baseline ef cacy measurement bp value for treatment group comparison proactive intervention vs usual care was calculated based on a $nmbr$ sample t test for continuous variables and chi square test for categorical variables cbp values were measured at baseline week $nmbr$ whereas information on all of the other variables listed was collected during screening abbreviations bmi body mass index bp blood pressure chd coronary heart disease crucial cluster randomized usual care vs caduet investigation assessing long term risk dbp diastolic blood pressure dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sd standard deviation sbp systolic blood pressure tc total cholesterol tg triglyceride,C0332293;C0030705;C0037623;C1415692;C1708288;C4318478;C3538928;C1947933;C1527178;C1705938;C0549178;C0439828;C0008041;C0042295;C0444706;C3541902;C1533716;C0745732;C3272378;C1516695;C1516698;C0220825;C1261322;C1552578;C1516048;C0062152
family history n,C0241889
pro active intervention,C0184661;C0886296;C1273869
previous angina n,C0205156;C0002962;C1552607
usual care,C3538928;C1947933
previous angioplasty n,C0205156;C0162577;C1548817;C1552607
odds ratio,C0028873
heart rates beats minutes,C0439385
value,C1522609
medical treatment,C0679624
proportion,C1709707
aspirin n,C0004057
with dm,C0011816;C3250443
beta blockers n,C0001645
bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
ace inhibitors n,C0003015
or $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
calcium antagonists n,C0006684
ldl c goal attainment,C0680230
time from symptoms to treatment,C0040223;C3541383;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
dual bp ldl c goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
interval from onset of symptoms,C1272706;C1552654;C1552713
without dm,C0011816;C3250443
to randomization,C0034656
interval from randomization to angiography,C1272706;C1552654;C1552713;C0002978
angiographic features,C1521970;C1706388;C2346469;C2348519
ap $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ cp $nmbr$ $nmbr$ the study speci c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm the ldl c target was $nmbr$ mg dl or $nmbr$ mg dl depending on risk factor status at baseline in accordance with ncep atp iii guidelines odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site an interaction between treatment effect and dm status was observed for bp goal attainment p $nmbr$ $nmbr$ and dual bp ldl c goal attainment p $nmbr$ $nmbr$ among patients with or without dm calculated based on a mixed effects linear model not adjusted for differences in baseline values abbreviations bp blood pressure dbp diastolic blood pressure dm diabetes mellitus ldl c low density lipoprotein cholesterol ncep atp iii national cholesterol education program adult treatment panel iii or odds ratio sbp systolic blood pressure,C0006938;C4050020;C1521840;C2986546;C0085805;C0439475;C0536221;C3813197;C4281799;C0011816;C3250443;C0439269;C0035648;C0449438;C0168634;C1442488;C1527178;C1705938;C0025663;C0449851;C0871511;C0332257;C1552866;C2700399;C1704640;C1706515;C4050026;C4319583;C4553629;C0205145;C1515974;C2825164;C1704675;C1518681;C1441672;C0680230;C0030705;C0444686;C1441506;C0205430;C0023732;C3160715;C1518422;C0456081;C0005810;C0005844;C0600103;C0488055;C0871470;C1306620
infarct related artery location,C0450429;C1515974;C4284930;C4284931
end of follow up,C0444930;C2746065
left anterior descending n,C0441998;C0205386;C1547177;C0369718;C0441922
intensive control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
standard control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
left circumflex n,C0205091;C0443246;C1552822
age when diabetes first diagnosed yr,C0001779;C0011847;C0439234;C0011849
rca n,
duration of diabetes yr,C0449238;C2926735
number of vessels disease,C0237753;C0449788
australia and new zealand,C0004340;C0027978;C0324547
non stenotic vessels n,C0333181;C0005847;C4049883
asia,C0003980
single vessel disease n,C0037179;C0042373;C0087136;C0205171
history of major macrovascular disease no,C0683519;C0730226;C0850708;C0944983
double vessel disease n,C0205173;C0042373;C1705764;C1705765
history of major microvascular disease no,C0683519;C0730226;C0850708;C0944983
triple vessel disease n,C0856738
macroalbuminuriaf,
degree of stenosis of diameter,C4034225;C1301886
microvascular eye diseased,C0015392;C0700042
evidence or thombus n,C3887511
history of microalbuminuria no,C3532606
figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals,C1705117;C4035091;C0425043;C0581603;C0439231;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1707455;C0680395;C1707156;C3274014;C3541345;C1272706
blood glucose control,C3267174
vildagliptin $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glycated hemoglobin nonstandardized level,C0202054
rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glycated hemoglobin standardized level,C0202054
hispanic or latino,C0086409;C0086528
all other,
fasting blood glucose mmol liter,C0428568;C0475211;C1261430
bmi group kg m^,C0022718;C0439209;C4054209
serum cholesterol mmol liter,C0587184;C0475211
alc,C1424945;C3811058
serum triglycerides mmol liter,C0542495;C0475211
alc group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
serum triglycerides pmol liter,C0542495;C0475211
fpg mmol $nmbr$,C0439190
serum creatinine pmol liter,C0201976;C0475211;C0600061
disease duration years,C0872146;C0439234
current smoking no,C0037369;C0453996;C1881674
rosiglitazone $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glucose lowering drug,C0017725;C0441994;C2003888;C0013227;C1254351
adjusted mean change kg,C0022718;C0439209;C4054209
gliclazide modified release no ^,C0017631;C1709058;C4544813
whole cohort,C0009247;C0599755
other sulfonylurea no,C0038766;C3536898
bmi $nmbr$,C0578022
metformin no,C0025598
etoricoxib group n $nmbr$ $nmbr$,C0972314;C0441848
thiazolidinedione no,C0289779;C1257987;C3537039
diclofenac group n $nmbr$ $nmbr$,C0012091;C0441848
acarbose no,C0050393
ppi use,C0042153;C0457083;C1947944
glinide no,C2266929
traditional nsaid use,C3897349;C0003211;C3536840
any oral hypoglycemic drug no,C0359086
cox $nmbr$ selective inhibitor use,C0042153;C0457083;C1947944
insulin no,C0021641;C1533581;C1579433;C3714501
systemic corticosteroid use,C0239126
none no,
methotrexate use,C0042153;C0457083;C1947944
other drugs,C0013227;C3687832
other dmard use,C0042153;C0457083;C1947944
aspirin no,C0004057
history of upper,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
other antiplatelet agent no,C0085826
gastrointestinal event,C0441471;C4019010
statins no,C0360714
regular ppi use,C0042153;C0457083;C1947944
other lipid modifying drug no,C0023779;C0392747;C0013227;C1254351
no regular ppi use,C0042153;C0457083;C1947944
any blood pressure lowering drug no,C0003364
regular aspirin use,C0042153;C0457083;C1947944
mean glycated hemoglobin reduction during characteristic follow up $nmbr$ ci percent,C0162119
no regular aspirin use,C0042153;C0457083;C1947944
intensive control n $nmbr$ no of patients percent,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389;C0030705;C0439165
etoricoxib n $nmbr$,C0972314
standard control n $nmbr$ no of patients percent,C1442989;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389;C2828392;C0030705;C0439165
diclofenac n $nmbr$,C0012091
relative risk reduction $nmbr$ cl percent,C0242492;C0439165
history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
blood glucose,C0005802
corticosteroid use,C0239126
treatment with any blood pressure,C0596197
established atherosclerotic cardiovascular disease,C0443211;C0004153;C1272684
lowering drugs,C0441994;C2003888;C0013227;C3687832
n n,C0369718;C0441922
treatment with antiplatelet drugs,C3469597
patients with any clinical event,C0030705;C0205210
intensive therapy n $nmbr$,C0039798;C0087111;C1363945
aspirin use p $nmbr$ $nmbr$ t,C0004057;C0042153;C0457083;C1947944
standard therapy n $nmbr$,C2936643
ppi use p $nmbr$ $nmbr$ t,C0358591;C0042153;C0457083;C1947944;C0871125;C3811894
median duration of diabetes yr,C0449238;C2926735
patients with complicated events,C0030705;C0231242
previous cardiovascular event,C0205156;C1320716;C1552607
patients with uncomplicated events,C0030705;C0441471;C3541888
race or ethnic group f,C0034510;C1706779;C3853635;C0441840
patients with any clinical event p $nmbr$ $nmbr$ o,C0030705;C0205210
education,C0013621;C0013622;C0013658;C0039401
no aspirin or ppi,C0004057;C0358591;C0871125;C3811894
less than high school,C0599395;C0683862;C0870649
ppi but no aspirin,C0358591;C0871125;C3811894
high school graduate,C0870649;C1549971
aspirin but no ppi,C0004057;C0358591;C0871125;C3811894
some college,C0557806
aspirin and ppi,C0004057;C0358591;C0871125;C3811894
college degree or higher,C0441889;C0449286;C0542560;C2348088;C0205250
patients with complicated events p $nmbr$ $nmbr$,C0030705;C0231242
cigarette smoking status,C1519386
$nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
any sulfonylurea,C0038766;C3536898
patients with uncomplicated events p o $nmbr$,C0030705;C0441471;C3541888
any thiazolidinedione,C0289779;C1257987;C3537039
combinations of aspirin and ppi use p $nmbr$ $nmbr$ t,C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036;C0358591;C0042153;C0457083;C1947944;C0871125;C3811894
any antihypertensive agent,C0003364
etoricoxib $nmbr$ mg n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
any thiazide diuretic,C0012802;C3536861
diclofenac $nmbr$ mg n $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fasting serum glucose mg dl,C0202041;C0439269;C3534430
age mean yrs sd,C0001779;C2699239
median triglyceride mg dl,C0041004;C0439269
sex n,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
potassium mg dl,C0032821;C0439269;C0202194;C0304475;C0597277;C3714637
native american,C0282204;C1515945
oxypurinol n $nmbr$,C0030086
body mass index mean kg m^ sd,C0022718;C0439209;C4054209;C2699239
age yrs mean sd,C0001779;C2699239
primary study joint n,C0205225;C0022417;C0392905;C1706309;C0439612;C0439631
nyha functional class iii,C1882086;C0205245;C0542341;C2700217
knee,C0022742;C0022745;C1963703
lvef mean sd,C0428772;C2699239;C0488728
hand,C0018563;C1552914
$nmbr$ mwt m,
left shoulder,C0524469
carvedilol,C0054836
acr functional class n,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
spironolactone,C0037982
class i,C0441885;C1319793;C2698967
idiopathic,C0332240
class ii,C0441886;C2698968
hypertensive,C0857121
class $nmbr$,C0456387;C1518526;C1705943
hospitalized,C0701159
prior antiinflammatory antirheumatic products n,C0003209;C0003191;C1515999
er visit,C0545082;C1512346;C2826704
rofecoxib,C0762662
new hf medication,C0013227;C3244316;C4284232
valdecoxib,C0913246
on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl,C0013227;C0439269;C0802604;C2598133;C4284232
ibuprofen,C0020740
sua,
naproxen,C0027396
mean $nmbr$ th to $nmbr$ thquartile bnp pg ml,C0039725;C0039738;C1420718;C4282123;C4285344
prior analgesic products n,C0332152;C0002771;C2826257
v alsartan hctz n,C0020261
acetaminophen,C0000970;C2917659
valsartan n,C0216784
history of upper gl events perforations ulcers bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean age years sd,C1510829;C2699239
low dose aspirin use strata n,C2608320;C0042153;C0457083;C1947944
msdbp mmhg sd,C0439475;C2699239
user,C1548600;C1706077
mssbp mmhg sd,C0439475;C2699239
nonuser,
mean weight kg sd,C0005910;C2699239;C0043100;C1305866;C1705104
increased risk for thrombotic cardiovascular event^ n,C1273410
mean bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
history of diagnosed hypertension prior to randomization n,C0455527;C0011900;C0034656
serum creatinine mean sd pmol l,C0201976;C0439284;C0600061
patient years,C0030705;C0439234
baseline aspirin use strata,C0004057;C0042153;C0457083;C1947944
bmi body mass index hctz hydrochlorothiazide msdbp mean sitting diastolic blood pressure mssbp mean sitting systolic blood pressure sd standard deviation,C1828170
arm,C0446516;C3715044;C4553528
pt years $nmbr$,C0032743;C0439234;C0699718
risk,C0035647;C4552904
continued use of gastroprotective agents gpa,C0549178;C1524063
severity,C0439793;C0522510
new use of gastroprotective agents gpa,C1518316;C1524063
mssbp,
parameters,C0449381
mssbp $nmbr$ mmhg,C0439475
infliximab,C0666743
j $nmbr$ $nmbr$,
$nmbr$ mg kg n $nmbr$,C0439272
sildenafil n $nmbr$,C0529793
combined n $nmbr$,C0205195
mean sd age y mean bmi category,C0683312;C3889287
sex female n,C0086287
missing ed duration y,C1551393;C0449238;C2926735;C1705492;C3272743
race white n,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
range ed etiology n,C0015127;C1314792;C1524003
disease characteristics,C0599878
mixed,C0205430;C3160715
disease duration yr mean sd,C0872146;C2699239
organic,C0747055
mayo score mean sd,C0444504;C2699239;C2347634;C2348143
psychogenic,C0458006
aminosalicylates,C0368663
mean iief ef score mean iief domain score by bmi,C3533236;C0578022
immunomodulatory agents,C0005525
ef domain,C1880389;C1883221;C3541951
extent of disease n,C0449279;C4553144
os domain,C1880389;C1883221;C3541951
left side only,C0205091
is domain luts severity,C0439793;C0522510
extensive,C0205231
moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
health related quality of life,C4279947
mean total ipss mean ipss by bmi,C0439175;C0439810
ibdq mean sd,C0444504;C2699239;C2347634;C2348143
storage subscore,C0337174;C1698986;C1753314
sf $nmbr$ pcs mean sd,C0037712;C2699239
voiding subscore,C0042034;C4067975
sf $nmbr$ mcs mean sd,C0037712;C2699239
mean qmax score by bmi,C3533236;C0578022
no of individuals,C0027361;C0237401
sd standard deviation bmi body mass index ed erectile,C1305855;C3538926;C0030847
i rosuvastatin n $nmbr$,C0021966;C0221138
dysfunction ef erectile function iief i,C0021966;C0221138
i placebo n $nmbr$,C0021966;C0032042;C1696465;C1706408;C0221138
nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
blood pressure mean sd mm hgt,C0428886;C2699239
erectile function ipss,C1019118;C1998280;C2827405;C3811063
fasting blood glucose mean sd mg dlt,C1413248;C3273706
international prostate symptom score,C1998280
impaired renal function,C1565489
luts lower urinary tract symptoms is,C0574785
estimated glomerular filtration rate,C3811844
intercourse satisfac,C0009253
normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
tion os overall satisfaction qmax maximal urinary flow rate,C4086680;C0429784
mild decrease $nmbr$,C0392756;C0547047
famotidine $nmbr$ mg n $nmbr$,C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderate decrease $nmbr$,C0392756;C0547047
sex male female n,C0086287
concomitant medication use,C0521115;C0240320
weight kg bmi kg m $nmbr$,C0005910;C1319635;C0043100;C1305866;C1705104
antihypertensive,C0003364
smoking status ongoing n,C1519386;C0549178
the metabolic syndrome^,C0524620
smoking status previous n,C1519386;C0205156;C1552607
body mass index $nmbr$ t,C0005893;C0578022;C1305855
alcohol consumption yes n,C0001948;C1549445;C1705108;C1710701
triglycerides $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
caffeine consumption yes n,C0948365;C1549445;C1705108;C1710701
diastolic blood pressure $nmbr$ mm hg,C0428883;C0439475;C1305849
hiatal hernia yes n,C3489393;C1549445;C1705108;C1710701
systolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620
helicobacter pylori infection n,C0850666
or taking antihypertensive medication,C1290952
pepsinogen i ii ratio,C0456603;C1547037
days with heartburna days,C0439228
fasting blood glucose $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
severity of heartburnb,C0439793;C0522510
$nmbr$ chd risk factors,C0035648;C1282512;C1553898
atenolol strategy n $nmbr$ $nmbr$,C0004147;C0679199
chd risk factors,C0035648;C1282512;C1553898
verapamil sr strategy n $nmbr$ $nmbr$,C1527129;C0679199
family history of premature chd,C0241889;C0151526;C0205252;C4018905
demographic,C0011298
smoking during the previous month,C2114448;C0332177;C0439231
age mean sd years,C1510829;C0444504;C2347634;C2348143
hypertension $nmbr$ $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
race ethnicity no,C0015031;C0243103
$nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
history of ml,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean of maximum cimt mean sd mm,C0444504;C0806909;C1552615;C2826546;C2347634;C2348143
chronic stable angina,C0340288
$nmbr$ carotid artery sites,C0007272;C0205145;C0162859
unstableangina,
common carotid artery sites,C0007272;C0205145;C0162859
dyslipidemia $nmbr$,C0242339
carotid bulb sites,C0007281;C0205145
stroke ortiab,C0038454;C4554100
internal carotid artery sites,C0007276;C0205145
renal insufficiency $nmbr$,C0035078;C1565489
mean of mean cimt mean sd mm,C0444504;C2347634;C2348143
diabetes $nmbr$,C0011847;C0011849
tolvaptan n $nmbr$,C1176308
obese,C0028754
otherf,
ever smoker,C3887636;C0337664
ejection fraction mean sd,C0489482;C2699239;C2700378
medications no,C0013227;C0802604;C2598133;C4284232
ischemic heart failure etiology,C0015127;C1314792;C1524003
aspirin antiplatelet,C0004057
previous hospitalization for heart failure,C0205156;C3898876;C1552607
antidiabetic,C0935929
nyha class,C1882083
lipid lowering,C0023779;C0441994;C2003888
chronic renal insufficiency,C0403447;C1561643
potassium,C0032821;C0202194;C0304475;C0597277;C3714637
valvular disease mitral,C3258293;C0746591
hrt,C0282402
baseline therapy,C0039798;C0087111;C1363945
systolic mean sd mm hg,C0039155;C0439475
ace inhibitors arbs,C0003015;C3888198
controlled $nmbr$ no,C2587213;C2911690
aldosterone blockers,C0002006
baseline cardiovascular assessment,C4684571
dyspnea frequent continuous,C0013404;C0549178;C1963100
bmi body mass index hrt hormone replacement therapy lvh left ventricular hypertrophy nsaids nonsteroidal anti inflammatory drugs pvd peripheral vascular disease tia transient ischemic attack ahistory of and or currently taking lipid lowering or antidiabetic medications bp $nmbr$ $nmbr$ for verapamil sustained release sr vs atenolol chistory of or currently have elevated serum creatinine but less than $nmbr$ mg dl dblood pressure control defined as,C3687361;C0521116;C0023779;C0441994;C2003888;C0037623;C1415692;C1708288;C4318478;C1527129;C1710261;C0004147;C0700225;C0439269;C0033095;C0460139;C1306345;C4284008;C1704788;C3539106
orthopnea frequent continuous,C0085619;C0549178
haplotype,C0018591
rales,C0034642;C0240859
no copies gly $nmbr$ glu $nmbr$ $nmbr$ c,C1948062;C0068000
pedal edema slight moderate marked,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0522501;C1706089
verapamil sr,C1527129
jugular venous distention $nmbr$ cm,C0425687
incidence,C0021149;C0220856
all cause mortality,C0015127;C0026565;C0026566;C1524003
v total n $nmbr$,C0439175;C0439810
cardiovascular death or heart failure hospitalization,C0011065;C1306577;C4082313;C4552775;C3898876
rerapamil sr strategy n $nmbr$,C0753208;C0679199;C1709991;C3813610;C3890900;C3891546
no of deaths,C0011065;C1306577
atenolol strategy n $nmbr$,C0004147;C0679199
tolvaptan,C1176308
mean age y sd,C0001779;C2699239
$nmbr$ placebo,C0032042;C1696465;C1706408
female race ethnicity,C0015031;C0243103
western europe,C0043129
smoking history ever,C1519384;C3887636
eastern europe,C0015177
dyslipidemia,C0242339
etiology,C0015127;C1314792;C1524003
cancer medications,C0013227;C0802604;C2598133;C4284232
dyspnea,C0013404;C1963100
baseline sbp mm hg,C0085805;C0439475
frequent or continuous,C0332183;C0549178
baseline dbp mm hg,C0168634;C0439475;C1442488
none or seldom,C0522498
baseline heart rate beat min,C0702093;C1524029;C3813700
congestion,C0700148;C2826600
not severe,C4316743
values are expressed as percentages unless otherwise indicated bmi body mass index cabg coronary artery bypass ischemic attack nsaids nonsteroidal anti inflammatory drugs sbp systolic bp dbp diastolic bp history of or currently taking antidiabetic or lipid lowering medications,C0042295;C0439165;C1549488;C1561533;C1553893;C0521116;C0935929;C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
severe,C0205082;C4050465;C4050466
graft pci percutaneous coronary intervention tia transient,C0040704;C0205374
systolic bp mm hg,C0871470;C0439475
verapamil sr n $nmbr$ no,C1527129
new york heart association class,C1882083
atenolol n $nmbr$ no,C0004147
serum sodium meq l,C0523891;C0439375
nontatal ml,C0439526;C1705224;C3887665
serum urea nitrogen mg dl,C0600137;C0439269;C1291218;C3683557
fatal and nonfatal ml,C1302234;C1705232;C0439526;C1705224;C3887665
avp pg ml,C1098706;C0439297;C1568204;C1708407
cv death,C0011065;C1306577;C4082313;C4552775
b natriuretic peptide pg ml,C0070338;C0439297
tg $nmbr$ hdl $nmbr$ n $nmbr$,C0337445;C3715113
p blocker use,C0042153;C0457083;C1947944
tg $nmbr$ hdl,C0337445;C3715113
ace inhibitor or arb use,C0003015;C4541021;C0042153;C0457083;C1947944
smoker a,C0337664
aldosterone use,C0042153;C0457083;C1947944
drinker a,C0556338
younger subjects aged,C0681850;C1550501;C1706203;C2349001;C2697811;C0001779;C0001792;C1999167
clinical history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
older subjects aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
hypertension $nmbr$,C0020538;C1963138
sertraline,C0074393;C0524265
systolic mmhg,C0039155;C0439475
married,C0024841;C0555047
diastolic mmhg,C0012000;C0439475
education years,C0013621;C0439234;C0013622;C0013658;C0039401
lipid profile,C1979963;C2003903
controls n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
triglyceride mg dl d,C0041004;C0439269
epa treatment n $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fatty acid composition,C0486616;C1555710
bmi kg m $nmbr$ cardiovascular history,C0022718;C0439209;C4054209;C1880008
cabgorptca,
data represent number of patients or mean standard deviation unless otherwise indicated a self reported information bc physician diagnosed diabetes or fasting plasma glucose $nmbr$ mg dl or hemoglobin a $nmbr$ c $nmbr$ $nmbr$ d physician diagnosed hypertension or systolic blood pressure $nmbr$ mmhg or diastolic blood pressure $nmbr$ mmhg median interquartile range ldl low density lipoprotein hdl high density lipoprotein tg triglyceride,C1511726;C3245479;C3714741;C1882932;C2360800;C1828170;C1444656;C0011847;C0011849;C0202042;C0439269;C0455280;C0020538;C1963138;C0488055;C0439475;C0871470;C1306620;C0065191
hypertension serum lipid values,C0428462;C0042295
hazard ratio and p value,C2985465;C1709380
triglyceride mmol l blood pressure,C0005823;C1271104;C1272641
high triglyceride low high density lipoprotein,C0151691
hmgcoa rl,C1419337;C3539667
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
pravastatin,C0085542
rivastigmine n $nmbr$,C0649350
other statin,C0360714
$nmbr$ $nmbr$ years n,C0439234
antiplatelet agent,C0085826
$nmbr$ years n,C0439234
other antihypertensive agents,C0003364
overall male female,C0043210;C0086287;C1705497;C1705498
hypoglycaemic agents,C0020616
ethnic origin n,C0015031
oriental,C0078988;C0699027
data are number of patients or mean sd unless otherwise indicated cabg coronary artery bypass grafting ptca percutaneous transluminal coronary angioplasty ldl low density lipoprotein hdl high density lipoprotein iqr i nterquarti le range hmg coa ri $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a reductase inhibitor bmi body mass index which is weight in kg divided by the square of height in metres median iqr,C1511726;C3245479;C3714741;C2360800;C0444504;C2699239;C2347634;C2348143;C0428776;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0549183;C0876920;C2347635;C2348144;C2939193
formal education years,C0681344;C0439234
control n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
duration of dementia symptoms months,C0436359;C0011265;C0497327
epa n $nmbr$,
criteria for subcortical vad by mri,C0243161;C0077973;C0024485;C1824234;C3890166
interaction p,C1704675
mean sd baseline scores,C3533236;C0168634;C1442488
previous cad,C1504769;C2239547;C3813548;C4284121
mhis score,C0449820;C4050231
non smoker,C0337672;C0425293;C4554605
vadas score,C0449820;C4050231
triglyceride mm,C4330985;C4554674
mmse score,C0449820;C4050231
ol l,
adcs adl score,C0449820;C4050231
ranolazine n $nmbr$,C0073633
gds score,C0449820;C4050231
age $nmbr$ y,C0001779
npi $nmbr$ score,C0449820;C4050231
weight median iqr kg,C0022718;C0439209;C4054209
younger patients aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
body mass index median iqr,C0005893;C0578022;C1305855
older patients aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
comorbidities,C0009488
rivastigmine,C0649350
cardiac history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
supine after $nmbr$ minutes change from baseline,C0038846;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
prior ml,C0439526;C1705224;C3887665
notable abnormalities,C0000768;C0000769
prior coronary revascularization,C0332152;C0877341;C2826257
high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
prior heart failure,C0018801;C0018802;C4554158
low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
estimated creatinine clearance,C0750572;C0812399
standing after $nmbr$ minute change from baseline,C0231472;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
index event,C0441471;C4019010
standing after $nmbr$ minutes change from baseline,C0231472;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
non st elevation ml,C0439526;C1705224;C3887665
normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972;C0017654;C0439445;C1424601
st segment depression $nmbr$ $nmbr$ mv,C1454484;C1705503;C4281602
mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
timi risk scoret,C0035647;C4552904
patients randomly assigned,C0030705;C1516050;C1552601
time from onset of pain to randomization median iqr h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
age at lipid randomization y,C0001779;C0065033
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
body mass index kg m $nmbr$ baseline systolic blood,C0022718;C0439209;C4054209;C0005767;C0005768;C0229664
coronary angiography during the index hospitalization,C0085532;C1548829
pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
cardiac medications during index hospitalization,C0013227;C0802604;C2598133;C4284232
baseline diastolic blood,C0005767;C0005768;C0229664
and or discharge,C0012621;C0030685;C2926602
history of coronary heart disease at,C0683519;C0730226;C0850708;C0944983
heparin,C0019134;C0770546
history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
glycoprotein llb llla receptor inhibitor,C0017968;C1999216
other atherosclerotic cvd st depression on,C0007222;C0520887
thienopyridine,C1120149
electrocardiogram,C0013798;C1547122;C1623258
ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021;C0521942;C3536793
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile,C0017654;C0439445;C1424601;C1979963;C2003903
abbreviations ace angiotensin converting enzyme iqr interquartile range ml myocardial infarction si conversion to convert creatinine clearance to ml s multiply by $nmbr$ $nmbr$ data are expressed as no total unless otherwise specified festimated using cockroft gault equation tthe timi risk score was used to categorize patients at low $nmbr$ $nmbr$ intermediate $nmbr$ $nmbr$ and high $nmbr$ $nmbr$ risk $nmbr$,C0022709;C0439836;C0439390;C1511726;C3245479;C3714741;C0439175;C0439810;C0205369;C1524063;C0035647;C0449820;C4050231;C4552904;C1273517;C0871968;C0030705;C0205103;C1550465;C2827755;C3889971;C0332167;C3272283;C4050568;C4319571
fasting triglycerides,C0015663;C0041004
no of events sample size i i,C0242618;C3811654
randomly assigned to ace,C1516050;C1552601
kaplan meier rates i i,C0021966;C0221138
inhibitor,C1999216
ranolazine,C0073633
randomly assigned to calcium channel blocker,C1516050;C1552601
hr $nmbr$ cl,C0596019
randomly assigned to diuretic,C1516050;C1552601
pfor interaction,C1151635;C1704675
esrd or $nmbr$ dedine in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
] $nmbr$,
esrd or $nmbr$ decline in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
timi risk score,C0035647;C0449820;C4050231;C4552904
gfr $nmbr$,C0017654;C1424601
] j $nmbr$,
gfr $nmbr$ $nmbr$,C0017654;C1424601
st segment depression $nmbr$ mm,C4330985;C4554674
aspirin erdp n $nmbr$ $nmbr$,C0004057
creatinine clearance,C0812399
europe israel or australia,C0015176;C0022271;C0004340
$nmbr$ mlymin,
latin america or south africa,C0023122;C0037712
early invasive,C0205281;C1334278
united states or canada,C0041703;C0006823
etanercept n $nmbr$,C0717758
chinese,C0008120;C0152035
demographic characteristics,C0683970
south asian,C1519427
female no,C0043210;C0086287;C1705497;C1705498
other asian,C0078988
age mean min max yrs,C0001779;C0444504;C2347634;C2348143
white european,C0239307;C1535514
duration of ra mean min max yrs,C0449238;C2926735
native latin,C0302891
comorbid diseasesa diabetesb,
bmi^,C0578022
insulin dependentc,C0021641;C1533581;C1579433;C3714501
tobacco use,C0040335;C0543414;C0841002;C3853727
oral hypoglycaemics only,C0359086
currently,C0521116
comorbidities other than diabetes,C0009488;C0011847;C0011849
previously,
chronic pulmonary disease,C0746102
no regular consumption,C0009830;C1947907
pneumonia in past year,C0032285;C0439234;C0439508
$nmbr$ $nmbr$ drinks wk,C0332174;C0439230
recurrent infections $nmbr$ per year,C0239998;C0439234;C0439508
$nmbr$ drinks wk,C0332174;C0439230
bronchitis,C0006277
exercise category,C3669314
sinusitis,C0037199;C4553555
sedentary,C0205254
urinary tract infection,C0042029;C0262655;C4554638
some physical activity,C0015259;C0026606
cardiovascular risk factors no,C0850624
intense physical activity,C0015259;C0026606
coronary artery disease,C0010054;C0010068;C1956346
time from qualifying stroke to randomization,C0040223;C3541383;C1514624;C0038454;C4554100
congestive heart failure definite,C0018802;C0439544;C1704787
median days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
at least two cardiovascular risk factors,C0035648;C0850624
$nmbr$ $nmbr$ days,C0439228
$nmbr$ days,C0439228
medically important infectionsa,C3898777;C4084912
toast classification of qualifying stroke,C1710306;C4521230;C1514624;C0038454;C4554100
serious adverse events,C1519255
etanercept,C0717758
large artery atherosclerosis,C0003850;C0004153
events,C0441471;C3541888
cardioembolism,
patients with diabetes b,C0030705;C0011847;C0011849
small artery occlusion lacune,C0226001;C0241970
patients without diabetes b,C0030705;C0011847;C0011849
acute stroke of other determined cause,C0751956;C0015127;C1524003
stroke of undetermined cause,C0038454;C0015127;C1524003
patients with chronic pulmonary disease,C0683521
score on modified rankin scale,C4049715
patients without chronic pulmonary disease,C0683521
baseline nihss score,C0449820;C4050231
adalimumab group n $nmbr$ t,C0036669
previous stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
men n,C0025266
atherosclerotic disease,C0333482;C0012634
mean age sd y,C0444504;C0001779;C2347634;C2348143
ischemic coronary artery disease,C0852149
mean weight sd kg,C0022718;C0439209;C4054209
paod,
intestinal area involved n,C0021853;C0017446;C0205146
deep vein thrombosis,C0149871
rectum,C0034896
aspirin erdp clopidogrel no of patients total no,C0004057;C0070166;C0030705;C0439175;C0439810
perianal or anus,C0442158;C0003461
prespecified analysis,C0002778;C0936012;C1524024
gastroduodenal,C0450199
any recurrent stroke,C2242682
jejunum,C0022378
other atherosclerotic event,C0441471;C4019010
abdominal or perianal fistula at baseline n,C0000726;C0267561;C0168634;C1442488
stroke risk score,C0449820;C4050231
mean cdai score sd,C3533236;C2699239
$nmbr$ $nmbr$ low risk,C3272281;C3538919
mean baseline ibdq score sd crp concentration mg l,C3533236;C0439268
$nmbr$ $nmbr$ moderate risk,C0035647;C4552904
median range,C1514721;C2348147;C3542016
$nmbr$ high risk,C0332167;C3272283;C4050568;C4319571
crp concentration $nmbr$ mg l n \,C0086045;C0439268;C1446561;C3827302
randomization to placebo or telmisartan,C0034656;C0032042;C1696465;C1706408;C0248719
previous loss of response to infliximab n,C0205156;C1517945;C1552607;C0666743
telmisartan,C0248719
previous intolerance of infliximab n,C0231199;C1744706;C2355652
statin use,C0042153;C0457083;C1947944
acute reaction,C0205178;C0443286
ace inhibitor use,C0042153;C0457083;C1947944
delayed reaction,C0205421;C0443286;C1545665;C3272602
time from onset of qualifying stroke to randomization,C0449244;C1514624;C0038454;C4554100
acute and delayed reaction,C0205178;C0205421;C0443286;C1545665;C3272602
slo days,C1416602;C0439228;C3539661
previous loss of response to and intolerance of infliximab n,C0205156;C1517945;C1552607;C0231199;C1744706;C2355652
small artery occlusion,C0226001;C0264995
antibodies to infliximab n,C3533054
undetermined other or cardioembolism,C0205258;C3536725;C4082977
indeterminate,C0205258
post hoc analysis,C0002778;C0936012;C1524024
concomitant medication n,C0521115;C0013227;C3244316;C4284232
medical history of hypertension,C0455527;C0262926
steroids,C0038317
any immunosuppressive agent,C0021081
baseline systolic blood pressure,C4274438
$nmbr$ aminosalicylates,C0368663
telmisartan n $nmbr$ $nmbr$,C0248719
placebo group n n,C0032042;C0441848;C1696465;C1706408
ethnic group no,C0015031;C1879937
adalimumab group n n,C1122087;C0441848
clinical history no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
primary analysis,C0002778;C0936012;C1524024
use of medication at baseline no,C1524063;C0168634;C1442488
remission in overall population,C0544452;C0687702
index stroke $nmbr$ days before randomization no,C0456712;C0439228
prespecified subgroup analyses,C2986480
toast classification,C1710306;C4521230
remission,C0544452;C0687702
score on modified rankin scale no,C4049715
patients with previous loss of response to infliximab,C0030705;C0205156;C1552607;C0666743
baseline nih stroke scale no ^,C1697238;C3484372
patients with previous intolerance of infliximab,C0030705;C0205156;C1552607
all recurrent strokes,C1836785
use of ace inhibitor,C1524063;C0003015;C4541021
patients with baseline crp concentration $nmbr$ mg l,C0030705;C0439268
$nmbr$ to $nmbr$ mm hg,C0439475
additional subgroup analyses,C1524062;C2986480
low risk $nmbr$ $nmbr$,C3272281;C3538919
patients not receiving immunosuppressive agents at baseline,C0030705;C1518422;C1514756;C0021081;C0168634;C1442488
moderate risk $nmbr$ $nmbr$,C0035647;C4552904
patients receiving immunosuppressive agents at baseline,C0030705;C1514756;C0021081;C0168634;C1442488
high risk $nmbr$,C0332167;C3272283;C4050568;C4319571
patients not receiving corticosteroids at baseline,C0030705;C1518422;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
all major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
patients receiving corticosteroids at baseline,C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
sl $nmbr$ mm hg,C0439475
patients with previous loss of response to and intolerance of infliximab,C0030705;C0205156;C1552607;C0231199;C1744706;C2355652
^ $nmbr$ days,C0439228
patients who received negative results on test for antibodies to infliximabt,C1334932;C0003241
rosuvastatin n $nmbr$,C0965129
patients who received indeterminate results on test for antibodies to infliximabt,C0456984;C0003241
heart disease risk factors,C0741920
patients who received positive results on test for antibodies to infliximabt,C1335447;C0003241
heart rate beats per min,C0425583;C0439385
pooled simvastatin factorial studies,C0074554;C2826344
admission for hf in previous year,C0184666;C0809949;C0439234;C0439508
atorvastatin factorial study,C0286651;C2826344
previous ami,C0205156;C4319936;C1552607
simvastatin monotherapy n $nmbr$ $nmbr$,C0074554
icd,C0021122
ezetimibe simvastatin n $nmbr$ $nmbr$,C1532737
history of atrial fibrillation,C0729790
atorvastatin monotherapy n $nmbr$,C0286651
copd,C0024117;C1412502;C3714496
ezetimibe simvastatin n $nmbr$,C1532737
neoplasia,C0027651;C1882062
body mass index kg nr,C0027496;C3844738
heart failure cause,C0015127;C1524003
crp mg l median sd,C0439268;C2699239
ischaemic,C0475224
tg mg dl median sd,C0439269;C2699239
dilatative,
apolipoprotein b mg dl,C0003593;C0439269
other cause,C0015127;C1524003
hdl mg dl,C3715113;C0439269
non detectable unknown,C0439673;C3541433;C4050014
physical examinations,C0031809
figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups,C1705241;C1705242;C3890735;C0441889;C4048285;C0030705;C0042295;C1882932;C2360800;C1709595;C0074554;C2349200;C4522255;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0369773;C2603361;C0332529;C1547017;C1079230
pulmonary rales,C0034642
tiotropium,C0213771
third heart sound,C0232237;C0232278
total randomised n,C0439175;C0439810
mitral insufficiency,C0026266
male n,C0086582;C1706180;C1706428;C1706429
aortic stenosis,C0003507
smoking history pack years,C1519384;C1277691
ecg findings,C0438154
screening visit $nmbr$,C0545082;C1512346;C2826704
qrs $nmbr$ ms,C2349943;C3539704;C3713294
fev $nmbr$ l pre bronchodilator,C3714541;C2599602
pathological q waves,C0429090
fev $nmbr$ predicted normal,C0520835;C0681842;C1882327
arbs,C3888198
fev $nmbr$ fvc,C3714541
diuretic drugs,C0013227;C3687832
fvc l,C3714541
oral anticoagulant drugs,C0354604
nice classification of copd severity of obstruction n [ $nmbr$ ],C0008902;C0008903;C0678229
other antiplatelet agents,C0085826
mild fev $nmbr$ predicted,C0681842;C1882327
moderate $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe fev,C0205082;C3714541;C4050465;C4050466
pulmonary medication during baseline,C0013227;C3244316;C4284232
laba n,
data are mean sd or number bmi body mass index sbp systolic blood pressure dbp diastolic blood pressure lvef left ventricular ejection fraction hf heart failure ami acute myocardial infarction cabg coronary artery bypass graft pci percutaneous coronary intervention icd implantable cardioverter de brillator copd chronic obstructive pulmonary disease ace angiotensin converting enzyme arbs angiotensin receptor blockers available for $nmbr$ patients $nmbr$ rosuvastatin $nmbr$ placebo,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0521942;C0815017;C0470187;C0030705
laba no ics n,C0815320;C4551720
rosuvastatin events patients,C0441471;C0030705;C3541888
ics n,C0815320;C4551720
placebo events patients,C0032042;C0030705;C1696465;C1706408
ics no laba n,C0815320;C4551720
age $nmbr$ years median,C0549183;C0876920;C2347635;C2348144;C2939193
laba plus ics n,C0815320;C4551720
ischaemic cause,C0015127;C1524003
no laba no ics n,C0815320;C4551720
non ischaemic cause,C0015127;C1524003
saba use occasions weekt,C0042153;C0457083;C1947944
nyha ii,C1710602;C4082587
trough fev response l,C0444506;C0871261;C1704632;C1706817;C2911692
nyha iii or iv,C0439070;C1705160;C0022326;C4265176
trough fvc response l,C0444506;C0871261;C1704632;C1706817;C2911692
total cholesterol $nmbr$ $nmbr$ mmol lt,C0023376;C0230426;C3887647;C4521399
effect size^,C0814843
laba tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
we recorded no significant interactions for any subgroup analysis nyha new york heart association lvef left ventricular ejection fraction $nmbr$ cl was calculated by cox proportional hazards model tmedian value data for total cholesterol were available for $nmbr$ patients $nmbr$ rosuvastatin $nmbr$ placebo,C0034869;C3853788;C0237688;C0428772;C0444686;C1441506;C0201950;C0543421;C0470187;C0030705
ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
n $nmbr$ pufa n $nmbr$,C0369718;C0032615;C0441922
ics no laba tiotropium n $nmbr$ placebo n $nmbr$,C0815320;C4551720;C0213771;C0032042;C1696465;C1706408
placebo n $nmbr$ l,C0032042;C1696465;C1706408
laba plus ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
bmi kg rrr,C0022718;C0439209;C4054209
no laba no ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
cause of heart failure,C0015127;C1524003
trough fev response l i,C0021966;C0221138
physical examination,C0031809;C1744699
effect size,C0814843
statin open,C0360714;C0175566
fev $nmbr$ predicted,C0681842;C1882327
tiotropium n $nmbr$ placebo n,C0213771;C0032042;C1696465;C1706408
fev,C3714541
placebo group n $nmbr$ j,C0441844
data are mean sd or number pufa polyunsaturated fatty acids bmi body mass index sbp systolic blood pressure dbp diastolic blood pressure nyha newyork heart association lvef left ventricular ejection fraction hf heartfailure ami acute myocardial infarction cabg coronary artery bypass graft pci percutaneous coronary intervention icd implantable cardioverter defibrillator copd chronic obstructive pulmonary disease ace angiotensin converting enzyme arbs angiotensin receptor blockers available for $nmbr$ patients $nmbr$ n $nmbr$ pufa $nmbr$ placebo,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0521942;C0815017;C0470187;C0030705
certolizumab group n $nmbr$,C1872109;C0441848
mean age yr range,C1514721;C2348147;C3542016
n $nmbr$ pufa events patients,C0032615;C0030705
nyhaii,
mean body mass indexj,C0444504;C0518010;C2347634;C2348143
nyhaiiioriv,
duration of disease yr^ mean,C0872146;C0439234
geometric mean ofcrp mg liter range,C1514721;C2348147;C3542016
we recorded no significant interactions for any subgroup analysis pufa polyunsaturated fatty acids nyha new york heart association lvef left ventricular ejection fraction $nmbr$ cl was calculated with a cox proportional hazards model tmedian value data for total cholesterol were available for $nmbr$ patients $nmbr$ n $nmbr$ pufa $nmbr$ placebo,C0034869;C3853788;C0237881;C1704675;C0750502;C1546944;C0232174;C0596019;C0444686;C1441506;C0201950;C0543421;C0470187;C0030705
disease site no ^,C0205145;C1515974;C2825164
parameter mean s d,C0549193;C0444504;C2347634;C2348143;C1704769;C2350001
terminal ileum,C0227327
total study itt population n $nmbr$,C3258257
lleocolon,
asian itt population total n $nmbr$,C0078988;C0032659;C1257890
previous infliximab therapy,C0205156;C4076075;C1552607
asian itt population by treatment group,C1257890
any therapy no,C0039798;C0087111;C1363945
combination n $nmbr$,C0205195;C1947911;C3811910
median infusions no range,C0549183;C0574032;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
dutasteride n $nmbr$,C0754659
previous hypersensitivity reaction no,C0205156;C0020517;C1552607
tamsulosin n $nmbr$,C0257343
resection performed no,C0015252;C0728940;C0884358
time since first luts years,C0556970;C0205435;C1279901
concurrent treatment at study entry no,C0679827;C1521826;C3161471
prostate volume cm $nmbr$,C1441416
glucocorticoids only,C0017710;C3540777;C3540778
mean total serum psa,C2986589;C0229671;C1546774;C1550100
immunosuppressive agents only,C0021081
ngml total mean ipss score,C2964552
glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778;C0205195;C0021081
qmax ml s,C0439526;C1705224;C3887665
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778;C0021081
bii score,C0449820;C4050231
certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
no total,C0439175;C0439810
bph related health status,C0005001;C0018759;C1704272
sexually active,C0241028
a decrease of $nmbr$ points in the cdai score,C0392756;C0547047;C0449820;C4050231
previous a blocker use,C0205156;C1552607;C0042153;C0457083;C1947944
with baseline crp level of $nmbr$ mg liter,C0441889;C0456079;C1547707;C2946261
previous $nmbr$ ari use,C0042153;C0457083;C1947944
at week $nmbr$,C0332174;C0439230
chondroitin,C0008454
at weeks $nmbr$ and $nmbr$,C0439230
g c,C0439267
no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
structural,C0678594
immunosuppressive agents at baseline,C0021081;C0168634;C1442488
gait,C0016928
no glucocorticoids at baseline,C0017710;C3540777;C3540778
subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
glucocorticoids at baseline,C0017710;C3540777;C3540778
age in years mean sd,C1510829;C0444504;C2347634;C2348143
previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
haq pain scale mean,C0444504;C2347634;C2348143
patients with remission,C1277626
years duration oa,C0029408;C3887876
placebo group n $nmbr$ f,C0441840
symptoms mean sd,C0444504;C2699239;C2347634;C2348143
male sex no of patients,C0086582;C0030705
percentages,C0439165;C1549488;C1561533
duration of disease yr,C0872146;C0439234
bmi $nmbr$ $nmbr$ overweight,C0578022;C0497406
current smoker no of patients,C3173209;C3241966;C0030705
bmi $nmbr$ obese,C0578022;C0028754
crp mg liter^,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
knees n,C0022742
geometric mean,C2986759
kl $nmbr$,C1366480;C1416656;C1704887
disease site no of patients,C0205145;C1515974;C2825164;C0030705
mean of jsw mm,C0444504;C2347634;C2348143
ileocolon,
median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
previous infliximab therapy no of patients,C0205156;C4076075;C1552607;C0030705
interquartile range mm,C4330985;C4554674
no of infusions,C0574032
figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width,C1518681;C3875154;C1517945;C0205363;C0224497;C1547282;C0681850;C1550501;C1706203;C2349001;C2697811
previous acute hypersensitivity reaction to infliximab no of patients,C0205156;C0413234;C1552607;C0030705
previous bowel resection performed no of patients,C0205156;C0741614;C1552607;C0884358;C0030705
figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C0028873;C1696465;C1706408;C1511726;C3245479;C3714741;C0022742;C0224497
concurrent treatment of crohn s disease at study entry no of patients ff,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2985574;C1705654;C0030705;C4554348
prior lower gi clinical event,C0441471;C4019010
glucocorticoids plus immunosuppressive agents,C0017710;C3540777;C3540778
prior upper gi clinical event,C0441471;C4019010
proton pump inhibitor use,C0042153;C0457083;C1947944
figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter,C1280519;C1707887;C1872109;C0030705;C0871261;C1704632;C1706817;C2911692;C0441837;C1547282;C0034746;C0032659;C1257890;C0332174;C0439230;C0441889;C0456079;C1547707;C2946261;C0441833;C1706365;C1999270;C0439165;C1549488;C1561533;C0205210;C1704788;C3539106;C0087111;C1292734;C1522326;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0475211
cox $nmbr$ selective nsaid use,C0042153;C0457083;C1947944
fondaparinux n $nmbr$,C1098510
rates per $nmbr$ patient years,C0871208;C1521828
age median range years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
prior lgi event,C0441471;C4019010
risk factor for venous thromboembolism no,C3495424;C3496592
no prior lgi event,C0441471;C4019010
obesity,C0028754;C1963185
age $nmbr$ $nmbr$,C0001779
history of venous,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no aspirin,C0004057
thromboembolism,C0040038
nonsmoker,C0337672;C0425293;C4554605
nyha grade iii or iv,C0205617;C0450094;C0475271;C0687697;C3889290;C4050000;C4283820;C4283821;C4283822;C0022326;C4265176
corticosteroid,C0001617;C3536709
chronic obstructive pulmonary,C0205191;C0549186;C0024109;C2707265;C2709248;C4522268
no corticosteroid,C0001617;C3536709
inflammatory bowel disease,C0021390
ascvd,C3665365
cancer surgery,C0920424
no ascvd,C3665365
femaleb,
no of risk factors for venous thromboembolism no,C0035648;C1553898;C1861172
prior ugi event,C0441471;C4019010
creatinine clearance no,C0812399
no prior ugi event,C0441471;C4019010
$nmbr$ $nmbr$ ml min $nmbr$,C0439445
total population n,C3258257
$nmbr$ ml min $nmbr$,C0439445
bmi category,C0683312;C3889287
randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ $nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
active n $nmbr$,C0205177;C3853793;C3888249
$nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
age when diabetes first diagnosed years mean sd,C0001779;C0011847;C2699239;C0011849
white not of hispanic origin,C0007457;C0043157;C0220938;C0086409
previous vascular disease,C0205156;C0042373;C1552607
african american,C0085756
history of major macrovascular disease n,C0683519;C0730226;C0850708;C0944983
american indian or alaskan native,C0002460;C0238611;C0302891
history of myocardial infarction n,C1275835
asian or pacific islander,C0078988;C0242191
history of stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
unknown none of the above,C0439673;C3541433;C4050014
history of major microvascular disease n,C0683519;C0730226;C0850708;C0944983
family history of diabetes,C1313937
history of macroalbuminuriat n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
exercise once weekly,C0015259;C1522704;C0558293
history of microvascular eye disease n,C0683519;C0730226;C0850708;C0944983
alcohol consumption once weekly,C0001948;C0558293
blood pressure control,C0005823;C1271104;C1272641
history of hyperlipidemia,C4695788
systolic blood pressure mm hg mean sd,C0428886;C2699239
baseline use of hormone therapy,C1524063;C0279025
diastolic blood pressure mm hg mean sd,C0428886;C2699239
available baseline blood specimen n,C0168634;C0178913;C1442488
history of currently treated hypertension n,C0455527;C0521116
total cholesterol to hdl cholesterol ratio,C0369300
other major risk factors,C0035648;C1553898
non hdl cholesterol mmol l,C0729627;C1532563;C1535899
serum total cholesterol mmol l mean sd,C0587184;C2699239;C1287371
hscrp mg l,C0439268
serum hdl cholesterol mmol l mean sd,C0428472;C2699239
aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
p inleraclion,C0369773;C2603361
urinary albumin creatinine ratio pg mg median iqr,C0486293;C1318293
no evenls,
microalbuminuria n,C0730345
evenls per $nmbr$ $nmbr$ palienl years,C0439234
serum creatinine pmol l mean sd,C0201976;C2699239;C0600061
$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
serum haemoglobin a $nmbr$ c concentration mean sd,C0683149;C2699239
family history ol diabetes,C1313937
number of patients with event,C2360800;C0441471;C4019010
menopause and ht,C0025320;C0567312;C0018510;C0677607
relative risk reduction $nmbr$ cl,C0242492;C0596019
poslmenopausal ht,C0018510;C0677607
pctindopnl indapamide n $nmbr$,C0021186
poslmenopausal no ht,C0018510;C0677607
$nmbr$ oto $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l,C1532563
$nmbr$ ito $nmbr$,C0022283
tolal cholesterol to hdl cholesterol ratio,C2938854
history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
non hdl cholesterol,C0729627;C1535899
history of microvascular disease,C0683519;C0730226;C0850708;C0944983
$nmbr$ $nmbr$ mg l,C0439268
treatment with any bp lowering drugs,C3469597;C0037623;C1415692;C1708288;C4318478
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mg l,C0439268
treatment with open label perindopril,C3640652;C0136123
tiotropium n $nmbr$,C0213771
treatment with statins,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
smoking history pack yr,C1519384;C0439234
treatment with anti platelet drugs,C3469597
duration of copd yr,C0449238;C2926735
combined macro micro,C0085672;C1553035;C3811161;C4049106
baseline spirometry,C0168634;C0037981;C1442488
european trial,C0239307;C0008976;C1535514
before bronchodilation,C1371299;C3537072
non european trial,C0239307;C0008976;C1535514
fev $nmbr$ liters,C3714541;C0475211
combined trials,C0205195;C0008976
fev $nmbr$ of predicted value,C3714541;C0681842;C1522609;C1882327
dronedarone n $nmbr$,C0766326
fvc liters,C3714541;C0475211
race no f,C0034510;C1706779;C3853635;C0016327
ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
body mass index no,C0005893;C0578022;C1305855
after bronchodilation,C1371299;C3537072
cardiovascular history no,C1880008
gold stage f,C0018026;C0016327;C1304897
structural heart disease,C1290384
sgrq total score units,C0439148;C1519795;C3853603
coronary artery disease^,C0010054;C0010068;C1956346
respiratory medication,C0418986
any,
cardiac valvular disease,C0018824
inhaled anticholinergic,C0242896;C3537004
nonischemic cardiomyopathy,C0878544
short acting,C1282927;C1806781;C2350002
implanted pacemaker,C0848753
long acting,C0205166;C1706317
implanted cardioverter defibrillator,C0021102;C0810516;C2828363
inhaled j $nmbr$ agonist,C0004048;C2987634
rheumatic heart disease,C0035439
inhaled,C0004048
hypertrophic cardiomyopathy,C0007194;C4551472
oral,C0442027;C4521986
congenital heart disease,C0152021
theophylline compound,C0205198;C1706082
left atrial anteroposterior diameter mm,C4330985;C4554674
mucolytic agent,C0026698
congestive heart failure no,C0018802
leukotriene receptor antagonist,C0595726;C3537183;C4521995
any disease,C0012634
supplemental oxygen,C4534306
nyha class i,C1882084
subgroup by treatment interaction p value,C1079230;C1515021
nyha class ii,C1882085
mean se,C0444504;C0036919;C2347634;C2348143
symptoms of atrial fibrillation in the $nmbr$ months before randomiza,C0683368;C1457887;C0439231
atio pla,C0456170
tion no,
full cohort,C0009247;C0599755
recent cardioversion within $nmbr$ days before randomization,C0332185;C0013778;C0034656
gold stage,C0205390;C1300072;C1306673
concomitant cardiovascular therapy no,C1707479
i ii,C1710602;C4082587
calcium channel blocker ratelowering,C0006684;C3536851;C4521885
e europe,C0015176
usa,C0041703
beta blocker except sotalol,C0001645;C0037707
w europe,C0015176
oral anticoagulant,C0354604
reversibility,C0449261
long term antiplatelet therapy,C0443252;C1096021
concomitant medication,C0013227;C3244316;C4284232
previous antiarrhythmic treatment no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
laba,
class ia,C0020980;C0694634;C1947960
ics,C0815320;C4551720
class ib,C2744579;C3890035;C4283819
laba ics,C0815320;C4551720
class ic,C0020750;C4554818
anticholinergic,C0242896;C3537004
class iii,C0441887;C2698969
anticholinergics,C0242896;C3537307;C3540711
class iv,C0441888;C2698970
colesevelam hydrochloride group n $nmbr$,C0541154;C0441848
sotalol,C0037707
height cm mean sd,C0444504;C2699239;C2347634;C2348143
hazard ratio for event $nmbr$ ci,C2985465;C0008107;C3259781
weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
left atrial diameter,C0225860;C0225861
hbalc mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ mm,C4330985;C4554674
fasting plasma glucose mg dl mean sd,C0202042;C2699239;C0455280
heart failure criteria met,C0428210;C1550543;C4317104
oral anti dm drug status no,C0442027;C4521986
conversion to sinus rhythm in,C1321500
metformin alone,C0025598;C0205171;C0439044;C0679994
previous use of amiodarone,C1524063;C0002598
metformin other oral anti dm drugs,C0025598;C0029167;C0175795;C0304289
yes stopped for trial,C1549445;C1705108;C1710701;C1272691;C0008976
concomitant medications in $nmbr$ of subjects no,C0013227;C0802604;C2598133;C4284232
previous use of antiarrhythmic drugs,C1524063
angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
sample size n,C0242618
p blocking agents selective,C0233660;C0332206
age in years mean,C1510829;C0444504;C2347634;C2348143
hmg coa reductase inhibitors,C0360714;C2756999;C3539119
$nmbr$ to $nmbr$ y n,
multivitamins,C0301532;C3714835
$nmbr$ y n,
other plain vitamin preparations,C0042890
education in years mean,C0013621;C0013622;C0013658;C0039401
platelet aggregation inhibitors excluding heparin,C0032177;C0019134;C0770546
clinic research experience n,C0002424;C0035168;C0242481;C0442592
propionic acid derivatives,C0033482;C0695274;C3540752
on bp medication n,C0037623;C0013227;C3244316;C4284232;C1415692;C1708288;C4318478
proton pump inhibitors,C0358591;C1384478;C3540020
hx of diabetes n,C0262926;C3814444
thiazides,C0541746
chd n,C0280604;C3542407
thyroid hormone,C0040135;C4522017
baseline ecg with lvh n,C0168634;C0232306;C1442488
concomitant oral anti dm drugs no a,C0029167;C0175795;C0304289
ascvd n,C3665365
sulfonylureasb,
bmi kg m $nmbr$ mean,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
thiazolidinedionesc,
glucose mg dl mean,C0444504;C2347634;C2348143
a glucosidase inhibitors $nmbr$,C1512211
potassium meq dl mean,C0444504;C2347634;C2348143
nateglinide and repaglinide,C0903898;C0246689
creatinine mg dl mean,C0444504;C2347634;C2348143
geographic region,C0017446
abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol,C0022709;C1305855;C0444686;C1441506;C0439209;C0332849;C0489786;C0681850;C1550501;C1706203;C2349001;C2697811;C1515187;C0442027;C4521986;C0013227;C1254351;C4288115;C3687832;C0042295;C0541154;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408;C0332257;C1552866;C2700399;C0008287;C0017642;C0040372;C0872972;C0289313;C0795660;C1512211;C0050393;C0066535
south n,C1710133
rolofylline dose,C0178602;C0869039;C1114758
pr virgin islands n,C0279759;C0042752;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
$nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
others n,C1955473;C3539125
male n n,C0086582;C1706180;C1706428;C1706429
time in trial,C0040223;C3541383;C0150312;C0008976;C0332285;C1707101
ischemic heart disease,C0010054;C0151744
no with visit,C0545082;C1512346;C2826704
atrial fibrillation atrial flutter,C0155709
sbp dbp mean,C0444504;C2347634;C2348143
nyha class when patient was last in stable condition before admission,C1882083;C0030705;C0677946;C3538874;C0184666;C0809949
no of drugs,C0013227;C3687832
bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n,C0054015;C0439297;C1095989;C1417808;C2982014;C4284038
on step $nmbr$ drug,C0013227;C1254351
creatinine clearance by c g ml min,C0151280
sd,C2699239
medications on admission,C0013227;C0802604;C2598133;C4284232;C0457453
figure percentage of subgroup with bp controlled sbp,C0439165;C1549488;C1561533;C0037623;C0085805;C1415692;C1708288;C4318478
aldosterone inhibitor,C0002007
aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
iv nitrates,C0022326;C0028125;C4265176
diff_measure dm added this as table had multiple headings,C0011816;C3250443;C1524062;C0039224;C1706074;C0439064
rank based on treatment placebo,C0032042;C1696465;C1706408
bl,C0005918;C0006413;C1552663;C2827109
baseline variable,C0439828;C4553760
diff_measure,C0079809;C0242485
placeboa,
am_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
atorvastatinb,
$nmbr$ $nmbr$ o lt,C0023376;C0230426;C3887647;C4521399
treatment lipid interaction,C0023779;C1704675
$nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
unadjusted hr $nmbr$ ci for $nmbr$ sd increment,C0008107;C3259781
body weight kg,C0022718;C0439209;C4054209
likelihood test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
$nmbr$ $nmbr$ l ot,C1318464;C1418208;C1705587
unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment,C0008107;C3259781
responder analyses achieving alc $nmbr$ $nmbr$,C0002778;C0936012;C1524024;C1424945;C3811058
apob apoa i,C0085201;C1677784
n responders,C0369718;C0441922
$nmbr$ e $nmbr$,
$nmbr$ $nmbr$ $nmbr$ t,C2603360
ldlc hdlc,C1416822;C1704429
baseline alc $nmbr$ $nmbr$,C1424945;C3811058
ldlc,C1416822
fasting lipids mmol $nmbr$,C0015663;C0023779;C0439190
apob,C0003593;C3252643
am_ delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
apoa i,C0085201;C1677784
ldl,
non hdlc,C1518422;C1704429
hdl,C3715113
tc hdlc,C0039411;C1704429;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
non hdl,C1518422;C3715113
cholesterol,C0008377
vldl,C0523560
febuxostat $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
blood pressure mmhg,C0005823;C0439475;C1271104;C1272641
allopurinol $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
minority,C0026192
subgroup analyses,C2986480
cardiovascular disease,C0007222
bl alc $nmbr$ $nmbr$,C1424945;C3811058
gout history mean sd years,C0018099;C0439234
blaic $nmbr$ $nmbr$,
history presence of tophi,C0150312;C0392148;C3854307
bl bmioo kg m^,C0022718;C0439209;C4054209
recent use of allopurinol within $nmbr$ days of,C1524063;C0002144;C0439228
bl bml $nmbr$ kg m^,C0022718;C0439209;C4054209
randomization,C0034656
bl bm $nmbr$ $nmbr$ kg m^,C0022718;C0439209;C4054209
mild to moderate renal impairment,C1299392;C1565489
bl bml $nmbr$ ke m^,C0005918;C0022558;C0006413;C1552663;C2827109
chlorthalidone vs amlodipine,C0008294;C0051696
e characteristic n,C1521970
chlorthalidone vs lisinopril,C0008294;C0065374
toricoxib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chlorthalidone vs doxazosin,C0008294;C0114873
age mean years sd,C1510829;C2699239
hr $nmbr$ ci univariate cox proportional hazard regression,C0684320;C0684321;C1836830
female $nmbr$,C0043210;C0086287;C1705497;C1705498
pef,C0030771;C1518922;C1542834
caucasian $nmbr$,C0007457;C0043157
ref,C1425988
body mass index mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
no ef data,C1511726;C3245479;C3714741
previous anti inflammatory antirheumatic products n,C0432633
hr $nmbr$ ci multivariate cox proportional hazard regression,C0684320;C0684321;C1836830
meloxicam,C0083381
hospitalized hf,C0018488;C1313497;C1538440;C3273279
piroxicam,C0031990
irbesartan n $nmbr$,C0288171
indomethacin,C0021246
clinical,C0205210
previous analgesic products n,C0205156;C0002771;C1552607
electrocardiographic findings no,C0438154
history of upper gi events perforations ulcers and bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0019080
left bundle branch block,C0023211;C0344420;C2828132
non user $nmbr$,C1518422;C1548600;C1706077
atrial fibrillation or flutter,C0004238;C0344434;C1963067;C0016385;C2242390
increased risk for thrombotic cardiovascular,C4699158;C0007226;C3887460
cause of heart failure no,C0015127;C1524003
event n,C0441471;C4019010
ischemia,C0022116;C4321499
history of diagnosed hypertension n,C0455527;C0011900
hospitalization for heart failure within previous $nmbr$ mo no,C3898876;C0026544;C0332177
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ pty $nmbr$,
angina symptoms^,C0858277
continued use of gpa,C0549178;C1524063
pci orcabg,C4049621
new use of gpa,C0205314;C1524063
stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
quality of life,C0034380;C0518214
air n $nmbr$,C0001861;C3536832
score on the minnesota living with heart failure scaled,C0449820;C4050231;C0018801;C0018802;C4554158;C0175659;C0349674;C1947916
ig n $nmbr$,C0021027;C0305052;C0360506
hemoglobin,C0019046
air ig n $nmbr$,C0001861;C0021027;C0305052;C0360506;C3536832
mean g dl,C0444504;C0439267;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
anemia no,C0002871;C1000483;C4554633
gender [n ],C0079399;C1522384;C0369718;C0441922
mean ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0444504;C0439445;C2347634;C2348143;C0005902
origin [n ],C0079946;C0439659;C1550512;C0369718;C0441922
potassium mmol liter,C0032821;C0475211;C0202194;C0304475;C0597277;C3714637
african,C0027567
nt probnp pg ml,C0669479;C0439297;C0754710
duration of diabetes years,C0449238;C2926735
medication no,C0013227;C3244316;C4284232
oam use [n ],C0042153;C0457083;C1947944;C0369718;C0441922
diureticff,
insulin secretagogue,C0021641;C4704833;C1533581;C1579433;C3714501
loop,C0445022
biguanides,C0005382;C0360396;C3540012
thiazide,C0541746
tzd,
antiarrhythmic drug,C0003195;C0301380
baseline insulin dose u kg [lsm se ],C0366513;C1300561;C0036919
antiplatelet,
baseline a $nmbr$ c [lsm se ],C0168634;C0036919;C1442488
a $nmbr$ c [n ],C1272460
prior insulin use years,C0240016;C0439234
plus minus values are means sd percentages may not total $nmbr$ because of rounding the body mass index is the weight in kilograms divided by the square of the height in meters to convert the values for creatinine to micromoles per liter multiply by $nmbr$ $nmbr$ ace denotes angiotensin converting enzyme cabg coronary artery bypass grafting nt probnp n terminal pro b type natriuretic peptide nyha new york heart association and pci percutaneous coro nary intervention race was reported by the investigators one patient in nyha class i was mistakenly included in the placebo group this category includes any angina like symptoms at any time in the past with no confirmation of diagnosis of coro nary heart disease required possible scores range from $nmbr$ to $nmbr$ with lower scores indicating a better quality of life anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women nt probnp levels are influenced by a variety of factors including age sex body mass index and renal function no clinically useful normal range has been established some patients were taking both loop and thiazide diuretics,C0042295;C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074;C0010294;C1561535;C0439300;C1719797;C2911648;C1452534;C4284014;C0040744;C1279380;C0034510;C1706779;C3853635;C1709908;C1882084;C0332257;C0032042;C1696465;C1706408;C0683312;C3889287;C1552866;C2700399;C0858277;C0040223;C3541383;C0521091;C0596672;C0441994;C0449820;C1548802;C2003888;C0002871;C1000483;C4554633;C1704788;C3539106;C1281911;C0439267;C0439241;C0025266;C0669479;C0754710;C0814287;C0232804;C3827682;C0086715;C0443211;C1272684;C0030705;C0445022;C0012802
algorithm $nmbr$,C0002045;C1553907
irbesartan,C0288171
number,C0237753;C0449788
no of patients no of events $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705;C0441471;C3541888
female male,C0086582;C1706180;C1706428;C1706429
use of beta blocker,C1524063;C0001645
duration since diagnosis years,C0449238;C2926735
hospitalization for heart failure within $nmbr$ mo,C3898876;C0026544;C0332177
time since start insulin years,C1301880
hba $nmbr$ c baseline,C0168634;C1442488
the plot shows hazard ratios and $nmbr$ confidence intervals for the primary outcome with patients stratified according to eight sub groups prespecified in the statistical analysis plan no heterogeneity was observed for these subgroups,C1547282;C2985465;C0009667;C0205225;C0439612;C0439631;C0030705;C0205363;C0205454;C3889277;C0019409;C0242960;C1441672;C1079230
fbg baseline,C0168634;C1442488
atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$,C1319635;C3643658
premixed insulin only,C0021641;C1533581;C1579433;C3714501
atorvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
premixed insulin with oads,C0021641;C1533581;C1579433;C3714501
ncep atp iii risk factors,C0035648;C1553898
insulin glargine oad,C0907402
the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides,C0023824;C0202117;C0439269;C0205195;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2360800;C0332257;C0023822;C1442160;C0392885;C0025266;C0043210;C0062152
insulin glargine oad od prandial,C0229089;C0439164;C1512019;C3273373;C3665488;C1998602;C4553624
other forms of atherosclerosis^,C0348078;C0376315
insulin glargine oad bd prandial,C0005126;C2344255;C4050145;C1998602;C4553624
multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$,C0035648;C1282512;C1553898;C0439234;C0439508
fbg mg dl,C0439269
family history of premature chdj,C0241889;C0151526;C0205252;C4018905
fbg mmol l,C1532563
metabolic syndrome $nmbr$ of $nmbr$ characteristics,C0524620;C1521970
rosuvastatin,C0965129
waist circumference s $nmbr$ men or $nmbr$ cm women,C0455829;C0025266;C0043210
mean yr,C0444504;C0439234;C2347634;C2348143
triglycerides $nmbr$ mg dl,C0041004;C0439269
$nmbr$ yr no,C0439234
nyha class no,C1882083
fasting blood glucose $nmbr$ mg dl,C0428568;C0439269;C1261430
past or current angina pectoris,C0521116;C0002962;C1705970
visit $nmbr$ ldl cholesterol strata,C0023824;C0202117
current atrial fibrillation or flutter on ecg,C0004238;C0344434;C1963067;C0016385;C2242390
pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
implantable cardioverter defibrillator,C0162589;C2825184
laboratory measurements,C0681902
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd dened as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
cholesterol mmol liter,C0008377;C0475211
benazepril amlodipine group n $nmbr$,C0051696;C0441848
apob apoa l ratio,C0456603;C1547037
benazepril hydrochlorothiazide group n $nmbr$,C0717481;C0441848
triglycerides mmol liter,C0041004;C0475211
race or ethnic group no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0016327
serum creatinine,C0201976;C0600061
nordic countries,C0036273
$nmbr$ tmol liter no,C0475211
estimated gfr,C0017654;C1424601
body mass index blood pressure mm hg,C0005893;C0439475;C0578022;C1305855
nt pro bnp pmol liter j,C0669479;C0754710
pulse beats min,C0232117;C0439385;C0391850;C1947910
hscrp mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C3811844;C0439445;C0005902
current medication no,C0746467
serum values^,C0229671;C0042295;C1546774;C1550100
loop diuretic,C0354100;C3536704
high density lipoprotein cholesterol mg dl,C0023822;C0439269
loop or thiazide diuretic,C0445022;C0012802;C3536861
previous antihypertensive treatment no,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
aldosterone antagonist,C0002007;C2757004;C3536833
no of agents,C0450442;C1254351;C1521826
digitalis glycoside,C0012253
antiplatelets agents,C0085826
antiarrhythmic therapy,C0039798;C0087111;C1363945
risk factors no,C0035648;C1553898
antiplatelet therapy,C1096021
previous hospitalization for unstable angina,C0019993;C0002965
anticoagulant therapy,C0150457
renal disease,C0022658
antiplatelet or anticoagulant therapy,C0150457
previous coronary revascularization,C0205156;C0877341;C1552607
placebo no of events no,C0032042;C1696465;C1706408;C0441471;C3541888
number of patients or mean sd,C2360800;C0444504;C2699239;C2347634;C2348143
rosuvastatin of patients rate,C0965129;C0030705
sitagliptin n $nmbr$,C1565750
iii and iv,C0439070;C1705160;C0022326;C4265176
nationality,C0027473
$nmbr$ mm hg,C0439475
indian,C1524069
heart rate,C0018810
korean,C1556095
$nmbr$ $nmbr$ bpm,
weight range kg,C0022718;C0439209;C4054209
previous revascularization,C0205156;C0581603;C1552607
body mass index range kg m $nmbr$,C0022718;C0439209;C4054209
cardiac rhythm,C0232187
duration of type $nmbr$ diabetes mellitus years,C0449238;C2926735
sinus rhythm,C0232201
all randomized patients range,C1514721;C2348147;C3542016
ldl cholesterol level,C0023824;C0201950;C0202117;C0428466
naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C1363945
$nmbr$ $nmbr$ mmol liter,C0439190;C0475211
fpg range mmol l,C1514721;C1532563;C2348147;C3542016
apob apoa i ratio,C0456603;C1547037
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
hdl cholesterol level,C0201950;C0428466
ls mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
triglyceride level,C0428475
ls mean between group difference $nmbr$ ci,C2347634;C0008107;C3259781
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
hba $nmbr$ c all countries,C0019016;C0454664;C1825777;C3538758
nt pro bnp,C0669479;C0754710
sitagliptin,C1565750
$nmbr$ $nmbr$ pmol liter,C0439192;C0475211
china,C0008115
hscrp level,C0441889;C0456079;C1547707;C2946261
india,C0021201;C2700456
$nmbr$ $nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
korea,C0022771
assigned to topiramate,C1516050;C1552601
sitagliptin $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ fasting plasma glucose fpg mmol l,C0202042;C1532563;C0455280
assigned to placebo,C1516050;C1552601
all countries,C0454664
migraine occurrence days month,C0149931;C0556971
sitagliptin $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ h postprandial plasma glucose ppg mmol l,C2827804;C0202042;C0455280
migraine duration h,C0033727;C0369286;C0441932;C0564385;C4528284
week o baseline mean sd,C0168634;C2699239;C1442488
migraine severity score,C0149931;C0457451
ls mean difference between treatment groups $nmbr$ ci,C1705241;C2347634;C1705242
acute medication intake days month,C0013227;C0556971;C3244316;C4284232
fasting indices,C0015663;C4033634
midas score,C0449820;C4050231
fasting insulin miu ml,C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
patients assessed,C0030705;C1516048
placebo $nmbr$,C0032042;C1696465;C1706408
hit $nmbr$ score,C0449820;C4050231
sitagliptin $nmbr$,C1565750
sf $nmbr$ mcs score,C0449820;C4050231
fasting proinsulin pmol l,C0015663;C0033362;C0439284;C3813208
sf $nmbr$ pcs score,C0449820;C4050231
fasting c peptide ng ml,C0015663;C0006558;C0439275
participants with metabolic syndrome,C0679646;C0524620
homa b,
participants without metabolic syndrome,C0679646;C0524620
homa ir,C0022065;C0022071;C1448132
number randomized,C0237753;C0449788;C0034656;C3815594
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ z,
womens,
quicki,
years of education,C0439234;C0013621;C0013622;C0013658;C0039401
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ y,
antihypertensive treatments,C0003364;C0087111
postprandial indices,C0376674;C4033634
atherosclerotic cvd,C0333482;C0007222
$nmbr$ h postprandial insulin miu ml,C0021641;C0439457;C1533581;C1579433;C3714501
history ol mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
$nmbr$ h postprandial proinsulin pmol l,C2827799;C0033362;C3813208
history ol coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ h postprandial c peptide ng ml,C2827809;C0006558
other ascvd,C3665365
insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min,C0600653;C0702093;C1524029;C3813700;C0918012;C1552854;C1637833;C2986546
st t wave,C0036056;C0429103;C3272372
placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
lelt ventricular hypertrophy,C0340279
composite index of insulin sensitivity isi,C0600653;C0918012;C1552854;C1637833;C2986546
history ol chd at baselines,C0280604;C3542407
disposition index,C0743223;C0600653;C0918012;C1552854;C1637833;C2986546;C1705555
bmi kg m,C0022718;C0439209;C4054209
no hypertension n $nmbr$,C0020538;C1963138
fasting glucose,C0015663;C0017725
hypertension n $nmbr$,C0020538;C1963138
cardiovascular metabolic syndrome risk lactors,C0007226;C0524620;C3887460
ecg abnormality resting,C0035253;C1512899
fasting glucose $nmbr$ mg dl,C0015663;C0439269
tc mmol l mg dl,C1532980
bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
ldl c mmol l mg dl,C1532980
fasting triglycerides $nmbr$ mg dl,C0015663;C0041004;C0439269
hdl c mmol l mg dl,C1532980
low hdl cholesterol,C0151691
tg mmol l mg dl [median],C1532980;C0549183;C0876920;C2347635;C2348144;C2939193
high blood pressure,C0020538;C2926615
antihypertensive drug,C0003364
lipid trial participantss,C0023779;C0008976
total antihypertensive use,C0042153;C0457083;C1947944
table_group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
^ blocker,
comparison,C1707455
angiotensin ii receptor blocker,C0521942;C3536793
with metabolic syndrome,C0524620
event patients in group incidence $nmbr$ person year,C0030705;C0021149;C0220856
without metabolic syndrome,C0524620
diet group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
a,
diet pravastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
amlodipine chlorthalidone,C0051696;C0008294
non dm,C1518422;C0011816;C3250443
combined cvd,C0205195;C0007222
current past,C0521116;C1705970
esrd,C0022661;C0035078;C2316810
uncontrolled,C0205318
b,
controlld,
lisinopril chlorthalidone,C0065374;C0008294
with placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
categories of urinary acr ^g mg,C0683312;C1300563
with alogliptin $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p for trend,C0369773;C2603361
with alogliptin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lowest normal n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
age group n,C0441848
low normal n $nmbr$,C0205251;C0205307;C0231683;C0439166;C2347086;C4553972;C1550472;C3890211;C4048187;C4321351;C4522223
black african american,C0085756
medium normal n $nmbr$,C0009458;C0205307;C0231683;C0439166;C2347086;C4553972;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
native hawaiian other,C0337920
high normal n $nmbr$,C0205250;C0205307;C0231683;C0439166;C2347086;C4553972;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
alaska native,C0682125
low medium microalbuminuria n $nmbr$,C0205251;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C1550472;C3890211;C4048187;C4321351;C4522223
baseline hba $nmbr$ c n,C0168634;C0019016;C1825777;C3538758;C1442488
high microalbuminuria to macroalbuminuria n $nmbr$,C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
patients $nmbr$,C0030705
male acr definition ^ g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diabetes duration years,C0011847;C0439234;C0011849
female acr definition ^g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glyburide dose duringthe study mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
female sex n,C0086287
with placebo,C0032042;C1696465;C1706408
white n medical history n,C0262926;C1704706
with alogliptin $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior angina pectoris,C0332152;C0002962;C2826257
with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior cabg,C0332152;C0010055;C2826257
n $nmbr$ $nmbr$,C0369718;C0441922
prior ptca or cabg,C0332152;C2936173;C2826257;C0010055
baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
current smoker n of patients,C3173209;C3241966
male n $nmbr$,C0086582;C1706180;C1706428;C1706429
dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799;C0439475;C0680730
female n $nmbr$,C0043210;C0086287;C1705497;C1705498
egfr ml mn $nmbr$ $nmbr$ m $nmbr$,C0026327;C0026405;C4285072
hispanic or latino n $nmbr$,C0086409;C0086528
mean serum potassium mg dl,C0302353;C0439269;C0543465
not hispanic or latino n $nmbr$,C1518424;C0086528
mean serum cholesterol mg dl,C0587184;C0439269
baseline body mass index,C0005893;C0578022;C1305855
lv function $nmbr$ $nmbr$ and,C0031843;C0542341;C0700205;C1705273
$nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
j $nmbr$ blocker,
aliskiren n $nmbr$,C1120110
potassium sparing diuretic,C0304490;C3536751
hydochlorothiazide n $nmbr$,
other diuretic,C0012798
obese patients n,C0028754;C0030705
digitalis,C0012252;C0304520
diabetes mellitus n,C0011849
active treatment,C1704532
duration of hypertension y,C0449238;C2926735
hr and $nmbr$ ci,C0008107;C3259781
mssbp mm hg,C0439475
low to medium microalbuminuria n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
msdbp mm hg,C0439475
urinary acr,C1412134;C1515941
primary outcome n $nmbr$,C0205225;C0439612;C0439631
values are presented as mean sd unless stated otherwise data shown are for the randomized population body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group obesity was defined as body mass index $nmbr$ kg m $nmbr$ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection evaluation and treatment of high blood cholesterol in adults adult treatment panel iii criteria $nmbr$ as any $nmbr$ of the following waist circumference $nmbr$ cm for men or $nmbr$ cm for women triglycerides $nmbr$ mg dl high density lipoprotein cholesterol $nmbr$ mg dl for men or $nmbr$ mg dl for women mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg fasting glucose $nmbr$ mg dl by medical history aliskiren n $nmbr$ hydrochlorothiazide n $nmbr$,C0042295;C0449450;C0444504;C2347634;C2348143;C1511726;C3245479;C3714741;C1547282;C0005893;C0578022;C1305855;C1551393;C1705492;C3272743;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0030705;C0020261;C1704788;C3539106;C0524620;C0220825;C1261322;C0596197;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455829;C0025266;C0023822;C0439269;C0439475;C0262926;C1704706
$nmbr$ $nmbr$ reference,C1514811;C1706462
aliskiren,C1120110
cardiovascular death n $nmbr$,C0007226;C0011065;C1306577;C4082313;C4552775;C3887460
hydrochlorothiazide,C0020261
all cause mortality n $nmbr$,C0015127;C0026565;C0026566;C1524003
$nmbr$ y n $nmbr$,
primary,C0205225;C0439612;C0439631
baseline mssbp msdbp mm hg,C0168634;C0439475;C1442488
companion $nmbr$ $nmbr$ hours,C0031268;C0439227;C0335343;C0682323
change in bp mm hg,C1268766;C0439475
companion wake up stroke,C0038454;C4554100
msdbp,
mean age y mean sd,C0001779;C2699239
changes from baseline in mssbp and msdbp are shown as least squares mean sem p $nmbr$ $nmbr$ vs $nmbr$ y,C0392747;C0443172;C1547282;C0023189
men women,C0025266;C0043210
placebo statin n $nmbr$ $nmbr$,C0032042;C0360714;C1696465;C1706408
mean weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
ezetimibe $nmbr$ mg statin n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
location,C0450429;C1515974;C4284930;C4284931
cad,C1504769;C2239547;C3813548;C4284121
south africa,C0037712
crp mean mg dl sd,C0439269;C2699239
australia,C0004340
ldl cholesterol mean mg dl sd,C0023824;C2699239;C0202117
ct findings,C2607943;C2926606;C3539655
triglycerides mean mg dl sd,C0439269;C2699239
$nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
high density lipoprotein cholesterol mean mg dl sd,C0023822;C2699239
$nmbr$ patients,C0030705
new stroke,C0038454;C4554100
figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides,C1705241;C1705242;C1142985;C0360714;C0032042;C1696465;C1706408;C0392747;C0443172;C4319952;C3890735;C4048285;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0062152
old stroke,C1536121
parameter variable,C0439828;C4553760
previous tia,C0007787;C0917805;C1054154
amlodipine vaisartan n $nmbr$,C0051696
previous stroke,C0038454;C4554100
age $nmbr$ years n,C1510829
mean systolic bp mmhg mean sd,C0871470;C2699239
f emale,C0016327
mean diastolic bp mmhg mean sd,C0428883;C2699239
race ethnicity n,C0034510;C0015031;C0243103;C1706779;C3853635
mean serum glucose mg dl mean sd,C0202041;C2699239;C3534430
hispanic black,C0005680;C0027567;C0085756;C0439541
mean bmi kg m $nmbr$ s d,C1275571
figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b,C0520511;C1704711;C1522706;C2349188;C3714939;C3854213;C1274040;C1546471;C2825142;C1524063;C0002778;C0030705;C0936012;C1524024;C4684790;C0009247;C0599755;C1522326;C0288672;C0032042;C1696465;C1706408;C0871208;C1521828;C0168634;C1442488;C0449820;C4050231;C1547282
mean blood pressure mmhg s d j,C0428886;C0488053
subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes,C1079230;C1527178;C1705938;C0683970;C0235828;C0205225;C1274040;C0439612;C0439631
severity n,C0439793;C0522510
baseline hb $nmbr$ g $nmbr$ $nmbr$ n $nmbr$,C0062408
mean pulse pressure mmhg s d,C0445074;C2347155
baseline hb $nmbr$ g i $nmbr$ n $nmbr$,C0062408;C0086706
populations,C0032659;C1257890
$nmbr$ placebo n $nmbr$,C0032042;C1696465;C1706408
intent to treat population n,C0087111;C0032659;C1257890;C1292734;C1522326
race or ethnicity n,C0034510;C1706779;C3853635;C0015031;C0243103
safety population n,C0036043;C0032659;C1257890;C1705187
diastolic bp mm hg,C0428883;C0439475
uacr mgg $nmbr$ gm,C0017480;C3854019
figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup,C3484017;C3484018;C0168634;C1442488;C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1079230;C0005680;C0027567;C0085756;C0439541;C1305855;C0745133;C0237753;C0449788;C0030705;C1292734
serum creatinine limo $nmbr$ $nmbr$,C0201976;C0600061
all patients n $nmbr$,C0030705
egfr ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
patients with fistulas at baseline,C0030705;C0016169;C0168634;C1442488
triglycerides mmolt $nmbr$ gm,C0017480;C3854019
adalimumab n $nmbr$,C1122087
serum albumin g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
all patients with fistulas n $nmbr$,C0030705;C0016169
hemoglobin g $nmbr$ $nmbr$,C1319312
male no,C0086582;C1706180;C1706428;C1706429
calcium mmol $nmbr$ $nmbr$,C0006675;C0439190;C0006726;C2936886;C3540037;C3714611
baseline cdai score mean sd,C0168634;C2699239;C1442488
phosphorus mmol $nmbr$ $nmbr$,C0031705;C0439190;C0080014;C3714498
crp concentration $nmbr$ $nmbr$ mg dl $nmbr$ mg l n,C2827881
p valuec,C0369773;C2603361
previous tnf antagonist exposure n,C0205156;C0231491;C1552607
hemoglobin gl^ $nmbr$ for combined hemoglobin groups,C0018229;C1423073;C1427674
any glucocorticoid,C0017710
hemoglobin gl^ $nmbr$ for baseline hemoglobin $nmbr$ gl^ $nmbr$,C0019046;C0018229;C1423073;C1427674
$nmbr$ mercaptopurine,C0000618
hemoglobin gl^ $nmbr$ for baseline hemoglobin gt $nmbr$ gl^ $nmbr$,C0019046;C0018229;C1423073;C1427674
no draining fistulas,C0013103;C0180499;C4265177;C0016169
gmr,C1522544;C1704695
week $nmbr$ of patients,C0332174;C0439230;C0030705
reduction,C0301630;C0392756;C1293152;C4551656
no baseline immunosuppressant use,C0042153;C0457083;C1947944
uacr mgg^ $nmbr$,
both adalimumab groups n $nmbr$,C1122087;C0441848
bsl hb gl $nmbr$,C0018229;C1423073;C1427674
$nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
rrr $nmbr$ cl,C0596019
baseline immunosuppressant use,C0042153;C0457083;C1947944
p valuea,C0369773;C2603361
no baseline cd related antibiotic use,C0042153;C0457083;C1947944
interaction $nmbr$,C1704675
baseline cd related antibiotic use,C0042153;C0457083;C1947944
k rate,C0871208;C1521828
exenatide,C0167117
cox bsl only,C1565830;C1549954
biasp $nmbr$,
cox bsl yr $nmbr$ hbd,C1549954;C0439234
bid,
esrd or death,C0022661;C0035078;C2316810;C0011065;C1306577;C4082313;C4552775
qd,C0332173
subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811;C0034656;C3815594
bsl baseline cl confidence interval esrd end stage renal disease hb hemoglobin k rate of events per $nmbr$ patient years of follow up rrr relative risk reduction yr year ^treatment effect of losartan versus placebo interaction test between treatment group and hemoglobin group $nmbr$ or $nmbr$ g i $nmbr$ cmultivariate cox model with baseline log urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin as covariates dmultivariate cox model with baseline log urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin and change in hemoglobin at year $nmbr$ as covariates,C0026538;C1554093;C3242279;C3242455;C0237455;C1626828;C1565830;C3161035;C3274659;C3714583;C3853906;C0019046;C0201976;C0600061;C0392747;C0443172;C1705241;C4319952;C0439234;C0439508
american indian alaska native,C0886378
hemoglobin category,C0683312;C3889287
black or african american,C0005680;C0027567;C0085756;C0439541
no anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
not hispanic or latino,C1518424;C0086528
improving anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1272745;C1319635
subject completion status n,C3891295
new anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
completed trial,C0205197;C0008976;C3854010
persistent anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
discontinued,C1444662
adverse eventy,
missing hb at yr $nmbr$,C0019046;C0439234
ineffective therapy,C0039798;C0087111;C1363945
bsl baseline cl confidence interval esrd end stage renal disease hb hemoglobin hr hazard ratio k rate of events per $nmbr$ patient years of follow up yr year multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin as covariates,C0026538;C0030705;C0439234;C0683312;C3889287;C0201976;C0600061;C0019046
non compliance,C0376405;C0457432
men total n $nmbr$,C0025266;C0439175;C0439810
otherz,
diet n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
diabetic history years x,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
diet pravastatin n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively,C0565965;C0019016;C1825777;C3538758;C0168634;C1442488;C0042295;C0167117;C0332173;C0243174
total n $nmbr$,C0439175;C0439810
dexlansoprazole mr,C0024485;C1417249;C2347167;C3254418;C4050513
mean sd y,C0444504;C2347634;C2348143
$nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sbp mean sd mm hg,C0085805;C0439475
non hispanic or latino,C1518424;C0086528
dbp mean sd mm hg,C0444504;C0439475;C2347634;C2348143
native hawaiian or other pacific islander,C0337920;C0242191
smoker n,C0337664
age y mean s d,C0001779;C0444504;C2347634;C2348143
drinking n,C0001948;C0684271;C0369718;C0441922
weight kg mean s d,C0005910;C1275571;C0043100;C1305866;C1705104
lipid values mmol l,C0023779;C1532563
height cm mean s d,C0439392;C0444504;C2347634;C2348143
tc mean sd,C0039411;C2699239;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
bm $nmbr$ kg m $nmbr$ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
ldl c mean sd,C0444504;C2699239;C2347634;C2348143
helicobacter pylori negative n,C4688581
hdl c mean sd,C0444504;C2699239;C2347634;C2348143
eo severity by la classification at baseline baseline of the healing study n,C0439793;C0522510;C0168634;C0043240;C0205249;C1442488
tg median interquartile range,C0337445;C1711350
d,
lp a mean sd,C0065058;C2699239;C1439335;C4553379
duration of treatment in the healing study n,C0444921;C0043240;C0205249
incidence rate no $nmbr$ person years,C1708485;C0027361;C0439234;C2347489
previous treatment in the healing study n,C1521826;C3161471
diet,C0012155;C0012159;C1519433;C2983588;C3668949
dexlansoprazole mr $nmbr$ mg qd,C0024485;C0332173;C1417249;C2347167;C3254418;C4050513
diet pravastatin,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
lansoprazole $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
heterogeneity p value,C0019409;C1709380;C0242960
characteristic age mean sd yr,C0001779;C0439234
chd cerebrovascular disease,C0280604;C0007820;C3542407
dronedarone n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0766326
hazard ratiof $nmbr$ ci,C0008107;C3259781
placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
chd cerebral infarction,C0280604;C0007785;C3542407
all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
$nmbr$ years $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439234
structural heart disease no f,C1290384;C0016327
id genotype,C0009450;C0017431;C0600091;C1441613
coronary heart disease no,C0010054;C0010068;C1956346
ii n $nmbr$,C1710602;C4082587
id n $nmbr$,C0009450;C0600091;C1441613
valvular heart disease no,C0018824;C1963123
dd n $nmbr$,C3538867;C3814791
nonischemic cardiomyopathy no,C0878544
race or ethnic group no,C0034510;C1706779;C3853635;C0015031;C1879937
history of chf nyha class ii or iii no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439070;C1705160
body mass index $nmbr$,C0005893;C0578022;C1305855
lvef no i,C0428772;C0488728;C0021966;C0221138
known duration of diabetes yr,C0449238;C2926735
lone atrial fibrillation no,C0340489
not available,C0686905
pacemaker no,C0030163;C0810633;C1546728;C3275122;C3853703
use of antihypertensive drugs,C1524063
medications in use at baseline no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
coronary revascularization procedure,C0877341
vitamin k antagonists,C3653316
lipid disorder,C0154251
early eptifibatide group n $nmbr$,C0253563;C0441848
amputation,C0002688;C0332840;C1546539
delayed eptifibatide group n $nmbr$,C0205421;C0441848;C1545665;C3272602
neuropathy,C0442874
median yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
laboratory variables,C0022877;C0439828;C3244292;C4283904
interquartile range yr,C1711350;C0439234
urinary albumin creatinine ratio median mg g range,C1514721;C2348147;C3542016
region ofenrollment,C0017446;C0205147
serum creatinine mg dlb,C0752347;C3890365
middle east africa or asia pacific,C0001741;C0003980
glomerular filtration rate $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1561549
median ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
serum cholesterol mg dld,C1414063;C2826331
interquartile range ml min,C1711350;C0439445
serum triglycerides mg dle,C0024138;C3542918
killip class ii iii or iv,C2697846;C0022326;C4265176
hemoglobin g dlf,C1319312
qualifying high risk features,C1514624;C0035648
glycosylated hemoglobin,C0017853
age $nmbr$ yr elevated biomarkers and st segment changes,C0001779;C0005516;C0232326
serum albumin g dl,C0036773;C0439267;C0728877
age $nmbr$ yr and elevated biomarkers,C0001779;C0439234;C0205250;C0005516;C3163633
elevated biomarkers and st segment changes,C0205250;C0005516;C3163633;C0232326
mean sd values are presented for all variables except medical history race or ethnic group and sex n and urinary albumin creatinine ratio median range abody mass index is the weight in kilograms divided by the square of the height in meters bto convert values to micromoles per liter multiply by $nmbr$ $nmbr$ estimated using the modified equation from the modification of diet in renal disease study dto convert values to millimoles per liter multiply by $nmbr$ $nmbr$ eto convert values to millimoles per liter multiply by $nmbr$ $nmbr$ ^to convert values to millimoles per liter multiply by $nmbr$ $nmbr$,C0444504;C0042295;C2347634;C2348143;C0449450;C0439828;C0034510;C1706779;C3853635;C0015031;C1879937;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0600653;C0918012;C1552854;C1637833;C2986546;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0439194;C0475211;C0750572;C1524063;C0552449;C0086153;C3671772;C0022658;C1532563;C1719797;C2911648;C0439190
age $nmbr$ yr and st segment changes,C0001779;C0439234;C0232326
losartan n n,C0126174
age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular,C0001779;C0005516;C0005847;C1558950;C1801960
placebo n n,C0032042;C1696465;C1706408
presentation to tertiary care hospital,C0449450;C0337954
adjusted $nmbr$ risk reduction losartan vs placebo $nmbr$ cl,C1137094;C0126174;C0032042;C0596019;C1696465;C1706408
randomized,C0034656;C3815594
composite endpoint of doubling of serum creatinine esrd or death,C2349179;C2826544;C0011065;C1306577;C4082313;C4552775
low $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
id,C0009450;C0600091;C1441613
intermediate $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
dd,C3538867;C3814791
high $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
doubling of serum creatinine,C0205173;C1705764
medical therapy during index hospitalization,C0418981;C0019993
or esrd,C0022661;C0035078;C2316810
antithrombin,C0003438;C0003440;C4521254
rosiglitazone,C0289313
unfractionated heparin only,C0019134;C2825026
metformin,C0025598
low molecular weight heparin only,C0019139;C3536766
glyburide,C0017628
both unfractionated heparin and low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
time since diagnosis of diabetes,C0040223;C3541383
$nmbr$ $nmbr$ years,C0439234
neither unfractionated heparin nor low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
a $nmbr$ c,
at any time,C0040223;C3541383
fasting insulin pmol l,C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
early use intended,C0042153;C0457083;C1947944;C1283828;C1551357
estrogen containing hormones,C0014939;C0019932;C2936882;C4542544
temporal data and management strategy,C1511726;C3245479;C3714741;C0001554;C0679199;C0376636;C1273870;C3273539
calcium supplements,C3540037
time from onset of symptoms to presentation hr,C1320528;C0449450
bisphosphonates,C0012544;C3541401
time from presentation to randomization hr,C0040223;C3541383;C0034656
glucocorticoids,C0017710;C3540777;C3540778
time from randomization to study drug initiation hr,C0040223;C3541383;C0013175;C0589507;C1158830;C1704686
thiazide diuretics,C0012802
time from randomization to coronary angiography hr,C0040223;C3541383;C0085532;C1548829
loop diuretics,C0354100
pci no,C4049621
py $nmbr$ $nmbr$,C0030428;C3538810
time from randomization to pci hr,C0040223;C3541383;C4049621
py,C0030428;C3538810
duration of infusion before pci hr,C0449238;C2926735;C4049621
number of patients with fractures,C2360800;C0016658
duration of infusion after pci hr,C0449238;C2926735;C4049621
fractures site not specified,C0449676;C1518422;C0205369
cabg no,C0010055
lower limb fractures,C0596838
time from randomization to cabg hr,C0040223;C3541383;C0010055
hip fracture,C0019557;C0149531;C4552776
duration of infusion before cabg hr,C0449238;C2926735;C0010055
others,C1955473;C3539125
medical management only no,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
ankle fracture,C0159877;C4552974
duration of infusion during medical management hr,C0449238;C2926735;C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
femur fracture,C0015802
early eptifibatide,C1279919;C0253563
fibula fracture,C0149699
delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
foot fracture,C0272774
troponin,C0041199
lower limb fracture,C0596838
positive,C0439178;C1446409;C1514241;C2825490;C3812269
patella fracture,C0159849
early clopidogrel intended,C1279919;C0070166;C1283828;C1551357
tibia fracture,C0040185
time to randomization,C0040223;C3541383
skull and facial bone fractures,C0037303;C2951888;C0743751
heparin use,C0239945
spinal fractures,C0080179;C0518450
unfractionated only,
thoracic cage fractures,C0222762;C0016658
low molecular weight only,C0041667
upper limb fractures,C0178316
type of hospital care,C0332307;C1547052
clavicle fracture,C0159658
tertiary,C0205372
hand fracture,C0435632
region of the world,C0017446;C0205147
humerus fracture,C0020162
region ofthe world,C0017446;C2700280;C0205147
radius fracture,C0034628
patient characteristics,C0815172
upper limb fracture,C0178316
arterial hypertension n,C0020538
wrist fracture,C0435630;C4553927
insulin requiring,C0021641;C1533581;C1579433;C3714501
py $nmbr$,C0030428;C3538810
history of mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pelvic fractures,C0149531
history of cabg surgery n,C0455610;C0010055
forearm fracture,C1305215
infarct characteristics,C0021308;C1521970
black participants,C0005680;C0679646;C0027567;C0085756;C0439541
infarct localization n,C0021308;C0475264;C1744691
nonblack participants,C0679646
killip class n,C1881332
i with mets n $nmbr$,C0021966;C0221138
arterial blood pressure mm hg,C1272641;C0439475
i without mets n $nmbr$,C0021966;C0221138
peak creatine kinase mb u l,C0010290;C0439339;C0523584
$nmbr$ $nmbr$ $nmbr$ b,
value for nteraction,C1522609
years of education mean sd,C0439234;C0013621;C0013622;C0013658;C0039401
$nmbr$ $nmbr$ yrs,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
currentd,
infarct localization,C0475264;C1744691
antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
non anterior,C1518422;C0205094
treated,C1522326
interval pain onset to admission,C1507009;C0184666;C0809949
untreated,C0332155
interval study drug to pci,C1272706;C0013175;C1552654;C1552713
history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
interval clopidogrel to pci,C1272706;C0070166;C1552654;C1552713
history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
clopidogrel plus aspirin n $nmbr$,C0070166;C0004057
$nmbr$ $nmbr$ $nmbr$ c,
aspirin n $nmbr$,C0004057
other atherosclerotic cvdd e,C0333482;C1859330
chads $nmbr$ ^,C0007928;C1413373
st t wave abnormality d,C0036056;C1839341;C3272372
mean score,C3533236
lvh by ecg or echocardiographyd,C0232306
score no,C0449820;C4050231
glycemic status f,C0449438;C0016327
history of atrial fibrillation type no,C0729790;C0332307;C1547052
impaired fasting glucose,C1272092
permanent,C0205355
normoglycemic,C0580545
paroxysmal,C0205311
history of chd at baseline d g,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488;C0439267
persistent,C0205322;C0332996
lipid trial participants,C1997894;C2242969
atrial fibrillation duration no,C0449238;C2926735
systolic mean sd mm hg h,C0456680
$nmbr$ mo to $nmbr$ yr,C0026544;C0332177
diastolic mean sd mm hg,C0012000;C0439475
history of hypertension no,C0455527
serum potassium level mean sd meq l,C0302353;C0439375;C0543465
history of stroke or tia no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
fasting serum glucose level mean sd mg dl,C0202045;C0439269
history of ischemic heart disease no,C0683519;C0730226;C0850708;C0944983
serum creatinine level mean sd mg dl,C0600061;C0439269
peripheral artery disease no,C1704436;C4025272
tc level mean sd mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
cardiac pacemaker no,C0030163;C0037189
ldl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
ecg findings at baseline no,C0438154;C0168634;C1442488
hdl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
atrial flutter,C0004239;C0344423;C1963068
hdl c level $nmbr$ mg dld,C1414063;C2826331
medication use at baseline no,C0240320;C0168634;C1442488
fasting triglyceride level mean sd mg dl,C0015663;C0428475;C0439269
vka,
cv mortality,C0026565;C0026566
antiarrhythmic agent,C0003195;C0301380
combined chd,C0280604;C3542407
reason for enrollment in active a no,C0392360;C0205177;C3853793;C3888249
non black participants,C0005680;C0679646;C0027567;C0085756;C0439541
specific risk of bleeding^,C0205369;C3251812;C1552740
i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
physician s judgment that vka inappropriate],C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
ii $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1710602;C4082587
patient s preference not to take vka only reason,C0030705;C0558295;C1549513;C1518422;C1515187;C0392360
doxazosin,C0114873
western europe and israel,C0043129;C0022271
clopidogrel plus aspirin yr,C0070166;C0004057
figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease,C1707455;C0077770;C1511726;C3245479;C3714741;C2985465;C0009667;C0871208;C1521828;C4330837;C0013227;C1254351;C0034510;C1706779;C3853635;C0280604;C3542407;C0010054;C0010068;C1956346;C0022661
aspirin only,C0004057
p women vs men,C0369773;C0043210;C2603361;C0025266
stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
overaii n $nmbr$,
mi or cad,C3810814;C1504769;C2239547;C3813548;C4284121
atenoioi n $nmbr$,
biack,
chads $nmbr$ score,C0449820;C4050231
vka therapy,C0039798;C0087111;C1363945
systoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
persistent or paroxysmal,C0205322;C0332996;C0205311
diastoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
reason for enrollment in active a,C0392360;C0205177;C3853793;C3888249
body mass index kg m^,C0022718;C0439209;C4054209
risk of bleeding,C3251812
corneii product mm ms,C2349943;C3539704;C3713294
physician s judgment that vka inappropriate,C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
sokoiow lyon voitage mv,C1454484;C1705503;C4281602
clopidogrel plus aspirin,C0070166;C0004057
current smokers n medicai history n,C3173209;C3241966
physician s judgment that vka nappropriate,C0031831;C0804815;C0022423
isoiated systoiic hypertension,C0020538;C1963138
all subjects,C0681850;C1550501;C1706203;C2349001;C2697811
cerebrovascuiar disease,C0012634
no diabetes mellitus,C0011849
peripherai arteriai disease,C0012634
weight median $nmbr$ th $nmbr$ th percentiles kg,C0022718;C0439209;C4054209
adjusted hr losartan vs atenolol,C0456081;C0126174;C0004147
body mass index median $nmbr$ th $nmbr$ th percentiles kg m $nmbr$,C0022718;C0439209;C4054209
women n $nmbr$ events,C0441471;C3541888
women n $nmbr$,C0043210
time from onset of pain to randomization median $nmbr$ th $nmbr$ th percentiles n,C0449244;C0034656;C0039725;C0039738;C1420718;C4282123;C4285344
ratet n,
treatment before randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
primary composite^,C0205199;C1547335
oral hypoglycemic agent,C0359086
cardiovascuiar mortaiity,
hab $nmbr$ c mean sem,C0444504;C2347634;C2348143
myocardiai infarction,C0021308
low density lipoprotein cholesterol median $nmbr$ th $nmbr$ th percentiles mg dl,C0023824;C0439269
totai mortaiity,
high density lipoprotein cholesterol median $nmbr$ th $nmbr$ th percentiles mg dl,C0023822;C0439269
hospitaiization for angina,C0002962
ranozaline,
hospitaiization for heart faiiure,C0018787
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781;C0369773;C2603361
vildagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019;C0369773;C2603361
viidagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
inclusion criteria no,C1512693
placebo glimepiride,C0032042;C0061323;C1696465;C1706408
$nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0332189;C0004238;C0344434;C1963067;C0026544;C0332177
age years mean s d,C1510829;C0444504;C2347634;C2348143
cardioversion in previous $nmbr$ wk,C0013778;C0205156;C1552607
hispanic latino,C0086409;C0086528
duration of last qualifying episode of atrial fibrillation $nmbr$ days,C0449238;C2926735;C1514624;C0332189;C0004238;C0344434;C1963067
bmi kg m^ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
heart failure lvef,C0428772;C0488728
hbaic mean s d,C0444504;C2347634;C2348143
history of hypertension for $nmbr$ mo or more,C0455527;C0026544;C0332177
hbaic group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
history of stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fpg mmol l mean s d,C0439433
documented coronary artery disease,C0010054;C0010068;C1956346
disease duration years mean s d,C0872146;C0439234
atrial fibrillation alone,C0004238;C0344434;C1963067;C0205171;C0439044;C0679994
duration of sulphonylurea use months mean s d,C1881378;C2826775
coexisting conditions no,C0012634;C0348080;C1705253;C3864998
fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged,C0349966;C1337208;C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C2349179;C2826544;C0001779;C0001792;C1999167
peripheral embolism,C0013922;C1704212
amlodipine valsartan $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous transient ischemic attack,C0007787;C0917805
amlodipine valsartan $nmbr$ $nmbr$ mg n $nmbr$ i,C0021966;C0221138
renal dysfunction,C1565489;C3279454
total study population n $nmbr$,C3258257
alcohol abuse,C0085762;C4050601
age ya,C0001779
electrocardiographic findings at randomization,C0438154;C0034656
age category,C0683312;C3889287
qrs interval $nmbr$ msec no,C0520880;C0439223
mssbp mm hga,C4330985;C4554674
left ventricular hypertrophy no,C0149721;C3484363
msdbp mm hga,C4330985;C4554674
pathologic q waves no,C0429089;C1305738
sitting pulse bpma,C0277814;C0232117;C0391850;C1947910;C2584297;C4050224
concomitant cardiovascular therapies no,C1707479
prior treatment,C1514463
class $nmbr$ antiarrhythmic agents,C0003195;C0301380
arb,C3888198
hf lvd or both,C0018488;C1313497;C1538440;C3273279
acei,
ccb,C0006684
use of antiarrhythmic agent,C1524063;C0003195;C0301380
severity of hypertensionb,C0439793;C0522510
use of beta blockers,C1524063;C0001645
more severe,C0205082;C4050465;C4050466
af alone,C0344434;C4049859;C0205171;C0439044;C0679994
less severe,C0205082;C4050465;C4050466
af alone refers to atrial fi brillation without coexisting cardiovascular conditions but with left atrial dilatation ace denotes angiotensin con verting enzyme hf heart failure and lvd left ventricular dysfunction,C0344434;C4049859;C0205171;C0439044;C0679994;C0205543;C0018792;C0007222;C1452534;C4284014;C0003018;C4521302;C0387288;C0014442;C0018801;C4521602;C0242698
diabetic status,C0241863;C0449438
nondiabetic,
ischemia on cecg n $nmbr$ $nmbr$,C0022116;C4321499
no ischemia n $nmbr$ $nmbr$,C0022116;C4321499
abbreviations acei angiotensin converting enzyme inhibitor arb angiotensin receptor blocker bpm beats per minute ccb calcium channel blocker msdbp mean sitting diastolic blood pressure mssbp mean sitting systolic blood pressure values are no unless otherwise indicated amean sd bmore severe $nmbr$ and $nmbr$ and $nmbr$ and $nmbr$ and,C0034787;C1622222;C1319893;C0042295;C1444656;C2699239;C0205082;C4050465;C4050466
age $nmbr$ yrs,C0001779
amlodipine valsartan $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body mass index kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
amlodipine wlsartan i $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior revascularization,C0332152;C0581603;C2826257
amlodipine valsartan $nmbr$ $nmbr$ vs $nmbr$ $nmbr$ mg,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
creatinine clearance $nmbr$ ml min,C0812399;C0439445
mssbp msdbp,
non st segment elevation mi,C1518422;C0520886
change from,C0392747;C0443172;C1705241;C4319952
st segment depression $nmbr$ $nmbr$ mv on admission,C1454484;C1705503;C4281602;C0457453
week and,C0332174;C0439230
elevated troponin $nmbr$ $nmbr$ mg l,C0041199;C0439268
baseline mm hg,C0168634;C0439475;C1442488
elevated bnp $nmbr$ pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
difference in change,C1705241;C1705242
intent of early invasive strategy,C0162425;C1283828;C1550453
disease severity,C0521117
intent of conservative strategy,C0162425;C1283828;C1550453
sem,
revascularization during index hospitalization,C0581603;C0019993
$nmbr$ ci p value,C0008107;C1709380;C3259781
ace inhibitors or arbs,C0003015;C3888198
endpoint week $nmbr$,C0332174;C0439230
cardiac medications at discharge,C0018787;C0806915;C1522601
intent to treatb,C0162425;C1283828;C1550453
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
primary end point,C2986535
less severe hypertension,C4013784
ischemia on cecg,C0022116;C4321499
more severe hypertension,C4013784
no p value for ischemia ischemia hr $nmbr$ ci interaction,C1709380;C0008107;C3259781
mean sd age years,C0444504;C1510829;C2347634;C2348143
$nmbr$ yrs of age n $nmbr$ $nmbr$,C0001779
mean sd bmi kg m $nmbr$,C0022718;C0439209;C4054209
no prior htn n $nmbr$ $nmbr$,C0332152;C0020538;C2826257
current $nmbr$ cigs day,C0332173;C0439228;C0439505
prior htn n $nmbr$ $nmbr$,C0332152;C0020538;C2826257
exercise,C0015259;C1522704
no dm n $nmbr$ $nmbr$,C0011816;C3250443
$nmbr$ week,C0332174;C0439230
dm n $nmbr$ $nmbr$,C0011816;C3250443
$nmbr$ $nmbr$ week,C0332174;C0439230
no prior angina n $nmbr$ $nmbr$,C0332152;C0002962;C2826257
$nmbr$ $nmbr$ month,C0332177;C0439231
prior angina n $nmbr$ $nmbr$,C0332152;C0002962;C2826257
postmenopausal hormone use,C0042153;C0457083;C1947944
no prior mi n $nmbr$ $nmbr$,C0332152;C2826257
aspirin group n $nmbr$ $nmbr$ $nmbr$ $nmbr$ person years,C0027361;C0439234;C2347489
prior mi n $nmbr$ $nmbr$,C0332152;C2826257
placebo group n $nmbr$ $nmbr$ $nmbr$ $nmbr$ person years,C0027361;C0439234;C2347489
no prior revascularization n $nmbr$ $nmbr$,C0332152;C0581603;C2826257
newly diagnosed asthma n,C0011900;C0004096;C2984299
prior revascularization n $nmbr$ $nmbr$,C0332152;C0581603;C2826257
active,C0205177;C3853793;C3888249
no prior hf n $nmbr$ $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
mets,C0812270;C1705694;C2939420
prior hf n $nmbr$ $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
non mets,C0812270;C1705694;C2939420
unstable angina n $nmbr$ $nmbr$,C0002965
placebo dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
nstemi n $nmbr$ $nmbr$,C3537184;C4255010
eze simva $nmbr$ $nmbr$ mg dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
no stsd $nmbr$ mm on admission n $nmbr$ $nmbr$,C0184666;C0809949
feno $nmbr$ dn $nmbr$,C1333964;C1707618
stsd $nmbr$ mm on admission n $nmbr$ $nmbr$,C0184666;C0809949
eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
low trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
placebo dn $nmbr$,C1333964;C1707618
moderate trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
high trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
conservative strategy n $nmbr$ $nmbr$,C0679199
waist circumference cm mean sd,C0455829;C2699239
early invasive strategy n $nmbr$ $nmbr$,C0205281;C0679199;C1334278
diagnosis of diabetes n,C0011900;C1704338;C1704656
ef $nmbr$ n $nmbr$ $nmbr$,
tg mg dl,C0337445;C0439269
ef,
non hdl c mg dl,C1518422;C0439269
negative ctnl n $nmbr$ $nmbr$,C0205160;C1513916;C2825415;C2825491;C3853545
apo b mg dl,C0003593;C0439269;C3252643
positive ctnl n $nmbr$,C0439178;C1446409;C1514241;C2825490;C3812269
tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
normal bnp ^ $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
apo a i mg dl,C0085201;C0439269;C1677784
elevated bnp $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
data are expressed as median sd except,C1511726;C3245479;C3714741;C0549183;C0876920;C2347635;C2348144;C2939193
medal,C0524670
data are expr,C1511726;C3245479;C3714741
edge ii,C1710602;C4082587
ssed as ls means,C0023668;C1704970
edge,C0205154;C2697523
by treatment arm,C1522541
oa,C0029408;C3887876
syncope,C0039070;C3541349;C4554644
ra,C3538806;C4048756
by cause of death,C0007465;C4050444
$nmbr$ mg cohort,C0009247;C0599755
sudden death,C0011071;C1964022;C4554103
etoricoxib $nmbr$ mg n $nmbr$ $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all patients $nmbr$ $nmbr$,C0030705
diclofenac $nmbr$ mg n $nmbr$ $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
verapamil sr $nmbr$ $nmbr$,C1527129
baseline creatinine clearance,C0168634;C0812399;C1442488
atenolol $nmbr$ $nmbr$,C0004147
$nmbr$ $nmbr$ ml s m $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0439390;C0439445;C0369718;C0441922
sbp mean sd mmhg,C0085805;C0439475
history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
dbp mean sd mmhg,C0444504;C0439475;C2347634;C2348143
cigarette users,C0677453;C1706077;C1704760;C3890423
heart rate mean sd b p m,C0018810;C0444504;C2347634;C2348143
history of symptomatic,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age mean sd year,C0439234;C0439508
ascvdor $nmbr$ cv risk factors,C0035648;C1553898
arrhythmias,C0003811
prior use of systemic,C1524063;C0205373
heart failure class i iii,C0441887;C2698969
corticosteroidsa,
renal impairment,C1565489
baseline anti hypertensive usea,C0168634;C0003364;C1442488
smoking ever,C0037369;C0453996;C1881674
ranolazine n $nmbr$ $nmbr$,C0073633
sbp systolic blood pressure sd standard deviation dbp diastolic blood pressure b p m beats per minute mi myocardial infarction tia transient ischaemic attack,C1305849;C0439385;C0007787
age yrs median $nmbr$ th $nmbr$ th,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
verapamil sr strategy,C1527129;C0679199
weight kg median $nmbr$ th $nmbr$ th,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
atenolol strategy,C0004147;C0679199
risk factors for atherosclerosis,C0035648;C1553898
adverse outcome,C1274040
prior coronary revascularization pci or cabg,C0877341;C4049621;C0010055
non fatal mi,C1302234;C3810814;C1705232
prior known stenosis $nmbr$,C0678234;C1261287;C2632116
ccsc at $nmbr$ month before enrollment,C1516705;C0332177;C0439231;C1516879;C1696073;C3888021
non fatal stroke,C0038454;C4554100
no prior mi,C0332152;C3810814;C2826257
coronary angiography during the index hospital stay,C0085532;C1548829
denosumab n $nmbr$,C1690432
cardiac medications during index hospital stay and or discharge,C0013227;C0802604;C2598133;C4284232;C0012621;C0030685;C2926602
all n $nmbr$,C0369718;C0441922
calcium channel blockerf,C0006685
$nmbr$ yr since menopause,C0439234;C0025320;C0567312
long acting nitratef,C0205166;C1706317
years since menopause,C0439234;C0025320;C0567312
data are expressed as n total unless otherwise speci ed systeme international unit conversion to convert creatinine clearance to ml s multiply by $nmbr$ $nmbr$ estimated with cockroft gault equation at discharge ace angiotensin converting enzyme cabg coronary artery bypass graft ccsc canadian cardiovascular society classi cation mi myocardial infarction pci percutaneous coronary intervention,C1511726;C3245479;C3714741;C0439175;C0439810;C0439453;C0439836;C0439390;C0750572;C0552449;C0030685
bodymass index kg m $nmbr$,C0022718;C0439209;C4054209
randomization to end of study,C0034656;C0444930;C2746065
lumbar spine bmd t score,C0449820;C4050231
major secondary end pointf,C0027627;C0175668;C0205436
serum ctx ng ml,C0010377;C0439275;C0631180;C3539598
cv death or ml,C0011065;C1306577;C4082313;C4552775;C0439526;C1705224;C3887665
serum p $nmbr$ np ^g liter,C0065827;C0475211;C1706141;C3887659
recurrent ischemia,C0022116;C4321499
serum trap $nmbr$ b u liter,C0184047;C0475211;C1336677;C1566918;C1706005;C1710330;C3887583
worsening angina,C0332271;C1457868;C1546960;C0002962
site,C0205145;C1515974;C2825164
severe recurrent ischemia,C0022116;C4321499
stratum,
intensification of antianginal therapy,C1511484
difference from baselinea,C1705241;C1705242
$nmbr$ days until end of study landmark analysis,C2826182;C0002778;C0936012;C1524024
difference from placeboa,C1705241;C1705242
ls mean,C0444504;C2347634;C2348143
data are reported as n event rates in parentheses are kaplan meier estimates at $nmbr$ year cardiovascular cv death myocardial infarction mi or recurrent ischemia cv death mi or severe recurrent ischemia,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1720943;C0027051;C0011065;C3810814;C1306577;C4082313;C4552775;C0022116;C4321499
ci b,C0008107;C3259781
new anti anginal therapy,C3242274;C1874267;C3537168
p value c,C1709380
tadalafil $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
denosumab,C1690432
tadalafil $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
trochanter,C0162370
ed severity visit $nmbr$,C0545082;C1512346;C2826704
one third radius,C0034627;C1306504
normal or mild iief ef $nmbr$ $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599;C3641331
total body without head,C0229960;C0018670;C1706305
moderate iief ef $nmbr$ $nmbr$ n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
volumetric bmd by qct,C0445383;C0412669
severe iief ef $nmbr$ $nmbr$ n,C0205082;C3641331;C4050465;C4050466
aggressive n $nmbr$,C0001807;C0580822
ed duration visit $nmbr$,C0545082;C1512346;C2826704
standard n $nmbr$,C1442989;C2828392
$nmbr$ moto,
gender women n,C0079399;C0043210;C1522384
$nmbr$ yr n,C0439234
body mass index bmi kg m $nmbr$,C0022718;C0439209;C4054209
iief ef domain score visit $nmbr$,C0545082;C1512346;C2826704
waist cm,C0230097
iief ef domain score visit $nmbr$ y,C0449820;C0545082;C1512346;C2826704;C4050231
ale,C0678386;C2632076
p value subgroup,C1079230;C1515021
diabetes therapy,C3274787;C3539002
p value interaction,C1709380;C1704675
lifestyle,C0023676
$nmbr$ yr n $nmbr$,C0439234
oral hypoglycemics,C0359086
$nmbr$ $nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
insulin plus oral,C0021641;C1533581;C1579433;C3714501
bph luts severity,C0439793;C0522510
egfr,C1739039;C3811844;C3812682
moderate ipss $nmbr$ n $nmbr$,C0205081;C1019118;C1998280;C2827405;C3811063;C1881878;C4049705;C4049706;C4085643;C4321335
aspirin use $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
severe ipss $nmbr$ n $nmbr$,C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
carotid,C0741968
psa,C3810537;C3813209
imt mm,C4330985;C4554674
$nmbr$ $nmbr$ ng ml n $nmbr$,C0439275
arterial area mm $nmbr$,C4330985;C4554674
prior a blocker use,C0332152;C2826257;C0042153;C0457083;C1947944
plaque score $nmbr$ $nmbr$,C0429153
yes n $nmbr$,C1549445;C1705108;C1710701
sk $nmbr$,
no n $nmbr$,C0369718;C0441922
plaque n,C0011389;C0241148;C0332461;C0333463;C4316797
prior ed therapy,C1514463;C3538926
cardiac,C0018787;C1522601
variable_level,C0441889;C0456079;C1547707;C2946261
lv mass,C0455825
moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
lv mass index g m $nmbr$ $nmbr$,C0455825;C0439267
normal mild ckd,C0205307;C1561643;C0231683;C0439166;C2347086;C4553972
lv ejection fraction,C0489482;C2700378
chd cl,C0280604;C0596019;C3542407
cvd,C0007222
abbreviations egfr estimated glomerular filtration rate imt intimal medial thickness lv left ventricular two sample comparison t tests were calculated based on log transformed variables geometric mean with $nmbr$ confidence interval in parenthesis,C3811844;C0871472;C1527178;C1705938;C0009667
sal $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
imt $nmbr$,C0334121;C1704614;C4318736
fp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aggressive $nmbr$,C0001807;C0580822
sfc $nmbr$ mg $nmbr$ mg,C4521536;C1319635
standard $nmbr$,C1442989;C2828392
total pack yrs,C0439175;C0439810
group dif $nmbr$,C0812246;C1710304
baseline fev $nmbr$,C0168634;C3714541;C1442488
p val $nmbr$,C0042285;C0523975
bmi kg m^ $nmbr$,C0022718;C0439209;C4054209
lvmi $nmbr$,
probability of event,C0033204;C0441471;C4019010
inter,C0205103;C1548610
non ics,C0815320;C4551720
non hdl mg dl,C1518422;C0439269
ng n $nmbr$ $nmbr$,C0017887;C0028074
$nmbr$ l $nmbr$,C0439394;C1706495;C3642217
lgm n $nmbr$,
current smoker yes,C1549445;C1705108;C1710701
non epa n $nmbr$,C1518422
primary prevention subgroup,C1079230;C1515021
average age year,C0439234;C0439508
secondary prevention subgroup,C1079230;C1515021
drinker,C0556338
no epa group n $nmbr$,C0441848
triglyceride median mg dl $nmbr$ [ $nmbr$ $nmbr$ percentile,C0439269;C1264641
epa group n $nmbr$,C0441848
$nmbr$ [ $nmbr$ $nmbr$,
cerebral thrombosis,C0079102;C0151945;C0795687
$nmbr$ [ $nmbr$ $nmbr$ ],
cerebral embolism,C0007780
fatty acid profile,C1979963;C2003903
tia,C0007787;C0917805;C1054154
glucose metabolism,C0596620
cerebral hemorrhage,C2937358
hba c,C0019016;C1825777;C3538758
subarachnoid hemorrhage,C0038525
$nmbr$ ll,
triglyceride mmol l,C0041004;C1532563
data are reported as percentage or mean standard deviation unless otherwise indicated ng normoglycemia igm impaired glucose metabolism ldl low density lipoprotein hdl high density lipoprotein fpg fasting plasma glucose a median interquartile range p $nmbr$ $nmbr$ vs ng p $nmbr$ $nmbr$ vs ng,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1828170;C0455280;C0549183;C1711350;C0876920;C2347635;C2348144;C2939193;C0017887;C0028074
aa mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
igm n $nmbr$,C1706005
epa mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
triglyceride median mg dl a [ $nmbr$ $nmbr$ percentile],C0041004;C0439269;C1264641
epa aa ratio,C0456603;C1547037
$nmbr$ [ $nmbr$ $nmbr$ js,C1552154
sbp indicates systolic blood pressure dbp diastolic blood pressure aa arachidonic acid epa eicosapentaenoic acid values for age bmi total cholesterol ldl cholesterol hdl cholesterol sbp dbp aa epa and epa aa ratio represent the mean values represent the median interquartile range p values are for the differences between the no epa and epa groups,C0085805;C1305849;C0042295;C2699193;C0456603;C1547037;C1882932;C0444504;C2347634;C2348143;C1711350;C1709380;C1705241;C1705242;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
diastolic fmmhff,C0012000
standard deviation triglyceride,C0871420;C0041004
non epa number of,C0237753;C0449788
no epa group no of events,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0441471;C3541888
epa hr events,C0441471;C3541888
epa group no of events,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0441471;C3541888
ng,C0017887;C0028074
metoprolol group n $nmbr$,C0025859;C0441848
igm,
preoperative heart rate beats per minute,C0439385
ng vs igm,C0017887;C0028074
interaction p $nmbr$ $nmbr$,C1704675
preoperative blood pressure mm hg patients fulfilling eligibility criteria,C0005823;C0030705;C1271104;C1272641;C1550543;C1512693
tadalafil,C1176316
stroke thought due to atherothrombotic disease,C0039869;C4319827
$nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hospitalisation for chf within $nmbr$ years of randomisation,C0019993;C0018802;C0439234;C0034656
$nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
undergoing major vascular surgery,C0679637
age y gender n,C0001779;C0079399;C1522384
three of seven risk factors,C0035648;C1553898
african descent,C0205386;C0680043
intrathoracic or intraperitoneal surgery,C0595836;C0038894;C0038895;C0543467;C1274039
weight kg duration of pah n,C0449238;C2926735
any history of congestive heart failure,C0455531
$nmbr$ y pathogenesis n,C0543483;C0699748
diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849;C0521116;C0359086
idiopathic familial,C0015576;C0241888
preoperative serum creatinine $nmbr$ pmol l,C0201976;C0439284;C0600061
anorexigen use,C0042153;C0457083;C1947944
history of a transient ischaemic attack,C0455536
connective tissue disease,C0009782
emergent urgent surgery,C0750573;C2188405
associated with an atrial septal defect,C0332281;C0018817
other cardiovascular risk factors,C0850624
surgical repair of vsd or pda $nmbr$ year duration,C0374711;C0018818;C0449238;C2926735
pre operative cardiac medications,C2347660
concomitant use of bosentan n,C1524063;C0252643
low molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766;C0354566
six minute walk distance m,C3900196
surgery,C0038894;C0038895;C0543467;C1274039
borg dyspnea score who functional class n,C0013404;C0205245;C0542341;C2700217;C1963100
vascular,C0005847;C1558950;C1801960
hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0449381;C4281788;C0030705;C4684790
intraperitoneal,C0442120
mean pulmonary artery pressure mm hg,C0428642;C0439475
orthopaedic,C0029355
cardiac index l mn m $nmbr$,C0026327;C0026405;C4285072
anaesthesia analgesia,C0002905
general,C0205246;C3812897;C3891294;C4521767
pulmonary vascular resistance dyne s cm $nmbr$,C0308914;C0600130
spinal,C0521329
dose,C0178602;C0869039;C1114758
lumbar epidural,C0581283
treatment effect,C1518681
general andthoracic epidural,C0228134;C0812144
all itt subjects,C0681850;C1550501;C1706203;C2349001;C2697811
general and lumbar epidural,C0205246;C3812897;C3891294;C4521767;C0581283
bosentan use,C0042153;C0457083;C1947944
regional anaesthesia,C0002911
pah etiology,C0015127;C1314792;C1524003
repaired s p shunts,C0205340;C0232180;C0542331;C1442858
data are mean sd or n ace angiotensin converting enzyme arb angiotensin receptor blocker chf congestive heart failure any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0034787;C0018802;C1622222;C0042153;C0457083;C1947944;C0038894;C0038895;C0543467;C1274039;C1514873
baseline $nmbr$ mlnute walk distance,C0168634;C0429886;C1442488
figure $nmbr$ subgroup analyses for the primary outcome,C2986480;C0205225;C0439612;C0439631
$nmbr$ meters,C0441074
valsartan n $nmbr$,C0216784
median $nmbr$ year old,C0439234;C0580836;C0439508
valsartan hctz n $nmbr$,C0216784;C0020261
baseline who function class,C0456387;C1518526;C1705943
age median interquartile range y,C0001779;C1711350
lor ii,C1710602;C4082587
age group no y,C0027362;C2348001
iii or iv,C0439070;C1705160;C0022326;C4265176
body mass index category no l,C0683312;C3889287;C0439394;C1706495;C3642217
table $nmbr$ not standard baseline characteristics table,C0039224;C1706074
lean,
fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs,C0349966;C3272907;C1337208;C0023824;C0445604;C1079230;C1515021
overweight $nmbr$ to,C0497406
saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$,C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
obese $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
saxa $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
weight median interquartile range kg,C0022718;C0439209;C4054209
metformin n $nmbr$ $nmbr$,C0025598
smoking status no,C1519386
age $nmbr$ years t,C1510829
concomitant therapy no,C1707479
sexy,
hormone therapy,C0279025
racey z,
oral contraceptives,C0009905
$nmbr$ t,C2603360
hctz hydrochlorothiazide based on wilcoxon $nmbr$ sample rank sum tests for age and body mass index t tests for systolic and diastolic blood and $nmbr$ tests for categorical variables t data were missing for some patients,C0020261;C1527178;C1705938;C0001779;C0005893;C0871472;C0578022;C1305855;C0005767;C0005768;C0229664;C0022885;C0392366;C1551393;C1705492;C3272743
fpg mg dl x,C0439269
pressure,C0033095;C0460139;C1306345;C4284008
figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin,C0019016;C2986480;C1825777;C3538758;C1611934
valsartan n n,C0216784
proportion of patients who achieved acr $nmbr$ n n,C1709707;C0030705
valsartan hctz n n,C0216784;C0020261
combined golimumab groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
entire evaluable cohort,C0009247;C0599755
dmard at baseline,C0242708;C0168634;C1442488
current nonsmokers,C0337672;C4554605
number of previous tnfa inhibitors,C0237753;C0449788
hctz hydrochlorothiazide based on a _ $nmbr$ test t data were missing for some patients,C0020261;C1527178;C1705938;C1551393;C1705492;C3272743
reason for discontinuation of previous tnfa inhibitor,C0392360;C0205156;C1552607
valsartan,C0216784
lack of effectiveness,C0235828
valsartan hctz,C0216784;C0020261
unrelated to effectiveness,C0445356;C1704623
current nonsmoker,C0337672;C0425293;C4554605
zoledronic acid,C0257685
diabetes status,C1317301
age at menopause yr,C1625754;C1629609
hctz hydrochlorothiazide data were missing for some patients,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
americas,C0002454;C0596070
characteristic and treatment,C1521970;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bmi kg m $nmbr$ a,C0578022;C1532718
bmia,
primary pci n $nmbr$,C0205225;C0439612;C0439631
abciximab facilitated pci n $nmbr$,C0288672;C4049621
weight kg a,C0022718;C0439209;C4054209
height loss,C0424641
combination facilitated pci n $nmbr$,C0205195;C1947911;C3811910
$nmbr$ $nmbr$ to $nmbr$ cm,
family history of cad diagnosed at,C0241889;C1504769;C2239547;C3813548;C4284121;C0011900
baseline vfx,C0168634;C1442488
past or current,C0521116;C1705970
history of falls,C1561668;C2919132
patients treated with insulin,C0030705;C0332293;C0021641;C1533581;C1579433;C3714501
physical activity hours walking wk,C0015259;C0439227;C0026606;C0080331;C4283795;C4321241;C4321242;C0332174;C0439230
previous mi no,C0205156;C3810814;C1552607
prior bisphosphonate usage,C0012544;C0457083;C2267018
previous chf no,C0205156;C0018802;C1552607
total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
hypertension no hypercholesterolemia no,C0020538;C1963138;C0020443;C1522133
patients treated,C0030705;C1522326
standardized total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
location of infarction no,C0450429;C1515974;C4284930;C4284931
femoral neck bmd g cm $nmbr$,C0015815;C0439267
inferior or posterior,C0542339;C0678975;C0205095
femoral neck t score,C0449820;C4050231
not localized,C1518422;C0392752
femoralneck t scorebybaselinevfxstatus,
$nmbr$ $nmbr$ vfx,
interval from symptom onset to qualifying ecg obtained in the er hr,C1272706;C1552654;C1552713;C1514624;C1623258;C1301820;C3810541;C3811131
$nmbr$ ml min,C0439445
door to balloon time hr,C4296144
category,C0683312;C3889287
peak procedural act sec,C0079613;C0565930;C1704930;C1869853;C3890007;C4048375
mean change in fn bmd,C0392747;C0443172;C1705241;C4319952
ace inhibitors through hospital discharge or day $nmbr$,C0003015;C0586003;C0332173;C0439228;C0439505
least squares mean between treatment difference $nmbr$ ci,C0023189;C0444504;C2347634;C2348143
beta blockers through hospital discharge or day $nmbr$,C0001645;C0586003;C0332173;C0439228;C0439505
p value within category,C1709380;C0683312;C3889287
primary pci no,C0205225;C0439612;C0439631
femoral neck t score and vfx status,C0449820;C4050231;C0449438
combination facilitated pci,C0205195;C4049621;C1947911;C3811910
op no vfx,
hazard ratio $nmbr$ confidence interval,C2985465;C0009667
op vfx,
baseline killip class,C0168634;C1881332;C1442488
no op no vfx,
history of diabetes mellitus,C0455488
no op vfx,
no or unknown,C0439673;C3541433;C4050014
height loss cm,C0424641
not anterior,C1518422;C0205094
prior bp use,C0042153;C0457083;C1947944
geographic location,C0017446
crcl ml min,C1846718;C0439445
rest of the world,C0035253;C1622890
$nmbr$ mg kg,C0439272
hub,C0063034;C1414372;C1708389
combined,C0205195
spoke,
patients randomized n,C0030705;C0034656;C3815594
time from symptom onset to randomization,C0449244;C0034656
white race n,C0007457;C0043157
$nmbr$ hr,
disease duration y,C0872146
time from qualifying ecg to balloon inflation,C0040223;C3541383;C1514624;C1623258;C0021398;C1318493
colonic area involved,C0017446;C0205146;C1314939
slowest third,C0439834;C0205437
left side n,C0205091
middle third,C0442050
extensive n,C0205231
fastest third,C0015663;C0205437;C0456962;C2985769
mayo clinic scoreb,C0002424;C0442592
time from symptom onset to balloon inflation,C0449244;C0021398;C1318493
c reactive proteinc,C0205332
index pci performed,C0600653;C4049621;C0918012;C1552854;C1637833;C2986546;C0884358
mean mg dl,C0444504;C0439269;C2347634;C2348143
pci delay due to low risk,C0205421;C0678226
median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
enrollment in lmwh substudy,C1516879;C1696073;C3888021
elevated crp n,C0742906
high risk,C0332167;C3272283;C4050568;C4319571
any ulcerative colitis medication,C0013227;C3244316;C4284232
sal n $nmbr$ $nmbr$,C0036140;C0037494;C0206136
$nmbr$ mg day,C0439422
fp n $nmbr$ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
immunomodulators,C0001551;C0005525;C1527392
sfc n $nmbr$ $nmbr$,C4521536
refractory to corticosteroids n,C0205269;C0001617;C3539185;C3540725;C3540726;C3540727
mean age sd yr,C0001779;C0439234
smoking status n,C1519386
mean body mass index sd kg m $nmbr$,C0022718;C0439209;C4054209
prior smoker,C0337671
baseline post bronchodilator fev $nmbr$ sd ml,C0439526;C1705224;C3887665
study,C0557651;C2603343
predicted post bronchodilator fev sd ml,C0439526;C1705224;C3887665
act $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
region n,C0017446;C0205147
nap,C0870935;C1423800;C4283878
asia pacific,C0003980
infliximab $nmbr$ mg kg versus placebo,C0666743;C0439272;C0032042;C1696465;C1706408
number of subjects in analysis,C0237753;C0449788;C0002778;C0936012;C1524024
corticosteroid refractory status,C0001617;C0449438;C3536709
baseline mean fev $nmbr$ sd ml,C0439526;C1705224;C3887665
uc disease duration,C0872146
adjusted rate of fev $nmbr$ decline se ml yr,C0456081;C0871208;C1521828
$nmbr$ years to $nmbr$ years,C0439234
effect of covariates on slopes,C1280500;C1518681;C2348382;C0807955
extent of disease,C0449279;C4553144
current n $nmbr$ $nmbr$,C0521116;C1705970
limited,C0439801;C2674459;C3542948;C4050251
former n $nmbr$ $nmbr$,C0205156;C0750523
baseline c reactive protein,C0006560;C1413716;C4048285
female n $nmbr$ $nmbr$,C0043210;C0086287;C1705497;C1705498
baseline mayo score,C0449820;C4050231
male n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
center location,C0450429;C1515974;C4284930;C4284931
$nmbr$ n $nmbr$,C0369718;C0441922
czech republic,C0206578
$nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
nc,C0027964;C0028407;C0067895;C0265987
predicted fev $nmbr$,C0681842;C3714541;C1882327
israel,C0022271
$nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
southern hemisphere,C1710133
united states n $nmbr$ $nmbr$,C0041703
$nmbr$ asa compounds at baseline,C0205198;C1706082
asia pacific n $nmbr$,C0003980
receiving,C1514756
eastern europe n $nmbr$ $nmbr$,C0015177
not receiving,C1518422;C1514756
western europe n $nmbr$ $nmbr$,C0043129
corticosteroids at baseline,C0001617;C3539185;C3540725;C3540726;C3540727
other n $nmbr$,C0369718;C0441922
$nmbr$ mg day p eq,C0205163;C0439185
ethnic origin,C0015031
$nmbr$ mp and or aza at baseline,C0024944;C0004482;C0168634;C1442488
white n $nmbr$ $nmbr$,C0007457;C0043157;C0220938
corticosteroids and or $nmbr$ mp and or aza at baseline,C0001617;C3539185;C3540725;C3540726;C3540727;C0024944;C0004482;C0168634;C1442488
black n $nmbr$,C0005680;C0027567;C0085756;C0439541
combined infliximab,C0205195;C0666743
asian n $nmbr$,C0078988
baseline age,C0168634;C0001779;C1442488
american hispanic n $nmbr$,C0596070;C0086409
$nmbr$ to $nmbr$ years,C0439234
$nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
baseline smoking status,C0168634;C1519386;C1442488
exacerbations in the year before study,C4086268;C0439234;C0439508;C0557651;C2603343
previous segmental resection s,C0205156;C2987624;C1552607
baseline sgrq total score,C0168634;C2964552;C1442488
nd,
with dm n proactive intervention n $nmbr$ a,C0011816;C0184661;C0886296;C1273869;C3250443
other uc related gi surgical procedures,C0439849;C0524722;C0445223
without dm n $nmbr$ i $nmbr$,C0021966;C0221138
glulisine oad,
usual care n $nmbr$ a,C3538928;C1947933
glulisine monotherapy,
p value $nmbr$,C1709380
oad only,
proactive intervention n $nmbr$ a,C0184661;C0886296;C1273869
itt patients n,C0030705
usual care n $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
mean age s d years,C0444504;C0001779;C2347634;C2348143;C0439234
sbp mm hg mean sdc,C1419891;C3273112
mean bmi s d kg m $nmbr$,C0444504;C0578022;C2347634;C2348143;C0022718;C0439209;C4054209
i $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
mean hba $nmbr$ c s d,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
dbp mm hg mean sdc,C1419891;C3273112
treatment with sulphonylurea n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
heart rate beats min mean sd,C0425583;C2699239
treatment with sulphonylurea biguanide n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
tc mg dl mean sd,C0439269;C2699239
fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0013175;C1710181
ldl c mg dl mean sd,C0439269;C2699239
hdl c mg dl mean sd,C0439269;C2699239
fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0444504;C2347634;C2348143;C0019016;C0033727;C0369286;C0441932;C0564385;C4528284;C1825777;C3538758;C2348070;C0202042;C0455280;C0015663;C1955477;C1710181
tg mg dl mean sd,C0439269;C2699239
placebo pioglitazone n $nmbr$,C0032042;C0071097;C1696465;C1706408
$nmbr$ year framingham chd risk,C0439234;C1282512;C0439508
alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
alogliptin $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ n,C0369718;C0441922
non hispanic,C1518424
treated patients with baseline and $nmbr$ post baseline ef cacy measurement bp value for treatment group comparison proactive intervention vs usual care was calculated based on a $nmbr$ sample t test for continuous variables and chi square test for categorical variables cbp values were measured at baseline week $nmbr$ whereas information on all of the other variables listed was collected during screening abbreviations bmi body mass index bp blood pressure chd coronary heart disease crucial cluster randomized usual care vs caduet investigation assessing long term risk dbp diastolic blood pressure dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sd standard deviation sbp systolic blood pressure tc total cholesterol tg triglyceride,C0332293;C0030705;C0037623;C1415692;C1708288;C4318478;C3538928;C1947933;C1527178;C1705938;C0549178;C0439828;C0008041;C0042295;C0444706;C3541902;C1533716;C0745732;C3272378;C1516695;C1516698;C0220825;C1261322;C1552578;C1516048;C0062152
diabetes history mean sd years,C0011847;C0439234;C0011849
pro active intervention,C0184661;C0886296;C1273869
pioglitazone dose mean sd mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
usual care,C3538928;C1947933
other hypoglycemic agent n,C0020616
odds ratio,C0028873
sulfonylurea,C0038766;C3536898
value,C1522609
$nmbr$ n of patients,C0369718;C0441922
proportion,C1709707
figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo,C0392747;C0443172;C0332174;C0439230;C0439780;C0062259;C0042295;C0019016;C1825777;C3538758;C0369773;C1520214;C2603361;C0032042;C1696465;C1706408
with dm,C0011816;C3250443
simvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg n $nmbr$,C1319635
or $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
lowest tg tertile,C1708760;C0337445
ldl c goal attainment,C0680230
tgs mg dl,C1156212;C0439269;C1537574
dual bp ldl c goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
non hdl cholesterol mg dl,C0729627;C0439269;C1535899
without dm,C0011816;C3250443
apob mg dl,C0003593;C0439269;C3252643
non hdl cholesterol apob ratio,C2938854
ap $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ cp $nmbr$ $nmbr$ the study speci c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm the ldl c target was $nmbr$ mg dl or $nmbr$ mg dl depending on risk factor status at baseline in accordance with ncep atp iii guidelines odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site an interaction between treatment effect and dm status was observed for bp goal attainment p $nmbr$ $nmbr$ and dual bp ldl c goal attainment p $nmbr$ $nmbr$ among patients with or without dm calculated based on a mixed effects linear model not adjusted for differences in baseline values abbreviations bp blood pressure dbp diastolic blood pressure dm diabetes mellitus ldl c low density lipoprotein cholesterol ncep atp iii national cholesterol education program adult treatment panel iii or odds ratio sbp systolic blood pressure,C0006938;C4050020;C1521840;C2986546;C0085805;C0439475;C0536221;C3813197;C4281799;C0011816;C3250443;C0439269;C0035648;C0449438;C0168634;C1442488;C1527178;C1705938;C0025663;C0449851;C0871511;C0332257;C1552866;C2700399;C1704640;C1706515;C4050026;C4319583;C4553629;C0205145;C1515974;C2825164;C1704675;C1518681;C1441672;C0680230;C0030705;C0444686;C1441506;C0205430;C0023732;C3160715;C1518422;C0456081;C0005810;C0005844;C0600103;C0488055;C0871470;C1306620
middle tg tertile,C0444598;C0337445;C0549183;C1552826
end of follow up,C0444930;C2746065
highest tg tertile,C1522410;C0337445
intensive control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
with tamsulosin,C0257343
standard control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
without tamsulosin,C0257343
age when diabetes first diagnosed yr,C0001779;C0011847;C0439234;C0011849
no japanese,C0376247;C1556094
duration of diabetes yr,C0449238;C2926735
time since bph diagnosis years,C0556970;C0005001;C1704272
australia and new zealand,C0004340;C0027978;C0324547
no previous alpha blocker use,C0042153;C0457083;C1947944
asia,C0003980
ipss unit,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
history of major macrovascular disease no,C0683519;C0730226;C0850708;C0944983
prostate volume ml,C0439526;C1705224;C3887665
history of major microvascular disease no,C0683519;C0730226;C0850708;C0944983
intervention group n $nmbr$,C0441848
macroalbuminuriaf,
hispanic latin american,C0019576
microvascular eye diseased,C0015392;C0700042
hawaiian pacific islander,C0337920;C0242191
history of microalbuminuria no,C3532606
age $nmbr$ years or more,C1510829
blood glucose control,C3267174
previous transient ischaemic attack ischaemic stroke previous warfarin use,C0042153;C0457083;C1947944
less than $nmbr$ year,C0439234;C0439508
glycated hemoglobin nonstandardized level,C0202054
$nmbr$ year or more,C0439234;C0439508
glycated hemoglobin standardized level,C0202054
no estimate,C0750572
fasting blood glucose mmol liter,C0428568;C0475211;C1261430
atrial fibrillation pattern,C0004238;C0449774;C0344434;C1963067
serum cholesterol mmol liter,C0587184;C0475211
atrial fibrillation onset,C0206132;C0332162
serum triglycerides mmol liter,C0542495;C0475211
left ventricular ejection,C2733342
serum triglycerides pmol liter,C0542495;C0475211
fraction,C1264633;C1554103
serum creatinine pmol liter,C0201976;C0475211;C0600061
figure $nmbr$ primary e cacy results by patient subgroup,C0205225;C1547647;C0439612;C0439631
current smoking no,C0037369;C0453996;C1881674
p value for trend,C1709380;C1521798;C4554533
glucose lowering drug,C0017725;C0441994;C2003888;C0013227;C1254351
age of completion of highest education years sd,C1510829;C0013621;C0013622;C0013658;C0039401
gliclazide modified release no ^,C0017631;C1709058;C4544813
history of major cardiovascular disease n,C0455539;C0205082;C0205164;C4318856;C4521762
other sulfonylurea no,C0038766;C3536898
myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
metformin no,C0025598
stroke n,C0038454;C4554100
thiazolidinedione no,C0289779;C1257987;C3537039
macroalbuminuria n,
acarbose no,C0050393
glinide no,C2266929
major diabetic eye disease n,C0205082;C0342245;C0205164;C4318856;C4521762
past smoker n,C0337664
any oral hypoglycemic drug no,C0359086
insulin no,C0021641;C1533581;C1579433;C3714501
current alcohol use n,C0521116;C0001948;C1705970
none no,
hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
other drugs,C0013227;C3687832
systolic bp mmhg sd,C0871470;C2699239
aspirin no,C0004057
diastolic bp mmhg sd,C0428883;C2699239
other antiplatelet agent no,C0085826
serum total cholesterol mmol l sd,C0587184;C2699239;C1287371
statins no,C0360714
serum creatinine ^mol l,C0201976;C0347982;C0600061
other lipid modifying drug no,C0023779;C0392747;C0013227;C1254351
estimated gfr ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ sd a,C0017654;C0439445;C1424601;C2699239
any blood pressure lowering drug no,C0003364
uacr mg mmol interquartile range b,C0567349;C1711350;C2348885
mean glycated hemoglobin reduction during characteristic follow up $nmbr$ ci percent,C0162119
number of events patients,C4330837
perindopril,C0136123
intensive control n $nmbr$ no of patients percent,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389;C0030705;C0439165
major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
standard control n $nmbr$ no of patients percent,C1442989;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389;C2828392;C0030705;C0439165
mmse $nmbr$,C0451306
relative risk reduction $nmbr$ cl percent,C0242492;C0439165
mmse,C0451306
blood glucose,C0005802
all cause death,C0011065;C1306577;C4082313;C4552775
treatment with any blood pressure,C0596197
shfm annual mortality,C0026565;C0026566
lowering drugs,C0441994;C2003888;C0013227;C3687832
quintile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C1508496
treatment with antiplatelet drugs,C3469597
randomized treatment n,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C3815594
intensive therapy n $nmbr$,C0039798;C0087111;C1363945
nyha class iii n,C1882086
standard therapy n $nmbr$,C2936643
ischemic hf n,C0475224;C0018488;C1313497;C1538440;C3273279
median duration of diabetes yr,C0449238;C2926735
furosemide equivalent mg kg,C0016860;C0439272
previous cardiovascular event,C0205156;C1320716;C1552607
digoxin n,C0012265
race or ethnic group f,C0034510;C1706779;C3853635;C0441840
ace i or arb n,C0021966;C0221138;C3888198
education,C0013621;C0013622;C0013658;C0039401
j $nmbr$ blocker n,
less than high school,C0599395;C0683862;C0870649
statin n,C0360714
high school graduate,C0870649;C1549971
carvedilol n,C0054836
some college,C0557806
qrs $nmbr$ ms n,C2349943;C3539704;C3713294
college degree or higher,C0441889;C0449286;C0542560;C2348088;C0205250
qrs width ms,C2349943;C3539704;C3713294
cigarette smoking status,C1519386
$nmbr$ min walk distance ft,C1881534;C3890579
any sulfonylurea,C0038766;C3536898
quintile n,C1508496
any thiazolidinedione,C0289779;C1257987;C3537039
total deaths n,C0439175;C0011065;C1306577;C0439810
any antihypertensive agent,C0003364
placebo mortality rate events per $nmbr$ person y,C0441471;C3541888
any thiazide diuretic,C0012802;C3536861
relative risk comparing icd therapy and placebo,C0242492;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408
fasting serum glucose mg dl,C0202041;C0439269;C3534430
relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd,C0242492;C0596019;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C1524063;C0233324;C1515273;C1705313;C2826302
median triglyceride mg dl,C0041004;C0439269
ii $nmbr$,C1710602;C4082587
potassium mg dl,C0032821;C0439269;C0202194;C0304475;C0597277;C3714637
iii $nmbr$,C0439070;C1705160
oxypurinol n $nmbr$,C0030086
iv $nmbr$,C0022326;C4265176
age yrs mean sd,C0001779;C2699239
v $nmbr$,
nyha functional class iii,C1882086;C0205245;C0542341;C2700217
gold stage ii,C0018026;C0441767;C1304897
lvef mean sd,C0428772;C2699239;C0488728
gold stage iii,C0018026;C0441771;C1304897
$nmbr$ mwt m,
gold stage iv,C0022326;C4265176
carvedilol,C0054836
fev $nmbr$ l,C3714541
spironolactone,C0037982
prebronchodilator,C2599602
idiopathic,C0332240
postbronchodilator,C2599594
hypertensive,C0857121
duration of copd years,C0449238;C2926735
hospitalized,C0701159
control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
er visit,C0545082;C1512346;C2826704
ratio $nmbr$ ci,C0008107;C3259781
new hf medication,C0013227;C3244316;C4284232
one or more copd exacerbations n n [ ],C0205447;C0740304
on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl,C0013227;C0439269;C0802604;C2598133;C4284232
median time to first exacerbation months [ $nmbr$ ci],C0205435;C0556969;C1279901;C0008107;C3259781
sua,
mean number of exacerbations per patient year [ $nmbr$ ci],C0444504;C0237753;C0449788;C2347634;C2348143;C0030705;C0439234;C0439508;C0008107;C3259781
mean $nmbr$ th to $nmbr$ thquartile bnp pg ml,C0039725;C0039738;C1420718;C4282123;C4285344
dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
v alsartan hctz n,C0020261
warfarin,C0043031
valsartan n,C0216784
male sex no total no,C0086582;C0439175;C0439810
mean age years sd,C1510829;C2699239
type of atrial fibrillation no total no,C0332307;C1547052;C0439175;C0439810
msdbp mmhg sd,C0439475;C2699239
chads $nmbr$ scoref,C0007928;C1413373
mssbp mmhg sd,C0439475;C2699239
$nmbr$ or $nmbr$ no total no,C0439175;C0439810
mean weight kg sd,C0005910;C2699239;C0043100;C1305866;C1705104
$nmbr$ no total no,C0439175;C0439810
mean bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
$nmbr$ $nmbr$ no total no,C0439175;C0439810
serum creatinine mean sd pmol l,C0201976;C0439284;C0600061
previous stroke or transient ischemic attack no total,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
bmi body mass index hctz hydrochlorothiazide msdbp mean sitting diastolic blood pressure mssbp mean sitting systolic blood pressure sd standard deviation,C1828170
heart failure no total no,C0018801;C0018802;C4554158;C0439175;C0439810
arm,C0446516;C3715044;C4553528
medications in use at baseline no total no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101;C0439175;C0439810
risk,C0035647;C4552904
arb or ace inhibitor,C3888198;C0003015;C4541021
severity,C0439793;C0522510
stating,C1301808;C1442792;C3148680
mssbp,
proton pump inhibitor,C0358591;C3536754;C4521480
mssbp $nmbr$ mmhg,C0439475
h $nmbr$ receptor antagonist,C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
j $nmbr$ $nmbr$,
long term vka therapy,C0039798;C0087111;C1363945
sildenafil n $nmbr$,C0529793
patients total no,C0439175;C0439810
mean sd age y mean bmi category,C0683312;C3889287
dabigatran $nmbr$ mg $nmbr$ mg per yr,C1319635;C0439234
missing ed duration y,C1551393;C0449238;C2926735;C1705492;C3272743
p value for interaction dosage with dabigatran $nmbr$ mg,C1709380;C0178602;C2986497;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
range ed etiology n,C0015127;C1314792;C1524003
$nmbr$ kg,C0022718;C0439209;C4054209
mixed,C0205430;C3160715
european or arab,C0239307;C1535514;C0282540;C1561448
organic,C0747055
$nmbr$ $nmbr$ ml min,C0439445
psychogenic,C0458006
$nmbr$ or $nmbr$,
mean iief ef score mean iief domain score by bmi,C3533236;C0578022
symptomatic heart failure,C0742758
ef domain,C1880389;C1883221;C3541951
central europe,C0682369
os domain,C1880389;C1883221;C3541951
south asia,C1710133;C0003980
is domain luts severity,C0439793;C0522510
east asia,C0015631
moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
aspirin use at baseline,C0042153;C0457083;C1947944
mean total ipss mean ipss by bmi,C0439175;C0439810
amiodarone use at baseline,C0042153;C0457083;C1947944
storage subscore,C0337174;C1698986;C1753314
ppi use at baseline,C0042153;C0457083;C1947944
voiding subscore,C0042034;C4067975
patients characteristics age years mean sd,C1510829;C2699239
mean qmax score by bmi,C3533236;C0578022
risk factors bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
sd standard deviation bmi body mass index ed erectile,C1305855;C3538926;C0030847
sbp mmhg mean sd,C0085805;C2699239
dysfunction ef erectile function iief i,C0021966;C0221138
heart rate b p m mean sd,C0018810;C0444504;C2699239;C2347634;C2348143
nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
alcohol consumption n,C0001948
erectile function ipss,C1019118;C1998280;C2827405;C3811063
nyha class n ii,C1882085
international prostate symptom score,C1998280
admission for hf in previous year n,C0184666;C0809949;C0205156;C0439234;C0439508;C1552607
luts lower urinary tract symptoms is,C0574785
previous ami n,C0205156;C1552607
intercourse satisfac,C0009253
previous stroke n,C0205156;C0038454;C4554100;C1552607
tion os overall satisfaction qmax maximal urinary flow rate,C4086680;C0429784
cabg n,C0010055
famotidine $nmbr$ mg n $nmbr$,C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pci n,C4049621
sex male female n,C0086287
icd n,C0021122
weight kg bmi kg m $nmbr$,C0005910;C1319635;C0043100;C1305866;C1705104
pacemaker n,C0030163;C0810633;C1546728;C3275122;C3853703
smoking status ongoing n,C1519386;C0549178
history of paroxysmal atrial fibrillation n,C0729790
smoking status previous n,C1519386;C0205156;C1552607
peripheral vascular disease n,C0085096
alcohol consumption yes n,C0001948;C1549445;C1705108;C1710701
chronic obstructive pulmonary disease n,C0024117
caffeine consumption yes n,C0948365;C1549445;C1705108;C1710701
neoplasia n,C0027651;C1882062
hiatal hernia yes n,C3489393;C1549445;C1705108;C1710701
ischemic aetiology n,C0475224;C0015127;C1314792;C1524003
helicobacter pylori infection n,C0850666
pulmonary rales n,C0034642
pepsinogen i ii ratio,C0456603;C1547037
third heart sound n,C0232237;C0232278
days with heartburna days,C0439228
mitral insufficiency n,C0026266
severity of heartburnb,C0439793;C0522510
aortic stenosis n,C0003507
atenolol strategy n $nmbr$ $nmbr$,C0004147;C0679199
qrs $nmbr$ ms n available for $nmbr$ patients,C2349943;C3539704;C3713294;C0470187;C0030705
verapamil sr strategy n $nmbr$ $nmbr$,C1527129;C0679199
demographic,C0011298
left ventricular hypertrophy n,C0149721;C3484363
age mean sd years,C1510829;C0444504;C2347634;C2348143
total cholesterol mg dl mean sd available for $nmbr$ patients,C0201950;C2699239;C0543421;C0470187;C0030705
race ethnicity no,C0015031;C0243103
ldl cholesterol mg dl mean sd available for $nmbr$ patients,C0023824;C2699239;C0202117;C0470187;C0030705
history of ml,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hdl cholesterol mg dl mean sd available for $nmbr$ patients,C0023822;C2699239;C0392885;C0470187;C0030705
chronic stable angina,C0340288
triglycerides mg dl mean sd available for $nmbr$ patients,C0439269;C2699239;C0470187;C0030705
unstableangina,
laboratory examination,C0260877
dyslipidemia $nmbr$,C0242339
haemoglobin g dl mean sd available for $nmbr$ patients,C0439267;C2699239;C0470187;C0030705
stroke ortiab,C0038454;C4554100
potassium meql mean sd available for $nmbr$ patients,C0032821;C2699239;C0202194;C0304475;C0597277;C3714637;C0470187;C0030705
renal insufficiency $nmbr$,C0035078;C1565489
ace inhibitors arbs n,C0003015;C3888198
diabetes $nmbr$,C0011847;C0011849
spironolactone n,C0037982
obese,C0028754
diuretic drugs n,C0012798;C0013227;C3687832
ever smoker,C3887636;C0337664
digitalis n,C0012252;C0304520
medications no,C0013227;C0802604;C2598133;C4284232
oral anticoagulant drugs n,C0354604
aspirin antiplatelet,C0004057
aspirin other antiplatelet agents n,C0004057;C0085826
antidiabetic,C0935929
nitrates n,C0028125
lipid lowering,C0023779;C0441994;C2003888
amiodarone n,C0002598
potassium,C0032821;C0202194;C0304475;C0597277;C3714637
hrt,C0282402
age $nmbr$ years $nmbr$,C1510829
ischemic aetiology,C0015127;C1314792;C1524003
systolic mean sd mm hg,C0039155;C0439475
controlled $nmbr$ no,C2587213;C2911690
non ischaemic aetiology,C0015127;C1314792;C1524003
nyha lll iv,C0022326;C4265176
history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
bmi body mass index hrt hormone replacement therapy lvh left ventricular hypertrophy nsaids nonsteroidal anti inflammatory drugs pvd peripheral vascular disease tia transient ischemic attack ahistory of and or currently taking lipid lowering or antidiabetic medications bp $nmbr$ $nmbr$ for verapamil sustained release sr vs atenolol chistory of or currently have elevated serum creatinine but less than $nmbr$ mg dl dblood pressure control defined as,C3687361;C0521116;C0023779;C0441994;C2003888;C0037623;C1415692;C1708288;C4318478;C1527129;C1710261;C0004147;C0700225;C0439269;C0033095;C0460139;C1306345;C4284008;C1704788;C3539106
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
haplotype,C0018591
total cholesterol $nmbr$,C0201950;C0543421
no copies gly $nmbr$ glu $nmbr$ $nmbr$ c,C1948062;C0068000
total cholesterol $nmbr$ $nmbr$ mg dl,C0201950;C0439269;C0543421
verapamil sr,C1527129
fluvastatin n $nmbr$,C0082608
incidence,C0021149;C0220856
v total n $nmbr$,C0439175;C0439810
male sex no risk factors,C0086582;C0035648;C1553898
myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
rerapamil sr strategy n $nmbr$,C0753208;C0679199;C1709991;C3813610;C3890900;C3891546
angina pectoris no,C0002962
atenolol strategy n $nmbr$,C0004147;C0679199
stroke or tia no,C0038454;C4554100;C0007787;C0917805;C1054154
mean age y sd,C0001779;C2699239
renal insufficiency no,C0035078;C1565489
female race ethnicity,C0015031;C0243103
copd no medication use,C0024117;C1412502;C3714496;C0240320
smoking history ever,C1519384;C3887636
dyslipidemia,C0242339
beta blocker no,C0001645
cancer medications,C0013227;C0802604;C2598133;C4284232
antiplatelet no,
baseline sbp mm hg,C0085805;C0439475
anticoagulant no,C0003280;C0848112;C3536711
baseline dbp mm hg,C0168634;C0439475;C1442488
ace inhibitor no,C0003015;C4541021
baseline heart rate beat min,C0702093;C1524029;C3813700
calcium antagonist no,C0006684
angiotensin ll receptor antagonist no,C0003018;C4521302;C4543207
values are expressed as percentages unless otherwise indicated bmi body mass index cabg coronary artery bypass ischemic attack nsaids nonsteroidal anti inflammatory drugs sbp systolic bp dbp diastolic bp history of or currently taking antidiabetic or lipid lowering medications,C0042295;C0439165;C1549488;C1561533;C1553893;C0521116;C0935929;C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
nitrate no,C0028125;C0699857;C3848573
graft pci percutaneous coronary intervention tia transient,C0040704;C0205374
diuretic no surgery,C0012798;C0038894;C0038895;C0543467;C1274039
verapamil sr n $nmbr$ no,C1527129
carotid artery no,C0007272;C0162859
atenolol n $nmbr$ no,C0004147
abdominal aortic no,C0000726;C0003483
nontatal ml,C0439526;C1705224;C3887665
open no,C0175566
fatal and nonfatal ml,C1302234;C1705232;C0439526;C1705224;C3887665
endovascular no,C0524425
cv death,C0011065;C1306577;C4082313;C4552775
lower limb arterial no,C0003842;C0221464
tg $nmbr$ hdl $nmbr$ n $nmbr$,C0337445;C3715113
p value for heterogeneity,C1709380;C0019409;C0242960
tg $nmbr$ hdl,C0337445;C3715113
no of events no of patients,C0441471;C3541888;C0030705
smoker a,C0337664
type of surgery,C0332307;C1547052
drinker a,C0556338
open,C0175566
clinical history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
endovascular,C0524425
hypertension $nmbr$,C0020538;C1963138
baseline high sensitivity crp,C3890735;C4048285
systolic mmhg,C0039155;C0439475
baseline ldl cholesterol,C0023824;C0202117
diastolic mmhg,C0012000;C0439475
baseline total cholesterol,C0201950;C0543421
lipid profile,C1979963;C2003903
cardiac risk,C0035647;C4552904
triglyceride mg dl d,C0041004;C0439269
intermediate,C0205103;C1550465;C2827755;C3889971
fatty acid composition,C0486616;C1555710
temporary discontinuation of study drug,C0457454;C1444662;C4552847
dexlansoprazole mr n $nmbr$,C0024485;C1417249;C2347167;C3254418;C4050513
data represent number of patients or mean standard deviation unless otherwise indicated a self reported information bc physician diagnosed diabetes or fasting plasma glucose $nmbr$ mg dl or hemoglobin a $nmbr$ c $nmbr$ $nmbr$ d physician diagnosed hypertension or systolic blood pressure $nmbr$ mmhg or diastolic blood pressure $nmbr$ mmhg median interquartile range ldl low density lipoprotein hdl high density lipoprotein tg triglyceride,C1511726;C3245479;C3714741;C1882932;C2360800;C1828170;C1444656;C0011847;C0011849;C0202042;C0439269;C0455280;C0020538;C1963138;C0488055;C0439475;C0871470;C1306620;C0065191
lansoprazole n $nmbr$,C0050940
hazard ratio and p value,C2985465;C1709380
mean age s d year,C0444504;C0001779;C2347634;C2348143;C0439234;C0439508
high triglyceride low high density lipoprotein,C0151691
missing,C1551393;C1705492;C3272743
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
mean bmii s d kg m $nmbr$,C0022718;C0439209;C4054209
rivastigmine n $nmbr$,C0649350
alcohol users n,C0556297
$nmbr$ $nmbr$ years n,C0439234
smokers n,C0337664
$nmbr$ years n,C0439234
caffeine users n,C3532939
overall male female,C0043210;C0086287;C1705497;C1705498
amlodipine valsartan $nmbr$ $nmbr$ mg v $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ethnic origin n,C0015031
amlodipine $nmbr$ mg v $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
oriental,C0078988;C0699027
baseline msdbp mmhg mean sd,C0168634;C2699239;C1442488
formal education years,C0681344;C0439234
baseline mssbp mmhg mean sd,C0168634;C2699239;C1442488
duration of dementia symptoms months,C0436359;C0011265;C0497327
duration of hypertension months,C0449238;C2926735
criteria for subcortical vad by mri,C0243161;C0077973;C0024485;C1824234;C3890166
mean sitting diastolic blood pressure,C1319894
mean sd baseline scores,C3533236;C0168634;C1442488
amlodipine and valsartan,C0051696;C0216784
mhis score,C0449820;C4050231
mean sitting systolic blood pressure,C1319893
vadas score,C0449820;C4050231
observation,C0302523;C0700325;C1964257;C3889687
mmse score,C0449820;C4050231
$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
adcs adl score,C0449820;C4050231
participants,C0679646
gds score,C0449820;C4050231
mean sd age y,C0444504;C0001779;C2347634;C2348143
npi $nmbr$ score,C0449820;C4050231
minimum maximum,C0806909;C1552615;C2826546
younger patients aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
study eye characteristics,C1568011;C0015392;C0700042
older patients aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
mean sd e etdrs visual acuity letter score snellen equivalent,C0205163;C0439185
rivastigmine,C0649350
duration of macular edema mo,C0449238;C2926735
supine after $nmbr$ minutes change from baseline,C0038846;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
iop mm hg,C0578862;C0439475
notable abnormalities,C0000768;C0000769
iop lowering medication,C0578862;C0441994;C2003888;C0013227;C3244316;C4284232
high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
phakic,
low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
imaging data mean sd,C0011923;C2699239;C0079595
standing after $nmbr$ minute change from baseline,C0231472;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
oct center point thickness pm,C0030266;C4049155
standing after $nmbr$ minutes change from baseline,C0231472;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
total macular volume mean sd mm $nmbr$,C4330985;C4554674
normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972;C0017654;C0439445;C1424601
area of retinal thickening within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
area of retinal hemorrhage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
patients randomly assigned,C0030705;C1516050;C1552601
area of fluorescein leakage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
age at lipid randomization y,C0001779;C0065033
$nmbr$ da of capillary nonperfusion in the eyec,C0011318;C3668815
body mass index kg m $nmbr$ baseline systolic blood,C0022718;C0439209;C4054209;C0005767;C0005768;C0229664
mean sd nonstudy eye e etdrs visual acuity letter score,C3533236;C0042812
pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
other clinical characteristics,C0683325
baseline diastolic blood,C0005767;C0005768;C0229664
history of cancer,C0455471
history of coronary heart disease at,C0683519;C0730226;C0850708;C0944983
history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography,C3161471;C0920367
rasagiline $nmbr$ mg day,C0525678;C0439422
other atherosclerotic cvd st depression on,C0007222;C0520887
electrocardiogram,C0013798;C1547122;C1623258
delayed start group n $nmbr$,C0205421;C0441848;C1545665;C3272602
early start group n $nmbr$,C0439659;C0441848
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile,C0017654;C0439445;C1424601;C1979963;C2003903
fasting triglycerides,C0015663;C0041004
time since diagnosis mo,C0040223;C3541383
randomly assigned to ace,C1516050;C1552601
total updrs score range $nmbr$ $nmbr$ y,C2964552;C1514721;C2348147;C3542016
inhibitor,C1999216
motor subscale range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
adl subscale range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
randomly assigned to calcium channel blocker,C1516050;C1552601
randomly assigned to diuretic,C1516050;C1552601
hoehn and yahr stage range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
result,C1274040;C1546471;C2825142
esrd or $nmbr$ dedine in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
s e,
esrd or $nmbr$ decline in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
$nmbr$ c i,C1547546
gfr $nmbr$,C0017654;C1424601
gfr $nmbr$ $nmbr$,C0017654;C1424601
first primary change in updrs score wk wk $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
aspirin erdp n $nmbr$ $nmbr$,C0004057
$nmbr$ mg day placebo,C0032042;C1696465;C1706408
europe israel or australia,C0015176;C0022271;C0004340
second primary estimated change in total updrs score from baseline to wk $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
latin america or south africa,C0023122;C0037712
$nmbr$ mg day early start,C0439422;C0439659
united states or canada,C0041703;C0006823
$nmbr$ mg day delayed start,C0439422;C0439659
chinese,C0008120;C0152035
$nmbr$ mg day early start delayed start,C0439422;C0205421;C1545665;C3272602
south asian,C1519427
third primary change in updrs score wk wk $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
other asian,C0078988
secondary change in total updrs score from baseline to final visit in phase $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205390;C1710475
white european,C0239307;C1535514
rituximab n $nmbr$,C0393022
native latin,C0302891
age mean yr sd,C0001779;C2699239
bmi^,C0578022
gender no,C0079399;C1522384
tobacco use,C0040335;C0543414;C0841002;C3853727
disease duration mean yr sd,C0872146;C2699239
currently,C0521116
since onset,C0206132;C0332162
previously,
since diagnosis,C0011900;C1704338;C1704656
no regular consumption,C0009830;C1947907
prior ms treatment with ifn beta or,C1514463;C0015980
$nmbr$ $nmbr$ drinks wk,C0332174;C0439230
glatiramer acetate no,C0289884
$nmbr$ drinks wk,C0332174;C0439230
no prior ms therapies,C1514463;C2349943;C3539704;C3713294
exercise category,C3669314
sedentary,C0205254
ended $nmbr$ days before trial entry,C0439228;C0008976
some physical activity,C0015259;C0026606
edss score,C0449820;C4050231
intense physical activity,C0015259;C0026606
median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
edss stratification no,C0451246;C1514983;C3887783
time from qualifying stroke to randomization,C0040223;C3541383;C1514624;C0038454;C4554100
median days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
total gadolinium enhancing lesion count no,C0439175;C0016911;C0439810;C2349975;C0750480;C1705566
$nmbr$ $nmbr$ days,C0439228
brain volume cm $nmbr$,C1113695
$nmbr$ days,C0439228
t $nmbr$ lesion volume mm $nmbr$,C4330985;C4554674
toast classification of qualifying stroke,C1710306;C4521230;C1514624;C0038454;C4554100
msfc timed $nmbr$ foot walk test median seconds,C0560030
large artery atherosclerosis,C0003850;C0004153
age gd lesion,C0221198;C1546698
cardioembolism,
effect estimate,C1280500;C0750572;C1518681;C2348382
small artery occlusion lacune,C0226001;C0241970
age $nmbr$ gadolinium lesion $nmbr$ n $nmbr$,C0001779;C0016911
acute stroke of other determined cause,C0751956;C0015127;C1524003
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019
stroke of undetermined cause,C0038454;C0015127;C1524003
reteplase abciximab facilitated pci n $nmbr$,C0256103;C0288672
score on modified rankin scale,C4049715
treated with insulin,C0332293;C0021641;C1533581;C1579433;C3714501
baseline nihss score,C0449820;C4050231
previous chf,C0205156;C0018802;C1552607
previous stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
location of infarction,C0450429;C1515974;C4284930;C4284931
atherosclerotic disease,C0333482;C0012634
inferior posterior,C0542339;C0205095;C0678975
ischemic coronary artery disease,C0852149
primary pci,C0205225;C0439612;C0439631
paod,
ret abx facil pci,C0389252;C4049621
deep vein thrombosis,C0149871
i $nmbr$,C0021966;C0221138
aspirin erdp clopidogrel no of patients total no,C0004057;C0070166;C0030705;C0439175;C0439810
no unknown,C0439673;C3541433;C4050014
sites,C0205145
prespecified analysis,C0002778;C0936012;C1524024
any recurrent stroke,C2242682
time of symptom onset to randomization hrs,C1320528;C0034656;C1568891
other atherosclerotic event,C0441471;C4019010
time of qualifying ecg to balloon inflation hrs,C0040223;C3541383;C1514624;C1623258;C0021398;C1318493
stroke risk score,C0449820;C4050231
tertile $nmbr$,
$nmbr$ $nmbr$ low risk,C3272281;C3538919
time of symptom onset to balloon inflation hrs,C1320528;C0021398;C1568891;C1318493
$nmbr$ $nmbr$ moderate risk,C0035647;C4552904
tertile $nmbr$ index pci performed,C0600653;C4049621;C0918012;C1552854;C1637833;C2986546;C0884358
$nmbr$ high risk,C0332167;C3272283;C4050568;C4319571
enrollment in lmwh,C1516879;C1696073;C3888021
randomization to placebo or telmisartan,C0034656;C0032042;C1696465;C1706408;C0248719
abx facil pci,C4049621
telmisartan,C0248719
n_,C0369718;C0441922
statin use,C0042153;C0457083;C1947944
cutoffs,C1442160
ace inhibitor use,C0042153;C0457083;C1947944
combo facilitated pci,C4049621
abciximab facilitated pci,C0288672;C4049621
time from onset of qualifying stroke to randomization,C0449244;C1514624;C0038454;C4554100
combo vs primary,C0205225;C0439612;C0439631
slo days,C1416602;C0439228;C3539661
abciximab vs primary,C0288672;C0205225;C0439612;C0439631
small artery occlusion,C0226001;C0264995
timi $nmbr$,
undetermined other or cardioembolism,C0205258;C3536725;C4082977
timi $nmbr$ and spoke,
post hoc analysis,C0002778;C0936012;C1524024
timi $nmbr$ and spoke and time $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
medical history of hypertension,C0455527;C0262926
alteplase n $nmbr$,C0032143
baseline systolic blood pressure,C4274438
baseline nihss,C0168634;C1697238;C1442488
telmisartan n $nmbr$ $nmbr$,C0248719
median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
ethnic group no,C0015031;C1879937
previous use of antiplatelet drugs,C1524063
clinical history no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
atrial flutter fibrillation,C0155709
use of medication at baseline no,C1524063;C0168634;C1442488
never smoked,C0037366;C0439994;C1881674
index stroke $nmbr$ days before randomization no,C0456712;C0439228
ex smoker,C0337671;C4555205
toast classification,C1710306;C4521230
time to treatment initiation min,C3494202;C0589507;C1158830;C1704686
score on modified rankin scale no,C4049715
time to treatment min t,C3494202;C0702093;C1524029;C3813700
baseline nih stroke scale no ^,C1697238;C3484372
odds ratio $nmbr$ cl,C0028873;C0596019
all recurrent strokes,C1836785
nihss at baseline,C1697238;C0168634;C1442488
use of ace inhibitor,C1524063;C0003015;C4541021
previous diabetes,C0011847;C0011849
$nmbr$ to $nmbr$ mm hg,C0439475
arial flutter or fibrillation,C0016385;C2242390;C0232197
low risk $nmbr$ $nmbr$,C3272281;C3538919
previous chronic use of antiplatelet drugs,C1524063
moderate risk $nmbr$ $nmbr$,C0035647;C4552904
itt population,C0032659;C1257890
high risk $nmbr$,C0332167;C3272283;C4050568;C4319571
intention to treat,C0162425;C1283828
all major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
intention to treat without st segment elevation myocardial infarction,C0162425;C1283828;C1536220
sl $nmbr$ mm hg,C0439475
^ $nmbr$ days,C0439228
intention to treat with st segment elevation myocardial infarction,C0162425;C1283828;C1536220
rosuvastatin n $nmbr$,C0965129
cangrelor n $nmbr$,C1121991
heart disease risk factors,C0741920
race or ethnic group no total no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0439175;C0439810;C0016327
interquartile range height cm,C1711350;C0489786
heart rate beats per min,C0425583;C0439385
stable angina no,C0340288
admission for hf in previous year,C0184666;C0809949;C0439234;C0439508
unstable angina no,C0002965
previous ami,C0205156;C4319936;C1552607
icd,C0021122
myocardial infarction without st segment elevation no,C1536220
history of atrial fibrillation,C0729790
st segment elevation myocardial infarction no,C1536220
copd,C0024117;C1412502;C3714496
other medical history no total no,C0262926;C1704706;C0439175;C0439810
neoplasia,C0027651;C1882062
family history of coronary artery disease,C2317524
heart failure cause,C0015127;C1524003
ptca or pci,C2936173;C4049621
ischaemic,C0475224
periprocedural medications no total no,C0013227;C0802604;C2598133;C4284232;C0439175;C0439810
dilatative,
bivalirudin,C0168273
other cause,C0015127;C1524003
glycoprotein iib iiia inhibitors,C0016011;C0243077
non detectable unknown,C0439673;C3541433;C4050014
study treatment no total no,C1521826;C0439175;C0439810
physical examinations,C0031809
no of target vessels,C0449618
pulmonary rales,C0034642
non drug eluting stent,C1518422;C1322815
third heart sound,C0232237;C0232278
angiographic complications site reported no total no,C0205145;C1515974;C2825164;C0684224;C0700287;C4319718;C0439175;C0439810
mitral insufficiency,C0026266
threatened abrupt vessel closure,C0185003;C1521802
aortic stenosis,C0003507
unsuccessful procedure,C0184661;C2700391;C3274430;C3539779
ecg findings,C0438154
abrupt vessel closure,C0185003;C1521802
qrs $nmbr$ ms,C2349943;C3539704;C3713294
new or suspected thrombus,C0205314;C0087086;C0302148;C3146237
pathological q waves,C0429090
acute stent thrombosis,C0205178;C3897493
arbs,C3888198
need for urgent coronary artery bypass grafting,C0439609;C0010055;C3272275
diuretic drugs,C0013227;C3687832
intravenous study drug administered no,C0683092;C1521801
oral anticoagulant drugs,C0354604
bolus administered no,C1186706;C1511237;C1705509;C3812160;C1521801
other antiplatelet agents,C0085826
infusion administered no total no,C0574032;C1827465;C1521801;C0439175;C0439810
duration of infusion hr,C0449238;C2926735
oral study drug administered no total no,C0013175;C1521801;C0439175;C0439810
figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population,C0028873;C2986535;C0011900;C1704338;C1704656;C0087111;C0032659;C1257890;C1292734;C1522326
data are mean sd or number bmi body mass index sbp systolic blood pressure dbp diastolic blood pressure lvef left ventricular ejection fraction hf heart failure ami acute myocardial infarction cabg coronary artery bypass graft pci percutaneous coronary intervention icd implantable cardioverter de brillator copd chronic obstructive pulmonary disease ace angiotensin converting enzyme arbs angiotensin receptor blockers available for $nmbr$ patients $nmbr$ rosuvastatin $nmbr$ placebo,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0521942;C0815017;C0470187;C0030705
hs crp,C3890735;C4048285
rosuvastatin events patients,C0441471;C0030705;C3541888
hs crp $nmbr$ $nmbr$ mg l,C3890735;C0439268;C4048285
placebo events patients,C0032042;C0030705;C1696465;C1706408
p all vs all,C0369773;C2603361
age $nmbr$ years median,C0549183;C0876920;C2347635;C2348144;C2939193
all n $nmbr$ f,C0369718;C0016327;C0441922
ischaemic cause,C0015127;C1524003
^ $nmbr$ y n,
non ischaemic cause,C0015127;C1524003
nyha class n,C1882083
nyha ii,C1710602;C4082587
atrial fibrillation or flutter ecg,C0004238;C0344434;C1963067;C0016385;C1623258;C2242390
nyha iii or iv,C0439070;C1705160;C0022326;C4265176
serum creatinine mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
total cholesterol $nmbr$ $nmbr$ mmol lt,C0023376;C0230426;C3887647;C4521399
serum creatinine $nmbr$ mmol l n,C0201976;C0600061
egfrmdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
we recorded no significant interactions for any subgroup analysis nyha new york heart association lvef left ventricular ejection fraction $nmbr$ cl was calculated by cox proportional hazards model tmedian value data for total cholesterol were available for $nmbr$ patients $nmbr$ rosuvastatin $nmbr$ placebo,C0034869;C3853788;C0237688;C0428772;C0444686;C1441506;C0201950;C0543421;C0470187;C0030705
egfrmdrd,
n $nmbr$ pufa n $nmbr$,C0369718;C0032615;C0441922
nt probnp pmol l^,C0669479;C0439284;C0754710
placebo n $nmbr$ l,C0032042;C1696465;C1706408
medication n,C0013227;C3244316;C4284232
bmi kg rrr,C0022718;C0439209;C4054209
antiplatelet or anticoagulant,C0003280;C0848112;C3536711
cause of heart failure,C0015127;C1524003
type of hospitalization,C3177060
physical examination,C0031809;C1744699
placebo n rate,C0871208;C1521828
statin open,C0360714;C0175566
rosuvastatin n rate,C0871208;C1521828
p subgroup,C1079230;C1515021
all cause,C0015127;C1524003
hospitalizations n,C0019993
data are mean sd or number pufa polyunsaturated fatty acids bmi body mass index sbp systolic blood pressure dbp diastolic blood pressure nyha newyork heart association lvef left ventricular ejection fraction hf heartfailure ami acute myocardial infarction cabg coronary artery bypass graft pci percutaneous coronary intervention icd implantable cardioverter defibrillator copd chronic obstructive pulmonary disease ace angiotensin converting enzyme arbs angiotensin receptor blockers available for $nmbr$ patients $nmbr$ n $nmbr$ pufa $nmbr$ placebo,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0521942;C0815017;C0470187;C0030705
cardiovascular,C0007226;C3887460
worsening heart failure,C0332271;C1457868;C1546960;C0018801;C0018802;C4554158
n $nmbr$ pufa events patients,C0032615;C0030705
noncardiovascular,
nyhaii,
nyhaiiioriv,
item,C1551338;C4554251
baseline median iq range,C1514721;C2348147;C3542016
we recorded no significant interactions for any subgroup analysis pufa polyunsaturated fatty acids nyha new york heart association lvef left ventricular ejection fraction $nmbr$ cl was calculated with a cox proportional hazards model tmedian value data for total cholesterol were available for $nmbr$ patients $nmbr$ n $nmbr$ pufa $nmbr$ placebo,C0034869;C3853788;C0237881;C1704675;C0750502;C1546944;C0232174;C0596019;C0444686;C1441506;C0201950;C0543421;C0470187;C0030705
$nmbr$ month follow up median iq range,C1514721;C2348147;C3542016
parameter mean s d,C0549193;C0444504;C2347634;C2348143;C1704769;C2350001
difference median,C0549183;C0876920;C2347635;C2348144;C2939193
total study itt population n $nmbr$,C3258257
p net difference,C1705241;C1705242
asian itt population total n $nmbr$,C0078988;C0032659;C1257890
triglycerides mmol lf,C1416933;C2986618;C4554443
asian itt population by treatment group,C1257890
placebo n rate $nmbr$,C0871208;C1521828
combination n $nmbr$,C0205195;C1947911;C3811910
rosuvastatin n rate $nmbr$,C0871208;C1521828
dutasteride n $nmbr$,C0754659
hazard ratio $nmbr$,C2985465
$nmbr$ ci $nmbr$,C0008107;C3259781
tamsulosin n $nmbr$,C0257343
subgroup p value $nmbr$,C1079230;C1709380;C1515021
time since first luts years,C0556970;C0205435;C1279901
interaction p value $nmbr$,C1704675;C1709380
prostate volume cm $nmbr$,C1441416
primary endpoint $nmbr$,C2986535
mean total serum psa,C2986589;C0229671;C1546774;C1550100
ngml total mean ipss score,C2964552
hs c reactive protein $nmbr$ $nmbr$ nlg l,C0006560;C1413716;C4048285
all randomized,C0034656;C3815594
qmax ml s,C0439526;C1705224;C3887665
bii score,C0449820;C4050231
coronary events $nmbr$,C0741923
bph related health status,C0005001;C0018759;C1704272
all cause mortality or hosp for worsening hf,C0015127;C0026565;C0026566;C1524003;C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
sexually active,C0241028
no of events rate,C0441471;C0871208;C1521828;C3541888
previous a blocker use,C0205156;C1552607;C0042153;C0457083;C1947944
placebo rosu vastatin,C0032042;C1099881;C1696465;C1706408
previous $nmbr$ ari use,C0042153;C0457083;C1947944
primary endpoint,C2986535
chondroitin,C0008454
hscrp $nmbr$ $nmbr$ mg l,C0439268
g c,C0439267
hscrp $nmbr$ $nmbr$ mga,C0065879
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$,
structural,C0678594
$nmbr$ $nmbr$ $nmbr$ $nmbr$ z $nmbr$ ze,
gait,C0016928
$nmbr$ $nmbr$ $nmbr$ d $nmbr$,
subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
$nmbr$ $nmbr$ j z $nmbr$ $nmbr$ e,
age in years mean sd,C1510829;C0444504;C2347634;C2348143
coronary endpoint,C2349179;C2826544
haq pain scale mean,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ c $nmbr$ $nmbr$ $nmbr$,
years duration oa,C0029408;C3887876
$nmbr$ $nmbr$ $nmbr$ $nmbr$ s $nmbr$,
symptoms mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
percentages,C0439165;C1549488;C1561533
hosp worsening hf,C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
bmi $nmbr$ $nmbr$ overweight,C0578022;C0497406
$nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$,
bmi $nmbr$ obese,C0578022;C0028754
all cause mort hf hosp,C0015127;C0018488;C1313497;C1538440;C3273279;C1524003
knees n,C0022742
hscrp $nmbr$ $nmbr$ mga $nmbr$ $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$,C0065879
kl $nmbr$,C1366480;C1416656;C1704887
$nmbr$ $nmbr$ $nmbr$ z $nmbr$,
mean of jsw mm,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ j,
median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
lm $nmbr$ $nmbr$,C1261082;C1551056
interquartile range mm,C4330985;C4554674
glargine $nmbr$,C0907402
sex male female,C0086287
figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width,C1518681;C3875154;C1517945;C0205363;C0224497;C1547282;C0681850;C1550501;C1706203;C2349001;C2697811
race ethnicity zz,C0015031;C2347310;C0243103
figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C0028873;C1696465;C1706408;C1511726;C3245479;C3714741;C0022742;C0224497
black african,C0337824
prior lower gi clinical event,C0441471;C4019010
descent,C0205386;C0680043
prior upper gi clinical event,C0441471;C4019010
hbaie,
proton pump inhibitor use,C0042153;C0457083;C1947944
concomitant oral glucose lowering agents zz,C0442027;C0017725;C4521986;C0441994;C2003888;C0450442;C2347310;C1254351;C1521826
cox $nmbr$ selective nsaid use,C0042153;C0457083;C1947944
met su tzd,C0428210;C0038642;C1705534;C1550543;C4317104
rates per $nmbr$ patient years,C0871208;C1521828
su tzd,C0038642;C1705534
prior lgi event,C0441471;C4019010
su met,C0428210;C1550543;C4317104
no prior lgi event,C0441471;C4019010
met tzd,C0428210;C1550543;C4317104
age $nmbr$ $nmbr$,C0001779
mmf n $nmbr$,C0083765;C0209368;C3848524
no aspirin,C0004057
ivc n $nmbr$,C4085887
nonsmoker,C0337672;C0425293;C4554605
age at diagnosis of sle years,C1828181;C3173302
corticosteroid,C0001617;C3536709
time since diagnosis of sle years,C0556970;C0011900;C1704338;C1704656
no corticosteroid,C0001617;C3536709
age at diagnosis of ln years,C1828181;C3173302
ascvd,C3665365
time since diagnosis of ln years,C0556970;C0011900;C1704338;C1704656
no ascvd,C3665365
renal biopsy class,C0456387;C1518526;C1705943
femaleb,
class iii iii v,C0441887;C2698969
prior ugi event,C0441471;C4019010
class iv iv v,C0441888;C2698970
no prior ugi event,C0441471;C4019010
class iv only,C0441888;C2698970
total population n,C3258257
class v only,C0456387;C1518526;C1705943
bmi category,C0683312;C3889287
scarring on renal biopsy,C0194073
$nmbr$ $nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ $nmbr$ a,
$nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
urine p cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
white not of hispanic origin,C0007457;C0043157;C0220938;C0086409
$nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
african american,C0085756
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e,
american indian or alaskan native,C0002460;C0238611;C0302891
$nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
asian or pacific islander,C0078988;C0242191
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
unknown none of the above,C0439673;C3541433;C4050014
gfr,C0017654;C1424601
family history of diabetes,C1313937
serum albumin concentration g l,C0439294;C0456615
exercise once weekly,C0015259;C1522704;C0558293
$nmbr$ $nmbr$ $nmbr$ $nmbr$ g,C0439267
alcohol consumption once weekly,C0001948;C0558293
$nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
history of hyperlipidemia,C4695788
patients with negative anti dsdna,C0030705;C0741099
baseline use of hormone therapy,C1524063;C0279025
antibody binding level at baseline,C0428536
available baseline blood specimen n,C0168634;C0178913;C1442488
geometric anti dsdna antibody binding level,C0428536
total cholesterol to hdl cholesterol ratio,C0369300
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
non hdl cholesterol mmol l,C0729627;C1532563;C1535899
$nmbr$ $nmbr$ $nmbr$ $nmbr$ j,
hscrp mg l,C0439268
patients with low,C0030705;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
concentrations at baseline,C0086045;C0168634;C1442488
p inleraclion,C0369773;C2603361
geometric c $nmbr$ concentration mg dl,C0086045;C0439269;C1446561;C3827302
no evenls,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ k,C0597277;C1708601
evenls per $nmbr$ $nmbr$ palienl years,C0439234
selena sledai total score,C0451528;C2964552
$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
dabigatran n $nmbr$,C2348066
family history ol diabetes,C1313937
warfarin n $nmbr$,C0043031
menopause and ht,C0025320;C0567312;C0018510;C0677607
estimated creatinine clearance ml min,C0812399;C0439445
poslmenopausal ht,C0018510;C0677607
type of index event no,C1561488;C0600653;C0918012;C1552854;C1637833;C2986546
poslmenopausal no ht,C0018510;C0677607
deep vein thrombosis only,C0149871
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l,C1532563
pulmonary embolism only,C0034065
tolal cholesterol to hdl cholesterol ratio,C2938854
both deep vein thrombosis and pulmonary embolism,C0149871;C0034065
non hdl cholesterol,C0729627;C1535899
neither deep vein thrombosis nor pulmonary embolism^,C0149871;C0034065
$nmbr$ $nmbr$ mg l,C0439268
cancer no,C0006826;C0998265;C1306459
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mg l,C0439268
previous venous thromboembolism no,C0205156;C1861172;C1552607
tiotropium n $nmbr$,C0213771
parenteral anticoagulation,C0003281;C2917212;C2919015;C3537050
smoking history pack yr,C1519384;C0439234
treatment before randomization days,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
duration of copd yr,C0449238;C2926735
treatment after randomization in the single dummy phase days],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0037179;C0439228;C0087136;C0205171
baseline spirometry,C0168634;C0037981;C1442488
unfractionated heparin no,C0019134;C2825026
before bronchodilation,C1371299;C3537072
low molecular weight heparin no,C0019139;C3536766
fev $nmbr$ liters,C3714541;C0475211
fondaparinux no,C1098510
fev $nmbr$ of predicted value,C3714541;C0681842;C1522609;C1882327
double dummy phase,C0205390;C1710475
fvc liters,C3714541;C0475211
exposure to study drug days,C0332157
ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
adherence to study regimen no,C1510802;C0040808;C2945654
after bronchodilation,C1371299;C3537072
percent of the time that inr was in the therapeutic range,C0439165;C0040223;C3541383;C0525032;C1704538;C0460097
gold stage f,C0018026;C0016327;C1304897
dabigatran,C2348066
sgrq total score units,C0439148;C1519795;C3853603
percentages of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
respiratory medication,C0418986
weight category,C0683312;C3889287
any,
bmi category kg m $nmbr$,C0022718;C0439209;C4054209
inhaled anticholinergic,C0242896;C3537004
creatinine clearance category [ml min],C0683312;C3889287;C0439445
short acting,C1282927;C1806781;C2350002
$nmbr$ ml mln,C1417190;C3815103
long acting,C0205166;C1706317
previous vte,C0205156;C0630906;C1552607
inhaled j $nmbr$ agonist,C0004048;C2987634
initial symptomatic pe,C0070939;C1880476;C4284304
inhaled,C0004048
active cancer at baseline,C0006826;C0998265;C1306459
oral,C0442027;C4521986
measure,C0079809;C0242485
theophylline compound,C0205198;C1706082
fenofibric acid,C0060179
mucolytic agent,C0026698
low dose statin,C0445550;C0360714;C1708745
leukotriene receptor antagonist,C0595726;C3537183;C4521995
supplemental oxygen,C4534306
fenofibric acid low dose statin,C0060179;C0360714
subgroup by treatment interaction p value,C1079230;C1515021
mean percentage change from baseline to final visit,C0392747;C0443172;C1705241;C4319952;C0545082;C1512346;C2826704
mean se,C0444504;C0036919;C2347634;C2348143
final,C0205088;C1546485;C3853528
atio pla,C0456170
efficacy variable,C0439828;C4553760
full cohort,C0009247;C0599755
fenofibric acid i low dose statin,C0060179;C0360714
gold stage,C0205390;C1300072;C1306673
final mean,C0444504;C2347634;C2348143
i ii,C1710602;C4082587
change mean se,C0392747;C0036919;C0443172;C1705241;C4319952
e europe,C0015176
apoal,
usa,C0041703
change meanlse,C0392747;C0443172;C1705241;C4319952
w europe,C0015176
baseline median,C0549183;C0876920;C2347635;C2348144;C2939193
reversibility,C0449261
change median q $nmbr$ q $nmbr$,C0392747;C0443172;C1705241;C4319952
concomitant medication,C0013227;C3244316;C4284232
vldl c,C0523560
laba,
total c,C0439175;C0439810
ics,C0815320;C4551720
moderate dose statin,C1709056;C0360714
laba ics,C0815320;C4551720
fenofibric acid moderate dose statin,C0060179;C0360714
anticholinergic,C0242896;C3537004
change meantse,C0392747;C0443172;C1705241;C4319952
anticholinergics,C0242896;C3537307;C3540711
safety variable,C0439828;C4553760
colesevelam hydrochloride group n $nmbr$,C0541154;C0441848
fenofibric acid $nmbr$ low dose statin,C0060179;C0360714
height cm mean sd,C0444504;C2699239;C2347634;C2348143
fenofibric acid i moderate dose statin,C0060179;C0360714
weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
investigator reported aes,C1412268;C2699274
hbalc mean sd,C0444504;C2699239;C2347634;C2348143
any treatment emergent ae,C0039798;C3887670;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fasting plasma glucose mg dl mean sd,C0202042;C2699239;C0455280
myalgia,C0231528;C4552646
oral anti dm drug status no,C0442027;C4521986
rhabdomyolysis,C0035410;C4552660
metformin alone,C0025598;C0205171;C0439044;C0679994
laboratory evaluations,C0022877;C0220825;C3244292;C4283904
metformin other oral anti dm drugs,C0025598;C0029167;C0175795;C0304289
alt $nmbr$ x uln on two consecutive visits,C1519815;C0205448
concomitant medications in $nmbr$ of subjects no,C0013227;C0802604;C2598133;C4284232
ast $nmbr$ x uln on two consecutive visits,C1519815;C0205448
angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
ck $nmbr$ xuln,C0009212;C0010287;C1872855
p blocking agents selective,C0233660;C0332206
creatinine $nmbr$ $nmbr$ x baseline and above uln,C0168634;C1442488;C1519815
hmg coa reductase inhibitors,C0360714;C2756999;C3539119
creatinine $nmbr$ x baseline,C0168634;C1442488
multivitamins,C0301532;C3714835
mean change s in fasting blood glucose [mg dl mmol l ],C0392747;C0443172;C1705241;C4319952;C0428568;C1261430;C0439268
other plain vitamin preparations,C0042890
f $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
platelet aggregation inhibitors excluding heparin,C0032177;C0019134;C0770546
neither t $nmbr$ dm nor mets,C0011816;C3250443;C0812270;C1705694;C2939420
propionic acid derivatives,C0033482;C0695274;C3540752
metabolic syndrome w o t $nmbr$ dm,C0524620;C0796110
proton pump inhibitors,C0358591;C1384478;C3540020
t $nmbr$ dm,C0011816;C3250443
thiazides,C0541746
a $nmbr$ ez $nmbr$,C0206578
thyroid hormone,C0040135;C4522017
mean age years s d,C0444504;C1510829;C2347634;C2348143
concomitant oral anti dm drugs no a,C0029167;C0175795;C0304289
other forms of,C0348078;C0376315
sulfonylureasb,
atherosclerosis^ n,C0003850;C0004153
thiazolidinedionesc,
multiple $nmbr$ chd risk,C0439064;C1282512
a glucosidase inhibitors $nmbr$,C1512211
factors that confer a,C1521761;C2827422
nateglinide and repaglinide,C0903898;C0246689
$nmbr$ year risk for chd,C0439234;C1282512;C0439508
family history of premature,C0241889;C0151526;C0205252;C4018905
abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol,C0022709;C1305855;C0444686;C1441506;C0439209;C0332849;C0489786;C0681850;C1550501;C1706203;C2349001;C2697811;C1515187;C0442027;C4521986;C0013227;C1254351;C4288115;C3687832;C0042295;C0541154;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408;C0332257;C1552866;C2700399;C0008287;C0017642;C0040372;C0872972;C0289313;C0795660;C1512211;C0050393;C0066535
tg $nmbr$ mg dl n o,C0337445;C0439269
rolofylline dose,C0178602;C0869039;C1114758
hbalc mean s d,C0444504;C2347634;C2348143
$nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline ldl c strata n o,C0168634;C1442488
male n n,C0086582;C1706180;C1706428;C1706429
$nmbr$ and $nmbr$ mg dl,C0439269
ischemic heart disease,C0010054;C0151744
$nmbr$ and,
atrial fibrillation atrial flutter,C0155709
parameter mg dl,C0549193;C0439269;C1704769;C2350001
nyha class when patient was last in stable condition before admission,C1882083;C0030705;C0677946;C3538874;C0184666;C0809949
mets w o t $nmbr$ dm,C0812270;C1705694;C2939420
bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n,C0054015;C0439297;C1095989;C1417808;C2982014;C4284038
a $nmbr$ ez $nmbr$ a $nmbr$ n $nmbr$ n $nmbr$,C0206578;C0369718;C0441922
creatinine clearance by c g ml min,C0151280
a $nmbr$ ezio a $nmbr$ n $nmbr$ n $nmbr$,C0369718;C0441922
medications on admission,C0013227;C0802604;C2598133;C4284232;C0457453
treatment difference $nmbr$ ci,C0008107;C3259781
aldosterone inhibitor,C0002007
apolipoprotein b^,C0003593
iv nitrates,C0022326;C0028125;C4265176
apolipoprotein a i,C0085201;C1677784
rank based on treatment placebo,C0032042;C1696465;C1706408
total cholesterol hdl c,C0023822
baseline variable,C0439828;C4553760
apo b apo a l,C1447574;C4521365
placeboa,
non hdl c hdl c,C1518422;C3715113
atorvastatinb,
treatment difference $nmbr$ cl,C0039798;C0596019;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment lipid interaction,C0023779;C1704675
age y mean sd,C0001779;C2699239
unadjusted hr $nmbr$ ci for $nmbr$ sd increment,C0008107;C3259781
men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
likelihood test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment,C0008107;C3259781
previous a blocker,C0205156;C1552607
apob apoa i,C0085201;C1677784
use,C0042153;C0457083;C1947944
$nmbr$ e $nmbr$,
sexually active $nmbr$,C0241028
ldlc hdlc,C1416822;C1704429
coronary artery,C0205042
ldlc,C1416822
calcium channel,C0006685
apob,C0003593;C3252643
blocker,
apoa i,C0085201;C1677784
angiotensin,C0003018;C4521302
non hdlc,C1518422;C1704429
converting enzyme inhibitor,C0014432;C0919438;C4521603
tc hdlc,C0039411;C1704429;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
angiotensin receptor,C0034787;C1622222
cholesterol,C0008377
oral diabetic agent,C0450442;C1254351;C1521826
febuxostat $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ipss mean sd,C0444504;C2699239;C2347634;C2348143
allopurinol $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ipss qol,C1019118;C0518214;C1998280;C2827405;C3811063
minority,C0026192
bii mean sd,C0444504;C2699239;C2347634;C2348143
cardiovascular disease,C0007222
tadalafil $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gout history mean sd years,C0018099;C0439234
tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history presence of tophi,C0150312;C0392148;C3854307
mild ed n $nmbr$,C2945599;C3538926
recent use of allopurinol within $nmbr$ days of,C1524063;C0002144;C0439228
moderate to severe ed n $nmbr$,C1299393;C3538926
randomization,C0034656
subgroup p interaction p,C1079230;C1515021
mild to moderate renal impairment,C1299392;C1565489
ipss ls mean se,C0023668;C0036919
chlorthalidone vs amlodipine,C0008294;C0051696
ipss qol ls mean se,C0023668;C0036919
chlorthalidone vs lisinopril,C0008294;C0065374
bii ls mean se,C0023668;C0036919
chlorthalidone vs doxazosin,C0008294;C0114873
a $nmbr$ e $nmbr$ n $nmbr$,C1272460
hr $nmbr$ ci univariate cox proportional hazard regression,C0684320;C0684321;C1836830
a $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
pef,C0030771;C1518922;C1542834
mean age years race,C0034510;C1706779;C3853635
ref,C1425988
body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
no ef data,C1511726;C3245479;C3714741
$nmbr$ concomitant medication,C0013227;C3244316;C4284232
hr $nmbr$ ci multivariate cox proportional hazard regression,C0684320;C0684321;C1836830
other forms of atherosclerosis,C0348078;C0376315
hospitalized hf,C0018488;C1313497;C1538440;C3273279
irbesartan n $nmbr$,C0288171
diabetes mellitus type $nmbr$ or $nmbr$,C1320657
clinical,C0205210
metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata,C0524620;C0023824
electrocardiographic findings no,C0438154
$nmbr$ but,
left bundle branch block,C0023211;C0344420;C2828132
figure $nmbr$ percentage of change from treated baseline in ldl cholesterol at week $nmbr$ a and week $nmbr$ b in prespeci ed subgroups treated with ezetimibe added to atorvastatin $nmbr$ mg versus up titration to atorvastatin $nmbr$ mg or atorvastatin $nmbr$ $nmbr$ mg a $nmbr$ atorvastatin $nmbr$ mg a $nmbr$ $nmbr$ $nmbr$ weeks of atorvastatin $nmbr$ mg followed by $nmbr$ weeks of atorvastatin $nmbr$ mg bl baseline bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol hs crp high sensitivity c reactive protein ldl c ldl cholesterol tg triglycerides,C0439165;C1549488;C1561533;C0168634;C1442488;C0332174;C0439230;C1706331;C0332293;C1142985;C1524062;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0547043;C0162621;C0332283;C0062152
atrial fibrillation or flutter,C0004238;C0344434;C1963067;C0016385;C2242390
mn na ve population,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0032659;C1257890
cause of heart failure no,C0015127;C1524003
uplift population,C0032659;C1257890
ischemia,C0022116;C4321499
all mn na ve patients,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0030705
hospitalization for heart failure within previous $nmbr$ mo no,C3898876;C0026544;C0332177
all non mn,C0026327;C0026405;C4285072
angina symptoms^,C0858277
sex m f,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0016327
pci orcabg,C4049621
active smokers,C0205177;C0337664;C3853793;C3888249
stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
copd history yrs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
quality of life,C0034380;C0518214
pre fev $nmbr$ pred,C0032952;C0044955
score on the minnesota living with heart failure scaled,C0449820;C4050231;C0018801;C0018802;C4554158;C0175659;C0349674;C1947916
post fev $nmbr$ pred,C0032952;C0044955
hemoglobin,C0019046
pre fvc pred,C0032952;C0044955
mean g dl,C0444504;C0439267;C2347634;C2348143
post fvc pred,C0032952;C0044955
anemia no,C0002871;C1000483;C4554633
$nmbr$ day l,C0332173;C0439228;C0439505
mean ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0444504;C0439445;C2347634;C2348143;C0005902
$nmbr$ month l,C0332177;C0439231
potassium mmol liter,C0032821;C0475211;C0202194;C0304475;C0597277;C3714637
$nmbr$ yrs l,
nt probnp pg ml,C0669479;C0439297;C0754710
decline ml yr $nmbr$,C0439526;C0439234;C1705224;C3887665
medication no,C0013227;C3244316;C4284232
pre fev $nmbr$,C0332152;C3714541;C0740175;C2257086;C3669034
diureticff,
post fev $nmbr$,C0687676;C3714541;C1704687;C3469826
loop,C0445022
pre fvc,C0332152;C3714541;C0740175;C2257086;C3669034
thiazide,C0541746
post fvc,C0687676;C3714541;C1704687;C3469826
antiarrhythmic drug,C0003195;C0301380
pre svc,C0332152;C0231957;C0740175;C2257086;C3669034
antiplatelet,
post svc,C0687676;C0231957;C1704687;C3469826
glipizide n $nmbr$,C0017642
duration of diabetes mellitus median iqr y,C0449238;C2926735
plus minus values are means sd percentages may not total $nmbr$ because of rounding the body mass index is the weight in kilograms divided by the square of the height in meters to convert the values for creatinine to micromoles per liter multiply by $nmbr$ $nmbr$ ace denotes angiotensin converting enzyme cabg coronary artery bypass grafting nt probnp n terminal pro b type natriuretic peptide nyha new york heart association and pci percutaneous coro nary intervention race was reported by the investigators one patient in nyha class i was mistakenly included in the placebo group this category includes any angina like symptoms at any time in the past with no confirmation of diagnosis of coro nary heart disease required possible scores range from $nmbr$ to $nmbr$ with lower scores indicating a better quality of life anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women nt probnp levels are influenced by a variety of factors including age sex body mass index and renal function no clinically useful normal range has been established some patients were taking both loop and thiazide diuretics,C0042295;C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074;C0010294;C1561535;C0439300;C1719797;C2911648;C1452534;C4284014;C0040744;C1279380;C0034510;C1706779;C3853635;C1709908;C1882084;C0332257;C0032042;C1696465;C1706408;C0683312;C3889287;C1552866;C2700399;C0858277;C0040223;C3541383;C0521091;C0596672;C0441994;C0449820;C1548802;C2003888;C0002871;C1000483;C4554633;C1704788;C3539106;C1281911;C0439267;C0439241;C0025266;C0669479;C0754710;C0814287;C0232804;C3827682;C0086715;C0443211;C1272684;C0030705;C0445022;C0012802
dyslipidemia n,C0242339
irbesartan,C0288171
prior myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
no of patients no of events $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705;C0441471;C3541888
presenting condition n,C0449450;C0012634;C0348080;C1705253;C3864998
use of beta blocker,C1524063;C0001645
acute coronary syndrome,C0948089
hospitalization for heart failure within $nmbr$ mo,C3898876;C0026544;C0332177
elective procedure,C0747973
baseline procedure n,C0168634;C0184661;C2700391;C3274430;C3539779;C1442488
the plot shows hazard ratios and $nmbr$ confidence intervals for the primary outcome with patients stratified according to eight sub groups prespecified in the statistical analysis plan no heterogeneity was observed for these subgroups,C1547282;C2985465;C0009667;C0205225;C0439612;C0439631;C0030705;C0205363;C0205454;C3889277;C0019409;C0242960;C1441672;C1079230
medication use n,C0240320
atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$,C1319635;C3643658
other antiplatelet,
atorvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fibrate or other lipid lowering agent,C0086440
ncep atp iii risk factors,C0035648;C1553898
serum creatinine mean sd mg dl,C0201976;C0439269;C0600061
the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides,C0023824;C0202117;C0439269;C0205195;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2360800;C0332257;C0023822;C1442160;C0392885;C0025266;C0043210;C0062152
hemoglobin a $nmbr$ c mean sd,C0019020;C2699239;C3889898
other forms of atherosclerosis^,C0348078;C0376315
bnp median iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$,C0035648;C1282512;C1553898;C0439234;C0439508
fasting insulin median iqr gu ml,C0015663;C0439526;C1705224;C3887665
family history of premature chdj,C0241889;C0151526;C0205252;C4018905
ldl cholesterol mean sd mg dl,C0023824;C0439269;C0202117
metabolic syndrome $nmbr$ of $nmbr$ characteristics,C0524620;C1521970
hdl cholesterol mean sd mg dl,C0023822;C0439269;C0392885
waist circumference s $nmbr$ men or $nmbr$ cm women,C0455829;C0025266;C0043210
triglycerides median iqr mg dl,C0041004;C0439269
triglycerides $nmbr$ mg dl,C0041004;C0439269
hscrp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
fasting blood glucose $nmbr$ mg dl,C0428568;C0439269;C1261430
mmp $nmbr$ median iqr gg l,C0017454;C0018370
visit $nmbr$ ldl cholesterol strata,C0023824;C0202117
as,
eu,C0015179;C3665627
sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
cardiac procedure,C1279986
prior oad,C0332152;C2826257
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd dened as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
drug naive,C0013227;C1254351
benazepril amlodipine group n $nmbr$,C0051696;C0441848
low dose combination therapy,C0009429;C0556895
benazepril hydrochlorothiazide group n $nmbr$,C0717481;C0441848
metformin monotherapy,C0025598
race or ethnic group no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0016327
su monotherapy,C0038642;C1705534
nordic countries,C0036273
smi,
systolic bp at baseline,C0871470;C0168634;C1442488
body mass index blood pressure mm hg,C0005893;C0439475;C0578022;C1305855
$nmbr$ mmhg,C0439475
pulse beats min,C0232117;C0439385;C0391850;C1947910
statin use at baseline,C0042153;C0457083;C1947944
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C3811844;C0439445;C0005902
diabetes duration,C0449238;C2926735
serum values^,C0229671;C0042295;C1546774;C1550100
hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
high density lipoprotein cholesterol mg dl,C0023822;C0439269
hdl c at baseline,C3715113;C0168634;C1442488
previous antihypertensive treatment no,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ldl c at baseline,C0168634;C1442488
no of agents,C0450442;C1254351;C1521826
triglycerides at baseline,C0041004;C0168634;C1442488
antiplatelets agents,C0085826
hscrp at baseline,C0168634;C1442488
risk factors no,C0035648;C1553898
percent atheroma volume at baseline,C1690016;C3887614
previous hospitalization for unstable angina,C0019993;C0002965
without baseline vertebral fracture,C0168634;C0080179;C1442488
renal disease,C0022658
with baseline vertebral fracture,C0168634;C0080179;C1442488
previous coronary revascularization,C0205156;C0877341;C1552607
flex pbo,C0031962
number of patients or mean sd,C2360800;C0444504;C2699239;C2347634;C2348143
flex ain,C0347129
sitagliptin n $nmbr$,C1565750
flex aln^,C0729594;C2681220
nationality,C0027473
body mass index kg m^ meanisd,C0022718;C0439209;C4054209
indian,C1524069
fall in last $nmbr$ months,C0085639;C0238715;C4553726
korean,C1556095
history of clinical fracture $nmbr$ years,C1272071;C0205210
weight range kg,C0022718;C0439209;C4054209
duration alendronate use years meanisd,C0102118;C0042153;C0457083;C1947944
body mass index range kg m $nmbr$,C0022718;C0439209;C4054209
using alendronate at baseline,C1524063;C0102118;C0168634;C1442488
duration of type $nmbr$ diabetes mellitus years,C0449238;C2926735
using hrt or raloxifene at baseline,C1524063;C0282402;C0244404;C0168634;C1442488
all randomized patients range,C1514721;C2348147;C3542016
time since start of fit years meanisd,C1301880
naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C1363945
time from end of fit years meanisd,C1522314
fpg range mmol l,C1514721;C1532563;C2348147;C3542016
flex baseline bmd g cm^ meanisd,C0168634;C0439267;C1442488
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
ls mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
flex baseline bmd t score at femoral neck meanisd,C0449820;C4050231
ls mean between group difference $nmbr$ ci,C2347634;C0008107;C3259781
$nmbr$ $nmbr$ fn t score,C0449820;C4050231
hba $nmbr$ c all countries,C0019016;C0454664;C1825777;C3538758
$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$,C0449820;C4050231
sitagliptin,C1565750
fn t score $nmbr$ $nmbr$,C0449820;C4050231
china,C0008115
flex baseline bmd t score at lumbar spine meanisd,C0449820;C4050231
india,C0021201;C2700456
$nmbr$ $nmbr$ ls t score,C0449820;C4050231
korea,C0022771
$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$,C0449820;C4050231
sitagliptin $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ fasting plasma glucose fpg mmol l,C0202042;C1532563;C0455280
ls t score $nmbr$ $nmbr$,C0449820;C4050231
all countries,C0454664
change in femoral neck bmd from fit baseline to flex baseline,C0742135;C0036572;C0168634;C1442488;C2349186;C4048158;C4553125
sitagliptin $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ h postprandial plasma glucose ppg mmol l,C2827804;C0202042;C0455280
gained bmd,C1517378
week o baseline mean sd,C0168634;C2699239;C1442488
lost bmd,C0745777;C3815882
ls mean difference between treatment groups $nmbr$ ci,C1705241;C2347634;C1705242
femoral neck f score at flex baseline,C0016327;C0449820;C4050231
fasting indices,C0015663;C4033634
nonvertebral,
morphometric vertebral,C0549207
fasting insulin miu ml,C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
pbo no o o ^,C0031962;C0483204
placebo $nmbr$,C0032042;C1696465;C1706408
sitagliptin $nmbr$,C1565750
ain no,C0347129
pbo no ^,C0031962
fasting proinsulin pmol l,C0015663;C0033362;C0439284;C3813208
nvf at flex baseline $nmbr$ flex fn t score,C0168634;C0449820;C4050231;C1442488
fasting c peptide ng ml,C0015663;C0006558;C0439275
homa b,
$nmbr$ $nmbr$ flex fn f score $nmbr$,C0449820;C4050231
homa ir,C0022065;C0022071;C1448132
flex fn f score $nmbr$ $nmbr$,C0449820;C4050231
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ z,
p value for interaction vertebral fracture at flex baseline,C1709380;C0080179;C0168634;C1442488
quicki,
$nmbr$ flex fn f score,C0449820;C4050231
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ y,
nateglinide n $nmbr$,C0903898
postprandial indices,C0376674;C4033634
race no i,C0034510;C1706779;C3853635;C0021966;C0221138
$nmbr$ h postprandial insulin miu ml,C0021641;C0439457;C1533581;C1579433;C3714501
body mass index^,C0005893;C0578022;C1305855
$nmbr$ h postprandial proinsulin pmol l,C2827799;C0033362;C3813208
waist circumference cmj,C0455829
$nmbr$ h postprandial c peptide ng ml,C2827809;C0006558
blood pressure while seated mm hg,C0005823;C1271104;C1272641;C0277814;C0439475;C1283233
insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min,C0600653;C0702093;C1524029;C3813700;C0918012;C1552854;C1637833;C2986546
family history of premature heart disease,C0850707
placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
reduced hdl cholesterol,C0151691
composite index of insulin sensitivity isi,C0600653;C0918012;C1552854;C1637833;C2986546
elevated non hdl cholesterol,C0729627;C1535899
disposition index,C0743223;C0600653;C0918012;C1552854;C1637833;C2986546;C1705555
history of cardiovascular disease no,C0455539
no hypertension n $nmbr$,C0020538;C1963138
angina or positive stress test,C0002962;C0015260;C3494508
hypertension n $nmbr$,C0020538;C1963138
multivessel coronary artery bypass grafting,C0010055
ecg abnormality resting,C0035253;C1512899
peripheral arterial stenosis,C4025272
tc mmol l mg dl,C1532980
lower limb angioplasty or bypass surgery,C0745788;C1536078
ldl c mmol l mg dl,C1532980
nontraumatic leg or foot amputation,C0023216;C1140621;C0188605
hdl c mmol l mg dl,C1532980
family history of diabetes mellitus no,C0260526;C1313937
tg mmol l mg dl [median],C1532980;C0549183;C0876920;C2347635;C2348144;C2939193
plasma glucose mmol per liter,C0202042;C0439190;C0455280
antihypertensive drug,C0003364
fasting,C0015663
total antihypertensive use,C0042153;C0457083;C1947944
$nmbr$ hr after glucose challenge,C3840385
^ blocker,
metabolic syndrome no ^,C0524620
angiotensin ii receptor blocker,C0521942;C3536793
lipids mg dl,C0023779;C0439269
event patients in group incidence $nmbr$ person year,C0030705;C0021149;C0220856
estimated gfr ml min $nmbr$ $nmbr$ m^,C0017654;C0439445;C1424601
diet group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ratio of urinary albumin mg to creatinine g,C0456603;C1547037;C0010294;C0439267;C1561535
diet pravastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
last study visit,C0545082;C1512346;C2826704
non dm,C1518422;C0011816;C3250443
alpha blocker,C0001641
current past,C0521116;C1705970
uncontrolled,C0205318
aspirin or other antiplatelet drug,C0004057;C0085826
controlld,
lipid modulating drug,C0023779;C0443264;C0013227;C1254351
with placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
antidiabetic drug i j,C0935929;C0021966;C0221138
with alogliptin $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
with alogliptin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nateglinide n n,C0903898
age group n,C0441848
hazard ratio $nmbr$ cl nateglinide vs placebo,C2985465;C0903898;C0032042;C1696465;C1706408
black african american,C0085756
two sided p value for hetero geneity,C0205448;C1709380
native hawaiian other,C0337920
all patients p $nmbr$ $nmbr$,C0030705
alaska native,C0682125
aslan,
baseline hba $nmbr$ c n,C0168634;C0019016;C1825777;C3538758;C1442488
fasting plasma glucose,C0202042;C0455280
patients $nmbr$,C0030705
$nmbr$ hr prandial glucose,C1998602;C0017725;C4553624
diabetes duration years,C0011847;C0439234;C0011849
body mass index[kh m^],C0005893;C0578022;C1305855;C0006797;C4554575
glyburide dose duringthe study mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
waist circumference[cm female cm male ],C0455829;C0086582;C1706180;C1706428;C1706429
with placebo,C0032042;C1696465;C1706408
history of cardiovascular disease,C0455539
with alogliptin $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ace inhibitor treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
n $nmbr$ $nmbr$,C0369718;C0441922
extended cardiovascular endpoint,C2349179;C2826544
baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
body mass index[kg m^],C0005893;C0578022;C1305855;C0022718;C0439209;C4054209
male n $nmbr$,C0086582;C1706180;C1706428;C1706429
section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
female n $nmbr$,C0043210;C0086287;C1705497;C1705498
core cardiovascular endpoint,C2349179;C2826544
hispanic or latino n $nmbr$,C0086409;C0086528
[kg m^],C0022718;C0439209;C4054209
not hispanic or latino n $nmbr$,C1518424;C0086528
[cm female cm male ],C0086582;C1706180;C1706428;C1706429
baseline body mass index,C0005893;C0578022;C1305855
sitting blood pressure mmhg,C0580946;C0439475
$nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
peripheral artery stenosis,C0038449
aliskiren n $nmbr$,C1120110
stroke of atherosclerotic origin,C0038454;C4554100
hydochlorothiazide n $nmbr$,
glycemic indexes,C1136206
obese patients n,C0028754;C0030705
fasting plasma glucose mmol liter,C0202042;C0475211;C0455280
diabetes mellitus n,C0011849
plasma glucose $nmbr$ hr after glucose load mmol liter,C0202042;C0455280
duration of hypertension y,C0449238;C2926735
metabolic syndrome no $nmbr$,C0524620
mssbp mm hg,C0439475
estimated gfr^,C0017654;C1424601
msdbp mm hg,C0439475
mean ml min $nmbr$ $nmbr$ m^,C0444504;C0439445;C2347634;C2348143
ratio of urinary albumin mg to creatinine g median,C0456603;C1547037;C0549183;C0876920;C2347635;C2348144;C2939193
values are presented as mean sd unless stated otherwise data shown are for the randomized population body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group obesity was defined as body mass index $nmbr$ kg m $nmbr$ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection evaluation and treatment of high blood cholesterol in adults adult treatment panel iii criteria $nmbr$ as any $nmbr$ of the following waist circumference $nmbr$ cm for men or $nmbr$ cm for women triglycerides $nmbr$ mg dl high density lipoprotein cholesterol $nmbr$ mg dl for men or $nmbr$ mg dl for women mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg fasting glucose $nmbr$ mg dl by medical history aliskiren n $nmbr$ hydrochlorothiazide n $nmbr$,C0042295;C0449450;C0444504;C2347634;C2348143;C1511726;C3245479;C3714741;C1547282;C0005893;C0578022;C1305855;C1551393;C1705492;C3272743;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0030705;C0020261;C1704788;C3539106;C0524620;C0220825;C1261322;C0596197;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455829;C0025266;C0023822;C0439269;C0439475;C0262926;C1704706
concomitant medication no ace inhibitor,C0013227;C3244316;C4284232;C0003015;C4541021
aliskiren,C1120110
any antihypertensive drug,C0003364
hydrochlorothiazide,C0020261
aspirin orother antiplatelet drug,C0004057
$nmbr$ y n $nmbr$,
antidiabetic drug,C0935929
baseline mssbp msdbp mm hg,C0168634;C0439475;C1442488
progression to diabetes,C1735364
change in bp mm hg,C1268766;C0439475
hazard ratio $nmbr$ cl valsartan vs placebo,C2985465;C0216784;C0032042;C1696465;C1706408
msdbp,
fenofibrate n $nmbr$,C0033228
changes from baseline in mssbp and msdbp are shown as least squares mean sem p $nmbr$ $nmbr$ vs $nmbr$ y,C0392747;C0443172;C1547282;C0023189
education no,C0013621;C0013622;C0013658;C0039401
placebo statin n $nmbr$ $nmbr$,C0032042;C0360714;C1696465;C1706408
high school graduate or ged,C0870649;C1549971;C1880947
ezetimibe $nmbr$ mg statin n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
missing data,C4684714
cad,C1504769;C2239547;C3813548;C4284121
previous cardiovascular event no,C0205156;C1320716;C1552607
crp mean mg dl sd,C0439269;C2699239
previous congestive heart failure no,C0205156;C0018802;C1552607
ldl cholesterol mean mg dl sd,C0023824;C2699239;C0202117
cigarette smoking status no,C1519386
triglycerides mean mg dl sd,C0439269;C2699239
amputation due to diabetes no,C0678226;C0598284
high density lipoprotein cholesterol mean mg dl sd,C0023822;C2699239
estimated glomerular filtration rate no,C3811844
$nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides,C1705241;C1705242;C1142985;C0360714;C0032042;C1696465;C1706408;C0392747;C0443172;C4319952;C3890735;C4048285;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0062152
plasma cholesterol mg dl,C0858034;C0439269
parameter variable,C0439828;C4553760
plasma triglyceride mg dl,C0032105;C0439269;C1550098;C4521445
amlodipine vaisartan n $nmbr$,C0051696
patient characteristics at randomization,C0815172;C0034656
age $nmbr$ years n,C1510829
f emale,C0016327
age years [median $nmbr$ th to $nmbr$ th percentile ],C1510829;C0039725;C0039738;C1420718;C4282123;C4285344
race ethnicity n,C0034510;C0015031;C0243103;C1706779;C3853635
weight kg m $nmbr$ [median $nmbr$ th to $nmbr$ th percentile ],C0022718;C0439209;C4054209;C0039725;C0039738;C1420718;C4282123;C4285344
hispanic black,C0005680;C0027567;C0085756;C0439541
bmi kg m $nmbr$ [median $nmbr$ th to $nmbr$ th percentile ],C0022718;C0439209;C4054209;C0039725;C0039738;C1420718;C4282123;C4285344
mean bmi kg m $nmbr$ s d,C1275571
antidiabetes drug usage [ n ],C0242510;C0369718;C0441922
biguanide metformin,C0005382;C0025598;C3537187;C4317165
mean blood pressure mmhg s d j,C0428886;C0488053
thiazolidinedione,C0289779;C1257987;C3537039
severity n,C0439793;C0522510
a glucosidase inhibitor,C1512211
mean pulse pressure mmhg s d,C0445074;C2347155
meglitinide,C0065880
populations,C0032659;C1257890
no antidiabetic drug,C0935929
intent to treat population n,C0087111;C0032659;C1257890;C1292734;C1522326
monotherapy,
safety population n,C0036043;C0032659;C1257890;C1705187
dual therapy,C0039798;C0087111;C1363945
figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup,C3484017;C3484018;C0168634;C1442488;C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1079230;C0005680;C0027567;C0085756;C0439541;C1305855;C0745133;C0237753;C0449788;C0030705;C1292734
three or more drugs,C0205449;C0013227;C3687832
all patients n $nmbr$,C0030705
patient characterization data are reproduced from morrow et al $nmbr$,C2707520;C1880022;C0040028;C0202311
patients with fistulas at baseline,C0030705;C0016169;C0168634;C1442488
patients with possible new dm at randomization fpg $nmbr$ $nmbr$,C0030705;C0011816;C3250443;C0034656
adalimumab n $nmbr$,C1122087
fpg month $nmbr$ mg dl,C0332177;C0439269;C0439231
all patients with fistulas n $nmbr$,C0030705;C0016169
change in fpg $nmbr$ to month $nmbr$ mg dl,C0392747;C0443172;C1705241;C4319952;C0332177;C0439269;C0439231
male no,C0086582;C1706180;C1706428;C1706429
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0008107;C3259781
baseline cdai score mean sd,C0168634;C2699239;C1442488
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
crp concentration $nmbr$ $nmbr$ mg dl $nmbr$ mg l n,C2827881
interaction,C1704675
previous tnf antagonist exposure n,C0205156;C0231491;C1552607
patients with possible new dm at randomization hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$,C0030705;C0011816;C3250443;C0034656;C0019016;C1825777;C3538758
any glucocorticoid,C0017710
hba $nmbr$ c month $nmbr$,C0332177;C0439231
$nmbr$ mercaptopurine,C0000618
change in hba $nmbr$ c $nmbr$ to month $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332177;C0439231
no draining fistulas,C0013103;C0180499;C4265177;C0016169
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ a $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
week $nmbr$ of patients,C0332174;C0439230;C0030705
febuxostat $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no baseline immunosuppressant use,C0042153;C0457083;C1947944
febuxostat $nmbr$ mg daily n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
both adalimumab groups n $nmbr$,C1122087;C0441848
allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
american indian or alaska native,C0002460;C0682125
baseline immunosuppressant use,C0042153;C0457083;C1947944
native hawaiian or other pacific,C0337920
no baseline cd related antibiotic use,C0042153;C0457083;C1947944
islander,
baseline cd related antibiotic use,C0042153;C0457083;C1947944
non ex drinker,C0457801
exenatide,C0167117
drinker $nmbr$ to $nmbr$ drinks week,C0556338;C0332174;C0439230
biasp $nmbr$,
serum urate mg dl,C0455272;C0439269
bid,
years with gout,C0439234;C0018099
qd,C0332173
completed previous febuxostat study,C2348557;C0205156;C1552607
subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811;C0034656;C3815594
renal functionb,C0022646
american indian alaska native,C0886378
moderately impaired,C0205081;C0221099;C1881878;C4085643;C4321491
black or african american,C0005680;C0027567;C0085756;C0439541
mildly impaired,C0750532;C0221099;C2945599
not hispanic or latino,C1518424;C0086528
normal,C0205307;C0231683;C0439166;C2347086;C4553972
subject completion status n,C3891295
including hypertension,C0020538;C1963138
completed trial,C0205197;C0008976;C3854010
use of low dose aspirin $nmbr$,C1524063;C2608320
discontinued,C1444662
mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
adverse eventy,
febuxostat $nmbr$ mg daily n $nmbr$ n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ineffective therapy,C0039798;C0087111;C1363945
renal functiona,C0022646
non compliance,C0376405;C0457432
baseline serum urate mg dl a,C0455272;C0439269
otherz,
baseline tophusa,C0168634;C1442488
diabetic history years x,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
completed prior febuxostat studya,C0205197;C0249529;C3854010
figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively,C0565965;C0019016;C1825777;C3538758;C0168634;C1442488;C0042295;C0167117;C0332173;C0243174
age $nmbr$ y n n,C0001779
dexlansoprazole mr,C0024485;C1417249;C2347167;C3254418;C4050513
white n n,C0007457;C0043157;C0220938
$nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diabetes mellitus n n,C0011849
non hispanic or latino,C1518424;C0086528
hypertension n n,C0020538;C1963138
native hawaiian or other pacific islander,C0337920;C0242191
hyperlipidemia n n,C0020473;C0428465;C4555212
age y mean s d,C0001779;C0444504;C2347634;C2348143
metabolic syndrome n n,C0524620
weight kg mean s d,C0005910;C1275571;C0043100;C1305866;C1705104
current smoker n n,C3173209;C3241966
height cm mean s d,C0439392;C0444504;C2347634;C2348143
prior mi n n,C0332152;C2826257
bm $nmbr$ kg m $nmbr$ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
prior coronary revascularization n n,C0332152;C0877341;C2826257
helicobacter pylori negative n,C4688581
prior angina n n,C0332152;C0002962;C2826257
eo severity by la classification at baseline baseline of the healing study n,C0439793;C0522510;C0168634;C0043240;C0205249;C1442488
prior heart failure n n,C0018801;C0018802;C4554158
d,
timi risk score n n,C0035647;C0449820;C4050231;C4552904
duration of treatment in the healing study n,C0444921;C0043240;C0205249
index event n n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
previous treatment in the healing study n,C1521826;C3161471
ua,C0041580;C0042014
dexlansoprazole mr $nmbr$ mg qd,C0024485;C0332173;C1417249;C2347167;C3254418;C4050513
nstemi,C3537184;C4255010
lansoprazole $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time from symptoms to randomization h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
characteristic age mean sd yr,C0001779;C0439234
women n $nmbr$ n n,C0043210
dronedarone n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0766326
men n $nmbr$ n n,C0025266
placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
angiography and revascularization,C0002978;C0581603
all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
angiography during index hospitalization,C0002978;C0019993
structural heart disease no f,C1290384;C0016327
angiographic extent of disease,C0449279;C4553144
$nmbr$ vessel,C0005847
coronary heart disease no,C0010054;C0010068;C1956346
$nmbr$ vessels,C0005847
valvular heart disease no,C0018824;C1963123
$nmbr$ vessels or left main,C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
nonischemic cardiomyopathy no,C0878544
pci during index hospitalization,C4049621;C0019993
history of chf nyha class ii or iii no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439070;C1705160
cabg during index hospitalization,C0010055;C0019993
lvef no i,C0428772;C0488728;C0021966;C0221138
gpiib iiia receptor inhibitor,C0016011;C1999216
lone atrial fibrillation no,C0340489
diabetic treatments,C0241863;C0087111
pacemaker no,C0030163;C0810633;C1546728;C3275122;C3853703
oral agents,C0450442;C1254351;C1521826
medications in use at baseline no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
diet alone,C0012155;C0012159;C1519433;C2983588;C3668949;C0205171;C0439044;C0679994
vitamin k antagonists,C3653316
p interaction women vs men,C0369773;C0043210;C2603361;C0025266
early eptifibatide group n $nmbr$,C0253563;C0441848
p $nmbr$ interaction women vs men,C0369773;C0043210;C2603361;C0025266
delayed eptifibatide group n $nmbr$,C0205421;C0441848;C1545665;C3272602
azathioprine n $nmbr$,C0004482
median yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
infliximab n $nmbr$,C0666743
interquartile range yr,C1711350;C0439234
combination therapy n $nmbr$,C0009429;C0556895
region ofenrollment,C0017446;C0205147
p valued,C0369773;C2603361
middle east africa or asia pacific,C0001741;C0003980
white race no t,C0007457;C0043157;C2603360
median ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
median age yr,C0001779;C0439234
interquartile range ml min,C1711350;C0439445
median body weight kg,C0022718;C0439209;C4054209
killip class ii iii or iv,C2697846;C0022326;C4265176
median disease duration yr,C0872146;C0439234
qualifying high risk features,C1514624;C0035648
median c reactive protein mg dl^,C0006560;C0439269;C1413716;C4048285
age $nmbr$ yr elevated biomarkers and st segment changes,C0001779;C0005516;C0232326
crohn s disease activity index score],C0010346;C4706353;C0600653;C0918012;C1552854;C1637833;C2986546
age $nmbr$ yr and elevated biomarkers,C0001779;C0439234;C0205250;C0005516;C3163633
gastrointestinal area involved no total no,C0017446;C0205146;C1314939;C0439175;C0439810
elevated biomarkers and st segment changes,C0205250;C0005516;C3163633;C0232326
ileum or colon,C0020885;C0009368;C3888384
age $nmbr$ yr and st segment changes,C0001779;C0439234;C0232326
ileum only,C0020885
age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular,C0001779;C0005516;C0005847;C1558950;C1801960
colon only,C0009368;C3888384
presentation to tertiary care hospital,C0449450;C0337954
proximal gastrointestinal tract,C0017189;C0521362
randomized,C0034656;C3815594
systemic corticosteroids no,C4053960
low $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
any type according to daily dose,C0332307;C1547052
intermediate $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
budesonide no,C0054201
high $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
$nmbr$ aminosalicylic compounds no,C0205198;C1706082
medical therapy during index hospitalization,C0418981;C0019993
proportion of patients in corticosteroid free clinical remission at week $nmbr$,C1709707;C0030705;C0205210;C0544452;C0687702
antithrombin,C0003438;C0003440;C4521254
ifx aza n $nmbr$,C0020823;C0004482
unfractionated heparin only,C0019134;C2825026
aza n $nmbr$,C0004482
low molecular weight heparin only,C0019139;C3536766
crohn s disease related surgery,C0010346;C0038894;C0038895;C0543467;C1274039
both unfractionated heparin and low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
with previous surgery,C0038894;C0038895;C0543467;C1274039
neither unfractionated heparin nor low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
without previous surgery,C0038894;C0038895;C0543467;C1274039
at any time,C0040223;C3541383
baseline corticosteroid use mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
early use intended,C0042153;C0457083;C1947944;C1283828;C1551357
with corticosteroid treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
temporal data and management strategy,C1511726;C3245479;C3714741;C0001554;C0679199;C0376636;C1273870;C3273539
duration of crohn s disease yrs,C0449238;C2926735;C0012634
time from onset of symptoms to presentation hr,C1320528;C0449450
baseline crp mg dl,C0168634;C0439269;C1442488
time from presentation to randomization hr,C0040223;C3541383;C0034656
europe lsrael,C0015176
time from randomization to study drug initiation hr,C0040223;C3541383;C0013175;C0589507;C1158830;C1704686
baseline $nmbr$ asa,C0004057;C3853627
time from randomization to coronary angiography hr,C0040223;C3541383;C0085532;C1548829
use $nmbr$ asa compounds,C0205198;C1706082
pci no,C4049621
no use of $nmbr$ asa compounds,C1524063;C0004057;C3853627
time from randomization to pci hr,C0040223;C3541383;C4049621
total group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
duration of infusion before pci hr,C0449238;C2926735;C4049621
ifx n $nmbr$,C0020823
duration of infusion after pci hr,C0449238;C2926735;C4049621
enox,C3147679
cabg no,C0010055
no dm,C0011816;C3250443
time from randomization to cabg hr,C0040223;C3541383;C0010055
no prior ml,C0439526;C1705224;C3887665
duration of infusion before cabg hr,C0449238;C2926735;C0010055
fibrinolytic,C0040044
medical management only no,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
fibrin specilic,C0015982
duration of infusion during medical management hr,C0449238;C2926735;C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
time to rx,C0040223;C3541383
early eptifibatide,C1279919;C0253563
amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
amlodipine $nmbr$ to $nmbr$ mg n $nmbr$,C0051696;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
troponin,C0041199
age sd yrs,C0001779;C2699239
positive,C0439178;C1446409;C1514241;C2825490;C3812269
age category n,C0001779;C0683312;C3889287
early clopidogrel intended,C1279919;C0070166;C1283828;C1551357
hypertension severity at baseline n,C0439793;C0522510
time to randomization,C0040223;C3541383
diabetic status n,C0241863;C0449438
heparin use,C0239945
ish status n,C0449438
unfractionated only,
bmi n,C0578022
low molecular weight only,C0041667
tiotropium nz $nmbr$,C0213771;C0027978
type of hospital care,C0332307;C1547052
control nz $nmbr$,C0243148;C0027978;C1550141;C1882979;C2587213;C3274648;C4553389
tertiary,C0205372
a demographics,C0011298;C1704791
region of the world,C0017446;C0205147
history pack years,C0019664;C1277691;C0019665;C0262512;C0262926;C1705255;C2004062
region ofthe world,C0017446;C2700280;C0205147
gold stage [n ],C0205390;C1300072;C1306673;C0369718;C0441922
patient characteristics,C0815172
pre bronchodilator,C2599602
arterial hypertension n,C0020538
post bronchodilator,C2599594
insulin requiring,C0021641;C1533581;C1579433;C3714501
patients with $nmbr$ $nmbr$ ml increase in fev $nmbr$ post bronchodilator,C0030705;C0439526;C1705224;C3887665;C3714541;C2599594
history of mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fvc predicted,C3714541;C0681842;C1882327
history of cabg surgery n,C0455610;C0010055
b concomitant respiratory medications [n ],C0521115;C0418986;C0369718;C0441922
infarct characteristics,C0021308;C1521970
any pulmonary medication,C0013227;C3244316;C4284232
infarct localization n,C0021308;C0475264;C1744691
anti cholinergics long acting,C0242896;C0205166;C1706317
killip class n,C1881332
anti cholinergics short acting a,C0242896;C1282927;C1806781;C2350002
arterial blood pressure mm hg,C1272641;C0439475
b agonists long acting a,C0243192;C2987634;C0205166;C1706317
peak creatine kinase mb u l,C0010290;C0439339;C0523584
b agonists short acting a,C0243192;C2987634;C1282927;C1806781;C2350002
value for nteraction,C1522609
leukotriene receptor antagonists,C0595726;C2757015;C3542962
$nmbr$ $nmbr$ yrs,
mucolytics,C0026698
history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
steroids inhaled a,C0038317;C0004048
steroids other,C0038317
infarct localization,C0475264;C1744691
theophyllines,C0039771
non anterior,C1518422;C0205094
mean yearly decline,C0332181;C0439508
interval pain onset to admission,C1507009;C0184666;C0809949
pred,C0032952;C0044955
interval study drug to pci,C1272706;C0013175;C1552654;C1552713
fev $nmbr$ pre bronchodilator,C3714541;C2599602
interval clopidogrel to pci,C1272706;C0070166;C1552654;C1552713
fev $nmbr$ post bronchodilator,C3714541;C2599594
clopidogrel plus aspirin n $nmbr$,C0070166;C0004057
fvc pre bronchodilator,C3714541;C2599602
aspirin n $nmbr$,C0004057
fvc post bronchodilator,C3714541;C2599594
chads $nmbr$ ^,C0007928;C1413373
baseline parameter,C0549193;C1704769;C2350001
mean score,C3533236
number of subjects,C0237753;C0449788
score no,C0449820;C4050231
asthma duration sd years,C0004096;C0439234;C2984299
history of atrial fibrillation type no,C0729790;C0332307;C1547052
fev $nmbr$ percent predicted sd,C0439165;C2699239
permanent,C0205355
am pef sd l min,C0702093;C1524029;C3813700
paroxysmal,C0205311
persistent,C0205322;C0332996
pm pef sd l min,C0702093;C1524029;C3813700
atrial fibrillation duration no,C0449238;C2926735
symptom score sd,C3476546;C2699239
$nmbr$ mo to $nmbr$ yr,C0026544;C0332177
albuterol use sd puffs day,C0332173;C0439228;C0439505
history of hypertension no,C0455527
figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean,C0030771;C1518922;C1542834;C1707156;C3274014;C3541345;C1882932;C1710181
history of stroke or tia no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean,C0392747;C0443172;C1705241;C4319952;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
history of ischemic heart disease no,C0683519;C0730226;C0850708;C0944983
figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean,C0436315;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
peripheral artery disease no,C1704436;C4025272
nyha ll lll patients with lvef,C1275491;C0030705;C0428772;C0488728
cardiac pacemaker no,C0030163;C0037189
remaining patients,C1527428;C0030705
ecg findings at baseline no,C0438154;C0168634;C1442488
age years sd,C1510829;C2699239
atrial flutter,C0004239;C0344423;C1963068
ischaemic dilated cardiomyopathy,C1960867
medication use at baseline no,C0240320;C0168634;C1442488
non rheumatic valvular heart disease,C1518422;C0264757
vka,
non ischaemic dilated cardiomyopathy,C1518422;C1960867
antiarrhythmic agent,C0003195;C0301380
hr [ $nmbr$ ci,C0008107;C3259781
reason for enrollment in active a no,C0392360;C0205177;C3853793;C3888249
overall population,C0032659;C1257890
specific risk of bleeding^,C0205369;C3251812;C1552740
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
physician s judgment that vka inappropriate],C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
left ventricular ejection fraction $nmbr$ $nmbr$ and nyha class ii iii at baseline,C0428772;C0488728;C1882086
patient s preference not to take vka only reason,C0030705;C0558295;C1549513;C1518422;C1515187;C0392360
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
western europe and israel,C0043129;C0022271
outcome measure,C0086749
clopidogrel plus aspirin yr,C0070166;C0004057
time to first cv hospitalization or death from any cause,C0040223;C3541383;C0007465
aspirin only,C0004057
first cv hospitalization,C0205435;C0019993;C1279901
stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
death from any cause,C0007465
mi or cad,C3810814;C1504769;C2239547;C3813548;C4284121
first hospitalization for chf or cv death,C0019993;C0018802;C0011065;C1306577;C4082313;C4552775
chads $nmbr$ score,C0449820;C4050231
indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vka therapy,C0039798;C0087111;C1363945
age yr mean sd,C0001779;C2699239
persistent or paroxysmal,C0205322;C0332996;C0205311
ics users n,C0815320;C1706077;C4551720
reason for enrollment in active a,C0392360;C0205177;C3853793;C3888249
smoking history pack years mean sd,C1277691;C2699239
risk of bleeding,C3251812
fevi l mean sd $nmbr$,C0429706;C2699239;C0849974;C1561566;C4528367
physician s judgment that vka inappropriate,C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
fevi predicted mean sd $nmbr$,C0429706;C2699239;C0849974;C1561566;C4528367
clopidogrel plus aspirin,C0070166;C0004057
fev $nmbr$ fvc mean sd $nmbr$,C0444504;C2699239;C2347634;C2348143
physician s judgment that vka nappropriate,C0031831;C0804815;C0022423
reversibility b $nmbr$ agonist mean sd $nmbr$,C0444504;C2699239;C2347634;C2348143
all subjects,C0681850;C1550501;C1706203;C2349001;C2697811
reversibility anticholinergic mean sd,C0242896;C2699239;C3537004
no diabetes mellitus,C0011849
figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups,C0444506;C3714541;C1705241;C1705242;C1554093;C3242279;C3242455;C0332849;C0168634;C1442488;C0001779;C1519386;C0004048;C0239126;C0009924;C1979874;C0032042;C2825972;C1696465;C1706408;C0178602;C0213771;C1079230
weight median $nmbr$ th $nmbr$ th percentiles kg,C0022718;C0439209;C4054209
aml val $nmbr$ $nmbr$ mg rr $nmbr$,C0023465;C4554402;C0023467
body mass index median $nmbr$ th $nmbr$ th percentiles kg m $nmbr$,C0022718;C0439209;C4054209
ami $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time from onset of pain to randomization median $nmbr$ th $nmbr$ th percentiles n,C0449244;C0034656;C0039725;C0039738;C1420718;C4282123;C4285344
sex n male,C0086582
treatment before randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
non elderly,C1518422;C0001792;C1999167
oral hypoglycemic agent,C0359086
elderly $nmbr$ years,C0001792;C0439234;C1999167
hab $nmbr$ c mean sem,C0444504;C2347634;C2348143
race ethnicity chinese,C0008120;C0152035
low density lipoprotein cholesterol median $nmbr$ th $nmbr$ th percentiles mg dl,C0023824;C0439269
bmi kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
high density lipoprotein cholesterol median $nmbr$ th $nmbr$ th percentiles mg dl,C0023822;C0439269
type $nmbr$ diabetes history n,C1320657;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ranozaline,
duration of hypertension years,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781;C0369773;C2603361
mean sitting dbp mmhg,C0277814;C0439475;C2584297;C4050224
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019;C0369773;C2603361
mean sitting sbp mmhg,C0085805;C0439475
inclusion criteria no,C1512693
least square mean se,C0023189;C0036919
$nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0332189;C0004238;C0344434;C1963067;C0026544;C0332177
difference se,C1705241;C0036919;C1705242
cardioversion in previous $nmbr$ wk,C0013778;C0205156;C1552607
aml val $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of last qualifying episode of atrial fibrillation $nmbr$ days,C0449238;C2926735;C1514624;C0332189;C0004238;C0344434;C1963067
ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
heart failure lvef,C0428772;C0488728
peripheral artery disease at baseline,C1704436;C4025272
history of hypertension for $nmbr$ mo or more,C0455527;C0026544;C0332177
no peripheral artery disease baseline,C0168634;C1442488
history of stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
epa,
documented coronary artery disease,C0010054;C0010068;C1956346
pad at baseline,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
atrial fibrillation alone,C0004238;C0344434;C1963067;C0205171;C0439044;C0679994
no pad baseline,C0168634;C1442488
coexisting conditions no,C0012634;C0348080;C1705253;C3864998
ezetimibe simvastatin $nmbr$ $nmbr$ mg n $nmbr$,C1532737;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
peripheral embolism,C0013922;C1704212
rosuvastatin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous transient ischemic attack,C0007787;C0917805
current cvd diabetes n,C0007222;C0011847;C0011849
renal dysfunction,C1565489;C3279454
high risk cvd n,C0332167;C3272283;C4050568;C4319571
alcohol abuse,C0085762;C4050601
mean $nmbr$ year cvd risk,C0007222;C0035647;C4552904
electrocardiographic findings at randomization,C0438154;C0034656
type $nmbr$ n,C0332307;C1547052
qrs interval $nmbr$ msec no,C0520880;C0439223
fasting lipid levels mmol l,C0428460;C1532563
left ventricular hypertrophy no,C0149721;C3484363
triglycerides median range,C1514721;C2348147;C3542016
pathologic q waves no,C0429089;C1305738
percentage patients reaching target,C0439165;C0030705;C1549488;C1561533;C2584321;C1521840;C2986546
concomitant cardiovascular therapies no,C1707479
exetimibe simvastatin,C0074554
class $nmbr$ antiarrhythmic agents,C0003195;C0301380
atorvastatin,C0286651
hf lvd or both,C0018488;C1313497;C1538440;C3273279
ldl c $nmbr$ $nmbr$ mmol l,C1532563
use of antiarrhythmic agent,C1524063;C0003195;C0301380
jbs $nmbr$ secondary prevention only $nmbr$,C0175692;C0679699;C0795841;C1416527
use of beta blockers,C1524063;C0001645
jbs $nmbr$ primary prevention only $nmbr$,C0175692;C0033144;C0795841;C1416527
af alone,C0344434;C4049859;C0205171;C0439044;C0679994
nice secondary prevention onlyb,C4087029;C0679699
nice primary prevention onlyb,C4087029;C0033144
af alone refers to atrial fi brillation without coexisting cardiovascular conditions but with left atrial dilatation ace denotes angiotensin con verting enzyme hf heart failure and lvd left ventricular dysfunction,C0344434;C4049859;C0205171;C0439044;C0679994;C0205543;C0018792;C0007222;C1452534;C4284014;C0003018;C4521302;C0387288;C0014442;C0018801;C4521602;C0242698
baseline ldl c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mmol lc,C0168634;C1442488;C0439190
ischemia on cecg n $nmbr$ $nmbr$,C0022116;C4321499
infliximab naive n $nmbr$,C0666743
no ischemia n $nmbr$ $nmbr$,C0022116;C4321499
infliximab experienced n $nmbr$,C0666743
age $nmbr$ yrs,C0001779
mean s d age years,C0444504;C1510829;C2347634;C2348143
body mass index kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
mean duration of disease years,C0872146;C0439234
prior revascularization,C0332152;C0581603;C2826257
location of crohn s disease,C0450429;C1515974;C4284930;C4284931;C0012634
creatinine clearance $nmbr$ ml min,C0812399;C0439445
upper gastrointestinal,C1282910;C0521362
non st segment elevation mi,C1518422;C0520886
resection performed,C0015252;C0728940;C0884358
st segment depression $nmbr$ $nmbr$ mv on admission,C1454484;C1705503;C4281602;C0457453
mean cdai score,C3533236;C0683448;C1413248;C3273706
elevated troponin $nmbr$ $nmbr$ mg l,C0041199;C0439268
geometric mean crp concentration mg l,C2986759;C0439268
elevated bnp $nmbr$ pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
penetrating disease,C0205321;C0012634
intent of early invasive strategy,C0162425;C1283828;C1550453
medications at baseline n,C0013227;C0802604;C2598133;C4284232
intent of conservative strategy,C0162425;C1283828;C1550453
no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
revascularization during index hospitalization,C0581603;C0019993
figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population,C0024501;C0871261;C1704632;C1706817;C2911692;C0544452;C0687702;C0332152;C0032659;C1257890
ace inhibitors or arbs,C0003015;C3888198
history of myocardial infarction,C1275835
cardiac medications at discharge,C0018787;C0806915;C1522601
history of cabg surgery,C0455610;C0010055
primary end point,C2986535
symptom onset to hospital admission,C4086878;C0184666
ischemia on cecg,C0022116;C4321499
intervention,C0184661;C0886296;C1273869
no p value for ischemia ischemia hr $nmbr$ ci interaction,C1709380;C0008107;C3259781
final timi flow grade post ppci,C0205088;C3272266;C1546485;C3853528
$nmbr$ yrs of age n $nmbr$ $nmbr$,C0001779
macce,
no prior htn n $nmbr$ $nmbr$,C0332152;C0020538;C2826257
lce n $nmbr$,C1423759;C3273355
prior htn n $nmbr$ $nmbr$,C0332152;C0020538;C2826257
lc n $nmbr$,
no dm n $nmbr$ $nmbr$,C0011816;C3250443
age mean yr,C0001779;C0439234
dm n $nmbr$ $nmbr$,C0011816;C3250443
men no,C0025266
no prior angina n $nmbr$ $nmbr$,C0332152;C0002962;C2826257
mean duration of pd yr,C0449238;C2926735
prior angina n $nmbr$ $nmbr$,C0332152;C0002962;C2826257
updrs total ii iii,C0439070;C1705160
no prior mi n $nmbr$ $nmbr$,C0332152;C2826257
updrs part ii adl,C0001288;C1420005
prior mi n $nmbr$ $nmbr$,C0332152;C2826257
updrs part iii motor,C1513492;C1705994
no prior revascularization n $nmbr$ $nmbr$,C0332152;C0581603;C2826257
hoehn yahr stage,C0205390;C1300072;C1306673
prior revascularization n $nmbr$ $nmbr$,C0332152;C0581603;C2826257
schwab england score,C0449820;C4050231
pdq $nmbr$,
no prior hf n $nmbr$ $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
previous antiparkinson medication no,C0205156;C0003405;C1552607
prior hf n $nmbr$ $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
dopamine agonist use no,C0042153;C0457083;C1947944
unstable angina n $nmbr$ $nmbr$,C0002965
nstemi n $nmbr$ $nmbr$,C3537184;C4255010
lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire,C1292728;C0337645;C0034394
no stsd $nmbr$ mm on admission n $nmbr$ $nmbr$,C0184666;C0809949
unified parkinson disease,C0030567;C1521736
stsd $nmbr$ mm on admission n $nmbr$ $nmbr$,C0184666;C0809949
olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$,C0386393;C1319635
low trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
olmesartan medoxomil $nmbr$ mg n $nmbr$,C0386393;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderate trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
age y [mean sd],C0001779;C0444504;C2699239;C2347634;C2348143
high trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
$nmbr$ [n ],C0369718;C0441922
conservative strategy n $nmbr$ $nmbr$,C0679199
males [n ],C0086582;C0369718;C0441922
early invasive strategy n $nmbr$ $nmbr$,C0205281;C0679199;C1334278
diabetes mellitus [n ],C0011849;C0369718;C0441922
ef $nmbr$ n $nmbr$ $nmbr$,
bmi kg m $nmbr$ [mean sd],C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
ef,
sedbp mmhg [mean_ sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
negative ctnl n $nmbr$ $nmbr$,C0205160;C1513916;C2825415;C2825491;C3853545
sesbp mmhg [mean _sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
positive ctnl n $nmbr$,C0439178;C1446409;C1514241;C2825490;C3812269
severity ofhypertension [n ]b,C0439793;C0522510;C0369718;C0441922
normal bnp ^ $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
mild,C2945599
elevated bnp $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
pre treatedforhypertension [n ],C0332152;C0740175;C2257086;C3669034;C0369718;C0441922
medal,C0524670
pre treatment[n ]c,C1550147;C2709094;C3539075;C3539076;C2349138
edge ii,C1710602;C4082587
calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
edge,C0205154;C2697523
low ceiling diuretic,C0205251;C0012798;C1550472;C3890211;C4048187;C4321351;C4522223
oa,C0029408;C3887876
bp in pre treated patients,C0037623;C1415692;C1708288;C4318478
ra,C3538806;C4048756
sedbp mmhg [mean _sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
$nmbr$ mg cohort,C0009247;C0599755
sesbp mmhg [mean sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
etoricoxib $nmbr$ mg n $nmbr$ $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
high dose statin,C0444956;C0360714
diclofenac $nmbr$ mg n $nmbr$ $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prevalence of each metabolic syndrome criterion,C0033105;C0220900
baseline creatinine clearance,C0168634;C0812399;C1442488
met criterion at blt n [ ],C0428210;C0243161;C1550543;C4317104
$nmbr$ $nmbr$ ml s m $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0439390;C0439445;C0369718;C0441922
met criterion at final n [ ],C0243161;C0205088;C1546485;C3853528
history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
elevated tg,C0205250;C0337445;C3163633
cigarette users,C0677453;C1706077;C1704760;C3890423
elevated blood pressure,C0020538;C0497247
history of symptomatic,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
met criterion at bl n [ ],C0243161;C0005918;C0006413;C1552663;C2827109
ascvdor $nmbr$ cv risk factors,C0035648;C1553898
elevated fasting glucose,C0015663;C0017725
prior use of systemic,C1524063;C0205373
increased waist circumference,C0205217;C0455829;C0442805
corticosteroidsa,
met criterion at finalt,C0428210;C0243161;C1550543;C4317104
baseline anti hypertensive usea,C0168634;C0003364;C1442488
n a,C1272460
ranolazine n $nmbr$ $nmbr$,C0073633
changes a in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C0524620;C2357172
age yrs median $nmbr$ th $nmbr$ th,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
bl mean mg dl mmol $nmbr$,C0567349;C2348885
weight kg median $nmbr$ th $nmbr$ th,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
mean a sem,C0444504;C2347634;C2348143
risk factors for atherosclerosis,C0035648;C1553898
$nmbr$ $nmbr$ lno^,
prior coronary revascularization pci or cabg,C0877341;C4049621;C0010055
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ti,C0039247;C0040302;C1553045;C1704756
prior known stenosis $nmbr$,C0678234;C1261287;C2632116
bl mean mmhg,C0005918;C0439475;C0006413;C1552663;C2827109
ccsc at $nmbr$ month before enrollment,C1516705;C0332177;C0439231;C1516879;C1696073;C3888021
mean a sd mmhg,C0444504;C2347634;C2348143;C2699239;C0439475
coronary angiography during the index hospital stay,C0085532;C1548829
fasting blood glucose,C0428568;C1261430
cardiac medications during index hospital stay and or discharge,C0013227;C0802604;C2598133;C4284232;C0012621;C0030685;C2926602
mean a sd mg dl mmol $nmbr$,C0444504;C2347634;C2348143;C0567349;C2348885
calcium channel blockerf,C0006685
bl mean cm,C0005918;C0006413;C1552663;C2827109
long acting nitratef,C0205166;C1706317
mean a sdt,C0444504;C2347634;C2348143
tiotropium $nmbr$ mg respimat n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
data are expressed as n total unless otherwise speci ed systeme international unit conversion to convert creatinine clearance to ml s multiply by $nmbr$ $nmbr$ estimated with cockroft gault equation at discharge ace angiotensin converting enzyme cabg coronary artery bypass graft ccsc canadian cardiovascular society classi cation mi myocardial infarction pci percutaneous coronary intervention,C1511726;C3245479;C3714741;C0439175;C0439810;C0439453;C0439836;C0439390;C0750572;C0552449;C0030685
placebo n z $nmbr$,C0032042;C1696465;C1706408
randomization to end of study,C0034656;C0444930;C2746065
screening visit,C0545082;C1512346;C2826704
major secondary end pointf,C0027627;C0175668;C0205436
current smoker ex smoker,C3173209;C3241966
cv death or ml,C0011065;C1306577;C4082313;C4552775;C0439526;C1705224;C3887665
time since copd diagnosis yrs,C0040223;C3541383
recurrent ischemia,C0022116;C4321499
pre bronchodilator fev $nmbr$ l,C2599602;C3714541
worsening angina,C0332271;C1457868;C1546960;C0002962
pre bronchodilator fev $nmbr$ predicted normal,C2599602;C0520835
severe recurrent ischemia,C0022116;C4321499
pre bronchodilator fvc l,C2599602;C3714541
intensification of antianginal therapy,C1511484
pre bronchodilator fev $nmbr$ fvc,C2599602;C3714541
$nmbr$ days until end of study landmark analysis,C2826182;C0002778;C0936012;C1524024
post bronchodilator fev $nmbr$ l a,C2599594;C3714541
data are reported as n event rates in parentheses are kaplan meier estimates at $nmbr$ year cardiovascular cv death myocardial infarction mi or recurrent ischemia cv death mi or severe recurrent ischemia,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1720943;C0027051;C0011065;C3810814;C1306577;C4082313;C4552775;C0022116;C4321499
post bronchodilator fev $nmbr$ predicted normal a,C2599594;C0520835
new anti anginal therapy,C3242274;C1874267;C3537168
reversibility of fev $nmbr$,C0449261;C3714541
tadalafil $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
post bronchodilator fvc l a,C2599594;C3714541
tadalafil $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
post bronchodilator fev $nmbr$ fvc a,C2599594;C3714541
ed severity visit $nmbr$,C0545082;C1512346;C2826704
randomisation visit baseline,C0168634;C1442488
normal or mild iief ef $nmbr$ $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599;C3641331
fvc l proportion taking pulmonary medications b,C1290952;C0024109;C2707265;C2709248;C4522268
moderate iief ef $nmbr$ $nmbr$ n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
any medication,C0013227;C3244316;C4284232
severe iief ef $nmbr$ $nmbr$ n,C0205082;C3641331;C4050465;C4050466
long acting b $nmbr$ agonists,C0243192;C2987634
ed duration visit $nmbr$,C0545082;C1512346;C2826704
short acting b $nmbr$ agonists,C0243192;C2987634
$nmbr$ moto,
inhaled corticosteroids,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727
$nmbr$ yr n,C0439234
oral corticosteroids,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
iief ef domain score visit $nmbr$,C0545082;C1512346;C2826704
xanthines,C0043318;C3541955
iief ef domain score visit $nmbr$ y,C0449820;C0545082;C1512346;C2826704;C4050231
short acting anticholinergics,C0242896;C3537307;C3540711
p value subgroup,C1079230;C1515021
supplementary oxygen,C0030054
p value interaction,C1709380;C1704675
laba users,C1706077
$nmbr$ yr n $nmbr$,C0439234
laba non users,C1518422;C1706077
$nmbr$ $nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
tiotropium $nmbr$ mg respimat n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bph luts severity,C0439793;C0522510
proportion taking pulmonary medications b,C1290952;C0024109;C2707265;C2709248;C4522268
moderate ipss $nmbr$ n $nmbr$,C0205081;C1019118;C1998280;C2827405;C3811063;C1881878;C4049705;C4049706;C4085643;C4321335
tiotropiumc,
severe ipss $nmbr$ n $nmbr$,C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
preamendment,C1548596
psa,C3810537;C3813209
postamendment,
$nmbr$ $nmbr$ ng ml n $nmbr$,C0439275
extended duration enoxaparin n $nmbr$,C0231448;C0206460;C0231449;C0439792
prior a blocker use,C0332152;C2826257;C0042153;C0457083;C1947944
asian or oriental,C0078988;C0699027
yes n $nmbr$,C1549445;C1705108;C1710701
region of enrollment n,C0017446;C0205147
no n $nmbr$,C0369718;C0441922
africa asia or the middle east,C0001737;C0003980;C0026068
prior ed therapy,C1514463;C3538926
body mass index $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
variable_level,C0441889;C0456079;C1547707;C2946261
primary enrollment diagnoses n,C0332137;C0801658
moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
acute infection without septic shock,C0275518;C0036983
normal mild ckd,C0205307;C1561643;C0231683;C0439166;C2347086;C4553972
acute respiratory insufficiency,C0865850
chd cl,C0280604;C0596019;C3542407
cvd,C0007222
post acute ischemic stroke,C0751956
sal $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
acute rheumatic disorders,C0001314
fp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
active cancer,C0006826;C0998265;C1306459
sfc $nmbr$ mg $nmbr$ mg,C4521536;C1319635
fracture,C0016658
total pack yrs,C0439175;C0439810
multiple diagnoses,C0439064;C0011900
baseline fev $nmbr$,C0168634;C3714541;C1442488
active inflammatory bowel disease,C0205177;C0021390;C3853793;C3888249
bmi kg m^ $nmbr$,C0022718;C0439209;C4054209
risk factors and immobility level n,C0035648;C1553898;C0231441;C0441889;C0456079;C1547707;C2946261
probability of event,C0033204;C0441471;C4019010
level $nmbr$ immobility,C0441889;C0231441;C0456079;C1547707;C2946261
non ics,C0815320;C4551720
level $nmbr$ immobility^,C0441889;C0231441;C0456079;C1547707;C2946261
ng n $nmbr$ $nmbr$,C0017887;C0028074
history of vte,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
lgm n $nmbr$,
active or previous cancer,C0205177;C3853793;C3888249;C0006826;C0998265;C1306459
non epa n $nmbr$,C1518422
obesity body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
average age year,C0439234;C0439508
venous insufficiency,C0042485
drinker,C0556338
chronic heart failure,C0018802;C0264716
triglyceride median mg dl $nmbr$ [ $nmbr$ $nmbr$ percentile,C0439269;C1264641
chronic respiratory failure,C0264492
$nmbr$ [ $nmbr$ $nmbr$,
chronic inflammatory disease,C1290886
$nmbr$ [ $nmbr$ $nmbr$ ],
family history of vte,C0241889;C0630906
fatty acid profile,C1979963;C2003903
thrombophilia,C0398623
glucose metabolism,C0596620
previous medications n,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
hba c,C0019016;C1825777;C3538758
$nmbr$ ll,
antiplatelet or anti inflammatory drugs,C0003209
antiplatelet drugs,C0085826;C2963157
data are reported as percentage or mean standard deviation unless otherwise indicated ng normoglycemia igm impaired glucose metabolism ldl low density lipoprotein hdl high density lipoprotein fpg fasting plasma glucose a median interquartile range p $nmbr$ $nmbr$ vs ng p $nmbr$ $nmbr$ vs ng,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1828170;C0455280;C0549183;C1711350;C0876920;C2347635;C2348144;C2939193;C0017887;C0028074
anti inflammatory drugs,C0003209
igm n $nmbr$,C1706005
extended duration enoxaparin n n,C0231448;C0206460;C0231449;C0439792
triglyceride median mg dl a [ $nmbr$ $nmbr$ percentile],C0041004;C0439269;C1264641
absolute risk difference ci,C0008107;C3259781
$nmbr$ [ $nmbr$ $nmbr$ js,C1552154
vte at day $nmbr$,C0630906;C0332173;C0439228;C0439505
diastolic fmmhff,C0012000
level $nmbr$,C0441889;C0456079;C1547707;C2946261
non epa number of,C0237753;C0449788
major bleeding events,C0441471;C3541888
epa hr events,C0441471;C3541888
scd,
ng,C0017887;C0028074
hradj $nmbr$ ci,C0008107;C3259781
igm,
qtc,
ng vs igm,C0017887;C0028074
$nmbr$ $nmbr$ referent,C1706462
interaction p $nmbr$ $nmbr$,C1704675
qtc $nmbr$ n $nmbr$,
tadalafil,C1176316
no prior mi n $nmbr$,C0332152;C2826257
$nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior mi n $nmbr$,C0332152;C2826257
$nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
age y gender n,C0001779;C0079399;C1522384
prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
african descent,C0205386;C0680043
bnp,C0054015;C1095989;C1417808;C2982014
weight kg duration of pah n,C0449238;C2926735
bnp $nmbr$ pg ml n $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
$nmbr$ y pathogenesis n,C0543483;C0699748
ef $nmbr$ n $nmbr$,
idiopathic familial,C0015576;C0241888
figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time,C0488055;C0871470;C1306620;C0428883;C1305849;C0949236;C0439234;C1705117;C0439508;C0040223;C3541383
anorexigen use,C0042153;C0457083;C1947944
om $nmbr$ mg aml $nmbr$ mg n $nmbr$,C1319635;C0023465;C0023467
connective tissue disease,C0009782
om $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
associated with an atrial septal defect,C0332281;C0018817
aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
surgical repair of vsd or pda $nmbr$ year duration,C0374711;C0018818;C0449238;C2926735
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
concomitant use of bosentan n,C1524063;C0252643
age group no,C0027362;C2348001
six minute walk distance m,C3900196
height mean sd cm,C0489786;C0444504;C2347634;C2348143
borg dyspnea score who functional class n,C0013404;C0205245;C0542341;C2700217;C1963100
bmi mean sd kg m^,C0022718;C0439209;C4054209
hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0449381;C4281788;C0030705;C4684790
bmi category no,C0683312;C3889287
mean pulmonary artery pressure mm hg,C0428642;C0439475
$nmbr$ kg m^ obesity,C0022718;C0439209;C4054209;C0028754;C1963185
cardiac index l mn m $nmbr$,C0026327;C0026405;C4285072
chronic kidney disease no t,C1561643;C4553188;C2603360
pulmonary vascular resistance dyne s cm $nmbr$,C0308914;C0600130
chronic cardiovascular disease no,C1290380
dose,C0178602;C0869039;C1114758
bp goal no,C0018017;C1571704
treatment effect,C1518681
baseline sesbp mean sd mm hg,C0168634;C0439475;C1442488
all itt subjects,C0681850;C1550501;C1706203;C2349001;C2697811
baseline sedbp mean sd mm hg,C0168634;C0439475;C1442488
bosentan use,C0042153;C0457083;C1947944
om $nmbr$ mg aml $nmbr$ mg,C1319635;C0023465;C0023467
pah etiology,C0015127;C1314792;C1524003
om $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
repaired s p shunts,C0205340;C0232180;C0542331;C1442858
aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
baseline $nmbr$ mlnute walk distance,C0168634;C0429886;C1442488
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
$nmbr$ meters,C0441074
bp variable mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
median $nmbr$ year old,C0439234;C0580836;C0439508
moderate severe n $nmbr$ n $nmbr$,C0205081;C0205082;C4050465;C4050466;C1881878;C4049705;C4049706;C4085643;C4321335
baseline who function class,C0456387;C1518526;C1705943
baseline bp mean sd,C0488053;C2699239
lor ii,C1710602;C4082587
change in sesbp ls mean se,C0392747;C0443172;C1705241;C4319952
iii or iv,C0439070;C1705160;C0022326;C4265176
change in sedbp ls mean se,C0392747;C0443172;C1705241;C4319952
table $nmbr$ not standard baseline characteristics table,C0039224;C1706074
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ll,
fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs,C0349966;C3272907;C1337208;C0023824;C0445604;C1079230;C1515021
cad and or crvd,C1504769;C2239547;C3813548;C4284121
saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$,C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ a,
saxa $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean preoperative abpi of the index,C0444504;C0445204;C2347634;C2348143
metformin n $nmbr$ $nmbr$,C0025598
limb sd,C0015385;C2699239
age $nmbr$ years t,C1510829
pad symptoms,C0683368;C1457887
sexy,
claudication only,C0021775;C0311395;C1456822
racey z,
rest pain,C0234253
$nmbr$ t,C2603360
ulcers gangrene,C0041582;C0017086
fpg mg dl x,C0439269
distal anastomosis,C0448964
figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin,C0019016;C2986480;C1825777;C3538758;C1611934
below knee popliteal,C0022742;C0442037;C0022745;C1963703
proportion of patients who achieved acr $nmbr$ n n,C1709707;C0030705
below knee popliteal crural,C0023216;C1140621
combined golimumab groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
beyond popliteal pedal,C0016504;C0687080
dmard at baseline,C0242708;C0168634;C1442488
all grafts,C0332835;C1527362
number of previous tnfa inhibitors,C0237753;C0449788
venous,C0042449;C0348013
reason for discontinuation of previous tnfa inhibitor,C0392360;C0205156;C1552607
prosthetic,
lack of effectiveness,C0235828
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
unrelated to effectiveness,C0445356;C1704623
graft occlusionsa,C0181074;C0332835;C1961139
zoledronic acid,C0257685
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
age at menopause yr,C1625754;C1629609
amputationsa,
americas,C0002454;C0596070
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
bmi kg m $nmbr$ a,C0578022;C1532718
placebo n[ $nmbr$,C0032042;C1696465;C1706408
bmia,
salmeterol n [ $nmbr$,C0073992
weight kg a,C0022718;C0439209;C4054209
fp n [ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
height loss,C0424641
sfc n [ $nmbr$,C4521536
$nmbr$ $nmbr$ to $nmbr$ cm,
age at enrolment years,C1510829;C1516879;C1696073;C3888021
baseline vfx,C0168634;C1442488
postbronchodilator fev $nmbr$ predicted,C0681842;C1882327
history of falls,C1561668;C2919132
$nmbr$ e $nmbr$ n,
physical activity hours walking wk,C0015259;C0439227;C0026606;C0080331;C4283795;C4321241;C4321242;C0332174;C0439230
geographical region n,C0017446;C0205147
prior bisphosphonate usage,C0012544;C0457083;C2267018
pack years smoked,C1277691;C0037366;C0439994;C1881674
total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
previous copd treatment n,C0024117;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1412502;C3714496
standardized total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
laba alone,C0205171;C0439044;C0679994
femoral neck bmd g cm $nmbr$,C0015815;C0439267
ics laba,C0815320;C4551720
femoral neck t score,C0449820;C4050231
neither ics nor laba,C0815320;C4551720
femoralneck t scorebybaselinevfxstatus,
previous mi n,C0205156;C1552607
$nmbr$ $nmbr$ vfx,
$nmbr$ ml min,C0439445
baseline cv treatment n y,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
category,C0683312;C3889287
baseline short acting anticholinergics n,C0168634;C0242896;C3537307;C3540711;C1442488
mean change in fn bmd,C0392747;C0443172;C1705241;C4319952
salmeterol n[ $nmbr$,C0073992
least squares mean between treatment difference $nmbr$ ci,C0023189;C0444504;C2347634;C2348143
fp n[ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
p value within category,C1709380;C0683312;C3889287
sfc n[ $nmbr$,C4521536
$nmbr$ e,
femoral neck t score and vfx status,C0449820;C4050231;C0449438
baseline cv treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
op no vfx,
op vfx,
baseline short acting anticholinergics,C0242896;C3537307;C3540711
no op no vfx,
severe oab subgroup,C1079230;C1515021
no op vfx,
full analysis set fas,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
height loss cm,C0424641
solifenacin n $nmbr$,C1099677
prior bp use,C0042153;C0457083;C1947944
age cohort no,C2348001
crcl ml min,C1846718;C0439445
diary variables mean sd,C0376660;C2699239
$nmbr$ mg kg,C0439272
urgency episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
combined,C0205195
incontinence episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
patients randomized n,C0030705;C0034656;C3815594
micturitions $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
white race n,C0007457;C0043157
nocturia episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
disease duration y,C0872146
wt second median,C0549183;C0876920;C2347635;C2348144;C2939193
colonic area involved,C0017446;C0205146;C1314939
ppbc score mean sd,C0444504;C2699239;C2347634;C2348143
iuss score mean sd,C0444504;C2699239;C2347634;C2348143
left side n,C0205091
extensive n,C0205231
ups score mean sd,C0334463;C2699239;C3542434
mayo clinic scoreb,C0002424;C0442592
oab q score mean sd,C3641332;C2699239
symptom bother,C1457887;C3854129
c reactive proteinc,C0205332
hrql mean sd,C0444504;C2699239;C2347634;C2348143
mean mg dl,C0444504;C0439269;C2347634;C2348143
coping,C0009967
median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
concern,C2699424
elevated crp n,C0742906
sleep,C0037313
any ulcerative colitis medication,C0013227;C3244316;C4284232
social interaction,C0037420
$nmbr$ mg day,C0439422
all n $nmbr$ $nmbr$,C0369718;C0441922
immunomodulators,C0001551;C0005525;C1527392
bivalirudin n $nmbr$ $nmbr$,C0168273
refractory to corticosteroids n,C0205269;C0001617;C3539185;C3540725;C3540726;C3540727
heparin plus gpi n $nmbr$ $nmbr$,C0019134;C0770546
smoking status n,C1519386
symptom onset to pci h,C4086878;C0033727;C0369286;C0441932;C0564385;C4528284
prior smoker,C0337671
killip class $nmbr$ $nmbr$,C1881332
study,C0557651;C2603343
anemia,C0002871;C1000483;C4554633
act $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
$nmbr$ diseased vessels,C0005847
nap,C0870935;C1423800;C4283878
anterior infarct location,C0450429;C1515974;C4284930;C4284931
infliximab $nmbr$ mg kg versus placebo,C0666743;C0439272;C0032042;C1696465;C1706408
initial timi flow grade $nmbr$,C0441800;C0919553;C3244287
corticosteroid refractory status,C0001617;C0449438;C3536709
stent implanted,C0522776
uc disease duration,C0872146
$nmbr$ years to $nmbr$ years,C0439234
final timi flow grade,C0441800;C0919553;C3244287
extent of disease,C0449279;C4553144
heart rate group at baseline,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
limited,C0439801;C2674459;C3542948;C4050251
$nmbr$ bpm n $nmbr$ l $nmbr$,
baseline c reactive protein,C0006560;C1413716;C4048285
cardiac parameters,C0018787;C0449381;C1522601
baseline mayo score,C0449820;C4050231
egfr ml min per $nmbr$ $nmbr$ kg m^,C1739039;C0439402;C3811844;C3812682
center location,C0450429;C1515974;C4284930;C4284931
duration of heart failure years,C0449238;C2926735
czech republic,C0206578
primary cause of heart failure,C0205225;C0015127;C1524003;C0439612;C0439631
nc,C0027964;C0028407;C0067895;C0265987
non ischaemic,C1518422;C0475224
israel,C0022271
history of atrial fibrillation and or flutter,C0729790;C0016385;C2242390
southern hemisphere,C1710133
treatment at randomisation,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ asa compounds at baseline,C0205198;C1706082
diuretic agents excluding antialdosterone,C0450442;C1254351;C1521826
receiving,C1514756
antialdosterone agents,C0450442;C1254351;C1521826
not receiving,C1518422;C1514756
cardiac glycosides,C0007158
corticosteroids at baseline,C0001617;C3539185;C3540725;C3540726;C3540727
devices,C0025080;C0220819;C0699733
$nmbr$ mg day p eq,C0205163;C0439185
crt,
$nmbr$ mp and or aza at baseline,C0024944;C0004482;C0168634;C1442488
heart rate at baseline bpm,C0018810;C0168634;C1442488
corticosteroids and or $nmbr$ mp and or aza at baseline,C0001617;C3539185;C3540725;C3540726;C3540727;C0024944;C0004482;C0168634;C1442488
ivabradine group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
combined infliximab,C0205195;C0666743
baseline age,C0168634;C0001779;C1442488
figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min,C0013806;C2199618;C2363129;C4050504;C1707455;C0032042;C1696465;C1706408;C2986535;C0184666;C0332271;C1457868;C1546960;C0018801;C0018802;C4554158;C0007226;C1555024;C3887460;C1508496;C0018810;C0332257;C1552866;C2700399;C0011065;C1306577;C0456081;C1512806;C0428876;C0812399;C2985465;C0702093;C1524029;C3813700
$nmbr$ to $nmbr$ years,C0439234
ivabradine group n $nmbr$,C0257190;C0441848
baseline smoking status,C0168634;C1519386;C1442488
sex male ethnic origin,C0086582;C0015031
previous segmental resection s,C0205156;C2987624;C1552607
bmi kg m $nmbr$ cardiac parameters,C0022718;C0439209;C4054209;C0018787;C0449381;C1522601
nd,
egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
other uc related gi surgical procedures,C0439849;C0524722;C0445223
glulisine oad,
medical history duration of heart failure years primary cause of heart failure,C0449238;C2926735
glulisine monotherapy,
history of atrial fibrillation or flutter treatment at randomisation,C0729790;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
oad only,
diuretic drugs excluding antialdosterone,C0013227;C3687832
itt patients n,C0030705
test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
mean age s d years,C0444504;C0001779;C2347634;C2348143;C0439234
s $nmbr$ years n $nmbr$,C0439234
mean bmi s d kg m $nmbr$,C0444504;C0578022;C2347634;C2348143;C0022718;C0439209;C4054209
no p blocker intake at randomisation n $nmbr$,C1512806;C0034656
mean hba $nmbr$ c s d,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
p blocker intake at randomisation n $nmbr$,C1512806;C0034656
treatment with sulphonylurea n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
non ischaemic n $nmbr$,C1518422;C0475224
treatment with sulphonylurea biguanide n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ischaemic n $nmbr$,C0475224
fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0013175;C1710181
nyha class ii n $nmbr$,C1882085
nyha class iii or iv n $nmbr$,C1882086;C0022326;C4265176
fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0444504;C2347634;C2348143;C0019016;C0033727;C0369286;C0441932;C0564385;C4528284;C1825777;C3538758;C2348070;C0202042;C0455280;C0015663;C1955477;C1710181
no history of diabetes n $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
placebo pioglitazone n $nmbr$,C0032042;C0071097;C1696465;C1706408
history of diabetes n $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no history of hypertension n $nmbr$,C0455527
alogliptin $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline heart rate,C0168634;C0018810;C1442488
$nmbr$ n,C0369718;C0441922
$nmbr$ bpm n $nmbr$,
non hispanic,C1518424
heparin dose regimen,C0019134;C2348331;C0770546
diabetes history mean sd years,C0011847;C0439234;C0011849
$nmbr$ standard n $nmbr$,C1442989;C2828392
pioglitazone dose mean sd mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
other hypoglycemic agent n,C0020616
heart failure at entry no,C0018801;C0018802;C4554158
sulfonylurea,C0038766;C3536898
previous events no,C0441471;C3541888
$nmbr$ n of patients,C0369718;C0441922
pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
electrocardiograph results no,C1274040;C1546471;C2825142
figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo,C0392747;C0443172;C0332174;C0439230;C0439780;C0062259;C0042295;C0019016;C1825777;C3538758;C0369773;C1520214;C2603361;C0032042;C1696465;C1706408
changes at baseline,C0392747;C0443172
simvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg n $nmbr$,C1319635
st depression $nmbr$ mm,C4330985;C4554674
lowest tg tertile,C1708760;C0337445
any dynamic st segment shift,C0333051;C2347509
tgs mg dl,C1156212;C0439269;C1537574
transient st elevation,C0040704;C0520886;C0205374
non hdl cholesterol mg dl,C0729627;C0439269;C1535899
positive troponin i or t no,C0439178;C0077401;C1446409;C1514241;C2825490;C3812269;C2603360
apob mg dl,C0003593;C0439269;C3252643
time from median iqr h,C0040223;C3541383
non hdl cholesterol apob ratio,C2938854
symptom onset to hospitalization,C4086878;C0019993
middle tg tertile,C0444598;C0337445;C0549183;C1552826
hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
highest tg tertile,C1522410;C0337445
enrollment to randomization,C1516879;C1696073;C3888021
with tamsulosin,C0257343
symptom onset to enrollment,C4086878;C1516879;C1696073;C3888021
without tamsulosin,C0257343
symptom onset to randomization,C4086878;C0034656
no japanese,C0376247;C1556094
angiographic characteristics no,C1521970
time since bph diagnosis years,C0556970;C0005001;C1704272
single vessel disease,C0037179;C0042373;C0087136;C0205171
antithrombotic use before enrollment no,C0042153;C0457083;C1947944
no previous alpha blocker use,C0042153;C0457083;C1947944
ipss unit,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
non pci intravenous unfractionated heparin,C1518422;C0354566
prostate volume ml,C0439526;C1705224;C3887665
subcutaneous unfractionated heparin,C0353681
intervention group n $nmbr$,C0441848
lmwh,C0019139;C3536766
hispanic latin american,C0019576
gpiib iiia inhibitors,C0016011;C0243077
hawaiian pacific islander,C0337920;C0242191
commercially available fondaparinux,C0470187;C1098510
age $nmbr$ years or more,C1510829
medication use before enrollment no,C0240320;C1516879;C1696073;C3888021
g blockers,C0439267
previous transient ischaemic attack ischaemic stroke previous warfarin use,C0042153;C0457083;C1947944
angiotensin receptor blockers,C0521942;C0815017
less than $nmbr$ year,C0439234;C0439508
$nmbr$ year or more,C0439234;C0439508
oral hypoglycemic agents,C0359086
no estimate,C0750572
ticlopidine,C0040207
prasugrel,C1620287
atrial fibrillation pattern,C0004238;C0449774;C0344434;C1963067
atrial fibrillation onset,C0206132;C0332162
aspirin dose mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total time of fondaparinux treatment before,C0439175;C0040223;C3541383;C0439810
left ventricular ejection,C2733342
and after pci median iqr d,C0549183;C0876920;C2347635;C2348144;C2939193
fraction,C1264633;C1554103
variables,C0439828
figure $nmbr$ primary e cacy results by patient subgroup,C0205225;C1547647;C0439612;C0439631
all with coenzyme q $nmbr$ n $nmbr$ $nmbr$,C0041536
p value for trend,C1709380;C1521798;C4554533
tertile $nmbr$ n $nmbr$,
age of completion of highest education years sd,C1510829;C0013621;C0013622;C0013658;C0039401
p value for trend across tertiles,C1709380;C1521798;C4554533
history of major cardiovascular disease n,C0455539;C0205082;C0205164;C4318856;C4521762
age $nmbr$ yrs n,C0001779
myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
nyha functional class n,C1882083;C0205245;C0542341;C2700217
stroke n,C0038454;C4554100
cabg or ptca pci,C0010055;C2936173;C4049621
macroalbuminuria n,
af or atrial flutter,C0344434;C4049859;C0004239;C0344423;C1963068
major diabetic eye disease n,C0205082;C0342245;C0205164;C4318856;C4521762
total cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
past smoker n,C0337664
ldl cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
current alcohol use n,C0521116;C0001948;C1705970
hdl cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
apoa $nmbr$ g l,C0439294;C0456615
systolic bp mmhg sd,C0871470;C2699239
apob g l,C0439294;C0456615
diastolic bp mmhg sd,C0428883;C2699239
serum creatinine xmol l,C0201976;C0600061
serum total cholesterol mmol l sd,C0587184;C2699239;C1287371
serum creatinine $nmbr$ xmol l n,C0201976;C0600061
serum creatinine ^mol l,C0201976;C0347982;C0600061
egfrmdrd ml min $nmbr$ $nmbr$ m $nmbr$ bsa,C0369637;C0441923
estimated gfr ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ sd a,C0017654;C0439445;C1424601;C2699239
nt probnp pmol h,C0033727;C0369286;C0441932;C0564385;C4528284
uacr mg mmol interquartile range b,C0567349;C1711350;C2348885
coenzyme q $nmbr$ p g ml,C0041536;C1300565
number of events patients,C4330837
hazard ratiof,C0598697
perindopril,C0136123
$nmbr$ clf,C3540486;C4553190
major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
subgroup p valuef,C1079230;C1515021
mmse $nmbr$,C0451306
all randomized all cause mortality,C0015127;C0026565;C0026566;C1524003
mmse,C0451306
all randomized coronary end point,C2349179;C2826544
all cause death,C0011065;C1306577;C4082313;C4552775
all randomized all cause mortality or hospitalization for worsening hf^,C0015127;C0026565;C0026566;C1524003;C0019993;C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
shfm annual mortality,C0026565;C0026566
type of end point,C0332307;C1547052
quintile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C1508496
subgroup p value,C1079230;C1709380;C1515021
randomized treatment n,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C3815594
hospitalizations,C0019993
nyha class iii n,C1882086
omeprazole,C0028978
ischemic hf n,C0475224;C0018488;C1313497;C1538440;C3273279
age yrf,C0001779
furosemide equivalent mg kg,C0016860;C0439272
white race no total no,C0007457;C0043157;C0439175;C0439810
digoxin n,C0012265
negative for helicobacter pylori no total no,C4688581;C0439175;C0439810
ace i or arb n,C0021966;C0221138;C3888198
nsaid use no total no,C0042153;C0457083;C1947944;C0439175;C0439810
j $nmbr$ blocker n,
cardiovascular history no total no,C1880008;C0439175;C0439810
statin n,C0360714
acs,C0742343;C4318612
carvedilol n,C0054836
other vascular disease,C0042373
qrs $nmbr$ ms n,C2349943;C3539704;C3713294
cardiovascular risk factors no total no,C0850624;C0439175;C0439810
qrs width ms,C2349943;C3539704;C3713294
current smoking no total no,C0037369;C0453996;C1881674;C0439175;C0439810
$nmbr$ min walk distance ft,C1881534;C3890579
current alcohol use no total no,C0521116;C0001948;C1705970;C0439175;C0439810
quintile n,C1508496
total deaths n,C0439175;C0011065;C1306577;C0439810
history of gi bleeding or ulcer no total no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0041582;C3887532;C0439175;C0439810
placebo mortality rate events per $nmbr$ person y,C0441471;C3541888
medications at study entry no total no,C0013175;C1705654;C0439175;C0439810
relative risk comparing icd therapy and placebo,C0242492;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408
supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups,C0598697;C0456603;C1610540;C0439064;C1079230
relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd,C0242492;C0596019;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C1524063;C0233324;C1515273;C1705313;C2826302
h pylori positive or indeterminate h pylori negative no nsaids used nsaids used male other race black white age $nmbr$ age $nmbr$ bmi $nmbr$ bmi $nmbr$ history of pad negative history of pad positive no aspirin use concomitant aspirin no statin use concomitant statin no clopidogrel use concomitant clopidogrel no hypertension hypertension no diabetes diabetes no hypercholesterolemia hypercholesterolemia no other risk factor other risk factors overall,C0439178;C1446409;C1514241;C2825490;C3812269;C0205258;C4688581;C0086582;C1706180;C1706428;C1706429;C0005680;C0004057;C0042153;C0457083;C1947944;C0360714;C0070166;C0020538;C1963138;C0011847;C0011849;C0020443;C1522133;C0035648;C1553898;C0282416;C1561607
ii $nmbr$,C1710602;C4082587
iii $nmbr$,C0439070;C1705160
supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease,C0598697;C0456603;C1610540;C0439064;C1079230;C0348078;C0042373;C0376315
iv $nmbr$,C0022326;C4265176
rolofylline,C0166128
v $nmbr$,
p valuej,C0369773;C2603361
gold stage ii,C0018026;C0441767;C1304897
measurements,C0242485
gold stage iii,C0018026;C0441771;C1304897
heart rate at rest in the supine position beats min,C0018810;C0035253;C1622890;C0038846;C0439385
gold stage iv,C0022326;C4265176
respiratory rate breaths min,C0231832;C0439386;C0489258
fev $nmbr$ l,C3714541
bnp pg ml h,C2827929
prebronchodilator,C2599602
nt probnp pg ml h,C2827929
postbronchodilator,C2599594
left ventricular ejection fraction within previous $nmbr$ mo,C0428772;C0488728
duration of copd years,C0449238;C2926735
heart failure $nmbr$ mo before admission,C0026544;C0332177
control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
biventricular pacemaker,C1719274
ratio $nmbr$ ci,C0008107;C3259781
copd or asthma,C0024117;C1412502;C3714496;C0004096;C2984299
one or more copd exacerbations n n [ ],C0205447;C0740304
treatment before admission,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
median time to first exacerbation months [ $nmbr$ ci],C0205435;C0556969;C1279901;C0008107;C3259781
aldosterone blocker,C0002006
mean number of exacerbations per patient year [ $nmbr$ ci],C0444504;C0237753;C0449788;C2347634;C2348143;C0030705;C0439234;C0439508;C0008107;C3259781
nitrates oral or topical,C0442027;C4521986;C0332237
dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment after admission,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
warfarin,C0043031
days of study drug administration $nmbr$ day,C2826182
male sex no total no,C0086582;C0439175;C0439810
$nmbr$ or $nmbr$ days,C0439228
type of atrial fibrillation no total no,C0332307;C1547052;C0439175;C0439810
medications through day $nmbr$,C0013227;C0802604;C2598133;C4284232
chads $nmbr$ scoref,C0007928;C1413373
total intravenous loop diuretic mg median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ or $nmbr$ no total no,C0439175;C0439810
intravenous inotropes or vasopressors,C0348016;C0042397
$nmbr$ no total no,C0439175;C0439810
intravenous vasodilators,C0443081
$nmbr$ $nmbr$ no total no,C0439175;C0439810
medications at discharge or day $nmbr$ if earlier,C0806915;C0332173;C0439228;C0439505;C1279919
previous stroke or transient ischemic attack no total,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
figure $nmbr$ a subgroup results for primary endpoint,C1274040;C1546471;C2825142
heart failure no total no,C0018801;C0018802;C4554158;C0439175;C0439810
figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou,C1274040;C1546471;C2825142;C0007226;C3887460;C0022646
medications in use at baseline no total no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101;C0439175;C0439810
placebo mtx n $nmbr$,C0032042;C0025677;C1417487;C1696465;C1706408
arb or ace inhibitor,C3888198;C0003015;C4541021
rituximab $nmbr$ x $nmbr$ mg mtx n $nmbr$,C0024671;C0025677;C1417487;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
stating,C1301808;C1442792;C3148680
percentage with disease duration,C0439165;C1549488;C1561533
proton pump inhibitor,C0358591;C3536754;C4521480
no previous dmard therapy,C0039798;C0087111;C1363945
h $nmbr$ receptor antagonist,C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
receiving concomitant corticosteroids,C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
long term vka therapy,C0039798;C0087111;C1363945
receiving concomitant nsaids and or cox $nmbr$ inhibitors,C1514756;C0521115;C0003211;C0085387
patients total no,C0439175;C0439810
swollen joint count $nmbr$ $nmbr$ possible joints,C0451521;C0332149;C1705910;C2362652
dabigatran $nmbr$ mg $nmbr$ mg per yr,C1319635;C0439234
tender joint count $nmbr$ $nmbr$ possible joints,C0451530;C0332149;C1705910;C2362652
p value for interaction dosage with dabigatran $nmbr$ mg,C1709380;C0178602;C2986497;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
c reactive protein mg dl,C0006560;C0439269;C1413716;C4048285
$nmbr$ kg,C0022718;C0439209;C4054209
health assessment questionnaire $nmbr$ $nmbr$ range,C1514721;C2348147;C3542016
european or arab,C0239307;C1535514;C0282540;C1561448
das $nmbr$ esr,C0051767;C3811131;C0057671
$nmbr$ $nmbr$ ml min,C0439445
$nmbr$ or $nmbr$,
rheumatoid factor positive,C0439178;C1446409;C1514241;C2825490;C3812269
symptomatic heart failure,C0742758
baseline mean mtss,C0168634;C0444504;C2347634;C2348143;C1442488
central europe,C0682369
seropositive rf ve and or acpa ve subgroup,C0035448;C0201660;C0748398;C1547111;C1525410;C1706063;C1079230;C1515021
south asia,C1710133;C0003980
seronegative rf ve and acpa ve subgroup,C0035448;C0201660;C0748398;C1547111;C1525410;C1706063;C1079230;C1515021
east asia,C0015631
placebo mtx,C0025677;C1417487
aspirin use at baseline,C0042153;C0457083;C1947944
rituximab $nmbr$ x $nmbr$ mg mtx,C0025677;C1417487
amiodarone use at baseline,C0042153;C0457083;C1947944
joint damage outcomes mitt population,C0032659;C1257890
ppi use at baseline,C0042153;C0457083;C1947944
n $nmbr$ t,C0369718;C0441922
patients characteristics age years mean sd,C1510829;C2699239
week $nmbr$,C0332174;C0439230
risk factors bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
change in mtss mean,C0392747;C0443172;C1705241;C4319952
sbp mmhg mean sd,C0085805;C2699239
change in erosion score mean,C0392747;C0443172;C1705241;C4319952
heart rate b p m mean sd,C0018810;C0444504;C2699239;C2347634;C2348143
patients with no progression,C0030705;C0242656;C0449258
alcohol consumption n,C0001948
or unadjusted,C1439367
itt,
nyha class n ii,C1882085
disease activity outcomes itt population week $nmbr$,C0332174;C0439230
admission for hf in previous year n,C0184666;C0809949;C0205156;C0439234;C0439508;C1552607
acr $nmbr$,C1412134;C1515941
previous ami n,C0205156;C1552607
major clinical response,C0205082;C4055223;C0205164;C4318856;C4521762
previous stroke n,C0205156;C0038454;C4554100;C1552607
mean acrn,C0444504;C2347634;C2348143
cabg n,C0010055
eular good response,C0871261;C1704632;C1706817;C2911692
pci n,C4049621
das $nmbr$ esr lda,C0051767;C4553195;C0057671
icd n,C0021122
das $nmbr$ esr remission,C0544452;C0687702
pacemaker n,C0030163;C0810633;C1546728;C3275122;C3853703
change in das $nmbr$ esr mean i physical function outcomes week $nmbr$,C0392747;C0443172;C1705241;C4319952
history of paroxysmal atrial fibrillation n,C0729790
change in haq di mean t,C0392747;C0443172;C1705241;C4319952
peripheral vascular disease n,C0085096
with haq di decrease $nmbr$ $nmbr$,C0392756;C0547047
chronic obstructive pulmonary disease n,C0024117
fenofibric acid n $nmbr$,C0060179
neoplasia n,C0027651;C1882062
rosuvastain fenofibric acid n $nmbr$,C0060179
ischemic aetiology n,C0475224;C0015127;C1314792;C1524003
type $nmbr$ diabetes mellitusa,C1320657
pulmonary rales n,C0034642
metabolic syndromeb,C0311400;C1524026;C2707259
third heart sound n,C0232237;C0232278
baseline lipids mg dl,C0023779;C0439269
mitral insufficiency n,C0026266
tg median min max,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
aortic stenosis n,C0003507
rosuvastatin fenofibric acid,C0965129;C0060179
qrs $nmbr$ ms n available for $nmbr$ patients,C2349943;C3539704;C3713294;C0470187;C0030705
diabeticb,
left ventricular hypertrophy n,C0149721;C3484363
final mean mg dl,C0205088;C0439269;C1546485;C3853528
total cholesterol mg dl mean sd available for $nmbr$ patients,C0201950;C2699239;C0543421;C0470187;C0030705
mean change se,C0392747;C0036919;C0443172;C1705241;C4319952
ldl cholesterol mg dl mean sd available for $nmbr$ patients,C0023824;C2699239;C0202117;C0470187;C0030705
$nmbr$ $nmbr$ c,
hdl cholesterol mg dl mean sd available for $nmbr$ patients,C0023822;C2699239;C0392885;C0470187;C0030705
hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sestandard error tg triglycerides,C0062152
triglycerides mg dl mean sd available for $nmbr$ patients,C0439269;C2699239;C0470187;C0030705
ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group,C0002680;C1522609;C3887950;C0023779;C1280500;C1518681;C2348382;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
laboratory examination,C0260877
brandomization was stratified by diabetic status,C0205363;C0241863
haemoglobin g dl mean sd available for $nmbr$ patients,C0439267;C2699239;C0470187;C0030705
crosuvastatin fenofibric acid vs rosuvastatin monotherapy,C0060179;C0965129
potassium meql mean sd available for $nmbr$ patients,C0032821;C2699239;C0202194;C0304475;C0597277;C3714637;C0470187;C0030705
drosuvastatin fenofibric acid vs fenofibric acid monotherapy,C0060179
ace inhibitors arbs n,C0003015;C3888198
cure trial,C1880198;C0008976
spironolactone n,C0037982
active a,C0205177;C3853793;C3888249
diuretic drugs n,C0012798;C0013227;C3687832
ancestry f,C0016327
digitalis n,C0012252;C0304520
european,C0239307;C1535514
oral anticoagulant drugs n,C0354604
latin american,C1553378
age yij,C0001779
aspirin other antiplatelet agents n,C0004057;C0085826
without stent,C0038257
nitrates n,C0028125
with stent,C0038257
amiodarone n,C0002598
metabolizer phenotype,C0031437;C1285572
age $nmbr$ years $nmbr$,C1510829
poor,C0032854;C0542537;C2700379
ischemic aetiology,C0015127;C1314792;C1524003
ultra,C0728475
non ischaemic aetiology,C0015127;C1314792;C1524003
outcome and metabolizer phenotype,C1274040;C0031437;C1285572
nyha lll iv,C0022326;C4265176
clopidogrel versus placebo,C0070166;C0032042;C1696465;C1706408
history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
patients with events total no of patients,C0030705;C0439175;C0439810
no history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
first primary composite outcome,C0205199;C1274040;C1547335
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
second primary composite outcome,C0205199;C1274040;C1547335
total cholesterol $nmbr$,C0201950;C0543421
primary composite outcome,C0205199;C1274040;C1547335
total cholesterol $nmbr$ $nmbr$ mg dl,C0201950;C0439269;C0543421
all participants n $nmbr$,C0679646
fluvastatin n $nmbr$,C0082608
dha n $nmbr$,C0142831;C2348308
male sex no risk factors,C0086582;C0035648;C1553898
education mean sd ya,C0013621;C0013622;C0013658;C0039401
myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
apoe e $nmbr$ carriers no,C0003595;C0007294;C0523511;C1412481
angina pectoris no,C0002962
body mass indexb,C0518010
stroke or tia no,C0038454;C4554100;C0007787;C0917805;C1054154
modified hachinski ischemia scale mean sd c,C0022116;C0175659;C0349674;C1947916;C4321499
renal insufficiency no,C0035078;C1565489
smokers no,C0337664
copd no medication use,C0024117;C1412502;C3714496;C0240320
beta blocker no,C0001645
blood pressure mean sd mm hg systolic,C0428886;C0039155
antiplatelet no,
mini mental state examination mean sd d,C0451306;C2699239
anticoagulant no,C0003280;C0848112;C3536711
cognitive subscale on alzheimer s disease assessment scale mean sd e,C0450989
ace inhibitor no,C0003015;C4541021
clinical dementia rating sum of boxes mean sd f,C0451074;C1515051
calcium antagonist no,C0006684
dha intake on food frequency questionnaire mean sd mg d,C1286336
angiotensin ll receptor antagonist no,C0003018;C4521302;C4543207
plasma dha mean sd weight,C0005910;C0043100;C1305866;C1705104
nitrate no,C0028125;C0699857;C3848573
cholinesterase inhibitor use at baseline no,C0042153;C0457083;C1947944
diuretic no surgery,C0012798;C0038894;C0038895;C0543467;C1274039
memantine use at baseline no,C0042153;C0457083;C1947944
carotid artery no,C0007272;C0162859
$nmbr$ mg dabigatran n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
abdominal aortic no,C0000726;C0003483
previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
open no,C0175566
no previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
endovascular no,C0524425
on aspirin at baseline,C0004057;C0168634;C1442488
lower limb arterial no,C0003842;C0221464
vitamin k antagonist naive,C1096489;C2267235
p value for heterogeneity,C1709380;C0019409;C0242960
on statins at baseline,C0360714;C0168634;C1442488
no of events no of patients,C0441471;C3541888;C0030705
rate per year,C0871208;C1521828
type of surgery,C0332307;C1547052
$nmbr$ mg dabigatran,C0024671;C2348066;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
open,C0175566
wafarin,
endovascular,C0524425
previous stroke or tl a,C0038454;C4554100;C0220928
baseline high sensitivity crp,C3890735;C4048285
no previous stroke ortia,C0205156;C0038454;C4554100;C1552607
baseline ldl cholesterol,C0023824;C0202117
ischaemic or unknown stroke,C0475224;C0038454;C4554100
baseline total cholesterol,C0201950;C0543421
previous stroke ortia $nmbr$ $nmbr$,C0205156;C0038454;C4554100;C1552607
cardiac risk,C0035647;C4552904
previous stroke ortia,C0205156;C0038454;C4554100;C1552607
intermediate,C0205103;C1550465;C2827755;C3889971
haemorrhagic stroke,C0553692
temporary discontinuation of study drug,C0457454;C1444662;C4552847
total bleeding,C0232100
dexlansoprazole mr n $nmbr$,C0024485;C1417249;C2347167;C3254418;C4050513
$nmbr$ gi,C1708130;C3539617;C4050121
lansoprazole n $nmbr$,C0050940
intracranial bleeding,C0151699
mean age s d year,C0444504;C0001779;C2347634;C2348143;C0439234;C0439508
gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
missing,C1551393;C1705492;C3272743
previous stroke or tl a $nmbr$ $nmbr$,C0038454;C4554100;C0220928
mean bmii s d kg m $nmbr$,C0022718;C0439209;C4054209
fenofibric acid $nmbr$ $nmbr$,C0060179
alcohol users n,C0556297
rosuvastain fenofibric acid $nmbr$ $nmbr$,C0060179
smokers n,C0337664
$nmbr$ n gender n,C0369718;C0079399;C1522384;C0441922
caffeine users n,C3532939
coronaiy artery disease,C0852949
amlodipine valsartan $nmbr$ $nmbr$ mg v $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
type $nmbr$ diabetes mellitus,C1320657
amlodipine $nmbr$ mg v $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
metabolic syndrome $nmbr$ baseline lipids mg dl,C0524620;C0439269
baseline msdbp mmhg mean sd,C0168634;C2699239;C1442488
fenofibric,
baseline mssbp mmhg mean sd,C0168634;C2699239;C1442488
l value,C0439394;C1522609;C1706495;C3642217
duration of hypertension months,C0449238;C2926735
j valuc l,
mean sitting diastolic blood pressure,C1319894
acid,C0001128;C0202406
amlodipine and valsartan,C0051696;C0216784
zt $nmbr$,
mean sitting systolic blood pressure,C1319893
se,C0036919
observation,C0302523;C0700325;C1964257;C3889687
silodosin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tamsulosin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants,C0679646
age yr n,C0001779;C0439234
mean sd age y,C0444504;C0001779;C2347634;C2348143
min max,C0702093;C1524029;C3813700
minimum maximum,C0806909;C1552615;C2826546
not estimable,C1518422
study eye characteristics,C1568011;C0015392;C0700042
ipss total score,C1019118;C2964552;C1998280;C2827405;C3811063
mean sd e etdrs visual acuity letter score snellen equivalent,C0205163;C0439185
ipss storage subscore,C1019118;C0337174;C1698986;C1753314;C1998280;C2827405;C3811063
ipss voiding subscore,C1019118;C0042034;C4067975;C1998280;C2827405;C3811063
duration of macular edema mo,C0449238;C2926735
iop mm hg,C0578862;C0439475
qol due to urinary symptoms,C0518214;C0426359
delighted,C3830544
iop lowering medication,C0578862;C0441994;C2003888;C0013227;C3244316;C4284232
phakic,
pleased,C3829994;C4264468
mostly satisfied,C0242428;C4049977;C4084799
imaging data mean sd,C0011923;C2699239;C0079595
mostly dissatisfied,C0870433;C4085546
oct center point thickness pm,C0030266;C4049155
unhappy,C1688635
total macular volume mean sd mm $nmbr$,C4330985;C4554674
terrible,C3827840
area of retinal thickening within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
urine qmax ml s,C0439526;C1705224;C3887665
area of retinal hemorrhage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
baseline triglycerides,C0168634;C0041004;C1442488
area of fluorescein leakage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
baseline trig $nmbr$ millycerides g dl,C0168634;C0439267;C1442488
$nmbr$ da of capillary nonperfusion in the eyec,C0011318;C3668815
baseline concentration,C0086045;C1446561;C3827302
mean sd nonstudy eye e etdrs visual acuity letter score,C3533236;C0042812
a $nmbr$ ez n $nmbr$,C0206578
other clinical characteristics,C0683325
a $nmbr$ n $nmbr$,C0369718;C0441922
history of cancer,C0455471
a $nmbr$ ez n $nmbr$ a $nmbr$ n $nmbr$,C0206578
abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography,C3161471;C0920367
triglyceride,C0041004
rasagiline $nmbr$ mg day,C0525678;C0439422
total ldl c,C0439175;C0439810
delayed start group n $nmbr$,C0205421;C0441848;C1545665;C3272602
ldl $nmbr$ c,
ldu c,
early start group n $nmbr$,C0439659;C0441848
hdl $nmbr$ c,C3715113
time since diagnosis mo,C0040223;C3541383
study end concentration,C0086045;C1446561;C3827302
total updrs score range $nmbr$ $nmbr$ y,C2964552;C1514721;C2348147;C3542016
acute dvt study,C0557651;C2603343
motor subscale range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
continued treatment study,C0549178;C3161471
adl subscale range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
rivaroxaban n $nmbr$,C1739768
hoehn and yahr stage range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
standard therapyy n $nmbr$,C1442989;C2828392
result,C1274040;C1546471;C2825142
s e,
male sex no weight no,C0086582;C0005910;C0043100;C1305866;C1705104
$nmbr$ c i,C1547546
missing data initial diagnosis no,C0011900;C1704338;C1704656
dvt,C0149871;C2926618;C3899446
first primary change in updrs score wk wk $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
$nmbr$ only $nmbr$ distal,C0205108;C4522154
$nmbr$ mg day placebo,C0032042;C1696465;C1706408
pe,C0070939;C1880476;C4284304
second primary estimated change in total updrs score from baseline to wk $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
time from onset of symptoms to randomization days,C1320528;C0034656;C0439228
$nmbr$ mg day early start,C0439422;C0439659
cause of dvt or pe no,C0015127;C1524003;C0070939;C1880476;C4284304
$nmbr$ mg day delayed start,C0439422;C0439659
unprovoked,
$nmbr$ mg day early start delayed start,C0439422;C0205421;C1545665;C3272602
recent surgery or trauma,C0038894;C0038895;C0543467;C1274039;C0043251;C1510467;C3263723;C3714660;C4049136
third primary change in updrs score wk wk $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
immobilization,C0020944;C4048292
secondary change in total updrs score from baseline to final visit in phase $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205390;C1710475
estrogen therapy,C0279494
rituximab n $nmbr$,C0393022
puerperium,C0034042;C0086839;C1879329
age mean yr sd,C0001779;C2699239
known thrombophilic condition no,C0012634;C0348080;C1705253;C3864998
gender no,C0079399;C1522384
previous vte no,C0205156;C0630906;C1552607
disease duration mean yr sd,C0872146;C2699239
rivaroxaban,C1739768
since onset,C0206132;C0332162
enoxaparin vka,C0206460
since diagnosis,C0011900;C1704338;C1704656
qverall,
prior ms treatment with ifn beta or,C1514463;C0015980
ofl,
glatiramer acetate no,C0289884
renal function creatinine clearance,C0232813;C0699829
no prior ms therapies,C1514463;C2349943;C3539704;C3713294
cardiac disease,C0018799
ended $nmbr$ days before trial entry,C0439228;C0008976
no cardiac cisease,C0018787;C1522601
edss score,C0449820;C4050231
intended duration of anticoagulation,C0449238;C2926735
median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
$nmbr$ months,C0439231
edss stratification no,C0451246;C1514983;C3887783
m,
total gadolinium enhancing lesion count no,C0439175;C0016911;C0439810;C2349975;C0750480;C1705566
patient anticoagulation before randomisation,C0003281;C2917212;C2919015;C3537050
previous episodes of dvt pe,C0332189;C0070939;C1880476;C4284304
brain volume cm $nmbr$,C1113695
idiopathic index dvt,C0149871;C2926618;C3899446
t $nmbr$ lesion volume mm $nmbr$,C4330985;C4554674
spontaneous dvt pe,C0070939;C1880476;C4284304
msfc timed $nmbr$ foot walk test median seconds,C0560030
secondary dvt pe,C0070939;C1880476;C4284304
age gd lesion,C0221198;C1546698
ill,C0231218
effect estimate,C1280500;C0750572;C1518681;C2348382
known thrombophilic condition,C0012634;C0348080;C1705253;C3864998
age $nmbr$ gadolinium lesion $nmbr$ n $nmbr$,C0001779;C0016911
no known thrombophilic condition,C0012634;C0348080;C1705253;C3864998
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019
location of index dvt,C0450429;C1515974;C4284930;C4284931
reteplase abciximab facilitated pci n $nmbr$,C0256103;C0288672
non extensive,C1518422;C0205231
treated with insulin,C0332293;C0021641;C1533581;C1579433;C3714501
p o,C0369773;C2603361
previous chf,C0205156;C0018802;C1552607
malignancy at randomisation,C0006826;C1306459;C4282132
location of infarction,C0450429;C1515974;C4284930;C4284931
no active cancer,C0006826;C0998265;C1306459
inferior posterior,C0542339;C0205095;C0678975
mobility at randomisation,C0080078;C0425245;C0449580;C4318935
primary pci,C0205225;C0439612;C0439631
no immobilization,C0020944;C4048292
ret abx facil pci,C0389252;C4049621
$nmbr$ j,
i $nmbr$,C0021966;C0221138
vitamin k antagonist received,C1096489;C2267235;C1514756
no unknown,C0439673;C3541433;C4050014
acenocoumarol,C0000956
sites,C0205145
cm,
time of symptom onset to randomization hrs,C1320528;C0034656;C1568891
sonth america,C0002454
time of qualifying ecg to balloon inflation hrs,C0040223;C3541383;C1514624;C1623258;C0021398;C1318493
kg,C0022718;C0439209;C4054209
tertile $nmbr$,
n n $nmbr$ $nmbr$,C0369718;C0441922
time of symptom onset to balloon inflation hrs,C1320528;C0021398;C1568891;C1318493
$nmbr$ $nmbr$ mvmin,
tertile $nmbr$ index pci performed,C0600653;C4049621;C0918012;C1552854;C1637833;C2986546;C0884358
$nmbr$ montlts,
enrollment in lmwh,C1516879;C1696073;C3888021
parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
abx facil pci,C4049621
uncodable,
n_,C0369718;C0441922
vka naive,
cutoffs,C1442160
vka experienced,
combo facilitated pci,C4049621
never been on a vka,C2003901
abciximab facilitated pci,C0288672;C4049621
ever been on a vka,
combo vs primary,C0205225;C0439612;C0439631
no vka at randomization,C0034656
abciximab vs primary,C0288672;C0205225;C0439612;C0439631
vka at randomization,C0034656
timi $nmbr$,
total randomized,C0439175;C0439810;C0034656;C3815594
timi $nmbr$ and spoke,
dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
timi $nmbr$ and spoke and time $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
chads $nmbr$ scoret,C0007928;C1413373
alteplase n $nmbr$,C0032143
prior transient ischemic attack,C0007787;C0917805
baseline nihss,C0168634;C1697238;C1442488
baseline aspirin use,C0042153;C0457083;C1947944
median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
event,C0441471;C4019010
previous use of antiplatelet drugs,C1524063
d $nmbr$,
atrial flutter fibrillation,C0155709
d $nmbr$ vs warfarin,C0043031
never smoked,C0037366;C0439994;C1881674
y,
ex smoker,C0337671;C4555205
interaction pf,C1704675;C3815179
time to treatment initiation min,C3494202;C0589507;C1158830;C1704686
stroke or systemic embolism,C0038454;C4554100;C0013922;C1704212
time to treatment min t,C3494202;C0702093;C1524029;C3813700
life threatening bleeding disabling stroke and death,C1546953;C0019080;C2826244;C3537125;C0038454;C4554100;C0011065;C1306577;C4082313;C4552775
odds ratio $nmbr$ cl,C0028873;C0596019
gastrointestinal bleeding,C0017181
nihss at baseline,C1697238;C0168634;C1442488
fa $nmbr$ mg $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous diabetes,C0011847;C0011849
r $nmbr$ mg n $nmbr$,C0687673;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
arial flutter or fibrillation,C0016385;C2242390;C0232197
r $nmbr$ mg fa $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous chronic use of antiplatelet drugs,C1524063
r $nmbr$ mg $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
itt population,C0032659;C1257890
body weight kg n,C0005910;C1305866
intention to treat,C0162425;C1283828
comorbidities n a,C0009488
intention to treat without st segment elevation myocardial infarction,C0162425;C1283828;C1536220
metabolic syndrome $nmbr$,C0524620
dm medication n c,C0011816;C0013227;C3244316;C4284232;C3250443
intention to treat with st segment elevation myocardial infarction,C0162425;C1283828;C1536220
glipizide,C0017642
cangrelor n $nmbr$,C1121991
pioglitazone,C0071097
race or ethnic group no total no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0439175;C0439810;C0016327
mean lipid values mg dl,C0023779;C0439269
interquartile range height cm,C1711350;C0489786
hdl cd,C0007928;C0034283;C4552032
stable angina no,C0340288
apobe,
unstable angina no,C0002965
fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
myocardial infarction without st segment elevation no,C1536220
r $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
st segment elevation myocardial infarction no,C1536220
r $nmbr$ mg fa,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
other medical history no total no,C0262926;C1704706;C0439175;C0439810
h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
family history of coronary artery disease,C2317524
baseline median mg l,C0168634;C0439268;C1442488
ptca or pci,C2936173;C4049621
final median mg l,C0205088;C0439268;C1546485;C3853528
periprocedural medications no total no,C0013227;C0802604;C2598133;C4284232;C0439175;C0439810
median change,C0392747;C0443172;C1705241;C4319952
bivalirudin,C0168273
value $nmbr$,C1522609
glycoprotein iib iiia inhibitors,C0016011;C0243077
ada $nmbr$ $nmbr$ n[ $nmbr$,C1060325;C3811629
study treatment no total no,C1521826;C0439175;C0439810
age years median range,C1514721;C2348147;C3542016
no of target vessels,C0449618
$nmbr$ $nmbr$ e $nmbr$,
$nmbr$ $nmbr$ $nmbr$ e $nmbr$,
non drug eluting stent,C1518422;C1322815
disease location,C0450429;C1515974;C4284930;C4284931
angiographic complications site reported no total no,C0205145;C1515974;C2825164;C0684224;C0700287;C4319718;C0439175;C0439810
extensive colitisy,C0205231
threatened abrupt vessel closure,C0185003;C1521802
unsuccessful procedure,C0184661;C2700391;C3274430;C3539779
left sided colitisz,C0205091;C0443246
otherx,
abrupt vessel closure,C0185003;C1521802
disease duration years median range,C1514721;C2348147;C3542016
new or suspected thrombus,C0205314;C0087086;C0302148;C3146237
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$ $nmbr$,
acute stent thrombosis,C0205178;C3897493
endoscopy subscore,C0014245
need for urgent coronary artery bypass grafting,C0439609;C0010055;C3272275
rectal bleeding subscore,C0018932;C0267596
intravenous study drug administered no,C0683092;C1521801
pga subscore,C0016410;C3541266;C4050369
bolus administered no,C1186706;C1511237;C1705509;C3812160;C1521801
stool frequency subscore,C0015733;C0183622
infusion administered no total no,C0574032;C1827465;C1521801;C0439175;C0439810
crp mg l median range,C1514721;C2348147;C3542016
duration of infusion hr,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$,
oral study drug administered no total no,C0013175;C1521801;C0439175;C0439810
corticosteroid without imm,C0001617;C3536709
figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population,C0028873;C2986535;C0011900;C1704338;C1704656;C0087111;C0032659;C1257890;C1292734;C1522326
imm without corticosteroid,C0205470;C0001617;C3536709
hs crp,C3890735;C4048285
corticosteroid imm,C0001617;C0205470;C3536709
hs crp $nmbr$ $nmbr$ mg l,C3890735;C0439268;C4048285
no corticosteroid no imm,C0001617;C3536709;C0205470
p all vs all,C0369773;C2603361
ada $nmbr$ $nmbr$ n $nmbr$,C1060325;C3811629
all n $nmbr$ f,C0369718;C0016327;C0441922
mayo $nmbr$,C0454788;C1077578
^ $nmbr$ y n,
remission n,C0544452;C0687702
nyha class n,C1882083
difference from placebo $nmbr$ ci,C1705241;C1705242
atrial fibrillation or flutter ecg,C0004238;C0344434;C1963067;C0016385;C1623258;C2242390
extensive colitis,C0009319;C1963084
serum creatinine mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
no extensive colitis,C0009319;C1963084
serum creatinine $nmbr$ mmol l n,C0201976;C0600061
imm corticosteroid,C0001617;C3536709
egfrmdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
no aminosalicylates,C0368663
egfrmdrd,
crp $nmbr$ mg l,C3890735;C0439268;C4048285
nt probnp pmol l^,C0669479;C0439284;C0754710
weight $nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
medication n,C0013227;C3244316;C4284232
weight $nmbr$ $nmbr$ kg $nmbr$ $nmbr$ kg,C0005910;C1319635;C0043100;C1305866;C1705104
antiplatelet or anticoagulant,C0003280;C0848112;C3536711
all patients with opg n $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
type of hospitalization,C3177060
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C0439297
placebo n rate,C0871208;C1521828
tertile $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C0439297
rosuvastatin n rate,C0871208;C1521828
p trend,C1521798;C4554533
p subgroup,C1079230;C1515021
end points,C2349179
all cause,C0015127;C1524003
non cv mortality,C0026565;C0026566
hospitalizations n,C0019993
hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
cardiovascular,C0007226;C3887460
combined end points,C0205195;C2349179
worsening heart failure,C0332271;C1457868;C1546960;C0018801;C0018802;C4554158
coronary,C0018787
noncardiovascular,
all cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C1524003;C0018488;C0019993;C1313497;C1538440;C3273279
item,C1551338;C4554251
cholesterol mmol l,C0008377;C1532563
baseline median iq range,C1514721;C2348147;C3542016
apob apoa $nmbr$ ratio,C0456603;C1547037
$nmbr$ month follow up median iq range,C1514721;C2348147;C3542016
serum creatinine umol lf,C1416933;C2986618;C4554443
difference median,C0549183;C0876920;C2347635;C2348144;C2939193
egfrmdrd ml min $nmbr$ $nmbr$ $nmbr$ m_ $nmbr$,C0439445
p net difference,C1705241;C1705242
nt probnp pmol l,C0669479;C0439284;C0754710
triglycerides mmol lf,C1416933;C2986618;C4554443
crp mg l,C3890735;C0439268;C4048285
placebo n rate $nmbr$,C0871208;C1521828
opg ng ml,C1262886;C0439275;C1336645;C1412836;C1710303
rosuvastatin n rate $nmbr$,C0871208;C1521828
current medication n,C0746467
hazard ratio $nmbr$,C2985465
$nmbr$ cit,C0008864;C0523573;C1427027;C4553421
$nmbr$ ci $nmbr$,C0008107;C3259781
all randomly assigned,C1516050;C1552601
subgroup p value $nmbr$,C1079230;C1709380;C1515021
coronary end point,C2349179;C2826544
interaction p value $nmbr$,C1704675;C1709380
all cause mortality or hf hospitalization^,C0015127;C0026565;C0026566;C1524003;C0018488;C0019993;C1313497;C1538440;C3273279
primary endpoint $nmbr$,C2986535
dexlansoprazole mr $nmbr$ mg n $nmbr$,C0024485;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1417249;C2347167;C3254418;C4050513
hs c reactive protein $nmbr$ $nmbr$ nlg l,C0006560;C1413716;C4048285
age at baseline years,C1510829;C0168634;C1442488
all randomized,C0034656;C3815594
ppi use within $nmbr$ months of randomization,C1524063;C0034656
coronary events $nmbr$,C0741923
alcohol drinker,C0001962;C0556338;C0001975
all cause mortality or hosp for worsening hf,C0015127;C0026565;C0026566;C1524003;C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
caffeine user,C3532939
no of events rate,C0441471;C0871208;C1521828;C3541888
indacaterol $nmbr$ gg qd,C0017454;C0332173;C0018370
placebo rosu vastatin,C0032042;C1099881;C1696465;C1706408
formoterol $nmbr$ gg bid,C0017454;C0018370
primary endpoint,C2986535
salmeterol $nmbr$ gg bid,C0017454;C0018370
hscrp $nmbr$ $nmbr$ mg l,C0439268
tiotropium $nmbr$ gg qd,C0017454;C0332173;C0018370
hscrp $nmbr$ $nmbr$ mga,C0065879
male female,C0043210;C0086287;C1705497;C1705498
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$,
fev $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
$nmbr$ $nmbr$ $nmbr$ $nmbr$ z $nmbr$ ze,
fev $nmbr$ predicteda,C3714541
$nmbr$ $nmbr$ $nmbr$ d $nmbr$,
ics use yes no,C0042153;C0457083;C1947944;C1512698
$nmbr$ $nmbr$ j z $nmbr$ $nmbr$ e,
ex smoker smoker,C0337671;C4555205
coronary endpoint,C2349179;C2826544
$nmbr$ $nmbr$ c $nmbr$ $nmbr$ $nmbr$,
history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0521116;C0018799;C1705970
$nmbr$ $nmbr$ $nmbr$ $nmbr$ s $nmbr$,
treatment duration days,C0444921;C0439228;C3259042
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
patients treated for $nmbr$ weeks,C0030705;C1522326;C0439230
hosp worsening hf,C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline,C0439165;C1549488;C1561533;C1412268;C2699274;C1518422;C0850624;C0168634;C1442488
$nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$,
ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus,C4049864;C1722260;C0439272;C0011849
all cause mort hf hosp,C0015127;C0018488;C1313497;C1538440;C3273279;C1524003
carisbamate $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hscrp $nmbr$ $nmbr$ mga $nmbr$ $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$,C0065879
carisbamate $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ z $nmbr$,
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ j,
time since epilepsy diagnosis years,C0556970;C0011900;C1704338;C1704656
lm $nmbr$ $nmbr$,C1261082;C1551056
number of previous reported aeds,C0237753;C0449788
glargine $nmbr$,C0907402
baseline monthly pos seizure rate,C0871208;C1521828
sex male female,C0086287
number of co aeds n,C0237753;C0449788
race ethnicity zz,C0015031;C2347310;C0243103
patients with $nmbr$ co aed,C0030705;C0887457
black african,C0337824
patients with $nmbr$ co aeds,C0030705;C0180309
descent,C0205386;C0680043
ugt induction status as randomizeda n,C0205263;C0449438;C0857127
hbaie,
inducing,C0205263
concomitant oral glucose lowering agents zz,C0442027;C0017725;C4521986;C0441994;C2003888;C0450442;C2347310;C1254351;C1521826
noninducing,
met su tzd,C0428210;C0038642;C1705534;C1550543;C4317104
ugt induction status per aeda n,C0205263;C0449438;C0857127
su tzd,C0038642;C1705534
syndrome n,C0039082
su met,C0428210;C1550543;C4317104
symptomatic localization related,C0475264;C1744691;C0439849;C0445223
met tzd,C0428210;C1550543;C4317104
cryptogenic localization related,C0475264;C1744691;C0439849;C0445223
mmf n $nmbr$,C0083765;C0209368;C3848524
undetermined,C0205258;C3536725;C4082977
ivc n $nmbr$,C4085887
saxa $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age at diagnosis of sle years,C1828181;C3173302
pbo n $nmbr$,C0031962
time since diagnosis of sle years,C0556970;C0011900;C1704338;C1704656
age category years n,C1510829;C0683312;C3889287
age at diagnosis of ln years,C1828181;C3173302
renal impairment n,C1565489
time since diagnosis of ln years,C0556970;C0011900;C1704338;C1704656
duration of t $nmbr$ dm years,C0449238;C2926735
renal biopsy class,C0456387;C1518526;C1705943
hba $nmbr$ c category n,C0019016;C0683312;C3889287;C1825777;C3538758
class iii iii v,C0441887;C2698969
fpg mmol l,C1532563
class iv iv v,C0441888;C2698970
crcb ml min mean s e,C0444504;C2347634;C2348143
class iv only,C0441888;C2698970
diabetes therapy n,C3274787;C3539002
class v only,C0456387;C1518526;C1705943
oral blood glucose lowering drug $nmbr$ $nmbr$ $nmbr$,C0442027;C0005802;C4521986;C0441994;C2003888;C0013227;C1254351
scarring on renal biopsy,C0194073
sulphonylurea,C0038766;C3536898
$nmbr$ $nmbr$ $nmbr$ a,
glinide,C2266929
urine p cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
oral blood glucose lowering,C0442027;C0005802;C4521986;C0441994;C2003888
$nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
drug and insulint,C0013227;C1254351
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e,
saxa $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
baseline hba $nmbr$ c mean s e,C0444504;C2347634;C2348143
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
week $nmbr$ hba $nmbr$ c mean s e,C0444504;C2347634;C2348143
gfr,C0017654;C1424601
adjusted change from baseline mean s e,C0392747;C0443172;C1705241;C4319952
serum albumin concentration g l,C0439294;C0456615
difference vs pbo,C1705241;C1705242;C0031962
$nmbr$ $nmbr$ $nmbr$ $nmbr$ g,C0439267
mean s e,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
moderate renal impairment,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
patients with negative anti dsdna,C0030705;C0741099
severe renal impairment,C0205082;C1565489;C4050465;C4050466
antibody binding level at baseline,C0428536
measures mmol l,C0079809;C1532563;C1879489
geometric anti dsdna antibody binding level,C0428536
baseline fpg mean s e,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
week $nmbr$ fpg mean s e,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ j,
adjusted change from baseline,C0392747;C0443172;C1705241;C4319952
patients with low,C0030705;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
differencevs pbo,C0031962
concentrations at baseline,C0086045;C0168634;C1442488
overall w $nmbr$ $nmbr$ $nmbr$,C0282416;C1561607
geometric c $nmbr$ concentration mg dl,C0086045;C0439269;C1446561;C3827302
combined therapy v $nmbr$ $nmbr$ $nmbr$,C0033972
$nmbr$ $nmbr$ $nmbr$ $nmbr$ k,C0597277;C1708601
dutasteride w $nmbr$ $nmbr$ $nmbr$,C0754659
selena sledai total score,C0451528;C2964552
tamsulosin w $nmbr$ $nmbr$ $nmbr$,C0257343
dabigatran n $nmbr$,C2348066
ipss o,C1019118;C1998280;C2827405;C3811063
warfarin n $nmbr$,C0043031
pv ml,C0439526;C1705224;C3887665
estimated creatinine clearance ml min,C0812399;C0439445
psa level ng ml,C4086720;C0439275
type of index event no,C1561488;C0600653;C0918012;C1552854;C1637833;C2986546
qmaxi rn l s,C2827110;C3540639;C4281819
deep vein thrombosis only,C0149871
previous treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pulmonary embolism only,C0034065
ipss hrql,C1019118;C1998280;C2827405;C3811063
both deep vein thrombosis and pulmonary embolism,C0149871;C0034065
at $nmbr$ years,C0439234
neither deep vein thrombosis nor pulmonary embolism^,C0149871;C0034065
rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl,C0301630;C0596019;C0392756;C1293152;C4551656
cancer no,C0006826;C0998265;C1306459
combined dutasteride ta msu losi n,C0039297;C0024776;C1412759;C1506978;C1705538;C3272501;C4553364
previous venous thromboembolism no,C0205156;C1861172;C1552607
dutasteride,C0754659
parenteral anticoagulation,C0003281;C2917212;C2919015;C3537050
tamsulosin,C0257343
treatment before randomization days,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
incidence o $nmbr$ $nmbr$ cl,C0021149;C0596019;C0220856
combined therapy vsdutasteride,C0033972
treatment after randomization in the single dummy phase days],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0037179;C0439228;C0087136;C0205171
combined therapy vsta msu iosin,C0033972;C0024776;C1412759
unfractionated heparin no,C0019134;C2825026
ipss,C1019118;C1998280;C2827405;C3811063
low molecular weight heparin no,C0019139;C3536766
change in das $nmbr$ $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
fondaparinux no,C1098510
week $nmbr$ responders n $nmbr$,C0332174;C0439230
double dummy phase,C0205390;C1710475
acr $nmbr$ week $nmbr$ responders n $nmbr$,C0332174;C0439230
exposure to study drug days,C0332157
all responders n $nmbr$,
adherence to study regimen no,C1510802;C0040808;C2945654
no previous dmard mean sd,C0205156;C2699239;C1552607
percent of the time that inr was in the therapeutic range,C0439165;C0040223;C3541383;C0525032;C1704538;C0460097
disease duration yrs mean sd,C0872146;C2699239
dabigatran,C2348066
mtx dose $nmbr$ mg week,C0332174;C0439230
percentages of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
steroid use,C0281991
weight category,C0683312;C3889287
rf positive $nmbr$ iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
bmi category kg m $nmbr$,C0022718;C0439209;C4054209
sjc mean sd,C0444504;C2699239;C2347634;C2348143
creatinine clearance category [ml min],C0683312;C3889287;C0439445
tjc mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ ml mln,C1417190;C3815103
mtss mean sd,C0444504;C2699239;C2347634;C2348143
previous vte,C0205156;C0630906;C1552607
das $nmbr$ range $nmbr$ $nmbr$ mean sd,C0051767;C2699239;C0057671
initial symptomatic pe,C0070939;C1880476;C4284304
pain vas range $nmbr$ $nmbr$ mm mean sd,C0042815;C2699239
active cancer at baseline,C0006826;C0998265;C1306459
haq di range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
measure,C0079809;C0242485
fenofibric acid,C0060179
fas range $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
low dose statin,C0445550;C0360714;C1708745
crp mean mg l sd,C0439268;C2699239
olmesartan n $nmbr$,C1098320
fenofibric acid low dose statin,C0060179;C0360714
duration yr,C0449238;C0439234;C2926735
mean percentage change from baseline to final visit,C0392747;C0443172;C1705241;C4319952;C0545082;C1512346;C2826704
prior treatment no,C1514463
final,C0205088;C1546485;C3853528
former smoker,C0337671
efficacy variable,C0439828;C4553760
metabolic syndrome no,C0524620
fenofibric acid i low dose statin,C0060179;C0360714
glucose mmol liter,C0017725;C0475211
final mean,C0444504;C2347634;C2348143
overall freedom population n $nmbr$,C0016694;C0032659;C1257890
change mean se,C0392747;C0036919;C0443172;C1705241;C4319952
prevalent vertebral fracture status,C0080179;C0449438
apoal,
change meanlse,C0392747;C0443172;C1705241;C4319952
femoral neck bmd t score,C0449820;C4050231
baseline median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0000768;C0221430;C0302142;C0369718;C0441922
change median q $nmbr$ q $nmbr$,C0392747;C0443172;C1705241;C4319952
age yr mean sd bmd t score mean sd,C0001779;C3533236
vldl c,C0523560
subjects with prevalent vertebral fracture n prevalent vertebral fracture,C0681850;C1550501;C1706203;C2349001;C2697811
total c,C0439175;C0439810
numbera,
moderate dose statin,C1709056;C0360714
severitya,
fenofibric acid moderate dose statin,C0060179;C0360714
salmeterol n $nmbr$,C0073992
change meantse,C0392747;C0443172;C1705241;C4319952
duration of copd yr f,C0449238;C2926735
safety variable,C0439828;C4553760
gold stage c,C0018026;C0441785;C1304897
spirometry after bronchodilation,C0037981;C1371299;C3537072
fenofibric acid $nmbr$ low dose statin,C0060179;C0360714
pulmonary medications,C0013227;C0802604;C2598133;C4284232
fenofibric acid i moderate dose statin,C0060179;C0360714
anticholinergic drug,C0242896
investigator reported aes,C1412268;C2699274
js $nmbr$ agonists,C0243192;C2987634
any treatment emergent ae,C0039798;C3887670;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
long acting^,C0205166;C1706317
myalgia,C0231528;C4552646
inhaled^,C0004048
rhabdomyolysis,C0035410;C4552660
with tiotropium,C0213771
laboratory evaluations,C0022877;C0220825;C3244292;C4283904
with long acting j $nmbr$ agonists,C0243192;C2987634
alt $nmbr$ x uln on two consecutive visits,C1519815;C0205448
methylxanthines,C0066447
ast $nmbr$ x uln on two consecutive visits,C1519815;C0205448
tiotropium no of patients total no,C0213771;C0030705;C0439175;C0439810
ck $nmbr$ xuln,C0009212;C0010287;C1872855
salmeterol no of patients total no,C0073992;C0030705;C0439175;C0439810
creatinine $nmbr$ $nmbr$ x baseline and above uln,C0168634;C1442488;C1519815
copd severity stage gold,C0018026;C1304897
creatinine $nmbr$ x baseline,C0168634;C1442488
stage ii,C0441767
mean change s in fasting blood glucose [mg dl mmol l ],C0392747;C0443172;C1705241;C4319952;C0428568;C1261430;C0439268
stage iii,C0441771
f $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
stage iv,C0022326;C4265176
neither t $nmbr$ dm nor mets,C0011816;C3250443;C0812270;C1705694;C2939420
noncurrent smoker,C0337664
metabolic syndrome w o t $nmbr$ dm,C0524620;C0796110
use of inhaled glucocorticoids at baseline,C1524063;C0004048;C0168634;C1442488
t $nmbr$ dm,C0011816;C3250443
isolated impaired glucose tolerance no,C0205409;C0271650;C1548221
a $nmbr$ ez $nmbr$,C0206578
both impaired glucose tolerance and impaired fasting glucose tolerance no,C0271650
mean age years s d,C0444504;C1510829;C2347634;C2348143
ratio of women to men,C0456603;C1547037;C0025266
other forms of,C0348078;C0376315
family history of diabetes no,C1313937
atherosclerosis^ n,C0003850;C0004153
history of gestational diabetes mellitus no of women,C2183115;C0043210
multiple $nmbr$ chd risk,C0439064;C1282512
factors that confer a,C1521761;C2827422
mean age yr,C0001779;C0439234
$nmbr$ year risk for chd,C0439234;C1282512;C0439508
mean bmi,C0444504;C0578022;C2347634;C2348143
bmi group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
family history of premature,C0241889;C0151526;C0205252;C4018905
hbaic,
tg $nmbr$ mg dl n o,C0337445;C0439269
$nmbr$ hr plasma glucose mg dl,C0202042;C0439269;C0455280
hbalc mean s d,C0444504;C2347634;C2348143
fasting plasma insulin mu liter,C0857690;C0475211
baseline ldl c strata n o,C0168634;C1442488
lipid levels mg dl,C0428460;C0439269
$nmbr$ and $nmbr$ mg dl,C0439269
$nmbr$ and,
fasting free fatty acids ^mol liter,C0015663;C0015688;C0347982
parameter mg dl,C0549193;C0439269;C1704769;C2350001
incidence rate per $nmbr$ person yr,C1708485;C0027361;C2347489
mets w o t $nmbr$ dm,C0812270;C1705694;C2939420
$nmbr$ s,
a $nmbr$ ez $nmbr$ a $nmbr$ n $nmbr$ n $nmbr$,C0206578;C0369718;C0441922
men $nmbr$ cm,C0025266
women $nmbr$ cm,C0043210
a $nmbr$ ezio a $nmbr$ n $nmbr$ n $nmbr$,C0369718;C0441922
treatment difference $nmbr$ ci,C0008107;C3259781
glucose test,C0337438;C0595310
isolated igt,C0205409;C1548221
apolipoprotein b^,C0003593
ifg and igt,C1334085;C1708411
apolipoprotein a i,C0085201;C1677784
time since diagnosis of diabetes n,C0040223;C3541383
total cholesterol hdl c,C0023822
acei arb therapy n,C0039798;C0087111;C1363945
apo b apo a l,C1447574;C4521365
urine acr geometric mean cv a b mg g,C2986759;C1300563
non hdl c hdl c,C1518422;C3715113
^ $nmbr$ mg g n,C1300563
treatment difference $nmbr$ cl,C0039798;C0596019;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ mg g n,C1300563
age y mean sd,C0001779;C2699239
mdrd egfr geometric mean cv a b ml,C0439526;C1705224;C3887665
men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
min per $nmbr$ $nmbr$ m $nmbr$,C0702093;C1524029;C3813700
men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
previous a blocker,C0205156;C1552607
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ n,C0439445;C0369718;C0441922
use,C0042153;C0457083;C1947944
$nmbr$ to $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ n,C0439445;C0369718;C0441922
sexually active $nmbr$,C0241028
rosiglitazone versus metformin,C0289313;C0025598
coronary artery,C0205042
rosiglitazone versus glyburide,C0289313;C0017628
albumin to creatinine ratio acr,C1412134;C1515941
calcium channel,C0006685
blocker,
normal acr $nmbr$ mg g,C0205307;C1300563;C0231683;C0439166;C2347086;C4553972
angiotensin,C0003018;C4521302
$nmbr$ year cumulative incidence ci,C0008107;C3259781
converting enzyme inhibitor,C0014432;C0919438;C4521603
albuminuria acr $nmbr$ m g g at baseline to normoalbuminuria,C1412134;C1515941;C1319635;C0168634;C1442488
angiotensin receptor,C0034787;C1622222
mdrd egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
oral diabetic agent,C0450442;C1254351;C1521826
normal or high egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ at baseline to low egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C0205250;C0439445;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C0168634;C1442488
ipss mean sd,C0444504;C2699239;C2347634;C2348143
normal egfr $nmbr$ egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ at baseline to high egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0168634;C1442488
ipss qol,C1019118;C0518214;C1998280;C2827405;C3811063
without hypertension at baseline to hypertension,C0020538;C1963138
bii mean sd,C0444504;C2699239;C2347634;C2348143
high dose statin pretreatment n $nmbr$,C0444956;C0360714
tadalafil $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
systemic hypertension,C0020538
tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clinical presentation,C2708283
mild ed n $nmbr$,C2945599;C3538926
medical therapy,C0418981
moderate to severe ed n $nmbr$,C1299393;C3538926
ace inhibitors sartans,C0003015;C1563745
subgroup p interaction p,C1079230;C1515021
multivessel pci,C4049621
ipss ls mean se,C0023668;C0036919
treated vessel,C1522326;C0005847
ipss qol ls mean se,C0023668;C0036919
left main,C0205091;C0205225;C1542147;C0443246;C1552822
bii ls mean se,C0023668;C0036919
left anterior descending,C0441998;C0205386;C1547177
a $nmbr$ e $nmbr$ n $nmbr$,C1272460
left circumflex,C0205091;C1880089;C0443246;C1552822
a $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
right coronary,C0225808
mean age years race,C0034510;C1706779;C3853635
saphenous vein graft,C0729538
body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
lesions b $nmbr$ c,C0221198
$nmbr$ concomitant medication,C0013227;C3244316;C4284232
antithrombotic therapy,C0039798;C0087111;C1363945
other forms of atherosclerosis,C0348078;C0376315
glycoprotein llb llla inhibitors,C0017968;C0243077
diabetes mellitus type $nmbr$ or $nmbr$,C1320657
stable angina,C0340288
metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata,C0524620;C0023824
single vessel pci,C0037179;C0005847;C0087136;C0205171
$nmbr$ but,
ilb iiia inhibitors,C4697913;C0243077
no ilb iiia inhibitors,C4697913;C0243077
figure $nmbr$ percentage of change from treated baseline in ldl cholesterol at week $nmbr$ a and week $nmbr$ b in prespeci ed subgroups treated with ezetimibe added to atorvastatin $nmbr$ mg versus up titration to atorvastatin $nmbr$ mg or atorvastatin $nmbr$ $nmbr$ mg a $nmbr$ atorvastatin $nmbr$ mg a $nmbr$ $nmbr$ $nmbr$ weeks of atorvastatin $nmbr$ mg followed by $nmbr$ weeks of atorvastatin $nmbr$ mg bl baseline bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol hs crp high sensitivity c reactive protein ldl c ldl cholesterol tg triglycerides,C0439165;C1549488;C1561533;C0168634;C1442488;C0332174;C0439230;C1706331;C0332293;C1142985;C1524062;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0547043;C0162621;C0332283;C0062152
bosentan n $nmbr$,C0252643
mn na ve population,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0032659;C1257890
location n,C0450429;C1515974;C4284930;C4284931
uplift population,C0032659;C1257890
japan and south korea,C0022341;C0022773
all mn na ve patients,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0030705
sex men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
all non mn,C0026327;C0026405;C4285072
median duration of symptoms range yr,C0436359;C0439234
sex m f,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0016327
median time since diagnosis range yr,C1554109;C0011900;C1704338;C1704656
active smokers,C0205177;C0337664;C3853793;C3888249
smoking history n,C1519384
copd history yrs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ever smoked current former,C0205156;C0750523
pre fev $nmbr$ pred,C0032952;C0044955
pulmonary function tests of predicted,C0024119;C2598152
post fev $nmbr$ pred,C0032952;C0044955
mean fvc sd,C0444504;C2699239;C2347634;C2348143
pre fvc pred,C0032952;C0044955
mean dlco sd,C0444504;C2699239;C2347634;C2348143
post fvc pred,C0032952;C0044955
$nmbr$ day l,C0332173;C0439228;C0439505
blood oxygenation mean sd,C0005767;C2699239;C0005768;C0229664
$nmbr$ month l,C0332177;C0439231
pao $nmbr$ at rest mm hg,C0232555;C1423784;C1427155;C4318615;C0035253;C0439475;C1622890
$nmbr$ yrs l,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
decline ml yr $nmbr$,C0439526;C0439234;C1705224;C3887665
aapo $nmbr$ at rest mm hg,C0035253;C0439475;C1622890
pre fev $nmbr$,C0332152;C3714541;C0740175;C2257086;C3669034
digital clubbing n,C0442015;C1883674;C0009080;C0149651;C0369718;C0441922
post fev $nmbr$,C0687676;C3714541;C1704687;C3469826
corticosteroid use $nmbr$ n,C0239126
pre fvc,C0332152;C3714541;C0740175;C2257086;C3669034
presence of honeycombing $nmbr$ n,C0150312;C0392148;C3854307;C0332468;C0349384;C0369718;C0441922
post fvc,C0687676;C3714541;C1704687;C3469826
baseline dyspnea index mean total score,C3533236
pre svc,C0332152;C0231957;C0740175;C2257086;C3669034
sf $nmbr$ health transition score,C0449820;C4050231
post svc,C0687676;C0231957;C1704687;C3469826
eq $nmbr$ d visual analog score,C0205163;C0439185;C0234621;C0243071
glipizide n $nmbr$,C0017642
use of supplemental oxygen n,C4067893;C4554557
duration of diabetes mellitus median iqr y,C0449238;C2926735
bosentan,C0252643
dyslipidemia n,C0242339
median $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
prior myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
us,C0815353;C3889164
presenting condition n,C0449450;C0012634;C0348080;C1705253;C3864998
baseline fvc l,C0168634;C1442488
acute coronary syndrome,C0948089
median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
elective procedure,C0747973
baseline dlco mmol kpa,C0263428;C0439474
min,C0702093;C1524029;C3813700
baseline procedure n,C0168634;C0184661;C2700391;C3274430;C3539779;C1442488
medication use n,C0240320
stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$,C1739039;C3811844;C3812682;C0439445
other antiplatelet,
stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$,C0205390;C0439526;C1705224;C3887665;C1300072;C1306673
fibrate or other lipid lowering agent,C0086440
taking calcium supplements at baseline n,C3540037;C0168634;C1442488
serum creatinine mean sd mg dl,C0201976;C0439269;C0600061
no alcohol consumption on average,C0001948;C1510992;C2825518
hemoglobin a $nmbr$ c mean sd,C0019020;C2699239;C3889898
over past $nmbr$ years n,C0439234
bnp median iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
eq $nmbr$ da health index status score,C0449820;C4050231
fasting insulin median iqr gu ml,C0015663;C0439526;C1705224;C3887665
opaqb physical function score,C4483112
ldl cholesterol mean sd mg dl,C0023824;C0439269;C0202117
low trauma fracture since age $nmbr$ n,C0521170;C0001779
hdl cholesterol mean sd mg dl,C0023822;C0439269;C0392885
prevalent vertebral fracture n,C0080179
triglycerides median iqr mg dl,C0041004;C0439269
serum albumin adjusted calcium mg dl,C0036785;C0439269;C0728876
hscrp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
serum vitamin d nmol l,C0312532
mmp $nmbr$ median iqr gg l,C0017454;C0018370
total hip bmd t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
as,
nadroparin n $nmbr$,C0206232
eu,C0015179;C3665627
no nadroparin n $nmbr$,C0206232
sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
prostate cancer,C0376358;C0600139;C2984325;C3541264
cardiac procedure,C1279986
time since primary diagnosis,C0040223;C3541383
prior oad,C0332152;C2826257
years,C0439234
drug naive,C0013227;C1254351
metastatic disease,C0027627;C2939419;C2939420
low dose combination therapy,C0009429;C0556895
karnofsky score $nmbr$,C0449820;C4050231
metformin monotherapy,C0025598
nsclc,C0007131
su monotherapy,C0038642;C1705534
squamous cell carcinoma,C0007137;C1302853
smi,
pancreatic cancer,C0235974;C0346647;C2984259
systolic bp at baseline,C0871470;C0168634;C1442488
nadroparin,C0206232
$nmbr$ mmhg,C0439475
nadroparin vs control,C0206232;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
statin use at baseline,C0042153;C0457083;C1947944
hormone refractory prostate carcinoma,C3887901
diabetes duration,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0008107;C3259781
hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
non small cell lung cancer,C0007131;C2984258;C3539721
hdl c at baseline,C3715113;C0168634;C1442488
facilitated pci n $nmbr$,C4049621
ldl c at baseline,C0168634;C1442488
actual or estimated weight kg,C0237400;C0022718;C0439209;C4054209
triglycerides at baseline,C0041004;C0168634;C1442488
killip class iv at randomization,C2697847;C0034656
hscrp at baseline,C0168634;C1442488
prior cabg surgery,C0455610;C0010055
percent atheroma volume at baseline,C1690016;C3887614
chronic treatment with aspirin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
without baseline vertebral fracture,C0168634;C0080179;C1442488
infarct location anterior,C0021308;C0205094
with baseline vertebral fracture,C0168634;C0080179;C1442488
time intervals,C0872291
flex pbo,C0031962
symptoms onset to first balloon inflation min,C4086878;C0021398;C1318493
flex ain,C0347129
randomization to first balloon inflation min,C0034656;C0021398;C1318493
flex aln^,C0729594;C2681220
treatment before catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
body mass index kg m^ meanisd,C0022718;C0439209;C4054209
bolus of heparin given,C1186706;C1511237;C1705509;C3812160
fall in last $nmbr$ months,C0085639;C0238715;C4553726
loading dose of clopidogrel or ticlopidine,C3714444;C0070166;C0040207
history of clinical fracture $nmbr$ years,C1272071;C0205210
glycoprotein llb illa inhibitor,C0017968;C1999216
duration alendronate use years meanisd,C0102118;C0042153;C0457083;C1947944
pci performed,C4049621;C0884358
using alendronate at baseline,C1524063;C0102118;C0168634;C1442488
cabg performed during index hospitalization,C0010055;C0884358;C0019993
using hrt or raloxifene at baseline,C1524063;C0282402;C0244404;C0168634;C1442488
treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0007430
time since start of fit years meanisd,C1301880
additional heparin,C0019134;C0770546
time from end of fit years meanisd,C1522314
glycoprotein llb llia inhibitor,C0017968;C1999216
flex baseline bmd g cm^ meanisd,C0168634;C0439267;C1442488
$nmbr$ day mortality,C0026565;C0026566
flex baseline bmd t score at femoral neck meanisd,C0449820;C4050231
$nmbr$ day cce,C0332173;C0439228;C0439505
$nmbr$ $nmbr$ fn t score,C0449820;C4050231
covariates,
$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$,C0449820;C4050231
or,
fn t score $nmbr$ $nmbr$,C0449820;C4050231
assigned treatment by sex interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
flex baseline bmd t score at lumbar spine meanisd,C0449820;C4050231
fpci vs ppci in women,C0043210
$nmbr$ $nmbr$ ls t score,C0449820;C4050231
fpci vs ppci in men,C0025266
$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$,C0449820;C4050231
rolofylline n $nmbr$ $nmbr$,C0166128
ls t score $nmbr$ $nmbr$,C0449820;C4050231
ecrcl ml min,C0439445
change in femoral neck bmd from fit baseline to flex baseline,C0742135;C0036572;C0168634;C1442488;C2349186;C4048158;C4553125
lvef within $nmbr$ months,C0428772;C0488728
gained bmd,C1517378
intravenous loop diuretics,C0348016;C0354100
lost bmd,C0745777;C3815882
furosemide,C0016860
femoral neck f score at flex baseline,C0016327;C0449820;C4050231
bumetanide,C0006376
nonvertebral,
ethacrynic acid,C0014963
morphometric vertebral,C0549207
torsemide,C0076840
pbo no o o ^,C0031962;C0483204
persistent wrf n $nmbr$,C0205322;C0332996
ain no,C0347129
no persistent wrf n $nmbr$ $nmbr$,C0205322;C0332996
pbo no ^,C0031962
bnp pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
nvf at flex baseline $nmbr$ flex fn t score,C0168634;C0449820;C4050231;C1442488
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ flex fn f score $nmbr$,C0449820;C4050231
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
flex fn f score $nmbr$ $nmbr$,C0449820;C4050231
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
p value for interaction vertebral fracture at flex baseline,C1709380;C0080179;C0168634;C1442488
hgb g dl,C0019029;C0439267;C0019046;C0518015;C1424337
$nmbr$ flex fn f score,C0449820;C4050231
nateglinide n $nmbr$,C0903898
total diuretic dose iv oral on day $nmbr$ mg,C0442027;C4521986
jvp $nmbr$ cm,
race no i,C0034510;C1706779;C3853635;C0021966;C0221138
heart failure $nmbr$ month before admission,C0332177;C0439231
body mass index^,C0005893;C0578022;C1305855
waist circumference cmj,C0455829
medical therapy before admission,C0418981;C0184666;C0809949
_ $nmbr$ $nmbr$ _ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
blood pressure while seated mm hg,C0005823;C1271104;C1272641;C0277814;C0439475;C1283233
or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603;C0549178;C0439828
family history of premature heart disease,C0850707
univariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
reduced hdl cholesterol,C0151691
multivariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
elevated non hdl cholesterol,C0729627;C1535899
$nmbr$ yrs,
history of cardiovascular disease no,C0455539
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
angina or positive stress test,C0002962;C0015260;C3494508
baseline crcl ml min,C0168634;C0439445;C1442488
multivessel coronary artery bypass grafting,C0010055
hemoglobin $nmbr$ men $nmbr$ women,C0019046;C0043210
peripheral arterial stenosis,C4025272
rolofylline rx,C1425688;C1521941;C2709207
lower limb angioplasty or bypass surgery,C0745788;C1536078
rolofylline n,C0166128
nontraumatic leg or foot amputation,C0023216;C1140621;C0188605
or primary outcome,C0205225;C1274040;C0439612;C0439631
family history of diabetes mellitus no,C0260526;C1313937
or morbidity and mortality,C0026538;C0220880;C0026565;C0026566
baseline ecrcl $nmbr$ $nmbr$ ml min,C0168634;C0439445;C1442488
plasma glucose mmol per liter,C0202042;C0439190;C0455280
fasting,C0015663
rolofylline n $nmbr$,C0166128
or $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
$nmbr$ hr after glucose challenge,C3840385
hr $nmbr$ cl $nmbr$ $nmbr$ b $nmbr$ $nmbr$ $nmbr$,C0596019
metabolic syndrome no ^,C0524620
baseline ecrcl k $nmbr$ to $nmbr$ ml min,C0597277;C1708601;C0439445
lipids mg dl,C0023779;C0439269
hr $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
estimated gfr ml min $nmbr$ $nmbr$ m^,C0017654;C0439445;C1424601
baseline ecro $nmbr$ mumin,C0168634;C1442488
ratio of urinary albumin mg to creatinine g,C0456603;C1547037;C0010294;C0439267;C1561535
rolofylline $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
last study visit,C0545082;C1512346;C2826704
baseline ecrq $nmbr$ $nmbr$ to $nmbr$ ml min,C0168634;C1442488;C0439445
alpha blocker,C0001641
aspirin or other antiplatelet drug,C0004057;C0085826
weight kg blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
$nmbr$ $nmbr$ no totalno,
lipid modulating drug,C0023779;C0443264;C0013227;C1254351
previous stroke or transient ischemic attack no total no,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
antidiabetic drug i j,C0935929;C0021966;C0221138
section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
hypertension no total no medications in use at baseline no total no,C0020538;C1963138;C0439175;C0439810;C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
nateglinide n n,C0903898
long term vitamin k antagonist,C1096489;C2267235
hazard ratio $nmbr$ cl nateglinide vs placebo,C2985465;C0903898;C0032042;C1696465;C1706408
pts,C1419129;C2698747
two sided p value for hetero geneity,C0205448;C1709380
war,C0043027
all patients p $nmbr$ $nmbr$,C0030705
dabigatran $nmbr$ vs warfarin p inter,C2348066;C0043031;C0205103;C1548610
aslan,
weight $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104
fasting plasma glucose,C0202042;C0455280
weight $nmbr$,C0005910;C0043100;C1305866;C1705104
cclear,
$nmbr$ hr prandial glucose,C1998602;C0017725;C4553624
cclear $nmbr$ $nmbr$,
body mass index[kh m^],C0005893;C0578022;C1305855;C0006797;C4554575
cclear $nmbr$,
waist circumference[cm female cm male ],C0455829;C0086582;C1706180;C1706428;C1706429
asa,C0004057;C3853627
history of cardiovascular disease,C0455539
no asa,C0004057;C3853627
ace inhibitor treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no amiodarone,C0002598
section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
ppi,C0358591;C0871125;C3811894
extended cardiovascular endpoint,C2349179;C2826544
noppi,
body mass index[kg m^],C0005893;C0578022;C1305855;C0022718;C0439209;C4054209
p inter,C0369773;C2603361;C0205103;C1548610
section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
no ppi,C0358591;C0871125;C3811894
core cardiovascular endpoint,C2349179;C2826544
daily dose $nmbr$ mg n $nmbr$,C2348070;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
[kg m^],C0022718;C0439209;C4054209
daily dose $nmbr$ $nmbr$ mg n $nmbr$,C2348070;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
[cm female cm male ],C0086582;C1706180;C1706428;C1706429
p value anova,C1709380;C0753802
sitting blood pressure mmhg,C0580946;C0439475
duration of asthma years,C0449238;C2926735
peripheral artery stenosis,C0038449
ics mg day,C0815320;C0439422;C4551720
stroke of atherosclerotic origin,C0038454;C4554100
laba use patients,C0042153;C0030705;C0457083;C1947944
glycemic indexes,C1136206
fev $nmbr$ post bronchodilator predicted normal,C0520835;C2599594
fasting plasma glucose mmol liter,C0202042;C0475211;C0455280
pef post bronchodilator predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
acq $nmbr$ score,C0449820;C4050231
plasma glucose $nmbr$ hr after glucose load mmol liter,C0202042;C0455280
exacerbations in previous year,C4086268;C0205156;C1552607
metabolic syndrome no $nmbr$,C0524620
as needed inhalations day,C0332173;C0439228;C0439505
estimated gfr^,C0017654;C1424601
days with asthma symptoms week,C0677547;C0004096;C2984299
mean ml min $nmbr$ $nmbr$ m^,C0444504;C0439445;C2347634;C2348143
night time awakenings week,C0456698
ratio of urinary albumin mg to creatinine g median,C0456603;C1547037;C0549183;C0876920;C2347635;C2348144;C2939193
concomitant medication no ace inhibitor,C0013227;C3244316;C4284232;C0003015;C4541021
figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients,C0040223;C3541383;C1319635;C0439422;C0030705
any antihypertensive drug,C0003364
in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$,C2986480;C0040223;C3541383;C1441672;C0332283;C0694649
aspirin orother antiplatelet drug,C0004057
stratum i,C0021966;C0221138
antidiabetic drug,C0935929
stratum ii,C1710602;C4082587
progression to diabetes,C1735364
r $nmbr$ ezio n $nmbr$,C0687673
hazard ratio $nmbr$ cl valsartan vs placebo,C2985465;C0216784;C0032042;C1696465;C1706408
r $nmbr$ n $nmbr$,C0687673
fenofibrate n $nmbr$,C0033228
american indian or alaska,C0002460;C0001905
education no,C0013621;C0013622;C0013658;C0039401
$nmbr$ d,
risk group,C0242444
high school graduate or ged,C0870649;C1549971;C1880947
missing data,C4684714
high risk with atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
previous cardiovascular event no,C0205156;C1320716;C1552607
high risk without atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
previous congestive heart failure no,C0205156;C0018802;C1552607
moderately high risk without atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
cigarette smoking status no,C1519386
baseline low density lipoprotein cholesterol mg dl,C0023824;C0439269
amputation due to diabetes no,C0678226;C0598284
sal n $nmbr$,C0036140;C0037494;C0206136
estimated glomerular filtration rate no,C3811844
fp n $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
$nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
sfc n $nmbr$,C4521536
plasma cholesterol mg dl,C0858034;C0439269
total ho population n $nmbr$,C3258257;C0019905;C1832110;C3889614
plasma triglyceride mg dl,C0032105;C0439269;C1550098;C4521445
total population n $nmbr$,C3258257
patient characteristics at randomization,C0815172;C0034656
age at enrollment years,C1510829;C1516879;C1696073;C3888021
age years [median $nmbr$ th to $nmbr$ th percentile ],C1510829;C0039725;C0039738;C1420718;C4282123;C4285344
geographical region,C0017446;C0205147
weight kg m $nmbr$ [median $nmbr$ th to $nmbr$ th percentile ],C0022718;C0439209;C4054209;C0039725;C0039738;C1420718;C4282123;C4285344
post bronchodilator fev $nmbr$ l,C2599594;C3714541
bmi kg m $nmbr$ [median $nmbr$ th to $nmbr$ th percentile ],C0022718;C0439209;C4054209;C0039725;C0039738;C1420718;C4282123;C4285344
post bronchodilator fev $nmbr$ predicted,C0681842;C1882327
antidiabetes drug usage [ n ],C0242510;C0369718;C0441922
reversibility predicted fev $nmbr$,C0449261;C3714541
biguanide metformin,C0005382;C0025598;C3537187;C4317165
pre bronchodilator fev $nmbr$ fvc ratio,C0456603;C1547037
thiazolidinedione,C0289779;C1257987;C3537039
a glucosidase inhibitor,C1512211
figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0439234;C0017446;C0205147;C0030705;C1522326;C0032042;C1696465;C1706408;C4521536;C0449820;C4050231;C0332272;C0018684;C4522046;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C1273937
meglitinide,C0065880
figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$,C2045651;C2964552;C0392747;C0443172;C1705241;C4319952;C0683312;C3889287;C0449820;C4050231;C0184511;C0018684;C0332272;C1561611;C4084203;C1524063;C0814908;C1705242;C0598981;C3146232;C0369773;C2603361
no antidiabetic drug,C0935929
certolizumab pegol n $nmbr$,C1872109
monotherapy,
age range,C1514721;C2348147;C3542016
dual therapy,C0039798;C0087111;C1363945
duration of disease since,C0872146
three or more drugs,C0205449;C0013227;C3687832
diagnosis y mean sd,C0011900;C2699239;C1704338;C1704656
patient characterization data are reproduced from morrow et al $nmbr$,C2707520;C1880022;C0040028;C0202311
baseline cdai mean sd,C0168634;C2699239;C1442488
patients with possible new dm at randomization fpg $nmbr$ $nmbr$,C0030705;C0011816;C3250443;C0034656
baseline hbi mean sd,C0168634;C2699239;C1442488
fpg month $nmbr$ mg dl,C0332177;C0439269;C0439231
geometric mean of baseline,C2986759;C0168634;C1442488
change in fpg $nmbr$ to month $nmbr$ mg dl,C0392747;C0443172;C1705241;C4319952;C0332177;C0439269;C0439231
crp mg l cv,C3538987;C4048877;C4318503
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0008107;C3259781
location of disease n,C0450429;C1515974;C4284930;C4284931
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
isolated upper gastrointestinal disease behavior n,C0810300
interaction,C1704675
inflammatory,C0333348
patients with possible new dm at randomization hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$,C0030705;C0011816;C3250443;C0034656;C0019016;C1825777;C3538758
stricturing,C1261287
hba $nmbr$ c month $nmbr$,C0332177;C0439231
penetrating no of resections n,C0205321;C0015252
change in hba $nmbr$ c $nmbr$ to month $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332177;C0439231
corticosteroid with or without immunosuppressants,C0001617;C3536709;C0021081
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ a $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
immunosuppressant with or without corticosteroid,C0021081;C0001617;C3536709
febuxostat $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
corticosteroid or immunosuppressant,C0001617;C3536709;C0021081
febuxostat $nmbr$ mg daily n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
corticosteroid and immunosuppressant,C0001617;C3536709;C0021081
allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
neither corticosteroid nor immunosuppressant,C0001617;C3536709;C0021081
american indian or alaska native,C0002460;C0682125
hrqol,C4279947;C4300252
native hawaiian or other pacific,C0337920
ibdq score mean sd,C0444504;C2699239;C2347634;C2348143
islander,
total scores total score range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
non ex drinker,C0457801
czp $nmbr$ mg n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
drinker $nmbr$ to $nmbr$ drinks week,C0556338;C0332174;C0439230
age yrs $nmbr$ $nmbr$,C0001779
serum urate mg dl,C0455272;C0439269
noncaucasian,
years with gout,C0439234;C0018099
disease location type terminal ileum,C0457464;C0227327
completed previous febuxostat study,C2348557;C0205156;C1552607
penetrating,C0205321
renal functionb,C0022646
prior surgery no,C0455610
moderately impaired,C0205081;C0221099;C1881878;C4085643;C4321491
disease duration,C0872146
mildly impaired,C0750532;C0221099;C2945599
$nmbr$ baseline mean,C0444504;C2347634;C2348143
normal,C0205307;C0231683;C0439166;C2347086;C4553972
im use no,C1556154
including hypertension,C0020538;C1963138
cs use no,C0042153;C0457083;C1947944
use of low dose aspirin $nmbr$,C1524063;C2608320
im or cs use no,C0042153;C0457083;C1947944
mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
im and cs use no,C0042153;C0457083;C1947944
febuxostat $nmbr$ mg daily n $nmbr$ n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous or current im use no,C0205156;C1552607;C0521116;C1556154;C1705970
renal functiona,C0022646
previous or current cs use no,C0205156;C1552607;C0042153;C0457083;C1947944
baseline serum urate mg dl a,C0455272;C0439269
previous or current use of im or cs no,C0205156;C1552607;C1524063;C0010182;C0271160;C3540510;C4085345
baseline tophusa,C0168634;C1442488
previous or current use of im and cs no,C0205156;C1552607;C1524063;C0010182;C0271160;C3540510;C4085345
completed prior febuxostat studya,C0205197;C0249529;C3854010
czp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age $nmbr$ y n n,C0001779
rest of world,C0035253;C1622890
white n n,C0007457;C0043157;C0220938
europe zone $nmbr$,C0015176;C1710706
diabetes mellitus n n,C0011849
ukraine,C0041580
hypertension n n,C0020538;C1963138
russia,C0035970
hyperlipidemia n n,C0020473;C0428465;C4555212
romania,C0035826
metabolic syndrome n n,C0524620
poland,C0032356
current smoker n n,C3173209;C3241966
new zealand,C0027978;C0324547
prior mi n n,C0332152;C2826257
latvia,C0023128
prior coronary revascularization n n,C0332152;C0877341;C2826257
italy,C0022277
prior angina n n,C0332152;C0002962;C2826257
hungary,C0020174
prior heart failure n n,C0018801;C0018802;C4554158
estonia,C0014908
germany,C0017480
timi risk score n n,C0035647;C0449820;C4050231;C4552904
canada,C0006823
index event n n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
brazil,C0006137
ua,C0041580;C0042014
belgium,C0004950
nstemi,C3537184;C4255010
austria,C0004348
time from symptoms to randomization h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
baseline corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
women n $nmbr$ n n,C0043210
no baseline corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
men n $nmbr$ n n,C0025266
$nmbr$ mg eow n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
angiography and revascularization,C0002978;C0581603
$nmbr$ mg ew n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
angiography during index hospitalization,C0002978;C0019993
male patients n,C0150904
angiographic extent of disease,C0449279;C4553144
$nmbr$ vessel,C0005847
body weight kg mean s d,C0005910;C1275571;C1305866
$nmbr$ vessels,C0005847
involved intestinal area n,C1879646;C0021853
gastroduodenum,C0391900
$nmbr$ vessels or left main,C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
pci during index hospitalization,C4049621;C0019993
draining cutaneous fistula at baseline n,C0013103;C0180499;C4265177;C0423772;C0168634;C1442488
cabg during index hospitalization,C0010055;C0019993
baseline cdai score mean s d,C0168634;C0444504;C2347634;C2348143;C1442488
gpiib iiia receptor inhibitor,C0016011;C1999216
c reactive protein mg dl_,C0006560;C0439269;C1413716;C4048285
diabetic treatments,C0241863;C0087111
previous tnf antagonist use n,C0205156;C0042153;C0457083;C1947944;C1552607
oral agents,C0450442;C1254351;C1521826
crohn s disease related medication at baseline n,C0010346;C0013227;C3244316;C4284232
diet alone,C0012155;C0012159;C1519433;C2983588;C3668949;C0205171;C0439044;C0679994
charm,C0849759
p interaction women vs men,C0369773;C0043210;C2603361;C0025266
adhere,C3714578
p $nmbr$ interaction women vs men,C0369773;C0043210;C2603361;C0025266
steroid free remission,C0544452;C0687702
azathioprine n $nmbr$,C0004482
steroid sparing remission,C0544452;C0687702
infliximab n $nmbr$,C0666743
steroid free cr $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
combination therapy n $nmbr$,C0009429;C0556895
remission by baseline steroid doses,C0544452;C0687702
p valued,C0369773;C2603361
remission by baseline duration of steroid,C0814126;C0038317
white race no t,C0007457;C0043157;C2603360
no history of migraine,C0455512
median age yr,C0001779;C0439234
migraine with aura,C0154723
median body weight kg,C0022718;C0439209;C4054209
migraine without aura,C0338480
median disease duration yr,C0872146;C0439234
prior migraine,C0332152;C0149931;C2826257
median c reactive protein mg dl^,C0006560;C0439269;C1413716;C4048285
characteristics no of participants,C1521970;C0679646
aspirin $nmbr$ $nmbr$,C0004057
crohn s disease activity index score],C0010346;C4706353;C0600653;C0918012;C1552854;C1637833;C2986546
placebo $nmbr$ $nmbr$,C0032042;C1696465;C1706408
gastrointestinal area involved no total no,C0017446;C0205146;C1314939;C0439175;C0439810
aspirin $nmbr$,C0004057
ileum or colon,C0020885;C0009368;C3888384
ileum only,C0020885
mean systolic blood pressure mm hg sd,C0428886;C2699239;C0488053
colon only,C0009368;C3888384
history of hypertension^,C0455527
proximal gastrointestinal tract,C0017189;C0521362
family history of myocardial infarction prior to age $nmbr$,C0455406;C0001779
systemic corticosteroids no,C4053960
r r $nmbr$ ci,C0008107;C3259781
any type according to daily dose,C0332307;C1547052
rr^ $nmbr$ ci,C0008107;C3259781
budesonide no,C0054201
major cvd,C0205082;C0007222;C0205164;C4318856;C4521762
$nmbr$ aminosalicylic compounds no,C0205198;C1706082
cvd death,C0011065;C1306577;C4082313;C4552775
proportion of patients in corticosteroid free clinical remission at week $nmbr$,C1709707;C0030705;C0205210;C0544452;C0687702
met n $nmbr$,C0428210;C1550543;C4317104
ifx aza n $nmbr$,C0020823;C0004482
avm n $nmbr$,C0003857;C0279476
aza n $nmbr$,C0004482
$nmbr$ $nmbr$ l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
$nmbr$ l $nmbr$ l $nmbr$ $nmbr$,C3539687
crohn s disease related surgery,C0010346;C0038894;C0038895;C0543467;C1274039
l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
with previous surgery,C0038894;C0038895;C0543467;C1274039
ll $nmbr$ $nmbr$,
without previous surgery,C0038894;C0038895;C0543467;C1274039
african america,C0027567;C0002454
baseline corticosteroid use mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ l $nmbr$ l $nmbr$,C3539687
with corticosteroid treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ l $nmbr$ l,C3539687
duration of crohn s disease yrs,C0449238;C2926735;C0012634
duration of diabetes,C0449238;C2926735
baseline crp mg dl,C0168634;C0439269;C1442488
$nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
europe lsrael,C0015176
hbalc mean sd ^,C0444504;C2699239;C2347634;C2348143
baseline $nmbr$ asa,C0004057;C3853627
fpg mmol l mean sd,C1532563;C2699239
use $nmbr$ asa compounds,C0205198;C1706082
l $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
no use of $nmbr$ asa compounds,C1524063;C0004057;C3853627
fracture history predefined n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
total group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ l l $nmbr$,C3539687
ifx n $nmbr$,C0020823
l l,C3539687
enox,C3147679
history of bone disease predefined n,C0683519;C0730226;C0850708;C0944983
no dm,C0011816;C3250443
priorbone disease,C0012634
no prior ml,C0439526;C1705224;C3887665
$nmbr$ l,C0439394;C1706495;C3642217
fibrinolytic,C0040044
fibrin specilic,C0015982
current bone disease,C0521116;C0005940;C1705970
time to rx,C0040223;C3541383
history of other medical conditions n,C0262926
amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
priorother predefined medical conditions,C0012634;C0348080;C1705253;C3864998
amlodipine $nmbr$ to $nmbr$ mg n $nmbr$,C0051696;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
priorother not predefined medical conditions,C0012634;C0348080;C1705253;C3864998
age sd yrs,C0001779;C2699239
current other predefined medical conditions,C0521116;C1705970;C0012634;C0348080;C1705253;C3864998
age category n,C0001779;C0683312;C3889287
currentother notpredefined medical conditions,C0012634;C0348080;C1705253;C3864998
hypertension severity at baseline n,C0439793;C0522510
risk factor predefined for falling at screening n,C0035648;C0000921;C0085639
diabetic status n,C0241863;C0449438
any condition,C0012634;C0348080;C1705253;C3864998
ish status n,C0449438
maternal history n,C0559473
bmi n,C0578022
osteoporosis,C0029456;C4554622
tiotropium nz $nmbr$,C0213771;C0027978
ll $nmbr$,
control nz $nmbr$,C0243148;C0027978;C1550141;C1882979;C2587213;C3274648;C4553389
paternal history n,C0424909
a demographics,C0011298;C1704791
current n,C0521116;C1705970
former n,C0205156;C0750523
history pack years,C0019664;C1277691;C0019665;C0262512;C0262926;C1705255;C2004062
years mean sd,C0439234;C2699239
gold stage [n ],C0205390;C1300072;C1306673;C0369718;C0441922
$nmbr$ $nmbr$ ll $nmbr$,
pre bronchodilator,C2599602
$nmbr$ l $nmbr$ l $nmbr$ $nmbr$ l,C3539687
post bronchodilator,C2599594
yes n,C1549445;C1705108;C1710701
patients with $nmbr$ $nmbr$ ml increase in fev $nmbr$ post bronchodilator,C0030705;C0439526;C1705224;C3887665;C3714541;C2599594
units per week mean sd,C0560588;C0444504;C2347634;C2348143
fvc predicted,C3714541;C0681842;C1882327
$nmbr$ $nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
b concomitant respiratory medications [n ],C0521115;C0418986;C0369718;C0441922
avm se,C0003857;C0036919;C0279476
any pulmonary medication,C0013227;C3244316;C4284232
met se,C0428210;C0036919;C1550543;C4317104
anti cholinergics long acting,C0242896;C0205166;C1706317
$nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
anti cholinergics short acting a,C0242896;C1282927;C1806781;C2350002
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c $nmbr$ r,C0722969
b agonists long acting a,C0243192;C2987634;C0205166;C1706317
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c $nmbr$,
b agonists short acting a,C0243192;C2987634;C1282927;C1806781;C2350002
distal one third of radius,C0450168;C0205447
leukotriene receptor antagonists,C0595726;C2757015;C3542962
week $nmbr$ mayo endoscopy subscorea,C0332174;C0014245;C0439230
mucolytics,C0026698
symptomatic remissionb n n,C0231220
steroids inhaled a,C0038317;C0004048
sustained mucosal healingc n n,C0443318;C0026724
steroids other,C0038317
mucosal healingc n n,C0026724
theophyllines,C0039771
sustained mucosal healingc,C0443318;C0026724
mean yearly decline,C0332181;C0439508
p value n n,C1709380
pred,C0032952;C0044955
nesiritide n $nmbr$,C0054015
fev $nmbr$ pre bronchodilator,C3714541;C2599602
sex no total no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0439175;C0439810
fev $nmbr$ post bronchodilator,C3714541;C2599594
race no total no f,C0034510;C1706779;C3853635;C0439175;C0439810;C0016327
fvc pre bronchodilator,C3714541;C2599602
systolic pressure mm hg,C0871470;C0439475
fvc post bronchodilator,C3714541;C2599594
heart rate at rest beats min,C0018810
baseline parameter,C0549193;C1704769;C2350001
bnp pg ml i,C0023806
number of subjects,C0237753;C0449788
asthma duration sd years,C0004096;C0439234;C2984299
n terminal pro bnp pg ml,C0669479;C0439297
fev $nmbr$ percent predicted sd,C0439165;C2699239
serum sodium mmol liter,C0523891;C0475211
am pef sd l min,C0702093;C1524029;C3813700
left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$,C0428772;C0488728;C0439175;C0439810
pm pef sd l min,C0702093;C1524029;C3813700
medical history no total no,C0262926;C1704706;C0439175;C0439810
symptom score sd,C3476546;C2699239
heart failure $nmbr$ yr before admission,C0018801;C0439234;C0018802;C4554158
albuterol use sd puffs day,C0332173;C0439228;C0439505
medical therapy before randomization no total no,C0418981;C0034656;C0439175;C0439810
figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean,C0030771;C1518922;C1542834;C1707156;C3274014;C3541345;C1882932;C1710181
nitrate oral or topical,C0442027;C4521986;C0332237
figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean,C0392747;C0443172;C1705241;C4319952;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
digoxin or digitalis glycoside,C0012265;C0012253
figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean,C0436315;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
hydralazine,C0020223
nyha ll lll patients with lvef,C1275491;C0030705;C0428772;C0488728
inotropic agent,C0304509
remaining patients,C1527428;C0030705
vasodilator,C0042402;C3537240
age years sd,C1510829;C2699239
use of medication from randomization through $nmbr$ hr no total no,C1524063;C0034656;C0439175;C0439810
ischaemic dilated cardiomyopathy,C1960867
time from hospitalization to randomization hr,C0040223;C3541383;C0034656
non rheumatic valvular heart disease,C1518422;C0264757
time from randomization to study drug administration hr,C0040223;C3541383;C0013175;C0150270;C3469597
non ischaemic dilated cardiomyopathy,C1518422;C1960867
administration of study drug bolus no total no,C0150270;C0262754;C3469597;C0439175;C0439810
hr [ $nmbr$ ci,C0008107;C3259781
duration of study drug administration hr,C0920470;C2348354
overall population,C0032659;C1257890
apixaban n $nmbr$,C1831808
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
risk factors specified as inclusion criteria no f,C0035648;C1553898;C0205369;C1512693;C0016327
left ventricular ejection fraction $nmbr$ $nmbr$ and nyha class ii iii at baseline,C0428772;C0488728;C1882086
myocardial infarction within the previous $nmbr$ yr,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
history of cerebrovascular disease,C0585890
outcome measure,C0086749
heart failure or lvef,C0018801;C0018802;C4554158;C0428772;C0488728
time to first cv hospitalization or death from any cause,C0040223;C3541383;C0007465
history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
first cv hospitalization,C0205435;C0019993;C1279901
no revascularization for index acs event,C0581603;C0441471;C4019010
death from any cause,C0007465
other medical history no,C0262926;C1704706
first hospitalization for chf or cv death,C0019993;C0018802;C0011065;C1306577;C4082313;C4552775
index acs event,C0441471;C4019010
indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time from event to randomization days,C0040223;C3541383;C0034656;C0439228
age yr mean sd,C0001779;C2699239
type of event no,C1561488
ics users n,C0815320;C1706077;C4551720
st segment elevation myocardial infarction,C1536220
smoking history pack years mean sd,C1277691;C2699239
non st segment elevation myocardial infarction,C1536220
fevi l mean sd $nmbr$,C0429706;C2699239;C0849974;C1561566;C4528367
elevated cardiac markers no t,C0205250;C1271630;C3163633;C2603360
fevi predicted mean sd $nmbr$,C0429706;C2699239;C0849974;C1561566;C4528367
management of event no,C0001554;C0376636;C1273870;C3273539
fev $nmbr$ fvc mean sd $nmbr$,C0444504;C2699239;C2347634;C2348143
medical therapy only,C0418981
reversibility b $nmbr$ agonist mean sd $nmbr$,C0444504;C2699239;C2347634;C2348143
use of parenteral antithrombotic agents no,C1524063;C1704311
reversibility anticholinergic mean sd,C0242896;C2699239;C3537004
selected medications no,C0013227;C0802604;C2598133;C4284232
figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups,C0444506;C3714541;C1705241;C1705242;C1554093;C3242279;C3242455;C0332849;C0168634;C1442488;C0001779;C1519386;C0004048;C0239126;C0009924;C1979874;C0032042;C2825972;C1696465;C1706408;C0178602;C0213771;C1079230
cv death ml ischemic stroke,C0011065;C0948008;C1306577;C4082313;C4552775
aml val $nmbr$ $nmbr$ mg rr $nmbr$,C0023465;C4554402;C0023467
subject group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ami $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
antiplatelet therapy dual,C0205173;C1554184
sex n male,C0086582
single,C0037179;C0087136;C0205171
non elderly,C1518422;C0001792;C1999167
acs type,C0332307;C1547052
elderly $nmbr$ years,C0001792;C0439234;C1999167
stemi,C1536220;C3538872
race ethnicity chinese,C0008120;C0152035
non stemi,C3537184
bmi kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
acs treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
type $nmbr$ diabetes history n,C1320657;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
apixaban dose or matching placebo,C0178602;C0869039;C1114758;C0032042;C1696465;C1706408
duration of hypertension years,C0449238;C2926735
$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sitting dbp mmhg,C0277814;C0439475;C2584297;C4050224
$nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sitting sbp mmhg,C0085805;C0439475
s $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
least square mean se,C0023189;C0036919
level of renal impairment,C0441889;C0456079;C1547707;C2946261
difference se,C1705241;C0036919;C1705242
severe or moderate,C0205082;C4050465;C4050466;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
aml val $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age group years,C1510829
ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
incidence [n n rate per $nmbr$ person years ],C0021149;C0220856;C0871208;C1521828
peripheral artery disease at baseline,C1704436;C4025272
nnt,C1417750
no peripheral artery disease baseline,C0168634;C1442488
age group y,C0441858
epa,
treatment groups [n nb ],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0028101;C0919442;C1705347;C4553907
pad at baseline,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
group a n $nmbr$,C0441848
no pad baseline,C0168634;C1442488
group b n $nmbr$,C0441848
ezetimibe simvastatin $nmbr$ $nmbr$ mg n $nmbr$,C1532737;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
group c n $nmbr$,C0441848
rosuvastatin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hyperlipidemia^,C0020473;C0428465;C4555212
current cvd diabetes n,C0007222;C0011847;C0011849
history of chd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
high risk cvd n,C0332167;C3272283;C4050568;C4319571
history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean $nmbr$ year cvd risk,C0007222;C0035647;C4552904
history of carotid artery disease,C0683519;C0730226;C0850708;C0944983
type $nmbr$ n,C0332307;C1547052
history of peripheral artery disease,C0683519;C0730226;C0850708;C0944983
fasting lipid levels mmol l,C0428460;C1532563
triglycerides median range,C1514721;C2348147;C3542016
figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus,C1707455;C0772326;C2353292;C1705241;C1705242;C1628982;C0013227;C3687832;C0030705;C3538926;C1079230;C1518422;C0439801;C1549649;C2349209
percentage patients reaching target,C0439165;C0030705;C1549488;C1561533;C2584321;C1521840;C2986546
baseline total ipss mean sd,C0168634;C2699239;C1442488
exetimibe simvastatin,C0074554
baseline bii mean sd,C0168634;C2699239;C1442488
atorvastatin,C0286651
baseline luts severity n,C0168634;C0439793;C0522510;C1442488
ldl c $nmbr$ $nmbr$ mmol l,C1532563
mild ipss,C1019118;C1998280;C2827405;C3811063
jbs $nmbr$ secondary prevention only $nmbr$,C0175692;C0679699;C0795841;C1416527
moderate $nmbr$ ipss,C1019118;C1998280;C2827405;C3811063
jbs $nmbr$ primary prevention only $nmbr$,C0175692;C0033144;C0795841;C1416527
severe ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
nice secondary prevention onlyb,C4087029;C0679699
qmax category n,C0683312;C3889287
nice primary prevention onlyb,C4087029;C0033144
$nmbr$ ml s,C0439526;C1705224;C3887665
baseline ldl c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mmol lc,C0168634;C1442488;C0439190
qmax ml s mean sd,C0439390;C2699239
infliximab naive n $nmbr$,C0666743
pvr volume ml mean sd,C0242852;C2699239;C0456261;C1419141
infliximab experienced n $nmbr$,C0666743
psa ng ml mean sd,C0439275;C2699239
mean s d age years,C0444504;C1510829;C2347634;C2348143
ed history n yes,C1549445;C1705108;C1710701
mean duration of disease years,C0872146;C0439234
ed severity n,C0439793;C0522510
location of crohn s disease,C0450429;C1515974;C4284930;C4284931;C0012634
ed duration $nmbr$ yr n,C0449238;C0439234;C2926735
upper gastrointestinal,C1282910;C0521362
sexually active with female,C0241028;C0043210;C0086287;C1705497;C1705498
resection performed,C0015252;C0728940;C0884358
partner n yes,C1549445;C1705108;C1710701
mean cdai score,C3533236;C0683448;C1413248;C3273706
pgi s n y,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
geometric mean crp concentration mg l,C2986759;C0439268
cgi s n z,C4526016
penetrating disease,C0205321;C0012634
previous therapies n,C0205156;C0087111;C1552607
medications at baseline n,C0013227;C0802604;C2598133;C4284232
a blockers,
no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
other bph luts therapy,C0039798;C0087111;C1363945
oab therapy,C0039798;C0087111;C1363945
figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population,C0024501;C0871261;C1704632;C1706817;C2911692;C0544452;C0687702;C0332152;C0032659;C1257890
ed therapy,C0039798;C0087111;C1363945
history of myocardial infarction,C1275835
placebo mean change sd,C0032042;C2699239;C1696465;C1706408
history of cabg surgery,C0455610;C0010055
tadalafil $nmbr$ mg mean change sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
symptom onset to hospital admission,C4086878;C0184666
ls mean treatment difference $nmbr$ ci,C0008107;C3259781
intervention,C0184661;C0886296;C1273869
baseline luts severity,C0439793;C0522510
final timi flow grade post ppci,C0205088;C3272266;C1546485;C3853528
moderate n $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
macce,
severe n $nmbr$ $nmbr$,C0205082;C4050465;C4050466
lce n $nmbr$,C1423759;C3273355
baseline ed severity,C0439793;C0522510
lc n $nmbr$,
mild n $nmbr$ $nmbr$ $nmbr$,C2945599
age mean yr,C0001779;C0439234
characteristic^,C1521970
men no,C0025266
bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$,C2700462;C2945744
mean duration of pd yr,C0449238;C2926735
bud $nmbr$ ptg n $nmbr$,C0039512;C1418830
updrs total ii iii,C0439070;C1705160
self reported descent n,C0681906;C2700446
updrs part ii adl,C0001288;C1420005
mexican,C0240339
updrs part iii motor,C1513492;C1705994
puerto rican,C0034043
hoehn yahr stage,C0205390;C1300072;C1306673
cuban,C1553379
schwab england score,C0449820;C4050231
south or central american,C1710133;C0238914
pdq $nmbr$,
caribbean,C0043122;C0206155;C1331005
previous antiparkinson medication no,C0205156;C0003405;C1552607
mixed hispanic,C0205430;C0086409;C3160715
dopamine agonist use no,C0042153;C0457083;C1947944
total ics dose at entry xg d,C2986497;C0017209;C1292284;C1421532
lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire,C1292728;C0337645;C0034394
predose fev^ at screening,C0439565;C3714541;C3812758;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
unified parkinson disease,C0030567;C1521736
l,C0439394;C1706495;C3642217
olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$,C0386393;C1319635
predicted,C0681842;C1882327
olmesartan medoxomil $nmbr$ mg n $nmbr$,C0386393;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
predose fev at randomization,C3714541;C0034656
age y [mean sd],C0001779;C0444504;C2699239;C2347634;C2348143
predose fvc l,C0439565;C3714541;C3812758
$nmbr$ [n ],C0369718;C0441922
at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
males [n ],C0086582;C0369718;C0441922
at randomization,C0034656
diabetes mellitus [n ],C0011849;C0369718;C0441922
predose fev fvc,C0439565;C3714541;C3812758
bmi kg m $nmbr$ [mean sd],C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
postdose fev fvc at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
sedbp mmhg [mean_ sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
reversibility in fev^ at,C0449261;C3714541
sesbp mmhg [mean _sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
screening l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
severity ofhypertension [n ]b,C0439793;C0522510;C0369718;C0441922
pef at baseline l_ min,C0030771;C1518922;C1542834
mild,C2945599
morning,C0332170
pre treatedforhypertension [n ],C0332152;C0740175;C2257086;C3669034;C0369718;C0441922
evening,C0587117
pre treatment[n ]c,C1550147;C2709094;C3539075;C3539076;C2349138
figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min,C0687676;C0010992;C1704687;C3469826;C0205363;C0017446;C0205147;C0392747;C0443172;C0444504;C2347634;C2348143;C0030771;C1518922;C1542834;C1705241;C4319952;C0439230;C0016529;C1306036;C1511726;C3245479;C3714741;C0849355;C0030705;C1522609;C0441846
calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
nonobese,
low ceiling diuretic,C0205251;C0012798;C1550472;C3890211;C4048187;C4321351;C4522223
obese $nmbr$ kg m^ $nmbr$,C0022718;C0439209;C4054209
bp in pre treated patients,C0037623;C1415692;C1708288;C4318478
a aml n $nmbr$,C0023465;C0023467
sedbp mmhg [mean _sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
aml n $nmbr$,C0023465;C0023467
sesbp mmhg [mean sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
mets n,C0812270;C1705694;C2939420
high dose statin,C0444956;C0360714
prevalence of each metabolic syndrome criterion,C0033105;C0220900
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi,C0301630;C4551656;C0332174;C0439230;C1319893;C0005893;C0578022;C1305855
met criterion at blt n [ ],C0428210;C0243161;C1550543;C4317104
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine,C0301630;C4551656;C0332174;C0439230;C1319893;C1319894;C0524620;C0812270;C1705694;C2939420;C0168634;C1710181;C1442488;C2937472;C0023465;C0023467
met criterion at final n [ ],C0243161;C0205088;C1546485;C3853528
figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine,C0439165;C1549488;C1561533;C0005823;C0018017;C0681850;C1550501;C1706203;C2349001;C2697811;C0524620;C0812270;C1705694;C2939420;C2937472;C0023465;C0023467
elevated tg,C0205250;C0337445;C3163633
oma oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
elevated blood pressure,C0020538;C0497247
oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
met criterion at bl n [ ],C0243161;C0005918;C0006413;C1552663;C2827109
age distribution years n,C1510829
elevated fasting glucose,C0015663;C0017725
serum total ige iu ml,C1441420;C0439458
increased waist circumference,C0205217;C0455829;C0442805
fev $nmbr$ predicted at baseline,C0681842;C1882327
met criterion at finalt,C0428210;C0243161;C1550543;C4317104
number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0449788;C0439234;C0439508
n a,C1272460
number of er visits in last year prior to baseline,C3810541;C1549755;C3811131;C0439234;C0439508
changes a in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C0524620;C2357172
number of hospitalizations in last year prior to baseline,C4086639;C0439234;C0439508
bl mean mg dl mmol $nmbr$,C0567349;C2348885
mean a sem,C0444504;C2347634;C2348143
night time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C0439230;C0332152
$nmbr$ $nmbr$ lno^,
ocs reduced stopped,C0392756;C1272691
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ti,C0039247;C0040302;C1553045;C1704756
ocs maintained increased,C0205217;C0442805
bl mean mmhg,C0005918;C0439475;C0006413;C1552663;C2827109
oma oat,C0028753;C0331496;C0939905;C3539067;C3897364
mean a sd mmhg,C0444504;C2347634;C2348143;C2699239;C0439475
oat,C0028753;C0331496;C0939905;C3539067;C3897364
fasting blood glucose,C0428568;C1261430
mean change from baseline in fev $nmbr$ predicted sd,C0392747;C0443172;C1705241;C4319952;C0681842;C2699239;C1882327
mean a sd mg dl mmol $nmbr$,C0444504;C2347634;C2348143;C0567349;C2348885
mean number of clinically significant asthma exacerbations,C0444504;C0237753;C0449788;C2347634;C2348143
bl mean cm,C0005918;C0006413;C1552663;C2827109
mean number of combined visits hospitalizations,C4086639
mean a sdt,C0444504;C2347634;C2348143
mean change from baseline in acq overall score sd,C0392747;C0443172;C1705241;C4319952;C0282416;C2699239;C1561607
tiotropium $nmbr$ mg respimat n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean change from baseline in the number of,C0392747;C0443172;C1705241;C4319952;C0237753;C0449788
placebo n z $nmbr$,C0032042;C1696465;C1706408
night time awakenings in past $nmbr$ weeks sd,C0860510;C0439230;C2699239
screening visit,C0545082;C1512346;C2826704
no metabolic syndrome,C0524620
current smoker ex smoker,C3173209;C3241966
canrenone n z $nmbr$,C0006882
time since copd diagnosis yrs,C0040223;C3541383
men n [ ],C0025266
pre bronchodilator fev $nmbr$ l,C2599602;C3714541
heart rate bpm $nmbr$,C0018810
pre bronchodilator fev $nmbr$ predicted normal,C2599602;C0520835
diabetes n [ ],C0011847;C0011849
pre bronchodilator fvc l,C2599602;C3714541
$nmbr$ [ $nmbr$ ],
pre bronchodilator fev $nmbr$ fvc,C2599602;C3714541
placebo n $nmbr$ n,C0032042;C1696465;C1706408
post bronchodilator fev $nmbr$ l a,C2599594;C3714541
denosumab n $nmbr$ n,C1690432
western europe australia new zealand,C0027978;C0324547
post bronchodilator fev $nmbr$ predicted normal a,C2599594;C0520835
reversibility of fev $nmbr$,C0449261;C3714541
prevalent vertebral fracture,C0080179
post bronchodilator fvc l a,C2599594;C3714541
prior nonvertebral fracture at age $nmbr$ years,C0016658;C1510829
post bronchodilator fev $nmbr$ fvc a,C2599594;C3714541
prior use of osteoporosis medications,C1524063
randomisation visit baseline,C0168634;C1442488
female subjects n $nmbr$,C0043210;C0086287;C1705497;C1705498
fvc l proportion taking pulmonary medications b,C1290952;C0024109;C2707265;C2709248;C4522268
male subjects n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
any medication,C0013227;C3244316;C4284232
african american black,C0005680;C0027567;C0085756;C0439541
american indian native alaskan,C0682125
long acting b $nmbr$ agonists,C0243192;C2987634
serum creatinine level,C0600061
short acting b $nmbr$ agonists,C0243192;C2987634
estimated creatinine clearancet,C0750572;C0010294;C1561535
inhaled corticosteroids,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727
$nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
oral corticosteroids,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
xanthines,C0043318;C3541955
baseline sua mean sd mg dl,C0168634;C0439269;C1442488
short acting anticholinergics,C0242896;C3537307;C3540711
presence of tophi,C0150312;C0392148;C3854307
supplementary oxygen,C0030054
years since last gout flare,C0439234;C0018099
laba users,C1706077
years with gout mean sd,C0439234;C0018099
laba non users,C1518422;C1706077
obesity bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
tiotropium $nmbr$ mg respimat n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline renal function eclcr,C0168634;C0232804;C1442488
proportion taking pulmonary medications b,C1290952;C0024109;C2707265;C2709248;C4522268
febuxostat $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropiumc,
allopurinol,C0002144
preamendment,C1548596
normal $nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
postamendment,
mild impairment $nmbr$ to $nmbr$ ml minute,C0221099;C0684336;C0439232;C0700321;C0702093;C1282918;C2347166
extended duration enoxaparin n $nmbr$,C0231448;C0206460;C0231449;C0439792
moderate or severe impairment $nmbr$ ml minute,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0439232;C0700321;C0702093;C1282918;C2347166
asian or oriental,C0078988;C0699027
vorapaxar n $nmbr$,C2974521
region of enrollment n,C0017446;C0205147
median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
africa asia or the middle east,C0001737;C0003980;C0026068
region of enrollment,C0017446;C0205147
body mass index $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
cardiovascular risk factors,C0850624
primary enrollment diagnoses n,C0332137;C0801658
renal function ml min,C0232804;C0439445
acute infection without septic shock,C0275518;C0036983
$nmbr$ $nmbr$ crcl,C1846718
$nmbr$ crcl,C1846718
acute respiratory insufficiency,C0865850
cardiovascular disease history,C1880008
post acute ischemic stroke,C0751956
positive troponin or ck mb,C0439178;C0041199;C1446409;C1514241;C2825490;C3812269;C0010290
acute rheumatic disorders,C0001314
symmetric t wave inversions,C0332516;C0520888;C2699744
active cancer,C0006826;C0998265;C1306459
iii iv,C0022326;C4265176
fracture,C0016658
stratification factors,C1514984
multiple diagnoses,C0439064;C0011900
intent to use glycoprotein iib iiia inhibitor,C0162425;C1283828;C1550453
active inflammatory bowel disease,C0205177;C0021390;C3853793;C3888249
intent to use direct thrombin,C0162425;C1283828;C1550453
risk factors and immobility level n,C0035648;C1553898;C0231441;C0441889;C0456079;C1547707;C2946261
antiplatelet at randomization,C0034656
level $nmbr$ immobility,C0441889;C0231441;C0456079;C1547707;C2946261
chads $nmbr$ score $nmbr$,C0449820;C4050231
level $nmbr$ immobility^,C0441889;C0231441;C0456079;C1547707;C2946261
history of vte,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean systolic blood pressure sd mm hg,C0428886;C0439475;C0488053
active or previous cancer,C0205177;C3853793;C3888249;C0006826;C0998265;C1306459
mean diastolic blood pressure sd mm hg,C0428886;C0439475;C0488053
obesity body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
type of atrial fibrillation n,C0332307;C1547052
venous insufficiency,C0042485
chads $nmbr$ components n,C0007928;C0449432;C1413373
chronic heart failure,C0018802;C0264716
medications in use at baseline n,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
chronic respiratory failure,C0264492
histamine $nmbr$ receptor antagonist,C0019590;C4521896
chronic inflammatory disease,C1290886
median time in therapeutic range for warfarin recipients,C1554109;C0043031;C1709854
family history of vte,C0241889;C0630906
chads $nmbr$ score per outcome,C0449820;C4050231
thrombophilia,C0398623
rate in all participants y,C0871208;C1521828
previous medications n,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
dabigatran $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
antiplatelet or anti inflammatory drugs,C0003209
absolute risk reduction $nmbr$ ci y,C3179139;C0008107;C3259781
antiplatelet drugs,C0085826;C2963157
total events n,C0439175;C0439810
anti inflammatory drugs,C0003209
rate y,C0871208;C1521828
extended duration enoxaparin n n,C0231448;C0206460;C0231449;C0439792
dabigatran $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
absolute risk difference ci,C0008107;C3259781
$nmbr$ $nmbr$ t,C2603360
vte at day $nmbr$,C0630906;C0332173;C0439228;C0439505
vascular death,C0011065;C1306577;C4082313;C4552775
level $nmbr$,C0441889;C0456079;C1547707;C2946261
total death,C0011065;C1306577;C4082313;C4552775
major bleeding events,C0441471;C3541888
placebo plus statin n $nmbr$,C0032042;C1696465;C1706408
scd,
extended release niacin plus statin n $nmbr$,C0027996;C1142562
hradj $nmbr$ ci,C0008107;C3259781
distribution no,C0520511;C1704711
qtc,
american indian alaskan native or aboriginal canadian,C0886378;C0935542;C0238884
$nmbr$ $nmbr$ referent,C1706462
multiracial or other,C1881928
qtc $nmbr$ n $nmbr$,
hispanic or non hispanic ethnic group no f,C0086409;C0015031;C1879937;C0016327
no prior mi n $nmbr$,C0332152;C2826257
presenting history or diagnosis no,C0449450;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0011900;C1704338;C1704656
prior mi n $nmbr$,C0332152;C2826257
stroke or cerebrovascular disease,C0038454;C4554100;C0007820
no prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
laboratory values in patients with history of diabetes,C0022877;C0042295;C3244292;C4283904;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
insulin tu ml,C0439526;C1705224;C3887665
bnp,C0054015;C1095989;C1417808;C2982014
concomitant medications no,C0013227;C0802604;C2598133;C4284232
bnp $nmbr$ pg ml n $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
use at baseline,C0042153;C0457083;C1947944
ef $nmbr$ n $nmbr$,
duration of prior statin therapy^,C0444917
figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time,C0488055;C0871470;C1306620;C0428883;C1305849;C0949236;C0439234;C1705117;C0439508;C0040223;C3541383
previous use of niacin or niaspan,C1524063;C0027996;C1142562;C1161310
om $nmbr$ mg aml $nmbr$ mg n $nmbr$,C1319635;C0023465;C0023467
aspirin or other antiplatelet or anticoagulant agent,C0004057;C0003280
om $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
number of copd exacerbations,C0237753;C0449788
aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
change from baseline of morning pef l min,C0392747;C0443172;C1705241;C4319952
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
tdi units,C0439148;C1519795;C3853603
age group no,C0027362;C2348001
s d,C0565930;C2603362
height mean sd cm,C0489786;C0444504;C2347634;C2348143
o $nmbr$,C0483204
bmi mean sd kg m^,C0022718;C0439209;C4054209
x $nmbr$,
study $nmbr$,C0557651;C2603343
bmi category no,C0683312;C3889287
indacaterol group n $nmbr$,C1722260;C0441848
$nmbr$ kg m^ obesity,C0022718;C0439209;C4054209;C0028754;C1963185
duration of copd y,C0449238;C2926735
chronic kidney disease no t,C1561643;C4553188;C2603360
severity of copd gold $nmbr$,C0439793;C0522510
chronic cardiovascular disease no,C1290380
severe or very severe,C0205082;C4050465;C4050466;C3641272;C4050419
bp goal no,C0018017;C1571704
fev $nmbr$ predicted post albuterol,C0687676;C0001927;C1704687;C3469826
baseline sesbp mean sd mm hg,C0168634;C0439475;C1442488
fev $nmbr$ fvc post albuterol,C3714541;C0687676;C0001927;C1704687;C3469826
baseline sedbp mean sd mm hg,C0168634;C0439475;C1442488
fev $nmbr$ pre albuterol l,C0332152;C0001927;C0740175;C2257086;C3669034
om $nmbr$ mg aml $nmbr$ mg,C1319635;C0023465;C0023467
fev $nmbr$ post albuterol l,C0687676;C0001927;C1704687;C3469826
om $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
fev $nmbr$ reversibility pre post albuterol,C0332152;C0001927;C0740175;C2257086;C3669034
aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
use of rescue albuterol puffs day,C1524063;C0001927
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
days without albuterol use,C0439228;C0001927
bp variable mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
baseline sgrq score,C0449820;C4050231
moderate severe n $nmbr$ n $nmbr$,C0205081;C0205082;C4050465;C4050466;C1881878;C4049705;C4049706;C4085643;C4321335
no of patients indacaterol placebo,C0030705;C0032042;C1696465;C1706408
baseline bp mean sd,C0488053;C2699239
treatment difference ml,C0439526;C1705224;C3887665
change in sesbp ls mean se,C0392747;C0443172;C1705241;C4319952
copd severity gold $nmbr$,C0018026;C1304897
change in sedbp ls mean se,C0392747;C0443172;C1705241;C4319952
use of ics,C1524063;C0815320;C4551720
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ll,
albuterol reversibility,C0001927;C0449261
cad and or crvd,C1504769;C2239547;C3813548;C4284121
males $nmbr$,C0086582
$nmbr$ $nmbr$ a,
females $nmbr$,C0086287
mean preoperative abpi of the index,C0444504;C0445204;C2347634;C2348143
waist hip ratio,C0205682
limb sd,C0015385;C2699239
males $nmbr$ $nmbr$,C0086582
pad symptoms,C0683368;C1457887
females $nmbr$ $nmbr$,C0086287
claudication only,C0021775;C0311395;C1456822
baseline hemoglobin aj^ values,C0004486;C0042295;C0230613
rest pain,C0234253
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
ulcers gangrene,C0041582;C0017086
hemoglobin aj^,C0004486;C0230613
distal anastomosis,C0448964
diabetes duration y,C0011847;C0011849
below knee popliteal,C0022742;C0442037;C0022745;C1963703
baseline hba $nmbr$ c category,C0683312;C3889287
below knee popliteal crural,C0023216;C1140621
liraglutide $nmbr$ $nmbr$ mg oad,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
beyond popliteal pedal,C0016504;C0687080
sitagliptin oad,C1565750
all grafts,C0332835;C1527362
glimepiride oad,C0061323
venous,C0042449;C0348013
rosiglitazone oad,C0289313
prosthetic,
exenatide oad,C0167117
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
hba $nmbr$ c $nmbr$ $nmbr$,C0019016;C1825777;C3538758
graft occlusionsa,C0181074;C0332835;C1961139
alc at weeko,C1424945;C3811058
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
amputationsa,
l i $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
alc at week $nmbr$,C1424945;C3811058
placebo n[ $nmbr$,C0032042;C1696465;C1706408
$nmbr$ $nmbr$ g l,C0439294;C0456615
salmeterol n [ $nmbr$,C0073992
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0019016;C1825777;C3538758
fp n [ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
$nmbr$ $nmbr$ fi $nmbr$,C4050619
sfc n [ $nmbr$,C4521536
hba $nmbr$ c s $nmbr$ s $nmbr$,C0019016;C1825777;C3538758
age at enrolment years,C1510829;C1516879;C1696073;C3888021
$nmbr$ s $nmbr$,
postbronchodilator fev $nmbr$ predicted,C0681842;C1882327
linagliptin n $nmbr$,C2746078
$nmbr$ e $nmbr$ n,
total comparators n $nmbr$,C0439175;C0439810
geographical region n,C0017446;C0205147
gender of patients,C0079399;C1522384
pack years smoked,C1277691;C0037366;C0439994;C1881674
race of patients,C0034510;C1706779;C3853635
previous copd treatment n,C0024117;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1412502;C3714496
hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
diabetes duration known of patients,C0011847;C0205309;C0011849
laba alone,C0205171;C0439044;C0679994
previous oral glucose lowering agents of patients,C0205156;C0017725;C1552607;C0441994;C2003888;C0600419
ics laba,C0815320;C4551720
cv risk factors of patients,C0035648;C1553898
neither ics nor laba,C0815320;C4551720
ex current smoker,C3173209;C3241966
previous mi n,C0205156;C1552607
egfr using cg mdrd formulae of patients,C1739039;C3811844;C3812682;C1524063;C3839656;C0012164;C0489829;C1705501
baseline cv treatment n y,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
severely impaired,C0205082;C0221099
baseline short acting anticholinergics n,C0168634;C0242896;C3537307;C3540711;C1442488
cv medication of patients,C0013227;C3244316;C4284232
salmeterol n[ $nmbr$,C0073992
acetyl salicylic acid,C0004057
fp n[ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
lipid lowering therapy,C0585943
sfc n[ $nmbr$,C4521536
any of the above,
$nmbr$ e,
framingham $nmbr$ year cv risk score,C0035647;C0449820;C4050231;C4552904
baseline cv treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
score,C0449820;C4050231
baseline short acting anticholinergics,C0242896;C3537307;C3540711
score $nmbr$ of patients,C0449820;C4050231;C0030705
severe oab subgroup,C1079230;C1515021
linagliptin patients with events total patients,C0030705;C0439175;C0439810
full analysis set fas,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
total comparators patients with events total patients,C0439175;C0030705;C0439810
solifenacin n $nmbr$,C1099677
cox hr $nmbr$ ci,C0008107;C3259781
age cohort no,C2348001
cmh rr $nmbr$ ci,C0008107;C3259781
diary variables mean sd,C0376660;C2699239
use of rescue medication,C1524063
urgency episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
investigator reported hypoglycaemia,C0020615;C4553659
incontinence episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ no,
micturitions $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
white no,C0007457;C0043157;C0220938
nocturia episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
black no,C0005680;C0027567;C0085756;C0439541
wt second median,C0549183;C0876920;C2347635;C2348144;C2939193
other no,
ppbc score mean sd,C0444504;C2699239;C2347634;C2348143
taking antihypertensive treatment at,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline no,C0168634;C1442488
iuss score mean sd,C0444504;C2699239;C2347634;C2348143
ups score mean sd,C0334463;C2699239;C3542434
treated at baseline mean sd mm hg,C1522326;C0439475
oab q score mean sd,C3641332;C2699239
untreated at baseline mean sd mm hg,C0332155;C0439475
symptom bother,C1457887;C3854129
eligibility risk factorsa,C0013893;C0035647;C4552904;C1548635
hrql mean sd,C0444504;C2699239;C2347634;C2348143
cigarette smoker no,C0337667
coping,C0009967
ascvd b no,C3665365
concern,C2699424
history of mi or stroke no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
sleep,C0037313
history of coronary revascularization no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
social interaction,C0037420
other ascvd no,C3665365
all n $nmbr$ $nmbr$,C0369718;C0441922
st t wave no,C0036056;C0429103;C3272372
bivalirudin n $nmbr$ $nmbr$,C0168273
lvh by ecg or echocardiography no,C0232306;C0013516
heparin plus gpi n $nmbr$ $nmbr$,C0019134;C0770546
lvh by minnesota code no,C0149721;C0009219;C0805701;C3889831
symptom onset to pci h,C4086878;C0033727;C0369286;C0441932;C0564385;C4528284
diabetes no c,C0011847;C0011849
killip class $nmbr$ $nmbr$,C1881332
history of chd at baseline no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
anemia,C0002871;C1000483;C4554633
lipid trial participants no,C1997894;C2242969
$nmbr$ diseased vessels,C0005847
non cardiovascular mortality,C0026565;C0026566
anterior infarct location,C0450429;C1515974;C4284930;C4284931
fatal chd nonfatal ml,C0439526;C1705224;C3887665
initial timi flow grade $nmbr$,C0441800;C0919553;C3244287
fatal nonfatal ccvd,C1302234;C1705232
stent implanted,C0522776
fatal nonfatal hospitalized heart failure,C0018801;C0018802;C4554158
final timi flow grade,C0441800;C0919553;C3244287
fatal nonfatal hospitalized stroke,C0038454;C4554100
heart rate group at baseline,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
kidney disease usrds,C0022658
$nmbr$ bpm n $nmbr$ l $nmbr$,
age $nmbr$ $nmbr$ y,C0001779
cardiac parameters,C0018787;C0449381;C1522601
nonblack,
egfr ml min per $nmbr$ $nmbr$ kg m^,C1739039;C0439402;C3811844;C3812682
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os,C0229090;C0230028;C0262950;C0393706;C1561953
duration of heart failure years,C0449238;C2926735
african americans,C0085756
primary cause of heart failure,C0205225;C0015127;C1524003;C0439612;C0439631
caucasians,C0007457;C0043157
non ischaemic,C1518422;C0475224
v hctz n $nmbr$,C0020261
history of atrial fibrillation and or flutter,C0729790;C0016385;C2242390
hctz n $nmbr$,C0020261
treatment at randomisation,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
prior antihypertensive medication n,C0332152;C0003364;C2826257
diuretic agents excluding antialdosterone,C0450442;C1254351;C1521826
diabetes status n,C1317301
antialdosterone agents,C0450442;C1254351;C1521826
normoglycemia^,
cardiac glycosides,C0007158
ifg prediabetes^,C1334085;C0362046;C1708411
devices,C0025080;C0220819;C0699733
cardiometabolic syndrome ^n,C0039082
crt,
mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
heart rate at baseline bpm,C0018810;C0168634;C1442488
mean sd waist circumference cm,C0444504;C0455829;C2347634;C2348143
ivabradine group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mean sd fpg mg dl,C0444504;C0439269;C2347634;C2348143
mean sd fasting insulin uu ml,C0444504;C2699239;C2347634;C2348143;C0015663;C0021641;C0439342;C1533581;C1579433;C3714501
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min,C0013806;C2199618;C2363129;C4050504;C1707455;C0032042;C1696465;C1706408;C2986535;C0184666;C0332271;C1457868;C1546960;C0018801;C0018802;C4554158;C0007226;C1555024;C3887460;C1508496;C0018810;C0332257;C1552866;C2700399;C0011065;C1306577;C0456081;C1512806;C0428876;C0812399;C2985465;C0702093;C1524029;C3813700
mean sd ldl c mg dl,C0444504;C0439269;C2347634;C2348143
ivabradine group n $nmbr$,C0257190;C0441848
mean sd hdl c mg dl,C0444504;C0439269;C2347634;C2348143
sex male ethnic origin,C0086582;C0015031
mean sd triglycerides mg dl,C0041004;C0439269
bmi kg m $nmbr$ cardiac parameters,C0022718;C0439209;C4054209;C0018787;C0449381;C1522601
mean sd mssbp mm hg,C0444504;C0439475;C2347634;C2348143
egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
mean sd msdbp mm hg,C0444504;C0439475;C2347634;C2348143
medical history duration of heart failure years primary cause of heart failure,C0449238;C2926735
mean sd $nmbr$ h asbp mm hg,C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
history of atrial fibrillation or flutter treatment at randomisation,C0729790;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mean sd $nmbr$ h adbp mm hg,C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
diuretic drugs excluding antialdosterone,C0013227;C3687832
v hctz,C0020261
test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
hctz,C0020261
s $nmbr$ years n $nmbr$,C0439234
change from baseline to eos mg dl,C0392747;C0443172;C1705241;C4319952;C1623465;C0439269;C1861303
no p blocker intake at randomisation n $nmbr$,C1512806;C0034656
ls mean difference $nmbr$ ci,C0008107;C3259781
p blocker intake at randomisation n $nmbr$,C1512806;C0034656
fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
non ischaemic n $nmbr$,C1518422;C0475224
change from baseline to eos uu ml,C0392747;C0443172;C1705241;C4319952;C1623465;C0439342;C1861303
ischaemic n $nmbr$,C0475224
$nmbr$ $nmbr$ $nmbr$ lf,C1416933;C2986618;C4554443
nyha class ii n $nmbr$,C1882085
regadenoson n $nmbr$,C1698215
nyha class iii or iv n $nmbr$,C1882086;C0022326;C4265176
mean sd years,C0444504;C0439234;C2347634;C2348143
no history of diabetes n $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ckd n t,C1561643
history of diabetes n $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
stage $nmbr$,C0205390;C1300072;C1306673
no history of hypertension n $nmbr$,C0455527
cad history and risk factors n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0035648;C1553898
baseline heart rate,C0168634;C0018810;C1442488
obesity bm $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ bpm n $nmbr$,
smoking $nmbr$ pack years,C0037369;C1277691;C0453996;C1881674
heparin dose regimen,C0019134;C2348331;C0770546
egfr ml minute $nmbr$ $nmbr$ m $nmbr$,C0439232;C0700321;C0702093;C1282918;C2347166
$nmbr$ standard n $nmbr$,C1442989;C2828392
regadenoson,C1698215
$nmbr$ low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
change from baseline stage $nmbr$ ckd,C0597205;C0679846
heart failure at entry no,C0018801;C0018802;C4554158
stable angina n,C0340288
previous events no,C0441471;C3541888
non st segment elevation,C1518422;C0520886
pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
mi n,C3810814
electrocardiograph results no,C1274040;C1546471;C2825142
congestive hf,C0018488;C1313497;C1538440;C3273279
changes at baseline,C0392747;C0443172
number of target vessels,C0237753;C0449788
st depression $nmbr$ mm,C4330985;C4554674
drug eluting stent n,C1322815
any dynamic st segment shift,C0333051;C2347509
bare metal stent n,C2825200
transient st elevation,C0040704;C0520886;C0205374
cangrelor,C1121991
positive troponin i or t no,C0439178;C0077401;C1446409;C1514241;C2825490;C3812269;C2603360
comparator,C1707454;C4553389;C4553390
time from median iqr h,C0040223;C3541383
or [ $nmbr$ cl],C0596019
symptom onset to hospitalization,C4086878;C0019993
death udmi idr,C0011065;C1306577;C4082313;C4552775
hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
death q mi idr,C0011065;C1306577;C4082313;C4552775
enrollment to randomization,C1516879;C1696073;C3888021
death q ml stent thrombosis,C0011065;C3897493;C1306577;C4082313;C4552775
symptom onset to enrollment,C4086878;C1516879;C1696073;C3888021
diabetic yes,C1549445;C1705108;C1710701
symptom onset to randomization,C4086878;C0034656
diabetic no,C0241863
angiographic characteristics no,C1521970
prior thienopyridine,C0332152;C1120149;C2826257
subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811;C0205363;C0168634;C1442488
single vessel disease,C0037179;C0042373;C0087136;C0205171
antithrombotic use before enrollment no,C0042153;C0457083;C1947944
low renin pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
non pci intravenous unfractionated heparin,C1518422;C0354566
normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$,C1533072;C4050009
subcutaneous unfractionated heparin,C0353681
received antihypertensive within last $nmbr$ days n,C0003364;C0439228
lmwh,C0019139;C3536766
diabetic n,C0241863
gpiib iiia inhibitors,C0016011;C0243077
mssbp sd mmhg,C2699239;C0439475
commercially available fondaparinux,C0470187;C1098510
msdbp sd mmhg,C2699239;C0439475
medication use before enrollment no,C0240320;C1516879;C1696073;C3888021
pra median min max ng ml h,C1533072;C4050009
g blockers,C0439267
african american n $nmbr$,C0085756
angiotensin receptor blockers,C0521942;C0815017
caucasian n $nmbr$ $nmbr$,C0007457;C0043157
oral hypoglycemic agents,C0359086
alcohol use n,C0001948
ticlopidine,C0040207
drinker $nmbr$ $nmbr$ drinks week,C0332174;C0439230
prasugrel,C1620287
non ex tobacco user,C1518422;C3853727
aspirin dose mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tobacco user,C3853727
total time of fondaparinux treatment before,C0439175;C0040223;C3541383;C0439810
tophi present n,C0221248;C0150312;C0449450
and after pci median iqr d,C0549183;C0876920;C2347635;C2348144;C2939193
renal function bn,C0005005;C0034700;C1706574;C4551963
variables,C0439828
any cardiovascular disease,C0007222
all with coenzyme q $nmbr$ n $nmbr$ $nmbr$,C0041536
cardiac arrhythmia,C0003811;C0264886;C1560249
tertile $nmbr$ n $nmbr$,
use of low dose aspirin $nmbr$ mg daily,C1524063;C2608320
p value for trend across tertiles,C1709380;C1521798;C4554533
figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min,C1280519;C1707887;C0085756;C0681850;C1550501;C1706203;C2349001;C2697811;C2945599;C1565489;C0439445
age $nmbr$ yrs n,C0001779
semuloparin n $nmbr$,C2700104
nyha functional class n,C1882083;C0205245;C0542341;C2700217
hazard ratio $nmbr$ ci j,C2985465;C0008107;C3259781
cabg or ptca pci,C0010055;C2936173;C4049621
any vte or vte related death no,C0630906;C0011065;C1306577;C4082313;C4552775
af or atrial flutter,C0344434;C4049859;C0004239;C0344423;C1963068
symptomatic deep vein thrombosis,C0231220;C0149871
total cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
upper limbs,C1140618
ldl cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
lower limbs,C0023216
hdl cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
proximal,C0205107;C4489236
apoa $nmbr$ g l,C0439294;C0456615
distal,C0205108;C4522154
apob g l,C0439294;C0456615
pulmonary embolism,C0034065
serum creatinine xmol l,C0201976;C0600061
nonfatal,
serum creatinine $nmbr$ xmol l n,C0201976;C0600061
symptomatic,C0231220
egfrmdrd ml min $nmbr$ $nmbr$ m $nmbr$ bsa,C0369637;C0441923
detected during tumor evaluation,C0442726;C1511790
nt probnp pmol h,C0033727;C0369286;C0441932;C0564385;C4528284
ne,C0027608;C0028219;C3538705
coenzyme q $nmbr$ p g ml,C0041536;C1300565
any vte related death,C0011065;C1306577;C4082313;C4552775
hazard ratiof,C0598697
outcome according to primary cancer site no total no,C1274040;C0872338;C0439175;C0439810
$nmbr$ clf,C3540486;C4553190
lung,C0024109
subgroup p valuef,C1079230;C1515021
pancreas,C0030274
all randomized all cause mortality,C0015127;C0026565;C0026566;C1524003
stomach,C0038351;C3714551
all randomized coronary end point,C2349179;C2826544
colon or rectum,C0009368;C3888384;C0034896
all randomized all cause mortality or hospitalization for worsening hf^,C0015127;C0026565;C0026566;C1524003;C0019993;C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
bladder,C0005682;C4319531
ovary,C0029939;C0227898
type of end point,C0332307;C1547052
subgroup p value,C1079230;C1709380;C1515021
outcome according to stage of cancer no total no,C1274040;C0027646;C0439175;C0439810
hospitalizations,C0019993
metastatic,C0036525;C1522484;C4085632
omeprazole,C0028978
locally advanced,C1517927;C0205179
age yrf,C0001779
outcome according to no of risk factors for vte,C1274040;C0035648;C1553898;C0630906
white race no total no,C0007457;C0043157;C0439175;C0439810
total phase $nmbr$ pooled n $nmbr$,C0439175;C0205390;C1710475;C0439810
negative for helicobacter pylori no total no,C4688581;C0439175;C0439810
low complement anti dsdna positive n $nmbr$,C0432633
nsaid use no total no,C0042153;C0457083;C1947944;C0439175;C0439810
mean selena sledai score sd,C3533236;C2699239
cardiovascular history no total no,C1880008;C0439175;C0439810
selena sledai $nmbr$,C0451528
acs,C0742343;C4318612
proteinuria $nmbr$ g $nmbr$ h,C0033687;C0560020;C1962972;C4554346
other vascular disease,C0042373
anti dsdna $nmbr$ iu ml,C0741099;C0439458
cardiovascular risk factors no total no,C0850624;C0439175;C0439810
igg $nmbr$ $nmbr$ g l,C0439294;C0456615
current smoking no total no,C0037369;C0453996;C1881674;C0439175;C0439810
low c $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
current alcohol use no total no,C0521116;C0001948;C1705970;C0439175;C0439810
$nmbr$ $nmbr$ mg day,C0439422
history of gi bleeding or ulcer no total no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0041582;C3887532;C0439175;C0439810
immunosuppressant use,C0042153;C0457083;C1947944
mean slicc damage index score sd,C3533236;C2699239
medications at study entry no total no,C0013175;C1705654;C0439175;C0439810
mean pga score sd,C3533236;C2699239
supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups,C0598697;C0456603;C1610540;C0439064;C1079230
figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis,C0024141;C0600653;C0918012;C1552854;C1637833;C2986546;C0683962
h pylori positive or indeterminate h pylori negative no nsaids used nsaids used male other race black white age $nmbr$ age $nmbr$ bmi $nmbr$ bmi $nmbr$ history of pad negative history of pad positive no aspirin use concomitant aspirin no statin use concomitant statin no clopidogrel use concomitant clopidogrel no hypertension hypertension no diabetes diabetes no hypercholesterolemia hypercholesterolemia no other risk factor other risk factors overall,C0439178;C1446409;C1514241;C2825490;C3812269;C0205258;C4688581;C0086582;C1706180;C1706428;C1706429;C0005680;C0004057;C0042153;C0457083;C1947944;C0360714;C0070166;C0020538;C1963138;C0011847;C0011849;C0020443;C1522133;C0035648;C1553898;C0282416;C1561607
horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p,C0205126;C0205132;C0008107;C0458097;C3259781;C1882932;C1705241;C1705242;C0032042;C1696465;C1706408;C1552961;C2347617;C3714763;C0205250;C0871261;C0441994;C1548802;C2003888;C0750572;C1518681;C0205128;C1723401;C0439272;C1704675
supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease,C0598697;C0456603;C1610540;C0439064;C1079230;C0348078;C0042373;C0376315
troponin positive n $nmbr$,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
rolofylline,C0166128
troponin negative n $nmbr$,C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
p valuej,C0369773;C2603361
measurements,C0242485
age median [iqr] y,C0549183;C0876920;C2347635;C2348144;C2939193
weight median [iqr] kg,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
heart rate at rest in the supine position beats min,C0018810;C0035253;C1622890;C0038846;C0439385
cardiac biomarker elevation,C0439775;C0702240
respiratory rate breaths min,C0231832;C0439386;C0489258
bnp pg ml h,C2827929
st segment deviation timi risk score,C0035647;C0449820;C4050231;C4552904
nt probnp pg ml h,C2827929
white blood cell count cellsx $nmbr$,C0023508;C0427512
hemoglobin g dl,C0439267
left ventricular ejection fraction within previous $nmbr$ mo,C0428772;C0488728
demographic variable,C0439828;C4553760
heart failure $nmbr$ mo before admission,C0026544;C0332177
vildagliptin $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
biventricular pacemaker,C1719274
vildagliptin $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
copd or asthma,C0024117;C1412502;C3714496;C0004096;C2984299
body weight,C0005910;C1305866
treatment before admission,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
aldosterone blocker,C0002006
$nmbr$ h ppg mmol l,C2827804;C1418888
nitrates oral or topical,C0442027;C4521986;C0332237
duration of t $nmbr$ dm,C0449238;C2926735
treatment after admission,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
days of study drug administration $nmbr$ day,C2826182
vildagliptin $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ or $nmbr$ days,C0439228
am s e,
ama s e,C0002461;C0279755;C2825862
medications through day $nmbr$,C0013227;C0802604;C2598133;C4284232
bmi at baseline kg m $nmbr$,C0578022;C0022718;C0439209;C4054209
total intravenous loop diuretic mg median,C0549183;C0876920;C2347635;C2348144;C2939193
duration of metformin therapy months,C0444917;C0025598
intravenous inotropes or vasopressors,C0348016;C0042397
duration of diabetes months,C0449238;C2926735
intravenous vasodilators,C0443081
golimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
medications at discharge or day $nmbr$ if earlier,C0806915;C0332173;C0439228;C0439505;C1279919
sex no male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0086582;C1706180;C1706428;C1706429
figure $nmbr$ a subgroup results for primary endpoint,C1274040;C1546471;C2825142
race no white,C0034510;C1706779;C3853635;C0007457;C0043157;C0220938
figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou,C1274040;C1546471;C2825142;C0007226;C3887460;C0022646
psa duration years,C0449238;C0439234;C2926735
placebo mtx n $nmbr$,C0032042;C0025677;C1417487;C1696465;C1706408
number of swollen joints $nmbr$ assessed,C0449813
rituximab $nmbr$ x $nmbr$ mg mtx n $nmbr$,C0024671;C0025677;C1417487;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number of tender joints $nmbr$ assessed,C0449813
percentage with disease duration,C0439165;C1549488;C1561533
das $nmbr$ crp,C3890735;C4048285
no previous dmard therapy,C0039798;C0087111;C1363945
psa modified shs of hands and feet,C0392747;C0018563;C1552914;C3889737;C0016504;C0347981
receiving concomitant corticosteroids,C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
erosion score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
receiving concomitant nsaids and or cox $nmbr$ inhibitors,C1514756;C0521115;C0003211;C0085387
jsn score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
swollen joint count $nmbr$ $nmbr$ possible joints,C0451521;C0332149;C1705910;C2362652
total score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
tender joint count $nmbr$ $nmbr$ possible joints,C0451530;C0332149;C1705910;C2362652
no of patients with $nmbr$ bsa affected,C0030705;C0392760;C1314939
c reactive protein mg dl,C0006560;C0439269;C1413716;C4048285
bsa affected,C0392760;C1314939
health assessment questionnaire $nmbr$ $nmbr$ range,C1514721;C2348147;C3542016
pasi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
das $nmbr$ esr,C0051767;C3811131;C0057671
no of patients with fingernail involvement,C0030705;C0222001;C1314939
rheumatoid factor positive,C0439178;C1446409;C1514241;C2825490;C3812269
no fingernails,C0222001
baseline mean mtss,C0168634;C0444504;C2347634;C2348143;C1442488
target nail napsi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
seropositive rf ve and or acpa ve subgroup,C0035448;C0201660;C0748398;C1547111;C1525410;C1706063;C1079230;C1515021
patients with dactylitis no,C0030705;C0239161
seronegative rf ve and acpa ve subgroup,C0035448;C0201660;C0748398;C1547111;C1525410;C1706063;C1079230;C1515021
dactylitis score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
placebo mtx,C0025677;C1417487
patients with enthesitis no,C0030705;C1282952
rituximab $nmbr$ x $nmbr$ mg mtx,C0025677;C1417487
psa modified mases score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
joint damage outcomes mitt population,C0032659;C1257890
haq score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
n $nmbr$ t,C0369718;C0441922
sf $nmbr$ health survey,C0037712;C0018762
week $nmbr$,C0332174;C0439230
pcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
change in mtss mean,C0392747;C0443172;C1705241;C4319952
mcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
change in erosion score mean,C0392747;C0443172;C1705241;C4319952
patients taking mtx no,C0025677;C1417487
patients with no progression,C0030705;C0242656;C0449258
mean median mtx dose mg week,C0332174;C0439230
or unadjusted,C1439367
golimumab combined n $nmbr$,C2353893;C0205195
itt,
change in psa modified shs baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
disease activity outcomes itt population week $nmbr$,C0332174;C0439230
total score,C2964552
acr $nmbr$,C1412134;C1515941
mtx at baseline,C0025677;C1417487
major clinical response,C0205082;C4055223;C0205164;C4318856;C4521762
p vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
mean acrn,C0444504;C2347634;C2348143
no mtx at baseline,C0025677;C1417487
eular good response,C0871261;C1704632;C1706817;C2911692
hands erosion score,C0449820;C4050231
das $nmbr$ esr lda,C0051767;C4553195;C0057671
jsn score,C0449820;C4050231
das $nmbr$ esr remission,C0544452;C0687702
total hands score,C2964552;C0018563;C1552914
change in das $nmbr$ esr mean i physical function outcomes week $nmbr$,C0392747;C0443172;C1705241;C4319952
feet erosion score,C0449820;C4050231
change in haq di mean t,C0392747;C0443172;C1705241;C4319952
total feet score,C2964552;C0016504;C0347981
with haq di decrease $nmbr$ $nmbr$,C0392756;C0547047
additional radiographic findings at week $nmbr$,C2607943;C2926606;C3539655
fenofibric acid n $nmbr$,C0060179
rosuvastain fenofibric acid n $nmbr$,C0060179
no new erosions among patients with $nmbr$ uninvolved joint at baseline,C0333307;C1959609;C0022417;C0392905;C1706309
type $nmbr$ diabetes mellitusa,C1320657
no new jsn among patients with $nmbr$ uninvolved joint at baseline,C0205314;C0030705;C0022417;C0392905;C1706309
metabolic syndromeb,C0311400;C1524026;C2707259
radiographic progression based on change from baseline sdc,C0242656;C0449258;C1527178;C1705938;C1419891;C3273112
baseline lipids mg dl,C0023779;C0439269
total psa modified shs,C2986589;C0392747;C3889737
tg median min max,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
erosion score,C0449820;C4050231
rosuvastatin fenofibric acid,C0965129;C0060179
patients with change from baseline in total psa modified shs $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
diabeticb,
diabetes bl,C0005918;C0006413;C1552663;C2827109
final mean mg dl,C0205088;C0439269;C1546485;C3853528
idm,C0270221
mean change se,C0392747;C0036919;C0443172;C1705241;C4319952
no pts,C1419129;C2698747
$nmbr$ $nmbr$ c,
lvh by ecgt blood pressure mm hg,C0149721;C0005823;C1271104;C1272641
hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sestandard error tg triglycerides,C0062152
sbp,C0085805
ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group,C0002680;C1522609;C3887950;C0023779;C1280500;C1518681;C2348382;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
dbp,C0536221;C3813197;C4281799
brandomization was stratified by diabetic status,C0205363;C0241863
bmi kg m $nmbr$ cholesterol mg dl,C0022718;C0439209;C4054209;C0008377;C0439269
crosuvastatin fenofibric acid vs rosuvastatin monotherapy,C0060179;C0965129
total no of events participants,C0439175;C0439810;C0441471;C0679646;C3541888
drosuvastatin fenofibric acid vs fenofibric acid monotherapy,C0060179
unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate,C0242444;C2987720
cure trial,C1880198;C0008976
adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$,C0008107;C3259781;C1707455;C0011847;C0011849;C0005918;C0006413;C1552663;C2827109;C0439234;C0439508
active a,C0205177;C3853793;C3888249
adjusted hr $nmbr$ ci comparing idm with bl,C0008107;C3259781;C1707455;C0270221;C0005918;C0006413;C1552663;C2827109
ancestry f,C0016327
cvd mortality,C0026565;C0026566
european,C0239307;C1535514
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p,C0369773;C2603361
latin american,C1553378
non cvd mortality,C0026565;C0026566
age yij,C0001779
nonfatal mi fatal chdt,C1302234;C1705232
without stent,C0038257
lisinopril cvd total,C0439175;C0439810
with stent,C0038257
no cases,C0868928;C1533148
metabolizer phenotype,C0031437;C1285572
allopurinol $nmbr$ $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
poor,C0032854;C0542537;C2700379
participated in a previous febuxostat studyb n,C0205156;C0249529;C1552607
ultra,C0728475
prior urate lowering therapies n,C1514463;C0441994;C2003888
outcome and metabolizer phenotype,C1274040;C0031437;C1285572
yes any,C1549445;C1705108;C1710701
clopidogrel versus placebo,C0070166;C0032042;C1696465;C1706408
febuxostat,C0249529
patients with events total no of patients,C0030705;C0439175;C0439810
probenecid,C0033209
first primary composite outcome,C0205199;C1274040;C1547335
renal functionc n,C0022646
second primary composite outcome,C0205199;C1274040;C1547335
any cardiovascular diseased,C0007226;C3887460
primary composite outcome,C0205199;C1274040;C1547335
use of low dose aspirin,C1524063;C2608320
all participants n $nmbr$,C0679646
figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit,C0444504;C3272907;C2347634;C2348143;C0455272;C0086960;C0205539;C1571999
dha n $nmbr$,C0142831;C2348308
p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation,C0369773;C2603361;C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0743559;C1608199;C1882932;C0871420
education mean sd ya,C0013621;C0013622;C0013658;C0039401
vorapaxar n $nmbr$ $nmbr$,C2974521
apoe e $nmbr$ carriers no,C0003595;C0007294;C0523511;C1412481
qualifying type of atherosclerosis no,C1514624;C0332307;C1547052
body mass indexb,C0518010
selected clinical characteristics no total no,C1707391;C0683325;C0439175;C0439810
modified hachinski ischemia scale mean sd c,C0022116;C0175659;C0349674;C1947916;C4321499
any coronary artery disease,C0010054;C0010068;C1956346
smokers no,C0337664
any peripheral arterial disease,C0085096;C1704436
blood pressure mean sd mm hg systolic,C0428886;C0039155
previous cerebrovascular event,C0441471;C4019010
mini mental state examination mean sd d,C0451306;C2699239
use of antiplatelet agents no total no,C1524063;C0085826;C0439175;C0439810
cognitive subscale on alzheimer s disease assessment scale mean sd e,C0450989
qualifying myocardial infarction,C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
clinical dementia rating sum of boxes mean sd f,C0451074;C1515051
qualifying peripheral arterial disease,C1514624;C0085096;C1704436
qualifying stroke,C1514624;C0038454;C4554100
dha intake on food frequency questionnaire mean sd mg d,C1286336
dipyridamole,C0012582
plasma dha mean sd weight,C0005910;C0043100;C1305866;C1705104
use of other medications no,C1524063
cholinesterase inhibitor use at baseline no,C0042153;C0457083;C1947944
angiotensin converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021;C0034787;C1622222
memantine use at baseline no,C0042153;C0457083;C1947944
subgroup overall,C1079230;C1515021;C0282416;C1561607
$nmbr$ mg dabigatran n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total no $nmbr$,C0439175;C0439810
previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
vorapaxar placebo $nmbr$ yr,C0032042;C0439234;C1696465;C1706408
no previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C2985465;C0596019
on aspirin at baseline,C0004057;C0168634;C1442488
qualifying atherosclerosis,C1514624;C0003850;C0004153
vitamin k antagonist naive,C1096489;C2267235
thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
on statins at baseline,C0360714;C0168634;C1442488
egfr mumin $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
rate per year,C0871208;C1521828
europe i,C0021966;C0221138
$nmbr$ mg dabigatran,C0024671;C2348066;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
europe ii,C1710602;C4082587
wafarin,
australia nz,C0004340;C0027978
previous stroke or tl a,C0038454;C4554100;C0220928
vorapaxar,C2974521
no previous stroke ortia,C0205156;C0038454;C4554100;C1552607
estimated glomerular filtration,C0750572;C0232809
ischaemic or unknown stroke,C0475224;C0038454;C4554100
sample size n by treatment,C0242618
previous stroke ortia $nmbr$ $nmbr$,C0205156;C0038454;C4554100;C1552607
american indian alaskan native n,C0886378
previous stroke ortia,C0205156;C0038454;C4554100;C1552607
asian pacific islander n,C0078988;C0242191
haemorrhagic stroke,C0553692
other n,C0369718;C0441922
total bleeding,C0232100
on antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ gi,C1708130;C3539617;C4050121
blood pressure at baseline,C0005823;C1271104;C1272641
intracranial bleeding,C0151699
gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
all participants mm hg sbp mean sd,C0439475;C2699239
dbp mean sd,C0444504;C2699239;C2347634;C2348143
previous stroke or tl a $nmbr$ $nmbr$,C0038454;C4554100;C0220928
fenofibric acid $nmbr$ $nmbr$,C0060179
treated at baseline mm hg sbp mean sd,C1522326;C0439475
rosuvastain fenofibric acid $nmbr$ $nmbr$,C0060179
untreated at baseline mm hg sbp mean sd,C0332155;C0439475
current cigarette smoker n,C3173209;C3241966
$nmbr$ n gender n,C0369718;C0079399;C1522384;C0441922
coronaiy artery disease,C0852949
type $nmbr$ diabetes n,C1320657
hdl c $nmbr$ mg dl n,C3715113;C0439269
type $nmbr$ diabetes mellitus,C1320657
lvh by electrocardiogram n,C0149721;C0013798;C1547122;C1623258
metabolic syndrome $nmbr$ baseline lipids mg dl,C0524620;C0439269
fenofibric,
fasting glucose mean sd mg dl,C0015663;C0439269
l value,C0439394;C1522609;C1706495;C3642217
total cholesterol mean sd mg dl,C0201950;C0439269;C0543421
j valuc l,
fasting triglycerides mean sd mg dl,C0015663;C0041004;C0439269
acid,C0001128;C0202406
nos $nmbr$ $nmbr$ c t n,C0326287;C1518425
zt $nmbr$,
cc,C0008318;C3538933
se,C0036919
ct,C0007673;C3540513;C3813556;C3888140
silodosin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tt,C1452561;C4554543
tamsulosin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nos $nmbr$ $nmbr$ a g n,C0326287;C1518425;C0439267
age yr n,C0001779;C0439234
aa,C0282379;C1235746;C1882141;C4554792
min max,C0702093;C1524029;C3813700
ag,C0002037;C0051080;C0152305;C3888235
not estimable,C1518422
gg,C0017454;C0018370
ipss total score,C1019118;C2964552;C1998280;C2827405;C3811063
nos $nmbr$ glu $nmbr$ asp g t n,C0326287;C0125690;C1518425
ipss storage subscore,C1019118;C0337174;C1698986;C1753314;C1998280;C2827405;C3811063
gt,C1435727;C1704693;C2697657
ipss voiding subscore,C1019118;C0042034;C4067975;C1998280;C2827405;C3811063
number of events event per $nmbr$ person years,C4330837;C0027361;C0439234;C2347489
qol due to urinary symptoms,C0518214;C0426359
rates,C0871208;C1521828
delighted,C3830544
genotype specific treatment effect hazard ratio $nmbr$ ci,C0008107;C3259781
pleased,C3829994;C4264468
genotype by treatment interaction p values,C0017431;C1709380
mostly satisfied,C0242428;C4049977;C4084799
outcome variant,C1274040;C0205419
mostly dissatisfied,C0870433;C4085546
genotype,C0017431
unhappy,C1688635
aml,C0023465;C0023467
terrible,C3827840
lis,C2247545
urine qmax ml s,C0439526;C1705224;C3887665
chl,C0019829
baseline triglycerides,C0168634;C0041004;C1442488
aml vs lis,C0023465;C0023467;C2247545
baseline trig $nmbr$ millycerides g dl,C0168634;C0439267;C1442488
aml vs chl,C0023465;C0023467;C0019829
baseline concentration,C0086045;C1446561;C3827302
chd primary outcome,C0205225;C1274040;C0439612;C0439631
a $nmbr$ ez n $nmbr$,C0206578
$nmbr$ c t,
a $nmbr$ n $nmbr$,C0369718;C0441922
ct tt,C1452561;C4554543
a $nmbr$ ez n $nmbr$ a $nmbr$ n $nmbr$,C0206578
$nmbr$ a g,C0439267
triglyceride,C0041004
ag gg,C0017454;C0018370
total ldl c,C0439175;C0439810
glu $nmbr$ asp g t,C0125690;C0439267
ldl $nmbr$ c,
gt tt,C1452561;C4554543
ldu c,
end stage renal disease,C0022661;C2316810
hdl $nmbr$ c,C3715113
normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C1739039;C3811844;C3812682
study end concentration,C0086045;C1446561;C3827302
mild reduction in egfr,C0301630;C0392756;C1293152;C4551656
acute dvt study,C0557651;C2603343
moderate severe reduction in egfr,C0301630;C0392756;C1293152;C4551656
continued treatment study,C0549178;C3161471
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
rivaroxaban n $nmbr$,C1739768
$nmbr$ $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
standard therapyy n $nmbr$,C1442989;C2828392
sample size,C0242618
male sex no weight no,C0086582;C0005910;C0043100;C1305866;C1705104
sbp mmghg mean sd,C0085805;C2699239
missing data initial diagnosis no,C0011900;C1704338;C1704656
dbp mmghg mean sd,C0444504;C2699239;C2347634;C2348143
dvt,C0149871;C2926618;C3899446
follow up in trial at $nmbr$ yr,C0589120;C1522577;C1704685;C3274571;C0150312;C0008976;C0332285;C1707101
$nmbr$ only $nmbr$ distal,C0205108;C4522154
sample sizea,C0370003;C2347026
pe,C0070939;C1880476;C4284304
taking statins n a,C0360714
time from onset of symptoms to randomization days,C1320528;C0034656;C0439228
mean sd d,C0444504;C2699239;C2347634;C2348143
cause of dvt or pe no,C0015127;C1524003;C0070939;C1880476;C4284304
total number of events participants,C4330837
unprovoked,
$nmbr$ yr rate $nmbr$ participants,C0439234;C0679646
recent surgery or trauma,C0038894;C0038895;C0543467;C1274039;C0043251;C1510467;C3263723;C3714660;C4049136
a compared wi,C0043193;C1520135
immobilization,C0020944;C4048292
th c,C0039725;C0039738;C1420718;C4282123;C4285344
estrogen therapy,C0279494
l compared wit,C0439394;C0043197;C1706495;C3642217
puerperium,C0034042;C0086839;C1879329
hc,C0020268;C0262499;C1413512
known thrombophilic condition no,C0012634;C0348080;C1705253;C3864998
chd total,C0439175;C0439810
previous vte no,C0205156;C0630906;C1552607
cvd total,C0439175;C0439810
rivaroxaban,C1739768
stroke total,C0439175;C0439810
enoxaparin vka,C0206460
hf total,C0439175;C0439810
qverall,
a compared w,C1707455
ofl,
l compared wi,C0043193;C1520135
renal function creatinine clearance,C0232813;C0699829
option,C1518601;C1550456
cardiac disease,C0018799
ambition,C0870128
no cardiac cisease,C0018787;C1522601
radiate,C0332301
intended duration of anticoagulation,C0449238;C2926735
toward,
$nmbr$ months,C0439231
lithe,
m,
all trials,C0008976
patient anticoagulation before randomisation,C0003281;C2917212;C2919015;C3537050
patient population,C0032659;C1257890
previous episodes of dvt pe,C0332189;C0070939;C1880476;C4284304
mtx ir,C0022065;C0022071;C1448132
idiopathic index dvt,C0149871;C2926618;C3899446
mtx naive or free,C0025677;C1417487;C0332296;C1880497;C1996904
spontaneous dvt pe,C0070939;C1880476;C4284304
anti tnf ir,C0022065;C0022071;C1448132
secondary dvt pe,C0070939;C1880476;C4284304
dmard ir,C0022065;C0022071;C1448132
ill,C0231218
dmard ir anti tnf ir,C0022065;C0022071;C1448132
known thrombophilic condition,C0012634;C0348080;C1705253;C3864998
$nmbr$ tcz mtx,C0025677;C1417487
no known thrombophilic condition,C0012634;C0348080;C1705253;C3864998
$nmbr$ tcz,
location of index dvt,C0450429;C1515974;C4284930;C4284931
mtx,C0025677;C1417487
non extensive,C1518422;C0205231
$nmbr$ tcz mtx mtx,C0025677;C1417487
p o,C0369773;C2603361
total n,C0439175;C0439810
malignancy at randomisation,C0006826;C1306459;C4282132
tcz mtx n,C0025677;C1417487
no active cancer,C0006826;C0998265;C1306459
$nmbr$ mono,C1551432;C1551969
mobility at randomisation,C0080078;C0425245;C0449580;C4318935
mtx n,C0025677;C1417487
no immobilization,C0020944;C4048292
white tcz mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
$nmbr$ j,
white mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
vitamin k antagonist received,C1096489;C2267235;C1514756
age mean s e,C0444504;C2347634;C2348143
acenocoumarol,C0000956
height cm mean s e,C0444504;C2347634;C2348143
cm,
weight kg mean s e,C0444504;C2347634;C2348143
sonth america,C0002454
ra duration years mean s e,C0444504;C2347634;C2348143
kg,C0022718;C0439209;C4054209
rf positive,C0439178;C1446409;C1514241;C2825490;C3812269
n n $nmbr$ $nmbr$,C0369718;C0441922
baseline das $nmbr$ mean s e,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ mvmin,
baseline haq mean s e,C0444504;C2347634;C2348143
$nmbr$ montlts,
baseline sjc mean s e,C0444504;C2347634;C2348143
parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
baseline tjc mean s e,C0444504;C2347634;C2348143
uncodable,
vka naive,
shared epitope a positive,C0237876;C0003316;C1522138;C0439178;C1446409;C1514241;C2825490;C3812269
vka experienced,
high dose arb n $nmbr$,C0444956;C3888198
never been on a vka,C2003901
arb ccb n $nmbr$,C3888198;C0006684
ever been on a vka,
$nmbr$ $nmbr$ y n,
no vka at randomization,C0034656
body height cm,C0005890;C0487985
vka at randomization,C0034656
bmi $nmbr$ n,C0578022
total randomized,C0439175;C0439810;C0034656;C3815594
egfr $nmbr$ n,C1739039;C3811844;C3812682
dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum values,C0229671;C0042295;C1546774;C1550100
chads $nmbr$ scoret,C0007928;C1413373
potassium mmol l,C0032821;C1532563;C0202194;C0304475;C0597277;C3714637
prior transient ischemic attack,C0007787;C0917805
casual plasma glucose mg dl,C0202042;C0439269;C0455280
baseline aspirin use,C0042153;C0457083;C1947944
current alcohol n,C0001962;C0001975
event,C0441471;C4019010
drug therapy n,C0013216;C0013217
d $nmbr$,
previous antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
d $nmbr$ vs warfarin,C0043031
insulin treatment,C0745343
y,
arb angiotensin ii receptor blocker ccb,C0521942;C0006684;C3536793
interaction pf,C1704675;C3815179
calcium channel blocker bmi body,C0242821;C0460148;C1268086;C4082212
stroke or systemic embolism,C0038454;C4554100;C0013922;C1704212
mass index,C0600653;C0918012;C1552854;C1637833;C2986546
life threatening bleeding disabling stroke and death,C1546953;C0019080;C2826244;C3537125;C0038454;C4554100;C0011065;C1306577;C4082313;C4552775
gastrointestinal bleeding,C0017181
bp blood pressure egfr estimated glomerular filtration rate men $nmbr$ en $nmbr$ x cr $nmbr$ $nmbr$ x age $nmbr$ $nmbr$ x $nmbr$ $nmbr$ hdl high density lipoprotein,C1363845
fa $nmbr$ mg $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
x cr $nmbr$ $nmbr$ x age,C0201975;C0001779;C3539604;C3711669;C4084730;C4553336;C4553337
r $nmbr$ mg n $nmbr$,C0687673;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ wom,
r $nmbr$ mg fa $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
data are mean standard deviation for continuous variables and number for categoric variables p,C1511726;C3245479;C3714741;C0871420;C0237753;C0449788
r $nmbr$ mg $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
values were calculated using t tests for continuous variables and chi square,C0042295;C0444686;C1441506;C1524063;C0871472;C0439828;C1552646
body weight kg n,C0005910;C1305866
tests for categoric,C0022885;C0392366
comorbidities n a,C0009488
crohn s disease,C0010346;C0012634
metabolic syndrome $nmbr$,C0524620
ulcerative colitis,C0009324
dm medication n c,C0011816;C0013227;C3244316;C4284232;C3250443
abatacept $nmbr$ $nmbr$ mg kg n $nmbr$,C1619966;C0439272
glipizide,C0017642
abatacept $nmbr$ mg kg n $nmbr$,C1619966;C0439272
pioglitazone,C0071097
mean disease duration y sd,C0872146;C2699239
mean lipid values mg dl,C0023779;C0439269
inadequate response intolerance to prior therapy,C0231199;C1744706;C2355652
hdl cd,C0007928;C0034283;C4552032
oral aminosalicylates,C0442027;C0368663;C4521986
apobe,
anti tnf agent s,C0450442;C1254351;C1521826
fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean hscrp mg l sd,C0439268;C2699239
r $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prednisone use,C0042153;C0457083;C1947944
r $nmbr$ mg fa,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean mayo score sd,C3533236;C2699239
h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
left sided disease only,C0205091;C0012634;C0443246
baseline median mg l,C0168634;C0439268;C1442488
extensive disease other,C0849867
final median mg l,C0205088;C0439268;C1546485;C3853528
median change,C0392747;C0443172;C1705241;C4319952
supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period,C2986480;C0237629;C0205263;C0439531;C1948053;C0857127
value $nmbr$,C1522609
non hispanic latino,C1518424;C0086528
ada $nmbr$ $nmbr$ n[ $nmbr$,C1060325;C3811629
baseline data,C1511726;C3245479;C3714741
age years median range,C1514721;C2348147;C3542016
gender m f,C0079399;C1522384;C0016327
$nmbr$ $nmbr$ e $nmbr$,
at c data,C1511726;C3245479;C3714741
$nmbr$ $nmbr$ $nmbr$ e $nmbr$,
final a $nmbr$ c,C0205088;C1546485;C3853528
disease location,C0450429;C1515974;C4284930;C4284931
at c change,C0392747;C0443172;C1705241;C4319952
extensive colitisy,C0205231
$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
fpg data,C1511726;C3245479;C3714741
left sided colitisz,C0205091;C0443246
final mg dl,C0205088;C0439269;C1546485;C3853528
otherx,
fpg change mg dl,C0392747;C0439269;C0443172;C1705241;C4319952
disease duration years median range,C1514721;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$ $nmbr$,
withdrawals n n,C1710677;C2349954;C2825032;C3812880;C4049634
voluntary,C0439656;C3543419
endoscopy subscore,C0014245
noncompliant,C0457432
rectal bleeding subscore,C0018932;C0267596
all noncompleters,
pga subscore,C0016410;C3541266;C4050369
indacaterol tiotropium n[ $nmbr$,C1722260;C0213771
stool frequency subscore,C0015733;C0183622
tiotropium placebo n[ $nmbr$,C0213771;C0032042;C1696465;C1706408
crp mg l median range,C1514721;C2348147;C3542016
tiotropium placeb n[ $nmbr$,C0213771
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$,
sex men women,C0009253;C0043210;C0036864;C0079399;C0804628;C1314687;C1522384
corticosteroid without imm,C0001617;C3536709
e,
imm without corticosteroid,C0205470;C0001617;C3536709
duration of copd years mean sd,C0449238;C2926735
corticosteroid imm,C0001617;C0205470;C3536709
severity of copd n,C0439793;C0522510
no corticosteroid no imm,C0001617;C3536709;C0205470
moderatey,
ada $nmbr$ $nmbr$ n $nmbr$,C1060325;C3811629
pack years mean sd,C1277691;C2699239
mayo $nmbr$,C0454788;C1077578
fev $nmbr$ predicted post salbutamol,C0681842;C0001927;C1882327
remission n,C0544452;C0687702
fev $nmbr$ fvc post salbutamol,C3714541;C0001927
difference from placebo $nmbr$ ci,C1705241;C1705242
fev $nmbr$ litres pre salbutamol mean sd,C0001927;C2699239
extensive colitis,C0009319;C1963084
fev $nmbr$ litres post salbutamol mean sd,C0001927;C2699239
no extensive colitis,C0009319;C1963084
fev $nmbr$ reversibilityz pre post salbutamol,C0332152;C0001927;C0740175;C2257086;C3669034
imm corticosteroid,C0001617;C3536709
fev $nmbr$ litres pre ipratropium mean sd,C0027235;C2699239
no aminosalicylates,C0368663
fev $nmbr$ litres post ipratropium mean sd,C0027235;C2699239
crp $nmbr$ mg l,C3890735;C0439268;C4048285
fev $nmbr$ reversibilityz pre post ipratropium,C0332152;C0027235;C0740175;C2257086;C3669034
weight $nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
weight $nmbr$ $nmbr$ kg $nmbr$ $nmbr$ kg,C0005910;C1319635;C0043100;C1305866;C1705104
trough fev $nmbr$,C0444506;C3714541
all patients with opg n $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
copd severity,C0439793;C0522510
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C0439297
$nmbr$ ml $nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0439526;C1705224;C3887665;C0369718;C0441922
tertile $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C0439297
ics use,C0042153;C0457083;C1947944
p trend,C1521798;C4554533
ics non users,C1518422;C1706077
end points,C2349179
ics users,C0815320;C1706077;C4551720
non cv mortality,C0026565;C0026566
nonmetabolic syndrome n $nmbr$,C0039082
hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
fpg mmol l mg dl,C1532980
combined end points,C0205195;C2349179
tg mmol l [mg dl],C0337445;C1532563;C0439269
coronary,C0018787
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
all cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C1524003;C0018488;C0019993;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
cholesterol mmol l,C0008377;C1532563
diet diet pravastatin,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
apob apoa $nmbr$ ratio,C0456603;C1547037
event patients $nmbr$ pt y,C0030705;C0032743;C0699718
serum creatinine umol lf,C1416933;C2986618;C4554443
non metsyn,C1518422
egfrmdrd ml min $nmbr$ $nmbr$ $nmbr$ m_ $nmbr$,C0439445
metsyn,
nt probnp pmol l,C0669479;C0439284;C0754710
metsyn with ldl $nmbr$ $nmbr$ mg dl,C0439269
crp mg l,C3890735;C0439268;C4048285
patients with ra as or psa n $nmbr$,C0030705;C3538806;C4048756;C3810537;C3813209
opg ng ml,C1262886;C0439275;C1336645;C1412836;C1710303
patients without ra as or psa n $nmbr$ $nmbr$,C0030705;C3538806;C4048756;C3810537;C3813209
current medication n,C0746467
no of patients with ra,C0030705;C3538806;C4048756
$nmbr$ cit,C0008864;C0523573;C1427027;C4553421
no of patients with as,C0030705
all randomly assigned,C1516050;C1552601
no of patients with psa,C0030705;C3810537;C3813209
coronary end point,C2349179;C2826544
history of cardiovascular events,C1880008
all cause mortality or hf hospitalization^,C0015127;C0026565;C0026566;C1524003;C0018488;C0019993;C1313497;C1538440;C3273279
angina pectorisf,C0002962
dexlansoprazole mr $nmbr$ mg n $nmbr$,C0024485;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1417249;C2347167;C3254418;C4050513
prerandomization statin therapy,C1278454
age at baseline years,C1510829;C0168634;C1442488
concomitant therapy,C1707479
ppi use within $nmbr$ months of randomization,C1524063;C0034656
ace inhibitors or angiotensin ii blockers,C0003015;C0003009;C1366631;C3714928
alcohol drinker,C0001962;C0556338;C0001975
atorvastatin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
caffeine user,C3532939
simvastatin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
indacaterol $nmbr$ gg qd,C0017454;C0332173;C0018370
total cholesterohhdl cholesterol ratio,C0456603;C1547037
formoterol $nmbr$ gg bid,C0017454;C0018370
ldl cholesterohhdl cholesterol ratio,C0456603;C1547037
salmeterol $nmbr$ gg bid,C0017454;C0018370
apo b apo a i ratio,C0456603;C1547037
tiotropium $nmbr$ gg qd,C0017454;C0332173;C0018370
no men,C0025266
male female,C0043210;C0086287;C1705497;C1705498
no women,C0043210
fev $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
known duration,C0449238;C2926735
fev $nmbr$ predicteda,C3714541
of t $nmbr$ dm years,C0011816;C0439234;C3250443
ics use yes no,C0042153;C0457083;C1947944;C1512698
hba $nmbr$ c range,C1514721;C2348147;C3542016
ex smoker smoker,C0337671;C4555205
hba $nmbr$ c distribution at baseline,C0520511;C1704711
history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0521116;C0018799;C1705970
$nmbr$ h pmg mmol l,C2827804
treatment duration days,C0444921;C0439228;C3259042
metformin dose,C0178602;C0869039;C1114758
patients treated for $nmbr$ weeks,C0030705;C1522326;C0439230
figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline,C0439165;C1549488;C1561533;C1412268;C2699274;C1518422;C0850624;C0168634;C1442488
figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index,C1705241;C1705242;C0168634;C1442488;C3875154;C0023668;C0205132;C0700221;C1550648;C1552960;C0369718;C0042295;C0441922;C2360800;C0032042;C1305855;C1696465;C1706408
insulin glargine,C0907402
ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus,C4049864;C1722260;C0439272;C0011849
standard care,C1442989;C1947933;C2828392
carisbamate $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior cardiovascular event no j,C0332152;C1320716;C2826257
carisbamate $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior stroke no,C0038454;C4554100
time since epilepsy diagnosis years,C0556970;C0011900;C1704338;C1704656
any albuminuria no,C0001925
number of previous reported aeds,C0237753;C0449788
ankle brachial index,C1328319;C3888326
baseline monthly pos seizure rate,C0871208;C1521828
glycemic characteristics,C1521970
number of co aeds n,C0237753;C0449788
prior diabetes,C0011847;C0011849
patients with $nmbr$ co aed,C0030705;C0887457
use oforal glucose lowering agent no,C0042153;C0017725;C0457083;C1947944;C0441994;C2003888;C0450442;C1254351;C1521826
patients with $nmbr$ co aeds,C0030705;C0180309
no use ofdiabetes drugs no,C0240320
ugt induction status as randomizeda n,C0205263;C0449438;C0857127
new diabetes no,C0011847;C0011849
inducing,C0205263
impaired glucose tolerance or impaired fasting glucose no,C0271650;C1272092
noninducing,
duration ofdiabetes yr,C0449238;C0439234;C2926735
ugt induction status per aeda n,C0205263;C0449438;C0857127
glycemic drugs,C0013227;C3687832
syndrome n,C0039082
sulfonylurea no,C0038766;C3536898
symptomatic localization related,C0475264;C1744691;C0439849;C0445223
cryptogenic localization related,C0475264;C1744691;C0439849;C0445223
nonglycemic cardiovascular risk factors systolic blood pressure mmhg,C0232104;C0439475
undetermined,C0205258;C3536725;C4082977
body mass index waist to hip ratio,C0205682;C1264679
saxa $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hdl cholesterol mg dl triglycerides mg dl,C3539687
pbo n $nmbr$,C0031962
creatinine mg dl urinary albumin to creatinine ratio,C2362049;C0456603;C1547037
age category years n,C1510829;C0683312;C3889287
other drugs no,C0013227;C3687832
renal impairment n,C1565489
thiazide diuretic,C0012802;C3536861
duration of t $nmbr$ dm years,C0449238;C2926735
other blood pressure drug,C0003364
hba $nmbr$ c category n,C0019016;C0683312;C3889287;C1825777;C3538758
antiplatelet drug,C0085826
fpg mmol l,C1532563
insulin glargine n $nmbr$ py,C0030428;C3538810
crcb ml min mean s e,C0444504;C2347634;C2348143
standard care n $nmbr$ py,C0030428;C3538810
diabetes therapy n,C3274787;C3539002
placebo allocation,C0032042;C1706778;C1696465;C1706408
oral blood glucose lowering drug $nmbr$ $nmbr$ $nmbr$,C0442027;C0005802;C4521986;C0441994;C2003888;C0013227;C1254351
omega $nmbr$ allocation,C1719844;C1706778
sulphonylurea,C0038766;C3536898
a $nmbr$ $nmbr$ $nmbr$ median,C0549183;C0876920;C2347635;C2348144;C2939193
glinide,C2266929
no prior cv event,C0441471;C4019010
oral blood glucose lowering,C0442027;C0005802;C4521986;C0441994;C2003888
prior cv event,C0441471;C4019010
drug and insulint,C0013227;C1254351
no metformin,C0025598
saxa $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no statin use,C0042153;C0457083;C1947944
baseline hba $nmbr$ c mean s e,C0444504;C2347634;C2348143
no ace i arb,C0021966;C3888198;C0221138
week $nmbr$ hba $nmbr$ c mean s e,C0444504;C2347634;C2348143
ace i arb,C0021966;C3888198;C0221138
adjusted change from baseline mean s e,C0392747;C0443172;C1705241;C4319952
ifg igt,C1334085;C1708411
difference vs pbo,C1705241;C1705242;C0031962
new dm,C0011816;C3250443
mean s e,C0444504;C2347634;C2348143
prior dm,C0011816;C3250443
moderate renal impairment,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
dabigatran $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
severe renal impairment,C0205082;C1565489;C4050465;C4050466
prior oac,C0332152;C2826257
measures mmol l,C0079809;C1532563;C1879489
crcl sd ml min,C1846718;C0439445
baseline fpg mean s e,C0444504;C2347634;C2348143
prior history of bleeding on oac,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
week $nmbr$ fpg mean s e,C0444504;C2347634;C2348143
pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703;C0021122
adjusted change from baseline,C0392747;C0443172;C1705241;C4319952
dental procedure,C0011331
differencevs pbo,C0031962
other diagnostic procedure,C0430022;C1546908
overall w $nmbr$ $nmbr$ $nmbr$,C0282416;C1561607
cataract removal,C0007389
combined therapy v $nmbr$ $nmbr$ $nmbr$,C0033972
colonoscopy,C0009378;C1548837
dutasteride w $nmbr$ $nmbr$ $nmbr$,C0754659
total hip or knee replacement,C0019552;C0022122;C1505163;C3538851;C4284725;C0086511
tamsulosin w $nmbr$ $nmbr$ $nmbr$,C0257343
cystoscopic procedure,C0184661;C2700391;C3274430;C3539779
ipss o,C1019118;C1998280;C2827405;C3811063
inguinal hernia repair,C0021446
pv ml,C0439526;C1705224;C3887665
laparoscopic cholecystectomy,C0162522
psa level ng ml,C4086720;C0439275
cabg or valve,C0010055;C0184252;C1186983;C1704414;C3888056
qmaxi rn l s,C2827110;C3540639;C4281819
colectomy partial or total,C0728938;C1550516;C0439175;C0439810
previous treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
peripheral angioplasty,C0162577;C1548817
ipss hrql,C1019118;C1998280;C2827405;C3811063
prostate biopsy,C0194804
at $nmbr$ years,C0439234
carotid endarterectomy,C0014099
rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl,C0301630;C0596019;C0392756;C1293152;C4551656
limb amputation,C0002689
combined dutasteride ta msu losi n,C0039297;C0024776;C1412759;C1506978;C1705538;C3272501;C4553364
d $nmbr$ n n,C0369718;C0441922
dutasteride,C0754659
warfarin n n,C0043031
tamsulosin,C0257343
d $nmbr$ vs warfarin rr $nmbr$ ci p value,C0008107;C1709380;C3259781
incidence o $nmbr$ $nmbr$ cl,C0021149;C0596019;C0220856
urgent surgery,C2188405
combined therapy vsdutasteride,C0033972
elective surgery,C0206058
combined therapy vsta msu iosin,C0033972;C0024776;C1412759
major surgery,C0679637
ipss,C1019118;C1998280;C2827405;C3811063
minor surgery,C0038904
change in das $nmbr$ $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
original dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
week $nmbr$ responders n $nmbr$,C0332174;C0439230
amended dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
acr $nmbr$ week $nmbr$ responders n $nmbr$,C0332174;C0439230
disease duration b $nmbr$ years n $nmbr$,C0872146;C0439234
all responders n $nmbr$,
disease duration $nmbr$ to b $nmbr$ years n $nmbr$,C0872146;C0439234
no previous dmard mean sd,C0205156;C2699239;C1552607
disease duration $nmbr$ years n $nmbr$,C0872146;C0439234
disease duration yrs mean sd,C0872146;C2699239
age yrs mean,C0444504;C2347634;C2348143
mtx dose $nmbr$ mg week,C0332174;C0439230
$nmbr$ $nmbr$ n,C0369718;C0441922
steroid use,C0281991
baseline cdai,C0683448;C1413248;C3273706
rf positive $nmbr$ iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
baseline ibdq total score mean,C0444504;C2347634;C2348143
sjc mean sd,C0444504;C2699239;C2347634;C2348143
fistula at baseline n,C0016169;C0168634;C1442488
tjc mean sd,C0444504;C2699239;C2347634;C2348143
prior,C0332152;C2826257
mtss mean sd,C0444504;C2699239;C2347634;C2348143
figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test,C0205210;C0544452;C0687702;C0332174;C0872146;C0439230;C0042295;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
das $nmbr$ range $nmbr$ $nmbr$ mean sd,C0051767;C2699239;C0057671
general anaesthesia,C0002915;C2930406
pain vas range $nmbr$ $nmbr$ mm mean sd,C0042815;C2699239
neuraxial anaesthesia,C0002903;C0002912;C0002930;C4049933
haq di range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
combination,C0205195;C1947911;C3811910
fas range $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
minimum,C1524031;C1552614;C2826545
crp mean mg l sd,C0439268;C2699239
maximum,C0806909;C1552615;C2826546
olmesartan n $nmbr$,C1098320
smoker or ex smoker n,C0337664;C0337671;C4555205
duration yr,C0449238;C0439234;C2926735
$nmbr$ years or,C0439234
prior treatment no,C1514463
figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events,C1707455;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1571583;C0205449;C1274040;C0680240;C1305863;C1861172;C0630906;C0026565;C0019080;C0026566
former smoker,C0337671
data are presented as the odds ratio with $nmbr$ confidence intervals,C1511726;C3245479;C3714741;C0449450;C0028873;C0009667
metabolic syndrome no,C0524620
telmisartan n $nmbr$,C0248719
glucose mmol liter,C0017725;C0475211
mri substudy n $nmbr$,C0024485;C1824234;C3890166
overall freedom population n $nmbr$,C0016694;C0032659;C1257890
sex male no,C0086582
prevalent vertebral fracture status,C0080179;C0449438
hypertension treated,C0020538;C1963138;C1522326
femoral neck bmd t score,C0449820;C4050231
clinical details,C0205210;C1522508
$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0000768;C0221430;C0302142;C0369718;C0441922
baseline nihss score median range,C1514721;C2348147;C3542016
age yr mean sd bmd t score mean sd,C0001779;C3533236
regular alcohol consumption per week no,C0205272;C0001948
subjects with prevalent vertebral fracture n prevalent vertebral fracture,C0681850;C1550501;C1706203;C2349001;C2697811
$nmbr$ drinks,C0452428
numbera,
$nmbr$ $nmbr$ drinks,C0452428
severitya,
some,
salmeterol n $nmbr$,C0073992
intense,C0522510
duration of copd yr f,C0449238;C2926735
toast classification of qualifying stroke no,C1710306;C4521230;C1514624;C0038454;C4554100
gold stage c,C0018026;C0441785;C1304897
other determined etiology,C0015127;C1314792;C1524003
spirometry after bronchodilation,C0037981;C1371299;C3537072
undetermined etiology,C0478157
pulmonary medications,C0013227;C0802604;C2598133;C4284232
antihypertensive medication open label no,C0003364;C1709323
anticholinergic drug,C0242896
js $nmbr$ agonists,C0243192;C2987634
alpha receptor antagonist,C0439095;C4543207;C2003941;C2350010
long acting^,C0205166;C1706317
beta receptor antagonist,C0330390;C4543207;C0439096;C2004068
inhaled^,C0004048
telmisartan group n $nmbr$,C0248719;C0441848
with tiotropium,C0213771
wml load at baseline mri,C1550025;C1704782;C1708715
with long acting j $nmbr$ agonists,C0243192;C2987634
total periventricular wml score mean sd,C2964552;C2699239
methylxanthines,C0066447
subcortical wml load diameter mm mean sd,C0552409;C2699239
tiotropium no of patients total no,C0213771;C0030705;C0439175;C0439810
wml load at follow up mri,C1550025;C1704782;C1708715
salmeterol no of patients total no,C0073992;C0030705;C0439175;C0439810
wml load at follow up mri stratified by baseline severity of wml load,C1550025;C1704782;C1708715;C0205363;C0168634;C1442488
copd severity stage gold,C0018026;C1304897
percent of patients,C0439165;C0030705
stage ii,C0441767
mild to moderate,C1299392
stage iii,C0441771
t $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C2603360;C0439275
stage iv,C0022326;C4265176
no patients,C0030705
noncurrent smoker,C0337664
hr b p m,
use of inhaled glucocorticoids at baseline,C1524063;C0004048;C0168634;C1442488
sbp dbp mmhg,C0085805;C0439475
isolated impaired glucose tolerance no,C0205409;C0271650;C1548221
ischaemic aetiology,C0015127;C1314792;C1524003
both impaired glucose tolerance and impaired fasting glucose tolerance no,C0271650
nyha classes iii iv,C0278962
ratio of women to men,C0456603;C1547037;C0025266
laboratory values,C0022877;C0042295;C3244292;C4283904
co morbidities,C0009488
family history of diabetes no,C1313937
atrial fibrillation flutter,C0155709
history of gestational diabetes mellitus no of women,C2183115;C0043210
pharmacological therapy for hf,C0039798;C0087111;C1363945
mean age yr,C0001779;C0439234
aceis,
mean bmi,C0444504;C0578022;C2347634;C2348143
aldosterone receptor antagonists,C1579268
bmi group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
biomarkers at baseline,C0005516;C0168634;C1442488
hbaic,
ptx $nmbr$ ng ml,C0030899;C0439275
$nmbr$ hr plasma glucose mg dl,C0202042;C0439269;C0455280
all cause mortality per $nmbr$ person years,C0015127;C0026565;C0026566;C1524003
fasting plasma insulin mu liter,C0857690;C0475211
cardiovascular mortality per $nmbr$ person years,C0026565;C0026566
lipid levels mg dl,C0428460;C0439269
fasting free fatty acids ^mol liter,C0015663;C0015688;C0347982
figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr,C0683150;C0683325;C1547282;C0086045;C1446561;C3827302;C1527178;C1705938;C0750572;C1739039;C3811844;C3812682
incidence rate per $nmbr$ person yr,C1708485;C0027361;C2347489
groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C1707455;C1708930;C2360800;C0683312;C3889287;C1444656;C1707156;C3274014;C3541345
$nmbr$ s,
serum k level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261;C0150270;C3469597
men $nmbr$ cm,C0025266
baseline $nmbr$ $nmbr$ meq l eos $nmbr$ $nmbr$ meq l,C0168634;C0439375;C1442488
women $nmbr$ cm,C0043210
baseline $nmbr$ $nmbr$ meq l eos,C1623465;C1861303
glucose test,C0337438;C0595310
baseline $nmbr$ $nmbr$ or,C0168634;C1442488
isolated igt,C0205409;C1548221
val hctz n $nmbr$,C0042285;C0020261;C0523975
ifg and igt,C1334085;C1708411
aml hctz n $nmbr$,C0023465;C0020261;C0023467
time since diagnosis of diabetes n,C0040223;C3541383
$nmbr$ y no,
acei arb therapy n,C0039798;C0087111;C1363945
diabetes status no,C1317301
urine acr geometric mean cv a b mg g,C2986759;C1300563
normoglycemic $nmbr$,C0580545
^ $nmbr$ mg g n,C1300563
prediabeticb,
$nmbr$ mg g n,C1300563
diabetic $nmbr$,C0241863
mdrd egfr geometric mean cv a b ml,C0439526;C1705224;C3887665
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
min per $nmbr$ $nmbr$ m $nmbr$,C0702093;C1524029;C3813700
hba $nmbr$ c mean sd,C0019016;C2699239;C1825777;C3538758
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ n,C0439445;C0369718;C0441922
baseline serum k meq l,C0302353;C0439375
$nmbr$ to $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ n,C0439445;C0369718;C0441922
eos serum k meq l,C0302353;C0439375
rosiglitazone versus metformin,C0289313;C0025598
figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0376674;C0017725;C0021641;C1533581;C1579433;C3714501;C0870536;C1275991;C2827788;C0168634;C1442488;C0444930;C0557651;C2603343;C2746065;C0030705;C0439375;C0597277;C1708601;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
rosiglitazone versus glyburide,C0289313;C0017628
albumin to creatinine ratio acr,C1412134;C1515941
figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0392747;C0443172;C1705241;C4319952;C0444930;C2746065;C0202042;C0455280;C0428357;C0376690;C1261415;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
normal acr $nmbr$ mg g,C0205307;C1300563;C0231683;C0439166;C2347086;C4553972
teaes,
$nmbr$ year cumulative incidence ci,C0008107;C3259781
non black n $nmbr$,C0005680;C0027567;C0085756;C0439541
albuminuria acr $nmbr$ m g g at baseline to normoalbuminuria,C1412134;C1515941;C1319635;C0168634;C1442488
all teaes,
mdrd egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
mild teaes,C2945599
moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
normal or high egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ at baseline to low egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C0205250;C0439445;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C0168634;C1442488
severe teaes,C0205082;C4050465;C4050466
normal egfr $nmbr$ egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ at baseline to high egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0168634;C1442488
drug related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
without hypertension at baseline to hypertension,C0020538;C1963138
discontinuations,C0457454
high dose statin pretreatment n $nmbr$,C0444956;C0360714
teaes $nmbr$ in any treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
systemic hypertension,C0020538
dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
clinical presentation,C2708283
headache,C0018681;C4553197
medical therapy,C0418981
urti,
ace inhibitors sartans,C0003015;C1563745
nasopharyngitis,C0027441
multivessel pci,C4049621
peripheral edema,C0085649
treated vessel,C1522326;C0005847
fatigue,C0015672;C3463815;C4050243;C4554645
left main,C0205091;C0205225;C1542147;C0443246;C1552822
muscle spasms,C0037763
left anterior descending,C0441998;C0205386;C1547177
nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
left circumflex,C0205091;C1880089;C0443246;C1552822
hypokalemia,C0020621;C4553966
right coronary,C0225808
uti,C0042029;C0077906;C1412376
saphenous vein graft,C0729538
joint swelling,C0152031
lesions b $nmbr$ c,C0221198
arthralgia,C0003862;C4551938
antithrombotic therapy,C0039798;C0087111;C1363945
diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
glycoprotein llb llla inhibitors,C0017968;C0243077
other teaes,
stable angina,C0340288
cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
hypotension,C0020649;C3163620
single vessel pci,C0037179;C0005847;C0087136;C0205171
orthostatic hypotension,C0020651
ilb iiia inhibitors,C4697913;C0243077
sedbp,
no ilb iiia inhibitors,C4697913;C0243077
^^^ $nmbr$ $nmbr$,
bosentan n $nmbr$,C0252643
sesbp,
location n,C0450429;C1515974;C4284930;C4284931
tofacitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
japan and south korea,C0022341;C0022773
duration of rheumatoid arthritis yr,C0449238;C2926735
sex men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
tender and swollen joints mean no,C0234234;C0444504;C2347634;C2348143
median duration of symptoms range yr,C0436359;C0439234
tender,C0234234
median time since diagnosis range yr,C1554109;C0011900;C1704338;C1704656
swollen,C0038999
smoking history n,C1519384
mean score on haq di,C3533236;C3826998;C4321476
ever smoked current former,C0205156;C0750523
das $nmbr$ $nmbr$ esr $nmbr$,C0051767;C3811131;C0057671
pulmonary function tests of predicted,C0024119;C2598152
score of $nmbr$ $nmbr$,C0449820;C4050231
mean fvc sd,C0444504;C2699239;C2347634;C2348143
mean score on das $nmbr$ $nmbr$ crp ^,C3533236;C0051767;C0057671
mean dlco sd,C0444504;C2699239;C2347634;C2348143
erythrocyte sedimentation rate mm hr,C1176468;C1619634
blood oxygenation mean sd,C0005767;C2699239;C0005768;C0229664
c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
pao $nmbr$ at rest mm hg,C0232555;C1423784;C1427155;C4318615;C0035253;C0439475;C1622890
positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff,C0741132;C1829901;C4554348
$nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
tnf inhibitor,C1448177;C1999216
aapo $nmbr$ at rest mm hg,C0035253;C0439475;C1622890
other biologic agent,C0005515
digital clubbing n,C0442015;C1883674;C0009080;C0149651;C0369718;C0441922
nonbiologic disease modifying drug other than methotrexate,C0392747;C4036059
corticosteroid use $nmbr$ n,C0239126
prior disease modifying drugs resulting in inadequate response mean no patient,C0012634;C0013227;C3687832;C0332294;C0205412;C0439856;C0030705
presence of honeycombing $nmbr$ n,C0150312;C0392148;C3854307;C0332468;C0349384;C0369718;C0441922
tofacitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline dyspnea index mean total score,C3533236
rheumatoid factor,C0035448;C0201660
sf $nmbr$ health transition score,C0449820;C4050231
anti ccp,C4318437
eq $nmbr$ d visual analog score,C0205163;C0439185;C0234621;C0243071
dmard biologic ir,C0022065;C0022071;C1448132
use of supplemental oxygen n,C4067893;C4554557
europe $nmbr$,C0015176
bosentan,C0252643
colesevelam n $nmbr$,C0541155
median $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
country n,C0454664;C1511538
us,C0815353;C3889164
mexico,C0025885
baseline fvc l,C0168634;C1442488
colombia,C3245499
median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
hba $nmbr$ ca mean sd,C0019016;C1825777;C3538758;C0444504;C2699239;C2347634;C2348143
baseline dlco mmol kpa,C0263428;C0439474
fpg mg dl mean sd,C0439269;C2699239
min,C0702093;C1524029;C3813700
$nmbr$ hour postload glucose,C0439227;C0017725;C0564385
stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$,C1739039;C3811844;C3812682;C0439445
mg dl mean sd,C0439269;C2699239
stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$,C0205390;C0439526;C1705224;C3887665;C1300072;C1306673
fasting insulin iiiu ml mean sd,C0015663;C0021641;C2699239;C1533581;C1579433;C3714501
taking calcium supplements at baseline n,C3540037;C0168634;C1442488
$nmbr$ years n $nmbr$,C0439234
no alcohol consumption on average,C0001948;C1510992;C2825518
hispanic n $nmbr$,C0086409
over past $nmbr$ years n,C0439234
fpg mean sd mg dl,C0444504;C0439269;C2347634;C2348143
eq $nmbr$ da health index status score,C0449820;C4050231
duration of diabetes mean sd y,C0449238;C2926735
opaqb physical function score,C4483112
background treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
low trauma fracture since age $nmbr$ n,C0521170;C0001779
diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949;C0015259;C1522704
prevalent vertebral fracture n,C0080179
sulfonylureaa,
serum albumin adjusted calcium mg dl,C0036785;C0439269;C0728876
thiazolidinedioneb,
insulina,
serum vitamin d nmol l,C0312532
$nmbr$ to $nmbr$ n $nmbr$,C0369718;C0441922
total hip bmd t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
a from baseline,C0168634;C1442488
nadroparin n $nmbr$,C0206232
weight ab,C0005910;C0043100;C1305866;C1705104
no nadroparin n $nmbr$,C0206232
total chol mg dl,C0201950;C0439269
prostate cancer,C0376358;C0600139;C2984325;C3541264
baselinec,
time since primary diagnosis,C0040223;C3541383
endpointc,
years,C0439234
endpoint baseline,C0168634;C1442488
metastatic disease,C0027627;C2939419;C2939420
weight b,C0005910;C0043100;C1305866;C1705104
karnofsky score $nmbr$,C0449820;C4050231
endpoint baselinec,C2349179;C2826544
nsclc,C0007131
parameter n,C0549193;C1704769;C2350001
squamous cell carcinoma,C0007137;C1302853
vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
pancreatic cancer,C0235974;C0346647;C2984259
upper respiratory tract infection,C0041912
nadroparin,C0206232
dyspepsia,C0013395;C4552968
nadroparin vs control,C0206232;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
decreased appetite,C0232462
hormone refractory prostate carcinoma,C3887901
hypoglycemia,C0020615;C4553659
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0008107;C3259781
with an sfua,
non small cell lung cancer,C0007131;C2984258;C3539721
without an sfua,
facilitated pci n $nmbr$,C4049621
alt u l,C1266129;C0439339;C4553172
actual or estimated weight kg,C0237400;C0022718;C0439209;C4054209
baselineb,
killip class iv at randomization,C2697847;C0034656
from baselineb,
prior cabg surgery,C0455610;C0010055
ast u l,C1415181;C0439339;C3891303
chronic treatment with aspirin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
upper respiratory tract infection $nmbr$ $nmbr$ $nmbr$,C0041912
infarct location anterior,C0021308;C0205094
a from baselineb,
time intervals,C0872291
$nmbr$ year framingham chd risk $nmbr$ mean sd,C1282512;C2699239
symptoms onset to first balloon inflation min,C4086878;C0021398;C1318493
efficacy measures,C0079809;C1879489
randomization to first balloon inflation min,C0034656;C0021398;C1318493
difference in ls mean $nmbr$ $nmbr$ cl,C1705241;C1705242
treatment before catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
without diabetes,C0011847;C0011849
bolus of heparin given,C1186706;C1511237;C1705509;C3812160
with diabetes,C0011847;C0011849
loading dose of clopidogrel or ticlopidine,C3714444;C0070166;C0040207
low density lipoprotein cholesterol,C0023824
glycoprotein llb illa inhibitor,C0017968;C1999216
aspirin plus placebo n $nmbr$,C0004057;C0032042;C1696465;C1706408
pci performed,C4049621;C0884358
aspirin plus clopidogrel n $nmbr$,C0004057;C0070166
cabg performed during index hospitalization,C0010055;C0884358;C0019993
male sex race or ethnic group f,C0034510;C1706779;C3853635;C0441840
treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0007430
black region or country,C0017446;C0205147;C0454664;C1511538
additional heparin,C0019134;C0770546
spain,C0037747
glycoprotein llb llia inhibitor,C0017968;C1999216
mean blood pressure at screening visit mm hg,C0428886;C0488053
$nmbr$ day mortality,C0026565;C0026566
previous clinical stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
$nmbr$ day cce,C0332173;C0439228;C0439505
current tobacco smoker qualifying event,C3173209;C3241966;C1514624;C0441471;C4019010
covariates,
transient ischemic attack type of lacunar syndrome,C0455703
or,
pure motor hemiparesis,C1513492;C0018989;C1705994
assigned treatment by sex interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pure sensory stroke,C0445254;C0038454;C4554100
fpci vs ppci in women,C0043210
sensorimotor stroke,C0038454;C4554100
fpci vs ppci in men,C0025266
use of aspirin at time of qualifying event,C1524063;C0004057;C0040223;C3541383;C1514624;C0441471;C4019010
rolofylline n $nmbr$ $nmbr$,C0166128
use of statin at any follow up visit,C1524063;C0360714;C0589121
ecrcl ml min,C0439445
vorapaxar group n $nmbr$,C2974521;C0441848
lvef within $nmbr$ months,C0428772;C0488728
median age iqr years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
intravenous loop diuretics,C0348016;C0354100
white ethnic origin,C0007457;C0015031;C0043157;C0220938
furosemide,C0016860
time from qualifying myocardial infarction,C0040223;C3541383;C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
bumetanide,C0006376
previous coronary revascularisation,C0205156;C0877341;C1552607
ethacrynic acid,C0014963
concomitant drugs,C0013227;C3687832
torsemide,C0076840
prior stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
persistent wrf n $nmbr$,C0205322;C0332996
planned thienopyridine at enrollment,C1709561;C1120149
no persistent wrf n $nmbr$ $nmbr$,C0205322;C0332996
prior stent,C0332152;C0038257;C2826257
bnp pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
azl m cld n $nmbr$,
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
azl m hctz n $nmbr$,C0020261
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
$nmbr$ f,C0016327
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
age categories y n,C2916832
hgb g dl,C0019029;C0439267;C0019046;C0518015;C1424337
egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n,C0683312;C0439445;C3889287;C0369718;C0441922
moderate impairment,C0221099;C0684336
total diuretic dose iv oral on day $nmbr$ mg,C0442027;C4521986
jvp $nmbr$ cm,
mild impairment,C0221099;C0684336
heart failure $nmbr$ month before admission,C0332177;C0439231
chronic kidney disease n,C1561643;C4553188
medical therapy before admission,C0418981;C0184666;C0809949
indacaterol n $nmbr$,C1722260
_ $nmbr$ $nmbr$ _ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
race caucasian,C0007457;C0043157
or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603;C0549178;C0439828
severity of copd n gold $nmbr$ moderate,C0439793;C0522510
univariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
severe very severea,C0205082;C0442824;C2984081;C4050465;C4050466
multivariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
fev $nmbr$ pred post albuterol,C0032952;C0044955;C0687676;C0001927;C1704687;C3469826
$nmbr$ yrs,
fev $nmbr$ reversibility b,C3714541;C0449261
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
baseline dyspnea index score,C0449820;C4050231
baseline crcl ml min,C0168634;C0439445;C1442488
gold ii,C1710602;C4082587
hemoglobin $nmbr$ men $nmbr$ women,C0019046;C0043210
gold iii iv,C0022326;C4265176
rolofylline rx,C1425688;C1521941;C2709207
indacaterol $nmbr$ pg,C0030827;C0072225;C1266240
rolofylline n,C0166128
bdi total score baseline,C0168634;C1442488
or primary outcome,C0205225;C1274040;C0439612;C0439631
tdi total score week $nmbr$ locf,C2964552;C2825507
or morbidity and mortality,C0026538;C0220880;C0026565;C0026566
sgrq total score baseline,C0168634;C1442488
baseline ecrcl $nmbr$ $nmbr$ ml min,C0168634;C0439445;C1442488
sgrq total score week $nmbr$ locf,C2964552;C2825507
rolofylline n $nmbr$,C0166128
moderate copdb [n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
or $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
severe copdc [n z $nmbr$ ],C0205082;C4050465;C4050466;C0369718;C0441922
hr $nmbr$ cl $nmbr$ $nmbr$ b $nmbr$ $nmbr$ $nmbr$,C0596019
indacaterol $nmbr$ mg[n z $nmbr$ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
baseline ecrcl k $nmbr$ to $nmbr$ ml min,C0597277;C1708601;C0439445
placebo [n z $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
hr $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
taiwan,C0039260
baseline ecro $nmbr$ mumin,C0168634;C1442488
japanese,C0376247;C1556094
rolofylline $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of copd,C0449238;C2926735
baseline ecrq $nmbr$ $nmbr$ to $nmbr$ ml min,C0168634;C1442488;C0439445
ex smoker current,C0521116;C1705970
weight kg blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
pack years,C1277691
$nmbr$ $nmbr$ no totalno,
fev $nmbr$ fvc a,C3714541
previous stroke or transient ischemic attack no total no,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
reversibility to,C0449261
salbutamol,C0001927
hypertension no total no medications in use at baseline no total no,C0020538;C1963138;C0439175;C0439810;C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
copd severity n,C0024117;C0439793;C0522510;C1412502;C3714496
long term vitamin k antagonist,C1096489;C2267235
pts,C1419129;C2698747
figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408;C1511728;C0032659;C1257890;C0205132;C0700221;C1550648;C1552960;C0441889;C0456079;C1547707;C2946261;C0023189;C0444504;C2347634;C2348143;C0162425;C1283828;C1550453;C0521346;C1546767
war,C0043027
a overall and subgroups bv statin potency,C0282416;C1561607;C0085166;C0360714;C1511278
dabigatran $nmbr$ vs warfarin p inter,C2348066;C0043031;C0205103;C1548610
low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
weight $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104
statin potency medium n $nmbr$,C0360714;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
weight $nmbr$,C0005910;C0043100;C1305866;C1705104
high n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
cclear,
caucasian n,C0007457;C0043157
cclear $nmbr$ $nmbr$,
african american n,C0085756
cclear $nmbr$,
dm n,C0011816;C3250443
asa,C0004057;C3853627
$nmbr$ $nmbr$ b b,
no asa,C0004057;C3853627
total c mg dl,C0439175;C0439269;C0439810
no amiodarone,C0002598
triglyceride mg dl $nmbr$,C0041004;C0439269
ppi,C0358591;C0871125;C3811894
total c hdl c ratio,C0456603;C1547037
noppi,
apoal mg dl,C0439269
p inter,C0369773;C2603361;C0205103;C1548610
lathosterol jimol l,C0064673
no ppi,C0358591;C0871125;C3811894
$nmbr$ sitosterol p mol l,C0037215;C0347982;C0220914
daily dose $nmbr$ mg n $nmbr$,C2348070;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lathosterol total c imol mmol,C0064673;C0439190
daily dose $nmbr$ $nmbr$ mg n $nmbr$,C2348070;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p value anova,C1709380;C0753802
p sitosterol total c imol mmol,C0037215;C0439190;C0220914
duration of asthma years,C0449238;C2926735
p sitosterol lathosterol,C0037215;C0064673;C0220914
ics mg day,C0815320;C0439422;C4551720
baseline sitosterol,C0037215;C0220914
laba use patients,C0042153;C0030705;C0457083;C1947944
baseline sitosterol cholesterol,C0037215;C0008377;C0220914
fev $nmbr$ post bronchodilator predicted normal,C0520835;C2599594
baseline sitosterol lathosterol,C0037215;C0064673;C0220914
absolute change,C1549031
pef post bronchodilator predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
triglyceride a,C0041004
acq $nmbr$ score,C0449820;C4050231
$nmbr$ $nmbr$ b,
exacerbations in previous year,C4086268;C0205156;C1552607
tc hdl c,C0039411;C3715113;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
as needed inhalations day,C0332173;C0439228;C0439505
percent change,C0392747;C0443172;C1705241;C4319952
days with asthma symptoms week,C0677547;C0004096;C2984299
bivalirudin n $nmbr$,C0168273
night time awakenings week,C0456698
heparin plus a gpi n $nmbr$,C0019134;C0770546
figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients,C0040223;C3541383;C1319635;C0439422;C0030705
coronary artery treated no,C0205042;C1522326
in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$,C2986480;C0040223;C3541383;C1441672;C0332283;C0694649
previous myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
stratum i,C0021966;C0221138
previous percutaneous coronary intervention,C0205156;C1532338;C1552607
stratum ii,C1710602;C4082587
previous coronary artery bypass surgery no,C2144990
r $nmbr$ ezio n $nmbr$,C0687673
estimated gfr ml min,C0017654;C0439445;C1424601
r $nmbr$ n $nmbr$,C0687673
time point,C2348792
american indian or alaska,C0002460;C0001905
ckd,C1561643
$nmbr$ d,
chronic cvd,C0205191;C0007222
risk group,C0242444
om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
high risk with atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
to goal,C0018017;C1571704
high risk without atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
week $nmbr$ et,C0332174;C0040028;C0439230
om $nmbr$ aml $nmbr$ hctz $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderately high risk without atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
om $nmbr$,C0028971;C1705272
baseline low density lipoprotein cholesterol mg dl,C0023824;C0439269
aml $nmbr$,C0023465;C0023467
sal n $nmbr$,C0036140;C0037494;C0206136
om $nmbr$ aml $nmbr$,C0023465;C0023467
fp n $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
$nmbr$ $nmbr$ cl,C0596019
sfc n $nmbr$,C4521536
s fs $nmbr$,C1517317;C3814419
total ho population n $nmbr$,C3258257;C0019905;C1832110;C3889614
o,C0483204
total population n $nmbr$,C3258257
drug related teaes,C0013227;C0439849;C0445223;C1254351
age at enrollment years,C1510829;C1516879;C1696073;C3888021
discontinuations teaes,C0457454
geographical region,C0017446;C0205147
f n,C0016327
post bronchodilator fev $nmbr$ l,C2599594;C3714541
s s $nmbr$,C0565930;C2603362
post bronchodilator fev $nmbr$ predicted,C0681842;C1882327
i u uj,C0021966;C0221138
reversibility predicted fev $nmbr$,C0449261;C3714541
q q $nmbr$ \,
pre bronchodilator fev $nmbr$ fvc ratio,C0456603;C1547037
$nmbr$ f $nmbr$ $nmbr$,C0016327
$nmbr$ $nmbr$ si,
figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0439234;C0017446;C0205147;C0030705;C1522326;C0032042;C1696465;C1706408;C4521536;C0449820;C4050231;C0332272;C0018684;C4522046;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C1273937
$nmbr$ f $nmbr$,C0016327
figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$,C2045651;C2964552;C0392747;C0443172;C1705241;C4319952;C0683312;C3889287;C0449820;C4050231;C0184511;C0018684;C0332272;C1561611;C4084203;C1524063;C0814908;C1705242;C0598981;C3146232;C0369773;C2603361
edema peripheral,C0013604;C0205100;C1717255
certolizumab pegol n $nmbr$,C1872109
$nmbr$ n qi,C0369718;C0376586;C0441922
age range,C1514721;C2348147;C3542016
hvookalemia,
duration of disease since,C0872146
sitagliptin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diagnosis y mean sd,C0011900;C2699239;C1704338;C1704656
body weight kg mean sd,C0005910;C2699239;C1305866
baseline cdai mean sd,C0168634;C2699239;C1442488
known duration of type $nmbr$ diabetes,C0449238;C2926735
baseline hbi mean sd,C0168634;C2699239;C1442488
hba $nmbr$ c mean sd [range],C0019016;C2699239;C1825777;C3538758;C1514721;C2348147;C3542016
geometric mean of baseline,C2986759;C0168634;C1442488
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
crp mg l cv,C3538987;C4048877;C4318503
hba $nmbr$ c distribution at baseline n,C0520511;C1704711
location of disease n,C0450429;C1515974;C4284930;C4284931
b $nmbr$,
isolated upper gastrointestinal disease behavior n,C0810300
$nmbr$ h pmg mmol l mean sd,C2827804;C2699239
inflammatory,C0333348
fasting insulin pmol l mean sd,C0015663;C0439284;C2699239
stricturing,C1261287
conventional treatment n $nmbr$,C2945704
penetrating no of resections n,C0205321;C0015252
monitoring n $nmbr$,C0150369;C1283169
corticosteroid with or without immunosuppressants,C0001617;C3536709;C0021081
medical history and risk factors no,C0262926;C1704706;C0035648;C1553898
immunosuppressant with or without corticosteroid,C0021081;C0001617;C3536709
prior cardiovascular event no,C0332152;C1320716;C2826257
corticosteroid or immunosuppressant,C0001617;C3536709;C0021081
coronary intervention,C0184661;C0886296;C1273869
corticosteroid and immunosuppressant,C0001617;C3536709;C0021081
stent implanted no,C0522776
neither corticosteroid nor immunosuppressant,C0001617;C3536709;C0021081
no of stents implanted,C0038257;C0021102;C2828363
hrqol,C4279947;C4300252
drug eluting stent implanted no,C1322815;C0021102;C2828363
ibdq score mean sd,C0444504;C2699239;C2347634;C2348143
stented vessel no,C0038257;C0005847
total scores total score range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
czp $nmbr$ mg n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
left main coronary artery,C1261082
age yrs $nmbr$ $nmbr$,C0001779
left anterior descending coronary artery,C0226032
noncaucasian,
left circumflex coronary artery,C0226037
disease location type terminal ileum,C0457464;C0227327
m o nito ring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
penetrating,C0205321
conventional treatment,C2945704
prior surgery no,C0455610
r elative risk $nmbr$ ci,C0008107;C3259781
disease duration,C0872146
full po pulatio n,C0443225;C0946289
$nmbr$ baseline mean,C0444504;C2347634;C2348143
bm i $nmbr$,C0021966;C0221138
im use no,C1556154
cs use no,C0042153;C0457083;C1947944
n o diabetes,C0011847;C0011849
im or cs use no,C0042153;C0457083;C1947944
no smo king,C1311076;C1364142;C1423784
no acs,C0742343;C4318612
im and cs use no,C0042153;C0457083;C1947944
number of stent $nmbr$,C0237753;C0449788
previous or current im use no,C0205156;C1552607;C0521116;C1556154;C1705970
number ste t $nmbr$,C0237753;C0449788
previous or current cs use no,C0205156;C1552607;C0042153;C0457083;C1947944
o $nmbr$ o $nmbr$ $nmbr$,C0483204
previous or current use of im or cs no,C0205156;C1552607;C1524063;C0010182;C0271160;C3540510;C4085345
planned valve surgery n,C0038894;C0038895;C0543467;C1274039
previous or current use of im and cs no,C0205156;C1552607;C1524063;C0010182;C0271160;C3540510;C4085345
body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
czp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
waist circumference cm sd,C0455829;C2699239
rest of world,C0035253;C1622890
europe zone $nmbr$,C0015176;C1710706
chronic renal failure n,C0022661;C1561643;C2316810
ukraine,C0041580
coronary heart disease n t,C0010054;C0010068;C1956346
russia,C0035970
prior percutaneous coronary intervention n,C0332152;C1532338;C2826257
romania,C0035826
prior cardiac surgery n,C0455610
poland,C0032356
coronary bypass n,C0010055
new zealand,C0027978;C0324547
valve surgery n,C0038894;C0038895;C0543467;C1274039
latvia,C0023128
other cardiac surgery n,C0018821;C0524727
italy,C0022277
prior arrhythmias n,C0332152;C0003811;C2826257
hungary,C0020174
other supraventricular tachycardia,C0039240;C1963244;C3815188
estonia,C0014908
ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446;C0232197
germany,C0017480
congestive heart failure n,C0018802
canada,C0006823
nyha class n i,C1882084
brazil,C0006137
ejection fraction percent sd,C0489482;C2699239;C2700378
belgium,C0004950
austria,C0004348
left atrial diameter mm sd,C0225860;C2699239;C0225861
baseline corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
prior implantable cardiodefibrillator n,C0332152;C0021102;C2826257
no baseline corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
prior pacemaker n,C0332152;C0030163;C0810633;C1546728;C3275122;C3853703;C2826257
$nmbr$ mg eow n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior cardiac resynchronization therapy n,C1167956
$nmbr$ mg ew n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior af ablation n,C0332152;C0344434;C4049859;C2826257
male patients n,C0150904
euroscore logistic median $nmbr$ th $nmbr$ th,C0039725;C0039738;C1420718;C4282123;C4285344
body weight kg mean s d,C0005910;C1275571;C1305866
euroscore additive median $nmbr$ th $nmbr$ th,C0039725;C0039738;C1420718;C4282123;C4285344
involved intestinal area n,C1879646;C0021853
medications at enrollment n,C0013227;C0802604;C2598133;C4284232
gastroduodenum,C0391900
angiotension converting enzyme inhibitor,C0014432;C0919438;C4521603
draining cutaneous fistula at baseline n,C0013103;C0180499;C4265177;C0423772;C0168634;C1442488
aldosterone antagonists,C0002007;C2757004
baseline cdai score mean s d,C0168634;C0444504;C2347634;C2348143;C1442488
antiplatelets or anticoagulants,C0003280
c reactive protein mg dl_,C0006560;C0439269;C1413716;C4048285
antiplatelets,
previous tnf antagonist use n,C0205156;C0042153;C0457083;C1947944;C1552607
other antiarrhythmics^,C0003195
subgroup name,C0027365;C1547383;C4522128
crohn s disease related medication at baseline n,C0010346;C0013227;C3244316;C4284232
subgroup level,C0441889;C0456079;C1547707;C2946261
charm,C0849759
adhere,C3714578
n $nmbr$ pufa,C0369718;C0032615;C0441922
age $nmbr$ years n $nmbr$,C1510829
steroid free remission,C0544452;C0687702
steroid sparing remission,C0544452;C0687702
sex male n $nmbr$,C0086582
country argentina n $nmbr$,C0454664;C0003761;C1504311;C1511538
steroid free cr $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
italy n $nmbr$,C0022277
remission by baseline steroid doses,C0544452;C0687702
usa n $nmbr$,C0041703
remission by baseline duration of steroid,C0814126;C0038317
cardiac valve surgery,C0018821;C0524727
no history of migraine,C0455512
cardiac valve surgery no n $nmbr$,C0018821;C0524727;C0369718;C0441922
migraine with aura,C0154723
hypertension no n $nmbr$,C0020538;C1963138;C0369718;C0441922
migraine without aura,C0338480
nyha class $nmbr$ $nmbr$,C1882083
prior migraine,C0332152;C0149931;C2826257
nyha class $nmbr$ $nmbr$ no n llll,C1882083;C0369718;C0441922
characteristics no of participants,C1521970;C0679646
aspirin $nmbr$ $nmbr$,C0004057
serum potassium,C0302353;C0543465
placebo $nmbr$ $nmbr$,C0032042;C1696465;C1706408
serum potassium $nmbr$ $nmbr$ mmol l n $nmbr$,C0302353;C0543465
aspirin $nmbr$,C0004057
$nmbr$ $nmbr$ mmol l n $nmbr$,C1532563
mean systolic blood pressure mm hg sd,C0428886;C2699239;C0488053
left atrial diameter $nmbr$ mm n $nmbr$,C0225860;C0225861
history of hypertension^,C0455527
$nmbr$ mm n $nmbr$,C4330985;C4554674
family history of myocardial infarction prior to age $nmbr$,C0455406;C0001779
ejection fraction $nmbr$ n $nmbr$,C0489482;C2700378
r r $nmbr$ ci,C0008107;C3259781
habitual fish intake,C0205353;C0556216
rr^ $nmbr$ ci,C0008107;C3259781
habitual fish intake $nmbr$ servings wk n $nmbr$,C0205353;C0556216
major cvd,C0205082;C0007222;C0205164;C4318856;C4521762
$nmbr$ servings wk n $nmbr$,C0332174;C0439230
cvd death,C0011065;C1306577;C4082313;C4552775
phospholipid omega $nmbr$ levels,C0031676;C0441889;C0202177
met n $nmbr$,C0428210;C1550543;C4317104
phospholipid omega $nmbr$ levels $nmbr$ n $nmbr$,C0031676;C0202177
avm n $nmbr$,C0003857;C0279476
study drug loading days actual,C2826182;C0237400
$nmbr$ $nmbr$ l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
study drug loading days actual $nmbr$ n $nmbr$,C2826182
$nmbr$ l $nmbr$ l $nmbr$ $nmbr$,C3539687
peri op beta blockers,C0347985;C0001645
l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
peri op beta blockers no n $nmbr$,C0347985;C0001645;C0369718;C0441922
ll $nmbr$ $nmbr$,
peri op statins,C0347985;C0360714
african america,C0027567;C0002454
peri op statins no n $nmbr$,C0347985;C0360714;C0369718;C0441922
$nmbr$ l $nmbr$ l $nmbr$,C3539687
peri op amiodarone,C0347985;C0002598
$nmbr$ l $nmbr$ l,C3539687
peri op amiodarone no n $nmbr$,C0347985;C0002598;C0369718;C0441922
duration of diabetes,C0449238;C2926735
peri op ace inhibitiors arbs,C0347985;C3888198
$nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
peri op ace inhibitors arbs no n $nmbr$,C0003015;C3888198;C0369718;C0441922
hbalc mean sd ^,C0444504;C2699239;C2347634;C2348143
on pump time,C0040223;C3541383
fpg mmol l mean sd,C1532563;C2699239
l $nmbr$ hrs min n $nmbr$,C0439393;C1568891
l $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
cross clamp time,C0175721;C0040223;C3541383;C1883710;C3810601
fracture history predefined n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cross damp time,C0040223;C3541383
$nmbr$ l l $nmbr$,C3539687
$nmbr$ $nmbr$ hrs min n $nmbr$,C0702093;C1524029;C3813700
l l,C3539687
canakinumab dose per mo,C0178602;C0869039;C1114758
history of bone disease predefined n,C0683519;C0730226;C0850708;C0944983
total group n $nmbr$,C0439175;C0441848;C0439810
priorbone disease,C0012634
blood pressure mm,C4330985;C4554674
$nmbr$ l,C0439394;C1706495;C3642217
geographic site,C0017446
current bone disease,C0521116;C0005940;C1705970
duration of diabetes mellitus y,C0449238;C2926735
history of other medical conditions n,C0262926
previous metformin use,C0042153;C0457083;C1947944
priorother predefined medical conditions,C0012634;C0348080;C1705253;C3864998
metformin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
priorother not predefined medical conditions,C0012634;C0348080;C1705253;C3864998
glucose mmol l,C0017725;C1532563
current other predefined medical conditions,C0521116;C1705970;C0012634;C0348080;C1705253;C3864998
insulin pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
currentother notpredefined medical conditions,C0012634;C0348080;C1705253;C3864998
il $nmbr$ ng l,C0020898;C0439297;C0021764;C0022271
risk factor predefined for falling at screening n,C0035648;C0000921;C0085639
fibrinogen g l,C0439294;C0456615
any condition,C0012634;C0348080;C1705253;C3864998
canakinumab dose per month,C0178602;C0869039;C1114758
maternal history n,C0559473
crp,C3890735;C4048285
osteoporosis,C0029456;C4554622
ll $nmbr$,
change median baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
paternal history n,C0424909
baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
current n,C0521116;C1705970
il $nmbr$,C0020898;C0021764;C0022271
former n,C0205156;C0750523
fibrinogen,C0016006;C1167394;C2587184;C3540039
years mean sd,C0439234;C2699239
n v n $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ ll $nmbr$,
v $nmbr$ n $nmbr$,C0369718;C0441922
$nmbr$ l $nmbr$ l $nmbr$ $nmbr$ l,C3539687
race asian n,C0034510;C0078988;C1706779;C3853635
yes n,C1549445;C1705108;C1710701
mean sd kg m $nmbr$,C0022718;C0439209;C4054209
units per week mean sd,C0560588;C0444504;C2347634;C2348143
nonsmoker n,C0337672;C0425293;C4554605
$nmbr$ $nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
baseline sbp,C0168634;C0085805;C1442488
avm se,C0003857;C0036919;C0279476
mean sd mmhg,C0444504;C0439475;C2347634;C2348143
met se,C0428210;C0036919;C1550543;C4317104
baseline dbp,C0536221;C3813197;C4281799
$nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
metabolism and nutrition,C0025519;C0025520;C0028707;C0392209;C0518896;C1442959
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c $nmbr$ r,C0722969
disorders soc,C0012634
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c $nmbr$,
cardiac disorders soc,C0018799
distal one third of radius,C0450168;C0205447
cerebral infarction,C0007785
week $nmbr$ mayo endoscopy subscorea,C0332174;C0014245;C0439230
cerebral ischemia,C0007785;C0917798
symptomatic remissionb n n,C0231220
apixaban $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sustained mucosal healingc n n,C0443318;C0026724
apixaban $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mucosal healingc n n,C0026724
mean kg,C0022718;C0439209;C4054209
sustained mucosal healingc,C0443318;C0026724
initial diagnosis no,C0011900;C1704338;C1704656
p value n n,C1709380
clinical presentation of vte at initial diagnosis no,C2708283;C0630906;C0011900;C1704338;C1704656
nesiritide n $nmbr$,C0054015
associated with transient or reversible risk factor,C0332281;C0040704;C0205374;C0205343;C0035648
sex no total no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0439175;C0439810
risk factors for recurrent vte no f,C0035648;C1553898;C0016327
race no total no f,C0034510;C1706779;C3853635;C0439175;C0439810;C0016327
persistent or permanent immobilization,C0205322;C0332996;C0020944;C4048292
systolic pressure mm hg,C0871470;C0439475
previous deep vein thrombosis or pulmonary embolism,C0205156;C0149871;C1552607;C0034065
heart rate at rest beats min,C0018810
known prothrombotic genotype,C0205309;C0017431
bnp pg ml i,C0023806
use of antiplatelet agents^,C1524063;C0085826
n terminal pro bnp pg ml,C0669479;C0439297
apixaban,C1831808
serum sodium mmol liter,C0523891;C0475211
apixaban $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apixaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$,C0428772;C0488728;C0439175;C0439810
pe with or without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
medical history no total no,C0262926;C1704706;C0439175;C0439810
dvt only,C0149871;C2926618;C3899446
heart failure $nmbr$ yr before admission,C0018801;C0439234;C0018802;C4554158
normal renal function,C0232805
medical therapy before randomization no total no,C0418981;C0034656;C0439175;C0439810
normal weight bmi,C4229017
nitrate oral or topical,C0442027;C4521986;C0332237
overweight bmi $nmbr$ to,C0497406;C0578022
digoxin or digitalis glycoside,C0012265;C0012253
obese bmi $nmbr$,C0028754;C0578022
hydralazine,C0020223
b a n $nmbr$,
inotropic agent,C0304509
b h n $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
vasodilator,C0042402;C3537240
previous coronary heart disease,C0010054;C0010068;C1956346
use of medication from randomization through $nmbr$ hr no total no,C1524063;C0034656;C0439175;C0439810
previous chronic kidney disease,C1561643;C4553188
time from hospitalization to randomization hr,C0040223;C3541383;C0034656
change in retinal pathology,C0392747;C0443172;C1705241;C4319952
time from randomization to study drug administration hr,C0040223;C3541383;C0013175;C0150270;C3469597
$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
administration of study drug bolus no total no,C0150270;C0262754;C3469597;C0439175;C0439810
$nmbr$ or $nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
duration of study drug administration hr,C0920470;C2348354
$nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463;C1551358;C0042903;C0023694;C1328010
apixaban n $nmbr$,C1831808
baseline a $nmbr$ c,C0168634;C1442488
risk factors specified as inclusion criteria no f,C0035648;C1553898;C0205369;C1512693;C0016327
baseline sbp mm,C4330985;C4554674
myocardial infarction within the previous $nmbr$ yr,C0027051;C0428953;C2926063;C3810814;C4552959
baseline ldl mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of cerebrovascular disease,C0585890
outcomes during accord,C1274040;C0680240
heart failure or lvef,C0018801;C0018802;C4554158;C0428772;C0488728
accord primary n,C0205225;C0439612;C0439631
history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fatal nonfatal mi n,C1302234;C1705232
no revascularization for index acs event,C0581603;C0441471;C4019010
fatal nonfatal stroke n,C1302234;C0038454;C4554100;C1705232
other medical history no,C0262926;C1704706
concomitant antiplatelet,C0521115
index acs event,C0441471;C4019010
no concomitant antiplatelet,C0521115
time from event to randomization days,C0040223;C3541383;C0034656;C0439228
de $nmbr$ n $nmbr$,C0011198;C0017480;C3541240
type of event no,C1561488
previous htn n,C0205156;C0020538;C1552607
st segment elevation myocardial infarction,C1536220
previous dm n,C0205156;C0011816;C3250443;C1552607
non st segment elevation myocardial infarction,C1536220
previous cad n,C0205156;C1504769;C2239547;C3813548;C4284121;C1552607
previous chf n,C0205156;C0018802;C1552607
elevated cardiac markers no t,C0205250;C1271630;C3163633;C2603360
chads score n,C0449820;C4050231
management of event no,C0001554;C0376636;C1273870;C3273539
medical therapy only,C0418981
previous renal disease n,C0205156;C0022658;C1552607
use of parenteral antithrombotic agents no,C1524063;C1704311
type of af n,C0332307;C1547052
selected medications no,C0013227;C0802604;C2598133;C4284232
duration antiplatelet use as of study duration sd,C1881378;C2826775
cv death ml ischemic stroke,C0011065;C0948008;C1306577;C4082313;C4552775
rate year,C0439234;C0439508
subject group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
stroke embolism,C0013922;C1704212
all stroke,C0038454;C4554100
antiplatelet therapy dual,C0205173;C1554184
major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
single,C0037179;C0087136;C0205171
acs type,C0332307;C1547052
minor bleed,C0026193;C0019080;C0205165
all bleed,C0019080
stemi,C1536220;C3538872
intracranial,C0524466
non stemi,C3537184
extracranial,C0580586
acs treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
with mets,C0812270;C1705694;C2939420
apixaban dose or matching placebo,C0178602;C0869039;C1114758;C0032042;C1696465;C1706408
ez simva $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
doubling statin dose,C0178602;C0869039;C1114758
$nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
s $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
multi racial,C0439064;C3266262
level of renal impairment,C0441889;C0456079;C1547707;C2946261
without mets,C0812270;C1705694;C2939420
severe or moderate,C0205082;C4050465;C4050466;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
mitt population,C0032659;C1257890
age group years,C1510829
oral treprostinil n $nmbr$,C0442027;C1145760;C4521986
incidence [n n rate per $nmbr$ person years ],C0021149;C0220856;C0871208;C1521828
not provided,C1518422
nnt,C1417750
pah origin cause,C0015127;C1524003
age group y,C0441858
ipah hpah,C0340543;C0637939;C1150929
treatment groups [n nb ],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0028101;C0919442;C1705347;C4553907
repaired chd,C0280604;C3542407
group a n $nmbr$,C0441848
hiv,C0019682;C0019699
group b n $nmbr$,C0441848
who functional class ii iii,C0441887;C2698969
group c n $nmbr$,C0441848
$nmbr$ mwd m,
hyperlipidemia^,C0020473;C0428465;C4555212
years since pah diagnosis,C0439234;C0011900;C1704338;C1704656
history of chd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p,C0392747;C0443172;C1705241;C4319952;C1274040;C1546471;C2825142;C0449450;C0084844;C1538994;C0332174;C0439230;C0007447;C0162425;C1283828;C1550453;C0032659;C0042295;C1257890
history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
subgoup_name,C0027365;C1547383;C4522128
history of carotid artery disease,C0683519;C0730226;C0850708;C0944983
subgroup_level,C0441889;C0456079;C1547707;C2946261
history of peripheral artery disease,C0683519;C0730226;C0850708;C0944983
image only,C1704254;C1704922;C3542466
chads $nmbr$,C0007928;C1413373
figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus,C1707455;C0772326;C2353292;C1705241;C1705242;C1628982;C0013227;C3687832;C0030705;C3538926;C1079230;C1518422;C0439801;C1549649;C2349209
r $nmbr$,C0205090;C0684010;C2603358
baseline total ipss mean sd,C0168634;C2699239;C1442488
af pattern,C0344434;C0449774;C4049859
baseline bii mean sd,C0168634;C2699239;C1442488
laa ostium,C0444567
baseline luts severity n,C0168634;C0439793;C0522510;C1442488
laa length,C1444754;C1706316
mild ipss,C1019118;C1998280;C2827405;C3811063
aliskiren valsartan n $nmbr$,C2733073
moderate $nmbr$ ipss,C1019118;C1998280;C2827405;C3811063
age y sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
severe ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
$nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
qmax category n,C0683312;C3889287
bmi kg m $nmbr$ uac no,C0022718;C0439209;C4054209
$nmbr$ ml s,C0439526;C1705224;C3887665
$nmbr$ $nmbr$ i $nmbr$ $nmbr$ n $nmbr$,
qmax ml s mean sd,C0439390;C2699239
$nmbr$ $nmbr$ mg g,C1300563
pvr volume ml mean sd,C0242852;C2699239;C0456261;C1419141
$nmbr$ mg g,C1300563
psa ng ml mean sd,C0439275;C2699239
$nmbr$ $nmbr$ i $nmbr$ $nmbr$ n $nmbr$ a,C0021966;C0221138
ed history n yes,C1549445;C1705108;C1710701
$nmbr$ hour masbp mm hg,C0439227;C0439475;C0564385
ed severity n,C0439793;C0522510
$nmbr$ hour madbp mm hg,C0439227;C0439475;C0564385
ed duration $nmbr$ yr n,C0449238;C0439234;C2926735
uac $nmbr$ mg g,C1300563
sexually active with female,C0241028;C0043210;C0086287;C1705497;C1705498
uac $nmbr$ $nmbr$ mg g,C1300563
partner n yes,C1549445;C1705108;C1710701
a v n $nmbr$,C1272460
pgi s n y,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
v n $nmbr$,C0369718;C0441922
cgi s n z,C4526016
bun mg dl,C0439269
previous therapies n,C0205156;C0087111;C1552607
serum potassium meq l,C0302353;C0439375;C0543465
a blockers,
age y $nmbr$ th $nmbr$ th percentiles,C0001779;C1264641
other bph luts therapy,C0039798;C0087111;C1363945
months from qualifying stroke,C0439231;C1514624;C0038454;C4554100
oab therapy,C0039798;C0087111;C1363945
selected clinical characteristics,C1707391;C0683325
ed therapy,C0039798;C0087111;C1363945
rankin scale $nmbr$,C0451405
placebo mean change sd,C0032042;C2699239;C1696465;C1706408
aspirin alone,C0004057;C0205171;C0439044;C0679994
tadalafil $nmbr$ mg mean change sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
thienopyridine alone,C1120149;C0205171;C0439044;C0679994
ls mean treatment difference $nmbr$ ci,C0008107;C3259781
dipyridamole alone,C0012582;C0205171;C0439044;C0679994
baseline luts severity,C0439793;C0522510
aspirin thienopyridine,C0004057;C1120149
moderate n $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
aspirin dipyridamole,C0732279
severe n $nmbr$ $nmbr$,C0205082;C4050465;C4050466
thienopyridine dipyridamole,C1120149;C0012582
baseline ed severity,C0439793;C0522510
other medications at enrollment,C0013227;C0802604;C2598133;C4284232
mild n $nmbr$ $nmbr$ $nmbr$,C2945599
vorapaxar no $nmbr$ y km,C2974521;C3887676
characteristic^,C1521970
placebo no $nmbr$ y km,C0032042;C1696465;C1706408;C3887676
bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$,C2700462;C2945744
efficacy end points,C1280519;C2349179;C1707887
bud $nmbr$ ptg n $nmbr$,C0039512;C1418830
cv death mi or stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
self reported descent n,C0681906;C2700446
cv death mi stroke or urgent coronary revascularization,C0038454;C4554100;C0439609;C0877341;C3272275
mexican,C0240339
any stroke,C0038454;C4554100
puerto rican,C0034043
urgent coronary revascularization,C0439609;C0877341;C3272275
cuban,C1553379
bleeding end points,C0019080;C2349179
south or central american,C1710133;C0238914
gusto moderate or severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
caribbean,C0043122;C0206155;C1331005
gusto severe,C0205082;C4050465;C4050466
mixed hispanic,C0205430;C0086409;C3160715
timi clinically significant,C0237881;C0750502;C1546944
total ics dose at entry xg d,C2986497;C0017209;C1292284;C1421532
timi non cabg major,C0205082;C0205164;C4318856;C4521762
predose fev^ at screening,C0439565;C3714541;C3812758;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
timi minor,C0026193;C0205165
l,C0439394;C1706495;C3642217
fatal bleeding,C1302234;C0019080;C1705232
predicted,C0681842;C1882327
intracranial hemorrhage,C0151699;C4554169
predose fev at randomization,C3714541;C0034656
intracerebral,C0442111
predose fvc l,C0439565;C3714541;C3812758
subdural epidural,C0228134;C0812144
at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
active control study,C2347179
at randomization,C0034656
placebo control study,C0683952
predose fev fvc,C0439565;C3714541;C3812758
estimated creatinine clearance ml min i,C0023806
postdose fev fvc at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
neither deep vein thrombosis nor pulmonary embolism,C0149871;C0034065
reversibility in fev^ at,C0449261;C3714541
immobilization no,C0020944;C4048292
screening l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
transient,C0040704;C0205374
pef at baseline l_ min,C0030771;C1518922;C1542834
known thrombophilia no,C0205309;C0398623
morning,C0332170
active cancer no,C0006826;C0998265;C1306459
evening,C0587117
previous cancer no,C0006826;C0998265;C1306459
figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min,C0687676;C0010992;C1704687;C3469826;C0205363;C0017446;C0205147;C0392747;C0443172;C0444504;C2347634;C2348143;C0030771;C1518922;C1542834;C1705241;C4319952;C0439230;C0016529;C1306036;C1511726;C3245479;C3714741;C0849355;C0030705;C1522609;C0441846
coronary artery disease no,C0010054;C0010068;C1956346
nonobese,
treatment duration before randomization days,C0444921;C3259042
obese $nmbr$ kg m^ $nmbr$,C0022718;C0439209;C4054209
enrolled from re cover study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
a aml n $nmbr$,C0023465;C0023467
dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
aml n $nmbr$,C0023465;C0023467
enrolled from re cover ii study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
mets n,C0812270;C1705694;C2939420
adherence to study regimen no ff,C1510802;C0040808;C2945654;C4554348
factors,C1521761;C2827422
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi,C0301630;C4551656;C0332174;C0439230;C1319893;C0005893;C0578022;C1305855
dabigatran event incidence n,C0021149;C0220856
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine,C0301630;C4551656;C0332174;C0439230;C1319893;C1319894;C0524620;C0812270;C1705694;C2939420;C0168634;C1710181;C1442488;C2937472;C0023465;C0023467
wafarin event incidence n,C0021149;C0220856
$nmbr$ to $nmbr$ kg,C0022718;C0439209;C4054209
figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine,C0439165;C1549488;C1561533;C0005823;C0018017;C0681850;C1550501;C1706203;C2349001;C2697811;C0524620;C0812270;C1705694;C2939420;C2937472;C0023465;C0023467
creatine clearance category,C0683312;C3889287
oma oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
$nmbr$ to $nmbr$ ml min,C0439445
oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
currently smokes,C0521116;C0037369
age distribution years n,C1510829
subgroup w r t re cover,C0180153;C1999244;C3888055
serum total ige iu ml,C1441420;C0439458
re cover $nmbr$ dabigatran,C0556581;C0180153;C1999244;C3888055;C2986904;C2348066
fev $nmbr$ predicted at baseline,C0681842;C1882327
re cover $nmbr$ warfarin,C0556581;C0180153;C1999244;C3888055;C2986904;C0043031
number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0449788;C0439234;C0439508
re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
number of er visits in last year prior to baseline,C3810541;C1549755;C3811131;C0439234;C0439508
non rollover,C0517067;C0543436
number of hospitalizations in last year prior to baseline,C4086639;C0439234;C0439508
symptomatic pe,C0070939;C1880476;C4284304
night time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C0439230;C0332152
history of $nmbr$ previous vte excluding index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
ocs reduced stopped,C0392756;C1272691
history of non hemor rhagic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ocs maintained increased,C0205217;C0442805
history of coronary artery disease,C1881055
oma oat,C0028753;C0331496;C0939905;C3539067;C3897364
p value for,C1709380
oat,C0028753;C0331496;C0939905;C3539067;C3897364
event incidence n,C0021149;C0220856
mean change from baseline in fev $nmbr$ predicted sd,C0392747;C0443172;C1705241;C4319952;C0681842;C2699239;C1882327
black or asian,C0005680;C0027567;C0085756;C0439541;C0078988
mean number of clinically significant asthma exacerbations,C0444504;C0237753;C0449788;C2347634;C2348143
l $nmbr$ kg,C1637390
mean number of combined visits hospitalizations,C4086639
never smoke,C0037366;C0439994;C1881674
mean change from baseline in acq overall score sd,C0392747;C0443172;C1705241;C4319952;C0282416;C2699239;C1561607
qualifying index event as pe,C1514624;C0441471;C4019010
mean change from baseline in the number of,C0392747;C0443172;C1705241;C4319952;C0237753;C0449788
budesonide mmx $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
night time awakenings in past $nmbr$ weeks sd,C0860510;C0439230;C2699239
entocort ec n $nmbr$,C1170256
no metabolic syndrome,C0524620
mean age years range,C1514721;C2348147;C3542016
canrenone n z $nmbr$,C0006882
uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
men n [ ],C0025266
mean disease duration years,C0872146;C0439234
heart rate bpm $nmbr$,C0018810
duration,C0449238;C2926735
diabetes n [ ],C0011847;C0011849
duration $nmbr$ to,C0449238;C2926735
$nmbr$ [ $nmbr$ ],
duration $nmbr$ years n,C0449238;C0439234;C2926735
placebo n $nmbr$ n,C0032042;C1696465;C1706408
disease extent n,C0012634;C0439792
denosumab n $nmbr$ n,C1690432
proctosigmoiditis,C0033252
western europe australia new zealand,C0027978;C0324547
prevalent vertebral fracture,C0080179
left sided colitis,C2887821
extensive pancolitis,C0205231;C0868908
prior nonvertebral fracture at age $nmbr$ years,C0016658;C1510829
mean baseline ucdai score,C3533236;C0168634;C1442488
prior use of osteoporosis medications,C1524063
mean baseline ei score,C3533236;C0022067;C1414370;C2348481
female subjects n $nmbr$,C0043210;C0086287;C1705497;C1705498
prior mesalazine use,C0042153;C0457083;C1947944
male subjects n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
prior sulfasalazine use,C0042153;C0457083;C1947944
african american black,C0005680;C0027567;C0085756;C0439541
nerd,
american indian native alaskan,C0682125
eo,C0332120
serum creatinine level,C0600061
gender male n,C0079399;C0086582;C1706180;C1706428;C1706429;C1522384
estimated creatinine clearancet,C0750572;C0010294;C1561535
american indian alaskan native,C0886378
$nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
native hawaiian pacific islander,C0337920;C0242191
baseline sua mean sd mg dl,C0168634;C0439269;C1442488
alcohol drinker n,C0001962;C0001975
presence of tophi,C0150312;C0392148;C3854307
caffeine user n,C3532939
years since last gout flare,C0439234;C0018099
h pylori status n,C0079488;C0449438
years with gout mean sd,C0439234;C0018099
baseline los angeles grade of eo n,C0441800;C0919553;C3244287
obesity bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
baseline renal function eclcr,C0168634;C0232804;C1442488
figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0267055;C0030705
febuxostat $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0521095;C1524063;C1708614
allopurinol,C0002144
no psa n $nmbr$,C3810537;C3813209
normal $nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
psa n $nmbr$,C3810537;C3813209
mild impairment $nmbr$ to $nmbr$ ml minute,C0221099;C0684336;C0439232;C0700321;C0702093;C1282918;C2347166
mean age years $nmbr$ ci,C0008107;C3259781
moderate or severe impairment $nmbr$ ml minute,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0439232;C0700321;C0702093;C1282918;C2347166
mean bmi $nmbr$ ci,C0008107;C3259781
vorapaxar n $nmbr$,C2974521
mean involved bsa $nmbr$ ci,C0008107;C3259781
median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
mean pasi score $nmbr$ ci,C0008107;C3259781
region of enrollment,C0017446;C0205147
mean dlqi score $nmbr$ ci,C0008107;C3259781
cardiovascular risk factors,C0850624
daily activities,C0871707
renal function ml min,C0232804;C0439445
leisure,C0086542
$nmbr$ $nmbr$ crcl,C1846718
personal relationships,C1552027
$nmbr$ crcl,C1846718
symptoms and feelings,C0683368;C1457887;C1527305
cardiovascular disease history,C1880008
treatment satisfaction,C3476649
positive troponin or ck mb,C0439178;C0041199;C1446409;C1514241;C2825490;C3812269;C0010290
work and school,C0043227;C0036375
symmetric t wave inversions,C0332516;C0520888;C2699744
mean eq $nmbr$ d response $nmbr$ ci,C0205163;C0439185;C0008107;C3259781
iii iv,C0022326;C4265176
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
stratification factors,C1514984
mean sf $nmbr$ score $nmbr$ ci,C0008107;C3259781
intent to use glycoprotein iib iiia inhibitor,C0162425;C1283828;C1550453
physical functioning,C0516981;C4049916
intent to use direct thrombin,C0162425;C1283828;C1550453
physical role,C0035820;C1705810;C3871154
antiplatelet at randomization,C0034656
bodily pain,C3890602
chads $nmbr$ score $nmbr$,C0449820;C4050231
general health,C0424575;C4018875
vitality,C0424589
mean systolic blood pressure sd mm hg,C0428886;C0439475;C0488053
social functioning,C0037395
mean diastolic blood pressure sd mm hg,C0428886;C0439475;C0488053
mental health,C0025353
type of atrial fibrillation n,C0332307;C1547052
emotional role,C0035820;C1705810;C3871154
chads $nmbr$ components n,C0007928;C0449432;C1413373
physical component summary,C0031809;C0205485;C1509143
medications in use at baseline n,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
mental component summary,C0229992;C0449432;C1705248
histamine $nmbr$ receptor antagonist,C0019590;C4521896
mean ham d score $nmbr$ ci,C0008107;C3259781
median time in therapeutic range for warfarin recipients,C1554109;C0043031;C1709854
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ tt,C1452561;C4554543
chads $nmbr$ score per outcome,C0449820;C4050231
no of events per $nmbr$ patient years,C0441471;C3541888;C0030705;C0439234
rate in all participants y,C0871208;C1521828
no psa,C3810537;C3813209
dabigatran $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
absolute risk reduction $nmbr$ ci y,C3179139;C0008107;C3259781
$nmbr$ mg qw $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
total events n,C0439175;C0439810
$nmbr$ mg biw $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
rate y,C0871208;C1521828
any event,C0441471;C4019010
dabigatran $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
arthritis,C0003864;C4552845
$nmbr$ $nmbr$ t,C2603360
back pain,C0004604;C1963071;C4553945
vascular death,C0011065;C1306577;C4082313;C4552775
bursitis,C0006444
total death,C0011065;C1306577;C4082313;C4552775
muscle twitching,C0026845;C4083049;C0231530
placebo plus statin n $nmbr$,C0032042;C1696465;C1706408
musculoskeletal stiffness,C0497254;C0427008;C2707260
extended release niacin plus statin n $nmbr$,C0027996;C1142562
neck pain,C0007859;C1963180;C4553909
distribution no,C0520511;C1704711
pain in extremity,C0030196;C4553007
american indian alaskan native or aboriginal canadian,C0886378;C0935542;C0238884
psoriatic arthropathy,C0003872
multiracial or other,C1881928
shoulder pain,C0037011
hispanic or non hispanic ethnic group no f,C0086409;C0015031;C1879937;C0016327
tendonitis,C0039503
presenting history or diagnosis no,C0449450;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0011900;C1704338;C1704656
low feno subgroup $nmbr$ $nmbr$ ppb n $nmbr$,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
stroke or cerebrovascular disease,C0038454;C4554100;C0007820
high feno subgroup $nmbr$ $nmbr$ ppb n $nmbr$,C0205250;C1079230;C1515021;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
laboratory values in patients with history of diabetes,C0022877;C0042295;C3244292;C4283904;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
low eosinophil subgroup $nmbr$ ml n $nmbr$,C0205251;C0014467;C1550472;C3890211;C4048187;C4321351;C4522223
insulin tu ml,C0439526;C1705224;C3887665
high eosinophil subgroup $nmbr$ ml n $nmbr$,C0205250;C0014467;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
concomitant medications no,C0013227;C0802604;C2598133;C4284232
low periostin subgroup $nmbr$ ng ml n $nmbr$,C0205251;C0439275;C1550472;C3890211;C4048187;C4321351;C4522223
use at baseline,C0042153;C0457083;C1947944
high periostin subgroup $nmbr$ ng ml n $nmbr$,C0205250;C0439275;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
duration of prior statin therapy^,C0444917
mean sd age yr,C0001779;C0439234
previous use of niacin or niaspan,C1524063;C0027996;C1142562;C1161310
mean body weight sd kg,C0022718;C0439209;C4054209
aspirin or other antiplatelet or anticoagulant agent,C0004057;C0003280
mean total serum ige sd iu ml,C0229671;C0439458;C1546774;C1550100
number of copd exacerbations,C0237753;C0449788
mean prebronchodilator fev $nmbr$ sd predicted,C0444504;C2699239;C2347634;C2348143;C0681842;C1882327
change from baseline of morning pef l min,C0392747;C0443172;C1705241;C4319952
hospitalized for asthma n,C0701159;C0004096;C2984299
tdi units,C0439148;C1519795;C3853603
mean sd number of exacerbations,C0237753;C0449788
s d,C0565930;C2603362
mean sd total asthma symptom scores,C3533236
o $nmbr$,C0483204
mean sd number of albuterol per day puff,C0237753;C0449788;C1533107;C1882376
x $nmbr$,
mean sd aqlq,C0444504;C4055434;C2347634;C2348143
study $nmbr$,C0557651;C2603343
mean sd feno ppb,C0444504;C1415800;C2347634;C2348143
indacaterol group n $nmbr$,C1722260;C0441848
mean eosinophil count per ml,C0200638;C0750879
duration of copd y,C0449238;C2926735
mean sd periostin ng ml,C0219433;C0439275;C1424662;C3812270
severity of copd gold $nmbr$,C0439793;C0522510
concomitant asthma medications n,C0004096;C0013227;C0802604;C2598133;C4284232;C2984299
severe or very severe,C0205082;C4050465;C4050466;C3641272;C4050419
m $nmbr$ subgroup,C1079230;C1515021
fev $nmbr$ predicted post albuterol,C0687676;C0001927;C1704687;C3469826
total asthma symptom score,C3533163;C0004096;C2984299
fev $nmbr$ fvc post albuterol,C3714541;C0687676;C0001927;C1704687;C3469826
albuterol use,C0042153;C0457083;C1947944
fev $nmbr$ pre albuterol l,C0332152;C0001927;C0740175;C2257086;C3669034
aqlq score,C0449820;C4050231
fev $nmbr$ post albuterol l,C0687676;C0001927;C1704687;C3469826
change from baseline in predicted fev $nmbr$,C0392747;C0443172;C1705241;C4319952;C0681842;C3714541;C1882327
fev $nmbr$ reversibility pre post albuterol,C0332152;C0001927;C0740175;C2257086;C3669034
low subgroup,C1079230;C1515021
use of rescue albuterol puffs day,C1524063;C0001927
high subgroup,C1079230;C1515021
days without albuterol use,C0439228;C0001927
feno placebo lsm,C0032042;C1696465;C1706408
baseline sgrq score,C0449820;C4050231
omalizumab lsm,C0966225
no of patients indacaterol placebo,C0030705;C0032042;C1696465;C1706408
lsm difference,C1705241;C1705242
treatment difference ml,C0439526;C1705224;C3887665
eosinophils,C0014467;C0200638
copd severity gold $nmbr$,C0018026;C1304897
placebo lsm,C0032042;C1696465;C1706408
use of ics,C1524063;C0815320;C4551720
periostin,C0219433;C1424662;C3812270
albuterol reversibility,C0001927;C0449261
diagnosis at presentation no,C0011900;C1704338;C1704656
males $nmbr$,C0086582
nste acs,C0742343;C4318612
females $nmbr$,C0086287
other countries,C0454664
waist hip ratio,C0205682
cardiac biomarker status no total no,C1999091;C2735302;C0439175;C0439810
males $nmbr$ $nmbr$,C0086582
abnormal,C0205161;C2347472;C2699333
females $nmbr$ $nmbr$,C0086287
clopidogrel $nmbr$ mg loading dose,C4086581
baseline hemoglobin aj^ values,C0004486;C0042295;C0230613
duration of pci min,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
drug eluting stent no,C1322815
hemoglobin aj^,C0004486;C0230613
bare metal stent no,C2825200
diabetes duration y,C0011847;C0011849
balloon angioplasty no,C0002996;C0002997
baseline hba $nmbr$ c category,C0683312;C3889287
cangrelor clopidogrel no of events total no,C1121991;C0070166;C0439175;C0439810
liraglutide $nmbr$ $nmbr$ mg oad,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diagnosis at presentation,C0011900;C1704338;C1704656
sitagliptin oad,C1565750
biomarker status,C0449442
glimepiride oad,C0061323
insulin dependent diabetes,C0011854
rosiglitazone oad,C0289313
previous tia or stroke,C0007787;C0917805;C1054154;C0038454;C4554100
exenatide oad,C0167117
hba $nmbr$ c $nmbr$ $nmbr$,C0019016;C1825777;C3538758
history of pad,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
alc at weeko,C1424945;C3811058
clopidogrel dose,C0178602;C0869039;C1114758
l i $nmbr$ $nmbr$,C0021966;C0221138
periprocedural anticoagulant,C0003280;C0848112;C3536711
bivalirudin only,C0168273
alc at week $nmbr$,C1424945;C3811058
heparin only,C0019134;C0770546
$nmbr$ $nmbr$ g l,C0439294;C0456615
arterial access,C0444454;C1554204
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0019016;C1825777;C3538758
femoral,C0015811
$nmbr$ $nmbr$ fi $nmbr$,C4050619
radial,C0442038;C0920847
hba $nmbr$ c s $nmbr$ s $nmbr$,C0019016;C1825777;C3538758
no of vessels,C0005847
$nmbr$ s $nmbr$,
stent type,C0332307;C1547052
linagliptin n $nmbr$,C2746078
drug eluting,C0013227;C1254351
total comparators n $nmbr$,C0439175;C0439810
bare metal,C0025552
gender of patients,C0079399;C1522384
aspirin dose,C4696290
race of patients,C0034510;C1706779;C3853635
timing of clopidogrel loading dose,C0449243;C1704250
hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
before pci,C4049621
diabetes duration known of patients,C0011847;C0205309;C0011849
after pci,C4049621
previous oral glucose lowering agents of patients,C0205156;C0017725;C1552607;C0441994;C2003888;C0600419
duration of study drug infusion,C0489652
cv risk factors of patients,C0035648;C1553898
fibrinolysis n $nmbr$,C0016017;C1305868
ex current smoker,C3173209;C3241966
p valuey,C0369773;C2603361
egfr using cg mdrd formulae of patients,C1739039;C3811844;C3812682;C1524063;C3839656;C0012164;C0489829;C1705501
killip class no total no i,C1881332;C0439175;C0439810;C0021966;C0221138
severely impaired,C0205082;C0221099
infarct location no total no,C0450429;C1515974;C4284930;C4284931;C0439175;C0439810
cv medication of patients,C0013227;C3244316;C4284232
previous coronary artery bypass grafting,C2144990
acetyl salicylic acid,C0004057
median time delay interquartile range min,C0702093;C1524029;C3813700
lipid lowering therapy,C0585943
any of the above,
symptom onset to first medical contact ambulance or emergency department,C4086878;C0002422;C3846685;C0562508
framingham $nmbr$ year cv risk score,C0035647;C0449820;C4050231;C4552904
randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079;C0007430;C0022877;C3244292;C4283904
score,C0449820;C4050231
randomization to arterial sheath insertion,C0034656;C0003842;C0221464
score $nmbr$ of patients,C0449820;C4050231;C0030705
symptom onset to arrival in catheterization laboratory,C4086878;C1555577;C1706079;C0007430;C0022877;C3244292;C4283904
linagliptin patients with events total patients,C0030705;C0439175;C0439810
symptom onset to start of reperfusion treatment tenecteplase or arterial sheath insertion,C4086878;C0035124;C0684253;C0021107;C0441587;C1512796;C1883719
total comparators patients with events total patients,C0439175;C0030705;C0439810
fibrinolysis primary pci n $nmbr$ n $nmbr$ no of patients total no,C0016017;C0205225;C0439612;C0439631;C1305868;C0030705;C0439175;C0439810
cox hr $nmbr$ ci,C0008107;C3259781
relative risk $nmbr$ ci ofprimary end point,C2349179;C2826544
cmh rr $nmbr$ ci,C0008107;C3259781
overall event rate,C0871208;C1521828
use of rescue medication,C1524063
ii iv,C0022326;C4265176
investigator reported hypoglycaemia,C0020615;C4553659
place of randomization,C0442504;C1533810;C1704765;C1882509
$nmbr$ no,
ambulance,C0002422;C3846685
white no,C0007457;C0043157;C0220938
community hospital,C0020003
black no,C0005680;C0027567;C0085756;C0439541
time of randomization,C0040223;C3541383
other no,
before amendment,C0680532;C2346732
taking antihypertensive treatment at,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
after amendment,C0680532;C2346732
baseline no,C0168634;C1442488
ranolazine n $nmbr$ placebo n $nmbr$,C0073633;C0032042;C1696465;C1706408
treated at baseline mean sd mm hg,C1522326;C0439475
prior angioplasty,C0162577;C1548817
untreated at baseline mean sd mm hg,C0332155;C0439475
prior bypass graft surgery,C0455610
eligibility risk factorsa,C0013893;C0035647;C4552904;C1548635
duration of diabetes yrs,C0449238;C2926735
cigarette smoker no,C0337667
antianginal medications,C0013227;C0802604;C2598133;C4284232
ascvd b no,C3665365
on $nmbr$,
history of mi or stroke no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
long acting nitrates,C0205166;C0028125;C1706317
history of coronary revascularization no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ace l arbs,C1452534;C3888198;C4284014
other ascvd no,C3665365
baseline heart rate beats min,C0439385
st t wave no,C0036056;C0429103;C3272372
baseline systolic blood pressure mm hg,C4274438;C0439475
lvh by ecg or echocardiography no,C0232306;C0013516
baseline diastolic blood pressure mm hg,C4274392;C0439475
lvh by minnesota code no,C0149721;C0009219;C0805701;C3889831
figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency,C2986480;C3695257
diabetes no c,C0011847;C0011849
history of chd at baseline no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention,C0456603;C1547037;C1705241;C1705242;C0023732;C0332152;C0007447;C0740175;C2257086;C3669034;C1079231;C1547282;C2986480;C0397581
lipid trial participants no,C1997894;C2242969
watchman n $nmbr$,C0335390
non cardiovascular mortality,C0026565;C0026566
height inches,C0489786;C0439204
weight lbs,C0439219;C3161851
fatal chd nonfatal ml,C0439526;C1705224;C3887665
hawaiian pacific,C0337920
fatal nonfatal ccvd,C1302234;C1705232
chads score,C0449820;C4050231
fatal nonfatal hospitalized heart failure,C0018801;C0018802;C4554158
warfarin naive,C0043031
fatal nonfatal hospitalized stroke,C0038454;C4554100
$nmbr$ days warfarin,C0439228;C0043031
kidney disease usrds,C0022658
experience,C0237607;C0596545
age $nmbr$ $nmbr$ y,C0001779
$nmbr$ yr warfarin experience,C0237607;C0596545
nonblack,
history of cad,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os,C0229090;C0230028;C0262950;C0393706;C1561953
mellitus,
african americans,C0085756
clinical characteristics n,C0683325
caucasians,C0007457;C0043157
egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
v hctz n $nmbr$,C0020261
pervious cerebrovascular event,C0441471;C4019010
hctz n $nmbr$,C0020261
pad details n,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
prior antihypertensive medication n,C0332152;C0003364;C2826257
peripheral arterial revascularization,C0003842;C0581603;C0221464
diabetes status n,C1317301
prior amputation,C0002688;C0332840;C1546539
normoglycemia^,
prior carotid intervention,C0184661;C0886296;C1273869
ifg prediabetes^,C1334085;C0362046;C1708411
abi,C1328319;C3888326
cardiometabolic syndrome ^n,C0039082
abi $nmbr$ $nmbr$,C1328319;C3888326
mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
claudication fontaine class $nmbr$,C0456387;C1518526;C1705943
mean sd waist circumference cm,C0444504;C0455829;C2347634;C2348143
baseline medical therapy n,C0168634;C0418981;C1442488
mean sd fpg mg dl,C0444504;C0439269;C2347634;C2348143
no antiplatelet therapy,C1096021
mean sd fasting insulin uu ml,C0444504;C2699239;C2347634;C2348143;C0015663;C0021641;C0439342;C1533581;C1579433;C3714501
aspirin and thienopyridine therapy,C0004057;C0039798;C0087111;C1363945
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
cilostazol,C0055729
mean sd ldl c mg dl,C0444504;C0439269;C2347634;C2348143
vorapaxar n $nmbr$ n,C2974521
mean sd hdl c mg dl,C0444504;C0439269;C2347634;C2348143
overall efficacy,C1280519;C1707887
mean sd triglycerides mg dl,C0041004;C0439269
cvd mi stroke,C0038454;C4554100
mean sd mssbp mm hg,C0444504;C0439475;C2347634;C2348143
cvd mi stroke urgent coronary revascularization,C0007222;C0877341
mean sd msdbp mm hg,C0444504;C0439475;C2347634;C2348143
cvd mi stroke urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
mean sd $nmbr$ h asbp mm hg,C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
cvd mi stroke revascularization urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
mean sd $nmbr$ h adbp mm hg,C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
peripheral limb vascular efficacy,C1280519;C1707887
v hctz,C0020261
hospitalization for acute limb ischemia,C0019993;C2945695
hctz,C0020261
any peripheral revascularization,C0205100;C0581603
change from baseline to eos mg dl,C0392747;C0443172;C1705241;C4319952;C1623465;C0439269;C1861303
urgent peripheral revascularization,C0205100;C0581603
ls mean difference $nmbr$ ci,C0008107;C3259781
elective peripheral revascularization,C0205100;C0581603
fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
any vascular efficacy,C1280519;C1707887
change from baseline to eos uu ml,C0392747;C0443172;C1705241;C4319952;C1623465;C0439342;C1861303
$nmbr$ $nmbr$ $nmbr$ lf,C1416933;C2986618;C4554443
urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
any revascularization,C0581603
regadenoson n $nmbr$,C1698215
bleeding,C0019080
mean sd years,C0444504;C0439234;C2347634;C2348143
gusto moderate severe bleed,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
ckd n t,C1561643
gusto severe bleed,C0205082;C0019080;C4050465;C4050466
stage $nmbr$,C0205390;C1300072;C1306673
fatal bleed,C1302234;C0019080;C1705232
cad history and risk factors n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0035648;C1553898
nebivolol n $nmbr$,C0068475
obesity bm $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
age years a,C1510829
smoking $nmbr$ pack years,C0037369;C1277691;C0453996;C1881674
trough seated sbp mmhg a,C0085805;C0439475
egfr ml minute $nmbr$ $nmbr$ m $nmbr$,C0439232;C0700321;C0702093;C1282918;C2347166
trough seated dbp mmhg a,C0277814;C0439475;C1283233
regadenoson,C1698215
trough seated hr bpm a,C0444506;C0277814;C1283233
change from baseline stage $nmbr$ ckd,C0597205;C0679846
all men,C0025266
stable angina n,C0340288
all women,C0043210
non st segment elevation,C1518422;C0520886
ethnicity t,C0015031;C0243103
mi n,C3810814
education y mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
congestive hf,C0018488;C1313497;C1538440;C3273279
treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
number of target vessels,C0237753;C0449788
blood pressure mm hg mean sd,C0428886;C2699239
drug eluting stent n,C1322815
dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd,C0439269;C2699239
bare metal stent n,C2825200
total glucose mg dl,C0017725;C0439269
cangrelor,C1121991
comparator,C1707454;C4553389;C4553390
diabetes mellitus classification,C0008902;C0008903;C0678229
or [ $nmbr$ cl],C0596019
diabetes mellitust,C0011847;C0011849
death udmi idr,C0011065;C1306577;C4082313;C4552775
normoglycemic^,C0580545
death q mi idr,C0011065;C1306577;C4082313;C4552775
history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
death q ml stent thrombosis,C0011065;C3897493;C1306577;C4082313;C4552775
st t wavett,C0036056;C3272372
$nmbr$ $nmbr$ $nmbr$ continued,C0549178
diabetic yes,C1549445;C1705108;C1710701
diabetic no,C0241863
estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
prior thienopyridine,C0332152;C1120149;C2826257
atrial fibrillation flutter n,C0155709
outcomes,C1274040
subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811;C0205363;C0168634;C1442488
$nmbr$ y rate per $nmbr$ persons se n,C0871208;C1521828
low renin pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
hazard ratio and $nmbr$ confidence interval,C2985465;C0009667
normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$,C1533072;C4050009
a c,
received antihypertensive within last $nmbr$ days n,C0003364;C0439228
l c,C0439394;C1706495;C3642217
diabetic n,C0241863
total randomized n,C0439175;C0034656;C3815594;C0439810
mssbp sd mmhg,C2699239;C0439475
chd nonfatal mi fatal chd,C0280604;C1302234;C1705232;C3542407
msdbp sd mmhg,C2699239;C0439475
secondary end points,C0027627;C2349179;C0175668;C0205436
pra median min max ng ml h,C1533072;C4050009
mortality outcomes,C0026565;C1274040;C0026566
african american n $nmbr$,C0085756
combined fatal nonfatal outcomes,C1548228
caucasian n $nmbr$ $nmbr$,C0007457;C0043157
heart failure treated hospitalized fatal,C1302234;C1705232
alcohol use n,C0001948
hospitalized fatal heart failure,C0018801;C0018802;C4554158
drinker $nmbr$ $nmbr$ drinks week,C0332174;C0439230
hospitalized angina,C0701159;C0002962
non ex tobacco user,C1518422;C3853727
insulin glargine n $nmbr$,C0907402
tobacco user,C3853727
standard care n $nmbr$,C1442989;C1947933;C2828392
tophi present n,C0221248;C0150312;C0449450
n $nmbr$ fatty acids n $nmbr$,C0369718;C0015684;C0441922
renal function bn,C0005005;C0034700;C1706574;C4551963
geographic distribution no,C0681686
any cardiovascular disease,C0007222
cardiac arrhythmia,C0003811;C0264886;C1560249
history of cvd and of cv risk factors no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0035648;C1553898
prior cardiovascular event,C0332152;C1320716;C2826257
use of low dose aspirin $nmbr$ mg daily,C1524063;C2608320
prior or new diabetes,C0332152;C2826257;C0011847;C0011849
figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min,C1280519;C1707887;C0085756;C0681850;C1550501;C1706203;C2349001;C2697811;C2945599;C1565489;C0439445
impaired glucose tolerance or impaired fasting glucose,C0271650;C1272092
semuloparin n $nmbr$,C2700104
microalbuminuria or macroalbuminuria,C0730345
hazard ratio $nmbr$ ci j,C2985465;C0008107;C3259781
dietary epa dha intake mg day,C1286104;C0439422
any vte or vte related death no,C0630906;C0011065;C1306577;C4082313;C4552775
heart rate beats per minute,C0439385
symptomatic deep vein thrombosis,C0231220;C0149871
laboratory investigations,C0022877;C1261322;C3244292;C4283904
upper limbs,C1140618
fasting plasma glucose mmol l,C0202042;C1532563;C0455280
lower limbs,C0023216
$nmbr$ $nmbr$ l l,C3539687
proximal,C0205107;C4489236
l l $nmbr$ $nmbr$,C3539687
distal,C0205108;C4522154
ldl cholesterol mmol,C0023824;C0439190;C0202117
pulmonary embolism,C0034065
serum creatinine gmol,C0201976;C0600061
nonfatal,
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
symptomatic,C0231220
urinary albumin creatinine ratio,C0486293;C1318293
detected during tumor evaluation,C0442726;C1511790
ne,C0027608;C0028219;C3538705
cardiovascular and oral hypoglycemic drugs no,C0007226;C3887460;C0359086
any vte related death,C0011065;C1306577;C4082313;C4552775
asa or antiplatelet agent,C0004057;C3853627;C0085826
other oral hypoglycemic drug s,C0359086
outcome according to primary cancer site no total no,C1274040;C0872338;C0439175;C0439810
carotid imt,C0334121;C1704614;C4318736
lung,C0024109
pancreas,C0030274
average maximum cimt mm,C4330985;C4554674
stomach,C0038351;C3714551
average of maximum common carotid cimt mm,C1510992;C2825518
colon or rectum,C0009368;C3888384;C0034896
$nmbr$ $nmbr$ h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
bladder,C0005682;C4319531
average maximum common and bifurcation cimt mm,C0205214;C1522138;C3245511;C4330985;C4554674
ovary,C0029939;C0227898
average of maximum far wall cimt mm,C1510992;C2825518
outcome according to stage of cancer no total no,C1274040;C0027646;C0439175;C0439810
insulin glargin arm,C0446516;C3715044;C4553528
metastatic,C0036525;C1522484;C4085632
insulin glargine slope lsm se mm year,C0439234;C0439508
locally advanced,C1517927;C0205179
standard care slope lsm se mm year,C0439234;C0439508
outcome according to no of risk factors for vte,C1274040;C0035648;C1553898;C0630906
difference glargine standard care lsm se mm year,C0439234;C0439508
total phase $nmbr$ pooled n $nmbr$,C0439175;C0205390;C1710475;C0439810
p value for interaction by region,C1709380;C1704675;C0017446;C0205147
low complement anti dsdna positive n $nmbr$,C0432633
north america n $nmbr$,C0028405
mean selena sledai score sd,C3533236;C2699239
south america n $nmbr$,C0037713
selena sledai $nmbr$,C0451528
n $nmbr$ fatty acit,C0369718;C0441922
proteinuria $nmbr$ g $nmbr$ h,C0033687;C0560020;C1962972;C4554346
s arm,C0446516;C3715044;C4553528
anti dsdna $nmbr$ iu ml,C0741099;C0439458
n $nmbr$ fatty acids slope lsm se mm year,C0439234;C0439508
igg $nmbr$ $nmbr$ g l,C0439294;C0456615
placebo slope lsm se mm year,C0439234;C0439508
low c $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
difference n $nmbr$ fa placebo lsm se mm year,C0439234;C0439508
$nmbr$ $nmbr$ mg day,C0439422
other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers,C0015176;C0004340;C0021201;C2700456;C1511726;C3245479;C3714741;C0344329;C0392748
immunosuppressant use,C0042153;C0457083;C1947944
n $nmbr$ fatty acids placebo lsm $nmbr$ cl,C0015684;C0596019
mean slicc damage index score sd,C3533236;C2699239
ageadj,
mean pga score sd,C3533236;C2699239
no previous cv event,C0441471;C4019010
figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis,C0024141;C0600653;C0918012;C1552854;C1637833;C2986546;C0683962
previous cv event,C0441471;C4019010
maximum cimt median,C0549183;C0876920;C2347635;C2348144;C2939193
horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p,C0205126;C0205132;C0008107;C0458097;C3259781;C1882932;C1705241;C1705242;C0032042;C1696465;C1706408;C1552961;C2347617;C3714763;C0205250;C0871261;C0441994;C1548802;C2003888;C0750572;C1518681;C0205128;C1723401;C0439272;C1704675
maximum cimt a med an,C0806909;C1552615;C2826546;C4321267
troponin positive n $nmbr$,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
hbalc medan,
troponin negative n $nmbr$,C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
age median [iqr] y,C0549183;C0876920;C2347635;C2348144;C2939193
tnglycendes median,C0549183;C0876920;C2347635;C2348144;C2939193
weight median [iqr] kg,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
tngtycendes a median,C0549183;C0876920;C2347635;C2348144;C2939193
cardiac biomarker elevation,C0439775;C0702240
fastng plasma glucose median,C0549183;C0876920;C2347635;C2348144;C2939193
st segment deviation timi risk score,C0035647;C0449820;C4050231;C4552904
fascng plasma glucose a medan,C0202042;C0455280
white blood cell count cellsx $nmbr$,C0023508;C0427512
no statin,C0360714
hemoglobin g dl,C0439267
stalin,
demographic variable,C0439828;C4553760
interactior p value,C1709380
vildagliptin $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
vildagliptin $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
triglycerides median,C0549183;C0876920;C2347635;C2348144;C2939193
body weight,C0005910;C1305866
fasting plasma glucose median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ h ppg mmol l,C2827804;C1418888
sita $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of t $nmbr$ dm,C0449238;C2926735
cana $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
other i,C0021966;C0221138
vildagliptin $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
a $nmbr$ c mmol mol,C3829066
am s e,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
ama s e,C0002461;C0279755;C2825862
duration of type $nmbr$ diabetes years,C0449238;C2926735
bmi at baseline kg m $nmbr$,C0578022;C0022718;C0439209;C4054209
supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1079230;C1515021
duration of metformin therapy months,C0444917;C0025598
ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0023189;C1710181;C1319635;C1418845
duration of diabetes months,C0449238;C2926735
covariate,
golimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cluster $nmbr$ diuretic n $nmbr$,C1555715;C0012798;C1704332
sex no male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0086582;C1706180;C1706428;C1706429
cluster $nmbr$ reversible no diuretic n $nmbr$,C1555715;C0205343;C1704332;C0012798
race no white,C0034510;C1706779;C3853635;C0007457;C0043157;C0220938
cluster $nmbr$ not reversible no diuretic n $nmbr$,C1555715;C1704332;C1518422;C0205343;C0012798
psa duration years,C0449238;C0439234;C2926735
age median years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
number of swollen joints $nmbr$ assessed,C0449813
iqr,
number of tender joints $nmbr$ assessed,C0449813
median m kg $nmbr$ iqr,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
das $nmbr$ crp,C3890735;C4048285
smoking mean,C0444504;C2347634;C2348143
psa modified shs of hands and feet,C0392747;C0018563;C1552914;C3889737;C0016504;C0347981
pack years iqr,C1277691
erosion score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
fev $nmbr$ predicted sd,C0681842;C2699239;C1882327
jsn score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
fev $nmbr$ reversibility sd,C0449261;C2699239
total score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
reversibility stratum,C0449261
[no yes],C1549445;C1705108;C1710701
no of patients with $nmbr$ bsa affected,C0030705;C0392760;C1314939
bsa affected,C0392760;C1314939
exacerbations requiring hospitalisation past year,C4086268;C0019993;C0439234;C0439508
pasi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
exacerbations requiring oral steroids antibiotics past year,C4086268;C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
no of patients with fingernail involvement,C0030705;C0222001;C1314939
baseline medications,C0013227;C0802604;C2598133;C4284232
no fingernails,C0222001
anti thrombotics,C0087086
lipid modifiers,C0023779;C4284280
target nail napsi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
blockers,
patients with dactylitis no,C0030705;C0239161
psycholeptics,C3653516
dactylitis score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
anti histamines,C0019590
patients with enthesitis no,C0030705;C1282952
anti anaemics,C0857322
psa modified mases score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
anti hypertensives,C0003364
haq score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
glargine,C0907402
sf $nmbr$ health survey,C0037712;C0018762
standard therapy,C2936643
pcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
$nmbr$ drinks week,C0332174;C0439230
mcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
$nmbr$ years education,C0013621;C0013622;C0013658;C0039401
patients taking mtx no,C0025677;C1417487
depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
mean median mtx dose mg week,C0332174;C0439230
$nmbr$ h pg mmol l,C2827798;C2827804
golimumab combined n $nmbr$,C2353893;C0205195
grip strength kg,C0022718;C0439209;C4054209
change in psa modified shs baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
bm $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
total score,C2964552
waist to hip male,C0230097;C0019552;C0022122;C1505163;C3538851;C4284725
mtx at baseline,C0025677;C1417487
waist to hip female,C0230097;C0019552;C0022122;C1505163;C3538851;C4284725
p vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
urine acr mg g,C0042036;C1300563;C0042037;C2963137
no mtx at baseline,C0025677;C1417487
egfr ml min,C1739039;C0439445;C3811844;C3812682
hands erosion score,C0449820;C4050231
alt units l,C1266129;C0439339;C4553172
jsn score,C0449820;C4050231
ldl mmol l,C1532563
total hands score,C2964552;C0018563;C1552914
hdl mmol l,C3715113;C1532563
feet erosion score,C0449820;C4050231
tg mmol l,C0337445;C1532563
total feet score,C2964552;C0016504;C0347981
omega $nmbr$ fa,C1719844
additional radiographic findings at week $nmbr$,C2607943;C2926606;C3539655
or $nmbr$ cl,C0596019
no new erosions among patients with $nmbr$ uninvolved joint at baseline,C0333307;C1959609;C0022417;C0392905;C1706309
age median,C0549183;C0876920;C2347635;C2348144;C2939193
no new jsn among patients with $nmbr$ uninvolved joint at baseline,C0205314;C0030705;C0022417;C0392905;C1706309
alcohol,C0001962;C0001975
radiographic progression based on change from baseline sdc,C0242656;C0449258;C1527178;C1705938;C1419891;C3273112
alcohol $nmbr$ wk,C0332174;C0439230
total psa modified shs,C2986589;C0392747;C3889737
no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
erosion score,C0449820;C4050231
a $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
patients with change from baseline in total psa modified shs $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
waist hip median,C0549183;C0876920;C2347635;C2348144;C2939193
diabetes bl,C0005918;C0006413;C1552663;C2827109
waisvhip median,C0549183;C0876920;C2347635;C2348144;C2939193
idm,C0270221
grip strength meidan,C0429271;C2598165
no pts,C1419129;C2698747
grip strength median,C0549183;C0876920;C2347635;C2348144;C2939193
lvh by ecgt blood pressure mm hg,C0149721;C0005823;C1271104;C1272641
urine acr median,C0549183;C0876920;C2347635;C2348144;C2939193
sbp,C0085805
diabetic subjects n $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
dbp,C0536221;C3813197;C4281799
non diabetic subjects n $nmbr$,C1518422;C0241863
bmi kg m $nmbr$ cholesterol mg dl,C0022718;C0439209;C4054209;C0008377;C0439269
alcohol usef n,C0001962;C0001975
total no of events participants,C0439175;C0439810;C0441471;C0679646;C3541888
serum urate mg dl n,C0455272;C0439269
unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate,C0242444;C2987720
years with gouty arthritis,C0439234;C0003868
adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$,C0008107;C3259781;C1707455;C0011847;C0011849;C0005918;C0006413;C1552663;C2827109;C0439234;C0439508
presence of tophi n,C0150312;C0392148;C3854307
adjusted hr $nmbr$ ci comparing idm with bl,C0008107;C3259781;C1707455;C0270221;C0005918;C0006413;C1552663;C2827109
renal function n,C0232804
cvd mortality,C0026565;C0026566
figure $nmbr$ achievement of sua,C0001072
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p,C0369773;C2603361
vildagliptin n $nmbr$,C1570906
non cvd mortality,C0026565;C0026566
gfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
nonfatal mi fatal chdt,C1302234;C1705232
normal $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
mild $nmbr$ to,C2945599
lisinopril cvd total,C0439175;C0439810
moderate $nmbr$ to,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
no cases,C0868928;C1533148
frailty status,C0424594;C0449438
allopurinol $nmbr$ $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
participated in a previous febuxostat studyb n,C0205156;C0249529;C1552607
frail,C0871754
prior urate lowering therapies n,C1514463;C0441994;C2003888
non frail,C1518422;C0871754
yes any,C1549445;C1705108;C1710701
tiotropium n z $nmbr$,C0213771
febuxostat,C0249529
control n z $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
probenecid,C0033209
copd duration y,C0024117;C0449238;C2926735;C1412502;C3714496
renal functionc n,C0022646
sabaa,
any cardiovascular diseased,C0007226;C3887460
labaa,
use of low dose aspirin,C1524063;C2608320
saaca,
figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit,C0444504;C3272907;C2347634;C2348143;C0455272;C0086960;C0205539;C1571999
laaca,
p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation,C0369773;C2603361;C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0743559;C1608199;C1882932;C0871420
icsa,
vorapaxar n $nmbr$ $nmbr$,C2974521
ocs,
qualifying type of atherosclerosis no,C1514624;C0332307;C1547052
mean sd change in pre bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
selected clinical characteristics no total no,C1707391;C0683325;C0439175;C0439810
visits $nmbr$ e $nmbr$,C0545082;C1512346
any coronary artery disease,C0010054;C0010068;C1956346
univariate p value,C1709380
any peripheral arterial disease,C0085096;C1704436
multivariate p value,C1709380
previous cerebrovascular event,C0441471;C4019010
male n z $nmbr$,C0086582;C1706180;C1706428;C1706429
use of antiplatelet agents no total no,C1524063;C0085826;C0439175;C0439810
female n z $nmbr$,C0043210;C0086287;C1705497;C1705498
qualifying myocardial infarction,C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
current smoker n z $nmbr$,C3173209;C3241966
qualifying peripheral arterial disease,C1514624;C0085096;C1704436
ex smoker n z $nmbr$,C0337671;C4555205
qualifying stroke,C1514624;C0038454;C4554100
treatment arm,C1522541
dipyridamole,C0012582
copd severity gold stage,C0205390;C1300072;C1306673
use of other medications no,C1524063
iorii n z $nmbr$,
angiotensin converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021;C0034787;C1622222
iii n z $nmbr$,C0439070;C1705160
subgroup overall,C1079230;C1515021;C0282416;C1561607
iv n z $nmbr$,C0022326;C4265176
total no $nmbr$,C0439175;C0439810
bronchodilator response ml,C0439526;C1705224;C3887665
vorapaxar placebo $nmbr$ yr,C0032042;C0439234;C1696465;C1706408
asia n $nmbr$,C0003980
hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C2985465;C0596019
eastern europe n $nmbr$,C0015177
qualifying atherosclerosis,C1514624;C0003850;C0004153
latin america n $nmbr$,C0023122
thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
western europe n $nmbr$,C0043129
egfr mumin $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
higher target group n $nmbr$,C0441848
europe i,C0021966;C0221138
lower target group n $nmbr$,C0441848
europe ii,C1710602;C4082587
blood pressure at entry mm hg,C0005823;C1271104;C1272641
australia nz,C0004340;C0027978
ischaemic heart disease,C0010054;C0151744
vorapaxar,C2974521
previous clinical stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
estimated glomerular filtration,C0750572;C0232809
current tobacco smoker,C3173209;C3241966
sample size n by treatment,C0242618
ischaemic stroke,C0948008
american indian alaskan native n,C0886378
number of antihypertensive medications at study entry,C1718138;C0557651;C1705654;C2603343
asian pacific islander n,C0078988;C0242191
mean number of antihypertensive medications at $nmbr$ year,C0444504;C1718138;C2347634;C2348143;C0439234;C0439508
other n,C0369718;C0441922
types of antihypertensive medications at $nmbr$ year,C0457591;C0439234;C0439508
on antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ace inhibitor arb,C0003015;C3888198;C4541021
blood pressure at baseline,C0005823;C1271104;C1272641
mean number of antihypertensive medication at last visit,C0444504;C0237753;C0449788;C2347634;C2348143;C0545082;C1512346;C2826704
all participants mm hg sbp mean sd,C0439475;C2699239
types of antihypertensive medications at last visit,C0457591;C0545082;C1512346;C2826704
dbp mean sd,C0444504;C2699239;C2347634;C2348143
statins used during follow up,C0360714;C1273517;C0589120;C1522577;C1704685;C3274571
treated at baseline mm hg sbp mean sd,C1522326;C0439475
number of events annualised rate [ ],C4330837
untreated at baseline mm hg sbp mean sd,C0332155;C0439475
age p $nmbr$ $nmbr$,C0001779
current cigarette smoker n,C3173209;C3241966
sex p $nmbr$ $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
type $nmbr$ diabetes n,C1320657
history of diabetes p $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hdl c $nmbr$ mg dl n,C3715113;C0439269
non diabetic n $nmbr$,C1518422;C0241863
lvh by electrocardiogram n,C0149721;C0013798;C1547122;C1623258
diabetes n $nmbr$,C0011847;C0011849
fasting glucose mean sd mg dl,C0015663;C0439269
race p $nmbr$ $nmbr$,C0034510;C1706779;C3853635
total cholesterol mean sd mg dl,C0201950;C0439269;C0543421
other mixed n $nmbr$,C0205430;C3160715
fasting triglycerides mean sd mg dl,C0015663;C0041004;C0439269
region of residence p $nmbr$ $nmbr$,C0017446;C0205147
nos $nmbr$ $nmbr$ c t n,C0326287;C1518425
spain n $nmbr$,C0037747
cc,C0008318;C3538933
baseline sbp p $nmbr$ $nmbr$,C0168634;C0085805;C1442488
ct,C0007673;C3540513;C3813556;C3888140
normotensive n $nmbr$,C2712122
tt,C1452561;C4554543
sbp median n $nmbr$,C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
nos $nmbr$ $nmbr$ a g n,C0326287;C1518425;C0439267
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
aa,C0282379;C1235746;C1882141;C4554792
ala carriers,C0523459;C0007294;C3888236
ag,C0002037;C0051080;C0152305;C3888235
pro pro homozygotes,C1120626;C0019904
gg,C0017454;C0018370
sex male n,C0086582
nos $nmbr$ glu $nmbr$ asp g t n,C0326287;C0125690;C1518425
mmol mol,C3829066
gt,C1435727;C1704693;C2697657
map mmhg,C0024779;C0439475;C1706473;C4050322
number of events event per $nmbr$ person years,C4330837;C0027361;C0439234;C2347489
uae p g min,C1519789;C0560021
rates,C0871208;C1521828
acei vs non acei,C1518422
genotype specific treatment effect hazard ratio $nmbr$ ci,C0008107;C3259781
renal events,C0441471;C3541888
genotype by treatment interaction p values,C0017431;C1709380
cvd events,C0441471;C3541888
outcome variant,C1274040;C0205419
composite events,C0441471;C3541888
genotype,C0017431
golimumab,C2353893
aml,C0023465;C0023467
$nmbr$ $nmbr$ mga n $nmbr$,C0065879
lis,C2247545
uc disease duration y,C0872146
chl,C0019829
limited to left side of colon,C0439801;C2674459;C3542948;C4050251
aml vs lis,C0023465;C0023467;C2247545
mayo score $nmbr$ $nmbr$,C0449820;C4050231
aml vs chl,C0023465;C0023467;C0019829
endoscopy subscore n,C0014245
chd primary outcome,C0205225;C1274040;C0439612;C0439631
moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ c t,
severe disease,C1836348
ct tt,C1452561;C4554543
crp mg l n,C3890735;C0439268;C4048285
$nmbr$ a g,C0439267
patients receiving any uc medication n,C0030705;C1514756;C0013227;C3244316;C4284232
ag gg,C0017454;C0018370
corticosteroids excluding budesonide,C0001617;C3539185;C3540725;C3540726;C3540727
glu $nmbr$ asp g t,C0125690;C0439267
$nmbr$ mg d peq,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gt tt,C1452561;C4554543
immunomodulatory drugs,C0013227;C3687832
end stage renal disease,C0022661;C2316810
$nmbr$ mercaptopurine azathioprine,C0000618;C0004482
normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C1739039;C3811844;C3812682
golimumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mild reduction in egfr,C0301630;C0392756;C1293152;C4551656
baseline corticosteroid use,C0168634;C0239126;C1442488
moderate severe reduction in egfr,C0301630;C0392756;C1293152;C4551656
ne ne,C0027608;C0028219;C3538705
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
normonatremic $nmbr$ meq l at baseline,C0439375;C0168634;C1442488
$nmbr$ $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
hyponatremic,C0857122
sample size,C0242618
p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo,C1709380;C1176308;C0857122;C0032042;C1696465;C1706408
sbp mmghg mean sd,C0085805;C2699239
placebo n $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
dbp mmghg mean sd,C0444504;C2699239;C2347634;C2348143
placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
follow up in trial at $nmbr$ yr,C0589120;C1522577;C1704685;C3274571;C0150312;C0008976;C0332285;C1707101
age y sd,C0001779;C2699239
sample sizea,C0370003;C2347026
systolic blood pressure mm hg sd,C0488055;C2699239;C0871470;C1306620
taking statins n a,C0360714
mean sd d,C0444504;C2699239;C2347634;C2348143
diastolic blood pressure mm hg sd,C0428883;C2699239;C1305849
total number of events participants,C4330837
heart rate sd,C0018810;C2699239
$nmbr$ yr rate $nmbr$ participants,C0439234;C0679646
history of htn,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
a compared wi,C0043193;C1520135
intravenous vasoactive drugs y,C0683092;C1980011
th c,C0039725;C0039738;C1420718;C4282123;C4285344
nesiritide z,C0054015
l compared wit,C0439394;C0043197;C1706495;C3642217
edema z,C0013604;C1717255
hc,C0020268;C0262499;C1413512
jvd $nmbr$ cm h $nmbr$ o,C0425687;C0455483
chd total,C0439175;C0439810
duration of hf y,C0449238;C2926735
cvd total,C0439175;C0439810
prior hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
stroke total,C0439175;C0439810
nyha iv,C0022326;C4265176
hf total,C0439175;C0439810
blood urea nitrogen mg dl,C0005845;C0439269;C0600137
a compared w,C1707455
non asian n $nmbr$ $nmbr$,C1518422;C0078988
l compared wi,C0043193;C1520135
$nmbr$ n weight kg,C0022718;C0439209;C4054209
option,C1518601;C1550456
type of atrial fibrillation,C0332307;C1547052
ambition,C0870128
paroxysmal n,C0205311
radiate,C0332301
persistent n,C0205322;C0332996
toward,
permanent n,C0205355
lithe,
all trials,C0008976
$nmbr$ n chads $nmbr$ score,C0449820;C4050231
patient population,C0032659;C1257890
previous stroke yes n previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
mtx ir,C0022065;C0022071;C1448132
heat failure,C0231174;C0680095
mtx naive or free,C0025677;C1417487;C0332296;C1880497;C1996904
diabetes mellitus yes n hypertension,C0020538;C1963138
anti tnf ir,C0022065;C0022071;C1448132
medication in use at the baseline,C0013227;C3244316;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
dmard ir,C0022065;C0022071;C1448132
arb n,C3888198
dmard ir anti tnf ir,C0022065;C0022071;C1448132
ace i n,C0021966;C0221138
$nmbr$ tcz mtx,C0025677;C1417487
blocker n,
$nmbr$ tcz,
verapamil n,C0042523
mtx,C0025677;C1417487
proton pump inhibitor n,C0358591;C3536754;C4521480
$nmbr$ tcz mtx mtx,C0025677;C1417487
h $nmbr$ blocker n long term vka therapy,C0039798;C0087111;C1363945
total n,C0439175;C0439810
experience n,C0237607;C0596545
tcz mtx n,C0025677;C1417487
non asian,C1518422;C0078988
$nmbr$ mono,C1551432;C1551969
event number,C0237753;C0449788
mtx n,C0025677;C1417487
tcz $nmbr$ mg kg n $nmbr$,C0439272
white tcz mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
positive hla b $nmbr$ status n,C1426226
white mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
as duration y mean sd,C0444504;C2699239;C2347634;C2348143
age mean s e,C0444504;C2347634;C2348143
swollen joints $nmbr$ n,C0152031
height cm mean s e,C0444504;C2347634;C2348143
basdai score mean sd,C0444504;C2699239;C2347634;C2348143
weight kg mean s e,C0444504;C2347634;C2348143
crp mg dl mean sd,C0439269;C2699239
ra duration years mean s e,C0444504;C2347634;C2348143
crp mg dl median,C0549183;C0876920;C2347635;C2348144;C2939193
rf positive,C0439178;C1446409;C1514241;C2825490;C3812269
rvalue for interaction,C1704675
baseline das $nmbr$ mean s e,C0444504;C2347634;C2348143
favors dabigatran,C0309049;C2348066
baseline haq mean s e,C0444504;C2347634;C2348143
no heart failure,C0018801;C0018802;C4554158
baseline sjc mean s e,C0444504;C2347634;C2348143
prior stroke tia,C0007787;C0917805;C1054154
baseline tjc mean s e,C0444504;C2347634;C2348143
no prior stroke tia,C0007787;C0917805;C1054154
shared epitope a positive,C0237876;C0003316;C1522138;C0439178;C1446409;C1514241;C2825490;C3812269
chadsa,
high dose arb n $nmbr$,C0444956;C3888198
chadsj $nmbr$,
arb ccb n $nmbr$,C3888198;C0006684
cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$,C1420648;C3714751
$nmbr$ $nmbr$ y n,
chajdsa vasc $nmbr$ $nmbr$,
chajdsj vasc $nmbr$,
body height cm,C0005890;C0487985
has bledo,C1019275
bmi $nmbr$ n,C0578022
has bled $nmbr$ $nmbr$,C0019080
egfr $nmbr$ n,C1739039;C3811844;C3812682
has bled $nmbr$,C0019080
serum values,C0229671;C0042295;C1546774;C1550100
sbp $nmbr$ mm hg,C0085805;C0439475
potassium mmol l,C0032821;C1532563;C0202194;C0304475;C0597277;C3714637
crcl,C1846718
casual plasma glucose mg dl,C0202042;C0439269;C0455280
crcl $nmbr$ ml min,C1846718;C0439445
current alcohol n,C0001962;C0001975
history of cad mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
drug therapy n,C0013216;C0013217
no cad mi,C1504769;C3810814;C2239547;C3813548;C4284121
previous antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
chadsj,
insulin treatment,C0745343
chajdsrvasc $nmbr$ $nmbr$,
arb angiotensin ii receptor blocker ccb,C0521942;C0006684;C3536793
chajdsj vasc $nmbr$ $nmbr$,
calcium channel blocker bmi body,C0242821;C0460148;C1268086;C4082212
sbp $nmbr$ mmhg,C0085805;C0439475
mass index,C0600653;C0918012;C1552854;C1637833;C2986546
nocad mi,C3810814
$nmbr$ e h,C0033727;C0369286;C0441932;C0564385;C4528284
bp blood pressure egfr estimated glomerular filtration rate men $nmbr$ en $nmbr$ x cr $nmbr$ $nmbr$ x age $nmbr$ $nmbr$ x $nmbr$ $nmbr$ hdl high density lipoprotein,C1363845
chads $nmbr$ $nmbr$,C0007928;C1413373
x cr $nmbr$ $nmbr$ x age,C0201975;C0001779;C3539604;C3711669;C4084730;C4553336;C4553337
chad $nmbr$ $nmbr$,C0007928;C1413373
$nmbr$ wom,
cha $nmbr$ ds $nmbr$ vasc $nmbr$,C1420648;C3714751
data are mean standard deviation for continuous variables and number for categoric variables p,C1511726;C3245479;C3714741;C0871420;C0237753;C0449788
sbp $nmbr$ mnn hg,C0025424;C0428257;C2347108;C2347109;C2348272
values were calculated using t tests for continuous variables and chi square,C0042295;C0444686;C1441506;C1524063;C0871472;C0439828;C1552646
intensified n $nmbr$,
tests for categoric,C0022885;C0392366
history of nicotine use,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
crohn s disease,C0010346;C0012634
history of alcohol use,C0551571;C0552479
ulcerative colitis,C0009324
chronic obstructive lung disease,C0024117
abatacept $nmbr$ $nmbr$ mg kg n $nmbr$,C1619966;C0439272
retinopathy stage $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0205390;C1300072;C1306673
abatacept $nmbr$ mg kg n $nmbr$,C1619966;C0439272
peripheral artery occlusive disease,C1306889
mean disease duration y sd,C0872146;C2699239
peripheral artery occlusive disease stage $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0699749
inadequate response intolerance to prior therapy,C0231199;C1744706;C2355652
cerebral vascular disease,C0007820
oral aminosalicylates,C0442027;C0368663;C4521986
peripheral neuropathy,C0031117
anti tnf agent s,C0450442;C1254351;C1521826
control baseline n $nmbr$,C0243148;C0168634;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
mean hscrp mg l sd,C0439268;C2699239
intensified baseline n $nmbr$,C0168634;C1442488
prednisone use,C0042153;C0457083;C1947944
control $nmbr$ months n $nmbr$,C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
mean mayo score sd,C3533236;C2699239
intensified $nmbr$ months n $nmbr$,C0439231
left sided disease only,C0205091;C0012634;C0443246
blood pressure systolic mm hg,C0005823;C0439475;C1271104;C1272641
extensive disease other,C0849867
ras antagonist,C0034678;C0231491;C0525678
supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period,C2986480;C0237629;C0205263;C0439531;C1948053;C0857127
ras target dose,C0178602;C0869039;C1114758
non hispanic latino,C1518424;C0086528
beta blocker target dose,C0178602;C0869039;C1114758
baseline data,C1511726;C3245479;C3714741
oral antidiabetic drugs,C0029167;C0175795;C0304289
gender m f,C0079399;C1522384;C0016327
normal cognitive,C0205307;C0231683;C0439166;C2347086;C4553972;C1516691
at c data,C1511726;C3245479;C3714741
impaired cognitive,C0221099;C1516691
final a $nmbr$ c,C0205088;C1546485;C3853528
status spmsq,C0449438
at c change,C0392747;C0443172;C1705241;C4319952
status spmsq $nmbr$,C0449438
$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
female gender,C0086287
fpg data,C1511726;C3245479;C3714741
treatment arm zoledronate,C1522541;C0392938
final mg dl,C0205088;C0439269;C1546485;C3853528
bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
fpg change mg dl,C0392747;C0439269;C0443172;C1705241;C4319952
total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0019552;C2699239;C0022122;C1505163;C3538851;C4284725
withdrawals n n,C1710677;C2349954;C2825032;C3812880;C4049634
voluntary,C0439656;C3543419
femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0015815;C2699239
noncompliant,C0457432
fn t score,C0449820;C4050231
all noncompleters,
op concomitant medications,C0013227;C0802604;C2598133;C4284232
indacaterol tiotropium n[ $nmbr$,C1722260;C0213771
charlson index,C0600653;C0918012;C1552854;C1637833;C2986546
tiotropium placebo n[ $nmbr$,C0213771;C0032042;C1696465;C1706408
normal cognitive function spmsq,C4296962
tiotropium placeb n[ $nmbr$,C0213771
impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest,C0009240;C0679646;C0392335;C4050130
sex men women,C0009253;C0043210;C0036864;C0079399;C0804628;C1314687;C1522384
chi square p value,C1552646;C1709380
e,
clinical fracture,C0205210;C0016658
duration of copd years mean sd,C0449238;C2926735
zoledronic acid arm,C0446516;C3715044;C4553528
severity of copd n,C0439793;C0522510
placebo arm,C0446516;C3715044;C4553528
moderatey,
sita $nmbr$,
pack years mean sd,C1277691;C2699239
pio $nmbr$,C0030800;C2347712
fev $nmbr$ predicted post salbutamol,C0681842;C0001927;C1882327
sita $nmbr$ pio $nmbr$,C0030800;C2347712
fev $nmbr$ fvc post salbutamol,C3714541;C0001927
american indian or native alaskan,C0002460;C0682125
fev $nmbr$ litres pre salbutamol mean sd,C0001927;C2699239
ethnicity hispanic or latino,C0015031;C0086409;C0243103;C0086528
fev $nmbr$ litres post salbutamol mean sd,C0001927;C2699239
a $nmbr$ c distribution,C0520511;C1704711
fev $nmbr$ reversibilityz pre post salbutamol,C0332152;C0001927;C0740175;C2257086;C3669034
$nmbr$ $nmbr$ and $nmbr$ $nmbr$,
fev $nmbr$ litres pre ipratropium mean sd,C0027235;C2699239
known duration of type $nmbr$ diabetes years,C0449238;C2926735
fev $nmbr$ litres post ipratropium mean sd,C0027235;C2699239
received an oral aha within $nmbr$ weeks prior to screening,C1514756;C0050451;C0772110;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
fev $nmbr$ reversibilityz pre post ipratropium,C0332152;C0027235;C0740175;C2257086;C3669034
sita pio $nmbr$ $nmbr$,C0030800;C2347712
fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
a $nmbr$ c at baseline,C0168634;C1442488
trough fev $nmbr$,C0444506;C3714541
a $nmbr$ c at baseline $nmbr$ $nmbr$,C0168634;C1442488
copd severity,C0439793;C0522510
empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ ml $nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0439526;C1705224;C3887665;C0369718;C0441922
o total randomized,C0439175;C0439810;C0034656;C3815594
ics use,C0042153;C0457083;C1947944
pen label empagliflozin $nmbr$ mg baseline hba $nmbr$ c $nmbr$,C0024671;C0019016;C1825777;C3538758;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ics non users,C1518422;C1706077
time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
ics users,C0815320;C1706077;C4551720
$nmbr$ year,C0439234;C0439508
nonmetabolic syndrome n $nmbr$,C0039082
mdg mmol l,C0024443;C1532563;C1417239;C2986643
fpg mmol l mg dl,C1532980
egfr ml min $nmbr$ $nmbr$ m $nmbr$ [mdrdequation],C1739039;C0439445;C3811844;C3812682
tg mmol l [mg dl],C0337445;C1532563;C0439269
patients with egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0030705;C0439445
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
change from baseline in hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0019016;C1825777;C3538758
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
difference vs placebo,C1705241;C1705242;C0032042;C1696465;C1706408
diet diet pravastatin,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
patients with egfr $nmbr$ $nmbr$ to $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0030705;C1739039;C3811844;C3812682;C0439445
event patients $nmbr$ pt y,C0030705;C0032743;C0699718
vedolizumab,C2742797
non metsyn,C1518422
cohort $nmbr$ n $nmbr$ f,C0009247;C0016327;C0599755
metsyn,
cohort $nmbr$ n $nmbr$,C0009247;C0599755
metsyn with ldl $nmbr$ $nmbr$ mg dl,C0439269
white race no,C0007457;C0043157
patients with ra as or psa n $nmbr$,C0030705;C3538806;C4048756;C3810537;C3813209
mayo clinic score,C0449820;C4050231
patients without ra as or psa n $nmbr$ $nmbr$,C0030705;C3538806;C4048756;C3810537;C3813209
partial mayo clinic scored,C0002424;C0442592;C0449820
no of patients with ra,C0030705;C3538806;C4048756
ibdq score,C0449820;C4050231
no of patients with as,C0030705
fecal calprotectin pg g,C0015733;C1638318
no of patients with psa,C0030705;C3810537;C3813209
site of disease no,C2945843;C0012634
history of cardiovascular events,C1880008
rectum and sigmoid colon only,C0034896;C0227391
angina pectorisf,C0002962
left side of colon,C0227388
prerandomization statin therapy,C1278454
proximal to the splenic flexure,C0205107;C4489236
concomitant therapy,C1707479
all of the colon,C0009368;C3888384
ace inhibitors or angiotensin ii blockers,C0003015;C0003009;C1366631;C3714928
concomitant medications for ulcerative colitis no,C0013227;C0802604;C2598133;C4284232
atorvastatin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
immunosuppressants onlyff,C0021081
simvastatin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778;C0021081
total cholesterohhdl cholesterol ratio,C0456603;C1547037
no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778;C0021081
ldl cholesterohhdl cholesterol ratio,C0456603;C1547037
prednisone equivalent dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apo b apo a i ratio,C0456603;C1547037
prior anti tnf therapy no,C1514463
no men,C0025266
prior failure of anti tnf therapy no,C0231174;C0680095;C0279936
no women,C0043210
$nmbr$ failure,C0231174;C0680095
known duration,C0449238;C2926735
inadequate response,C0871261;C1704632;C1706817;C2911692
of t $nmbr$ dm years,C0011816;C0439234;C3250443
loss of response,C1517945;C0871261;C1704632;C1706817;C2911692
hba $nmbr$ c range,C1514721;C2348147;C3542016
unacceptable adverse events,C0877248;C1705413
hba $nmbr$ c distribution at baseline,C0520511;C1704711
hemoglobin concentration g liter,C1319312;C0475211
$nmbr$ h pmg mmol l,C2827804
white cell count x $nmbr$ _ $nmbr$ liter,C0023508;C0475211;C0427512
metformin dose,C0178602;C0869039;C1114758
estimated difference,C1705241;C1705242
figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index,C1705241;C1705242;C0168634;C1442488;C3875154;C0023668;C0205132;C0700221;C1550648;C1552960;C0369718;C0042295;C0441922;C2360800;C0032042;C1305855;C1696465;C1706408
duration of ulcerative colitis,C0449238;C2926735
insulin glargine,C0907402
$nmbr$ to $nmbr$ y,
standard care,C1442989;C1947933;C2828392
pancolitis,C0868908
prior cardiovascular event no j,C0332152;C1320716;C2826257
baseline composite mayo clinic score,C4055211;C0002424;C0442592
prior stroke no,C0038454;C4554100
baseline fecal calprotectin,C0015733;C0950624;C1335798;C1366582
any albuminuria no,C0001925
$nmbr$ mcg g,C0439272
ankle brachial index,C1328319;C3888326
prior treatment history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
glycemic characteristics,C1521970
any prior anti tnf treatment failure,C1514463
prior diabetes,C0011847;C0011849
prior immunnosupressive failure but no anti tnf failure,C0332152;C0231174;C0680095;C2826257
use oforal glucose lowering agent no,C0042153;C0017725;C0457083;C1947944;C0441994;C2003888;C0450442;C1254351;C1521826
prior corticosteroid failure only,C0231174;C0680095
no use ofdiabetes drugs no,C0240320
stratification variables,C1514983;C0439828
new diabetes no,C0011847;C0011849
concomitant corticosteroid use,C0521115;C0239126
impaired glucose tolerance or impaired fasting glucose no,C0271650;C1272092
no concomitant cortcosteroid use,C0042153;C0457083;C1947944
duration ofdiabetes yr,C0449238;C0439234;C2926735
concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
glycemic drugs,C0013227;C3687832
no concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
sulfonylurea no,C0038766;C3536898
patients with deep vein thrombosis only,C0030705;C0149871
nonglycemic cardiovascular risk factors systolic blood pressure mmhg,C0232104;C0439475
patients with pulmonary embolism,C0030705;C0034065
body mass index waist to hip ratio,C0205682;C1264679
edoxaban n $nmbr$,C2975435
creatinine clearance $nmbr$ to,C0812399
hdl cholesterol mg dl triglycerides mg dl,C3539687
patients receiving $nmbr$ mg of edoxaban at randomization no f,C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0034656;C0016327
creatinine mg dl urinary albumin to creatinine ratio,C2362049;C0456603;C1547037
other drugs no,C0013227;C3687832
anatomical extent of qualifying event no t,C0220784;C0439792;C1514624;C0441471;C4019010;C2603360
not assessable,C1883425
thiazide diuretic,C0012802;C3536861
concomitant dvt no baseline nt probnp no,C0149871;C2926618;C3899446;C0669479;C0754710
other blood pressure drug,C0003364
patients with measurement,C0030705;C0242485
antiplatelet drug,C0085826
patients with level $nmbr$ pg ml,C0030705;C0439297
insulin glargine n $nmbr$ py,C0030428;C3538810
standard care n $nmbr$ py,C0030428;C3538810
right ventricular dysfunction no total no,C0242707;C1556315;C0439175;C0439810
placebo allocation,C0032042;C1706778;C1696465;C1706408
causes of dvt or pe no ^,C0015127;C1314792;C0070939;C1880476;C4284304
omega $nmbr$ allocation,C1719844;C1706778
temporary risk factor,C0205374;C0035648;C1548539;C3245481
a $nmbr$ $nmbr$ $nmbr$ median,C0549183;C0876920;C2347635;C2348144;C2939193
edoxaban,C2975435
no prior cv event,C0441471;C4019010
presenting diagnosis,C0449450;C0011900;C1704338;C1704656
prior cv event,C0441471;C4019010
pe with without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
no metformin,C0025598
gendar,
no statin use,C0042153;C0457083;C1947944
baseline risk factors,C0035648;C1553898
no ace i arb,C0021966;C3888198;C0221138
temporary factors,C1521761;C2827422
ace i arb,C0021966;C3888198;C0221138
all others,C1955473;C3539125
ifg igt,C1334085;C1708411
need for $nmbr$ mg edoxaban dose at randomization,C4086581;C2975435;C0034656
new dm,C0011816;C3250443
body weight at randomization ixrs,C0005910;C1305866
prior dm,C0011816;C3250443
$nmbr$ is $nmbr$ $nmbr$,
dabigatran $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body weight at randomization,C0005910;C1305866
prior oac,C0332152;C2826257
creatinine clearance at randomization,C0812399;C0034656
crcl sd ml min,C1846718;C0439445
fragile,
prior history of bleeding on oac,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fl $nmbr$ b,C1300812;C1708024
pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703;C0021122
southern europe,C0037724
dental procedure,C0011331
nordic,C0331873
other diagnostic procedure,C0430022;C1546908
china japan,C0008115;C0022341
cataract removal,C0007389
south africa south america,C0037713
colonoscopy,C0009378;C1548837
usa canada,C0041703;C0006823
total hip or knee replacement,C0019552;C0022122;C1505163;C3538851;C4284725;C0086511
$nmbr$ t $nmbr$ $nmbr$,C2603360
cystoscopic procedure,C0184661;C2700391;C3274430;C3539779
american indian or,C0002460
inguinal hernia repair,C0021446
native hawaiian or,C0337920
laparoscopic cholecystectomy,C0162522
other pacific islander,C0242191
cabg or valve,C0010055;C0184252;C1186983;C1704414;C3888056
medical history cancer,C0006826;C0998265;C1306459
colectomy partial or total,C0728938;C1550516;C0439175;C0439810
no history of cancer,C0455471
peripheral angioplasty,C0162577;C1548817
active cancer at randomisation,C0006826;C0998265;C1306459
prostate biopsy,C0194804
center level inr percent timein therapeutic range for warfarin subjects,C0460097;C0043031
carotid endarterectomy,C0014099
initial heparin treatment duration on or after randomization,C0444921;C3259042;C0034656
limb amputation,C0002689
initial heparin treatment duration,C0444921;C3259042
d $nmbr$ n n,C0369718;C0441922
median $nmbr$ days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
warfarin n n,C0043031
initial type of heparin treatment received,C0019134;C0455708;C0770546;C1514756
d $nmbr$ vs warfarin rr $nmbr$ ci p value,C0008107;C1709380;C3259781
concomitant aspirin use,C0042153;C0457083;C1947944
urgent surgery,C2188405
n t,C0369718;C0441922
elective surgery,C0206058
need for $nmbr$ ng edoxaban dose at randomization,C0017887;C0028074;C0034656
major surgery,C0679637
body weight at randonization ixrs,C0005910;C1305866
minor surgery,C0038904
creatinine clearance at randomization ixrs,C0812399;C0034656
original dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
$nmbr$ $nmbr$ ml rain,C0439526;C0034640;C1705224;C3887665
amended dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
ho,C0019905;C1832110;C3889614
disease duration b $nmbr$ years n $nmbr$,C0872146;C0439234
hordic,
disease duration $nmbr$ to b $nmbr$ years n $nmbr$,C0872146;C0439234
china tjapan,C0008115
disease duration $nmbr$ years n $nmbr$,C0872146;C0439234
fl $nmbr$ $nmbr$,C1300812;C1708024
age yrs mean,C0444504;C2347634;C2348143
active cancer at randomization,C0006826;C0998265;C1306459
$nmbr$ $nmbr$ n,C0369718;C0441922
ho active cancer,C0006826;C0998265;C1306459
baseline cdai,C0683448;C1413248;C3273706
center level ihr percent time in therapeutic range for warfarin subjects,C1554109;C0681850;C1550501;C1706203;C2349001;C2697811
baseline ibdq total score mean,C0444504;C2347634;C2348143
ib $nmbr$ $nmbr$,C2744579;C3890035;C4283819
fistula at baseline n,C0016169;C0168634;C1442488
saxagliptin n $nmbr$,C1611934
prior,C0332152;C2826257
hispanic ethnic group no i,C0015031;C1879937;C0021966;C0221138
figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test,C0205210;C0544452;C0687702;C0332174;C0872146;C0439230;C0042295;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
weight^,C0005910;C0043100;C1305866;C1705104
general anaesthesia,C0002915;C2930406
$nmbr$ kg no,C0022718;C0439209;C4054209
neuraxial anaesthesia,C0002903;C0002912;C0002930;C4049933
duration of diabetes yr^,C0449238;C2926735
combination,C0205195;C1947911;C3811910
established atherosclerotic disease no,C0333482;C0012634
minimum,C1524031;C1552614;C2826545
dyslipidemia no,C0242339
maximum,C0806909;C1552615;C2826546
prior heart failure no,C0018801;C0018802;C4554158
smoker or ex smoker n,C0337664;C0337671;C4555205
prior coronary revascularization no,C0332152;C0877341;C2826257
$nmbr$ years or,C0439234
mean ml min,C0444504;C0439445;C2347634;C2348143
albumin to creatinine ratio i,C0021966;C0221138
figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events,C1707455;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1571583;C0205449;C1274040;C0680240;C1305863;C1861172;C0630906;C0026565;C0019080;C0026566
$nmbr$ yr km rate,C0871208;C1521828
data are presented as the odds ratio with $nmbr$ confidence intervals,C1511726;C3245479;C3714741;C0449450;C0028873;C0009667
saxagliptin,C1611934
telmisartan n $nmbr$,C0248719
atherosclerosis,C0003850;C0004153
mri substudy n $nmbr$,C0024485;C1824234;C3890166
established,C0443211;C1272684
sex male no,C0086582
multiple risk factors,C0035648;C1553898
hypertension treated,C0020538;C1963138;C1522326
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
clinical details,C0205210;C1522508
baseline glycated hemoglobin,C0168634;C0017853;C1442488
baseline nihss score median range,C1514721;C2348147;C3542016
baseline insulin,C0021641;C1533581;C1579433;C3714501
regular alcohol consumption per week no,C0205272;C0001948
baseline sulfonylurea,C0038766;C3536898
$nmbr$ drinks,C0452428
baseline metformin,C0168634;C0025598;C1442488
$nmbr$ $nmbr$ drinks,C0452428
baseline thiazolidinedione,C0289779;C1257987;C3537039
some,
baseline microalbumin,C0201838;C2362049
intense,C0522510
creatinine ratio,C0456603;C1547037
toast classification of qualifying stroke no,C1710306;C4521230;C1514624;C0038454;C4554100
_ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
other determined etiology,C0015127;C1314792;C1524003
p vaiue interaction,C0369773;C1704675;C2603361
undetermined etiology,C0478157
saxagiiptin,
antihypertensive medication open label no,C0003364;C1709323
piacebo,
alpha receptor antagonist,C0439095;C4543207;C2003941;C2350010
$nmbr$ $nmbr$ to $nmbr$ i iot,C0021966;C0006196;C0221138
beta receptor antagonist,C0330390;C4543207;C0439096;C2004068
prior hypertension,C0020538;C1963138
telmisartan group n $nmbr$,C0248719;C0441848
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
wml load at baseline mri,C1550025;C1704782;C1708715
baseline aspirin,C0168634;C0004057;C1442488
total periventricular wml score mean sd,C2964552;C2699239
baseline statin,C0168634;C0360714;C1442488
subcortical wml load diameter mm mean sd,C0552409;C2699239
baseline acei arb,C0168634;C3888198;C1442488
wml load at follow up mri,C1550025;C1704782;C1708715
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$ t,C2603360
baseline ccb,C0168634;C0006684;C1442488
wml load at follow up mri stratified by baseline severity of wml load,C1550025;C1704782;C1708715;C0205363;C0168634;C1442488
baseline diuretic,C0168634;C0012798;C1442488
percent of patients,C0439165;C0030705
alogliptin n $nmbr$,C1958126
mild to moderate,C1299392
race or ethnic group no t,C0034510;C1706779;C3853635;C0015031;C1879937;C2603360
t $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C2603360;C0439275
region of world no,C0017446;C0205147
no patients,C0030705
united states and canada,C0041703;C0006823
hr b p m,
sbp dbp mmhg,C0085805;C0439475
western europe australia new zealand and middle east,C0027978;C0324547;C0026068
ischaemic aetiology,C0015127;C1314792;C1524003
central and south america and mexico,C0205099;C1879652;C0037713;C0025885
nyha classes iii iv,C0278962
eastern europe and africa,C0015177;C0001737
laboratory values,C0022877;C0042295;C3244292;C4283904
asia and pacific islands,C0003980;C0030168
co morbidities,C0009488
cardiovascular risk factors and history no,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
atrial fibrillation flutter,C0155709
estimated glomerular filtration rate^,C3811844
pharmacological therapy for hf,C0039798;C0087111;C1363945
median ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
aceis,
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ no,C0439445
aldosterone receptor antagonists,C1579268
index acs no,C0742343;C4318612
biomarkers at baseline,C0005516;C0168634;C1442488
unstable angina requiring hospitalization,C0002965;C0019993
ptx $nmbr$ ng ml,C0030899;C0439275
time between index acs and randomization days,C0040223;C3541383;C0034656;C0439228
all cause mortality per $nmbr$ person years,C0015127;C0026565;C0026566;C1524003
alogliptin,C1958126
cardiovascular mortality per $nmbr$ person years,C0026565;C0026566
hazard,C0598697
with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr,C0683150;C0683325;C1547282;C0086045;C1446561;C3827302;C1527178;C1705938;C0750572;C1739039;C3811844;C3812682
overall treatment effect,C0282416;C1518681;C1561607
groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C1707455;C1708930;C2360800;C0683312;C3889287;C1444656;C1707156;C3274014;C3541345
ratio,C0456603;C1547037
serum k level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261;C0150270;C3469597
history of ml before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
baseline $nmbr$ $nmbr$ meq l eos $nmbr$ $nmbr$ meq l,C0168634;C0439375;C1442488
history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0010055;C0441471;C4019010
baseline $nmbr$ $nmbr$ meq l eos,C1623465;C1861303
history of chf before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
baseline $nmbr$ $nmbr$ or,C0168634;C1442488
baseline bmi,C0168634;C0578022;C1442488
val hctz n $nmbr$,C0042285;C0020261;C0523975
$nmbr$ and $nmbr$ years,C0439234
aml hctz n $nmbr$,C0023465;C0020261;C0023467
baseline glycemic control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
$nmbr$ y no,
hba $nmbr$ c $nmbr$ level,C0441889;C0456079;C1547707;C2946261
diabetes status no,C1317301
insulin use at baseline,C0240016;C0168634;C1442488
normoglycemic $nmbr$,C0580545
biguanide use at baseline,C0042153;C0457083;C1947944
prediabeticb,
thiazolidinedione use at baseline,C0042153;C0457083;C1947944
diabetic $nmbr$,C0241863
sulfonylurea use at baseline,C0042153;C0457083;C1947944
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
united states canada,C0041703;C0006823
hba $nmbr$ c mean sd,C0019016;C2699239;C1825777;C3538758
mexico central south america,C0007674
baseline serum k meq l,C0302353;C0439375
western europe australia new zealand middle east,C0043128;C0026068
eos serum k meq l,C0302353;C0439375
eastern europe africa,C0001741
figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0376674;C0017725;C0021641;C1533581;C1579433;C3714501;C0870536;C1275991;C2827788;C0168634;C1442488;C0444930;C0557651;C2603343;C2746065;C0030705;C0439375;C0597277;C1708601;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
renal function,C0232804
normalfunction or mild impairment,C0221099;C0684336
figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0392747;C0443172;C1705241;C4319952;C0444930;C2746065;C0202042;C0455280;C0428357;C0376690;C1261415;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0221099;C0684336
teaes,
golimumab $nmbr$ mg kg mtx,C0025677;C1417487
non black n $nmbr$,C0005680;C0027567;C0085756;C0439541
randomised patients n,C0030705
all teaes,
median iq range,C1514721;C2348147;C3542016
mild teaes,C2945599
total vdh s score $nmbr$ $nmbr$ n,C2964552
moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
erosion score $nmbr$ $nmbr$,C0449820;C4050231
severe teaes,C0205082;C4050465;C4050466
jsn score $nmbr$ $nmbr$,C0449820;C4050231
drug related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
crp normal,C0205307;C0231683;C0439166;C2347086;C4553972
discontinuations,C0457454
cdai $nmbr$ $nmbr$,C0683448;C1413248;C3273706
teaes $nmbr$ in any treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
disease activity n,C1292728
dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
low $nmbr$ $nmbr$ and,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
headache,C0018681;C4553197
moderate $nmbr$ and,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
urti,
high $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
nasopharyngitis,C0027441
sdai $nmbr$ $nmbr$,C3871128
peripheral edema,C0085649
haq di $nmbr$ $nmbr$,C3826998;C4321476
fatigue,C0015672;C3463815;C4050243;C4554645
direction of hr,C0449738
muscle spasms,C0037763
right,C0205090;C0444532
nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
centre,C0205099;C3810851
hypokalemia,C0020621;C4553966
causaslan,
uti,C0042029;C0077906;C1412376
left,C0205091;C0443246;C1552822
joint swelling,C0152031
middle,C0444598;C0549183;C1552826
arthralgia,C0003862;C4551938
period i,C0021966;C0221138
diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
e $nmbr$ a $nmbr$,
other teaes,
period ii,C1710602;C4082587
cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hypotension,C0020649;C3163620
northamerica,
orthostatic hypotension,C0020651
bmi x $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
sedbp,
^^^ $nmbr$ $nmbr$,
pre enrollment antihyperglycemic therapy,C1882440;C0020616
sesbp,
insulin based,C0021641;C1533581;C1579433;C3714501;C1527178;C1705938
tofacitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sulfonylurea based,C0038766;C3536898;C1527178;C1705938
duration of rheumatoid arthritis yr,C0449238;C2926735
thiazolidinedione based,C0289779;C1257987;C3537039;C1527178;C1705938
tender and swollen joints mean no,C0234234;C0444504;C2347634;C2348143
chronic kidney disease stage egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1561643;C0439445;C4553188
tender,C0234234
stage $nmbr$ b $nmbr$ and,C0441781
swollen,C0038999
stage $nmbr$ a $nmbr$ and,C0205390;C1300072;C1306673
mean score on haq di,C3533236;C3826998;C4321476
stage $nmbr$ $nmbr$,C0205390;C1300072;C1306673
das $nmbr$ $nmbr$ esr $nmbr$,C0051767;C3811131;C0057671
urinary albumin creatinine ratioa mg g,C0486293;C1300563;C4281686
score of $nmbr$ $nmbr$,C0449820;C4050231
urinary protein creatinine ratioa mg mg,C0369901;C1319635;C0428627
mean score on das $nmbr$ $nmbr$ crp ^,C3533236;C0051767;C0057671
patients with diabetic nephropathy,C0030705;C0011881;C1442864
erythrocyte sedimentation rate mm hr,C1176468;C1619634
difference from placebo,C1705241;C1705242
c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
this study,C0557651;C2603343
positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff,C0741132;C1829901;C4554348
stage $nmbr$ b egfr $nmbr$ and,C1739039;C3811844;C3812682
tnf inhibitor,C1448177;C1999216
stage $nmbr$ a egfr $nmbr$ and,C0205390;C1300072;C1306673;C1739039;C3811844;C3812682
other biologic agent,C0005515
age y median range,C1514721;C2348147;C3542016
weight kg median range,C1514721;C2348147;C3542016
nonbiologic disease modifying drug other than methotrexate,C0392747;C4036059
uc duration y mean range,C1514721;C2348147;C3542016
prior disease modifying drugs resulting in inadequate response mean no patient,C0012634;C0013227;C3687832;C0332294;C0205412;C0439856;C0030705
partial mayo score mean sd,C0444504;C2699239;C2347634;C2348143
tofacitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rheumatoid factor,C0035448;C0201660
crp nmol l median range,C1514721;C2348147;C3542016
anti ccp,C4318437
comorbidites n,
dmard biologic ir,C0022065;C0022071;C1448132
gastroesophageal reflux disease,C0017168;C4553201
europe $nmbr$,C0015176
asthma,C0004096;C2984299
colesevelam n $nmbr$,C0541155
oral corticosteroid,C0442027;C0001617;C3536709;C4521986
country n,C0454664;C1511538
azathioprine $nmbr$ mercaptopurine,C0004482;C0000618
mexico,C0025885
corticosteroid azathioprine $nmbr$ mercaptopurine,C0001617;C0000618;C3536709
colombia,C3245499
corticosteroid or azathioprine $nmbr$ mercaptopurine,C0001617;C3536709;C0004482;C0000618
hba $nmbr$ ca mean sd,C0019016;C1825777;C3538758;C0444504;C2699239;C2347634;C2348143
prior therapy with tnf antagonist n,C1514463
fpg mg dl mean sd,C0439269;C2699239
figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both,C0242492;C4554402;C0557651;C2603343;C0205195;C0947630;C0008107;C3259781;C0026175;C0338297;C0032042;C0031962;C1696465;C1706408;C0030705;C3272598;C1448177;C1456820;C1522669;C0008976;C0205171;C0439044;C0679994
$nmbr$ hour postload glucose,C0439227;C0017725;C0564385
statin n $nmbr$,C0360714
mg dl mean sd,C0439269;C2699239
$nmbr$ $nmbr$ y,
fasting insulin iiiu ml mean sd,C0015663;C0021641;C2699239;C1533581;C1579433;C3714501
nste mi,C3537184;C4255010
$nmbr$ years n $nmbr$,C0439234
active smoking,C0037369;C0453996;C1881674
hispanic n $nmbr$,C0086409
total cholesterol $nmbr$ mg dl,C0201950;C0439269;C0543421
fpg mean sd mg dl,C0444504;C0439269;C2347634;C2348143
ecrcl,
duration of diabetes mean sd y,C0449238;C2926735
egfr ml min m $nmbr$,C1739039;C0439445;C3811844;C3812682
background treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous pci or cabg,C0205156;C4049621;C1552607;C0010055
diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949;C0015259;C1522704
baseline lvef,C0428772;C0488728
sulfonylureaa,
high risk clinical features,C0035648
thiazolidinedioneb,
insulina,
laboratory variables at baseline,C0022877;C0439828;C3244292;C4283904
$nmbr$ to $nmbr$ n $nmbr$,C0369718;C0441922
haemoglobin mg dl,C0019046;C0439269
a from baseline,C0168634;C1442488
ctn i ng ml,C0021966;C0439275;C0221138
weight ab,C0005910;C0043100;C1305866;C1705104
$nmbr$ $nmbr$ z,
total chol mg dl,C0201950;C0439269
ck mb ng ml,C0010290;C0439275
baselinec,
glycemia mg dl,C0005802;C0439269
endpointc,
time intervals h,C0033727;C0369286;C0441932;C0564385;C4528284
endpoint baseline,C0168634;C1442488
randomization to angiography,C0034656;C0002978
weight b,C0005910;C0043100;C1305866;C1705104
randomization to angiography distribution time,C0034656;C0681683
endpoint baselinec,C2349179;C2826544
within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
parameter n,C0549193;C1704769;C2350001
after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
hospital stay days,C0587438
upper respiratory tract infection,C0041912
angiographic data and treatment,C1511726;C3245479;C3714741;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
dyspepsia,C0013395;C4552968
contrast volume ml,C0439526;C1705224;C3887665
decreased appetite,C0232462
contrast volume $nmbr$ ml,C0439526;C1705224;C3887665
hypoglycemia,C0020615;C4553659
additional angiography,C1524062;C0002978
with an sfua,
within $nmbr$ h after first procedure,C0033727;C0369286;C0441932;C0564385;C4528284
without an sfua,
management distribution,C0520511;C1704711
alt u l,C1266129;C0439339;C4553172
pci data,C1511726;C3245479;C3714741
baselineb,
contrast nephropathy risk score,C0035647;C0449820;C4050231;C4552904
from baselineb,
score distribution,C0520511;C1704711
ast u l,C1415181;C0439339;C3891303
medications at coronary angiography,C0013227;C0802604;C2598133;C4284232
upper respiratory tract infection $nmbr$ $nmbr$ $nmbr$,C0041912
gp llb llla inhibitors,C1705010;C0243077;C3811116
a from baselineb,
medications at discharge,C0806915
$nmbr$ year framingham chd risk $nmbr$ mean sd,C1282512;C2699239
events statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
efficacy measures,C0079809;C1879489
events control group,C0441471;C0009932;C3541888
difference in ls mean $nmbr$ $nmbr$ cl,C1705241;C1705242
orc $nmbr$ cl,C1167125;C0596019
without diabetes,C0011847;C0011849
oradj $nmbr$ cl,C0596019
with diabetes,C0011847;C0011849
baseline ecrcl,C0168634;C1442488
low density lipoprotein cholesterol,C0023824
contrast volume,C0449468;C1690016;C1705102;C2700258
aspirin plus placebo n $nmbr$,C0004057;C0032042;C1696465;C1706408
$nmbr$ ml,C0439526;C1705224;C3887665
aspirin plus clopidogrel n $nmbr$,C0004057;C0070166
ci aki risk score,C0035647;C0449820;C4050231;C4552904
male sex race or ethnic group f,C0034510;C1706779;C3853635;C0441840
clopidogrel aspirin n $nmbr$,C0070166;C0004057
black region or country,C0017446;C0205147;C0454664;C1511538
previous coronary angioplasty n,C2114427
spain,C0037747
multivessel disease n,C0012634
mean blood pressure at screening visit mm hg,C0428886;C0488053
clinical indication at the index procedure n,C2315323;C2347896
previous clinical stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
discharge medication n,C0012621;C0013227;C3244316;C4284232;C0030685;C2926602
current tobacco smoker qualifying event,C3173209;C3241966;C1514624;C0441471;C4019010
vessel treated n,C0005847;C1522326
transient ischemic attack type of lacunar syndrome,C0455703
left anterior descending artery n,C0226032
pure motor hemiparesis,C1513492;C0018989;C1705994
left circumflex artery n,C0226037
pure sensory stroke,C0445254;C0038454;C4554100
sensorimotor stroke,C0038454;C4554100
right coronary artery n,C1261316
use of aspirin at time of qualifying event,C1524063;C0004057;C0040223;C3541383;C1514624;C0441471;C4019010
left main coronary artery n,C1261082
use of statin at any follow up visit,C1524063;C0360714;C0589121
graft n,C0181074;C0332835;C1961139
vorapaxar group n $nmbr$,C2974521;C0441848
multivessel intervention n,C0184661;C0886296;C1273869
median age iqr years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
acc aha lesion class b $nmbr$ or c n,C4072694;C0221198;C1546698
white ethnic origin,C0007457;C0015031;C0043157;C0220938
bifurcation n,C0184906;C3146289
time from qualifying myocardial infarction,C0040223;C3541383;C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
calcification n,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
previous coronary revascularisation,C0205156;C0877341;C1552607
total occlusion n,C0001168;C0011382;C0028778;C0441597;C1110554;C1947917
concomitant drugs,C0013227;C3687832
stents per lesion n,C0038257;C0221198;C1546698
prior stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
stent length per lesion mm,C1444754;C1706316
planned thienopyridine at enrollment,C1709561;C1120149
type of drug eluting stent n,C0457591
prior stent,C0332152;C0038257;C2826257
sirolimus,C0072980
azl m cld n $nmbr$,
paclitaxel,C0144576
azl m hctz n $nmbr$,C0020261
zotarolimus,C1700035
$nmbr$ f,C0016327
everolimus,C0541315
age categories y n,C2916832
event rate of primary endpoints,C0871208;C1521828
egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n,C0683312;C0439445;C3889287;C0369718;C0441922
aspirin alone n $nmbr$ $nmbr$ $nmbr$,C0004057;C0205171;C0439044;C0679994
moderate impairment,C0221099;C0684336
aspirin clopidogrel n $nmbr$ $nmbr$ $nmbr$,C0004057;C0070166
mild impairment,C0221099;C0684336
cohort,C0009247;C0599755
chronic kidney disease n,C1561643;C4553188
first n $nmbr$,C0205435;C1279901
indacaterol n $nmbr$,C1722260
second n $nmbr$,C0205436;C0457385;C0565930;C1561503;C1705190
race caucasian,C0007457;C0043157
$nmbr$ mon n $nmbr$,
severity of copd n gold $nmbr$ moderate,C0439793;C0522510
$nmbr$ yo n $nmbr$,C1413296
severe very severea,C0205082;C0442824;C2984081;C4050465;C4050466
bifurcation,C0184906;C3146289
fev $nmbr$ pred post albuterol,C0032952;C0044955;C0687676;C0001927;C1704687;C3469826
left main disease,C0205091;C0012634;C0443246;C1552822
fev $nmbr$ reversibility b,C3714541;C0449261
long $nmbr$ mm stenting yes n $nmbr$,C0205166;C0038257;C2348535;C1706317
baseline dyspnea index score,C0449820;C4050231
multivessel stenting,C0038257;C2348535
gold ii,C1710602;C4082587
type of des,C0332307;C1547052
gold iii iv,C0022326;C4265176
older des n $nmbr$,C0011702;C4551552
indacaterol $nmbr$ pg,C0030827;C0072225;C1266240
new des n $nmbr$,C0205314;C0011702;C4551552
bdi total score baseline,C0168634;C1442488
predictive factor,C0683956
tdi total score week $nmbr$ locf,C2964552;C2825507
age yr range,C1514721;C2348147;C3542016
sgrq total score baseline,C0168634;C1442488
bmi no,C0578022
sgrq total score week $nmbr$ locf,C2964552;C2825507
lifestyle behaviors,C0004927;C0677505
moderate copdb [n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
alcohol consumption no,C0001948
severe copdc [n z $nmbr$ ],C0205082;C4050465;C4050466;C0369718;C0441922
comorbidities concomitant medications,C0013227;C0802604;C2598133;C4284232
indacaterol $nmbr$ mg[n z $nmbr$ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
comorbidities no,C0009488
placebo [n z $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
cardiovascular disorder,C0007222
taiwan,C0039260
cardiac disorder,C0018799
japanese,C0376247;C1556094
no antihypertensive medication,C0003364
duration of copd,C0449238;C2926735
one antihypertensive medication,C0205447;C0003364
ex smoker current,C0521116;C1705970
two or more antihypertensive medications,C0205448;C0003364
pack years,C1277691
statin s,C0360714
fev $nmbr$ fvc a,C3714541
ed characteristics,C3538926;C1521970
reversibility to,C0449261
ed $nmbr$ yr no,C3538926;C0439234
salbutamol,C0001927
ed etiology no,C0015127;C1314792;C1524003
copd severity n,C0024117;C0439793;C0522510;C1412502;C3714496
ed severity no a,C0439793;C0522510
figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408;C1511728;C0032659;C1257890;C0205132;C0700221;C1550648;C1552960;C0441889;C0456079;C1547707;C2946261;C0023189;C0444504;C2347634;C2348143;C0162425;C1283828;C1550453;C0521346;C1546767
mild iief ef $nmbr$ $nmbr$,C2945599;C3641331
a overall and subgroups bv statin potency,C0282416;C1561607;C0085166;C0360714;C1511278
moderate iief ef $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
severe iief ef,C0205082;C3641331;C4050465;C4050466
statin potency medium n $nmbr$,C0360714;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
previous pde $nmbr$ i therapy no,C0039798;C0087111;C1363945
high n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
ls mean change,C0392747;C0443172;C1705241;C4319952
caucasian n,C0007457;C0043157
pbo adjusted ls mean change,C0392747;C0443172;C1705241;C4319952
african american n,C0085756
overally,
dm n,C0011816;C3250443
alcohol consumption at baseline,C0001948;C0168634;C1442488
$nmbr$ $nmbr$ b b,
smoker at baseline,C0337664;C0168634;C1442488
total c mg dl,C0439175;C0439269;C0439810
antihypertensive use,C0042153;C0457083;C1947944
triglyceride mg dl $nmbr$,C0041004;C0439269
none at baseline,C0168634;C1442488
total c hdl c ratio,C0456603;C1547037
one at baseline,C0205447;C0168634;C1442488
apoal mg dl,C0439269
two or more at baseline,C0205448;C0168634;C1442488
lathosterol jimol l,C0064673
ed duration,C0449238;C2926735
$nmbr$ sitosterol p mol l,C0037215;C0347982;C0220914
pretreatment concomitant treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lathosterol total c imol mmol,C0064673;C0439190
ics laba nz $nmbr$,C0815320;C0027978;C4551720
p sitosterol total c imol mmol,C0037215;C0439190;C0220914
ics laba n z $nmbr$,C0815320;C4551720
p sitosterol lathosterol,C0037215;C0064673;C0220914
$nmbr$ years n z $nmbr$,C0439234
baseline sitosterol,C0037215;C0220914
current n z $nmbr$,C0521116;C1705970
baseline sitosterol cholesterol,C0037215;C0008377;C0220914
former n z $nmbr$,C0205156;C0750523
baseline sitosterol lathosterol,C0037215;C0064673;C0220914
moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
absolute change,C1549031
severe n z $nmbr$,C0205082;C4050465;C4050466
triglyceride a,C0041004
very severe n z $nmbr$,C3641272;C4050419
$nmbr$ $nmbr$ b,
north america n z $nmbr$,C0028405
tc hdl c,C0039411;C3715113;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
europe n z $nmbr$,C0015176
percent change,C0392747;C0443172;C1705241;C4319952
rest of world n z $nmbr$,C0035253;C1622890
bivalirudin n $nmbr$,C0168273
age mean,C0444504;C2347634;C2348143
heparin plus a gpi n $nmbr$,C0019134;C0770546
years sd,C0439234;C2699239
coronary artery treated no,C0205042;C1522326
very severe,C3641272;C4050419
previous myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
lung function mean,C0444504;C2347634;C2348143
previous percutaneous coronary intervention,C0205156;C1532338;C1552607
prebronchodilator fev $nmbr$ l,C2599602;C3714541
previous coronary artery bypass surgery no,C2144990
postbronchodilator fev $nmbr$ l,C2599594;C3714541
estimated gfr ml min,C0017654;C0439445;C1424601
prebronchodilator fev $nmbr$ predicted,C0681842;C1882327
time point,C2348792
concomitant treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ckd,C1561643
with laba n pretreatment,C1550147;C2709094;C3539075;C3539076
chronic cvd,C0205191;C0007222
with ics n,C0815320;C4551720
om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
to goal,C0018017;C1571704
week $nmbr$ et,C0332174;C0040028;C0439230
figure $nmbr$ rate ratios and $nmbr$ con dence intervals for reduction of moderate or severe copd exacerbations in the itt population and subpopulations copd chronic obstructive pulmonary disease ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0871208;C0456603;C1610540;C1521828;C1272706;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0740304;C0032659;C1257890;C0162425;C1283828;C1550453
om $nmbr$ aml $nmbr$ hctz $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
om $nmbr$,C0028971;C1705272
figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
aml $nmbr$,C0023465;C0023467
risedronate n $nmbr$,C0246719
om $nmbr$ aml $nmbr$,C0023465;C0023467
history of osteoporotic fracture n a,C4075937
$nmbr$ $nmbr$ cl,C0596019
serum $nmbr$ hydroxyvitamin d ng ml,C0020337;C0439275
s fs $nmbr$,C1517317;C3814419
duration of prior alendronate use months,C1881378;C2826775
o,C0483204
$nmbr$ tob $nmbr$ months n,C1420851;C0439231
drug related teaes,C0013227;C0439849;C0445223;C1254351
$nmbr$ months n,C0439231
discontinuations teaes,C0457454
time since prior alendronate use n,C1279919;C2362777
f n,C0016327
$nmbr$ tob $nmbr$ months,C1420851;C0439231
s s $nmbr$,C0565930;C2603362
never took alendronate,C2003901;C1515187;C0102118
i u uj,C0021966;C0221138
still taking alendronate at study entry n,C0102118;C0557651;C2603343
q q $nmbr$ \,
serum ctx $nmbr$ ng ml median iqr,C0010377;C0439275;C0631180;C3539598
$nmbr$ f $nmbr$ $nmbr$,C0016327
lower tertile b $nmbr$ $nmbr$,C0441994;C1548802;C2003888
$nmbr$ $nmbr$ si,
middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$,C0444598;C0549183;C1552826
$nmbr$ f $nmbr$,C0016327
upper tertile $nmbr$ $nmbr$,C1282910
edema peripheral,C0013604;C0205100;C1717255
glycopyrronium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ n qi,C0369718;C0376586;C0441922
tiotropium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hvookalemia,
gender n male,C0086582;C1706180;C1706428;C1706429
sitagliptin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd body mass index kg m $nmbr$,C0022718;C0439209;C4054209
body weight kg mean sd,C0005910;C2699239;C1305866
mean sd duration of copd years,C0449238;C2926735
known duration of type $nmbr$ diabetes,C0449238;C2926735
severity of the disease gold $nmbr$ n,C0521117;C0018026;C1304897
hba $nmbr$ c mean sd [range],C0019016;C2699239;C1825777;C3538758;C1514721;C2348147;C3542016
copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
$nmbr$ exacerbations,C4086268
hba $nmbr$ c distribution at baseline n,C0520511;C1704711
ics use at baseline n,C0042153;C0457083;C1947944
b $nmbr$,
mean sd duration of smoking pack years,C0449238;C2926735
$nmbr$ h pmg mmol l mean sd,C2827804;C2699239
mean sd fev $nmbr$ l pre bronchodilator,C0444504;C2599602;C2347634;C2348143
fasting insulin pmol l mean sd,C0015663;C0439284;C2699239
mean sd fev $nmbr$ l post bronchodilator,C0444504;C2347634;C2348143;C2599594
conventional treatment n $nmbr$,C2945704
mean sd post bronchodilator fev $nmbr$ percentage predicted,C0439165;C1549488;C1561533;C0681842;C1882327
monitoring n $nmbr$,C0150369;C1283169
mean sd post bronchodilator fev $nmbr$ reversibility,C2599594;C0449261
medical history and risk factors no,C0262926;C1704706;C0035648;C1553898
mean sd post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
prior cardiovascular event no,C0332152;C1320716;C2826257
figure $nmbr$ subgroup analyses for the primary efficacy endpoint,C2986480;C2986535
coronary intervention,C0184661;C0886296;C1273869
ipst n $nmbr$,
stent implanted no,C0522776
no ipst n $nmbr$ $nmbr$,
no of stents implanted,C0038257;C0021102;C2828363
prior ptca pci,C0332152;C4049621;C2826257
drug eluting stent implanted no,C1322815;C0021102;C2828363
non u s,C1518422;C0041703
stented vessel no,C0038257;C0005847
patient presentation,C0030705;C0449450
left main coronary artery,C1261082
baseline cardiac biomarkers,C2735101;C2735102
left anterior descending coronary artery,C0226032
periprocedural medications,C0013227;C0802604;C2598133;C4284232
clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
left circumflex coronary artery,C0226037
glycoprotein iib iiia inhibitor,C0016011;C1999216
m o nito ring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
catheter access site,C0449652
conventional treatment,C2945704
brachial,C0445456
r elative risk $nmbr$ ci,C0008107;C3259781
length of stay randomization to discharge h,C0023303;C0034656;C0033727;C0369286;C0441932;C0564385;C4528284
full po pulatio n,C0443225;C0946289
ipst,
bm i $nmbr$,C0021966;C0221138
no ipst,
n o diabetes,C0011847;C0011849
or [ $nmbr$ ci],C0008107;C3259781
no smo king,C1311076;C1364142;C1423784
p [int],C0369773;C3272375;C2603361
no acs,C0742343;C4318612
lm bifurcation treated,C0184906;C3146289;C1522326
number of stent $nmbr$,C0237753;C0449788
lm bifurcation not treated,C0184906;C3146289;C1518422;C1522326
number ste t $nmbr$,C0237753;C0449788
$nmbr$ vessel pci,C0005847;C4049621
o $nmbr$ o $nmbr$ $nmbr$,C0483204
$nmbr$ mg clopidogrel load,C1550025;C1704782;C1708715
planned valve surgery n,C0038894;C0038895;C0543467;C1274039
losartan plus placebo n $nmbr$,C0126174;C0032042;C1696465;C1706408
body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
losartan plus lisinopril n $nmbr$,C0126174;C0065374
waist circumference cm sd,C0455829;C2699239
hispanic ethnic group no f,C0015031;C1879937;C0016327
chronic renal failure n,C0022661;C1561643;C2316810
serum potassium mmol liter,C0302353;C0475211;C0543465
coronary heart disease n t,C0010054;C0010068;C1956346
mean ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
prior percutaneous coronary intervention n,C0332152;C1532338;C2826257
category no total no,C0683312;C3889287;C0439175;C0439810
prior cardiac surgery n,C0455610
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
coronary bypass n,C0010055
urinary albumin to creatinine ratio^,C0486293;C1318293
valve surgery n,C0038894;C0038895;C0543467;C1274039
urinary protein to creatinine ratio,C0428627;C1318206
other cardiac surgery n,C0018821;C0524727
use of ace inhibitor arb or both no,C1524063;C0003015;C4541021
prior arrhythmias n,C0332152;C0003811;C2826257
ace inhibitor monotherapy,C0003015;C4541021
other supraventricular tachycardia,C0039240;C1963244;C3815188
arb monotherapy,C3888198
ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446;C0232197
both ace inhibitor and arb,C0003015;C4541021;C3888198
congestive heart failure n,C0018802
neither ace inhibitor nor arb,C0003015;C4541021;C3888198
nyha class n i,C1882084
blood pressure medications at randomization no total no,C0849164;C0439175;C0439810
ejection fraction percent sd,C0489482;C2699239;C2700378
[ $nmbr$ cl],C0596019
losartan placebo,C0032042;C1696465;C1706408
left atrial diameter mm sd,C0225860;C2699239;C0225861
losartan lisinopril,C0126174;C0065374
prior implantable cardiodefibrillator n,C0332152;C0021102;C2826257
[ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
prior pacemaker n,C0332152;C0030163;C0810633;C1546728;C3275122;C3853703;C2826257
albuminuria $nmbr$ gram gram cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
prior cardiac resynchronization therapy n,C1167956
previously on acei arb,C3888198
prior af ablation n,C0332152;C0344434;C4049859;C2826257
age $nmbr$ years old,C1510829;C0580836
euroscore logistic median $nmbr$ th $nmbr$ th,C0039725;C0039738;C1420718;C4282123;C4285344
black and other,C0005680;C0027567;C0085756;C0439541
euroscore additive median $nmbr$ th $nmbr$ th,C0039725;C0039738;C1420718;C4282123;C4285344
stenting plus medical therapy n $nmbr$,C0038257;C2348535
medications at enrollment n,C0013227;C0802604;C2598133;C4284232
medical therapy only n $nmbr$,C0418981;C0369718;C0441922
angiotension converting enzyme inhibitor,C0014432;C0919438;C4521603
blood pressure at target level,C0005823;C1271104;C1272641
aldosterone antagonists,C0002007;C2757004
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ ^,C0017654;C0439445;C1424601
antiplatelets or anticoagulants,C0003280
antiplatelets,
stage $nmbr$ chronic kidney disease,C1561643;C4553188
other antiarrhythmics^,C0003195
method of identification ofstenosis,C1301921
subgroup name,C0027365;C1547383;C4522128
angiography,C0002978
subgroup level,C0441889;C0456079;C1547707;C2946261
duplex ultrasonography,C3825392
n $nmbr$ pufa,C0369718;C0032615;C0441922
computed tomographic angiography,C1441526;C0002978;C1880157
age $nmbr$ years n $nmbr$,C1510829
magnetic resonance angiography,C0243032
sex male n $nmbr$,C0086582
medical history and risk factors,C0262926;C1704706;C0035648;C1553898
country argentina n $nmbr$,C0454664;C0003761;C1504311;C1511538
history of heart failure,C0455531
italy n $nmbr$,C0022277
smoking in past yr,C0037369;C0453996;C1881674;C0439234
usa n $nmbr$,C0041703
angiographic findings,C2607943;C2926606;C3539655
cardiac valve surgery,C0018821;C0524727
stenosis as assessed by core laboratory,C0678234;C1261287;C2632116;C0022877;C3244292;C4283904
cardiac valve surgery no n $nmbr$,C0018821;C0524727;C0369718;C0441922
stenosis as assessed by investigator,C0678234;C1261287;C2632116;C0035173
hypertension no n $nmbr$,C0020538;C1963138;C0369718;C0441922
global ischemia,C0205246;C0022116;C4321499;C2348867
nyha class $nmbr$ $nmbr$,C1882083
bilateral disease j j,C1511113
nyha class $nmbr$ $nmbr$ no n llll,C1882083;C0369718;C0441922
stent plus medical therapy,C0038257;C0418981
serum potassium,C0302353;C0543465
medical therapy alone,C0418981;C0205171;C0439044;C0679994
serum potassium $nmbr$ $nmbr$ mmol l n $nmbr$,C0302353;C0543465
no of patients total no,C0030705;C0439175;C0439810
$nmbr$ $nmbr$ mmol l n $nmbr$,C1532563
creatinine level,C0428279
u s sites,C0041703;C0205145
left atrial diameter $nmbr$ mm n $nmbr$,C0225860;C0225861
maximal diameter stenosis,C0678234;C1261287;C2632116
$nmbr$ mm n $nmbr$,C4330985;C4554674
characteristicsa,
ejection fraction $nmbr$ n $nmbr$,C0489482;C2700378
varespladib n $nmbr$,C2713485
habitual fish intake,C0205353;C0556216
otherb,
habitual fish intake $nmbr$ servings wk n $nmbr$,C0205353;C0556216
western europe and lebanon,C0043129;C0023190
$nmbr$ servings wk n $nmbr$,C0332174;C0439230
present smokerc,C0150312;C0449450
phospholipid omega $nmbr$ levels,C0031676;C0441889;C0202177
body mass index mean sd d,C0005893;C2699239;C0578022;C1305855
phospholipid omega $nmbr$ levels $nmbr$ n $nmbr$,C0031676;C0202177
prior lipid modifying therapy,C1514463;C0023779
study drug loading days actual,C2826182;C0237400
unstable angina biomarker negative,C0205160;C1513916;C2825415;C2825491;C3853545
study drug loading days actual $nmbr$ n $nmbr$,C2826182
index event to randomization median iqr h,C0441471;C4019010
peri op beta blockers,C0347985;C0001645
pci or cabg surgery for index event,C4049621;C0038894;C0038895;C0543467;C1274039
peri op beta blockers no n $nmbr$,C0347985;C0001645;C0369718;C0441922
medications at randomization,C0013227;C0802604;C2598133;C4284232
peri op statins,C0347985;C0360714
clopidogrel ticlopidine or prasugrel,C0070166;C0040207;C1620287
peri op statins no n $nmbr$,C0347985;C0360714;C0369718;C0441922
biochemical parameters at randomization mean,C0449381;C0034656
peri op amiodarone,C0347985;C0002598
sd mg dl,C2699239;C0439269
peri op amiodarone no n $nmbr$,C0347985;C0002598;C0369718;C0441922
c reactive protein median iqr mg l,C0006560;C0439268;C1413716;C4048285
peri op ace inhibitiors arbs,C0347985;C3888198
concomitant atorvastatin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
peri op ace inhibitors arbs no n $nmbr$,C0003015;C3888198;C0369718;C0441922
varespladib,C2713485
on pump time,C0040223;C3541383
a primary composite outcome,C0205199;C1274040;C1547335
l $nmbr$ hrs min n $nmbr$,C0439393;C1568891
baseline lipid therapy,C0039798;C0087111;C1363945
cross clamp time,C0175721;C0040223;C3541383;C1883710;C3810601
primary indication,C1549995
cross damp time,C0040223;C3541383
pci postindex event,C0441471;C4019010
$nmbr$ $nmbr$ hrs min n $nmbr$,C0702093;C1524029;C3813700
diabetes at baseline,C0011847;C0011849
canakinumab dose per mo,C0178602;C0869039;C1114758
hypertension at baseline,C0020538;C1963138
total group n $nmbr$,C0439175;C0441848;C0439810
b myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
blood pressure mm,C4330985;C4554674
high dose edoxaban n $nmbr$,C0444956;C2975435
geographic site,C0017446
low dose edoxaban n $nmbr$,C0445550;C1708745
duration of diabetes mellitus y,C0449238;C2926735
asia pacific region and south africa,C0017446;C0205147;C0037712
previous metformin use,C0042153;C0457083;C1947944
paroxysmal atrial fibrillation no,C0235480;C4050122
metformin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
qualifying risk factor no,C1514624;C0035648
glucose mmol l,C0017725;C1532563
prior stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
insulin pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
hypertension requiring treatment,C0020538;C1963138;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
il $nmbr$ ng l,C0020898;C0439297;C0021764;C0022271
$nmbr$ $nmbr$ no,
fibrinogen g l,C0439294;C0456615
dose reduction at randomization no i,C0301630;C0392756;C1293152;C4551656;C0021966;C0221138
canakinumab dose per month,C0178602;C0869039;C1114758
use of verapamil or quinidine,C1524063;C0042523;C0034414
crp,C3890735;C4048285
previous use of vitamin k antagonist for $nmbr$ days no,C1524063;C1096489;C2267235;C0439228
change median baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
medication at time of randomization no,C0013227;C3244316;C4284232
baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
digoxin or digitalis preparation,C0012265;C0304520
il $nmbr$,C0020898;C0021764;C0022271
edoxaban high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
fibrinogen,C0016006;C1167394;C2587184;C3540039
edoxaban low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
n v n $nmbr$,C0369718;C0441922
af type,C0332307;C1547052
v $nmbr$ n $nmbr$,C0369718;C0441922
prior stroke or tza,C0038454;C4554100;C0039298
race asian n,C0034510;C0078988;C1706779;C3853635
$nmbr$ p $nmbr$,C0369773;C2603361
mean sd kg m $nmbr$,C0022718;C0439209;C4054209
cha $nmbr$ s $nmbr$ score,C1420648;C0449820;C4050231
nonsmoker n,C0337672;C0425293;C4554605
dose adjusted,C0178602;C0869039;C1114758;C0456081
baseline sbp,C0168634;C0085805;C1442488
center level ttr,C0032923;C1421224
mean sd mmhg,C0444504;C0439475;C2347634;C2348143
high dose edoxaban vs warfarin interaction p value,C0444956;C2975435;C0043031;C1709380
baseline dbp,C0536221;C3813197;C4281799
low dose edoxaban vs warfarin interaction p value,C0445550;C2975435;C1708745;C0043031;C1709380
metabolism and nutrition,C0025519;C0025520;C0028707;C0392209;C0518896;C1442959
edoxaban warfarin,C2975435;C0043031
disorders soc,C0012634
congestive heart,C0742742;C0018787
cardiac disorders soc,C0018799
failure,C0231174;C0680095
cerebral infarction,C0007785
amiodarone ote at baseline,C0002598;C0168634;C1442488
cerebral ischemia,C0007785;C0917798
ff $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
apixaban $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ff vi $nmbr$ $nmbr$ ig n $nmbr$,C0205999;C0021027;C0305052;C0360506
apixaban $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
never smoked n,C2003901;C0037366;C0439994;C1881674
mean kg,C0022718;C0439209;C4054209
former smoker n,C0337671
initial diagnosis no,C0011900;C1704338;C1704656
number of exacerbations in last $nmbr$ months,C0237753;C0449788;C0439231
clinical presentation of vte at initial diagnosis no,C2708283;C0630906;C0011900;C1704338;C1704656
screening prebronchodilator fev $nmbr$ l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
associated with transient or reversible risk factor,C0332281;C0040704;C0205374;C0205343;C0035648
screening predicted fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
risk factors for recurrent vte no f,C0035648;C1553898;C0016327
screening reversibility fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
persistent or permanent immobilization,C0205322;C0332996;C0020944;C4048292
screening absolute reversibility fev $nmbr$ ml,C0439526;C1705224;C3887665
previous deep vein thrombosis or pulmonary embolism,C0205156;C0149871;C1552607;C0034065
baseline acq $nmbr$ score,C0449820;C4050231
known prothrombotic genotype,C0205309;C0017431
percentage of patients using ics or ics laba on entry,C0439165;C1549488;C1561533;C1524063;C0815320;C4551720;C1705654
use of antiplatelet agents^,C1524063;C0085826
ics only,C0815320;C4551720
apixaban,C1831808
ff $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
apixaban $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
apixaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
argentina,C0003761;C1504311
pe with or without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
philippines,C0031529
dvt only,C0149871;C2926618;C3899446
japan,C0022341
normal renal function,C0232805
baseline fev l,C0168634;C1442488
normal weight bmi,C4229017
f,C0016327
overweight bmi $nmbr$ to,C0497406;C0578022
grouped region,C0017446;C0205147
obese bmi $nmbr$,C0028754;C0578022
australasia,C0282279;C1257882
b a n $nmbr$,
b h n $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
values are mean sd median [quartile range] or ace indicates angiotensin converting enzyme arb angiotensin receptor blocker bnp b type natriuretic peptide bp blood pressure bun blood urea nitrogen lvef left ventricular ejection fraction and nt probnp n terminal pro b type natriuretic peptide,C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016;C1452534;C4284014;C0005845;C0428772;C0600137;C0754710
previous coronary heart disease,C0010054;C0010068;C1956346
alive n $nmbr$,C2584946;C4551704
previous chronic kidney disease,C1561643;C4553188
dead n $nmbr$,C0011065
change in retinal pathology,C0392747;C0443172;C1705241;C4319952
lvef within $nmbr$ mo,C0428772;C0488728
$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
total intravenous loop diuretics mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ or $nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
bun mmol l,C1532563
$nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463;C1551358;C0042903;C0023694;C1328010
no readmission n $nmbr$,C1548168;C4489276
baseline a $nmbr$ c,C0168634;C1442488
readmission n $nmbr$,C1548168;C4489276
baseline sbp mm,C4330985;C4554674
increase creatinine,C0010294;C1561535
baseline ldl mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
increase creatinine $nmbr$ $nmbr$ mg dl,C0010294;C0439269;C1561535
outcomes during accord,C1274040;C0680240
no hemoconcentration hemoconcentration,C0549409;C0854379
accord primary n,C0205225;C0439612;C0439631
participants no,C0679646
fatal nonfatal mi n,C1302234;C1705232
gi bleed,C1708130;C0019080;C3539617;C4050121
fatal nonfatal stroke n,C1302234;C0038454;C4554100;C1705232
no gi bleed,C1708130;C0019080;C3539617;C4050121
concomitant antiplatelet,C0521115
participants randomized,C0679646;C0034656;C3815594
no concomitant antiplatelet,C0521115
no a,
de $nmbr$ n $nmbr$,C0011198;C0017480;C3541240
black non black,C0005680;C0027567;C0085756;C0439541
previous htn n,C0205156;C0020538;C1552607
hispanic non hispanic,C0086409;C1518422
previous dm n,C0205156;C0011816;C3250443;C1552607
women taking estrogen,C0014939;C2936882;C4542544
previous cad n,C0205156;C1504769;C2239547;C3813548;C4284121;C1552607
hdl mean sd mg dl,C0444504;C0439269;C2347634;C2348143
previous chf n,C0205156;C0018802;C1552607
diabetes classificationa,C0011847;C0011849
chads score n,C0449820;C4050231
nondiabetes,
previous renal disease n,C0205156;C0022658;C1552607
mean sd mg kg $nmbr$,C0444504;C0439272;C2347634;C2348143
type of af n,C0332307;C1547052
yes no,C1512698
duration antiplatelet use as of study duration sd,C1881378;C2826775
history mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
rate year,C0439234;C0439508
history coronary,C0019664;C0018787;C0019665;C0262512;C0262926;C1705255;C2004062
stroke embolism,C0013922;C1704212
other atherosclerotic,C0333482
all stroke,C0038454;C4554100
lvh by minnesota code,C0149721;C0009219;C0805701;C3889831
major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
unadjusted hr $nmbr$ ci a,C0008107;C3259781
minor bleed,C0026193;C0019080;C0205165
lisinopril vs chlorthalidone,C0065374;C0008294
all bleed,C0019080
lisinopril vs amlodipineb,C0065374
intracranial,C0524466
aspirin at baseline,C0004057;C0168634;C1442488
extracranial,C0580586
no aspirin at baseline,C0004057;C0168634;C1442488
with mets,C0812270;C1705694;C2939420
asthma population n $nmbr$,C0004096;C0032659;C1257890;C2984299
ez simva $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
copd population n $nmbr$,C0024117;C0032659;C1257890;C1412502;C3714496
doubling statin dose,C0178602;C0869039;C1114758
duration of disease years,C0872146;C0439234
rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
self reported disease severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
multi racial,C0439064;C3266262
current inhaler,C0021461;C1881212;C4319647
without mets,C0812270;C1705694;C2939420
diskus only n,C1553480;C0369718;C0441922
mitt population,C0032659;C1257890
handihaler and diskus n,C1553480
oral treprostinil n $nmbr$,C0442027;C1145760;C4521986
handihaler only n,C0369718;C0441922
not provided,C1518422
mdi hfa n,C0993596;C0015458;C1839839;C4049613
pah origin cause,C0015127;C1524003
dpi other than diskus n,C1553480
ipah hpah,C0340543;C0637939;C1150929
qva $nmbr$ $nmbr$ pg once daily n $nmbr$,C0030827;C0072225;C1266240;C0332173
repaired chd,C0280604;C3542407
hiv,C0019682;C0019699
sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$,C0030827;C0585361;C0072225;C1266240
ics users at baseline,C1706077;C0168634;C1442488
who functional class ii iii,C0441887;C2698969
$nmbr$ mwd m,
smoking history r,C0205090;C0684010;C2603358
years since pah diagnosis,C0439234;C0011900;C1704338;C1704656
ex smokers,C0337671;C4555205
estimated number of pack years,C0237753;C0449788
figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p,C0392747;C0443172;C1705241;C4319952;C1274040;C1546471;C2825142;C0449450;C0084844;C1538994;C0332174;C0439230;C0007447;C0162425;C1283828;C1550453;C0032659;C0042295;C1257890
copd exacerbation history in the previous year n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
subgoup_name,C0027365;C1547383;C4522128
pre bronchodilator fev l,C2599602;C3714541
subgroup_level,C0441889;C0456079;C1547707;C2946261
post bronchodilator fev l,C2599594;C3714541
image only,C1704254;C1704922;C3542466
pre bronchodilator fev predicted,C2599602;C3714541;C0681842;C1882327
chads $nmbr$,C0007928;C1413373
post bronchodilator fev predicted,C2599594;C3714541;C0681842;C1882327
r $nmbr$,C0205090;C0684010;C2603358
af pattern,C0344434;C0449774;C4049859
post bronchodilator fev reversibility,C2599594;C0449261
laa ostium,C0444567
post bronchodilator fev fvc,C2599594;C3714541
laa length,C1444754;C1706316
lsm $nmbr$ cl,C0596019
aliskiren valsartan n $nmbr$,C2733073
overall qvai $nmbr$ sfc,C0282416;C4521536;C1561607
ex smokers qvai $nmbr$ sfc,C0337671;C4521536;C4555205
age y sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
$nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ o o $nmbr$ o $nmbr$,C0483204
bmi kg m $nmbr$ uac no,C0022718;C0439209;C4054209
smokers qva $nmbr$ $nmbr$ fc,C0337664;C2983605
$nmbr$ $nmbr$ i $nmbr$ $nmbr$ n $nmbr$,
moderate cord qva $nmbr$ sfc,C0205081;C4521536;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ $nmbr$ mg g,C1300563
severe cord qvai $nmbr$ sfc,C0205082;C4521536;C4050465;C4050466
$nmbr$ mg g,C1300563
o $nmbr$ o oo $nmbr$ o $nmbr$ o,C0483204
$nmbr$ $nmbr$ i $nmbr$ $nmbr$ n $nmbr$ a,C0021966;C0221138
men qvai $nmbr$ sfc,C0025266;C4521536
$nmbr$ hour masbp mm hg,C0439227;C0439475;C0564385
women qva $nmbr$ sfc,C0043210;C4521536
$nmbr$ hour madbp mm hg,C0439227;C0439475;C0564385
ics non users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
uac $nmbr$ mg g,C1300563
$nmbr$ oo $nmbr$ o $nmbr$,
uac $nmbr$ $nmbr$ mg g,C1300563
ics users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
a v n $nmbr$,C1272460
age $nmbr$ qvai $nmbr$ sfc,C0001779;C4521536
v n $nmbr$,C0369718;C0441922
$nmbr$ ml min n $nmbr$,C0439445
bun mg dl,C0439269
median $nmbr$ th $nmbr$ th percentile,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
serum potassium meq l,C0302353;C0439375;C0543465
af duration n,C0344434;C0449238;C2926735;C4049859
age y $nmbr$ th $nmbr$ th percentiles,C0001779;C1264641
$nmbr$ mo $nmbr$ y,C0026544;C0332177
months from qualifying stroke,C0439231;C1514624;C0038454;C4554100
chads $nmbr$ risk factors n,C0035648;C1553898
selected clinical characteristics,C1707391;C0683325
chads $nmbr$ score n,C0449820;C4050231
rankin scale $nmbr$,C0451405
any anticoagulant,C0003280;C0848112;C3536711
aspirin alone,C0004057;C0205171;C0439044;C0679994
events n y,C0441471;C3541888
thienopyridine alone,C1120149;C0205171;C0439044;C0679994
dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
dipyridamole alone,C0012582;C0205171;C0439044;C0679994
dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aspirin thienopyridine,C0004057;C1120149
outcome according to renal function level in ml min,C1274040;C0232804;C0439445
aspirin dipyridamole,C0732279
dabigatran $nmbr$ mg bid events n y,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
thienopyridine dipyridamole,C1120149;C0012582
warfarin events n y,C0043031;C0441471;C3541888
other medications at enrollment,C0013227;C0802604;C2598133;C4284232
p value inter,C1709380;C0205103;C1548610
vorapaxar no $nmbr$ y km,C2974521;C3887676
life threatening bleed,C1546953;C0019080;C2826244;C3537125
placebo no $nmbr$ y km,C0032042;C1696465;C1706408;C3887676
intracranial bleed,C0151699
efficacy end points,C1280519;C2349179;C1707887
net clinical benefit,C1456447;C4684590;C3853572;C3887809;C3890893
cv death mi or stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
czp $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
cv death mi stroke or urgent coronary revascularization,C0038454;C4554100;C0439609;C0877341;C3272275
arthritis characteristics,C0003864;C1521970;C4552845
any stroke,C0038454;C4554100
crp median range mg literl,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
urgent coronary revascularization,C0439609;C0877341;C3272275
esr median range mm hour,C0439227;C0564385
bleeding end points,C0019080;C2349179
tender joint count range $nmbr$ $nmbr$ joints,C0451530;C1514721;C2348147;C3542016
gusto moderate or severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
swollen joint count range $nmbr$ $nmbr$ joints,C0451521;C1514721;C2348147;C3542016
gusto severe,C0205082;C4050465;C4050466
modified total sharp score,C0392747;C2964552;C3889737
timi clinically significant,C0237881;C0750502;C1546944
joint space narrowing score,C0449820;C4050231
timi non cabg major,C0205082;C0205164;C4318856;C4521762
physician s assessment of disease activity vas mm,C0031831;C0804815;C1261322;C1516048
timi minor,C0026193;C0205165
enthesitis,C1282952
fatal bleeding,C1302234;C0019080;C1705232
lei $nmbr$,C0023401;C0428209
intracranial hemorrhage,C0151699;C4554169
dactylitis,C0239161
intracerebral,C0442111
ldi $nmbr$,
subdural epidural,C0228134;C0812144
psoriasis characteristics,C0033860;C1521970
active control study,C2347179
$nmbr$ bsa psoriasis no,C0033860
placebo control study,C0683952
pasi median range,C1514721;C2348147;C3542016
estimated creatinine clearance ml min i,C0023806
nail involvement,C0027342;C1314939;C1432728;C3538766
neither deep vein thrombosis nor pulmonary embolism,C0149871;C0034065
mnapsi,
immobilization no,C0020944;C4048292
patient reported outcomes,C2987124
transient,C0040704;C0205374
patient assessment of disease activity mm,C0679830;C1292728
known thrombophilia no,C0205309;C0398623
patient assessment of arthritis pain mm,C0679830
active cancer no,C0006826;C0998265;C1306459
fatigue range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
previous cancer no,C0006826;C0998265;C1306459
haq di range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
coronary artery disease no,C0010054;C0010068;C1956346
sf $nmbr$ pcs,C1864389;C1882368
treatment duration before randomization days,C0444921;C3259042
sf $nmbr$ mcs,C0037712
enrolled from re cover study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
psaqol,
dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
dlqi,C3899393
enrolled from re cover ii study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
dlqi patients with $nmbr$ bsa psoriasis,C0030705;C0033860
adherence to study regimen no ff,C1510802;C0040808;C2945654;C4554348
prior tnf inhibitor exposure no,C0274281;C0332157
factors,C1521761;C2827422
adalimumab,C1122087
dabigatran event incidence n,C0021149;C0220856
no prior tnf inhibitor exposure,C0274281;C0332157
wafarin event incidence n,C0021149;C0220856
prior tnf inhibitor exposure,C0274281;C0332157
$nmbr$ to $nmbr$ kg,C0022718;C0439209;C4054209
czp combined arms n $nmbr$,C0054841;C0205195;C1861828;C1872109
creatine clearance category,C0683312;C3889287
pain mm,C4330985;C4554674
$nmbr$ to $nmbr$ ml min,C0439445
haq di,C3826998;C4321476
currently smokes,C0521116;C0037369
indacaterol $nmbr$ ug n $nmbr$,C0041573;C0439211
subgroup w r t re cover,C0180153;C1999244;C3888055
indian indian subcontinent,C0454693
re cover $nmbr$ dabigatran,C0556581;C0180153;C1999244;C3888055;C2986904;C2348066
smokers,C0337664
re cover $nmbr$ warfarin,C0556581;C0180153;C1999244;C3888055;C2986904;C0043031
fevi l,C0429706;C0849974;C1561566;C4528367
re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
non rollover,C0517067;C0543436
reversibility to salbutamol,C1271924
symptomatic pe,C0070939;C1880476;C4284304
n indacaterol $nmbr$ ug indacaterol $nmbr$ ug placebo,C0032042;C1696465;C1706408
history of $nmbr$ previous vte excluding index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
indacaterol $nmbr$ ug versus placebo,C0041573;C0439211;C0032042;C1696465;C1706408
history of non hemor rhagic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211
history of coronary artery disease,C1881055
intent to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
p value for,C1709380
theophylline use at screening,C0241361;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
event incidence n,C0021149;C0220856
saba reversibility,C0449261
black or asian,C0005680;C0027567;C0085756;C0439541;C0078988
figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c,C1709707;C0681850;C1550501;C1706203;C2349001;C2697811;C1521840;C2986546;C1704788;C3539106;C0332167;C0442804;C3272283;C4050568;C4319571;C4321397;C0596269;C0205210;C0205195;C1947911;C3811910;C0332257;C1552866;C2700399
l $nmbr$ kg,C1637390
abatacept $nmbr$ $nmbr$ n $nmbr$,C1619966
never smoke,C0037366;C0439994;C1881674
class iv glomerulonephritis,C0441888;C0017658;C2698970
qualifying index event as pe,C1514624;C0441471;C4019010
duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$,C0449238;C2926735
budesonide mmx $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline creatinine median range mg dl,C0010294;C0439269;C1561535
entocort ec n $nmbr$,C1170256
mean age years range,C1514721;C2348147;C3542016
baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$,C0567349;C2348885
uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline upgr $nmbr$ gm gm $nmbr$ mg mmole,C0567349;C2348885
mean disease duration years,C0872146;C0439234
prestudy treatment status,C0749659
duration,C0449238;C2926735
naive no treatment for current flare,C2827774;C1517205;C3540542
duration $nmbr$ to,C0449238;C2926735
recent treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
duration $nmbr$ years n,C0449238;C0439234;C2926735
inadequate response $nmbr$ months mmf ggs,C0205412;C0083765;C0209368;C3848524;C0439856
disease extent n,C0012634;C0439792
baseline prednisone or oral prednisone equivalent daily dose,C0168634;C0032952;C1442488;C2348070
proctosigmoiditis,C0033252
mean sd mg n $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
left sided colitis,C2887821
goncomitant treatment with age inhibitors angiotensin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
receptor blockers,C0597357
extensive pancolitis,C0205231;C0868908
premature discontinuation,C0457454;C1444662;C4552847
mean baseline ucdai score,C3533236;C0168634;C1442488
adverse event,C0877248
mean baseline ei score,C3533236;C0022067;C1414370;C2348481
lack of efficacy,C0235828
prior mesalazine use,C0042153;C0457083;C1947944
withdrew consent,C2349954;C1511481;C1554192;C2923685
prior sulfasalazine use,C0042153;C0457083;C1947944
nerd,
no longer met study criteria,C0428210;C0243161;C1550543;C4317104
eo,C0332120
poor compliance noncompliance,C0376405;C0457432
gender male n,C0079399;C0086582;C1706180;C1706428;C1706429;C1522384
pregnancy,C0032961
american indian alaskan native,C0886378
ind gly n $nmbr$,C0017890;C0523677
native hawaiian pacific islander,C0337920;C0242191
ind pbo n $nmbr$,C4049864;C0031962
alcohol drinker n,C0001962;C0001975
severity of airflow limitation gold $nmbr$ n,C0439793;C0522510
caffeine user n,C3532939
baseline copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
h pylori status n,C0079488;C0449438
$nmbr$ exacerbation,C4086268
baseline los angeles grade of eo n,C0441800;C0919553;C3244287
mean sd fev $nmbr$ postbronchodilator l,C0444504;C2347634;C2348143
mean sd postbronchodilator fev $nmbr$ predicted,C0681842;C1882327
figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0267055;C0030705
mean sd postbronchodilator fev $nmbr$ reversibility,C0444504;C0449261;C2347634;C2348143
statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0521095;C1524063;C1708614
mean sd postbronchodilator fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
no psa n $nmbr$,C3810537;C3813209
lsm $nmbr$ ci,C0008107;C3259781
psa n $nmbr$,C3810537;C3813209
moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0231999;C0443288;C0449295
mean age years $nmbr$ ci,C0008107;C3259781
severe or worse airflow limitation,C0205082;C4050465;C4050466;C0443288;C0449295
mean bmi $nmbr$ ci,C0008107;C3259781
smoking ex smoker,C0037369;C0337664;C0453996;C1881674
mean involved bsa $nmbr$ ci,C0008107;C3259781
smoking current smoker,C3173209;C3241966
mean pasi score $nmbr$ ci,C0008107;C3259781
ics use at baseline no,C0042153;C0457083;C1947944
mean dlqi score $nmbr$ ci,C0008107;C3259781
ics use at baseline yes,C0042153;C0457083;C1947944
daily activities,C0871707
reversibility $nmbr$,C0449261
leisure,C0086542
bmi $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
personal relationships,C1552027
revive i,C0021966;C0221138
symptoms and feelings,C0683368;C1457887;C1527305
revive ii,
treatment satisfaction,C3476649
levosimendan n $nmbr$,C0246904
work and school,C0043227;C0036375
basal only,C0205112
mean eq $nmbr$ d response $nmbr$ ci,C0205163;C0439185;C0008107;C3259781
$nmbr$ $nmbr$ lung fields,C0225759
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
legs only,C1140621
mean sf $nmbr$ score $nmbr$ ci,C0008107;C3259781
sacral and or lumbar,C0036037;C0024090
physical functioning,C0516981;C4049916
iv vasodilator,C0042402;C3537240
physical role,C0035820;C1705810;C3871154
iv inotropic drug,C1971835
bodily pain,C3890602
both iv vasodilator and inotrope,C0042402;C3537240
general health,C0424575;C4018875
vitality,C0424589
figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization,C2985465;C0015127;C1524003;C0032042;C1696465;C1706408;C0005811;C0034656
social functioning,C0037395
coenzyme q $nmbr$,C0041536
mental health,C0025353
categorical variables,C0439828
emotional role,C0035820;C1705810;C3871154
continuous variables mean sd,C0439828;C2699239
physical component summary,C0031809;C0205485;C1509143
age at onset y,C0206132;C3870509
mental component summary,C0229992;C0449432;C1705248
age at diagnosis y,C1828181;C3173302
mean ham d score $nmbr$ ci,C0008107;C3259781
duration of pd y,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ tt,C1452561;C4554543
diagnosed y,C0011900
no of events per $nmbr$ patient years,C0441471;C3541888;C0030705;C0439234
updrs score,C0449820;C4050231
no psa,C3810537;C3813209
mental,C0229992
placebo $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
adl,C0001288;C1420005
$nmbr$ mg qw $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
motor,C1513492;C1705994
$nmbr$ mg biw $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
hoehn and yahr stage,C0205390;C1300072;C1306673
any event,C0441471;C4019010
modified se adl scale,C0175659;C0349674;C1947916
arthritis,C0003864;C4552845
pdqol scale,C0175659;C0349674;C1947916
back pain,C0004604;C1963071;C4553945
modified rankin score,C0392747;C0449820;C4050231;C3889737
bursitis,C0006444
symbol digit score,C0449820;C4050231
muscle twitching,C0026845;C4083049;C0231530
$nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
musculoskeletal stiffness,C0497254;C0427008;C2707260
p value lnteraction,C1709380
neck pain,C0007859;C1963180;C4553909
bl h y unilateral,C0005918;C0006413;C1552663;C2827109;C0205092
pain in extremity,C0030196;C4553007
bl h y bilateral,C0005918;C0006413;C1552663;C2827109;C0238767
psoriatic arthropathy,C0003872
bl updrs low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
shoulder pain,C0037011
bl updrs high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
tendonitis,C0039503
table $nmbr$ selected baseline characteristics of the study patients,C4684572
low feno subgroup $nmbr$ $nmbr$ ppb n $nmbr$,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
spironolactone n $nmbr$,C0037982
high feno subgroup $nmbr$ $nmbr$ ppb n $nmbr$,C0205250;C1079230;C1515021;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
nyha functional classification no,C1275491;C0205245;C0542341;C2700217
low eosinophil subgroup $nmbr$ ml n $nmbr$,C0205251;C0014467;C1550472;C3890211;C4048187;C4321351;C4522223
eligibility stratum,C0013893;C1548635
high eosinophil subgroup $nmbr$ ml n $nmbr$,C0205250;C0014467;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
hospitalization in previous year with management of heart failure as major component no,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539;C0449432;C1705248
low periostin subgroup $nmbr$ ng ml n $nmbr$,C0205251;C0439275;C1550472;C3890211;C4048187;C4321351;C4522223
elevated natriuretic peptides in previous $nmbr$ days no,C1144709;C0205156;C1552607
high periostin subgroup $nmbr$ ng ml n $nmbr$,C0205250;C0439275;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
current smoker no blood pressure mm hg,C3173209;C3241966;C0005823;C0439475;C1271104;C1272641
mean sd age yr,C0001779;C0439234
region of enrollment no,C0017446;C0205147
mean body weight sd kg,C0022718;C0439209;C4054209
russia and georgia,C0035970;C0017452;C0017454
mean total serum ige sd iu ml,C0229671;C0439458;C1546774;C1550100
no of events patients,C0441471;C0030705;C3541888
mean prebronchodilator fev $nmbr$ sd predicted,C0444504;C2699239;C2347634;C2348143;C0681842;C1882327
randomization stratum,C0034656
hospitalized for asthma n,C0701159;C0004096;C2984299
not hospitalized for heart failure in the year prior to study enrollment,C0701159;C0018801;C0018802;C4554158;C0332152;C3258203
mean sd number of exacerbations,C0237753;C0449788
hospitalized for heart failure during that time period,C0701159;C0018801;C0018802;C4554158;C1948053
mean sd total asthma symptom scores,C3533236
ejection fraction based on local reading,C0489482;C2700378;C1527178;C1705938
mean sd number of albuterol per day puff,C0237753;C0449788;C1533107;C1882376
less than the median,C0549183;C0876920;C2347635;C2348144;C2939193
mean sd aqlq,C0444504;C4055434;C2347634;C2348143
at or above the median,C0549183;C0876920;C2347635;C2348144;C2939193
mean sd feno ppb,C0444504;C1415800;C2347634;C2348143
less than $nmbr$,
mean eosinophil count per ml,C0200638;C0750879
greater than or equal to $nmbr$,C0439093;C0205163
mean sd periostin ng ml,C0219433;C0439275;C1424662;C3812270
$nmbr$ years or older,C0439234;C0580836
concomitant asthma medications n,C0004096;C0013227;C0802604;C2598133;C4284232;C2984299
yes insulin treated,C0021641;C1533581;C1579433;C3714501;C1522326
m $nmbr$ subgroup,C1079230;C1515021
yes non insulin treated,C1549445;C1705108;C1710701;C1518422;C0021641;C1533581;C1579433;C3714501
total asthma symptom score,C3533163;C0004096;C2984299
new york heart association congestive heart failure class,C1882083
albuterol use,C0042153;C0457083;C1947944
less than $nmbr$ mm hg,C0439475
aqlq score,C0449820;C4050231
greater than or equal to $nmbr$ mm hg,C0439093;C0205163;C0439475
change from baseline in predicted fev $nmbr$,C0392747;C0443172;C1705241;C4319952;C0681842;C3714541;C1882327
use of statins,C1524063;C0360714
low subgroup,C1079230;C1515021
pulse pressure,C0949236
high subgroup,C1079230;C1515021
less than $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
feno placebo lsm,C0032042;C1696465;C1706408
greater than or equal to $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439093;C0205163;C0439445
omalizumab lsm,C0966225
racial category,C0683312;C3889287
lsm difference,C1705241;C1705242
use of cardiac medication,C1524063
eosinophils,C0014467;C0200638
use of blood pressure lowering medication,C1524063
placebo lsm,C0032042;C1696465;C1706408
quartiles of fgf $nmbr$ ru ml,C2828255;C0016026;C0919505
periostin,C0219433;C1424662;C3812270
current tobacco use,C0040335;C0543414;C0841002;C3853727
diagnosis at presentation no,C0011900;C1704338;C1704656
prior pci or cabg,C0332152;C4049621;C2826257;C0010055
nste acs,C0742343;C4318612
apo a $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
other countries,C0454664
$nmbr$ year km,C0439234;C3887676;C0439508
cardiac biomarker status no total no,C1999091;C2735302;C0439175;C0439810
fgf $nmbr$ low egfr $nmbr$,C1739039;C3811844;C3812682
abnormal,C0205161;C2347472;C2699333
fgf $nmbr$ high egfr $nmbr$,C1739039;C3811844;C3812682
clopidogrel $nmbr$ mg loading dose,C4086581
pinteraction $nmbr$ $nmbr$,
duration of pci min,C0449238;C2926735
$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0008107;C3259781
drug eluting stent no,C1322815
t $nmbr$ $nmbr$,C2603360
bare metal stent no,C2825200
hr $nmbr$ $nmbr$,
balloon angioplasty no,C0002996;C0002997
risk categories,C0035647;C0683312;C4552904
cangrelor clopidogrel no of events total no,C1121991;C0070166;C0439175;C0439810
fgf $nmbr$ low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
diagnosis at presentation,C0011900;C1704338;C1704656
fgf $nmbr$ low $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
biomarker status,C0449442
fgf $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
insulin dependent diabetes,C0011854
fgf $nmbr$ high $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
previous tia or stroke,C0007787;C0917805;C1054154;C0038454;C4554100
p interaction $nmbr$ $nmbr$,C0369773;C1704675;C2603361
history of pad,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ mw distance m,C0024548;C0012751;C0026385;C0556966
clopidogrel dose,C0178602;C0869039;C1114758
randomized treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
periprocedural anticoagulant,C0003280;C0848112;C3536711
ischemic hf etiology,C0015127;C1314792;C1524003
bivalirudin only,C0168273
pulmonary disease,C0024115
heparin only,C0019134;C0770546
ace i or arb,C0021966;C0221138;C3888198
arterial access,C0444454;C1554204
$nmbr$ yr km mortality rate,C0026565;C0205848
femoral,C0015811
icd vs placebo,C0021122;C0032042;C1696465;C1706408
radial,C0442038;C0920847
amiodarone vs placebo,C0002598;C0032042;C1696465;C1706408
no of vessels,C0005847
patients $nmbr$ y,C0030705
stent type,C0332307;C1547052
duration of diabetes y,C0449238;C2926735
drug eluting,C0013227;C1254351
patients with cardiac disorders n,C0741926
bare metal,C0025552
aspirin dose,C4696290
patients on antihypertensive medications n,C0030705;C0003364
timing of clopidogrel loading dose,C0449243;C1704250
number of patients randomized,C2360800;C0034656;C3815594
before pci,C4049621
number of swollen joints $nmbr$ $nmbr$,C0449813
after pci,C4049621
number of tender joints $nmbr$ $nmbr$,C0449813
duration of study drug infusion,C0489652
psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$,C0018563;C0016504;C0347981;C1552914
fibrinolysis n $nmbr$,C0016017;C1305868
all patients n,C0030705
p valuey,C0369773;C2603361
patients receiving mtx n,C0030705;C1514756;C0025677;C1417487
killip class no total no i,C1881332;C0439175;C0439810;C0021966;C0221138
patients not receiving mtx n,C0030705;C1518422;C1514756;C0025677;C1417487
infarct location no total no,C0450429;C1515974;C4284930;C4284931;C0439175;C0439810
patients with dactylitis,C0030705;C0239161
previous coronary artery bypass grafting,C2144990
dactylitis score $nmbr$ $nmbr$,C0449820;C4050231
median time delay interquartile range min,C0702093;C1524029;C3813700
patients with enthesitis,C0030705;C1282952
symptom onset to first medical contact ambulance or emergency department,C4086878;C0002422;C3846685;C0562508
psa modified mases score $nmbr$ $nmbr$,C0449820;C4050231
patients with $nmbr$ bsa,C0030705
randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079;C0007430;C0022877;C3244292;C4283904
haq di score $nmbr$ $nmbr$,C0449820;C4050231
randomization to arterial sheath insertion,C0034656;C0003842;C0221464
patients with fingernail involvement,C0522476
symptom onset to arrival in catheterization laboratory,C4086878;C1555577;C1706079;C0007430;C0022877;C3244292;C4283904
napsi score $nmbr$ $nmbr$ of target fingernail,C0449820;C4050231;C1521840;C0222001;C2986546
symptom onset to start of reperfusion treatment tenecteplase or arterial sheath insertion,C4086878;C0035124;C0684253;C0021107;C0441587;C1512796;C1883719
sf $nmbr$ summary scores,C0037712;C0449820
fibrinolysis primary pci n $nmbr$ n $nmbr$ no of patients total no,C0016017;C0205225;C0439612;C0439631;C1305868;C0030705;C0439175;C0439810
pcs score,C0449820;C4050231
relative risk $nmbr$ ci ofprimary end point,C2349179;C2826544
mcs score,C0449820;C4050231
overall event rate,C0871208;C1521828
patients receiving mtx,C0030705;C1514756;C0025677;C1417487
ii iv,C0022326;C4265176
eplerenone n $nmbr$,C0961485
place of randomization,C0442504;C1533810;C1704765;C1882509
race no b,C0034510;C1706779;C3853635
ambulance,C0002422;C3846685
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0017654;C0439445;C1424601;C0005902
community hospital,C0020003
serum potassium mmol l,C0302353;C1532563;C0543465
time of randomization,C0040223;C3541383
anterior mi,C3536746
before amendment,C0680532;C2346732
concomitant treatments at randomization,C0087111;C0034656
after amendment,C0680532;C2346732
acetylsalicylic acid,C0004057
ranolazine n $nmbr$ placebo n $nmbr$,C0073633;C0032042;C1696465;C1706408
prior angioplasty,C0162577;C1548817
p $nmbr$ y $nmbr$ antagonists,C0369773;C0243076;C2603361
heparins and fondaparinux,C0019134;C1098510
prior bypass graft surgery,C0455610
gp iib iiia inhibitors,C0016011;C0243077
duration of diabetes yrs,C0449238;C2926735
fibrinolytics,C0040044
antianginal medications,C0013227;C0802604;C2598133;C4284232
on $nmbr$,
pci thrombolysis at randomization,C0520997;C0034656
thrombolysis,C0520997
long acting nitrates,C0205166;C0028125;C1706317
no reperfusion,C0035124;C0684253
ace l arbs,C1452534;C3888198;C4284014
n participants,C0369718;C0679646;C0441922
baseline heart rate beats min,C0439385
age group $nmbr$,C0027362;C2348001
baseline systolic blood pressure mm hg,C4274438;C0439475
systolic blood pressure median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
baseline diastolic blood pressure mm hg,C4274392;C0439475
pulse pressure median $nmbr$ $nmbr$ ],C0549183;C0876920;C2347635;C2348144;C2939193
figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency,C2986480;C3695257
heart rate median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention,C0456603;C1547037;C1705241;C1705242;C0023732;C0332152;C0007447;C0740175;C2257086;C3669034;C1079231;C1547282;C2986480;C0397581
prior bb plus acbi plus arb use,C0004739;C0332297;C0042153;C0457083;C1947944
watchman n $nmbr$,C0335390
prior acbi or arb use,C0332152;C2826257;C0042153;C0457083;C1947944
height inches,C0489786;C0439204
anterior or non anterior ml,C0205094;C0439526;C1705224;C3887665
weight lbs,C0439219;C3161851
acute reperfusion,C0035124;C0684253
hawaiian pacific,C0337920
$nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
chads score,C0449820;C4050231
not perfused,C1518422;C1549542
warfarin naive,C0043031
use of pci or thrombolysis within one day of randomization,C1524063;C4049621;C0520997;C3844320
$nmbr$ days warfarin,C0439228;C0043031
first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms,C0178602;C0033727;C0369286;C0441932;C0564385;C4528284;C0869039;C1114758;C0687676;C4086878;C1704687;C3469826
experience,C0237607;C0596545
$nmbr$ $nmbr$ hours,C0439227
$nmbr$ yr warfarin experience,C0237607;C0596545
cardiac enzyates raised,C0018787;C1522601;C0442818
history of cad,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig,C2986535;C0205199;C1547335;C0961485;C0032042;C1696465;C1706408
mellitus,
zoledronic acid n $nmbr$,C0257685
clinical characteristics n,C0683325
age groups n,C0441848
egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
baseline bmi kg m $nmbr$,C0022718;C0439209;C4054209
pervious cerebrovascular event,C0441471;C4019010
baseline t score at femoral neck n,C0449820;C4050231
pad details n,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
entry hip fracture location n,C3260017
peripheral arterial revascularization,C0003842;C0581603;C0221464
intertrochanteric,C0745355
prior amputation,C0002688;C0332840;C1546539
subtrochanteric,
prior carotid intervention,C0184661;C0886296;C1273869
fracture history n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
abi,C1328319;C3888326
hip fracture only,C0019557;C0149531;C4552776
abi $nmbr$ $nmbr$,C1328319;C3888326
hip other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725;C0016658
claudication fontaine class $nmbr$,C0456387;C1518526;C1705943
hip $nmbr$ vertebral fractures,C0019557
baseline medical therapy n,C0168634;C0418981;C1442488
hip nonvertebral vertebral,C0019552;C0549207;C0022122;C1505163;C3538851;C4284725
no antiplatelet therapy,C1096021
fractures,C0016658
aspirin and thienopyridine therapy,C0004057;C0039798;C0087111;C1363945
cilostazol,C0055729
time to first infusion from hip surgery days n,C0040223;C3541383;C0596706;C0439228
vorapaxar n $nmbr$ n,C2974521
$nmbr$ weeks,C0439230
overall efficacy,C1280519;C1707887
baseline serum calcium level n,C0036785;C0728876
cvd mi stroke,C0038454;C4554100
prior use of osteoporosis medications n,C1524063
cvd mi stroke urgent coronary revascularization,C0007222;C0877341
bone mineral density g cm $nmbr$ mean sd,C0005938;C2699239;C0177804
cvd mi stroke urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
eq $nmbr$ dprofile mobility n,C0205163;C0080078;C0425245;C0449580;C4318935;C0439185
cvd mi stroke revascularization urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
walking,C0080331;C4283795;C4321241;C4321242
peripheral limb vascular efficacy,C1280519;C1707887
some walking,C0080331;C4283795;C4321241;C4321242
hospitalization for acute limb ischemia,C0019993;C2945695
mental status baseline spmsq scores n,C0278060;C0168634;C1442488
any peripheral revascularization,C0205100;C0581603
charlson comobility score n,C0449820;C4050231
urgent peripheral revascularization,C0205100;C0581603
between treatment comparison of percentage change from baseline in total hip bmd,C1299575;C1707455;C0168634;C1442488
elective peripheral revascularization,C0205100;C0581603
month $nmbr$ subgroup x treatment interaction p value,C0039798;C1709380;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
any vascular efficacy,C1280519;C1707887
age groups,C0027362
urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
t score at femoral neck,C3854607;C0015815
any revascularization,C0581603
$nmbr$ $nmbr$ and,
bleeding,C0019080
hip fracture $nmbr$,C0019557;C0149531;C4552776
gusto moderate severe bleed,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
time to first infusion,C0040223;C3541383
gusto severe bleed,C0205082;C0019080;C4050465;C4050466
calcium level,C0201925;C0428302
fatal bleed,C1302234;C0019080;C1705232
charlson,
nebivolol n $nmbr$,C0068475
mental status,C0278060
age years a,C1510829
eq $nmbr$ d mobility,C0205163;C0439185;C0080078;C0425245;C0449580;C4318935
trough seated sbp mmhg a,C0085805;C0439475
age mean sd years n,C1510829;C0444504;C2347634;C2348143
trough seated dbp mmhg a,C0277814;C0439475;C1283233
education mean sd years,C0013621;C0439234;C0013622;C0013658;C0039401
trough seated hr bpm a,C0444506;C0277814;C1283233
weight mean sd lbs,C0439219;C3161851
all men,C0025266
antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
all women,C0043210
st t wave n,C0036056;C0429103;C3272372
ethnicity t,C0015031;C0243103
lvh by ecg or echo n,C0232306;C0058928;C1655045
education y mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
visit $nmbr$ blood pressures,C0545082;C1272641;C1512346;C2826704
treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bp,C0037623;C1415692;C1708288;C4318478
blood pressure mm hg mean sd,C0428886;C2699239
serum potassium mean sd mmol l,C0302353;C1532563;C0543465
dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd,C0439269;C2699239
fasting serum glucose mean sd mg dl,C0202041;C0439269;C3534430
total glucose mg dl,C0017725;C0439269
serum cholesterol mean sd mg dl,C0587184;C0439269
diabetes mellitus classification,C0008902;C0008903;C0678229
treatment groups n,C0039798;C0441848;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
diabetes mellitust,C0011847;C0011849
history of mi or stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
normoglycemic^,C0580545
amlodipine vs chlorthalidone normal,C0051696;C0205307;C0231683;C0439166;C2347086;C4553972
history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
amlodipine vs chlorthalidone overweight,C0051696;C0008294;C0497406
st t wavett,C0036056;C3272372
amlodipine vs chlorthalidone obese,C0051696;C0008294;C0028754
$nmbr$ $nmbr$ $nmbr$ continued,C0549178
favors amlodipine favors chlorthalidone,C0051696;C0008294
estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
favors favors amlodipine chlorthalidone,C0051696;C0008294
atrial fibrillation flutter n,C0155709
lisinopril vs chlorthalidone normal,C0065374;C0205307;C0231683;C0439166;C2347086;C4553972
outcomes,C1274040
lisinopril vs chlorthalidone overweight,C0065374;C0008294;C0497406
$nmbr$ y rate per $nmbr$ persons se n,C0871208;C1521828
lisinopril vs chlorthalidone obese,C0065374;C0008294;C0028754
hazard ratio and $nmbr$ confidence interval,C2985465;C0009667
favors lisinopril favors chlorthalidone,C0065374;C0008294
a c,
favors favors lisinopril chlorthalidone,C0065374;C0008294
l c,C0439394;C1706495;C3642217
dulaglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total randomized n,C0439175;C0034656;C3815594;C0439810
fsg mg dl,C0439269
chd nonfatal mi fatal chd,C0280604;C1302234;C1705232;C3542407
prestudy treatment a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
secondary end points,C0027627;C2349179;C0175668;C0205436
no oam,
mortality outcomes,C0026565;C1274040;C0026566
$nmbr$ oam,
combined fatal nonfatal outcomes,C1548228
dulaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
heart failure treated hospitalized fatal,C1302234;C1705232
oam,
hospitalized fatal heart failure,C0018801;C0018802;C4554158
overall population n $nmbr$,C0282416;C0032659;C1257890;C1561607
hospitalized angina,C0701159;C0002962
tnf antagonist failure population n $nmbr$,C0231174;C0032659;C1257890;C0680095
insulin glargine n $nmbr$,C0907402
tnf antagonist naive subgroup n $nmbr$,C0231491;C1079230;C1515021
standard care n $nmbr$,C1442989;C1947933;C2828392
median age y range,C1514721;C2348147;C3542016
n $nmbr$ fatty acids n $nmbr$,C0369718;C0015684;C0441922
mean body weight kg range,C1514721;C2348147;C3542016
geographic distribution no,C0681686
median body mass index kg m $nmbr$ range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
history of cvd and of cv risk factors no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0035648;C1553898
median crohn s disease duration y range,C0549183;C0010346;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
prior cardiovascular event,C0332152;C1320716;C2826257
mean crp level mg l sd,C0439268;C2699239
prior or new diabetes,C0332152;C2826257;C0011847;C0011849
mean fecal calprotectin level mg g stool sd,C1300563;C2699239
impaired glucose tolerance or impaired fasting glucose,C0271650;C1272092
disease localization n,C0012634;C0475264;C1744691
microalbuminuria or macroalbuminuria,C0730345
ileocolonic both ileum and colon,C0020885;C0009368;C3888384
dietary epa dha intake mg day,C1286104;C0439422
history of crohn s disease surgery n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634;C0038894;C0038895;C0543467;C1274039
heart rate beats per minute,C0439385
history of fistulizing disease n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
laboratory investigations,C0022877;C1261322;C3244292;C4283904
corticosteroid use n,C0239126
fasting plasma glucose mmol l,C0202042;C1532563;C0455280
immunosuppressive use n,C0021081;C0042153;C0457083;C1947944
$nmbr$ $nmbr$ l l,C3539687
mesalamine use n a,C0127615;C0042153;C0457083;C1947944
l l $nmbr$ $nmbr$,C3539687
prior immunosuppressive exposure n,C0021081;C0274281;C0332157
ldl cholesterol mmol,C0023824;C0439190;C0202117
prior tnf antagonist failure n b,C3887647;C0231174;C0680095
serum creatinine gmol,C0201976;C0600061
$nmbr$ prior tnf antagonist failure n b,C3887647;C0231174;C0680095
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
$nmbr$ prior tnf antagonist failures n b,C3887647;C0231174;C0680095
urinary albumin creatinine ratio,C0486293;C1318293
overall n u $nmbr$,C0282416;C0439148;C1561607
cardiovascular and oral hypoglycemic drugs no,C0007226;C3887460;C0359086
insulin glargine n $nmbr$ ll,C0907402
asa or antiplatelet agent,C0004057;C3853627;C0085826
omega $nmbr$ fatty acid n $nmbr$,C1719844;C0015684
other oral hypoglycemic drug s,C0359086
placebo n $nmbr$ o,C0032042;C1696465;C1706408
carotid imt,C0334121;C1704614;C4318736
previous cardiovascular disease,C0205156;C0007222;C1552607
average maximum cimt mm,C4330985;C4554674
present smoker,C0150312;C0337664;C0449450
average of maximum common carotid cimt mm,C1510992;C2825518
laser or vitrectomy,C0023089;C0458142;C1023865;C1706315;C0042903
$nmbr$ $nmbr$ h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
depression^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
average maximum common and bifurcation cimt mm,C0205214;C1522138;C3245511;C4330985;C4554674
hba,C0019016;C1825777;C3538758
average of maximum far wall cimt mm,C1510992;C2825518
mini mental state examination,C0451306
insulin glargin arm,C0446516;C3715044;C4553528
digit symbol substitution,C1555721;C1706204
insulin glargine slope lsm se mm year,C0439234;C0439508
a mini mental state examination insulin glargine vs standard care,C0451306;C0907402;C1442989;C1947933;C2828392
standard care slope lsm se mm year,C0439234;C0439508
insulin glargine vs standard care least squares mean $nmbr$ cl,C0907402;C0023189;C0596019
difference glargine standard care lsm se mm year,C0439234;C0439508
p $nmbr$ interaction,C0369773;C1704675;C2603361
p value for interaction by region,C1709380;C1704675;C0017446;C0205147
number insulin glargine,C0237753;C0907402;C0449788
north america n $nmbr$,C0028405
number standard care,C1442989;C1947933;C2828392
south america n $nmbr$,C0037713
o oo $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0483204
n $nmbr$ fatty acit,C0369718;C0441922
$nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
s arm,C0446516;C3715044;C4553528
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$,
education $nmbr$ years,C0013621;C0439234;C0013622;C0013658;C0039401
n $nmbr$ fatty acids slope lsm se mm year,C0439234;C0439508
education $nmbr$ $nmbr$ years,C0013621;C0439234;C0013622;C0013658;C0039401
placebo slope lsm se mm year,C0439234;C0439508
hba median,C0549183;C0876920;C2347635;C2348144;C2939193
difference n $nmbr$ fa placebo lsm se mm year,C0439234;C0439508
hbak median,C0549183;C0876920;C2347635;C2348144;C2939193
other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers,C0015176;C0004340;C0021201;C2700456;C1511726;C3245479;C3714741;C0344329;C0392748
o oi $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0029118;C0029434
n $nmbr$ fatty acids placebo lsm $nmbr$ cl,C0015684;C0596019
omega $nmbr$ fatty acid,C1719844;C0015684
ageadj,
b digit symbol substitution insulin glargine vs standard care,C0907402;C1442989;C1947933;C2828392
no previous cv event,C0441471;C4019010
$nmbr$ $nmbr$ $nmbr$ $nmbr$ too $nmbr$,
previous cv event,C0441471;C4019010
hbalc median,C0549183;C0876920;C2347635;C2348144;C2939193
maximum cimt median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l $nmbr$ to $nmbr$ $nmbr$,C0439394;C1706495;C3642217
maximum cimt a med an,C0806909;C1552615;C2826546;C4321267
omega $nmbr$ fatty acid vs placebo least squares mean $nmbr$ cl,C1719844;C0015684;C0023189;C0596019
hbalc medan,
number omega $nmbr$ number placeb fatty acid,C0237753;C0015684;C0449788
hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
a mini mental state examination omega $nmbr$ fatty acids vs placebo,C0451306;C0015684;C0032042;C1696465;C1706408
tnglycendes median,C0549183;C0876920;C2347635;C2348144;C2939193
b digit symbol substitution omega $nmbr$ fatty acids vs placebo,C0582802;C0015684;C3241971;C0032042;C1696465;C1706408
tngtycendes a median,C0549183;C0876920;C2347635;C2348144;C2939193
etn mtx n $nmbr$,C0014758;C0025677;C1417487;C0717758
fastng plasma glucose median,C0549183;C0876920;C2347635;C2348144;C2939193
csdmards mtx n $nmbr$,C0025677;C1417487
fascng plasma glucose a medan,C0202042;C0455280
hcq mtx n $nmbr$,C0020336;C0025677;C1417487
no statin,C0360714
ssz mtx n $nmbr$,C0025677;C1417487
stalin,
lef mtx n $nmbr$,C0025677;C1417487
interactior p value,C1709380
race n b,C0034510;C1706779;C3853635
hba $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
african latin american,C0085756
triglycerides median,C0549183;C0876920;C2347635;C2348144;C2939193
mestizos,C0682082
fasting plasma glucose median,C0549183;C0876920;C2347635;C2348144;C2939193
sjc $nmbr$ joints,C0022417;C0392905
sita $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tjc $nmbr$ joints,C0022417;C0392905
cana $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cdai,C0683448;C1413248;C3273706
other i,C0021966;C0221138
haq,C0102923;C0451208
a $nmbr$ c mmol mol,C3829066
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0012634;C3900351;C0032659;C1257890
duration of type $nmbr$ diabetes years,C0449238;C2926735
n $nmbr$ for etn mtx n $nmbr$ for dmards,C0369718;C0441922;C0014758;C0025677;C1417487;C0717758;C0242708
supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1079230;C1515021
supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348;C3900351
ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0023189;C1710181;C1319635;C1418845
a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards,C0012634;C0032659;C1257890;C0014758;C0025677;C1417487;C0717758;C0242708
covariate,
a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C1836348;C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
cluster $nmbr$ diuretic n $nmbr$,C1555715;C0012798;C1704332
race n a,C0034510;C1706779;C3853635
cluster $nmbr$ reversible no diuretic n $nmbr$,C1555715;C0205343;C1704332;C0012798
region n a,C0017446;C0205147
cluster $nmbr$ not reversible no diuretic n $nmbr$,C1555715;C1704332;C1518422;C0205343;C0012798
central south america,C0007674
age median years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
mean sd hba $nmbr$ c level,C0441889;C0456079;C1547707;C2946261
iqr,
mean sd duration of t $nmbr$ dm y,C0449238;C2926735
median m kg $nmbr$ iqr,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
patients with microvascular complications n,C0030705;C0009566;C1171258
smoking mean,C0444504;C2347634;C2348143
patients with cardiac disorders n c,C0741926
pack years iqr,C1277691
mean treatment exposure wk,C0332174;C0439230
fev $nmbr$ predicted sd,C0681842;C2699239;C1882327
$nmbr$ st tertile,C0036056;C3272372
fev $nmbr$ reversibility sd,C0449261;C2699239
$nmbr$ nd tertile $nmbr$ to $nmbr$ $nmbr$ to,
reversibility stratum,C0449261
$nmbr$ rd tertile $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] d,C0439422
[no yes],C1549445;C1705108;C1710701
cana $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
exacerbations requiring hospitalisation past year,C4086268;C0019993;C0439234;C0439508
baseline mg dl mmol l,C0439268
exacerbations requiring oral steroids antibiotics past year,C4086268;C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
ls mean se,C0023668;C0036919
baseline medications,C0013227;C0802604;C2598133;C4284232
change mg dl mmol l,C0439268
anti thrombotics,C0087086
difference vs pbo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
lipid modifiers,C0023779;C4284280
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
blockers,
tcz sc $nmbr$ mg every other week n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332174;C0439230
psycholeptics,C3653516
pbo sc every other week n $nmbr$,C0031962;C0282380;C0332174;C0439230
anti histamines,C0019590
weight group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
anti anaemics,C0857322
other dmards,C0242708
anti hypertensives,C0003364
previous dmards mean sd,C0205156;C2699239;C1552607
glargine,C0907402
previously failed anti tnf treatment no,C0231175;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
standard therapy,C2936643
laboratory tests,C0022885
$nmbr$ drinks week,C0332174;C0439230
rf positive no,C0439178;C1446409;C1514241;C2825490;C3812269
$nmbr$ years education,C0013621;C0013622;C0013658;C0039401
acpa positive no,C0439178;C1446409;C1514241;C2825490;C3812269
depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
$nmbr$ h pg mmol l,C2827798;C2827804
crp level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
grip strength kg,C0022718;C0439209;C4054209
esr mean sd mg dl,C0444504;C0439269;C2347634;C2348143
bm $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
disease activity,C1292728
waist to hip male,C0230097;C0019552;C0022122;C1505163;C3538851;C4284725
duration of ra mean sd years,C0449238;C2926735
waist to hip female,C0230097;C0019552;C0022122;C1505163;C3538851;C4284725
tender joints $nmbr$ joint count mean sd,C0451530;C2699239
urine acr mg g,C0042036;C1300563;C0042037;C2963137
swollen joints $nmbr$ joint count mean sd,C0451521;C2699239
egfr ml min,C1739039;C0439445;C3811844;C3812682
das $nmbr$ mean sd,C0051767;C2699239;C0057671
alt units l,C1266129;C0439339;C4553172
shs mean sd,C0444504;C2699239;C2347634;C2348143
ldl mmol l,C1532563
jsn mean sd,C0444504;C2699239;C2347634;C2348143
hdl mmol l,C3715113;C1532563
erosion mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
tg mmol l,C0337445;C1532563
haq di score range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
omega $nmbr$ fa,C1719844
pain vas range $nmbr$ $nmbr$ mean sd,C0042815;C2699239
or $nmbr$ cl,C0596019
patient global assessment of disease,C4054229
age median,C0549183;C0876920;C2347635;C2348144;C2939193
activity range $nmbr$ $nmbr$ mean sd,C0205177;C2699239;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
alcohol,C0001962;C0001975
physician global assessment of disease,C4050369
alcohol $nmbr$ wk,C0332174;C0439230
study $nmbr$ $nmbr$,C0557651;C2603343
no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
olodaterol,C2934193
a $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ g n $nmbr$,C0439267
waist hip median,C0549183;C0876920;C2347635;C2348144;C2939193
pre bronchodilator mean sd fev $nmbr$ l,C2599602;C0444504;C2347634;C2348143
waisvhip median,C0549183;C0876920;C2347635;C2348144;C2939193
mean sd fev $nmbr$ l,C0444504;C2347634;C2348143
grip strength meidan,C0429271;C2598165
mean sd predicted normal fev $nmbr$,C0205307;C3714541;C0231683;C0439166;C2347086;C4553972
grip strength median,C0549183;C0876920;C2347635;C2348144;C2939193
mean sd fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
urine acr median,C0549183;C0876920;C2347635;C2348144;C2939193
mean sd change from pre to post bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
diabetic subjects n $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
gold stage n,C0018026;C0205390;C1300072;C1306673;C1304897
non diabetic subjects n $nmbr$,C1518422;C0241863
baseline pulmonary medications,C0013227;C0802604;C2598133;C4284232
alcohol usef n,C0001962;C0001975
any pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
serum urate mg dl n,C0455272;C0439269
sama b n,C1075468
years with gouty arthritis,C0439234;C0003868
lama tiotropium b n,C0999593;C0213771;C1416775
presence of tophi n,C0150312;C0392148;C3854307
saba inhaled c n,C0004048
renal function n,C0232804
laba inhaled d n,C0004048;C0369718;C0441922
figure $nmbr$ achievement of sua,C0001072
oral adrenergics n,C0442027;C0001637;C4521986
vildagliptin n $nmbr$,C1570906
steroids n,C0038317
gfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
inhaledb,
normal $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
oralb,
mild $nmbr$ to,C2945599
xanthines b n,C0043318;C3541955
moderate $nmbr$ to,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
mean se auc^p l,C0036919;C0376690
frailty status,C0424594;C0449438
olodaterol $nmbr$ jig,C2934193
hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
tiotropium n $nmbr$ non tiotropium n $nmbr$,C0213771;C1518422
frail,C0871754
non tiotropium,C1518422;C0213771
non frail,C1518422;C0871754
mean se trough l,C0444504;C0036919;C2347634;C2348143
tiotropium n z $nmbr$,C0213771
tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$,C0213771;C1518422
control n z $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
n unless otherwise specified,C0369718;C0441922;C0205369
copd duration y,C0024117;C0449238;C2926735;C1412502;C3714496
a vs c,
sabaa,
l vs c,C0439394;C1706495;C3642217
labaa,
education years mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
saaca,
type ii diabetes,C0011860
laaca,
icsa,
hx cabg,C0262926;C0010055;C3814444
ocs,
hx mi or stroke,C0262926;C3810814;C3814444;C0038454;C4554100
oascvd,
mean sd change in pre bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
visits $nmbr$ e $nmbr$,C0545082;C1512346
antihypertensive medication $nmbr$,C0003364
estrogen,C0014939;C2936882;C4542544
univariate p value,C1709380
multivariate p value,C1709380
heart rate mean sd,C0018810;C2699239
male n z $nmbr$,C0086582;C1706180;C1706428;C1706429
lvh by ecg minnesota code,C0232306;C0009219;C0805701;C3889831
female n z $nmbr$,C0043210;C0086287;C1705497;C1705498
cholesterol mg dl mean sd,C0439269;C2699239
current smoker n z $nmbr$,C3173209;C3241966
fasting glucose mg dl mean sd,C0439269;C2699239
ex smoker n z $nmbr$,C0337671;C4555205
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
treatment arm,C1522541
blood pressure mmhg mean sd,C0428886;C2699239
copd severity gold stage,C0205390;C1300072;C1306673
systolic total,C0439175;C0439810
iorii n z $nmbr$,
diastolic total,C0439175;C0439810
iii n z $nmbr$,C0439070;C1705160
systolic treated at baseline,C0039155;C1522326;C0168634;C1442488
iv n z $nmbr$,C0022326;C4265176
diastolic treated at baseline,C0012000;C1522326;C0168634;C1442488
bronchodilator response ml,C0439526;C1705224;C3887665
asia n $nmbr$,C0003980
interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure,C1704675;C1709380;C0332283;C1719822;C4281991;C0051696;C0008294;C0001779;C0011847;C0065374;C0011849;C0085096;C1704436;C0008976;C0019993;C0184661;C2700391;C3274430;C3539779
eastern europe n $nmbr$,C0015177
$nmbr$ mg mtx,C0025677;C1417487
latin america n $nmbr$,C0023122
patients with prior dmard use n a,C0030705;C0042153;C0457083;C1947944
western europe n $nmbr$,C0043129
hydroxychloroquine,C0020336
sulfasalazine,C0036078
higher target group n $nmbr$,C0441848
lower target group n $nmbr$,C0441848
patients taking oral corticosteroids at baseline n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
prednisone or equivalent dose mg day,C0032952;C0178602;C0439422;C0869039;C1114758
blood pressure at entry mm hg,C0005823;C1271104;C1272641
anti ccp antibody positive n,C0432633
ischaemic heart disease,C0010054;C0151744
total vdh s score,C2964552
previous clinical stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
diuretics group n $nmbr$,C0012798;C0441848
current tobacco smoker,C3173209;C3241966
no diuretics group n $nmbr$,C0012798;C0441848
ischaemic stroke,C0948008
on drug treatment,C0150270;C3469597
number of antihypertensive medications at study entry,C1718138;C0557651;C1705654;C2603343
mean number of antihypertensive medications at $nmbr$ year,C0444504;C1718138;C2347634;C2348143;C0439234;C0439508
positive family history of type $nmbr$ diabetes,C1313937
types of antihypertensive medications at $nmbr$ year,C0457591;C0439234;C0439508
history of peripheral arterial disease,C0683519;C0730226;C0850708;C0944983
ace inhibitor arb,C0003015;C3888198;C4541021
pulse rate bpm,C0232117
mean number of antihypertensive medication at last visit,C0444504;C0237753;C0449788;C2347634;C2348143;C0545082;C1512346;C2826704
uric acid mg dl,C0041980;C0439269
types of antihypertensive medications at last visit,C0457591;C0545082;C1512346;C2826704
k mmol l,C0597277;C1532563;C1708601
statins used during follow up,C0360714;C1273517;C0589120;C1522577;C1704685;C3274571
na mmol l,C0597484;C1532563;C1272460;C1546968;C1879645;C4049872;C4552882
number of events annualised rate [ ],C4330837
triglyceride mg dl,C0041004;C0439269
age p $nmbr$ $nmbr$,C0001779
non diuretics,C1518422;C0012798
sex p $nmbr$ $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
fbs $nmbr$ mg dl,C3812213;C0439269
history of diabetes p $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fbs,C3812213
with beta blocker,C0001645
non diabetic n $nmbr$,C1518422;C0241863
diabetes n $nmbr$,C0011847;C0011849
without beta blocker,C0001645
race p $nmbr$ $nmbr$,C0034510;C1706779;C3853635
with acei arb,C3888198
other mixed n $nmbr$,C0205430;C3160715
without acei arb,C3888198
region of residence p $nmbr$ $nmbr$,C0017446;C0205147
continuation n $nmbr$,
spain n $nmbr$,C0037747
interruption n $nmbr$,C0332453;C1512900
baseline sbp p $nmbr$ $nmbr$,C0168634;C0085805;C1442488
age in years,C1510829
normotensive n $nmbr$,C2712122
older than $nmbr$ years,C0580836;C0439234
sbp median n $nmbr$,C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
body weight index kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
dyslipidaemia,C0242339
ala carriers,C0523459;C0007294;C3888236
high on treatment platelet reactivity,C0039798;C0005821;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pro pro homozygotes,C1120626;C0019904
prior percutaneous coronary intervention,C0332152;C1532338;C2826257
sex male n,C0086582
prior coronary artery bypass graft,C0010055;C1260596
mmol mol,C3829066
calcium channel inhibitor,C0006685;C1999216
map mmhg,C0024779;C0439475;C1706473;C4050322
drug eluting stent implanted,C1322815;C0021102;C2828363
uae p g min,C1519789;C0560021
first generation stentt,C0205435;C0079411;C3146294;C1279901
acei vs non acei,C1518422
second generation stent,C0079411;C0038257;C3146294
renal events,C0441471;C3541888
stented vessel,C0038257;C0005847
cvd events,C0441471;C3541888
coronary artery bypass graft,C0010055;C1260596
composite events,C0441471;C3541888
continuation,
golimumab,C2353893
interruption,C0332453;C1512900
$nmbr$ $nmbr$ mga n $nmbr$,C0065879
aqc $nmbr$,
uc disease duration y,C0872146
woman,C0043210;C4281745
limited to left side of colon,C0439801;C2674459;C3542948;C4050251
no smoking,C0037369;C0453996;C1881674
mayo score $nmbr$ $nmbr$,C0449820;C4050231
number stent $nmbr$,C0237753;C0038257;C0449788
endoscopy subscore n,C0014245
full population,C0032659;C1257890
moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
aqc,
severe disease,C1836348
olodaterol $nmbr$ gg n $nmbr$,C0017454;C0018370
formoterol $nmbr$ gg n $nmbr$,C0017454;C0018370
crp mg l n,C3890735;C0439268;C4048285
pre bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
patients receiving any uc medication n,C0030705;C1514756;C0013227;C3244316;C4284232
corticosteroids excluding budesonide,C0001617;C3539185;C3540725;C3540726;C3540727
post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ mg d peq,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd of predicted normal fev $nmbr$,C2699239;C0520835
immunomodulatory drugs,C0013227;C3687832
baseline pulmonary medication b n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
$nmbr$ mercaptopurine azathioprine,C0000618;C0004482
samac,
golimumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lamad,
sabae,
baseline corticosteroid use,C0168634;C0239126;C1442488
icsf,
ne ne,C0027608;C0028219;C3538705
xanthinesg,
normonatremic $nmbr$ meq l at baseline,C0439375;C0168634;C1442488
mean se auc $nmbr$ $nmbr$ l,C0036919;C0376690
hyponatremic,C0857122
placebo tiotropium n $nmbr$ non tiotropium n $nmbr$,C0032042;C0213771;C1696465;C1706408
p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo,C1709380;C1176308;C0857122;C0032042;C1696465;C1706408
olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
placebo n $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$,C0060657;C0213771
placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
omalizumab,C0966225
age y sd,C0001779;C2699239
x $nmbr$ years,C0439234
systolic blood pressure mm hg sd,C0488055;C2699239;C0871470;C1306620
o $nmbr$ kg n,C0022718;C0439209;C4054209
diastolic blood pressure mm hg sd,C0428883;C2699239;C1305849
body mass index kgm _ $nmbr$,C0005893;C0578022;C1305855
heart rate sd,C0018810;C2699239
time since diagnosis of ciu csu years $nmbr$,C0556970;C0011900;C1704338;C1704656
history of htn,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cu index test n $nmbr$,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
intravenous vasoactive drugs y,C0683092;C1980011
no of previous ciu csu medications,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
nesiritide z,C0054015
median range total ige level iuml $nmbr$,C0439175;C0439810
edema z,C0013604;C1717255
in clinic uas $nmbr$,C0150312;C0002424;C0442592;C0332285;C1707101
jvd $nmbr$ cm h $nmbr$ o,C0425687;C0455483
uas $nmbr$,
duration of hf y,C0449238;C2926735
weekly iss $nmbr$,C1740819;C1845118
prior hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
weekly number of hives score $nmbr$,C0237753;C0449788
nyha iv,C0022326;C4265176
overall dlqi score $nmbr$,C0282416;C3897059;C1561607
blood urea nitrogen mg dl,C0005845;C0439269;C0600137
angioedema present n $nmbr$,C0002994;C0150312;C0449450
non asian n $nmbr$ $nmbr$,C1518422;C0078988
lsm difference $nmbr$ cl,C1705241;C0596019;C1705242
$nmbr$ n weight kg,C0022718;C0439209;C4054209
sia,C1225105;C1551538
type of atrial fibrillation,C0332307;C1547052
non united states,C1518422;C0041703
paroxysmal n,C0205311
baseline weekly itch severity score,C0033774;C0457451;C1422257
persistent n,C0205322;C0332996
baseline urticaria activity score,C0042109;C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939;C1559188
permanent n,C0205355
a median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ n chads $nmbr$ score,C0449820;C4050231
body weiqht,C0242821;C0460148;C1268086;C4082212
previous stroke yes n previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
positive cu index test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
heat failure,C0231174;C0680095
presence of angioedema at baseline,C0150312;C0392148;C3854307;C0168634;C1442488
diabetes mellitus yes n hypertension,C0020538;C1963138
previous use of systemic steroids for ciu csu,C0281991;C0578870
medication in use at the baseline,C0013227;C3244316;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
level of thyroperoxidase antibody at baseline,C0428536;C0168634;C1442488
arb n,C3888198
high $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
ace i n,C0021966;C0221138
normal $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
blocker n,
duration of disease before baseline,C0872146;C0168634;C1442488
verapamil n,C0042523
previous number of ciu csu medications,C0205156;C1718138;C1552607
proton pump inhibitor n,C0358591;C3536754;C4521480
figure $nmbr$,
h $nmbr$ blocker n long term vka therapy,C0039798;C0087111;C1363945
b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug,C0018623;C0456603;C1610540;C0030705;C0441767;C1706317;C0009667;C0242708
experience n,C0237607;C0596545
lipoprotein a mg dl,C0065058;C0439269;C0125953;C1096202;C1439335
non asian,C1518422;C0078988
event number,C0237753;C0449788
fasting blood glucose mg dl,C0428568;C0439269;C1261430
$nmbr$ a,
tcz $nmbr$ mg kg n $nmbr$,C0439272
former or current smokers,C0205156;C0750523;C3173209;C3241966
positive hla b $nmbr$ status n,C1426226
baseline high density lipoprotein cholesterol mg dl,C0023822;C0439269
as duration y mean sd,C0444504;C2699239;C2347634;C2348143
no of cardiovascular events cardiovascular events $nmbr$ person years,C1320716;C0027361;C2347489
swollen joints $nmbr$ n,C0152031
pfor trend,C1521798;C4554533
basdai score mean sd,C0444504;C2699239;C2347634;C2348143
chd plus cerebral infarction,C0280604;C3542407
crp mg dl mean sd,C0439269;C2699239
total deaths,C0011065;C1306577
crp mg dl median,C0549183;C0876920;C2347635;C2348144;C2939193
pharmaco invasive n $nmbr$,C0205281;C1334278
rvalue for interaction,C1704675
age $nmbr$ y n,C0001779
favors dabigatran,C0309049;C2348066
killip class ii iv n,C2697847
no heart failure,C0018801;C0018802;C4554158
timi risk score $nmbr$ n,C0035647;C0449820;C4050231;C4552904
prior stroke tia,C0007787;C0917805;C1054154
time to randomization from symptom onset,C0040223;C3541383;C4086878
no prior stroke tia,C0007787;C0917805;C1054154
$nmbr$ h n,C0033727;C0369286;C0441932;C0564385;C4528284
chadsa,
chadsj $nmbr$,
anterior n,C0205094
cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$,C1420648;C3714751
inferior n,C0542339;C0678975
chajdsa vasc $nmbr$ $nmbr$,
ambulance n,C0002422;C3846685
chajdsj vasc $nmbr$,
community hospital n,C0020003
has bledo,C1019275
all cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C1524003
has bled $nmbr$ $nmbr$,C0019080
age [years] interaction p $nmbr$ $nmbr$,C0001779;C0439234;C1704675
has bled $nmbr$,C0019080
time to randomisation [hours] interaction p $nmbr$ $nmbr$,C0040223;C3541383;C0439227;C1704675
sbp $nmbr$ mm hg,C0085805;C0439475
previous ml interaction p $nmbr$ $nmbr$,C0205156;C0439526;C1705224;C3887665;C1552607
crcl,C1846718
sex interaction p $nmbr$ $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
crcl $nmbr$ ml min,C1846718;C0439445
systolic blood pressure [mmhg] interaction p $nmbr$ $nmbr$,C0488055;C0871470;C1306620;C0439475;C1704675
history of cad mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
killip class interaction p $nmbr$ $nmbr$,C1881332;C1704675
no cad mi,C1504769;C3810814;C2239547;C3813548;C4284121
infarct location interactsn p $nmbr$ $nmbr$,C0021308;C0450429;C1515974;C4284930;C4284931
chadsj,
other diabetes interaction p $nmbr$ $nmbr$,C0011847;C0011849
chajdsrvasc $nmbr$ $nmbr$,
yes weight [kg] interaction p $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209;C1704675
chajdsj vasc $nmbr$ $nmbr$,
p lace of randomization interaction p $nmbr$ $nmbr$,C0280109;C0453991
sbp $nmbr$ mmhg,C0085805;C0439475
timi risk score interaction p $nmbr$ $nmbr$,C0035647;C0449820;C4050231;C4552904
nocad mi,C3810814
time of randomization interaction p $nmbr$ $nmbr$,C0040223;C3541383
$nmbr$ e h,C0033727;C0369286;C0441932;C0564385;C4528284
prehospital ticagrelor n $nmbr$,C1999375
chads $nmbr$ $nmbr$,C0007928;C1413373
in hospital ticagrelor n $nmbr$,C0019994;C1510665
chad $nmbr$ $nmbr$,C0007928;C1413373
bmi $nmbr$ no f,C0578022;C0016327
cha $nmbr$ ds $nmbr$ vasc $nmbr$,C1420648;C3714751
timi risk score no t,C0035647;C0449820;C4050231;C4552904;C2603360
sbp $nmbr$ mnn hg,C0025424;C0428257;C2347108;C2347109;C2348272
intensified n $nmbr$,
killip class i no,C2697844
history of nicotine use,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
first medical contact no,C0332158;C0337611;C1705415;C3812666
in ambulance,C0002422;C3846685
history of alcohol use,C0551571;C0552479
in emergency department before ambulance transfer,C0562508;C0002422;C3846685
chronic obstructive lung disease,C0024117
procedures for index event,C0025664;C0184661;C2700391;C3538935
retinopathy stage $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0205390;C1300072;C1306673
coronary angiography no,C0085532;C1548829
peripheral artery occlusive disease,C1306889
femoral access no total no,C0444454;C1554204;C0439175;C0439810
peripheral artery occlusive disease stage $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0699749
radial access no total no,C0444454;C1554204;C0439175;C0439810
cerebral vascular disease,C0007820
missing data no total no,C4684714;C0439175;C0439810
peripheral neuropathy,C0031117
thromboaspiration no,
control baseline n $nmbr$,C0243148;C0168634;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
with stent^l,C0038257
intensified baseline n $nmbr$,C0168634;C1442488
no pci or cabg no,C4049621;C0010055
control $nmbr$ months n $nmbr$,C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
study medication no,C0013227;C3244316;C4284232
intensified $nmbr$ months n $nmbr$,C0439231
first loading dose,C0205435;C3714444;C1279901
blood pressure systolic mm hg,C0005823;C0439475;C1271104;C1272641
second loading dose,C0205436;C3714444;C0457385;C0565930;C1561503;C1705190
ras antagonist,C0034678;C0231491;C0525678
maintenance dose,C3714445
ras target dose,C0178602;C0869039;C1114758
any use,C0042153;C0457083;C1947944
beta blocker target dose,C0178602;C0869039;C1114758
other antithrombotic medication for index event no,C0013227;C3244316;C4284232
oral antidiabetic drugs,C0029167;C0175795;C0304289
glycoprotein ilb iiia inhibitor before pci],C0017968;C1999216
normal cognitive,C0205307;C0231683;C0439166;C2347086;C4553972;C1516691
intravenous anticoagulant during hospitalization,C0003280;C0848112;C3536711
impaired cognitive,C0221099;C1516691
combination therapy,C0009429;C0556895
status spmsq,C0449438
total patients,C0439175;C0030705;C0439810
status spmsq $nmbr$,C0449438
endpoint rate,C0871208;C1521828
female gender,C0086287
p value int,C1709380;C3272375
treatment arm zoledronate,C1522541;C0392938
pre h,C0033727;C0369286;C0441932;C0564385;C4528284
bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
in h,C0033727;C0369286;C0441932;C0564385;C4528284
total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0019552;C2699239;C0022122;C1505163;C3538851;C4284725
n nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0015815;C2699239
so $nmbr$,
fn t score,C0449820;C4050231
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ j $nmbr$,
op concomitant medications,C0013227;C0802604;C2598133;C4284232
location of ml,C0450429;C1515974;C4284930;C4284931
charlson index,C0600653;C0918012;C1552854;C1637833;C2986546
tim $nmbr$ nsk score,C0449820;C4050231
normal cognitive function spmsq,C4296962
highest killip classiciation pre pci,C1522410;C0332152;C0740175;C2257086;C3669034
impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest,C0009240;C0679646;C0392335;C4050130
$nmbr$ ix,C0015491
chi square p value,C1552646;C1709380
prior asa use,C0042153;C0457083;C1947944
clinical fracture,C0205210;C0016658
gpiib llla inhibitor use before angiography,C0042153;C0457083;C1947944
zoledronic acid arm,C0446516;C3715044;C4553528
morphine use for index event pci,C0242000;C0441471;C4019010
placebo arm,C0446516;C3715044;C4553528
heparin fondaparinux or bivalirudin use between index event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
sita $nmbr$,
total atients,C0439175;C0439810
pio $nmbr$,C0030800;C2347712
tlmi risk score,C0035647;C0449820;C4050231;C4552904
sita $nmbr$ pio $nmbr$,C0030800;C2347712
so,
american indian or native alaskan,C0002460;C0682125
gpifo llia inhibitor use before angography,C0042153;C0457083;C1947944
ethnicity hispanic or latino,C0015031;C0086409;C0243103;C0086528
heparin fondaparinux or brvalirudin use between oex event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
a $nmbr$ c distribution,C0520511;C1704711
ivabradine n $nmbr$,C0257190
$nmbr$ $nmbr$ and $nmbr$ $nmbr$,
cardiovascular risk factors and medical history,C0850624;C0262926;C1704706
known duration of type $nmbr$ diabetes years,C0449238;C2926735
duration of coronary artery disease yr,C0872146
received an oral aha within $nmbr$ weeks prior to screening,C1514756;C0050451;C0772110;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
previous coronary revascularization no,C0205156;C0877341;C1552607
sita pio $nmbr$ $nmbr$,C0030800;C2347712
angina status no,C0002962;C0449438
a $nmbr$ c at baseline,C0168634;C1442488
no symptoms,C0683368;C1457887
a $nmbr$ c at baseline $nmbr$ $nmbr$,C0168634;C1442488
ccs class,C1879987
empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous stroke no,C0038454;C4554100
o total randomized,C0439175;C0439810;C0034656;C3815594
concomitant treatment no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pen label empagliflozin $nmbr$ mg baseline hba $nmbr$ c $nmbr$,C0024671;C0019016;C1825777;C3538758;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
antiplatelet agent or anticoagulant,C0085826;C0003280;C0848112;C3536711
time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
angiotensin il receptor blocker,C0034787;C1622222
$nmbr$ year,C0439234;C0439508
dihydropyridine calcium channel blocker,C2945601
mdg mmol l,C0024443;C1532563;C1417239;C2986643
diltiazem or verapamil,C0012373;C0042523
egfr ml min $nmbr$ $nmbr$ m $nmbr$ [mdrdequation],C1739039;C0439445;C3811844;C3812682
antidiabetic agent,C0935929
patients with egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0030705;C0439445
plus minus values are means sd there were no significant differences at,C0042295;C1704970;C2699239;C0237881;C0750502;C1546944
change from baseline in hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0019016;C1825777;C3538758
denotes angiotensin converting enzyme,C0022709;C1452534
difference vs placebo,C1705241;C1705242;C0032042;C1696465;C1706408
j the body mass index is the weight in kilograms divided by the square of the,C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595
patients with egfr $nmbr$ $nmbr$ to $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0030705;C1739039;C3811844;C3812682;C0439445
height in meters,C0489786;C0441074
vedolizumab,C2742797
race was determined by the investigator during the patient s interview,C0034510;C1706779;C3853635;C0521095;C0035173;C0030705;C0021822;C0935630
cohort $nmbr$ n $nmbr$ f,C0009247;C0016327;C0599755
classes on the canadian cardiovascular society ccs scale range from i to iv,C0007226;C1879987;C3887460;C0022326;C4265176
cohort $nmbr$ n $nmbr$,C0009247;C0599755
with higher classes indicating greater limitations on physical activity owing to,C0456387;C1518526;C1705943;C4019422;C0449295;C0015259;C0026606
white race no,C0007457;C0043157
ivabradine,C0257190
mayo clinic score,C0449820;C4050231
no of events total no,C0439175;C0439810
partial mayo clinic scored,C0002424;C0442592;C0449820
angina class at baseline,C0456387;C1518526;C1705943
ibdq score,C0449820;C4050231
class i or no symptoms,C0441885;C1319793;C2698967;C0683368;C1457887
fecal calprotectin pg g,C0015733;C1638318
beta blocker use at randomization,C0042153;C0457083;C1947944
site of disease no,C2945843;C0012634
$nmbr$ beats min,C0439385
rectum and sigmoid colon only,C0034896;C0227391
total by treatment,C0439175;C0439810
left side of colon,C0227388
early,C1279919
proximal to the splenic flexure,C0205107;C4489236
delayed,C0205421;C1545665;C3272602
all of the colon,C0009368;C3888384
vka n $nmbr$,
concomitant medications for ulcerative colitis no,C0013227;C0802604;C2598133;C4284232
creatinine clearance an,C0812399
immunosuppressants onlyff,C0021081
prior non cns se,C0332152;C0036919;C2826257
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778;C0021081
prior tia,C0007787;C0917805;C1054154
no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778;C0021081
nyha class iii iv,C0278962
prednisone equivalent dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vascular disease,C0042373
prior anti tnf therapy no,C1514463
first diagnosed,C0205435;C1279901;C0011900
prior failure of anti tnf therapy no,C0231174;C0680095;C0279936
long standing persistent,C0205322;C0332996
$nmbr$ failure,C0231174;C0680095
cha $nmbr$ ds $nmbr$ vasc score n,C1420648;C0449820;C4050231
inadequate response,C0871261;C1704632;C1706817;C2911692
$nmbr$ or $nmbr$ if female only,C0043210;C0086287;C1705497;C1705498
loss of response,C1517945;C0871261;C1704632;C1706817;C2911692
$nmbr$ except for female alone,C0043210;C0086287;C1705497;C1705498;C0205171;C0439044;C0679994
unacceptable adverse events,C0877248;C1705413
oac experienced bn,C0005005;C0034700;C1706574;C4551963
hemoglobin concentration g liter,C1319312;C0475211
antiarrhythmic drugs n,C0003195
white cell count x $nmbr$ _ $nmbr$ liter,C0023508;C0475211;C0427512
dronedarone,C0766326
estimated difference,C1705241;C1705242
flecainide,C0016229
duration of ulcerative colitis,C0449238;C2926735
propafenone,C0033429
$nmbr$ to $nmbr$ y,
others classes i and iiic,C0441885;C1319793;C2698967
pancolitis,C0868908
outcome_type,C0332307;C1547052
baseline composite mayo clinic score,C4055211;C0002424;C0442592
efficacy n a,C1280519;C1707887
baseline fecal calprotectin,C0015733;C0950624;C1335798;C1366582
safety n b,C0036043;C1705187
$nmbr$ mcg g,C0439272
fatal,C1302234;C1705232
prior treatment history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
critical site,C0205145;C1515974;C2825164
any prior anti tnf treatment failure,C1514463
ich,C0019191;C3272597;C3281105
prior immunnosupressive failure but no anti tnf failure,C0332152;C0231174;C0680095;C2826257
hb decrease $nmbr$ g dl,C0439267
prior corticosteroid failure only,C0231174;C0680095
transfusion $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C1879316;C0229664;C0370231;C1546552;C1608383
stratification variables,C1514983;C0439828
prior heart failure n $nmbr$ $nmbr$,C0018801;C0018802;C4554158
concomitant corticosteroid use,C0521115;C0239126
no prior heart failure n $nmbr$ $nmbr$,C0018801;C0018802;C4554158
no concomitant cortcosteroid use,C0042153;C0457083;C1947944
age years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
multiracial n,C1881928
no concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
weight kg median iqr,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
patients with deep vein thrombosis only,C0030705;C0149871
weight $nmbr$ kg n,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
patients with pulmonary embolism,C0030705;C0034065
body mass index kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
edoxaban n $nmbr$,C2975435
body mass index $nmbr$ n,C0005893;C0578022;C1305855
creatinine clearance $nmbr$ to,C0812399
duration of diabetes median iqr,C0449238;C2926735
patients receiving $nmbr$ mg of edoxaban at randomization no f,C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0034656;C0016327
established atherosclerotic disease n,C0333482;C0012634
anatomical extent of qualifying event no t,C0220784;C0439792;C1514624;C0441471;C4019010;C2603360
prior coronary revascularization n,C0332152;C0877341;C2826257
not assessable,C1883425
glycated hemoglobin median iqr,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
concomitant dvt no baseline nt probnp no,C0149871;C2926618;C3899446;C0669479;C0754710
glycated hemoglobin n,C0062408
patients with measurement,C0030705;C0242485
fasting serum glucose mg dl median iqr,C0202041;C0439269;C3534430
patients with level $nmbr$ pg ml,C0030705;C0439297
estimated glomerular filtration rate ml min median iqr,C3811844;C0439445
right ventricular dysfunction no total no,C0242707;C1556315;C0439175;C0439810
estimated glomerular filtration rate n,C3811844
causes of dvt or pe no ^,C0015127;C1314792;C0070939;C1880476;C4284304
albumin creatinine ratio mg mmol median iqr,C0486293;C1318293
temporary risk factor,C0205374;C0035648;C1548539;C3245481
albumin creatinine ratio n,C0486293;C1318293
edoxaban,C2975435
$nmbr$ $nmbr$ mg mmol,C0567349;C2348885
presenting diagnosis,C0449450;C0011900;C1704338;C1704656
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
pe with without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
baseline cardiovascular medications n,C0168634;C0007220;C1442488
gendar,
baseline anti hyperglycemic medications n,C0432633;C0013227;C0802604;C2598133;C4284232
baseline risk factors,C0035648;C1553898
thiazolidinediones,C1257987;C3541957
temporary factors,C1521761;C2827422
state,C1301808;C1442792;C3148680
all others,C1955473;C3539125
glomerular filtration rate,C0017654;C1561549
need for $nmbr$ mg edoxaban dose at randomization,C4086581;C2975435;C0034656
baseline albumin,C0168634;C0001924;C1442488
body weight at randomization ixrs,C0005910;C1305866
creatinine ratio pg mg,C0010294;C1627892;C1561535
$nmbr$ is $nmbr$ $nmbr$,
baseline beta blocker,C0168634;C0001645;C1442488
body weight at randomization,C0005910;C1305866
baseline calcium antagonist,C0168634;C0006684;C1442488
creatinine clearance at randomization,C0812399;C0034656
mepolizumab,C0969324
fragile,
intravenous n $nmbr$,C0348016
fl $nmbr$ b,C1300812;C1708024
subcutaneous n $nmbr$,C0443315
southern europe,C0037724
mean age range yr,C0001779;C0439234
nordic,C0331873
former smoker no,C0337671
china japan,C0008115;C0022341
duration of asthma yr,C0449238;C2926735
south africa south america,C0037713
usa canada,C0041703;C0006823
use of oral glucocorticoids,C1524063
$nmbr$ t $nmbr$ $nmbr$,C2603360
maintenance use no,C0042153;C0457083;C1947944
american indian or,C0002460
mean daily dose range mg i,C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
native hawaiian or,C0337920
allergic rhinitis no,C1334103;C2607914;C4552864
other pacific islander,C0242191
fev $nmbr$,C3714541
medical history cancer,C0006826;C0998265;C1306459
before bronchodilation liters,C1371299;C0475211;C3537072
no history of cancer,C0455471
percent of predicted value before bronchodilation^,C1882327;C1371299;C3537072
fevt fvc ratio,C0456603;C1547037
active cancer at randomisation,C0006826;C0998265;C1306459
morning peak expiratory flow liters min,C0702093;C1524029;C3813700
center level inr percent timein therapeutic range for warfarin subjects,C0460097;C0043031
score on asthma control questionnaire,C4706265
initial heparin treatment duration on or after randomization,C0444921;C3259042;C0034656
initial heparin treatment duration,C0444921;C3259042
score on st george s respiratory questionnaire^^,C0449820;C4050231;C0521346;C0034394;C1546767
median $nmbr$ days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
geometric mean ige on loge scale u ml,C0439340;C1880521;C2945590
initial type of heparin treatment received,C0019134;C0455708;C0770546;C1514756
geometric mean blood eosinophil count on loge scale cells ^ljj,C2986759;C0200638
concomitant aspirin use,C0042153;C0457083;C1947944
asthma exacerbations,C0349790
n t,C0369718;C0441922
severe episodes in previous year no patient,C0205082;C0332189;C4050465;C4050466;C0030705
need for $nmbr$ ng edoxaban dose at randomization,C0017887;C0028074;C0034656
necessitating hospitalization in previous year no,C0019993;C0205156;C1552607
body weight at randonization ixrs,C0005910;C1305866
history of asthma related intubation no,C0455544;C0021925
creatinine clearance at randomization ixrs,C0812399;C0034656
p $nmbr$ z $nmbr$ n $nmbr$,C0369773;C2603361
$nmbr$ $nmbr$ ml rain,C0439526;C0034640;C1705224;C3887665
$nmbr$ to $nmbr$ n,C0369718;C0441922
ho,C0019905;C1832110;C3889614
north america oceania,C0282279;C4085681
hordic,
femoral neck t score mean sd,C0015815;C2699239
china tjapan,C0008115
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n,C0369718;C0441922
fl $nmbr$ $nmbr$,C1300812;C1708024
mean bmd sd g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
active cancer at randomization,C0006826;C0998265;C1306459
lumbar,C0024090
ho active cancer,C0006826;C0998265;C1306459
prior medication use n,C0332152;C0240320;C2826257
center level ihr percent time in therapeutic range for warfarin subjects,C1554109;C0681850;C1550501;C1706203;C2349001;C2697811
calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
ib $nmbr$ $nmbr$,C2744579;C3890035;C4283819
serms,C0732611
saxagliptin n $nmbr$,C1611934
other osteoporosis medication,C0013227;C3244316;C4284232
hispanic ethnic group no i,C0015031;C1879937;C0021966;C0221138
mean sd days since,C0444504;C0439228;C2347634;C2348143
weight^,C0005910;C0043100;C1305866;C1705104
last infusion in the horizon pft,C0574032;C1827465
$nmbr$ kg no,C0022718;C0439209;C4054209
core study to first infusion,C0557651;C2603343
duration of diabetes yr^,C0449238;C2926735
in extension study,C0557651;C2603343
established atherosclerotic disease no,C0333482;C0012634
with ckd intensive n $nmbr$,C1561643
dyslipidemia no,C0242339
with ckd standard n $nmbr$,C1561643;C1442989;C2828392
prior heart failure no,C0018801;C0018802;C4554158
no ckd intensive n $nmbr$,C1561643
prior coronary revascularization no,C0332152;C0877341;C2826257
no ckd standard n $nmbr$,C1561643;C1442989;C2828392
mean ml min,C0444504;C0439445;C2347634;C2348143
o $nmbr$ $nmbr$,C0483204
albumin to creatinine ratio i,C0021966;C0221138
uacr mg g,C1300563
$nmbr$ yr km rate,C0871208;C1521828
no ckd,C1561643
saxagliptin,C1611934
ckd stage $nmbr$,C0205390;C1300072;C1306673
atherosclerosis,C0003850;C0004153
serum glucose mg dl,C0202041;C0439269;C3534430
established,C0443211;C1272684
duration of dm years,C0449238;C2926735
multiple risk factors,C0035648;C1553898
history of cvd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
merformin,
baseline glycated hemoglobin,C0168634;C0017853;C1442488
any anti hypertensive agent,C0003364
baseline insulin,C0021641;C1533581;C1579433;C3714501
dihydropyridine ccbs,C0012315;C0006684;C0220821
baseline sulfonylurea,C0038766;C3536898
non dihydropyridine ccbs,C0012315;C0006684;C0220821
baseline metformin,C0168634;C0025598;C1442488
fibrate,
baseline thiazolidinedione,C0289779;C1257987;C3537039
hdl female,C0043210;C0086287;C1705497;C1705498
baseline microalbumin,C0201838;C2362049
hdl male,C0086582;C1706180;C1706428;C1706429
creatinine ratio,C0456603;C1547037
ohs graduate,C0588053;C1547183
_ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
hs graduate ged,C0588053;C1880947;C1547183
p vaiue interaction,C0369773;C1704675;C2603361
some college tech,C0557806;C1826596
saxagiiptin,
piacebo,
college graduate or more,C0682187
$nmbr$ $nmbr$ to $nmbr$ i iot,C0021966;C0006196;C0221138
network,C0150775;C1513822;C1705739;C1882071
g,C0439267
prior hypertension,C0020538;C1963138
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
fp sal $nmbr$ $nmbr$ pg n $nmbr$,C0016704;C0030827;C0072225;C1266240;C1419068;C1419906;C3541238;C3541412
baseline aspirin,C0168634;C0004057;C1442488
sal $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
baseline statin,C0168634;C0360714;C1442488
copd type,C0332307;C1547052
baseline acei arb,C0168634;C3888198;C1442488
chronic bronchitis,C0008677
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$ t,C2603360
emphysema,C0013990;C0034067
baseline ccb,C0168634;C0006684;C1442488
smoking pack years,C0037369;C1277691;C0453996;C1881674
baseline diuretic,C0168634;C0012798;C1442488
baseline pre bronchodilator fev $nmbr$ l,C0168634;C2599602;C1442488
alogliptin n $nmbr$,C1958126
baseline predicted fev $nmbr$,C0168634;C3714541;C1442488
race or ethnic group no t,C0034510;C1706779;C3853635;C0015031;C1879937;C2603360
fev $nmbr$ reversibility,C3714541;C0449261
region of world no,C0017446;C0205147
non reversible,C1518422;C0205343
united states and canada,C0041703;C0006823
reversible,C0205343
western europe australia new zealand and middle east,C0027978;C0324547;C0026068
ratio fp sal sal $nmbr$ ci,C0008107;C3259781
central and south america and mexico,C0205099;C1879652;C0037713;C0025885
severe exacerbations itt population n,C0205082;C0032659;C1257890;C4050465;C4050466
eastern europe and africa,C0015177;C0001737
patients having exacerbation,C0030705;C4086268
asia and pacific islands,C0003980;C0030168
number of exacerbations,C0237753;C0449788
mean annualized exacerbation rate,C0871208;C1521828
cardiovascular risk factors and history no,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
estimated glomerular filtration rate^,C3811844
moderate severe exacerbations itt population n,C0205081;C0032659;C1257890;C1881878;C4049705;C4049706;C4085643;C4321335
median ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
moderate severe exacerbations patient subgroups n,C0205081;C0030705;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ no,C0439445
baseline post bronchodilator predicted fev $nmbr$ and prior ics use,C2599594;C3714541;C0042153;C0457083;C1947944
index acs no,C0742343;C4318612
baseline post bronchodilator predicted fev $nmbr$ and no prior ics use,C2599594;C3714541;C0042153;C0457083;C1947944
unstable angina requiring hospitalization,C0002965;C0019993
baseline post bronchodilator predicted fev $nmbr$ and concurrent tiotropium use,C2599594;C3714541;C0042153;C0457083;C1947944
time between index acs and randomization days,C0040223;C3541383;C0034656;C0439228
exacerbations,C4086268
alogliptin,C1958126
baseline post bronchodilator predicted fev $nmbr$ and no concurrent tiotropium,C2599594;C3714541;C0205420;C0213771
hazard,C0598697
baseline post bronchodilator predicted fev $nmbr$,C2599594;C3714541
with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
patients using concurrent tiotropium,C0030705;C1524063;C0205420;C0213771
overall treatment effect,C0282416;C1518681;C1561607
$nmbr$ mg empagliflozin,C0024671;C3490348;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ratio,C0456603;C1547037
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd,C1739039;C0439445;C3811844;C3812682;C3839656
history of ml before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
hba $nmbr$ c [mmol mol],C0019016;C1825777;C3538758;C3829066
history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0010055;C0441471;C4019010
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
history of chf before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
years since diagnosis of type $nmbr$ diabetes n,C0439234;C1320657
baseline bmi,C0168634;C0578022;C1442488
sbp office measurement mmhg,C0085805;C0439475
$nmbr$ and $nmbr$ years,C0439234
sbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
baseline glycemic control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
dbp office measurement mmhg,C0242485;C0439475
hba $nmbr$ c $nmbr$ level,C0441889;C0456079;C1547707;C2946261
dbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
insulin use at baseline,C0240016;C0168634;C1442488
pulse rate mean $nmbr$ h bpm,C0232117;C0033727;C0369286;C0441932;C0564385;C4528284
biguanide use at baseline,C0042153;C0457083;C1947944
number of antihypertensive medications n,C1718138
thiazolidinedione use at baseline,C0042153;C0457083;C1947944
daytime mean sbp abpm at week $nmbr$ mmhg,C0332169;C0085805
sulfonylurea use at baseline,C0042153;C0457083;C1947944
change from baseline mmhg,C0392747;C0443172;C1705241;C4319952
united states canada,C0041703;C0006823
nighttime mean sbp abpm at week $nmbr$ mmhg,C0240526;C0085805
mexico central south america,C0007674
daytime mean dbp abpm at week $nmbr$ mmhg,C0332169;C0332174;C0439230
western europe australia new zealand middle east,C0043128;C0026068
nighttime mean dbp abpm at week $nmbr$ mmhg,C0240526;C0332174;C0439230
eastern europe africa,C0001741
mean $nmbr$ h sbp,C0033727;C0085805;C0369286;C0441932;C0564385;C4528284
renal function,C0232804
patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0030705;C0037623;C1415692;C1708288;C4318478;C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
normalfunction or mild impairment,C0221099;C0684336
change from baseline in mean $nmbr$ h sbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0221099;C0684336
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
golimumab $nmbr$ mg kg mtx,C0025677;C1417487
mean $nmbr$ h dbp,C0536221;C3813197;C4281799
randomised patients n,C0030705
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
median iq range,C1514721;C2348147;C3542016
change from baseline in mean $nmbr$ h dbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
total vdh s score $nmbr$ $nmbr$ n,C2964552
fish oil n $nmbr$,C0016157
erosion score $nmbr$ $nmbr$,C0449820;C4050231
demographic and medical variables,C0011298;C0199168;C0439828;C0205476
jsn score $nmbr$ $nmbr$,C0449820;C4050231
coronary disease,C0010068;C1956346
crp normal,C0205307;C0231683;C0439166;C2347086;C4553972
class l ll heart failure,C0456387;C1518526;C1705943;C0018801;C0018802;C4554158
cdai $nmbr$ $nmbr$,C0683448;C1413248;C3273706
cardiac and echocardiography parameters,C0018787;C1522601;C0013516;C0449381
disease activity n,C1292728
sinus rhythm at baseline,C0232201;C0168634;C1442488
low $nmbr$ $nmbr$ and,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
$nmbr$ lead ecg heart rate beats min,C0439385
moderate $nmbr$ and,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
high $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
left atrial dimension cm,C2950135
sdai $nmbr$ $nmbr$,C3871128
left ventricular hypertrophy on echo,C0149721;C3484363
haq di $nmbr$ $nmbr$,C3826998;C4321476
left ventricular ejection fraction af history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
direction of hr,C0449738
right,C0205090;C0444532
paroxysmal af,C0235480
centre,C0205099;C3810851
persistent af,C0344434;C4049859
causaslan,
time since first af diagnosis yrs,C0040223;C3541383
left,C0205091;C0443246;C1552822
class i or iii aad use in $nmbr$ months before enrollment,C0441885;C1319793;C2698967;C0042153;C0457083;C1947944;C1516879;C1696073;C3888021
middle,C0444598;C0549183;C1552826
acei or arb,C3888198
period i,C0021966;C0221138
figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups,C0243132;C1554210;C2745955;C0332152;C1079230;C0740175;C2257086;C3669034
e $nmbr$ a $nmbr$,
placebo every $nmbr$ weeks n $nmbr$,C0032042;C1696465;C1706408;C0439230
period ii,C1710602;C4082587
evolocumab $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo monthly n $nmbr$,C0032042;C0332177;C1696465;C1706408
northamerica,
evolocumab $nmbr$ mg monthly n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bmi x $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
ldl cholesterol at baseline mmol l ldl cholesterol at screening,C0023824;C0202117;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
pre enrollment antihyperglycemic therapy,C1882440;C0020616
other lipid parameters,C0023779;C0449381
insulin based,C0021641;C1533581;C1579433;C3714501;C1527178;C1705938
apolipoprotein b g l,C1447574;C4319541
sulfonylurea based,C0038766;C3536898;C1527178;C1705938
apolipoprotein a $nmbr$ g l,C1447574;C4319541
thiazolidinedione based,C0289779;C1257987;C3537039;C1527178;C1705938
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
chronic kidney disease stage egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1561643;C0439445;C4553188
lipoprotein a nmol l,C0065058;C0439282;C0125953;C1096202;C1439335
stage $nmbr$ b $nmbr$ and,C0441781
hscrp nmol l,C0439282
stage $nmbr$ a $nmbr$ and,C0205390;C1300072;C1306673
unbound pcsk $nmbr$ nmol l,C0439282
stage $nmbr$ $nmbr$,C0205390;C1300072;C1306673
urinary albumin creatinine ratioa mg g,C0486293;C1300563;C4281686
figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C1696465;C1706408;C0168634;C1442488;C0332174;C0439230;C0871236;C0023824;C0086045;C0202117;C0178602;C1521801;C0743559;C1608199;C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0686905
urinary protein creatinine ratioa mg mg,C0369901;C1319635;C0428627
black or african,C0005680;C0027567;C0085756;C0439541
patients with diabetic nephropathy,C0030705;C0011881;C1442864
american,C0596070
difference from placebo,C1705241;C1705242
region no c,C0017446;C0205147
this study,C0557651;C2603343
central south,C0205099;C1710133;C1879652
stage $nmbr$ b egfr $nmbr$ and,C1739039;C3811844;C3812682
america,C0002454
stage $nmbr$ a egfr $nmbr$ and,C0205390;C1300072;C1306673;C1739039;C3811844;C3812682
otherd,
age y median range,C1514721;C2348147;C3542016
duration of t $nmbr$ dm y,C0449238;C2926735
weight kg median range,C1514721;C2348147;C3542016
taking antihypertensive medication at baseline no e,C0003364
uc duration y mean range,C1514721;C2348147;C3542016
dbp $nmbr$ mmhg,C0536221;C0439475;C3813197;C4281799
partial mayo score mean sd,C0444504;C2699239;C2347634;C2348143
on antihypertensive medication at baseline n,C0003364;C0168634;C1442488
crp nmol l median range,C1514721;C2348147;C3542016
saxa dapa met n $nmbr$,C0428210;C1550543;C4317104
comorbidites n,
saxa met n $nmbr$,C0428210;C1550543;C4317104
gastroesophageal reflux disease,C0017168;C4553201
dapa met n $nmbr$,C0428210;C1550543;C4317104
asthma,C0004096;C2984299
hba $nmbr$ c category,C0683312;C3889287
oral corticosteroid,C0442027;C0001617;C3536709;C4521986
$nmbr$ and $nmbr$ and,
azathioprine $nmbr$ mercaptopurine,C0004482;C0000618
$nmbr$ $nmbr$ mmol mol,C3829066
corticosteroid azathioprine $nmbr$ mercaptopurine,C0001617;C0000618;C3536709
ppg mg dl,C1418888;C0439269
corticosteroid or azathioprine $nmbr$ mercaptopurine,C0001617;C3536709;C0004482;C0000618
baseline hba $nmbr$ c subgroup,C1079230;C1515021
prior therapy with tnf antagonist n,C1514463
baseline mean sd [mmol mol],C0168634;C2699239;C1442488;C3829066
adjusted mean change from baseline $nmbr$ ci [mmol mol],C0392747;C0443172;C1705241;C4319952;C3829066
figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both,C0242492;C4554402;C0557651;C2603343;C0205195;C0947630;C0008107;C3259781;C0026175;C0338297;C0032042;C0031962;C1696465;C1706408;C0030705;C3272598;C1448177;C1456820;C1522669;C0008976;C0205171;C0439044;C0679994
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
statin n $nmbr$,C0360714
mean $nmbr$ ci difference vs saxa dapa met,C1705241;C1705242;C0428210;C1550543;C4317104
$nmbr$ $nmbr$ y,
$nmbr$ to $nmbr$ to,
nste mi,C3537184;C4255010
age subgroup y,C0001779;C1079230;C1515021
active smoking,C0037369;C0453996;C1881674
x n,
total cholesterol $nmbr$ mg dl,C0201950;C0439269;C0543421
proportion $nmbr$ ci adjusted for baseline hba $nmbr$ c,C0008107;C3259781;C0456081;C0019016;C1825777;C3538758
ecrcl,
$nmbr$ to $nmbr$ to $nmbr$ mmol mol,C3829066
egfr ml min m $nmbr$,C1739039;C0439445;C3811844;C3812682
secukinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous pci or cabg,C0205156;C4049621;C1552607;C0010055
weight kg $nmbr$,C0022718;C0439209;C4054209
baseline lvef,C0428772;C0488728
time since psoriasis diagnosis years $nmbr$,C0556970;C0011900;C1704338;C1704656
high risk clinical features,C0035648
pasi score $nmbr$,C0449820;C4050231
laboratory variables at baseline,C0022877;C0439828;C3244292;C4283904
bsa involved $nmbr$,C1314939
haemoglobin mg dl,C0019046;C0439269
iga mod $nmbr$ score n,C0011860;C0449820;C4050231
ctn i ng ml,C0021966;C0439275;C0221138
$nmbr$ moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ $nmbr$ z,
$nmbr$ severe disease,C1836348
ck mb ng ml,C0010290;C0439275
psa reported n,C0684224;C0700287;C4319718
glycemia mg dl,C0005802;C0439269
conventional agents,C0450442;C1254351;C1521826
time intervals h,C0033727;C0369286;C0441932;C0564385;C4528284
topical,C0332237
randomization to angiography,C0034656;C0002978
phototherapy previous systemic treatment n,C0031765;C0678812
randomization to angiography distribution time,C0034656;C0681683
biologic,C0005515;C0205460
within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
anti p $nmbr$,
after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
anti tnf,C1448177
hospital stay days,C0587438
japanese subpopulation,C0376247;C1257890;C1556094
angiographic data and treatment,C1511726;C3245479;C3714741;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
visit week,C0332174;C0439230
contrast volume ml,C0439526;C1705224;C3887665
secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
contrast volume $nmbr$ ml,C0439526;C1705224;C3887665
pasi $nmbr$,C4528685
additional angiography,C1524062;C0002978
iga $nmbr$ $nmbr$,C2825347
within $nmbr$ h after first procedure,C0033727;C0369286;C0441932;C0564385;C4528284
abatacept plus mtx n $nmbr$,C1619966;C0025677;C1417487
management distribution,C0520511;C1704711
abatacept monotherapy n $nmbr$,C1619966
pci data,C1511726;C3245479;C3714741
mtx n $nmbr$,C0025677;C1417487
contrast nephropathy risk score,C0035647;C0449820;C4050231;C4552904
age year median,C0549183;C0876920;C2347635;C2348144;C2939193
score distribution,C0520511;C1704711
weight kg median,C0549183;C0876920;C2347635;C2348144;C2939193
medications at coronary angiography,C0013227;C0802604;C2598133;C4284232
female sex number,C0237753;C0449788
gp llb llla inhibitors,C1705010;C0243077;C3811116
white race number,C0237753;C0449788
medications at discharge,C0806915
geographic region number,C0237753;C0449788
events statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
row,C1552840;C1552846
events control group,C0441471;C0009932;C3541888
ra symptom duration year,C0439234;C0439508
orc $nmbr$ cl,C1167125;C0596019
ra symptom duration,C0449238;C2926735
oradj $nmbr$ cl,C0596019
rf positive number,C0035448;C3812269;C0201660;C0748398;C1547111
baseline ecrcl,C0168634;C1442488
tender joint count $nmbr$ joints,C0451530
contrast volume,C0449468;C1690016;C1705102;C2700258
swollen joint count $nmbr$ joints,C0451521
$nmbr$ ml,C0439526;C1705224;C3887665
patient global assessment $nmbr$ $nmbr$ mm vas,C0042815;C3536884;C3827561
ci aki risk score,C0035647;C0449820;C4050231;C4552904
physician global assessment $nmbr$ $nmbr$ mm vas,C0042815;C3536884;C3827561
clopidogrel aspirin n $nmbr$,C0070166;C0004057
pain $nmbr$ $nmbr$ mm vas,C0042815;C4330985;C4554674
previous coronary angioplasty n,C2114427
physical function $nmbr$ $nmbr$ short form $nmbr$ subscale,C0597240;C0700329
multivessel disease n,C0012634
missing number n,C0237753;C0449788
clinical indication at the index procedure n,C2315323;C2347896
median $nmbr$ $nmbr$ number n,C0237753;C0449788
discharge medication n,C0012621;C0013227;C3244316;C4284232;C0030685;C2926602
haq di number,C0237753;C0449788
vessel treated n,C0005847;C1522326
symptom duration,C0449238;C2926735
left anterior descending artery n,C0226032
median $nmbr$ $nmbr$ years number n,C0439234;C0237753;C0449788
$nmbr$ months number n,C0439231;C0237753;C0449788
left circumflex artery n,C0226037
pain $nmbr$ mm vas,C0042815;C4330985;C4554674
right coronary artery n,C1261316
median $nmbr$ number n,C0237753;C0449788
left main coronary artery n,C1261082
erosion,C0333307;C1880549;C1959609;C3887524
graft n,C0181074;C0332835;C1961139
q $nmbr$ $nmbr$ $nmbr$ q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
multivessel intervention n,C0184661;C0886296;C1273869
q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
acc aha lesion class b $nmbr$ or c n,C4072694;C0221198;C1546698
osteitis,C0029400
bifurcation n,C0184906;C3146289
q $nmbr$ $nmbr$ q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
calcification n,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
q $nmbr$ $nmbr$ $nmbr$ q $nmbr$ $nmbr$ number n,C0237753;C0449788
total occlusion n,C0001168;C0011382;C0028778;C0441597;C1110554;C1947917
q $nmbr$ $nmbr$ number n,C0237753;C0449788
stents per lesion n,C0038257;C0221198;C1546698
synovitis,C0039103
stent length per lesion mm,C1444754;C1706316
device group n $nmbr$,C0441848
type of drug eluting stent n,C0457591
age mean sd [range] y,C0001779;C2699239;C1514721;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
sirolimus,C0072980
paclitaxel,C0144576
heart rate mean sd [range] beats min,C0018810;C2699239;C1514721;C2348147;C3542016;C0439385
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
zotarolimus,C1700035
everolimus,C0541315
blood pressure mean sd [range] mm hg,C0428886;C2699239;C1514721;C2348147;C3542016;C0439475
event rate of primary endpoints,C0871208;C1521828
body mass index mean sd [range]a,C0005893;C2699239;C0578022;C1305855;C1514721;C2348147;C3542016
aspirin alone n $nmbr$ $nmbr$ $nmbr$,C0004057;C0205171;C0439044;C0679994
chads $nmbr$ scoreb,C0007928;C1413373
aspirin clopidogrel n $nmbr$ $nmbr$ $nmbr$,C0004057;C0070166
mean sd [range],C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016
cohort,C0009247;C0599755
risk factors for stroke no,C0035648;C1553898
first n $nmbr$,C0205435;C1279901
previous ischemic stroke ortia,C0205156;C0948008;C1552607
second n $nmbr$,C0205436;C0457385;C0565930;C1561503;C1705190
lv ejection fraction mean sd [range],C0489482;C2699239;C2700378;C1514721;C2348147;C3542016
$nmbr$ mon n $nmbr$,
classification of af no,C0008902;C0008903;C0678229
$nmbr$ yo n $nmbr$,C1413296
onsetofaf no,
bifurcation,C0184906;C3146289
previous warfarin use no,C0042153;C0457083;C1947944
left main disease,C0205091;C0012634;C0443246;C1552822
source,C0449416;C1705919;C4521696
long $nmbr$ mm stenting yes n $nmbr$,C0205166;C0038257;C2348535;C1706317
device group,C1706365
multivessel stenting,C0038257;C2348535
history of tia or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
type of des,C0332307;C1547052
prior years taking warfarin,C0332152;C0043031;C2826257
older des n $nmbr$,C0011702;C4551552
median $nmbr$ mm,C4330985;C4554674
new des n $nmbr$,C0205314;C0011702;C4551552
continued thienopyridine n $nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
predictive factor,C0683956
placebo n $nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
age yr range,C1514721;C2348147;C3542016
subject characteristics,C0681884;C1519021;C1706465
bmi no,C0578022
current cigarette smoker or within past year,C3173209;C3241966;C0439234;C0439508
lifestyle behaviors,C0004927;C0677505
positive stress test,C0015260;C3494508
alcohol consumption no,C0001948
indication for pci,C0392360;C3146298
comorbidities concomitant medications,C0013227;C0802604;C2598133;C4284232
treatment characteristics,C0039798;C1521970;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
comorbidities no,C0009488
des type at index procedure,C0011702;C0455713;C4551552
cardiovascular disorder,C0007222
everolimus eluting,C0541315
cardiac disorder,C0018799
paclitaxel eluting,C0144576
no antihypertensive medication,C0003364
zotarolimus eluting,C1700035
one antihypertensive medication,C0205447;C0003364
sirolimus eluting,C0072980
two or more antihypertensive medications,C0205448;C0003364
$nmbr$ des type,C0332307;C1547052
statin s,C0360714
number of treated lesions,C0449791;C1522326
ed characteristics,C3538926;C1521970
number of treated vessels,C0237753;C0449788
ed $nmbr$ yr no,C3538926;C0439234
number of stents,C0237753;C0449788
ed etiology no,C0015127;C1314792;C1524003
minimum stent diameter,C4054490;C0038257
ed severity no a,C0439793;C0522510
total stent length,C1444754;C1706316
mild iief ef $nmbr$ $nmbr$,C2945599;C3641331
lesion characteristics,C1286326
moderate iief ef $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
n $nmbr$ lesions,C0369718;C0221198;C0441922
severe iief ef,C0205082;C3641331;C4050465;C4050466
treated vessel s,C1522326;C0005847
previous pde $nmbr$ i therapy no,C0039798;C0087111;C1363945
native coronary,C0302891;C0018787
ls mean change,C0392747;C0443172;C1705241;C4319952
lad,
pbo adjusted ls mean change,C0392747;C0443172;C1705241;C4319952
rca,
overally,
venous graft,C0181074;C0332835;C1961139
alcohol consumption at baseline,C0001948;C0168634;C1442488
arterial graft,C0450140
smoker at baseline,C0337664;C0168634;C1442488
modified acc aha lesion class b $nmbr$ or cj,C4072694;C0221198;C1546698;C0007481
antihypertensive use,C0042153;C0457083;C1947944
continued thienopyridine n,C0549178;C1120149
none at baseline,C0168634;C1442488
hr $nmbr$ and $nmbr$ cl,C0596019
one at baseline,C0205447;C0168634;C1442488
no current tobacco use,C0040335;C0543414;C0841002;C3853727
two or more at baseline,C0205448;C0168634;C1442488
no prior pci,C0332152;C4049621;C2826257
ed duration,C0449238;C2926735
no prior cabg,C0332152;C0010055;C2826257
pretreatment concomitant treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
clinical or lesion rf for st,C0205210;C0035448;C0201660;C0748398;C1547111
ics laba nz $nmbr$,C0815320;C0027978;C4551720
no clinical or lesion rfs for st,C0205210;C0341703;C0036056;C3272372
ics laba n z $nmbr$,C0815320;C4551720
any clinical or lesion rf for st,C0205210;C0035448;C0201660;C0748398;C1547111
$nmbr$ years n z $nmbr$,C0439234
european union,C0015179
current n z $nmbr$,C0521116;C1705970
aspirin dose at randomization,C4696290;C0034656
former n z $nmbr$,C0205156;C0750523
thienopyridine type,C0332307;C1547052
moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
clopiodogrel,
severe n z $nmbr$,C0205082;C4050465;C4050466
des type,C0332307;C1547052
very severe n z $nmbr$,C3641272;C4050419
zotarolimust,
north america n z $nmbr$,C0028405
americas n $nmbr$,C0002454;C0596070
europe n z $nmbr$,C0015176
russia georgia n $nmbr$,C0017452;C0017454
rest of world n z $nmbr$,C0035253;C1622890
ejection fraction nyha class n,C0489482;C1882083;C2700378
age mean,C0444504;C2347634;C2348143
stratum n,
years sd,C0439234;C2699239
any cardiovascular disease history n,C1880008
very severe,C3641272;C4050419
insulin treated,C0021641;C1533581;C1579433;C3714501;C1522326
lung function mean,C0444504;C2347634;C2348143
percutaneous coronary intervention or coronary artery bypass graft surgery n,C1532338;C0010055
prebronchodilator fev $nmbr$ l,C2599602;C3714541
angina n,C0002962
postbronchodilator fev $nmbr$ l,C2599594;C3714541
sodium,C0037473;C0597484;C3541959;C3714642
prebronchodilator fev $nmbr$ predicted,C0681842;C1882327
estimated glomerular filtration rate ml min per $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
concomitant treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bnp pg mlt,C0030827;C4553833;C0072225;C1266240
with laba n pretreatment,C1550147;C2709094;C3539075;C3539076
nt probnp pg mlt,C0669479;C4553833;C0754710
with ics n,C0815320;C4551720
angiotensin converting enzyme or angiotensin receptor blocker,C0022709;C1452534;C0034787;C1622222
long acting nitrate,C0028125;C0699857;C3848573
figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
bnp indicates brain natriuretic peptide and nyha new york heart association,C0054015;C1095989;C1417808;C2982014;C0459867
figure $nmbr$ rate ratios and $nmbr$ con dence intervals for reduction of moderate or severe copd exacerbations in the itt population and subpopulations copd chronic obstructive pulmonary disease ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0871208;C0456603;C1610540;C1521828;C1272706;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0740304;C0032659;C1257890;C0162425;C1283828;C1550453
tcomparison of proportion of patients with nyha class lll iv heart failure,C1709707;C0030705;C0018801;C0018802;C4554158
data reported as n or median quartiles $nmbr$ $nmbr$,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C0549183;C2828255;C0876920;C2347635;C2348144;C2939193
figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
tamong those enrolling via bnp stratum the study qualifying bnp or,C0054015;C1095989;C1417808;C2982014;C0557651;C2603343;C1514624
risedronate n $nmbr$,C0246719
nt probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0669479;C0042295;C0754710;C0588446;C4684790
history of osteoporotic fracture n a,C4075937
$nmbr$ $nmbr$ values were not collected for $nmbr$ patients $nmbr$ $nmbr$ who were enrolled,C0042295;C1516695;C1516698;C4684790
serum $nmbr$ hydroxyvitamin d ng ml,C0020337;C0439275
duration of prior alendronate use months,C1881378;C2826775
before a change to the enrollment form was implemented in august $nmbr$ bnp,C0392747;C0443172;C1705241;C4319952;C4520547;C0054015;C1095989;C1417808;C2982014
$nmbr$ tob $nmbr$ months n,C1420851;C0439231
values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0042295;C0588446;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ months n,C0439231
patients in the placebo group nt probnp values were reported for $nmbr$ patients,C0030705;C0669479;C0754710;C0588446
time since prior alendronate use n,C1279919;C2362777
in the spironolactone group and $nmbr$ patients in the placebo group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0030705;C0032042;C1696465;C1706408
$nmbr$ tob $nmbr$ months,C1420851;C0439231
p regional difference,C0369773;C0682132;C2603361
never took alendronate,C2003901;C1515187;C0102118
p treatment by region interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
still taking alendronate at study entry n,C0102118;C0557651;C2603343
no with event [incidence rate per $nmbr$ patient y],C0441471;C4019010;C1708485;C0030705
serum ctx $nmbr$ ng ml median iqr,C0010377;C0439275;C0631180;C3539598
hr $nmbr$ ci p value,C0008107;C1709380;C3259781
lower tertile b $nmbr$ $nmbr$,C0441994;C1548802;C2003888
$nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$,C0444598;C0549183;C1552826
aborted cardiac arrest,C0018790;C4553105
upper tertile $nmbr$ $nmbr$,C1282910
hospitalization for heart failure,C3898876
glycopyrronium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
recurrent heart failure,C0018801;C0018802;C4554158
tiotropium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ events[ $nmbr$ $nmbr$ ],C0441471;C3541888
gender n male,C0086582;C1706180;C1706428;C1706429
irr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4082285
mean sd body mass index kg m $nmbr$,C0022718;C0439209;C4054209
all cause hospitalization,C0015127;C0019993;C1524003
mean sd duration of copd years,C0449238;C2926735
doubling of creatinine,C0205173;C1705764
severity of the disease gold $nmbr$ n,C0521117;C0018026;C1304897
creatinine $nmbr$ $nmbr$ mg dl,C0010294;C0439269;C1561535
copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hyperkalemia potassium $nmbr$ $nmbr$ mmol l,C0020461;C1532563;C4552983
$nmbr$ exacerbations,C4086268
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
ics use at baseline n,C0042153;C0457083;C1947944
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
mean sd duration of smoking pack years,C0449238;C2926735
hypokalemia potassium,C0032821;C0202194;C0304475;C0597277;C3714637
mean sd fev $nmbr$ l pre bronchodilator,C0444504;C2599602;C2347634;C2348143
figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use,C1274040;C1546471;C2825142;C0021641;C0008976;C1533581;C1579433;C3714501;C0392747;C0443172;C1709707;C0030705;C0019016;C2825507;C1825777;C3538758;C0005910;C1305866;C0007222;C0679831;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538987;C0035648;C4048877;C4318503;C0020538;C1963138;C0360714;C0042153;C0457083;C1947944
mean sd fev $nmbr$ l post bronchodilator,C0444504;C2347634;C2348143;C2599594
abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error,C0019045;C1710181
mean sd post bronchodilator fev $nmbr$ percentage predicted,C0439165;C1549488;C1561533;C0681842;C1882327
amlodipine lisinopril chlorthalidone comparison,C0008294;C1707455
mean sd post bronchodilator fev $nmbr$ reversibility,C2599594;C0449261
no in trial stroke n $nmbr$ $nmbr$,C0008976;C0038454;C4554100
mean sd post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
in trial nonfatal or fatal stroke n $nmbr$ $nmbr$,C0150312;C0008976;C0332285;C1707101;C1302234;C0038454;C4554100;C1705232
figure $nmbr$ subgroup analyses for the primary efficacy endpoint,C2986480;C2986535
education in years mean sd,C0013621;C0013622;C0013658;C0039401
ipst n $nmbr$,
lipids medications,C0013227;C0802604;C2598133;C4284232
no ipst n $nmbr$ $nmbr$,
prior ptca pci,C0332152;C4049621;C2826257
blood pressure in mm hg mean sd,C0428886;C0488053
sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
non u s,C1518422;C0041703
patient presentation,C0030705;C0449450
dbp at visit $nmbr$,C0536221;C3813197;C4281799
baseline cardiac biomarkers,C2735101;C2735102
pulse in beats minute mean sd,C0232117;C0391850;C1947910
periprocedural medications,C0013227;C0802604;C2598133;C4284232
eligibility risk factors n,C0035648;C1553898
clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
glycoprotein iib iiia inhibitor,C0016011;C1999216
major st depression or t wave inversion,C0041696;C1269683;C0520888
catheter access site,C0449652
lvh by echo or ecg,C0149721;C0058928;C1655045;C1623258
brachial,C0445456
history chd,C0280604;C3542407
length of stay randomization to discharge h,C0023303;C0034656;C0033727;C0369286;C0441932;C0564385;C4528284
atrial fibrillation on baseline ecg n,C0344434;C0168634;C1442488
ipst,
baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0017654;C0439445;C1424601;C0369718;C0441922
no ipst,
biochemical measures mean sd,C0079809;C2699239;C1879489
or [ $nmbr$ ci],C0008107;C3259781
in trial $nmbr$ year rates per $nmbr$ se total events number at risk,C1264674;C1444641
p [int],C0369773;C3272375;C2603361
in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk,C0150312;C0008976;C0332285;C1707101;C1264674;C1444641
lm bifurcation treated,C0184906;C3146289;C1522326
chlor,C0308648
lm bifurcation not treated,C0184906;C3146289;C1518422;C1522326
$nmbr$ fe black,C0005680;C0027567;C0085756;C0439541
$nmbr$ vessel pci,C0005847;C4049621
ment,C0084844;C1538994
$nmbr$ mg clopidogrel load,C1550025;C1704782;C1708715
women t,C0043210
losartan plus placebo n $nmbr$,C0126174;C0032042;C1696465;C1706408
no atrial fibrillation,C0004238;C0344434;C1963067
losartan plus lisinopril n $nmbr$,C0126174;C0065374
chd at baseline,C0280604;C3542407
hispanic ethnic group no f,C0015031;C1879937;C0016327
no chd at baseline,C0280604;C3542407
serum potassium mmol liter,C0302353;C0475211;C0543465
crcl at baseline,C1846718;C0168634;C1442488
mean ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
prior stemi,C1536220;C3538872
category no total no,C0683312;C3889287;C0439175;C0439810
baseline medical therapy,C0168634;C0418981;C1442488
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
vorapaxar $nmbr$ y,C2974521
urinary albumin to creatinine ratio^,C0486293;C1318293
placebo r,C0205090;C0684010;C2603358
urinary protein to creatinine ratio,C0428627;C1318206
hx stroke tia,C0007787;C0917805;C1054154
use of ace inhibitor arb or both no,C1524063;C0003015;C4541021
no stroke tia,C0007787;C0917805;C1054154
ace inhibitor monotherapy,C0003015;C4541021
no prior stemi,C1536220;C3538872
arb monotherapy,C3888198
mi $nmbr$ months,C3810814;C0439231
both ace inhibitor and arb,C0003015;C4541021;C3888198
rando in na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
neither ace inhibitor nor arb,C0003015;C4541021;C3888198
not rando in na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
blood pressure medications at randomization no total no,C0849164;C0439175;C0439810
asa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
[ $nmbr$ cl],C0596019
des,C0011702;C4551552
losartan placebo,C0032042;C1696465;C1706408
no des,C0011702;C4551552
losartan lisinopril,C0126174;C0065374
carotid revascularization,C0741968;C0581603
[ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
all ischemic stroke,C0948008
albuminuria $nmbr$ gram gram cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
ischemic stroke with hemnrrhnaic cnnversinn,C0948008
previously on acei arb,C3888198
ischemic stroke without hemorrhagic conversior,C0948008
age $nmbr$ years old,C1510829;C0580836
table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline,C4684572;C0034656;C3815594;C1524063;C0021641;C0439465;C1533581;C1579433;C3714501
black and other,C0005680;C0027567;C0085756;C0439541
stenting plus medical therapy n $nmbr$,C0038257;C2348535
acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline,C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0002460;C0238611;C0337920;C1165245;C0439064;C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0679646;C0205447;C0457464;C0168634;C1442488
medical therapy only n $nmbr$,C0418981;C0369718;C0441922
canagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
blood pressure at target level,C0005823;C1271104;C1272641
duration of diabetes years mean sd,C0449238;C2926735
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ ^,C0017654;C0439445;C1424601
insulin dose iu day median,C0549183;C0876920;C2347635;C2348144;C2939193
stage $nmbr$ chronic kidney disease,C1561643;C4553188
insulin therapy n,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
method of identification ofstenosis,C1301921
basal plus bolus,C0205112;C1186706;C1511237;C1705509;C3812160
angiography,C0002978
basal alone,C0205112;C0205171;C0439044;C0679994
duplex ultrasonography,C3825392
bolus alone,C1186706;C1511237;C1705509;C3812160;C0205171;C0439044;C0679994
computed tomographic angiography,C1441526;C0002978;C1880157
other drug therapy n,C0013216;C0013217
magnetic resonance angiography,C0243032
antithrombotic,
medical history and risk factors,C0262926;C1704706;C0035648;C1553898
microvascular disease n,C0443258;C0012634
nephropathy,C0022658
history of heart failure,C0455531
smoking in past yr,C0037369;C0453996;C1881674;C0439234
atherosclerotic vascular disease n,C0004153
angiographic findings,C2607943;C2926606;C3539655
cerebrovascular,C1880018
stenosis as assessed by core laboratory,C0678234;C1261287;C2632116;C0022877;C3244292;C4283904
peripheral,C0205100
stenosis as assessed by investigator,C0678234;C1261287;C2632116;C0035173
dbp mmhg mean sd,C0439475;C2699239
global ischemia,C0205246;C0022116;C4321499;C2348867
total cholesterol mmol l mean sd,C0201950;C2699239;C0543421
bilateral disease j j,C1511113
triglycerides mmol l mean sd,C1532563;C2699239
stent plus medical therapy,C0038257;C0418981
hdl cholesterol mmol l mean sd,C0023822;C2699239;C0392885
medical therapy alone,C0418981;C0205171;C0439044;C0679994
ldl cholesterol mmol l mean sd,C0023824;C2699239;C0202117
no of patients total no,C0030705;C0439175;C0439810
ldl to hdl cholesterol ratio mean sd,C0428621;C1171408
creatinine level,C0428279
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
u s sites,C0041703;C0205145
acr mg g mean sd,C1300563;C2699239
maximal diameter stenosis,C0678234;C1261287;C2632116
figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks,C1280500;C0178602;C0869039;C1114758;C1707455;C0032042;C1696465;C1706408;C0019016;C1079232;C1825777;C3538758
characteristicsa,
total study population n $nmbr$ $nmbr$,C3258257
varespladib n $nmbr$,C2713485
$nmbr$ predicted arr n $nmbr$,C0681842;C1882327
otherb,
caucasian ethnicity,C0015031;C0243103
western europe and lebanon,C0043129;C0023190
past smoking,C0037369;C0453996;C1881674
present smokerc,C0150312;C0449450
never smoking,C0037369;C0453996;C1881674
body mass index mean sd d,C0005893;C2699239;C0578022;C1305855
alcohol use $nmbr$ drink wk,C0332174;C0439230
prior lipid modifying therapy,C1514463;C0023779
peri or postmenopausal,C0347985;C0232970
unstable angina biomarker negative,C0205160;C1513916;C2825415;C2825491;C3853545
hormone replacement therapy use,C0042153;C0457083;C1947944
index event to randomization median iqr h,C0441471;C4019010
high density lipoprotein mg dl,C0023821;C0439269
pci or cabg surgery for index event,C4049621;C0038894;C0038895;C0543467;C1274039
high sensitivity c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
medications at randomization,C0013227;C0802604;C2598133;C4284232
clopidogrel ticlopidine or prasugrel,C0070166;C0040207;C1620287
blood pressure lowering medication use,C0240320
biochemical parameters at randomization mean,C0449381;C0034656
lipid lowering medication use,C0023779;C0441994;C2003888;C0240320
sd mg dl,C2699239;C0439269
family history of cancera,C0241889
c reactive protein median iqr mg l,C0006560;C0439268;C1413716;C4048285
history of dyspepsia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
concomitant atorvastatin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
randomized to aspirin use,C0034656;C3815594
varespladib,C2713485
$nmbr$ year predicted risk of,C0035647;C4552904
a primary composite outcome,C0205199;C1274040;C1547335
colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
baseline lipid therapy,C0039798;C0087111;C1363945
non colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
primary indication,C1549995
major gastro intestinal bleeding,C0205082;C0017181;C0205164;C4318856;C4521762
pci postindex event,C0441471;C4019010
total study population,C3258257
diabetes at baseline,C0011847;C0011849
women $nmbr$ years,C0043210;C0439234
hypertension at baseline,C0020538;C1963138
arr $nmbr$ ci,C0008107;C3259781
b myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
annt or bnnh $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ to $nmbr$ a,
high dose edoxaban n $nmbr$,C0444956;C2975435
$nmbr$ b $nmbr$ b to $nmbr$ a,
low dose edoxaban n $nmbr$,C0445550;C1708745
$nmbr$ $nmbr$ to $nmbr$ b,
asia pacific region and south africa,C0017446;C0205147;C0037712
total adjusted weight of $nmbr$ $nmbr$ for gastrointestinal bleeding,C0005910;C0043100;C1305866;C1705104;C0017181
paroxysmal atrial fibrillation no,C0235480;C4050122
vi $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
qualifying risk factor no,C1514624;C0035648
ff vi $nmbr$ mg $nmbr$ mg n $nmbr$,C0205999;C1319635
prior stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
smoking status n former,C0205156;C0750523
hypertension requiring treatment,C0020538;C1963138;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ $nmbr$ no,
total pack years mean sd,C1277691;C2699239
baseline fev $nmbr$ predicted,C0681842;C1882327
dose reduction at randomization no i,C0301630;C0392756;C1293152;C4551656;C0021966;C0221138
post bronchodilator reversibility fev $nmbr$ mean sd,C2599594;C2699239
use of verapamil or quinidine,C1524063;C0042523;C0034414
previous pneumonia,C0205156;C0032285;C1552607
previous use of vitamin k antagonist for $nmbr$ days no,C1524063;C1096489;C2267235;C0439228
i ii fev $nmbr$ $nmbr$ predicted,C0681842;C1882327
medication at time of randomization no,C0013227;C3244316;C4284232
iii fev $nmbr$ $nmbr$,C0439070;C3714541;C1705160
digoxin or digitalis preparation,C0012265;C0304520
iv fev $nmbr$,C0022326;C3714541;C4265176
edoxaban high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
leukocytes $nmbr$ nl,C0027778;C0560008;C3892223
edoxaban low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
neutrophils $nmbr$ nl,C0027778;C0560008;C3892223
af type,C0332307;C1547052
monocytes $nmbr$ nl,C0027778;C0560008;C3892223
prior stroke or tza,C0038454;C4554100;C0039298
lymphocytes $nmbr$ il,C0020898;C0021764;C0022271
$nmbr$ p $nmbr$,C0369773;C2603361
hemoglobin mg dl,C0019046;C0439269
cha $nmbr$ s $nmbr$ score,C1420648;C0449820;C4050231
ctn l ng ml,C0917591;C0439275
dose adjusted,C0178602;C0869039;C1114758;C0456081
angiographic data,C1511726;C3245479;C3714741
center level ttr,C0032923;C1421224
pci revascularization,C4049621;C0581603
high dose edoxaban vs warfarin interaction p value,C0444956;C2975435;C0043031;C1709380
odds ratio adj $nmbr$ cl,C0028873;C0596019
low dose edoxaban vs warfarin interaction p value,C0445550;C2975435;C1708745;C0043031;C1709380
baseline hs crp tertiles mg i],C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
edoxaban warfarin,C2975435;C0043031
$nmbr$ st $nmbr$ $nmbr$,C0036056;C3272372
congestive heart,C0742742;C0018787
$nmbr$ nd $nmbr$ $nmbr$,
failure,C0231174;C0680095
$nmbr$ rd $nmbr$ $nmbr$,C0694666;C4553350
amiodarone ote at baseline,C0002598;C0168634;C1442488
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
ff $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
ff vi $nmbr$ $nmbr$ ig n $nmbr$,C0205999;C0021027;C0305052;C0360506
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
never smoked n,C2003901;C0037366;C0439994;C1881674
established atherosclerotic disease,C0333482;C0012634
former smoker n,C0337671
clinical and laboratory measurements,C0205210;C0681902
number of exacerbations in last $nmbr$ months,C0237753;C0449788;C0439231
acr mg mmol,C0567349;C2348885
screening prebronchodilator fev $nmbr$ l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
acr,C1412134;C1515941
screening predicted fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
screening reversibility fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
baseline cv medications,C0013227;C0802604;C2598133;C4284232
screening absolute reversibility fev $nmbr$ ml,C0439526;C1705224;C3887665
b blockers,
baseline acq $nmbr$ score,C0449820;C4050231
baseline anti hyperglycemic medications,C0013227;C0802604;C2598133;C4284232
percentage of patients using ics or ics laba on entry,C0439165;C1549488;C1561533;C1524063;C0815320;C4551720;C1705654
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
ics only,C0815320;C4551720
saxagliptin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ff $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
saxagliptin $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
saxagliptin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
argentina,C0003761;C1504311
cv death mi ischemic stroke,C0011065;C0948008;C1306577;C4082313;C4552775
philippines,C0031529
japan,C0022341
cv death mi ischemic stroke hospitalization for hf coronary revascularization ua,C0019993;C0877341
baseline fev l,C0168634;C1442488
hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
f,C0016327
$nmbr$ yr km n,C0439234;C3887676
grouped region,C0017446;C0205147
s,
australasia,C0282279;C1257882
egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
cv death ml ischemic stroke hosp for hf cor revasc ua,C0011065;C0948008;C1306577;C4082313;C4552775
hosp for hf,C0018488;C1313497;C1538440;C3273279
values are mean sd median [quartile range] or ace indicates angiotensin converting enzyme arb angiotensin receptor blocker bnp b type natriuretic peptide bp blood pressure bun blood urea nitrogen lvef left ventricular ejection fraction and nt probnp n terminal pro b type natriuretic peptide,C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016;C1452534;C4284014;C0005845;C0428772;C0600137;C0754710
primary renal endpoint,C2986535;C0022646
alive n $nmbr$,C2584946;C4551704
primary renal endpoint or death,C2986535;C0022646;C0011065;C1306577;C4082313;C4552775
dead n $nmbr$,C0011065
hosp for hypoglycemia,C0020615;C4553659
lvef within $nmbr$ mo,C0428772;C0488728
major hypoglycemia,C0020615;C4553659
total intravenous loop diuretics mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
initiation of insulin,C0589507;C1158830;C1704686
bun mmol l,C1532563
any new anti hyperglycemic rx,C1425688;C1521941;C2709207
no readmission n $nmbr$,C1548168;C4489276
worsened,C1457868;C4084902
readmission n $nmbr$,C1548168;C4489276
no change,C0392747;C0443172;C1705241;C4319952
increase creatinine,C0010294;C1561535
improved,C0184511;C0332272;C1561611;C4084203
increase creatinine $nmbr$ $nmbr$ mg dl,C0010294;C0439269;C1561535
olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no hemoconcentration hemoconcentration,C0549409;C0854379
tiotropium $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants no,C0679646
tiotropium $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gi bleed,C1708130;C0019080;C3539617;C4050121
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no gi bleed,C1708130;C0019080;C3539617;C4050121
tiotropium olodaterol $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants randomized,C0679646;C0034656;C3815594
participants n,C0679646
no a,
$nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
black non black,C0005680;C0027567;C0085756;C0439541
$nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
hispanic non hispanic,C0086409;C1518422
$nmbr$ $nmbr$ i i,C0021966;C0221138
women taking estrogen,C0014939;C2936882;C4542544
$nmbr$ i $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
hdl mean sd mg dl,C0444504;C0439269;C2347634;C2348143
$nmbr$ i $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
diabetes classificationa,C0011847;C0011849
$nmbr$ ii $nmbr$ $nmbr$,C1710602;C4082587
nondiabetes,
pre bronchodilator screening fev $nmbr$ ml,C0439526;C1705224;C3887665
mean sd mg kg $nmbr$,C0444504;C0439272;C2347634;C2348143
i $nmbr$ $nmbr$,C0021966;C0221138
yes no,C1512698
i $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
history mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
ii $nmbr$ $nmbr$,C1710602;C4082587
history coronary,C0019664;C0018787;C0019665;C0262512;C0262926;C1705255;C2004062
post bronchodilator screening fev $nmbr$ ml,C0439526;C1705224;C3887665
other atherosclerotic,C0333482
i $nmbr$ $nmbr$ ii,C1710602;C4082587
lvh by minnesota code,C0149721;C0009219;C0805701;C3889831
i $nmbr$ $nmbr$ i,C0021966;C0221138
unadjusted hr $nmbr$ ci a,C0008107;C3259781
change from pre to,C0392747;C0443172;C1705241;C4319952
lisinopril vs chlorthalidone,C0065374;C0008294
i $nmbr$ i $nmbr$,C0021966;C0221138
lisinopril vs amlodipineb,C0065374
i $nmbr$ i i $nmbr$,C0021966;C0221138
aspirin at baseline,C0004057;C0168634;C1442488
post bronchodilator fev $nmbr$ ml,C0439526;C1705224;C3887665
no aspirin at baseline,C0004057;C0168634;C1442488
$nmbr$ $nmbr$ ii $nmbr$,C1710602;C4082587
$nmbr$ i ii $nmbr$,C1710602;C4082587
asthma population n $nmbr$,C0004096;C0032659;C1257890;C2984299
fev $nmbr$ pred,C0032952;C0044955
copd population n $nmbr$,C0024117;C0032659;C1257890;C1412502;C3714496
$nmbr$ fevi ^ $nmbr$ pred,C0032952;C0044955
duration of disease years,C0872146;C0439234
i $nmbr$ i,C0021966;C0221138
self reported disease severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
$nmbr$ fevi $nmbr$,C0849974;C1561566;C4528367
current inhaler,C0021461;C1881212;C4319647
$nmbr$ fev $nmbr$,C3714541
diskus only n,C1553480;C0369718;C0441922
ii $nmbr$ ii $nmbr$,C1710602;C4082587
handihaler and diskus n,C1553480
baseline pulmonary medication,C0013227;C3244316;C4284232
handihaler only n,C0369718;C0441922
sama $nmbr$,C1075468
mdi hfa n,C0993596;C0015458;C1839839;C4049613
i $nmbr$ i i $nmbr$ $nmbr$,C0021966;C0221138
dpi other than diskus n,C1553480
i $nmbr$ i $nmbr$ i,C0021966;C0221138
qva $nmbr$ $nmbr$ pg once daily n $nmbr$,C0030827;C0072225;C1266240;C0332173
lama,C0999593;C1416775
sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$,C0030827;C0585361;C0072225;C1266240
saba,
ics users at baseline,C1706077;C0168634;C1442488
xanthines $nmbr$,C0043318;C3541955
smoking history r,C0205090;C0684010;C2603358
baseline cardiovascular medication,C0168634;C0007220;C1442488
ex smokers,C0337671;C4555205
i $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
estimated number of pack years,C0237753;C0449788
ii $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
copd exacerbation history in the previous year n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
treatment comparison,C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pre bronchodilator fev l,C2599602;C3714541
ics usage,C0815320;C0457083;C4551720
post bronchodilator fev l,C2599594;C3714541
adjusted mean se $nmbr$ ci,C0008107;C3259781
pre bronchodilator fev predicted,C2599602;C3714541;C0681842;C1882327
fevi auc $nmbr$ $nmbr$ l,C0429706;C0376690;C0849974;C1561566;C4528367
post bronchodilator fev predicted,C2599594;C3714541;C0681842;C1882327
common study baseline,C0168634;C1442488
post bronchodilator fev reversibility,C2599594;C0449261
tiotropium olodaterol $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
post bronchodilator fev fvc,C2599594;C3714541
versus olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
lsm $nmbr$ cl,C0596019
versus tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
overall qvai $nmbr$ sfc,C0282416;C4521536;C1561607
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
ex smokers qvai $nmbr$ sfc,C0337671;C4521536;C4555205
versus tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
$nmbr$ o o $nmbr$ o $nmbr$,C0483204
versus tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
smokers qva $nmbr$ $nmbr$ fc,C0337664;C2983605
trough fevi l,C0444506;C0429706;C0849974;C1561566;C4528367
moderate cord qva $nmbr$ sfc,C0205081;C4521536;C1881878;C4049705;C4049706;C4085643;C4321335
dapagliflozin $nmbr$ mg day n $nmbr$,C2353951;C0439422
severe cord qvai $nmbr$ sfc,C0205082;C4521536;C4050465;C4050466
type $nmbr$ diabetes duration mean sd years,C1320657;C0439234
o $nmbr$ o oo $nmbr$ o $nmbr$ o,C0483204
hba $nmbr$ c mean sd [mmol mol],C0019016;C2699239;C1825777;C3538758;C3829066
men qvai $nmbr$ sfc,C0025266;C4521536
fpg mean sd mg dl [mmol l],C0444504;C0439269;C2347634;C2348143;C1532563
women qva $nmbr$ sfc,C0043210;C4521536
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
ics non users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
prior history of cardiovascular disease n,C0332152;C0455539;C2826257
$nmbr$ oo $nmbr$ o $nmbr$,
concomitant medications n,C0521115;C0013227;C0802604;C2598133;C4284232
ics users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
antihypertensives,C0003364
age $nmbr$ qvai $nmbr$ sfc,C0001779;C4521536
angiotensin receptor blocker and or ace,C0034787;C1622222;C1452534;C4284014
$nmbr$ ml min n $nmbr$,C0439445
dapagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
median $nmbr$ th $nmbr$ th percentile,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ $nmbr$ mmol l [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0030705;C1532563;C3829066;C0008107;C0036919;C3259781
af duration n,C0344434;C0449238;C2926735;C4049859
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
$nmbr$ mo $nmbr$ y,C0026544;C0332177
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
chads $nmbr$ risk factors n,C0035648;C1553898
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ to $nmbr$ $nmbr$ to $nmbr$ mmol mol [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0019016;C0030705;C1825777;C3538758;C3829066;C0008107;C0036919;C3259781
chads $nmbr$ score n,C0449820;C4050231
any anticoagulant,C0003280;C0848112;C3536711
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ $nmbr$ mmol mol [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0030705;C3829066;C0008107;C0036919;C3259781
events n y,C0441471;C3541888
open label phase baseline week $nmbr$,C0332174;C0439230
dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
randomized double blind reversal phase baseline week $nmbr$,C0332174;C0439230
dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total cohort,C0009247;C0599755
outcome according to renal function level in ml min,C1274040;C0232804;C0439445
azl ma,C0024443;C3887485
azl m cldb,
dabigatran $nmbr$ mg bid events n y,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
azl m,
warfarin events n y,C0043031;C0441471;C3541888
race no c,C0034510;C1706779;C3853635
p value inter,C1709380;C0205103;C1548610
baseline dbp mean sd mm hg,C0168634;C0439475;C1442488
life threatening bleed,C1546953;C0019080;C2826244;C3537125
baseline sbp mean sd mm hg,C0085805;C0439475
intracranial bleed,C0151699
table $nmbr$ baseline demographics and clinical characteristics,C0011298;C1704791;C0683325
net clinical benefit,C1456447;C4684590;C3853572;C3887809;C3890893
czp $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation,C0030705;C3272598;C0332293;C0013175;C0168634;C1442488;C1299575;C0457987;C0871420
arthritis characteristics,C0003864;C1521970;C4552845
linagliptin,C2746078
crp median range mg literl,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients treated set n,C0030705;C0036849;C1442518;C1705195
esr median range mm hour,C0439227;C0564385
males n,C0086582
tender joint count range $nmbr$ $nmbr$ joints,C0451530;C1514721;C2348147;C3542016
renal function egfr according to mdrd n,C1739039;C3811844;C3812682
swollen joint count range $nmbr$ $nmbr$ joints,C0451521;C1514721;C2348147;C3542016
normal $nmbr$ ml min,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
modified total sharp score,C0392747;C2964552;C3889737
mild impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
joint space narrowing score,C0449820;C4050231
moderate impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
physician s assessment of disease activity vas mm,C0031831;C0804815;C1261322;C1516048
severe to end stage impairment $nmbr$ ml min,C0205082;C4050465;C4050466
enthesitis,C1282952
patients full analysis sety n,C0030705;C0002778;C0936012;C1524024
lei $nmbr$,C0023401;C0428209
hba $nmbr$ c mmol mol mean sd,C3829066;C2699239
dactylitis,C0239161
time since diagnosis of diabetes mean sd,C0040223;C3541383
ldi $nmbr$,
type of basal insulin n,C0457592
psoriasis characteristics,C0033860;C1521970
insulin detemir,C0537270
$nmbr$ bsa psoriasis no,C0033860
nph,C0020258;C0027442
pasi median range,C1514721;C2348147;C3542016
concomitant oads n,C0521115
nail involvement,C0027342;C1314939;C1432728;C3538766
pioglitazone only,C0071097
mnapsi,
metformin pioglitazone,C1635037
patient reported outcomes,C2987124
patient assessment of disease activity mm,C0679830;C1292728
figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0457592;C0001779;C2986798;C0020258;C0332173;C0027442
patient assessment of arthritis pain mm,C0679830
baseline cardiovascular disease,C0168634;C0007222;C1442488
fatigue range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
dilated cardiomyopathy,C0007193;C2984282
haq di range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
haemodynamics and lv function,C0019010;C4281788;C0031843;C0542341;C0700205;C1705273
sf $nmbr$ pcs,C1864389;C1882368
lvdd mm,C4330985;C4554674
sf $nmbr$ mcs,C0037712
laboratory findings,C0587081
psaqol,
haemoglobin g dl,C0439267
dlqi,C3899393
albumin mg dl,C0001924;C0439269
dlqi patients with $nmbr$ bsa psoriasis,C0030705;C0033860
baseline medication,C0013227;C3244316;C4284232
prior tnf inhibitor exposure no,C0274281;C0332157
number event total,C0439175;C0439810
adalimumab,C1122087
$nmbr$ c i lower,C0441994;C1548802;C2003888
no prior tnf inhibitor exposure,C0274281;C0332157
upper,C1282910
prior tnf inhibitor exposure,C0274281;C0332157
age y o,C0001779
czp combined arms n $nmbr$,C0054841;C0205195;C1861828;C1872109
taci n $nmbr$,C0666480;C1425349;C4284230
pain mm,C4330985;C4554674
paci n $nmbr$,C1165245
haq di,C3826998;C4321476
poci n $nmbr$,
indacaterol $nmbr$ ug n $nmbr$,C0041573;C0439211
laci n $nmbr$,C1420705;C3273314;C4281721
indian indian subcontinent,C0454693
sss score,C0449820;C4050231
smokers,C0337664
duration of symptoms h,C0436359;C0033727;C0369286;C0441932;C0564385;C4528284
fevi l,C0429706;C0849974;C1561566;C4528367
treatment with candesartan,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
current or previous atrial fibrillation,C0521116;C1705970;C0004238;C0344434;C1963067
reversibility to salbutamol,C1271924
current use of an ace inhibitor,C1524063;C0003015;C4541021
n indacaterol $nmbr$ ug indacaterol $nmbr$ ug placebo,C0032042;C1696465;C1706408
thrombolytic treatment before randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
indacaterol $nmbr$ ug versus placebo,C0041573;C0439211;C0032042;C1696465;C1706408
composite vascular endpoint,C2349179;C2826544
indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211
functional outcome mrs $nmbr$ $nmbr$,C1522706;C2349188;C3714939;C3854213
intent to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
candesartan,C0717550
theophylline use at screening,C0241361;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
taci,C0666480;C1425349;C4284230
saba reversibility,C0449261
paci,C1165245
figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c,C1709707;C0681850;C1550501;C1706203;C2349001;C2697811;C1521840;C2986546;C1704788;C3539106;C0332167;C0442804;C3272283;C4050568;C4319571;C4321397;C0596269;C0205210;C0205195;C1947911;C3811910;C0332257;C1552866;C2700399
poci,
abatacept $nmbr$ $nmbr$ n $nmbr$,C1619966
laci,C1420705;C3273314;C4281721
class iv glomerulonephritis,C0441888;C0017658;C2698970
prespecified subgroups,C1079230
duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$,C0449238;C2926735
anacetrapib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fc ldl c mg dl,C2983605;C0439269
baseline creatinine median range mg dl,C0010294;C0439269;C1561535
use of concomitant lipid modifying therapy,C1524063;C1707479
baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$,C0567349;C2348885
statin only n,C0360714;C0369718;C0441922
baseline upgr $nmbr$ gm gm $nmbr$ mg mmole,C0567349;C2348885
statin ezetimibe n,C0360714;C1142985
prestudy treatment status,C0749659
statin fibrate or,C0360714
naive no treatment for current flare,C2827774;C1517205;C3540542
niacin n,C0027996;C1142562
recent treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
type of concomitant statin,C0332307;C1547052
inadequate response $nmbr$ months mmf ggs,C0205412;C0083765;C0209368;C3848524;C0439856
simvastatin n,C0074554
baseline prednisone or oral prednisone equivalent daily dose,C0168634;C0032952;C1442488;C2348070
atorvastatin n,C0286651
mean sd mg n $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rosuvastatin n,C0965129
goncomitant treatment with age inhibitors angiotensin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fc ldl c friedewald calculated,C2983605;C0444686;C1441506
receptor blockers,C0597357
low density lipoprotein choles,C0023823
premature discontinuation,C0457454;C1444662;C4552847
terol hdl c high density lipoprotein cholesterol,C0023822
adverse event,C0877248
sd standard,C1442989;C2828392
lack of efficacy,C0235828
deviation tg triglyceride,C0012727;C0041004;C0205419;C1705236
withdrew consent,C2349954;C1511481;C1554192;C2923685
percent change from baseline at week $nmbr$,C3272907;C0332174;C0439230
no longer met study criteria,C0428210;C0243161;C1550543;C4317104
difference in ls means $nmbr$ ci,C1705241;C1705242
poor compliance noncompliance,C0376405;C0457432
pregnancy,C0032961
ls mean $nmbr$ ci,C0008107;C3259781
vs placebo,C0032042;C1696465;C1706408
ind gly n $nmbr$,C0017890;C0523677
ind pbo n $nmbr$,C4049864;C0031962
anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hdl c,C0168634;C3715113;C1442488
severity of airflow limitation gold $nmbr$ n,C0439793;C0522510
baseline fc ldl c,C0168634;C1442488
baseline copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ exacerbation,C4086268
baseline tg,C0168634;C0337445;C1442488
statin only,C0360714
mean sd fev $nmbr$ postbronchodilator l,C0444504;C2347634;C2348143
statin ezetimibe,C0360714;C1142985
mean sd postbronchodilator fev $nmbr$ predicted,C0681842;C1882327
statin fibrate or niacin,C0360714;C0027996;C1142562
mean sd postbronchodilator fev $nmbr$ reversibility,C0444504;C0449261;C2347634;C2348143
dm n $nmbr$,C0011816;C3250443
mean sd postbronchodilator fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
no dm n $nmbr$,C0011816;C3250443
lsm $nmbr$ ci,C0008107;C3259781
median age $nmbr$ $nmbr$ y,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193
moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0231999;C0443288;C0449295
hyperlipidemia n,C0020473;C0428465;C4555212
severe or worse airflow limitation,C0205082;C4050465;C4050466;C0443288;C0449295
current tobacco abuse n,C0521116;C0040336;C1705970
smoking ex smoker,C0037369;C0337664;C0453996;C1881674
peripheral arterial disease n,C0085096;C1704436
smoking current smoker,C3173209;C3241966
history of heart failure n,C0455531
ics use at baseline no,C0042153;C0457083;C1947944
previous pci cabg n,C0205156;C0010055;C1552607
ics use at baseline yes,C0042153;C0457083;C1947944
baseline gfr,C0017654;C1424601
reversibility $nmbr$,C0449261
baseline medications n,C0168634;C0013227;C0802604;C2598133;C4284232;C1442488
bmi $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
acei arb,C3888198
revive i,C0021966;C0221138
revive ii,
baseline diabetes mellitus therapy n,C0168634;C0948092;C1442488
levosimendan n $nmbr$,C0246904
lifestyle modifications,C0870811;C2960841
basal only,C0205112
noninsulin therapy,C0039798;C0087111;C1363945
$nmbr$ $nmbr$ lung fields,C0225759
insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
legs only,C1140621
vorapaxar event rate n $nmbr$,C0441471;C0871208;C1521828;C4019010
sacral and or lumbar,C0036037;C0024090
placebo event rate n $nmbr$,C0032042;C0441471;C4019010;C1696465;C1706408
iv vasodilator,C0042402;C3537240
cvd mi or stroke,C0007222;C3810814;C0038454;C4554100
iv inotropic drug,C1971835
cvd or mi,C0007222;C3810814
both iv vasodilator and inotrope,C0042402;C3537240
cvd mi stroke or recurrent ischemia urgent revascularization,C0038454;C4554100;C0022116;C0581603;C4321499
figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization,C2985465;C0015127;C1524003;C0032042;C1696465;C1706408;C0005811;C0034656
cvd mi stroke or recurrent ischemia urgent revascularization or hospitalization for unstable angina,C0038454;C4554100;C0022116;C0581603;C4321499;C0019993;C0002965
coenzyme q $nmbr$,C0041536
recurrent ischemia urgent revascularization,C0022116;C0581603;C4321499
categorical variables,C0439828
hospitalization for unstable angina,C0019993;C0002965
continuous variables mean sd,C0439828;C2699239
patients treated with statins n $nmbr$,C0030705;C0332293;C0360714
age at onset y,C0206132;C3870509
patients not treated with statins n $nmbr$,C0030705;C0332293;C0360714
age at diagnosis y,C1828181;C3173302
mean bmi kg m $nmbr$,C0022718;C0439209;C4054209
duration of pd y,C0449238;C2926735
creatinine clearance n,C0812399
diagnosed y,C0011900
planned treatment duration n,C4528394
updrs score,C0449820;C4050231
index event n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
mental,C0229992
only dvt,C0149871;C2926618;C3899446
adl,C0001288;C1420005
pe dvt,C0149871;C2926618;C3899446
motor,C1513492;C1705994
index event not confirmed,C0441471;C4019010;C0521093;C0750484
hoehn and yahr stage,C0205390;C1300072;C1306673
immobilization at randomization n,C0020944;C4048292
modified se adl scale,C0175659;C0349674;C1947916
active cancer at randomization n,C0006826;C0998265;C1306459
pdqol scale,C0175659;C0349674;C1947916
ischemic heart disease n,C0010054;C0151744
modified rankin score,C0392747;C0449820;C4050231;C3889737
ischemic cerebrovascular disease n,C0475224;C0007820
symbol digit score,C0449820;C4050231
asa use at baseline n,C0042153;C0457083;C1947944
$nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
asastoppedat randomization n,C0034656
p value lnteraction,C1709380
recurrent vte statin use vs non use,C0042153;C0457083;C1947944
bl h y unilateral,C0005918;C0006413;C1552663;C2827109;C0205092
asa use at baseline,C0042153;C0457083;C1947944
bl h y bilateral,C0005918;C0006413;C1552663;C2827109;C0238767
no asa use at baseline,C0042153;C0457083;C1947944
bl updrs low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
no cardiac disease,C0018799
bl updrs high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
major bleeding statin use vs non use,C0042153;C0457083;C1947944
table $nmbr$ selected baseline characteristics of the study patients,C4684572
included in this study n $nmbr$,C0332257;C0557651;C2603343
spironolactone n $nmbr$,C0037982
patients with early cd n $nmbr$,C0030705;C0007928;C0034283;C4552032
nyha functional classification no,C1275491;C0205245;C0542341;C2700217
disease duration year median,C0549183;C0876920;C2347635;C2348144;C2939193
eligibility stratum,C0013893;C1548635
crp median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
hospitalization in previous year with management of heart failure as major component no,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539;C0449432;C1705248
crp $nmbr$ $nmbr$ mg dl n,C3890735;C0439269;C4048285
elevated natriuretic peptides in previous $nmbr$ days no,C1144709;C0205156;C1552607
cdai score mean s d,C0449820;C0444504;C2347634;C2348143;C4050231
current smoker no blood pressure mm hg,C3173209;C3241966;C0005823;C0439475;C1271104;C1272641
gastrointestinal area involved n total n,C0017446;C0205146
region of enrollment no,C0017446;C0205147
upper gastrointestinal tract,C3203348
russia and georgia,C0035970;C0017452;C0017454
baseline crohn s disease medications,C0168634;C0010346;C1442488;C0013227;C0802604;C2598133;C4284232
no of events patients,C0441471;C0030705;C3541888
systemic corticosteroids n,C4053960
randomization stratum,C0034656
budesonide n,C0054201
not hospitalized for heart failure in the year prior to study enrollment,C0701159;C0018801;C0018802;C4554158;C0332152;C3258203
$nmbr$ asa compounds n,C0004057;C3853627
hospitalized for heart failure during that time period,C0701159;C0018801;C0018802;C4554158;C1948053
history of bowel resections n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ejection fraction based on local reading,C0489482;C2700378;C1527178;C1705938
early crohn s disease,C1279919;C0010346;C0012634
less than the median,C0549183;C0876920;C2347635;C2348144;C2939193
non early crohn s disease,C1279919;C0010346;C0012634
at or above the median,C0549183;C0876920;C2347635;C2348144;C2939193
azathioprine monotherapy,C0004482
less than $nmbr$,
infliximab monotherapy,C0666743
greater than or equal to $nmbr$,C0439093;C0205163
infliximab combination therapy,C4076075
$nmbr$ years or older,C0439234;C0580836
remission component of variable,C0449432;C1705248
yes insulin treated,C0021641;C1533581;C1579433;C3714501;C1522326
cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
yes non insulin treated,C1549445;C1705108;C1710701;C1518422;C0021641;C1533581;C1579433;C3714501
mh,C0026514;C2930980
new york heart association congestive heart failure class,C1882083
crpnorm,
less than $nmbr$ mm hg,C0439475
cr mh,C0026514;C2930980
greater than or equal to $nmbr$ mm hg,C0439093;C0205163;C0439475
cr crpnorm,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
use of statins,C1524063;C0360714
mh crpnorm,C0026514;C2930980
pulse pressure,C0949236
cr mh crpnorm,C0201975;C0026514;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
less than $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
[ $nmbr$ ci],C0008107;C3259781
greater than or equal to $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439093;C0205163;C0439445
a aza treatment ref,C0004482;C1425988
racial category,C0683312;C3889287
ifx treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
use of cardiac medication,C1524063
combination treatment ifx aza,C0020823;C0004482
use of blood pressure lowering medication,C1524063
previous cd related surgery ref a,C0007928;C1425988;C0034283;C4552032
quartiles of fgf $nmbr$ ru ml,C2828255;C0016026;C0919505
no previous cd related surgery $nmbr$,C0038894;C0038895;C0543467;C1274039
current tobacco use,C0040335;C0543414;C0841002;C3853727
b aza treatment ref,C0004482;C1425988
prior pci or cabg,C0332152;C4049621;C2826257;C0010055
history of bowel resection ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
apo a $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ year km,C0439234;C3887676;C0439508
c kza treatment ref,C0039798;C1425988;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fgf $nmbr$ low egfr $nmbr$,C1739039;C3811844;C3812682
no hospitalization in the past $nmbr$ months prior to baseline ref,C0019993;C0439231;C0168634;C1425988;C1442488
fgf $nmbr$ high egfr $nmbr$,C1739039;C3811844;C3812682
hospitalization in the past $nmbr$ months prior to baseline,C0019993;C0439231;C0168634;C1442488
pinteraction $nmbr$ $nmbr$,
no history of extra intestinal manifestations of ibd ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0008107;C3259781
history of extra intestinal manifestations of ibd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
t $nmbr$ $nmbr$,C2603360
d aza treatment ref,C0004482;C1425988
hr $nmbr$ $nmbr$,
no steroid use at baseline ref,C0281991;C0168634;C1442488
risk categories,C0035647;C0683312;C4552904
on steroid at baseline,C0038317;C0168634;C1442488
fgf $nmbr$ low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
e aza treatment ref,C0004482;C1425988
fgf $nmbr$ low $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
reslizumab n $nmbr$,C1869620
fgf $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
median age years iqr,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
fgf $nmbr$ high $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
mean body mass index kg mq,C0005893;C0024853;C0578022;C1305855
p interaction $nmbr$ $nmbr$,C0369773;C1704675;C2603361
$nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
$nmbr$ mw distance m,C0024548;C0012751;C0026385;C0556966
mean time since diagnosis years,C0556970;C0011900;C1704338;C1704656
randomized treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mean ics use at enrolment pg,C0042153;C0457083;C1947944
ischemic hf etiology,C0015127;C1314792;C1524003
oral corticosteroid use at enrolmentt,C0239126
pulmonary disease,C0024115
laba use at enrolment,C0042153;C0457083;C1947944
ace i or arb,C0021966;C0221138;C3888198
mean prebronchodilation l,C0444504;C2347634;C2348143
$nmbr$ yr km mortality rate,C0026565;C0205848
mean predicted value prebronchodilation,C0444504;C0681842;C1882327;C2347634;C2348143
icd vs placebo,C0021122;C0032042;C1696465;C1706408
mean reversibility,C0444504;C0449261;C2347634;C2348143
amiodarone vs placebo,C0002598;C0032042;C1696465;C1706408
patients $nmbr$ y,C0030705
mean aqlq total score t,C3533236
duration of diabetes y,C0449238;C2926735
mean acq $nmbr$ scores,C3533236;C2919686
mean asui scored,C0444504;C2347634;C2348143;C0449820
patients with cardiac disorders n,C0741926
saba use in past $nmbr$ days,C0042153;C0457083;C1947944;C0439228
patients on antihypertensive medications n,C0030705;C0003364
mean number of puffs per day,C0444504;C0237753;C0449788;C2347634;C2348143;C0332173;C0439228;C0439505
number of patients randomized,C2360800;C0034656;C3815594
number of swollen joints $nmbr$ $nmbr$,C0449813
mean blood eosinophil count cells per pl,C0444504;C0200638;C2347634;C2348143
number of tender joints $nmbr$ $nmbr$,C0449813
mean number of caes in past $nmbr$ months number per patient ],C0444504;C0237753;C0449788;C2347634;C2348143;C0439231;C0030705
psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$,C0018563;C0016504;C0347981;C1552914
reslizumab,C1869620
all patients n,C0030705
place,C0442504;C1533810;C1704765;C1882509
patients receiving mtx n,C0030705;C1514756;C0025677;C1417487
rate ratio $nmbr$ cl,C0456603;C0596019;C1547037
patients not receiving mtx n,C0030705;C1518422;C1514756;C0025677;C1417487
ocs at baseline,C0168634;C1442488
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$,C0483204
patients with dactylitis,C0030705;C0239161
ics plus laba,C0815320;C4551720
dactylitis score $nmbr$ $nmbr$,C0449820;C4050231
ics no laba,C0815320;C4551720
patients with enthesitis,C0030705;C1282952
psa modified mases score $nmbr$ $nmbr$,C0449820;C4050231
body mass index kg mj previous diagnosis,C0005893;C0332132;C0578022;C1305855
patients with $nmbr$ bsa,C0030705
use of concomitant lipid lowering treatment,C1524063;C0023779
haq di score $nmbr$ $nmbr$,C0449820;C4050231
statin with ezetimibe,C0360714;C1142985
patients with fingernail involvement,C0522476
type of concomitant statin by daily dose,C0332307;C1547052;C2348070
napsi score $nmbr$ $nmbr$ of target fingernail,C0449820;C4050231;C1521840;C0222001;C2986546
simvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sf $nmbr$ summary scores,C0037712;C0449820
atorvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pcs score,C0449820;C4050231
pravastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mcs score,C0449820;C4050231
fluvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients receiving mtx,C0030705;C1514756;C0025677;C1417487
baseline lipid and lipoprotein values,C0168634;C0023779;C1442488;C0023820;C0042295
eplerenone n $nmbr$,C0961485
apo a $nmbr$ g l,C1447574;C4521365
race no b,C0034510;C1706779;C3853635
lp a pmol l,C0065058;C0439284;C1439335;C4553379
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0017654;C0439445;C1424601;C0005902
age s $nmbr$ years n $nmbr$ $nmbr$,C1510829
serum potassium mmol l,C0302353;C1532563;C0543465
baseline tg level n $nmbr$ $nmbr$,C0168634;C0337445;C1442488
anterior mi,C3536746
baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
concomitant treatments at randomization,C0087111;C0034656
statin only n $nmbr$ $nmbr$,C0360714;C0369718;C0441922
acetylsalicylic acid,C0004057
statin ezetimibe n $nmbr$ $nmbr$,C0360714;C1142985
p $nmbr$ y $nmbr$ antagonists,C0369773;C0243076;C2603361
other n $nmbr$ $nmbr$ ],C0369718;C0441922
heparins and fondaparinux,C0019134;C1098510
simvastatin n $nmbr$ $nmbr$,C0074554
gp iib iiia inhibitors,C0016011;C0243077
atorvastatin n $nmbr$ $nmbr$,C0286651
fibrinolytics,C0040044
rosuvastatin n $nmbr$ $nmbr$,C0965129
pci thrombolysis at randomization,C0520997;C0034656
diabetics yes n $nmbr$ $nmbr$,C0241863;C1549445;C1705108;C1710701
thrombolysis,C0520997
diabetics no n $nmbr$ $nmbr$,C0241863;C0369718;C0441922
no reperfusion,C0035124;C0684253
baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
n participants,C0369718;C0679646;C0441922
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
age group $nmbr$,C0027362;C2348001
baseline hdl c level n s $nmbr$ $nmbr$,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
systolic blood pressure median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
pulse pressure median $nmbr$ $nmbr$ ],C0549183;C0876920;C2347635;C2348144;C2939193
baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0337445;C1442488;C0439269
heart rate median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
other n $nmbr$ $nmbr$,C0369718;C0441922
prior bb plus acbi plus arb use,C0004739;C0332297;C0042153;C0457083;C1947944
baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
prior acbi or arb use,C0332152;C2826257;C0042153;C0457083;C1947944
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
anterior or non anterior ml,C0205094;C0439526;C1705224;C3887665
baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
acute reperfusion,C0035124;C0684253
p value $nmbr$ years,C1709380;C0439234
$nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
saxagliptin n $nmbr$ $nmbr$,C1611934
not perfused,C1518422;C1549542
pharmacotherapy,C0013216;C0013217
use of pci or thrombolysis within one day of randomization,C1524063;C4049621;C0520997;C3844320
$nmbr$ years placebo n $nmbr$ $nmbr$ saxagliptin n $nmbr$ $nmbr$,C0439234;C0032042;C1696465;C1706408
first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms,C0178602;C0033727;C0369286;C0441932;C0564385;C4528284;C0869039;C1114758;C0687676;C4086878;C1704687;C3469826
km event rate,C0871208;C1521828
$nmbr$ $nmbr$ hours,C0439227
interaction p value $nmbr$ $nmbr$,C1704675;C1709380
cardiac enzyates raised,C0018787;C1522601;C0442818
secondary,C0027627;C0175668;C0205436
figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig,C2986535;C0205199;C1547335;C0961485;C0032042;C1696465;C1706408
nonfatal ischemic stroke,C0948008
zoledronic acid n $nmbr$,C0257685
hospitalization for due to,C0019993
age groups n,C0441848
doubling of creatinine level,C0205173;C1705764
baseline bmi kg m $nmbr$,C0022718;C0439209;C4054209
initiation of dialysis renal transplantation or creatinine $nmbr$ $nmbr$ mg dl $nmbr$ mmol l,C0589507;C1158830;C1704686;C0439268
baseline t score at femoral neck n,C0449820;C4050231
history of heart failure at baseline,C0455531;C0168634;C1442488
entry hip fracture location n,C3260017
no history of heart failure at baseline,C0455531;C0168634;C1442488
intertrochanteric,C0745355
baseline hba $nmbr$ c concentration,C0086045;C1446561;C3827302
subtrochanteric,
bodyweight kg,C0022718;C0439209;C4054209
fracture history n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cardiovascular risk factors and history,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hip fracture only,C0019557;C0149531;C4552776
egfr ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
hip other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725;C0016658
egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
hip $nmbr$ vertebral fractures,C0019557
time from index acs event to randomisation days,C0040223;C3541383;C0034656;C0439228
hip nonvertebral vertebral,C0019552;C0549207;C0022122;C1505163;C3538851;C4284725
nyha chf class,C1882083;C0018802
fractures,C0016658
baseline bnp concentration pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
time to first infusion from hip surgery days n,C0040223;C3541383;C0596706;C0439228
baseline concomitant cardiovascular medications,C0168634;C0007220;C1442488
$nmbr$ weeks,C0439230
ace inhibitor arb or both,C0003015;C3888198;C4541021
baseline serum calcium level n,C0036785;C0728876
mras,C1335594;C1367476
prior use of osteoporosis medications n,C1524063
primary mace endpoint,C2986535;C0349381;C0949745;C1445339
bone mineral density g cm $nmbr$ mean sd,C0005938;C2699239;C0177804
non fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
eq $nmbr$ dprofile mobility n,C0205163;C0080078;C0425245;C0449580;C4318935;C0439185
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ t,C2603360
walking,C0080331;C4283795;C4321241;C4321242
pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455531
some walking,C0080331;C4283795;C4321241;C4321242
secondary mace endpoint,C4528314;C0349381;C0949745;C1445339
mental status baseline spmsq scores n,C0278060;C0168634;C1442488
urgent revascularisation due to unstable angina,C0581603;C0002965
charlson comobility score n,C0449820;C4050231
cardiovascular death and hospital admission for heart failure,C0011065;C1306577;C4082313;C4552775;C0184666;C0018801;C0018802;C4554158
between treatment comparison of percentage change from baseline in total hip bmd,C1299575;C1707455;C0168634;C1442488
hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
month $nmbr$ subgroup x treatment interaction p value,C0039798;C1709380;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
normal responder n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
age groups,C0027362
sensitive responder n $nmbr$,C0020517;C0332324;C1522640
t score at femoral neck,C3854607;C0015815
highly sensitive responder n $nmbr$,C0439822
$nmbr$ $nmbr$ and,
median age [interquartile range] yr,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193;C1711350;C0439234
hip fracture $nmbr$,C0019557;C0149531;C4552776
atrial fibrillation no,C0004238;C0344434;C1963067
time to first infusion,C0040223;C3541383
qualifying risk factors no,C1514624;C0035648;C1553898
calcium level,C0201925;C0428302
chads $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
charlson,
previous exposure to a vitamin k antagonist no current or former never,C0332157;C1096489;C2267235;C0521116;C1705970;C0205156;C0750523
mental status,C0278060
medications at time of randomization no,C0013227;C0802604;C2598133;C4284232
eq $nmbr$ d mobility,C0205163;C0439185;C0080078;C0425245;C0449580;C4318935
digoxin or digitalis preparations,C0012265;C0304520
age mean sd years n,C1510829;C0444504;C2347634;C2348143
asia pacific and south africa,C0003980;C0037712
education mean sd years,C0013621;C0439234;C0013622;C0013658;C0039401
edoxaban higher dose vs warfarin,C2975435;C0444956;C0043031
weight mean sd lbs,C0439219;C3161851
edoxaban lower dose vs warfarin,C2975435;C0445550;C1708745;C0043031
antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
higher dose,C0444956
st t wave n,C0036056;C0429103;C3272372
lower dose,C0445550;C1708745
lvh by ecg or echo n,C0232306;C0058928;C1655045
pinteraction,
visit $nmbr$ blood pressures,C0545082;C1272641;C1512346;C2826704
any overt bleed,C0019080
bp,C0037623;C1415692;C1708288;C4318478
normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
serum potassium mean sd mmol l,C0302353;C1532563;C0543465
sensitive,C0020517;C0332324;C1522640
fasting serum glucose mean sd mg dl,C0202041;C0439269;C3534430
highly sensitive,C0439822
serum cholesterol mean sd mg dl,C0587184;C0439269
major or clinically relevant non major bleed,C0205082;C0205164;C4318856;C4521762;C0019080
clinically relevant non,C2347946;C1518422
treatment groups n,C0039798;C0441848;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
history of mi or stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
clinically relevant non major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
background therapy,C0039798;C0087111;C1363945
amlodipine vs chlorthalidone normal,C0051696;C0205307;C0231683;C0439166;C2347086;C4553972
su,C0038642;C1705534
amlodipine vs chlorthalidone overweight,C0051696;C0008294;C0497406
biguanide,C0005382;C3537187;C4317165
amlodipine vs chlorthalidone obese,C0051696;C0008294;C0028754
agi,C1299007
favors amlodipine favors chlorthalidone,C0051696;C0008294
dpp $nmbr$ inhibitor,C1414174;C1999216
favors favors amlodipine chlorthalidone,C0051696;C0008294
study drug,C0013175
lisinopril vs chlorthalidone normal,C0065374;C0205307;C0231683;C0439166;C2347086;C4553972
empagliflozin,C3490348
lisinopril vs chlorthalidone overweight,C0065374;C0008294;C0497406
metformin open label,C0025598;C1709323
lisinopril vs chlorthalidone obese,C0065374;C0008294;C0028754
time since diagnosis of t $nmbr$ dm,C0040223;C3541383
favors lisinopril favors chlorthalidone,C0065374;C0008294
figure must be in supplement is not in paper,C0242295;C1947943;C2348609;C1518422;C0030351;C1547566
favors favors lisinopril chlorthalidone,C0065374;C0008294
ticagrelor $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dulaglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fsg mg dl,C0439269
multivessel coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
prestudy treatment a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
history of pci no total no t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439175;C0439810;C2603360
no oam,
$nmbr$ prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ oam,
qualifying events,C1514624;C0441471;C3541888
dulaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
years since myocardial infarction,C0439234;C0027051;C0428953;C2926063;C3810814;C4552959
oam,
type of myocardial infarction no,C0332307;C1547052
overall population n $nmbr$,C0282416;C0032659;C1257890;C1561607
unknown type,C0332307;C1547052
tnf antagonist failure population n $nmbr$,C0231174;C0032659;C1257890;C0680095
medication at enrollment no,C0013227;C3244316;C4284232
tnf antagonist naive subgroup n $nmbr$,C0231491;C1079230;C1515021
aspirin at any dose,C4696290
median age y range,C1514721;C2348147;C3542016
ticagrelor $nmbr$ mg $nmbr$ year km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean body weight kg range,C1514721;C2348147;C3542016
placebo $nmbr$ year km,C0032042;C3887676;C1696465;C1706408
median body mass index kg m $nmbr$ range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
age at randomization,C0001779;C0034656
median crohn s disease duration y range,C0549183;C0010346;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
median $nmbr$ kg,C0022718;C0439209;C4054209
mean crp level mg l sd,C0439268;C2699239
second prior mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
mean fecal calprotectin level mg g stool sd,C1300563;C2699239
second mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
disease localization n,C0012634;C0475264;C1744691
no second mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
ileocolonic both ileum and colon,C0020885;C0009368;C3888384
no multivessel disease,C0012634
history of crohn s disease surgery n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634;C0038894;C0038895;C0543467;C1274039
non endstage renal dysfunction,C1565489;C3279454
history of fistulizing disease n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
no renal dysfunction,C1565489;C3279454
corticosteroid use n,C0239126
heparin alone n $nmbr$,C0019134;C0205171;C0439044;C0679994;C0770546
immunosuppressive use n,C0021081;C0042153;C0457083;C1947944
heparin plus tirofiban n $nmbr$,C0019134;C0770546
mesalamine use n a,C0127615;C0042153;C0457083;C1947944
type of ml no,C0332307;C1547052
prior immunosuppressive exposure n,C0021081;C0274281;C0332157
symptom onset to hospital arrival median iqr h,C4086878;C0019994;C1510665
prior tnf antagonist failure n b,C3887647;C0231174;C0680095
killip class $nmbr$ no,C1881332
$nmbr$ prior tnf antagonist failure n b,C3887647;C0231174;C0680095
anemia no total,C0002871;C1000483;C4554633;C0439175;C0439810
$nmbr$ prior tnf antagonist failures n b,C3887647;C0231174;C0680095
crusade bleeding score mean sd ^,C0019080;C2699239
overall n u $nmbr$,C0282416;C0439148;C1561607
$nmbr$ moderate or high bleeding risk no total,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0332167;C3272283;C4050568;C4319571;C0439175;C0439810
insulin glargine n $nmbr$ ll,C0907402
heparin tirofiban n $nmbr$,C0019134;C0247025;C0770546
omega $nmbr$ fatty acid n $nmbr$,C1719844;C0015684
no of events total no $nmbr$,C0439175;C0439810
placebo n $nmbr$ o,C0032042;C1696465;C1706408
$nmbr$ years old,C0439234;C0580836
previous cardiovascular disease,C0205156;C0007222;C1552607
class ll iv,C0456387;C1518526;C1705943;C0022326;C4265176
present smoker,C0150312;C0337664;C0449450
transradial,
laser or vitrectomy,C0023089;C0458142;C1023865;C1706315;C0042903
transfemoral,
depression^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
previous cv events,C0441471;C3541888
hba,C0019016;C1825777;C3538758
crusade score,C0449820;C4050231
mini mental state examination,C0451306
lad artery,C0003842;C0226004
digit symbol substitution,C1555721;C1706204
non lad artery,C0003842;C0226004
a mini mental state examination insulin glargine vs standard care,C0451306;C0907402;C1442989;C1947933;C2828392
killip ciass,
insulin glargine vs standard care least squares mean $nmbr$ cl,C0907402;C0023189;C0596019
ciass ll iv,C0022326;C4265176
p $nmbr$ interaction,C0369773;C1704675;C2603361
ciass i,C0021966;C0221138
number insulin glargine,C0237753;C0907402;C0449788
creatinine ciearance,C0010294;C1561535
number standard care,C1442989;C1947933;C2828392
$nmbr$ mi min,C0702093;C1524029;C3813700
o oo $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0483204
arteriai access,C0444454;C1554204
$nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
no of events totol no,C0441471;C3541888
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$,
placebo golimumab $nmbr$ mg $nmbr$ mga b,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
education $nmbr$ years,C0013621;C0439234;C0013622;C0013658;C0039401
$nmbr$ mg $nmbr$ mgc,C0024671;C3888239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
education $nmbr$ $nmbr$ years,C0013621;C0439234;C0013622;C0013658;C0039401
$nmbr$ mg $nmbr$ mgb,C0024671;C0373680;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba median,C0549183;C0876920;C2347635;C2348144;C2939193
randomized patients,C0034656;C0030705;C3815594
hbak median,C0549183;C0876920;C2347635;C2348144;C2939193
psa modified shs $nmbr$ $nmbr$,C3810537;C0392747;C3889737;C3813209
o oi $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0029118;C0029434
ptga $nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
omega $nmbr$ fatty acid,C1719844;C0015684
pasi score $nmbr$ $nmbr$ d,C0449820;C4050231
b digit symbol substitution insulin glargine vs standard care,C0907402;C1442989;C1947933;C2828392
methotrexate use at baseline,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ $nmbr$ $nmbr$ too $nmbr$,
placebo to golimumab $nmbr$ mg $nmbr$ mgt,C0032042;C1696465;C1706408
hbalc median,C0549183;C0876920;C2347635;C2348144;C2939193
golimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l $nmbr$ to $nmbr$ $nmbr$,C0439394;C1706495;C3642217
mtx use at baseline,C0042153;C0457083;C1947944
omega $nmbr$ fatty acid vs placebo least squares mean $nmbr$ cl,C1719844;C0015684;C0023189;C0596019
no mtx use at baseline,C0042153;C0457083;C1947944
number omega $nmbr$ number placeb fatty acid,C0237753;C0015684;C0449788
no patients with available data,C2707520;C0470187
a mini mental state examination omega $nmbr$ fatty acids vs placebo,C0451306;C0015684;C0032042;C1696465;C1706408
myocardial infarction at presentation n $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
b digit symbol substitution omega $nmbr$ fatty acids vs placebo,C0582802;C0015684;C3241971;C0032042;C1696465;C1706408
no myocardial infarction at presentation n $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
etn mtx n $nmbr$,C0014758;C0025677;C1417487;C0717758
thienopyridine n $nmbr$,C1120149
csdmards mtx n $nmbr$,C0025677;C1417487
non white race,C0007457;C0043157
hcq mtx n $nmbr$,C0020336;C0025677;C1417487
any risk factor for stent thrombosis,C0035648;C3897493
ssz mtx n $nmbr$,C0025677;C1417487
renal insufficiency or failure,C0035078;C1565489;C0231174;C0680095
lef mtx n $nmbr$,C0025677;C1417487
more than $nmbr$ vessels stented,C0005847;C0038257
race n b,C0034510;C1706779;C3853635
more than $nmbr$ lesions per vessel,C0221198;C0005847
african latin american,C0085756
lesion length $nmbr$ mm,C4330985;C4554674
mestizos,C0682082
bifurcation lesion,C0221198;C1546698
sjc $nmbr$ joints,C0022417;C0392905
in stent restenosis of des,C3272317;C0011702;C4551552
tjc $nmbr$ joints,C0022417;C0392905
vein graft stented,C0042449;C0181074;C0332835;C1961139;C0038257
cdai,C0683448;C1413248;C3273706
unprotected left main stented,C0205091;C0038257;C0443246;C1552822
haq,C0102923;C0451208
thrombus containing lesion,C0087086;C0302148;C3146237;C0332256;C2700400;C0221198;C1546698
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0012634;C3900351;C0032659;C1257890
prior brachytherapy,C0332152;C0006098;C2826257
n $nmbr$ for etn mtx n $nmbr$ for dmards,C0369718;C0441922;C0014758;C0025677;C1417487;C0717758;C0242708
thienopyridine at randomization,C1120149;C0034656
supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348;C3900351
type of des at index procedure,C0332307;C1547052;C0184661;C2700391;C3274430;C3539779
a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards,C0012634;C0032659;C1257890;C0014758;C0025677;C1417487;C0717758;C0242708
$nmbr$ type,C0332307;C1547052
a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C1836348;C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
no of treated lesions,C1522326;C0221198
race n a,C0034510;C1706779;C3853635
no of treated vessels,C1522326;C0005847
region n a,C0017446;C0205147
no of stents,C0038257
central south america,C0007674
total stent length mm,C4330985;C4554674
mean sd hba $nmbr$ c level,C0441889;C0456079;C1547707;C2946261
lesions,C0221198
mean sd duration of t $nmbr$ dm y,C0449238;C2926735
native coronary artery lesions,C0205042;C0221198
patients with microvascular complications n,C0030705;C0009566;C1171258
in stent restenosis,C3272317
patients with cardiac disorders n c,C0741926
extreme tortuosity,C0205403;C0333076;C3641272;C4085555
mean treatment exposure wk,C0332174;C0439230
heavy calcification,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
$nmbr$ st tertile,C0036056;C3272372
modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C3541413;C0050451;C0221198;C1546698;C0772110
$nmbr$ nd tertile $nmbr$ to $nmbr$ $nmbr$ to,
figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction,C0021149;C0220856;C0446516;C3715044;C4553528;C0441833;C1706365;C1999270;C0155626;C3541950
$nmbr$ rd tertile $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] d,C0439422
age y median $nmbr$ th to $nmbr$ th percentiles,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
cana $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
qualifying type of atherosclerosis n,C1514624;C0332307;C1547052
baseline mg dl mmol l,C0439268
selected clinical characteristics n,C1707391;C0683325
ls mean se,C0023668;C0036919
peripheral revascularization,C0205100;C0581603
change mg dl mmol l,C0439268
any established coronary artery disease,C0010054;C0010068;C1956346
difference vs pbo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
any established peripheral arterial disease,C0085096;C1704436
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
ace inhibitors or arb,C0003015;C3888198
tcz sc $nmbr$ mg every other week n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332174;C0439230
lipid lowering medications,C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
pbo sc every other week n $nmbr$,C0031962;C0282380;C0332174;C0439230
vorapaxar placebo $nmbr$ yr km rate,C0871208;C1521828
weight group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
planned thienopyridine at baseline,C1120149;C0168634;C1442488
other dmards,C0242708
mitt population n $nmbr$,C0032659;C1257890
previous dmards mean sd,C0205156;C2699239;C1552607
bmi $nmbr$ kg m $nmbr$ population n $nmbr$,C0022718;C0439209;C4054209;C0032659;C1257890
previously failed anti tnf treatment no,C0231175;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
laboratory tests,C0022885
hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl,C0967300;C0439269
rf positive no,C0439178;C1446409;C1514241;C2825490;C3812269
dapagliflozin $nmbr$ mg group n $nmbr$,C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
acpa positive no,C0439178;C1446409;C1514241;C2825490;C3812269
subjects $nmbr$ years of age n,C1510829
crp level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
bw mean sd kg,C0022718;C0439209;C4054209
esr mean sd mg dl,C0444504;C0439269;C2347634;C2348143
qualifying cv event n,C1514624;C3538987;C0441471;C4019010;C4048877;C4318503
disease activity,C1292728
not reported,C0684224;C0700287;C4319718
duration of ra mean sd years,C0449238;C2926735
time from most recent qualifying,C0040223;C3541383;C1514624
tender joints $nmbr$ joint count mean sd,C0451530;C2699239
cv event years,C0441471;C0439234;C4019010
swollen joints $nmbr$ joint count mean sd,C0451521;C2699239
duration of hypertension n,C0449238;C2926735
das $nmbr$ mean sd,C0051767;C2699239;C0057671
seated sbp mean sd mmhg,C0085805;C0439475
shs mean sd,C0444504;C2699239;C2347634;C2348143
seated dbp mean sd mmhg,C0277814;C0439475;C1283233
jsn mean sd,C0444504;C2699239;C2347634;C2348143
type $nmbr$ diabetes duration years,C1320657;C0439234
erosion mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
fpg mean sd mmol l,C0444504;C1532563;C2347634;C2348143
haq di score range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
type of treatment n,C0455708
pain vas range $nmbr$ $nmbr$ mean sd,C0042815;C2699239
oad,
patient global assessment of disease,C4054229
oad plus insulin,C0021641;C1533581;C1579433;C3714501
activity range $nmbr$ $nmbr$ mean sd,C0205177;C2699239;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
daily insulin dose mean sd iu,C0049272;C0439453;C0694756
physician global assessment of disease,C4050369
oads n,
study $nmbr$ $nmbr$,C0557651;C2603343
aceis arbs,C3888198
olodaterol,C2934193
full analysis set,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
$nmbr$ g n $nmbr$,C0439267
hba $nmbr$ c at $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
pre bronchodilator mean sd fev $nmbr$ l,C2599602;C0444504;C2347634;C2348143
change from baseline adjusted mean $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
mean sd fev $nmbr$ l,C0444504;C2347634;C2348143
responders of three item end point at $nmbr$ weeks,C2349179;C2826544;C0439230
mean sd predicted normal fev $nmbr$,C0205307;C3714541;C0231683;C0439166;C2347086;C4553972
seated sbp at $nmbr$ weeks mmhg,C0277814;C0085805;C1283233
mean sd fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
bw at $nmbr$ weeks kg,C0005910;C0006041;C2986891
mean sd change from pre to post bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
patients with bw decrease of $nmbr$ in patients with baseline bmi of $nmbr$ kg m $nmbr$,C0030705;C0005910;C0006041;C2986891;C0022718;C0439209;C4054209
gold stage n,C0018026;C0205390;C1300072;C1306673;C1304897
fpg mmol lt,C0023376;C0230426;C3887647;C4521399
baseline pulmonary medications,C0013227;C0802604;C2598133;C4284232
insulin lispro mix $nmbr$,C0205430;C1421951;C1720722;C4553942
any pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
caucasians n $nmbr$,C0007457;C0043157
sama b n,C1075468
asians n $nmbr$,C0078988
lama tiotropium b n,C0999593;C0213771;C1416775
mg dl fpg mmol l,C0439268
saba inhaled c n,C0004048
phg,
laba inhaled d n,C0004048;C0369718;C0441922
fhg,
oral adrenergics n,C0442027;C0001637;C4521986
fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc,C0871261;C0168634;C1442488;C2349179;C2826544;C0205430;C1421951;C1720722;C4553942;C0019016;C2828255;C1825777;C3538758;C0015663;C0020456;C0376690;C4552833;C1855520
steroids n,C0038317
all patients on maximally tolerated statin other llt,C0030705;C0360714;C2347090
inhaledb,
oralb,
aiirocumab n $nmbr$,
xanthines b n,C0043318;C3541955
any cv history risk factors n,C0035648;C1553898
mean se auc^p l,C0036919;C0376690
chd history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
olodaterol $nmbr$ jig,C2934193
chd risk equivalents n,C1282512;C0439185;C4049980
tiotropium n $nmbr$ non tiotropium n $nmbr$,C0213771;C1518422
lipid medication n,C0023779;C0013227;C3244316;C4284232
any statin,C0360714
non tiotropium,C1518422;C0213771
mean se trough l,C0444504;C0036919;C2347634;C2348143
high dose statin use at screening,C0042153;C0457083;C1947944
other llt use,C0042153;C0457083;C1947944
tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$,C0213771;C1518422
ezetimibe use,C0042153;C0457083;C1947944
n unless otherwise specified,C0369718;C0441922;C0205369
a vs c,
lipid parameters mg dl mean sd,C0439269;C2699239
l vs c,C0439394;C1706495;C3642217
ldl c calculated,C0444686;C1441506
education years mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
ldl c measured,C0444706;C3541902
lp a,C0065058;C1439335;C4553379
type ii diabetes,C0011860
fasting tgs,C0015663;C1156212;C1537574
hx cabg,C0262926;C0010055;C3814444
aiirocumab,
hx mi or stroke,C0262926;C3810814;C3814444;C0038454;C4554100
placebo estimated mean,C0444504;C2347634;C2348143
oascvd,
consistency of effect,C0332529;C1547017
antihypertensive medication $nmbr$,C0003364
estimated mean,C0444504;C2347634;C2348143
estrogen,C0014939;C2936882;C4542544
not hispanic latino,C1518424;C0086528
heart rate mean sd,C0018810;C2699239
statin treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lvh by ecg minnesota code,C0232306;C0009219;C0805701;C3889831
high intensity statin,C4081854;C0360714
cholesterol mg dl mean sd,C0439269;C2699239
no high intensity statin,C4081854;C0360714
fasting glucose mg dl mean sd,C0439269;C2699239
other llt at randomization,C2347090;C0034656
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
statin with other llt,C0360714;C2347090
blood pressure mmhg mean sd,C0428886;C2699239
statin without other llt,C0360714;C2347090
systolic total,C0439175;C0439810
history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
diastolic total,C0439175;C0439810
prior history ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
systolic treated at baseline,C0039155;C1522326;C0168634;C1442488
no prior ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
diastolic treated at baseline,C0012000;C1522326;C0168634;C1442488
moderate ckd at randomization,C1561643;C0034656
interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure,C1704675;C1709380;C0332283;C1719822;C4281991;C0051696;C0008294;C0001779;C0011847;C0065374;C0011849;C0085096;C1704436;C0008976;C0019993;C0184661;C2700391;C3274430;C3539779
no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ mg mtx,C0025677;C1417487
diabetes at randomization,C0011847;C0011849
patients with prior dmard use n a,C0030705;C0042153;C0457083;C1947944
estimated mean $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
hydroxychloroquine,C0020336
age years mean $nmbr$ sd,C1510829;C2699239
sulfasalazine,C0036078
weight kg mean $nmbr$ sd,C0005910;C2699239;C0043100;C1305866;C1705104
patients taking oral corticosteroids at baseline n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
bmi kg m $nmbr$ mean $nmbr$ sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
prednisone or equivalent dose mg day,C0032952;C0178602;C0439422;C0869039;C1114758
hba $nmbr$ c mean $nmbr$ sd,C0019016;C2699239;C1825777;C3538758
anti ccp antibody positive n,C0432633
hba $nmbr$ c mmol mol mean,C0444504;C2347634;C2348143
total vdh s score,C2964552
fsg mg dl mean sd,C0439269;C2699239
diuretics group n $nmbr$,C0012798;C0441848
diabetes duration years mean sd,C0011847;C2699239;C0011849
no diuretics group n $nmbr$,C0012798;C0441848
took prior antihyperglycemic agent any,C1515187;C0450442;C1254351;C1521826
on drug treatment,C0150270;C3469597
sulfonylureas,C0038766;C3653359
concomitant lipid lowering therapy any,C0585943
positive family history of type $nmbr$ diabetes,C1313937
fibrates,C1449704;C3540783
history of peripheral arterial disease,C0683519;C0730226;C0850708;C0944983
niacin,C0027996;C1142562
pulse rate bpm,C0232117
duration of diabetes years t,C0449238;C2926735
uric acid mg dl,C0041980;C0439269
qualifying hba $nmbr$ c,C1514624;C0019016;C1825777;C3538758
k mmol l,C0597277;C1532563;C1708601
urinary albumin creatinine ratio mg g,C0486293;C1300563;C1318293
na mmol l,C0597484;C1532563;C1272460;C1546968;C1879645;C4049872;C4552882
prior cardiovascular disease,C0332152;C0007222;C2826257
triglyceride mg dl,C0041004;C0439269
$nmbr$ coronary stenosis,C0242231
non diuretics,C1518422;C0012798
prior cerebrovascular disease,C0332152;C0007820;C2826257
fbs $nmbr$ mg dl,C3812213;C0439269
prior peripheral arterial disease,C0085096;C1704436
fbs,C3812213
nyha class $nmbr$ or higher,C1882083;C0205250
with beta blocker,C0001645
antihyperglycemic,C0020616
without beta blocker,C0001645
ezetimibe,C1142985
with acei arb,C3888198
age subgroups,C0001779;C1079230
without acei arb,C3888198
^median,C0549183;C0876920;C2347635;C2348144;C2939193
continuation n $nmbr$,
asia pacific and other,C0003980
interruption n $nmbr$,C0332453;C1512900
diabetes duration subgroups,C0011847;C1079230;C0011849
age in years,C1510829
diabetes therapy at baseline alone or in combination,C3274787;C3539002;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
older than $nmbr$ years,C0580836;C0439234
thiazolidinedione includes pioglitazone,C0289779;C1257987;C3537039;C0332257;C1552866;C2700399;C0071097
body weight index kg m $nmbr$,C0022718;C0439209;C4054209
hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
dyslipidaemia,C0242339
renal function subgroups,C0232804;C1079230
high on treatment platelet reactivity,C0039798;C0005821;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
systolic blood pressure subgroups,C0488055;C1079230;C0871470;C1306620
prior percutaneous coronary intervention,C0332152;C1532338;C2826257
diastolic blood pressure subgroups,C0428883;C1079230;C1305849
prior coronary artery bypass graft,C0010055;C1260596
body mass index subgroups,C0005893;C1079230;C0578022;C1305855
calcium channel inhibitor,C0006685;C1999216
^median median,C0549183;C0876920;C2347635;C2348144;C2939193
drug eluting stent implanted,C1322815;C0021102;C2828363
a $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
first generation stentt,C0205435;C0079411;C3146294;C1279901
medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232;C1883727;C0034656
second generation stent,C0079411;C0038257;C3146294
asteria i ii,C1710602;C4082587
stented vessel,C0038257;C0005847
glacial $nmbr$,
coronary artery bypass graft,C0010055;C1260596
placebo n [ $nmbr$,C0032042;C1696465;C1706408
continuation,
omalizumab $nmbr$ mg n [ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
interruption,C0332453;C1512900
aqc $nmbr$,
time since diagnosis of ciu csuf y,C0040223;C3541383
woman,C0043210;C4281745
positive cu index test z n,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
no smoking,C0037369;C0453996;C1881674
no of previous ciu csu medications mean median,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
number stent $nmbr$,C0237753;C0038257;C0449788
previous use of systemic steroids n,C0281991
full population,C0032659;C1257890
total ige levelx iu ml median range,C1514721;C2348147;C3542016
aqc,
in clinic uask,C0150312;C0002424;C0442592;C0332285;C1707101
olodaterol $nmbr$ gg n $nmbr$,C0017454;C0018370
weekly iss,C1740819;C1845118
formoterol $nmbr$ gg n $nmbr$,C0017454;C0018370
weekly number of hives score,C0237753;C0449788
pre bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
weekly size of largest hives score,C0456389;C0042109
post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
overall dlqi score,C0282416;C3897059;C1561607
mean sd of predicted normal fev $nmbr$,C2699239;C0520835
angioedema present n,C0002994;C0150312;C0449450
baseline pulmonary medication b n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
primary key efficacy endpoint,C2986535
samac,
change from baseline to week $nmbr$ in weekly iss,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C1740819;C1845118
lamad,
additional endpoints,C1524062;C2349179
sabae,
change from baseline to week $nmbr$ in uas $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
icsf,
xanthinesg,
change from baseline to week $nmbr$ in weekly no of hives score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0042109;C0449820;C4050231
mean se auc $nmbr$ $nmbr$ l,C0036919;C0376690
median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f,C0040223;C3541383;C0871261;C1704632;C1706817;C2911692
placebo tiotropium n $nmbr$ non tiotropium n $nmbr$,C0032042;C0213771;C1696465;C1706408
$nmbr$ $nmbr$ ne ne,C0027608;C0028219;C3538705
olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
hr vs placebo $nmbr$ ci,C0008107;C3259781
patients with weekly iss mid response n v,C0030705;C0332174;C0871261;C1704632;C1706817;C2911692
formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$,C0060657;C0213771
omalizumab,C0966225
change from baseline to week $nmbr$ in weekly size of largest hive score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0456389;C0042109;C0221232
x $nmbr$ years,C0439234
change from baseline to week $nmbr$ in dlqi scorez,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C3899393
o $nmbr$ kg n,C0022718;C0439209;C4054209
proportion of angioedema free days from week $nmbr$ to week $nmbr$ x,C1709707;C0002994;C0332174;C0439230
body mass index kgm _ $nmbr$,C0005893;C0578022;C1305855
lvef $nmbr$ n $nmbr$ $nmbr$ a,C0428772;C0488728
time since diagnosis of ciu csu years $nmbr$,C0556970;C0011900;C1704338;C1704656
prior angiography showing stenosis $nmbr$ n $nmbr$ $nmbr$ a,C0332152;C0002978;C2826257;C1547282;C0678234;C1261287;C2632116
cu index test n $nmbr$,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
bnp $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
no of previous ciu csu medications,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
tni ultrapositive $nmbr$ $nmbr$ g l n $nmbr$ $nmbr$,C0439294;C0456615
median range total ige level iuml $nmbr$,C0439175;C0439810
medications during hospitalization or at discharge,C0013227;C0802604;C2598133;C4284232;C0012621;C0030685;C2926602
in clinic uas $nmbr$,C0150312;C0002424;C0442592;C0332285;C1707101
ranotazine vs placebo km failure rate,C0231174;C0680095
uas $nmbr$,
hr $nmbr$ s ci,C0008107;C3259781
weekly iss $nmbr$,C1740819;C1845118
primary ep cvd mi ri,C0035487;C1826843
weekly number of hives score $nmbr$,C0237753;C0449788
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$,
overall dlqi score $nmbr$,C0282416;C3897059;C1561607
$nmbr$ $nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
angioedema present n $nmbr$,C0002994;C0150312;C0449450
no pci,C4049621
lsm difference $nmbr$ cl,C1705241;C0596019;C1705242
$nmbr$ $nmbr$ vi $nmbr$ $nmbr$,C0205999
sia,C1225105;C1551538
$nmbr$ $nmbr$ s,
non united states,C1518422;C0041703
ranolazine vs placebo km failure rate,C0073633;C0231174;C0680095
baseline weekly itch severity score,C0033774;C0457451;C1422257
hr $nmbr$ s a,
rec ischemia requiring revasc,C0022116;C4321499;C0378365
baseline urticaria activity score,C0042109;C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939;C1559188
a median,C0549183;C0876920;C2347635;C2348144;C2939193
rec ischemia leading to hosp,C0022116;C4321499;C0332152;C1522538
body weiqht,C0242821;C0460148;C1268086;C4082212
rec ischemia,C0022116;C4321499
due to ecg changes,C0855329
positive cu index test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
presence of angioedema at baseline,C0150312;C0392148;C3854307;C0168634;C1442488
rec ischemia leading to hasp,C0022116;C4321499;C0332152;C1522538
previous use of systemic steroids for ciu csu,C0281991;C0578870
rec ischemia due to ecg changes,C0022116;C4321499
level of thyroperoxidase antibody at baseline,C0428536;C0168634;C1442488
rec ischemia due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
high $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
de $nmbr$ mg bid n $nmbr$ $nmbr$,C0011198;C0017480;C3541240
normal $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
warfarin n $nmbr$ $nmbr$,C0043031
duration of disease before baseline,C0872146;C0168634;C1442488
gfr ckd epi,C1561643;C0162734;C4281721
previous number of ciu csu medications,C0205156;C1718138;C1552607
ckd stages,C1561643;C1306673
figure $nmbr$,
$nmbr$ $nmbr$ to $nmbr$ ml min,C0439445
b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug,C0018623;C0456603;C1610540;C0030705;C0441767;C1706317;C0009667;C0242708
history of stroke see tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
lipoprotein a mg dl,C0065058;C0439269;C0125953;C1096202;C1439335
hypertension requiring medical treatment,C0020538;C1963138;C0679624
fasting blood glucose mg dl,C0428568;C0439269;C1261430
previous vka use stratified randomization,C0042153;C4687737;C0457083;C1947944
$nmbr$ a,
naive,
former or current smokers,C0205156;C0750523;C3173209;C3241966
experienced,
baseline high density lipoprotein cholesterol mg dl,C0023822;C0439269
duration of previous use of vka months,C1881378;C2826775
q $nmbr$ q $nmbr$,
no of cardiovascular events cardiovascular events $nmbr$ person years,C1320716;C0027361;C2347489
normal study termination,C1549081;C1692758
pfor trend,C1521798;C4554533
concomitant medication $nmbr$,C0013227;C3244316;C4284232
chd plus cerebral infarction,C0280604;C3542407
p gp inhibitor,C3898062
total deaths,C0011065;C1306577
vitamins,C0042890;C3540032;C3714649
pharmaco invasive n $nmbr$,C0205281;C1334278
oral hypoglycemic,C0359086
age $nmbr$ y n,C0001779
alpha blocker other vasodilator,C0001641;C0042402;C3537240
killip class ii iv n,C2697847
previous vka use,C0042153;C0457083;C1947944
timi risk score $nmbr$ n,C0035647;C0449820;C4050231;C4552904
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$,
time to randomization from symptom onset,C0040223;C3541383;C4086878
adjusted mean se change from baseline,C0392747;C0443172;C1705241;C4319952
$nmbr$ h n,C0033727;C0369286;C0441932;C0564385;C4528284
p value vs previous time point,C1709380;C0205156;C2348792;C1552607
anterior n,C0205094
calculated annual decline mean se,C0332181;C0036919
inferior n,C0542339;C0678975
adjusted mean _ se change from baseline,C0392747;C0443172;C1705241;C4319952
ambulance n,C0002422;C3846685
elderly patients n $nmbr$,C0870602
community hospital n,C0020003
very elderly patients n $nmbr$,C0442824;C0870602;C2984081
all cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C1524003
p between age groups,C0441849;C1959644
age [years] interaction p $nmbr$ $nmbr$,C0001779;C0439234;C1704675
olmesartan along with ccb n $nmbr$,C1098320;C0006684
time to randomisation [hours] interaction p $nmbr$ $nmbr$,C0040223;C3541383;C0439227;C1704675
olmesartan along with diuretic n $nmbr$,C1098320;C0012798
previous ml interaction p $nmbr$ $nmbr$,C0205156;C0439526;C1705224;C3887665;C1552607
grade of hypertension,C0441800;C0919553;C3244287
sex interaction p $nmbr$ $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
grade $nmbr$,C0441800;C0919553;C3244287
systolic blood pressure [mmhg] interaction p $nmbr$ $nmbr$,C0488055;C0871470;C1306620;C0439475;C1704675
previous history of cardiovascular events,C2004062
killip class interaction p $nmbr$ $nmbr$,C1881332;C1704675
drinking,C0001948;C0684271
infarct location interactsn p $nmbr$ $nmbr$,C0021308;C0450429;C1515974;C4284930;C4284931
number of visits median,C1549755;C0549183;C0876920;C2347635;C2348144;C2939193
other diabetes interaction p $nmbr$ $nmbr$,C0011847;C0011849
number of visits mean sd,C1549755;C0444504;C2347634;C2348143
yes weight [kg] interaction p $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209;C1704675
treatment effects,C1518681
p lace of randomization interaction p $nmbr$ $nmbr$,C0280109;C0453991
sbp during the follow up period mmhg,C0085805;C0589120;C1522577;C1704685;C3274571
timi risk score interaction p $nmbr$ $nmbr$,C0035647;C0449820;C4050231;C4552904
dbp during the follow up period mmhg,C0536221;C3813197;C4281799
time of randomization interaction p $nmbr$ $nmbr$,C0040223;C3541383
uncover $nmbr$,
prehospital ticagrelor n $nmbr$,C1999375
ixekizumab every $nmbr$ weeks n $nmbr$,C3489764;C0439230
in hospital ticagrelor n $nmbr$,C0019994;C1510665
nx,C0445085
bmi $nmbr$ no f,C0578022;C0016327
bmi kg per m $nmbr$,C0022718;C0439209;C4054209
timi risk score no t,C0035647;C0449820;C4050231;C4552904;C2603360
psoriasis duration years,C0033860;C0439234
killip class i no,C2697844
percentage of bsa involved,C0439165;C1549488;C1561533;C1314939
first medical contact no,C0332158;C0337611;C1705415;C3812666
spga $nmbr$,
in ambulance,C0002422;C3846685
pasi,C4528685
in emergency department before ambulance transfer,C0562508;C0002422;C3846685
qids sr $nmbr$,C4331197
procedures for index event,C0025664;C0184661;C2700391;C3538935
napsit,
coronary angiography no,C0085532;C1548829
itch nrs,C2240043;C4050142
femoral access no total no,C0444454;C1554204;C0439175;C0439810
previous therapy,C0039798;C0087111;C1363945
radial access no total no,C0444454;C1554204;C0439175;C0439810
topical prescription,C0033080;C1521941
missing data no total no,C4684714;C0439175;C0439810
topical non prescription,C0332237;C1518422;C0033080;C1521941
thromboaspiration no,
phototherapy,C0031765
with stent^l,C0038257
non biological systemic,C0445097;C0205373
no pci or cabg no,C4049621;C0010055
biological,C0005532;C0205460
study medication no,C0013227;C3244316;C4284232
qva $nmbr$ $nmbr$ $nmbr$ ig od n $nmbr$,C0021027;C0229089;C0439164;C1512019;C3273373;C3665488;C0305052;C0360506
first loading dose,C0205435;C3714444;C1279901
sfc $nmbr$ $nmbr$ ig bid n $nmbr$,C0021027;C0305052;C0360506
second loading dose,C0205436;C3714444;C0457385;C0565930;C1561503;C1705190
copd severity n a,C0024117;C0439793;C0522510;C1412502;C3714496
maintenance dose,C3714445
gold $nmbr$ groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
any use,C0042153;C0457083;C1947944
gold b,C0018026;C1304897
other antithrombotic medication for index event no,C0013227;C3244316;C4284232
gold d,C0018026;C1304897
glycoprotein ilb iiia inhibitor before pci],C0017968;C1999216
patients with prior copd related,C0030705;C0332152;C2826257;C0024117;C0439849;C0445223;C1412502;C3714496
intravenous anticoagulant during hospitalization,C0003280;C0848112;C3536711
ics users at baseline n,C1706077;C0168634;C1442488
combination therapy,C0009429;C0556895
postbronchodilator fev $nmbr$ reversibility,C2599594;C0449261
total patients,C0439175;C0030705;C0439810
postbronchodilator fev $nmbr$ fvc,C2599594;C3714541
endpoint rate,C0871208;C1521828
cat score,C0449820;C4050231
p value int,C1709380;C3272375
cat score category,C0683312;C3889287
pre h,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ mild,C2945599
in h,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
n nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
$nmbr$ $nmbr$ severe,C0205082;C4050465;C4050466
so $nmbr$,
$nmbr$ $nmbr$ very severe,C3641272;C4050419
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ j $nmbr$,
bdi focal score,C0449820;C4050231
location of ml,C0450429;C1515974;C4284930;C4284931
sgrq total score,C2964552
tim $nmbr$ nsk score,C0449820;C4050231
mmrc grade,C0441800;C0919553;C3244287
highest killip classiciation pre pci,C1522410;C0332152;C0740175;C2257086;C3669034
smoking history current smoker,C3173209;C3241966
$nmbr$ ix,C0015491
smoking history ex smoker,C1519384;C0337664
prior asa use,C0042153;C0457083;C1947944
copd severity mild moderate,C0439793;C0522510;C1299392
gpiib llla inhibitor use before angiography,C0042153;C0457083;C1947944
copd severity severe very severe,C0024117;C0205082;C4050465;C4050466;C1412502;C3714496
morphine use for index event pci,C0242000;C0441471;C4019010
baseline ics use yes,C1549445;C1705108;C1710701
heparin fondaparinux or bivalirudin use between index event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
baseline ics use no,C0042153;C0457083;C1947944
total atients,C0439175;C0439810
copd exacerbation yes,C1549445;C1705108;C1710701
tlmi risk score,C0035647;C0449820;C4050231;C4552904
copd exacerbation no,C0740304
so,
diabetics n $nmbr$,C0241863
gpifo llia inhibitor use before angography,C0042153;C0457083;C1947944
non diabetics n $nmbr$,C1518422;C0241863
heparin fondaparinux or brvalirudin use between oex event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
patients with dm n $nmbr$,C0030705;C0011816;C3250443
ivabradine n $nmbr$,C0257190
patients without dm n $nmbr$,C0030705;C0011816;C3250443
cardiovascular risk factors and medical history,C0850624;C0262926;C1704706
patients with dm vs patients without dm,C0030705;C0011816;C3250443
duration of coronary artery disease yr,C0872146
age\\yr,C0001779;C0439234
previous coronary revascularization no,C0205156;C0877341;C1552607
b $nmbr$ $nmbr$,
angina status no,C0002962;C0449438
year,C0439234;C0439508
no symptoms,C0683368;C1457887
male sex \ no,C0086582
ccs class,C1879987
body mass index \ kg m $nmbr$,C0022718;C0439209;C4054209
previous stroke no,C0038454;C4554100
ischemic stroke incl uncertain,C0948008;C0087130;C4085655
concomitant treatment no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hba $nmbr$ c \n,C0019016;C1825777;C3538758
antiplatelet agent or anticoagulant,C0085826;C0003280;C0848112;C3536711
\mean sd,C0444504;C2699239;C2347634;C2348143
angiotensin il receptor blocker,C0034787;C1622222
af type no,C0332307;C1547052
dihydropyridine calcium channel blocker,C2945601
median crcl ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
diltiazem or verapamil,C0012373;C0042523
peripheral arterial disease no,C0085096;C1704436
antidiabetic agent,C0935929
baseline chads $nmbr$ a c,C0168634;C1442488
plus minus values are means sd there were no significant differences at,C0042295;C1704970;C2699239;C0237881;C0750502;C1546944
baseline cha $nmbr$ ds $nmbr$ vascb c,C0168634;C1420648;C1442488
denotes angiotensin converting enzyme,C0022709;C1452534
patients without dm n $nmbr$ $nmbr$,C0030705;C0011816;C3250443
j the body mass index is the weight in kilograms divided by the square of the,C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595
ustekinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
height in meters,C0489786;C0441074
psoriasis,C0033860
race was determined by the investigator during the patient s interview,C0034510;C1706779;C3853635;C0521095;C0035173;C0030705;C0021822;C0935630
patients with psoriasis $nmbr$ of body surface area,C0030705;C0005902
classes on the canadian cardiovascular society ccs scale range from i to iv,C0007226;C1879987;C3887460;C0022326;C4265176
pasi score,C0449820;C4050231
dlqi score,C3897059
with higher classes indicating greater limitations on physical activity owing to,C0456387;C1518526;C1705943;C4019422;C0449295;C0015259;C0026606
ivabradine,C0257190
swollen joint count,C0451521
no of events total no,C0439175;C0439810
tender joint count,C0451530
haq di score,C0449820;C4050231
angina class at baseline,C0456387;C1518526;C1705943
dactylitis in $nmbr$ digit,C0239161;C0582802;C3241971
class i or no symptoms,C0441885;C1319793;C2698967;C0683368;C1457887
dactylitis score,C0449820;C4050231
beta blocker use at randomization,C0042153;C0457083;C1947944
enthesitis score,C0449820;C4050231
$nmbr$ beats min,C0439385
dose mg week,C0332174;C0439230
total by treatment,C0439175;C0439810
mean dose sd mg week,C0332174;C0439230
early,C1279919
dose mg day,C0178602;C0439422;C0869039;C1114758
delayed,C0205421;C1545665;C3272602
vka n $nmbr$,
mean dose sd mg day,C0178602;C0439422;C0869039;C1114758
creatinine clearance an,C0812399
non steroidal anti inflammatory drugs,C0003211
prior non cns se,C0332152;C0036919;C2826257
placebo to ustekinumab $nmbr$ mgt,C0032042;C1696465;C1706408
prior tia,C0007787;C0917805;C1054154
ustekinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nyha class iii iv,C0278962
ustekinumab combined,C1608841;C0205195
patients randomized no,C0030705;C0034656;C3815594
vascular disease,C0042373
first diagnosed,C0205435;C1279901;C0011900
clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
patients no,C0030705
long standing persistent,C0205322;C0332996
acr response by baseline weight,C0871261;C1704632;C1706817;C2911692
cha $nmbr$ ds $nmbr$ vasc score n,C1420648;C0449820;C4050231
no total no,C0439175;C0439810
$nmbr$ or $nmbr$ if female only,C0043210;C0086287;C1705497;C1705498
$nmbr$ except for female alone,C0043210;C0086287;C1705497;C1705498;C0205171;C0439044;C0679994
acr response by baseline mtx use no total no acr $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C1412134;C1515941
oac experienced bn,C0005005;C0034700;C1706574;C4551963
good moderate response,C0205170;C4085643
change from baseline median iqr,C0392747;C0443172;C1705241;C4319952
antiarrhythmic drugs n,C0003195
dronedarone,C0766326
patients with improvement $nmbr$ $nmbr$,C0030705;C2986411
flecainide,C0016229
patients with $nmbr$ bsa at baseline no,C0030705;C0168634;C1442488
propafenone,C0033429
pasi $nmbr$ at week $nmbr$,C4528685;C0332174;C0439230
no total no t,C0439175;C0439810;C2603360
others classes i and iiic,C0441885;C1319793;C2698967
pasi $nmbr$ no total no $nmbr$,C4528685;C0439175;C0439810
outcome_type,C0332307;C1547052
efficacy n a,C1280519;C1707887
pasi response by baseline weight no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
safety n b,C0036043;C1705187
pasi response by baseline mtx use no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
fatal,C1302234;C1705232
$nmbr$ $nmbr$ $nmbr$ $nmbr$ continued,C0549178
critical site,C0205145;C1515974;C2825164
patients with dactylitis at baseline no,C0030705;C0239161;C0168634;C1442488
ich,C0019191;C3272597;C3281105
dactylitis score at baseline median iqr week $nmbr$,C0449820;C4050231
hb decrease $nmbr$ g dl,C0439267
score improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
transfusion $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C1879316;C0229664;C0370231;C1546552;C1608383
percent improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
prior heart failure n $nmbr$ $nmbr$,C0018801;C0018802;C4554158
patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C0239161;C0332174;C1282952;C0439230
no prior heart failure n $nmbr$ $nmbr$,C0018801;C0018802;C4554158
patients with enthesitis at baseline no,C0030705;C1282952;C0168634;C1442488
age years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
enthesitis score at baseline median iqr week $nmbr$,C0449820;C4050231
multiracial n,C1881928
patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score,C0030705;C1282952;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
weight kg median iqr,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
mean $nmbr$ sd,C0444504;C2699239;C2347634;C2348143
weight $nmbr$ kg n,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
median iqr change from baseline to week $nmbr$ in psa modified total shs score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
body mass index kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight,C0444504;C0168634;C1442488;C2347634;C2348143;C0332174;C0439230;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0005910;C0043100;C1305866;C1705104
body mass index $nmbr$ n,C0005893;C0578022;C1305855
$nmbr$ kg mtx use,C0042153;C0457083;C1947944
duration of diabetes median iqr,C0449238;C2926735
patients with change from baseline in psa modified total shs score $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
established atherosclerotic disease n,C0333482;C0012634
low risk n $nmbr$ $nmbr$,C3272281;C3538919
prior coronary revascularization n,C0332152;C0877341;C2826257
high risk n $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
glycated hemoglobin median iqr,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
time since diagnosis of copd years,C0556970;C0011900;C1704338;C1704656
glycated hemoglobin n,C0062408
spirometry,C0037981
fasting serum glucose mg dl median iqr,C0202041;C0439269;C3534430
respiratory medication taken at baseline n,C0418986;C1883727;C0168634;C1442488
estimated glomerular filtration rate ml min median iqr,C3811844;C0439445
other steroids,C0038317
estimated glomerular filtration rate n,C3811844
ics laba free or fdc,C0332296;C1880497;C1996904;C0340427;C1413520;C3539652
albumin creatinine ratio mg mmol median iqr,C0486293;C1318293
patient classification,C0008902;C0008903;C0678229
albumin creatinine ratio n,C0486293;C1318293
salmeterol,C0073992
$nmbr$ $nmbr$ mg mmol,C0567349;C2348885
tiotropium vs salmeterol,C0213771;C0073992
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
number of patients with events,C2360800;C0441471;C3541888
baseline cardiovascular medications n,C0168634;C0007220;C1442488
low risk,C3272281;C3538919
baseline anti hyperglycemic medications n,C0432633;C0013227;C0802604;C2598133;C4284232
infrequent exacerbator,C0521114
thiazolidinediones,C1257987;C3541957
frequent exacerbator,C0332183
state,C1301808;C1442792;C3148680
low risk ics,C0815320;C4551720
glomerular filtration rate,C0017654;C1561549
high risk ics,C0815320;C4551720
baseline albumin,C0168634;C0001924;C1442488
olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
creatinine ratio pg mg,C0010294;C1627892;C1561535
tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
baseline beta blocker,C0168634;C0001645;C1442488
tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
baseline calcium antagonist,C0168634;C0006684;C1442488
gold $nmbr$ $nmbr$,C0018026;C1304897
mepolizumab,C0969324
current smoker n post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
intravenous n $nmbr$,C0348016
mean sd fevi ml,C0439526;C1705224;C3887665
subcutaneous n $nmbr$,C0443315
mean sd change from pre to post bronchodilator fevi ml,C2599594;C3481639
mean age range yr,C0001779;C0439234
mean sd fevi fvc,C0802741;C3815113
former smoker no,C0337671
mean sd of predicted normal fevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
duration of asthma yr,C0449238;C2926735
gold $nmbr$ $nmbr$ n $nmbr$,C0018026;C1304897
use of oral glucocorticoids,C1524063
olodaterol sgg,C2934193
maintenance use no,C0042153;C0457083;C1947944
tiotropium olodaterol $nmbr$ $nmbr$,C4032878
mean daily dose range mg i,C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd change from pre to post bronchodilator fevi nil,C2599594;C3481639
allergic rhinitis no,C1334103;C2607914;C4552864
gold $nmbr$ $nmbr$ $nmbr$,C0018026;C1304897
fev $nmbr$,C3714541
mean sd eevi ml,C0439526;C1705224;C3887665
before bronchodilation liters,C1371299;C0475211;C3537072
mean sd fevi evc,C0013903;C0429711;C1414479
percent of predicted value before bronchodilation^,C1882327;C1371299;C3537072
mean sd of predicted normal eevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
fevt fvc ratio,C0456603;C1547037
adjusted mean se fevi auco_ $nmbr$ ml,C0439526;C1705224;C3887665
morning peak expiratory flow liters min,C0702093;C1524029;C3813700
adjusted mean se trough fevi ml,C0439526;C1705224;C3887665
score on asthma control questionnaire,C4706265
global initiative for chronic obstructive lung disease $nmbr$,C0849867;C0424093
score on st george s respiratory questionnaire^^,C0449820;C4050231;C0521346;C0034394;C1546767
versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C4032878;C0030827;C0072225;C1266240
geometric mean ige on loge scale u ml,C0439340;C1880521;C2945590
global initiative for chronic obstructive lung disease $nmbr$ $nmbr$,C0849867;C0424093
geometric mean blood eosinophil count on loge scale cells ^ljj,C2986759;C0200638
median interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
asthma exacerbations,C0349790
saudi arabia,C0036243
severe episodes in previous year no patient,C0205082;C0332189;C4050465;C4050466;C0030705
time from pah diagnosis months,C0011900;C0556969;C1704338;C1704656
necessitating hospitalization in previous year no,C0019993;C0205156;C1552607
aetiology of pah,C0015127;C1314792;C1524003
history of asthma related intubation no,C0455544;C0021925
familial,C0015576;C0241888
p $nmbr$ z $nmbr$ n $nmbr$,C0369773;C2603361
repaired congenital shunts,C0232180;C0542331;C1442858
$nmbr$ to $nmbr$ n,C0369718;C0441922
drugs and toxins,C0013227;C3687832;C0040549
north america oceania,C0282279;C4085681
$nmbr$ min walk distance m,C0702093;C0429886;C1524029;C3813700
femoral neck t score mean sd,C0015815;C2699239
who functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n,C0369718;C0441922
nt probnp $nmbr$ pmol l $nmbr$,C0669479;C0439284;C0754710
mean bmd sd g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
baseline sildenafil dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lumbar,C0024090
$nmbr$ $nmbr$ $nmbr$ y,
prior medication use n,C0332152;C0240320;C2826257
body weight mean sd kg,C0022718;C0439209;C4054209
calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
egfr mean sd ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
serms,C0732611
hdl cy,C0010622;C0332298;C2239193
other osteoporosis medication,C0013227;C3244316;C4284232
baseline mean _ sd mg dl,C0168634;C0439269;C1442488
mean sd days since,C0444504;C0439228;C2347634;C2348143
ls mean change from baseline _ se,C0392747;C0443172;C1705241;C4319952
last infusion in the horizon pft,C0574032;C1827465
ldl cz,C0206578
core study to first infusion,C0557651;C2603343
ldl c hdl cx,C3715113
in extension study,C0557651;C2603343
baseline mean _ sd mg mg,C0168634;C1319635;C1442488
with ckd intensive n $nmbr$,C1561643
liraglutide n $nmbr$,C1456408
with ckd standard n $nmbr$,C1561643;C1442989;C2828392
hispanic or latino ethnic groupf,C0086409;C0086528;C0015031;C0680174
no ckd intensive n $nmbr$,C1561643
body mass index categories no c,C0005893;C0683312;C0578022;C1305855
no ckd standard n $nmbr$,C1561643;C1442989;C2828392
$nmbr$ $nmbr$ $nmbr$ overweight,C0497406
o $nmbr$ $nmbr$,C0483204
$nmbr$ $nmbr$ $nmbr$ obese class i,C3853264
uacr mg g,C1300563
$nmbr$ $nmbr$ $nmbr$ obese class ii,C3853263
no ckd,C1561643
$nmbr$ obese class iii,C1319441
ckd stage $nmbr$,C0205390;C1300072;C1306673
fasting insulin tiu ml,C0015663;C0439526;C1705224;C3887665
serum glucose mg dl,C0202041;C0439269;C3534430
free fatty acids mmol liter,C0015688;C0475211
duration of dm years,C0449238;C2926735
prediabetes no $nmbr$,C0362046
history of cvd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
estimated means and difference,C0750572;C1704970;C1705241;C1705242
merformin,
mean baseline bmi,C0168634;C0578022;C1442488
any anti hypertensive agent,C0003364
liraglutide $nmbr$ $nmbr$ mg mean n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dihydropyridine ccbs,C0012315;C0006684;C0220821
placebo mean n,C0032042;C0444504;C2347634;C2348143;C1696465;C1706408
non dihydropyridine ccbs,C0012315;C0006684;C0220821
pooled analysis,C0002778;C0936012;C1524024
fibrate,
bmi $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0578022
hdl female,C0043210;C0086287;C1705497;C1705498
estimated response rate and odds ratio,C0750572;C0237629;C0028873
hdl male,C0086582;C1706180;C1706428;C1706429
estimated odds ratio,C0750572;C0028873
ohs graduate,C0588053;C1547183
number of previous anti tnf treatments for psoriatic arthritis,C0237753;C0449788;C0087111;C0003872
hs graduate ged,C0588053;C1880947;C1547183
methotrexate use at randomisation,C0042153;C0457083;C1947944
some college tech,C0557806;C1826596
systemic glucocorticoid use at randomisation,C0042153;C0457083;C1947944
college graduate or more,C0682187
patients with specific disease characteristics,C0683521;C0815172
network,C0150775;C1513822;C1705739;C1882071
psoriasis body surface area $nmbr$,C0033860;C0005902
g,C0439267
dactylitis count,C0750480;C1705566
fp sal $nmbr$ $nmbr$ pg n $nmbr$,C0016704;C0030827;C0072225;C1266240;C1419068;C1419906;C3541238;C3541412
enthesitis count,C0750480;C1705566
sal $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
baseline disease and quality of life scores,C0168634;C0012634;C1442488;C3476431
copd type,C0332307;C1547052
physician s global assessment vas,C0031831;C0804815;C0042815;C3536884;C3827561
chronic bronchitis,C0008677
pain vas,C0042815
emphysema,C0013990;C0034067
patient s global assessment vas,C0030705;C0042815;C3536884;C3827561
smoking pack years,C0037369;C1277691;C0453996;C1881674
odds ratio versus placebo $nmbr$ ci,C0028873;C0008107;C3259781
baseline pre bronchodilator fev $nmbr$ l,C0168634;C2599602;C1442488
p value versus placebo,C1709380;C0032042;C1696465;C1706408
baseline predicted fev $nmbr$,C0168634;C3714541;C1442488
anti tnf naive patients,C1448177;C0030705
fev $nmbr$ reversibility,C3714541;C0449261
acr $nmbr$ response,C0871261;C1704632;C1706817;C2911692
non reversible,C1518422;C0205343
pasi $nmbr$ response,C0871261;C1704632;C1706817;C2911692
reversible,C0205343
anti tnf ir patients,C0022065;C0030705;C0022071;C1448132
ratio fp sal sal $nmbr$ ci,C0008107;C3259781
czp mtx n $nmbr$,C0054841;C0025677;C1417487;C1861828;C1872109
severe exacerbations itt population n,C0205082;C0032659;C1257890;C4050465;C4050466
pbo mtx n $nmbr$,C0031962;C0025677;C1417487
patients having exacerbation,C0030705;C4086268
ra duration months,C0449238;C0439231;C2926735
number of exacerbations,C0237753;C0449788
$nmbr$ $nmbr$ months n,C0439231
mean annualized exacerbation rate,C0871208;C1521828
previous dmards use n,C0205156;C0042153;C0457083;C1947944;C1552607
moderate severe exacerbations itt population n,C0205081;C0032659;C1257890;C1881878;C4049705;C4049706;C4085643;C4321335
steroid use at baseline n,C0281991;C0168634;C1442488
moderate severe exacerbations patient subgroups n,C0205081;C0030705;C1881878;C4049705;C4049706;C4085643;C4321335
high titre $nmbr$ times of uln n,C0040223;C1632851
baseline post bronchodilator predicted fev $nmbr$ and prior ics use,C2599594;C3714541;C0042153;C0457083;C1947944
titre u ml t,C0439340;C1880521;C2945590
baseline post bronchodilator predicted fev $nmbr$ and no prior ics use,C2599594;C3714541;C0042153;C0457083;C1947944
rf positive n,C0035448;C0201660;C0748398;C1547111
baseline post bronchodilator predicted fev $nmbr$ and concurrent tiotropium use,C2599594;C3714541;C0042153;C0457083;C1947944
bone erosion judged by physician n,C0587240;C0221191;C0031831;C0804815
exacerbations,C4086268
ptgada mm,C4330985;C4554674
baseline post bronchodilator predicted fev $nmbr$ and no concurrent tiotropium,C2599594;C3714541;C0205420;C0213771
phgada mm,C4330985;C4554674
baseline post bronchodilator predicted fev $nmbr$,C2599594;C3714541
esr mm h,C3811131;C0456680
patients using concurrent tiotropium,C0030705;C1524063;C0205420;C0213771
mmp $nmbr$ ng ml,C0623362;C0439275;C0919336
$nmbr$ mg empagliflozin,C0024671;C3490348;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sdai,C3871128
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd,C1739039;C0439445;C3811844;C3812682;C3839656
mtss,
hba $nmbr$ c [mmol mol],C0019016;C1825777;C3538758;C3829066
average weekly mtx dose mg week,C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
parameter at baseline,C0549193;C1704769;C2350001
years since diagnosis of type $nmbr$ diabetes n,C0439234;C1320657
czp mtx,C0025677;C1417487
sbp office measurement mmhg,C0085805;C0439475
pbo mtx,C0025677;C1417487
sbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
mtss cfb mean sd,C0009002;C2699239;C1824728
dbp office measurement mmhg,C0242485;C0439475
anti ccp antibody u ml,C0439340;C1880521;C2945590
dbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
rf iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
pulse rate mean $nmbr$ h bpm,C0232117;C0033727;C0369286;C0441932;C0564385;C4528284
concomitant mtx average dose mg week,C0332174;C0439230
number of antihypertensive medications n,C1718138
creatinine clearance category ml min no b,C0812399;C0439445
daytime mean sbp abpm at week $nmbr$ mmhg,C0332169;C0085805
medical conditions no,C0012634;C0348080;C1705253;C3864998
change from baseline mmhg,C0392747;C0443172;C1705241;C4319952
previous cancerc,C0205156;C1552607
nighttime mean sbp abpm at week $nmbr$ mmhg,C0240526;C0085805
previousdistaldeep veinthrombosisorsuperficial vein thrombosis,C0042487
daytime mean dbp abpm at week $nmbr$ mmhg,C0332169;C0332174;C0439230
method used to diagnose the incident pulmonary embolism no,C0025663;C0449851;C0871511;C1273517;C0011900;C1551358;C0034065
nighttime mean dbp abpm at week $nmbr$ mmhg,C0240526;C0332174;C0439230
high probability ventilation perfusion lung scanning,C0560738
mean $nmbr$ h sbp,C0033727;C0085805;C0369286;C0441932;C0564385;C4528284
spiralcomputedtomographyangiography,
patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0030705;C0037623;C1415692;C1708288;C4318478;C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
associatedproximaldeep veinthrombosisatdiagnosis no,
change from baseline in mean $nmbr$ h sbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
characteristics of pulmonary embolism at inclusion,C1521970;C0034065;C0007637;C1512693
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
residual perfusion defect $nmbr$ on lung scan no,C0031001;C1457869;C4281794;C0203683
mean $nmbr$ h dbp,C0536221;C3813197;C4281799
residual deep vein thrombosis no,C1609982;C0149871
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
systolic pulmonary arterial pressure mean sd mm hg,C0871470;C0439475
change from baseline in mean $nmbr$ h dbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
d dimer level mean sd ng mld,C0023522;C1539265;C3539688;C3539689
fish oil n $nmbr$,C0016157
thrombophilia no e,C0398623
demographic and medical variables,C0011298;C0199168;C0439828;C0205476
minor,C0026193;C0205165
coronary disease,C0010068;C1956346
major,C0205082;C0205164;C4318856;C4521762
class l ll heart failure,C0456387;C1518526;C1705943;C0018801;C0018802;C4554158
treatmentofpulmonary embolismpriorto randomization,C0034656
cardiac and echocardiography parameters,C0018787;C1522601;C0013516;C0449381
warfarin no,C0043031
sinus rhythm at baseline,C0232201;C0168634;C1442488
fluindione no,C0117899
$nmbr$ lead ecg heart rate beats min,C0439385
acecoumarol no,
left atrial dimension cm,C2950135
duration of initial anticoagulation mean sd mo,C0449238;C2926735
percentage of time in therapeutic inr range mean sd,C0439165;C1549488;C1561533;C0460097;C2699239
left ventricular hypertrophy on echo,C0149721;C3484363
use of compression stockings no,C1524063;C0038348
left ventricular ejection fraction af history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
main concomitant treatments no,C0205225;C0087111;C1542147
paroxysmal af,C0235480
accp bleeding risk at inclusion no f,C3251812;C0007637;C1512693;C0016327
persistent af,C0344434;C4049859
low no risk factor,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0035648
time since first af diagnosis yrs,C0040223;C3541383
moderate $nmbr$ risk factor,C0205081;C0035648;C1881878;C4049705;C4049706;C4085643;C4321335
class i or iii aad use in $nmbr$ months before enrollment,C0441885;C1319793;C2698967;C0042153;C0457083;C1947944;C1516879;C1696073;C3888021
high $nmbr$ risk factor,C0035648
acei or arb,C3888198
p for i,C0369773;C2603361
figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups,C0243132;C1554210;C2745955;C0332152;C1079230;C0740175;C2257086;C3669034
previous cancer,C0006826;C0998265;C1306459
placebo every $nmbr$ weeks n $nmbr$,C0032042;C1696465;C1706408;C0439230
pe associated with dvt at diagnosis,C0070939;C1880476;C4284304;C0332281;C0149871;C2926618;C3899446;C0011900;C1704338;C1704656
evolocumab $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
time in therapeutic range before inclusion,C1554109;C0007637;C1512693
placebo monthly n $nmbr$,C0032042;C0332177;C1696465;C1706408
perfusion defectsatinclusion,C0031001;C4281794
evolocumab $nmbr$ mg monthly n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
right ventriculardysfunction atinclusion,C0205090;C0444532
ldl cholesterol at baseline mmol l ldl cholesterol at screening,C0023824;C0202117;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
d dimer levelsatinclusion,C0060323
other lipid parameters,C0023779;C0449381
$nmbr$ microg l,
apolipoprotein b g l,C1447574;C4319541
accp score,C0449820;C4050231
apolipoprotein a $nmbr$ g l,C1447574;C4319541
compression stockings,C0038348
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
liraglutide $nmbr$ $nmbr$ mg day n $nmbr$,C1456408;C0439422
lipoprotein a nmol l,C0065058;C0439282;C0125953;C1096202;C1439335
mean s d duration of diabetes years,C0449238;C2926735
hscrp nmol l,C0439282
women men,C0043210;C0025266
unbound pcsk $nmbr$ nmol l,C0439282
mean s d weight kg,C0022718;C0439209;C4054209
mean s d bmi kg m $nmbr$,C0022718;C0439209;C4054209
figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C1696465;C1706408;C0168634;C1442488;C0332174;C0439230;C0871236;C0023824;C0086045;C0202117;C0178602;C1521801;C0743559;C1608199;C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0686905
mean s d hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
black or african,C0005680;C0027567;C0085756;C0439541
mean s d fpg,C0444504;C2347634;C2348143
american,C0596070
metformin no yes,C0025598;C1549445;C1705108;C1710701
region no c,C0017446;C0205147
basal insulin analogue insulin,C0650607;C2825028
central south,C0205099;C1710133;C1879652
detemir insulin glargine,C0537270;C0907402
america,C0002454
otherd,
basal insulin analogue dose coefficient,C0366513;C1707429
duration of t $nmbr$ dm y,C0449238;C2926735
of variation iu,C0049272;C0439453;C0694756
taking antihypertensive medication at baseline no e,C0003364
liraglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r,C0205090;C0684010;C2603358
dbp $nmbr$ mmhg,C0536221;C0439475;C3813197;C4281799
baseline hba $nmbr$ c $nmbr$ $nmbr$,C0168634;C0019016;C1825777;C3538758;C1442488
on antihypertensive medication at baseline n,C0003364;C0168634;C1442488
east asian,C1707877;C0078988
saxa dapa met n $nmbr$,C0428210;C1550543;C4317104
non east asian,C1518422;C0078988
saxa met n $nmbr$,C0428210;C1550543;C4317104
dapa met n $nmbr$,C0428210;C1550543;C4317104
p value for east asian versus non east asian,C1709380;C0078988;C1518422
hba $nmbr$ c category,C0683312;C3889287
age years mean _ sd,C1510829;C2699239
$nmbr$ and $nmbr$ and,
weight of $nmbr$ kg n,C0005910;C0043100;C1305866;C1705104
$nmbr$ $nmbr$ mmol mol,C3829066
crcl of $nmbr$ $nmbr$ ml min n,C1846718;C0439445
ppg mg dl,C1418888;C0439269
patients meeting the criteria to receive $nmbr$ mg of,C0030705;C0556656;C0243161;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hba $nmbr$ c subgroup,C1079230;C1515021
edoxaban at randomization n,C2975435;C0034656
baseline mean sd [mmol mol],C0168634;C2699239;C1442488;C3829066
anatomic extent of qualifying event n x,C0220784;C0439792;C1514624;C0441471;C4019010
adjusted mean change from baseline $nmbr$ ci [mmol mol],C0392747;C0443172;C1705241;C4319952;C3829066
concomitant dvt n,C0521115;C0149871;C2926618;C3899446
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
right ventricular dysfunction n n j,C0242707;C1556315
mean $nmbr$ ci difference vs saxa dapa met,C1705241;C1705242;C0428210;C1550543;C4317104
causes of dvt or pe n,C0015127;C1314792;C0070939;C1880476;C4284304
$nmbr$ to $nmbr$ to,
non east asianf,C1518422;C1707877
age subgroup y,C0001779;C1079230;C1515021
edoxaban n $nmbr$ n n,C2975435
x n,
warfarin n $nmbr$ n n,C0043031
proportion $nmbr$ ci adjusted for baseline hba $nmbr$ c,C0008107;C3259781;C0456081;C0019016;C1825777;C3538758
hr with edoxaban $nmbr$ ci,C2975435;C0008107;C3259781
$nmbr$ to $nmbr$ to $nmbr$ mmol mol,C3829066
event during overall,C0441471;C4019010
secukinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
study period fatal pe,C0070939;C1880476;C4284304
weight kg $nmbr$,C0022718;C0439209;C4054209
death with pe not,C0011065;C1306577;C4082313;C4552775;C1518422
time since psoriasis diagnosis years $nmbr$,C0556970;C0011900;C1704338;C1704656
ruled out non fatal pe with or,C1446409;C0070939;C1880476;C4284304
pasi score $nmbr$,C0449820;C4050231
without dvt dvt alone,C0149871;C2926618;C3899446;C0205171;C0439044;C0679994
bsa involved $nmbr$,C1314939
event during on,C0441471;C4019010
iga mod $nmbr$ score n,C0011860;C0449820;C4050231
treatment period index dvt event,C0441471;C4019010
$nmbr$ moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
during overall study period,C0439531;C1948053
$nmbr$ severe disease,C1836348
index pe event during,C0441471;C4019010
psa reported n,C0684224;C0700287;C4319718
overall study period,C0439531;C1948053
conventional agents,C0450442;C1254351;C1521826
topical,C0332237
gaviscon da n $nmbr$,C0061146;C0011318;C3668815
phototherapy previous systemic treatment n,C0031765;C0678812
bmi kg m $nmbr$ median range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
biologic,C0005515;C0205460
erd n,
anti p $nmbr$,
la grade a n f,C0441800;C0919553;C3244287;C0369718;C0016327;C0441922
anti tnf,C1448177
la grade b n f,C1881342;C0016327
japanese subpopulation,C0376247;C1257890;C1556094
fdc $nmbr$ $nmbr$ g n $nmbr$,C0340427;C0439267;C1413520;C3539652
visit week,C0332174;C0439230
aclidinium $nmbr$ g n $nmbr$,C2699757;C0439267
secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
formoterol $nmbr$ g n $nmbr$,C0060657;C0439267
pasi $nmbr$,C4528685
number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C0205156;C0439231;C1552607
iga $nmbr$ $nmbr$,C2825347
prior copd medicationa n,C0332152;C0024117;C1412502;C3714496;C2826257
abatacept plus mtx n $nmbr$,C1619966;C0025677;C1417487
any copd medication,C0013227;C3244316;C4284232
abatacept monotherapy n $nmbr$,C1619966
e rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
mtx n $nmbr$,C0025677;C1417487
overall night time copd symptom severity scorec,C0240526;C1319166
age year median,C0549183;C0876920;C2347635;C2348144;C2939193
overall early morning copd symptom severity scorec,C0024117;C1319166;C1412502;C3714496
weight kg median,C0549183;C0876920;C2347635;C2348144;C2939193
gold group n,C0018026;C0441848;C1304897
female sex number,C0237753;C0449788
gold group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
white race number,C0237753;C0449788
fdc $nmbr$ $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
geographic region number,C0237753;C0449788
fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
row,C1552840;C1552846
fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C1266240
ra symptom duration year,C0439234;C0439508
aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
ra symptom duration,C0449238;C2926735
formoterol $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
rf positive number,C0035448;C3812269;C0201660;C0748398;C1547111
hcru a,
tender joint count $nmbr$ joints,C0451530
fdc $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
swollen joint count $nmbr$ joints,C0451521
rr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4554402
patient global assessment $nmbr$ $nmbr$ mm vas,C0042815;C3536884;C3827561
rro $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
physician global assessment $nmbr$ $nmbr$ mm vas,C0042815;C3536884;C3827561
aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
pain $nmbr$ $nmbr$ mm vas,C0042815;C4330985;C4554674
formoterol $nmbr$ pg,C0030827;C0072225;C1266240
physical function $nmbr$ $nmbr$ short form $nmbr$ subscale,C0597240;C0700329
exact b,C2828393;C4050514
outcome type,C0332307;C1547052
missing number n,C0237753;C0449788
outcome severity,C0439793;C0522510
median $nmbr$ $nmbr$ number n,C0237753;C0449788
any severity,C0439793;C0522510
haq di number,C0237753;C0449788
moderate severity,C0439793;C0522510
symptom duration,C0449238;C2926735
baseline ics,C0815320;C4551720
median $nmbr$ $nmbr$ years number n,C0439234;C0237753;C0449788
with concomitant ics,C0815320;C4551720
$nmbr$ months number n,C0439231;C0237753;C0449788
without concomitant ics,C0815320;C4551720
pain $nmbr$ mm vas,C0042815;C4330985;C4554674
rr $nmbr$ $nmbr$,C4554402
median $nmbr$ number n,C0237753;C0449788
mtx sio mg week,C0332174;C0439230
erosion,C0333307;C1880549;C1959609;C3887524
mtx $nmbr$ and si $nmbr$ mg week,C0025677;C1417487;C0332174;C0439230
q $nmbr$ $nmbr$ $nmbr$ q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
mtx $nmbr$ mg week,C0332174;C0439230
q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
czp $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
osteitis,C0029400
czp $nmbr$ mg n lll,C0024671;C1261077;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
q $nmbr$ $nmbr$ q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
acr response acr $nmbr$,C1412134;C0871261;C1704632;C1706817;C2911692;C1515941
q $nmbr$ $nmbr$ $nmbr$ q $nmbr$ $nmbr$ number n,C0237753;C0449788
change from baseline in,C0392747;C0443172;C1705241;C4319952
q $nmbr$ $nmbr$ number n,C0237753;C0449788
synovitis,C0039103
das $nmbr$ esr mean sd das $nmbr$ esr remission,C0544452;C0687702
eda,C0162359;C1539327;C3539920;C3887494
device group n $nmbr$,C0441848
age mean sd [range] y,C0001779;C2699239;C1514721;C2348147;C3542016
mean change in radiographic end points shs mean sd,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
erosion score mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
heart rate mean sd [range] beats min,C0018810;C2699239;C1514721;C2348147;C3542016;C0439385
fsn score mean sd,C0444504;C2699239;C2347634;C2348143
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
teaes cases per $nmbr$ patient years ci,C0868928;C1533148
blood pressure mean sd [range] mm hg,C0428886;C2699239;C1514721;C2348147;C3542016;C0439475
mtx $nmbr$ $nmbr$ mg week,C0332174;C0439230
body mass index mean sd [range]a,C0005893;C2699239;C0578022;C1305855;C1514721;C2348147;C3542016
related to study druga,C0439849;C0445223
chads $nmbr$ scoreb,C0007928;C1413373
leading to study withdrawal,C0332152;C0557651;C2603343;C1522538
mean sd [range],C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016
leading to death,C0332152;C0011065;C1306577;C4082313;C4552775;C1522538
risk factors for stroke no,C0035648;C1553898
gastrointestinal gi disorders,C0017178;C1708130;C3539617;C4050121
infections,C3714514
previous ischemic stroke ortia,C0205156;C0948008;C1552607
serious teaes,C0205404
lv ejection fraction mean sd [range],C0489482;C2699239;C2700378;C1514721;C2348147;C3542016
most frequent gi disorders,C0332183;C0012634
classification of af no,C0008902;C0008903;C0678229
most frequent infections,C0239998
onsetofaf no,
most frequent non infectious teaesb,C0332183;C1518422
previous warfarin use no,C0042153;C0457083;C1947944
pyrexia,C0015967
source,C0449416;C1705919;C4521696
rash,C0015230
device group,C1706365
contusion,C0009938
history of tia or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
most frequent serious teaes,C0332183;C0205404
prior years taking warfarin,C0332152;C0043031;C2826257
serious infections,C0205404;C3714514
median $nmbr$ mm,C4330985;C4554674
serious gi disorder,C0205404;C0012634
continued thienopyridine n $nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
pneumonia,C0032285
placebo n $nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
erysipelas,C0014733
subject characteristics,C0681884;C1519021;C1706465
disseminated tuberculosis,C0152915
current cigarette smoker or within past year,C3173209;C3241966;C0439234;C0439508
investigations,C1261322
positive stress test,C0015260;C3494508
alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708;C0205217;C0442805
indication for pci,C0392360;C3146298
aspartate aminotransferase increased,C0004002;C0205217;C0442805
treatment characteristics,C0039798;C1521970;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
c group n $nmbr$,C0441848
des type at index procedure,C0011702;C0455713;C4551552
nc group n $nmbr$,C0027964;C0441848;C0028407;C0067895;C0265987
everolimus eluting,C0541315
systolic blood pressure mmhg mean sd,C0428886;C2699239
paclitaxel eluting,C0144576
zotarolimus eluting,C1700035
diastolic blood pressure mmhg mean sd,C0428886;C2699239
sirolimus eluting,C0072980
left ventricular systolic dysfunction n,C1277187;C1963159;C4553199
$nmbr$ des type,C0332307;C1547052
serum creatinine mg dl mean sd,C0201976;C2699239;C0600061
number of treated lesions,C0449791;C1522326
ldl cholesterol mg dl mean sd,C0023824;C2699239;C0202117
number of treated vessels,C0237753;C0449788
hdl cholesterol mg dl mean sd,C0023822;C2699239;C0392885
number of stents,C0237753;C0449788
triglyceride mg dl mean sd,C0439269;C2699239
minimum stent diameter,C4054490;C0038257
concomitant medications after randomization,C0013227;C0802604;C2598133;C4284232
total stent length,C1444754;C1706316
aceis n,
lesion characteristics,C1286326
b blockers n,
n $nmbr$ lesions,C0369718;C0221198;C0441922
ca channel blockers n,C3887642;C0870261
treated vessel s,C1522326;C0005847
statins n,C0360714
native coronary,C0302891;C0018787
number of diseased vessels mean sd,C0237753;C0449788
lad,
rca,
left main disease n,C0205091;C0012634;C0443246;C1552822
venous graft,C0181074;C0332835;C1961139
type b $nmbr$ c lesions n,C4264484;C0221198
arterial graft,C0450140
des implantation for restenosis n,C0021107;C0029976
modified acc aha lesion class b $nmbr$ or cj,C4072694;C0221198;C1546698;C0007481
sirolimus eluting stent use n,C0038257;C0042153;C0457083;C1947944
continued thienopyridine n,C0549178;C1120149
paclitaxel eluting stent use n,C0038257;C0042153;C0457083;C1947944
hr $nmbr$ and $nmbr$ cl,C0596019
number of implanted stents n mean sd,C0237753;C0449788
no current tobacco use,C0040335;C0543414;C0841002;C3853727
total length of implanted stents mm mean sd,C0439175;C0449462;C0439810
no prior pci,C0332152;C4049621;C2826257
rotablator use n,C0042153;C0457083;C1947944
no prior cabg,C0332152;C0010055;C2826257
clinical or lesion rf for st,C0205210;C0035448;C0201660;C0748398;C1547111
aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan,C0003015;C0151691;C2757044
no clinical or lesion rfs for st,C0205210;C0341703;C0036056;C3272372
aspirin only n $nmbr$ $nmbr$,C0004057;C0369718;C0441922
any clinical or lesion rf for st,C0205210;C0035448;C0201660;C0748398;C1547111
aspirin i clopidogrel n $nmbr$ $nmbr$,C0004057;C0021966;C0221138
european union,C0015179
history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
aspirin dose at randomization,C4696290;C0034656
hf or lvef,C0018488;C1313497;C1538440;C3273279;C0428772;C0488728
thienopyridine type,C0332307;C1547052
type of event,C1561488
clopiodogrel,
elevated cardiac markers,C0205250;C1271630;C3163633
des type,C0332307;C1547052
use of parenteral antithrombotic,C1524063;C0030547;C4522267
zotarolimust,
selected baseline medications,C0013227;C0802604;C2598133;C4284232
americas n $nmbr$,C0002454;C0596070
aspirin $nmbr$ clopidogrel,C0004057;C0070166
russia georgia n $nmbr$,C0017452;C0017454
apixaban vs placebo,C1831808;C0032042;C1696465;C1706408
ejection fraction nyha class n,C0489482;C1882083;C2700378
rate n,C0871208;C1521828
stratum n,
cv death mi or ischemic stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0948008
any cardiovascular disease history n,C1880008
stent thrombosis,C3897493
insulin treated,C0021641;C1533581;C1579433;C3714501;C1522326
timi major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
percutaneous coronary intervention or coronary artery bypass graft surgery n,C1532338;C0010055
timi major or minor bleeding,C0205082;C0205164;C4318856;C4521762;C0026193;C0019080;C0205165
angina n,C0002962
bdmard naive,
sodium,C0037473;C0597484;C3541959;C3714642
bdmard ir,C0022065;C0022071;C1448132
estimated glomerular filtration rate ml min per $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
tofacitinib $nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bnp pg mlt,C0030827;C4553833;C0072225;C1266240
mean sd weight kg,C0022718;C0439209;C4054209
nt probnp pg mlt,C0669479;C4553833;C0754710
europe and canada,C0015176;C0006823
angiotensin converting enzyme or angiotensin receptor blocker,C0022709;C1452534;C0034787;C1622222
mean sd disease duration years,C0872146;C0439234
long acting nitrate,C0028125;C0699857;C3848573
mean sd bmi,C0444504;C0578022;C2347634;C2348143
bnp indicates brain natriuretic peptide and nyha new york heart association,C0054015;C1095989;C1417808;C2982014;C0459867
rf,C0035448;C0201660;C0748398;C1547111
tcomparison of proportion of patients with nyha class lll iv heart failure,C1709707;C0030705;C0018801;C0018802;C4554158
anti ccp $nmbr$ units,C0439148;C1519795;C3853603
data reported as n or median quartiles $nmbr$ $nmbr$,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C0549183;C2828255;C0876920;C2347635;C2348144;C2939193
mean sd das $nmbr$ $nmbr$ esr,C0051767;C3811131;C0057671
mean sd sdai,C0444504;C3871128;C2347634;C2348143
tamong those enrolling via bnp stratum the study qualifying bnp or,C0054015;C1095989;C1417808;C2982014;C0557651;C2603343;C1514624
mean sd cdai,C0683448;C1413248;C3273706
nt probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0669479;C0042295;C0754710;C0588446;C4684790
mean sd tender joint count,C0444504;C0451530;C2347634;C2348143
$nmbr$ $nmbr$ values were not collected for $nmbr$ patients $nmbr$ $nmbr$ who were enrolled,C0042295;C1516695;C1516698;C4684790
mean sd swollen joint count,C0444504;C0451521;C2347634;C2348143
before a change to the enrollment form was implemented in august $nmbr$ bnp,C0392747;C0443172;C1705241;C4319952;C4520547;C0054015;C1095989;C1417808;C2982014
mean sd pain vas,C0444504;C0042815;C2347634;C2348143
values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0042295;C0588446;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mean sd ptga vas,C0042815;C3536884;C3827561
patients in the placebo group nt probnp values were reported for $nmbr$ patients,C0030705;C0669479;C0754710;C0588446
mean sd pga vas,C0042815;C3536884;C3827561
in the spironolactone group and $nmbr$ patients in the placebo group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0030705;C0032042;C1696465;C1706408
mean sd crp mg l,C0444504;C0439268;C2347634;C2348143
p regional difference,C0369773;C0682132;C2603361
mean sd esr mm h,C0444504;C0456680;C2347634;C2348143
p treatment by region interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previously taken methotrexate,C1883727;C0025677
no with event [incidence rate per $nmbr$ patient y],C0441471;C4019010;C1708485;C0030705
previously taken dmards other than methotrexate,C0242708;C0025677
hr $nmbr$ ci p value,C0008107;C1709380;C3259781
previously taken tnfi,C1883727
$nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
previously taken any other dmards n,C1883727;C0242708
aborted cardiac arrest,C0018790;C4553105
abatacept,C1619966
hospitalization for heart failure,C3898876
anakinra,C0245109
recurrent heart failure,C0018801;C0018802;C4554158
rituximab,C0393022
$nmbr$ events[ $nmbr$ $nmbr$ ],C0441471;C3541888
tocilizumab,C1609165
irr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4082285
tnfi no other bdmard taken t n,C1883727
all cause hospitalization,C0015127;C0019993;C1524003
one tnfi,C0205447
doubling of creatinine,C0205173;C1705764
multiple tnfi,C0439064
creatinine $nmbr$ $nmbr$ mg dl,C0010294;C0439269;C1561535
other bdmards no tnfi taken t n,C1883727
hyperkalemia potassium $nmbr$ $nmbr$ mmol l,C0020461;C1532563;C4552983
tnfi and other bdmardst n,
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
one tnfi and,C0205447
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
other bdmard,
hypokalemia potassium,C0032821;C0202194;C0304475;C0597277;C3714637
multiple tnfi and other bdmards,C0439064
parameter $nmbr$ ci,C0008107;C3259781
figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use,C1274040;C1546471;C2825142;C0021641;C0008976;C1533581;C1579433;C3714501;C0392747;C0443172;C1709707;C0030705;C0019016;C2825507;C1825777;C3538758;C0005910;C1305866;C0007222;C0679831;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538987;C0035648;C4048877;C4318503;C0020538;C1963138;C0360714;C0042153;C0457083;C1947944
das $nmbr$ $nmbr$ esr,C0051767;C3811131;C0057671
abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error,C0019045;C1710181
haq di improvement $nmbr$ $nmbr$,C3826998;C2986411;C4321476
amlodipine lisinopril chlorthalidone comparison,C0008294;C1707455
total ipss,C1019118;C1998280;C2827405;C3811063
no in trial stroke n $nmbr$ $nmbr$,C0008976;C0038454;C4554100
age category n $nmbr$ years,C1510829;C0683312;C3889287
in trial nonfatal or fatal stroke n $nmbr$ $nmbr$,C0150312;C0008976;C0332285;C1707101;C1302234;C0038454;C4554100;C1705232
baseline sd,C0168634;C2699239;C1442488
education in years mean sd,C0013621;C0013622;C0013658;C0039401
end point sd,C2349179;C2699239;C2826544
lipids medications,C0013227;C0802604;C2598133;C4284232
ls mean change se,C0023668;C0036919
blood pressure in mm hg mean sd,C0428886;C0488053
pbo adjusted ls mean change se,C0023668;C0036919
sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
luts severity,C0439793;C0522510
dbp at visit $nmbr$,C0536221;C3813197;C4281799
mild moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
pulse in beats minute mean sd,C0232117;C0391850;C1947910
mean age sd,C0001779;C2699239
eligibility risk factors n,C0035648;C1553898
severe ipss $nmbr$ age group,C0027362;C2348001
history coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
lifestyle behaviours,C0004927;C0677505
major st depression or t wave inversion,C0041696;C1269683;C0520888
body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
lvh by echo or ecg,C0149721;C0058928;C1655045;C1623258
$nmbr$ years bmi,C0439234;C0578022
history chd,C0280604;C3542407
mean bmi sd,C0444504;C2699239;C2347634;C2348143
atrial fibrillation on baseline ecg n,C0344434;C0168634;C1442488
comorbidities and concomitant medications,C0009488;C0013227;C0802604;C2598133;C4284232
baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0017654;C0439445;C1424601;C0369718;C0441922
diabetes mellitus n yes,C1549445;C1705108;C1710701
biochemical measures mean sd,C0079809;C2699239;C1879489
$nmbr$ kg m $nmbr$ smokers,C0022718;C0439209;C4054209;C0337664
in trial $nmbr$ year rates per $nmbr$ se total events number at risk,C1264674;C1444641
glycaemic control hba $nmbr$ c n,C0243148;C0019016;C1825777;C3538758;C1550141;C1882979;C2587213;C3274648;C4553389
in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk,C0150312;C0008976;C0332285;C1707101;C1264674;C1444641
diabetic therapy use n no therapy,C0039798;C0042153;C0457083;C1947944;C0087111;C1363945
chlor,C0308648
oral agent,C0450442;C1254351;C1521826
$nmbr$ fe black,C0005680;C0027567;C0085756;C0439541
glycaemic control group,C0009932
ment,C0084844;C1538994
oral agent and or insulin therapy,C0450442;C1254351;C1521826;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
women t,C0043210
hyperlipidaemia n yes,C1549445;C1705108;C1710701
no atrial fibrillation,C0004238;C0344434;C1963067
hyperlipidaemia therapy use n no lipid lowering agent therapy,C0020473;C0039798;C0087111;C1363945;C0428465;C4555212;C0585943
chd at baseline,C0280604;C3542407
combined insulin oral hypoglycaemic agent use,C0240016
no chd at baseline,C0280604;C3542407
statin medication,C0013227;C3244316;C4284232
crcl at baseline,C1846718;C0168634;C1442488
other lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
prior stemi,C1536220;C3538872
statin and or other lipid lowering agent therapy,C0360714;C0585943
baseline medical therapy,C0168634;C0418981;C1442488
hypertension n yes,C1549445;C1705108;C1710701
vorapaxar $nmbr$ y,C2974521
antihypertensive medication use n,C0003364;C0240320
placebo r,C0205090;C0684010;C2603358
number of antihypertensive medications used n no antihypertensive therapy,C1718138;C0585941
hx stroke tia,C0007787;C0917805;C1054154
combined statin and other lipid lowering agent use,C0205195;C0360714;C0042153;C0457083;C1947944
no stroke tia,C0007787;C0917805;C1054154
type of antihypertensive medication use among patients using antihypertensive medications n,C0457591;C0030705;C1524063;C0003364
no prior stemi,C1536220;C3538872
antihypertensive agent use,C0042153;C0457083;C1947944
mi $nmbr$ months,C3810814;C0439231
centrally acting sympathomimetics,C3653511
rando in na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
number of antihypertensive agent reported,C0237753;C0449788;C0684224;C0700287;C4319718
not rando in na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
$nmbr$ med at baseline,C4321267;C0168634;C1442488
asa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ med at baseline cardiac disorder,C4321267;C0018799
des,C0011702;C4551552
cardiac disorder n,C0018799
no des,C0011702;C4551552
cardiovascular disorder n,C0007222
carotid revascularization,C0741968;C0581603
all ischemic stroke,C0948008
no cardiovascular disorder $nmbr$,C0007222
ischemic stroke with hemnrrhnaic cnnversinn,C0948008
ischaemic heart disease or cerebrovascular disorder n,C0010054;C0151744;C0007820
ischemic stroke without hemorrhagic conversior,C0948008
cardiac arrhythmia n,C0003811;C0264886;C1560249
luts bph characteristics,C0005001;C1521970;C1704272
table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline,C4684572;C0034656;C3815594;C1524063;C0021641;C0439465;C1533581;C1579433;C3714501
combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n,C0018801;C0878544;C0018802;C0521117;C1292730
acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline,C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0002460;C0238611;C0337920;C1165245;C0439064;C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0679646;C0205447;C0457464;C0168634;C1442488
combined ischaemic heart disease and or cerebrovascular disorder,C0010054;C0151744;C0007820
canagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mild to moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
duration of diabetes years mean sd,C0449238;C2926735
mean total ipss sd,C0439175;C2699239;C0439810
insulin dose iu day median,C0549183;C0876920;C2347635;C2348144;C2939193
mean ipss voiding subscore sd,C0042034;C2699239;C4067975
insulin therapy n,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
mean ipss storage sub score sd,C3533236;C2699239
basal plus bolus,C0205112;C1186706;C1511237;C1705509;C3812160
mean ipss qol sd,C0444504;C2699239;C2347634;C2348143
basal alone,C0205112;C0205171;C0439044;C0679994
combined cardiac failure cardiomyopathy or other cardiac disorders,C0018801;C0878544;C0018802;C0018799
bolus alone,C1186706;C1511237;C1705509;C3812160;C0205171;C0439044;C0679994
$nmbr$ uln,C1519815
other drug therapy n,C0013216;C0013217
pi,C0122626;C0429863;C3537219;C3539772
antithrombotic,
ppci,
microvascular disease n,C0443258;C0012634
prior chf,C0332152;C0018802;C2826257
nephropathy,C0022658
to $nmbr$,
atherosclerotic vascular disease n,C0004153
killip class i,C2697844
cerebrovascular,C1880018
timi risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
peripheral,C0205100
inferior mi,C0340305;C3542426
dbp mmhg mean sd,C0439475;C2699239
baseline rst segment elevation mm,C4330985;C4554674
total cholesterol mmol l mean sd,C0201950;C2699239;C0543421
baseline rst segment,C0168634;C0441635;C1442488
triglycerides mmol l mean sd,C1532563;C2699239
deviation mm,C4330985;C4554674
hdl cholesterol mmol l mean sd,C0023822;C2699239;C0392885
q waves in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
ldl cholesterol mmol l mean sd,C0023824;C2699239;C0202117
figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf,C0242492;C0018802
ldl to hdl cholesterol ratio mean sd,C0428621;C1171408
upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0013806;C0018802;C0449244;C0034656;C1442160;C0456081;C0027051;C0428953;C2926063;C3810814;C4552959;C0205307;C0231683;C0439166;C2347086;C4553972
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
cyclosporine n $nmbr$,C0010592;C0010594
acr mg g mean sd,C1300563;C2699239
killip class at admission no total no,C1881332;C0184666;C0809949;C0439175;C0439810
figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks,C1280500;C0178602;C0869039;C1114758;C1707455;C0032042;C1696465;C1706408;C0019016;C1079232;C1825777;C3538758
previous ischemic heart disease no,C0010054;C0151744
total study population n $nmbr$ $nmbr$,C3258257
treated with cabg no total no,C0332293;C0010055;C0439175;C0439810
$nmbr$ predicted arr n $nmbr$,C0681842;C1882327
treated with pci no total no,C0332293;C4049621;C0439175;C0439810
caucasian ethnicity,C0015031;C0243103
managed medically no total no,C1273870;C0439175;C0439810
past smoking,C0037369;C0453996;C1881674
previous heart failure no,C0018801;C0018802;C4554158
never smoking,C0037369;C0453996;C1881674
subgroup sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
alcohol use $nmbr$ drink wk,C0332174;C0439230
cyclo,C1172566
peri or postmenopausal,C0347985;C0232970
p value for interaction $nmbr$ $nmbr$,C1709380;C1704675
hormone replacement therapy use,C0042153;C0457083;C1947944
no of events total,C0439175;C0439810
high density lipoprotein mg dl,C0023821;C0439269
initial timi flow,C0205265;C3272266;C1279901;C1555582;C1705685
high sensitivity c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
final timi flow,C0205088;C3272266;C1546485;C3853528
blood pressure lowering medication use,C0240320
symptom onset,C4086878
lipid lowering medication use,C0023779;C0441994;C2003888;C0240320
$nmbr$ $nmbr$ s $nmbr$,
family history of cancera,C0241889
rentrop score,C0449820;C4050231
history of dyspepsia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
killip at baseline,C0168634;C1442488
randomized to aspirin use,C0034656;C3815594
proximal mainleft,C0205107;C4489236
$nmbr$ year predicted risk of,C0035647;C4552904
medial distal diag,C0205098;C0348026
colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
thrombus aspiration,C0220787;C0349707;C0700198;C2712334;C2827071
fh $nmbr$,
non colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
fh ii,C1854107
major gastro intestinal bleeding,C0205082;C0017181;C0205164;C4318856;C4521762
alirocumab n $nmbr$,C3491162
total study population,C3258257
diagnosis of heterozygous familial hypercholester,C0011900;C1704338;C1704656
women $nmbr$ years,C0043210;C0439234
olaemia n,
arr $nmbr$ ci,C0008107;C3259781
genotyping,C1285573
annt or bnnh $nmbr$ ci,C0008107;C3259781
clinical criteria $nmbr$,C0205210;C0243161
$nmbr$ $nmbr$ to $nmbr$ a,
$nmbr$ b $nmbr$ b to $nmbr$ a,
coronary heart disease n b,C0010054;C0010068;C1956346
$nmbr$ $nmbr$ to $nmbr$ b,
coronary heart disease risk equivalents n c,C1277690;C0439185;C4049980
total adjusted weight of $nmbr$ $nmbr$ for gastrointestinal bleeding,C0005910;C0043100;C1305866;C1705104;C0017181
type $nmbr$ diabetes n d,C1320657
vi $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
statin use n,C0360714;C0042153;C0457083;C1947944
ff vi $nmbr$ mg $nmbr$ mg n $nmbr$,C0205999;C1319635
high dose statin use n e,C0444956;C0042153;C0457083;C1947944
smoking status n former,C0205156;C0750523
change from baseline ls means se,C0392747;C0443172;C1705241;C4319952
total pack years mean sd,C1277691;C2699239
alirocumab,C3491162
baseline fev $nmbr$ predicted,C0681842;C1882327
prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
post bronchodilator reversibility fev $nmbr$ mean sd,C2599594;C2699239
high intensity,C4081854
previous pneumonia,C0205156;C0032285;C1552607
lowzmedium intensity,C0522510
i ii fev $nmbr$ $nmbr$ predicted,C0681842;C1882327
dose of atorvastatin,C0178602;C0869039;C1114758
iii fev $nmbr$ $nmbr$,C0439070;C3714541;C1705160
dose of rosuvastatin,C0178602;C0869039;C1114758
iv fev $nmbr$,C0022326;C3714541;C4265176
llt other than statin at randomization,C2347090;C0360714;C0034656
leukocytes $nmbr$ nl,C0027778;C0560008;C3892223
no thienopyridine,C1120149
neutrophils $nmbr$ nl,C0027778;C0560008;C3892223
tp vs no tp,C0036183;C3541334
monocytes $nmbr$ nl,C0027778;C0560008;C3892223
weight $nmbr$ kg,C0022718;C0439209;C4054209
lymphocytes $nmbr$ il,C0020898;C0021764;C0022271
vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hemoglobin mg dl,C0019046;C0439269
any coronary revascularization,C0877341
ctn l ng ml,C0917591;C0439275
previous cabg total,C0439175;C0439810
angiographic data,C1511726;C3245479;C3714741
previous pci total,C0439175;C0439810
pci revascularization,C4049621;C0581603
previous stenting previous pci,C0038257;C4049621;C2348535
odds ratio adj $nmbr$ cl,C0028873;C0596019
des previous stenting,C0038257;C2348535
baseline hs crp tertiles mg i],C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time from qualifying mi,C0040223;C3541383;C1514624;C3810814
$nmbr$ st $nmbr$ $nmbr$,C0036056;C3272372
$nmbr$ $nmbr$ mo,C0026544;C0332177
$nmbr$ nd $nmbr$ $nmbr$,
n $nmbr$ yr km event rate,C0871208;C1521828
$nmbr$ rd $nmbr$ $nmbr$,C0694666;C4553350
p int,C0369773;C3272375;C2603361
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
cv death mi stroke,C0038454;C4554100
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
cv death mi stroke ucr,C0011065;C0038454;C4554100;C1306577;C4082313;C4552775
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
ucr,
established atherosclerotic disease,C0333482;C0012634
fracture during follow up,C0016658;C0589120;C1522577;C1704685;C3274571
clinical and laboratory measurements,C0205210;C0681902
no n $nmbr$ $nmbr$,C0369718;C0441922
acr mg mmol,C0567349;C2348885
age median iqr years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
acr,C1412134;C1515941
all others n,C1955473;C3539125
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
hispanic latino ethnicity n,C0086409;C0015031;C0243103
baseline cv medications,C0013227;C0802604;C2598133;C4284232
weight median sd kg,C0022718;C0439209;C4054209
b blockers,
bmi median sd kg m $nmbr$,C0022718;C0439209;C4054209
baseline anti hyperglycemic medications,C0013227;C0802604;C2598133;C4284232
diabetes duration median iqr years,C0011847;C0439234;C0011849
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
prior heart failure n,C0018801;C0018802;C4554158
saxagliptin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline measurements,C0168634;C0242485;C1442488
saxagliptin $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
egfr median sd ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
saxagliptin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
albumin to creatinine ratio,C0486293;C1318293
cv death mi ischemic stroke,C0011065;C0948008;C1306577;C4082313;C4552775
median sd mg mmol,C0567349;C2348885
cv death mi ischemic stroke hospitalization for hf coronary revascularization ua,C0019993;C0877341
hba $nmbr$ c median sd,C0019016;C2699239;C1825777;C3538758
hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
fasting serum glucose median sd mg dl,C0202041;C0439269;C3534430
$nmbr$ yr km n,C0439234;C3887676
baseline cv medications n,C0168634;C0013227;C0802604;C2598133;C4284232;C1442488
s,
baseline antihyperglycemic medications n,C0020616;C0013227;C0802604;C2598133;C4284232
egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
cl $nmbr$,C0596019
cv death ml ischemic stroke hosp for hf cor revasc ua,C0011065;C0948008;C1306577;C4082313;C4552775
$nmbr$ m,
hosp for hf,C0018488;C1313497;C1538440;C3273279
cvd subjects,C0681850;C1550501;C1706203;C2349001;C2697811
primary renal endpoint,C2986535;C0022646
m $nmbr$ s,C0439493;C1513009
primary renal endpoint or death,C2986535;C0022646;C0011065;C1306577;C4082313;C4552775
mrf subjects,C0681850;C1550501;C1706203;C2349001;C2697811
hosp for hypoglycemia,C0020615;C4553659
renal function normal mild,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599
major hypoglycemia,C0020615;C4553659
renal function moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
initiation of insulin,C0589507;C1158830;C1704686
renal function severe,C0232804;C0205082;C4050465;C4050466
any new anti hyperglycemic rx,C1425688;C1521941;C2709207
region north america,C0017446;C0028405;C0205147
worsened,C1457868;C4084902
region latin america,C0017446;C0023122;C0205147
no change,C0392747;C0443172;C1705241;C4319952
region asia paafic,C0017446;C0003980;C0205147
improved,C0184511;C0332272;C1561611;C4084203
region europe,C0017446;C0015176;C0205147
olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
region europe union,C0015176;C2825217
tiotropium $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
race n y,C0034510;C1706779;C3853635
tiotropium $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
known duration of t $nmbr$ dm y,C0449238;C2926735
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of cvd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
tiotropium olodaterol $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
goal,C0018017;C1571704
participants n,C0679646
baseline n,C0168634;C1442488
$nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
week $nmbr$ n,C0332174;C0439230
$nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
or for cana vs pbo $nmbr$ ci,C1418845;C0008107;C3259781
$nmbr$ $nmbr$ i i,C0021966;C0221138
p value nominal,C1709380
$nmbr$ i $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
body weight reduction $nmbr$,C1262477
$nmbr$ i $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
$nmbr$ ii $nmbr$ $nmbr$,C1710602;C4082587
week $nmbr$ n or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
pre bronchodilator screening fev $nmbr$ ml,C0439526;C1705224;C3887665
ldl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
i $nmbr$ $nmbr$,C0021966;C0221138
hdl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
i $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
composite endpoint a $nmbr$ c $nmbr$ $nmbr$ bp,C0037623;C1415692;C1708288;C4318478
ii $nmbr$ $nmbr$,C1710602;C4082587
$nmbr$ $nmbr$ mmhg ldl c $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
post bronchodilator screening fev $nmbr$ ml,C0439526;C1705224;C3887665
week $nmbr$ n ^,C0332174;C0439230
i $nmbr$ $nmbr$ ii,C1710602;C4082587
male patients^,C0150904
i $nmbr$ $nmbr$ i,C0021966;C0221138
female patients^,C0150905
change from pre to,C0392747;C0443172;C1705241;C4319952
week $nmbr$ n j,C0332174;C0439230
i $nmbr$ i $nmbr$,C0021966;C0221138
week $nmbr$ n $nmbr$,C0332174;C0439230
i $nmbr$ i i $nmbr$,C0021966;C0221138
composite endpoint a $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mmhg ldl c $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
post bronchodilator fev $nmbr$ ml,C0439526;C1705224;C3887665
ef $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,
$nmbr$ $nmbr$ ii $nmbr$,C1710602;C4082587
black race,C0005680
$nmbr$ i ii $nmbr$,C1710602;C4082587
russia georgia,C0017452;C0017454
fev $nmbr$ pred,C0032952;C0044955
history of hf hospitalization,C0551577;C0018488;C1313497;C1538440;C3273279
$nmbr$ fevi ^ $nmbr$ pred,C0032952;C0044955
i $nmbr$ i,C0021966;C0221138
history of diabetes nyha class,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ fevi $nmbr$,C0849974;C1561566;C4528367
heart rate b p m,C0018810
$nmbr$ fev $nmbr$,C3714541
body mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ii $nmbr$ ii $nmbr$,C1710602;C4082587
ace arb,C1452534;C3888198;C4284014
baseline pulmonary medication,C0013227;C3244316;C4284232
all patients n $nmbr$ $nmbr$,C0030705
sama $nmbr$,C1075468
ejection fraction group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
i $nmbr$ i i $nmbr$ $nmbr$,C0021966;C0221138
continuous lvef $nmbr$ treatment interaction,C0039798;C1704675;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
i $nmbr$ i $nmbr$ i,C0021966;C0221138
event rate per $nmbr$ patient years,C0871208;C1521828
lama,C0999593;C1416775
hr unadjusted,C1439367
saba,
referent,C1706462
xanthines $nmbr$,C0043318;C3541955
hr adjusted,C0456081
baseline cardiovascular medication,C0168634;C0007220;C1442488
treatment effect hr,C1518681
i $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
hr adjusteda,
ii $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
empagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment comparison,C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pooled empagliflozin n $nmbr$,C1709595;C2349200;C4522255
ics usage,C0815320;C0457083;C4551720
other missing,C1551393;C1705492;C3272743
adjusted mean se $nmbr$ ci,C0008107;C3259781
north america plus australia and new zealand,C0028405;C0004340;C0027978;C0324547
fevi auc $nmbr$ $nmbr$ l,C0429706;C0376690;C0849974;C1561566;C4528367
africa,C0001737
common study baseline,C0168634;C1442488
body mass index kg m $nmbr$ t,C0005893;C1532718;C0578022;C1305855
tiotropium olodaterol $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
cv risk factor no,C3538987;C0035648;C4048877;C4318503
versus olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
multi vessel coronary artery disease,C1299432
versus tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
history of stroke $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
single vessel coronary artery disease $nmbr$,C0581374
versus tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
cardiac failure,C0018801;C0018802
versus tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
time since diagnosis of type $nmbr$ diabetes no,C0040223;C3541383
trough fevi l,C0444506;C0429706;C0849974;C1561566;C4528367
glucose lowering therapy no,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
dapagliflozin $nmbr$ mg day n $nmbr$,C2353951;C0439422
medication taken alone or in combination,C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
type $nmbr$ diabetes duration mean sd years,C1320657;C0439234
median daily dose iu,C0049272;C0439453;C0694756
hba $nmbr$ c mean sd [mmol mol],C0019016;C2699239;C1825777;C3538758;C3829066
dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
fpg mean sd mg dl [mmol l],C0444504;C0439269;C2347634;C2348143;C1532563
glucagon like peptide $nmbr$ agonist,C0014361;C2987634
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
anti hypertensive therapy no,C0585941
prior history of cardiovascular disease n,C0332152;C0455539;C2826257
angiotensin converting enzyme inhibitors angiotensin receptor blockers,C0521942;C0815017
concomitant medications n,C0521115;C0013227;C0802604;C2598133;C4284232
mineralocorticoid receptor antagonists,C1373021;C1579268
antihypertensives,C0003364
renin inhibitors,C2917241;C3653375
angiotensin receptor blocker and or ace,C0034787;C1622222;C1452534;C4284014
anti coagulants no,C0848112
dapagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
low density lipoprotein cholesterol mg dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ $nmbr$ mmol l [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0030705;C1532563;C3829066;C0008107;C0036919;C3259781
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ tt,C3811844;C0439445;C1452561;C4554543
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
urine albumin to creatinine ratio no,C0455271;C1318330
$nmbr$ to $nmbr$ mg g,C1300563
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ to $nmbr$ $nmbr$ to $nmbr$ mmol mol [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0019016;C0030705;C1825777;C3538758;C3829066;C0008107;C0036919;C3259781
patients with event patients analyzed,C0030705;C0441471;C4019010;C0936012
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ $nmbr$ mmol mol [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0030705;C3829066;C0008107;C0036919;C3259781
sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
open label phase baseline week $nmbr$,C0332174;C0439230
urine albumin to creatinine ratio,C0455271;C1318330
randomized double blind reversal phase baseline week $nmbr$,C0332174;C0439230
cardiovascular risk,C0007226;C0035647;C4552904;C3887460
total cohort,C0009247;C0599755
only cerebrovascular disease,C0007820
azl ma,C0024443;C3887485
only coronary artery disease,C0010054;C0010068;C1956346
azl m cldb,
only peripheral artery disease,C1704436;C4025272
azl m,
$nmbr$ or $nmbr$ high cardiovascular risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
race no c,C0034510;C1706779;C3853635
statins ezetimibe,C0360714;C1142985
baseline dbp mean sd mm hg,C0168634;C0439475;C1442488
prior ptca or pci,C0332152;C2936173;C2826257;C4049621
baseline sbp mean sd mm hg,C0085805;C0439475
primary endpoint death mi idr st,C0036056;C3272372
table $nmbr$ baseline demographics and clinical characteristics,C0011298;C1704791;C0683325
ischemia driven revascularization,C0022116;C0581603;C4321499
all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation,C0030705;C3272598;C0332293;C0013175;C0168634;C1442488;C1299575;C0457987;C0871420
gusto bleeding severe moderate,C0019080;C1299393
linagliptin,C2746078
timi bleeding major minor,C0019080;C4441842
patients treated set n,C0030705;C0036849;C1442518;C1705195
acuity bleeding major minor,C0019080;C4441842
males n,C0086582
no of previous anti tnf drugs no,C0205156;C1552607;C0013227;C3687832
renal function egfr according to mdrd n,C1739039;C3811844;C3812682
use of methotrexate at randomization,C1524063;C0025677;C0034656
normal $nmbr$ ml min,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
use of systemic glucocorticoid at random,C1524063;C0017710;C0034656;C0439605
mild impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
ization no,
moderate impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
patients with specific disease characteris,C0683521;C0205369;C1552740
tics no,C0040188;C0278076;C2169806;C3889970
severe to end stage impairment $nmbr$ ml min,C0205082;C4050465;C4050466
psoriasis affecting $nmbr$ of body surface,C0033860;C0392760;C1314939;C0489451
patients full analysis sety n,C0030705;C0002778;C0936012;C1524024
area,C0017446;C0205146
hba $nmbr$ c mmol mol mean sd,C3829066;C2699239
disease and quality of life scores,C0012634;C3476431
time since diagnosis of diabetes mean sd,C0040223;C3541383
tender joint count of $nmbr$ joints,C0451530
type of basal insulin n,C0457592
swollen joint count of $nmbr$ joints,C0451521
insulin detemir,C0537270
pasi^i,C0021966;C0221138
nph,C0020258;C0027442
physician s global assessment of dis,C0031831;C0804815;C0281858;C0451119;C1444662;C1970187
concomitant oads n,C0521115
pioglitazone only,C0071097
ease activity],C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
metformin pioglitazone,C1635037
haq di scoreff,C3826998;C4321476
psoriatic arthritis pain],C4317006
figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0457592;C0001779;C2986798;C0020258;C0332173;C0027442
patient s global assessment of,C0030705;C0281858
baseline cardiovascular disease,C0168634;C0007222;C1442488
disease activity],C1292728
dilated cardiomyopathy,C0007193;C2984282
sf $nmbr$ physical component summaryjj,C0037712;C0031809;C0205485;C1509143
haemodynamics and lv function,C0019010;C4281788;C0031843;C0542341;C0700205;C1705273
efficacy endpoint,C2349179;C2826544
lvdd mm,C4330985;C4554674
secukinumab,C3179547
laboratory findings,C0587081
iv $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
haemoglobin g dl,C0439267
anti tnf naive patients $nmbr$,C1448177;C0030705
albumin mg dl,C0001924;C0439269
acr $nmbr$ response n n,C1412134;C0871261;C1704632;C1706817;C2911692;C1515941
baseline medication,C0013227;C3244316;C4284232
das $nmbr$ crp ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
number event total,C0439175;C0439810
anti tnf experienced patients,C1448177;C0030705
$nmbr$ c i lower,C0441994;C1548802;C2003888
no of hospitalised patients,C0030705
upper,C1282910
aplxaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age y o,C0001779
apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
taci n $nmbr$,C0666480;C1425349;C4284230
apixaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
paci n $nmbr$,C1165245
table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C4684572;C0205363;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0039601
poci n $nmbr$,
main effect baseline hormone,C0019932;C4521914
laci n $nmbr$,C1420705;C3273314;C4281721
baseline total ipss,C1019118;C1998280;C2827405;C3811063
sss score,C0449820;C4050231
unadjusteda beta se,C0330390;C0036919;C0439096;C2004068
duration of symptoms h,C0436359;C0033727;C0369286;C0441932;C0564385;C4528284
adjustedb c beta se,C0330390;C0036919;C0439096;C2004068
treatment with candesartan,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
stratified by,C0205363
current or previous atrial fibrillation,C0521116;C1705970;C0004238;C0344434;C1963067
linear regression,C0023733;C2346679
current use of an ace inhibitor,C1524063;C0003015;C4541021
treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
thrombolytic treatment before randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
testosterone level nmol l,C0428412;C0439282;C0523912
composite vascular endpoint,C2349179;C2826544
testosterone nmol l,C0039601;C0439282
functional outcome mrs $nmbr$ $nmbr$,C1522706;C2349188;C3714939;C3854213
continuous,C0549178
candesartan,C0717550
low tt,C1452561;C4554543
taci,C0666480;C1425349;C4284230
high tt $nmbr$ $nmbr$ n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
paci,C1165245
estradiol pmol l,C0014912;C0439284
poci,
baseline outcomes,C0168634;C1274040;C1442488
laci,C1420705;C3273314;C4281721
prespecified subgroups,C1079230
logistic regression,C0206031
odds ratios $nmbr$ ci,C0008107;C3259781
anacetrapib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ipss v,C1019118;C1998280;C2827405;C3811063
fc ldl c mg dl,C2983605;C0439269
moderate $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
use of concomitant lipid modifying therapy,C1524063;C1707479
ipss s,C1019118;C1998280;C2827405;C3811063
statin only n,C0360714;C0369718;C0441922
severe $nmbr$,C0205082;C4050465;C4050466
statin ezetimibe n,C0360714;C1142985
ipss categories,C1019118;C0683312;C1998280;C2827405;C3811063
statin fibrate or,C0360714
hormones,C0019932
niacin n,C0027996;C1142562
testosterone tt nmol l,C0039601;C0439282
type of concomitant statin,C0332307;C1547052
simvastatin n,C0074554
estradiol e $nmbr$ pmol l,C0014912;C0439284
atorvastatin n,C0286651
estradiol quartiles,C0014912;C2828255
rosuvastatin n,C0965129
$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l,C0036056;C0439284;C3272372
fc ldl c friedewald calculated,C2983605;C0444686;C1441506
$nmbr$ nd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0439284
low density lipoprotein choles,C0023823
$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0694666;C0439284;C4553350
$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l,C0039725;C0439284;C0039738;C1420718;C4282123;C4285344
terol hdl c high density lipoprotein cholesterol,C0023822
american indian or alaskan,C0002460;C0238611
sd standard,C1442989;C2828392
alcohol useb,C0001962;C0001975
deviation tg triglyceride,C0012727;C0041004;C0205419;C1705236
smokingb,
percent change from baseline at week $nmbr$,C3272907;C0332174;C0439230
obese $nmbr$ kg m $nmbr$ b,C0028754;C1532718
difference in ls means $nmbr$ ci,C1705241;C1705242
comorbid conditionsb,
ls mean $nmbr$ ci,C0008107;C3259781
cardiac diseasec,C0018787;C1522601
vs placebo,C0032042;C1696465;C1706408
medication useb,C0013227;C3244316;C4284232
anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
psychoactivesd,
baseline hdl c,C0168634;C3715113;C1442488
diabetese,
baseline fc ldl c,C0168634;C1442488
other lipid lowering drugs,C0086440
baseline tg,C0168634;C0337445;C1442488
alpha blockers,C0001641
statin only,C0360714
angiotensin receptive blocker,C0003018;C4521302
statin ezetimibe,C0360714;C1142985
other antihypertensive medications,C0003364
statin fibrate or niacin,C0360714;C0027996;C1142562
cyp $nmbr$ a $nmbr$ inhibitors,C1418793;C0243077;C2634343
dm n $nmbr$,C0011816;C3250443
alpha reductase inhibitors,C0597153;C1655741
no dm n $nmbr$,C0011816;C3250443
previous pde $nmbr$ inhibitors,C0205156;C0031638;C1552607
median age $nmbr$ $nmbr$ y,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193
hyperlipidemia n,C0020473;C0428465;C4555212
hemoglobin a $nmbr$ c,C0019020;C3889898
good control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
current tobacco abuse n,C0521116;C0040336;C1705970
fair control $nmbr$ $nmbr$ $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
peripheral arterial disease n,C0085096;C1704436
cholesterol nmol l,C0008377;C0439282
history of heart failure n,C0455531
previous pci cabg n,C0205156;C0010055;C1552607
glucose non fasting or random nmol l,C0017725;C1518422;C0015663;C0034656;C0439282;C0439605
baseline gfr,C0017654;C1424601
standard bp lowering,C1442989;C2828392;C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
baseline medications n,C0168634;C0013227;C0802604;C2598133;C4284232;C1442488
intensive bp lowering,C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
acei arb,C3888198
latino,C0086528
baseline diabetes mellitus therapy n,C0168634;C0948092;C1442488
intensive glycemia lowering,C0005802;C0441994;C2003888
lifestyle modifications,C0870811;C2960841
cornell index pv,C0030840;C0032463
noninsulin therapy,C0039798;C0087111;C1363945
safety population,C0032659;C1257890
insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
brv $nmbr$ mg day n $nmbr$,C0155502;C0439422
vorapaxar event rate n $nmbr$,C0441471;C0871208;C1521828;C4019010
brv $nmbr$ mg day n,C0155502;C0439422
placebo event rate n $nmbr$,C0032042;C0441471;C4019010;C1696465;C1706408
gender female n,C0079399;C0043210;C0086287;C1705497;C1705498;C1522384
cvd mi or stroke,C0007222;C3810814;C0038454;C4554100
europe eu,C0015179;C3665627
cvd or mi,C0007222;C3810814
asia pacific other,C0003980
cvd mi stroke or recurrent ischemia urgent revascularization,C0038454;C4554100;C0022116;C0581603;C4321499
europe non eu,C0015179;C3665627
duration of epilepsy years mean sd,C0449238;C2926735
cvd mi stroke or recurrent ischemia urgent revascularization or hospitalization for unstable angina,C0038454;C4554100;C0022116;C0581603;C4321499;C0019993;C0002965
age at first seizure years mean sd,C1510829;C0036572;C1959629;C4553401
recurrent ischemia urgent revascularization,C0022116;C0581603;C4321499
hospitalization for unstable angina,C0019993;C0002965
baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1442488
patients treated with statins n $nmbr$,C0030705;C0332293;C0360714
number of prior aeds n,C0237753;C0449788
patients not treated with statins n $nmbr$,C0030705;C0332293;C0360714
number of concomitant aeds n,C0237753;C0449788
mean bmi kg m $nmbr$,C0022718;C0439209;C4054209
concomitant aedsa,C0521115
carbamazepine,C0006949;C0006950;C0682993
creatinine clearance n,C0812399
lamotrigine,C0064636;C0524166
planned treatment duration n,C4528394
valproate,C0080356
index event n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
oxcarbazepine,C0069751
only dvt,C0149871;C2926618;C3899446
topiramate,C0076829
pe dvt,C0149871;C2926618;C3899446
lacosamide,C0893761
index event not confirmed,C0441471;C4019010;C0521093;C0750484
lev status n,C0023556;C0449438
immobilization at randomization n,C0020944;C4048292
never used lev,C1273517;C0023556
active cancer at randomization n,C0006826;C0998265;C1306459
prior lev use,C0042153;C0457083;C1947944
ischemic heart disease n,C0010054;C0151744
ischemic cerebrovascular disease n,C0475224;C0007820
subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure,C2986480;C0032664;C0149775;C0332152;C0023556;C2826257;C0030705;C0871208;C1521828;C0168634;C1442488;C0301630;C0392756;C1293152;C4551656;C0392360;C0444930;C2746065;C1264674;C0237753;C0449788;C0332293;C0377265;C3693636;C0657912;C0003299;C0751495;C0206132;C0332162
asa use at baseline n,C0042153;C0457083;C1947944
spirono n $nmbr$,
asastoppedat randomization n,C0034656
enrollment strata prior hospitalization,C0332152;C0019993;C2826257
recurrent vte statin use vs non use,C0042153;C0457083;C1947944
physical characteristics,C0031809;C1521970;C0205485;C1509143
asa use at baseline,C0042153;C0457083;C1947944
hematocrit,C0018935;C0518014
no asa use at baseline,C0042153;C0457083;C1947944
prior hf hospitalization n $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
no cardiac disease,C0018799
elevated natriuretic peptide level n $nmbr$,C1144709;C2709270;C3537020
major bleeding statin use vs non use,C0042153;C0457083;C1947944
p for interact,C0369773;C2603361
included in this study n $nmbr$,C0332257;C0557651;C2603343
lv heart structure,C0023128;C0018787;C0731033;C1881413
patients with early cd n $nmbr$,C0030705;C0007928;C0034283;C4552032
lvedv ml,C0439526;C1705224;C3887665
disease duration year median,C0549183;C0876920;C2347635;C2348144;C2939193
lvesv ml,C0439526;C1705224;C3887665
crp median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
mean wall thickness cm,C4054557;C0677535
crp $nmbr$ $nmbr$ mg dl n,C3890735;C0439269;C4048285
lv mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cdai score mean s d,C0449820;C0444504;C2347634;C2348143;C4050231
relative wall thickness,C0080103;C0205345;C1547039
gastrointestinal area involved n total n,C0017446;C0205146
lav ml,C0439526;C1705224;C3887665
upper gastrointestinal tract,C3203348
la diameter,C0023031;C1301886;C0023749;C0230347;C2346906;C4553351
baseline crohn s disease medications,C0168634;C0010346;C1442488;C0013227;C0802604;C2598133;C4284232
lv function,C0031843;C0542341;C0700205;C1705273
systemic corticosteroids n,C4053960
e a ratio,C0456603;C1547037
budesonide n,C0054201
tdi e septal cm sec,C0205976;C0439392;C2674784;C3714807
$nmbr$ asa compounds n,C0004057;C3853627
e e septal,C0442004
history of bowel resections n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
rv and pulmonary vascular,C0035190;C3889272;C0459963;C1508661
early crohn s disease,C1279919;C0010346;C0012634
tr jet velocity m sec,C0439830;C1547053;C0565930
non early crohn s disease,C1279919;C0010346;C0012634
rvfac,
azathioprine monotherapy,C0004482
enrolled in the americas,C4684790;C0002454;C0596070
infliximab monotherapy,C0666743
enrolled in russia or georgia,C4684790;C0035970;C0017452;C0017454
infliximab combination therapy,C4076075
baseline adjusted hr,C0168634;C0456081;C1442488
remission component of variable,C0449432;C1705248
alvedv per ml,C0439526;C1705224;C3887665
cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
alvesv per ml,C0439526;C1705224;C3887665
mh,C0026514;C2930980
alvmi per g m $nmbr$,C0439267
crpnorm,
alvef per $nmbr$,
cr mh,C0026514;C2930980
ae a ratio per $nmbr$ $nmbr$ unit,C3887670;C0456603;C1547037
cr crpnorm,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
ae per cm s,C3887670
mh crpnorm,C0026514;C2930980
ae e ratio per $nmbr$ unit,C0456603;C1547037
cr mh crpnorm,C0201975;C0026514;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
alav per ml,C0439526;C1705224;C3887665
[ $nmbr$ ci],C0008107;C3259781
apasp per mmhg,C0439475
a aza treatment ref,C0004482;C1425988
arvfac per $nmbr$,
ifx treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
sbp at baseline,C0085805;C0168634;C1442488
combination treatment ifx aza,C0020823;C0004482
sd of sbp,C2699239;C0085805
previous cd related surgery ref a,C0007928;C1425988;C0034283;C4552032
range of sbp,C1514721;C2348147;C3542016
no previous cd related surgery $nmbr$,C0038894;C0038895;C0543467;C1274039
change in sbp,C0392747;C0443172;C1705241;C4319952
b aza treatment ref,C0004482;C1425988
bp lowering treatment n $nmbr$,C0037623;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1415692;C1708288;C4318478
history of bowel resection ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
r tpa,C0032143
no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
time to treatment h,C3494202;C0033727;C0369286;C0441932;C0564385;C4528284
c kza treatment ref,C0039798;C1425988;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
nihss score,C0449820;C4050231
no hospitalization in the past $nmbr$ months prior to baseline ref,C0019993;C0439231;C0168634;C1425988;C1442488
stroke subtype,C0038454;C0449560;C4554100
hospitalization in the past $nmbr$ months prior to baseline,C0019993;C0439231;C0168634;C1442488
infarct size,C0021308;C0456389
no history of extra intestinal manifestations of ibd ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no infarct visible,C0021308;C0205379
history of extra intestinal manifestations of ibd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
small medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
d aza treatment ref,C0004482;C1425988
large very large,C0549177;C0442824;C2984081
no steroid use at baseline ref,C0281991;C0168634;C1442488
symptomatic infarct swelling,C0013604;C0038999
on steroid at baseline,C0038317;C0168634;C1442488
symptomatic ich,C0019191;C3272597;C3281105
e aza treatment ref,C0004482;C1425988
nd not due to swelling or ich,C0678226;C0013604;C0038999;C0019191;C3272597;C3281105
reslizumab n $nmbr$,C1869620
early ichaem ic stroke,C0038454;C4554100
median age years iqr,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
any early adverse event,C1279919;C0877248
mean body mass index kg mq,C0005893;C0024853;C0578022;C1305855
early death,C1836407
$nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
poor outcome at $nmbr$ months,C3806166;C0439231
mean time since diagnosis years,C0556970;C0011900;C1704338;C1704656
numbers of events,C4330837
mean ics use at enrolment pg,C0042153;C0457083;C1947944
ors $nmbr$ cis,C1504308;C1742862
oral corticosteroid use at enrolmentt,C0239126
$nmbr$ days to $nmbr$ year n $nmbr$,C0556972
laba use at enrolment,C0042153;C0457083;C1947944
age median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
mean prebronchodilation l,C0444504;C2347634;C2348143
caucasiana,
bmi median iqr,C0578022;C0549183;C0876920;C2347635;C2348144;C2939193
mean predicted value prebronchodilation,C0444504;C0681842;C1882327;C2347634;C2348143
mean reversibility,C0444504;C0449261;C2347634;C2348143
multivessel cad,C1504769;C2239547;C3813548;C4284121
pci for index mi,C4049621;C0600653;C0918012;C1552854;C1637833;C2986546
mean aqlq total score t,C3533236
mean acq $nmbr$ scores,C3533236;C2919686
history of more than $nmbr$ prior mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean asui scored,C0444504;C2347634;C2348143;C0449820
egfr at baseline $nmbr$ ml min b,C1739039;C3811844;C3812682
saba use in past $nmbr$ days,C0042153;C0457083;C1947944;C0439228
months from mi median iqr,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
mean number of puffs per day,C0444504;C0237753;C0449788;C2347634;C2348143;C0332173;C0439228;C0439505
mi type unknown,C0439673;C3541433;C4050014
mean blood eosinophil count cells per pl,C0444504;C0200638;C2347634;C2348143
figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0178602;C0439542;C1707455;C0032042;C1696465;C1706408;C0030705;C0424092;C2349954;C2825032;C3853865;C0439228;C0034656;C1514624;C0439231;C0332152
mean number of caes in past $nmbr$ months number per patient ],C0444504;C0237753;C0449788;C2347634;C2348143;C0439231;C0030705
age mean sd yrs,C0001779;C0444504;C2347634;C2348143
reslizumab,C1869620
history myocardial infarction,C0155668;C1275835
place,C0442504;C1533810;C1704765;C1882509
history pci,C0019664;C4049621;C0019665;C0262512;C0262926;C1705255;C2004062
rate ratio $nmbr$ cl,C0456603;C0596019;C1547037
anti platelet therapy,C0039798;C0087111;C1363945
ocs at baseline,C0168634;C1442488
time to end of study ivus median iqr days,C3698632
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$,C0483204
cardiovascular events,C1320716
ics plus laba,C0815320;C4551720
hospitalization for acs,C0019993;C0742343;C4318612
ics no laba,C0815320;C4551720
arterial revascularization,C0003842;C0581603;C0221464
body mass index kg mj previous diagnosis,C0005893;C0332132;C0578022;C1305855
first mace,C0349381;C0949745;C1445339
use of concomitant lipid lowering treatment,C1524063;C0023779
biochemical events,C0441471;C3541888
statin with ezetimibe,C0360714;C1142985
hyperkalemia $nmbr$ $nmbr$ meq l,C0020461;C0439375;C4552983
type of concomitant statin by daily dose,C0332307;C1547052;C2348070
elevated creatinine $nmbr$ pmol l,C0151578;C0439284;C0700225
simvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
elevated bun $nmbr$ $nmbr$ meq l,C0151539;C0439375
atorvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aliskiren dm vs dm,C0011816;C3250443
pravastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo dm vs dm,C0011816;C3250443
fluvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dm aliskiren vs placebo,C0011816;C1120110;C3250443;C0032042;C1696465;C1706408
baseline lipid and lipoprotein values,C0168634;C0023779;C1442488;C0023820;C0042295
hard mace,C0349381;C0949745;C1445339
apo a $nmbr$ g l,C1447574;C4521365
hba $nmbr$ c $nmbr$,C0019016;C1825777;C3538758
lp a pmol l,C0065058;C0439284;C1439335;C4553379
hbalc $nmbr$ n $nmbr$,
age s $nmbr$ years n $nmbr$ $nmbr$,C1510829
established cardiovascular disease,C0443211;C0007222;C1272684
baseline tg level n $nmbr$ $nmbr$,C0168634;C0337445;C1442488
egfr $nmbr$ ml min,C1739039;C0439445;C3811844;C3812682
baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
urine albumin creatinine ratio mg g,C0455271;C1300563;C1318330
statin only n $nmbr$ $nmbr$,C0360714;C0369718;C0441922
antihyperglycemic medications,C0013227;C0802604;C2598133;C4284232
statin ezetimibe n $nmbr$ $nmbr$,C0360714;C1142985
cardiovascular medications,C0007220
other n $nmbr$ $nmbr$ ],C0369718;C0441922
adp antagonist,C0523452;C0231491
simvastatin n $nmbr$ $nmbr$,C0074554
cvdeath ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
atorvastatin n $nmbr$ $nmbr$,C0286651
cv death ml ischemic stroke hospitalization for unstable angina revascularization or heart failure,C0019993;C0002965;C0018801;C0018802;C4554158
rosuvastatin n $nmbr$ $nmbr$,C0965129
risk score category points,C1552961;C2347617;C3714763
diabetics yes n $nmbr$ $nmbr$,C0241863;C1549445;C1705108;C1710701
western europe and other,C0043129
diabetics no n $nmbr$ $nmbr$,C0241863;C0369718;C0441922
creatinine mmol,C0010294;C0439190;C1561535
baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
hemoglobin g l,C0635222
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
nyha functional class i,C1882084;C0205245;C0542341;C2700217
baseline hdl c level n s $nmbr$ $nmbr$,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
kccq score,C0449820;C4050231
baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
coronary artery bypass surgery,C0010055
baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0337445;C1442488;C0439269
diuretic agent,C0450442;C1254351;C1521826
other n $nmbr$ $nmbr$,C0369718;C0441922
mineralocorticoid receptor antagonist,C1579268
baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
oral anticoagulant agent,C0354604
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
cardiac resynchronization therapy,C1167956
baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
risk category points,C1552961;C2347617;C3714763
p value $nmbr$ years,C1709380;C0439234
enalapril lcz $nmbr$ n $nmbr$ n $nmbr$,C0014025
saxagliptin n $nmbr$ $nmbr$,C1611934
enalapril n $nmbr$,C0014025
pharmacotherapy,C0013216;C0013217
lcz $nmbr$ n $nmbr$,
$nmbr$ years placebo n $nmbr$ $nmbr$ saxagliptin n $nmbr$ $nmbr$,C0439234;C0032042;C1696465;C1706408
cv death or hf hospitalization n,C0011065;C1306577;C4082313;C4552775;C0018488;C0019993;C1313497;C1538440;C3273279
km event rate,C0871208;C1521828
ratet $nmbr$ cl,C0596019
interaction p value $nmbr$ $nmbr$,C1704675;C1709380
cv death n,C0011065;C1306577;C4082313;C4552775
secondary,C0027627;C0175668;C0205436
hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
nonfatal ischemic stroke,C0948008
all cause death n,C0015127;C0011065;C1306577;C4082313;C4552775;C1524003
hospitalization for due to,C0019993
hr bpm,
doubling of creatinine level,C0205173;C1705764
creatinine mol l,C0010294;C0347982;C1561535
initiation of dialysis renal transplantation or creatinine $nmbr$ $nmbr$ mg dl $nmbr$ mmol l,C0589507;C1158830;C1704686;C0439268
median bnp iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
history of heart failure at baseline,C0455531;C0168634;C1442488
median nt probnp iqr pg ml,C0669479;C0439297;C0754710
no history of heart failure at baseline,C0455531;C0168634;C1442488
ischaemic etiology n,C0475224;C0015127;C1314792;C1524003
baseline hba $nmbr$ c concentration,C0086045;C1446561;C3827302
nyha,C1275491
bodyweight kg,C0022718;C0439209;C4054209
hospitalization for heart failure n,C3898876
cardiovascular risk factors and history,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
coronary artery bypass grafting n,C0010055
egfr ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
percutaneous coronary intervention n,C1532338
egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
diuretic n,C0012798
time from index acs event to randomisation days,C0040223;C3541383;C0034656;C0439228
beta blocker n,C0001645
nyha chf class,C1882083;C0018802
mineralocorticoid receptor antagonist n,C1579268
baseline bnp concentration pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
oral anticoagulant n,C0354604
baseline concomitant cardiovascular medications,C0168634;C0007220;C1442488
antiplatelet agent n,C0085826
ace inhibitor arb or both,C0003015;C3888198;C4541021
lipid lowering agent n,C0086440
mras,C1335594;C1367476
implantable cardioverter defibrillator n,C0162589;C2825184
primary mace endpoint,C2986535;C0349381;C0949745;C1445339
cardiac resynchronization therapy n,C1167956
non fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
enalapril,C0014025
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ t,C2603360
lcz $nmbr$,
pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455531
cv death or hf hosp,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
secondary mace endpoint,C4528314;C0349381;C0949745;C1445339
hf hosp,C0018488;C1313497;C1538440;C3273279
urgent revascularisation due to unstable angina,C0581603;C0002965
acd,C4554601
cardiovascular death and hospital admission for heart failure,C0011065;C1306577;C4082313;C4552775;C0184666;C0018801;C0018802;C4554158
hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure,C0488055;C0871470;C1306620
normal responder n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
psoriasis duration mean sd years,C0033860;C0439234
sensitive responder n $nmbr$,C0020517;C0332324;C1522640
bsa affected mean sd,C0392760;C2699239;C1314939
highly sensitive responder n $nmbr$,C0439822
pasi score mean sd,C0444504;C2699239;C2347634;C2348143
median age [interquartile range] yr,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193;C1711350;C0439234
fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy,C0349966;C1337208;C0237629;C1515119
atrial fibrillation no,C0004238;C0344434;C1963067
tiotropium $nmbr$ g n $nmbr$,C0213771;C0439267
qualifying risk factors no,C1514624;C0035648;C1553898
tiotropium $nmbr$ $nmbr$ g n $nmbr$,C0213771;C0439267
chads $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
median range duration of asthma y,C0449238;C2926735
previous exposure to a vitamin k antagonist no current or former never,C0332157;C1096489;C2267235;C0521116;C1705970;C0205156;C0750523
fev $nmbr$ at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
medications at time of randomization no,C0013227;C0802604;C2598133;C4284232
actual l,C0237400
digoxin or digitalis preparations,C0012265;C0304520
of predicted,C0681842;C1882327
asia pacific and south africa,C0003980;C0037712
fev $nmbr$ at baseline randomization,C3714541;C0168634;C0034656;C1442488
edoxaban higher dose vs warfarin,C2975435;C0444956;C0043031
fvc,C3714541
edoxaban lower dose vs warfarin,C2975435;C0445550;C1708745;C0043031
fev $nmbr$ fvc at baseline randomization,C3714541;C0034656
higher dose,C0444956
pefam l min,C0702093;C1524029;C3813700
lower dose,C0445550;C1708745
pefpm l min,C0702093;C1524029;C3813700
pinteraction,
acq $nmbr$ total score,C2919686;C2964552
any overt bleed,C0019080
ics dose of stable maintenance treatment g,C3714445
normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0549193;C1704769;C2350001
sensitive,C0020517;C0332324;C1522640
active vs placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
highly sensitive,C0439822
adjusted mean of difference se ml,C0444504;C2347634;C2348143
major or clinically relevant non major bleed,C0205082;C0205164;C4318856;C4521762;C0019080
peak fev $nmbr$ $nmbr$ $nmbr$ h response,C0871261;C1704632;C1706817;C2911692
clinically relevant non,C2347946;C1518422
trough fev $nmbr$ response,C0871261;C1704632;C1706817;C2911692
clinically relevant non major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
fev $nmbr$ of predicted normal post bronchodilator,C3714541;C0205307;C0231683;C0439166;C2347086;C4553972;C2599594
background therapy,C0039798;C0087111;C1363945
dabigatran $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
su,C0038642;C1705534
enoxaparin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
biguanide,C0005382;C3537187;C4317165
number of treated patients,C2360800;C1522326
agi,C1299007
females n,C0086287
dpp $nmbr$ inhibitor,C1414174;C1999216
body mass indexa,C0518010
study drug,C0013175
previous vte n,C0205156;C0630906;C1552607
empagliflozin,C3490348
creatinine clearanceb ml min,C0010294;C0439445;C1561535
metformin open label,C0025598;C1709323
racec n,C4287599
time since diagnosis of t $nmbr$ dm,C0040223;C3541383
australia new zealand south africa,C0027978;C0037712;C0324547
figure must be in supplement is not in paper,C0242295;C1947943;C2348609;C1518422;C0030351;C1547566
patients treated and operated n,C0030705;C1522326;C3242339
ticagrelor $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
anesthesiad n,
multivessel coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
general alone,C0205246;C3812897;C3891294;C4521767;C0205171;C0439044;C0679994
history of pci no total no t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439175;C0439810;C2603360
neuraxial alonee,
$nmbr$ prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
combinationf,
qualifying events,C1514624;C0441471;C3541888
mean duration of surgery sd min,C0449238;C2926735
years since myocardial infarction,C0439234;C0027051;C0428953;C2926063;C3810814;C4552959
study treatment,C1521826
type of myocardial infarction no,C0332307;C1547052
mean time to first subcutaneous injectiong h in relation to surgery hr,C0040223;C3541383;C0038894;C0038895;C0543467;C1274039
unknown type,C0332307;C1547052
mean time to first oral dose postsurgeryh hr,C0040223;C3541383
medication at enrollment no,C0013227;C3244316;C4284232
median range duration of hospital stayi d,C0449238;C2926735
aspirin at any dose,C4696290
median range treatment duration d,C0444921;C3259042
ticagrelor $nmbr$ mg $nmbr$ year km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
enoxaparn $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ year km,C0032042;C3887676;C1696465;C1706408
estimate $nmbr$ cl,C0750572;C0596019
age at randomization,C0001779;C0034656
weight [kg],C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209
median $nmbr$ kg,C0022718;C0439209;C4054209
creatinine clearance [ml min],C0812399;C0439445
second prior mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
n c,C2349138
second mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
bmi [kg m $nmbr$ ],C0578022;C0022718;C0439209;C4054209
no second mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
age [years],C0001779;C0439234
no multivessel disease,C0012634
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0016327
non endstage renal dysfunction,C1565489;C3279454
monotherapy $nmbr$,
no renal dysfunction,C1565489;C3279454
add on to met $nmbr$,C1883712;C0428210;C1550543;C4317104
heparin alone n $nmbr$,C0019134;C0205171;C0439044;C0679994;C0770546
add on to met su $nmbr$,C1883712;C0038642;C1705534
heparin plus tirofiban n $nmbr$,C0019134;C0770546
mean sd age y race n,C0001779;C0034510;C1706779;C3853635
type of ml no,C0332307;C1547052
othery ethnicity n,C0015031;C0243103
symptom onset to hospital arrival median iqr h,C4086878;C0019994;C1510665
mean sd hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
killip class $nmbr$ no,C1881332
latin american subgroup,C1079230;C1515021
anemia no total,C0002871;C1000483;C4554633;C0439175;C0439810
add on to met,C1883712;C0428210;C1550543;C4317104
crusade bleeding score mean sd ^,C0019080;C2699239
add on to met su,C1883712;C0038642;C1705534
cana,C1418845
$nmbr$ moderate or high bleeding risk no total,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0332167;C3272283;C4050568;C4319571;C0439175;C0439810
heparin tirofiban n $nmbr$,C0019134;C0247025;C0770546
figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$,C1268766;C0032659;C1257890;C1553378;C1079230;C0031962;C0681867;C1706449
no of events total no $nmbr$,C0439175;C0439810
bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified,C0038944;C1112705;C1705982;C1273937;C0031962;C1707455;C0884358;C0002778;C0936012;C1524024;C1518422
$nmbr$ years old,C0439234;C0580836
class ll iv,C0456387;C1518526;C1705943;C0022326;C4265176
pooled non canvas studies n $nmbr$ non cana n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0947630;C1319635
transradial,
canvas n $nmbr$ placebo n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0032042;C1319635;C1696465;C1706408
transfemoral,
overall population n $nmbr$ $nmbr$ non cana n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0032659;C1319635;C1257890
previous cv events,C0441471;C3541888
othera,
crusade score,C0449820;C4050231
fpg mg dl mmol l,C0439268
lad artery,C0003842;C0226004
microvascular complicationsb,C0443258
non lad artery,C0003842;C0226004
use of loop diuretics,C1524063;C0354100
killip ciass,
prior cv history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ciass ll iv,C0022326;C4265176
all cana,C1418845
ciass i,C0021966;C0221138
$nmbr$ years of age,C1510829
creatinine ciearance,C0010294;C1561535
duration of t $nmbr$ dm $nmbr$ years,C0449238;C2926735
$nmbr$ mi min,C0702093;C1524029;C3813700
egfr $nmbr$ ml min $nmbr$ $nmbr$ mz,C0026655;C1705291
arteriai access,C0444454;C1554204
no fracture history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no of events totol no,C0441471;C3541888
fracture history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
placebo golimumab $nmbr$ mg $nmbr$ mga b,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
microvascular complications n,C0443258;C0009566;C1171258
$nmbr$ mg $nmbr$ mgc,C0024671;C3888239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
use of loop diuretics n,C1524063;C0354100
$nmbr$ mg $nmbr$ mgb,C0024671;C0373680;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior cv history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
randomized patients,C0034656;C0030705;C3815594
continued thienopyridine n $nmbr$ $nmbr$,C0549178;C1120149
psa modified shs $nmbr$ $nmbr$,C3810537;C0392747;C3889737;C3813209
non white raceb,C0007457;C0043157;C0220938
ptga $nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
hispanic or latino ethnic groupb,C0086409;C0086528;C0015031;C0680174
pasi score $nmbr$ $nmbr$ d,C0449820;C4050231
body mass indexc,C0518010
methotrexate use at baseline,C0042153;C0457083;C1947944
renal insufficiency failure,C0035078;C1963154
placebo to golimumab $nmbr$ mg $nmbr$ mgt,C0032042;C1696465;C1706408
prior cancer,C0006826;C0998265;C1306459
golimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
indication for index pci,C0392360;C3146298
mtx use at baseline,C0042153;C0457083;C1947944
unstable anginad,C0443343;C1883468
no mtx use at baseline,C0042153;C0457083;C1947944
type of stent at index procedure,C0332307;C1547052;C0184661;C2700391;C3274430;C3539779
no patients with available data,C2707520;C0470187
continued thienopyridine,C0549178;C1120149
myocardial infarction at presentation n $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
p value for interactiont,C1709380
no myocardial infarction at presentation n $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
no mi,C3810814
thienopyridine n $nmbr$,C1120149
bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478;C1274040;C1546471;C2825142
non white race,C0007457;C0043157
ethnicity $nmbr$,C0015031;C0243103
any risk factor for stent thrombosis,C0035648;C3897493
mean change in sbp from baseline mmhg mean sd,C0392747;C0443172;C1705241;C4319952;C0168634;C2699239;C1442488
renal insufficiency or failure,C0035078;C1565489;C0231174;C0680095
education yrs mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
more than $nmbr$ vessels stented,C0005847;C0038257
receiving antihypertensive treatment n blood pressure mm hg mean sd,C1514756;C0428886;C2699239
more than $nmbr$ lesions per vessel,C0221198;C0005847
mean change in dbp from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952;C0439269;C2699239
lesion length $nmbr$ mm,C4330985;C4554674
baseline lipid profile mg dl mean sd,C0439269;C2699239
bifurcation lesion,C0221198;C1546698
participants at baseline n,C0679646;C0168634;C1442488
in stent restenosis of des,C3272317;C0011702;C4551552
fasting glucose mg dl diabetes classification,C0008902;C0008903;C0678229
vein graft stented,C0042449;C0181074;C0332835;C1961139;C0038257
diabetesz,
unprotected left main stented,C0205091;C0038257;C0443246;C1552822
mean sd baseline,C0168634;C1442488
thrombus containing lesion,C0087086;C0302148;C3146237;C0332256;C2700400;C0221198;C1546698
impaired fasting glucosex,C0221099;C0015663
prior brachytherapy,C0332152;C0006098;C2826257
baseline if have $nmbr$ yr follow up,C0168634;C1442488;C0589120;C1522577;C1704685;C3274571
thienopyridine at randomization,C1120149;C0034656
lipid trial participantsk,C0023779;C0008976
type of des at index procedure,C0332307;C1547052;C0184661;C2700391;C3274430;C3539779
change from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952
$nmbr$ type,C0332307;C1547052
fasting glucose $nmbr$ mg dl n,C0015663;C0439269
no of treated lesions,C1522326;C0221198
st t waveft,C0036056;C3272372
no of treated vessels,C1522326;C0005847
history of lvh on electrocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013798;C1547122;C1623258
no of stents,C0038257
history of lvh on echocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013516;C2243117
total stent length mm,C4330985;C4554674
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
lesions,C0221198
additional antihypertensive subgroup,C1079230;C1515021
native coronary artery lesions,C0205042;C0221198
dapagliflozin n $nmbr$,C2353951
in stent restenosis,C3272317
women ethnic origin,C0043210;C0015031
extreme tortuosity,C0205403;C0333076;C3641272;C4085555
$nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
heavy calcification,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
hbaj mmol mol,C3829066
modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C3541413;C0050451;C0221198;C1546698;C0772110
participants taking insulin,C0679646;C3842788
figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction,C0021149;C0220856;C0446516;C3715044;C4553528;C0441833;C1706365;C1999270;C0155626;C3541950
selective vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
age y median $nmbr$ th to $nmbr$ th percentiles,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
carotid artery disease,C0007273
qualifying type of atherosclerosis n,C1514624;C0332307;C1547052
history of dyslipidaemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
selected clinical characteristics n,C1707391;C0683325
recent cardiovascular eventf,C0332185;C0007226;C3887460
peripheral revascularization,C0205100;C0581603
egfr ml min per $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
any established coronary artery disease,C0010054;C0010068;C1956346
seated sbp n,C0277814;C0085805;C1283233
any established peripheral arterial disease,C0085096;C1704436
baseline mean seated sbp mm hg sd,C0439475;C2699239
ace inhibitors or arb,C0003015;C3888198
sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
lipid lowering medications,C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
hba $nmbr$ c n,C0019016;C1825777;C3538758
vorapaxar placebo $nmbr$ yr km rate,C0871208;C1521828
hba $nmbr$ c baseline mean hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
planned thienopyridine at baseline,C1120149;C0168634;C1442488
hba $nmbr$ c difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
mitt population n $nmbr$,C0032659;C1257890
ambulatory sbp n,C0439841;C0085805
bmi $nmbr$ kg m $nmbr$ population n $nmbr$,C0022718;C0439209;C4054209;C0032659;C1257890
baseline mean ambulatory sbp mm hg sd,C0439475;C2699239
canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ambulatory sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl,C0967300;C0439269
serum uric acid n,C0455272;C0700634
dapagliflozin $nmbr$ mg group n $nmbr$,C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline mean serum uric acid pmol l sd,C0455272;C2699239;C0700634
subjects $nmbr$ years of age n,C1510829
serum uric acid difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
bw mean sd kg,C0022718;C0439209;C4054209
dapagliflozin,C2353951
qualifying cv event n,C1514624;C3538987;C0441471;C4019010;C4048877;C4318503
beta blocker subgroup,C0751987
not reported,C0684224;C0700287;C4319718
o $nmbr$ o $nmbr$ loto $nmbr$ $nmbr$,C0483204
time from most recent qualifying,C0040223;C3541383;C1514624
calcium channel blocker subgroup,C1079230;C1515021
cv event years,C0441471;C0439234;C4019010
diuretic subgroup,C1079230;C1515021
duration of hypertension n,C0449238;C2926735
laa closure n $nmbr$,C0185003;C1521802
seated sbp mean sd mmhg,C0085805;C0439475
long term warfarin n $nmbr$,C0443252;C0043031
seated dbp mean sd mmhg,C0277814;C0439475;C1283233
previous myocardiaunfarction,C0205156;C1552607
type $nmbr$ diabetes duration years,C1320657;C0439234
previous major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
fpg mean sd mmol l,C0444504;C1532563;C2347634;C2348143
$nmbr$ _ $nmbr$ $nmbr$ $nmbr$,
type of treatment n,C0455708
cha $nmbr$ ds $nmbr$ vasc,C1420648;C3714751
oad,
$nmbr$ _ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
oad plus insulin,C0021641;C1533581;C1579433;C3714501
modified has bled,C0392747;C3889737;C0019080
daily insulin dose mean sd iu,C0049272;C0439453;C0694756
laa closure,C0185003;C1521802
oads n,
hazard ratio $nmbr$ confi dence interval,C1272706;C1552654;C1552713
aceis arbs,C3888198
modified has bled $nmbr$,C0392747;C3889737;C0019080
full analysis set,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
no history of tia stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hba $nmbr$ c at $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
history of tia stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
change from baseline adjusted mean $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
lixisenatide n $nmbr$,C2973895
responders of three item end point at $nmbr$ weeks,C2349179;C2826544;C0439230
retinopathy no,C0035309;C1962966
seated sbp at $nmbr$ weeks mmhg,C0277814;C0085805;C1283233
neuropathy no,C0442874
bw at $nmbr$ weeks kg,C0005910;C0006041;C2986891
race no t,C0034510;C1706779;C3853635;C2603360
patients with bw decrease of $nmbr$ in patients with baseline bmi of $nmbr$ kg m $nmbr$,C0030705;C0005910;C0006041;C2986891;C0022718;C0439209;C4054209
hispanic ethnic group no t,C0015031;C1879937;C2603360
fpg mmol lt,C0023376;C0230426;C3887647;C4521399
geographic region no,C0017446
insulin lispro mix $nmbr$,C0205430;C1421951;C1720722;C4553942
africa or near east,C0001737;C1707877
caucasians n $nmbr$,C0007457;C0043157
south or central america,C1710133;C0007674
asians n $nmbr$,C0078988
myocardial infarction before index acs no,C0027051;C0428953;C2926063;C3810814;C4552959
mg dl fpg mmol l,C0439268
medical history at randomization no,C0262926;C1704706
phg,
qualifying acs event no,C1514624;C0441471;C4019010
fhg,
unclassified,C0205426;C1546437;C2347854;C4085229
fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc,C0871261;C0168634;C1442488;C2349179;C2826544;C0205430;C1421951;C1720722;C4553942;C0019016;C2828255;C1825777;C3538758;C0015663;C0020456;C0376690;C4552833;C1855520
days from acs to randomization,C0439228;C0742343;C4318612;C0034656
all patients on maximally tolerated statin other llt,C0030705;C0360714;C2347090
urinary albumin creatinine ratio^,C0486293;C1318293
aiirocumab n $nmbr$,
less than $nmbr$ y ears,C0013443;C0521421
any cv history risk factors n,C0035648;C1553898
not hispanic,C1518424
chd history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
africa near east,C0001741
chd risk equivalents n,C1282512;C0439185;C4049980
south central america,C0037713
lipid medication n,C0023779;C0013227;C3244316;C4284232
days between acs and rand,C0439228;C0742343;C4318612;C1555436
any statin,C0360714
$nmbr$ to less than $nmbr$,
high dose statin use at screening,C0042153;C0457083;C1947944
$nmbr$ or greater,C1704243
other llt use,C0042153;C0457083;C1947944
region us,C0815353;C3889164
ezetimibe use,C0042153;C0457083;C1947944
non us,C0815353;C3889164
lipid parameters mg dl mean sd,C0439269;C2699239
dm duration,C0449238;C2926735
ldl c calculated,C0444686;C1441506
$nmbr$ years or more,C0439234
ldl c measured,C0444706;C3541902
less than $nmbr$ $nmbr$,
lp a,C0065058;C1439335;C4553379
$nmbr$ $nmbr$ or more,
fasting tgs,C0015663;C1156212;C1537574
less than $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
aiirocumab,
$nmbr$ kg m $nmbr$ or more,C0022718;C0439209;C4054209
placebo estimated mean,C0444504;C2347634;C2348143
acs event,C0441471;C4019010
consistency of effect,C0332529;C1547017
pcr after acs,C0032520;C3853643;C4050242
estimated mean,C0444504;C2347634;C2348143
ace arb use,C0042153;C0457083;C1947944
not hispanic latino,C1518424;C0086528
uacr,
statin treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
stent n $nmbr$,C0038257
high intensity statin,C4081854;C0360714
medical therapy n $nmbr$,C0418981
no high intensity statin,C4081854;C0360714
stenosis core lab,C0678234;C4684837;C1261287;C2632116
other llt at randomization,C2347090;C0034656
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
statin with other llt,C0360714;C2347090
stenosis investigator,C0678234;C0035173;C1261287;C2632116
statin without other llt,C0360714;C2347090
peak systolic pressure gradient,C4687747
history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
mean systolic pressure gradient,C4687744
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ $nmbr$,
prior history ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
stent,C0038257
no prior ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
a by quantiles,C1709792
moderate ckd at randomization,C1561643;C0034656
percent stenosis [core lab],C0678234;C1261287;C2632116;C4684837
no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
percent stenosis [investigator],C0678234;C1261287;C2632116;C0035173
diabetes at randomization,C0011847;C0011849
$nmbr$ o $nmbr$,C0483204
estimated mean $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
b historic clinical thresholds,C0205210;C0449864
age years mean $nmbr$ sd,C1510829;C2699239
$nmbr$ $nmbr$ q,
weight kg mean $nmbr$ sd,C0005910;C2699239;C0043100;C1305866;C1705104
any albuminuria,C0001925
bmi kg m $nmbr$ mean $nmbr$ sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
ankle brachial index $nmbr$ $nmbr$,C1328319;C3888326
hba $nmbr$ c mean $nmbr$ sd,C0019016;C2699239;C1825777;C3538758
diabetes with use of oral diabetes drugs,C0020616;C1524063
hba $nmbr$ c mmol mol mean,C0444504;C2347634;C2348143
diabetes with no use of diabetes drugs,C0020616;C1524063
fsg mg dl mean sd,C0439269;C2699239
new diabetes,C0011847;C0011849
diabetes duration years mean sd,C0011847;C2699239;C0011849
igt or ifg,C1334085;C1708411
took prior antihyperglycemic agent any,C1515187;C0450442;C1254351;C1521826
fasting glucose mmol l,C0015663;C1532563
sulfonylureas,C0038766;C3653359
hbalc mmol mol,C3829066
concomitant lipid lowering therapy any,C0585943
nonglycemic cardiovascular risk factors,C0850624
fibrates,C1449704;C3540783
creatinine p mol l,C0010294;C0347982;C1561535
niacin,C0027996;C1142562
urine acr mg mmol,C0567349;C2348885
duration of diabetes years t,C0449238;C2926735
other antihypertensive drug,C0003364
qualifying hba $nmbr$ c,C1514624;C0019016;C1825777;C3538758
insulin glargine n x,C0907402
urinary albumin creatinine ratio mg g,C0486293;C1300563;C1318293
standard care n,C1442989;C1947933;C2828392
prior cardiovascular disease,C0332152;C0007222;C2826257
first co primary outcome,C0205225;C1274040;C0439612;C0439631
$nmbr$ coronary stenosis,C0242231
s $nmbr$ $nmbr$ s,C0565930;C2603362
prior cerebrovascular disease,C0332152;C0007820;C2826257
alc $nmbr$ $nmbr$,C1424945;C3811058
prior peripheral arterial disease,C0085096;C1704436
no metformin use,C0042153;C0457083;C1947944
nyha class $nmbr$ or higher,C1882083;C0205250
metformin use,C0042153;C0457083;C1947944
antihyperglycemic,C0020616
neither ace i nor arb use,C0021966;C0221138;C0042153;C0457083;C1947944
ezetimibe,C1142985
ace i or arb use,C0021966;C0221138;C0042153;C0457083;C1947944
age subgroups,C0001779;C1079230
^median,C0549183;C0876920;C2347635;C2348144;C2939193
new om,C0028971;C1705272
asia pacific and other,C0003980
prior om,C0028971;C1705272
diabetes duration subgroups,C0011847;C1079230;C0011849
second co primary outcome,C0205225;C1274040;C0439612;C0439631
s $nmbr$ $nmbr$ $nmbr$,
diabetes therapy at baseline alone or in combination,C3274787;C3539002;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
standard care allocation,C1442989;C1706778;C2828392
thiazolidinedione includes pioglitazone,C0289779;C1257987;C3537039;C0332257;C1552866;C2700399;C0071097
insulin glargine allocation,C0907402;C1706778
hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
heart rate $nmbr$ bpm,C0018810
renal function subgroups,C0232804;C1079230
no betablocker use,C0042153;C0457083;C1947944
systolic blood pressure subgroups,C0488055;C1079230;C0871470;C1306620
betablocker use,C0042153;C0457083;C1947944
diastolic blood pressure subgroups,C0428883;C1079230;C1305849
omega $nmbr$ fa intake $nmbr$ st third,C0036056;C3272372
body mass index subgroups,C0005893;C1079230;C0578022;C1305855
omega $nmbr$ fa intake $nmbr$ nd third,C1512806;C0205437
^median median,C0549183;C0876920;C2347635;C2348144;C2939193
omega $nmbr$ fa intake $nmbr$ d third,C1719844;C1512806;C0205437
a $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
triglycerides $nmbr$ st third,C0036056;C3272372
medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232;C1883727;C0034656
triglycerides $nmbr$ nd third,C0041004;C0205437
asteria i ii,C1710602;C4082587
triglycerides $nmbr$ d third,C0041004;C0205437
glacial $nmbr$,
selexipag n $nmbr$,C2000145
placebo n [ $nmbr$,C0032042;C1696465;C1706408
western europe and australia,C0043129;C0004340
omalizumab $nmbr$ mg n [ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time since diagnosis of pah yrf,C0040223;C3541383
time since diagnosis of ciu csuf y,C0040223;C3541383
pah classification no,C0008902;C0008903;C0678229
positive cu index test z n,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
heritable,C0439660
no of previous ciu csu medications mean median,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
associated with connective tissue disease,C0332281
previous use of systemic steroids n,C0281991
associated with corrected congenital shunts,C0332281;C0009678;C1744681
total ige levelx iu ml median range,C1514721;C2348147;C3542016
associated with hiv infection,C0332281;C0019693
in clinic uask,C0150312;C0002424;C0442592;C0332285;C1707101
associated with drug or toxin exposure,C0332281;C0013227;C1254351;C0040537
weekly iss,C1740819;C1845118
who functional class no c,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
weekly number of hives score,C0237753;C0449788
$nmbr$ minute walk distance m,C0439232;C0429886;C0700321;C0702093;C1282918;C2347166
weekly size of largest hives score,C0456389;C0042109
use of medications for pah no,C1524063;C0030123;C3203102;C4284467
overall dlqi score,C0282416;C3897059;C1561607
endothelin receptor antagonists,C1134681;C2266875
angioedema present n,C0002994;C0150312;C0449450
phosphodiesterase type $nmbr$ inhibitors,C0031638;C1656262;C3539996
primary key efficacy endpoint,C2986535
endothelin receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C1134681;C2266875
change from baseline to week $nmbr$ in weekly iss,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C1740819;C1845118
selexipag,C2000145
additional endpoints,C1524062;C2349179
no of patients no of events,C0030705;C0441471;C3541888
change from baseline to week $nmbr$ in uas $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
pah therapy at baseline,C0039798;C0087111;C1363945
change from baseline to week $nmbr$ in weekly no of hives score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0042109;C0449820;C4050231
era and pde $nmbr$ inhibitors,C1521863;C3495919;C0031638
median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f,C0040223;C3541383;C0871261;C1704632;C1706817;C2911692
era monotherapy,C1521863;C3495919
$nmbr$ $nmbr$ ne ne,C0027608;C0028219;C3538705
pde $nmbr$ inhibitor monotherapy,C0031638
hr vs placebo $nmbr$ ci,C0008107;C3259781
no pah therapy,C0039798;C0087111;C1363945
patients with weekly iss mid response n v,C0030705;C0332174;C0871261;C1704632;C1706817;C2911692
l ll,C0439394;C1706495;C3642217
change from baseline to week $nmbr$ in weekly size of largest hive score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0456389;C0042109;C0221232
age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
change from baseline to week $nmbr$ in dlqi scorez,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C3899393
ipah hpah hiv drug or toxin induced,C0013227;C1254351;C0040549;C0205263;C4522020
proportion of angioedema free days from week $nmbr$ to week $nmbr$ x,C1709707;C0002994;C0332174;C0439230
assoc with connective tissue disease,C0009782
lvef $nmbr$ n $nmbr$ $nmbr$ a,C0428772;C0488728
assoc with corrected congenital shunts,C0205202;C0009678;C1744681
prior angiography showing stenosis $nmbr$ n $nmbr$ $nmbr$ a,C0332152;C0002978;C2826257;C1547282;C0678234;C1261287;C2632116
western europe australia,C0043128
bnp $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
japan n $nmbr$,C0022341
tni ultrapositive $nmbr$ $nmbr$ g l n $nmbr$ $nmbr$,C0439294;C0456615
not japan n $nmbr$ $nmbr$,C1518422;C0022341
medications during hospitalization or at discharge,C0013227;C0802604;C2598133;C4284232;C0012621;C0030685;C2926602
overall n $nmbr$ $nmbr$,C0282416;C1561607
ranotazine vs placebo km failure rate,C0231174;C0680095
range min max,C1514721;C0702093;C1524029;C3813700;C2348147;C3542016
hr $nmbr$ s ci,C0008107;C3259781
screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C4684572;C0035245
primary ep cvd mi ri,C0035487;C1826843
screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$,
predicted pre bronchodilator fev $nmbr$,C2599602;C3714541
$nmbr$ $nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
absolute reversibility in fev $nmbr$ ml,C0205344;C0449261
no pci,C4049621
baseline fev $nmbr$ l,C0168634;C1442488
$nmbr$ $nmbr$ vi $nmbr$ $nmbr$,C0205999
predicted fev at baseline,C3714541;C0168634;C1442488
$nmbr$ $nmbr$ s,
ff vi $nmbr$ $nmbr$ pg od,C0229089;C0439164;C1512019;C3273373;C3665488
ranolazine vs placebo km failure rate,C0073633;C0231174;C0680095
ff $nmbr$ pgod,C4554348
hr $nmbr$ s a,
ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
rec ischemia requiring revasc,C0022116;C4321499;C0378365
difference vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
rec ischemia leading to hosp,C0022116;C4321499;C0332152;C1522538
difference vs ff $nmbr$ pg $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
rec ischemia,C0022116;C4321499
not japan,C1518422;C0022341
due to ecg changes,C0855329
white $nmbr$ $nmbr$,C0007457;C0043157;C0220938
due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
black african american $nmbr$ $nmbr$,C0085756
rec ischemia leading to hasp,C0022116;C4321499;C0332152;C1522538
asian $nmbr$ $nmbr$,C0078988
rec ischemia due to ecg changes,C0022116;C4321499
other $nmbr$ $nmbr$ t,C2603360
rec ischemia due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
pooled trials n $nmbr$,C1709595;C2349200;C4522255
de $nmbr$ mg bid n $nmbr$ $nmbr$,C0011198;C0017480;C3541240
wc cm,C0013123;C2825512
warfarin n $nmbr$ $nmbr$,C0043031
insulin pmol l t vital signs,C0150404;C0518766
gfr ckd epi,C1561643;C0162734;C4281721
pulse beats min cholesterol mmol l,C2827896
ckd stages,C1561643;C1306673
ffa mmol l,C0015688;C1532563
$nmbr$ $nmbr$ to $nmbr$ ml min,C0439445
prediabetes n,C0362046
history of stroke see tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
dyslipidaemia n,C0242339
hypertension requiring medical treatment,C0020538;C1963138;C0679624
dyslipidaemia and hypertension n,C0242339;C0020538;C1963138
previous vka use stratified randomization,C0042153;C4687737;C0457083;C1947944
individuals with normoglycaemia,C0027361;C0237401
naive,
individuals with prediabetes,C0027361;C0237401
experienced,
individuals with t $nmbr$ dm scale diabetes,C0027361;C0237401
duration of previous use of vka months,C1881378;C2826775
estimated treatment difference,C1705241;C1705242
q $nmbr$ q $nmbr$,
test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0034510;C1706779;C3853635
normal study termination,C1549081;C1692758
liraglutide $nmbr$ $nmbr$ mg ls means n,C0024671;C0023668;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concomitant medication $nmbr$,C0013227;C3244316;C4284232
placebo ls means n,C0032042;C0023668;C1696465;C1706408
p gp inhibitor,C3898062
etd [ $nmbr$ ci],C0008107;C3259781
vitamins,C0042890;C3540032;C3714649
number of individuals,C1549735
oral hypoglycemic,C0359086
current weekly alcohol use,C0332174;C0001948
alpha blocker other vasodilator,C0001641;C0042402;C3537240
age at completion of highest level of,C0001779;C4321237
previous vka use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$,
exercise times per week minimum,C0456698
adjusted mean se change from baseline,C0392747;C0443172;C1705241;C4319952
$nmbr$ min time,C0040223;C3541383
p value vs previous time point,C1709380;C0205156;C2348792;C1552607
ace arb medication,C0013227;C3244316;C4284232
calculated annual decline mean se,C0332181;C0036919
any blood pressure medications,C0849164
adjusted mean _ se change from baseline,C0392747;C0443172;C1705241;C4319952
lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
elderly patients n $nmbr$,C0870602
aspirin or thienopyridines,C0004057;C1120149;C2936588
very elderly patients n $nmbr$,C0442824;C0870602;C2984081
no of events women men,C0043210;C0025266
p between age groups,C0441849;C1959644
ratio of hrs $nmbr$ ci p for sex interaction,C0456603;C1547037;C0009253;C1704675;C0036864;C0079399;C0804628;C1314687;C1522384
olmesartan along with ccb n $nmbr$,C1098320;C0006684
primary outcomes,C0205225;C1274040;C0439612;C0439631
olmesartan along with diuretic n $nmbr$,C1098320;C0012798
major cardiovascular,C0007226;C3887460
grade of hypertension,C0441800;C0919553;C3244287
all cardiovascular,C0007226;C3887460
grade $nmbr$,C0441800;C0919553;C3244287
major coronary,C0205082;C0018787;C0205164;C4318856;C4521762
previous history of cardiovascular events,C2004062
major cerebrovascular,C0205082;C0205164;C4318856;C4521762;C1880018
drinking,C0001948;C0684271
all cancer,C0006826;C0998265;C1306459
number of visits median,C1549755;C0549183;C0876920;C2347635;C2348144;C2939193
no of events womenmen,C0441471;C3541888
number of visits mean sd,C1549755;C0444504;C2347634;C2348143
ratio of hrs $nmbr$ cl p for sex interaction,C0456603;C1547037;C0009253;C1704675;C0036864;C0079399;C0804628;C1314687;C1522384
treatment effects,C1518681
no previous diagnosis of diabetes mellitus,C0332132;C0011849
sbp during the follow up period mmhg,C0085805;C0589120;C1522577;C1704685;C3274571
previous diabetes mellitus,C0205156;C0011849;C1552607
dbp during the follow up period mmhg,C0536221;C3813197;C4281799
any hba $nmbr$ c,C0019016;C1825777;C3538758
uncover $nmbr$,
lcz $nmbr$ treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ixekizumab every $nmbr$ weeks n $nmbr$,C3489764;C0439230
hba $nmbr$ c median q $nmbr$ q $nmbr$,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
nx,C0445085
hf duration y n,C0018488;C0449238;C2926735;C1313497;C1538440;C3273279
bmi kg per m $nmbr$,C0022718;C0439209;C4054209
jugular venous distension n,C0425687
psoriasis duration years,C0033860;C0439234
edema n,C0013604;C1717255
percentage of bsa involved,C0439165;C1549488;C1561533;C1314939
rales n,C0034642;C0240859
spga $nmbr$,
ckd egfr,C1739039;C3811844;C3812682
pasi,C4528685
icd crt d n,C0021122
qids sr $nmbr$,C4331197
crt p d n,C0369718;C0441922
napsit,
ischemic cause,C0015127;C1524003
itch nrs,C2240043;C4050142
previous af,C0344434;C4049859
previous therapy,C0039798;C0087111;C1363945
mra,C0243032;C1609165;C3891069
topical prescription,C0033080;C1521941
antiplatelets any,
topical non prescription,C0332237;C1518422;C0033080;C1521941
hypoglycemic agent,C0020616
phototherapy,C0031765
normoglycemia,
non biological systemic,C0445097;C0205373
pre diabetes mellitus,C0362046
biological,C0005532;C0205460
undiagnosed diabetes mellitus,C1408353;C0011849
qva $nmbr$ $nmbr$ $nmbr$ ig od n $nmbr$,C0021027;C0229089;C0439164;C1512019;C3273373;C3665488;C0305052;C0360506
p values for interaction,C1709380;C1704675
sfc $nmbr$ $nmbr$ ig bid n $nmbr$,C0021027;C0305052;C0360506
hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279;C0011065;C1306577;C4082313;C4552775
copd severity n a,C0024117;C0439793;C0522510;C1412502;C3714496
significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0026544;C0332177
gold $nmbr$ groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
normal hba $nmbr$ c n $nmbr$,C0205307;C0019016;C1825777;C3538758;C0231683;C0439166;C2347086;C4553972
gold b,C0018026;C1304897
pre diabetes mellitus n $nmbr$,C0011849;C0362046
gold d,C0018026;C1304897
undiagnosed diabetes mellitus n $nmbr$,C1408353;C0011849
patients with prior copd related,C0030705;C0332152;C2826257;C0024117;C0439849;C0445223;C1412502;C3714496
diabetes mellitus n $nmbr$,C0011849
ics users at baseline n,C1706077;C0168634;C1442488
p values of interaction,C1709380;C1704675
postbronchodilator fev $nmbr$ reversibility,C2599594;C0449261
hypotension n,C0020649;C3163620
postbronchodilator fev $nmbr$ fvc,C2599594;C3714541
symptomatic hypotension,C0020649;C3163620
cat score,C0449820;C4050231
symptomatic hypotension with sbp,C0020649;C3163620
cat score category,C0683312;C3889287
leading to study drug discontinuation,C0332152;C0013175;C1522538
$nmbr$ $nmbr$ mild,C2945599
serum creatinine $nmbr$ $nmbr$ mg dl,C0201976;C0439269;C0600061
$nmbr$ $nmbr$ moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
hyperkalemia n,C0020461;C4552983
$nmbr$ $nmbr$ severe,C0205082;C4050465;C4050466
serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
$nmbr$ $nmbr$ very severe,C3641272;C4050419
cough n,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
bdi focal score,C0449820;C4050231
any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
sgrq total score,C2964552
angioedema adjudicated n,C0002994
mmrc grade,C0441800;C0919553;C3244287
no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0019590
smoking history current smoker,C3173209;C3241966
catecholamines or corticosteroids without hospitalization,C0007412;C0001617;C3539185;C3540725;C3540726;C3540727
smoking history ex smoker,C1519384;C0337664
hospitalized without airway compromise,C0701159;C4055482
copd severity mild moderate,C0439793;C0522510;C1299392
airway compromise,C4055482
copd severity severe very severe,C0024117;C0205082;C4050465;C4050466;C1412502;C3714496
any adverse event leading to study drug discontinuation n,C0877248;C0332152;C0013175;C1522538
baseline ics use yes,C1549445;C1705108;C1710701
female subgroup,C1079230;C1515021
baseline ics use no,C0042153;C0457083;C1947944
body mass kg,C0022718;C0439209;C4054209
copd exacerbation yes,C1549445;C1705108;C1710701
type of mi,C0332307;C1547052
copd exacerbation no,C0740304
symptom onset to hospital arrival hours,C4086878;C0019994;C1510665
diabetics n $nmbr$,C0241863
killip class ii,C2697845
non diabetics n $nmbr$,C1518422;C0241863
crusade bleeding score,C0449820;C4050231
patients with dm n $nmbr$,C0030705;C0011816;C3250443
$nmbr$ $nmbr$ _ $nmbr$,
patients without dm n $nmbr$,C0030705;C0011816;C3250443
nace primary endpoint,C2986535
patients with dm vs patients without dm,C0030705;C0011816;C3250443
cardiac death,C0376297
age\\yr,C0001779;C0439234
reinfarction,
b $nmbr$ $nmbr$,
ischemic tvr,C0475224
year,C0439234;C0439508
all bleeding,C0019080
male sex \ no,C0086582
barc $nmbr$ $nmbr$,
body mass index \ kg m $nmbr$,C0022718;C0439209;C4054209
thrombocytopenia,C0040034;C0392386
ischemic stroke incl uncertain,C0948008;C0087130;C4085655
definite,C0439544;C1704787
hba $nmbr$ c \n,C0019016;C1825777;C3538758
probable,C0033204;C0332148
\mean sd,C0444504;C2699239;C2347634;C2348143
acute,C0205178
af type no,C0332307;C1547052
subacute $nmbr$ $nmbr$ days,C0205365;C0439228
median crcl ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
p value cangrelor versus clopidogrel in women,C1709380;C1121991;C0070166;C0043210
peripheral arterial disease no,C0085096;C1704436
p value cangrelor versus clopidogrel in men,C1709380;C1121991;C0070166;C0025266
baseline chads $nmbr$ a c,C0168634;C1442488
p value men versus women,C1709380;C0025266;C0043210
baseline cha $nmbr$ ds $nmbr$ vascb c,C0168634;C1420648;C1442488
age y median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
patients without dm n $nmbr$ $nmbr$,C0030705;C0011816;C3250443
dx at presentation n,C3538936;C0449450
ustekinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nsteacs,
psoriasis,C0033860
cardiac biomarker n,C1271630
patients with psoriasis $nmbr$ of body surface area,C0030705;C0005902
previous heart failure,C0018801;C0018802;C4554158
pasi score,C0449820;C4050231
baseline hemoglobin median iqr g dl,C0439267
dlqi score,C3897059
baseline hematocrit median iqr,C0168634;C0018935;C0518014;C1442488
swollen joint count,C0451521
periprocedural medications n clopidogrel $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tender joint count,C0451530
clopidogrel $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
haq di score,C0449820;C4050231
duration of pci min median n iqr,C0449238;C2926735
dactylitis in $nmbr$ digit,C0239161;C0582802;C3241971
poba n,
dactylitis score,C0449820;C4050231
access site,C0589360
enthesitis score,C0449820;C4050231
p interaction rx arm sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
dose mg week,C0332174;C0439230
cangrelor n $nmbr$ n n,C1121991
mean dose sd mg week,C0332174;C0439230
clopidogrel n $nmbr$ n n,C0070166
dose mg day,C0178602;C0439422;C0869039;C1114758
unadjusted or $nmbr$ ci p value,C1439367;C0008107;C1709380;C3259781
mean dose sd mg day,C0178602;C0439422;C0869039;C1114758
adjusted or $nmbr$ ci p value,C0456081;C0008107;C1709380;C3259781
non steroidal anti inflammatory drugs,C0003211
q wave mi,C0861151
placebo to ustekinumab $nmbr$ mgt,C0032042;C1696465;C1706408
death or stent thrombosis,C0011065;C1306577;C4082313;C4552775;C3897493
ustekinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
death q wave mi or ischemia driven revasc,C0011065;C0861151;C1306577;C4082313;C4552775;C0022116;C0378365;C4321499
ustekinumab combined,C1608841;C0205195
primary gusto severe bleeding,C0205082;C0019080;C4050465;C4050466
patients randomized no,C0030705;C0034656;C3815594
primary gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
gusto severe or life threatening,C0205082;C4050465;C4050466;C1546953;C2826244;C3537125
patients no,C0030705
gusto moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
acr response by baseline weight,C0871261;C1704632;C1706817;C2911692
timi major,C0205082;C0205164;C4318856;C4521762
no total no,C0439175;C0439810
timi major or minor,C0205082;C0205164;C4318856;C4521762;C0026193;C0205165
acr response by baseline mtx use no total no acr $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C1412134;C1515941
any blood transfusion,C0005841;C0281867
good moderate response,C0205170;C4085643
acuity major,C0205082;C0205164;C4318856;C4521762
change from baseline median iqr,C0392747;C0443172;C1705241;C4319952
acuity minor,C0026193;C0205165
patients with improvement $nmbr$ $nmbr$,C0030705;C2986411
acuity major or minor,C0205082;C0205164;C4318856;C4521762;C0026193;C0205165
patients with $nmbr$ bsa at baseline no,C0030705;C0168634;C1442488
renal parameters,C0022646;C0449381
pasi $nmbr$ at week $nmbr$,C4528685;C0332174;C0439230
egfr ml min $nmbr$ $nmbr$ mz,C0026655;C1705291
no total no t,C0439175;C0439810;C2603360
u c mg g,C1532633;C2608091
pasi $nmbr$ no total no $nmbr$,C4528685;C0439175;C0439810
haemoglobin mmol l,C0635222
pasi response by baseline weight no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
calcium mmol l,C0006675;C1532563;C0006726;C2936886;C3540037;C3714611
pasi response by baseline mtx use no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
phosphate mmol l,C0031603;C1532563;C0031701;C1601799
$nmbr$ $nmbr$ $nmbr$ $nmbr$ continued,C0549178
other risk factors,C0035648;C1553898
patients with dactylitis at baseline no,C0030705;C0239161;C0168634;C1442488
hba]c mmol mol,C0019016;C1825777;C3538758;C3829066
dactylitis score at baseline median iqr week $nmbr$,C0449820;C4050231
concomitant drug treatment,C0150270;C3469597
score improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
event rate,C0871208;C1521828
percent improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
cardiovascular subgroup,C1079230;C1515021
patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C0239161;C0332174;C1282952;C0439230
renal subgroup,C1079230;C1515021
patients with enthesitis at baseline no,C0030705;C1282952;C0168634;C1442488
albuminuria,C0001925
enthesitis score at baseline median iqr week $nmbr$,C0449820;C4050231
normoalbuminuria or microalbuminuria,C0730345
patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score,C0030705;C1282952;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
egfr and albuminuria,C1739039;C3811844;C3812682;C0001925
mean $nmbr$ sd,C0444504;C2699239;C2347634;C2348143
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ and normoalbuminuria or microalbuminuria,C1739039;C0439445;C3811844;C3812682;C0730345
median iqr change from baseline to week $nmbr$ in psa modified total shs score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ and macroalbuminuria,C1739039;C0439445;C3811844;C3812682
median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight,C0444504;C0168634;C1442488;C2347634;C2348143;C0332174;C0439230;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0005910;C0043100;C1305866;C1705104
number of e,C0237753;C0449788
$nmbr$ kg mtx use,C0042153;C0457083;C1947944
vents patients,C0030705
p for heterogeneity,C0369773;C2603361
patients with change from baseline in psa modified total shs score $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
sulfonylurea derivatives,C0038766
low risk n $nmbr$ $nmbr$,C3272281;C3538919
$nmbr$ $nmbr$ mm,C4330985;C4554674
high risk n $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
time since diagnosis of copd years,C0556970;C0011900;C1704338;C1704656
$nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
spirometry,C0037981
baseline ^ste mm,C4330985;C4554674
respiratory medication taken at baseline n,C0418986;C1883727;C0168634;C1442488
baseline ste in worst lead mm,C1420459;C3811127
other steroids,C0038317
baseline std mm,C4330985;C4554674
ics laba free or fdc,C0332296;C1880497;C1996904;C0340427;C1413520;C3539652
q wave in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
patient classification,C0008902;C0008903;C0678229
salmeterol,C0073992
time from sx onset to baseline ecg min,C1519428;C0449244;C3539997;C3815196;C0702093;C1524029;C3813700
tiotropium vs salmeterol,C0213771;C0073992
cana $nmbr$ met n $nmbr$,C1418845;C0428210;C1550543;C4317104
cana $nmbr$ n $nmbr$,C1418845
number of patients with events,C2360800;C0441471;C3541888
low risk,C3272281;C3538919
race n t,C0034510;C1706779;C3853635
infrequent exacerbator,C0521114
$nmbr$ $nmbr$ $nmbr$ mmol mol,C3829066
frequent exacerbator,C0332183
figure $nmbr$ effects on ef cacy parameters,C1280500;C0449381
low risk ics,C0815320;C4551720
c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C1079230;C3829066;C0332174;C0439230
high risk ics,C0815320;C4551720
apremilast,C1678805
olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
$nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
duration mean sd years,C0444504;C0439234;C2347634;C2348143
tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
prior use of conventional dmards only biologic nai ve n,C1524063;C0242708;C0005515;C3537218;C0205460;C0369718;C0441922
gold $nmbr$ $nmbr$,C0018026;C1304897
prior use of biologics n,C1524063;C0005515;C0005522;C4553887
current smoker n post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
prior biologic therapeutic failures n,C0005515;C0087111;C0302350;C0205460
mean sd fevi ml,C0439526;C1705224;C3887665
baseline dmard use n,C0168634;C0042153;C0457083;C1947944;C1442488
mean sd change from pre to post bronchodilator fevi ml,C2599594;C3481639
mtx mean dose $nmbr$ $nmbr$ mg wk,C0366550;C1881833
mean sd fevi fvc,C0802741;C3815113
leflunomide mean dose $nmbr$ $nmbr$ mg day,C0063041;C0439422
mean sd of predicted normal fevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
sulfasalazine mean dose $nmbr$ $nmbr$ g day,C0036078;C0439417
gold $nmbr$ $nmbr$ n $nmbr$,C0018026;C1304897
baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n,C0168634;C0439422;C1442488
olodaterol sgg,C2934193
sjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
tiotropium olodaterol $nmbr$ $nmbr$,C4032878
tjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
mean sd change from pre to post bronchodilator fevi nil,C2599594;C3481639
haq di $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
gold $nmbr$ $nmbr$ $nmbr$,C0018026;C1304897
crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd,C0086715;C2699239
mean sd eevi ml,C0439526;C1705224;C3887665
patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0030705;C0281858;C1292728
mean sd fevi evc,C0013903;C0429711;C1414479
physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0031831;C0804815;C0281858;C1292728
mean sd of predicted normal eevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
das $nmbr$ crp mean sd,C0051767;C2699239;C0057671
adjusted mean se fevi auco_ $nmbr$ ml,C0439526;C1705224;C3887665
bsa $nmbr$ n t,
adjusted mean se trough fevi ml,C0439526;C1705224;C3887665
pasi score $nmbr$ $nmbr$ t mean sd,C0444504;C2699239;C2347634;C2348143
global initiative for chronic obstructive lung disease $nmbr$,C0849867;C0424093
presence of enthesitis n,C0150312;C0392148;C3854307
versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C4032878;C0030827;C0072225;C1266240
mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
global initiative for chronic obstructive lung disease $nmbr$ $nmbr$,C0849867;C0424093
presence of dactylitis n,C0150312;C0392148;C3854307
median interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
dactylitis count $nmbr$ $nmbr$ mean sd,C0239161;C2699239
saudi arabia,C0036243
week $nmbr$ itt population,C0032659;C1257890
time from pah diagnosis months,C0011900;C0556969;C1704338;C1704656
apremilast $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aetiology of pah,C0015127;C1314792;C1524003
concomitant conventional dmard use,C0042153;C0457083;C1947944
familial,C0015576;C0241888
prior biologic exposure,C0274281;C0332157
repaired congenital shunts,C0232180;C0542331;C1442858
biologic naive,C0005515;C0205460
drugs and toxins,C0013227;C3687832;C0040549
prior biologic use,C0042153;C0457083;C1947944
$nmbr$ min walk distance m,C0702093;C0429886;C1524029;C3813700
biologic therapeutic failure,C0231174;C0680095
who functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
trial,C0008976
nt probnp $nmbr$ pmol l $nmbr$,C0669479;C0439284;C0754710
trial $nmbr$,C0008976
baseline sildenafil dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
scale obesity and prediabetes,C0028754;C1963185;C0362046
$nmbr$ $nmbr$ $nmbr$ y,
scale diabetes,C0011847;C0011849
body weight mean sd kg,C0022718;C0439209;C4054209
phase $nmbr$ dose finding trial,C0037088;C0008976;C0243095;C2825141
egfr mean sd ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
biometric parameters,C0449381
hdl cy,C0010622;C0332298;C2239193
[sd],C2699239
baseline mean _ sd mg dl,C0168634;C0439269;C1442488
glycaemic parameters,C0449381
ls mean change from baseline _ se,C0392747;C0443172;C1705241;C4319952
mean hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
ldl cz,C0206578
mean hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
ldl c hdl cx,C3715113
individuals with pre diabetes n,C0027361;C0237401
baseline mean _ sd mg mg,C0168634;C1319635;C1442488
individuals with type $nmbr$ diabetes n,C0027361;C0237401
liraglutide n $nmbr$,C1456408
normoglycaemic individuals n,C0580545;C0027361;C0237401
hispanic or latino ethnic groupf,C0086409;C0086528;C0015031;C0680174
figure $nmbr$ liraglutide exposure and body weight loss in men and women,C0274281;C0332157;C2911645;C0025266;C0043210
body mass index categories no c,C0005893;C0683312;C0578022;C1305855
$nmbr$ $nmbr$ $nmbr$ overweight,C0497406
liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0005911;C0025266;C0043210;C0042295;C1180280;C0444504;C2347634;C2348143;C0205120;C0205119;C1552595;C1882932;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602;C0205132;C0750572;C0032659;C1257890;C0205452;C0032042;C1696465;C1706408;C1456408;C0023693;C1306462;C1570446;C1881376;C3842678;C4050248;C4521367;C0028754;C1963185;C0008976;C0011847;C0011849;C0282460
$nmbr$ $nmbr$ $nmbr$ obese class i,C3853264
figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c,C0274281;C0332157;C0019020;C3889898
$nmbr$ $nmbr$ $nmbr$ obese class ii,C3853263
$nmbr$ obese class iii,C1319441
exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0392747;C0443172;C1705241;C4319952;C0027361;C0237401;C0497406;C0028754;C1963185;C1320657;C0205363;C0008976;C0444504;C0042295;C2347634;C2348143;C0205423;C0032042;C0205132;C1696465;C1706408;C1882932;C0750572;C0057717;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602
demographic feature,C0683970
fasting insulin tiu ml,C0015663;C0439526;C1705224;C3887665
black race no total no f,C0005680;C0439175;C0439810;C0016327
free fatty acids mmol liter,C0015688;C0475211
prediabetes no $nmbr$,C0362046
hispanic ethnic group no total no j,C0015031;C1879937;C0439175;C0439810
estimated means and difference,C0750572;C1704970;C1705241;C1705242
stroke no total no,C0038454;C4554100;C0439175;C0439810
mean baseline bmi,C0168634;C0578022;C1442488
at entry,C1705654
liraglutide $nmbr$ $nmbr$ mg mean n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
placebo mean n,C0032042;C0444504;C2347634;C2348143;C1696465;C1706408
atrial fibrillation no total no,C0004238;C0344434;C1963067;C0439175;C0439810
pooled analysis,C0002778;C0936012;C1524024
physical and cognitive examination,C0031809;C0205485;C1509143;C1516691;C4321457
bmi $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0578022
score on modified mini mental state examination median iqr,C4304091;C0549183;C0876920;C2347635;C2348144;C2939193
estimated response rate and odds ratio,C0750572;C0237629;C0028873
score on nih stroke scale median iqr,C4049715
estimated odds ratio,C0750572;C0028873
score on modified rankin scale median iqr,C4049715
number of previous anti tnf treatments for psoriatic arthritis,C0237753;C0449788;C0087111;C0003872
median fasting insulin iqr pu per milliliter,C0549183;C0876920;C2347635;C2348144;C2939193;C0015663;C0021641;C0018387;C1533581;C1579433;C3714501
methotrexate use at randomisation,C0042153;C0457083;C1947944
homa ir index median iqr,C0022065;C0022071;C1448132
systemic glucocorticoid use at randomisation,C0042153;C0457083;C1947944
fasting cholesterol mg dl,C0015663;C0008377;C0439269
patients with specific disease characteristics,C0683521;C0815172
statin no total no,C0360714;C0439175;C0439810
psoriasis body surface area $nmbr$,C0033860;C0005902
antiplatelet no total no,C0439175;C0439810
dactylitis count,C0750480;C1705566
oral anticoagulant no total no,C0354604;C0439175;C0439810
enthesitis count,C0750480;C1705566
ace inhibitor or angiotensin receptor blocker no total no,C0003015;C4541021;C0034787;C1622222;C0439175;C0439810
baseline disease and quality of life scores,C0168634;C0012634;C1442488;C3476431
diuretic no total no,C0012798;C0439175;C0439810
physician s global assessment vas,C0031831;C0804815;C0042815;C3536884;C3827561
beta blocker no total no,C0001645;C0439175;C0439810
pain vas,C0042815
interval after index event,C1272706;C1552654;C1552713
patient s global assessment vas,C0030705;C0042815;C3536884;C3827561
no of days to homa ir testing median iqr,C0439228;C0022065;C0022071;C1448132
odds ratio versus placebo $nmbr$ ci,C0028873;C0008107;C3259781
no of days to randomization median iqr,C0439228;C0034656;C0549183;C0876920;C2347635;C2348144;C2939193
p value versus placebo,C1709380;C0032042;C1696465;C1706408
homa ir index,C0600653;C0918012;C1552854;C1637833;C2986546
anti tnf naive patients,C1448177;C0030705
medication adherence,C2364172
acr $nmbr$ response,C0871261;C1704632;C1706817;C2911692
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
pasi $nmbr$ response,C0871261;C1704632;C1706817;C2911692
mean lvef,C0428772;C0488728
anti tnf ir patients,C0022065;C0030705;C0022071;C1448132
prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
czp mtx n $nmbr$,C0054841;C0025677;C1417487;C1861828;C1872109
ischemic cardiomyopathy,C0349782
pbo mtx n $nmbr$,C0031962;C0025677;C1417487
history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ra duration months,C0449238;C0439231;C2926735
icd or crt d,C0021122
$nmbr$ $nmbr$ months n,C0439231
hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
previous dmards use n,C0205156;C0042153;C0457083;C1947944;C1552607
breakfastb,
steroid use at baseline n,C0281991;C0168634;C1442488
lunchb,
high titre $nmbr$ times of uln n,C0040223;C1632851
evening mealb,C0587117
titre u ml t,C0439340;C1880521;C2945590
lm $nmbr$ bid n $nmbr$,C1261082;C1551056
rf positive n,C0035448;C0201660;C0748398;C1547111
igl n $nmbr$,C0021037;C0314619;C2247518
bone erosion judged by physician n,C0587240;C0221191;C0031831;C0804815
glycemic variability mmol lc,C2827666;C0439190
ptgada mm,C4330985;C4554674
insulin glargine dose at screening visit iu,C0366513
phgada mm,C4330985;C4554674
esr mm h,C3811131;C0456680
figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1550335;C0332293;C0982221;C0907402;C0332173;C0293359;C0021037;C0314619;C2247518;C0439745;C4319846;C1998602;C0020456;C0521095;C0205449;C0005803;C1979963;C2003903;C0237881;C0750502;C1546944
mmp $nmbr$ ng ml,C0623362;C0439275;C0919336
data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values,C1511726;C3245479;C3714741;C0449450;C1706992;C0683607;C0444504;C0039725;C1532337;C0039738;C1420718;C4282123;C4285344
sdai,C3871128
table $nmbr$ characteristics of the patients at baseline,C0039224;C0815172;C1706074;C0168634;C1442488
mtss,
fluticasone salmeterol n $nmbr$,C0939232
average weekly mtx dose mg week,C0332174;C0439230
fluticasone alone n $nmbr$,C0082607;C0205171;C0439044;C0679994
parameter at baseline,C0549193;C1704769;C2350001
patients with diabetes mellitus n $nmbr$,C0030705;C0011849
czp mtx,C0025677;C1417487
patients without diabetes mellitus n $nmbr$,C0030705;C0011849
pbo mtx,C0025677;C1417487
patients with diabetes mellitus,C0030705;C0011849
mtss cfb mean sd,C0009002;C2699239;C1824728
continued thienopyridine n $nmbr$,C0549178;C1120149
anti ccp antibody u ml,C0439340;C1880521;C2945590
hispanic or latino ethnic group,C0086409;C0015031;C1879937
rf iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
oral medications,C0304289
concomitant mtx average dose mg week,C0332174;C0439230
without insulin or insulin modifying therapy,C0021641;C1533581;C1579433;C3714501;C0392747;C0039798;C0087111;C1363945
creatinine clearance category ml min no b,C0812399;C0439445
lesion s,C0221198;C1546698
medical conditions no,C0012634;C0348080;C1705253;C3864998
modified acc aha lesion class b $nmbr$ or c,C4072694;C0221198;C1546698
previous cancerc,C0205156;C1552607
figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding,C0475224;C0085415;C1518681;C0749659;C0439231;C0030705;C1274040;C3897493;C0441471;C3541888;C0205082;C4050465;C4050466;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
previousdistaldeep veinthrombosisorsuperficial vein thrombosis,C0042487
reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$,C1869620;C0439272
method used to diagnose the incident pulmonary embolism no,C0025663;C0449851;C0871511;C1273517;C0011900;C1551358;C0034065
bmi mean kg m $nmbr$,C0022718;C0439209;C4054209
high probability ventilation perfusion lung scanning,C0560738
years since diagnosis mean,C0439234;C0011900;C1704338;C1704656
spiralcomputedtomographyangiography,
ics use at enrollment mean mg d,C0042153;C0457083;C1947944
associatedproximaldeep veinthrombosisatdiagnosis no,
exacerbation within previous $nmbr$ mo no,C4086268;C0026544;C0332177
characteristics of pulmonary embolism at inclusion,C1521970;C0034065;C0007637;C1512693
acq score mean,C0444504;C2347634;C2348143
residual perfusion defect $nmbr$ on lung scan no,C0031001;C1457869;C4281794;C0203683
airway reversibility,C0178987;C0449261;C0458827
residual deep vein thrombosis no,C1609982;C0149871
fev $nmbr$ mean l,C0444504;C2347634;C2348143
systolic pulmonary arterial pressure mean sd mm hg,C0871470;C0439475
rescue medication use mean inhalations previous $nmbr$ d,C0004048;C0354922;C0205156;C1552607
d dimer level mean sd ng mld,C0023522;C1539265;C3539688;C3539689
blood eosinophils mean range cells ml,C2699156
thrombophilia no e,C0398623
treated with laba,C0332293
minor,C0026193;C0205165
major,C0205082;C0205164;C4318856;C4521762
baricitinib $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatmentofpulmonary embolismpriorto randomization,C0034656
positive for anti cyclic citrullinated peptide antibody no f,C0741132;C1320283;C0016327
warfarin no,C0043031
positive for rheumatoid factor no t,C0439178;C1446409;C1514241;C2825490;C3812269;C2603360
fluindione no,C0117899
no of previous biologic dmards no,C0205156;C4055380;C1552607
acecoumarol no,
tnf inhibitors,C1448177;C0243077
duration of initial anticoagulation mean sd mo,C0449238;C2926735
non tnf inhibitors,C1448177;C0243077
percentage of time in therapeutic inr range mean sd,C0439165;C1549488;C1561533;C0460097;C2699239
swollen joint count of $nmbr$ joints examined,C0451521;C0332128
use of compression stockings no,C1524063;C0038348
tender joint count of $nmbr$ joints examined,C0451530;C0332128
main concomitant treatments no,C0205225;C0087111;C1542147
scores for global and pain assessments,C0449820;C0205246;C2348867;C0030198
accp bleeding risk at inclusion no f,C3251812;C0007637;C1512693;C0016327
physician s global assessment,C0031831;C0804815;C0281858
low no risk factor,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0035648
patient s global assessment,C0030705;C0281858
moderate $nmbr$ risk factor,C0205081;C0035648;C1881878;C4049705;C4049706;C4085643;C4321335
patient s assessment of pain,C0030705;C0030198
high $nmbr$ risk factor,C0035648
haq di scored,C3826998;C4321476;C0449820
p for i,C0369773;C2603361
high sensitivity crp mg liter,C1441604;C0475211
previous cancer,C0006826;C0998265;C1306459
esr mm hr,C3811131;C4330985;C4554674
pe associated with dvt at diagnosis,C0070939;C1880476;C4284304;C0332281;C0149871;C2926618;C3899446;C0011900;C1704338;C1704656
simplified disease activity index score,C4706353
time in therapeutic range before inclusion,C1554109;C0007637;C1512693
baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
perfusion defectsatinclusion,C0031001;C4281794
of prior bdmards,C0332152;C2826257
right ventriculardysfunction atinclusion,C0205090;C0444532
of prior tnfi among non tnfi naive,C0332152;C1518422;C2826257
d dimer levelsatinclusion,C0060323
of prior non tnfi bdmards,C0332152;C1518422;C2826257
$nmbr$ microg l,
characteristica,
accp score,C0449820;C4050231
ukpds $nmbr$ year risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
compression stockings,C0038348
ukpds $nmbr$ year risk score,C0035647;C0449820;C4050231;C4552904
liraglutide $nmbr$ $nmbr$ mg day n $nmbr$,C1456408;C0439422
saxagliptin $nmbr$ $nmbr$ mg n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean s d duration of diabetes years,C0449238;C2926735
saxagliptin $nmbr$ mg n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
women men,C0043210;C0025266
t $nmbr$ dm duration y,C0011816;C0449238;C2926735;C3250443
mean s d weight kg,C0022718;C0439209;C4054209
baseline fpg,C0168634;C1442488
mean s d bmi kg m $nmbr$,C0022718;C0439209;C4054209
baseline $nmbr$ h ppg,C0033727;C1418888;C0369286;C0441932;C0564385;C4528284
mean s d hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
mean s d fpg,C0444504;C2347634;C2348143
mmol l [n],C1532563;C0369718;C0441922
metformin no yes,C0025598;C1549445;C1705108;C1710701
saxagliptin $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
basal insulin analogue insulin,C0650607;C2825028
saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
detemir insulin glargine,C0537270;C0907402
baseline mean se,C0168634;C0036919;C1442488
basal insulin analogue dose coefficient,C0366513;C1707429
week $nmbr$ mean se,C0332174;C0036919;C0439230
of variation iu,C0049272;C0439453;C0694756
adjusted mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
liraglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment by subgroup interaction p $nmbr$ $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
r,C0205090;C0684010;C2603358
ppg mmol l,C1418888;C1532563
baseline hba $nmbr$ c $nmbr$ $nmbr$,C0168634;C0019016;C1825777;C3538758;C1442488
adjusted mean change,C0392747;C0443172;C1705241;C4319952
east asian,C1707877;C0078988
from baseline $nmbr$ ci,C0008107;C3259781
non east asian,C1518422;C0078988
white race no y left ventricular ejection fraction,C0007457;C0043157;C0428772;C0488728
p value for east asian versus non east asian,C1709380;C0078988;C1518422
nyha functional classification no i,C1275491;C0205245;C0542341;C2700217;C0021966;C0221138
age years mean _ sd,C1510829;C2699239
hospitalization in previous year with management of heart failure,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539
weight of $nmbr$ kg n,C0005910;C0043100;C1305866;C1705104
as major component no,C0449432;C1705248
crcl of $nmbr$ $nmbr$ ml min n,C1846718;C0439445
qrs $nmbr$ ms $nmbr$ cl n $nmbr$,C2349943;C0596019;C3539704;C3713294
patients meeting the criteria to receive $nmbr$ mg of,C0030705;C0556656;C0243161;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hr $nmbr$ cl pvalue,C0596019
edoxaban at randomization n,C2975435;C0034656
adjusted hr $nmbr$ cl pvalue,C0456081;C0596019
anatomic extent of qualifying event n x,C0220784;C0439792;C1514624;C0441471;C4019010
$nmbr$ events,C0441471;C3541888
concomitant dvt n,C0521115;C0149871;C2926618;C3899446
$nmbr$ $nmbr$ per $nmbr$ py,C0030428;C3538810
right ventricular dysfunction n n j,C0242707;C1556315
$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C3541888;C0030428;C3538810
causes of dvt or pe n,C0015127;C1314792;C0070939;C1880476;C4284304
$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C4019010;C0030428;C3538810
non east asianf,C1518422;C1707877
heart failure hospitalizations,C3898876
edoxaban n $nmbr$ n n,C2975435
persistent faol n [ $nmbr$,C0205322;C0332996
warfarin n $nmbr$ n n,C0043031
persistent faod n [ $nmbr$,C0205322;C0332996
hr with edoxaban $nmbr$ ci,C2975435;C0008107;C3259781
inconsistent fao n [ $nmbr$,C0442809;C0016457
event during overall,C0441471;C4019010
total n [ $nmbr$,C0439175;C0439810
study period fatal pe,C0070939;C1880476;C4284304
duration of asthma y,C0449238;C2926735
death with pe not,C0011065;C1306577;C4082313;C4552775;C1518422
predose fev $nmbr$ l,C0439565;C3714541;C3812758
ruled out non fatal pe with or,C1446409;C0070939;C1880476;C4284304
fevj predicted t,C0681842;C1882327
without dvt dvt alone,C0149871;C2926618;C3899446;C0205171;C0439044;C0679994
fvc predicted t,C0681842;C1882327
event during on,C0441471;C4019010
baseline ics dose n,C0168634;C0178602;C0869039;C1114758;C1442488
treatment period index dvt event,C0441471;C4019010
moderatex,
highjj,
during overall study period,C0439531;C1948053
rescue medication use inh d,C0240320;C0022209
index pe event during,C0441471;C4019010
asthma control days,C0004096;C0439228;C2984299
overall study period,C0439531;C1948053
gaviscon da n $nmbr$,C0061146;C0011318;C3668815
figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status,C0439565;C2986411;C3812758;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0016457;C0449438
bmi kg m $nmbr$ median range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol,C0168634;C1442488;C1704788;C3539106;C0444706;C3541902;C0220908;C1522609;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C1551351;C0205436;C0060657;C0457385;C0565930;C1561503;C1705190
erd n,
losmapimod n $nmbr$,C3272847
la grade a n f,C0441800;C0919553;C3244287;C0369718;C0016327;C0441922
body mass index median iqr b,C0005893;C0578022;C1305855
la grade b n f,C1881342;C0016327
baseline egfr,C1739039;C3811844;C3812682
fdc $nmbr$ $nmbr$ g n $nmbr$,C0340427;C0439267;C1413520;C3539652
prior coronary artery bypass graft surgery,C0010055
aclidinium $nmbr$ g n $nmbr$,C2699757;C0439267
prior peripheralarterialdisease,C0332152;C2826257
formoterol $nmbr$ g n $nmbr$,C0060657;C0439267
prior ischemic stroke,C0332152;C0948008;C2826257
number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C0205156;C0439231;C1552607
baseline laboratory values median iqr d,C0022877;C0042295;C3244292;C4283904
prior copd medicationa n,C0332152;C0024117;C1412502;C3714496;C2826257
high sensitivityc reactive protein mg l,C0033684;C0439268
any copd medication,C0013227;C3244316;C4284232
n terminal pro brain natriuretic peptide pg ml,C3272900;C0439297
e rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
index events,C0441471;C3541888
overall night time copd symptom severity scorec,C0240526;C1319166
non st elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
overall early morning copd symptom severity scorec,C0024117;C1319166;C1412502;C3714496
gold group n,C0018026;C0441848;C1304897
st elevation myocardial infarction,C1536220;C3538872
gold group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
catheterization performed for qualifying event,C0007430;C0884358;C1514624;C0441471;C4019010
fdc $nmbr$ $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
pciperformed for qualifying event,C1514624;C0441471;C4019010
fibrinolytic for qualifying event,C0040044;C1514624;C0441471;C4019010
fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C1266240
time from study drug administration to coronary revascularization median iqr h,C0040227;C0206209;C2349982;C0033727;C0369286;C0441932;C0564385;C4528284
aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
useofmedical therapyathospitaldischarge,
formoterol $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
hcru a,
ace inhibitor or angiotensin receptor blocker,C0003015;C4541021;C0034787;C1622222
fdc $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
events no,C0441471;C3541888
rr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4554402
$nmbr$ wk kaplan meier rate,C0871208;C1521828
rro $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
losmapimod,C3272847
aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
qualifying diagnosis,C1514624;C0011900;C1704338;C1704656
formoterol $nmbr$ pg,C0030827;C0072225;C1266240
non st elevation mi,C0520886;C3810814
exact b,C2828393;C4050514
st elevation mi,C0520886;C3810814
outcome type,C0332307;C1547052
chronic kidney disease,C1561643;C4553188
outcome severity,C0439793;C0522510
prior pci or cabg surgery,C0332152;C4049621;C2826257;C0038894;C0038895;C0543467;C1274039
any severity,C0439793;C0522510
planned treatment strategy,C0599880;C0679199
moderate severity,C0439793;C0522510
invasive,C0205281;C1334278
baseline ics,C0815320;C4551720
conservative,
with concomitant ics,C0815320;C4551720
actual treatment strategy,C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
without concomitant ics,C0815320;C4551720
medical management only,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
rr $nmbr$ $nmbr$,C4554402
time from randomization to pci st elevation mi min,C0040223;C3541383;C0702093;C1524029;C3813700
mtx sio mg week,C0332174;C0439230
time from randomization to pci non st elevation mi h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
mtx $nmbr$ and si $nmbr$ mg week,C0025677;C1417487;C0332174;C0439230
no of predictors of cardiovascular risk,C0007226;C0035647;C4552904;C3887460
mtx $nmbr$ mg week,C0332174;C0439230
index mi n $nmbr$ $nmbr$,C0600653;C0918012;C1552854;C1637833;C2986546
czp $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
any mi n $nmbr$ $nmbr$,C3810814
czp $nmbr$ mg n lll,C0024671;C1261077;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no mi n $nmbr$ $nmbr$,C3810814
acr response acr $nmbr$,C1412134;C0871261;C1704632;C1706817;C2911692;C1515941
pvaluefor any mi versus no mi,C3810814
change from baseline in,C0392747;C0443172;C1705241;C4319952
race nonwhitet,C0034510;C1706779;C3853635
das $nmbr$ esr mean sd das $nmbr$ esr remission,C0544452;C0687702
diet controlled or no,C0743195
eda,C0162359;C1539327;C3539920;C3887494
history of major bleeding,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean change in radiographic end points shs mean sd,C0392747;C0443172;C1705241;C4319952
indication for index procedure,C2315323;C0600653;C0918012;C1552854;C1637833;C2986546
erosion score mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
unstable anginat,C0443343;C1883468
fsn score mean sd,C0444504;C2699239;C2347634;C2348143
any mi,C3810814
teaes cases per $nmbr$ patient years ci,C0868928;C1533148
ischemic outcomes,C0475224;C1274040
mtx $nmbr$ $nmbr$ mg week,C0332174;C0439230
continue thienopyridine n $nmbr$,C0549178;C1120149
related to study druga,C0439849;C0445223
stratified hazard ratio $nmbr$ ci,C0008107;C3259781
leading to study withdrawal,C0332152;C0557651;C2603343;C1522538
stratified log rank p value,C0205363;C1709380
leading to death,C0332152;C0011065;C1306577;C4082313;C4552775;C1522538
stent thrombosis arc definite probable,C0033204;C0332148
gastrointestinal gi disorders,C0017178;C1708130;C3539617;C4050121
macce death mi stroke,C0038454;C4554100
infections,C3714514
stent thrombosis related mi,C3897493;C3810814
serious teaes,C0205404
non stent thrombosis related mi,C3897493;C3810814
most frequent gi disorders,C0332183;C0012634
bleeding outcomes,C0019080;C1274040
most frequent infections,C0239998
log rank p value,C0667477;C1709380;C0699794
most frequent non infectious teaesb,C0332183;C1518422
gusto severe moderate,C1299393
pyrexia,C0015967
barc types $nmbr$ $nmbr$ or $nmbr$,C0332307
rash,C0015230
log rank,C0667477;C0699794
contusion,C0009938
no diabetes n $nmbr$ $nmbr$,C0011847;C0011849
most frequent serious teaes,C0332183;C0205404
diabetes n $nmbr$ $nmbr$,C0011847;C0011849
serious infections,C0205404;C3714514
qualifying mi type,C1514624;C0332307;C1547052
serious gi disorder,C0205404;C0012634
qualifying mi,C1514624;C3810814
pneumonia,C0032285
erysipelas,C0014733
history of second prior mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
disseminated tuberculosis,C0152915
non end stage renal dysfunction,C1565489;C3279454
investigations,C1261322
multivessel coronary artery disease,C0010054;C0010068;C1956346
alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708;C0205217;C0442805
history of hypercholesterolemia,C1533076
aspartate aminotransferase increased,C0004002;C0205217;C0442805
history of stroke or transient ischemic attack,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805
c group n $nmbr$,C0441848
prior coronary artery bypass grafting,C0332152;C0010055;C2826257
nc group n $nmbr$,C0027964;C0441848;C0028407;C0067895;C0265987
history of percutaneous coronary intervention,C1320647;C4554713
systolic blood pressure mmhg mean sd,C0428886;C2699239
ace i or angiotensin receptor blocker,C0021966;C0221138;C0034787;C1622222
diastolic blood pressure mmhg mean sd,C0428886;C2699239
history of diabetes requiring drugs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013227;C3687832
figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes,C0871208;C1521828;C1709595;C1999375;C2349200;C4522255;C0206655;C0446516;C2681631;C3715044;C4553528;C0011847;C0011849
left ventricular systolic dysfunction n,C1277187;C1963159;C4553199
no pad n $nmbr$ $nmbr$,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
serum creatinine mg dl mean sd,C0201976;C2699239;C0600061
pad n $nmbr$ $nmbr$,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
ldl cholesterol mg dl mean sd,C0023824;C2699239;C0202117
history of copd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hdl cholesterol mg dl mean sd,C0023822;C2699239;C0392885
history of stroke or tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
triglyceride mg dl mean sd,C0439269;C2699239
history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038257;C2348535
concomitant medications after randomization,C0013227;C0802604;C2598133;C4284232
history of claudication,C2315493
aceis n,
western europe including south africa,C0043129
b blockers n,
asia australia new zealand,C0027978;C0324547
ca channel blockers n,C3887642;C0870261
time from qualifying mi yrs,C0040223;C3541383;C1514624;C3810814
statins n,C0360714
qualifying mi $nmbr$ yrs prior,C1514624;C0332152;C2826257
number of diseased vessels mean sd,C0237753;C0449788
time from last dose of p $nmbr$ y $nmbr$ inhibitor days,C0946444
left main disease n,C0205091;C0012634;C0443246;C1552822
beta blocker use at baseline,C0042153;C0457083;C1947944
type b $nmbr$ c lesions n,C4264484;C0221198
ace i or arb use at baseline,C0021966;C0221138;C0042153;C0457083;C1947944
des implantation for restenosis n,C0021107;C0029976
central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results,C1999375;C0030705;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657;C1274040;C1546471;C2825142
sirolimus eluting stent use n,C0038257;C0042153;C0457083;C1947944
peripheral artery disease pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
paclitaxel eluting stent use n,C0038257;C0042153;C0457083;C1947944
adolescents aged $nmbr$ $nmbr$ y no,C0001779;C0001792;C1999167
number of implanted stents n mean sd,C0237753;C0449788
adults aged $nmbr$ y no,C0001675;C0001779;C0001792;C1999167
total length of implanted stents mm mean sd,C0439175;C0449462;C0439810
non hispanic non latino,C1518424;C0086528
rotablator use n,C0042153;C0457083;C1947944
mean time since diagnosis y,C0040223;C3541383
aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan,C0003015;C0151691;C2757044
exacerbation within $nmbr$ mo,C4086268;C0026544;C0332177
aspirin only n $nmbr$ $nmbr$,C0004057;C0369718;C0441922
aqlq score mean,C0444504;C2347634;C2348143
aspirin i clopidogrel n $nmbr$ $nmbr$,C0004057;C0021966;C0221138
asui score mean,C0444504;C2347634;C2348143
history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
airway reversibility mean,C0444504;C2347634;C2348143
hf or lvef,C0018488;C1313497;C1538440;C3273279;C0428772;C0488728
fev $nmbr$ mean predicted,C0444504;C2347634;C2348143;C0681842;C1882327
type of event,C1561488
rescue use mean no of inhalations d,C0444504;C2347634;C2348143;C0004048;C0354922
elevated cardiac markers,C0205250;C1271630;C3163633
blood eosinophils mean range cells mlb,C0005773
use of parenteral antithrombotic,C1524063;C0030547;C4522267
total daily dose of ics mean gc,C2348070;C0444504;C2347634;C2348143
selected baseline medications,C0013227;C0802604;C2598133;C4284232
a reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
aspirin $nmbr$ clopidogrel,C0004057;C0070166
b reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
apixaban vs placebo,C1831808;C0032042;C1696465;C1706408
eos count cells pl,C3897966;C4049765
rate n,C0871208;C1521828
mensa,
cv death mi or ischemic stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0948008
sirius,
stent thrombosis,C3897493
prior oma use,C0042153;C0457083;C1947944
timi major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
no prior oma use,C0042153;C0457083;C1947944
timi major or minor bleeding,C0205082;C0205164;C4318856;C4521762;C0026193;C0019080;C0205165
mepo n $nmbr$,
bdmard naive,
prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
bdmard ir,C0022065;C0022071;C1448132
no prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
tofacitinib $nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
annual exacerbation rate,C0871208;C1521828
mean sd weight kg,C0022718;C0439209;C4054209
age mean range years,C1510829;C0444504;C2347634;C2348143
europe and canada,C0015176;C0006823
rate ratio mepo pbo $nmbr$ ci,C0008107;C3259781
mean sd disease duration years,C0872146;C0439234
female n race n,C0043210;C0034510;C1706779;C3853635;C0086287;C1705497;C1705498
mean sd bmi,C0444504;C0578022;C2347634;C2348143
change from baseline in acq $nmbr$,C0392747;C0443172;C1705241;C4319952;C2919686
rf,C0035448;C0201660;C0748398;C1547111
score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci,C3533236;C0008107;C3259781
anti ccp $nmbr$ units,C0439148;C1519795;C3853603
change from baseline in sgrq,C0392747;C0443172;C1705241;C4319952
mean sd das $nmbr$ $nmbr$ esr,C0051767;C3811131;C0057671
change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se,C0392747;C0443172;C1705241;C4319952;C0030771;C1518922;C1542834
mean sd sdai,C0444504;C3871128;C2347634;C2348143
hispanic ethnicity n,C0086409;C0015031;C0243103
mean sd cdai,C0683448;C1413248;C3273706
difference mepo pbo $nmbr$ ci,C0008107;C3259781
mean sd tender joint count,C0444504;C0451530;C2347634;C2348143
change from baseline in pre bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
mean sd swollen joint count,C0444504;C0451521;C2347634;C2348143
fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci,C3714541;C0008107;C3259781
mean sd pain vas,C0444504;C0042815;C2347634;C2348143
duration of asthma,C0449238;C2926735
mean sd ptga vas,C0042815;C3536884;C3827561
change from baseline in post bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
mean sd pga vas,C0042815;C3536884;C3827561
mean sd years daily ocs use n,C0332173;C0042153;C0457083;C1947944
mean sd crp mg l,C0444504;C0439268;C2347634;C2348143
ocs dose mean sd,C0178602;C2699239;C0869039;C1114758
mean sd esr mm h,C0444504;C0456680;C2347634;C2348143
ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll,C0456603;C1547037;C0200638;C0750879;C0007584;C0007634
previously taken methotrexate,C1883727;C0025677
mg day,C0439422
previously taken dmards other than methotrexate,C0242708;C0025677
ratio mepo pbo $nmbr$ ci,C0008107;C3259781
previously taken tnfi,C1883727
eosinophils cells ll inclusion criteria n,C0007584;C0007634;C1512693
previously taken any other dmards n,C1883727;C0242708
ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml,C0456603;C1547037;C0806481;C2986759;C0439340;C1880521;C2945590
abatacept,C1619966
$nmbr$ in previous,C0205156;C1552607
anakinra,C0245109
$nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
rituximab,C0393022
predicted pre bd,C0005126;C2344255;C4050145
tocilizumab,C1609165
fev $nmbr$ mean sd pre bd fev $nmbr$ fvc,C0005126;C3714541;C2344255;C4050145
tnfi no other bdmard taken t n,C1883727
mean sd reversibility fev $nmbr$ at,C0444504;C3714541;C2347634;C2348143
one tnfi,C0205447
screening mean sd morning pef mean,C0220908;C0030771;C1518922;C1542834;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
multiple tnfi,C0439064
other bdmards no tnfi taken t n,C1883727
sd l min acq $nmbr$ score mean sd,C0449820;C0444504;C2347634;C2348143;C4050231
tnfi and other bdmardst n,
sgrq score mean sd,C0444504;C2699239;C2347634;C2348143
one tnfi and,C0205447
total ige geometric,C0439175;C0439810
other bdmard,
mean sd on loge scale u ml,C2699239;C0439340;C1880521;C2945590
multiple tnfi and other bdmards,C0439064
blood eosinophil count geometric mean sd loge scale cells ll,C0005773
parameter $nmbr$ ci,C0008107;C3259781
severe exacerbations,C0205082;C4086268;C4050465;C4050466
das $nmbr$ $nmbr$ esr,C0051767;C3811131;C0057671
in previous year mean sd,C0205156;C2699239;C1552607
haq di improvement $nmbr$ $nmbr$,C3826998;C2986411;C4321476
exacerbations in previous year requiring hospitalization and or ed visit n,C4086268;C0205156;C1552607;C0019993;C0545082;C1512346;C2826704
total ipss,C1019118;C1998280;C2827405;C3811063
exacerbations in previous year requiring hospitalization n,C4086268;C0205156;C1552607;C0019993
age category n $nmbr$ years,C1510829;C0683312;C3889287
randomised patients with spondylitis at baseline n,C0030705;C0038012;C0168634;C1442488
baseline sd,C0168634;C2699239;C1442488
randomised patients with basdai assessment at baseline and week $nmbr$,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
end point sd,C2349179;C2699239;C2826544
nn $nmbr$,C0027779;C1850406;C4283741;C4284038
ls mean change se,C0023668;C0036919
mean sd improvement from baseline to week $nmbr$ in basdai,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004
pbo adjusted ls mean change se,C0023668;C0036919
randomised patients with basdai assessment at baseline and week $nmbr$ n,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
luts severity,C0439793;C0522510
mean sd improvement from baseline to week $nmbr$ in basdai questions,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004;C1522634
mild moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
question $nmbr$ fatigue tiredness,C0015672;C4553152
mean age sd,C0001779;C2699239
question $nmbr$ neck back hip pain,C0007859;C1963180;C4553909
severe ipss $nmbr$ age group,C0027362;C2348001
question $nmbr$ pain swelling in joints other than neck back hips,C0152031;C0004600;C0019552;C0205095;C0460009;C1995000
lifestyle behaviours,C0004927;C0677505
question $nmbr$ discomfort from any areas tender to touch pressure,C2364135;C0205146;C4319729;C0033095;C0460139;C1306345;C4284008
body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
question $nmbr$ morning stiffness since arising,C1522634;C0457086;C0332284;C4019053;C4318616
$nmbr$ years bmi,C0439234;C0578022
question $nmbr$ length of morning stiffness since arising,C1444754;C1706316;C0332284;C4019053;C4318616
mean bmi sd,C0444504;C2699239;C2347634;C2348143
basdai responses at week $nmbr$,C0871261;C0332174;C0439230
comorbidities and concomitant medications,C0009488;C0013227;C0802604;C2598133;C4284232
basdai $nmbr$ n,C1998004
diabetes mellitus n yes,C1549445;C1705108;C1710701
haq di improvement from baseline to week $nmbr$,C3826998;C2986411;C4321476;C0332174;C0439230
$nmbr$ kg m $nmbr$ smokers,C0022718;C0439209;C4054209;C0337664
randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline,C0522476;C0168634;C1442488
glycaemic control hba $nmbr$ c n,C0243148;C0019016;C1825777;C3538758;C1550141;C1882979;C2587213;C3274648;C4553389
dlqi improvement from baseline to week $nmbr$,C2986411;C0168634;C1442488;C0332174;C0439230
diabetic therapy use n no therapy,C0039798;C0042153;C0457083;C1947944;C0087111;C1363945
randomised patients with dactylitis at baseline,C0030705;C0239161;C0168634;C1442488
oral agent,C0450442;C1254351;C1521826
improvement in dactylitis score at week $nmbr$ n,C2986411;C0239161;C0332174;C0439230
glycaemic control group,C0009932
patients with dactylitis at week $nmbr$ n,C0030705;C0239161;C0332174;C0439230
oral agent and or insulin therapy,C0450442;C1254351;C1521826;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
randomised patients with enthesitis at baselinet,C0030705;C1282952
hyperlipidaemia n yes,C1549445;C1705108;C1710701
improvement in enthesitis score at week $nmbr$ n,C2986411;C0449820;C4050231;C0332174;C0439230
hyperlipidaemia therapy use n no lipid lowering agent therapy,C0020473;C0039798;C0087111;C1363945;C0428465;C4555212;C0585943
patients with enthesitis at week $nmbr$ n,C0030705;C1282952;C0332174;C0439230
combined insulin oral hypoglycaemic agent use,C0240016
standard treatment n $nmbr$,C4684780
statin medication,C0013227;C3244316;C4284232
mra regimen n $nmbr$,C0243032;C0040808;C2945654;C1609165;C3891069
other lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
risk factors and medical history,C0035648;C1553898;C0262926;C1704706
statin and or other lipid lowering agent therapy,C0360714;C0585943
presentation,C0449450
hypertension n yes,C1549445;C1705108;C1710701
creatinine clearance ml min $nmbr$,C0812399;C0439445
antihypertensive medication use n,C0003364;C0240320
potassium at admission mmol l $nmbr$,C0032821;C0202194;C0304475;C0597277;C3714637
number of antihypertensive medications used n no antihypertensive therapy,C1718138;C0585941
admission grace score,C0449820;C4050231
combined statin and other lipid lowering agent use,C0205195;C0360714;C0042153;C0457083;C1947944
in hospital medication,C0013227;C3244316;C4284232
type of antihypertensive medication use among patients using antihypertensive medications n,C0457591;C0030705;C1524063;C0003364
p $nmbr$ y $nmbr$ antagonist,C0369773;C0231491;C2603361
antihypertensive agent use,C0042153;C0457083;C1947944
fibrinolysist,
centrally acting sympathomimetics,C3653511
glycoprotein iib iiia inhibitort,C0016011
number of antihypertensive agent reported,C0237753;C0449788;C0684224;C0700287;C4319718
interventional or surgical procedures,C0184661;C3274035;C0543467
$nmbr$ med at baseline,C4321267;C0168634;C1442488
primary pcit,C0205225;C0439612;C0439631
$nmbr$ med at baseline cardiac disorder,C4321267;C0018799
demographic characteristic,C0011298;C1521970
cardiac disorder n,C0018799
umec $nmbr$ $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
cardiovascular disorder n,C0007222
tio $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
no cardiovascular disorder $nmbr$,C0007222
umec $nmbr$ $nmbr$ mcg n $nmbr$,C0439211;C3463985
ischaemic heart disease or cerebrovascular disorder n,C0010054;C0151744;C0007820
tio i $nmbr$ mcg n $nmbr$,C0021966;C0221138
cardiac arrhythmia n,C0003811;C0264886;C1560249
treatment diff vs tio $nmbr$ ci,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0008107;C3259781
luts bph characteristics,C0005001;C1521970;C1704272
gold grade $nmbr$,C0441800;C0919553;C3244287
combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n,C0018801;C0878544;C0018802;C0521117;C1292730
ls mean change from baseline ml se a,C0392747;C0443172;C1705241;C4319952
combined ischaemic heart disease and or cerebrovascular disorder,C0010054;C0151744;C0007820
$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
mild to moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
current smoker at screening n,C3173209;C3241966
mean total ipss sd,C0439175;C2699239;C0439810
smoking pack yearsa,C0037369;C0453996;C1881674
mean ipss voiding subscore sd,C0042034;C2699239;C4067975
post salbutamol fev $nmbr$ l b mean sd,C0001927;C2699239
mean ipss storage sub score sd,C3533236;C2699239
gold group b,C0018026;C4522078;C1304897
mean ipss qol sd,C0444504;C2699239;C2347634;C2348143
post salbutamol fev $nmbr$ fvcb mean sd,C0001927;C2699239
combined cardiac failure cardiomyopathy or other cardiac disorders,C0018801;C0878544;C0018802;C0018799
reversibility to salbutamolc d mean sd,C0449261;C0444504;C2699239;C2347634;C2348143
$nmbr$ uln,C1519815
gold group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
pi,C0122626;C0429863;C3537219;C3539772
nonreversible,
ppci,
ics users at screening,C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
prior chf,C0332152;C0018802;C2826257
gold grades $nmbr$ $nmbr$ percent predicted fev n,C0018026;C0439165;C1304897
to $nmbr$,
grade $nmbr$ moderate copd n,C0205081;C0024117;C1412502;C3714496;C1881878;C4049705;C4049706;C4085643;C4321335
killip class i,C2697844
ics non users at screening,C1518422;C1706077
timi risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
grade $nmbr$ severe copd n,C0205082;C0024117;C1412502;C3714496;C4050465;C4050466
inferior mi,C0340305;C3542426
gold groups a d using mmrcb,C0441838;C1524063
baseline rst segment elevation mm,C4330985;C4554674
gold grade $nmbr$ and ics users at screening,C0441800;C0919553;C3244287;C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
baseline rst segment,C0168634;C0441635;C1442488
group b low risk more symptoms n,C3272281;C3538919;C0683368;C1457887
deviation mm,C4330985;C4554674
group d high risk more symptoms n,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0332167;C3272283;C4050568;C4319571;C0683368;C1457887
q waves in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
gold grade $nmbr$ and ics non users at screening,C0441800;C0919553;C3244287;C1518422;C1706077
figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf,C0242492;C0018802
ics use at screening,C0042153;C0457083;C1947944
upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0013806;C0018802;C0449244;C0034656;C1442160;C0456081;C0027051;C0428953;C2926063;C3810814;C4552959;C0205307;C0231683;C0439166;C2347086;C4553972
ics nonusers n,C0815320;C4551720
cyclosporine n $nmbr$,C0010592;C0010594
proportion of patients with trough fevi $nmbr$ ml above baseline n,C1709707;C0030705;C0439526;C1705224;C3887665
killip class at admission no total no,C1881332;C0184666;C0809949;C0439175;C0439810
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
previous ischemic heart disease no,C0010054;C0151744
heterogeneity test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
treated with cabg no total no,C0332293;C0010055;C0439175;C0439810
chi squared,C1552646
treated with pci no total no,C0332293;C4049621;C0439175;C0439810
previous statin use,C0042153;C0457083;C1947944
managed medically no total no,C1273870;C0439175;C0439810
troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
previous heart failure no,C0018801;C0018802;C4554158
$nmbr$ $nmbr$ ng ml,C0439275
subgroup sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
duration of assigned regimen before surgery,C0449238;C2926735;C0038894;C0038895;C0543467;C1274039
cyclo,C1172566
surgical technique,C0683469
p value for interaction $nmbr$ $nmbr$,C1709380;C1704675
on pump,C3842462
no of events total,C0439175;C0439810
off pump,C1518543;C0182537
initial timi flow,C0205265;C3272266;C1279901;C1555582;C1705685
procedure,C0184661;C2700391;C3274430;C3539779
final timi flow,C0205088;C3272266;C1546485;C3853528
aortic valve replacement,C0003506
symptom onset,C4086878
postoperative glucocorticoid use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ s $nmbr$,
postoperative nsaid or glucocorticoid use,C0003211;C3536840;C0042153;C0457083;C1947944
rentrop score,C0449820;C4050231
trend het test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
killip at baseline,C0168634;C1442488
duration of assigned regimen before surgery post randomisation characteristic,C0449238;C2926735;C0034656;C1521970
proximal mainleft,C0205107;C4489236
xi $nmbr$ $nmbr$,C1720296
medial distal diag,C0205098;C0348026
xi $nmbr$,C1720296
thrombus aspiration,C0220787;C0349707;C0700198;C2712334;C2827071
percentage difference $nmbr$ cl,C0439165;C0596019;C1549488;C1561533
fh $nmbr$,
surgical technique post randomisation characteristic,C0683469;C1521970
fh ii,C1854107
avr,C0449217
alirocumab n $nmbr$,C3491162
postoperative glucocorticoid use post randomisation characteristic,C0017710;C1521970
diagnosis of heterozygous familial hypercholester,C0011900;C1704338;C1704656
postoperative nsaid or glucocorticoid use post randomisation characteristic,C0003211;C3536840;C0017710;C1521970
olaemia n,
x $nmbr$ $nmbr$,
genotyping,C1285573
dulaglutide $nmbr$ $nmbr$ mgf,C1366394;C3712803;C3887684
clinical criteria $nmbr$,C0205210;C0243161
age $nmbr$ vears n $nmbr$,C0001779
coronary heart disease n b,C0010054;C0010068;C1956346
previous oral antidiabetic medication use n,C1527415
coronary heart disease risk equivalents n c,C1277690;C0439185;C4049980
no oral antidiabetic medication,C0175795
type $nmbr$ diabetes n d,C1320657
$nmbr$ oral antidiabetic medication,C0175795
statin use n,C0360714;C0042153;C0457083;C1947944
insulin oral antidiabetic medication s,C0175795
high dose statin use n e,C0444956;C0042153;C0457083;C1947944
figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study,C0392747;C0443172;C1705241;C4319952;C0439230;C0027361;C0237401
change from baseline ls means se,C0392747;C0443172;C1705241;C4319952
data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years,C1511726;C3245479;C3714741;C0449450;C0023668;C2708217;C2708218;C0017853;C0439234
alirocumab,C3491162
europe and australia,C0015176;C0004340
prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
latin and north america,C0028405
high intensity,C4081854
systemic corticosteroids n a,C4053960
lowzmedium intensity,C0522510
das $nmbr$ esr mean sd,C0051767;C2699239;C0057671
dose of atorvastatin,C0178602;C0869039;C1114758
moderate disease activity $nmbr$ $nmbr$ to,C1513375;C3833417
dose of rosuvastatin,C0178602;C0869039;C1114758
high disease activity $nmbr$ $nmbr$ n,C4699623
llt other than statin at randomization,C2347090;C0360714;C0034656
sdai mean sd,C0444504;C2699239;C2347634;C2348143
no thienopyridine,C1120149
cdai mean sd,C0444504;C2699239;C2347634;C2348143
tp vs no tp,C0036183;C3541334
haq di mean sd,C3826998;C2699239;C4321476
weight $nmbr$ kg,C0022718;C0439209;C4054209
tjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
any coronary revascularization,C0877341
sjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
previous cabg total,C0439175;C0439810
esr mm h median min max,C3642211
previous pci total,C0439175;C0439810
crp mg l median min max,C0439420
previous stenting previous pci,C0038257;C4049621;C2348535
months since ra was first diagnosed mean sd,C0439231;C3538806;C4048756;C0011900;C2699239
des previous stenting,C0038257;C2348535
$nmbr$ months mean sd,C0439231;C2699239
time from qualifying mi,C0040223;C3541383;C1514624;C3810814
months since first ra symptom mean sd f,C0439231;C0016327
$nmbr$ $nmbr$ mo,C0026544;C0332177
rf positive $nmbr$ iu ml n,C0035448;C0439458;C0201660;C0748398;C1547111
n $nmbr$ yr km event rate,C0871208;C1521828
acpa positive $nmbr$ iu ml n,C0439178;C0439458;C1446409;C1514241;C2825490;C3812269
p int,C0369773;C3272375;C2603361
mtss median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
cv death mi stroke,C0038454;C4554100
$nmbr$ months median min max,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
cv death mi stroke ucr,C0011065;C0038454;C4554100;C1306577;C4082313;C4552775
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
ucr,
erosion score median min max,C0333307;C0449820;C4050231;C1880549;C1959609;C3887524
fracture during follow up,C0016658;C0589120;C1522577;C1704685;C3274571
jsn median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
no n $nmbr$ $nmbr$,C0369718;C0441922
presence of erosions n,C0150312;C0392148;C3854307
age median iqr years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot,C2986480;C0205363;C0040223;C3541383;C0011900;C1704338;C1704656;C0025677;C1417487;C0441837;C0028873;C0086312
all others n,C1955473;C3539125
indacaterol glycopyrronium group n $nmbr$,C1722260;C0441848
hispanic latino ethnicity n,C0086409;C0015031;C0243103
salmeterol fluticasone group n $nmbr$,C0939232;C0441848
weight median sd kg,C0022718;C0439209;C4054209
use of inhaled glucocorticoids at screening no,C1524063;C0004048;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
bmi median sd kg m $nmbr$,C0022718;C0439209;C4054209
severity of copd no f,C0439793;C0522510;C0016327
diabetes duration median iqr years,C0011847;C0439234;C0011849
group a,C0441835;C4522145
prior heart failure n,C0018801;C0018802;C4554158
group b,C4522078
baseline measurements,C0168634;C0242485;C1442488
group c,C0441837
egfr median sd ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
albumin to creatinine ratio,C0486293;C1318293
post bronchodilator fev $nmbr$ liters,C2599594;C0475211
median sd mg mmol,C0567349;C2348885
post bronchodilator fev $nmbr$ of predicted value,C2599594;C3714541;C0681842;C1522609;C1882327
hba $nmbr$ c median sd,C0019016;C2699239;C1825777;C3538758
post bronchodilator ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
fasting serum glucose median sd mg dl,C0202041;C0439269;C3534430
total score on the sgrq c i,C2964552;C3826872
baseline cv medications n,C0168634;C0013227;C0802604;C2598133;C4284232;C1442488
indacaterol glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
baseline antihyperglycemic medications n,C0020616;C0013227;C0802604;C2598133;C4284232
salmeterol fluticasone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
cl $nmbr$,C0596019
smoking status at screening,C1519386
$nmbr$ m,
severity of airflow limitation,C0439793;C0522510
cvd subjects,C0681850;C1550501;C1706203;C2349001;C2697811
severity of copd,C0439793;C0522510
m $nmbr$ s,C0439493;C1513009
copd exacerbations during the previous year,C0740304;C0205156;C1552607
mrf subjects,C0681850;C1550501;C1706203;C2349001;C2697811
inhaled glucocorticoid use at screening,C0042153;C0457083;C1947944
renal function normal mild,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599
no use,C0042153;C0457083;C1947944
renal function moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
laba use at screening,C0042153;C0457083;C1947944
renal function severe,C0232804;C0205082;C4050465;C4050466
laba inhaled glucocorticoid use at screening,C0042153;C0457083;C1947944
region north america,C0017446;C0028405;C0205147
lama use at screening,C0042153;C0457083;C1947944
region latin america,C0017446;C0023122;C0205147
included in analysis,C0332257;C0002778;C0936012;C1524024
region asia paafic,C0017446;C0003980;C0205147
total sample $nmbr$,C0370003;C2347026
region europe,C0017446;C0015176;C0205147
age at baseline in years mean sd,C0001779;C0168634;C1442488;C0439234;C2699239
region europe union,C0015176;C2825217
$nmbr$ $nmbr$ lo i,C0021966;C0221138
race n y,C0034510;C1706779;C3853635
time from parkinson s disease diagnosis in months mean sd,C0040223;C3541383;C0439231;C2699239
known duration of t $nmbr$ dm y,C0449238;C2926735
total updrs score baseline mean sd,C2964552;C2699239
history of cvd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
goal,C0018017;C1571704
activities of daily living updrs subscore baseline mean sd,C0001288;C4050548
baseline n,C0168634;C1442488
motor updrs subscore baseline mean sd,C0168634;C2699239;C1442488
week $nmbr$ n,C0332174;C0439230
mental activities updrs subscore baseline mean sd,C0168634;C2699239;C1442488
or for cana vs pbo $nmbr$ ci,C1418845;C0008107;C3259781
hoehn and yahr stage baseline mean sd,C0168634;C2699239;C1442488
p value nominal,C1709380
initial treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
body weight reduction $nmbr$,C1262477
$nmbr$ mg $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
placebo $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
week $nmbr$ n or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
gentype,
weeks,C0439230
ldl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
weeks_measured,C0444706;C3541902
hdl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0443172;C1705241;C4319952;C0456081;C0168634;C1442488
composite endpoint a $nmbr$ c $nmbr$ $nmbr$ bp,C0037623;C1415692;C1708288;C4318478
$nmbr$ to $nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ mmhg ldl c $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
$nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
week $nmbr$ n ^,C0332174;C0439230
event rate vr,C0441471;C3476815;C4019010
male patients^,C0150904
edoxaban vs warfarin,C2975435;C0043031
female patients^,C0150905
$nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
week $nmbr$ n j,C0332174;C0439230
edo,
week $nmbr$ n $nmbr$,C0332174;C0439230
stroke see,C0042789;C1947903
composite endpoint a $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mmhg ldl c $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
type of af,C0332307;C1547052
ef $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,
persisent,
black race,C0005680
fatal stroke,C0038454;C4554100
russia georgia,C0017452;C0017454
crcl ml min at randomization,C0439445;C0034656
history of hf hospitalization,C0551577;C0018488;C1313497;C1538440;C3273279
cha $nmbr$ ds $nmbr$ vasc score,C0449820;C4050231
history of diabetes nyha class,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
has bled score $nmbr$,C0449820;C4050231
heart rate b p m,C0018810
major gl bleeding,C0018229;C0019080;C1423073;C1427674
body mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time in therapeutic range,C1554109
ace arb,C1452534;C3888198;C4284014
dose reduction at randomization,C0301630;C0392756;C1293152;C4551656
all patients n $nmbr$ $nmbr$,C0030705
prior vka experience,C0237607;C0596545
ejection fraction group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
medication at time of randomization,C0013227;C3244316;C4284232
continuous lvef $nmbr$ treatment interaction,C0039798;C1704675;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
gly $nmbr$ $nmbr$ mg b i d n $nmbr$,C0439422
event rate per $nmbr$ patient years,C0871208;C1521828
ind $nmbr$ mg q d n $nmbr$,C4049864;C0439422
hr unadjusted,C1439367
number of pack years,C0237753;C0449788
referent,C1706462
severity of copd airflow limitation n,C0439793;C0522510
hr adjusted,C0456081
moderate gold $nmbr$,C0018026;C1304897
treatment effect hr,C1518681
severe gold $nmbr$,C0018026;C1304897
hr adjusteda,
very severe gold $nmbr$,C0018026;C1304897
empagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
severity of copd combined assessment n,C0439793;C0522510
pooled empagliflozin n $nmbr$,C1709595;C2349200;C4522255
mmrc dyspnea scale n,C0013404;C0175659;C0349674;C1947916;C1963100
other missing,C1551393;C1705492;C3272743
copd assessment test cat score,C0237855;C0237856
north america plus australia and new zealand,C0028405;C0004340;C0027978;C0324547
post bronchodilator fev $nmbr$ reversibility a,C2599594;C0449261
africa,C0001737
ccv history condition,C0683519
body mass index kg m $nmbr$ t,C0005893;C1532718;C0578022;C1305855
gly $nmbr$ $nmbr$ gg b i d n n,C1415124;C0152277
cv risk factor no,C3538987;C0035648;C4048877;C4318503
ind $nmbr$ gg q d n n,C0017454;C0018370
multi vessel coronary artery disease,C1299432
severity of airflow obstruction,C0439793;C0522510
history of stroke $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mild or moderate copd,C2945599;C0024117;C1412502;C3714496
single vessel coronary artery disease $nmbr$,C0581374
severe or very severe copd,C0205082;C4050465;C4050466;C0024117;C1412502;C3714496
cardiac failure,C0018801;C0018802
ics use at baseline,C0042153;C0457083;C1947944
time since diagnosis of type $nmbr$ diabetes no,C0040223;C3541383
ccv history condition at baseline,C0683519;C0168634;C1442488
glucose lowering therapy no,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
history of atrial fibrillation flutter,C0729790
medication taken alone or in combination,C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
history of cardiac arrhythmia,C3494593
median daily dose iu,C0049272;C0439453;C0694756
long acting bronchodilator use at screening,C0042153;C0457083;C1947944
dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
attain,
glucagon like peptide $nmbr$ agonist,C0014361;C2987634
augment copd,C0205217;C0024117;C1412502;C3714496
anti hypertensive therapy no,C0585941
pooled analysis sample,C1709595
angiotensin converting enzyme inhibitors angiotensin receptor blockers,C0521942;C0815017
aclidinium $nmbr$ g n $nmbr$ a,C2699757;C0439267
mineralocorticoid receptor antagonists,C1373021;C1579268
placebo n $nmbr$ a,C0032042;C1696465;C1706408
renin inhibitors,C2917241;C3653375
aclidinium $nmbr$ g n $nmbr$ b,C2699757;C0439267
anti coagulants no,C0848112
placebo n $nmbr$ b,C0032042;C1696465;C1706408
low density lipoprotein cholesterol mg dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all patients n $nmbr$ b,C0030705
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ tt,C3811844;C0439445;C1452561;C4554543
post bronchodilator fev $nmbr$ l mean sd c,C2599594;C0444504;C2347634;C2348143
urine albumin to creatinine ratio no,C0455271;C1318330
post bronchodilator fev $nmbr$ predicted mean sd c,C2599594;C0444504;C2347634;C2348143
$nmbr$ to $nmbr$ mg g,C1300563
bronchial reversibility sd,C0205039;C2699239;C1442216
patients with event patients analyzed,C0030705;C0441471;C4019010;C0936012
number of exacerbations in previous year mean sd,C0237753;C0449788;C0205156;C2699239;C1552607
sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
rs breathlessnessb,C0035970;C3714753;C3813325
urine albumin to creatinine ratio,C0455271;C1318330
rs cough sputumc,C0035970;C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C3714753;C3813325
cardiovascular risk,C0007226;C0035647;C4552904;C3887460
rs chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
only cerebrovascular disease,C0007820
rs totala,C0035970;C3714753;C3813325
only coronary artery disease,C0010054;C0010068;C1956346
aclidinium $nmbr$ g bid n $nmbr$,C2699757;C0439267
only peripheral artery disease,C1704436;C4025272
gold group a,C0441835;C4522145
$nmbr$ or $nmbr$ high cardiovascular risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
gold group c,C0018026;C0441837;C1304897
statins ezetimibe,C0360714;C1142985
prior ptca or pci,C0332152;C2936173;C2826257;C4049621
fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f,C0392747;C0443172;C1705241;C4319952;C0035970;C0449820;C3714753;C3813325;C1709707;C0282416;C1561607;C0441835;C4522145;C2964552;C0013404;C0119082;C0016327
primary endpoint death mi idr st,C0036056;C3272372
rs cough sputum domain g and h rs chest symptoms domain p,C0370205;C0119082;C0150618;C0035970;C3714753;C3813325
ischemia driven revascularization,C0022116;C0581603;C4321499
lixisenatide,C2973895
gusto bleeding severe moderate,C0019080;C1299393
high i $nmbr$ baseline hba $nmbr$ c,C0021966;C0019016;C1825777;C3538758;C0221138
timi bleeding major minor,C0019080;C4441842
high i $nmbr$ kg m $nmbr$ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
acuity bleeding major minor,C0019080;C4441842
short,C1282927;C1806781;C2350002
no of previous anti tnf drugs no,C0205156;C1552607;C0013227;C3687832
long i $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
use of methotrexate at randomization,C1524063;C0025677;C0034656
i $nmbr$ years of age,C0021966;C1510829;C0221138
use of systemic glucocorticoid at random,C1524063;C0017710;C0034656;C0439605
low $nmbr$ baseline hbalc,C0205251;C0168634;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
ization no,
getgoal l asia,C0003980
patients with specific disease characteris,C0683521;C0205369;C1552740
getgoal s,
tics no,C0040188;C0278076;C2169806;C3889970
high $nmbr$ baseline hbalc,C0205250;C0168634;C1442488;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
psoriasis affecting $nmbr$ of body surface,C0033860;C0392760;C1314939;C0489451
low $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
area,C0017446;C0205146
high $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
disease and quality of life scores,C0012634;C3476431
short $nmbr$ years duration of diabetes,C0439593;C0011847;C0011849
tender joint count of $nmbr$ joints,C0451530
long $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
swollen joint count of $nmbr$ joints,C0451521
suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
pasi^i,C0021966;C0221138
suit quartile $nmbr$ $nmbr$ $nmbr$,C2828255
physician s global assessment of dis,C0031831;C0804815;C0281858;C0451119;C1444662;C1970187
suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
ease activity],C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
t $nmbr$ d duration years,C2603360;C0449238;C0439234;C2926735
haq di scoreff,C3826998;C4321476
oad use n,C0042153;C0457083;C1947944
psoriatic arthritis pain],C4317006
oad history years,C0019664;C0439234;C0019665;C0262512;C0262926;C1705255;C2004062
patient s global assessment of,C0030705;C0281858
ppg post meal test mmol l,C0376674;C1532563
disease activity],C1292728
suit index nmol mmol,C1532564;C1533073
sf $nmbr$ physical component summaryjj,C0037712;C0031809;C0205485;C1509143
no cv event n $nmbr$ $nmbr$,C3538987;C0441471;C4019010;C4048877;C4318503
efficacy endpoint,C2349179;C2826544
nonfatal mi n $nmbr$,C3810814
secukinumab,C3179547
hhf n $nmbr$,
iv $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nonfatal stroke n $nmbr$,C0038454;C4554100
anti tnf naive patients $nmbr$,C1448177;C0030705
ua n $nmbr$,C0041580;C0042014
acr $nmbr$ response n n,C1412134;C0871261;C1704632;C1706817;C2911692;C1515941
cv risk factors and history,C0035648;C1553898;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
das $nmbr$ crp ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
alogliptin n,C1958126
anti tnf experienced patients,C1448177;C0030705
$nmbr$ kg ma $nmbr$,C0024443;C3887485
no of hospitalised patients,C0030705
$nmbr$ years and $nmbr$ years,C0439234
aplxaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
western europe australia new zealand middle eai,C0043128;C0027978;C0324547
apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
normal function or mild impairment,C4296962;C0221099;C0684336
apixaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
liraglutide n $nmbr$ $nmbr$,C1456408
table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C4684572;C0205363;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0039601
heart failurea,C0018787
main effect baseline hormone,C0019932;C4521914
established cvd age $nmbr$,C0007222;C0001779
baseline total ipss,C1019118;C1998280;C2827405;C3811063
$nmbr$ stenosis of coronary carotid or lower extremity arteries,C0007282;C0242231;C0226415
unadjusteda beta se,C0330390;C0036919;C0439096;C2004068
documented symptomatic chdb,C1301725;C0231220;C1609436
adjustedb c beta se,C0330390;C0036919;C0439096;C2004068
documented asymptomatic cardiac ischemiac,C0231221;C0018787;C1522601
stratified by,C0205363
heart failure nyha ii iii,C0439070;C1705160
linear regression,C0023733;C2346679
chronic kidney diseased,C0022646;C0227665
treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
cvd risk factors age $nmbr$,C0001783
testosterone level nmol l,C0428412;C0439282;C0523912
microalbuminuria or proteinuria,C0730345;C0033687;C1962972;C4554346
testosterone nmol l,C0039601;C0439282
continuous,C0549178
hypertension and left ventricular hypertrophy,C0020538;C1963138;C0149721;C3484363
low tt,C1452561;C4554543
left ventricular systolic or diastolic dysfunction,C0225897;C0039155;C0520863
high tt $nmbr$ $nmbr$ n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
normal egfr $nmbr$,C1739039;C3811844;C3812682
estradiol pmol l,C0014912;C0439284
mild impairment egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
baseline outcomes,C0168634;C1274040;C1442488
moderate impairment egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
logistic regression,C0206031
severe impairment egfr,C1739039;C3811844;C3812682
odds ratios $nmbr$ ci,C0008107;C3259781
liraglutide,C1456408
ipss v,C1019118;C1998280;C2827405;C3811063
table $nmbr$ characteristics of the patients at baseline according,C0039224;C0815172;C1706074;C0168634;C1442488;C0680240
moderate $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
to the estimated glomerular filtration r,C0205090;C0684010;C2603358
ipss s,C1019118;C1998280;C2827405;C3811063
ate egfr,C1739039;C3811844;C3812682
severe $nmbr$,C0205082;C4050465;C4050466
ipss categories,C1019118;C0683312;C1998280;C2827405;C3811063
hormones,C0019932
testosterone tt nmol l,C0039601;C0439282
estradiol e $nmbr$ pmol l,C0014912;C0439284
p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition,C1709380;C1704970;C2699239;C0017654;C1424601;C0750572;C3839656;C1739039;C3811844;C3812682;C0686905;C0030705;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0237881;C0750502;C1546944;C0041420;C0681848;C0023822;C1704436;C4025272;C0439232;C0700321;C0702093;C1282918;C2347166;C0042295;C0008377;C1532563;C1719797;C2911648;C0041004;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0017853;C1522609;C1551393;C1705492;C3272743;C0456603;C1547037;C0444706;C3541902;C0439208;C0065055;C0032042;C1696465;C1706408;C0017351;C0021034;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0205447;C0439526;C1705224;C3887665;C0231174;C0680095;C0521095;C1140263;C0012634;C0348080;C1705253;C3864998
estradiol quartiles,C0014912;C2828255
patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less,C0030705;C0439526;C1705224;C3887665;C0439232;C0700321;C0702093;C1282918;C2347166
$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l,C0036056;C0439284;C3272372
patients with minute per,C0030705;C0439232;C0700321;C0702093;C1282918;C2347166
$nmbr$ nd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0439284
egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more,C1739039;C3811844;C3812682
$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0694666;C0439284;C4553350
empagliflozin n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C3490348
$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l,C0039725;C0439284;C0039738;C1420718;C4282123;C4285344
interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no,C1272706;C1552654;C1552713;C1550351
american indian or alaskan,C0002460;C0238611
urinary albumin to creatinine ratio no,C0486293;C1318293
alcohol useb,C0001962;C0001975
low density lipoprotein^,C0023823
smokingb,
high density lipoprotein],C0023821
obese $nmbr$ kg m $nmbr$ b,C0028754;C1532718
angiotensin converting enzyme inhibitor or angiotensin,C0003015;C2757044;C3536837;C4541021;C0003018;C4521302
comorbid conditionsb,
receptor blocker,C0597357
cardiac diseasec,C0018787;C1522601
statin and or ezetimibe,C0360714;C1142985
medication useb,C0013227;C3244316;C4284232
anti hypertensive therapy,C0585941
psychoactivesd,
ace inhibitor and or arb,C0003015;C4541021;C3888198
diabetese,
us n $nmbr$,C0815353;C3889164
other lipid lowering drugs,C0086440
non us n $nmbr$,C1518422;C0815353;C3889164
alpha blockers,C0001641
mean sd n,C0444504;C2347634;C2348143
angiotensin receptive blocker,C0003018;C4521302
cardiac biomarker status,C1999091;C2735302
other antihypertensive medications,C0003364
number of vessels treated index pci,C0237753;C0449788
cyp $nmbr$ a $nmbr$ inhibitors,C1418793;C0243077;C2634343
time from hospital admission to pci h median q $nmbr$ q $nmbr$,C3854258;C3854259;C0033727;C0369286;C0441932;C0564385;C4528284
alpha reductase inhibitors,C0597153;C1655741
efficacy,C1280519;C1707887
previous pde $nmbr$ inhibitors,C0205156;C0031638;C1552607
primary end point death mi idr st,C0036056;C3272372
hemoglobin a $nmbr$ c,C0019020;C3889898
key secondary end point st,C0036056;C3272372
good control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
idr,
fair control $nmbr$ $nmbr$ $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
death from cardiovascular causes,C0007465;C0007226;C3887460
cholesterol nmol l,C0008377;C0439282
death q wave mi idr,C0011065;C0861151;C1306577;C4082313;C4552775
glucose non fasting or random nmol l,C0017725;C1518422;C0015663;C0034656;C0439282;C0439605
death st,C0036056;C3272372
standard bp lowering,C1442989;C2828392;C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
safety non cabg related bleeding,C0010055;C0019080
intensive bp lowering,C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
gusto defined bleeding,C1704788;C0019080;C3539106
latino,C0086528
primary safety end point severe life threatening,C1546953;C2826244;C3537125
intensive glycemia lowering,C0005802;C0441994;C2003888
timi defined bleeding,C1704788;C0019080;C3539106
cornell index pv,C0030840;C0032463
acuity defined bleeding,C0750509;C0019080
safety population,C0032659;C1257890
efficacy and safety net adverse clinical events,C1280519;C1707887;C0877248;C1705413
brv $nmbr$ mg day n $nmbr$,C0155502;C0439422
brv $nmbr$ mg day n,C0155502;C0439422
death mi idr st gusto defined moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
gold $nmbr$,C0018026;C1304897
gender female n,C0079399;C0043210;C0086287;C1705497;C1705498;C1522384
gold a,C0018026;C1304897
europe eu,C0015179;C3665627
gold c,C0018026;C1304897
asia pacific other,C0003980
naive no,
europe non eu,C0015179;C3665627
naive yes,C1549445;C1705108;C1710701
duration of epilepsy years mean sd,C0449238;C2926735
ics no,C0815320;C4551720
age at first seizure years mean sd,C1510829;C0036572;C1959629;C4553401
ics yes,C1549445;C1705108;C1710701
baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1442488
mean sd pre bronchodilator,C0444504;C2599602;C2347634;C2348143
number of prior aeds n,C0237753;C0449788
mean sd post bronchodilator,C0444504;C2699239;C2347634;C2348143;C2599594
number of concomitant aeds n,C0237753;C0449788
fev $nmbr$ fvc ratio sd,C0456603;C2699239;C1547037
concomitant aedsa,C0521115
baseline pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
carbamazepine,C0006949;C0006950;C0682993
sama,C1075468
lamotrigine,C0064636;C0524166
valproate,C0080356
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C1304897;C0012634
oxcarbazepine,C0069751
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C0012634;C1304897
topiramate,C0076829
lacosamide,C0893761
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408
lev status n,C0023556;C0449438
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C1514756;C1518422
never used lev,C1273517;C0023556
rotigotine n $nmbr$,C1700683;C4318637
prior lev use,C0042153;C0457083;C1947944
stage of pda,C0205390;C1300072;C1306673
early n,C1279919
subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure,C2986480;C0032664;C0149775;C0332152;C0023556;C2826257;C0030705;C0871208;C1521828;C0168634;C1442488;C0301630;C0392756;C1293152;C4551656;C0392360;C0444930;C2746065;C1264674;C0237753;C0449788;C0332293;C0377265;C3693636;C0657912;C0003299;C0751495;C0206132;C0332162
advanced n,C0205179
spirono n $nmbr$,
time since pd diagnosis mean sd,C0040223;C3541383
enrollment strata prior hospitalization,C0332152;C0019993;C2826257
years modified hoehn and yahr stage n,C0439234;C0679846
physical characteristics,C0031809;C1521970;C0205485;C1509143
brv dosage mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hematocrit,C0018935;C0518014
racial group n,C0441848
prior hf hospitalization n $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
whitea,C1021495
elevated natriuretic peptide level n $nmbr$,C1144709;C2709270;C3537020
baseline focal seizure frequency $nmbr$ days median q $nmbr$ q $nmbr$,C0149775;C0751495
p for interact,C0369773;C2603361
seizure types reported during baseline b n,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
lv heart structure,C0023128;C0018787;C0731033;C1881413
simple partial ia,C0020980;C0694634;C1947960
lvedv ml,C0439526;C1705224;C3887665
complex partial ib,C2744579;C3890035;C4283819
lvesv ml,C0439526;C1705224;C3887665
partial evolving to secondarily generalized ic,C0728938;C1550516;C0205246;C0020750;C4554818
mean wall thickness cm,C4054557;C0677535
no of prior aeds c n,C0332152;C0180309;C2826257
lv mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
most common concomitant aeds d n,C0205214;C0180309;C1522138;C3245511;C0369718;C0441922
relative wall thickness,C0080103;C0205345;C1547039
prior lev treatment,C1514463;C0023556
lav ml,C0439526;C1705224;C3887665
lev naive,C0023556
la diameter,C0023031;C1301886;C0023749;C0230347;C2346906;C4553351
central eastern europe russia,C0682369;C0035970
lv function,C0031843;C0542341;C0700205;C1705273
syst bp mmhg,C0037623;C0439475;C1415692;C1708288;C4318478
e a ratio,C0456603;C1547037
nt probnp pg mla iqr,C0669479;C0754710
tdi e septal cm sec,C0205976;C0439392;C2674784;C3714807
ckd egfr $nmbr$ b,C1561643;C1739039;C3811844;C3812682
e e septal,C0442004
central eastern europe and russia,C0682369;C0035970
rv and pulmonary vascular,C0035190;C3889272;C0459963;C1508661
event rates per $nmbr$ patient years $nmbr$ ci,C0871208;C1521828
tr jet velocity m sec,C0439830;C1547053;C0565930
$nmbr$ $nmbr$ ref,C1425988
rvfac,
adjustedahr,
enrolled in the americas,C4684790;C0002454;C0596070
all cause mortality no of events,C0015127;C0026565;C0026566;C1524003;C0441471;C3541888
enrolled in russia or georgia,C4684790;C0035970;C0017452;C0017454
significant worsening in kccq clinical,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960
baseline adjusted hr,C0168634;C0456081;C1442488
score $nmbr$ at $nmbr$ monthsb unadjusted or,C0449820;C4050231;C1439367
alvedv per ml,C0439526;C1705224;C3887665
adjustedaor,
alvesv per ml,C0439526;C1705224;C3887665
overall hr $nmbr$ cl,C0282416;C0596019;C1561607
alvmi per g m $nmbr$,C0439267
north america hr $nmbr$ cl,C0028405;C0596019
alvef per $nmbr$,
western europe hr $nmbr$ cl,C0043129;C0596019
ae a ratio per $nmbr$ $nmbr$ unit,C3887670;C0456603;C1547037
central eastern europe and russia hr $nmbr$ cl,C0682369;C0035970;C0596019
ae per cm s,C3887670
latin america hr $nmbr$ cl,C0023122;C0596019
ae e ratio per $nmbr$ unit,C0456603;C1547037
asia pacific hr $nmbr$ cl,C0003980;C0596019
alav per ml,C0439526;C1705224;C3887665
significant worsening in kccq clinical score $nmbr$ at $nmbr$ months $nmbr$,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0439231
apasp per mmhg,C0439475
renal function at randomization,C0232804;C0034656
arvfac per $nmbr$,
moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274776;C0439445
sbp at baseline,C0085805;C0168634;C1442488
mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],C2945599;C0031847;C0439445;C0277785;C3887504;C3887505
sd of sbp,C2699239;C0085805
mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274775;C0439445
range of sbp,C1514721;C2348147;C3542016
normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C4296962;C0439445
change in sbp,C0392747;C0443172;C1705241;C4319952
bmi median iqr kg m $nmbr$,C0022718;C0439209;C4054209
bp lowering treatment n $nmbr$,C0037623;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1415692;C1708288;C4318478
crcl median iqr ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
r tpa,C0032143
current or prior smoking,C0521116;C1705970;C0037369;C0453996;C1881674
time to treatment h,C3494202;C0033727;C0369286;C0441932;C0564385;C4528284
other vascular disease cvd or pad,C0042373;C0007222;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
nihss score,C0449820;C4050231
asia pacific and africa,C0003980;C0001737
stroke subtype,C0038454;C0449560;C4554100
chads $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
infarct size,C0021308;C0456389
cha $nmbr$ ds $nmbr$ vasc mean sd,C0444504;C2699239;C2347634;C2348143
no infarct visible,C0021308;C0205379
small medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
modified has bled score mean sd,C0392747;C3889737;C0444504;C2699239;C2347634;C2348143
large very large,C0549177;C0442824;C2984081
intermediate $nmbr$,C0205103;C1550465;C2827755;C3889971
symptomatic infarct swelling,C0013604;C0038999
potent phosphorylated glycoprotein inhibitor use,C0042153;C0457083;C1947944
symptomatic ich,C0019191;C3272597;C3281105
prior vka use for $nmbr$ d,C0042153;C0457083;C1947944
nd not due to swelling or ich,C0678226;C0013604;C0038999;C0019191;C3272597;C3281105
medication at randomization,C0013227;C3244316;C4284232
early ichaem ic stroke,C0038454;C4554100
time in therapeutic range median iqr,C1554109
any early adverse event,C1279919;C0877248
n n yr,C0369718;C0439234;C0441922
early death,C1836407
warf,C0043031
poor outcome at $nmbr$ months,C3806166;C0439231
hder,C3898895
numbers of events,C4330837
stroke or se s se,C0038454;C4554100;C0036919
ors $nmbr$ cis,C1504308;C1742862
crcl $nmbr$ $nmbr$,C1846718
crci $nmbr$,
$nmbr$ days to $nmbr$ year n $nmbr$,C0556972
major bleeding mb,C0019080;C0024853
age median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
caucasiana,
s se mb or death,C0036919;C0024853;C0011065;C1306577;C4082313;C4552775
bmi median iqr,C0578022;C0549183;C0876920;C2347635;C2348144;C2939193
previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
multivessel cad,C1504769;C2239547;C3813548;C4284121
no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
pci for index mi,C4049621;C0600653;C0918012;C1552854;C1637833;C2986546
warfarin n $nmbr$ n y,C0043031
history of more than $nmbr$ prior mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
higher dose edoxaban n $nmbr$ n y,C0444956;C2975435
egfr at baseline $nmbr$ ml min b,C1739039;C3811844;C3812682
higher dose edoxaban vs warfarin,C0444956;C2975435;C0043031
months from mi median iqr,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
ard per $nmbr$ $nmbr$ patient years $nmbr$ ci,C1817569;C1826411
mi type unknown,C0439673;C3541433;C4050014
previous stroke tia,C0007787;C0917805;C1054154
no previous stroke tia,C0007787;C0917805;C1054154
figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0178602;C0439542;C1707455;C0032042;C1696465;C1706408;C0030705;C0424092;C2349954;C2825032;C3853865;C0439228;C0034656;C1514624;C0439231;C0332152
cvd stroke see,C0042789;C1947903
age mean sd yrs,C0001779;C0444504;C2347634;C2348143
all cause death stroke see,C0042789;C1947903
history myocardial infarction,C0155668;C1275835
atrial fibrillation type n,C0004238;C0344434;C1963067
history pci,C0019664;C4049621;C0019665;C0262512;C0262926;C1705255;C2004062
permanent af,C0344434;C4049859
anti platelet therapy,C0039798;C0087111;C1363945
qualifying risk factor n,C1514624;C0035648
time to end of study ivus median iqr days,C3698632
chads $nmbr$ score $nmbr$ $nmbr$ n,C0449820;C4050231
cardiovascular events,C1320716
dose reduction n,C0178602;C0301630;C0392756;C1293152;C4551656;C0869039;C1114758
hospitalization for acs,C0019993;C0742343;C4318612
renal impairment crcl,C1565489;C1846718
arterial revascularization,C0003842;C0581603;C0221464
low body weight,C0041667
first mace,C0349381;C0949745;C1445339
nondisabling nonfatal stroke,C0038454;C4554100
biochemical events,C0441471;C3541888
vka naive n,
hyperkalemia $nmbr$ $nmbr$ meq l,C0020461;C0439375;C4552983
medication at randomization n,C0013227;C3244316;C4284232
elevated creatinine $nmbr$ pmol l,C0151578;C0439284;C0700225
disabling stroke,C0038454;C4554100
elevated bun $nmbr$ $nmbr$ meq l,C0151539;C0439375
disabling or fatal stroke,C0038454;C4554100
aliskiren dm vs dm,C0011816;C3250443
primary hemorrhagic stroke,C0205225;C0553692;C0439612;C0439631
placebo dm vs dm,C0011816;C3250443
primary ischemic stroke,C0205225;C0948008;C0439612;C0439631
dm aliskiren vs placebo,C0011816;C1120110;C3250443;C0032042;C1696465;C1706408
no prior hf hospitalization n $nmbr$ $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
hard mace,C0349381;C0949745;C1445339
nyha functional class at randomization,C1882083;C0205245;C0542341;C2700217
hba $nmbr$ c $nmbr$,C0019016;C1825777;C3538758
western europe plus other,C0043129
hbalc $nmbr$ n $nmbr$,
ace,C1452534;C4284014
established cardiovascular disease,C0443211;C0007222;C1272684
[ $nmbr$ $nmbr$ $nmbr$ ],
egfr $nmbr$ ml min,C1739039;C0439445;C3811844;C3812682
figure $nmbr$ treatment effect of sacubitril valsartan therapy,C1518681
urine albumin creatinine ratio mg g,C0455271;C1300563;C1318330
note have already got interaction values from the paper itself,C1316572;C1317574;C0042295;C0030351;C1547566
antihyperglycemic medications,C0013227;C0802604;C2598133;C4284232
elevated serum creatinine $nmbr$ $nmbr$ mg dl,C0700225;C0439269
cardiovascular medications,C0007220
elevated serum potassium $nmbr$ $nmbr$ mmol l,C0553704;C1532563
adp antagonist,C0523452;C0231491
drug discontinuation not due to death,C0457454;C1444662;C4552847;C0678226;C0011065;C1306577;C4082313;C4552775
cvdeath ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
any dose reduction,C0301630;C0392756;C1293152;C4551656
cv death ml ischemic stroke hospitalization for unstable angina revascularization or heart failure,C0019993;C0002965;C0018801;C0018802;C4554158
average daily dose,C1510992;C2348070;C2825518
risk score category points,C1552961;C2347617;C3714763
of target,C1521840;C2986546
western europe and other,C0043129
sacubitril valsartan,C4033631
creatinine mmol,C0010294;C0439190;C1561535
no prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
hemoglobin g l,C0635222
vildagliptin metformin vldm,C1570906;C0025598
nyha functional class i,C1882084;C0205245;C0542341;C2700217
metformin hdm,C0025598
kccq score,C0449820;C4050231
age distribution n,C0001782
coronary artery bypass surgery,C0010055
bmi distribution n,C0578022;C0520511;C1704711
diuretic agent,C0450442;C1254351;C1521826
mean s d duration of t $nmbr$ dm years,C0449238;C2926735
mineralocorticoid receptor antagonist,C1579268
mean s d baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
oral anticoagulant agent,C0354604
mean s d baseline fpg mmol l,C0168634;C1532563;C1442488
cardiac resynchronization therapy,C1167956
mean s d metformin dose mg day,C0025598;C0439422
risk category points,C1552961;C2347617;C3714763
age $nmbr$ years and bmi $nmbr$ kg m $nmbr$,C1510829;C0022718;C0439209;C4054209
enalapril lcz $nmbr$ n $nmbr$ n $nmbr$,C0014025
vldm n $nmbr$,
enalapril n $nmbr$,C0014025
hdm n $nmbr$,
lcz $nmbr$ n $nmbr$,
hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
cv death or hf hospitalization n,C0011065;C1306577;C4082313;C4552775;C0018488;C0019993;C1313497;C1538440;C3273279
hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions,C0019016;C1825777;C3538758;C1708130;C0559546;C3539617;C4050121
ratet $nmbr$ cl,C0596019
reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$,C0301630;C0392756;C1293152;C4551656;C0168634;C1442488
cv death n,C0011065;C1306577;C4082313;C4552775
mean age y median range,C1514721;C2348147;C3542016
hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
all cause death n,C0015127;C0011065;C1306577;C4082313;C4552775;C1524003
systolic blood pressure mm hg median range,C1514721;C2348147;C3542016
hr bpm,
diastolic blood pressure mm hg median range,C1514721;C2348147;C3542016
creatinine mol l,C0010294;C0347982;C1561535
previous ischemic stroke n,C0205156;C0948008;C1552607
median bnp iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
previous coronary artery disease n,C0010054;C0010068;C1956346
median nt probnp iqr pg ml,C0669479;C0439297;C0754710
history of diabetes mellitus n,C0455488
ischaemic etiology n,C0475224;C0015127;C1314792;C1524003
history of hypercholesterolemia n,C1533076
nyha,C1275491
baseline scales median range,C1514721;C2348147;C3542016
hospitalization for heart failure n,C3898876
nihss at randomization,C1697238;C0034656
coronary artery bypass grafting n,C0010055
stroke subtype n,C0038454;C0449560;C4554100
percutaneous coronary intervention n,C1532338
laa,
diuretic n,C0012798
soe or sue,
beta blocker n,C0001645
extracranial carotid stenosis n,C0580586;C0007282
mineralocorticoid receptor antagonist n,C1579268
medications at timing of randomization n,C2359859;C0034656
oral anticoagulant n,C0354604
antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177;C0034656
antiplatelet agent n,C0085826
antidiabetic agents,C0935929
lipid lowering agent n,C0086440
time from onset to randomization h mean sd,C0449244;C0033727;C2699239;C0369286;C0441932;C0564385;C4528284
implantable cardioverter defibrillator n,C0162589;C2825184
time from onset to medication h mean sd,C0449244;C0013227;C2699239;C3244316;C4284232
cardiac resynchronization therapy n,C1167956
event rates,C0871208;C1521828
enalapril,C0014025
p value for variance,C1709380;C1711260;C2348152
lcz $nmbr$,
placebo plus aspirin,C0032042;C1696465;C1706408
cv death or hf hosp,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hf hosp,C0018488;C1313497;C1538440;C3273279
time to treatment,C3494202
acd,C4554601
hospital factor $nmbr$,C1521761;C2827422
$nmbr$ enroll,
bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure,C0488055;C0871470;C1306620
$nmbr$ beds,C0004916
psoriasis duration mean sd years,C0033860;C0439234
lesion location,C0450429;C1515974;C4284930;C4284931
bsa affected mean sd,C0392760;C2699239;C1314939
cortical only,C0001613;C0007776;C0022655
pasi score mean sd,C0444504;C2699239;C2347634;C2348143
non cortical,C0001613;C0007776;C0022655
fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy,C0349966;C1337208;C0237629;C1515119
vascular territory $nmbr$,C1301808;C2983136
tiotropium $nmbr$ g n $nmbr$,C0213771;C0439267
anterior circulation,C0005775;C1516559
tiotropium $nmbr$ $nmbr$ g n $nmbr$,C0213771;C0439267
posterior circulation,C0005775;C1516559
median range duration of asthma y,C0449238;C2926735
mca,C0149566
fev $nmbr$ at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
with n $nmbr$,C0369718;C0441922
actual l,C0237400
without n $nmbr$ $nmbr$,C0369718;C0441922
of predicted,C0681842;C1882327
asia pacific or other,C0003980
fev $nmbr$ at baseline randomization,C3714541;C0168634;C0034656;C1442488
diabetesduration mean sd y,C0444504;C2347634;C2348143
fvc,C3714541
glycated hemoglobin mean sd,C0017853;C2699239
fev $nmbr$ fvc at baseline randomization,C3714541;C0034656
glycatedhemoglobin category,C0683312;C3889287
pefam l min,C0702093;C1524029;C3813700
priorvascular disease,C0012634
pefpm l min,C0702093;C1524029;C3813700
peripheral artery,C0489868
priorheartfailure,
acq $nmbr$ total score,C2919686;C2964552
ics dose of stable maintenance treatment g,C3714445
baseline heart failure severity amongthose with priorheartfailure,C0018801;C0018802;C4554158
treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0549193;C1704769;C2350001
nyha class iii,C1882086
active vs placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
nyha class iv,C1882087
adjusted mean of difference se ml,C0444504;C2347634;C2348143
nyha class not reported,C1882083;C0684224;C0700287;C4319718
peak fev $nmbr$ $nmbr$ $nmbr$ h response,C0871261;C1704632;C1706817;C2911692
bloodpressure mean sd m m hg,C0025424;C0428257;C2347108;C2347109;C2348272
trough fev $nmbr$ response,C0871261;C1704632;C1706817;C2911692
body massindex mean sd a,C0242821;C2699239;C0460148;C1268086;C4082212
fev $nmbr$ of predicted normal post bronchodilator,C3714541;C0205307;C0231683;C0439166;C2347086;C4553972;C2599594
cigarettesmoking,
antihyperglycemictherapies,
dabigatran $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
enoxaparin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nonaspirin antiplatelet agent,C0722138;C0085826
number of treated patients,C2360800;C1522326
sitagliptin no total no,C1565750;C0439175;C0439810
females n,C0086287
placebo no total no,C0032042;C1696465;C1706408;C0439175;C0439810
body mass indexa,C0518010
p value fo interactio,C1709380
previous vte n,C0205156;C0630906;C1552607
region latin american,C0017446;C1553378;C0205147
diabetes duration median,C0549183;C0876920;C2347635;C2348144;C2939193
creatinine clearanceb ml min,C0010294;C0439445;C1561535
racec n,C4287599
prior congestive heart failure yes,C1549445;C1705108;C1710701
australia new zealand south africa,C0027978;C0037712;C0324547
baseline heart failure severity nyha class i,C0018801;C1882084;C0018802;C4554158
patients treated and operated n,C0030705;C1522326;C3242339
prior myocardial infarction yes,C1549445;C1705108;C1710701
anesthesiad n,
prior coronary artery disease yes,C1549445;C1705108;C1710701
general alone,C0205246;C3812897;C3891294;C4521767;C0205171;C0439044;C0679994
prior hypertension yes,C1549445;C1705108;C1710701
neuraxial alonee,
body mass index median,C0549183;C0876920;C2347635;C2348144;C2939193
combinationf,
systolic blood pressure mm hg $nmbr$,C0488055;C0439475;C0871470;C1306620
mean duration of surgery sd min,C0449238;C2926735
glycated hemoglobin median p,C0062418;C3891442
study treatment,C1521826
renal function $nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0232804;C0439445
mean time to first subcutaneous injectiong h in relation to surgery hr,C0040223;C3541383;C0038894;C0038895;C0543467;C1274039
$nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
mean time to first oral dose postsurgeryh hr,C0040223;C3541383
$nmbr$ to $nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$ a,C0369637;C0441923
median range duration of hospital stayi d,C0449238;C2926735
$nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$ a,C0369637;C0441923
median range treatment duration d,C0444921;C3259042
insulin yes,C1549445;C1705108;C1710701
enoxaparn $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
thiazolidinedione yes,C1549445;C1705108;C1710701
estimate $nmbr$ cl,C0750572;C0596019
ace inhibitor yes,C1549445;C1705108;C1710701
weight [kg],C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209
angiotensin receptor blocker yes,C1549445;C1705108;C1710701
creatinine clearance [ml min],C0812399;C0439445
p blocker yes,C1549445;C1705108;C1710701
n c,C2349138
diuretic thiazide,C0012802
bmi [kg m $nmbr$ ],C0578022;C0022718;C0439209;C4054209
lvef median iqr,C0428772;C0488728
age [years],C0001779;C0439234
hfpef ef n $nmbr$,
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0016327
systolic bp mmhg mean sd,C0488053;C2699239
monotherapy $nmbr$,
diastolic bp mmhg mean sd,C0488053;C2699239
add on to met $nmbr$,C1883712;C0428210;C1550543;C4317104
mitral regurgitation,C0026266
add on to met su $nmbr$,C1883712;C0038642;C1705534
heart failure hf,C0018488;C1313497;C1538440;C3273279
mean sd age y race n,C0001779;C0034510;C1706779;C3853635
hospitalization for hf previous year,C0019993;C0018488;C1313497;C1538440;C3273279
othery ethnicity n,C0015031;C0243103
hf hospitalizations median iqr,C0018488;C0019993;C1313497;C1538440;C3273279
mean sd hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
stroke or pvd,C0038454;C4554100;C0085096;C4521226
latin american subgroup,C1079230;C1515021
aicd,C0972395;C2611803;C3537205;C3546309
add on to met,C1883712;C0428210;C1550543;C4317104
medication prior to admission,C0013227;C3244316;C4284232
add on to met su,C1883712;C0038642;C1705534
ccbs,C0006684
cana,C1418845
presenting signs and symptoms,C0449450;C0220912;C0220913;C0311392;C0683368;C1457887
figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$,C1268766;C0032659;C1257890;C1553378;C1079230;C0031962;C0681867;C1706449
orthopnea,C0085619
dyspnea at rest nyha iv,C0743330;C0022326;C4265176
bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified,C0038944;C1112705;C1705982;C1273937;C0031962;C1707455;C0884358;C0002778;C0936012;C1524024;C1518422
edema,C0013604;C1717255
pooled non canvas studies n $nmbr$ non cana n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0947630;C1319635
jvp,
canvas n $nmbr$ placebo n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0032042;C1319635;C1696465;C1706408
n $nmbr$ yrs,C0369718;C0441922
overall population n $nmbr$ $nmbr$ non cana n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0032659;C1319635;C1257890
inflammation,C0021368
othera,
crp ng ml,C3890735;C0439275;C4048285
fpg mg dl mmol l,C0439268
d dimer ng ml,C0060323;C0439275
microvascular complicationsb,C0443258
gdf $nmbr$ ng ml,C1418244;C0439275
use of loop diuretics,C1524063;C0354100
interleukin $nmbr$ pg ml,C0021764;C0439297;C1527200
prior cv history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pentraxin $nmbr$ ng ml,C0439275
all cana,C1418845
procalcitonin ng ml,C0072027;C0439275
$nmbr$ years of age,C1510829
pigr ng ml,C1418569;C0439275
duration of t $nmbr$ dm $nmbr$ years,C0449238;C2926735
psap b ng ml,C1418975;C0439275;C1420002;C1425004
egfr $nmbr$ ml min $nmbr$ $nmbr$ mz,C0026655;C1705291
rage ng ml,C0034634;C0439275;C3539760;C3815186
no fracture history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
tnf r $nmbr$ a ng ml,C1363984;C1706001;C0439275
fracture history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
wap $nmbr$ c ng ml,C0439275
microvascular complications n,C0443258;C0009566;C1171258
oxidative stress,C0242606
use of loop diuretics n,C1524063;C0354100
mpo ng ml,C0439275
prior cv history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
remodeling,
continued thienopyridine n $nmbr$ $nmbr$,C0549178;C1120149
syndecan $nmbr$ ng ml,C0075691;C0439275;C1419891
non white raceb,C0007457;C0043157;C0220938
periostin ng ml,C0219433;C0439275;C1424662;C3812270
hispanic or latino ethnic groupb,C0086409;C0086528;C0015031;C0680174
galectin $nmbr$ ng ml,C0607430;C0439275
body mass indexc,C0518010
osteopontin ng ml,C0069676;C0439275;C1420369;C1505427;C4084879
renal insufficiency failure,C0035078;C1963154
cardiac stretch,C0018787;C0600080;C1522601
prior cancer,C0006826;C0998265;C1306459
st $nmbr$ ng ml,C0036056;C0439275;C3272372
indication for index pci,C0392360;C3146298
troponin i pg ml,C0077401;C0439297
unstable anginad,C0443343;C1883468
angiogenesis,C0302600;C1519670
type of stent at index procedure,C0332307;C1547052;C0184661;C2700391;C3274430;C3539779
vegfr ng ml,C1568520;C0439275
continued thienopyridine,C0549178;C1120149
angiogenin ng ml,C0051844;C0439275;C1367482
p value for interactiont,C1709380
mesothelin ng ml,C0380162;C0439275;C1334533
no mi,C3810814
neuropilin ng ml,C0287275;C0439275
bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478;C1274040;C1546471;C2825142
proadm ng ml,C0439275
ethnicity $nmbr$,C0015031;C0243103
ntpro cnp ng ml,C3889729;C0439275
mean change in sbp from baseline mmhg mean sd,C0392747;C0443172;C1705241;C4319952;C0168634;C2699239;C1442488
endothelin $nmbr$ pg ml,C0079284;C0439297
education yrs mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
troy ng ml,C1420811;C0439275;C1883402
receiving antihypertensive treatment n blood pressure mm hg mean sd,C1514756;C0428886;C2699239
arteriosclerosis,C0003850
mean change in dbp from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952;C0439269;C2699239
esam ng ml,C1424976;C0439275
baseline lipid profile mg dl mean sd,C0439269;C2699239
ltbr ng ml,C1416931;C0439275
participants at baseline n,C0679646;C0168634;C1442488
ngal ng ml,C0215955;C0439275;C1416806;C2346625
kim $nmbr$ pg ml,C0439297
fasting glucose mg dl diabetes classification,C0008902;C0008903;C0678229
diabetesz,
pioglitazone n $nmbr$ $nmbr$,C0071097
mean sd baseline,C0168634;C1442488
laboratory data mean sd,C0022877;C2699239;C3244292;C4283904
impaired fasting glucosex,C0221099;C0015663
insulin mu ml,C0021641;C0439339;C1533581;C1579433;C3714501
baseline if have $nmbr$ yr follow up,C0168634;C1442488;C0589120;C1522577;C1704685;C3274571
dysglycemic categories n,C0683312
lipid trial participantsk,C0023779;C0008976
ada ifg,C1334085;C1708411
change from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952
$nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
fasting glucose $nmbr$ mg dl n,C0015663;C0439269
who idf ifg,C1334085;C1708411
st t waveft,C0036056;C3272372
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
hba $nmbr$ c $nmbr$ $nmbr$ to,C0019016;C1825777;C3538758
history of lvh on electrocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013798;C1547122;C1623258
ncep atp iii metabolic syndrome features n,C1864620
history of lvh on echocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013516;C2243117
antihypertensive medication or,C0003364
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
sbp dbp $nmbr$ $nmbr$ mmhg,C0085805;C0439475
additional antihypertensive subgroup,C1079230;C1515021
abdominal obesity,C0311277
dapagliflozin n $nmbr$,C2353951
number s of features present,C0237753;C0449788;C0150312;C0449450
women ethnic origin,C0043210;C0015031
$nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
pioglitazone events n,C0071097;C0441471;C3541888
placebo events n,C0032042;C0441471;C3541888;C1696465;C1706408
hbaj mmol mol,C3829066
hispanic ethnicity,C0015031;C0243103
participants taking insulin,C0679646;C3842788
hypertension history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
selective vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
coronary artery disease history,C0683519
carotid artery disease,C0007273
aerobic activity,C0001701
history of dyslipidaemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
not at goal,C1518422;C0018017;C1571704
recent cardiovascular eventf,C0332185;C0007226;C3887460
at goal,C0018017;C1571704
egfr ml min per $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
ada impaired fasting glucose,C1060325;C1272092;C3811629
seated sbp n,C0277814;C0085805;C1283233
present $nmbr$ mg dl,C0150312;C0439269;C0449450
baseline mean seated sbp mm hg sd,C0439475;C2699239
who idf impaired fasting glucose,C3272598;C1272092
sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
homa,
hba $nmbr$ c n,C0019016;C1825777;C3538758
$nmbr$ men $nmbr$ women,C0025266;C0043210
hba $nmbr$ c baseline mean hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
linagliptin n z $nmbr$,C2746078
hba $nmbr$ c difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
presence of mets a,C0150312;C0392148;C3854307
ambulatory sbp n,C0439841;C0085805
$nmbr$ e $nmbr$ years,C0439234
baseline mean ambulatory sbp mm hg sd,C0439475;C2699239
homa ir mean sd mu l mmol l b,C0022065;C0439342;C0022071;C1448132
ambulatory sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
homa ir b,C0022065;C0022071;C1448132
serum uric acid n,C0455272;C0700634
$nmbr$ $nmbr$ mu l mmol l,C0439342;C0439190
baseline mean serum uric acid pmol l sd,C0455272;C2699239;C0700634
fasting c peptide nmol l c,C0015663;C0607868
serum uric acid difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
previous oad,C0205156;C1552607
dapagliflozin,C2353951
placebo adjusted mean difference in hba $nmbr$ c $nmbr$ ci [ p value],C0444504;C1705241;C1705242;C2347634;C2348143;C1709380
beta blocker subgroup,C0751987
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [,
o $nmbr$ o $nmbr$ loto $nmbr$ $nmbr$,C0483204
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
calcium channel blocker subgroup,C1079230;C1515021
homa ir mu l^mmol l,C0022065;C0439342;C0022071;C1448132
diuretic subgroup,C1079230;C1515021
presence of mets,C0150312;C0392148;C3854307
laa closure n $nmbr$,C0185003;C1521802
aclidinium formoterol $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
long term warfarin n $nmbr$,C0443252;C0043031
salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
previous myocardiaunfarction,C0205156;C1552607
gold classification,C0008902;C0008903;C0678229
previous major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
smoking consumption pack years,C0425291;C1277691
$nmbr$ _ $nmbr$ $nmbr$ $nmbr$,
exacerbation in previous year,C4086268;C0205156;C1552607
cha $nmbr$ ds $nmbr$ vasc,C1420648;C3714751
prior copd medication,C0013227;C3244316;C4284232
$nmbr$ _ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
laba lama,C0999593;C1416775
modified has bled,C0392747;C3889737;C0019080
laba lama ics,C0815320;C4551720
laa closure,C0185003;C1521802
fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
hazard ratio $nmbr$ confi dence interval,C1272706;C1552654;C1552713
post bronchodilator fevi $nmbr$ predicted,C0681842;C1882327
modified has bled $nmbr$,C0392747;C3889737;C0019080
bronchial reversibility,C0205039;C0449261;C1442216
no history of tia stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
bdi focal score $nmbr$,C0449820;C4050231
history of tia stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cat total score $nmbr$,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
lixisenatide n $nmbr$,C2973895
sgrq total score $nmbr$,C2964552
retinopathy no,C0035309;C1962966
duration of ra,C0449238;C2926735
neuropathy no,C0442874
tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1948050;C0332173;C0439228;C0439505
race no t,C0034510;C1706779;C3853635;C2603360
early n $nmbr$,C1279919
hispanic ethnic group no t,C0015031;C1879937;C2603360
established n $nmbr$,C0443211;C1272684
geographic region no,C0017446
tjc,
africa or near east,C0001737;C1707877
sjc,
south or central america,C1710133;C0007674
vdhmtss,
myocardial infarction before index acs no,C0027051;C0428953;C2926063;C3810814;C4552959
hscrp mg dl,C0439269
medical history at randomization no,C0262926;C1704706
acpa positive,C0439178;C1446409;C1514241;C2825490;C3812269
qualifying acs event no,C1514624;C0441471;C4019010
figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p,C4055223;C0030705;C1279919;C3538806;C4048756
unclassified,C0205426;C1546437;C2347854;C4085229
acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis,C0035452;C4706353;C0014779;C0003873
days from acs to randomization,C0439228;C0742343;C4318612;C0034656
a no vhd n $nmbr$ $nmbr$,
urinary albumin creatinine ratio^,C0486293;C1318293
b vhd n $nmbr$,
less than $nmbr$ y ears,C0013443;C0521421
not hispanic,C1518424
c right sided vhd n $nmbr$,C0205090;C0444532
africa near east,C0001741
d mitral stenosis vhd n $nmbr$,C0026269;C0264766
south central america,C0037713
bonferroni adjusted p value b vs a,C0456081;C1709380
days between acs and rand,C0439228;C0742343;C4318612;C1555436
bonferroni adjusted p value c vs a,C0456081;C1709380
$nmbr$ to less than $nmbr$,
bonferroni adjusted p value d vs a,C0456081;C1709380
$nmbr$ or greater,C1704243
vhd event rate year n,C0439234;C0439508
region us,C0815353;C3889164
no vhd event rate year n,C0439234;C0439508
non us,C0815353;C3889164
adiusted hazard ratio,C2985465
dm duration,C0449238;C2926735
persistent af n,C0205322;C0332996
$nmbr$ years or more,C0439234
strokezsee,
less than $nmbr$ $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
$nmbr$ $nmbr$ or more,
crcl at baseline ml min,C1846718;C0439445
less than $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
moderate renal impairment n,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ kg m $nmbr$ or more,C0022718;C0439209;C4054209
coronary artery disease n,C0010054;C0010068;C1956346
acs event,C0441471;C4019010
vitamin k antagonist experienced n,C1096489;C2267235
pcr after acs,C0032520;C3853643;C4050242
history of stroke see tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ace arb use,C0042153;C0457083;C1947944
on sulfonylurea,C0038766;C3536898
uacr,
alone,C0205171;C0439044;C0679994
stent n $nmbr$,C0038257
plus metformin,C0025598
medical therapy n $nmbr$,C0418981
hba $nmbr$ c distribution,C0520511;C1704711
stenosis core lab,C0678234;C4684837;C1261287;C2632116
$nmbr$ h pmg mg dl,C0033727;C0439269;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
fasting insulin giu ml,C0015663;C0439526;C1705224;C3887665
stenosis investigator,C0678234;C0035173;C1261287;C2632116
homa p,
peak systolic pressure gradient,C4687747
efficacy parameter,C0549193;C1704769;C2350001
mean systolic pressure gradient,C4687744
subset of patients on metformin,C1515021;C0030705;C0025598
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ $nmbr$,
subset of patients not on metformin,C1515021;C0030705;C1518422;C0025598
stent,C0038257
ls mean change from baseline $nmbr$,C0392747;C0443172;C1705241;C4319952
a by quantiles,C1709792
difference in ls means $nmbr$ ci $nmbr$,C1705241;C1705242
percent stenosis [core lab],C0678234;C1261287;C2632116;C4684837
total n $nmbr$ n,C0439175;C0439810
percent stenosis [investigator],C0678234;C1261287;C2632116;C0035173
min max age,C0702093;C0001779;C1524029;C3813700
$nmbr$ o $nmbr$,C0483204
duration of ra years,C0449238;C2926735
b historic clinical thresholds,C0205210;C0449864
$nmbr$ $nmbr$ q,
ara functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
any albuminuria,C0001925
biologics user,C1548600;C1706077
ankle brachial index $nmbr$ $nmbr$,C1328319;C3888326
methotrexate user,C1548600;C1706077
diabetes with use of oral diabetes drugs,C0020616;C1524063
low dose corticosteroid user,C1548600;C1706077
dmard user,C1548600;C1706077
diabetes with no use of diabetes drugs,C0020616;C1524063
dmard or corticosteroid,C0242708;C0001617;C3536709
new diabetes,C0011847;C0011849
igt or ifg,C1334085;C1708411
fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i,C1705241;C1705242;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0168634;C1442488;C0439230;C0021966;C0221138
fasting glucose mmol l,C0015663;C1532563
colchicine n $nmbr$,C0009262
hbalc mmol mol,C3829066
no colchicine n $nmbr$,C0009262
nonglycemic cardiovascular risk factors,C0850624
age y mean range,C1514721;C2348147;C3542016
creatinine p mol l,C0010294;C0347982;C1561535
creatinine mg dl mean sd,C0439269;C2699239
urine acr mg mmol,C0567349;C2348885
ef mean sd,C0444504;C2699239;C2347634;C2348143
other antihypertensive drug,C0003364
ef b $nmbr$,
insulin glargine n x,C0907402
valvular heart disease,C0018824;C1963123
$nmbr$ $nmbr$ range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
standard care n,C1442989;C1947933;C2828392
age y n $nmbr$,C0001779
first co primary outcome,C0205225;C1274040;C0439612;C0439631
age $nmbr$ $nmbr$ y n $nmbr$,C0001779
s $nmbr$ $nmbr$ s,C0565930;C2603362
alc $nmbr$ $nmbr$,C1424945;C3811058
$nmbr$ y kaplan meier rate $nmbr$ ci,C0008107;C3259781
no metformin use,C0042153;C0457083;C1947944
female race white,C0007457;C0043157;C0220938
metformin use,C0042153;C0457083;C1947944
cv death mi stroke recurrent ischemia,C0022116;C4321499
neither ace i nor arb use,C0021966;C0221138;C0042153;C0457083;C1947944
with rehospitalization urgent coronary revascularization,C0439609;C0877341;C3272275
ace i or arb use,C0021966;C0221138;C0042153;C0457083;C1947944
age b $nmbr$ y n $nmbr$,C0001779
new om,C0028971;C1705272
other race,C0034510;C1706779;C3853635
prior om,C0028971;C1705272
bmi kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
second co primary outcome,C0205225;C1274040;C0439612;C0439631
gusto moderate severe bleeding,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
s $nmbr$ $nmbr$ $nmbr$,
gusto moderate bleeding ich,C0019191;C3272597;C3281105
standard care allocation,C1442989;C1706778;C2828392
hyperlipidmemia,
insulin glargine allocation,C0907402;C1706778
net clinical benefit cv death mi stroke gusto moderate severe bleeding,C4684590;C0019080
heart rate $nmbr$ bpm,C0018810
thienopyridine at baseline,C1120149;C0168634;C1442488
no betablocker use,C0042153;C0457083;C1947944
aspirin dose at baseline mg,C4696290
betablocker use,C0042153;C0457083;C1947944
secukinumab $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
omega $nmbr$ fa intake $nmbr$ st third,C0036056;C3272372
range race n,C1514721;C0034510;C1706779;C3853635;C2348147;C3542016
omega $nmbr$ fa intake $nmbr$ nd third,C1512806;C0205437
height cm mean sd a,C0444504;C2699239;C2347634;C2348143
omega $nmbr$ fa intake $nmbr$ d third,C1719844;C1512806;C0205437
bmi kg m $nmbr$ mean sd a,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
triglycerides $nmbr$ st third,C0036056;C3272372
range iga modified $nmbr$ score n,C0392747;C0449820;C4050231;C3889737
triglycerides $nmbr$ nd third,C0041004;C0205437
time since first psoriasis diagnosis y mean sd,C0040223;C3541383
triglycerides $nmbr$ d third,C0041004;C0205437
previous exposure to systemic psoriasis therapyb yes n,C0332157;C0033860
selexipag n $nmbr$,C2000145
previous exposure to biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
western europe and australia,C0043129;C0004340
previous exposure to non biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
time since diagnosis of pah yrf,C0040223;C3541383
tpasi $nmbr$,
pah classification no,C0008902;C0008903;C0678229
ulpasi $nmbr$,
heritable,C0439660
llpasi $nmbr$,
associated with connective tissue disease,C0332281
patient characteristic,C0030705;C1521970
associated with corrected congenital shunts,C0332281;C0009678;C1744681
on omt,
off omt,
associated with hiv infection,C0332281;C0019693
on omt n $nmbr$,
associated with drug or toxin exposure,C0332281;C0013227;C1254351;C0040537
off omt n $nmbr$,
who functional class no c,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
p value on vs off omt,C1709380
$nmbr$ minute walk distance m,C0439232;C0429886;C0700321;C0702093;C1282918;C2347166
reduced ef,C0392756
use of medications for pah no,C1524063;C0030123;C3203102;C4284467
thienopyridine drug at start of open label period,C0013191;C1705425
endothelin receptor antagonists,C1134681;C2266875
number of treated lesions per patient,C0449791;C1522326;C0030705
phosphodiesterase type $nmbr$ inhibitors,C0031638;C1656262;C3539996
number of treated vessels per patient,C0237753;C0449788;C0030705
endothelin receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C1134681;C2266875
number of stents per patient,C0237753;C0449788;C0030705
selexipag,C2000145
total stent length mm mean sd,C0038257;C2699239
no of patients no of events,C0030705;C0441471;C3541888
treated vessel native coronary,C0005847;C0018787
pah therapy at baseline,C0039798;C0087111;C1363945
modified acc aha lesion class b $nmbr$ c,C0101856
era and pde $nmbr$ inhibitors,C1521863;C3495919;C0031638
unadjusted p value for interaction,C1439367;C1709380
era monotherapy,C1521863;C3495919
adjusted hr $nmbr$ ci,C0008107;C3259781
pde $nmbr$ inhibitor monotherapy,C0031638
no pah therapy,C0039798;C0087111;C1363945
p value for adjusted hr,C1709380;C0456081
l ll,C0439394;C1706495;C3642217
adjusted p value for interaction,C0456081;C1709380
age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
ipah hpah hiv drug or toxin induced,C0013227;C1254351;C0040549;C0205263;C4522020
no stroke n $nmbr$ $nmbr$,C0038454;C4554100
stroke n $nmbr$,C0038454;C4554100
assoc with connective tissue disease,C0009782
weight in kg median iqr,C0005910;C0043100;C1305866;C1705104
assoc with corrected congenital shunts,C0205202;C0009678;C1744681
sbp mm hg median iqr,C0085805;C0439475
western europe australia,C0043128
dbp mm hg median iqr,C0536221;C0439475;C3813197;C4281799
japan n $nmbr$,C0022341
cardiovascular history,C1880008
not japan n $nmbr$ $nmbr$,C1518422;C0022341
history of second prior mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
overall n $nmbr$ $nmbr$,C0282416;C1561607
multivessel cad n,C1504769;C2239547;C3813548;C4284121
range min max,C1514721;C0702093;C1524029;C3813700;C2348147;C3542016
history of cabg n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C4684572;C0035245
screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
history of pci n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
predicted pre bronchodilator fev $nmbr$,C2599602;C3714541
qualifying nstemi n,C1514624;C3537184;C4255010
absolute reversibility in fev $nmbr$ ml,C0205344;C0449261
history of chf n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline fev $nmbr$ l,C0168634;C1442488
history of atrial fibrillation n,C0729790
predicted fev at baseline,C3714541;C0168634;C1442488
history of tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ff vi $nmbr$ $nmbr$ pg od,C0229089;C0439164;C1512019;C3273373;C3665488
medical therapies,C0418981
ff $nmbr$ pgod,C4554348
ace inhibitor n,C0003015;C4541021
ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
ticagrelor $nmbr$ mg $nmbr$ yr km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
difference vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
difference vs ff $nmbr$ pg $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0008107;C3259781
not japan,C1518422;C0022341
p interactio n,C0369773;C2603361
white $nmbr$ $nmbr$,C0007457;C0043157;C0220938
no history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
black african american $nmbr$ $nmbr$,C0085756
no history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
asian $nmbr$ $nmbr$,C0078988
low dose,C0445550;C1708745
other $nmbr$ $nmbr$ t,C2603360
high dose,C0444956
pooled trials n $nmbr$,C1709595;C2349200;C4522255
budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$,C1276807;C0439267
wc cm,C0013123;C2825512
budesonide $nmbr$ ^g n $nmbr$,C0054201;C0439267
insulin pmol l t vital signs,C0150404;C0518766
budesonide formoterol $nmbr$ ^g $nmbr$ $nmbr$ ^g n $nmbr$,C1276807
pulse beats min cholesterol mmol l,C2827896
budesonide formoterol n $nmbr$,C1276807
ffa mmol l,C0015688;C1532563
budesonide n $nmbr$,C0054201
prediabetes n,C0362046
age yr age group no,C0027362;C2348001
dyslipidaemia n,C0242339
female sex no race no f,C0086287;C0034510;C1706779;C3853635;C0016327
dyslipidaemia and hypertension n,C0242339;C0020538;C1963138
mean time since asthma,C0040223;C3541383
individuals with normoglycaemia,C0027361;C0237401
diagnosis yr,C0011900;C0439234;C1704338;C1704656
individuals with prediabetes,C0027361;C0237401
mean acq $nmbr$ score at randomization,C3533236;C0034656
individuals with t $nmbr$ dm scale diabetes,C0027361;C0237401
asthma control status at randomization no,C0004096;C0449438;C2984299
estimated treatment difference,C1705241;C1705242
controlled acq $nmbr$,C2587213;C2919686;C2911690
test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0034510;C1706779;C3853635
uncontrolled acq $nmbr$ $nmbr$ $nmbr$,C0205318;C2919686
liraglutide $nmbr$ $nmbr$ mg ls means n,C0024671;C0023668;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
exacerbations in past $nmbr$ mo no,C4086268;C0026544;C0332177
placebo ls means n,C0032042;C0023668;C1696465;C1706408
daily dose of inhaled glucocorticoid no,C2348070;C0004048
etd [ $nmbr$ ci],C0008107;C3259781
medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
number of individuals,C1549735
monitoring group n $nmbr$,C0150369;C0441848;C1283169
current weekly alcohol use,C0332174;C0001948
body mass index kg m,C0022718;C0439209;C4054209
age at completion of highest level of,C0001779;C4321237
inflammatory disease,C1290884
exercise times per week minimum,C0456698
previous cardiovascular events,C0205156;C1320716;C1552607
$nmbr$ min time,C0040223;C3541383
concomitant medication after randomisation,C0013227;C3244316;C4284232
ace arb medication,C0013227;C3244316;C4284232
mra spironolactone or eplerenone,C0243032;C0037982;C1609165;C3891069;C0961485
any blood pressure medications,C0849164
secondary pci,C0027627;C4049621;C0175668;C0205436
lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
coronary angiography and intervention,C0085532;C1548829;C0184661;C0886296;C1273869
aspirin or thienopyridines,C0004057;C1120149;C2936588
radial access,C0444454;C1554204
no of events women men,C0043210;C0025266
one vessel disease,C3275121
ratio of hrs $nmbr$ ci p for sex interaction,C0456603;C1547037;C0009253;C1704675;C0036864;C0079399;C0804628;C1314687;C1522384
two vessel disease,C0581375
primary outcomes,C0205225;C1274040;C0439612;C0439631
three vessel disease,C3272265
major cardiovascular,C0007226;C3887460
multivessel two vessel three vessel or left main,C0205448;C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
all cardiovascular,C0007226;C3887460
number of stents implanted,C0237753;C0449788;C0021102;C2828363
major coronary,C0205082;C0018787;C0205164;C4318856;C4521762
drug eluting stent implanted at least one,C1322815;C0205447
major cerebrovascular,C0205082;C0205164;C4318856;C4521762;C1880018
stented vessels,C0038257;C0005847
all cancer,C0006826;C0998265;C1306459
coronary bypass graft,C1260596
no of events womenmen,C0441471;C3541888
creatinine clearance at admission ml min,C0184666;C0151280;C0809949
ratio of hrs $nmbr$ cl p for sex interaction,C0456603;C1547037;C0009253;C1704675;C0036864;C0079399;C0804628;C1314687;C1522384
monitoring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no previous diagnosis of diabetes mellitus,C0332132;C0011849
t $nmbr$,C2603360
previous diabetes mellitus,C0205156;C0011849;C1552607
no hypertension,C0020538;C1963138
any hba $nmbr$ c,C0019016;C1825777;C3538758
no current smoking,C0037369;C0453996;C1881674
lcz $nmbr$ treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
st,C0036056;C3272372
hba $nmbr$ c median q $nmbr$ q $nmbr$,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
creat clearance,C0449297;C1382187;C2825073;C4554548
hf duration y n,C0018488;C0449238;C2926735;C1313497;C1538440;C3273279
creat clearance $nmbr$ ml min,C0201975;C0439445
jugular venous distension n,C0425687
no prior cancer,C0006826;C0998265;C1306459
edema n,C0013604;C1717255
no prior heart failure,C0018801;C0018802;C4554158
rales n,C0034642;C0240859
one vessel,C0205447;C0005847
ckd egfr,C1739039;C3811844;C3812682
multi vessel or left main,C0439064;C0005847;C3266262;C0205091;C0205225;C1542147;C0443246;C1552822
icd crt d n,C0021122
bms,
crt p d n,C0369718;C0441922
length of stent median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
ischemic cause,C0015127;C1524003
number of stent l or $nmbr$ or $nmbr$,C0237753;C0449788
previous af,C0344434;C4049859
roflumilast n $nmbr$ $nmbr$,C0965618
mra,C0243032;C1609165;C3891069
age mean sd yr,C0001779;C0439234
antiplatelets any,
total cigarette pack years mean sd,C1303175;C2699239
hypoglycemic agent,C0020616
normoglycemia,
copd duration mean sd yr,C0024117;C0439234;C1412502;C3714496
pre diabetes mellitus,C0362046
prebronchodilator fev $nmbr$ mean sd l,C0444504;C2347634;C2348143
undiagnosed diabetes mellitus,C1408353;C0011849
post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
p values for interaction,C1709380;C1704675
predicted prebronchodilator fev $nmbr$ mean sd l,C0681842;C0444504;C2347634;C2348143;C1882327
hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279;C0011065;C1306577;C4082313;C4552775
predicted post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0026544;C0332177
post bronchodilator fev $nmbr$ fvc ratio mean sd,C2599594;C2699239
normal hba $nmbr$ c n $nmbr$,C0205307;C0019016;C1825777;C3538758;C0231683;C0439166;C2347086;C4553972
no of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
pre diabetes mellitus n $nmbr$,C0011849;C0362046
$nmbr$ mo mean sd x,C0026544;C0332177
undiagnosed diabetes mellitus n $nmbr$,C1408353;C0011849
year n,C0439234;C0439508
diabetes mellitus n $nmbr$,C0011849
prior hospitalizations n,C0332152;C0019993;C2826257
p values of interaction,C1709380;C1704675
cat score mean sd,C0007450;C2699239;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
hypotension n,C0020649;C3163620
exact pro total score mean sd,C2964552;C2699239
symptomatic hypotension,C0020649;C3163620
ics laba therapy n,C0039798;C0087111;C1363945
symptomatic hypotension with sbp,C0020649;C3163620
fluticasone propionate salmeterol fdc,C0340427;C1413520;C3539652
leading to study drug discontinuation,C0332152;C0013175;C1522538
budesonide formoterol fdc,C0340427;C1413520;C3539652
serum creatinine $nmbr$ $nmbr$ mg dl,C0201976;C0439269;C0600061
lama use n,C0042153;C0457083;C1947944
hyperkalemia n,C0020461;C4552983
brv $nmbr$ mg day,C0155502;C0439422
serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
brv overall,C0155502;C0282416;C1561607
cough n,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
etiology n,C0015127;C1314792;C1524003
any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
cryptogenic,C0332240
angioedema adjudicated n,C0002994
$nmbr$ b,
no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0019590
mean sd [range] duration of epilepsy years,C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016;C0449238;C2926735
catecholamines or corticosteroids without hospitalization,C0007412;C0001617;C3539185;C3540725;C3540726;C3540727
median minimum maximum focal seizure frequency $nmbr$ days at baseline,C0149775;C0439228
hospitalized without airway compromise,C0701159;C4055482
prior lev treatment n,C1514463;C0023556
airway compromise,C4055482
concomitant aedsb n,C0521115
$nmbr$ teae,
any adverse event leading to study drug discontinuation n,C0877248;C0332152;C0013175;C1522538
female subgroup,C1079230;C1515021
teaes leading to discontinuation of study drug,C0332152;C0013175;C1522538
body mass kg,C0022718;C0439209;C4054209
saes,C1519255;C1622657;C4553214
drug related saes,C1519255;C1622657;C4553214
type of mi,C0332307;C1547052
symptom onset to hospital arrival hours,C4086878;C0019994;C1510665
teaes reported by $nmbr$ patients in the overall brv group n,C1709908;C0155502;C0441848
killip class ii,C2697845
paresthesia,C0030554;C4553220
somnolence,C0013144;C2830004;C4553740
crusade bleeding score,C0449820;C4050231
$nmbr$ $nmbr$ _ $nmbr$,
cataract,C0086543;C4555209
nace primary endpoint,C2986535
constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
convulsion,C0036572;C4048158
cardiac death,C0376297
reinfarction,
cystitis,C0010692;C0600041;C1963088
ischemic tvr,C0475224
hyponatremia,C0020625;C4553967
all bleeding,C0019080
hot climate subset,C0178683;C1515021
barc $nmbr$ $nmbr$,
other climate subset,C0008946;C1515021
thrombocytopenia,C0040034;C0392386
sex n b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
definite,C0439544;C1704787
otherc,
probable,C0033204;C0332148
high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
acute,C0205178
high dosage ics plus laba with baseline blood eosinophils,C0815320;C4551720;C0168634;C0014467;C1442488
subacute $nmbr$ $nmbr$ days,C0205365;C0439228
benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p value cangrelor versus clopidogrel in women,C1709380;C1121991;C0070166;C0043210
local eosinophil count cells per pl t,C0007584
p value cangrelor versus clopidogrel in men,C1709380;C1121991;C0070166;C0025266
central eosinophil count cells per pl t,C0007584
p value men versus women,C1709380;C0025266;C0043210
prebronchodilator fev $nmbr$ l t,C2599602;C3714541
age y median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
prebronchodilator fev $nmbr$ predicted normal t,C0520835;C0681842;C1882327
dx at presentation n,C3538936;C0449450
fev $nmbr$ fvc prebronchodilatort,C3714541
nsteacs,
reversibility t,C0449261
cardiac biomarker n,C1271630
time since asthma diagnosis years,C0556970;C0004096;C2984299
previous heart failure,C0018801;C0018802;C4554158
number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C0439231
baseline hemoglobin median iqr g dl,C0439267
number resulting in emergency department visit,C0237753;C0449788;C0332294;C0562508
baseline hematocrit median iqr,C0168634;C0018935;C0518014;C1442488
patients with $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268;C0332294;C0562508
periprocedural medications n clopidogrel $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number resulting in hospital admission,C0237753;C0449788;C0184666
clopidogrel $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268;C0184666
duration of pci min median n iqr,C0449238;C2926735
poba n,
diagnosis of allergic rhinitis,C0011900;C1704338;C1704656
access site,C0589360
nasal polyps,C0027430
p interaction rx arm sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
atopic based on phadiatop test,C0392707;C1527178;C1705938
cangrelor n $nmbr$ n n,C1121991
history of omalizumab treatment,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
clopidogrel n $nmbr$ n n,C0070166
aqlq s $nmbr$ scorets,C4055434
unadjusted or $nmbr$ ci p value,C1439367;C0008107;C1709380;C3259781
smoking pack year years fl,C1300812;C1708024
adjusted or $nmbr$ ci p value,C0456081;C0008107;C1709380;C3259781
empty,C1880497
a beuralizuinab $nmbr$ ing q $nmbr$ w,
q wave mi,C0861151
death or stent thrombosis,C0011065;C1306577;C4082313;C4552775;C3897493
b benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estimate $nmbr$ ci,C0008107;C3259781
death q wave mi or ischemia driven revasc,C0011065;C0861151;C1306577;C4082313;C4552775;C0022116;C0378365;C4321499
baseline ocs use,C0042153;C0457083;C1947944
primary gusto severe bleeding,C0205082;C0019080;C4050465;C4050466
geo graphic region,C0017446;C0205147
primary gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
exacerbations in the prev year,C4086268;C0439234;C0439508
gusto severe or life threatening,C0205082;C4050465;C4050466;C1546953;C2826244;C3537125
nasal polyps at baseline,C0027430;C0168634;C1442488
gusto moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ige at baseline,C0168634;C1442488
timi major,C0205082;C0205164;C4318856;C4521762
$nmbr$ iu l,C0439457
timi major or minor,C0205082;C0205164;C4318856;C4521762;C0026193;C0205165
$nmbr$ to $nmbr$ iu l,C0439457
any blood transfusion,C0005841;C0281867
atopic at baseline,C0392707;C0168634;C1442488
acuity major,C0205082;C0205164;C4318856;C4521762
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$,
acuity minor,C0026193;C0205165
prior therapy with omalizumab,C1514463;C0966225
acuity major or minor,C0205082;C0205164;C4318856;C4521762;C0026193;C0205165
renal parameters,C0022646;C0449381
high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
egfr ml min $nmbr$ $nmbr$ mz,C0026655;C1705291
eosinophil count cells per pl,C0007584
u c mg g,C1532633;C2608091
central eosinophil count cells per pl,C0007584
haemoglobin mmol l,C0635222
predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
calcium mmol l,C0006675;C1532563;C0006726;C2936886;C3540037;C3714611
prebronchodilator fev $nmbr$ fvc,C2599602;C3714541
phosphate mmol l,C0031603;C1532563;C0031701;C1601799
acq $nmbr$ scoret,C2919686
other risk factors,C0035648;C1553898
number resulting in ed visit,C0237753;C0449788;C0332294
hba]c mmol mol,C0019016;C1825777;C3538758;C3829066
patients with $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268;C0332294
concomitant drug treatment,C0150270;C3469597
aqlq s $nmbr$ scored,C4055434;C0449820
event rate,C0871208;C1521828
nicotine pack years,C0028040;C1277691
cardiovascular subgroup,C1079230;C1515021
appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l,C0871208;C0456603;C1547037;C1521828;C1079230;C1515021;C0032042;C1696465;C1706408;C2982078;C1514756;C0014467;C0347983
renal subgroup,C1079230;C1515021
at increased fall risk n $nmbr$,C4699158
albuminuria,C0001925
notatincreased fall risk n $nmbr$ $nmbr$,C1268740
normoalbuminuria or microalbuminuria,C0730345
randomization group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
egfr and albuminuria,C1739039;C3811844;C3812682;C0001925
higher dose edoxaban regimen,C2348331
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ and normoalbuminuria or microalbuminuria,C1739039;C0439445;C3811844;C3812682;C0730345
lower dose edoxaban regimen,C2348331
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ and macroalbuminuria,C1739039;C0439445;C3811844;C3812682
has bled score,C0449820;C4050231
number of e,C0237753;C0449788
crcl at randomization ml min,C1846718;C0439445
vents patients,C0030705
aspirin use at randomization,C0042153;C0457083;C1947944
p for heterogeneity,C0369773;C2603361
dose reduced at randomization,C0178602;C0869039;C1114758;C0392756;C0034656
sulfonylurea derivatives,C0038766
ttr warfarin arm only,C0446516;C3715044;C4553528
$nmbr$ $nmbr$ mm,C4330985;C4554674
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
charlson comorbidity index,C4546361
$nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
increased risk falls,C1849142
baseline ^ste mm,C4330985;C4554674
no increased risk falls,C1849142
baseline ste in worst lead mm,C1420459;C3811127
univariable,
baseline std mm,C4330985;C4554674
multivariable,
bone fracture,C0016658
q wave in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
bone fracture due to fall,C0016658;C0678226
time from sx onset to baseline ecg min,C1519428;C0449244;C3539997;C3815196;C0702093;C1524029;C3813700
malignancy death,C0011065;C1306577;C4082313;C4552775
cana $nmbr$ met n $nmbr$,C1418845;C0428210;C1550543;C4317104
cana $nmbr$ n $nmbr$,C1418845
net ep $nmbr$,C1880476;C4321526
race n t,C0034510;C1706779;C3853635
major crnm bleed,C0205082;C0019080;C0205164;C4318856;C4521762
death or ich,C0011065;C1306577;C4082313;C4552775;C0019191;C3272597;C3281105
$nmbr$ $nmbr$ $nmbr$ mmol mol,C3829066
abaloparatide sc n,C4042342;C0282380
figure $nmbr$ effects on ef cacy parameters,C1280500;C0449381
all participantsa,
c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C1079230;C3829066;C0332174;C0439230
t score categories lumbar spineb,C3854607
apremilast,C1678805
total hipc,C0439175;C0439810
$nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
femoral neckc,C0015811
duration mean sd years,C0444504;C0439234;C2347634;C2348143
fracture status prevalent vertebral fractured,C0016658;C0549207;C4554413
prior use of conventional dmards only biologic nai ve n,C1524063;C0242708;C0005515;C3537218;C0205460;C0369718;C0441922
prior nonvertebral fracture,C0332152;C0016658;C2826257
prior use of biologics n,C1524063;C0005515;C0005522;C4553887
age categories,C2916832
prior biologic therapeutic failures n,C0005515;C0087111;C0302350;C0205460
abl sc n n,C0023139;C0282380;C1704928;C3890208
baseline dmard use n,C0168634;C0042153;C0457083;C1947944;C1442488
placebo mean,C0444504;C2347634;C2348143
mtx mean dose $nmbr$ $nmbr$ mg wk,C0366550;C1881833
abl sc mean,C0444504;C2347634;C2348143
leflunomide mean dose $nmbr$ $nmbr$ mg day,C0063041;C0439422
least squares mean difference $nmbr$ ci,C0008107;C3259781
sulfasalazine mean dose $nmbr$ $nmbr$ g day,C0036078;C0439417
interaction p valuef,C1704675
baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n,C0168634;C0439422;C1442488
o os,C2673162
sjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
lavolta $nmbr$,
tjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
lavolta ii,C1710602;C4082587
haq di $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd,C0086715;C2699239
lebrikizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0030705;C0281858;C1292728
body mass index kg mq,C0005893;C0024853;C0578022;C1305855
physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0031831;C0804815;C0281858;C1292728
median range duration of asthma years,C0449238;C2926735
das $nmbr$ crp mean sd,C0051767;C2699239;C0057671
baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba,C2827928;C0117996;C0205163;C0439185
bsa $nmbr$ n t,
mean ics fluticasone propionate dpi or equivalent pg per day,C0444504;C0117996;C2347634;C2348143;C0205163;C2827928;C0439185
pasi score $nmbr$ $nmbr$ t mean sd,C0444504;C2699239;C2347634;C2348143
pre bronchodilator fevj,C2599602
presence of enthesitis n,C0150312;C0392148;C3854307
absolute l,C0205344
mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
t jj $nmbr$ $nmbr$,C2603360
presence of dactylitis n,C0150312;C0392148;C3854307
median serum periostin ng ml t,C0219433;C0439275;C1424662;C3812270
dactylitis count $nmbr$ $nmbr$ mean sd,C0239161;C2699239
median feno ppb f,C0549183;C0016327;C0876920;C2347635;C2348144;C2939193
week $nmbr$ itt population,C0032659;C1257890
tj $nmbr$ $nmbr$,C0039247
apremilast $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
median blood eosinophil count cells per pl t,C0549183;C0200638;C0876920;C2347635;C2348144;C2939193
concomitant conventional dmard use,C0042153;C0457083;C1947944
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t,C0005516;C0439275;C0005773
prior biologic exposure,C0274281;C0332157
patients with $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268;C0205156;C0439231;C1552607
biologic naive,C0005515;C0205460
adjusted exacerbation rate per patient peryear,C0871208;C1521828
prior biologic use,C0042153;C0457083;C1947944
rate difference lebrikizumab placebo,C0032042;C1696465;C1706408
biologic therapeutic failure,C0231174;C0680095
rate reduction,C0301630;C0392756;C1293152;C4551656
trial,C0008976
trial $nmbr$,C0008976
rate ratio lebrikizumab vs placebo $nmbr$ cl,C0456603;C2981360;C1547037;C0032042;C0596019;C1696465;C1706408
scale obesity and prediabetes,C0028754;C1963185;C0362046
biomarker high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
scale diabetes,C0011847;C0011849
lebrikizumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
phase $nmbr$ dose finding trial,C0037088;C0008976;C0243095;C2825141
lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
biometric parameters,C0449381
biomarker low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
[sd],C2699239
periostin high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
glycaemic parameters,C0449381
periostin low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
mean hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
eosinophil high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
mean hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
eosinophil low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
individuals with pre diabetes n,C0027361;C0237401
change from baseline in fevj mb,C0392747;C0443172;C1705241;C4319952;C0024853
individuals with type $nmbr$ diabetes n,C0027361;C0237401
adjusted mean se,C0444504;C0036919;C2347634;C2348143
normoglycaemic individuals n,C0580545;C0027361;C0237401
difference in means $nmbr$ cl,C1705241;C1705242
time to first exacerbation,C0040223;C3541383
figure $nmbr$ liraglutide exposure and body weight loss in men and women,C0274281;C0332157;C2911645;C0025266;C0043210
patients with event n,C0030705;C0441471;C4019010
liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0005911;C0025266;C0043210;C0042295;C1180280;C0444504;C2347634;C2348143;C0205120;C0205119;C1552595;C1882932;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602;C0205132;C0750572;C0032659;C1257890;C0205452;C0032042;C1696465;C1706408;C1456408;C0023693;C1306462;C1570446;C1881376;C3842678;C4050248;C4521367;C0028754;C1963185;C0008976;C0011847;C0011849;C0282460
median time to event weeks,C0040223;C3541383
figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c,C0274281;C0332157;C0019020;C3889898
asthma related health,C0004096;C0018684;C2984299
care use,C0042153;C0457083;C1947944
exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0392747;C0443172;C1705241;C4319952;C0027361;C0237401;C0497406;C0028754;C1963185;C1320657;C0205363;C0008976;C0444504;C0042295;C2347634;C2348143;C0205423;C0032042;C0205132;C1696465;C1706408;C1882932;C0750572;C0057717;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602
health care use rate peryear,C0814514;C0871208;C1521828
demographic feature,C0683970
rate difference events year,C0439234;C0439508
black race no total no f,C0005680;C0439175;C0439810;C0016327
oil,C0028908;C0032085;C1517288;C3541397
hispanic ethnic group no total no j,C0015031;C1879937;C0439175;C0439810
change from baseline in aqlq s score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
stroke no total no,C0038454;C4554100;C0439175;C0439810
change from baseline in rescue medication use puffs per day,C0392747;C0443172;C1705241;C4319952;C0240320;C1533107
at entry,C1705654
change from baseline in acq $nmbr$ score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
difference in means,C1705241;C1705242
atrial fibrillation no total no,C0004238;C0344434;C1963067;C0439175;C0439810
ifg,C1334085;C1708411
physical and cognitive examination,C0031809;C0205485;C1509143;C1516691;C4321457
no dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
score on modified mini mental state examination median iqr,C4304091;C0549183;C0876920;C2347635;C2348144;C2939193
evomab n $nmbr$,
score on nih stroke scale median iqr,C4049715
cerebrovascular or peripheral arterial disease n,C1880018;C0085096;C1704436
score on modified rankin scale median iqr,C4049715
current cigarette use n,C0521116;C0694535;C1705970
median fasting insulin iqr pu per milliliter,C0549183;C0876920;C2347635;C2348144;C2939193;C0015663;C0021641;C0018387;C1533581;C1579433;C3714501
statin use at study entry n,C0360714;C0869040
homa ir index median iqr,C0022065;C0022071;C1448132
other lipid modifying drug use at study entry n,C0023779;C0392747;C0242510
fasting cholesterol mg dl,C0015663;C0008377;C0439269
ncep risk category at study entry n,C2983287;C2983669
statin no total no,C0360714;C0439175;C0439810
moderately high risk,C0332167;C3272283;C4050568;C4319571
antiplatelet no total no,C0439175;C0439810
moderate risk,C0035647;C4552904
oral anticoagulant no total no,C0354604;C0439175;C0439810
waist circumference mean sd cm,C0455829;C0444504;C2347634;C2348143
ace inhibitor or angiotensin receptor blocker no total no,C0003015;C4541021;C0034787;C1622222;C0439175;C0439810
fpg median q $nmbr$ q $nmbr$ mmol l,C0549183;C1532563;C0876920;C2347635;C2348144;C2939193
diuretic no total no,C0012798;C0439175;C0439810
insulin median q $nmbr$ q $nmbr$ pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
beta blocker no total no,C0001645;C0439175;C0439810
c peptide median q $nmbr$ q $nmbr$ nmol l,C0607868
interval after index event,C1272706;C1552654;C1552713
homa_ b median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
no of days to homa ir testing median iqr,C0439228;C0022065;C0022071;C1448132
homa_ir median q $nmbr$ q $nmbr$ $nmbr$,C0022065;C0022071;C1448132
no of days to randomization median iqr,C0439228;C0034656;C0549183;C0876920;C2347635;C2348144;C2939193
lipid parameters,C0023779;C0449381
homa ir index,C0600653;C0918012;C1552854;C1637833;C2986546
low density lipoprotein cholesterol mean sd mmol l,C0023824;C1532563
medication adherence,C2364172
lipoprotein a median qi q $nmbr$ nmol l,C0065058;C0439282;C0125953;C1096202;C1439335
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
triglycerides median qi q $nmbr$ mmol l,C0041004;C1532563
mean lvef,C0428772;C0488728
high density lipoprotein cholesterol mean sd mmol l,C0023822;C1532563
prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
apolipoprotein b mean sd g l,C1447574;C4319541
ischemic cardiomyopathy,C0349782
history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
type $nmbr$ diabetes pbo n $nmbr$ vs evomab n $nmbr$,C1320657;C0031962
icd or crt d,C0021122
ifg pbo n $nmbr$ vs evomab n $nmbr$,C1334085;C0031962;C1708411
hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
mets pbo n $nmbr$ vs evomab n $nmbr$,C0812270;C0031962;C1705694;C2939420
breakfastb,
no dysglycaemia or mets pbo n $nmbr$ vs evomab n $nmbr$,C1960636;C0812270;C0031962;C1705694;C2939420
lunchb,
hba $nmbr$ c tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
evening mealb,C0587117
fpg tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
lm $nmbr$ bid n $nmbr$,C1261082;C1551056
insulin tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
igl n $nmbr$,C0021037;C0314619;C2247518
c peptide tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
glycemic variability mmol lc,C2827666;C0439190
homa_ b tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
insulin glargine dose at screening visit iu,C0366513
homa_ir tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
low density lipoprotein cholesterol tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1550335;C0332293;C0982221;C0907402;C0332173;C0293359;C0021037;C0314619;C2247518;C0439745;C4319846;C1998602;C0020456;C0521095;C0205449;C0005803;C1979963;C2003903;C0237881;C0750502;C1546944
lipoprotein a tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values,C1511726;C3245479;C3714741;C0449450;C1706992;C0683607;C0444504;C0039725;C1532337;C0039738;C1420718;C4282123;C4285344
triglycerides tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
table $nmbr$ characteristics of the patients at baseline,C0039224;C0815172;C1706074;C0168634;C1442488
fluticasone salmeterol n $nmbr$,C0939232
high density lipoprotein cholesterol tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
fluticasone alone n $nmbr$,C0082607;C0205171;C0439044;C0679994
apolipoprotein b tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
patients with diabetes mellitus n $nmbr$,C0030705;C0011849
evolocumab,C3529352
safety,C0036043;C1705187
patients without diabetes mellitus n $nmbr$,C0030705;C0011849
dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
patients with diabetes mellitus,C0030705;C0011849
all subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
continued thienopyridine n $nmbr$,C0549178;C1120149
hispanic or latino ethnic group,C0086409;C0015031;C1879937
postbaseline new onset diabetes n,C0746890;C0011847;C0011849
oral medications,C0304289
any adverse event ae,C0877248;C3887670
without insulin or insulin modifying therapy,C0021641;C1533581;C1579433;C3714501;C0392747;C0039798;C0087111;C1363945
baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
lesion s,C0221198;C1546698
most common aes in any group,C1412268;C2699274
modified acc aha lesion class b $nmbr$ or c,C4072694;C0221198;C1546698
baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
influenza,C0021400;C0021403
figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding,C0475224;C0085415;C1518681;C0749659;C0439231;C0030705;C1274040;C3897493;C0441471;C3541888;C0205082;C4050465;C4050466;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
serious,C0205404
reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$,C1869620;C0439272
leading to discontinuation,C0332152;C0457454;C1444662;C4552847;C1522538
bmi mean kg m $nmbr$,C0022718;C0439209;C4054209
ck $nmbr$ x uln $nmbr$,C0009212;C1519815;C0010287;C1872855
years since diagnosis mean,C0439234;C0011900;C1704338;C1704656
alt or ast $nmbr$ x uln $nmbr$,C1266129;C4553172;C1415181;C1519815;C3891303
ics use at enrollment mean mg d,C0042153;C0457083;C1947944
total bilirubin $nmbr$ x uln $nmbr$,C0005437;C1519815;C0368753
exacerbation within previous $nmbr$ mo no,C4086268;C0026544;C0332177
potential injection site reactions,C3245505;C0151735
acq score mean,C0444504;C2347634;C2348143
postbaseline binding antibodies,C1145667;C0003241;C1167622
airway reversibility,C0178987;C0449261;C0458827
semaglutide n $nmbr$,C3885068
fev $nmbr$ mean l,C0444504;C2347634;C2348143
low density lipoprotein cholesterol mg dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rescue medication use mean inhalations previous $nmbr$ d,C0004048;C0354922;C0205156;C1552607
never smoked no,C0037366;C0439994;C1881674
blood eosinophils mean range cells ml,C2699156
tnf naive patientsa,C1448177
treated with laba,C0332293
tnf failure patientsa,C0231174;C0680095
baricitinib $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vedolizumab cohort $nmbr$ n $nmbr$,C0009247;C0599755
positive for anti cyclic citrullinated peptide antibody no f,C0741132;C1320283;C0016327
disease duration y mean sd,C0872146;C2699239
positive for rheumatoid factor no t,C0439178;C1446409;C1514241;C2825490;C3812269;C2603360
mayo clinic score mean sd,C0002424;C2699239;C0442592
no of previous biologic dmards no,C0205156;C4055380;C1552607
fcal mg g mean sd,C1300563;C2699239
tnf inhibitors,C1448177;C0243077
cs only,C0010182;C0271160;C3540510;C4085345
non tnf inhibitors,C1448177;C0243077
is only,
swollen joint count of $nmbr$ joints examined,C0451521;C0332128
cs and is,C0010182;C0271160;C3540510;C4085345
tender joint count of $nmbr$ joints examined,C0451530;C0332128
no cs and is,C0010182;C0271160;C3540510;C4085345
scores for global and pain assessments,C0449820;C0205246;C2348867;C0030198
type of tnf failure n b,C0332307;C1547052
physician s global assessment,C0031831;C0804815;C0281858
intolerance,C0231199;C1744706;C2355652
patient s global assessment,C0030705;C0281858
tnf naive,C1448177
tnf failure,C0231174;C0680095
patient s assessment of pain,C0030705;C0030198
point difference $nmbr$ ci,C0008107;C3259781
haq di scored,C3826998;C4321476;C0449820
clinical response,C4055223
high sensitivity crp mg liter,C1441604;C0475211
clinical remission,C0205210;C0544452;C0687702
esr mm hr,C3811131;C4330985;C4554674
mucosal healing,C0043240;C0205249
simplified disease activity index score,C4706353
durable clinical response,C4055223
baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
durable clinical remission,C0205210;C0544452;C0687702
of prior bdmards,C0332152;C2826257
of those on steroids at baseline,C0038317;C0168634;C1442488
of prior tnfi among non tnfi naive,C0332152;C1518422;C2826257
corticosteroid free remission,C0544452;C0687702
of prior non tnfi bdmards,C0332152;C1518422;C2826257
patients not receiving statin,C0030705;C1518422;C1514756;C0360714
characteristica,
patients receiving statin,C0030705;C1514756;C0360714
ukpds $nmbr$ year risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
$nmbr$ q $nmbr$ w n $nmbr$,
ukpds $nmbr$ year risk score,C0035647;C0449820;C4050231;C4552904
race black or african american n,C0005680;C0027567;C0085756;C0439541
saxagliptin $nmbr$ $nmbr$ mg n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ethnicity hispanic latino n,C0015031;C0086409;C0243103
saxagliptin $nmbr$ mg n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diagnosis of hefh n,C0011900;C1704338;C1704656
t $nmbr$ dm duration y,C0011816;C0449238;C2926735;C3250443
by genotyping,C1285573
baseline fpg,C0168634;C1442488
by who simon broome criteria,C0443058;C0243161
baseline $nmbr$ h ppg,C0033727;C1418888;C0369286;C0441932;C0564385;C4528284
diabetes mellitus type $nmbr$ n,C1320657
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
cardiovascular risk n,C0007226;C0035647;C4552904;C3887460
mmol l [n],C1532563;C0369718;C0441922
very high,C0442804;C4321397
saxagliptin $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lipid treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients on atorvastatin rosuvastatin or simvastatin at,C0030705;C0286651;C0074554
baseline mean se,C0168634;C0036919;C1442488
randomization n,C0034656
week $nmbr$ mean se,C0332174;C0036919;C0439230
any llt other than statins n b,C2347090;C0360714
adjusted mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
any llt other than nutraceuticals n,C2347090;C1518478
treatment by subgroup interaction p $nmbr$ $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ezetimibe n,C1142985
ppg mmol l,C1418888;C1532563
nutraceuticals n,C1518478
adjusted mean change,C0392747;C0443172;C1705241;C4319952
baseline lipid parameters mg dl mmol l or g l,C0439268;C0439294;C0456615
from baseline $nmbr$ ci,C0008107;C3259781
ldl c calculated mean sd,C0444504;C2699239;C2347634;C2348143
white race no y left ventricular ejection fraction,C0007457;C0043157;C0428772;C0488728
ldl c measured mean sd,C0444504;C2699239;C2347634;C2348143
nyha functional classification no i,C1275491;C0205245;C0542341;C2700217;C0021966;C0221138
non hdl c mean sd,C0444504;C2699239;C2347634;C2348143
hospitalization in previous year with management of heart failure,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539
total cholesterol mean sd,C0201950;C2699239;C0543421
as major component no,C0449432;C1705248
apo b mean sd,C0003593;C2699239;C3252643
qrs $nmbr$ ms $nmbr$ cl n $nmbr$,C2349943;C0596019;C3539704;C3713294
lp a median q $nmbr$ q $nmbr$,C0065058;C1439335;C4553379
hr $nmbr$ cl pvalue,C0596019
fasting tgs median q $nmbr$ q $nmbr$,C0015663;C0549183;C0876920;C2347635;C2348144;C2939193
adjusted hr $nmbr$ cl pvalue,C0456081;C0596019
apo a $nmbr$ mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
$nmbr$ events,C0441471;C3541888
change from baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
$nmbr$ $nmbr$ per $nmbr$ py,C0030428;C3538810
no statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C3541888;C0030428;C3538810
statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C4019010;C0030428;C3538810
$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
heart failure hospitalizations,C3898876
moderate chronic kidney disease,C1561643;C4553188
persistent faol n [ $nmbr$,C0205322;C0332996
baseline total pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
persistent faod n [ $nmbr$,C0205322;C0332996
below median,C0549183;C0876920;C2347635;C2348144;C2939193
inconsistent fao n [ $nmbr$,C0442809;C0016457
baseline free pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
total n [ $nmbr$,C0439175;C0439810
statin intolerant,C0360714;C0231200
duration of asthma y,C0449238;C2926735
alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
predose fev $nmbr$ l,C0439565;C3714541;C3812758
baseline ldl c mg dl,C0168634;C0439269;C1442488
fevj predicted t,C0681842;C1882327
baseline hdl c mg dl,C0168634;C0439269;C1442488
fvc predicted t,C0681842;C1882327
baseline fasting tgs mg dl,C0168634;C1442488;C0015663;C1156212;C0439269;C1537574
baseline ics dose n,C0168634;C0178602;C0869039;C1114758;C1442488
moderatex,
baseline lp a mg dl,C0065058;C0439269;C1439335;C4553379
highjj,
cohort $nmbr$ uacr,C0009247;C0599755
rescue medication use inh d,C0240320;C0022209
cohort $nmbr$ uacr $nmbr$ $nmbr$ mg g,C0009247;C1300563;C0599755
asthma control days,C0004096;C0439228;C2984299
uacr not available,C0686905
figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status,C0439565;C2986411;C3812758;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0016457;C0449438
statin usage,C0360714;C0457083
cigarette smoking in the past year,C0239059;C0700219
baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol,C0168634;C1442488;C1704788;C3539106;C0444706;C3541902;C0220908;C1522609;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C1551351;C0205436;C0060657;C0457385;C0565930;C1561503;C1705190
albumin creatinine ratio,C0486293;C1318293
losmapimod n $nmbr$,C3272847
core laboratory percent stenosis,C0678234;C1261287;C2632116
body mass index median iqr b,C0005893;C0578022;C1305855
acr deciles,C1412134;C1515941
baseline egfr,C1739039;C3811844;C3812682
stable angina n $nmbr$ $nmbr$,C0340288
prior coronary artery bypass graft surgery,C0010055
acs n $nmbr$ $nmbr$,C0742343;C4318612
prior peripheralarterialdisease,C0332152;C2826257
u s site,C0205145;C1515974;C2825164
prior ischemic stroke,C0332152;C0948008;C2826257
inter p value,C0205103;C1548610;C1709380
baseline laboratory values median iqr d,C0022877;C0042295;C3244292;C4283904
d mi idr st,C0036056;C3272372
high sensitivityc reactive protein mg l,C0033684;C0439268
qmi,
n terminal pro brain natriuretic peptide pg ml,C3272900;C0439297
any gusto bleeding,C0019080
index events,C0441471;C3541888
severe life ttireatening,C0205082;C0376558;C4050465;C4050466
severe moderate,C1299393
non st elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
any timi bleeding,C0019080
st elevation myocardial infarction,C1536220;C3538872
any acuity bleeding,C0750509;C0019080
catheterization performed for qualifying event,C0007430;C0884358;C1514624;C0441471;C4019010
pciperformed for qualifying event,C1514624;C0441471;C4019010
any blood product transfusion,C0005841;C0281867
fibrinolytic for qualifying event,C0040044;C1514624;C0441471;C4019010
fvc $nmbr$ predicted,C0681842;C1882327
nintedanib n $nmbr$,C2930789
time from study drug administration to coronary revascularization median iqr h,C0040227;C0206209;C2349982;C0033727;C0369286;C0441932;C0564385;C4528284
time since diagnosis years,C0556970;C0011900;C1704338;C1704656
useofmedical therapyathospitaldischarge,
centrilobular emphysema,C0221227
p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
fvc ml,C0439526;C1705224;C3887665
ace inhibitor or angiotensin receptor blocker,C0003015;C4541021;C0034787;C1622222
fev $nmbr$ fvc ratio,C0456603;C1547037
events no,C0441471;C3541888
$nmbr$ wk kaplan meier rate,C0871208;C1521828
diffusion capacity of the lung for carbon monoxide predicted,C0231971;C0007018;C4520712;C0681842;C1882327
losmapimod,C3272847
st george s respiratory questionnaire total score,C1553316;C0034394;C2964552
qualifying diagnosis,C1514624;C0011900;C1704338;C1704656
composite physiologic index,C0600653;C0918012;C1552854;C1637833;C2986546
non st elevation mi,C0520886;C3810814
absolute decline in fvc $nmbr$ predicted or death n,C0205344;C0681842;C1882327;C0011065;C1306577;C4082313;C4552775
st elevation mi,C0520886;C3810814
treatment by subgroup interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
criterion reached first n,C0243161;C0205435;C1279901
chronic kidney disease,C1561643;C4553188
absolute decline in fvc $nmbr$ predicted,C0205344;C0681842;C1882327
prior pci or cabg surgery,C0332152;C4049621;C2826257;C0038894;C0038895;C0543467;C1274039
linagliptin metformin,C3264599
planned treatment strategy,C0599880;C0679199
invasive,C0205281;C1334278
age n,C0001779
conservative,
native american alaskan,C0682125
actual treatment strategy,C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
diabetes duration n,C0011847;C0011849
medical management only,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
hba $nmbr$ c mean sd b,C0019016;C0444504;C2347634;C2348143;C1825777;C3538758
time from randomization to pci st elevation mi min,C0040223;C3541383;C0702093;C1524029;C3813700
hba $nmbr$ c n b,C0019016;C1825777;C3538758
fasting plasma glucose mg dl mean sd b,C0202042;C0439269;C0455280
time from randomization to pci non st elevation mi h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
number of antidiabetes drugs at screening n,C0237753;C0449788;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
no of predictors of cardiovascular risk,C0007226;C0035647;C4552904;C3887460
index mi n $nmbr$ $nmbr$,C0600653;C0918012;C1552854;C1637833;C2986546
renal function egfr ml min $nmbr$ $nmbr$ m $nmbr$ according to mdrd n,C0232804;C0439445;C3839656
any mi n $nmbr$ $nmbr$,C3810814
mild impairment $nmbr$ to,C0221099;C0684336
no mi n $nmbr$ $nmbr$,C3810814
moderate impairment $nmbr$ to,C0221099;C0684336
pvaluefor any mi versus no mi,C3810814
severe impairment,C0221099;C0684336
race nonwhitet,C0034510;C1706779;C3853635
macrovascular disease n,C0012634
diet controlled or no,C0743195
difference $nmbr$ cl,C1705241;C0596019;C1705242
history of major bleeding,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baricitinib $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
indication for index procedure,C2315323;C0600653;C0918012;C1552854;C1637833;C2986546
duration of rheumatoid arthritis year,C0449238;C2926735
unstable anginat,C0443343;C1883468
anticyclic citrullinated peptide positive^ n,C1320283;C0439178;C1446409;C1514241;C2825490;C3812269
any mi,C3810814
rheumatoid factor positive n,C0035448;C0201660
ischemic outcomes,C0475224;C1274040
$nmbr$ erosion n,C0333307;C1880549;C1959609;C3887524
continue thienopyridine n $nmbr$,C0549178;C1120149
mtss units,C0439148;C1519795;C3853603
stratified hazard ratio $nmbr$ ci,C0008107;C3259781
prior conventional synthetic dmards n,C0332152;C0242708;C2826257
stratified log rank p value,C0205363;C1709380
swollen joint count of $nmbr$,C0451521
stent thrombosis arc definite probable,C0033204;C0332148
tender joint count of $nmbr$,C0451530
macce death mi stroke,C0038454;C4554100
high sensitivity c reactive protein mg ltt,C0006560;C1413716;C4048285
stent thrombosis related mi,C3897493;C3810814
erythrocyte sedimentation rate mm hour,C0439227;C0564385
non stent thrombosis related mi,C3897493;C3810814
simplified disease activity index,C3869582
bleeding outcomes,C0019080;C1274040
a acr $nmbr$,C1412134;C1515941
log rank p value,C0667477;C1709380;C0699794
week $nmbr$ overall population,C0032659;C1257890
gusto severe moderate,C1299393
background csdmard category,C0683312;C3889287
barc types $nmbr$ $nmbr$ or $nmbr$,C0332307
mtx only,C0025677;C1417487
log rank,C0667477;C0699794
non mtx csdmards,C0025677;C1417487
no diabetes n $nmbr$ $nmbr$,C0011847;C0011849
mtx other csdmards,C0025677;C1417487
diabetes n $nmbr$ $nmbr$,C0011847;C0011849
b acr $nmbr$,C1412134;C1515941
qualifying mi type,C1514624;C0332307;C1547052
nteraction p value,C1709380
qualifying mi,C1514624;C3810814
c das $nmbr$ crp,C3890735;C4048285
history of second prior mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
statin users n $nmbr$,C0360714;C1706077
non end stage renal dysfunction,C1565489;C3279454
statin non users n $nmbr$,C0360714;C1518422
multivessel coronary artery disease,C0010054;C0010068;C1956346
mean predicted fvc sd,C0444504;C2699239;C2347634;C2348143
history of hypercholesterolemia,C1533076
mean predicted dlco sd,C0444504;C2699239;C2347634;C2348143
history of stroke or transient ischemic attack,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805
mean $nmbr$ mwd m sd,C0444504;C2347634;C2348143;C2699239
prior coronary artery bypass grafting,C0332152;C0010055;C2826257
mean ucsd sobq score sd,C3533236;C2699239
history of percutaneous coronary intervention,C1320647;C4554713
chronic renal failure,C0022661;C1561643;C2316810
ace i or angiotensin receptor blocker,C0021966;C0221138;C0034787;C1622222
cardiovascular risk factors n,C0850624
history of diabetes requiring drugs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013227;C3687832
hypercholesterolaemia,C0020443;C1522133
smoker current former,C0205156;C0750523
figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes,C0871208;C1521828;C1709595;C1999375;C2349200;C4522255;C0206655;C0446516;C2681631;C3715044;C4553528;C0011847;C0011849
obesity t,C0028754;C1963185
no pad n $nmbr$ $nmbr$,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
crude analysis n,C0002778;C0936012;C1524024
pad n $nmbr$ $nmbr$,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
history of copd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
bivariate frailty model statin users vs non users,C0360714;C1706077;C1518422
history of stroke or tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
disease progression composite outcome,C0679250;C3542417
history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038257;C2348535
first disease progression outcome to occur,C0679250;C3542417;C1709305;C2745955;C4284875
history of claudication,C2315493
absolute fvc decrease $nmbr$,C0392756;C0547047
$nmbr$ mwd decrease $nmbr$ m,C0392756;C0547047
western europe including south africa,C0043129
mortality,C0026565;C0026566
asia australia new zealand,C0027978;C0324547
ipf related,C0034069;C1800706;C0439849;C0445223
time from qualifying mi yrs,C0040223;C3541383;C1514624;C3810814
fvc change,C0392747;C0443172;C1705241;C4319952
qualifying mi $nmbr$ yrs prior,C1514624;C0332152;C2826257
absolute decrease $nmbr$,C0392756;C0547047
time from last dose of p $nmbr$ y $nmbr$ inhibitor days,C0946444
relative decrease $nmbr$,C0392756;C0547047
beta blocker use at baseline,C0042153;C0457083;C1947944
death or absolute fvc decrease $nmbr$,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047
ace i or arb use at baseline,C0021966;C0221138;C0042153;C0457083;C1947944
death or $nmbr$ mwd decrease $nmbr$ m,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047
central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results,C1999375;C0030705;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657;C1274040;C1546471;C2825142
hospitalisation,C0019993
peripheral artery disease pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
respiratory related^,C0439849;C0445223
adolescents aged $nmbr$ $nmbr$ y no,C0001779;C0001792;C1999167
ind gly $nmbr$ $nmbr$ pg o d n $nmbr$,C0017890;C2827928;C0523677
adults aged $nmbr$ y no,C0001675;C0001779;C0001792;C1999167
sfc $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
non hispanic non latino,C1518424;C0086528
gold $nmbr$ groups n,C0018026;C0441848;C1304897
mean time since diagnosis y,C0040223;C3541383
icsusers atbaseline n,
exacerbation within $nmbr$ mo,C4086268;C0026544;C0332177
catscorecategory n,
aqlq score mean,C0444504;C2347634;C2348143
mmrc grade n,C0441800;C0919553;C3244287
asui score mean,C0444504;C2347634;C2348143
post bronchodilator fev $nmbr$ reversibility,C2599594;C0449261
airway reversibility mean,C0444504;C2347634;C2348143
post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
fev $nmbr$ mean predicted,C0444504;C2347634;C2348143;C0681842;C1882327
figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone,C0086312;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0332174;C0439230;C1079230
rescue use mean no of inhalations d,C0444504;C2347634;C2348143;C0004048;C0354922
stage $nmbr$ a,C0205390;C1300072;C1306673
blood eosinophils mean range cells mlb,C0005773
stage $nmbr$ b,C0441781
total daily dose of ics mean gc,C2348070;C0444504;C2347634;C2348143
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
a reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
b reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
eos count cells pl,C3897966;C4049765
glucose lowering therapies,C0017725;C0441994;C2003888;C0087111
mensa,
treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
sirius,
cv endpoints n,C3538987;C2349179;C4048877;C4318503
prior oma use,C0042153;C0457083;C1947944
$nmbr$ point mace,C0349381;C0949745;C1445339
no prior oma use,C0042153;C0457083;C1947944
tocilizumab n $nmbr$,C1609165
mepo n $nmbr$,
white ethnicity,C0015031;C0243103
prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
das $nmbr$,C0051767;C0057671
no prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
number of previous dmards,C0237753;C0449788
annual exacerbation rate,C0871208;C1521828
baseline diabetes,C0011847;C0011849
age mean range years,C1510829;C0444504;C2347634;C2348143
il $nmbr$ pg ml,C0020898;C0439297;C0021764;C0022271
rate ratio mepo pbo $nmbr$ ci,C0008107;C3259781
tender joint count n $nmbr$,C0451530
female n race n,C0043210;C0034510;C1706779;C3853635;C0086287;C1705497;C1705498
swollen joint count n $nmbr$,C0451521
change from baseline in acq $nmbr$,C0392747;C0443172;C1705241;C4319952;C2919686
haemoglobin g l,C0635222
score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci,C3533236;C0008107;C3259781
troponin t pg ml,C0077404;C0439297;C1420827
change from baseline in sgrq,C0392747;C0443172;C1705241;C4319952
fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction,C1280500;C1518681;C2348382;C0669479;C3538926;C0754710;C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675
change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se,C0392747;C0443172;C1705241;C4319952;C0030771;C1518922;C1542834
no peripheral revascularization n $nmbr$ $nmbr$,C0205100;C0581603
hispanic ethnicity n,C0086409;C0015031;C0243103
peripheral revascularization n $nmbr$,C0205100;C0581603
difference mepo pbo $nmbr$ ci,C0008107;C3259781
never smoker,C0425293
change from baseline in pre bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
history of atrial fibrillation or fl utter,C0729790;C1300812;C1708024
fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci,C3714541;C0008107;C3259781
egfr crcl,C1739039;C1846718;C3811844;C3812682
duration of asthma,C0449238;C2926735
peripheral artery disease details,C1704436;C1522508;C4025272
change from baseline in post bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
peripheral artery revascularization without amputation,C0489868;C0581603
mean sd years daily ocs use n,C0332173;C0042153;C0457083;C1947944
statin therapy,C1278454
ocs dose mean sd,C0178602;C2699239;C0869039;C1114758
figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline,C0871208;C1521828;C0589120;C1522577;C1704685;C3274571;C0002688;C0332840;C1546539
ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll,C0456603;C1547037;C0200638;C0750879;C0007584;C0007634
mod sev exacerbation rate,C0871208;C1521828
mg day,C0439422
ff vi $nmbr$ $nmbr$,C4554348;C0205999
ratio mepo pbo $nmbr$ ci,C0008107;C3259781
current smoker n $nmbr$ $nmbr$,C3173209;C3241966
eosinophils cells ll inclusion criteria n,C0007584;C0007634;C1512693
former smoker n $nmbr$ $nmbr$,C0337671
ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml,C0456603;C1547037;C0806481;C2986759;C0439340;C1880521;C2945590
cv entry criteria,C1705654;C0243161
$nmbr$ in previous,C0205156;C1552607
$nmbr$ $nmbr$ cv disease n $nmbr$ $nmbr$,C0007222
$nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$,C0035647;C4552904;C1518422;C0012634
predicted pre bd,C0005126;C2344255;C4050145
hispanic latino n $nmbr$,C0086409;C0086528
fev $nmbr$ mean sd pre bd fev $nmbr$ fvc,C0005126;C3714541;C2344255;C4050145
not hispanic latino n $nmbr$ $nmbr$,C1518424;C0086528
mean sd reversibility fev $nmbr$ at,C0444504;C3714541;C2347634;C2348143
asian n $nmbr$ $nmbr$,C0078988
screening mean sd morning pef mean,C0220908;C0030771;C1518922;C1542834;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
african american african heritage n $nmbr$,C0085756;C2986513
sd l min acq $nmbr$ score mean sd,C0449820;C0444504;C2347634;C2348143;C4050231
usa n $nmbr$ $nmbr$,C0041703
sgrq score mean sd,C0444504;C2699239;C2347634;C2348143
asia n $nmbr$ $nmbr$,C0003980
total ige geometric,C0439175;C0439810
europe $nmbr$ n $nmbr$ $nmbr$,C0015176
mean sd on loge scale u ml,C2699239;C0439340;C1880521;C2945590
rest of world n $nmbr$,C0035253;C1622890
blood eosinophil count geometric mean sd loge scale cells ll,C0005773
history of moderate severe exacerbation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
severe exacerbations,C0205082;C4086268;C4050465;C4050466
history of hospitalization for an exacerbation,C0551577;C4086268
in previous year mean sd,C0205156;C2699239;C1552607
hospitalized exacerbation rates,C0871208;C1521828
exacerbations in previous year requiring hospitalization and or ed visit n,C4086268;C0205156;C1552607;C0019993;C0545082;C1512346;C2826704
mod sev exacerbation rates,C0871208;C1521828
exacerbations in previous year requiring hospitalization n,C4086268;C0205156;C1552607;C0019993
favors ffa i favors placebo,C0032042;C1696465;C1706408
randomised patients with spondylitis at baseline n,C0030705;C0038012;C0168634;C1442488
ff vi,C4554348;C0205999
b_ $nmbr$,
randomised patients with basdai assessment at baseline and week $nmbr$,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
nn $nmbr$,C0027779;C1850406;C4283741;C4284038
$nmbr$ t i,C0021966;C0221138
mean sd improvement from baseline to week $nmbr$ in basdai,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004
h,C0033727;C0369286;C0441932;C0564385;C4528284
randomised patients with basdai assessment at baseline and week $nmbr$ n,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
predicted fev,C0681842;C3714541;C1882327
mean sd improvement from baseline to week $nmbr$ in basdai questions,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004;C1522634
history of hospitalized for an exacerbation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4086268
question $nmbr$ fatigue tiredness,C0015672;C4553152
predicted fev^,C0681842;C3714541;C1882327
question $nmbr$ neck back hip pain,C0007859;C1963180;C4553909
moderate severe exacerbation,C0205081;C4086268;C1881878;C4049705;C4049706;C4085643;C4321335
question $nmbr$ pain swelling in joints other than neck back hips,C0152031;C0004600;C0019552;C0205095;C0460009;C1995000
hospitalized for an exacerbation,C0701159;C4086268
question $nmbr$ discomfort from any areas tender to touch pressure,C2364135;C0205146;C4319729;C0033095;C0460139;C1306345;C4284008
mn population,C0032659;C1257890
question $nmbr$ morning stiffness since arising,C1522634;C0457086;C0332284;C4019053;C4318616
umec vi $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205999
question $nmbr$ length of morning stiffness since arising,C1444754;C1706316;C0332284;C4019053;C4318616
tio n $nmbr$ $nmbr$,
basdai responses at week $nmbr$,C0871261;C0332174;C0439230
current smoker at screeninga n,C3173209;C3241966
basdai $nmbr$ n,C1998004
smoking pack yearsb n,C0037369;C0453996;C1881674
haq di improvement from baseline to week $nmbr$,C3826998;C2986411;C4321476;C0332174;C0439230
reversible to albuterolc d n,C0205343;C0369718;C0441922
randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline,C0522476;C0168634;C1442488
post albuterol predicted fev $nmbr$ mean sd e,C0001927;C0444504;C2347634;C2348143
dlqi improvement from baseline to week $nmbr$,C2986411;C0168634;C1442488;C0332174;C0439230
gold stage nf,C0018026;C0205390;C1300072;C1306673;C1304897
randomised patients with dactylitis at baseline,C0030705;C0239161;C0168634;C1442488
ics use at screeningg n,C0042153;C0457083;C1947944
improvement in dactylitis score at week $nmbr$ n,C2986411;C0239161;C0332174;C0439230
exacerbation historyh n,C4086268
patients with dactylitis at week $nmbr$ n,C0030705;C0239161;C0332174;C0439230
required corticosteroid and or antibiotic without hospitalization,C0001617;C3536709;C0003232;C0019993
randomised patients with enthesitis at baselinet,C0030705;C1282952
required hospitalization,C1708385
improvement in enthesitis score at week $nmbr$ n,C2986411;C0449820;C4050231;C0332174;C0439230
components of the first cid,C0449432;C0205435;C1279901
patients with enthesitis at week $nmbr$ n,C0030705;C1282952;C0332174;C0439230
umec vi $nmbr$ $nmbr$ $nmbr$,C0205999
standard treatment n $nmbr$,C4684780
tio,
mra regimen n $nmbr$,C0243032;C0040808;C2945654;C1609165;C3891069
hazard ratio umec vi vs tio $nmbr$ ci,C2985465;C0205999;C0008107;C3259781
risk factors and medical history,C0035648;C1553898;C0262926;C1704706
itt population n,C0032659;C1257890
presentation,C0449450
c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0547047
creatinine clearance ml min $nmbr$,C0812399;C0439445
c $nmbr$ unit sgrq total score increase,C2964552;C0442805
potassium at admission mmol l $nmbr$,C0032821;C0202194;C0304475;C0597277;C3714637
moderate to severe copd exacerbation,C1299393;C0740304
admission grace score,C0449820;C4050231
mn population n,C0026327;C0026405;C4285072
in hospital medication,C0013227;C3244316;C4284232
re cover re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
p $nmbr$ y $nmbr$ antagonist,C0369773;C0231491;C2603361
re medy,
fibrinolysist,
not tested,C1518422;C0392366
glycoprotein iib iiia inhibitort,C0016011
de n $nmbr$,C0011198;C0017480;C3541240
interventional or surgical procedures,C0184661;C3274035;C0543467
bmi mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
primary pcit,C0205225;C0439612;C0439631
crcl mean ml min sd,C0439445;C2699239
demographic characteristic,C0011298;C1521970
qualifying symptomatic event n a,C1514624;C0231220;C0441471;C4019010
umec $nmbr$ $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
pe and dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
tio $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
pe only,C0070939;C1880476;C4284304
umec $nmbr$ $nmbr$ mcg n $nmbr$,C0439211;C3463985
neither pe nor dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
tio i $nmbr$ mcg n $nmbr$,C0021966;C0221138
non transient risk factors for recurrent vte n,C0035648;C1553898
treatment diff vs tio $nmbr$ ci,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0008107;C3259781
active cancer at any timeb,C0006826;C0998265;C1306459
gold grade $nmbr$,C0441800;C0919553;C3244287
concomitant anticoagulant antithrombotic or nsaid n,C0521115;C0003280;C0848112;C3536711;C0003211;C3536840
ls mean change from baseline ml se a,C0392747;C0443172;C1705241;C4319952
vte vte related deathsa n n,C0439849;C0445223
$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
pulmonary embolisma n n,C0024109;C2707265;C2709248;C4522268
current smoker at screening n,C3173209;C3241966
vte vte related deathsb n n,C0439849;C0445223
smoking pack yearsa,C0037369;C0453996;C1881674
pulmonary embolismb n n,C0024109;C2707265;C2709248;C4522268
post salbutamol fev $nmbr$ l b mean sd,C0001927;C2699239
de,C0011198;C0017480;C3541240
gold group b,C0018026;C4522078;C1304897
treatment de vs warfarin by thrombophilia interaction,C0011198;C0017480;C3541240;C0043031;C0398623
post salbutamol fev $nmbr$ fvcb mean sd,C0001927;C2699239
mbesc n n,
reversibility to salbutamolc d mean sd,C0449261;C0444504;C2699239;C2347634;C2348143
mbes crbesc,
gold group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mbesb n n,
nonreversible,
mbes crbesb n n,
ics users at screening,C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
p value for mra vs no mra,C1709380;C0243032;C1609165;C3891069
gold grades $nmbr$ $nmbr$ percent predicted fev n,C0018026;C0439165;C1304897
no mra at baseline,C0243032;C1609165;C3891069
grade $nmbr$ moderate copd n,C0205081;C0024117;C1412502;C3714496;C1881878;C4049705;C4049706;C4085643;C4321335
mra at baseline,C0243032;C1609165;C3891069
ics non users at screening,C1518422;C1706077
sacubitril valsartan n $nmbr$,C4033631
grade $nmbr$ severe copd n,C0205082;C0024117;C1412502;C3714496;C4050465;C4050466
heart rate mean sd beats min,C0439385
gold groups a d using mmrcb,C0441838;C1524063
creatinine mean sd mg dl,C0010294;C0439269;C1561535
gold grade $nmbr$ and ics users at screening,C0441800;C0919553;C3244287;C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
potassium mean sd meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
group b low risk more symptoms n,C3272281;C3538919;C0683368;C1457887
clinical features of hf,C0683325;C0018488;C1313497;C1538440;C3273279
group d high risk more symptoms n,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0332167;C3272283;C4050568;C4319571;C0683368;C1457887
left ventricular ef mean sd,C0225897;C2699239
gold grade $nmbr$ and ics non users at screening,C0441800;C0919553;C3244287;C1518422;C1706077
nt probnp median iqr pg ml,C0669479;C0439297;C0754710
ics use at screening,C0042153;C0457083;C1947944
treatment at randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ics nonusers n,C0815320;C4551720
mra use,C0042153;C0457083;C1947944
proportion of patients with trough fevi $nmbr$ ml above baseline n,C1709707;C0030705;C0439526;C1705224;C3887665
patients receiving enl no,C0030705;C1514756
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
incidence^,C0021149;C0220856
heterogeneity test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
patients receiving lcz no,C0030705;C1514756
chi squared,C1552646
hr enl vs lcz $nmbr$ cl,C0596019
previous statin use,C0042153;C0457083;C1947944
adjusted hr enl vs lcz $nmbr$ cl,C0456081;C0596019
troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
hyperkalemia,C0020461;C4552983
$nmbr$ $nmbr$ ng ml,C0439275
severe hyperkalemia s,C0020461;C4552983
duration of assigned regimen before surgery,C0449238;C2926735;C0038894;C0038895;C0543467;C1274039
evolocumab n $nmbr$,C3529352
surgical technique,C0683469
bmi mean sd b,C0578022;C0444504;C2347634;C2348143
on pump,C3842462
baseline statin usec,C0168634;C0439224;C1442488
off pump,C1518543;C0182537
lntensityd,
procedure,C0184661;C2700391;C3274430;C3539779
baseline ezetimibe usec,C0168634;C0439224;C1442488
aortic valve replacement,C0003506
characteristic at baseline,C1521970;C0168634;C1442488
postoperative glucocorticoid use,C0042153;C0457083;C1947944
pav mean $nmbr$ ci,C0008107;C3259781
postoperative nsaid or glucocorticoid use,C0003211;C3536840;C0042153;C0457083;C1947944
evolocumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
trend het test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
on treatment,C4684449
duration of assigned regimen before surgery post randomisation characteristic,C0449238;C2926735;C0034656;C1521970
age years median n $nmbr$ $nmbr$,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
xi $nmbr$ $nmbr$,C1720296
race non white n $nmbr$ $nmbr$,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
xi $nmbr$,C1720296
race white n $nmbr$ $nmbr$,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
percentage difference $nmbr$ cl,C0439165;C0596019;C1549488;C1561533
no history of mi n $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
surgical technique post randomisation characteristic,C0683469;C1521970
history of mi n $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
avr,C0449217
non smoker n $nmbr$ $nmbr$,C0337672;C0425293;C4554605
postoperative glucocorticoid use post randomisation characteristic,C0017710;C1521970
baseline pav median n $nmbr$ $nmbr$,C0168634;C0058890;C1442488
postoperative nsaid or glucocorticoid use post randomisation characteristic,C0003211;C3536840;C0017710;C1521970
baseline tav median n $nmbr$ $nmbr$,C0168634;C0279686;C1442488
x $nmbr$ $nmbr$,
non high density lipoprotein mg dl baseline median n $nmbr$ $nmbr$,C1535899;C0439269
dulaglutide $nmbr$ $nmbr$ mgf,C1366394;C3712803;C3887684
proprotein convertase subtil kexin typ $nmbr$ ng ml baseline median n $nmbr$ $nmbr$,C1100660;C0439275
age $nmbr$ vears n $nmbr$,C0001779
no family history of chd n $nmbr$ $nmbr$,C0241889;C0280604;C3542407
previous oral antidiabetic medication use n,C1527415
no oral antidiabetic medication,C0175795
family history of chd n $nmbr$ $nmbr$,C0241889;C0280604;C3542407
$nmbr$ oral antidiabetic medication,C0175795
no type $nmbr$ diabetes n $nmbr$ $nmbr$,C1320657
insulin oral antidiabetic medication s,C0175795
type $nmbr$ diabetes n $nmbr$ $nmbr$,C1320657
no prior statin n $nmbr$ $nmbr$,C0332152;C0360714;C2826257
figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study,C0392747;C0443172;C1705241;C4319952;C0439230;C0027361;C0237401
prior statin n $nmbr$ $nmbr$,C0332152;C0360714;C2826257
data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years,C1511726;C3245479;C3714741;C0449450;C0023668;C2708217;C2708218;C0017853;C0439234
non high dose statin n $nmbr$ $nmbr$,C0444956;C0360714
europe and australia,C0015176;C0004340
high dose statin n $nmbr$ $nmbr$,C0444956;C0360714
latin and north america,C0028405
change in pav mean $nmbr$ cl,C0392747;C0443172;C1705241;C4319952
systemic corticosteroids n a,C4053960
agea,
das $nmbr$ esr mean sd,C0051767;C2699239;C0057671
current cigarette use,C0521116;C0694535;C1705970
moderate disease activity $nmbr$ $nmbr$ to,C1513375;C3833417
baseline pava,C0168634;C0135567;C1442488
high disease activity $nmbr$ $nmbr$ n,C4699623
baseline tava,C0168634;C1442488
sdai mean sd,C0444504;C2699239;C2347634;C2348143
baseline non hdl ca,C1518422;C3715113
cdai mean sd,C0444504;C2699239;C2347634;C2348143
baseline pcsi,C0168634;C1442488
haq di mean sd,C3826998;C2699239;C4321476
prior statin use,C0042153;C0457083;C1947944
tjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
statin intensity per acc ahac,C0522510;C0175754;C0282160;C3541413
sjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
moderate low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
esr mm h median min max,C3642211
chlorthalidone $nmbr$,C0008294
crp mg l median min max,C0439420
amlodipine lisinopril $nmbr$,C0051696;C0065374
months since ra was first diagnosed mean sd,C0439231;C3538806;C4048756;C0011900;C2699239
total $nmbr$,C0439175;C0439810
$nmbr$ months mean sd,C0439231;C2699239
white non hispanic n,C1533020;C1533021
months since first ra symptom mean sd f,C0439231;C0016327
black non hispanic n,C1533017;C1533018
rf positive $nmbr$ iu ml n,C0035448;C0439458;C0201660;C0748398;C1547111
white hispanic n,C1533020;C1533021
acpa positive $nmbr$ iu ml n,C0439178;C0439458;C1446409;C1514241;C2825490;C3812269
black hispanic n,C1533017;C1533018
mtss median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
receiving antihypertensive treatment,C1514756;C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ months median min max,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
n blood pressure mean sd mm hg,C0428886;C0439475
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
major st depression or t wave,C0041696;C1269683;C0429103
erosion score median min max,C0333307;C0449820;C4050231;C1880549;C1959609;C3887524
inversion,C0021943;C0021945;C1705687;C2349984
jsn median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
diabetes t,C0011847;C0011849
presence of erosions n,C0150312;C0392148;C3854307
medication use at baseline n,C0240320;C0168634;C1442488
supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot,C2986480;C0205363;C0040223;C3541383;C0011900;C1704338;C1704656;C0025677;C1417487;C0441837;C0028873;C0086312
females only,C0086287
indacaterol glycopyrronium group n $nmbr$,C1722260;C0441848
atenolol use at $nmbr$ month,C0042153;C0457083;C1947944
salmeterol fluticasone group n $nmbr$,C0939232;C0441848
cholesterol mean sd n,C0008377;C0444504;C2347634;C2348143
use of inhaled glucocorticoids at screening no,C1524063;C0004048;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
serum creatinine mean sd n,C0201976;C0600061
severity of copd no f,C0439793;C0522510;C0016327
egfr mean sd n,C1739039;C0444504;C2347634;C2348143;C3811844;C3812682
group a,C0441835;C4522145
baseline mdrd,C0168634;C3839656;C1442488
group b,C4522078
baseline ckd epi,C1561643;C0162734;C4281721
group c,C0441837
lipid trial participants n,C1997894;C2242969
group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
post bronchodilator fev $nmbr$ liters,C2599594;C0475211
baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
post bronchodilator fev $nmbr$ of predicted value,C2599594;C3714541;C0681842;C1522609;C1882327
no cvd,C0007222
post bronchodilator ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
prevalent cvd,C0007222
total score on the sgrq c i,C2964552;C3826872
healthy weight,C0005910;C0043100;C1305866;C1705104
indacaterol glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
overweight,C0497406
salmeterol fluticasone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
no estrogen,C0014939;C2936882;C4542544
smoking status at screening,C1519386
budesonide symptom days a week,C0054201;C0439228;C0332174;C0439230
severity of airflow limitation,C0439793;C0522510
placebo symptom days a week,C0032042;C0439228;C1696465;C1706408;C0332174;C0439230
severity of copd,C0439793;C0522510
$nmbr$ tol n $nmbr$,
copd exacerbations during the previous year,C0740304;C0205156;C1552607
lto,
inhaled glucocorticoid use at screening,C0042153;C0457083;C1947944
$nmbr$ n $nmbr$ l $nmbr$,C0369718;C0441922
no use,C0042153;C0457083;C1947944
age mean age years sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
laba use at screening,C0042153;C0457083;C1947944
$nmbr$ u,C0439148
laba inhaled glucocorticoid use at screening,C0042153;C0457083;C1947944
passive smoker,C0425309
lama use at screening,C0042153;C0457083;C1947944
prebronchodilator fevj predicted,C2599602;C0681842;C1882327
included in analysis,C0332257;C0002778;C0936012;C1524024
postbronchodilator fevj predicted,C2599594;C0681842;C1882327
total sample $nmbr$,C0370003;C2347026
controllertreatment before entry,C1705654
age at baseline in years mean sd,C0001779;C0168634;C1442488;C0439234;C2699239
inhaled corticosteroid,C0004048;C0001617;C3536709
$nmbr$ $nmbr$ lo i,C0021966;C0221138
oral or other systemic corticosteroid,C0442027;C4521986;C4053960
time from parkinson s disease diagnosis in months mean sd,C0040223;C3541383;C0439231;C2699239
xanthine,C0043314;C0043318
cromoglicate,C0010347
total updrs score baseline mean sd,C2964552;C2699239
leukotriene modifier,C0205349;C1514623;C1516451;C3542952
activities of daily living updrs subscore baseline mean sd,C0001288;C4050548
time to first sare,C0040223;C3541383
motor updrs subscore baseline mean sd,C0168634;C2699239;C1442488
cumulative incidence lyear,C0021149;C0220856
mental activities updrs subscore baseline mean sd,C0168634;C2699239;C1442488
cumulative incidence $nmbr$ years,C0021149;C0439234;C0220856
hoehn and yahr stage baseline mean sd,C0168634;C2699239;C1442488
rate of sares,C0871208;C1521828
initial treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
rate per $nmbr$ patient years,C0871208;C1521828
$nmbr$ mg $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ year mean change from baseline,C0392747;C0443172;C1705241;C4319952
placebo $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
$nmbr$ to $nmbr$ $nmbr$,
gentype,
prebronchodilator fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
weeks,C0439230
lyear mean change from baseline,C0392747;C0443172;C1705241;C4319952
weeks_measured,C0444706;C3541902
time to first inhaled corticosteroid,C0040223;C3541383
mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0443172;C1705241;C4319952;C0456081;C0168634;C1442488
time to first oral or systemic corticosteroid,C0040223;C3541383;C4053960
$nmbr$ to $nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
$nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
rate of oral or systemic corticosteroid,C0871208;C1521828;C4053960
event rate vr,C0441471;C3476815;C4019010
asthma symptoms in the past $nmbr$ weeks,C0683368;C1457887
edoxaban vs warfarin,C2975435;C0043031
mean proportion,C0444504;C1709707;C2347634;C2348143
$nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852;C0439230
edo,
sleeping problems in the past $nmbr$ weeks,C0037313;C0424522;C4050403;C1546466;C0439230
stroke see,C0042789;C1947903
symptom free days in the past $nmbr$ weeks,C0332296;C0677547;C1880497;C1996904
type of af,C0332307;C1547052
$nmbr$ to $nmbr$ symptom days per week,C1457887;C0677547;C3854129
persisent,
lto $nmbr$ symptom days per week,C1457887;C0677547;C3854129
fatal stroke,C0038454;C4554100
$nmbr$ symptom days per week,C1457887;C0677547;C3854129
crcl ml min at randomization,C0439445;C0034656
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$,C0596019
cha $nmbr$ ds $nmbr$ vasc score,C0449820;C4050231
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
has bled score $nmbr$,C0449820;C4050231
a prebronchodilator fevl predicted,C2599602;C0681842;C1882327
major gl bleeding,C0018229;C0019080;C1423073;C1427674
baseline symptom days perweek,C0168634;C0439228;C1442488
time in therapeutic range,C1554109
mean difference $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
dose reduction at randomization,C0301630;C0392756;C1293152;C4551656
yearl,
prior vka experience,C0237607;C0596545
b postbronchodilator fevl predicted,C2599594;C0681842;C1882327
medication at time of randomization,C0013227;C3244316;C4284232
baseline feature,C1521970;C1706388;C2346469;C2348519
gly $nmbr$ $nmbr$ mg b i d n $nmbr$,C0439422
lived alone,C0205171;C0439044;C0679994
ind $nmbr$ mg q d n $nmbr$,C4049864;C0439422
stroke at entry,C0038454;C4554100
number of pack years,C0237753;C0449788
nih stroke scale,C1697238;C3484372
severity of copd airflow limitation n,C0439793;C0522510
health practices,C0018684;C0237607
moderate gold $nmbr$,C0018026;C1304897
$nmbr$ $nmbr$ drinks day if male female,C0332173;C0439228;C0439505;C0043210;C0086287;C1705497;C1705498
severe gold $nmbr$,C0018026;C1304897
aerobic exercise,C0001701
very severe gold $nmbr$,C0018026;C1304897
cognitive,C1516691
severity of copd combined assessment n,C0439793;C0522510
and physical examination,C0031809;C1744699
mmrc dyspnea scale n,C0013404;C0175659;C0349674;C1947916;C1963100
$nmbr$ ms score,C0449820;C4050231
copd assessment test cat score,C0237855;C0237856
antidepressant,C0003289
post bronchodilator fev $nmbr$ reversibility a,C2599594;C0449261
benzodiazepine or bzra,C0005064;C3536850;C4048284
ccv history condition,C0683519
epilepsy drug,C0013227;C1254351
gly $nmbr$ $nmbr$ gg b i d n n,C1415124;C0152277
osteoporosis drug,C0013227;C1254351
ind $nmbr$ gg q d n n,C0017454;C0018370
vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
severity of airflow obstruction,C0439793;C0522510
fxs,C0016667
mild or moderate copd,C2945599;C0024117;C1412502;C3714496
risk delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
severe or very severe copd,C0205082;C4050465;C4050466;C0024117;C1412502;C3714496
any site,C0205145;C1515974;C2825164
ics use at baseline,C0042153;C0457083;C1947944
upper limb,C1140618
ccv history condition at baseline,C0683519;C0168634;C1442488
distal lower,C0441994;C1548802;C2003888
limb,C0015385
history of atrial fibrillation flutter,C0729790
hip femur,C0019552;C0015811;C0022122;C1505163;C3538851;C4284725
history of cardiac arrhythmia,C3494593
rib,C0035561
long acting bronchodilator use at screening,C0042153;C0457083;C1947944
black or african america,C0005680;C0027567;C0085756;C0439541;C0002454
attain,
chd risk no,C1282512
augment copd,C0205217;C0024117;C1412502;C3714496
very high risk,C0332167;C0442804;C3272283;C4050568;C4319571;C4321397
pooled analysis sample,C1709595
lower risk,C3272281;C3538919
aclidinium $nmbr$ g n $nmbr$ a,C2699757;C0439267
placebo n $nmbr$ a,C0032042;C1696465;C1706408
at ldl c bq goal at baseline no,C0018017;C1571704
aclidinium $nmbr$ g n $nmbr$ b,C2699757;C0439267
prior diagnosis no,C0332132
placebo n $nmbr$ b,C0032042;C1696465;C1706408
use of concomitant lipid lowering therapy no,C1524063;C0585943
all patients n $nmbr$ b,C0030705
statin with niacin,C0360714;C0027996;C1142562
post bronchodilator fev $nmbr$ l mean sd c,C2599594;C0444504;C2347634;C2348143
statin with fibrate,C0360714
other $nmbr$,
post bronchodilator fev $nmbr$ predicted mean sd c,C2599594;C0444504;C2347634;C2348143
type of concomitant statin by daily dose no,C0332307;C1547052;C2348070
bronchial reversibility sd,C0205039;C2699239;C1442216
lovastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number of exacerbations in previous year mean sd,C0237753;C0449788;C0205156;C2699239;C1552607
pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rs breathlessnessb,C0035970;C3714753;C3813325
baseline lipid lipoprotein values,C0443602;C0042295
rs cough sputumc,C0035970;C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C3714753;C3813325
ldl c bq mg dl mean sd,C0439269;C2699239
rs chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
non hdl c mg dl mean sd,C0439269;C2699239
rs totala,C0035970;C3714753;C3813325
apo b mg dl mean sd,C0003593;C2699239;C3252643
aclidinium $nmbr$ g bid n $nmbr$,C2699757;C0439267
gold group a,C0441835;C4522145
apo a l mg dl mean sd,C1447574;C2699239;C4521365
gold group c,C0018026;C0441837;C1304897
figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison,C1705241;C1705242;C0008107;C3259781;C1079231;C1079232;C3715113;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1707455;C1696465;C1706408
fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f,C0392747;C0443172;C1705241;C4319952;C0035970;C0449820;C3714753;C3813325;C1709707;C0282416;C1561607;C0441835;C4522145;C2964552;C0013404;C0119082;C0016327
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
rs cough sputum domain g and h rs chest symptoms domain p,C0370205;C0119082;C0150618;C0035970;C3714753;C3813325
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
lixisenatide,C2973895
uniti $nmbr$,
high i $nmbr$ baseline hba $nmbr$ c,C0021966;C0019016;C1825777;C3538758;C0221138
im uniti,
ustekinu,
high i $nmbr$ kg m $nmbr$ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
mab,C0003250;C0369637
short,C1282927;C1806781;C2350002
usteki,
long i $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
numab,
i $nmbr$ years of age,C0021966;C1510829;C0221138
$nmbr$ mg kgf n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
low $nmbr$ baseline hbalc,C0205251;C0168634;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
$nmbr$ mg $nmbr$ wk n $nmbr$,C1881833
getgoal l asia,C0003980
duration of disease yr t,C0872146;C0439234
getgoal s,
median c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
high $nmbr$ baseline hbalc,C0205250;C0168634;C1442488;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
median fecal calprotectin mg kg gi areas involved no,C0205146;C4319729;C1314939
low $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
proximal gi tract,C0205107;C0017189;C4489236
high $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
perianal gi tract,C0442158;C0017189
short $nmbr$ years duration of diabetes,C0439593;C0011847;C0011849
medications for crohn s disease taken at baseline no,C0013227;C0802604;C2598133;C4284232;C0012634;C1883727;C0168634;C1442488
long $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
one or more medications,C0205447;C0013227;C0802604;C2598133;C4284232
suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
immunosuppressant^,C0021081
suit quartile $nmbr$ $nmbr$ $nmbr$,C2828255
aminosalicylate,C0368663;C2825094
suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
glucocorticoid],C0017710
t $nmbr$ d duration years,C2603360;C0449238;C0439234;C2926735
history of disease refractory to treatment with tnf antagonist no,C0683519;C0730226;C0850708;C0944983;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
oad use n,C0042153;C0457083;C1947944
no history of tnf antagonist treatment no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
oad history years,C0019664;C0439234;C0019665;C0262512;C0262926;C1705255;C2004062
history of tnf antagonist treatment failure no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ppg post meal test mmol l,C0376674;C1532563
patients who received $nmbr$ drug,C0013227;C1254351
suit index nmol mmol,C1532564;C1533073
patients who received $nmbr$ or $nmbr$ drugs,C0030705;C3272598;C1514756;C0013227;C3687832
no cv event n $nmbr$ $nmbr$,C3538987;C0441471;C4019010;C4048877;C4318503
primary nonresponse,C0205225;C0439612;C0439631
nonfatal mi n $nmbr$,C3810814
secondary nonresponse,C0027627;C0175668;C0205436
hhf n $nmbr$,
unacceptable side effects,C0001688;C0877248;C0879626
nonfatal stroke n $nmbr$,C0038454;C4554100
uistekinumab $nmbr$ mg kg,C0439272
ua n $nmbr$,C0041580;C0042014
weight at baseline,C1303013
cv risk factors and history,C0035648;C1553898;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ st quartile,C0036056;C2828255;C3272372
alogliptin n,C1958126
$nmbr$ st and $nmbr$ nd quartile,C0036056;C3272372;C2828255
$nmbr$ kg ma $nmbr$,C0024443;C3887485
$nmbr$ nd and $nmbr$ rd quartile,C0694666;C2828255;C4553350
$nmbr$ years and $nmbr$ years,C0439234
$nmbr$ rd quartile,C0694666;C2828255;C4553350
western europe australia new zealand middle eai,C0043128;C0027978;C0324547
crohn s disease duration,C0010346;C0872146
normal function or mild impairment,C4296962;C0221099;C0684336
$nmbr$ to $nmbr$ yrs,
liraglutide n $nmbr$ $nmbr$,C1456408
involved gastrointestinal areas,C1879646;C0521362
heart failurea,C0018787
secukinumab intravenous $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
established cvd age $nmbr$,C0007222;C0001779
time since as diagnosis mean sd years,C0040223;C3541383;C0011900;C0439234;C1704338;C1704656
$nmbr$ stenosis of coronary carotid or lower extremity arteries,C0007282;C0242231;C0226415
hla b $nmbr$ positive n,C1426226
documented symptomatic chdb,C1301725;C0231220;C1609436
anti tnf naive n,C1448177
documented asymptomatic cardiac ischemiac,C0231221;C0018787;C1522601
hscrp median min max mg l,C0549183;C2827895;C0876920;C2347635;C2348144;C2939193
heart failure nyha ii iii,C0439070;C1705160
elevated hscrp $nmbr$ mg l n,C0205250;C0439268;C3163633
chronic kidney diseased,C0022646;C0227665
total basdai mean sd,C0439175;C2699239;C0439810
cvd risk factors age $nmbr$,C0001783
basfi mean sd,C0444504;C2699239;C2347634;C2348143
microalbuminuria or proteinuria,C0730345;C0033687;C1962972;C4554346
basmi linear mean sd,C0205132;C2699239
hypertension and left ventricular hypertrophy,C0020538;C1963138;C0149721;C3484363
msasss mean sd,C0444504;C2699239;C2347634;C2348143
left ventricular systolic or diastolic dysfunction,C0225897;C0039155;C0520863
syndesmophyte present n,C0221690;C0150312;C0449450
normal egfr $nmbr$,C1739039;C3811844;C3812682
total back pain mean sd,C0004604;C2699239;C1963071;C4553945
mild impairment egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
patient s global assessment of disease activity mean sd,C0030705;C0281858;C1292728
moderate impairment egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
severe impairment egfr,C1739039;C3811844;C3812682
placebo secukinumab pooled,C0032042;C3179547;C1696465;C1706408;C1709595;C2349200;C4522255
liraglutide,C1456408
change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
table $nmbr$ characteristics of the patients at baseline according,C0039224;C0815172;C1706074;C0168634;C1442488;C0680240
patients with syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
to the estimated glomerular filtration r,C0205090;C0684010;C2603358
patients without syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
ate egfr,C1739039;C3811844;C3812682
elevated hscrp,C0205250;C3163633
normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
smokers at baseline,C0337664;C0168634;C1442488
non smokers at baseline,C0337672;C4554605
p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition,C1709380;C1704970;C2699239;C0017654;C1424601;C0750572;C3839656;C1739039;C3811844;C3812682;C0686905;C0030705;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0237881;C0750502;C1546944;C0041420;C0681848;C0023822;C1704436;C4025272;C0439232;C0700321;C0702093;C1282918;C2347166;C0042295;C0008377;C1532563;C1719797;C2911648;C0041004;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0017853;C1522609;C1551393;C1705492;C3272743;C0456603;C1547037;C0444706;C3541902;C0439208;C0065055;C0032042;C1696465;C1706408;C0017351;C0021034;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0205447;C0439526;C1705224;C3887665;C0231174;C0680095;C0521095;C1140263;C0012634;C0348080;C1705253;C3864998
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less,C0030705;C0439526;C1705224;C3887665;C0439232;C0700321;C0702093;C1282918;C2347166
sbp mm hg office measurement mean sd,C0439475;C2699239
patients with minute per,C0030705;C0439232;C0700321;C0702093;C1282918;C2347166
sbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more,C1739039;C3811844;C3812682
dbp mm hg office measurement mean sd,C0439475;C2699239
empagliflozin n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C3490348
dbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no,C1272706;C1552654;C1552713;C1550351
pulse rate bpm mean $nmbr$ h mean sd,C0232117;C2699239
urinary albumin to creatinine ratio no,C0486293;C1318293
time since diagnosis of t $nmbr$ dm y n,C0040223;C3541383
low density lipoprotein^,C0023823
use of diuretics n,C1524063;C0012798
high density lipoprotein],C0023821
use of ace inhibitors arbs n,C1524063;C0003015
angiotensin converting enzyme inhibitor or angiotensin,C0003015;C2757044;C3536837;C4541021;C0003018;C4521302
$nmbr$ antihypertensive medication,C0003364
receptor blocker,C0597357
$nmbr$ antihypertensive medications,C0003364
statin and or ezetimibe,C0360714;C1142985
$nmbr$ aes,C1412268;C2699274
anti hypertensive therapy,C0585941
$nmbr$ drug related aes,C1412268;C2699274
ace inhibitor and or arb,C0003015;C4541021;C3888198
$nmbr$ aes leading to discontinuation,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
us n $nmbr$,C0815353;C3889164
$nmbr$ serious aes,C1412268;C2699274
non us n $nmbr$,C1518422;C0815353;C3889164
special interest categories,C0205555;C0683312
hypoglycemiat,
mean sd n,C0444504;C2347634;C2348143
events requiring assistance,C0441471;C3541888;C0018896;C1269765
cardiac biomarker status,C1999091;C2735302
events consistent with uti,C0441471;C3541888;C0332290;C0042029;C0077906;C1412376
number of vessels treated index pci,C0237753;C0449788
events consistent with genital infection,C0441471;C3541888;C0332290;C0729552
time from hospital admission to pci h median q $nmbr$ q $nmbr$,C3854258;C3854259;C0033727;C0369286;C0441932;C0564385;C4528284
events consistent with volume depletion,C0441471;C3541888;C0332290;C0546884
efficacy,C1280519;C1707887
positive orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
primary end point death mi idr st,C0036056;C3272372
no diuretic therapy,C0948575
key secondary end point st,C0036056;C3272372
diuretic therapy,C0948575
idr,
no ace inhibitor arb therapy,C1444755;C3888198
death from cardiovascular causes,C0007465;C0007226;C3887460
ace inhibitor arb therapy,C1444755;C3888198
death q wave mi idr,C0011065;C0861151;C1306577;C4082313;C4552775
empa $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
death st,C0036056;C3272372
hypoglycemia^,C0020615;C4553659
safety non cabg related bleeding,C0010055;C0019080
non cana n $nmbr$,C1518422;C1418845
gusto defined bleeding,C1704788;C0019080;C3539106
baseline hbalc,C0168634;C1442488
primary safety end point severe life threatening,C1546953;C2826244;C3537125
baseline hbalc $nmbr$ to,C0168634;C1442488
timi defined bleeding,C1704788;C0019080;C3539106
baseline hbalc $nmbr$,C0168634;C1442488
acuity defined bleeding,C0750509;C0019080
genital mycotic infections male $nmbr$,C0564768
efficacy and safety net adverse clinical events,C1280519;C1707887;C0877248;C1705413
utis,C0042029
death mi idr st gusto defined moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
osmotic diuresis related aes,C1412268;C2699274
gold $nmbr$,C0018026;C1304897
volume depletion related aes,C1412268;C2699274
gold a,C0018026;C1304897
olodaterol $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gold c,C0018026;C1304897
tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$,C4032878;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
naive no,
co morbidities a n,C0009488;C0369718;C0441922
naive yes,C1549445;C1705108;C1710701
cardiac rhythm disorders,C0264886
ics no,C0815320;C4551720
ics yes,C1549445;C1705108;C1710701
vascular disordersb,C0005847;C1558950;C1801960
gold n,C0018026;C1304897
mean sd pre bronchodilator,C0444504;C2599602;C2347634;C2348143
$nmbr$ $nmbr$ e,
mean sd post bronchodilator,C0444504;C2699239;C2347634;C2348143;C2599594
baseline cardiovascular medication c n,C0168634;C0007220;C1442488
fev $nmbr$ fvc ratio sd,C0456603;C2699239;C1547037
mean sd extent of exposure days,C0439792;C0274281;C0332157
baseline pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
sama,C1075468
cardiac rhythm disorder at baseline no,C0264886;C0168634;C1442488
cardiac rhythm disorder at baseline yes,C0264886;C0168634;C1442488
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C1304897;C0012634
meddra smq,C1140263
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C0012634;C1304897
olodaterol $nmbr$ m g,C2934193;C0439267
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408
tiotropium $nmbr$ m g,C0213771;C0439267
total patients n,C0439175;C0030705;C0439810
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C1514756;C1518422
any aes n,C1412268;C2699274
rotigotine n $nmbr$,C1700683;C4318637
tachyarrhythmias n,C0080203
stage of pda,C0205390;C1300072;C1306673
supraventricular tachyarrhythmias incl atrial,C1698480;C3853833
early n,C1279919
fibrillation flutter,C0016385;C2242390
advanced n,C0205179
ventricular tachyarrhythmias,C3827656
time since pd diagnosis mean sd,C0040223;C3541383
ischaemic heart disease n,C0010054;C0151744
years modified hoehn and yahr stage n,C0439234;C0679846
other ischaemic heart disease non infarction,C0027051;C1518422
brv dosage mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cardiac failure n,C0018801;C0018802
racial group n,C0441848
cerebrovascular disorders n,C0007820
whitea,C1021495
haemorrhagic,C0333275
baseline focal seizure frequency $nmbr$ days median q $nmbr$ q $nmbr$,C0149775;C0751495
racea,
seizure types reported during baseline b n,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
copd disease severity,C0024117;C0521117;C1412502;C3714496
simple partial ia,C0020980;C0694634;C1947960
chinese subgroup,C1079230;C1515021
complex partial ib,C2744579;C3890035;C4283819
korea republic of,C0022773
partial evolving to secondarily generalized ic,C0728938;C1550516;C0205246;C0020750;C4554818
malaysia,C0024552
no of prior aeds c n,C0332152;C0180309;C2826257
body weighta kg,C0022718;C0439209;C4054209
most common concomitant aeds d n,C0205214;C0180309;C1522138;C3245511;C0369718;C0441922
belimumab $nmbr$ mg sc n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior lev treatment,C1514463;C0023556
age mean $nmbr$ sd years,C1510829;C0444504;C2347634;C2348143
lev naive,C0023556
weight mean $nmbr$ sd kg,C0022718;C0439209;C4054209
central eastern europe russia,C0682369;C0035970
enrollment by region no,C1516879;C1696073;C3888021
syst bp mmhg,C0037623;C0439475;C1415692;C1708288;C4318478
americas excluding us,C0002454;C0596070
nt probnp pg mla iqr,C0669479;C0754710
western europe australia israel,C0043128;C0022271
ckd egfr $nmbr$ b,C1561643;C1739039;C3811844;C3812682
disease duration median range years,C0872146;C0439234
central eastern europe and russia,C0682369;C0035970
selena sledai range u $nmbr$ u $nmbr$ t,C0451528;C0439148
event rates per $nmbr$ patient years $nmbr$ ci,C0871208;C1521828
score of $nmbr$ no,C0449820;C4050231
$nmbr$ $nmbr$ ref,C1425988
organ system involvement no,C0460002;C1314939
adjustedahr,
mucocutaneous,
all cause mortality no of events,C0015127;C0026565;C0026566;C1524003;C0441471;C3541888
musculoskeletal,C0497254;C2707260
significant worsening in kccq clinical,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960
immunologic,C0152036;C0205470
score $nmbr$ at $nmbr$ monthsb unadjusted or,C0449820;C4050231;C1439367
renal,C0022646
adjustedaor,
hematologic,C0018943;C0205488
overall hr $nmbr$ cl,C0282416;C0596019;C1561607
cardiovascular and respiratory,C0007226;C3887460;C0521346;C1546767
north america hr $nmbr$ cl,C0028405;C0596019
constitutional,C1511487
western europe hr $nmbr$ cl,C0043129;C0596019
central nervous system,C3540014;C3714787
central eastern europe and russia hr $nmbr$ cl,C0682369;C0035970;C0596019
disease hare no i,C0242372;C1425660;C0021966;C0221138
latin america hr $nmbr$ cl,C0023122;C0596019
at least $nmbr$ flare,C1517205;C3540542
asia pacific hr $nmbr$ cl,C0003980;C0596019
at least $nmbr$ severe flare,C1517205;C3540542
significant worsening in kccq clinical score $nmbr$ at $nmbr$ months $nmbr$,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0439231
physician s global assessment mean $nmbr$ sd,C0031831;C0804815;C0281858;C2699239
renal function at randomization,C0232804;C0034656
$nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274776;C0439445
facit fatigue mean $nmbr$ sd range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],C2945599;C0031847;C0439445;C0277785;C3887504;C3887505
corticosteroids only,C0001617;C3539185;C3540725;C3540726;C3540727
mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274775;C0439445
immunosuppressants only,C0021081
normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C4296962;C0439445
antimalarials only,C0003374
bmi median iqr kg m $nmbr$,C0022718;C0439209;C4054209
corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
crcl median iqr ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727;C0003374
current or prior smoking,C0521116;C1705970;C0037369;C0453996;C1881674
immunosuppressants and antimalarials only,C0021081;C0003374
corticosteroids immunosuppressants and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727;C0003374
other vascular disease cvd or pad,C0042373;C0007222;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
mycophenolate mofetil,C0209368
asia pacific and africa,C0003980;C0001737
sri response,C0871261;C1704632;C1706817;C2911692
chads $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
overall n $nmbr$ vs $nmbr$,C0282416;C1561607
cha $nmbr$ ds $nmbr$ vasc mean sd,C0444504;C2699239;C2347634;C2348143
ss at baseline,C2699257;C3891295;C4551874
modified has bled score mean sd,C0392747;C3889737;C0444504;C2699239;C2347634;C2348143
ss $nmbr$ n $nmbr$ vs $nmbr$,C2699257;C3891295;C4551874
intermediate $nmbr$,C0205103;C1550465;C2827755;C3889971
black race n $nmbr$ vs $nmbr$,C0005680
potent phosphorylated glycoprotein inhibitor use,C0042153;C0457083;C1947944
prior vka use for $nmbr$ d,C0042153;C0457083;C1947944
non black race n $nmbr$ vs $nmbr$,C1518422;C0005680
medication at randomization,C0013227;C3244316;C4284232
race and ss at baseline,C0034510;C1706779;C3853635;C2699257;C3891295;C4551874
time in therapeutic range median iqr,C1554109
black race and ss $nmbr$ n $nmbr$ vs $nmbr$,C0005680;C2699257;C3891295;C4551874
i $nmbr$ $nmbr$ vs $nmbr$ $nmbr$,C0021966;C0221138
n n yr,C0369718;C0439234;C0441922
warf,C0043031
non black race and ss $nmbr$ n $nmbr$ vs $nmbr$,C1518422;C0005680;C2699257;C3891295;C4551874
hder,C3898895
baseline body weight quartile,C1303013;C2828255
stroke or se s se,C0038454;C4554100;C0036919
q $nmbr$ $nmbr$ $nmbr$ kg n $nmbr$ vs $nmbr$,C0022718;C0439209;C4054209
crcl $nmbr$ $nmbr$,C1846718
q $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ kg n $nmbr$ vs $nmbr$,C0022718;C0439209;C4054209
crci $nmbr$,
steroid use at baseline,C0281991;C0168634;C1442488
major bleeding mb,C0019080;C0024853
steroids n $nmbr$ vs $nmbr$,C0038317
s se mb or death,C0036919;C0024853;C0011065;C1306577;C4082313;C4552775
no steroids n $nmbr$ vs $nmbr$,C0038317
previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
vonoprazan $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
aget y,
warfarin n $nmbr$ n y,C0043031
bmit,
higher dose edoxaban n $nmbr$ n y,C0444956;C2975435
previous smoker,C0337671
higher dose edoxaban vs warfarin,C0444956;C2975435;C0043031
every day,C0332173;C0439228;C0439505
$nmbr$ or $nmbr$ d wk,C0332174;C0439230
ard per $nmbr$ $nmbr$ patient years $nmbr$ ci,C1817569;C1826411
$nmbr$ or $nmbr$ d mo,C0026544;C0332177
previous stroke tia,C0007787;C0917805;C1054154
never drink,C2003901;C0452428
no previous stroke tia,C0007787;C0917805;C1054154
caffeine consumption,C0948365
cvd stroke see,C0042789;C1947903
modi fied la grade,C0441800;C0919553;C3244287
all cause death stroke see,C0042789;C1947903
heartburn severity during the run in periodt,C0439793;C0522510
atrial fibrillation type n,C0004238;C0344434;C1963067
esophageal hiatal hernia,C3489393
permanent af,C0344434;C4049859
yes z $nmbr$ cm,C1549445;C1705108;C1710701
qualifying risk factor n,C1514624;C0035648
yes o $nmbr$ cm,C1549445;C1705108;C1710701
chads $nmbr$ score $nmbr$ $nmbr$ n,C0449820;C4050231
h pylori serology,C0036745;C0220911;C0455278
dose reduction n,C0178602;C0301630;C0392756;C1293152;C4551656;C0869039;C1114758
renal impairment crcl,C1565489;C1846718
history of h pylori eradication,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
low body weight,C0041667
yes r $nmbr$ y,C1549445;C1705108;C1710701;C0205090;C0684010;C2603358
yes $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
nondisabling nonfatal stroke,C0038454;C4554100
vka naive n,
serum gastrint pg ml,C0229671;C0439297;C1546774;C1550100
medication at randomization n,C0013227;C3244316;C4284232
serum pepsinogen i iit,C0077923;C0523816
disabling stroke,C0038454;C4554100
czp mtx^mtx,C0054841;C0025677;C1417487;C1861828;C1872109
disabling or fatal stroke,C0038454;C4554100
pbo mtx^mtx,C0031962;C0025677;C1417487
primary hemorrhagic stroke,C0205225;C0553692;C0439612;C0439631
total patients n $nmbr$,C0439175;C0030705;C0439810
primary ischemic stroke,C0205225;C0948008;C0439612;C0439631
patients entering pt period n $nmbr$,C0030705;C1522196;C0032743;C0439531;C1948053;C0699718
no prior hf hospitalization n $nmbr$ $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
db baseline week $nmbr$,C0332174;C0439230
nyha functional class at randomization,C1882083;C0205245;C0542341;C2700217
pt baseline week $nmbr$,C0332174;C0439230
western europe plus other,C0043129
average weekly mtx dose mg week t,C0366550;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ace,C1452534;C4284014
czp mtx to mtx,C0054841;C0025677;C1417487;C1861828;C1872109
[ $nmbr$ $nmbr$ $nmbr$ ],
pbo mtx to mtx,C0031962;C0025677;C1417487
figure $nmbr$ treatment effect of sacubitril valsartan therapy,C1518681
mtss cfb,C0009002;C1824728
note have already got interaction values from the paper itself,C1316572;C1317574;C0042295;C0030351;C1547566
baseline factor,C1521761;C2827422
elevated serum creatinine $nmbr$ $nmbr$ mg dl,C0700225;C0439269
baseline erosion,C0333307;C1880549;C1959609;C3887524
elevated serum potassium $nmbr$ $nmbr$ mmol l,C0553704;C1532563
tnf alpha pg ml,C1448177;C0439297;C1456820;C1522669
drug discontinuation not due to death,C0457454;C1444662;C4552847;C0678226;C0011065;C1306577;C4082313;C4552775
baseline steroids,C0168634;C0038317;C1442488
any dose reduction,C0301630;C0392756;C1293152;C4551656
mtx exposure mg week,C0332174;C0439230
average daily dose,C1510992;C2348070;C2825518
age of onset,C0206132;C3175530
of target,C1521840;C2986546
age of onset $nmbr$ years n $nmbr$,C0206132;C3175530
sacubitril valsartan,C4033631
icsa plus laba n,
no prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
geographical location n,C4545686
vildagliptin metformin vldm,C1570906;C0025598
ocs n,
metformin hdm,C0025598
fev $nmbr$ l mean sd,C0444504;C2699239;C2347634;C2348143
age distribution n,C0001782
fev $nmbr$ predicted mean sd,C0444504;C2699239;C2347634;C2348143
bmi distribution n,C0578022;C0520511;C1704711
acq $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
mean s d duration of t $nmbr$ dm years,C0449238;C2926735
aqlq score mean sd,C0444504;C2699239;C2347634;C2348143
mean s d baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
asui score mean sd,C0444504;C2699239;C2347634;C2348143
mean s d baseline fpg mmol l,C0168634;C1532563;C1442488
blood eosinophils cells ml,C2699156
mean s d metformin dose mg day,C0025598;C0439422
allergic disease by historyb n,C0020517;C0851444
age $nmbr$ years and bmi $nmbr$ kg m $nmbr$,C1510829;C0022718;C0439209;C4054209
atopy specific ige c n,C0392707;C0205369;C1552740;C3539705
vldm n $nmbr$,
chronic sinusitis nasal polypsd n,C0149516;C0028429;C4520890
hdm n $nmbr$,
resllzumab,
hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
demographic data,C4684639
hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions,C0019016;C1825777;C3538758;C1708130;C0559546;C3539617;C4050121
alprostadil n $nmbr$,C0002335
reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$,C0301630;C0392756;C1293152;C4551656;C0168634;C1442488
gender male female number,C0237753;C0449788
mean age y median range,C1514721;C2348147;C3542016
risk factors and diabetes status,C0035648;C1553898;C1317301
caffeine,C0006644;C0236734
systolic blood pressure mm hg median range,C1514721;C2348147;C3542016
complete healinga,C0205197;C0725685;C3853530;C4283785
diastolic blood pressure mm hg median range,C1514721;C2348147;C3542016
major amputationsb,C0205082;C0205164;C4318856;C4521762
previous ischemic stroke n,C0205156;C0948008;C1552607
alprostadil n n,C0002335
previous coronary artery disease n,C0010054;C0010068;C1956346
interim analysis,C4684691
history of diabetes mellitus n,C0455488
overall analysis,C0002778;C0936012;C1524024
history of hypercholesterolemia n,C1533076
cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c,C0205341;C0008107;C3259781
baseline scales median range,C1514721;C2348147;C3542016
statistic,C2348149;C2828391
nihss at randomization,C1697238;C0034656
statisticd,
stroke subtype n,C0038454;C0449560;C4554100
interim analysis all patients,C4684691;C0030705
laa,
e $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
soe or sue,
final analysis all patients,C0002778;C0936012;C1524024;C0030705
extracranial carotid stenosis n,C0580586;C0007282
duration of paod years mean sd,C0449238;C2926735
medications at timing of randomization n,C2359859;C0034656
intensity of rest pain mmvas mean sd,C1320357;C4085211
antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177;C0034656
systolic pressure at ankle level mmhg mean sd,C0871470
antidiabetic agents,C0935929
analgesic medication n,C0002771
time from onset to randomization h mean sd,C0449244;C0033727;C2699239;C0369286;C0441932;C0564385;C4528284
past treatment for paod,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
time from onset to medication h mean sd,C0449244;C0013227;C2699239;C3244316;C4284232
medical treatment n,C0679624
event rates,C0871208;C1521828
revascularisation n,C0581603
p value for variance,C1709380;C1711260;C2348152
amputations n,C0002688
placebo plus aspirin,C0032042;C1696465;C1706408
ischaemic skin lesions,C0475224;C0037284
history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
number of lesions n a,C0449791
time to treatment,C3494202
size cm $nmbr$ mean standard deviation,C1828170
hospital factor $nmbr$,C1521761;C2827422
type,C0332307;C1547052
$nmbr$ enroll,
ulcer n a,C0041582;C3887532
$nmbr$ beds,C0004916
necrosis n a,C0027540;C1334928
lesion location,C0450429;C1515974;C4284930;C4284931
base,C0002055;C0178499;C1880279
cortical only,C0001613;C0007776;C0022655
clean n a,C1947930
non cortical,C0001613;C0007776;C0022655
granulating n a,C1272460
vascular territory $nmbr$,C1301808;C2983136
infected n a,C0439663
anterior circulation,C0005775;C1516559
missing n a,C1551393;C1705492;C3272743
posterior circulation,C0005775;C1516559
serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mca,C0149566
serum mg $nmbr$ $nmbr$ mmol l normal mg hvpermagnesemia,C2827881
with n $nmbr$,C0369718;C0441922
pbo n $nmbr$ $nmbr$,C0031962
without n $nmbr$ $nmbr$,C0369718;C0441922
cana $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
asia pacific or other,C0003980
ethnicity n b,C0015031;C0243103
diabetesduration mean sd y,C0444504;C2347634;C2348143
hba $nmbr$ c mmol mole,C0019016;C3829066;C1825777;C3538758
glycated hemoglobin mean sd,C0017853;C2699239
baseline serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glycatedhemoglobin category,C0683312;C3889287
baseline serum mg $nmbr$ $nmbr$ mmol l,C0439268
priorvascular disease,C0012634
baseline mmol l,C0168634;C1532563;C1442488
peripheral artery,C0489868
priorheartfailure,
week $nmbr$ mmol l,C0332174;C1532563;C0439230
baseline heart failure severity amongthose with priorheartfailure,C0018801;C0018802;C4554158
total number of patients,C2360800
nyha class iii,C1882086
egfr mean sd,C0444504;C2699239;C2347634;C2348143
nyha class iv,C1882087
egfr $nmbr$ to,C1739039;C3811844;C3812682
nyha class not reported,C1882083;C0684224;C0700287;C4319718
egfr $nmbr$ ml min n,C1739039;C0439445;C3811844;C3812682
af first diagnosis $nmbr$ years n,C0205435;C0011900;C1704338;C1704656;C1279901
bloodpressure mean sd m m hg,C0025424;C0428257;C2347108;C2347109;C2348272
af on baseline ecg n,C0344434;C4049859
body massindex mean sd a,C0242821;C2699239;C0460148;C1268086;C4082212
cigarettesmoking,
$nmbr$ or $nmbr$ n,C0369718;C0441922
antihyperglycemictherapies,
cha $nmbr$ ds $nmbr$ vasc score mean sd,C0444504;C2699239;C2347634;C2348143
nonaspirin antiplatelet agent,C0722138;C0085826
risk factors for stroke,C0035648;C1553898
sitagliptin no total no,C1565750;C0439175;C0439810
previous stroke or tia n,C0038454;C4554100;C0007787;C0917805;C1054154
placebo no total no,C0032042;C1696465;C1706408;C0439175;C0439810
heart failure n,C0018801;C0018802;C4554158
p value fo interactio,C1709380
hypertension receiving treatment n,C0020538;C1963138;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
region latin american,C0017446;C1553378;C0205147
valvular heart disease n,C0018824;C1963123
diabetes duration median,C0549183;C0876920;C2347635;C2348144;C2939193
concomitant medications at baseline,C0013227;C0802604;C2598133;C4284232
prior congestive heart failure yes,C1549445;C1705108;C1710701
arb or ace inhibitor n,C3888198;C0003015;C4541021
baseline heart failure severity nyha class i,C0018801;C1882084;C0018802;C4554158
ppi or h $nmbr$ receptor antagonist n,C0358591;C0871125;C3811894;C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
prior myocardial infarction yes,C1549445;C1705108;C1710701
on oac at time of randomisation n,C0040223;C0034656;C3541383
prior coronary artery disease yes,C1549445;C1705108;C1710701
dabigatran $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior hypertension yes,C1549445;C1705108;C1710701
dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
body mass index median,C0549183;C0876920;C2347635;C2348144;C2939193
dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clinical outcome,C0205210;C1274040
systolic blood pressure mm hg $nmbr$,C0488055;C0439475;C0871470;C1306620
number of events,C4330837
glycated hemoglobin median p,C0062418;C3891442
event rate year,C0439234;C0439508
renal function $nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0232804;C0439445
p value for interaction age groups,C1709380
$nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
p value for interaction age continuous,C1709380;C0001779;C0549178
$nmbr$ to $nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$ a,C0369637;C0441923
stroke non,C0038454;C1518422;C4554100
$nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$ a,C0369637;C0441923
cns systemic embolism,C0013922;C1704212
insulin yes,C1549445;C1705108;C1710701
$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$,C0024671;C3254570;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
thiazolidinedione yes,C1549445;C1705108;C1710701
duration of rheumatoid arthritis years,C0449238;C2926735
ace inhibitor yes,C1549445;C1705108;C1710701
anti ccp antibody positive,C0741132
angiotensin receptor blocker yes,C1549445;C1705108;C1710701
das $nmbr$ c reactive protein,C0006560;C1413716;C4048285
p blocker yes,C1549445;C1705108;C1710701
diuretic thiazide,C0012802
clinical disease activity index score $nmbr$ $nmbr$,C4706353
lvef median iqr,C0428772;C0488728
simplified disease activity index score $nmbr$ $nmbr$,C4706353
hfpef ef n $nmbr$,
duration of morning,C0449238;C2926735
systolic bp mmhg mean sd,C0488053;C2699239
stiffness min,C0702093;C1524029;C3813700
diastolic bp mmhg mean sd,C0488053;C2699239
conventional synthetic dmard use at baseline,C0042153;C0457083;C1947944
mitral regurgitation,C0026266
methotrexate dose at baseline,C0178602;C0869039;C1114758
heart failure hf,C0018488;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ mg week,C0332174;C0439230
hospitalization for hf previous year,C0019993;C0018488;C1313497;C1538440;C3273279
sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hf hospitalizations median iqr,C0018488;C0019993;C1313497;C1538440;C3273279
evaluable for acr $nmbr$ at week $nmbr$ n,C1516986;C1412134;C1515941;C0332174;C0439230
stroke or pvd,C0038454;C4554100;C0085096;C4521226
acr $nmbr$ response at week $nmbr$ n,C0871261;C1704632;C1706817;C2911692
aicd,C0972395;C2611803;C3537205;C3546309
prior anti tnf therapy,C1514463
medication prior to admission,C0013227;C3244316;C4284232
received $nmbr$ prior anti tnf therapy n,C1514463
ccbs,C0006684
received $nmbr$ prior anti tnf therapies n,C1514463
presenting signs and symptoms,C0449450;C0220912;C0220913;C0311392;C0683368;C1457887
prior biologic therapy including anti tnfs,C0278947;C1448177
orthopnea,C0085619
received $nmbr$ prior biologic therapy n,C1514756;C0278947
dyspnea at rest nyha iv,C0743330;C0022326;C4265176
received $nmbr$ prior biologic therapies n,C1514756;C0278947
edema,C0013604;C1717255
low $nmbr$ $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
jvp,
intermediate $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
n $nmbr$ yrs,C0369718;C0441922
high $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
inflammation,C0021368
coexisting conditions,C0012634;C0348080;C1705253;C3864998
crp ng ml,C3890735;C0439275;C4048285
previous ml before index acs,C0439526;C1705224;C3887665
d dimer ng ml,C0060323;C0439275
previous pci before index acs,C0205156;C4049621;C1552607
gdf $nmbr$ ng ml,C1418244;C0439275
previous cabg before index acs,C0205156;C0010055;C1552607
interleukin $nmbr$ pg ml,C0021764;C0439297;C1527200
before index acs event,C0441471;C4019010
pentraxin $nmbr$ ng ml,C0439275
at index acs event,C0441471;C4019010
procalcitonin ng ml,C0072027;C0439275
ml with st segment elevation,C0439526;C1705224;C3887665
pigr ng ml,C1418569;C0439275
ml without st segment elevation,C0439526;C1705224;C3887665
psap b ng ml,C1418975;C0439275;C1420002;C1425004
pre randomization pci,C0034656;C4049621
rage ng ml,C0034634;C0439275;C3539760;C3815186
time from acs to randomization,C0040223;C3541383;C0034656
tnf r $nmbr$ a ng ml,C1363984;C1706001;C0439275
$nmbr$ $nmbr$ $nmbr$ o $nmbr$ o,C0483204
wap $nmbr$ c ng ml,C0439275
low risk ri $nmbr$ $nmbr$,C0035487;C1826843
oxidative stress,C0242606
intermediate risk ri $nmbr$,C0035487;C1826843
mpo ng ml,C0439275
high risk ri $nmbr$,C0035487;C1826843
remodeling,
ez simva,C0206578
syndecan $nmbr$ ng ml,C0075691;C0439275;C1419891
arr,C2170357;C4084934
periostin ng ml,C0219433;C0439275;C1424662;C3812270
risk model endpoint,C2349179;C2826544
galectin $nmbr$ ng ml,C0607430;C0439275
pre specified trial endpoints,C2826245;C2349179
osteopontin ng ml,C0069676;C0439275;C1420369;C1505427;C4084879
secondary $nmbr$,C0027627;C0175668;C0205436
cardiac stretch,C0018787;C0600080;C1522601
individual endpoints,C0027361;C2349179;C0237401
st $nmbr$ ng ml,C0036056;C0439275;C3272372
cor revasc,C0018787;C0378365;C0056331
troponin i pg ml,C0077401;C0439297
urgent cor revasc,C0018787;C0378365;C0056331
angiogenesis,C0302600;C1519670
acm,C0001143;C1549040
vegfr ng ml,C1568520;C0439275
pooled,C1709595;C2349200;C4522255
angiogenin ng ml,C0051844;C0439275;C1367482
seizure types reported during baseline n a,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
mesothelin ng ml,C0380162;C0439275;C1334533
number of prior aeds n b,C0237753;C0449788
neuropilin ng ml,C0287275;C0439275
most common concomitant aeds n,C0205214;C0180309;C1522138;C3245511
proadm ng ml,C0439275
phenytoin,C0031507;C0202454
ntpro cnp ng ml,C3889729;C0439275
levetiracetam,C0377265;C3693636
endothelin $nmbr$ pg ml,C0079284;C0439297
patients with minimal important change in qolie $nmbr$ p,C0030705;C3845594
troy ng ml,C1420811;C0439275;C1883402
minimal important change threshold improvement,C3845594;C2986411
arteriosclerosis,C0003850
$nmbr$ focal seizure frequency responders,C0149775;C0751495
esam ng ml,C1424976;C0439275
cognitive functioning,C1516691;C0205245;C0542341;C4552744
ltbr ng ml,C1416931;C0439275
emotional well being,C2984554;C3641833
ngal ng ml,C0215955;C0439275;C1416806;C2346625
energy fatigue,C0015672;C3463815;C4050243;C4554645
kim $nmbr$ pg ml,C0439297
medication effects,C1319171
pioglitazone n $nmbr$ $nmbr$,C0071097
overall quality of life,C3641830
laboratory data mean sd,C0022877;C2699239;C3244292;C4283904
seizure worry,C0036572;C0233481;C1959629;C4553401
insulin mu ml,C0021641;C0439339;C1533581;C1579433;C3714501
daily activities social functioning,C0871707;C0037395
dysglycemic categories n,C0683312
$nmbr$ $nmbr$ $nmbr$ obesity class $nmbr$,C0456387;C1518526;C1705943
ada ifg,C1334085;C1708411
$nmbr$ obesity class $nmbr$,C0456387;C1518526;C1705943
$nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
glycated haemoglobin,C0017853
who idf ifg,C1334085;C1708411
$nmbr$ h plasma glucose during ogtt mmol l,C0202042;C0455280
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
women n $nmbr$ vs $nmbr$,C0043210
hba $nmbr$ c $nmbr$ $nmbr$ to,C0019016;C1825777;C3538758
men n $nmbr$ vs $nmbr$,C0025266
ncep atp iii metabolic syndrome features n,C1864620
vldl cholesterol,C0023826;C0523560
antihypertensive medication or,C0003364
free fatty acids mmol l,C0015688;C1532563
sbp dbp $nmbr$ $nmbr$ mmhg,C0085805;C0439475
dyslipidaemiat,
abdominal obesity,C0311277
hypertensiont,
number s of features present,C0237753;C0449788;C0150312;C0449450
dyslipidaemia and hypertensiont,C0242339
pioglitazone events n,C0071097;C0441471;C3541888
estimated proportions and odds ratios,C0750572;C1709707;C0028873
placebo events n,C0032042;C0441471;C3541888;C1696465;C1706408
interaction between treatment and baseline bmi category,C1704675;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0683312;C3889287
hispanic ethnicity,C0015031;C0243103
estimated means and treatment differences,C0750572;C1704970;C1705241;C1705242
hypertension history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
llraglutide $nmbr$ $nmbr$ mg mean n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
coronary artery disease history,C0683519
baseline hstni,C0168634;C1442488
aerobic activity,C0001701
$nmbr$ ng l n $nmbr$,C0439297
not at goal,C1518422;C0018017;C1571704
p value trend,C1521798;C4554533
at goal,C0018017;C1571704
glycohemoglobin,C0202054;C0696092
ada impaired fasting glucose,C1060325;C1272092;C3811629
prior coronary intervention or coronary artery bypass grafting,C0184661;C0886296;C1273869;C0010055
present $nmbr$ mg dl,C0150312;C0439269;C0449450
index inclusion acute coronary syndrome,C0007637;C0948089;C1512693
who idf impaired fasting glucose,C3272598;C1272092
time from acute coronary syndrome to randomization days,C0040223;C3541383;C0034656;C0439228
homa,
$nmbr$ men $nmbr$ women,C0025266;C0043210
median egfr interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
linagliptin n z $nmbr$,C2746078
$nmbr$ ng l n $nmbr$ n,C0439297
presence of mets a,C0150312;C0392148;C3854307
cardiovascular death nonfatal myocardial infarction nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ e $nmbr$ years,C0439234
nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
homa ir mean sd mu l mmol l b,C0022065;C0439342;C0022071;C1448132
cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
homa ir b,C0022065;C0022071;C1448132
cardiovascular death or nonfatal myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ $nmbr$ mu l mmol l,C0439342;C0439190
demographic features,C0683970
fasting c peptide nmol l c,C0015663;C0607868
black race n,C0005680
previous oad,C0205156;C1552607
hispanic ethnic group n,C0441848
clinical history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
placebo adjusted mean difference in hba $nmbr$ c $nmbr$ ci [ p value],C0444504;C1705241;C1705242;C2347634;C2348143;C1709380
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [,
stroke at entry vs transient ischemic attack,C0038454;C4554100;C0007787;C0917805
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
prior stroke before index event,C0332152;C0456712;C2826257
homa ir mu l^mmol l,C0022065;C0439342;C0022071;C1448132
coronary angioplasty or stenting,C0002997;C0190211;C0038257;C2348535
presence of mets,C0150312;C0392148;C3854307
carotid artery intervention,C0397581
aclidinium formoterol $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
fasting glucose mmol l mean sd,C1532563;C2699239
salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
insulin iu ml median q $nmbr$ q $nmbr$,C0021641;C0439458;C1533581;C1579433;C3714501
gold classification,C0008902;C0008903;C0678229
homa ir median q $nmbr$ q $nmbr$,C0022065;C0022071;C1448132
smoking consumption pack years,C0425291;C1277691
hdl cholesterol mmol l men mean sd,C0023822;C2699239;C0392885
exacerbation in previous year,C4086268;C0205156;C1552607
hdl cholesterol mmol l women mean sd,C0023822;C2699239;C0392885
prior copd medication,C0013227;C3244316;C4284232
c reactive protein median q $nmbr$ q $nmbr$,C0006560;C1413716;C4048285
laba lama,C0999593;C1416775
other antihypertensive,C0003364
laba lama ics,C0815320;C4551720
aspirin and other antiplatelet,C0004057
fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
nonaspirin antiplatelet,C0722138
post bronchodilator fevi $nmbr$ predicted,C0681842;C1882327
coumadin,C0699129
bronchial reversibility,C0205039;C0449261;C1442216
other anticoagulant,C0003280;C0848112;C3536711
bdi focal score $nmbr$,C0449820;C4050231
pioglitazone pts n,C0071097;C1419129;C2698747
cat total score $nmbr$,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
placebo pts n,C0032042;C1419129;C2698747;C1696465;C1706408
sgrq total score $nmbr$,C2964552
$nmbr$ z $nmbr$,
duration of ra,C0449238;C2926735
white other,C0007457;C0043157;C0220938
tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1948050;C0332173;C0439228;C0439505
absent $nmbr$ mg dl,C0332197;C0439269;C4285062
early n $nmbr$,C1279919
homa median,C0549183;C0876920;C2347635;C2348144;C2939193
established n $nmbr$,C0443211;C1272684
arb ace,C1452534;C4284014
tjc,
$nmbr$ $nmbr$ o,C0483204
sjc,
copd n $nmbr$,C0024117;C1412502;C3714496
vdhmtss,
copd placebo n $nmbr$,C0024117;C0032042;C1696465;C1706408;C1412502;C3714496
hscrp mg dl,C0439269
copd rosuvastatin n $nmbr$,C0024117;C0965129;C1412502;C3714496
acpa positive,C0439178;C1446409;C1514241;C2825490;C3812269
copd placebo $nmbr$ pt n,C0024117;C0032042;C1696465;C1706408;C1412502;C3714496
figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p,C4055223;C0030705;C1279919;C3538806;C4048756
copd rosuvastatin $nmbr$ pt n,C0024117;C0032743;C0699718;C1412502;C3714496
acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis,C0035452;C4706353;C0014779;C0003873
model $nmbr$,C3161035;C3274659;C3714583;C3853906
a no vhd n $nmbr$ $nmbr$,
symptoms,C0683368;C1457887
b vhd n $nmbr$,
nyha ii n,C1275491;C1710602;C4082587
c right sided vhd n $nmbr$,C0205090;C0444532
nyha iii n,C1275491;C0439070;C1705160
nyha iv n,C1275491;C0022326;C4265176
d mitral stenosis vhd n $nmbr$,C0026269;C0264766
former current smoker n,C0337671
bonferroni adjusted p value b vs a,C0456081;C1709380
previous hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
bonferroni adjusted p value c vs a,C0456081;C1709380
previous cabg n,C0205156;C0010055;C1552607
bonferroni adjusted p value d vs a,C0456081;C1709380
previous pci n,C0205156;C1552607
vhd event rate year n,C0439234;C0439508
pm n,C0030266;C4049155
no vhd event rate year n,C0439234;C0439508
history of atrial arrhythmia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
adiusted hazard ratio,C2985465
previous cancer n,C0205156;C0006826;C0998265;C1306459;C1552607
persistent af n,C0205322;C0332996
ischaemic n,C0475224
strokezsee,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
dilatative n,
crcl at baseline ml min,C1846718;C0439445
hypertensive n,C0857121
other cause n,C0015127;C1524003
moderate renal impairment n,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
coronary artery disease n,C0010054;C0010068;C1956346
non detectable unknown n,C1518422;C0439673;C3541433;C4050014
s $nmbr$ gallop n,
vitamin k antagonist experienced n,C1096489;C2267235
mitral regurgitation n,C0026266
history of stroke see tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ecg,C1623258
on sulfonylurea,C0038766;C3536898
pathologic q waves n,C0429089;C1305738
alone,C0205171;C0439044;C0679994
lv hypertrophy n,C0149721
plus metformin,C0025598
qrs duration $nmbr$ ms n,C2349943;C3539704;C3713294
hba $nmbr$ c distribution,C0520511;C1704711
diuretics n,C0012798
$nmbr$ h pmg mg dl,C0033727;C0439269;C0369286;C0441932;C0564385;C4528284
calcium channel blockers n,C0006684;C2757014
fasting insulin giu ml,C0015663;C0439526;C1705224;C3887665
homa p,
beta blockers all n,C0001645;C0369718;C0441922
efficacy parameter,C0549193;C1704769;C2350001
other antiplatelet agents n,C0085826
subset of patients on metformin,C1515021;C0030705;C0025598
$nmbr$ blood eosinophils at baseline,C0014467;C0168634;C1442488
subset of patients not on metformin,C1515021;C0030705;C1518422;C0025598
ind gly $nmbr$ $nmbr$ mg once daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
ls mean change from baseline $nmbr$,C0392747;C0443172;C1705241;C4319952
sfc $nmbr$ $nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
difference in ls means $nmbr$ ci $nmbr$,C1705241;C1705242
ind gly $nmbr$ $nmbr$ mg once daily n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
total n $nmbr$ n,C0439175;C0439810
sfc $nmbr$ $nmbr$ mg twice daily n $nmbr$ $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
min max age,C0702093;C0001779;C1524029;C3813700
ics use at screening n,C0042153;C0457083;C1947944
duration of ra years,C0449238;C2926735
laba use at screening n,C0042153;C0457083;C1947944
ara functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
lama use at screening n,C0042153;C0457083;C1947944
biologics user,C1548600;C1706077
laba ics use at screening n,C0042153;C0457083;C1947944
methotrexate user,C1548600;C1706077
triple therapy use at screening n,C0042153;C0457083;C1947944
low dose corticosteroid user,C1548600;C1706077
smoking status at screening n,C1519386
dmard user,C1548600;C1706077
severity ofcopd gold $nmbr$ n,C0439793;C0018026;C1304897;C0522510
dmard or corticosteroid,C0242708;C0001617;C3536709
low risk and fewer symptoms group a,C3272281;C3538919;C0441835;C4522145
fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i,C1705241;C1705242;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0168634;C1442488;C0439230;C0021966;C0221138
low risk and more symptoms group b,C3272281;C3538919;C0683368;C4522078;C1457887
colchicine n $nmbr$,C0009262
high risk and fewer symptoms group c,C0332167;C3272283;C4050568;C4319571;C0683368;C0441837;C1457887
no colchicine n $nmbr$,C0009262
high risk and more symptoms group d,C0332167;C3272283;C4050568;C4319571;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
age y mean range,C1514721;C2348147;C3542016
severity of airflow limitation gold $nmbr$ $nmbr$ n,C0439793;C0522510
creatinine mg dl mean sd,C0439269;C2699239
mild gold $nmbr$,C0018026;C1304897
ef mean sd,C0444504;C2699239;C2347634;C2348143
post bronchodilator fev $nmbr$ reversibility percentage of baseline value,C0439165;C1549488;C1561533
ef b $nmbr$,
number of copd exacerbations in the previous year n,C0237753;C0449788;C0205156;C0439234;C0439508;C1552607
valvular heart disease,C0018824;C1963123
no of patients ind gly sfc,C0030705;C0017890;C0523677
$nmbr$ $nmbr$ range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
annualized rate ind gly sfc,C0017890;C4521536;C0523677
age y n $nmbr$,C0001779
rate ratio $nmbr$ ci,C0008107;C3259781
age $nmbr$ $nmbr$ y n $nmbr$,C0001779
blood eosinophils count,C0200638;C0750879
$nmbr$ y kaplan meier rate $nmbr$ ci,C0008107;C3259781
$nmbr$ cells ul,C0439378
female race white,C0007457;C0043157;C0220938
$nmbr$ to $nmbr$ cells ul,C0439378
cv death mi stroke recurrent ischemia,C0022116;C4321499
$nmbr$ cells pl,C3897966;C4049765
with rehospitalization urgent coronary revascularization,C0439609;C0877341;C3272275
$nmbr$ to $nmbr$ cells,C0007584;C0007634
age b $nmbr$ y n $nmbr$,C0001779
pl $nmbr$ $nmbr$,C3897966;C4049765
other race,C0034510;C1706779;C3853635
exposed n $nmbr$,C0332157
bmi kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
naive n $nmbr$,
gusto moderate severe bleeding,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
no of prior aeds n,C0332152;C0180309;C2826257
gusto moderate bleeding ich,C0019191;C3272597;C3281105
$nmbr$ $nmbr$ a $nmbr$ $nmbr$ $nmbr$ $nmbr$,
hyperlipidmemia,
$nmbr$ $nmbr$ b $nmbr$ $nmbr$ $nmbr$ $nmbr$,
net clinical benefit cv death mi stroke gusto moderate severe bleeding,C4684590;C0019080
$nmbr$ $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,
thienopyridine at baseline,C1120149;C0168634;C1442488
number of prior aeds,C0237753;C0449788
aspirin dose at baseline mg,C4696290
lev exposed,C0023556;C0332157
secukinumab $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ responder rate n,C0871208;C1521828
range race n,C1514721;C0034510;C1706779;C3853635;C2348147;C3542016
cbz exposed,C0006949;C0332157
height cm mean sd a,C0444504;C2699239;C2347634;C2348143
cbz naive,C0006949
tpm exposed,C0076829;C0332157
bmi kg m $nmbr$ mean sd a,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
tpm naive,C0076829
range iga modified $nmbr$ score n,C0392747;C0449820;C4050231;C3889737
ltg exposed,C1420817;C4521367;C4521846;C0332157
time since first psoriasis diagnosis y mean sd,C0040223;C3541383
ltg naive,C1420817;C4521367;C4521846
previous exposure to systemic psoriasis therapyb yes n,C0332157;C0033860
placebo no diabetes n $nmbr$,C0032042;C1696465;C1706408;C0011847;C0011849
previous exposure to biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
placebo diabetes n $nmbr$,C0011847;C0011849
previous exposure to non biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
ticagrelor $nmbr$ mg no diabetes n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0011847;C0011849
tpasi $nmbr$,
ticagrelor $nmbr$ mg diabetes n $nmbr$,C0011847;C0011849
ulpasi $nmbr$,
caucasian race,C0007457
llpasi $nmbr$,
kg m $nmbr$,C0022718;C0439209;C4054209
patient characteristic,C0030705;C1521970
on omt,
prior mi diagnosis,C0332132;C3810814
off omt,
years since mi median,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
on omt n $nmbr$,
prior transient ischaemic,C0040704;C0475224;C0205374
off omt n $nmbr$,
attack,C0277793;C1261512;C1304680
p value on vs off omt,C1709380
time since last dose of,C0946444
reduced ef,C0392756
study medication pre dose,C0801821;C3174092
thienopyridine drug at start of open label period,C0013191;C1705425
median h,C0033727;C0369286;C0441932;C0564385;C4528284
number of treated lesions per patient,C0449791;C1522326;C0030705
beta blocker use,C0042153;C0457083;C1947944
number of treated vessels per patient,C0237753;C0449788;C0030705
hypoglycaemic therapy,C0039798;C0087111;C1363945
number of stents per patient,C0237753;C0449788;C0030705
diet controlled,C0743195
total stent length mm mean sd,C0038257;C2699239
ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treated vessel native coronary,C0005847;C0018787
lta max response to $nmbr$ pm adp defined hpr patients,C2611142;C0030266;C4049155
modified acc aha lesion class b $nmbr$ c,C0101856
pre dose,C0439565;C3812758
unadjusted p value for interaction,C1439367;C1709380
p value for dm vs no dm,C1709380;C0011816;C3250443
adjusted hr $nmbr$ ci,C0008107;C3259781
post dose,C0439568
p value for adjusted hr,C1709380;C0456081
verifynow pru defined hpr patients,C1337105;C0030705
adjusted p value for interaction,C0456081;C1709380
vasp pri defined hpr patients,C0034044;C0030705;C1826843;C3539761;C3539762
gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
vhd,
no vhd,
no stroke n $nmbr$ $nmbr$,C0038454;C4554100
stroke n $nmbr$,C0038454;C4554100
aspirin use at randomization n,C0042153;C0457083;C1947944
weight in kg median iqr,C0005910;C0043100;C1305866;C1705104
history of coronary artery disease n,C1881055
sbp mm hg median iqr,C0085805;C0439475
history of carotid disease n,C0683519;C0730226;C0850708;C0944983
dbp mm hg median iqr,C0536221;C0439475;C3813197;C4281799
history of diabetes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cardiovascular history,C1880008
history of stroke or tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
history of second prior mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
itt cohort overall study period,C0439531;C1948053
multivessel cad n,C1504769;C2239547;C3813548;C4284121
edoxaban hd n $nmbr$,C2975435
history of cabg n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
edoxaban ld n $nmbr$,C2975435;C0694649
history of pci n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hd edoxaban vs warfarin,C2975435;C0043031
qualifying nstemi n,C1514624;C3537184;C4255010
ld edoxaban vs warfarin,C0694649;C2975435;C0043031
history of chf n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
stroke or see,C0038454;C4554100;C0042789;C1947903
history of atrial fibrillation n,C0729790
ischemic stroke or see,C0948008;C0042789;C1947903
history of tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hemorrhagic,C0333275
medical therapies,C0418981
disabling or fatal,C1302234;C1705232
ace inhibitor n,C0003015;C4541021
key secondary end points,C0027627;C2349179;C0175668;C0205436
ticagrelor $nmbr$ mg $nmbr$ yr km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
stroke see or cv death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
stroke see or death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0008107;C3259781
other end points,C2349179
p interactio n,C0369773;C2603361
death or disabling stroke,C0011065;C1306577;C4082313;C4552775;C0038454;C4554100
any cause,C0015127;C1524003
no history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cv,C3538987;C4048877;C4318503
no history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
aspirin $nmbr$ mg n $nmbr$,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
low dose,C0445550;C1708745
weight no,C0005910;C0043100;C1305866;C1705104
high dose,C0444956
index event no,C0441471;C4019010
budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$,C1276807;C0439267
isolated deep vein thrombosis,C0205409;C0149871;C1548221
budesonide $nmbr$ ^g n $nmbr$,C0054201;C0439267
isolated pulmonary embolism,C0205409;C0034065;C1548221
budesonide formoterol $nmbr$ ^g $nmbr$ $nmbr$ ^g n $nmbr$,C1276807
index event asymptomatic or unconfirmed,C0441471;C0231221;C4019010;C1547326
budesonide formoterol n $nmbr$,C1276807
classification of index venous thromboembolism no,C0008902;C0008903;C0678229
budesonide n $nmbr$,C0054201
provoked,C1444748
age yr age group no,C0027362;C2348001
hormonal therapy no,C0279025
female sex no race no f,C0086287;C0034510;C1706779;C3853635;C0016327
estrogens,C0014939;C3537250;C3541386;C3714615
mean time since asthma,C0040223;C3541383
progestins,C0033306
diagnosis yr,C0011900;C0439234;C1704338;C1704656
median duration of study drug administration iqr days,C0920470;C2348354
mean acq $nmbr$ score at randomization,C3533236;C0034656
individual intended study duration no,C0027361;C0489652;C0237401
asthma control status at randomization no,C0004096;C0449438;C2984299
rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
controlled acq $nmbr$,C2587213;C2919686;C2911690
aspirin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
uncontrolled acq $nmbr$ $nmbr$ $nmbr$,C0205318;C2919686
presentation of index event,C0449450;C0441471;C4019010
exacerbations in past $nmbr$ mo no,C4086268;C0026544;C0332177
pulmonary embolism deep vein thrombosis,C0392108;C0852030
daily dose of inhaled glucocorticoid no,C2348070;C0004048
extent of index event,C0439792;C0441471;C4019010
medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
monitoring group n $nmbr$,C0150369;C0441848;C1283169
history of recurrent venous thromboembolism,C0455533
risk factor profile index event,C0441471;C4019010
body mass index kg m,C0022718;C0439209;C4054209
duration of pre randomization anticoagulant therapy,C2711563
inflammatory disease,C1290884
known thrombophilia,C0205309;C0398623
previous cardiovascular events,C0205156;C1320716;C1552607
concomitant medication after randomisation,C0013227;C3244316;C4284232
history of cv disease,C0683519;C0730226;C0850708;C0944983
any ae,C3887670
mra spironolactone or eplerenone,C0243032;C0037982;C1609165;C3891069;C0961485
aes leading to,C1412268;C2699274;C0332152;C1522538
secondary pci,C0027627;C4049621;C0175668;C0205436
discontinu ation,
coronary angiography and intervention,C0085532;C1548829;C0184661;C0886296;C1273869
aes related to,C1412268;C2699274;C0439849;C0445223
radial access,C0444454;C1554204
study druga,C0557651;C2603343
one vessel disease,C3275121
serious aes,C1412268;C2699274
two vessel disease,C0581375
baseline statin use,C0042153;C0457083;C1947944
three vessel disease,C3272265
cv risk factors,C0035648;C1553898
multivessel two vessel three vessel or left main,C0205448;C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
uncontrolled on oad s,C0205318
number of stents implanted,C0237753;C0449788;C0021102;C2828363
uncontrolled on basal insulin,C0205318;C0650607
drug eluting stent implanted at least one,C1322815;C0205447
dual i extension,C0231448;C1880641
stented vessels,C0038257;C0005847
dual iv,C0022326;C4265176
coronary bypass graft,C1260596
dual ii,C1710602;C4082587
creatinine clearance at admission ml min,C0184666;C0151280;C0809949
global trial population,C0032659;C1257890
monitoring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
indian subpopulation,C1524069;C1257890
t $nmbr$,C2603360
ideglira,C4308663
no hypertension,C0020538;C1963138
ideg,
no current smoking,C0037369;C0453996;C1881674
lira,C1555441
st,C0036056;C3272372
number of people n,C0237753;C0449788
creat clearance,C0449297;C1382187;C2825073;C4554548
oad at screening n,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
creat clearance $nmbr$ ml min,C0201975;C0439445
metformin su,C0038642;C1705534
no prior cancer,C0006826;C0998265;C1306459
np tercile $nmbr$ bnp,C0054015;C1095989;C1417808;C2982014
no prior heart failure,C0018801;C0018802;C4554158
nptercile $nmbr$ bnp $nmbr$ $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
one vessel,C0205447;C0005847
np tercile $nmbr$ bnp $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
multi vessel or left main,C0439064;C0005847;C3266262;C0205091;C0205225;C1542147;C0443246;C1552822
pvaluefor trend,C1521798;C4554533
bms,
nt probnp median pg ml,C0669479;C0439297;C0754710
length of stent median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
i or ii,C0021966;C0221138
number of stent l or $nmbr$ or $nmbr$,C0237753;C0449788
hf symptoms and signs,C0683368;C1457887;C0220912;C0220913;C0311392
roflumilast n $nmbr$ $nmbr$,C0965618
pnd,C1417807;C1956415;C4552608
age mean sd yr,C0001779;C0439234
dyspnea t,C0013404;C1963100
total cigarette pack years mean sd,C1303175;C2699239
jvp $nmbr$ cm h $nmbr$ o,C0455483
copd duration mean sd yr,C0024117;C0439234;C1412502;C3714496
ankle edema,C0235439
prebronchodilator fev $nmbr$ mean sd l,C0444504;C2347634;C2348143
pulmonary congestion cxr,C0006888;C0039985
post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
sodium meq l,C0037473;C0439375;C0597484;C3541959;C3714642
predicted prebronchodilator fev $nmbr$ mean sd l,C0681842;C0444504;C2347634;C2348143;C1882327
microalbuminuria mg g cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
predicted post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
total bilirubin mg dl,C0005437;C0439269;C0368753
post bronchodilator fev $nmbr$ fvc ratio mean sd,C2599594;C2699239
albumin g dl,C0001924;C0439267
no of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
lvh on ecg,C0232306
$nmbr$ mo mean sd x,C0026544;C0332177
diuretic agents,C0450442;C1254351;C1521826
year n,C0439234;C0439508
long acting nitrate agents,C0450442;C1254351;C1521826
prior hospitalizations n,C0332152;C0019993;C2826257
bnp ntbnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
cat score mean sd,C0007450;C2699239;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
bnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
exact pro total score mean sd,C2964552;C2699239
ntbnp n $nmbr$,
ics laba therapy n,C0039798;C0087111;C1363945
dyspnoea n $nmbr$,C0013404;C1963100
fluticasone propionate salmeterol fdc,C0340427;C1413520;C3539652
no dyspnoea n $nmbr$,C0013404;C1963100
budesonide formoterol fdc,C0340427;C1413520;C3539652
non usa,C1518422;C0041703
lama use n,C0042153;C0457083;C1947944
with dyspnoea,C0013404;C1963100
brv $nmbr$ mg day,C0155502;C0439422
without dyspnoea,C0013404;C1963100
brv overall,C0155502;C0282416;C1561607
cangrelor dyspnoea vs no dyspnoea,C0013404;C1963100
etiology n,C0015127;C1314792;C1524003
clopidogrel dyspnoea vs no dyspnoea,C0013404;C1963100
cryptogenic,C0332240
death mi idr st,C0036056;C3272372
$nmbr$ b,
p inter action,C0205103;C0441472;C3266814;C1548610
mean sd [range] duration of epilepsy years,C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016;C0449238;C2926735
non cabg related bleeding at $nmbr$ h,C0010055;C0019080
median minimum maximum focal seizure frequency $nmbr$ days at baseline,C0149775;C0439228
severe life threatening,C1546953;C2826244;C3537125
prior lev treatment n,C1514463;C0023556
fixed triple n $nmbr$,C0443218;C0205174;C2827483;C3714578
concomitant aedsb n,C0521115
open triple n $nmbr$,C0175566;C0205174
$nmbr$ teae,
blood leucocyte concentration $nmbr$ cells per l,C0005773;C0347983
teaes leading to discontinuation of study drug,C0332152;C0013175;C1522538
blood eosinophil concentration $nmbr$ cells per l,C0005773;C0347983
saes,C1519255;C1622657;C4553214
blood eosinophil proportion,C0014467;C1709707
drug related saes,C1519255;C1622657;C4553214
time since first copd diagnosis years,C0556970;C0011900;C1704338;C1704656
teaes reported by $nmbr$ patients in the overall brv group n,C1709908;C0155502;C0441848
of predicted normal value,C0681842;C0086715;C1882327
paresthesia,C0030554;C4553220
inspiratory capacity l,C0021610;C0802663
somnolence,C0013144;C2830004;C4553740
chronic bronchitist,C0205191
cataract,C0086543;C4555209
constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
exacerbation rate in the previous year range,C0871208;C1521828
convulsion,C0036572;C4048158
cat total score,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
cystitis,C0010692;C0600041;C1963088
copd medication at study entry,C0024117;C0013175;C1412502;C3714496
hyponatremia,C0020625;C4553967
ics lama,C0999593;C1416775
hot climate subset,C0178683;C1515021
spacer use during the study,C0221874;C0869040
other climate subset,C0008946;C1515021
patients with at least one concomitant disease,C0683521
sex n b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
myocardial ischaemia,C0010054;C0151744
otherc,
ischaemic cardiomyopathy,C0349782
high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
coronary artery osteochondrosis,C0029376;C0029429;C0729346
cholecystitis chronic,C0008325;C0205191;C1963083;C4553186
high dosage ics plus laba with baseline blood eosinophils,C0815320;C4551720;C0168634;C0014467;C1442488
subgroup levels,C1079230;C0441889;C1515021
benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estimate,C0750572
local eosinophil count cells per pl t,C0007584
overall itt n $nmbr$,C0282416;C1561607
central eosinophil count cells per pl t,C0007584
mar imputation random n $nmbr$,C0034656;C0439605
prebronchodilator fev $nmbr$ l t,C2599602;C3714541
cr imputation random n $nmbr$,C0201975;C0034656;C0439605;C3539604;C3711669;C4084730;C4553336;C4553337
prebronchodilator fev $nmbr$ predicted normal t,C0520835;C0681842;C1882327
very severe itt n $nmbr$,C3641272;C4050419
fev $nmbr$ fvc prebronchodilatort,C3714541
severe itt n $nmbr$,C0205082;C4050465;C4050466
reversibility t,C0449261
ex smokers itt n $nmbr$,C0337671;C4555205
time since asthma diagnosis years,C0556970;C0004096;C2984299
current smokers itt n $nmbr$,C3173209;C3241966
number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C0439231
males itt n $nmbr$,C0086582
number resulting in emergency department visit,C0237753;C0449788;C0332294;C0562508
females itt n $nmbr$,C0086287
patients with $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268;C0332294;C0562508
reversibility s $nmbr$ itt n $nmbr$,C0449261
number resulting in hospital admission,C0237753;C0449788;C0184666
reversibility $nmbr$ itt n $nmbr$,C0449261
patients with $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268;C0184666
chronic bronchitis itt n $nmbr$,C0008677
diagnosis of allergic rhinitis,C0011900;C1704338;C1704656
emphysema itt n $nmbr$,C0013990;C0034067
nasal polyps,C0027430
mixed itt n $nmbr$,C0205430;C3160715
atopic based on phadiatop test,C0392707;C1527178;C1705938
$nmbr$ exacerbation in prev $nmbr$ m n $nmbr$,C4086268;C1552852;C0369718;C0441922
history of omalizumab treatment,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cardiovascular disease n $nmbr$,C0007222
aqlq s $nmbr$ scorets,C4055434
no cardiovascular disease n $nmbr$,C0007222
smoking pack year years fl,C1300812;C1708024
eosinophils $nmbr$ n $nmbr$,C0014467;C0200638
empty,C1880497
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
a beuralizuinab $nmbr$ ing q $nmbr$ w,
age $nmbr$ $nmbr$ years n $nmbr$,C1510829
b benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
overall per protocol n $nmbr$,C0282416;C1698058;C1561607
estimate $nmbr$ ci,C0008107;C3259781
bocf iike imputation random n $nmbr$,C0034656;C0439605
baseline ocs use,C0042153;C0457083;C1947944
eosinophils $nmbr$ itt n $nmbr$,C0014467;C0200638
geo graphic region,C0017446;C0205147
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ itt n $nmbr$,C0014467;C0200638
exacerbations in the prev year,C4086268;C0439234;C0439508
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^ itt n $nmbr$,C0014467;C0200638
nasal polyps at baseline,C0027430;C0168634;C1442488
age $nmbr$ years itt n $nmbr$,C1510829
ige at baseline,C0168634;C1442488
age $nmbr$ $nmbr$ years itt n $nmbr$,C1510829
$nmbr$ iu l,C0439457
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^^ itt n $nmbr$,C0014467;C0200638
$nmbr$ to $nmbr$ iu l,C0439457
rate $nmbr$ patient years,C0030705;C0439234
atopic at baseline,C0392707;C0168634;C1442488
$nmbr$ or $nmbr$ high risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$,
statin or ezetimibe,C0360714;C1142985
prior therapy with omalizumab,C1514463;C0966225
antihypertensive therapy,C0585941
high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
vitamin k antagonist,C1096489;C2267235
eosinophil count cells per pl,C0007584
patients with event analyzed,C0030705;C0441471;C4019010;C0936012
central eosinophil count cells per pl,C0007584
lue for interaction,C1704675
predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
$nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
prebronchodilator fev $nmbr$ fvc,C2599602;C3714541
$nmbr$ to $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
acq $nmbr$ scoret,C2919686
sbp $nmbr$ mm hg and or dbp $nmbr$ mm hg $nmbr$ $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
number resulting in ed visit,C0237753;C0449788;C0332294
sbp $nmbr$ mm hg and dbp $nmbr$ mm hg $nmbr$ $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
patients with $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268;C0332294
iglarlixi fixed ratio combination,C0205195;C1947911;C3811910
aqlq s $nmbr$ scored,C4055434;C0449820
iglar insulin glargine l $nmbr$ u,C0907402;C0439148
nicotine pack years,C0028040;C1277691
hbalc $nmbr$,
mean change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l,C0871208;C0456603;C1547037;C1521828;C1079230;C1515021;C0032042;C1696465;C1706408;C2982078;C1514756;C0014467;C0347983
mean difference seb,C0059386;C1309881;C1423585;C3815268
at increased fall risk n $nmbr$,C4699158
daily iglar dose at week $nmbr$ u,C2348070;C0560588
notatincreased fall risk n $nmbr$ $nmbr$,C1268740
l $nmbr$ years,C0439394;C0439234;C1706495;C3642217
randomization group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
t $nmbr$ dm duration years,C0011816;C0439234;C3250443
higher dose edoxaban regimen,C2348331
pool of fh i and ii studies,C0337051;C1509144;C2349200;C1710602;C0947630;C4082587
lower dose edoxaban regimen,C2348331
has bled score,C0449820;C4050231
pool of long term hefh patients only and high fh,C0337051;C1509144;C2349200;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
alirocumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crcl at randomization ml min,C1846718;C0439445
q $nmbr$ w n $nmbr$ $nmbr$,
aspirin use at randomization,C0042153;C0457083;C1947944
race n white,C0007457;C0043157;C0220938
dose reduced at randomization,C0178602;C0869039;C1114758;C0392756;C0034656
diabetes type ii n,C0011860
ttr warfarin arm only,C0446516;C3715044;C4553528
charlson comorbidity index,C4546361
coronary heart disease n cardiovascular risk per protocol n very high,C0442804;C4321397
increased risk falls,C1849142
patients with no prior cvd primary,C0030705;C1335497
no increased risk falls,C1849142
prevention n patients on llt other than statin n,C0199176;C0030705;C1706420;C2700409;C0360714
univariable,
ldl c calculated mg dl mean sd,C0439269;C2699239
multivariable,
total cholesterol mg dl mean sd,C0201950;C2699239;C0543421
bone fracture,C0016658
lp a mg dl median q $nmbr$ q $nmbr$,C0065058;C0439269;C1439335;C4553379
bone fracture due to fall,C0016658;C0678226
triglycerides mg dl median q $nmbr$ q $nmbr$,C0041004;C0439269
malignancy death,C0011065;C1306577;C4082313;C4552775
apo a $nmbr$ mg dl mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
net ep $nmbr$,C1880476;C4321526
factor at baseline,C1521761;C2827422
major crnm bleed,C0205082;C0019080;C0205164;C4318856;C4521762
percentage of patients receiving dose adjustment,C0439165;C1549488;C1561533;C1514756;C2826232
death or ich,C0011065;C1306577;C4082313;C4552775;C0019191;C3272597;C3281105
distance to ldl c goal,C0012751;C0018017;C1571704
abaloparatide sc n,C4042342;C0282380
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
all participantsa,
$nmbr$ i,C0021966;C0221138
t score categories lumbar spineb,C3854607
$nmbr$ kg nr,C0027496;C3844738
total hipc,C0439175;C0439810
ltt other than statin,C0360714
femoral neckc,C0015811
no reference,C1514811;C1706462
fracture status prevalent vertebral fractured,C0016658;C0549207;C4554413
$nmbr$ $nmbr$ $nmbr$ $nmbr$ o $nmbr$,C0483204
prior nonvertebral fracture,C0332152;C0016658;C2826257
mepolizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age categories,C2916832
number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
abl sc n n,C0023139;C0282380;C1704928;C3890208
patients with $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0545082;C1512346;C2826704;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
placebo mean,C0444504;C2347634;C2348143
patients with $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
abl sc mean,C0444504;C2347634;C2348143
current oral corticosteroid use,C1527415
least squares mean difference $nmbr$ ci,C0008107;C3259781
oral corticosteroid dose mg day,C0001617;C0439422;C3536709
interaction p valuef,C1704675
current inhaled corticosteroid use,C0004048;C0239126
o os,C2673162
th $nmbr$,C0039725;C0039738;C1420718;C4282123;C4285344
lavolta $nmbr$,
current laba use,C0042153;C0457083;C1947944
lavolta ii,C1710602;C4082587
current lra use,C0042153;C0457083;C1947944
lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current xanthine derivative use,C0042153;C0457083;C1947944
lebrikizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current lama use,C0042153;C0457083;C1947944
body mass index kg mq,C0005893;C0024853;C0578022;C1305855
measures of lung function,C0079809;C1879489
median range duration of asthma years,C0449238;C2926735
pre bronchodilator fev^ l,C2599602;C3714541
baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba,C2827928;C0117996;C0205163;C0439185
percentage of predicted pre bronchodilator fev^,C0439165;C1549488;C1561533
mean ics fluticasone propionate dpi or equivalent pg per day,C0444504;C0117996;C2347634;C2348143;C0205163;C2827928;C0439185
percentage of fevj reversibility,C0439165;C1549488;C1561533
pre bronchodilator fevj,C2599602
pre bronchodilator fef $nmbr$ $nmbr$ ml s baseline blood eosinophil count,C0200638;C0750879
absolute l,C0205344
baseline geometric mean $nmbr$ l,C0168634;C2986759;C1442488
t jj $nmbr$ $nmbr$,C2603360
$nmbr$ per pl at screening,C3897966;C4049765
median serum periostin ng ml t,C0219433;C0439275;C1424662;C3812270
$nmbr$ per pl in $nmbr$ months before screening,C3897966;C4049765;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
median feno ppb f,C0549183;C0016327;C0876920;C2347635;C2348144;C2939193
total sgrq score,C2964552
tj $nmbr$ $nmbr$,C0039247
baseline presence of nasal polyps,C0150312;C0392148;C3854307
median blood eosinophil count cells per pl t,C0549183;C0200638;C0876920;C2347635;C2348144;C2939193
positive atopic status,C0392707;C0449438
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t,C0005516;C0439275;C0005773
eosinophil count,C0200638;C0750879
patients with $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268;C0205156;C0439231;C1552607
mean change in sgrq,C0392747;C0443172;C1705241;C4319952
adjusted exacerbation rate per patient peryear,C0871208;C1521828
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0596019
rate difference lebrikizumab placebo,C0032042;C1696465;C1706408
mean change in fev $nmbr$,C0392747;C0443172;C1705241;C4319952
rate reduction,C0301630;C0392756;C1293152;C4551656
$nmbr$ $nmbr$ cl $nmbr$ to $nmbr$,C0596019
rate ratio lebrikizumab vs placebo $nmbr$ cl,C0456603;C2981360;C1547037;C0032042;C0596019;C1696465;C1706408
mean change in acq score,C0392747;C0443172;C1705241;C4319952
biomarker high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
exacerbation rate per year,C0871208;C1521828
lebrikizumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ularitide n $nmbr$,C0077910
lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
biomarker low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
nonblack race no j,C0034510;C1706779;C3853635
periostin high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
left ventricular ejection fraction no total no,C0428772;C0488728;C0439175;C0439810
periostin low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
interval between clinical evaluation and initiation oftreatment no,C2826267;C0589507;C1158830;C1704686
eosinophil high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
previous episode of heart failure,C0332189;C0018801;C0018802;C4554158
eosinophil low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
nyha class within past month no total no,C1882083;C0332177;C0439231;C0439175;C0439810
change from baseline in fevj mb,C0392747;C0443172;C1705241;C4319952;C0024853
adjusted mean se,C0444504;C0036919;C2347634;C2348143
median n terminal probnp iqr pg ml,C0669479;C0439297
difference in means $nmbr$ cl,C1705241;C1705242
median cardiac troponin t iqr pg ml,C3538889;C0439297
time to first exacerbation,C0040223;C3541383
treatment at randomization no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
patients with event n,C0030705;C0441471;C4019010
intravenous nitrates,C0348016;C0028125
median time to event weeks,C0040223;C3541383
intravenous dobutamine,C0348016;C0012963
asthma related health,C0004096;C0018684;C2984299
ularitide n n,C0077910
care use,C0042153;C0457083;C1947944
white caucasian,C0043157
health care use rate peryear,C0814514;C0871208;C1521828
baseline systolic bp,C0168634;C0871470;C1442488
rate difference events year,C0439234;C0439508
time from first evaluation,C0040223;C3541383
oil,C0028908;C0032085;C1517288;C3541397
$nmbr$ hrs,C1568891
change from baseline in aqlq s score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
reported in ecrf,C0684224;C0700287;C4319718
change from baseline in rescue medication use puffs per day,C0392747;C0443172;C1705241;C4319952;C0240320;C1533107
not reported in ecrf,C0684224;C0700287;C4319718
change from baseline in acq $nmbr$ score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
gfr as assessed by mdrd,C0017654;C1424601;C3839656
difference in means,C1705241;C1705242
history of chronic hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ifg,C1334085;C1708411
troponin t,C0077404;C1420827
no dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
baricitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
evomab n $nmbr$,
female patients n,C0150905
cerebrovascular or peripheral arterial disease n,C1880018;C0085096;C1704436
duration of ra time from symptom onset years,C0449238;C2926735;C4086878;C0439234
current cigarette use n,C0521116;C0694535;C1705970
concomitant corticosteroid use n,C0521115;C0239126
statin use at study entry n,C0360714;C0869040
concomitant mtx use n,C0025677;C0042153;C0457083;C1947944;C1417487
other lipid modifying drug use at study entry n,C0023779;C0392747;C0242510
mean sd mtx dose mg week,C0332174;C0439230
ncep risk category at study entry n,C2983287;C2983669
number of prior csdmards n,C0237753;C0449788
moderately high risk,C0332167;C3272283;C4050568;C4319571
number of concomitant csdmards n,C0237753;C0449788
moderate risk,C0035647;C4552904
non mtx,C0025677;C1417487
waist circumference mean sd cm,C0455829;C0444504;C2347634;C2348143
mtx non mtx,C0025677;C1417487
fpg median q $nmbr$ q $nmbr$ mmol l,C0549183;C1532563;C0876920;C2347635;C2348144;C2939193
$nmbr$ non mtx,C0025677;C1417487
das $nmbr$ hscrp,C0051767;C0057671
insulin median q $nmbr$ q $nmbr$ pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
patient reported outcome measures,C4277735
c peptide median q $nmbr$ q $nmbr$ nmol l,C0607868
health assessment questionnaire disability index,C4321476
homa_ b median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
patient s global assessment of disease,C0030705;C0281858
homa_ir median q $nmbr$ q $nmbr$ $nmbr$,C0022065;C0022071;C1448132
activity $nmbr$ $nmbr$ vas,C0042815;C3536884;C3827561
lipid parameters,C0023779;C0449381
patient s assessment of pain $nmbr$ $nmbr$ vas,C0030705;C0030198
low density lipoprotein cholesterol mean sd mmol l,C0023824;C1532563
functional assessment of chronic illness,C0278372;C0008679
lipoprotein a median qi q $nmbr$ nmol l,C0065058;C0439282;C0125953;C1096202;C1439335
therapy fatigue facit f $nmbr$ $nmbr$,C0015672;C3272505;C3463815;C4050243;C4554645
triglycerides median qi q $nmbr$ mmol l,C0041004;C1532563
short form $nmbr$ sf $nmbr$,C2964478;C0037712
high density lipoprotein cholesterol mean sd mmol l,C0023822;C1532563
physical component score pcs,C1864389;C1882368
apolipoprotein b mean sd g l,C1447574;C4319541
mental component score mcs,C0229992;C0449432;C1705248
type $nmbr$ diabetes pbo n $nmbr$ vs evomab n $nmbr$,C1320657;C0031962
european quality of life $nmbr$ dimensions $nmbr$ level eq $nmbr$ d,C0205163;C0439185
ifg pbo n $nmbr$ vs evomab n $nmbr$,C1334085;C0031962;C1708411
health state index score uk algorithm,C0002045;C1553907
mets pbo n $nmbr$ vs evomab n $nmbr$,C0812270;C0031962;C1705694;C2939420
vas $nmbr$ $nmbr$,C0042815;C3536884;C3827561
no dysglycaemia or mets pbo n $nmbr$ vs evomab n $nmbr$,C1960636;C0812270;C0031962;C1705694;C2939420
mtx other csomards,C0025677;C1417487
hba $nmbr$ c tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
mtx othetcsdmards,C0025677;C1417487
fpg tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
fluticasone furoate n $nmbr$,C1948374
insulin tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
vilanterol n $nmbr$,C2935023
c peptide tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
homa_ b tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
diabetes with target organ disease,C0011847;C0011849
high risk receiving treatment for,C0332167;C3272283;C4050568;C4319571;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
homa_ir tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
concomitant cardiovascular therapy taken $nmbr$ days,C1707479;C0439228
low density lipoprotein cholesterol tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
antithrombotic coagulant,C0009117
lipoprotein a tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
ras aldosterone inhibitor^,C1514727
triglycerides tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
beta $nmbr$ selective,C0330390;C0439096;C2004068
high density lipoprotein cholesterol tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
dihydropyridine,C0012315;C0220821
apolipoprotein b tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
long acting or short acting nitrates,C0205166;C1706317;C1282927;C0028125;C1806781;C2350002
evolocumab,C3529352
current smoker n $nmbr$,C3173209;C3241966
safety,C0036043;C1705187
former smoker n $nmbr$,C0337671
dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
$nmbr$ years to,C0439234
all subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
$nmbr$ $nmbr$ with cv disease n $nmbr$,C0007222
postbaseline new onset diabetes n,C0746890;C0011847;C0011849
$nmbr$ $nmbr$ with cv risk but not disease n $nmbr$,C0035647;C4552904;C1518422;C0012634
any adverse event ae,C0877248;C3887670
europe $nmbr$ n $nmbr$,C0015176
baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
ischemic heart disease indicator no n $nmbr$ l,C0021212;C1235732;C1522602;C0369718;C0441922
most common aes in any group,C1412268;C2699274
vascular disease indicator no n $nmbr$,C0021212;C1235732;C1522602;C0369718;C0441922
baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
iglarlixi,
influenza,C0021400;C0021403
iglar,
serious,C0205404
lixi,
leading to discontinuation,C0332152;C0457454;C1444662;C4552847;C1522538
week $nmbr$ changea,C0332174;C4349366;C0439230
ck $nmbr$ x uln $nmbr$,C0009212;C1519815;C0010287;C1872855
$nmbr$ hour ppg mmol l,C0439227;C1532563;C0564385
alt or ast $nmbr$ x uln $nmbr$,C1266129;C4553172;C1415181;C1519815;C3891303
hypoglycaemiad,
total bilirubin $nmbr$ x uln $nmbr$,C0005437;C1519815;C0368753
events patient year n,C0030705;C0439234;C0439508
potential injection site reactions,C3245505;C0151735
mean baseline n,C0444504;C0168634;C1442488;C2347634;C2348143
postbaseline binding antibodies,C1145667;C0003241;C1167622
$nmbr$ $nmbr$ f $nmbr$,C0016327
semaglutide n $nmbr$,C3885068
subpopulation analyses according to bmi,C1514228;C0578022
low density lipoprotein cholesterol mg dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
octave induction $nmbr$,C0205263;C0857127
never smoked no,C0037366;C0439994;C1881674
octave sustain,C0443318;C2732140
tnf naive patientsa,C1448177
male sex no f,C0086582;C0016327
tnf failure patientsa,C0231174;C0680095
induction trial group assignment no,C1320290;C1516050
vedolizumab cohort $nmbr$ n $nmbr$,C0009247;C0599755
tofacitinib $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
disease duration y mean sd,C0872146;C2699239
remission at maintenance trial entry no,C0544452;C0687702
mayo clinic score mean sd,C0002424;C2699239;C0442592
extent of disease no total no ^,C0449279;C4553144;C0439175;C0439810
fcal mg g mean sd,C1300563;C2699239
extensive colitis or pancolitis,C0009319;C1963084;C0868908
cs only,C0010182;C0271160;C3540510;C4085345
total mayo score,C2964552;C0454788;C1077578
is only,
partial mayo score,C0449820;C4050231
cs and is,C0010182;C0271160;C3540510;C4085345
c reactive protein mg literj,C0006560;C1413716;C4048285
no cs and is,C0010182;C0271160;C3540510;C4085345
oral glucocorticoid use at baseline no t,C1527415;C0017710;C2603360
type of tnf failure n b,C0332307;C1547052
previous treatment with tnf antagonist no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
intolerance,C0231199;C1744706;C2355652
previous treatment failure no,C0162643;C0235828;C0521983;C1547544
tnf naive,C1448177
tnf antagonist,C1448177;C0231491
tnf failure,C0231174;C0680095
immunosuppressant^^,C0021081
point difference $nmbr$ ci,C0008107;C3259781
tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clinical response,C4055223
prior tnf antagonist treatment yes,C1549445;C1705108;C1710701
clinical remission,C0205210;C0544452;C0687702
prior tnf antagonist treatment no,C1514463;C0231491
mucosal healing,C0043240;C0205249
prior tnf antagonist failure yes,C1549445;C1705108;C1710701
durable clinical response,C4055223
prior tnf antagonist failure no,C0231174;C0680095
durable clinical remission,C0205210;C0544452;C0687702
corticosteroid use at baseline yes,C0239126;C0168634;C1442488
of those on steroids at baseline,C0038317;C0168634;C1442488
corticosteroid use at baseline no,C0239126;C0168634;C1442488
corticosteroid free remission,C0544452;C0687702
geographic region europe,C0017446;C0015176
patients not receiving statin,C0030705;C1518422;C1514756;C0360714
geographic region north america,C0017446;C0028405
patients receiving statin,C0030705;C1514756;C0360714
geographic region other,C0017446
$nmbr$ q $nmbr$ w n $nmbr$,
abatacept n $nmbr$,C1619966
race black or african american n,C0005680;C0027567;C0085756;C0439541
dip involvement n,C3539618;C1314939
ethnicity hispanic latino n,C0015031;C0086409;C0243103
patient global assessment of disease activity vas $nmbr$ $nmbr$ mm,C4054228;C0042815;C3536884;C3827561
diagnosis of hefh n,C0011900;C1704338;C1704656
by genotyping,C1285573
physician global assessment of disease activity vas $nmbr$ $nmbr$ mm,C4050369;C0042815;C3536884;C3827561
by who simon broome criteria,C0443058;C0243161
patient global assessment of pain vas $nmbr$ $nmbr$ mm,C4054229
diabetes mellitus type $nmbr$ n,C1320657
elevated crp ulnt n,C0742906
cardiovascular risk n,C0007226;C0035647;C4552904;C3887460
psa modified total shs,C0392747;C0439175;C0439810;C3889737
very high,C0442804;C4321397
psoriasis covering $nmbr$ bsa n,C0033860;C0180153;C0439844
lipid treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
enthesitis n,C1282952
patients on atorvastatin rosuvastatin or simvastatin at,C0030705;C0286651;C0074554
dactylitis n,C0239161
randomization n,C0034656
anti ccp positive $nmbr$ u ml n,C0432633;C0439340;C1880521;C2945590
any llt other than statins n b,C2347090;C0360714
prior tnfi n,C0332152;C2826257
any llt other than nutraceuticals n,C2347090;C1518478
concomitant methotrexate n,C0521115;C0025677
ezetimibe n,C1142985
concomitant csdmards other than methotrexate n,C0521115;C0025677
nutraceuticals n,C1518478
concomitant oral corticosteroids n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
baseline lipid parameters mg dl mmol l or g l,C0439268;C0439294;C0456615
estimated difference $nmbr$ ci,C0008107;C3259781
ldl c calculated mean sd,C0444504;C2699239;C2347634;C2348143
abatacept open label abatacept,C1619966;C1709323
ldl c measured mean sd,C0444504;C2699239;C2347634;C2348143
placebo open label abatacept,C1709323;C1619966
non hdl c mean sd,C0444504;C2699239;C2347634;C2348143
tnfi naive,
total cholesterol mean sd,C0201950;C2699239;C0543421
tnfi exposed,C0332157
apo b mean sd,C0003593;C2699239;C3252643
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ $nmbr$,
lp a median q $nmbr$ q $nmbr$,C0065058;C1439335;C4553379
lvh n $nmbr$,C0149721
fasting tgs median q $nmbr$ q $nmbr$,C0015663;C0549183;C0876920;C2347635;C2348144;C2939193
non cns embolism,C0013922;C1704212
apo a $nmbr$ mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
medication use at entry,C0240320;C1705654
change from baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
antiplateletsa,
no statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
arbs or ace inhibitors,C3888198;C0003015
_ $nmbr$,
statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
electrocardiography,C0013798;C1623258
$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r wave in avl mm,C0429091;C0449216
moderate chronic kidney disease,C1561643;C4553188
s wave in v $nmbr$ mm,C0429094;C4330985;C4554674
baseline total pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
strain,C0080194;C0456178;C1518614;C2987481
below median,C0549183;C0876920;C2347635;C2348144;C2939193
lv ejection fractionb,C0023128;C0302131;C0336969;C0812388;C0731033;C1881413
baseline free pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
p value d $nmbr$ mg vs warfarin,C1709380;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
statin intolerant,C0360714;C0231200
yr,C0439234
alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
d $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
baseline ldl c mg dl,C0168634;C0439269;C1442488
pravastatin sodium,C0700474
baseline hdl c mg dl,C0168634;C0439269;C1442488
medication use no total no,C0240320;C0439175;C0439810
baseline fasting tgs mg dl,C0168634;C1442488;C0015663;C1156212;C0439269;C1537574
current cigarette smoking no,C0239059;C0700219
baseline lp a mg dl,C0065058;C0439269;C1439335;C4553379
lipid values,C0023779;C0042295
cohort $nmbr$ uacr,C0009247;C0599755
antihypertensive randomization no a,C0003364;C0034656
cohort $nmbr$ uacr $nmbr$ $nmbr$ mg g,C0009247;C1300563;C0599755
years of follow up mean sd [maximum],C0439234;C0589120;C1522577;C1704685;C3274571;C0806909;C1552615;C2826546
uacr not available,C0686905
cumulative events,C0441471;C3541888
statin usage,C0360714;C0457083
$nmbr$ y incidence rate se per $nmbr$ participants,C1708485;C0036919
cigarette smoking in the past year,C0239059;C0700219
pravastatin vs usual care,C0085542;C3538928;C1947933
albumin creatinine ratio,C0486293;C1318293
cvd deaths,C0011065;C1306577
core laboratory percent stenosis,C0678234;C1261287;C2632116
chd deaths,C0011065;C1306577
acr deciles,C1412134;C1515941
stroke deaths,C0011065;C1306577
stable angina n $nmbr$ $nmbr$,C0340288
non cvd deaths,C0011065;C1306577
acs n $nmbr$ $nmbr$,C0742343;C4318612
cause of death unknown,C0277589
u s site,C0205145;C1515974;C2825164
inter p value,C0205103;C1548610;C1709380
fatal chd and nonfatal mia,C0280604;C3542407;C1417154
stroke fatal and nonfatal,C0038454;C4554100;C1302234;C1705232
d mi idr st,C0036056;C3272372
qmi,
heart failure hospitalized or fatal,C0018801;C0018802;C4554158;C0701159;C1302234;C1705232
any gusto bleeding,C0019080
cancer fatal and nonfatal,C0006826;C0998265;C1306459;C1302234;C1705232
severe life ttireatening,C0205082;C0376558;C4050465;C4050466
secukinumab pooled n $nmbr$,C1709595;C2349200;C4522255
severe moderate,C1299393
current smoker at baseline n,C3173209;C3241966
any timi bleeding,C0019080
methotrexate use at randomization n,C0042153;C0457083;C1947944
any acuity bleeding,C0750509;C0019080
sulfasalazine use at randomization n,C0042153;C0457083;C1947944
any blood product transfusion,C0005841;C0281867
corticosteroid use at randomization n,C0239126;C0034656
fvc $nmbr$ predicted,C0681842;C1882327
total back pain $nmbr$ $nmbr$ mm vas mean sd,C0042815;C2699239
nintedanib n $nmbr$,C2930789
nocturnal back pain $nmbr$ $nmbr$ mm vas mean sd,C1970122;C2699239
time since diagnosis years,C0556970;C0011900;C1704338;C1704656
basdai total mean sd,C0439175;C2699239;C0439810
centrilobular emphysema,C0221227
hscrp mg l median min max,C0439420
fvc ml,C0439526;C1705224;C3887665
mean time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
fev $nmbr$ fvc ratio,C0456603;C1547037
anti tnf na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
diffusion capacity of the lung for carbon monoxide predicted,C0231971;C0007018;C4520712;C0681842;C1882327
endpoints,C2349179
st george s respiratory questionnaire total score,C1553316;C0034394;C2964552
hscrp exp ls mean change se,C0023668;C0036919
composite physiologic index,C0600653;C0918012;C1552854;C1637833;C2986546
asas $nmbr$ $nmbr$ n,C0004057;C3853627
absolute decline in fvc $nmbr$ predicted or death n,C0205344;C0681842;C1882327;C0011065;C1306577;C4082313;C4552775
sf $nmbr$ pcs ls mean change se,C0023668;C0036919
treatment by subgroup interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
asqol ls mean change se,C0023668;C0036919
criterion reached first n,C0243161;C0205435;C1279901
asas partial remission n,C1521726;C4552913;C4552914
absolute decline in fvc $nmbr$ predicted,C0205344;C0681842;C1882327
criterion,C0243161
linagliptin metformin,C3264599
placebo controlled period,C0439531;C1948053
age n,C0001779
any secukinumab n $nmbr$,C3179547
native american alaskan,C0682125
no of patients with events,C0030705;C0441471;C3541888
diabetes duration n,C0011847;C0011849
any sae,C1519255;C1622657;C4553214
hba $nmbr$ c mean sd b,C0019016;C0444504;C2347634;C2348143;C1825777;C3538758
infections and infestations,C3714514;C0851341
hba $nmbr$ c n b,C0019016;C1825777;C3538758
most common aes,C1412268;C2699274
fasting plasma glucose mg dl mean sd b,C0202042;C0439269;C0455280
mouth ulceration,C0149745
leukopenia,C0023530;C0750394
number of antidiabetes drugs at screening n,C0237753;C0449788;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
pharyngitis,C0031350;C4553308
renal function egfr ml min $nmbr$ $nmbr$ m $nmbr$ according to mdrd n,C0232804;C0439445;C3839656
osteoprotegerin decreased,C0538161;C1308614;C1336645;C0205216;C0392756;C0442797
mild impairment $nmbr$ to,C0221099;C0684336
oropharyngeal pain,C2363731;C4554669
moderate impairment $nmbr$ to,C0221099;C0684336
lymphadenopathy,C0497156;C4282165
severe impairment,C0221099;C0684336
rhinitis,C0035455
macrovascular disease n,C0012634
neutropenia,C0023530;C0027947;C0853697
difference $nmbr$ cl,C1705241;C0596019;C1705242
gastroenteritis,C0017160
baricitinib $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ab ff $nmbr$ $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
duration of rheumatoid arthritis year,C0449238;C2926735
ab $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
anticyclic citrullinated peptide positive^ n,C1320283;C0439178;C1446409;C1514241;C2825490;C3812269
ff $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
rheumatoid factor positive n,C0035448;C0201660
cigarette smoking mean pack years sd,C1303175;C2699239
$nmbr$ erosion n,C0333307;C1880549;C1959609;C3887524
mean fev $nmbr$ l sd,C0444504;C2699239;C2347634;C2348143
mtss units,C0439148;C1519795;C3853603
post bronchodilator percent of predicted fev $nmbr$ sd,C2599594;C1882327
prior conventional synthetic dmards n,C0332152;C0242708;C2826257
moderate n a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
swollen joint count of $nmbr$,C0451521
severe n b,C0205082;C4050465;C4050466
tender joint count of $nmbr$,C0451530
mean number of exacerbations in previous $nmbr$ months sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
high sensitivity c reactive protein mg ltt,C0006560;C1413716;C4048285
mean bdi focal score sd,C3533236;C2699239
erythrocyte sedimentation rate mm hour,C0439227;C0564385
mean sgrq total score sd,C3533236;C2699239
simplified disease activity index,C3869582
previous treatment with a laba and or lama n c,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775
a acr $nmbr$,C1412134;C1515941
baseline ics use n,C0168634;C0042153;C0457083;C1947944;C1442488
week $nmbr$ overall population,C0032659;C1257890
background csdmard category,C0683312;C3889287
fig $nmbr$ analysis of time to first cid event in patients who a received treatment with a laba and or lama and b did not receive treatment with a laba and or lama prior to the study,C0349966;C1718396;C1337208;C0441471;C4019010;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775;C1518422;C1514756
mtx only,C0025677;C1417487
fig $nmbr$ analysis of time to first cid event in patients with a moderate and b severe copd at baseline itt population,C0349966;C1718396;C1337208;C0441471;C4019010;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0024117;C1412502;C3714496
non mtx csdmards,C0025677;C1417487
tnt and ideal pooled,C1512612;C1709595;C2349200;C4522255
mtx other csdmards,C0025677;C1417487
without psoriasis n $nmbr$,C0033860
b acr $nmbr$,C1412134;C1515941
with psoriasis n $nmbr$,C0033860
nteraction p value,C1709380
without psoriasis n $nmbr$ $nmbr$,C0033860
c das $nmbr$ crp,C3890735;C4048285
p valueb,C0369773;C2603361
\ $nmbr$ $nmbr$,
statin users n $nmbr$,C0360714;C1706077
duration of psoriasis years,C0449238;C2926735
statin non users n $nmbr$,C0360714;C1518422
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [n $nmbr$ ],C0369718;C0441922
mean predicted fvc sd,C0444504;C2699239;C2347634;C2348143
cerebrovascular disease n,C0007820
mean predicted dlco sd,C0444504;C2699239;C2347634;C2348143
baseline concomitant therapies,C0168634;C1707479;C1442488
mean $nmbr$ mwd m sd,C0444504;C2347634;C2348143;C2699239
calcium channel antagonists n,C0006684;C2757014
mean ucsd sobq score sd,C3533236;C2699239
ace inhibitors or angiotensin ii,C0003015;C0003009;C1366631;C3714928
chronic renal failure,C0022661;C1561643;C2316810
receptor blockers n,C0597357
cardiovascular risk factors n,C0850624
baseline lipid and apolipoprotein levels,C0168634;C0023779;C1442488;C0003591;C0441889
hypercholesterolaemia,C0020443;C1522133
smoker current former,C0205156;C0750523
total cholesterol hdl c ratio,C0523558
obesity t,C0028754;C1963185
apoa $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
crude analysis n,C0002778;C0936012;C1524024
patients without psoriasis n $nmbr$,C0030705;C0033860
bivariate frailty model statin users vs non users,C0360714;C1706077;C1518422
patients with psoriasis n $nmbr$,C0030705;C0033860
disease progression composite outcome,C0679250;C3542417
interaction treatment by psoriasis p value $nmbr$,C3258078;C1709380
first disease progression outcome to occur,C0679250;C3542417;C1709305;C2745955;C4284875
atorvastatin ls means difference $nmbr$ mg $nmbr$ ci a n $nmbr$,C0008107;C3259781;C0369718;C0441922
absolute fvc decrease $nmbr$,C0392756;C0547047
ls means difference $nmbr$ ci $nmbr$,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
$nmbr$ mwd decrease $nmbr$ m,C0392756;C0547047
mortality,C0026565;C0026566
apob apoal,C0003593;C3252643
ipf related,C0034069;C1800706;C0439849;C0445223
ato $nmbr$ mg and sim $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fvc change,C0392747;C0443172;C1705241;C4319952
ato $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
absolute decrease $nmbr$,C0392756;C0547047
lsms difference $nmbr$ ci $nmbr$,C0008107;C3259781
relative decrease $nmbr$,C0392756;C0547047
ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
death or absolute fvc decrease $nmbr$,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047
incidence rate of cv events n,C1708485;C0441471;C3541888
death or $nmbr$ mwd decrease $nmbr$ m,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047
hazard ratio $nmbr$ ci $nmbr$ with vs without psoriasis,C0008107;C3259781;C0033860
hospitalisation,C0019993
total v $nmbr$ $nmbr$,C0439175;C0439810
respiratory related^,C0439849;C0445223
all treatments,C0087111
ind gly $nmbr$ $nmbr$ pg o d n $nmbr$,C0017890;C2827928;C0523677
atorvastatin $nmbr$ mg and simvastatin $nmbr$ $nmbr$ mg zi $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043476
sfc $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
atorvastatin $nmbr$ mg zi $nmbr$,C0024671;C0043476;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gold $nmbr$ groups n,C0018026;C0441848;C1304897
canagliflozin n $nmbr$,C2974540
icsusers atbaseline n,
history of heart failure no,C0455531
catscorecategory n,
history of microvascular disease no,C0683519;C0730226;C0850708;C0944983
mmrc grade n,C0441800;C0919553;C3244287
history of atherosclerotic vascular disease no,C0683519;C0730226;C0850708;C0944983
post bronchodilator fev $nmbr$ reversibility,C2599594;C0449261
history of cardiovascular disease no ^,C0455539
post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
history of amputation no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone,C0086312;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0332174;C0439230;C1079230
ratio of ldl to hdl,C0456603;C1547037;C3715113
stage $nmbr$ a,C0205390;C1300072;C1306673
egfr ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
stage $nmbr$ b,C0441781
albumin measurements^^,C0201838
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
median albumin to creatinine ratio interquartile range,C0486293;C1711350;C1318293
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
normoalbuminuria no total no,C0439175;C0439810
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
microalbuminuria no total no,C0730345;C0439175;C0439810
glucose lowering therapies,C0017725;C0441994;C2003888;C0087111
macroalbuminuria no total no,C0439175;C0439810
treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
canagliflozin,C2974540
cv endpoints n,C3538987;C2349179;C4048877;C4318503
no of participants per $nmbr$ patient yr,C0679646;C0030705;C0439234
$nmbr$ point mace,C0349381;C0949745;C1445339
canvas,C3281223
tocilizumab n $nmbr$,C1609165
canvas r,C0205090;C0684010;C2603358
white ethnicity,C0015031;C0243103
central america and south america,C0007674;C0037713
das $nmbr$,C0051767;C0057671
systolic blood pressure $nmbr$ mm hg or diastolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620;C0428883;C1305849
number of previous dmards,C0237753;C0449788
history of amputation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline diabetes,C0011847;C0011849
insulin use,C0240016
il $nmbr$ pg ml,C0020898;C0439297;C0021764;C0022271
antithrombotic use,C0042153;C0457083;C1947944
tender joint count n $nmbr$,C0451530
raas inhibitor use,C0042153;C0457083;C1947944
swollen joint count n $nmbr$,C0451521
diuretic use,C0042153;C0457083;C1947944
haemoglobin g l,C0635222
hba $nmbr$ ca mmol mol,C0019016;C1825777;C3538758;C3829066
troponin t pg ml,C0077404;C0439297;C1420827
time since diagnosis of diabetesa n,C0040223;C3541383
fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction,C1280500;C1518681;C2348382;C0669479;C3538926;C0754710;C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675
systolic blood pressurea mm hg,C0005767;C0439475;C0005768;C0229664
no peripheral revascularization n $nmbr$ $nmbr$,C0205100;C0581603
diastolic blood pressurea mmhg,C0005767;C0439475;C0005768;C0229664
peripheral revascularization n $nmbr$,C0205100;C0581603
egfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
never smoker,C0425293
egfr ckd epi cystatin c ml min $nmbr$ $nmbr$ m $nmbr$,C0071744;C0439445;C1413772
history of atrial fibrillation or fl utter,C0729790;C1300812;C1708024
egfr ckd epi cystatinc ml min $nmbr$ $nmbr$ m $nmbr$ n,C0162734;C0439445;C4281721;C0369718;C0441922
egfr crcl,C1739039;C1846718;C3811844;C3812682
uacra mg g gmean gcv,C1300563;C0017066
peripheral artery disease details,C1704436;C1522508;C4025272
uacra mg g n,C1300563
peripheral artery revascularization without amputation,C0489868;C0581603
oral antidiabetes monotherapya n,C0442027;C4521986
statin therapy,C1278454
oral antidiabetes combination therapy without insulina n,C0009429;C0556895
figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline,C0871208;C1521828;C0589120;C1522577;C1704685;C3274571;C0002688;C0332840;C1546539
insulina n,
mod sev exacerbation rate,C0871208;C1521828
antihypertensive therapy n,C0585941
ff vi $nmbr$ $nmbr$,C4554348;C0205999
^ blockers,
current smoker n $nmbr$ $nmbr$,C3173209;C3241966
number of participants,C0237753;C0449788
former smoker n $nmbr$ $nmbr$,C0337671
baseline hbalc $nmbr$ $nmbr$ $nmbr$ mmol mol $nmbr$,C0168634;C3829066;C1442488
cv entry criteria,C1705654;C0243161
baseline uacr,C0168634;C1442488
$nmbr$ $nmbr$ cv disease n $nmbr$ $nmbr$,C0007222
baseline uacr $nmbr$ mg g,C0168634;C1300563;C1442488
$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$,C0035647;C4552904;C1518422;C0012634
normoalbuminuria at baseline $nmbr$ of patients treated,C0168634;C0030705;C1442488;C1522326
hispanic latino n $nmbr$,C0086409;C0086528
microalbuminuria at baseline $nmbr$ of patients treated,C0730345;C0030705;C1522326
not hispanic latino n $nmbr$ $nmbr$,C1518424;C0086528
macroalbuminuria at baseline $nmbr$ of patients treated,C0168634;C0030705;C1442488;C1522326
asian n $nmbr$ $nmbr$,C0078988
empagliflozin n $nmbr$,C3490348
african american african heritage n $nmbr$,C0085756;C2986513
other or missing data,C4684714
usa n $nmbr$ $nmbr$,C0041703
ldl cholesterolt,
asia n $nmbr$ $nmbr$,C0003980
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ t,C0439445;C0369637;C0441923
europe $nmbr$ n $nmbr$ $nmbr$,C0015176
rest of world n $nmbr$,C0035253;C1622890
medical history of diabetic retinopathy,C0262926;C0011884
patients with normoalbuminuria at baseline,C0030705;C0168634;C1442488
history of moderate severe exacerbation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
patients with microalbuminuria at baseline,C0030705;C0730345;C0168634;C1442488
history of hospitalization for an exacerbation,C0551577;C4086268
patients with macroalbuminuria at baseline,C0030705;C0168634;C1442488
hospitalized exacerbation rates,C0871208;C1521828
n analysed,C0369718;C0441922
mod sev exacerbation rates,C0871208;C1521828
uric acid tertile $nmbr$ $nmbr$ $nmbr$ mg dl,C0041980;C0439269
favors ffa i favors placebo,C0032042;C1696465;C1706408
uric acid tertile $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg dl,C0041980;C0439269
ff vi,C4554348;C0205999
characteristic no,C1521970
b_ $nmbr$,
digoxin n $nmbr$ $nmbr$,C0012265
h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
no digoxin n $nmbr$ $nmbr$ $nmbr$,C0012265
$nmbr$ t i,C0021966;C0221138
h,C0033727;C0369286;C0441932;C0564385;C4528284
white race n $nmbr$ $nmbr$,C0007457;C0043157
predicted fev,C0681842;C3714541;C1882327
type of atrial fibrillation n $nmbr$ $nmbr$,C0332307;C1547052
history of hospitalized for an exacerbation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4086268
qualifying risk factor,C1514624;C0035648
predicted fev^,C0681842;C3714541;C1882327
coronary artery disease n $nmbr$ $nmbr$,C0010054;C0010068;C1956346
moderate severe exacerbation,C0205081;C4086268;C1881878;C4049705;C4049706;C4085643;C4321335
nyha iii or iv n $nmbr$ $nmbr$,C0439070;C1705160;C0022326;C4265176
hospitalized for an exacerbation,C0701159;C4086268
peripheral arterial disease n $nmbr$ $nmbr$,C0085096;C1704436
mn population,C0032659;C1257890
former current smoker n $nmbr$ $nmbr$,C0337671
umec vi $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205999
mitral valve disease n $nmbr$ $nmbr$,C0026265;C4553832
tio n $nmbr$ $nmbr$,
aortic valve disease n $nmbr$ $nmbr$,C1260873;C4553103
current smoker at screeninga n,C3173209;C3241966
prior electrical cardioversion for af n $nmbr$ $nmbr$,C0013778;C0542380
smoking pack yearsb n,C0037369;C0453996;C1881674
charlson comorbidity index mean sd,C4546361;C2699239
reversible to albuterolc d n,C0205343;C0369718;C0441922
heart rate mean sd bpm n $nmbr$ $nmbr$,C0018810;C0444504;C2347634;C2348143
post albuterol predicted fev $nmbr$ mean sd e,C0001927;C0444504;C2347634;C2348143
hypertrophy per ecg n $nmbr$ $nmbr$,C0020564;C1623258
gold stage nf,C0018026;C0205390;C1300072;C1306673;C1304897
vitamin k antagonist experiencedk n $nmbr$ $nmbr$,C1096489;C2267235
ics use at screeningg n,C0042153;C0457083;C1947944
antiarrhythmics,C0003195
exacerbation historyh n,C4086268
class ii b blockers,C0441886;C2698968
required corticosteroid and or antibiotic without hospitalization,C0001617;C3536709;C0003232;C0019993
raas inhibitor,C1999216
required hospitalization,C1708385
high dose edoxaban,C0444956;C2975435
components of the first cid,C0449432;C0205435;C1279901
low dose edoxaban,C0445550;C2975435;C1708745
umec vi $nmbr$ $nmbr$ $nmbr$,C0205999
digoxin scd no y,C0012265
tio,
no digoxin scd no y,C0012265
hazard ratio umec vi vs tio $nmbr$ ci,C2985465;C0205999;C0008107;C3259781
persistent permanent,C0205322;C0205355;C0332996
itt population n,C0032659;C1257890
t mean,C0444504;C2347634;C2348143
c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0547047
lv hypertrophy per ecg,C0232306
c $nmbr$ unit sgrq total score increase,C2964552;C0442805
b blockers at baseline,C0168634;C1442488
moderate to severe copd exacerbation,C1299393;C0740304
diuretic use at baseline,C0042153;C0457083;C1947944
mn population n,C0026327;C0026405;C4285072
normal responders n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
re cover re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
sensitive responders n $nmbr$,C0020517;C0332324;C1522640
re medy,
highly sensitive responders n $nmbr$,C0439822
not tested,C1518422;C0392366
age year mean sd,C0001779;C2699239
de n $nmbr$,C0011198;C0017480;C3541240
creatinine clearance ml min mean sd,C0439445;C2699239
bmi mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
edoxaban dose adjusted at randomisation n,C0178602;C0869039;C1114758;C0456081;C0034656
crcl mean ml min sd,C0439445;C2699239
bleeding events during first $nmbr$ days of treatmen,C0441471;C3541888
qualifying symptomatic event n a,C1514624;C0231220;C0441471;C4019010
t,C2603360
pe and dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
bleeding events during the entire study,C0441471;C3541888
pe only,C0070939;C1880476;C4284304
adj hr $nmbr$ cl a,C0001552;C0596019;C2826286
neither pe nor dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
p b int,C1539794;C3272375
non transient risk factors for recurrent vte n,C0035648;C1553898
total bleeds,C0232100
active cancer at any timeb,C0006826;C0998265;C1306459
major and crnm bleeds,C0205082;C0205164;C4318856;C4521762;C0019080
concomitant anticoagulant antithrombotic or nsaid n,C0521115;C0003280;C0848112;C3536711;C0003211;C3536840
laba ics n $nmbr$,C0815320;C4551720
vte vte related deathsa n n,C0439849;C0445223
laba or lamab n $nmbr$,
pulmonary embolisma n n,C0024109;C2707265;C2709248;C4522268
ind glyb n $nmbr$,C4049864;C1415124
vte vte related deathsb n n,C0439849;C0445223
post bronchodilator fev $nmbr$ predicted of normal value,C0681842;C1882327
pulmonary embolismb n n,C0024109;C2707265;C2709248;C4522268
dyspnoea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
de,C0011198;C0017480;C3541240
number of exacerbation in the previous $nmbr$ months n,C0237753;C0449788;C0205156;C0439231;C1552607
treatment de vs warfarin by thrombophilia interaction,C0011198;C0017480;C3541240;C0043031;C0398623
baseline treatments n a,C0168634;C0087111;C1442488
mbesc n n,
lama only monotherapy,C0999593;C1416775
mbes crbesc,
laba only monotherapy,
mbesb n n,
laba ics free or fixed dose combination,C0332296;C1880497;C1996904;C0178602;C0205195;C1947911;C3811910;C0869039;C1114758
mbes crbesb n n,
othersc,
p value for mra vs no mra,C1709380;C0243032;C1609165;C3891069
laba ics versus indzgly lsm difference $nmbr$ cl,C0815320;C4551720;C1705241;C0596019;C1705242
no mra at baseline,C0243032;C1609165;C3891069
indzgly,
mra at baseline,C0243032;C1609165;C3891069
exacerbations in the previous year,C4086268;C0205156;C1552607
sacubitril valsartan n $nmbr$,C4033631
fev $nmbr$ at baseline,C3714541;C0168634;C1442488
heart rate mean sd beats min,C0439385
mmrc at baseline,C3826977;C0168634;C1442488
creatinine mean sd mg dl,C0010294;C0439269;C1561535
form bud,C2700462;C2945744
potassium mean sd meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
sfc,C4521536
clinical features of hf,C0683325;C0018488;C1313497;C1538440;C3273279
laba or lama,C0999593;C1416775
ind gly,C0017890;C0523677
left ventricular ef mean sd,C0225897;C2699239
laba or lama versus ind gly lsm difference $nmbr$ cl,C0999593;C1416775;C0017890;C0596019;C0523677
nt probnp median iqr pg ml,C0669479;C0439297;C0754710
fev at baseline,C3714541;C0168634;C1442488
treatment at randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pooled itt,C1709595;C2349200;C4522255
mra use,C0042153;C0457083;C1947944
cat $nmbr$ n $nmbr$ $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
patients receiving enl no,C0030705;C1514756
median y range,C1514721;C2348147;C3542016
incidence^,C0021149;C0220856
mean mmrc grade units sd,C0439148;C2699239;C1519795;C3853603
patients receiving lcz no,C0030705;C1514756
mean sgrq total score,C3533236
hr enl vs lcz $nmbr$ cl,C0596019
use of ics at baseline,C1524063;C0815320;C4551720;C0168634;C1442488
adjusted hr enl vs lcz $nmbr$ cl,C0456081;C0596019
mean copd duration y sd,C0024117;C2699239;C1412502;C3714496
hyperkalemia,C0020461;C4552983
severe hyperkalemia s,C0020461;C4552983
mean number of exacerbations in previous y sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
evolocumab n $nmbr$,C3529352
mean postbronchodilatora fev $nmbr$ predicted sd,C0444504;C2699239;C2347634;C2348143
bmi mean sd b,C0578022;C0444504;C2347634;C2348143
reversible to bronchodilator b,C0205343;C0006280
baseline statin usec,C0168634;C0439224;C1442488
favors comparator,C1707454;C4553389;C4553390
lntensityd,
gff mdi,C0993596;C1839839;C4049613
baseline ezetimibe usec,C0168634;C0439224;C1442488
gp mdi,C0993596;C1839839;C4049613
characteristic at baseline,C1521970;C0168634;C1442488
ff mdi,C0993596;C1839839;C4049613
pav mean $nmbr$ ci,C0008107;C3259781
placebo mdi,C0993596;C1839839;C4049613
evolocumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
on treatment,C4684449
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
age years median n $nmbr$ $nmbr$,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
empagliflozin $nmbr$ mg day n $nmbr$,C3490348;C0439422
race non white n $nmbr$ $nmbr$,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
parameters at baseline,C0449381;C0168634;C1442488
race white n $nmbr$ $nmbr$,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
a bmi subgroups,C0578022;C1079230
no history of mi n $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
b age subgroups,C1304659;C0001779
history of mi n $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
non smoker n $nmbr$ $nmbr$,C0337672;C0425293;C4554605
fpg,
baseline pav median n $nmbr$ $nmbr$,C0168634;C0058890;C1442488
n $nmbr$ l $nmbr$,C0369718;C0441922
baseline tav median n $nmbr$ $nmbr$,C0168634;C0279686;C1442488
n l $nmbr$,C0369718;C0441922
non high density lipoprotein mg dl baseline median n $nmbr$ $nmbr$,C1535899;C0439269
baseline cardiac biomarkers elevated,C2735101;C2735102;C0205250;C3163633
proprotein convertase subtil kexin typ $nmbr$ ng ml baseline median n $nmbr$ $nmbr$,C1100660;C0439275
tobacco abuse,C0040336
no family history of chd n $nmbr$ $nmbr$,C0241889;C0280604;C3542407
radial access site,C0442038;C0589360;C0920847
family history of chd n $nmbr$ $nmbr$,C0241889;C0280604;C3542407
$nmbr$ vessels with $nmbr$ stenosis,C0679403
no type $nmbr$ diabetes n $nmbr$ $nmbr$,C1320657
$nmbr$ vessels treated,C0005847;C1522326
type $nmbr$ diabetes n $nmbr$ $nmbr$,C1320657
treatment with drugeluting stent,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no prior statin n $nmbr$ $nmbr$,C0332152;C0360714;C2826257
baseline aspirin dose,C0168634;C4696290;C1442488
prior statin n $nmbr$ $nmbr$,C0332152;C0360714;C2826257
intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clopidogrel dose on before pci,C0178602;C0869039;C1114758;C4049621
non high dose statin n $nmbr$ $nmbr$,C0444956;C0360714
bivalirudin used during pci,C0168273;C1273517;C4049621
high dose statin n $nmbr$ $nmbr$,C0444956;C0360714
gpi used during pci,C1415351;C1273517;C4049621
change in pav mean $nmbr$ cl,C0392747;C0443172;C1705241;C4319952
duration from hospital admission to pci h median iqr,C0449238;C2926735;C0033727;C0369286;C0441932;C0564385;C4528284
agea,
duration from clopidogrel placebo to pci min median iqr,C0449238;C2926735;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
current cigarette use,C0521116;C0694535;C1705970
baseline pava,C0168634;C0135567;C1442488
pci duration in min median iqr,C0449238;C2926735
baseline tava,C0168634;C1442488
death mi idr or st,C0011065;C1306577;C4082313;C4552775;C0036056;C3272372
st arc definite only,C0036056;C3272372;C0439544;C1704787
baseline non hdl ca,C1518422;C3715113
gusto moderate severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
baseline pcsi,C0168634;C1442488
prior statin use,C0042153;C0457083;C1947944
timi major minor,C4441842
statin intensity per acc ahac,C0522510;C0175754;C0282160;C3541413
death mi idr st or gusto severe bleeding,C0036056;C3272372;C0205082;C0019080;C4050465;C4050466
moderate low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
death mi idr st or gusto moderate severe bleeding,C0036056;C3272372;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
chlorthalidone $nmbr$,C0008294
death mi idr st or any timi bleeding,C0036056;C3272372;C0019080
amlodipine lisinopril $nmbr$,C0051696;C0065374
p value nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
total $nmbr$,C0439175;C0439810
net composite,C0205199;C1547335
white non hispanic n,C1533020;C1533021
death mi idr st or gusto mod sev bleeding,C0036056;C3272372;C0011860;C0019080
black non hispanic n,C1533017;C1533018
pah ctd,C1335071;C1442905
white hispanic n,C1533020;C1533021
pah ssc,C0030123;C3897657;C3203102;C4284467
black hispanic n,C1533017;C1533018
pah sle,C0030123;C0024141;C3203102;C4284467
receiving antihypertensive treatment,C1514756;C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pah mctd ctd other,C1335071;C1442905
age years geographic region,C1510829;C0017446
n blood pressure mean sd mm hg,C0428886;C0439475
time since diagnosis of pah years,C0556970;C0011900;C1704338;C1704656
major st depression or t wave,C0041696;C1269683;C0429103
use of medication for pah,C1524063;C0030123;C3203102;C4284467
inversion,C0021943;C0021945;C1705687;C2349984
era,C1521863;C3495919
diabetes t,C0011847;C0011849
pde $nmbr$ i,C0021966;C0221138
medication use at baseline n,C0240320;C0168634;C1442488
era and pde $nmbr$ i,C1521863;C3495919;C0021966;C0221138
females only,C0086287
other medications,C0013227;C0802604;C2598133;C4284232
atenolol use at $nmbr$ month,C0042153;C0457083;C1947944
corticosteroids $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
cholesterol mean sd n,C0008377;C0444504;C2347634;C2348143
placebo patients events n,C0032042;C0030705;C1696465;C1706408
serum creatinine mean sd n,C0201976;C0600061
selexipag patients events n,C0030705;C0441471;C3541888
egfr mean sd n,C1739039;C0444504;C2347634;C2348143;C3811844;C3812682
overall study population,C0282416;C2348561;C1561607
baseline mdrd,C0168634;C3839656;C1442488
overall ctd,C1335071;C1442905
baseline ckd epi,C1561643;C0162734;C4281721
pde $nmbr$ i monotherapy,C0021966;C0221138
lipid trial participants n,C1997894;C2242969
no pah specific therapy,C0039798;C0087111;C1363945
baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
ctd population subgroup,C1079230;C1515021
baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
pah ssc systemic sclerosis,C0030123;C0036421;C3203102;C4284467
no cvd,C0007222
pah sle systemic lupus erythematosus,C0030123;C0024141;C3203102;C4284467
prevalent cvd,C0007222
pooled pah mctd and pah,C0030123;C0026272;C3203102;C4284467
healthy weight,C0005910;C0043100;C1305866;C1705104
years since pd diagnosis mean sd,C0439234;C0011900;C1704338;C1704656
overweight,C0497406
duration of disease n,C0872146
no estrogen,C0014939;C2936882;C4542544
hoehn yahr stage on n,C0205390;C1300072;C1306673
budesonide symptom days a week,C0054201;C0439228;C0332174;C0439230
hoehn yahr stage off n,C0205390;C1300072;C1306673
placebo symptom days a week,C0032042;C0439228;C1696465;C1706408;C0332174;C0439230
levodopa dose mean sd mg day,C0023570;C0439422
$nmbr$ tol n $nmbr$,
concomitant pd medications at baseline n c d,C0013227;C0802604;C2598133;C4284232
lto,
tertiary amines,C3653356
$nmbr$ n $nmbr$ l $nmbr$,C0369718;C0441922
dopa and dopa derivativese,C0013023
age mean age years sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
adamantane derivatives,C3653470
$nmbr$ u,C0439148
entacapone,C0165921
passive smoker,C0425309
monoamine oxidase b inhibitors,C2917290;C3653412
prebronchodilator fevj predicted,C2599602;C0681842;C1882327
postbronchodilator fevj predicted,C2599594;C0681842;C1882327
daily off time mean sd h dayf,C0332173;C0033727;C0369286;C0441932;C0564385;C4528284
controllertreatment before entry,C1705654
mean sd baseline score,C3533236;C0168634;C1442488
inhaled corticosteroid,C0004048;C0001617;C3536709
mean sd change from baseline to eom,C0392747;C0443172;C1705241;C4319952;C0241886
oral or other systemic corticosteroid,C0442027;C4521986;C4053960
ls mean [ $nmbr$ ci] treatment difference vs placebo,C0444504;C2347634;C2348143;C0008107;C3259781;C1705241;C1705242;C0032042;C1696465;C1706408
xanthine,C0043314;C0043318
p value ancova treatment difference a,C1705241;C1705242
cromoglicate,C0010347
number of off periods,C0237753;C0449788;C0439531;C1948053
leukotriene modifier,C0205349;C1514623;C1516451;C3542952
absolute time spent on h day,C0439546;C0680968;C0033727;C0369286;C0441932;C0564385;C4528284
time to first sare,C0040223;C3541383
absolute time spent on without troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
cumulative incidence lyear,C0021149;C0220856
absolute time spent on with troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
cumulative incidence $nmbr$ years,C0021149;C0439234;C0220856
patient status after wake up of days patient woke off,C0449437;C1170730;C0442696;C0585034
rate of sares,C0871208;C1521828
patient status after wake up of days patient woke on without troublesome dyskinesia,C0449437;C1170730;C0442696;C0585034;C0013384
rate per $nmbr$ patient years,C0871208;C1521828
patient status after wake up of days patient woke on with troublesome dyskinesia,C0449437;C1170730;C0442696;C0585034;C0013384
$nmbr$ year mean change from baseline,C0392747;C0443172;C1705241;C4319952
updrs iii motor,C1513492;C1705994
$nmbr$ to $nmbr$ $nmbr$,
overall $nmbr$ $nmbr$,C0282416;C1561607
prebronchodilator fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
with ckd $nmbr$,C1561643
lyear mean change from baseline,C0392747;C0443172;C1705241;C4319952
without ckd $nmbr$,C1561643
time to first inhaled corticosteroid,C0040223;C3541383
mean or n,C0444504;C2347634;C2348143;C0369718;C0441922
time to first oral or systemic corticosteroid,C0040223;C3541383;C4053960
sd or,C2699239
rate of oral or systemic corticosteroid,C0871208;C1521828;C4053960
latin,
asthma symptoms in the past $nmbr$ weeks,C0683368;C1457887
median urine acr mg g iqr,C0042036;C1300563;C0042037;C2963137
mean proportion,C0444504;C1709707;C2347634;C2348143
median fasting serum glucose mg dl iqr,C0202041;C0439269;C3534430
restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852;C0439230
glycemic status,C0449438
sleeping problems in the past $nmbr$ weeks,C0037313;C0424522;C4050403;C1546466;C0439230
igt ifg,C1334085;C1708411
symptom free days in the past $nmbr$ weeks,C0332296;C0677547;C1880497;C1996904
other glucose status,C0017725;C0449438
$nmbr$ to $nmbr$ symptom days per week,C1457887;C0677547;C3854129
dcct a $nmbr$ c,
lto $nmbr$ symptom days per week,C1457887;C0677547;C3854129
duration dm in dm years,C0011816;C0439234;C3250443
$nmbr$ symptom days per week,C1457887;C0677547;C3854129
pulse pressure mm hg,C0949236;C0439475
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$,C0596019
median pulse pressure mm hg iqr,C0949236;C0439475
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
n $nmbr$ fatty acids,C0369718;C0015684;C0441922
a prebronchodilator fevl predicted,C2599602;C0681842;C1882327
no glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
baseline symptom days perweek,C0168634;C0439228;C1442488
other bp drug,C0013227;C1254351
mean difference $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
median tg iqr,C0549183;C0337445;C0876920;C2347635;C2348144;C2939193
yearl,
ckd rate events,C0441471;C3541888
b postbronchodilator fevl predicted,C2599594;C0681842;C1882327
no ckd rate events,C0441471;C3541888
baseline feature,C1521970;C1706388;C2346469;C2348519
cv death non fatal mi or non fatal stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
lived alone,C0205171;C0439044;C0679994
secondary outcome,C0027627;C1274040;C0175668;C0205436
stroke at entry,C0038454;C4554100
stroke any,C0038454;C4554100
nih stroke scale,C1697238;C3484372
stroke non fatal,C0038454;C4554100;C1518422;C1302234;C1705232
health practices,C0018684;C0237607
primary outcome plus revascularization or nonfatal hf,C0205225;C1274040;C0439612;C0439631;C0018488;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ drinks day if male female,C0332173;C0439228;C0439505;C0043210;C0086287;C1705497;C1705498
major coronary disease event fatal non fatal mi,C0741923;C3810814
aerobic exercise,C0001701
ckd n,C1561643
cognitive,C1516691
no ckd n,C1561643
and physical examination,C0031809;C1744699
$nmbr$ yrs or more,
$nmbr$ ms score,C0449820;C4050231
diabetes melitus,C0011847;C0011849
antidepressant,C0003289
treatment glargine,C0039798;C0907402;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
benzodiazepine or bzra,C0005064;C3536850;C4048284
rivaroxaban plus aspirin n $nmbr$,C1739768;C0004057
epilepsy drug,C0013227;C1254351
rivaroxaban alone n $nmbr$,C0205171;C0439044;C0679994
osteoporosis drug,C0013227;C1254351
tobacco use no,C0040335;C0543414;C0841002;C3853727
vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
heart failure no,C0018801;C0018802;C4554158
fxs,C0016667
estimated gfr no $nmbr$,C0017654;C1424601
risk delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
western europe israel australia or south africa,C0043128;C0037712
any site,C0205145;C1515974;C2825164
upper limb,C1140618
nontrial ppi,C0358591;C0871125;C3811894
rivaroxaban aspirin,C1739768;C0004057
distal lower,C0441994;C1548802;C2003888
limb,C0015385
hazard ratio for cardiovascular death stroke or myocardial infarction $nmbr$ ci,C2985465;C0027051;C0008107;C3259781
hip femur,C0019552;C0015811;C0022122;C1505163;C3538851;C4284725
baseline tobacco use,C0040335;C0543414;C0841002;C3853727
rib,C0035561
baseline dyslipidemia,C0168634;C0242339;C1442488
black or african america,C0005680;C0027567;C0085756;C0439541;C0002454
socalone n $nmbr$,
chd risk no,C1282512
evolocumab soc n $nmbr$,C3529352
very high risk,C0332167;C0442804;C3272283;C4050568;C4319571;C4321397
type $nmbr$ diabetes mellitus $nmbr$,C1320657
lower risk,C3272281;C3538919
high risk of diabetes,C0332167
at ldl c bq goal at baseline no,C0018017;C1571704
cerebrovascular or peripheral arterial disease,C1880018;C0085096;C1704436
prior diagnosis no,C0332132
fasting plasma glucose mmol l $nmbr$,C0202042;C1532563;C0455280
use of concomitant lipid lowering therapy no,C1524063;C0585943
fasting plasma glucose mg dl $nmbr$,C0202042;C0439269;C0455280
statin with niacin,C0360714;C0027996;C1142562
visit,C0545082;C1512346;C2826704
statin with fibrate,C0360714
ldl c in mmol l baseline mean sd [n] wk $nmbr$ and change mean se [n],C1532563;C0168634;C1442488;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
other $nmbr$,
fasting plasma glucose in mmol l median q $nmbr$ q $nmbr$ [n],C0583513;C1532563
type of concomitant statin by daily dose no,C0332307;C1547052;C2348070
hba $nmbr$ c in median q $nmbr$ q $nmbr$ [n],C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
lovastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
weight in kg baseline mean sd [n] wk $nmbr$ and change mean se [n],C0022718;C1303013;C0439209;C4054209;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
soc,
baseline lipid lipoprotein values,C0443602;C0042295
evomab soc,
ldl c bq mg dl mean sd,C0439269;C2699239
change to week $nmbr$,C0392747;C0443172;C1705241;C4319952
non hdl c mg dl mean sd,C0439269;C2699239
[ $nmbr$ [,
apo b mg dl mean sd,C0003593;C2699239;C3252643
ldl c in mmol l mean sd for baseline [n] mean se for week $nmbr$ [n],C1532563;C0444504;C2347634;C2348143;C0168634;C1442488;C0369718;C0441922;C0036919;C0332174;C0439230
apo a l mg dl mean sd,C1447574;C2699239;C4521365
any placebo,C0032042;C1696465;C1706408
evomab,
figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison,C1705241;C1705242;C0008107;C3259781;C1079231;C1079232;C3715113;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1707455;C1696465;C1706408
[ $nmbr$,
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
high risk for diabetes,C0332167;C3272283;C4050568;C4319571
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
enrolled into osler,C4684790
uniti $nmbr$,
did not enrol into osler,C1518422
im uniti,
phi n $nmbr$,C1333690;C1704947;C1706536;C2975867;C4084801
ustekinu,
ppci n $nmbr$,
mab,C0003250;C0369637
previous angina pectoris,C0205156;C0002962;C1552607
usteki,
previous coronary intervention,C0184661;C0886296;C1273869
numab,
family history of coronary disease,C0850707
$nmbr$ mg kgf n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
high risk $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
$nmbr$ mg $nmbr$ wk n $nmbr$,C1881833
duration of disease yr t,C0872146;C0439234
red blood cell counting $nmbr$ l,C0014792;C0750480;C1705566;C0439394;C1706495;C3642217
platelet $nmbr$ l,C0456525
median c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
mean platelet volume fl,C1300812;C1708024
median fecal calprotectin mg kg gi areas involved no,C0205146;C4319729;C1314939
proximal gi tract,C0205107;C0017189;C4489236
scr gmol l,C1539487;C4050416
ppci in $nmbr$,
perianal gi tract,C0442158;C0017189
no of panents total no $nmbr$,C0439175;C0439810
medications for crohn s disease taken at baseline no,C0013227;C0802604;C2598133;C4284232;C0012634;C1883727;C0168634;C1442488
overal event rate,C0871208;C1521828
one or more medications,C0205447;C0013227;C0802604;C2598133;C4284232
$nmbr$ $nmbr$ hr,
immunosuppressant^,C0021081
$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
aminosalicylate,C0368663;C2825094
iiiv,
glucocorticoid],C0017710
anacetrapib n $nmbr$ $nmbr$,C2604745
history of disease refractory to treatment with tnf antagonist no,C0683519;C0730226;C0850708;C0944983;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous disease no f,C0205156;C0012634;C1552607;C0016327
no history of tnf antagonist treatment no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean mm hg,C0444504;C0439475;C2347634;C2348143
history of tnf antagonist treatment failure no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
level no,C0441889;C0456079;C1547707;C2946261
patients who received $nmbr$ drug,C0013227;C1254351
lipid difference mg dl,C0023779;C0439269
patients who received $nmbr$ or $nmbr$ drugs,C0030705;C3272598;C1514756;C0013227;C3687832
no of participants with events,C0679646;C0441471;C3541888
primary nonresponse,C0205225;C0439612;C0439631
anacetrapib n $nmbr$,C2604745
secondary nonresponse,C0027627;C0175668;C0205436
rate ratio,C0871208;C0456603;C1547037;C1521828
unacceptable side effects,C0001688;C0877248;C0879626
age at randomization years,C1510829;C0034656
uistekinumab $nmbr$ mg kg,C0439272
prior disease,C0332152;C0012634;C2826257
weight at baseline,C1303013
time since qualifying event,C0040223;C3541383;C1514624;C0441471;C4019010
$nmbr$ st quartile,C0036056;C2828255;C3272372
waisthip ratio,C0456603;C1547037
$nmbr$ st and $nmbr$ nd quartile,C0036056;C3272372;C2828255
current drinker,C0556297
$nmbr$ nd and $nmbr$ rd quartile,C0694666;C2828255;C4553350
former non drinker,C0205156;C0457801;C0750523
$nmbr$ rd quartile,C0694666;C2828255;C4553350
medication,C0013227;C3244316;C4284232
crohn s disease duration,C0010346;C0872146
apolipoprotein a $nmbr$ mg dl,C0003592;C0439269;C0523508
$nmbr$ to $nmbr$ yrs,
glomerular filtration rate ml min $nmbr$ $nmbr$ ma,C0024443;C3887485
involved gastrointestinal areas,C1879646;C0521362
urinary albumimcreatinine ratio,C0456603;C1547037
secukinumab intravenous $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
micro albuminuria,C0085672;C0001925;C1553035;C3811161;C4049106
time since as diagnosis mean sd years,C0040223;C3541383;C0011900;C0439234;C1704338;C1704656
macro albuminuria,C2984010;C0001925
hla b $nmbr$ positive n,C1426226
gly $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
anti tnf naive n,C1448177
severity of copda airflow limitation n,C0439793;C0522510
hscrp median min max mg l,C0549183;C2827895;C0876920;C2347635;C2348144;C2939193
severity of copda combined assessment of copd n,C0439793;C0522510
elevated hscrp $nmbr$ mg l n,C0205250;C0439268;C3163633
discontinuation of lama prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
total basdai mean sd,C0439175;C2699239;C0439810
discontinuation of ics laba prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
basfi mean sd,C0444504;C2699239;C2347634;C2348143
pre bronchodilator fev i l,C2599602;C0021966;C0221138
basmi linear mean sd,C0205132;C2699239
post bronchodilator fevx l,C2599594
msasss mean sd,C0444504;C2699239;C2347634;C2348143
post bronchodilator fev i reversibility b,C2599594;C0021966;C0221138
syndesmophyte present n,C0221690;C0150312;C0449450
fev auc i $nmbr$ h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
total back pain mean sd,C0004604;C2699239;C1963071;C4553945
ics use yes,C1549445;C1705108;C1710701
patient s global assessment of disease activity mean sd,C0030705;C0281858;C1292728
ics use no,C0042153;C0457083;C1947944
placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ bmi kg m,C0022718;C0439209;C4054209
placebo secukinumab pooled,C0032042;C3179547;C1696465;C1706408;C1709595;C2349200;C4522255
renal function egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0232804;C0439445
change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
ace inhibitors and arb,C0003015;C3888198
patients with syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
insulin na ive,C3435805;C4554334
patients without syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
not treated,C1518422;C1522326
elevated hscrp,C0205250;C3163633
insulin oad,C0021641;C1533581;C1579433;C3714501
normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
combined estimated gfr and albuminuria status,C0017654;C1424601;C0001925;C0449438
smokers at baseline,C0337664;C0168634;C1442488
estimated gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ and microalbuminuria or macroalbuminuria,C0017654;C0439445;C1424601;C0730345
non smokers at baseline,C0337672;C4554605
estimated gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ or no microalbuminuria or macroalbuminuria,C0017654;C0439445;C1424601;C0730345
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
tiotropium group n $nmbr$,C0213771;C0441848
sbp mm hg office measurement mean sd,C0439475;C2699239
former smoking,C0037369;C0453996;C1881674
sbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
smoking index pack yr,C0037369;C0439234;C0453996;C1881674
dbp mm hg office measurement mean sd,C0439475;C2699239
duration of copd days^,C0449238;C2926735
dbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
previous respiratory disease other than copd no,C0035204;C0035242
pulse rate bpm mean $nmbr$ h mean sd,C0232117;C2699239
previous medication for respiratory disease no,C0418986
time since diagnosis of t $nmbr$ dm y n,C0040223;C3541383
traditional chinese medicine for respiratory disease no,C0025124;C1515884
use of diuretics n,C1524063;C0012798
spirometric values at baseline,C0042295;C0168634;C1442488
use of ace inhibitors arbs n,C1524063;C0003015
before bronchodilator use,C0042153;C0457083;C1947944
$nmbr$ antihypertensive medication,C0003364
after bronchodilator use,C0042153;C0457083;C1947944
$nmbr$ antihypertensive medications,C0003364
airflow reversibility no,C0231999;C0449261
$nmbr$ aes,C1412268;C2699274
gold stage no,C0205390;C1300072;C1306673
$nmbr$ drug related aes,C1412268;C2699274
cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
$nmbr$ aes leading to discontinuation,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
mmrc dyspnea scale score t t,C0013404;C4049715;C1963100
$nmbr$ serious aes,C1412268;C2699274
ccq score,C0449820;C4050231
special interest categories,C0205555;C0683312
follow up,C0589120;C1522577;C1704685;C3274571
hypoglycemiat,
difference tiotropium placebo ml $nmbr$ ci,C0008107;C3259781
events requiring assistance,C0441471;C3541888;C0018896;C1269765
p values,C1709380
events consistent with uti,C0441471;C3541888;C0332290;C0042029;C0077906;C1412376
pre bronchodilation fev $nmbr$,C0439566;C3714541
events consistent with genital infection,C0441471;C3541888;C0332290;C0729552
month $nmbr$,C0332177;C0439231
events consistent with volume depletion,C0441471;C3541888;C0332290;C0546884
post bronchodilation fev $nmbr$,C0439576;C3714541
positive orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
pre bronchodilation fvc,C0439566;C3714541
no diuretic therapy,C0948575
post bronchodilation fvc,C0439576;C3714541
diuretic therapy,C0948575
table $nmbr$ baseline characteristics of early dmard naive patients with ra participating in the swefot trial,C4684572;C3538806;C4048756;C0679823;C0008976
no ace inhibitor arb therapy,C1444755;C3888198
ace inhibitor arb therapy,C1444755;C3888198
empa $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with available bmi for univariate analyses or with all data available for the multivariate model did not differ from the original swefot trial population proportions n were compared with pearson s $nmbr$ continuous variables medians iqr were compared with independent samples mann whitney u tests all patients who originally participated in the swefot missing data were as follows in number n bmi $nmbr$ smoking status $nmbr$ rf status $nmbr$ anti acpa status $nmbr$ concurrent prednisolone use $nmbr$ haq $nmbr$ univariate model where the das $nmbr$ at $nmbr$ months and baseline bmi were required missing data n were as follows smoking status $nmbr$ rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ and haq $nmbr$ multivariate model shown in table $nmbr$ and gure $nmbr$ a missing data points n were as follows rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ acpa anticitrullinated protein antibody bmi body mass index das $nmbr$ $nmbr$ joint count disease activity score dmard disease modifying rheumatic drug haq health assessment questionnaire ra rheumatoid arthritis rf rheumatoid factor swefot swedish pharmacotherapy trial,C0030705;C0470187;C0683962;C1511726;C3245479;C3714741;C3161035;C3274659;C3714583;C3853906;C1518422;C0008976;C0032659;C1257890;C1707455;C0549178;C0439828;C0242927;C3272598;C4684714;C1519386;C0035448;C0201660;C0748398;C1547111;C0051767;C0057671;C0439231;C0168634;C0578022;C1442488;C1514873;C0332283;C1719822;C4281991;C0042153;C0457083;C1947944;C1547282;C0039224;C1706074;C1552961;C2347617;C3714763;C1537044;C1954799;C0392747;C0304229
hypoglycemia^,C0020615;C4553659
swefot n $nmbr$,
non cana n $nmbr$,C1518422;C1418845
univariatet n $nmbr$,
baseline hbalc,C0168634;C1442488
multivariate^ n $nmbr$,
baseline hbalc $nmbr$ to,C0168634;C1442488
proportions n,C1709707
baseline hbalc $nmbr$,C0168634;C1442488
obese bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
genital mycotic infections male $nmbr$,C0564768
overweight bmi $nmbr$ $nmbr$ $nmbr$,C0497406;C0578022
utis,C0042029
normal bmi,C4229017
osmotic diuresis related aes,C1412268;C2699274
concurrent prednisolone,C0205420;C0032950
volume depletion related aes,C1412268;C2699274
medians iqr,C0549183
olodaterol $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
symptom duration months,C0449238;C0439231;C2926735
tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$,C4032878;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
haq score,C0449820;C4050231
co morbidities a n,C0009488;C0369718;C0441922
year from randomization,C0439234;C0439508
first year,C0439234;C0439508
cardiac rhythm disorders,C0264886
second year,C0439234;C0439508
vascular disordersb,C0005847;C1558950;C1801960
third yeart,C0205437
gold n,C0018026;C1304897
chd disease death,C0011065;C1306577;C4082313;C4552775
$nmbr$ $nmbr$ e,
placebo km,C0032042;C3887676;C1696465;C1706408
baseline cardiovascular medication c n,C0168634;C0007220;C1442488
ticagrelor $nmbr$ mg km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd extent of exposure days,C0439792;C0274281;C0332157
cv death myocardial infarction stroke,C0038454;C4554100
cardiac rhythm disorder at baseline no,C0264886;C0168634;C1442488
metrex modified intention to treat population with an eosinophilic phenotypey,C0087111;C0032659;C1257890;C1292734;C1522326
cardiac rhythm disorder at baseline yes,C0264886;C0168634;C1442488
metrex overall modified intention to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
meddra smq,C1140263
metreo modified intention to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
olodaterol $nmbr$ m g,C2934193;C0439267
smoking history no,C1519384
tiotropium $nmbr$ m g,C0213771;C0439267
moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0740304;C4050465;C4050466
total patients n,C0439175;C0030705;C0439810
no in the $nmbr$ mo before screening,C0026544;C0332177
any aes n,C1412268;C2699274
tachyarrhythmias n,C0080203
one or more requiring hospitalization in $nmbr$ mo before screening no $nmbr$,C0205447;C0019993;C0026544;C0332177;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
supraventricular tachyarrhythmias incl atrial,C1698480;C3853833
gold group d no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
fibrillation flutter,C0016385;C2242390
postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ventricular tachyarrhythmias,C3827656
percent of predicted fev $nmbr$,C1882327;C3714541
ischaemic heart disease n,C0010054;C0151744
blood eosinophil count $nmbr$ mm $nmbr$ at screening no,C4330985;C4554674;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
other ischaemic heart disease non infarction,C0027051;C1518422
geometric mean blood eosinophil count sd on a loge scale cells mm $nmbr$,C0200638;C2699239
cardiac failure n,C0018801;C0018802
blood eosinophil count $nmbr$ mm $nmbr$ in $nmbr$ months before screening no,C4330985;C4554674;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
cerebrovascular disorders n,C0007820
blood eosinophil count cells mm $nmbr$ no,C4330985;C4554674
haemorrhagic,C0333275
mepolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
racea,
of patients meeting criterion total no of patients,C0439175;C0439810;C0030705
copd disease severity,C0024117;C0521117;C1412502;C3714496
sotagliflozin n $nmbr$,C3896939
chinese subgroup,C1079230;C1515021
race or ethnic group no white,C0034510;C1706779;C3853635;C0015031;C1879937;C0007457;C0043157;C0220938
korea republic of,C0022773
malaysia,C0024552
native american or alaska native,C0282204;C1515945;C0682125
bmij,
body weighta kg,C0022718;C0439209;C4054209
bmi $nmbr$ no,C0578022
belimumab $nmbr$ mg sc n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean $nmbr$ sd years,C1510829;C0444504;C2347634;C2348143
systolic blood pressure $nmbr$ mm hg no,C0488055;C0439475;C0871470;C1306620
weight mean $nmbr$ sd kg,C0022718;C0439209;C4054209
daily total dose of insulin lu kg,C2348070
enrollment by region no,C1516879;C1696073;C3888021
insulin dose lu day,C0332173;C0439228;C0439505
americas excluding us,C0002454;C0596070
basal,C0205112
western europe australia israel,C0043128;C0022271
bolus and corrections,C1186706;C1511237;C1705509;C3812160;C1705565;C1947976
disease duration median range years,C0872146;C0439234
type of insulin therapy no $nmbr$,C0457592;C0039798;C0087111;C1363945
selena sledai range u $nmbr$ u $nmbr$ t,C0451528;C0439148
subcutaneous injections,C0021499
score of $nmbr$ no,C0449820;C4050231
sotagliflozin,C3896939
organ system involvement no,C0460002;C1314939
no totalno,
mucocutaneous,
percentage points,C1552961;C2347617;C3714763
musculoskeletal,C0497254;C2707260
patients with glycated hemoglobin $nmbr$ $nmbr$ and no severe hypoglycemia or diabetic ketoacidosis,C0030705;C0017853;C0205082;C0020615;C4553659;C4050465;C4050466;C0011880
immunologic,C0152036;C0205470
patients who used insulin pump,C0030705;C1140609
renal,C0022646
patients who did not use insulin pump,C0030705;C3272598;C1140609
hematologic,C0018943;C0205488
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode of severe hypoglycemia,C0030705;C0017853;C0332189;C0020615;C4553659
cardiovascular and respiratory,C0007226;C3887460;C0521346;C1546767
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode ofdiabetic ketoacidosis,C0030705;C0017853;C0022638;C0220982
constitutional,C1511487
randomization groups $nmbr$ and $nmbr$,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
central nervous system,C3540014;C3714787
pfo closure group n $nmbr$,C0185003;C0441848;C1521802
disease hare no i,C0242372;C1425660;C0021966;C0221138
antiplatelet only group n $nmbr$,C0441848
at least $nmbr$ flare,C1517205;C3540542
anticoagulant group n $nmbr$,C0003280;C0441848;C0848112;C3536711
at least $nmbr$ severe flare,C1517205;C3540542
antiplatelet onl group n $nmbr$,C0441848
physician s global assessment mean $nmbr$ sd,C0031831;C0804815;C0281858;C2699239
body mass index $nmbr$ no f,C0005893;C0578022;C1305855;C0016327
$nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
oral contraceptive pills no total no,C0009905;C0009906;C0029151;C0439175;C0439810
facit fatigue mean $nmbr$ sd range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
migraine no,C0149931
corticosteroids only,C0001617;C3539185;C3540725;C3540726;C3540727
stroke no,C0038454;C4554100
immunosuppressants only,C0021081
deep vein thrombosis or pulmonary embolism no,C0149871;C0034065
antimalarials only,C0003374
qualifying event no,C1514624;C0441471;C4019010
corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
carotid infarct,C0741968;C0021308
corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727;C0003374
vertebrobasilar infarct,C0545733;C0021308
immunosuppressants and antimalarials only,C0021081;C0003374
modified rankin scale no,C2984908;C3854213
corticosteroids immunosuppressants and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727;C0003374
rope score,C0449820;C4050231
mycophenolate mofetil,C0209368
septal anomaly no,C0332447;C1704258
sri response,C0871261;C1704632;C1706817;C2911692
overall n $nmbr$ vs $nmbr$,C0282416;C1561607
pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
ss at baseline,C2699257;C3891295;C4551874
pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
ss $nmbr$ n $nmbr$ vs $nmbr$,C2699257;C3891295;C4551874
pfo with mild to moderate shunt and atrial septal aneurysm,C1299392;C0232180;C0542331;C1442858;C0521533
black race n $nmbr$ vs $nmbr$,C0005680
pfo closure,C0185003;C1521802
no of strokes,C0038454
non black race n $nmbr$ vs $nmbr$,C1518422;C0005680
age at randomisation,C0001779;C0034656
race and ss at baseline,C0034510;C1706779;C3853635;C2699257;C3891295;C4551874
patent foramen ovale,C0016522;C0344724
black race and ss $nmbr$ n $nmbr$ vs $nmbr$,C0005680;C2699257;C3891295;C4551874
large shunt,C0232180;C0542331;C1442858
i $nmbr$ $nmbr$ vs $nmbr$ $nmbr$,C0021966;C0221138
pfo asa,C0004057;C3853627
non black race and ss $nmbr$ n $nmbr$ vs $nmbr$,C1518422;C0005680;C2699257;C3891295;C4551874
fluticasone furoate and vilanterol n $nmbr$,C1948374;C2935023
baseline body weight quartile,C1303013;C2828255
body mass index $nmbr$ kg nrn,C0005893;C1425210;C0578022;C1305855
q $nmbr$ $nmbr$ $nmbr$ kg n $nmbr$ vs $nmbr$,C0022718;C0439209;C4054209
asthma control test score at baseline,C2733224;C0168634;C1442488
q $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ kg n $nmbr$ vs $nmbr$,C0022718;C0439209;C4054209
duration of asthma $nmbr$ years,C0449238;C2926735
steroid use at baseline,C0281991;C0168634;C1442488
daytime symptoms more than twice per week,C0683368;C1457887;C1720725;C1948050;C0332174;C0439230
steroids n $nmbr$ vs $nmbr$,C0038317
nocturnal symptoms in past week,C0683368;C1457887;C0332174;C0439230
no steroids n $nmbr$ vs $nmbr$,C0038317
number of exacerbations $nmbr$ months before randomisation,C0237753;C0449788;C0034656
vonoprazan $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aget y,
figure s $nmbr$ baseline subgroups and act scores at week $nmbr$ pea population,C0168634;C1079230;C1442488;C0449820;C0030738;C0069964;C0070939;C1262903;C3257529
bmit,
patients with prevalent kidney disease at baseline,C0683521;C0168634;C1442488
previous smoker,C0337671
patients without prevalent kidney disease at baseline,C0683521;C0168634;C1442488
every day,C0332173;C0439228;C0439505
cv risk factor,C3538987;C0035648;C4048877;C4318503
$nmbr$ or $nmbr$ d wk,C0332174;C0439230
peripheral artery diseasef,C0489868
$nmbr$ or $nmbr$ d mo,C0026544;C0332177
single vessel coronary artery disease,C0581374
never drink,C2003901;C0452428
glucose lowering therapy,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
caffeine consumption,C0948365
anti coagulants,C0848112
modi fied la grade,C0441800;C0919553;C3244287
total cholesterol mg dl^,C0201950;C0439269;C0543421
heartburn severity during the run in periodt,C0439793;C0522510
low density lipoprotein cholesterol mg dl,C0023824;C0439269
esophageal hiatal hernia,C3489393
high density lipoprotein cholesterol mg dl^,C0023822;C0439269
yes z $nmbr$ cm,C1549445;C1705108;C1710701
triglycerides mg dl^,C0041004;C0439269
yes o $nmbr$ cm,C1549445;C1705108;C1710701
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
h pylori serology,C0036745;C0220911;C0455278
patients with egfr,C0030705;C1739039;C3811844;C3812682
history of h pylori eradication,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
patients with egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ at baseline,C0030705;C0439445;C0168634;C1442488
yes r $nmbr$ y,C1549445;C1705108;C1710701;C0205090;C0684010;C2603358
change from baseline at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
yes $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
serum uric acid mg dl,C0455272;C0439269;C0700634
serum gastrint pg ml,C0229671;C0439297;C1546774;C1550100
asian oriental,C0078988;C0699027
serum pepsinogen i iit,C0077923;C0523816
not reported unknown,C0439673;C3541433;C4050014
czp mtx^mtx,C0054841;C0025677;C1417487;C1861828;C1872109
mean s d hbalc,C0444504;C2347634;C2348143
pbo mtx^mtx,C0031962;C0025677;C1417487
mean s d hbalc mmol mol,C0444504;C3829066;C2347634;C2348143
total patients n $nmbr$,C0439175;C0030705;C0439810
chda,
patients entering pt period n $nmbr$,C0030705;C1522196;C0032743;C0439531;C1948053;C0699718
no ascvd additional cv risk factors n,C0035648;C1553898
db baseline week $nmbr$,C0332174;C0439230
micro macro albuminuria ckd and or retinopathy,C0001925;C1561643;C0035309;C1962966
pt baseline week $nmbr$,C0332174;C0439230
$nmbr$ additional cv risk factors $nmbr$,C0035648;C1553898
average weekly mtx dose mg week t,C0366550;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
median q $nmbr$ q $nmbr$ duration of diabetes years,C0449238;C2926735
czp mtx to mtx,C0054841;C0025677;C1417487;C1861828;C1872109
median q $nmbr$ q $nmbr$ duration of insulin use years,C1881378;C2826775
pbo mtx to mtx,C0031962;C0025677;C1417487
mtss cfb,C0009002;C1824728
mean s d systolic blood pressure mm hg,C0428886;C0439475;C0488053
baseline factor,C1521761;C2827422
mean s d diastolic blood pressure mm hg,C0428886;C0439475;C0488053
baseline erosion,C0333307;C1880549;C1959609;C3887524
mean s d egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
tnf alpha pg ml,C1448177;C0439297;C1456820;C1522669
ckdc n,
baseline steroids,C0168634;C0038317;C1442488
baseline lipids,C0168634;C0023779;C1442488
mtx exposure mg week,C0332174;C0439230
mean s d calculated ldl cholesterol,C0023824;C0202117
age of onset,C0206132;C3175530
mean s d measured ldl cholesterol,C0023824;C0202117
age of onset $nmbr$ years n $nmbr$,C0206132;C3175530
mean s d apob mg dl,C0003593;C0439269;C3252643
icsa plus laba n,
mean s d non hdl cholesterol,C0729627;C1535899
geographical location n,C4545686
median q $nmbr$ q $nmbr$ tgs,C1156212;C1537574
ocs n,
mean s d hdl cholesterol,C0023822;C0392885
fev $nmbr$ l mean sd,C0444504;C2699239;C2347634;C2348143
median q $nmbr$ q $nmbr$ lp a mg dl,C0065058;C0439269;C1439335;C4553379
fev $nmbr$ predicted mean sd,C0444504;C2699239;C2347634;C2348143
mean s d apoc ll $nmbr$ mg dl,C0444504;C0003594;C2347634;C2348143;C0439269
acq $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
median q $nmbr$ q $nmbr$ tg rich lipoprotein cholesterol,C0337445;C0065055
aqlq score mean sd,C0444504;C2699239;C2347634;C2348143
mean s d ldl particle number nmol l,C2612459;C0439282
asui score mean sd,C0444504;C2699239;C2347634;C2348143
mean s d ldl particle size nm,C0203634;C0312860;C3890923
blood eosinophils cells ml,C2699156
mean s d free pcsk $nmbr$ ng ml,C0332296;C0439275;C1880497;C1996904
allergic disease by historyb n,C0020517;C0851444
mean s d total pcsk $nmbr$ ng ml,C0439175;C0439275;C0439810
atopy specific ige c n,C0392707;C0205369;C1552740;C3539705
concomitant lipid lowering therapy n,C0585943
chronic sinusitis nasal polypsd n,C0149516;C0028429;C4520890
statin intensity $nmbr$ $nmbr$,C0360714;C0522510
resllzumab,
statin monotherapy,C0360714
demographic data,C4684639
any other llts other than statin,C2347090;C0360714
alprostadil n $nmbr$,C0002335
cholesterol absorption inhibitor ezetimibe,C0003277;C1142985
gender male female number,C0237753;C0449788
statin intolerance $nmbr$ n,C0360714;C0231199;C1744706;C2355652
risk factors and diabetes status,C0035648;C1553898;C1317301
concomitant antihyperglycaemic drugs n,C0020616;C0013227;C3687832
caffeine,C0006644;C0236734
any other antihyperglycaemic drugs,C0013227;C3687832
complete healinga,C0205197;C0725685;C3853530;C4283785
biguanides metformin,C0005382;C0025598;C0360396;C3540012
major amputationsb,C0205082;C0205164;C4318856;C4521762
median q $nmbr$ q $nmbr$ total daily insulin dose $nmbr$,C2348070
alprostadil n n,C0002335
iu,C0049272;C0439453;C0694756
interim analysis,C4684691
lu kg,C0022718;C0439209;C4054209
overall analysis,C0002778;C0936012;C1524024
t $nmbr$ d,C2603360
cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c,C0205341;C0008107;C3259781
difference vs placebo [ $nmbr$ cl] p,C1705241;C1705242;C0032042;C1696465;C1706408;C0596019;C0369773;C2603361
statistic,C2348149;C2828391
statisticd,
ls mean s e primary endpoint change from baseline to week $nmbr$,C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
interim analysis all patients,C4684691;C0030705
e $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
selected key secondary efficacy endpoints,C4528314;C1280519;C1707887
final analysis all patients,C0002778;C0936012;C1524024;C0030705
change from baseline mean s e,C0392747;C0443172;C1705241;C4319952
duration of paod years mean sd,C0449238;C2926735
calculated ldl cholesterol week $nmbr$,C0332174;C0439230
intensity of rest pain mmvas mean sd,C1320357;C4085211
non hdl cholesterol week $nmbr$,C0332174;C0439230
systolic pressure at ankle level mmhg mean sd,C0871470
apob week $nmbr$,C0332174;C0439230
analgesic medication n,C0002771
total cholesterol week $nmbr$,C0332174;C0439230
past treatment for paod,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lp a week $nmbr$,C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$,
medical treatment n,C0679624
hdl cholesterol week $nmbr$ a,C0332174;C0439230
revascularisation n,C0581603
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ b,
amputations n,C0002688
triglycerides week $nmbr$ a,C0332174;C0439230
ischaemic skin lesions,C0475224;C0037284
ldl particle numbers week $nmbr$,C0332174;C0439230
number of lesions n a,C0449791
ldl particle size week $nmbr$,C0332174;C0439230
size cm $nmbr$ mean standard deviation,C1828170
ls mean difference se vs placebo,C0023668;C0036919;C0032042;C1696465;C1706408
type,C0332307;C1547052
ali,
ulcer n a,C0041582;C3887532
age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
necrosis n a,C0027540;C1334928
duration of diabetes by tertiles,C0449238;C2926735
base,C0002055;C0178499;C1880279
ascvd as per protocol,C3665365;C1698058
clean n a,C1947930
ascvd including tia,C3665365;C0007787;C0917805;C1054154
granulating n a,C1272460
any statin versus no statin at randomization,C0360714;C0034656
infected n a,C0439663
any statin with without llt,C0360714;C2347090
missing n a,C1551393;C1705492;C3272743
no statin vs statin alone vs any statin plus other llt,C0360714;C0205171;C0439044;C0679994;C2347090
serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no statin llt,C0360714;C2347090
serum mg $nmbr$ $nmbr$ mmol l normal mg hvpermagnesemia,C2827881
statin alone,C0360714;C0205171;C0439044;C0679994
pbo n $nmbr$ $nmbr$,C0031962
any statin other llt,C0360714;C2347090
cana $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
high intensity statin vs medium or low intensity statin at randomization,C4081854;C0360714;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C0596836
ethnicity n b,C0015031;C0243103
medium or low intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C0596836;C0360714
hba $nmbr$ c mmol mole,C0019016;C3829066;C1825777;C3538758
baseline serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
baseline serum mg $nmbr$ $nmbr$ mmol l,C0439268
egfr in $nmbr$ classes,C1739039;C3811844;C3812682
baseline mmol l,C0168634;C1532563;C1442488
baseline albumin creatinine ratio in $nmbr$ classes,C0486293;C1318293
week $nmbr$ mmol l,C0332174;C1532563;C0439230
diabetic kidney disease,C0011881
category $nmbr$,C0683312;C3889287
total number of patients,C2360800
category $nmbr$ and $nmbr$,C0683312;C3889287
egfr mean sd,C0444504;C2699239;C2347634;C2348143
calculated ldl c in $nmbr$ classes,C0444686;C0456387;C1518526;C1705943;C4019422;C1441506
egfr $nmbr$ to,C1739039;C3811844;C3812682
non hdl c in $nmbr$ classes,C1518422;C3715113
egfr $nmbr$ ml min n,C1739039;C0439445;C3811844;C3812682
baseline trl c in $nmbr$ classes,C0456387;C1518526;C1705943;C4019422
af first diagnosis $nmbr$ years n,C0205435;C0011900;C1704338;C1704656;C1279901
baseline trl c by quintiles,C0168634;C1442488
af on baseline ecg n,C0344434;C4049859
$nmbr$ or $nmbr$ n,C0369718;C0441922
baseline hdl c in $nmbr$ classes,C0168634;C3715113;C1442488
cha $nmbr$ ds $nmbr$ vasc score mean sd,C0444504;C2699239;C2347634;C2348143
low hdl c for men,C0151691;C0025266
risk factors for stroke,C0035648;C1553898
high hdl c for men $nmbr$ mg dl for women $nmbr$ mg dl,C3715113;C0439269;C0043210
previous stroke or tia n,C0038454;C4554100;C0007787;C0917805;C1054154
baseline triglycerides in $nmbr$ classes,C0168634;C0041004;C1442488
heart failure n,C0018801;C0018802;C4554158
baseline triglycerides by quintiles,C0168634;C0041004;C1442488
hypertension receiving treatment n,C0020538;C1963138;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline lp a in $nmbr$ classes,C0065058;C1439335;C4553379
valvular heart disease n,C0018824;C1963123
baseline total pcsk $nmbr$ level by median,C0441889;C0456079;C1547707;C2946261
concomitant medications at baseline,C0013227;C0802604;C2598133;C4284232
$nmbr$ ng ml,C0439275
arb or ace inhibitor n,C3888198;C0003015;C4541021
baseline free pcsk $nmbr$ level by median,C0441889;C0456079;C1547707;C2946261
ppi or h $nmbr$ receptor antagonist n,C0358591;C0871125;C3811894;C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
baseline hba $nmbr$ c in $nmbr$ classes,C0456387;C1518526;C1705943;C4019422
on oac at time of randomisation n,C0040223;C0034656;C3541383
diabetes mellitus status,C1317301
dabigatran $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
controlled,C2587213;C2911690
dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
baseline insulin daily dose kg,C0022718;C0439209;C4054209
dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ u kg day,C1532634
clinical outcome,C0205210;C1274040
exenatide n $nmbr$,C0167117
number of events,C4330837
indian american or alaska native,C1524069;C0596070;C0682125
event rate year,C0439234;C0439508
european subcategories,C0239307;C1515010;C1535514
p value for interaction age groups,C1709380
prior cv event at randomization,C0441471;C4019010
p value for interaction age continuous,C1709380;C0001779;C0549178
history of congestive heart failure,C0455531
stroke non,C0038454;C1518422;C4554100
egfr via mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
cns systemic embolism,C0013922;C1704212
antihyperglycemic medication usage,C0013227;C0457083;C3244316;C4284232
$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$,C0024671;C3254570;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
oral agents use,C1527415;C0450442;C1254351;C1521826
duration of rheumatoid arthritis years,C0449238;C2926735
$nmbr$ oral agents,C0450442;C1254351;C1521826
anti ccp antibody positive,C0741132
insulin alone,C0021641;C1533581;C1579433;C3714501;C0205171;C0439044;C0679994
das $nmbr$ c reactive protein,C0006560;C1413716;C4048285
insulin plus $nmbr$ oral agent,C0021641;C1533581;C1579433;C3714501
pramlintide,C0537551
clinical disease activity index score $nmbr$ $nmbr$,C4706353
non sulfonylurea secretagogues,C0038766;C4704833;C3536898
simplified disease activity index score $nmbr$ $nmbr$,C4706353
duration of morning,C0449238;C2926735
alpha glucosidase inhibitors,C1299007;C2756986;C3539108
stiffness min,C0702093;C1524029;C3813700
glp $nmbr$ receptor agonist other than study drug,C4543206
conventional synthetic dmard use at baseline,C0042153;C0457083;C1947944
exenatide lar,C1419115;C3814448
methotrexate dose at baseline,C0178602;C0869039;C1114758
other glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
$nmbr$ $nmbr$ mg week,C0332174;C0439230
dpp $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945
sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vildagliptin,C1570906
allogliptin,
evaluable for acr $nmbr$ at week $nmbr$ n,C1516986;C1412134;C1515941;C0332174;C0439230
sglt $nmbr$ inhibitors^,C3665045
acr $nmbr$ response at week $nmbr$ n,C0871261;C1704632;C1706817;C2911692
dapagliflozint,
prior anti tnf therapy,C1514463
other sglt $nmbr$ inhibitor,C1999216
received $nmbr$ prior anti tnf therapy n,C1514463
other antihyperglycemic agents not listed,C0020616;C0745732;C3272378
received $nmbr$ prior anti tnf therapies n,C1514463
cardiovascular medication usage,C0007220;C0457083
prior biologic therapy including anti tnfs,C0278947;C1448177
antihypertensive antianginal and other cardiovascular medications,C1874267;C3537168;C0007220
received $nmbr$ prior biologic therapy n,C1514756;C0278947
aldosterone antagonists e g spironolactone,C0002007;C2757004;C0037982
received $nmbr$ prior biologic therapies n,C1514756;C0278947
alpha $nmbr$ blockers,C0001641
low $nmbr$ $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
renin inhibitor e g aliskerin,C1960108;C3537174;C4521920
intermediate $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
digoxin digitalis glycoside,C0012265;C0012253
high $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
antithrombotic and anticoagulant medications,C0003280
coexisting conditions,C0012634;C0348080;C1705253;C3864998
previous ml before index acs,C0439526;C1705224;C3887665
vitamin k antagonist e g warfarin coumarol,C1096489;C2267235;C0043031
previous pci before index acs,C0205156;C4049621;C1552607
factor xa inhibitor,C2825027;C4553708
previous cabg before index acs,C0205156;C0010055;C1552607
direct thrombin inhibitors,C0003440;C3541936
before index acs event,C0441471;C4019010
other anti platelet agents,C0040616;C0005821
at index acs event,C0441471;C4019010
clopidogrel ticlopidine,C0070166;C0040207
ml with st segment elevation,C0439526;C1705224;C3887665
lipid lowering medications^,C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
statini,
ml without st segment elevation,C0439526;C1705224;C3887665
niacini,
pre randomization pci,C0034656;C4049621
other medication usage,C0013227;C0457083;C3244316;C4284232
time from acs to randomization,C0040223;C3541383;C0034656
hormone replacement therapy,C0282402
$nmbr$ $nmbr$ $nmbr$ o $nmbr$ o,C0483204
chronic non steroidal antiinflammatory drugs,C0205191;C0003211
low risk ri $nmbr$ $nmbr$,C0035487;C1826843
chronic cox $nmbr$ inhibitors,C0205191;C0085387
intermediate risk ri $nmbr$,C0035487;C1826843
fish oil,C0016157
high risk ri $nmbr$,C0035487;C1826843
exenatide no of events total no,C0167117;C0439175;C0439810
ez simva,C0206578
arr,C2170357;C4084934
placebo no of events total no,C0032042;C1696465;C1706408;C0439175;C0439810
risk model endpoint,C2349179;C2826544
indian american or alaskan native,C1524069;C0596070;C0238611;C0302891
pre specified trial endpoints,C2826245;C2349179
antihyperglycemic oral agent therapy,C0039798;C0087111;C1363945
secondary $nmbr$,C0027627;C0175668;C0205436
glycated hemoglobin level,C0202054
individual endpoints,C0027361;C2349179;C0237401
estimated gfr renal function stage,C0205390;C1300072;C1306673
cor revasc,C0018787;C0378365;C0056331
stage $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C0439445;C1300072;C1306673
urgent cor revasc,C0018787;C0378365;C0056331
stage $nmbr$ $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C0439445;C1300072;C1306673
acm,C0001143;C1549040
stage $nmbr$ a $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C1300072;C1306673;C0439445
pooled,C1709595;C2349200;C4522255
stage $nmbr$ b $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0441781;C0439445
seizure types reported during baseline n a,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
previous cardiovascular event at randomization,C1320716;C0034656
number of prior aeds n b,C0237753;C0449788
ertugliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
most common concomitant aeds n,C0205214;C0180309;C1522138;C3245511
background aha therapy at screening n,C0039798;C0087111;C1363945
phenytoin,C0031507;C0202454
dpp $nmbr$ inhibitors,C1414174;C0243077
levetiracetam,C0377265;C3693636
sulphonylureas,C0038766
patients with minimal important change in qolie $nmbr$ p,C0030705;C3845594
two agents,C0450442;C1254351;C1521826
minimal important change threshold improvement,C3845594;C2986411
three or more agents,C0205449;C0450442;C1254351;C1521826
$nmbr$ focal seizure frequency responders,C0149775;C0751495
one or more blood pressure medications n,C0205447;C0849164
cognitive functioning,C1516691;C0205245;C0542341;C4552744
ras agents,C0450442;C1254351;C1521826
emotional well being,C2984554;C3641833
other anti hypertensives,C0003364
energy fatigue,C0015672;C3463815;C4050243;C4554645
c peptide,C0006558
medication effects,C1319171
ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
overall quality of life,C3641830
subgroup analysis change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0392747;C0443172;C1705241;C4319952;C0019016;C0332174;C0439230;C1825777;C3538758;C0683312;C3889287
seizure worry,C0036572;C0233481;C1959629;C4553401
baseline hba $nmbr$ c median $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
daily activities social functioning,C0871707;C0037395
ls mean $nmbr$ ci mmol mol,C0008107;C3829066;C3259781
$nmbr$ $nmbr$ $nmbr$ obesity class $nmbr$,C0456387;C1518526;C1705943
difference in ls mean vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
$nmbr$ obesity class $nmbr$,C0456387;C1518526;C1705943
glycated haemoglobin,C0017853
difference in ls mean vs placebo $nmbr$ ci mmol mol,C1705241;C1705242;C0008107;C3829066;C3259781
baseline hba $nmbr$ c $nmbr$ $nmbr$ to,C0168634;C0019016;C1825777;C3538758;C1442488
$nmbr$ h plasma glucose during ogtt mmol l,C0202042;C0455280
baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
women n $nmbr$ vs $nmbr$,C0043210
pravastatin n $nmbr$,C0085542
men n $nmbr$ vs $nmbr$,C0025266
$nmbr$ month n $nmbr$,C0332177;C0439231
vldl cholesterol,C0023826;C0523560
ischemic stroke subtype,C0948008;C0449560
free fatty acids mmol l,C0015688;C1532563
atherothrombotic stroke n,C0038454;C4554100
dyslipidaemiat,
hypertensiont,
lacunar infarction n,C0333559
dyslipidaemia and hypertensiont,C0242339
undetermined etiology n,C0478157
estimated proportions and odds ratios,C0750572;C1709707;C0028873
use of antiplatelet agents n,C1524063;C0085826
interaction between treatment and baseline bmi category,C1704675;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0683312;C3889287
use of anti hypertensive agents n,C1524063;C0003364
estimated means and treatment differences,C0750572;C1704970;C1705241;C1705242
incidence of each outcome,C0021149;C0220856
llraglutide $nmbr$ $nmbr$ mg mean n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
stroke and tia n,C0038454;C4554100;C0007787;C0917805;C1054154
baseline hstni,C0168634;C1442488
incidence $nmbr$ person year,C0027361;C0439234;C0439508;C2347489
$nmbr$ ng l n $nmbr$,C0439297
all strokes n,C0038454
p value trend,C1521798;C4554533
atherothrombotic infarction n,C0021308
glycohemoglobin,C0202054;C0696092
cardioembolic infarction n,C0021308
prior coronary intervention or coronary artery bypass grafting,C0184661;C0886296;C1273869;C0010055
intracranial hemorrhage n,C0151699;C4554169
tia n,C0007787;C0917805;C1054154
index inclusion acute coronary syndrome,C0007637;C0948089;C1512693
vascular accidents n,C0005847;C0000924;C1558950;C1801960
time from acute coronary syndrome to randomization days,C0040223;C3541383;C0034656;C0439228
death n,C0011065;C1306577;C4082313;C4552775
median egfr interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
hospitalization n,C0019993
$nmbr$ ng l n $nmbr$ n,C0439297
bmi kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
cardiovascular death nonfatal myocardial infarction nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959
patient s history of,C0030705;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
prior non haemorrhagic stroke,C0332152;C0553692;C2826257
cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
chronic renal disease,C0022661;C1561643
cardiovascular death or nonfatal myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
index event information,C0441471;C1533716;C4019010
demographic features,C0683970
first medical contact in ambulance,C0332158;C0337611;C1705415;C3812666
black race n,C0005680
hispanic ethnic group n,C0441848
minutes from symptom onset to prehospital ecg median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
clinical history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
minutes from prehospital ecg to pci median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
stroke at entry vs transient ischemic attack,C0038454;C4554100;C0007787;C0917805
minutes from pre pci angiography to post pci angiography median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0002978;C0549183;C0876920;C2347635;C2348144;C2939193
prior stroke before index event,C0332152;C0456712;C2826257
received first loading dose,C0205435;C3714444;C1279901
coronary angioplasty or stenting,C0002997;C0190211;C0038257;C2348535
risk level at admission,C2923839;C0184666;C0809949
carotid artery intervention,C0397581
culprit vessel,C0005847
fasting glucose mmol l mean sd,C1532563;C2699239
no culprit vessel identified,C0005847;C0205396;C1550043
normal coronary angiography,C0853522
insulin iu ml median q $nmbr$ q $nmbr$,C0021641;C0439458;C1533581;C1579433;C3714501
femoral access,C0444454;C1554204
homa ir median q $nmbr$ q $nmbr$,C0022065;C0022071;C1448132
thromboaspiration,
hdl cholesterol mmol l men mean sd,C0023822;C2699239;C0392885
with any stent,C0038257
hdl cholesterol mmol l women mean sd,C0023822;C2699239;C0392885
with des,C0011702;C4551552
c reactive protein median q $nmbr$ q $nmbr$,C0006560;C1413716;C4048285
no revascularisation,C0581603
other antihypertensive,C0003364
any glycoprotein iib iiia inhibitor use,C0042153;C0457083;C1947944
aspirin and other antiplatelet,C0004057
glycoprotein iib iiia inhibitor use before angiography,C0042153;C0457083;C1947944
nonaspirin antiplatelet,C0722138
intravenous anticoagulant prior to pre pci angiography,C0003280;C0848112;C3536711
coumadin,C0699129
intravenous anticoagulant during hospitalisation,C0003280;C0848112;C3536711
other anticoagulant,C0003280;C0848112;C3536711
pre hospital ticagrelor n $nmbr$,C0332152;C0019994;C1510665;C0740175;C2257086;C3669034
pioglitazone pts n,C0071097;C1419129;C2698747
model n,C3161035;C3274659;C3714583;C3853906
placebo pts n,C0032042;C1419129;C2698747;C1696465;C1706408
patients with endpoin t n,C0030705
$nmbr$ z $nmbr$,
composite of death mi stro ke urgent revasc definit e acute stent thrombosis,C0205199;C1547335
white other,C0007457;C0043157;C0220938
absent $nmbr$ mg dl,C0332197;C0439269;C4285062
composite of death mi urg ent revasc,C0205199;C1547335
homa median,C0549183;C0876920;C2347635;C2348144;C2939193
nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038;C0750572
urgent revascularizati on,C0439609;C3272275
arb ace,C1452534;C4284014
$nmbr$ $nmbr$ o,C0483204
definite acute stent thrombosis,C0205178;C3897493
copd n $nmbr$,C0024117;C1412502;C3714496
acute stent thrombosis definite or probable,C0205178;C3897493;C0439544;C1704787;C0033204;C0332148
copd placebo n $nmbr$,C0024117;C0032042;C1696465;C1706408;C1412502;C3714496
enalapril aliskiren dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
copd rosuvastatin n $nmbr$,C0024117;C0965129;C1412502;C3714496
aliskiren dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
copd placebo $nmbr$ pt n,C0024117;C0032042;C1696465;C1706408;C1412502;C3714496
enalapril dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
copd rosuvastatin $nmbr$ pt n,C0024117;C0032743;C0699718;C1412502;C3714496
hazard ratio or difference $nmbr$ $nmbr$ cl p value,C2985465;C0596019;C1709380
model $nmbr$,C3161035;C3274659;C3714583;C3853906
enalapril aliskiren n $nmbr$,C0014025;C1120110
symptoms,C0683368;C1457887
cv death or first hhf,C0011065;C1306577;C4082313;C4552775;C0205435;C1279901
nyha ii n,C1275491;C1710602;C4082587
race $nmbr$,C0034510;C1706779;C3853635
nyha iii n,C1275491;C0439070;C1705160
non diabetes,C0011847;C0011849
nyha iv n,C1275491;C0022326;C4265176
first hhf,C0205435;C1279901
former current smoker n,C0337671
non ischaemic cardiomyopathy,C1518422;C0349782
previous hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
time since diagnosis of heart failure,C0040223;C3541383
previous cabg n,C0205156;C0010055;C1552607
kccq $nmbr$ months,C3476798;C0439231
previous pci n,C0205156;C1552607
nyha functional class at screening,C1882083;C0205245;C0542341;C2700217
pm n,C0030266;C4049155
physiological measures,C0079809;C1879489
history of atrial arrhythmia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
other outcomes,C1274040
previous cancer n,C0205156;C0006826;C0998265;C1306459;C1552607
laboratory measures,C0079809;C1879489
ischaemic n,C0475224
nt probnp pg ml q $nmbr$ q $nmbr$,C0669479;C0439297;C0754710
dilatative n,
change in nt probnp at $nmbr$,C0392747;C0443172;C1705241;C4319952
hypertensive n,C0857121
months log transformed,C1708728;C2986775;C1510411
other cause n,C0015127;C1524003
beta adrenergic blocker,C0001645;C2757061;C3536830
non detectable unknown n,C1518422;C0439673;C3541433;C4050014
devices for heart failure at screening visit,C0025078;C2024216;C0545082;C1512346;C2826704
s $nmbr$ gallop n,
crt p,
mitral regurgitation n,C0026266
crt d,
ecg,C1623258
change in nt probnp at $nmbr$ months log transformed,C0392747;C0443172;C1705241;C4319952;C1708728;C2986775;C1510411
pathologic q waves n,C0429089;C1305738
change in sbp $nmbr$ months,C0392747;C0443172;C1705241;C4319952
lv hypertrophy n,C0149721
hyperkalaemia investigator reported,C0020461;C0035173;C4552983;C0684224;C0700287;C4319718
qrs duration $nmbr$ ms n,C2349943;C3539704;C3713294
hyperkalaemia serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
diuretics n,C0012798
symptomatic hypotension sbp,C0020649;C0085805;C3163620
calcium channel blockers n,C0006684;C2757014
deterioration in renal function investigator reported,C0868945;C0232804;C0684224;C0700287;C4319718
beta blockers all n,C0001645;C0369718;C0441922
elevated serum creatinine $nmbr$ $nmbr$ mg dl_,C0700225;C0439269
other antiplatelet agents n,C0085826
cough investigator reported,C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727;C0684224;C0700287;C4319718
$nmbr$ blood eosinophils at baseline,C0014467;C0168634;C1442488
cough leading to study drug discontinuation,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C0332152;C0013175;C1522538
ind gly $nmbr$ $nmbr$ mg once daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
fig $nmbr$ acr $nmbr$ $nmbr$ and $nmbr$ response rates by baseline tnf status at weeks $nmbr$ $nmbr$ and $nmbr$,C1412134;C1515941;C0237629;C0168634;C1442488;C0439230
sfc $nmbr$ $nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fig $nmbr$ acr $nmbr$ acr $nmbr$ and acr $nmbr$ response rates by baseline mtx use at weeks $nmbr$ $nmbr$ and $nmbr$,C0349966;C1337208;C0237629;C0025677;C1417487;C0439230
ind gly $nmbr$ $nmbr$ mg once daily n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
no stroke n $nmbr$,C0038454;C4554100
sfc $nmbr$ $nmbr$ mg twice daily n $nmbr$ $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
any stroke n $nmbr$,C0038454;C4554100
ics use at screening n,C0042153;C0457083;C1947944
prior ml before index acs,C0439526;C1705224;C3887665
laba use at screening n,C0042153;C0457083;C1947944
prior cabg before index acs,C0332152;C0010055;C2826257
lama use at screening n,C0042153;C0457083;C1947944
cha $nmbr$ ds $nmbr$ vasc score median iqr,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
laba ics use at screening n,C0042153;C0457083;C1947944
labs at the index acs event,C0587081;C0441471;C4019010
triple therapy use at screening n,C0042153;C0457083;C1947944
total cholesterol median iqr mg dl,C0201950;C0439269;C0543421
smoking status at screening n,C1519386
ldl c median iqr mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
severity ofcopd gold $nmbr$ n,C0439793;C0018026;C1304897;C0522510
hdl c median iqr mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
low risk and fewer symptoms group a,C3272281;C3538919;C0441835;C4522145
time from acs to randomization median iqr,C0040223;C3541383;C0034656;C0549183;C0876920;C2347635;C2348144;C2939193
low risk and more symptoms group b,C3272281;C3538919;C0683368;C4522078;C1457887
labs at randomization,C0587081;C0034656
high risk and fewer symptoms group c,C0332167;C3272283;C4050568;C4319571;C0683368;C0441837;C1457887
hs crp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
high risk and more symptoms group d,C0332167;C3272283;C4050568;C4319571;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
egfr median iqr ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
severity of airflow limitation gold $nmbr$ $nmbr$ n,C0439793;C0522510
no prior stroke,C0038454;C4554100
mild gold $nmbr$,C0018026;C1304897
htn,C0020538
post bronchodilator fev $nmbr$ reversibility percentage of baseline value,C0439165;C1549488;C1561533
no htn,C0020538
number of copd exacerbations in the previous year n,C0237753;C0449788;C0205156;C0439234;C0439508;C1552607
crcl $nmbr$,C1846718
no of patients ind gly sfc,C0030705;C0017890;C0523677
prior llt,C0332152;C2347090;C2826257
annualized rate ind gly sfc,C0017890;C4521536;C0523677
no prior llt,C0332152;C2347090;C2826257
rate ratio $nmbr$ ci,C0008107;C3259781
ldl csmedian,
blood eosinophils count,C0200638;C0750879
ldl c median,C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ cells ul,C0439378
simva n $nmbr$ n,
$nmbr$ to $nmbr$ cells ul,C0439378
ez simva n $nmbr$ n,C0206578
$nmbr$ cells pl,C3897966;C4049765
arr $nmbr$ cl,C2170357;C0596019;C4084934
$nmbr$ to $nmbr$ cells,C0007584;C0007634
stroke of any etiology,C0038454;C4554100
pl $nmbr$ $nmbr$,C3897966;C4049765
primary trial end point,C2986535;C0008976
exposed n $nmbr$,C0332157
other individual and exploratory end points,C0027361;C0237401;C2349179
naive n $nmbr$,
coronary heart disease death,C0376297
no of prior aeds n,C0332152;C0180309;C2826257
cv death ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
$nmbr$ $nmbr$ a $nmbr$ $nmbr$ $nmbr$ $nmbr$,
patients no total no,C0030705;C0439175;C0439810
$nmbr$ $nmbr$ b $nmbr$ $nmbr$ $nmbr$ $nmbr$,
stroke vs tia,C0038454;C4554100;C0007787;C0917805;C1054154
$nmbr$ $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,
index event subtype,C0441471;C0449560;C4019010
number of prior aeds,C0237753;C0449788
large vessel atherosclerosis,C0225990;C0003850;C0004153
lev exposed,C0023556;C0332157
lacunar,
$nmbr$ responder rate n,C0871208;C1521828
cardioembolic,
cbz exposed,C0006949;C0332157
other defined,C1704788;C3539106
cbz naive,C0006949
motor weakness,C1513492;C3714552;C1705994
tpm exposed,C0076829;C0332157
aphasia,C0003537
tpm naive,C0076829
modified rankin scale score,C2984908;C3854213
ltg exposed,C1420817;C4521367;C4521846;C0332157
systolic blood pressure mean sd mm hga,C0428886;C0488055;C0871470;C1306620
ltg naive,C1420817;C4521367;C4521846
hemoglobin a $nmbr$ c mean sd b,C0062248
placebo no diabetes n $nmbr$,C0032042;C1696465;C1706408;C0011847;C0011849
risk difference,C0035647;C1705241;C1705242;C4552904
placebo diabetes n $nmbr$,C0011847;C0011849
feature,C1521970;C1706388;C2346469;C2348519
ticagrelor $nmbr$ mg no diabetes n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0011847;C0011849
p int f,C0369773;C0016327;C2603361
ticagrelor $nmbr$ mg diabetes n $nmbr$,C0011847;C0011849
htn hx,C0262926;C3814444
caucasian race,C0007457
placebo [n $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
kg m $nmbr$,C0022718;C0439209;C4054209
tofacitinib $nmbr$ mg bid [n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
prior mi diagnosis,C0332132;C3810814
placebo [n $nmbr$,C0032042;C1696465;C1706408;C0369718;C0441922
years since mi median,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
age mean years [sd],C1510829;C0444504;C2347634;C2348143;C2699239
prior transient ischaemic,C0040704;C0475224;C0205374
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$,
attack,C0277793;C1261512;C1304680
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ a,
time since last dose of,C0946444
gender n [ ] male,C0079399;C1522384;C0086582;C1706180;C1706428;C1706429
study medication pre dose,C0801821;C3174092
duration of disease median,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
median h,C0033727;C0369286;C0441932;C0564385;C4528284
years [range],C0439234;C1514721;C2348147;C3542016
beta blocker use,C0042153;C0457083;C1947944
previous anti tnf therapy n [ ],C0205156;C1552607
hypoglycaemic therapy,C0039798;C0087111;C1363945
$nmbr$ [ $nmbr$ $nmbr$ a,
diet controlled,C0743195
concomitant aminosalicylates n [ ] concomitant corticosteroids n [ ] mayo score mean [sd],C0521115;C0368663;C0001617;C3539185;C3540725;C3540726;C3540727;C0444504;C2347634;C2348143;C2699239
ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ _ $nmbr$ s,
lta max response to $nmbr$ pm adp defined hpr patients,C2611142;C0030266;C4049155
ibdq total score mean [sd],C0444504;C2347634;C2348143;C2699239
pre dose,C0439565;C3812758
ibdq domain scores mean [sd],C0444504;C2347634;C2348143;C2699239
p value for dm vs no dm,C1709380;C0011816;C3250443
bowel function,C0011135
post dose,C0439568
systemic symptoms,C0683368;C1457887
verifynow pru defined hpr patients,C1337105;C0030705
emotional status,C0013987;C0449438;C0849912
vasp pri defined hpr patients,C0034044;C0030705;C1826843;C3539761;C3539762
social function,C0037395
vhd,
sf $nmbr$ v $nmbr$ pcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
no vhd,
sf $nmbr$ v $nmbr$ mcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
aspirin use at randomization n,C0042153;C0457083;C1947944
sf $nmbr$ v $nmbr$ domain scores mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
history of coronary artery disease n,C1881055
physical function,C0516981;C4049916
history of carotid disease n,C0683519;C0730226;C0850708;C0944983
role physical,C0035820;C0031809;C0205485;C1509143;C1705810;C3871154
history of diabetes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
role emotional,C0035820;C0013987;C0849912;C1705810;C3871154
history of stroke or tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
octave induction $nmbr$ and $nmbr$,C0205263;C0857127
itt cohort overall study period,C0439531;C1948053
ls mean change from baseline in ibdq total score at week $nmbr$ mean [se],C0392747;C0443172;C1705241;C4319952;C2964552;C0036919
edoxaban hd n $nmbr$,C2975435
corticosteroid use at baseline,C0239126;C0168634;C1442488
edoxaban ld n $nmbr$,C2975435;C0694649
placebo n $nmbr$ i,C0021966;C0221138
hd edoxaban vs warfarin,C2975435;C0043031
patient demographics age yr,C4698447;C0439234
ld edoxaban vs warfarin,C0694649;C2975435;C0043031
disease characteristics duration of psoriatic arthritis yr,C0872146;C0003872
stroke or see,C0038454;C4554100;C0042789;C1947903
$nmbr$ $nmbr$ o $nmbr$,C0483204
ischemic stroke or see,C0948008;C0042789;C1947903
leeds enthesitis index^ score $nmbr$ no,C0449820;C4050231
hemorrhagic,C0333275
disabling or fatal,C1302234;C1705232
dactylitis severity score score $nmbr$ no,C0239161;C0457451
key secondary end points,C0027627;C2349179;C0175668;C0205436
swollen joint count of $nmbr$ joints assessed no,C0451521;C1516048
stroke see or cv death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
tender or painful joint count of $nmbr$ joints assessed no,C0234234;C0750480;C1705566;C1516048
stroke see or death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
elevated high sensitivity crp no,C0742906;C1441604
other end points,C2349179
affected body surface area $nmbr$ no,C0005902;C1879646
death or disabling stroke,C0011065;C1306577;C4082313;C4552775;C0038454;C4554100
median pasi score range i i,C0021966;C0221138
any cause,C0015127;C1524003
day $nmbr$ oral glucocorticoid use no,C1527415;C0017710
cv,C3538987;C4048877;C4318503
concomitant use of conventional synthetic dmard up to $nmbr$ mo no methotrexate,C1524063;C0242708;C0026544;C0332177;C0025677
aspirin $nmbr$ mg n $nmbr$,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
leflunomide,C0063041
weight no,C0005910;C0043100;C1305866;C1705104
otherj^,
index event no,C0441471;C4019010
methotrexate dose on day $nmbr$ mg per wl,C4086581
isolated deep vein thrombosis,C0205409;C0149871;C1548221
no of previous tne inhibitors,C0205156;C0243077;C1552607
isolated pulmonary embolism,C0205409;C0034065;C1548221
previous use of other biologic agents in addition to tne,C1524063;C0005515;C3896585
index event asymptomatic or unconfirmed,C0441471;C0231221;C4019010;C1547326
inhibitors no se $nmbr$ physical functioning score^^,C0243077;C4483112
classification of index venous thromboembolism no,C0008902;C0008903;C0678229
eacit e total score,C2964552
provoked,C1444748
figure s $nmbr$ american college of rheumatology $nmbr$ response rate and change from baseline in health assessment questionnaire disability index at month $nmbr$ by number of prior tnfi inadequate responses,C0035452;C0237629;C0392747;C0443172;C1705241;C4319952;C4321476;C0332177;C0439231;C0237753;C0449788
hormonal therapy no,C0279025
high sensitivity c reactive protein stratification,C0006560;C1514983;C1413716;C4048285
estrogens,C0014939;C3537250;C3541386;C3714615
$nmbr$ to $nmbr$ mg l n $nmbr$,C0439268
progestins,C0033306
$nmbr$ mg l n $nmbr$,C0439268
median duration of study drug administration iqr days,C0920470;C2348354
coronary bypass surgery,C0010055
individual intended study duration no,C0027361;C0489652;C0237401
index acs,C0742343;C4318612
rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
major adverse cardiovascular events,C0877248;C1705413
aspirin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
urgent revascularization because of unstable angina,C0581603;C0002965
presentation of index event,C0449450;C0441471;C4019010
complex anatomy n $nmbr$ $nmbr$,C0439855;C0002808;C0700276;C1384516;C1704241
pulmonary embolism deep vein thrombosis,C0392108;C0852030
noncomplex anatomy n $nmbr$ $nmbr$,C0002808;C0700276;C1384516
extent of index event,C0439792;C0441471;C4019010
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
history of recurrent venous thromboembolism,C0455533
stroke transient ischemic attack,C0007787;C0917805
risk factor profile index event,C0441471;C4019010
anatomic complexity characteristics,C0220784;C1521970
duration of pre randomization anticoagulant therapy,C2711563
$nmbr$ lesions per vessel,C0221198;C0005847
known thrombophilia,C0205309;C0398623
bifurcation lesion with side branch $nmbr$ $nmbr$ mm stented,C0221198;C1546698;C0038257
history of cv disease,C0683519;C0730226;C0850708;C0944983
vein bypass graft stented,C0398147;C0038257
any ae,C3887670
stent diameter $nmbr$ mm,C4330985;C4554674
aes leading to,C1412268;C2699274;C0332152;C1522538
central illustration dual antiplatelet therapy with complex lesions cumulative incidence of endpoint events from $nmbr$ to $nmbr$ months after randomization,C0205173;C1096021;C1554184;C0439231;C0034656
discontinu ation,
aes related to,C1412268;C2699274;C0439849;C0445223
the endpoint events were strati ed by randomized treatment arm and number of anatomical complexity characteristics outcomes were analyzed comparing randomized treatments among subgroups of subjects with $nmbr$ n $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$ or $nmbr$ or more n $nmbr$ anatomic complexity characteristics to assess whether treatment effects differed depending on the number of complexity factors,C0441471;C3541888;C3538926;C1522541;C0237753;C0449788;C0936012;C1707455;C0034656;C0087111;C3815594;C0369718;C0441922;C0220784;C1521970;C1516048;C1518681
study druga,C0557651;C2603343
ischemic stroke vs tia,C0948008;C0007787;C0917805;C1054154
serious aes,C1412268;C2699274
modified rankin scale at screening $nmbr$ $nmbr$,C2984908;C3854213
baseline statin use,C0042153;C0457083;C1947944
nihss at randomization $nmbr$ $nmbr$,C1697238;C0034656
cv risk factors,C0035648;C1553898
int p,C3272375
uncontrolled on oad s,C0205318
carotid stenosis,C0007282
uncontrolled on basal insulin,C0205318;C0650607
canagliflozin dose,C0178602;C0869039;C1114758
dual i extension,C0231448;C1880641
aged $nmbr$ y or older n,C0001779;C0001792;C1999167;C0580836
dual iv,C0022326;C4265176
bmi o $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
dual ii,C1710602;C4082587
bmi $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
global trial population,C0032659;C1257890
duration of diabetes y mean sd,C0449238;C2926735
indian subpopulation,C1524069;C1257890
duration of oral antidiabetic treatment y mean sd,C0444921
ideglira,C4308663
egfr category n,C1739039;C0683312;C3889287;C3811844;C3812682
ideg,
lira,C1555441
$nmbr$ to o $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0483204;C0439445
number of people n,C0237753;C0449788
serum creatinine gmol l mean sd,C0201976;C2699239;C0600061
oad at screening n,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
subgroup treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
metformin su,C0038642;C1705534
baseline value,C0168634;C1522609;C1442488
np tercile $nmbr$ bnp,C0054015;C1095989;C1417808;C2982014
difference a vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
nptercile $nmbr$ bnp $nmbr$ $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
baseline bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
np tercile $nmbr$ bnp $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
baseline egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
pvaluefor trend,C1521798;C4554533
duration of diabetes $nmbr$ years,C0449238;C2926735
nt probnp median pg ml,C0669479;C0439297;C0754710
baseline su dose $nmbr$ $nmbr$ maximal,C0205289;C0806909;C4049713
i or ii,C0021966;C0221138
calima japandhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$ y,C0178602;C0815320;C4551720;C2986497;C0005773
hf symptoms and signs,C0683368;C1457887;C0220912;C0220913;C0311392
calima overalldhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$,C0178602;C0815320;C4551720;C2986497;C0005773
pnd,C1417807;C1956415;C4552608
benralizumab q $nmbr$ w n $nmbr$,C2982078
dyspnea t,C0013404;C1963100
age [years] median range,C0001779;C0439234;C1514721;C2348147;C3542016
jvp $nmbr$ cm h $nmbr$ o,C0455483
body mass index [kg m $nmbr$ ] mean sd,C0005893;C0578022;C1305855;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
ankle edema,C0235439
time since asthma diagnosis [years] median range,C0040223;C3541383;C0439234;C1514721;C2348147;C3542016
pulmonary congestion cxr,C0006888;C0039985
oral corticosteroid use n,C1527415
sodium meq l,C0037473;C0439375;C0597484;C3541959;C3714642
number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C0439231
microalbuminuria mg g cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
ed visit related to exacerbation n,C0545082;C1512346;C2826704;C0439849;C0445223
total bilirubin mg dl,C0005437;C0439269;C0368753
hospitalisation related to exacerbation n,C0019993;C0439849;C0445223
albumin g dl,C0001924;C0439267
fev $nmbr$ prebronchodilator [l] mean sd,C3714541;C2599602;C0439394;C1706495;C3642217;C0444504;C2699239;C2347634;C2348143
lvh on ecg,C0232306
fev $nmbr$ prebronchodilator [ pn] mean sd,C3714541;C2599602;C0219433;C1549735;C3541307;C4049640;C4049767;C0444504;C2699239;C2347634;C2348143
diuretic agents,C0450442;C1254351;C1521826
fev $nmbr$ fvc prebronchodilator mean sd,C0444504;C2699239;C2347634;C2348143
long acting nitrate agents,C0450442;C1254351;C1521826
reversibility [ ] median range,C0449261;C1514721;C2348147;C3542016
bnp ntbnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
total asthma symptom score mean sdz,C3533163;C0004096;C2984299
bnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
local eosinophil count [cells ml] median range,C0200638;C0750879;C2699156;C1514721;C2348147;C3542016
ntbnp n $nmbr$,
dyspnoea n $nmbr$,C0013404;C1963100
calima japan n $nmbr$,C0022341
no dyspnoea n $nmbr$,C0013404;C1963100
calima overall n $nmbr$,C0282416;C1561607
benralizumab,C2982078
non usa,C1518422;C0041703
q $nmbr$ w n $nmbr$,
with dyspnoea,C0013404;C1963100
without dyspnoea,C0013404;C1963100
number of exacerbations in the last $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
cangrelor dyspnoea vs no dyspnoea,C0013404;C1963100
total asthma symptom score mean sd,C3533163;C2699239
clopidogrel dyspnoea vs no dyspnoea,C0013404;C1963100
local eosinophil count [cells l] median range,C0200638;C0750879;C0347983;C1514721;C2348147;C3542016
death mi idr st,C0036056;C3272372
japanese subgroup n $nmbr$,C0376247;C1079230;C1515021;C1556094
p inter action,C0205103;C0441472;C3266814;C1548610
any ae n,C3887670
non cabg related bleeding at $nmbr$ h,C0010055;C0019080
aes in $nmbr$ japanese patients in a study arm n,C1412268;C2699274;C0557651;C0446516;C3715044;C4553528;C2603343
severe life threatening,C1546953;C2826244;C3537125
allergic rhinitis,C1334103;C2607914;C4552864
fixed triple n $nmbr$,C0443218;C0205174;C2827483;C3714578
eczema,C0013595;C4553957
bacterial pneumonia,C0004626
open triple n $nmbr$,C0175566;C0205174
urticaria,C0042109;C1559188
blood leucocyte concentration $nmbr$ cells per l,C0005773;C0347983
upper respiratory tract inflammation,C0877266
blood eosinophil concentration $nmbr$ cells per l,C0005773;C0347983
epistaxis,C0014591;C4554627
blood eosinophil proportion,C0014467;C1709707
dermatitis atopic,C0011603;C0392707
time since first copd diagnosis years,C0556970;C0011900;C1704338;C1704656
injection site reaction n,C0151735;C4551923
of predicted normal value,C0681842;C0086715;C1882327
hypersensitivity n,C0020517;C0520946
inspiratory capacity l,C0021610;C0802663
any drug related ae n,C0013227;C0439849;C0445223;C1254351
chronic bronchitist,C0205191
any ae leading to discontinuation n,C3887670;C0332152;C0457454;C1444662;C4552847;C1522538
exacerbation rate in the previous year range,C0871208;C1521828
any serious ae n,C0205404;C3887670
cat total score,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
deaths n,C0011065;C1306577
copd medication at study entry,C0024117;C0013175;C1412502;C3714496
low dose rivaroxaban plus aspirin n $nmbr$,C2608320;C1739768
ics lama,C0999593;C1416775
body mass index kq nrn,C0005893;C1425210;C0578022;C1305855
spacer use during the study,C0221874;C0869040
systolic blood pressure mm hq,C0488055;C0871470;C1306620
patients with at least one concomitant disease,C0683521
diastolic blood pressure mm hq,C0428883;C1305849
myocardial ischaemia,C0010054;C0151744
smokinq status,C0449438
ischaemic cardiomyopathy,C0349782
lipid lowerinq druq,C0023779
coronary artery osteochondrosis,C0029376;C0029429;C0729346
e blocker,
cholecystitis chronic,C0008325;C0205191;C1963083;C4553186
reqion,
subgroup levels,C1079230;C0441889;C1515021
north american,C0425358;C2700615
estimate,C0750572
south american,C0425359
overall itt n $nmbr$,C0282416;C1561607
western european includinq australia israel and south africa,C0043128;C0022271;C0037712
mar imputation random n $nmbr$,C0034656;C0439605
eastern european,C0239309
cr imputation random n $nmbr$,C0201975;C0034656;C0439605;C3539604;C3711669;C4084730;C4553336;C4553337
low dose rivaroxaban aspirin n n,C2608320;C1739768
very severe itt n $nmbr$,C3641272;C4050419
aspirin alone n n,C0004057;C0205171;C0439044;C0679994
severe itt n $nmbr$,C0205082;C4050465;C4050466
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ oo,C0483204
ex smokers itt n $nmbr$,C0337671;C4555205
w est europe,C3811127;C0015176;C3890902
current smokers itt n $nmbr$,C3173209;C3241966
east europe,C1707877;C0015176
males itt n $nmbr$,C0086582
y es,C0013754;C0205944
females itt n $nmbr$,C0086287
n o,C0369718;C0441922
reversibility s $nmbr$ itt n $nmbr$,C0449261
no previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
reversibility $nmbr$ itt n $nmbr$,C0449261
history of pci ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
chronic bronchitis itt n $nmbr$,C0008677
history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
emphysema itt n $nmbr$,C0013990;C0034067
myocardial infarction cabg pci,C0027051;C4049621;C0428953;C2926063;C3810814;C4552959
mixed itt n $nmbr$,C0205430;C3160715
$nmbr$ mmol l,C1532563
$nmbr$ exacerbation in prev $nmbr$ m n $nmbr$,C4086268;C1552852;C0369718;C0441922
non smokers receiving lipid lowering drugs p blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
cardiovascular disease n $nmbr$,C0007222
west europe,C1705493;C0015176
no cardiovascular disease n $nmbr$,C0007222
no previous myocardial infarction $nmbr$ $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
eosinophils $nmbr$ n $nmbr$,C0014467;C0200638
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
non smokers receiving lipid lowering drugs $nmbr$ blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
age $nmbr$ $nmbr$ years n $nmbr$,C1510829
w hite,
overall per protocol n $nmbr$,C0282416;C1698058;C1561607
mean systolic blood pressure mm hg,C0428886;C0439475;C0488053
bocf iike imputation random n $nmbr$,C0034656;C0439605
mean diastolic blood pressure mm hg,C0428886;C0439475;C0488053
eosinophils $nmbr$ itt n $nmbr$,C0014467;C0200638
risk factors for pad,C0035648;C1553898
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ itt n $nmbr$,C0014467;C0200638
median total cholesterol mmol l,C0201950;C1532563;C0543421
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^ itt n $nmbr$,C0014467;C0200638
previous aorta femoral or lower extremity bypass surgery pta of iliac or infrainguinal artery,C0003483;C0015811;C0187763;C3274435;C0003842;C0226004
age $nmbr$ years itt n $nmbr$,C1510829
history of intermittent claudication and abi $nmbr$,C2315493;C1328319;C3888326
age $nmbr$ $nmbr$ years itt n $nmbr$,C1510829
previous limb or foot amputation,C0205156;C0015385;C1552607;C0188605
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^^ itt n $nmbr$,C0014467;C0200638
symptomatic pad of lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
rate $nmbr$ patient years,C0030705;C0439234
carotid artery diseaset,C0007272;C0162859
$nmbr$ or $nmbr$ high risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
symptomatic padt,C0231220
statin or ezetimibe,C0360714;C1142985
cad and abi,C1504769;C2239547;C3813548;C4284121;C1328319;C3888326
antihypertensive therapy,C0585941
normal $nmbr$ $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
vitamin k antagonist,C1096489;C2267235
non study ppi use,C0869040;C0358591;C0871125;C3811894
patients with event analyzed,C0030705;C0441471;C4019010;C0936012
low dose rivaroxaban aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
lue for interaction,C1704675
aspirin alone group no of events total n,C0004057;C2826346;C0439175;C0439810
$nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
no of events total n,C0439175;C0439810
$nmbr$ to $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
former or never,C0205156;C0750523;C2003901
sbp $nmbr$ mm hg and or dbp $nmbr$ mm hg $nmbr$ $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
symptomatic pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
sbp $nmbr$ mm hg and dbp $nmbr$ mm hg $nmbr$ $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
pad lower extremities,C0182158;C0023216;C0332568;C3540603;C3669270;C3814046;C4319657
iglarlixi fixed ratio combination,C0205195;C1947911;C3811910
overall pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
iglar insulin glargine l $nmbr$ u,C0907402;C0439148
demographics and clinical characteristics,C0011298;C1704791;C0683325
hbalc $nmbr$,
all completers n $nmbr$ $nmbr$,
mean change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
$nmbr$ hba $nmbr$ c,C0019016;C1825777;C3538758
mean difference seb,C0059386;C1309881;C1423585;C3815268
hba $nmbr$ c $nmbr$ n $nmbr$ $nmbr$,C0019016;C1825777;C3538758
daily iglar dose at week $nmbr$ u,C2348070;C0560588
duration of t $nmbr$ d years,C0449238;C2926735;C0439234
l $nmbr$ years,C0439394;C0439234;C1706495;C3642217
screening bmi kg m $nmbr$,C0022718;C0439209;C4054209
t $nmbr$ dm duration years,C0011816;C0439234;C3250443
screening hba $nmbr$ c,C0220908;C0019016;C1825777;C3538758;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
pool of fh i and ii studies,C0337051;C1509144;C2349200;C1710602;C0947630;C4082587
basal insulin dose at run in u day,C0366513;C0456683
pool of long term hefh patients only and high fh,C0337051;C1509144;C2349200;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
iglar dose at randomization u day,C0178602;C0869039;C1114758
alirocumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all completers,
q $nmbr$ w n $nmbr$ $nmbr$,
ls mean change sea,C0023668;C0036493
race n white,C0007457;C0043157;C0220938
ls mean difference seb,C0059386;C1309881;C1423585;C3815268
diabetes type ii n,C0011860
$nmbr$ confidence interval,C0009667
coronary heart disease n cardiovascular risk per protocol n very high,C0442804;C4321397
dose n,C0178602;C0869039;C1114758
patients with no prior cvd primary,C0030705;C1335497
$nmbr$ c,
prevention n patients on llt other than statin n,C0199176;C0030705;C1706420;C2700409;C0360714
mean iglar dose sd u day,C0178602;C0456683;C0869039;C1114758
ldl c calculated mg dl mean sd,C0439269;C2699239
mean lixi dose sd lg day,C0332173;C0439228;C0439505
total cholesterol mg dl mean sd,C0201950;C2699239;C0543421
age categories n,C2916832
lp a mg dl median q $nmbr$ q $nmbr$,C0065058;C0439269;C1439335;C4553379
bmi categories n,C0578022;C0683312
triglycerides mg dl median q $nmbr$ q $nmbr$,C0041004;C0439269
duration of type $nmbr$ diabetes categories n,C1547660;C1320657
apo a $nmbr$ mg dl mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
hba $nmbr$ c categories n,C0019016;C0683312;C1825777;C3538758
factor at baseline,C1521761;C2827422
fasting plasma glucose categories n,C0202042;C0455280
percentage of patients receiving dose adjustment,C0439165;C1549488;C1561533;C1514756;C2826232
metformin use n,C0025598;C0042153;C0457083;C1947944
distance to ldl c goal,C0012751;C0018017;C1571704
total daily insulin dose u,C2348070;C0439148
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
insulin type n,C0457592
$nmbr$ i,C0021966;C0221138
intermediate acting,C0205103;C1550465;C2827755;C3889971
$nmbr$ kg nr,C0027496;C3844738
intermediate long acting fast acting,C0015663;C0456962;C2985769
ltt other than statin,C0360714
long acting intermediate long acting fast acting,C0015663;C0456962;C2985769
no reference,C1514811;C1706462
individuals without diabetes n $nmbr$ $nmbr$,C0027361;C0237401
$nmbr$ $nmbr$ $nmbr$ $nmbr$ o $nmbr$,C0483204
baseline bmi $nmbr$ to,C0168634;C0578022;C1442488
mepolizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
liraglutide $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0545082;C1512346;C2826704;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
prediabetes,C0362046
patients with $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
individuals with diabetes n $nmbr$,C0027361;C0237401
current oral corticosteroid use,C1527415
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
oral corticosteroid dose mg day,C0001617;C0439422;C3536709
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$ change from baseline to $nmbr$ weeks,C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
current inhaled corticosteroid use,C0004048;C0239126
liraglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
th $nmbr$,C0039725;C0039738;C1420718;C4282123;C4285344
etd $nmbr$ ci,C0008107;C3259781
current laba use,C0042153;C0457083;C1947944
iwqol lite total score arbitrary units,C1264693;C0439148;C1519795;C3853603
current lra use,C0042153;C0457083;C1947944
iwqol lite physical score arbitrary units,C1264693;C0439148;C1519795;C3853603
current xanthine derivative use,C0042153;C0457083;C1947944
current lama use,C0042153;C0457083;C1947944
baseline bmi $nmbr$ to $nmbr$ kg m $nmbr$ n $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0578022;C1442488;C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
measures of lung function,C0079809;C1879489
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ change from baseline to $nmbr$ weeks,C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
pre bronchodilator fev^ l,C2599602;C3714541
canakinumab hscrp $nmbr$ $nmbr$ mg l at $nmbr$ months n $nmbr$,C0439268;C0439231
percentage of predicted pre bronchodilator fev^,C0439165;C1549488;C1561533
canakinumab hscrp,C2718773
percentage of fevj reversibility,C0439165;C1549488;C1561533
unknown or missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
pre bronchodilator fef $nmbr$ $nmbr$ ml s baseline blood eosinophil count,C0200638;C0750879
renin angiotensin inhibitors,C2917241;C3653375
baseline geometric mean $nmbr$ l,C0168634;C2986759;C1442488
anti ischaemia agents,C0450442;C1254351;C1521826
$nmbr$ per pl at screening,C3897966;C4049765
interleukin $nmbr$ ng l,C0021764;C0439297;C1527200
$nmbr$ per pl in $nmbr$ months before screening,C3897966;C4049765;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
randomised to canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total sgrq score,C2964552
primary cardiovascular endpoint,C2986535;C0007226;C3887460
baseline presence of nasal polyps,C0150312;C0392148;C3854307
incidence rate per $nmbr$ person years,C1708485;C0027361;C2347489
canakinumab,C2718773
positive atopic status,C0392707;C0449438
ldl cholesterol $nmbr$ $nmbr$ mmol l,C0023824;C1532563;C0202117
eosinophil count,C0200638;C0750879
hscrp $nmbr$ to,
mean change in sgrq,C0392747;C0443172;C1705241;C4319952
hscrp $nmbr$ mg l,C0439268
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0596019
hdl cholesterol $nmbr$ $nmbr$ mmol l,C0023822;C1532563;C0392885
mean change in fev $nmbr$,C0392747;C0443172;C1705241;C4319952
triglycerides $nmbr$ $nmbr$ mmol l,C0041004;C1532563
$nmbr$ $nmbr$ cl $nmbr$ to $nmbr$,C0596019
secondary cardiovascular endpoint,C4528314;C0007226;C3887460
mean change in acq score,C0392747;C0443172;C1705241;C4319952
sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
exacerbation rate per year,C0871208;C1521828
$nmbr$ sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
ularitide n $nmbr$,C0077910
pulse pressure mmhg,C0949236;C0439475
group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
randomization to,C0034656
nonblack race no j,C0034510;C1706779;C3853635
nyha class iii or iv n,C1882086;C0022326;C4265176
left ventricular ejection fraction no total no,C0428772;C0488728;C0439175;C0439810
enrolment through hf,C1516879;C1696073;C3888021
interval between clinical evaluation and initiation oftreatment no,C2826267;C0589507;C1158830;C1704686
hospitalization stratum n,C0019993
previous episode of heart failure,C0332189;C0018801;C0018802;C4554158
co morbidities n,C0009488
nyha class within past month no total no,C1882083;C0332177;C0439231;C0439175;C0439810
acei and or arb,C3888198
median n terminal probnp iqr pg ml,C0669479;C0439297
other anti hypertensive,C0003364
median cardiac troponin t iqr pg ml,C3538889;C0439297
anti hypertensive,C0003364
treatment at randomization no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
laboratory testing,C0022885
intravenous nitrates,C0348016;C0028125
rate ml min $nmbr$ $nmbr$ m $nmbr$,C0871208;C0439445;C1521828
intravenous dobutamine,C0348016;C0012963
ecg and imaging data,C1623258;C1511726;C3245479;C3714741
ularitide n n,C0077910
ecg left ventricular,C1623258;C0225897
white caucasian,C0043157
hypertrophy n,C0020564
baseline systolic bp,C0168634;C0871470;C1442488
ecg atrial fibrillation n,C0004238;C0344434;C1963067
time from first evaluation,C0040223;C3541383
composite endpoint,C2349179;C2826544
$nmbr$ hrs,C1568891
event rate per $nmbr$ person years,C0871208;C1521828
reported in ecrf,C0684224;C0700287;C4319718
crude model hr $nmbr$ ci,C0008107;C3259781
not reported in ecrf,C0684224;C0700287;C4319718
multivariable adjusted model hr $nmbr$ ci,C0008107;C3259781
gfr as assessed by mdrd,C0017654;C1424601;C3839656
recurrent hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
history of chronic hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hyperkalaemia,C0020461;C4552983
troponin t,C0077404;C1420827
hypokalaemia,C0020621;C4553966
baricitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
men n $nmbr$ $nmbr$,C0025266
female patients n,C0150905
prior lipid lowering agent use,C0042153;C0457083;C1947944
duration of ra time from symptom onset years,C0449238;C2926735;C4086878;C0439234
at qualifying event,C1514624;C0441471;C4019010
concomitant corticosteroid use n,C0521115;C0239126
dual antiplatelet,C0205173;C1554184
concomitant mtx use n,C0025677;C0042153;C0457083;C1947944;C1417487
pbo simva $nmbr$ yr km rale,C0031962;C0034642
mean sd mtx dose mg week,C0332174;C0439230
eze simva $nmbr$ yr km rale,C0439234;C0034642
number of prior csdmards n,C0237753;C0449788
any death,C0011065;C1306577;C4082313;C4552775
number of concomitant csdmards n,C0237753;C0449788
coronary revascularization $nmbr$ days after randomization,C0877341;C0439228
non mtx,C0025677;C1417487
cardiovascular death myocardial infarction stroke,C0027051;C0428953;C2926063;C3810814;C4552959
mtx non mtx,C0025677;C1417487
pint,C0560012;C3811619;C3890014;C3890556
cardiovasculardeath,
$nmbr$ non mtx,C0025677;C1417487
das $nmbr$ hscrp,C0051767;C0057671
cardiovasculardeath myocardial infarction stroke,C0038454;C4554100
placebo simvastatin,C0032042;C0074554;C1696465;C1706408
patient reported outcome measures,C4277735
ezetimibe simvastatin,C1532737
health assessment questionnaire disability index,C4321476
pin,C0175718;C1168556;C1704584
patient s global assessment of disease,C0030705;C0281858
permanently stopped study drug because of adverse events,C0041755
activity $nmbr$ $nmbr$ vas,C0042815;C3536884;C3827561
alt ast or both $nmbr$ x uln,C3831581;C1519815
patient s assessment of pain $nmbr$ $nmbr$ vas,C0030705;C0030198
gallbladder related aes,C1412268;C2699274
functional assessment of chronic illness,C0278372;C0008679
rhabdomyolysis or myopathy,C0035410;C4552660;C0026848
therapy fatigue facit f $nmbr$ $nmbr$,C0015672;C3272505;C3463815;C4050243;C4554645
rhabdomyolysis myopathy or myalgia with ck elevation $nmbr$ x uln,C0035410;C0026848;C4552660;C0231528;C4552646
short form $nmbr$ sf $nmbr$,C2964478;C0037712
myopathy,C0026848
physical component score pcs,C1864389;C1882368
ertugliflozin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mental component score mcs,C0229992;C0449432;C1705248
medical history of cv disease or heart failure n,C0262926;C0018801;C0018802;C4554158
european quality of life $nmbr$ dimensions $nmbr$ level eq $nmbr$ d,C0205163;C0439185
currently on aha therapy,C0050451;C0039798;C0087111;C1363945;C0772110
health state index score uk algorithm,C0002045;C1553907
glp $nmbr$ receptor agonists,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
vas $nmbr$ $nmbr$,C0042815;C3536884;C3827561
insulins and analogs,C0021641;C3537244;C4049919;C0243071
mtx other csomards,C0025677;C1417487
overall cohort primary analysis,C0086027;C0205225;C0439612;C0439631
mtx othetcsdmards,C0025677;C1417487
difference in ls means $nmbr$ ci versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408
fluticasone furoate n $nmbr$,C1948374
stage $nmbr$ a ckd cohort secondary analysis,C0205390;C1300072;C1306673;C0086027;C0027627;C0175668;C0205436
vilanterol n $nmbr$,C2935023
cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
overall cohort post hoc analysis excluding metformin users,C0086027;C0025598
diabetes with target organ disease,C0011847;C0011849
stage $nmbr$ a ckd cohort post hoc analysis excluding metformin users,C0205390;C1300072;C1306673;C0086027;C0025598
week $nmbr$ a,C0332174;C0439230
high risk receiving treatment for,C0332167;C3272283;C4050568;C4319571;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
concomitant cardiovascular therapy taken $nmbr$ days,C1707479;C0439228
table $nmbr$ baseline characteristics in america between patients w wo resistant htn,C4684572;C0002454;C0030705;C1980014
antithrombotic coagulant,C0009117
ras aldosterone inhibitor^,C1514727
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker bb beta blocker bmi body mass index bnp brain natriuretic peptide ccb calcium channel blocker dbp diastolic blood pressure egfr estimated glomerular ltration rate hr heart rate sbp systolic blood pressure w wo with or without,C4528226;C1980014
beta $nmbr$ selective,C0330390;C0439096;C2004068
america all patients,C0002454;C0030705
dihydropyridine,C0012315;C0220821
america rhtn only,C0002454
long acting or short acting nitrates,C0205166;C1706317;C1282927;C0028125;C1806781;C2350002
no resistant htn n $nmbr$ $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
current smoker n $nmbr$,C3173209;C3241966
resistant htn n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
former smoker n $nmbr$,C0337671
resistant htn placebo n $nmbr$,C0020538;C0032042;C1696465;C1706408
$nmbr$ years to,C0439234
resistant htn spiro n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
$nmbr$ $nmbr$ with cv disease n $nmbr$,C0007222
race_white,C0007457;C0043157;C0220938
$nmbr$ $nmbr$ with cv risk but not disease n $nmbr$,C0035647;C4552904;C1518422;C0012634
nyha_class,C1882083
europe $nmbr$ n $nmbr$,C0015176
eligibility strata,C0013893;C1548635
ischemic heart disease indicator no n $nmbr$ l,C0021212;C1235732;C1522602;C0369718;C0441922
elevated bnp,C0054015;C1095989;C1417808;C2982014
vascular disease indicator no n $nmbr$,C0021212;C1235732;C1522602;C0369718;C0441922
ace or arb,C1452534;C4284014;C3888198
iglarlixi,
bb,C0004739;C0332297
iglar,
hb g dl,C0439267
lixi,
table $nmbr$ outcomes in americas according to the presence absence of rhtn,C1274040;C0002454;C0596070;C0332197;C1689985
week $nmbr$ changea,C0332174;C4349366;C0439230
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker ci con dence interval cvd cardiovascular death hf heart failure hr hazard ratio rhtn resistant hypertension afrom unadjusted model bstrati ed by eligibility strata cfurther adjusted for age ace arb diabetes,C0596525;C3538926;C0013893;C1548635;C4300468
$nmbr$ hour ppg mmol l,C0439227;C1532563;C0564385
rhtn,
hypoglycaemiad,
no rhtn,
events patient year n,C0030705;C0439234;C0439508
number and of participants with events and incidence rate per $nmbr$ person year,C0237753;C0449788;C0679646;C0441471;C3541888;C1708485;C0027361;C2347489
mean baseline n,C0444504;C0168634;C1442488;C2347634;C2348143
unadjusted model hr $nmbr$ ci p value,C0008107;C1709380;C3259781
$nmbr$ $nmbr$ f $nmbr$,C0016327
strata modelb hr $nmbr$ ci p value,C0008107;C1709380;C3259781
subpopulation analyses according to bmi,C1514228;C0578022
adjusted modelc hr $nmbr$ ci p value,C0008107;C1709380;C3259781
octave induction $nmbr$,C0205263;C0857127
octave sustain,C0443318;C2732140
p for interaction between rhtn and no rhtn and treatmenta,C0369773;C2603361
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr,
male sex no f,C0086582;C0016327
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
induction trial group assignment no,C1320290;C1516050
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per pyr $nmbr$ pyr,
tofacitinib $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
recurrent hf,C0018488;C1313497;C1538440;C3273279
remission at maintenance trial entry no,C0544452;C0687702
$nmbr$ $nmbr$ per $nmbr$ pyr,
extent of disease no total no ^,C0449279;C4553144;C0439175;C0439810
$nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr pyr,
extensive colitis or pancolitis,C0009319;C1963084;C0868908
itca $nmbr$ $nmbr$ mg day n $nmbr$,C0165330;C0439422
total mayo score,C2964552;C0454788;C1077578
femalesex,
partial mayo score,C0449820;C4050231
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
c reactive protein mg literj,C0006560;C1413716;C4048285
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
oral glucocorticoid use at baseline no t,C1527415;C0017710;C2603360
egfr ml min bsa,C1739039;C0439445;C3811844;C3812682
previous treatment with tnf antagonist no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
medications at baselinet,C0013227;C0802604;C2598133;C4284232
previous treatment failure no,C0162643;C0235828;C0521983;C1547544
metforminmonotherapy,
tnf antagonist,C1448177;C0231491
metformin su tzd,C0025598;C0038642;C1705534
immunosuppressant^^,C0021081
tah n $nmbr$,C0404079
tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ta n $nmbr$,C0039297;C1506978;C1705538;C3272501;C4553364
prior tnf antagonist treatment yes,C1549445;C1705108;C1710701
anthropometrics mean sd,C0444504;C2699239;C2347634;C2348143
prior tnf antagonist treatment no,C1514463;C0231491
vital signs mean sd,C0150404;C2699239;C0518766
prior tnf antagonist failure yes,C1549445;C1705108;C1710701
baseline sitting sbp $nmbr$ mm hg,C0085805;C0439475
prior tnf antagonist failure no,C0231174;C0680095
baseline sitting dbp mm hg,C0168634;C0439475;C1442488
corticosteroid use at baseline yes,C0239126;C0168634;C1442488
comorbidity no,C0009488
corticosteroid use at baseline no,C0239126;C0168634;C1442488
dm or ckd,C0011816;C3250443;C1561643
geographic region europe,C0017446;C0015176
female gender n,C0086287
geographic region north america,C0017446;C0028405
crcl ml min mean sd,C0439445;C2699239
geographic region other,C0017446
prespecified medical conditions n f,C0199168;C0016327;C0205476
abatacept n $nmbr$,C1619966
cardiovascular disease n,C0007222
dip involvement n,C3539618;C1314939
cancer n,C0006826;C0998265;C1306459
patient global assessment of disease activity vas $nmbr$ $nmbr$ mm,C4054228;C0042815;C3536884;C3827561
number of medications n,C1718138
aspirin use n,C0004057;C0042153;C0457083;C1947944
physician global assessment of disease activity vas $nmbr$ $nmbr$ mm,C4050369;C0042815;C3536884;C3827561
dose adjustment n,C2826232
patient global assessment of pain vas $nmbr$ $nmbr$ mm,C4054229
dose adjustment reason $nmbr$ kg,C0022718;C0439209;C4054209
elevated crp ulnt n,C0742906
crcl $nmbr$ $nmbr$ ml min,C1846718;C0439445
psa modified total shs,C0392747;C0439175;C0439810;C3889737
p gp use,C0042153;C0457083;C1947944
psoriasis covering $nmbr$ bsa n,C0033860;C0180153;C0439844
two or more,C0205448
enthesitis n,C1282952
treatment duration mean sd,C0444921;C2699239;C3259042
dactylitis n,C0239161
unprovoked vte n,C0630906
anti ccp positive $nmbr$ u ml n,C0432633;C0439340;C1880521;C2945590
index events dvt n,C0441471;C0149871;C2926618;C3899446;C3541888
prior tnfi n,C0332152;C2826257
extent of index dvt n of dvt patients,C0439792;C0030705
concomitant methotrexate n,C0521115;C0025677
index events pe dvt n,C0070939;C0149871;C2926618;C3899446;C1880476;C4284304
concomitant csdmards other than methotrexate n,C0521115;C0025677
extent of index pe n of pe patients,C0439792;C0030705
concomitant oral corticosteroids n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
nt probnp $nmbr$ ng ml n,C4284038;C0439275
estimated difference $nmbr$ ci,C0008107;C3259781
edoxaban n n rate,C0871208;C1521828
abatacept open label abatacept,C1619966;C1709323
warfarin n n rate,C0871208;C1521828
placebo open label abatacept,C1709323;C1619966
primary efficacy outcome recurrent vte during overall study period,C0543472;C0630906
tnfi naive,
tnfi exposed,C0332157
primary safety outcome major or clinically relevant non major bleeding,C0205082;C0205164;C4318856;C4521762;C0019080
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ $nmbr$,
net clinical benefit on treatment vte or major bleeding,C1516635;C0630906;C0205082;C0019080;C0205164;C4318856;C4521762
lvh n $nmbr$,C0149721
diabetes absent $nmbr$ $nmbr$ $nmbr$,C0011847;C0011849;C0332197;C4285062
non cns embolism,C0013922;C1704212
diabetes present $nmbr$ $nmbr$ $nmbr$,C0150312;C0449450
medication use at entry,C0240320;C1705654
median weight kg iqr,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
antiplateletsa,
median body mass index kg m $nmbr$ iqr,C0022718;C0439209;C4054209
arbs or ace inhibitors,C3888198;C0003015
medications before admission,C0013227;C0802604;C2598133;C4284232
_ $nmbr$,
at index event,C0441471;C4019010
electrocardiography,C0013798;C1623258
diagnostic angiography,C0002978
r wave in avl mm,C0429091;C0449216
laboratory values at admission median and iqr,C0022877;C0042295;C3244292;C4283904
s wave in v $nmbr$ mm,C0429094;C4330985;C4554674
no prior statin use,C0042153;C0457083;C1947944
strain,C0080194;C0456178;C1518614;C2987481
high density lipoprotein cholesterol mg l,C0023822;C0439268
lv ejection fractionb,C0023128;C0302131;C0336969;C0812388;C0731033;C1881413
triglycerides mg l,C0041004;C0439268
p value d $nmbr$ mg vs warfarin,C1709380;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
creatine clearance ml min,C0373595;C0439445
yr,C0439234
laboratory values at randomization median and iqr,C0022877;C0042295;C3244292;C4283904
d $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
statin during admission,C0360714;C0184666;C0809949
pravastatin sodium,C0700474
no statin during admission,C0360714;C0184666;C0809949
medication use no total no,C0240320;C0439175;C0439810
km event at $nmbr$ y,C0441471;C4019010
current cigarette smoking no,C0239059;C0700219
primary end points,C0205225;C2349179;C0439612;C0439631
lipid values,C0023779;C0042295
secondary end points $nmbr$,C0027627;C2349179;C0175668;C0205436
antihypertensive randomization no a,C0003364;C0034656
secondary end points ii,C1710602;C4082587
years of follow up mean sd [maximum],C0439234;C0589120;C1522577;C1704685;C3274571;C0806909;C1552615;C2826546
secondary end points iii,C0439070;C1705160
cumulative events,C0441471;C3541888
tertiary end points,C0205372;C2349179
$nmbr$ y incidence rate se per $nmbr$ participants,C1708485;C0036919
alanine aminotransferase or aspartate aminotransferase $nmbr$ x upper limit of normal n $nmbr$,C0001899;C0057041;C1415274;C3887708;C0004002;C1519815
pravastatin vs usual care,C0085542;C3538928;C1947933
dm absent,C0011816;C3250443;C0332197;C4285062
cvd deaths,C0011065;C1306577
dm present,C0150312;C0449450
chd deaths,C0011065;C1306577
cholecystectomy n $nmbr$,C0008320
stroke deaths,C0011065;C1306577
gall bladder adverse event n $nmbr$,C0016976;C0877248
non cvd deaths,C0011065;C1306577
rhabdomyolysis n $nmbr$,C0035410;C4552660
cause of death unknown,C0277589
fatal chd and nonfatal mia,C0280604;C3542407;C1417154
rhabdomyolysis myopathy or elevated creatine phosphokinase $nmbr$ x upper limit of normal n $nmbr$,C0035410;C0026848;C4552660;C1519815
stroke fatal and nonfatal,C0038454;C4554100;C1302234;C1705232
hemorrhagic stroke n $nmbr$,C0553692
heart failure hospitalized or fatal,C0018801;C0018802;C4554158;C0701159;C1302234;C1705232
cancer n $nmbr$,C0006826;C0998265;C1306459
cancer fatal and nonfatal,C0006826;C0998265;C1306459;C1302234;C1705232
e $nmbr$ n $nmbr$,
secukinumab pooled n $nmbr$,C1709595;C2349200;C4522255
s $nmbr$ n $nmbr$,C2986823
current smoker at baseline n,C3173209;C3241966
e $nmbr$ s $nmbr$ n $nmbr$,C3846405
testing order,C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
methotrexate use at randomization n,C0042153;C0457083;C1947944
hba $nmbr$ c change from baseline,C0392747;C0443172;C1705241;C4319952
sulfasalazine use at randomization n,C0042153;C0457083;C1947944
e $nmbr$ s $nmbr$ vs s $nmbr$,C3846405
corticosteroid use at randomization n,C0239126;C0034656
e $nmbr$ s $nmbr$ vs e $nmbr$,C3846405
total back pain $nmbr$ $nmbr$ mm vas mean sd,C0042815;C2699239
body weight change from baseline,C0005911
nocturnal back pain $nmbr$ $nmbr$ mm vas mean sd,C1970122;C2699239
fasting plasma glucose change from baseline,C0392747;C0443172;C1705241;C4319952
basdai total mean sd,C0439175;C2699239;C0439810
hscrp mg l median min max,C0439420
systolic blood pressure change from baseline,C1268766
mean time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
hba $nmbr$ c patients,C0019016;C0030705;C1825777;C3538758
anti tnf na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
dynamic measure of cell function s change from baseline assessed for mmtt subset only,C0079809;C0242485;C0392747;C0443172;C1705241;C4319952;C1516048;C1515021
endpoints,C2349179
liraglutide $nmbr$,C1456408
hscrp exp ls mean change se,C0023668;C0036919
hbaie mean sd,C0444504;C2699239;C2347634;C2348143
asas $nmbr$ $nmbr$ n,C0004057;C3853627
hbajc mmol mol mean sd,C3829066;C2699239
sf $nmbr$ pcs ls mean change se,C0023668;C0036919
diabetes duration mean sd,C0011847;C2699239;C0011849
asqol ls mean change se,C0023668;C0036919
caleitonin ng l males mean sd,C0439297;C2699239
asas partial remission n,C1521726;C4552913;C4552914
$nmbr$ $nmbr$ lo $nmbr$ $nmbr$,C0206579;C1232424
criterion,C0243161
caleitonin ng l females mean sd,C0439297;C2699239
placebo controlled period,C0439531;C1948053
lo lo lo,C0206579;C1232424
any secukinumab n $nmbr$,C3179547
egfr n normal egfr $nmbr$ ml min em^,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
no of patients with events,C0030705;C0441471;C3541888
mild impairment egfr $nmbr$ $nmbr$ ml min m^,C0221099;C0439445;C0684336
any sae,C1519255;C1622657;C4553214
moderate impairment egfr $nmbr$ $nmbr$ ml min m^,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335
infections and infestations,C3714514;C0851341
patients with established cv disease aged $nmbr$ years,C0683521
most common aes,C1412268;C2699274
n patients with risk faetors for cv disease aged $nmbr$,C0030705;C0035647;C4552904;C0007222;C0001779;C0001792;C1999167
mouth ulceration,C0149745
years n smoking n current,C0521116;C1705970
leukopenia,C0023530;C0750394
use of proton inhibitors n,C1524063;C0033727
pharyngitis,C0031350;C4553308
use of h $nmbr$ bloekers n,C1524063;C0033727;C0369286;C0441932;C0564385;C4528284
osteoprotegerin decreased,C0538161;C1308614;C1336645;C0205216;C0392756;C0442797
oropharyngeal pain,C2363731;C4554669
history of thyroid disease n,C0683519;C0730226;C0850708;C0944983
lymphadenopathy,C0497156;C4282165
ct calcitonin cv cardiovascular egfr estimated glomerular filtration rate hbalc glycated hemoglobin h $nmbr$ histamine $nmbr$ iqr interquartile range n number of patients sd standard deviation,C2986735;C0030705;C0871420
rhinitis,C0035455
high uln,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
neutropenia,C0023530;C0027947;C0853697
$nmbr$ ng l,C0439297
gastroenteritis,C0017160
ulnand,
ab ff $nmbr$ $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
cdmard,
ab $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
none cdmard naive or past use at baseline,C0042153;C0457083;C1947944;C0168634;C1442488
ff $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
ixeq $nmbr$ w n $nmbr$,C0369718;C0441922
cigarette smoking mean pack years sd,C1303175;C2699239
time since psa diagnosis years mean sd,C0556970;C0011900;C1704338;C1704656
mean fev $nmbr$ l sd,C0444504;C2699239;C2347634;C2348143
tender joint count $nmbr$ joints mean sd,C0451530;C2699239
post bronchodilator percent of predicted fev $nmbr$ sd,C2599594;C1882327
swollen joint count $nmbr$ joints mean sd,C0451521;C2699239
moderate n a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
haq di total score mean sd,C2964552;C2699239
severe n b,C0205082;C4050465;C4050466
van der heijde mtss mean sd,C0444504;C2699239;C2347634;C2348143
mean number of exacerbations in previous $nmbr$ months sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
figure $nmbr$ acr response rates at $nmbr$ weeks in patients treated with pbo ixeq $nmbr$ w or ixeq $nmbr$ w alone or in combination with cdmards or mtx the proportions of patients achieving acr $nmbr$ a acr $nmbr$ b and acr $nmbr$ c are shown,C0237629;C0439230;C0030705;C0332293;C0031962;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910;C0025677;C1417487;C1709707;C1412134;C1515941;C1547282
mean bdi focal score sd,C3533236;C2699239
overallb,
mean sgrq total score sd,C3533236;C2699239
who fc ii symptoms at baseline,C0683368;C1457887
previous treatment with a laba and or lama n c,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775
who fc iii symptoms at baseline,C0683368;C1457887
baseline ics use n,C0168634;C0042153;C0457083;C1947944;C1442488
time since pah diagnosisc years,C0556970;C0030123;C3203102;C4284467
fig $nmbr$ analysis of time to first cid event in patients who a received treatment with a laba and or lama and b did not receive treatment with a laba and or lama prior to the study,C0349966;C1718396;C1337208;C0441471;C4019010;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775;C1518422;C1514756
pah classification,C0008902;C0008903;C0678229
fig $nmbr$ analysis of time to first cid event in patients with a moderate and b severe copd at baseline itt population,C0349966;C1718396;C1337208;C0441471;C4019010;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0024117;C1412502;C3714496
associated with ctd,C0332281;C1335071;C1442905
tnt and ideal pooled,C1512612;C1709595;C2349200;C4522255
associated with corrected,C0332281;C0205202
without psoriasis n $nmbr$,C0033860
congenital shunts,C0232180;C0542331;C1442858
with psoriasis n $nmbr$,C0033860
associated with drug toxin,C0332281;C0013227;C1254351
without psoriasis n $nmbr$ $nmbr$,C0033860
exposure,C0274281;C0332157
p valueb,C0369773;C2603361
p value for interaction $nmbr$,C1709380;C1704675
\ $nmbr$ $nmbr$,
patients events n,C0030705;C0441471;C3541888
duration of psoriasis years,C0449238;C2926735
selexipag vs placebo hazard ratio $nmbr$ cl,C2000145;C2985465;C0596019
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [n $nmbr$ ],C0369718;C0441922
time to first morbidity mortality event up to the end of the treatment periodd,C0040223;C3541383;C0444930;C2746065
cerebrovascular disease n,C0007820
time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931;C0030123;C3203102;C4284467;C0019993;C0678226;C0444930;C2746065
baseline concomitant therapies,C0168634;C1707479;C1442488
time to all cause death up to end of the study,C1301931;C0444930;C2746065
calcium channel antagonists n,C0006684;C2757014
open label population,C0032659;C1257890
ace inhibitors or angiotensin ii,C0003015;C0003009;C1366631;C3714928
randomize,
receptor blockers n,C0597357
d population,C0032659;C1257890
baseline lipid and apolipoprotein levels,C0168634;C0023779;C1442488;C0003591;C0441889
demographic disease characteristics at baseline,C0599878
total cholesterol hdl c ratio,C0523558
etn $nmbr$ mg mtx n $nmbr$,C0014758;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0717758
apoa $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
prior tobacco use n,C0040335;C0543414;C0841002;C3853727
patients without psoriasis n $nmbr$,C0030705;C0033860
acpa positive n,C0439178;C1446409;C1514241;C2825490;C3812269
patients with psoriasis n $nmbr$,C0030705;C0033860
clinical and patient reported characteristics at baseline and randomization,C0205210;C0815172;C4684572;C0034656
interaction treatment by psoriasis p value $nmbr$,C3258078;C1709380
tjc $nmbr$ $nmbr$,
atorvastatin ls means difference $nmbr$ mg $nmbr$ ci a n $nmbr$,C0008107;C3259781;C0369718;C0441922
sjc $nmbr$ $nmbr$,
ls means difference $nmbr$ ci $nmbr$,C0008107;C3259781
esr $nmbr$ $nmbr$ mm hour,C0439227;C0564385
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
pga $nmbr$ $nmbr$,C0016410;C3541266;C4050369
apob apoal,C0003593;C3252643
ptga $nmbr$ $nmbr$,
ato $nmbr$ mg and sim $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
general health vas $nmbr$ $nmbr$ mm,C4330985;C4554674
ato $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pain vas $nmbr$ $nmbr$ mm,C4330985;C4554674
lsms difference $nmbr$ ci $nmbr$,C0008107;C3259781
total haq $nmbr$ $nmbr$,C0102923;C0451208
ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
radiographic characteristics at baseline and randomization,C0444708;C4684572;C0034656
incidence rate of cv events n,C1708485;C0441471;C3541888
mtss $nmbr$ $nmbr$,
hazard ratio $nmbr$ ci $nmbr$ with vs without psoriasis,C0008107;C3259781;C0033860
total v $nmbr$ $nmbr$,C0439175;C0439810
fig $nmbr$ continuous and categorical baseline predictors of disease activity score based on $nmbr$ joints das $nmbr$ a simplified disease activity index sdai b and clinical disease activity index cdai c remission using univariate logistic regression unadjusted if the $nmbr$ ci does not contain the value $nmbr$ $nmbr$ the predictor is statistically significant at $nmbr$ $nmbr$ non significant predictors black significant predictors gray,C0349966;C1337208;C0549178;C0035648;C1527178;C1705938;C3869582;C3871128;C0544452;C1524063;C0206031;C1439367;C0008107;C3259781;C1518422;C0332256;C2700400;C1522609;C2698872;C0237881;C0005680;C0027567;C0085756;C0439541
all treatments,C0087111
mvd n $nmbr$ $nmbr$,C1417507;C3272839
atorvastatin $nmbr$ mg and simvastatin $nmbr$ $nmbr$ mg zi $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043476
no mvd n $nmbr$ $nmbr$,C1417507;C3272839
atorvastatin $nmbr$ mg zi $nmbr$,C0024671;C0043476;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
qualifying mi stemi,C1514624;C1536220;C3538872
canagliflozin n $nmbr$,C2974540
figure $nmbr$ ef cacy of ticagrelor,C1419788;C3274822
history of heart failure no,C0455531
supplementary figure s $nmbr$ mda response through $nmbr$ weeks by disease duration,C0871261;C1704632;C1706817;C2911692;C0872146
history of microvascular disease no,C0683519;C0730226;C0850708;C0944983
met atopy and ige $nmbr$ $nmbr$ ku l criteria n $nmbr$,C0392707;C3539705;C0439340;C0243161
history of atherosclerotic vascular disease no,C0683519;C0730226;C0850708;C0944983
did not meet atopy and ige $nmbr$ $nmbr$ ku lcriteriaa n $nmbr$ $nmbr$,C0392707;C3539705;C0022804;C1337080;C1532717;C1881335
history of cardiovascular disease no ^,C0455539
ige high $nmbr$ ku l n $nmbr$ $nmbr$,C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
igelow n $nmbr$ $nmbr$,
history of amputation no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
atopy n $nmbr$ $nmbr$,C0392707;C3539705
ratio of ldl to hdl,C0456603;C1547037;C3715113
no atopy n $nmbr$,C0392707;C3539705
egfr ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
albumin measurements^^,C0201838
body mass index kg m $nmbr$ mean sd c,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
median albumin to creatinine ratio interquartile range,C0486293;C1711350;C1318293
eosinophil count cells pl median range c,C0200638;C0750879
normoalbuminuria no total no,C0439175;C0439810
fev $nmbr$ pre bronchodilator l mean sd c,C2599602;C0444504;C2347634;C2348143
microalbuminuria no total no,C0730345;C0439175;C0439810
fev $nmbr$ pre bronchodilator predicted normal mean sd c d,C0520835;C2599602
macroalbuminuria no total no,C0439175;C0439810
reversibility median range c,C0449261;C0549183;C0876920;C2347635;C2348144;C2939193
canagliflozin,C2974540
exacerbations in previous $nmbr$ mo n mean sd,C4086268;C0026544;C0332177
no of participants per $nmbr$ patient yr,C0679646;C0030705;C0439234
acq $nmbr$ score mean sd e,C0449820;C0444504;C2347634;C2348143;C4050231
canvas,C3281223
aqlq s $nmbr$ score mean sd c f,C0444504;C0016327;C2347634;C2348143
canvas r,C0205090;C0684010;C2603358
atopy by phadiatop test n,C0392707;C3539705
central america and south america,C0007674;C0037713
ige ku l median range c,C0439340;C0549183;C0876920;C2347635;C2348144;C2939193
systolic blood pressure $nmbr$ mm hg or diastolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620;C0428883;C1305849
nasal polyps n,C0027430
history of amputation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
maintenance ocs use n,C0024501;C0042153;C0457083;C1947944
insulin use,C0240016
ige low $nmbr$ ku l n $nmbr$ $nmbr$,C0205251;C0439340;C1550472;C3890211;C4048187;C4321351;C4522223
antithrombotic use,C0042153;C0457083;C1947944
annual asthma exacerbation rates,C0871208;C1521828
raas inhibitor use,C0042153;C0457083;C1947944
patients analyzed n,C0030705;C0936012
diuretic use,C0042153;C0457083;C1947944
rate estimate $nmbr$ ci,C0008107;C3259781
hba $nmbr$ ca mmol mol,C0019016;C1825777;C3538758;C3829066
absolute difference estimate vs placebo $nmbr$ ci,C1549031;C0750572;C0008107;C3259781
time since diagnosis of diabetesa n,C0040223;C3541383
rate ratio vs placebo $nmbr$ ci,C0871208;C0456603;C1547037;C1521828;C0008107;C3259781
systolic blood pressurea mm hg,C0005767;C0439475;C0005768;C0229664
nominal p vs placebo,C0032042;C1696465;C1706408
pre bronchodilator fevi change,C2599602;C3481639
diastolic blood pressurea mmhg,C0005767;C0439475;C0005768;C0229664
patients in analysis n,C0030705;C0002778;C0936012;C1524024
egfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
patients with eot data n,C2707520
egfr ckd epi cystatin c ml min $nmbr$ $nmbr$ m $nmbr$,C0071744;C0439445;C1413772
ls mean difference vs placebo $nmbr$ ci,C0444504;C1705241;C1705242;C2347634;C2348143;C0008107;C3259781
egfr ckd epi cystatinc ml min $nmbr$ $nmbr$ m $nmbr$ n,C0162734;C0439445;C4281721;C0369718;C0441922
igelow,
uacra mg g gmean gcv,C1300563;C0017066
absolutedifferenceestimate vs placebo $nmbr$ ci,C0008107;C3259781
uacra mg g n,C1300563
montelukast n $nmbr$,C0298130
oral antidiabetes monotherapya n,C0442027;C4521986
lebrikizumab n $nmbr$,C2981360
oral antidiabetes combination therapy without insulina n,C0009429;C0556895
pre bronchodilator fev $nmbr$,C2599602;C3714541
insulina n,
absolute litres,C0205344;C0475211
antihypertensive therapy n,C0585941
aqlq s score,C0449820;C4050231
^ blockers,
median serum periostin ng mla,C0017887;C0599973;C0028074
number of participants,C0237753;C0449788
median feno ppba,C0549183;C0876920;C2347635;C2348144;C2939193
baseline hbalc $nmbr$ $nmbr$ $nmbr$ mmol mol $nmbr$,C0168634;C3829066;C1442488
baseline uacr,C0168634;C1442488
median blood eosinophil count cells per pla,C0200638;C0456170
baseline uacr $nmbr$ mg g,C0168634;C1300563;C1442488
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl na,C0005516;C0439275;C0005773
normoalbuminuria at baseline $nmbr$ of patients treated,C0168634;C0030705;C1442488;C1522326
biomarker low periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl na,C0005516;C0439275;C0005773
microalbuminuria at baseline $nmbr$ of patients treated,C0730345;C0030705;C1522326
saba puffs per day at baseline,C1533107;C0332173;C0439228;C0439505;C0168634;C1442488
macroalbuminuria at baseline $nmbr$ of patients treated,C0168634;C0030705;C1442488;C1522326
fig $nmbr$ absolute change in fev $nmbr$ from baseline at week $nmbr$ mitt patients top biomarker high group middle biomarker low group bottom,C0349966;C1549031;C1337208;C0168634;C1442488
empagliflozin n $nmbr$,C3490348
ltg subgroup n $nmbr$,C1420817;C1079230;C1515021;C4521367;C4521846
other or missing data,C4684714
tpm subgroup n $nmbr$,C0076829;C1079230;C1515021
ldl cholesterolt,
brv overalla n $nmbr$,C0155502
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ t,C0439445;C0369637;C0441923
whiteb,
medical history of diabetic retinopathy,C0262926;C0011884
regions n,C0017446;C0205147
patients with normoalbuminuria at baseline,C0030705;C0168634;C1442488
age at time of first seizure,C0001779;C0036572;C1959629;C4553401
patients with microalbuminuria at baseline,C0030705;C0730345;C0168634;C1442488
lev status,C0023556;C0449438
patients with macroalbuminuria at baseline,C0030705;C0168634;C1442488
previous lev only,C0205156;C0023556;C1552607
n analysed,C0369718;C0441922
number of concomitant aedsc,C0237753;C0449788
uric acid tertile $nmbr$ $nmbr$ $nmbr$ mg dl,C0041980;C0439269
aed inducer status,C0887457;C0449438
uric acid tertile $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg dl,C0041980;C0439269
no inducer at core study entry,C3898767;C0444669;C1167518;C1706352;C1882467;C3274653
characteristic no,C1521970
no of prior aedsd,C0332152;C2826257
digoxin n $nmbr$ $nmbr$,C0012265
seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
no digoxin n $nmbr$ $nmbr$ $nmbr$,C0012265
type ia,C0020980;C0694634;C1947960
white race n $nmbr$ $nmbr$,C0007457;C0043157
type ib,C2744579;C3890035;C4283819
type of atrial fibrillation n $nmbr$ $nmbr$,C0332307;C1547052
type ic,C0020750;C4554818
qualifying risk factor,C1514624;C0035648
baseline weight kg,C0022718;C0439209;C4054209
coronary artery disease n $nmbr$ $nmbr$,C0010054;C0010068;C1956346
region pooled,C0017446;C0205147;C1709595;C2349200;C4522255
nyha iii or iv n $nmbr$ $nmbr$,C0439070;C1705160;C0022326;C4265176
usa and canada,C0041703;C0006823
peripheral arterial disease n $nmbr$ $nmbr$,C0085096;C1704436
seropositivity,
former current smoker n $nmbr$ $nmbr$,C0337671
rf or acpa positive,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
mitral valve disease n $nmbr$ $nmbr$,C0026265;C4553832
rf and acpa negative,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
aortic valve disease n $nmbr$ $nmbr$,C1260873;C4553103
no of prior bdmards,C0332152;C2826257
prior electrical cardioversion for af n $nmbr$ $nmbr$,C0013778;C0542380
no of prior tnfi,C0332152;C2826257
charlson comorbidity index mean sd,C4546361;C2699239
prior tnfi treatment,C1514463
heart rate mean sd bpm n $nmbr$ $nmbr$,C0018810;C0444504;C2347634;C2348143
etn yes,C1549445;C1705108;C1710701
hypertrophy per ecg n $nmbr$ $nmbr$,C0020564;C1623258
etn no,C0014758;C0717758
vitamin k antagonist experiencedk n $nmbr$ $nmbr$,C1096489;C2267235
ada yes,C1549445;C1705108;C1710701
antiarrhythmics,C0003195
ada no,C1060325;C3811629
class ii b blockers,C0441886;C2698968
inflix yes,C1549445;C1705108;C1710701
raas inhibitor,C1999216
inflix no,C0666743
high dose edoxaban,C0444956;C2975435
no of non tnfi,C1518422
low dose edoxaban,C0445550;C2975435;C1708745
no of tnfi among non tnfi naive,C1518422
digoxin scd no y,C0012265
bdp ff g n $nmbr$,C0004906;C0439267;C1422585;C1538710
no digoxin scd no y,C0012265
blood leukocyte count $nmbr$ cells per l,C0005771;C0009555
persistent permanent,C0205322;C0205355;C0332996
blood eosinophil count $nmbr$ cells per l,C0200638
t mean,C0444504;C2347634;C2348143
blood eosinophil,C0014467
lv hypertrophy per ecg,C0232306
fev_ l,C3714541
b blockers at baseline,C0168634;C1442488
proportion of predicted normal fev $nmbr$ value,C1709707;C0086715
diuretic use at baseline,C0042153;C0457083;C1947944
clinical copd phenotype^,C0031437;C1285572
normal responders n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
mixed chronic bronchitis and emphysema,C0205430;C0008677;C3160715;C0013990;C0034067
sensitive responders n $nmbr$,C0020517;C0332324;C1522640
moderate or severe exacerbations in the previous year range,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
highly sensitive responders n $nmbr$,C0439822
copd medication taken for at least $nmbr$ months before st,C0013227;C3244316;C4284232;C1883727;C0439231;C0036056;C3272372
age year mean sd,C0001779;C2699239
udy entry,C1705654
creatinine clearance ml min mean sd,C0439445;C2699239
benign prostatic hyperplasia,C1704272
edoxaban dose adjusted at randomisation n,C0178602;C0869039;C1114758;C0456081;C0034656
overall pp n $nmbr$,C0030375;C0063017;C4319755
bleeding events during first $nmbr$ days of treatmen,C0441471;C3541888
sensitivity analyses,C0020517;C0036667;C0312418;C0427965;C1511883;C1522640;C2346484;C2349185
t,C2603360
mar itt n $nmbr$,C3829202;C4255469
bleeding events during the entire study,C0441471;C3541888
cr itt n $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
adj hr $nmbr$ cl a,C0001552;C0596019;C2826286
post bronchodilator fev $nmbr$ at screening,C2599594;C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
p b int,C1539794;C3272375
males n $nmbr$,C0086582
total bleeds,C0232100
females n $nmbr$,C0086287
major and crnm bleeds,C0205082;C0205164;C4318856;C4521762;C0019080
ex smokers n $nmbr$,C0337671;C4555205
laba ics n $nmbr$,C0815320;C4551720
current smokers n $nmbr$,C3173209;C3241966
laba or lamab n $nmbr$,
reversibility $nmbr$ n $nmbr$,C0449261
ind glyb n $nmbr$,C4049864;C1415124
chronic bronchitis n $nmbr$,C0008677
post bronchodilator fev $nmbr$ predicted of normal value,C0681842;C1882327
emphysema n $nmbr$,C0013990;C0034067
dyspnoea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
mixed n $nmbr$,C0205430;C3160715
number of exacerbation in the previous $nmbr$ months n,C0237753;C0449788;C0205156;C0439231;C1552607
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ l n $nmbr$,C0014467;C0200638
baseline treatments n a,C0168634;C0087111;C1442488
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
lama only monotherapy,C0999593;C1416775
prediabetese,
laba only monotherapy,
prior admb,C0332152;C2826257
laba ics free or fixed dose combination,C0332296;C1880497;C1996904;C0178602;C0205195;C1947911;C3811910;C0869039;C1114758
no prior admc,C0332152;C2826257
othersc,
all diabetesd,
laba ics versus indzgly lsm difference $nmbr$ cl,C0815320;C4551720;C1705241;C0596019;C1705242
dmab n $nmbr$,C0012411
indzgly,
white or caucasian n,C0007457;C0043157;C0220938
exacerbations in the previous year,C4086268;C0205156;C1552607
serum ctx i ng ml,C0631180;C0439275
fev $nmbr$ at baseline,C3714541;C0168634;C1442488
$nmbr$ oh vitamin d ng ml,C0014695;C0439275;C0042866;C2936842;C3537249;C3714503
mmrc at baseline,C3826977;C0168634;C1442488
baseline use of adm n,C0168634;C1524063;C1442488
form bud,C2700462;C2945744
insulins,C0021641;C3537244;C4049919
sfc,C4521536
a glucosidase inhibitors,C1512211
laba or lama,C0999593;C1416775
meglitinides glinides,C0065880;C3537178;C1579432
ind gly,C0017890;C0523677
baseline numberf of adm classes n,C0168634;C0215825;C4521767;C1442488
laba or lama versus ind gly lsm difference $nmbr$ cl,C0999593;C1416775;C0017890;C0596019;C0523677
all dulaglutide $nmbr$ $nmbr$ mg insulin lispro insulin glargine n $nmbr$,C0907402
fev at baseline,C3714541;C0168634;C1442488
pooled itt,C1709595;C2349200;C4522255
insulin glargine insulin lispro award $nmbr$ n $nmbr$,C0293359
cat $nmbr$ n $nmbr$ $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
placebo insulin glargine award $nmbr$ n $nmbr$,C0907402;C0004446
median y range,C1514721;C2348147;C3542016
ef $nmbr$ $nmbr$ hfmref n $nmbr$ $nmbr$,
ef $nmbr$ hfpef n $nmbr$ $nmbr$,
mean mmrc grade units sd,C0439148;C2699239;C1519795;C3853603
physical exam oedema,C0013604;C1717255
mean sgrq total score,C3533236
creatinine mg dl_,C0010294;C0439269;C1561535
use of ics at baseline,C1524063;C0815320;C4551720;C0168634;C1442488
hf cause,C0015127;C1524003
mean copd duration y sd,C0024117;C2699239;C1412502;C3714496
previous hf,C0018488;C1313497;C1538440;C3273279
mean number of exacerbations in previous y sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
af,C0344434;C4049859
mean postbronchodilatora fev $nmbr$ predicted sd,C0444504;C2699239;C2347634;C2348143
other vasodilator,C0042402;C3537240
reversible to bronchodilator b,C0205343;C0006280
anti arrhythmic,C0003195;C3537142
favors comparator,C1707454;C4553389;C4553390
ef $nmbr$ $nmbr$,
gff mdi,C0993596;C1839839;C4049613
ef $nmbr$,
gp mdi,C0993596;C1839839;C4049613
cv death hf hospitalization,C0011065;C0019993;C1306577;C4082313;C4552775
ff mdi,C0993596;C1839839;C4049613
incidence rate,C1708485
placebo mdi,C0993596;C1839839;C4049613
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$ $nmbr$,
cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
unadjusted irr,C1439367;C4082285
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
azl m $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
age mean sd yearsa,C0001779;C0444504;C2347634;C2348143
empagliflozin $nmbr$ mg day n $nmbr$,C3490348;C0439422
weight mean sd kgb,C0005910;C0043100;C1305866;C1705104
parameters at baseline,C0449381;C0168634;C1442488
bmi mean sd kg m $nmbr$ c,C0444504;C1532718;C2347634;C2348143
a bmi subgroups,C0578022;C1079230
concomitant medication n d,C0521115;C0013227;C3244316;C4284232
b age subgroups,C1304659;C0001779
medication continued into double blind treatment period,C0013227;C3244316;C4284232;C0549178;C0013072
empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fpg,
initiated use during double blind treatment period,C0042153;C0457083;C1947944
n $nmbr$ l $nmbr$,C0369718;C0441922
smoking classification n,C0008902;C0008903;C0678229
n l $nmbr$,C0369718;C0441922
scsbp mean sd mmhge,C0444504;C2347634;C2348143
baseline cardiac biomarkers elevated,C2735101;C2735102;C0205250;C3163633
scdbp mean sd mmhgf,C0444504;C2347634;C2348143
tobacco abuse,C0040336
prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
radial access site,C0442038;C0589360;C0920847
no prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
$nmbr$ vessels with $nmbr$ stenosis,C0679403
age median $nmbr$ th $nmbr$ th y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
$nmbr$ vessels treated,C0005847;C1522326
history of diabetes mellitus no,C0455488
treatment with drugeluting stent,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
prior mi within $nmbr$ y no,C0332152;C3810814;C2826257
baseline aspirin dose,C0168634;C4696290;C1442488
history of pvd no,C4534349
intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
history of hf or lvef b $nmbr$ with index event no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0428772;C0441471;C4019010;C0488728
clopidogrel dose on before pci,C0178602;C0869039;C1114758;C4049621
history of impaired renal function no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
bivalirudin used during pci,C0168273;C1273517;C4049621
no revascularization for index acs event no,C0581603;C0441471;C4019010
gpi used during pci,C1415351;C1273517;C4049621
hf,C0018488;C1313497;C1538440;C3273279
duration from hospital admission to pci h median iqr,C0449238;C2926735;C0033727;C0369286;C0441932;C0564385;C4528284
revascularization history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
duration from clopidogrel placebo to pci min median iqr,C0449238;C2926735;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pci duration in min median iqr,C0449238;C2926735
cabg history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
death mi idr or st,C0011065;C1306577;C4082313;C4552775;C0036056;C3272372
acs management no,C0001554;C0376636;C1273870;C3273539
st arc definite only,C0036056;C3272372;C0439544;C1704787
dual antiplatelet therapy,C0205173;C1096021;C1554184
gusto moderate severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
cardiovascular death mi or stroke,C0007226;C3810814;C3887460;C0038454;C4554100
timi major minor,C4441842
timi major minor bleeding,C4441842;C0019080
death mi idr st or gusto severe bleeding,C0036056;C3272372;C0205082;C0019080;C4050465;C4050466
any bleeding,C0019080
death mi idr st or gusto moderate severe bleeding,C0036056;C3272372;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
all death,C0011065;C1306577;C4082313;C4552775
death mi idr st or any timi bleeding,C0036056;C3272372;C0019080
six study placebo controlled set,C0036849;C1442518;C1705195
p value nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
ra beam,C0338248;C2347880;C4521565
net composite,C0205199;C1547335
all baricitinib ra n $nmbr$,C4044947;C3538806;C4048756
death mi idr st or gusto mod sev bleeding,C0036056;C3272372;C0011860;C0019080
$nmbr$ years of age n,C1510829
pah ctd,C1335071;C1442905
tobacco use yes n,C0040335;C0543414;C0841002;C3853727
pah ssc,C0030123;C3897657;C3203102;C4284467
duration of rat years,C0449238;C2926735
pah sle,C0030123;C0024141;C3203102;C4284467
central south america and mexico,C0007674;C0025885
pah mctd ctd other,C1335071;C1442905
asia excluding japan,C0003980;C0022341
age years geographic region,C1510829;C0017446
hscrp mg l median first third quartiles,C0439268;C2828255
time since diagnosis of pah years,C0556970;C0011900;C1704338;C1704656
baricitinib $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
use of medication for pah,C1524063;C0030123;C3203102;C4284467
non statin n $nmbr$,C1518422;C0360714
era,C1521863;C3495919
patients with draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
pde $nmbr$ i,C0021966;C0221138
patients without draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
era and pde $nmbr$ i,C1521863;C3495919;C0021966;C0221138
vdz pbo [n $nmbr$ ],C0031962;C0369718;C0441922
other medications,C0013227;C0802604;C2598133;C4284232
vdz vdz [n $nmbr$ ],C0369718;C0441922
corticosteroids $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
age [year] mean sda,C0001779;C0439234;C0439508;C0276477;C1428349;C1553165
placebo patients events n,C0032042;C0030705;C1696465;C1706408
male sex n [ ],C0086582
selexipag patients events n,C0030705;C0441471;C3541888
current smoker n [ ],C3173209;C3241966
overall study population,C0282416;C2348561;C1561607
disease duration [year] mean sda,C0872146;C0439234;C0439508;C0276477;C1428349;C1553165
overall ctd,C1335071;C1442905
cdai score mean sda,C0276477;C1428349;C1553165
pde $nmbr$ i monotherapy,C0021966;C0221138
crp [mg l] median,C3890735;C4048285;C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
no pah specific therapy,C0039798;C0087111;C1363945
disease site n [ ],C0012634;C0205145;C1515974;C2825164
ctd population subgroup,C1079230;C1515021
prior surgery for cd n [ ],C0455610;C0007928;C0034283;C4552032
pah ssc systemic sclerosis,C0030123;C0036421;C3203102;C4284467
prior tnf antagonist failure n [ ],C0231491;C0231174;C0680095
pah sle systemic lupus erythematosus,C0030123;C0024141;C3203102;C4284467
concomitant medication n [ ],C0521115;C0013227;C3244316;C4284232
pooled pah mctd and pah,C0030123;C0026272;C3203102;C4284467
cs,C0010182;C0271160;C3540510;C4085345
years since pd diagnosis mean sd,C0439234;C0011900;C1704338;C1704656
imm,C0205470
duration of disease n,C0872146
cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
hoehn yahr stage on n,C0205390;C1300072;C1306673
neither cs nor imm,C0010182;C0271160;C3540510;C4085345;C0205470
hoehn yahr stage off n,C0205390;C1300072;C1306673
history of fistulising disease n [ ],C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
levodopa dose mean sd mg day,C0023570;C0439422
concomitant antibiotic use n [ ],C0003232;C0042153;C0457083;C1947944
concomitant pd medications at baseline n c d,C0013227;C0802604;C2598133;C4284232
number of draining fistulae per patient n,C0237753;C0449788;C0013103;C0180499;C4265177;C0016169;C0030705
tertiary amines,C3653356
[ ],
dopa and dopa derivativese,C0013023
patients with perianal fistulae n [ ],C0030705;C0267561
adamantane derivatives,C3653470
psa ng ml,C3810537;C0439275;C3813209
entacapone,C0165921
drinker n,C0556338
monoamine oxidase b inhibitors,C2917290;C3653412
ex drinker,C0337679
daily off time mean sd h dayf,C0332173;C0033727;C0369286;C0441932;C0564385;C4528284
underlying disease,C4067746;C0012634
mean sd baseline score,C3533236;C0168634;C1442488
erectile dysfunction,C0242350;C1961100
mean sd change from baseline to eom,C0392747;C0443172;C1705241;C4319952;C0241886
pde $nmbr$ inhibitors,C0031638
ls mean [ $nmbr$ ci] treatment difference vs placebo,C0444504;C2347634;C2348143;C0008107;C3259781;C1705241;C1705242;C0032042;C1696465;C1706408
irritative subscore,
p value ancova treatment difference a,C1705241;C1705242
obstructive subscore,C0549186
number of off periods,C0237753;C0449788;C0439531;C1948053
qol,C0518214
absolute time spent on h day,C0439546;C0680968;C0033727;C0369286;C0441932;C0564385;C4528284
voided volume ml,C0439526;C1705224;C3887665
absolute time spent on without troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
pvr ml,C0439526;C1705224;C3887665
absolute time spent on with troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
tamsulosin $nmbr$ $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
patient status after wake up of days patient woke off,C0449437;C1170730;C0442696;C0585034
tamsulosin $nmbr$ $nmbr$ mg vs $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patient status after wake up of days patient woke on without troublesome dyskinesia,C0449437;C1170730;C0442696;C0585034;C0013384
t $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ baseline,C0168634;C1442488
patient status after wake up of days patient woke on with troublesome dyskinesia,C0449437;C1170730;C0442696;C0585034;C0013384
ancova result,C1274040;C1546471;C2825142
updrs iii motor,C1513492;C1705994
ls mean difference se,C0023668;C0036919
overall $nmbr$ $nmbr$,C0282416;C1561607
with ckd $nmbr$,C1561643
participants with heart failure,C0679646;C0018801;C0018802;C4554158
without ckd $nmbr$,C1561643
participants without heart failure,C0679646;C0018801;C0018802;C4554158
mean or n,C0444504;C2347634;C2348143;C0369718;C0441922
p value heart failure vs no heart failure,C0018801;C0018802;C4554158
sd or,C2699239
duration of diabetes mellitus y mean sd,C0449238;C2926735
latin,
microvascular disease history n,C0443258;C0683519
median urine acr mg g iqr,C0042036;C1300563;C0042037;C2963137
atherosclerotic vascular disease history n t,C0004153
median fasting serum glucose mg dl iqr,C0202041;C0439269;C3534430
cardiovascular disease history n,C1880008
glycemic status,C0449438
history of amputation n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
igt ifg,C1334085;C1708411
ldl hdl cholesterol ratio mean sd,C0428621;C2699239
other glucose status,C0017725;C0449438
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C3811844;C0439445;C0444504;C2699239;C2347634;C2348143
dcct a $nmbr$ c,
micro or macroalbuminuria n,C0085672;C1553035;C3811161;C4049106
duration dm in dm years,C0011816;C0439234;C3250443
concomitant drug therapies n,C0013216
pulse pressure mm hg,C0949236;C0439475
renin angiotensin aldosterone system blocker,C0086907
median pulse pressure mm hg iqr,C0949236;C0439475
glucagon like peptide $nmbr$ receptor agonist,C0014361;C4543206
n $nmbr$ fatty acids,C0369718;C0015684;C0441922
patients per $nmbr$ patient years,C0030705;C0439234
no glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
ard $nmbr$ cl per $nmbr$ patient years,C0596019;C0030705
other bp drug,C0013227;C1254351
cardiovascular death or hospitalized hf,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
median tg iqr,C0549183;C0337445;C0876920;C2347635;C2348144;C2939193
no history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ckd rate events,C0441471;C3541888
fatal or nonlatal myocardial inlarctlon,C1302234;C1705232;C0027061;C1522564
no ckd rate events,C0441471;C3541888
fatal or nonlatal stroke,C1302234;C1705232;C0038454;C4554100
cv death non fatal mi or non fatal stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
serious decline in kidney function $nmbr$,C0205404;C0232804
secondary outcome,C0027627;C1274040;C0175668;C0205436
number of previous anti tnf treatments for psa n,C0237753;C0449788;C1448177;C0087111
stroke any,C0038454;C4554100
time since diagnosis of psa years mean sd,C0556970;C0011900;C1704338;C1704656
stroke non fatal,C0038454;C4554100;C1518422;C1302234;C1705232
mtx use at randomization n,C0042153;C0457083;C1947944
primary outcome plus revascularization or nonfatal hf,C0205225;C1274040;C0439612;C0439631;C0018488;C1313497;C1538440;C3273279
systemic glucocorticoid use at randomization n,C0042153;C0457083;C1947944
major coronary disease event fatal non fatal mi,C0741923;C3810814
patients with specific disease characteristics n,C0683521;C0815172
ckd n,C1561643
psoriasis $nmbr$ of bsa,C0033860
no ckd n,C1561643
presence of dactylitis,C0150312;C0392148;C3854307
$nmbr$ yrs or more,
presence of enthesitis,C0150312;C0392148;C3854307
diabetes melitus,C0011847;C0011849
disease and quality of life scores mean sd,C0012634;C3476431;C2699239
treatment glargine,C0039798;C0907402;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pasia,
rivaroxaban plus aspirin n $nmbr$,C1739768;C0004057
psa pain vas,C3810537;C0042815;C3813209
rivaroxaban alone n $nmbr$,C0205171;C0439044;C0679994
all doses n $nmbr$,C0178602
tobacco use no,C0040335;C0543414;C0841002;C3853727
alcohol use $nmbr$ day,C0332173;C0439228;C0439505
heart failure no,C0018801;C0018802;C4554158
daily exercise,C0015259;C1522704
estimated gfr no $nmbr$,C0017654;C1424601
impaired fasting glucose $nmbr$ mg dl,C1272092;C0439269
western europe israel australia or south africa,C0043128;C0037712
canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
nontrial ppi,C0358591;C0871125;C3811894
all canakinumab,C2718773
rivaroxaban aspirin,C1739768;C0004057
n events n at risk,C0369718;C0441471;C3541888;C0441922;C1444641
hazard ratio for cardiovascular death stroke or myocardial infarction $nmbr$ ci,C2985465;C0027051;C0008107;C3259781
hazard ratio $nmbr$ ci vs placebo,C0008107;C3259781;C0032042;C1696465;C1706408
baseline tobacco use,C0040335;C0543414;C0841002;C3853727
p value vs placebo,C1709380;C0032042;C1696465;C1706408
baseline dyslipidemia,C0168634;C0242339;C1442488
baseline prediabetes,C0168634;C0362046;C1442488
socalone n $nmbr$,
baseline normoglycemia,C0168634;C1442488
evolocumab soc n $nmbr$,C3529352
hazard ratio vs placebo,C2985465;C0032042;C1696465;C1706408
type $nmbr$ diabetes mellitus $nmbr$,C1320657
p heterogeneity,C0019409;C0242960
high risk of diabetes,C0332167
hazard ratio $nmbr$ ci for adjudicated type $nmbr$ diabetes,C0008107;C3259781
cerebrovascular or peripheral arterial disease,C1880018;C0085096;C1704436
risk marker and model,C1519104;C3161035;C3274659;C3714583;C3853906
fasting plasma glucose mmol l $nmbr$,C0202042;C1532563;C0455280
hscrp range mg l,C1514721;C0439268;C2348147;C3542016
fasting plasma glucose mg dl $nmbr$,C0202042;C0439269;C0455280
model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
visit,C0545082;C1512346;C2826704
il $nmbr$ range ng l,C0020898;C0439297;C0021764;C0022271
ldl c in mmol l baseline mean sd [n] wk $nmbr$ and change mean se [n],C1532563;C0168634;C1442488;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fasting plasma glucose in mmol l median q $nmbr$ q $nmbr$ [n],C0583513;C1532563
week $nmbr$ czp $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c in median q $nmbr$ q $nmbr$ [n],C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
weight in kg baseline mean sd [n] wk $nmbr$ and change mean se [n],C0022718;C1303013;C0439209;C4054209;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
demographic characteristics mean sd unless otherwise indicated,C0683970;C2699239;C1444656
soc,
mean sd unless otherwise indicated,C0444504;C2699239;C2347634;C2348143;C1444656
evomab soc,
time from psoriatic arthritis diagnosis [a] years,C0040223;C3541383;C0439234
change to week $nmbr$,C0392747;C0443172;C1705241;C4319952
crp mg l [b] median min max,C3890735;C0439268;C4048285;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
[ $nmbr$ [,
tender joint count $nmbr$ $nmbr$ joints,C0451530
ldl c in mmol l mean sd for baseline [n] mean se for week $nmbr$ [n],C1532563;C0444504;C2347634;C2348143;C0168634;C1442488;C0369718;C0441922;C0036919;C0332174;C0439230
swollen joint count $nmbr$ $nmbr$ joints,C0451521
any placebo,C0032042;C1696465;C1706408
psoriasis bsa $nmbr$ n,C0033860
evomab,
[ $nmbr$,
pasi [c] median min max,C4528685;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
high risk for diabetes,C0332167;C3272283;C4050568;C4319571
prior use of synthetic dmards n,C1524063;C0242708
enrolled into osler,C4684790
concomitant use of nsaids to week $nmbr$,C1524063;C0003211;C0332174;C0439230
did not enrol into osler,C1518422
prior anti tnf exposure,C0332152;C2826257
phi n $nmbr$,C1333690;C1704947;C1706536;C2975867;C4084801
concomitant use of mtx to week $nmbr$,C1524063;C0025677;C1417487;C0332174;C0439230
ppci n $nmbr$,
week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous angina pectoris,C0205156;C0002962;C1552607
week $nmbr$ czp dose combined,C0178602;C0869039;C1114758;C0205195
previous coronary intervention,C0184661;C0886296;C1273869
pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C1861828;C1872109;C0205195
family history of coronary disease,C0850707
mtss at baseline observed case,C0168634;C0868928;C1706255;C1706256;C1442488
high risk $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
n observed,C0369718;C0441922;C1441672
[min max],C0702093;C1524029;C3813700
red blood cell counting $nmbr$ l,C0014792;C0750480;C1705566;C0439394;C1706495;C3642217
mmrm estimates ls mean se [ $nmbr$ ci],C0008107;C3259781
platelet $nmbr$ l,C0456525
mtss at,
mean platelet volume fl,C1300812;C1708024
czp baseline,C0168634;C1442488
scr gmol l,C1539487;C4050416
cfb at week $nmbr$,C0009002;C1824728
ppci in $nmbr$,
observed case,C0868928;C1706255;C1706256
no of panents total no $nmbr$,C0439175;C0439810
rate of non progression defined as cfb in mtss $nmbr$ $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
overal event rate,C0871208;C1521828
$nmbr$ $nmbr$ hr,
rate of non progression defined as cfb in mtss $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
blisibimod n $nmbr$,C3713826
iiiv,
gender female male,C0086582;C1706180;C1706428;C1706429
anacetrapib n $nmbr$ $nmbr$,C2604745
central and south america,C0205099;C1879652;C0037713
previous disease no f,C0205156;C0012634;C1552607;C0016327
selena sledai mean score sd,C3533236;C2699239
mean mm hg,C0444504;C0439475;C2347634;C2348143
selena sledai activity n,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
level no,C0441889;C0456079;C1547707;C2946261
total score $nmbr$,C2964552
lipid difference mg dl,C0023779;C0439269
dermal,C0221928;C1522447
no of participants with events,C0679646;C0441471;C3541888
bilag a b or c domain score n,C1880389;C0449820;C4050231;C1883221;C3541951
anacetrapib n $nmbr$,C2604745
haematological,
rate ratio,C0871208;C0456603;C1547037;C1521828
pga score mean sd,C0016410;C2699239;C3541266;C4050369
age at randomization years,C1510829;C0034656
pga score range,C1514721;C2348147;C3542016
prior disease,C0332152;C0012634;C2826257
corticosteroid dose prednisone,C0001617;C0032952;C3536709
time since qualifying event,C0040223;C3541383;C1514624;C0441471;C4019010
dose equivalent mg sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
waisthip ratio,C0456603;C1547037
smedian prednisone dose n,C0032952;C0178602;C0869039;C1114758
current drinker,C0556297
systemic sle medications n,C0024141;C0013227;C0802604;C2598133;C4284232
former non drinker,C0205156;C0457801;C0750523
any including corticosteroid,C0001617;C3536709
medication,C0013227;C3244316;C4284232
antimalarial,C0003374;C3536844;C4552582
apolipoprotein a $nmbr$ mg dl,C0003592;C0439269;C0523508
mycophenolate any derivative,C0883242;C1527240
glomerular filtration rate ml min $nmbr$ $nmbr$ ma,C0024443;C3887485
sle markers n,C0024141;C0005516
urinary albumimcreatinine ratio,C0456603;C1547037
anti dsdna positive,C0439178;C1446409;C1514241;C2825490;C3812269
micro albuminuria,C0085672;C0001925;C1553035;C3811161;C4049106
low c $nmbr$ c $nmbr$ and anti dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0012854;C0311474
macro albuminuria,C2984010;C0001925
upcr n,
gly $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
s $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
severity of copda airflow limitation n,C0439793;C0522510
s $nmbr$ mg mmol,C0567349;C2348885
severity of copda combined assessment of copd n,C0439793;C0522510
patients without diabetes,C0030705;C0011847;C0011849
discontinuation of lama prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
patients with diabetes,C0030705;C0011847;C0011849
discontinuation of ics laba prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
previous hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
pre bronchodilator fev i l,C2599602;C0021966;C0221138
ntprobnp pg ml,C0669479;C0439297;C0754710
post bronchodilator fevx l,C2599594
treatments at randomisation,C0087111;C0034656
post bronchodilator fev i reversibility b,C2599594;C0021966;C0221138
difference $nmbr$ ci p value,C0008107;C1709380;C3259781
fev auc i $nmbr$ h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p,C0369773;C2603361
ics use yes,C1549445;C1705108;C1710701
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
ics use no,C0042153;C0457083;C1947944
characteristic outcome,C1521970;C1274040
$nmbr$ bmi kg m,C0022718;C0439209;C4054209
nonblack n $nmbr$,
standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
renal function egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0232804;C0439445
ace inhibitors and arb,C0003015;C3888198
bnp nt probnp,C0669479;C0754710
insulin na ive,C3435805;C4554334
qrs duration ms,C2349943;C3539704;C3713294
not treated,C1518422;C1522326
egfr ml kg per $nmbr$ $nmbr$ m $nmbr$,C1739039;C1300574;C3811844;C3812682
insulin oad,C0021641;C1533581;C1579433;C3714501
hf signs and symptoms,C0220912;C0220913;C0311392;C0683368;C1457887
combined estimated gfr and albuminuria status,C0017654;C1424601;C0001925;C0449438
paroxysmal nocturnal dyspnea,C1956415
estimated gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ and microalbuminuria or macroalbuminuria,C0017654;C0439445;C1424601;C0730345
not present at screening but within previous year,C0150312;C0449450;C0205156;C0439234;C0439508;C1552607
present at screening,C0150312;C0449450
estimated gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ or no microalbuminuria or macroalbuminuria,C0017654;C0439445;C1424601;C0730345
tiotropium group n $nmbr$,C0213771;C0441848
chest x ray,C0039985
former smoking,C0037369;C0453996;C1881674
comorbid illnesses,C0221423
smoking index pack yr,C0037369;C0439234;C0453996;C1881674
any cvd history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
duration of copd days^,C0449238;C2926735
insulin treated dm,C0011816;C3250443
previous respiratory disease other than copd no,C0035204;C0035242
non insulin treated dm,C0011816;C3250443
previous medication for respiratory disease no,C0418986
adjusted hazard ratio or interaction p value,C0456081;C2985465;C1704675;C1709380
traditional chinese medicine for respiratory disease no,C0025124;C1515884
black n $nmbr$ adjusted hazard ratio,C0456081;C2985465
spirometric values at baseline,C0042295;C0168634;C1442488
nonblack n $nmbr$ adjusted hazard ratio,C0456081;C2985465
before bronchodilator use,C0042153;C0457083;C1947944
sc belimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
after bronchodilator use,C0042153;C0457083;C1947944
sri $nmbr$ response rate,C1420401;C0237629
airflow reversibility no,C0231999;C0449261
$nmbr$ point reduction in selena sledai score,C0301630;C0392756;C1293152;C4551656
gold stage no,C0205390;C1300072;C1306673
no worsening in pga,C0332271;C0016410;C3541266;C4050369;C1457868;C1546960
cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
no new a or and no more than $nmbr$ new bilag b domain score,C0205314;C0449820;C4050231
mmrc dyspnea scale score t t,C0013404;C4049715;C1963100
baricitinib $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ccq score,C0449820;C4050231
us w $nmbr$,C0815353;C3889164
follow up,C0589120;C1522577;C1704685;C3274571
row n $nmbr$,C1552840;C1552846
difference tiotropium placebo ml $nmbr$ ci,C0008107;C3259781
body mass index kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
p values,C1709380
time from symptom onset of ra years median,C1320528
pre bronchodilation fev $nmbr$,C0439566;C3714541
time from ra diagnosis years median,C0556970;C0011900;C1704338;C1704656
month $nmbr$,C0332177;C0439231
seropositivity status n,C0449438
post bronchodilation fev $nmbr$,C0439576;C3714541
rf and acpa positive n,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
pre bronchodilation fvc,C0439566;C3714541
rf negative and acpa positive n,C0205160;C1513916;C2825415;C2825491;C3853545;C0439178;C1446409;C1514241;C2825490;C3812269
post bronchodilation fvc,C0439576;C3714541
rf positive and acpa negative n,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
table $nmbr$ baseline characteristics of early dmard naive patients with ra participating in the swefot trial,C4684572;C3538806;C4048756;C0679823;C0008976
rf and acpa negative n,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
no of previous csdmards n,C0205156;C1552607
current corticosteroid use n,C0521116;C0239126;C1705970
patients with available bmi for univariate analyses or with all data available for the multivariate model did not differ from the original swefot trial population proportions n were compared with pearson s $nmbr$ continuous variables medians iqr were compared with independent samples mann whitney u tests all patients who originally participated in the swefot missing data were as follows in number n bmi $nmbr$ smoking status $nmbr$ rf status $nmbr$ anti acpa status $nmbr$ concurrent prednisolone use $nmbr$ haq $nmbr$ univariate model where the das $nmbr$ at $nmbr$ months and baseline bmi were required missing data n were as follows smoking status $nmbr$ rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ and haq $nmbr$ multivariate model shown in table $nmbr$ and gure $nmbr$ a missing data points n were as follows rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ acpa anticitrullinated protein antibody bmi body mass index das $nmbr$ $nmbr$ joint count disease activity score dmard disease modifying rheumatic drug haq health assessment questionnaire ra rheumatoid arthritis rf rheumatoid factor swefot swedish pharmacotherapy trial,C0030705;C0470187;C0683962;C1511726;C3245479;C3714741;C3161035;C3274659;C3714583;C3853906;C1518422;C0008976;C0032659;C1257890;C1707455;C0549178;C0439828;C0242927;C3272598;C4684714;C1519386;C0035448;C0201660;C0748398;C1547111;C0051767;C0057671;C0439231;C0168634;C0578022;C1442488;C1514873;C0332283;C1719822;C4281991;C0042153;C0457083;C1947944;C1547282;C0039224;C1706074;C1552961;C2347617;C3714763;C1537044;C1954799;C0392747;C0304229
mtx average weekly dose mg week mean sd,C0366550;C2699239
swefot n $nmbr$,
tender joint count $nmbr$ mean sd,C0451530;C2699239
univariatet n $nmbr$,
multivariate^ n $nmbr$,
swollen joint count $nmbr$ mean sd,C0451521;C2699239
proportions n,C1709707
patient global assessment of disease activity mean sd,C4054228;C0444504;C2347634;C2348143
obese bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
patient assessment of pain $nmbr$ $nmbr$ mm mean sd,C0679830
overweight bmi $nmbr$ $nmbr$ $nmbr$,C0497406;C0578022
physician global assessment of disease activity mean sd,C4050369;C0444504;C2347634;C2348143
normal bmi,C4229017
hscrp mean sd,C0444504;C2699239;C2347634;C2348143
concurrent prednisolone,C0205420;C0032950
das $nmbr$ hscrp mean sd,C0051767;C2699239;C0057671
medians iqr,C0549183
esr mm h mean sd,C0456680;C2699239
symptom duration months,C0449238;C0439231;C2926735
bone erosion score mean sd,C0587240;C2699239
haq score,C0449820;C4050231
joint space narrowing score mean sd,C1859695;C2699239
year from randomization,C0439234;C0439508
first year,C0439234;C0439508
table baseline characteristics by study and blood pressure intervention in participants with baseline egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ or higher,C4684572;C0184661;C0886296;C1273869;C0168634;C0439445;C1442488;C0205250
second year,C0439234;C0439508
third yeart,C0205437
data are number of patients mean sd or median iqr accord action to control cardiovascular risk in diabetes acr albumin creatinine ratio egfr estimated glomerular filtration rate mdrd modification of diet in renal disease n a not applicable n r not reported sprint systolic blood pressure intervention trial defined in the accord trial as one or more of myocardial infarction stroke angina coronary artery bypass graft percutaneous transluminal coronary intervention or other revascularisation procedure defined in sprint as one or more of myocardial infarction acute coronary syndrome coronary revascularisation carotid revascularisation peripheral arterial disease with revascularisation greater than $nmbr$ stenosis of coronary carotid or lower extremity artery or abdominal aortic aneurysm $nmbr$ mm or larger $nmbr$ participants assigned the standard intervention and $nmbr$ allocated the intensive intervention had a fasting plasma glucose greater than $nmbr$ $nmbr$ mmol l at baseline estimated by four variable mdrd equation,C1511726;C3245479;C3714741;C2360800;C0444504;C2347634;C2348143;C0441472;C3266814;C0086153;C3671772;C0022658;C0205090;C0684010;C2603358;C0814861;C1704788;C3539106;C0205447;C0010055;C1260596;C0184661;C2700391;C3274430;C3539779;C0948089;C0085096;C1704436;C0581603;C0439093;C0007282;C0226415;C4330985;C4554674;C0549177;C0679646;C1704243;C1516050;C1552601;C0886296;C1273869;C0202042;C0455280;C1532563;C0168634;C1442488;C0750572;C0205450
chd disease death,C0011065;C1306577;C4082313;C4552775
accord trial,C0680240;C0008976
placebo km,C0032042;C3887676;C1696465;C1706408
sprint,
ticagrelor $nmbr$ mg km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
intensive n $nmbr$,
cv death myocardial infarction stroke,C0038454;C4554100
clinical atherosclerotic disease,C0205210;C0012634
metrex modified intention to treat population with an eosinophilic phenotypey,C0087111;C0032659;C1257890;C1292734;C1522326
antihypertensive agents n per patient,C0003364
metrex overall modified intention to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
n r,C0205090;C0684010;C2603358
metreo modified intention to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
urinary acr mg mmol,C0567349;C2348885
smoking history no,C1519384
sprint acr,C1412134;C1515941
moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0740304;C4050465;C4050466
sprint acr $nmbr$ $nmbr$,C1412134;C1515941
no in the $nmbr$ mo before screening,C0026544;C0332177
accord acr,C1412134;C1515941
one or more requiring hospitalization in $nmbr$ mo before screening no $nmbr$,C0205447;C0019993;C0026544;C0332177;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
accord acr $nmbr$ $nmbr$,C1412134;C1515941
gold group d no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
absolute risk difference $nmbr$ cl,C1549031;C0596019
postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
sustain $nmbr$,C0443318;C2732140
percent of predicted fev $nmbr$,C1882327;C3714541
pooled analysis of sustain $nmbr$ $nmbr$ trials,C0002778;C0936012;C1524024;C0443318;C2732140;C0008976
blood eosinophil count $nmbr$ mm $nmbr$ at screening no,C4330985;C4554674;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
semaglutide,C3885068
semaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
geometric mean blood eosinophil count sd on a loge scale cells mm $nmbr$,C0200638;C2699239
exenatide er,C3810541;C3811131
blood eosinophil count $nmbr$ mm $nmbr$ in $nmbr$ months before screening no,C4330985;C4554674;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
placebo add on to basal insulin,C1883712;C0650607
blood eosinophil count cells mm $nmbr$ no,C4330985;C4554674
elderly,C0001792;C1999167
mepolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
bw kg,C0022718;C0439209;C4054209
of patients meeting criterion total no of patients,C0439175;C0439810;C0030705
mdrd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
sotagliflozin n $nmbr$,C3896939
blood pressure mmhg systolic,C0005823;C0039155;C1271104;C1272641
race or ethnic group no white,C0034510;C1706779;C3853635;C0015031;C1879937;C0007457;C0043157;C0220938
dyspnea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
native american or alaska native,C0282204;C1515945;C0682125
number of patients with exacerbations in the previous $nmbr$ months n,C2360800;C4086268;C0205156;C1552607
bmij,
ccq total score,C2964552
bmi $nmbr$ no,C0578022
tofacitinib $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
systolic blood pressure $nmbr$ mm hg no,C0488055;C0439475;C0871470;C1306620
induction study treatment,C4049995
daily total dose of insulin lu kg,C2348070
in remission at maintenance study baseline,C0544452;C0687702
insulin dose lu day,C0332173;C0439228;C0439505
ibdq total score,C2964552
basal,C0205112
baseline crp category mg l,C0168634;C0439268;C1442488
bolus and corrections,C1186706;C1511237;C1705509;C3812160;C1705565;C1947976
prior anti tnf treatment,C1514463;C1448177
type of insulin therapy no $nmbr$,C0457592;C0039798;C0087111;C1363945
prior anti tnf failure,C0332152;C2826257
subcutaneous injections,C0021499
prior immunosuppressant failure,C0231174;C0680095
sotagliflozin,C3896939
prior corticosteroid treatment,C1514463;C0001617;C3536709
no totalno,
steroid use at baseline mg day,C0281991;C0439422
percentage points,C1552961;C2347617;C3714763
subsets,C1515021
patients with glycated hemoglobin $nmbr$ $nmbr$ and no severe hypoglycemia or diabetic ketoacidosis,C0030705;C0017853;C0205082;C0020615;C4553659;C4050465;C4050466;C0011880
dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients who used insulin pump,C0030705;C1140609
semaglutide exposure nmol l,C0274281;C0439282;C0332157
patients who did not use insulin pump,C0030705;C3272598;C1140609
mean change from baseline points,C0392747;C0443172;C1705241;C4319952
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode of severe hypoglycemia,C0030705;C0017853;C0332189;C0020615;C4553659
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg points,C0392747;C0443172;C1705241;C4319952;C1552961;C2347617;C3714763
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode ofdiabetic ketoacidosis,C0030705;C0017853;C0022638;C0220982
mean change from baseline,C0392747;C0443172;C1705241;C4319952
randomization groups $nmbr$ and $nmbr$,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg,C0392747;C0443172;C1705241;C4319952;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pfo closure group n $nmbr$,C0185003;C0441848;C1521802
$nmbr$ participants with highest body weight,C0679646;C0948775
antiplatelet only group n $nmbr$,C0441848
$nmbr$ participants with lowest body weight,C0679646;C0041667
anticoagulant group n $nmbr$,C0003280;C0441848;C0848112;C3536711
$nmbr$ participants with highest hba $nmbr$ c,C0679646;C0019016;C1825777;C3538758
antiplatelet onl group n $nmbr$,C0441848
$nmbr$ participants with lowest hba $nmbr$ c,C0679646;C0019016;C1825777;C3538758
body mass index $nmbr$ no f,C0005893;C0578022;C1305855;C0016327
sustain $nmbr$ semaglutide vs placebo,C0443318;C2732140;C3885068;C0032042;C1696465;C1706408
oral contraceptive pills no total no,C0009905;C0009906;C0029151;C0439175;C0439810
sustain $nmbr$ semaglutide vs sitagliptin $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
migraine no,C0149931
sustain $nmbr$ semaglutide vs exenatide er $nmbr$ $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
stroke no,C0038454;C4554100
sustain $nmbr$ semaglutide vs iglar,C0443318;C2732140;C3885068
deep vein thrombosis or pulmonary embolism no,C0149871;C0034065
sustain $nmbr$ semaglutide add on to insulin vs placebo,C0443318;C2732140;C1883712;C0021641;C1533581;C1579433;C3714501;C0032042;C1696465;C1706408
qualifying event no,C1514624;C0441471;C4019010
$nmbr$ wk,C0332174;C0439230
carotid infarct,C0741968;C0021308
baseline characteristics mean sd a,C4684572;C2699239
vertebrobasilar infarct,C0545733;C0021308
subject disposition n,C0681850;C0743223;C1705555;C1550501;C1706203;C2349001;C2697811
modified rankin scale no,C2984908;C3854213
exposed,C0332157
rope score,C0449820;C4050231
trial completers,C0008976
septal anomaly no,C0332447;C1704258
premature treatment discontinuation,C0457454;C1444662;C4552847
pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
subjects with imputed value for end of treatment body weight,C0681850;C1550501;C1706203;C2349001;C2697811;C2983672;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
adverse events any grade,C0877248;C1705413;C0441800;C0919553;C3244287
pfo with mild to moderate shunt and atrial septal aneurysm,C1299392;C0232180;C0542331;C1442858;C0521533
gastrointestinal disorders,C0017178
pfo closure,C0185003;C1521802
adverse events leading to premature treatment discontinuation,C0877248;C1705413;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no of strokes,C0038454
nausea and or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767;C0877248;C1705413
age at randomisation,C0001779;C0034656
participants with a history of cabg,C0679646;C0010055
patent foramen ovale,C0016522;C0344724
large shunt,C0232180;C0542331;C1442858
participants without a history of cabg,C0679646;C0010055
pfo asa,C0004057;C3853627
time since cabg,C0040223;C3541383
fluticasone furoate and vilanterol n $nmbr$,C1948374;C2935023
cv disease,C0007222
history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
body mass index $nmbr$ kg nrn,C0005893;C1425210;C0578022;C1305855
peripheral artery diseaseb,C0489868
asthma control test score at baseline,C2733224;C0168634;C1442488
duration of asthma $nmbr$ years,C0449238;C2926735
single vessel coronary artery diseasea,C0265903;C0005847
daytime symptoms more than twice per week,C0683368;C1457887;C1720725;C1948050;C0332174;C0439230
cardiac failurec,C0018787;C1522601
nocturnal symptoms in past week,C0683368;C1457887;C0332174;C0439230
hba $nmbr$ c mmol mold,C0019016;C0369241;C1825777;C3538758
number of exacerbations $nmbr$ months before randomisation,C0237753;C0449788;C0034656
hba $nmbr$ c d,C0019016;C1825777;C3538758
angiotensin converting enzyme inhibitor angiotensin receptor blocker,C0034787;C1622222
figure s $nmbr$ baseline subgroups and act scores at week $nmbr$ pea population,C0168634;C1079230;C1442488;C0449820;C0030738;C0069964;C0070939;C1262903;C3257529
renin inhibitor,C1960108;C3537174;C4521920
patients with prevalent kidney disease at baseline,C0683521;C0168634;C1442488
total cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
patients without prevalent kidney disease at baseline,C0683521;C0168634;C1442488
ldl cholesterol mmol lf,C1416933;C2986618;C4554443
cv risk factor,C3538987;C0035648;C4048877;C4318503
hdl cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
peripheral artery diseasef,C0489868
triacylglycerol mmol le,C0023190;C0439090;C1423767;C2697858
single vessel coronary artery disease,C0581374
egfr mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
glucose lowering therapy,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
empagliflozin n with event n,C3490348;C0441471;C4019010
anti coagulants,C0848112
placebo analysed,C0032042;C1696465;C1706408
total cholesterol mg dl^,C0201950;C0439269;C0543421
all participants history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
low density lipoprotein cholesterol mg dl,C0023824;C0439269
three point mace,C0349381;C0949745;C1445339
high density lipoprotein cholesterol mg dl^,C0023822;C0439269
fatal or non fatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
triglycerides mg dl^,C0041004;C0439269
fatal or non fatal stroke,C1302234;C1705232;C0038454;C4554100
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
hospitalisation for heart failure,C3898876
patients with egfr,C0030705;C1739039;C3811844;C3812682
heart failure hospitalisation or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
patients with egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ at baseline,C0030705;C0439445;C0168634;C1442488
incident or worsening nephropathy,C1551358;C0332271;C1457868;C1546960;C0022658
change from baseline at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
placebo $nmbr$ $nmbr$ ml n $nmbr$,C0032042;C0439526;C1705224;C3887665;C1696465;C1706408
serum uric acid mg dl,C0455272;C0439269;C0700634
dupiiumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
asian oriental,C0078988;C0699027
prebronchodilator fevi liters,C0429706;C0475211;C0849974;C1561566;C4528367
not reported unknown,C0439673;C3541433;C4050014
percent of predicted normal value,C1882327
mean s d hbalc,C0444504;C2347634;C2348143
fevi reversibility,C3830088
mean s d hbalc mmol mol,C0444504;C3829066;C2347634;C2348143
no of exacerbations in past year,C4086268;C0439234;C0439508
chda,
use of high dose inhaled glucocorticoid no,C1524063;C0444956
no ascvd additional cv risk factors n,C0035648;C1553898
ongoing atopic or allergic condition no,C0549178;C0392707;C0851444
micro macro albuminuria ckd and or retinopathy,C0001925;C1561643;C0035309;C1962966
$nmbr$ additional cv risk factors $nmbr$,C0035648;C1553898
nasal polyposis or chronic rhinosinusitis no,C0027430;C0149516
median q $nmbr$ q $nmbr$ duration of diabetes years,C0449238;C2926735
no of pack yr,C1968515;C0439234;C2825051;C2828395
biomarker levels,C0005516;C0441889
median q $nmbr$ q $nmbr$ duration of insulin use years,C1881378;C2826775
blood eosinophil count cells mm,C4330985;C4554674
mean s d systolic blood pressure mm hg,C0428886;C0439475;C0488053
feno ppb,C1415800
mean s d diastolic blood pressure mm hg,C0428886;C0439475;C0488053
total ige lu ml,C0439175;C2697941;C0439810
mean s d egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
relative risk vs placebo $nmbr$ cl,C0242492;C0032042;C0596019;C1696465;C1706408
ckdc n,
dupilumab $nmbr$,C3660996
baseline lipids,C0168634;C0023779;C1442488
$nmbr$ cells mm^,C4330985;C4554674
mean s d calculated ldl cholesterol,C0023824;C0202117
$nmbr$ to $nmbr$ cells mm,C4330985;C4554674
mean s d measured ldl cholesterol,C0023824;C0202117
fraction of exhaled nitric oxide,C1264633;C0028128;C3810607
mean s d apob mg dl,C0003593;C0439269;C3252643
$nmbr$ ppb,C1415800
mean s d non hdl cholesterol,C0729627;C1535899
$nmbr$ to $nmbr$ ppb,C1415800
median q $nmbr$ q $nmbr$ tgs,C1156212;C1537574
$nmbr$ to $nmbr$ cells mm^,C4330985;C4554674
mean s d hdl cholesterol,C0023822;C0392885
gene,C0017337
median q $nmbr$ q $nmbr$ lp a mg dl,C0065058;C0439269;C1439335;C4553379
snp,C0752046;C1527094
mean s d apoc ll $nmbr$ mg dl,C0444504;C0003594;C2347634;C2348143;C0439269
short term n $nmbr$,C0443303
median q $nmbr$ q $nmbr$ tg rich lipoprotein cholesterol,C0337445;C0065055
long term n $nmbr$,C0443252
mean s d ldl particle number nmol l,C2612459;C0439282
p $nmbr$ cl,C0369773;C0596019;C2603361
mean s d ldl particle size nm,C0203634;C0312860;C3890923
octi,
rs $nmbr$,C0035970;C3714753;C3813325
mean s d free pcsk $nmbr$ ng ml,C0332296;C0439275;C1880497;C1996904
mate,C0682323;C1260875
mean s d total pcsk $nmbr$ ng ml,C0439175;C0439275;C0439810
atm locus,C3711796;C1708726
concomitant lipid lowering therapy n,C0585943
atm locm,C3711796
statin intensity $nmbr$ $nmbr$,C0360714;C0522510
ocn,C1412791;C2347392
statin monotherapy,C0360714
octi mate $nmbr$,C0682323;C1260875
any other llts other than statin,C2347090;C0360714
short term^,C0443303
cholesterol absorption inhibitor ezetimibe,C0003277;C1142985
long term,C0443252
statin intolerance $nmbr$ n,C0360714;C0231199;C1744706;C2355652
rs $nmbr$ rs $nmbr$,C0035970;C3714753;C3813325
concomitant antihyperglycaemic drugs n,C0020616;C0013227;C3687832
rs $nmbr$ aa rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C4554792;C3714753;C3813325
any other antihyperglycaemic drugs,C0013227;C3687832
rs $nmbr$ ac rs $nmbr$,C0001246;C0003354;C1412573;C2000891;C3539770
biguanides metformin,C0005382;C0025598;C0360396;C3540012
rs $nmbr$ cc rs $nmbr$,C0035970;C0008318;C3538933;C3714753;C3813325
median q $nmbr$ q $nmbr$ total daily insulin dose $nmbr$,C2348070
active canakinumab n $nmbr$ $nmbr$,C0205177;C2718773;C3853793;C3888249
iu,C0049272;C0439453;C0694756
serum creatinine mol l,C0201976;C0347982;C0600061
lu kg,C0022718;C0439209;C4054209
serum albumin g l,C0439294;C0456615
t $nmbr$ d,C2603360
difference vs placebo [ $nmbr$ cl] p,C1705241;C1705242;C0032042;C1696465;C1706408;C0596019;C0369773;C2603361
serum calcium mmol l,C0036785;C1532563;C0728876
serum phosphate mmol l,C0036820;C1532563
ls mean s e primary endpoint change from baseline to week $nmbr$,C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
protein in urine $nmbr$,C0033687
selected key secondary efficacy endpoints,C4528314;C1280519;C1707887
glucose in urine $nmbr$,C0004076
change from baseline mean s e,C0392747;C0443172;C1705241;C4319952
urine albumin creatinine ratio mg mmol,C0567349;C2348885
calculated ldl cholesterol week $nmbr$,C0332174;C0439230
canakinumab dose,C0178602;C0869039;C1114758
non hdl cholesterol week $nmbr$,C0332174;C0439230
ptrend across doses,C0178602
apob week $nmbr$,C0332174;C0439230
all doses,C0178602
total cholesterol week $nmbr$,C0332174;C0439230
incidence rate n,C1708485
lp a week $nmbr$,C0332174;C0439230
uacr $nmbr$ mg mmol,C0567349;C2348885
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$,
figure $nmbr$ clinical remission from week $nmbr$ through week $nmbr$ of treatment among a all randomised patients entering the long term extension and b by induction study subgroups sc subcutaneous tnf tumour necrosis factor q $nmbr$ w every $nmbr$ weeks q $nmbr$ w every $nmbr$ weeks,C0205210;C0544452;C0687702;C0332174;C0439230;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0030705;C1522196;C0443252;C0231448;C1880641;C0033453;C0046774;C1824728
hdl cholesterol week $nmbr$ a,C0332174;C0439230
tnf antagonist naive,C1448177;C0231491
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ b,
tnf antagonist exposed,C1448177;C0231491;C0332157
triglycerides week $nmbr$ a,C0332174;C0439230
vedolizumab n $nmbr$,C2742797
ldl particle numbers week $nmbr$,C0332174;C0439230
age y median min max,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
ldl particle size week $nmbr$,C0332174;C0439230
weight kg median min max,C0005910;C1532757;C0043100;C1305866;C1705104
ls mean difference se vs placebo,C0023668;C0036919;C0032042;C1696465;C1706408
duration of disease y median min max,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
ali,
complete mayo clinic score median min max,C0205197;C0002424;C0442592;C0725685;C3853530;C4283785
age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
history of elms n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
duration of diabetes by tertiles,C0449238;C2926735
elms n,C0330531;C2980688
ascvd as per protocol,C3665365;C1698058
concomitant medications yes n,C0521115;C0013227;C0802604;C2598133;C4284232
ascvd including tia,C3665365;C0007787;C0917805;C1054154
imm only,C0205470
any statin versus no statin at randomization,C0360714;C0034656
no cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
any statin with without llt,C0360714;C2347090
type of tnf antagonist failure n o,C0332307;C1547052
no statin vs statin alone vs any statin plus other llt,C0360714;C0205171;C0439044;C0679994;C2347090
weight kg median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
no statin llt,C0360714;C2347090
statin alone,C0360714;C0205171;C0439044;C0679994
disease duration y median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
any statin other llt,C0360714;C2347090
cdai score median min max,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
high intensity statin vs medium or low intensity statin at randomization,C4081854;C0360714;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C0596836
prior surgery for cd n,C0455610;C0007928;C0034283;C4552032
medium or low intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C0596836;C0360714
history of fistullzing disease n,C0683519;C0730226;C0850708;C0944983
draining fistulae n,C0013103;C0180499;C4265177;C0016169
prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
egfr in $nmbr$ classes,C1739039;C3811844;C3812682
type of tnf antagonist failure n,C0332307;C1547052
inadequate response ^,C0871261;C1704632;C1706817;C2911692
baseline albumin creatinine ratio in $nmbr$ classes,C0486293;C1318293
loss of response s,C1517945;C0871261;C1704632;C1706817;C2911692
diabetic kidney disease,C0011881
category $nmbr$,C0683312;C3889287
category $nmbr$ and $nmbr$,C0683312;C3889287
figure $nmbr$ rbs and sfs in patients with uc percentage change from baseline in rbs in the overall itt a tnf antagonist naive b and tnf antagonist exposed c populations and in sfs in the overall itt d tnf antagonist naive e and tnf antagonist exposed f populations after vdz or pbo administration adata points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se bdifference adjusted o f c $nmbr$ h $nmbr$ a ngcei[vd $nmbr$ z i npdibcoat]e s asdtajutisstteicdalmseiagnni change from bl for vdz adjusted mean change from bl for pbo upper limit cance at a nominal signi cance level of $nmbr$ $nmbr$ statistical signi cance and non signi cance patients with baseline rbs $nmbr$ or sfs $nmbr$ were excluded from this analysis of note the number of patients varies per study population at weeks $nmbr$ $nmbr$ and $nmbr$ and is reported below the x axis bl baseline ci con dence interval itt intent to treat ns nonsigni cance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C0392475;C0030705;C0392747;C0443172;C1705241;C4319952;C0282416;C1561607;C3887647;C0231491;C2348484;C1448177;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0033727;C0369286;C0441932;C0564385;C4528284;C0036916;C0021966;C0221138;C0031962;C0557837;C0038215;C1829939;C0168634;C1442488;C0332196;C1554077;C2828389;C2360800;C1548673;C2348561;C0439230;C0684224;C0700287;C4319718;C0018932;C2742797;C0267596
calculated ldl c in $nmbr$ classes,C0444686;C0456387;C1518526;C1705943;C4019422;C1441506
figure $nmbr$ proportion of patients with uc who achieved the composite score rbs $nmbr$ and sfs $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance cl confidence interval ns nonsignificance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C1709707;C0030705;C3272598;C4055211;C0392475;C0814896;C0237881;C1709380;C0009667;C2742797
non hdl c in $nmbr$ classes,C1518422;C3715113
baseline trl c in $nmbr$ classes,C0456387;C1518526;C1705943;C4019422
figure $nmbr$ abdominal pain subscores in patients with cd percentage change from baseline in aps in overall itt a tnf antagonist naive s and tnf antagonist exposed c populations and percentage change from baseline in lsfs in overall itt d tnf antagonist naive and tnf antagonist exposed f populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0000737;C4554323;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C1448177;C0231491;C2348484;C0243902;C1456377;C3538776;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
baseline trl c by quintiles,C0168634;C1442488
baseline hdl c in $nmbr$ classes,C0168634;C3715113;C1442488
figure $nmbr$ combined score of abdominal pain and loose stool frequency in patients with cd percentage change from baseline in aps and lsfs in the overall itt a tnf antagonist naive s and tnf antagonist exposed c populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0582148;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C0243902;C1456377;C3538776;C1448177;C0231491;C2348484;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
low hdl c for men,C0151691;C0025266
figure $nmbr$ proportion of patients with cd gemini $nmbr$ and $nmbr$ who achieved the average daily composite score of aps $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance aps abdominal pain subscore cl confidence interval lsfs loose stool frequency subscore ns nonsignificance pbo placebo vdz vedolizumab,C1709707;C0030705;C0007928;C0034283;C4552032;C3272598;C4055211;C0001468;C1706670;C0814896;C0237881;C1709380;C0518090;C2742797;C4082250
high hdl c for men $nmbr$ mg dl for women $nmbr$ mg dl,C3715113;C0439269;C0043210
tnf na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
baseline triglycerides in $nmbr$ classes,C0168634;C0041004;C1442488
pain vas mean change from baselinea,C0392747;C0443172;C1705241;C4319952
baseline triglycerides by quintiles,C0168634;C0041004;C1442488
sf $nmbr$ bodily pain mean change from baselineb,C0392747;C0443172;C1705241;C4319952
baseline lp a in $nmbr$ classes,C0065058;C1439335;C4553379
eq $nmbr$ d $nmbr$ l no pain or discomfortc,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
baseline total pcsk $nmbr$ level by median,C0441889;C0456079;C1547707;C2946261
tnf ir,C0022065;C0022071;C1448132
$nmbr$ ng ml,C0439275
pain vas mean change from baselined,C0392747;C0443172;C1705241;C4319952
baseline free pcsk $nmbr$ level by median,C0441889;C0456079;C1547707;C2946261
sf $nmbr$ bodily pain mean change from baselinee,C0392747;C0443172;C1705241;C4319952
baseline hba $nmbr$ c in $nmbr$ classes,C0456387;C1518526;C1705943;C4019422
eq $nmbr$ d $nmbr$ l no pain or discomfortf,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
diabetes mellitus status,C1317301
low nfs nfs,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
controlled,C2587213;C2911690
indeterminate nfs $nmbr$ $nmbr$ nfs,C0205258;C1555018
baseline insulin daily dose kg,C0022718;C0439209;C4054209
high nfs nfs $nmbr$ $nmbr$ n $nmbr$,C0205250;C1513839;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
$nmbr$ u kg day,C1532634
p value low vs high nfs^,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205250;C1555018;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
exenatide n $nmbr$,C0167117
p j $nmbr$ trend,C1521798;C4554533
indian american or alaska native,C1524069;C0596070;C0682125
body mass index kg m^^,C0022718;C0439209;C4054209
european subcategories,C0239307;C1515010;C1535514
ezetimibe simvastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
prior cv event at randomization,C0441471;C4019010
past cardiovascular history no,C1880008
history of congestive heart failure,C0455531
any lipid lowering agent use,C0042153;C0457083;C1947944
egfr via mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
at index event no,C0441471;C4019010
antihyperglycemic medication usage,C0013227;C0457083;C3244316;C4284232
diagnostic catheterization,C0596429
oral agents use,C1527415;C0450442;C1254351;C1521826
prerandomization pci,C4049621
$nmbr$ oral agents,C0450442;C1254351;C1521826
laboratory parameters median iqr,C0022877;C0449381;C3244292;C4283904
insulin alone,C0021641;C1533581;C1579433;C3714501;C0205171;C0439044;C0679994
alanine aminotransferase u l,C0001899;C0439339;C0057041;C1415274;C3887708
insulin plus $nmbr$ oral agent,C0021641;C1533581;C1579433;C3714501
aspartate aminotransferase u l,C0004002;C0439339
pramlintide,C0537551
gamma glutamyltransferase u l,C0017040;C0439339
non sulfonylurea secretagogues,C0038766;C4704833;C3536898
c reactive protein u l,C0006560;C0439339;C1413716;C4048285
alpha glucosidase inhibitors,C1299007;C2756986;C3539108
platelets xlooo mm^,C4330985;C4554674
glp $nmbr$ receptor agonist other than study drug,C4543206
exenatide lar,C1419115;C3814448
total cholesterol mg dl ^,C0201950;C0439269;C0543421
other glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
hemoglobin ale,C0678386;C2632076
dpp $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945
outcome n,C1274040
vildagliptin,C1570906
high nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
allogliptin,
low nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
sglt $nmbr$ inhibitors^,C3665045
placebo simva,C0032042;C1696465;C1706408
dapagliflozint,
death from cv causes major coronary event or nonfatal stroke,C0376297;C0038454;C4554100
other sglt $nmbr$ inhibitor,C1999216
secondary endpoints,C4528314
other antihyperglycemic agents not listed,C0020616;C0745732;C3272378
$nmbr$ death from any cause major coronary event or nonfatal stroke,C0007465;C0376297;C0038454;C4554100
cardiovascular medication usage,C0007220;C0457083
ii death from coronary heart disease nonfatal mi coronary revascularization $nmbr$ days,C0376297
antihypertensive antianginal and other cardiovascular medications,C1874267;C3537168;C0007220
iii death from cv causes nonfatal mi hospitalization for ua all revascularization $nmbr$ days nonfatal stroke,C0007465;C0019993;C0041580;C0042014;C0038454;C4554100
aldosterone antagonists e g spironolactone,C0002007;C2757004;C0037982
tertiary endpoints,C0205372;C2349179
alpha $nmbr$ blockers,C0001641
death from coronary heart disease,C0376297
renin inhibitor e g aliskerin,C1960108;C3537174;C4521920
urgent coronaiy revascularization $nmbr$ days,C0439609;C0439228;C3272275
digoxin digitalis glycoside,C0012265;C0012253
clinical endpoint,C2347784
antithrombotic and anticoagulant medications,C0003280
km rates p s,C0234833;C0722388
vitamin k antagonist e g warfarin coumarol,C1096489;C2267235;C0043031
km rates e s,C3887676;C0871208;C1521828
factor xa inhibitor,C2825027;C4553708
hr $nmbr$ c,
direct thrombin inhibitors,C0003440;C3541936
primary endpoint^,C2986535
other anti platelet agents,C0040616;C0005821
nfs,C1555018
clopidogrel ticlopidine,C0070166;C0040207
nfs $nmbr$ $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
lipid lowering medications^,C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
secondary p,C0027627;C0175668;C0205436
statini,
secondary ip,C1308226;C4049997
niacini,
secondary iii,C0439070;C1705160
other medication usage,C0013227;C0457083;C3244316;C4284232
p inte faction,C0369773;C2603361
hormone replacement therapy,C0282402
upa $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chronic non steroidal antiinflammatory drugs,C0205191;C0003211
characteristic_name,C0027365;C1547383;C4522128
chronic cox $nmbr$ inhibitors,C0205191;C0085387
characteristic_level,C0441889;C0456079;C1547707;C2946261
fish oil,C0016157
n america,C0369718;C0002454;C0441922
exenatide no of events total no,C0167117;C0439175;C0439810
placebo n l $nmbr$,C0032042;C1696465;C1706408
placebo no of events total no,C0032042;C1696465;C1706408;C0439175;C0439810
upadacitinib $nmbr$ mg n l $nmbr$,C0439268
indian american or alaskan native,C1524069;C0596070;C0238611;C0302891
time since rheumatoid arthritis diagnosis years,C0556970;C0003873
antihyperglycemic oral agent therapy,C0039798;C0087111;C1363945
u $nmbr$ $nmbr$ $nmbr$,C0439148
glycated hemoglobin level,C0202054
tj $nmbr$,C0039247
estimated gfr renal function stage,C0205390;C1300072;C1306673
age years geographical distribution of patients,C0001782
stage $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C0439445;C1300072;C1306673
previous bdmard received,C0205156;C1552607;C1514756
stage $nmbr$ $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C0439445;C1300072;C1306673
stratum $nmbr$ inadequate response or intolerance to $nmbr$ $nmbr$ bdmards of same moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
stage $nmbr$ a $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C1300072;C1306673;C0439445
stratum $nmbr$ inadequate response or intolerance to $nmbr$ bdmards of same moa or $nmbr$ of multiple moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652;C0439064;C4551881
stage $nmbr$ b $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0441781;C0439445
inadequate response or intolerance to $nmbr$ anti tnfdrug,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
previous cardiovascular event at randomization,C1320716;C0034656
lack of efficacy with $nmbr$ bdmard,C0235828
ertugliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lack of efficacy with $nmbr$ anti interleukin $nmbr$,C0235828;C0021764;C1527200
background aha therapy at screening n,C0039798;C0087111;C1363945
t] $nmbr$,C2603360
dpp $nmbr$ inhibitors,C1414174;C0243077
csdmard use at baseline^,C0042153;C0457083;C1947944
sulphonylureas,C0038766
methotrexate alone^,C0025677;C0205171;C0439044;C0679994
two agents,C0450442;C1254351;C1521826
methotrexate plus other csdmardfl,C0025677
three or more agents,C0205449;C0450442;C1254351;C1521826
methotrexate dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
one or more blood pressure medications n,C0205447;C0849164
csdmard otherthan methotrexate,C0025677
ras agents,C0450442;C1254351;C1521826
chloroquine,C0008269
other anti hypertensives,C0003364
oral glucocorticoid use,C1527415;C0017710
c peptide,C0006558
oral glucocorticoid dose mg prednisone equivalent,C0205163;C0439185
ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rheumatoid factor and acpa positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
subgroup analysis change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0392747;C0443172;C1705241;C4319952;C0019016;C0332174;C0439230;C1825777;C3538758;C0683312;C3889287
rheumatoid factor or acpa positive or both,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
baseline hba $nmbr$ c median $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
patient s ga $nmbr$ $nmbr$ mm vas,C0030705;C0042815;C3536884;C3827561
ls mean $nmbr$ ci mmol mol,C0008107;C3829066;C3259781
physician s ga $nmbr$ $nmbr$ mmvas,C0031831;C0804815;C0016993
difference in ls mean vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
clinical disease activity index,C3869583
difference in ls mean vs placebo $nmbr$ ci mmol mol,C1705241;C1705242;C0008107;C3829066;C3259781
morning stiffness severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
baseline hba $nmbr$ c $nmbr$ $nmbr$ to,C0168634;C0019016;C1825777;C3538758;C1442488
morning stiffness duration min,C0702093;C1524029;C3813700
baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
uniti $nmbr$ and uniti $nmbr$ im uniti,
pravastatin n $nmbr$,C0085542
ustekinumab n $nmbr$,C1608841
$nmbr$ month n $nmbr$,C0332177;C0439231
cd duration y,C0007928;C0034283;C4552032
ischemic stroke subtype,C0948008;C0449560
involved gl areas,C1879646;C0018229;C1423073;C1427674
atherothrombotic stroke n,C0038454;C4554100
ileum only n,C0020885;C0369718;C0441922
lacunar infarction n,C0333559
colon only n,C0009368;C3888384;C0369718;C0441922
undetermined etiology n,C0478157
ileum and colon n,C0020885;C0009368;C3888384
use of antiplatelet agents n,C1524063;C0085826
proximal gl tract n,C0205107;C0018229;C1423073;C1427674;C4489236
perianal n,C0442158
use of anti hypertensive agents n,C1524063;C0003364
cd complications,C0009566;C1171258
incidence of each outcome,C0021149;C0220856
stroke and tia n,C0038454;C4554100;C0007787;C0917805;C1054154
intra abdominal abscess past,C0243001
incidence $nmbr$ person year,C0027361;C0439234;C0439508;C2347489
sinus tracts perforation ^ n,C0854572
all strokes n,C0038454
fistula n,C0016169
atherothrombotic infarction n,C0021308
bowel stricturing n,C0021853;C4083257;C1261287;C0369718;C0441922
cardioembolic infarction n,C0021308
patients with evaluable endoscopy,C2986511;C0014245
intracranial hemorrhage n,C0151699;C4554169
data n,C1511726;C3245479;C3714741
tia n,C0007787;C0917805;C1054154
patients with eligible ses cd score,C0030705;C0007928;C0034283;C4552032
or ulcerations n,C0041582
vascular accidents n,C0005847;C0000924;C1558950;C1801960
death n,C0011065;C1306577;C4082313;C4552775
ses cd mean sd,C0007928;C2699239;C0034283;C4552032
hospitalization n,C0019993
endoscopic disease severity,C0014245;C0521117;C0442418
bmi kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
total ses cd score at,C2964552;C0007928;C0034283;C4552032
patient s history of,C0030705;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline of induction n,C0168634;C1442488
mild $nmbr$ $nmbr$,C2945599
prior non haemorrhagic stroke,C0332152;C0553692;C2826257
patients who had ulcerations at,C0030705;C3272598;C0041582
chronic renal disease,C0022661;C1561643
baseline of induction,C0168634;C1442488
index event information,C0441471;C1533716;C4019010
lieum only n,C0369718;C0441922
first medical contact in ambulance,C0332158;C0337611;C1705415;C3812666
ileum ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
minutes from symptom onset to prehospital ecg median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
colon ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
minutes from prehospital ecg to pci median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
minutes from pre pci angiography to post pci angiography median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0002978;C0549183;C0876920;C2347635;C2348144;C2939193
received first loading dose,C0205435;C3714444;C1279901
figure $nmbr$ endoscopy as sessments at week $nmbr$ pooled ustekinumab vs placebo a by induction study b randomized pa tients with eligible ses cd score or ulcerations at in duction baseline note $nmbr$ pooled ustekinumab group comprises patients receiving ustekinumab $nmbr$ mg and tiered ustekinu mab doses approximating $nmbr$ mg kg combined for analyses patients who prior to the designated analysis timepoint had a cd related surgery due to lack of ef cacy or had an initiation of speci ed prohibited medication had their baseline value carried forward or were considered to not have mucosal healing patients with missing segments at the designated analysis timepoint had their base line score or ulceration status at baseline for the missing segment s carried forward $nmbr$ clinically meaningful endoscopic improvement ses cd reduction $nmbr$ from induction baseline endoscopic response ses cd reduc tion $nmbr$ from induction baseline endoscopic remission ses cd total score $nmbr$ mucosal healing complete absence of ul cers in patients with ulcers at baseline cd crohn s disease ses simpli ed endoscopic disease severity score,C0014245;C0332174;C1608841;C0439230;C0032042;C1696465;C1706408;C0034656;C0030428;C3541314;C3815594;C0449820;C4050231;C0041582;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2700400;C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0003250;C0178602;C0369637;C0332232;C0439272;C0205195;C0002778;C2348792;C0936012;C1524024;C0038894;C0038895;C0543467;C1274039;C0138547;C4288398;C0168634;C0439780;C1442488;C0750591;C1518422;C0026724;C0449438;C1963256;C3887532;C1551393;C0441635;C1705492;C3272743;C0301630;C0392756;C1293152;C4551656;C0007928;C0034283;C4552032;C0442418;C0332197;C1689985;C0010346;C0521117
risk level at admission,C2923839;C0184666;C0809949
sex women men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
culprit vessel,C0005847
race or ethnic origin,C0034510;C1706779;C3853635;C0015031
no culprit vessel identified,C0005847;C0205396;C1550043
native american or alaskan native,C0282204;C1515945;C0238611;C0302891
normal coronary angiography,C0853522
hba $nmbr$ c mmol mol [se],C0019016;C3829066;C1825777;C3538758;C0036919
femoral access,C0444454;C1554204
sitting systolic blood pressure mm hg,C1319893;C0439475
thromboaspiration,
sitting diastolic blood pressure mm hg,C1319894;C0439475
with any stent,C0038257
total daily insulin dose u day,C2348070;C0456683
with des,C0011702;C4551552
duration of chronic kidney disease years,C0872146
no revascularisation,C0581603
any glycoprotein iib iiia inhibitor use,C0042153;C0457083;C1947944
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
glycoprotein iib iiia inhibitor use before angiography,C0042153;C0457083;C1947944
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
intravenous anticoagulant prior to pre pci angiography,C0003280;C0848112;C3536711
baseline egfr $nmbr$ to,C1739039;C3811844;C3812682
intravenous anticoagulant during hospitalisation,C0003280;C0848112;C3536711
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ mean [se],C1739039;C3811844;C3812682;C0444504;C2347634;C2348143;C0036919
pre hospital ticagrelor n $nmbr$,C0332152;C0019994;C1510665;C0740175;C2257086;C3669034
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
model n,C3161035;C3274659;C3714583;C3853906
uacr mg g median [iqr],C0549183;C0876920;C2347635;C2348144;C2939193
patients with endpoin t n,C0030705
normal albuminuria uacr,C0205307;C0001925;C0231683;C0439166;C2347086;C4553972
composite of death mi stro ke urgent revasc definit e acute stent thrombosis,C0205199;C1547335
microalbuminuria uacr $nmbr$ $nmbr$,C0730345
composite of death mi urg ent revasc,C0205199;C1547335
macroalbuminuria uacr $nmbr$,
nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038;C0750572
angiotensin converting enzyme inhibitor or angiotensin receptor blocker use mitt population,C0003015;C2757044;C3536837;C4541021;C0032659;C1257890
urgent revascularizati on,C0439609;C3272275
indacaterol glycopyrronium $nmbr$ $nmbr$ g o d,C1722260;C0439267
definite acute stent thrombosis,C0205178;C3897493
salmeterol fluticasone $nmbr$ $nmbr$ g b i d,C0439417
acute stent thrombosis definite or probable,C0205178;C3897493;C0439544;C1704787;C0033204;C0332148
copd severitya n,C0024117;C1412502;C3714496
enalapril aliskiren dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
sgrq c total scoreb,C3826872;C0439175;C0439810
aliskiren dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
data presented as mean sd unless otherwise specified acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ] gold $nmbr$ [ $nmbr$ ] bon a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status the mcid is a change of $nmbr$ units on a scale of $nmbr$ $nmbr$ with higher scores indicating more severe dyspnea on a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status,C1511726;C3245479;C3714741;C0449450;C0444504;C2347634;C2348143;C0439793;C0522510;C1527178;C1705938;C0018026;C1304897;C1552041;C2986536;C0175659;C0349674;C1947916;C0205250;C0449820;C0332271;C0018759;C1279889;C1457868;C0392747;C0443172;C1705241;C4319952;C2080700
enalapril dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
hazard ratio or difference $nmbr$ $nmbr$ cl p value,C2985465;C0596019;C1709380
b i d twice daily cat copd assessment test copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s fvc forced vital capacity gold global initiative for chronic obstructive lung disease ics inhaled corticosteroid mcid minimum clinically important difference mmrc modified medical research council o d once daily sd standard deviation sgrq c st george s respiratory questionnaire for copd,C0016529;C1306036;C0205246;C0424093;C2348867;C0024117;C0079816;C0871420;C1553316;C0034394;C1412502;C3714496
enalapril aliskiren n $nmbr$,C0014025;C1120110
baseline eosinophil $nmbr$ cells l,C0014467;C0347983
cv death or first hhf,C0011065;C1306577;C4082313;C4552775;C0205435;C1279901
very severe copd,C0024117;C1412502;C3714496
race $nmbr$,C0034510;C1706779;C3853635
severe copd,C0024117;C1412502;C3714496
non diabetes,C0011847;C0011849
moderate copd,C0024117;C1412502;C3714496
first hhf,C0205435;C1279901
egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
non ischaemic cardiomyopathy,C1518422;C0349782
drug therapy,C0013216;C0013217
time since diagnosis of heart failure,C0040223;C3541383
renin angiotensin system inhibitor,C1960108;C3537174;C4521920
kccq $nmbr$ months,C3476798;C0439231
microvascular disease history,C0443258;C0683519
nyha functional class at screening,C1882083;C0205245;C0542341;C2700217
atherosclerotic vascular disease history,C0683519
physiological measures,C0079809;C1879489
ratio of ldl to hdl cholesterol,C0456603;C1547037;C0023822;C0392885
other outcomes,C1274040
urinary albumin to creatinine ratio,C0486293;C1318293
laboratory measures,C0079809;C1879489
mg g,C1300563
nt probnp pg ml q $nmbr$ q $nmbr$,C0669479;C0439297;C0754710
mg mmol,C0567349;C2348885
change in nt probnp at $nmbr$,C0392747;C0443172;C1705241;C4319952
normoalbuminuria,
months log transformed,C1708728;C2986775;C1510411
composite of doubling of serum creatinine end stage kidney disease or death from renal causes,C0205199;C1547335;C0007465;C0022646
beta adrenergic blocker,C0001645;C2757061;C3536830
composite of $nmbr$ reduction in egfr end stage kidney disease or death from renal causes,C0205199;C1547335;C0022661;C2316810;C0007465;C0022646
devices for heart failure at screening visit,C0025078;C2024216;C0545082;C1512346;C2826704
pvaluefor interaction $nmbr$ $nmbr$,C1704675
crt p,
$nmbr$ $nmbr$ o $nmbr$ s o $nmbr$,C0483204
crt d,
central or south america,C0205099;C1879652;C0037713
change in nt probnp at $nmbr$ months log transformed,C0392747;C0443172;C1705241;C4319952;C1708728;C2986775;C1510411
rest ofthe world,C0035253;C2700280;C1622890
change in sbp $nmbr$ months,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ o $nmbr$ i $nmbr$,C0021966;C0221138
hyperkalaemia investigator reported,C0020461;C0035173;C4552983;C0684224;C0700287;C4319718
$nmbr$ $nmbr$ o $nmbr$ i o $nmbr$,C0021966;C0221138
hyperkalaemia serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
systolic blood pressure $nmbr$ mm hg or diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
symptomatic hypotension sbp,C0020649;C0085805;C3163620
blood pressure $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
deterioration in renal function investigator reported,C0868945;C0232804;C0684224;C0700287;C4319718
elevated serum creatinine $nmbr$ $nmbr$ mg dl_,C0700225;C0439269
systolic blood pressure $nmbr$ mm hg and diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
cough investigator reported,C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727;C0684224;C0700287;C4319718
$nmbr$ o $nmbr$ o $nmbr$,C0483204
hbai,
cough leading to study drug discontinuation,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C0332152;C0013175;C1522538
ecfr ml min per $nmbr$ $nmbr$ m,C0439445
fig $nmbr$ acr $nmbr$ $nmbr$ and $nmbr$ response rates by baseline tnf status at weeks $nmbr$ $nmbr$ and $nmbr$,C1412134;C1515941;C0237629;C0168634;C1442488;C0439230
baseline albuminuria,C0168634;C0001925;C1442488
fig $nmbr$ acr $nmbr$ acr $nmbr$ and acr $nmbr$ response rates by baseline mtx use at weeks $nmbr$ $nmbr$ and $nmbr$,C0349966;C1337208;C0237629;C0025677;C1417487;C0439230
renin angiotensin system inhibitor use,C0042153;C0457083;C1947944
no stroke n $nmbr$,C0038454;C4554100
loop diuretic use,C0042153;C0457083;C1947944
any stroke n $nmbr$,C0038454;C4554100
sotagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior ml before index acs,C0439526;C1705224;C3887665
race or ethnic group n,C0034510;C1706779;C3853635;C0441848
prior cabg before index acs,C0332152;C0010055;C2826257
hispanic latino ethnicity,C0015031;C0243103
cha $nmbr$ ds $nmbr$ vasc score median iqr,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
alc mmol mol,C1424945;C3829066;C3811058
labs at the index acs event,C0587081;C0441471;C4019010
mg dl sd,C0439269;C2699239
total cholesterol median iqr mg dl,C0201950;C0439269;C0543421
body mass index $nmbr$ kg m n,C0022718;C0439209;C4054209;C0369718;C0441922
ldl c median iqr mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
hdl c median iqr mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
systolic blood pressure $nmbr$ mm hg n,C0488055;C0871470;C1306620
time from acs to randomization median iqr,C0040223;C3541383;C0034656;C0549183;C0876920;C2347635;C2348144;C2939193
total daily insulin dose lu kg,C0022718;C0439209;C4054209
labs at randomization,C0587081;C0034656
mdi,C0993596;C1839839;C4049613
csii,
hs crp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
egfr median iqr ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
figure $nmbr$ lsm percent a and absolute b change from baseline in insulin dose at $nmbr$ and $nmbr$ weeks baseline values are iu day,C0439165;C1549031;C0168634;C1442488;C0366513;C0042295;C0439465
no prior stroke,C0038454;C4554100
drug therapy no,C0013216;C0013217
htn,C0020538
glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
no htn,C0020538
microvascular disease history no,C0443258;C0683519
crcl $nmbr$,C1846718
atherosclerotic vascular disease history no,C0683519
prior llt,C0332152;C2347090;C2826257
cv disease history no,C0683519
no prior llt,C0332152;C2347090;C2826257
systolic bp mm hg mean sd,C0488053;C2699239
ldl csmedian,
diastolic bp mm hg mean sd,C0488053;C2699239
ldl c median,C0549183;C0876920;C2347635;C2348144;C2939193
glycohemoglobin mean sd,C0202054;C2699239;C0696092
simva n $nmbr$ n,
hdl c mmol l mean sd,C1532563;C2699239
ez simva n $nmbr$ n,C0206578
ldl c mmol l mean sd,C1532563;C2699239
arr $nmbr$ cl,C2170357;C0596019;C4084934
ldl c hdl c ratio mean sd,C0428621;C2699239
stroke of any etiology,C0038454;C4554100
uacr mg g median iqr,C1300563;C0549183;C0876920;C2347635;C2348144;C2939193
primary trial end point,C2986535;C0008976
normoalbuminuria no,
other individual and exploratory end points,C0027361;C0237401;C2349179
micro or macroalbuminuria no,C0085672;C1553035;C3811161;C4049106
coronary heart disease death,C0376297
patients with an event per $nmbr$ patient years,C0030705;C0441471;C4019010;C0439234
cv death ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
number of participants with an event,C0237753;C0449788;C0441471;C4019010
patients no total no,C0030705;C0439175;C0439810
canagiiflozin,
stroke vs tia,C0038454;C4554100;C0007787;C0917805;C1054154
interaction p vaiue,C1704675
index event subtype,C0441471;C0449560;C4019010
fatal nonfatal ml,C0439526;C1705224;C3887665
large vessel atherosclerosis,C0225990;C0003850;C0004153
fatal nonfatal stroke,C0038454;C4554100
lacunar,
renal composite,C0205199;C1547335
cardioembolic,
geometric mean uacr,C2986759
other defined,C1704788;C3539106
dabigatran $nmbr$ mg b i d,C0439422
motor weakness,C1513492;C3714552;C1705994
nsaid at least once,C0003211;C3536840
aphasia,C0003537
never nsaid,C0003211;C3536840
modified rankin scale score,C2984908;C3854213
hr vs warfarin $nmbr$ ci,C0008107;C3259781
systolic blood pressure mean sd mm hga,C0428886;C0488055;C0871470;C1306620
gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
hemoglobin a $nmbr$ c mean sd b,C0062248
stroke se,C0038454;C0036919;C4554100
risk difference,C0035647;C1705241;C1705242;C4552904
duration of disease y,C0872146
feature,C1521970;C1706388;C2346469;C2348519
daily bowel movements,C0332173;C0011135
p int f,C0369773;C0016327;C2603361
$nmbr$ mg l,C0439268
htn hx,C0262926;C3814444
oral corticosteroid use at baseline,C0239126
placebo [n $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
mean dose,C0444504;C0178602;C0869039;C1114758;C2347634;C2348143
tofacitinib $nmbr$ mg bid [n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
median dose range,C0178602;C0869039;C1114758
placebo [n $nmbr$,C0032042;C1696465;C1706408;C0369718;C0441922
dapagliflozin $nmbr$ mg insulin n $nmbr$,C0024671;C0021641;C1533581;C1579433;C3714501;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean years [sd],C1510829;C0444504;C2347634;C2348143;C2699239
placebo insulin n $nmbr$,C0032042;C0021641;C1533581;C1579433;C3714501;C1696465;C1706408
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$,
total baseline insulin dose,C2986497
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ a,
dose iu,C0049272;C0439453;C0694756
gender n [ ] male,C0079399;C1522384;C0086582;C1706180;C1706428;C1706429
dose weight iu kg,C0005910;C0439463;C0043100;C1305866;C1705104
duration of disease median,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
method of insulin administration,C0087111;C1547585
years [range],C0439234;C1514721;C2348147;C3542016
use of cgm yes,C1524063;C1549445;C1705108;C1710701
previous anti tnf therapy n [ ],C0205156;C1552607
hba $nmbr$ c at randomization,C0019016;C0034656;C1825777;C3538758
$nmbr$ [ $nmbr$ $nmbr$ a,
subgroup statistics,C0038215;C0600673
concomitant aminosalicylates n [ ] concomitant corticosteroids n [ ] mayo score mean [sd],C0521115;C0368663;C0001617;C3539185;C3540725;C3540726;C3540727;C0444504;C2347634;C2348143;C2699239
for patients using personal cgm,C0030705;C1524063;C1519021
$nmbr$ _ $nmbr$ s,
adjusted mean change from baseline,C0392747;C0443172;C1705241;C4319952
ibdq total score mean [sd],C0444504;C2347634;C2348143;C2699239
difference from placebo $nmbr$ cl,C1705241;C1705242
ibdq domain scores mean [sd],C0444504;C2347634;C2348143;C2699239
for patients not using personal cgm,C0030705;C1518422;C1524063;C1519021
bowel function,C0011135
use of cgm interaction test p value^,C1524063;C1709380
systemic symptoms,C0683368;C1457887
adjusted mean change from baseline se,C0392747;C0443172;C1705241;C4319952
emotional status,C0013987;C0449438;C0849912
patients n n a,C0030705
social function,C0037395
overall pea population,C0032659;C1257890
sf $nmbr$ v $nmbr$ pcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
ics subset,C0815320;C1515021;C4551720
sf $nmbr$ v $nmbr$ mcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
ics laba subset,C0815320;C1515021;C4551720
sf $nmbr$ v $nmbr$ domain scores mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
ff vi n $nmbr$,C4554348;C0205999
physical function,C0516981;C4049916
uc n $nmbr$,
role physical,C0035820;C0031809;C0205485;C1509143;C1705810;C3871154
adjusted or $nmbr$ ci b,C0456081;C0008107;C3259781
role emotional,C0035820;C0013987;C0849912;C1705810;C3871154
adjusted or $nmbr$ ci c,C0456081;C0008107;C3259781
octave induction $nmbr$ and $nmbr$,C0205263;C0857127
act total score $nmbr$ and or improvement from baseline $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375;C2986411;C0168634;C1442488
ls mean change from baseline in ibdq total score at week $nmbr$ mean [se],C0392747;C0443172;C1705241;C4319952;C2964552;C0036919
act total score $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375
corticosteroid use at baseline,C0239126;C0168634;C1442488
improvement from baseline $nmbr$,C2986411;C0168634;C1442488
placebo n $nmbr$ i,C0021966;C0221138
difference ff vi versus uc $nmbr$ ci b,C1705241;C0205999;C1705242;C0008107;C3259781
patient demographics age yr,C4698447;C0439234
difference ff vi versus uc $nmbr$ ci c,C1705241;C0205999;C1705242;C0008107;C3259781
disease characteristics duration of psoriatic arthritis yr,C0872146;C0003872
percent work time missed due to asthma,C0043227;C0040223;C3541383;C1705492;C0678226
$nmbr$ $nmbr$ o $nmbr$,C0483204
percent impairment while working due to asthma,C0221099;C0684336;C0043227;C0678226
leeds enthesitis index^ score $nmbr$ no,C0449820;C4050231
percent overall work impairment due to asthma,C0221099;C0684336
dactylitis severity score score $nmbr$ no,C0239161;C0457451
percent activity impairment due to asthma,C0221099;C0684336
swollen joint count of $nmbr$ joints assessed no,C0451521;C1516048
proportion of responders n n,C1709707
tender or painful joint count of $nmbr$ joints assessed no,C0234234;C0750480;C1705566;C1516048
ffa i,C0021966;C0221138
elevated high sensitivity crp no,C0742906;C1441604
uc,
affected body surface area $nmbr$ no,C0005902;C1879646
environmental stimuli,C0450025
median pasi score range i i,C0021966;C0221138
activity limitation,C0443288;C0449295
day $nmbr$ oral glucocorticoid use no,C1527415;C0017710
emotional function,C0031843;C0542341;C0700205;C1705273
concomitant use of conventional synthetic dmard up to $nmbr$ mo no methotrexate,C1524063;C0242708;C0026544;C0332177;C0025677
secukinumab $nmbr$ mg no load n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1550025;C1704782;C1708715
leflunomide,C0063041
time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
otherj^,
hla b $nmbr$ positive at baseline n,C0439178;C1446409;C1514241;C2825490;C3812269
methotrexate dose on day $nmbr$ mg per wl,C4086581
tnfi na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
no of previous tne inhibitors,C0205156;C0243077;C1552607
total basdai score mean sd,C2964552;C2699239
previous use of other biologic agents in addition to tne,C1524063;C0005515;C3896585
total back pain score $nmbr$ $nmbr$ mm scale mean sd,C1504479;C2699239
inhibitors no se $nmbr$ physical functioning score^^,C0243077;C4483112
previous systemic treatment n,C0205156;C0678812;C1552607
eacit e total score,C2964552
methotrexate use at randomization,C0042153;C0457083;C1947944
figure s $nmbr$ american college of rheumatology $nmbr$ response rate and change from baseline in health assessment questionnaire disability index at month $nmbr$ by number of prior tnfi inadequate responses,C0035452;C0237629;C0392747;C0443172;C1705241;C4319952;C4321476;C0332177;C0439231;C0237753;C0449788
sulfasalazine use at randomization,C0042153;C0457083;C1947944
high sensitivity c reactive protein stratification,C0006560;C1514983;C1413716;C4048285
corticosteroid use at randomization,C0239126;C0034656
$nmbr$ to $nmbr$ mg l n $nmbr$,C0439268
cumulative nsaid score mean sd,C0003211;C2699239;C3536840
$nmbr$ mg l n $nmbr$,C0439268
uveitis,C0042164;C1963266
coronary bypass surgery,C0010055
tnf alpha inhibitor naive,C1448177;C1456820;C1522669
index acs,C0742343;C4318612
tnf alpha inhibitor inadequate response,C0871261;C1704632;C1706817;C2911692
major adverse cardiovascular events,C0877248;C1705413
asas $nmbr$,C0004057;C3853627
urgent revascularization because of unstable angina,C0581603;C0002965
hscrp post baseline baseline ratio ls mean se,C0023668;C0036919
complex anatomy n $nmbr$ $nmbr$,C0439855;C0002808;C0700276;C1384516;C1704241
asas $nmbr$ $nmbr$,C0004057;C3853627
noncomplex anatomy n $nmbr$ $nmbr$,C0002808;C0700276;C1384516
basdai ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
sf $nmbr$ pcs ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
stroke transient ischemic attack,C0007787;C0917805
asqol ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
anatomic complexity characteristics,C0220784;C1521970
benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ lesions per vessel,C0221198;C0005847
a $nmbr$ $nmbr$ $nmbr$ a $nmbr$,
bifurcation lesion with side branch $nmbr$ $nmbr$ mm stented,C0221198;C1546698;C0038257
a $nmbr$ $nmbr$,
vein bypass graft stented,C0398147;C0038257
$nmbr$ nil,C0442734
stent diameter $nmbr$ mm,C4330985;C4554674
other^,
central illustration dual antiplatelet therapy with complex lesions cumulative incidence of endpoint events from $nmbr$ to $nmbr$ months after randomization,C0205173;C1096021;C1554184;C0439231;C0034656
bmp kg m $nmbr$,C0022718;C0439209;C4054209
eosinophil counf cells pl,C3897966;C4049765
the endpoint events were strati ed by randomized treatment arm and number of anatomical complexity characteristics outcomes were analyzed comparing randomized treatments among subgroups of subjects with $nmbr$ n $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$ or $nmbr$ or more n $nmbr$ anatomic complexity characteristics to assess whether treatment effects differed depending on the number of complexity factors,C0441471;C3541888;C3538926;C1522541;C0237753;C0449788;C0936012;C1707455;C0034656;C0087111;C3815594;C0369718;C0441922;C0220784;C1521970;C1516048;C1518681
pre bronchodilator fevr l,C2599602;C1708033
ischemic stroke vs tia,C0948008;C0007787;C0917805;C1054154
pre bronchodilator fevr pred,C0032952;C0044955
modified rankin scale at screening $nmbr$ $nmbr$,C2984908;C3854213
$nmbr$ $nmbr$ $nmbr$ a $nmbr$,
nihss at randomization $nmbr$ $nmbr$,C1697238;C0034656
pre bronchodilator fevi fvc,C0802741;C3815113
int p,C3272375
$nmbr$ i $nmbr$ $nmbr$ ai,C0003504;C4551710
carotid stenosis,C0007282
pre bronchodilator fvc pred,C0032952;C0044955
canagliflozin dose,C0178602;C0869039;C1114758
age at asthma diagnosis years,C1828181;C3173302
aged $nmbr$ y or older n,C0001779;C0001792;C1999167;C0580836
exacerbations in the past $nmbr$ months n,C4086268;C0439231
bmi o $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
tass,C0559483
bmi $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
aqlq si $nmbr$ score,C0449820;C4050231
duration of diabetes y mean sd,C0449238;C2926735
atopic,C0392707
duration of oral antidiabetic treatment y mean sd,C0444921
ocs use,C0042153;C0457083;C1947944
egfr category n,C1739039;C0683312;C3889287;C3811844;C3812682
subgroup name level,C0441889;C0456079;C1547707;C2946261
$nmbr$ to o $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0483204;C0439445
fas,
serum creatinine gmol l mean sd,C0201976;C2699239;C0600061
no ocs,
subgroup treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no nasal polyps,C0027430
baseline value,C0168634;C1522609;C1442488
pre bd fvc,C0005126;C3714541;C2344255;C4050145
difference a vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
pre bd fvc s $nmbr$ of predicted,C0005126;C3714541;C2344255;C4050145;C0681842;C1882327
baseline bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
s $nmbr$ exacerbations,C4086268
baseline egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
age at diagnosis s $nmbr$ years,C1828181;C3173302;C0439234
duration of diabetes $nmbr$ years,C0449238;C2926735
age at diagnosis,C1828181;C3173302
baseline su dose $nmbr$ $nmbr$ maximal,C0205289;C0806909;C4049713
either ocs use nasal polyps pre bd fvc,C0027430;C3714541
calima japandhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$ y,C0178602;C0815320;C4551720;C2986497;C0005773
no ocs use no nasal polyps pre bd fvc s $nmbr$ of predicted and age at diagnosis,C0042153;C0457083;C1947944;C0027430;C3714541;C0681842;C1882327;C1828181;C3173302
aspirin group n $nmbr$,C0004057;C0441848
calima overalldhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$,C0178602;C0815320;C4551720;C2986497;C0005773
white race no i,C0007457;C0043157;C0021966;C0221138
benralizumab q $nmbr$ w n $nmbr$,C2982078
participant reported hypertension no,C0020538;C1963138
age [years] median range,C0001779;C0439234;C1514721;C2348147;C3542016
aspirin use before screening no,C0042153;C0457083;C1947944
body mass index [kg m $nmbr$ ] mean sd,C0005893;C0578022;C1305855;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
statin use no,C0042153;C0457083;C1947944
time since asthma diagnosis [years] median range,C0040223;C3541383;C0439234;C1514721;C2348147;C3542016
median interquartile range yr,C1711350;C0439234
oral corticosteroid use n,C1527415
vascular risk score no ^,C0449820;C4050231
number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C0439231
aspirin n $nmbr$ no of participants with events,C0004057;C0679646;C0441471;C3541888
ed visit related to exacerbation n,C0545082;C1512346;C2826704;C0439849;C0445223
placebo n $nmbr$ no of participants with events,C0032042;C1696465;C1706408;C0679646;C0441471;C3541888
hospitalisation related to exacerbation n,C0019993;C0439849;C0445223
heterogeneity or trend p vaiue,C0019409;C0242960;C1521798;C4554533
fev $nmbr$ prebronchodilator [l] mean sd,C3714541;C2599602;C0439394;C1706495;C3642217;C0444504;C2699239;C2347634;C2348143
body mass index kg m ^,C0022718;C0439209;C4054209
fev $nmbr$ prebronchodilator [ pn] mean sd,C3714541;C2599602;C0219433;C1549735;C3541307;C4049640;C4049767;C0444504;C2699239;C2347634;C2348143
weight at randomization kg,C2985844;C0022718;C0439209;C4054209
fev $nmbr$ fvc prebronchodilator mean sd,C0444504;C2699239;C2347634;C2348143
prior aspirin use,C0042153;C0457083;C1947944
reversibility [ ] median range,C0449261;C1514721;C2348147;C3542016
vascular risk score,C0449820;C4050231
total asthma symptom score mean sdz,C3533163;C0004096;C2984299
low $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
local eosinophil count [cells ml] median range,C0200638;C0750879;C2699156;C1514721;C2348147;C3542016
other treatment assignment,C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
calima japan n $nmbr$,C0022341
omega $nmbr$ fatty acids,C1719844;C0015684
calima overall n $nmbr$,C0282416;C1561607
moderate s $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
benralizumab,C2982078
q $nmbr$ w n $nmbr$,
fatty acid group n $nmbr$,C0015684;C0441848
unknown no,C0439673;C3541433;C4050014
number of exacerbations in the last $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
patient reported hypertension no,C0020538;C1963138
total asthma symptom score mean sd,C3533163;C2699239
medication use no,C0240320
local eosinophil count [cells l] median range,C0200638;C0750879;C0347983;C1514721;C2348147;C3542016
median iqr yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
japanese subgroup n $nmbr$,C0376247;C1079230;C1515021;C1556094
systolic blood pressure^,C0488055;C0871470;C1306620
any ae n,C3887670
$nmbr$ mm hg no,C0439475
aes in $nmbr$ japanese patients in a study arm n,C1412268;C2699274;C0557651;C0446516;C3715044;C4553528;C2603343
omega $nmbr$ fa n $nmbr$,C1719844
allergic rhinitis,C1334103;C2607914;C4552864
heterogeneity or trend p value,C0019409;C0242960;C1521798;C1709380;C4554533
eczema,C0013595;C4553957
percentage,C0439165;C1549488;C1561533
bacterial pneumonia,C0004626
body mass index kg m^ ^,C0022718;C0439209;C4054209
urticaria,C0042109;C1559188
canakinumab $nmbr$ month on treatment il $nmbr$ above the median value $nmbr$ $nmbr$ ng l n $nmbr$,C0020898;C0021764;C0022271;C0549183;C0439297;C0876920;C2347635;C2348144;C2939193
upper respiratory tract inflammation,C0877266
epistaxis,C0014591;C4554627
canakinumab $nmbr$ month on treatment il $nmbr$ below the median value,C0020898;C0021764;C0022271;C0549183;C0876920;C2347635;C2348144;C2939193
dermatitis atopic,C0011603;C0392707
unknown missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
injection site reaction n,C0151735;C4551923
randomized to canakinumab $nmbr$ mg,C0034656;C3815594
hypersensitivity n,C0020517;C0520946
treatment group on treatment il $nmbr$ threshold,C0020898;C0449864;C0021764;C0022271
any drug related ae n,C0013227;C0439849;C0445223;C1254351
incidence rate n a,C1708485
any ae leading to discontinuation n,C3887670;C0332152;C0457454;C1444662;C4552847;C1522538
hradjusted $nmbr$ ci b,C0008107;C3259781
any serious ae n,C0205404;C3887670
$nmbr$ ref,C1425988
deaths n,C0011065;C1306577
canakinumab il $nmbr$ top tertilec,C0020898;C0021764;C0022271
low dose rivaroxaban plus aspirin n $nmbr$,C2608320;C1739768
canakinumab il $nmbr$ middle tertile,C0020898;C0021764;C0022271
body mass index kq nrn,C0005893;C1425210;C0578022;C1305855
canakinumab il $nmbr$ lowest tertile,C0020898;C0021764;C0022271
p value for trend across categories,C1709380;C1521798;C4554533;C0683312
systolic blood pressure mm hq,C0488055;C0871470;C1306620
experimental intervention group n $nmbr$,C0441848
diastolic blood pressure mm hq,C0428883;C1305849
mean body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
smokinq status,C0449438
insulin dependent diabetes mellitus,C0011854
lipid lowerinq druq,C0023779
stable coronary artery disease,C0010054;C0010068;C1956346
e blocker,
reqion,
percutaneous coronary intervention done,C1532338;C1272695
north american,C0425358;C2700615
vascular access site,C0589360
south american,C0425359
lesions treated per patient,C0221198;C1522326;C0030705
western european includinq australia israel and south africa,C0043128;C0022271;C0037712
one lesion,C0221198;C1546698
eastern european,C0239309
two lesions,C0205448;C0221198
low dose rivaroxaban aspirin n n,C2608320;C1739768
three or more lesions,C0205449;C0221198
aspirin alone n n,C0004057;C0205171;C0439044;C0679994
treated lesions,C1522326;C0221198
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ oo,C0483204
n lesions,C0369718;C0221198;C0441922
w est europe,C3811127;C0015176;C3890902
stented lesions,C0038257;C0221198
east europe,C1707877;C0015176
index percutaneous coronary intervention,C0600653;C1532338;C0918012;C1552854;C1637833;C2986546
y es,C0013754;C0205944
n stented lesions,C0038257;C0221198
n o,C0369718;C0441922
mean stents per lesion sd,C0038257;C0221198;C1546698
no previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
biolimus a $nmbr$ eluting stent,C0038257
history of pci ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
other stent,C0038257
history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean total stent length per lesion mm sd,C1444754;C1706316
myocardial infarction cabg pci,C0027051;C4049621;C0428953;C2926063;C3810814;C4552959
mean stent diameter per lesion mm sd,C0038257;C0552409
$nmbr$ mmol l,C1532563
direct stenting per lesion,C0038257;C2348535
non smokers receiving lipid lowering drugs p blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
bifurcation per lesion,C0184906;C3146289
west europe,C1705493;C0015176
thrombus aspiration done per lesion,C0220787;C0349707;C0700198;C2712334;C2827071;C1272695;C0221198;C1546698
no previous myocardial infarction $nmbr$ $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
timi flow,C3272266
non smokers receiving lipid lowering drugs $nmbr$ blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
pre procedure,C3272300
w hite,
post procedure,C3272301
experimental treatment group,C0949266;C2585119
mean systolic blood pressure mm hg,C0428886;C0439475;C0488053
control group,C0009932
mean diastolic blood pressure mm hg,C0428886;C0439475;C0488053
indication,C0392360;C3146298
risk factors for pad,C0035648;C1553898
s $nmbr$ years,C0439234
median total cholesterol mmol l,C0201950;C1532563;C0543421
renal failure,C0035078;C1963154
previous aorta femoral or lower extremity bypass surgery pta of iliac or infrainguinal artery,C0003483;C0015811;C0187763;C3274435;C0003842;C0226004
left main treated,C0205091;C1522326;C0443246;C1552822
history of intermittent claudication and abi $nmbr$,C2315493;C1328319;C3888326
type of reference treatment strategy,C0455708;C0679199
previous limb or foot amputation,C0205156;C0015385;C1552607;C0188605
use of ticagrelor,C1524063;C1999375
symptomatic pad of lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
use of clopidogrel,C1524063;C0070166
carotid artery diseaset,C0007272;C0162859
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ o $nmbr$,C0483204
symptomatic padt,C0231220
cld $nmbr$ mg n l $nmbr$,C0439268
cad and abi,C1504769;C2239547;C3813548;C4284121;C1328319;C3888326
azl m $nmbr$ mg $nmbr$ cld $nmbr$ mg n l $nmbr$,C2827881
normal $nmbr$ $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
$nmbr$ $nmbr$ $nmbr$ l l,C3539687
non study ppi use,C0869040;C0358591;C0871125;C3811894
non hispanic and latino,C1518424;C0086528
low dose rivaroxaban aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
not collected^,C1516695;C1516698
aspirin alone group no of events total n,C0004057;C2826346;C0439175;C0439810
bmi kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
no of events total n,C0439175;C0439810
anti hypertensive treatment history n,C0432633
former or never,C0205156;C0750523;C2003901
raas inhibitors,C0243077
symptomatic pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
change from baseline to final apbm,C0392747;C0443172;C1705241;C4319952;C0205088;C1546485;C3853528
pad lower extremities,C0182158;C0023216;C0332568;C3540603;C3669270;C3814046;C4319657
cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
overall pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
azl m $nmbr$ mg cld $nmbr$ mg,C1319635
demographics and clinical characteristics,C0011298;C1704791;C0683325
p value overall,C1709380;C0282416;C1561607
all completers n $nmbr$ $nmbr$,
baseline $nmbr$ hour mean sbp mm hg,C0085805;C0439475
$nmbr$ hba $nmbr$ c,C0019016;C1825777;C3538758
cgfr ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
hba $nmbr$ c $nmbr$ n $nmbr$ $nmbr$,C0019016;C1825777;C3538758
people with diabetes n $nmbr$,C0027361;C0011847;C0011849
duration of t $nmbr$ d years,C0449238;C2926735;C0439234
people without diabetes n $nmbr$,C0027361;C0011847;C0011849
screening bmi kg m $nmbr$,C0022718;C0439209;C4054209
screening hba $nmbr$ c,C0220908;C0019016;C1825777;C3538758;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
atherosclerotic coronary heart disease ischaemic stroke or peripheral arterial disease n n number of people in phase $nmbr$ studies only high intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily,C0010054;C0948008;C0237753;C0449788;C0205390;C0947630;C1710475;C4081854;C0360714;C1704788;C3539106;C0024671;C0965129;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
basal insulin dose at run in u day,C0366513;C0456683
heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
iglar dose at randomization u day,C0178602;C0869039;C1114758
high intensity statins,C4081854;C0360714
all completers,
any other lipid lowering therapy n,C0585943
ls mean change sea,C0023668;C0036493
anti hyperglycaemic agent n,C0432633;C1321567
ls mean difference seb,C0059386;C1309881;C1423585;C3815268
injectable anti hyperglycaemic n,C1272883;C0432633
$nmbr$ confidence interval,C0009667
insulin n,C0021641;C1533581;C1579433;C3714501
dose n,C0178602;C0869039;C1114758
triglycerides median q $nmbr$ q $nmbr$,C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ c,
duration of total exposure to study treatment weeks,C0439175;C2826870;C0439810;C1521826;C0439230
mean iglar dose sd u day,C0178602;C0456683;C0869039;C1114758
teaes of special interest,C0205555;C0543488
mean lixi dose sd lg day,C0332173;C0439228;C0439505
study population,C2348561
age categories n,C2916832
proportion of individuals a alirocumab placebo,C1709707;C0027361;C0237401;C0032042;C1696465;C1706408
bmi categories n,C0578022;C0683312
rate per $nmbr$ patient years control vs alirocumab i,C0489879;C0030705;C0021966;C0221138
duration of type $nmbr$ diabetes categories n,C1547660;C1320657
hr vs control $nmbr$ cl,C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389
hba $nmbr$ c categories n,C0019016;C0683312;C1825777;C3538758
lisrs,
fasting plasma glucose categories n,C0202042;C0455280
neurocognitive disorders,C0029227;C4041080
metformin use n,C0025598;C0042153;C0457083;C1947944
neurologicai events,C0441471;C3541888
total daily insulin dose u,C2348070;C0439148
hepatic disorders,C0023895
insulin type n,C0457592
general allergic events,C0441471;C3541888
intermediate acting,C0205103;C1550465;C2827755;C3889971
ophthalmologic events,C0441471;C3541888
intermediate long acting fast acting,C0015663;C0456962;C2985769
dm or diabetic complications,C0011816;C3250443;C0342257
adjudicated mace $nmbr$,C0349381;C0949745;C1445339
long acting intermediate long acting fast acting,C0015663;C0456962;C2985769
teaes in a $nmbr$ of individuals,C0027361;C0237401
individuals without diabetes n $nmbr$ $nmbr$,C0027361;C0237401
proportion of individuals control alirocumab,C1709707;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
baseline bmi $nmbr$ to,C0168634;C0578022;C1442488
rate per $nmbr$ patient years control vs alirocumab,C0489879;C0030705;C3491162
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
k,C0597277;C1708601
liraglutide $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
prediabetes,C0362046
at,
individuals with diabetes n $nmbr$,C0027361;C0237401
ta,C0039297;C1506978;C1705538;C3272501;C4553364
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
tk,C0041405;C0220928;C4050092
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$ change from baseline to $nmbr$ weeks,C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
week $nmbr$ czp dose combined n $nmbr$,C0054841;C0178602;C0869039;C1114758;C1861828;C1872109
liraglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dmard n $nmbr$,C0242708
etd $nmbr$ ci,C0008107;C3259781
demographic characteristics mean sd unless otherwise stated,C0683970;C2699239;C1301808;C1442792
iwqol lite total score arbitrary units,C1264693;C0439148;C1519795;C3853603
disease characteristics n unless otherwise stated,C0599878;C1301808;C1442792
iwqol lite physical score arbitrary units,C1264693;C0439148;C1519795;C3853603
prior use of synthetic dmards,C1524063;C0242708
baseline bmi $nmbr$ to $nmbr$ kg m $nmbr$ n $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0578022;C1442488;C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
concomitant use of corticosteroids,C1524063
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ change from baseline to $nmbr$ weeks,C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
tender joint count $nmbr$ $nmbr$ joints mean sd,C0451530;C2699239
canakinumab hscrp $nmbr$ $nmbr$ mg l at $nmbr$ months n $nmbr$,C0439268;C0439231
swollen joint count $nmbr$ $nmbr$ joints mean sd,C0451521;C2699239
canakinumab hscrp,C2718773
patients with psoriasis bsa $nmbr$,C0030705;C0033860
unknown or missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
pasi mean sd,C0444504;C2699239;C2347634;C2348143
renin angiotensin inhibitors,C2917241;C3653375
patients with enthesitis lei $nmbr$,C0030705;C1282952
anti ischaemia agents,C0450442;C1254351;C1521826
lei mean sd,C0444504;C2699239;C2347634;C2348143
interleukin $nmbr$ ng l,C0021764;C0439297;C1527200
patients with dactylitisa,C0030705
randomised to canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ldi mean sd a,C0444504;C2699239;C2347634;C2348143
primary cardiovascular endpoint,C2986535;C0007226;C3887460
patients with nail psoriasis mnapsi $nmbr$,C0030705;C0406322
incidence rate per $nmbr$ person years,C1708485;C0027361;C2347489
mnapsi mean sd,C0444504;C2699239;C2347634;C2348143
canakinumab,C2718773
observed,C1441672
ldl cholesterol $nmbr$ $nmbr$ mmol l,C0023824;C1532563;C0202117
imputed,C2699638
hscrp $nmbr$ to,
clinical and patient reported outcomes observed n unless otherwise indicated,C0205210;C2987124;C1441672;C1444656
hscrp $nmbr$ mg l,C0439268
pasi $nmbr$ a,C4528685
hdl cholesterol $nmbr$ $nmbr$ mmol l,C0023822;C1532563;C0392885
ldi mean [sd]b,C0444504;C2347634;C2348143;C2699239
triglycerides $nmbr$ $nmbr$ mmol l,C0041004;C1532563
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ] n $nmbr$,C0369718;C0441922
secondary cardiovascular endpoint,C4528314;C0007226;C3887460
total resolution of dactylitisb,C1514893;C1706463;C2699488
sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
lei mean [sd]c,C0444504;C2347634;C2348143;C2699239
$nmbr$ sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
total resolution of enthesitisc,C1514893;C1706463;C2699488
pulse pressure mmhg,C0949236;C0439475
mnapsi mean [sd]d,C0444504;C2347634;C2348143;C2699239
randomization to,C0034656
total resolution of nail psoriasisd,C1514893;C1706463;C2699488
nyha class iii or iv n,C1882086;C0022326;C4265176
haq di mean [sd],C0444504;C2347634;C2348143;C2699239
enrolment through hf,C1516879;C1696073;C3888021
haq di mcide,C3826998;C4321476
hospitalization stratum n,C0019993
uc [gemini $nmbr$ ],
co morbidities n,C0009488
cd [gemini $nmbr$ ],C0007928;C0034283;C4552032
acei and or arb,C3888198
vdz n \ $nmbr$,
other anti hypertensive,C0003364
vdz pla n $nmbr$,C0456170
anti hypertensive,C0003364
pla n $nmbr$,C0456170
laboratory testing,C0022885
vdz n $nmbr$,
rate ml min $nmbr$ $nmbr$ m $nmbr$,C0871208;C0439445;C1521828
pla $nmbr$,C0456170
ecg and imaging data,C1623258;C1511726;C3245479;C3714741
disease duration mean [sd] years,C0444504;C2347634;C2348143;C2699239;C0439234
ecg left ventricular,C1623258;C0225897
disease duration $nmbr$ years $nmbr$ [ ] disease activity s,C0872146;C0439234;C1292728
hypertrophy n,C0020564
cdai mean [sd],C0444504;C2347634;C2348143;C2699239
ecg atrial fibrillation n,C0004238;C0344434;C1963067
cdai $nmbr$ n [ ],C0683448;C1413248;C3273706
composite endpoint,C2349179;C2826544
ms mean [sd],C0444504;C2347634;C2348143;C2699239
event rate per $nmbr$ person years,C0871208;C1521828
ms,C2349943;C3539704;C3713294
crude model hr $nmbr$ ci,C0008107;C3259781
ms $nmbr$ $nmbr$ n [ ],C2349943;C3539704;C3713294
multivariable adjusted model hr $nmbr$ ci,C0008107;C3259781
crp mean [sd] mg $nmbr$,C0444504;C2347634;C2348143;C2699239;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
recurrent hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
crp $nmbr$ mg $nmbr$ n [ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hyperkalaemia,C0020461;C4552983
concomitant therapy n [ ],C1707479
hypokalaemia,C0020621;C4553966
cs and im,C0010182;C0271160;C3540510;C4085345
men n $nmbr$ $nmbr$,C0025266
im on]y,
prior lipid lowering agent use,C0042153;C0457083;C1947944
prior tnf antagonist n [ ],C0332152;C0231491;C2826257
at qualifying event,C1514624;C0441471;C4019010
smoking status n [ ],C1519386
dual antiplatelet,C0205173;C1554184
pbo simva $nmbr$ yr km rale,C0031962;C0034642
supplementary figure $nmbr$ incidence of arthritis arthralgia in patients receiving corticosteroids at baseline according to tapering of corticosteroids in the previous $nmbr$ weeks in a patients with crohn s disease n $nmbr$ and b patients with ulcerative colitis n $nmbr$ this analysis includes patients who received $nmbr$ mg prednisone equivalent per day at baseline,C0021149;C0220856;C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727;C0441640;C1548969;C0439230;C0010346;C0012634;C0009324;C0002778;C0936012;C1524024;C0332257;C1552866;C2700399;C0205163;C0439185;C0168634;C1442488
eze simva $nmbr$ yr km rale,C0439234;C0034642
aii participants n $nmbr$,C1424250;C0679646;C2698414
any death,C0011065;C1306577;C4082313;C4552775
anti gad positive n $nmbr$,C0270549;C0439178;C1446409;C1514241;C2825490;C3812269;C1414925
coronary revascularization $nmbr$ days after randomization,C0877341;C0439228
anti gad negative n $nmbr$,C0270549;C0205160;C1513916;C2825415;C2825491;C3853545;C1414925
cardiovascular death myocardial infarction stroke,C0027051;C0428953;C2926063;C3810814;C4552959
prior cvd,C0332152;C0007222;C2826257
pint,C0560012;C3811619;C3890014;C3890556
thyroid disease,C0040128
cardiovasculardeath,
ethnic background,C0015031
cardiovasculardeath myocardial infarction stroke,C0038454;C4554100
prior gestational diabetes,C0332152;C0085207;C2826257
placebo simvastatin,C0032042;C0074554;C1696465;C1706408
alcohol $nmbr$ drinks per week,C0556297;C0332174;C0439230
ezetimibe simvastatin,C1532737
education level,C0013621;C0013658
pin,C0175718;C1168556;C1704584
education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
permanently stopped study drug because of adverse events,C0041755
education $nmbr$ y,C0013621;C0013622;C0013658;C0039401
alt ast or both $nmbr$ x uln,C3831581;C1519815
creatinine pmol l,C0010294;C0439284;C1561535
gallbladder related aes,C1412268;C2699274
acr $nmbr$ mg g,C1412134;C1300563;C1515941
rhabdomyolysis or myopathy,C0035410;C4552660;C0026848
f plasma glucose mmol l,C0202042;C1532563;C0455280
rhabdomyolysis myopathy or myalgia with ck elevation $nmbr$ x uln,C0035410;C0026848;C4552660;C0231528;C4552646
statin users,C0360714;C1706077
myopathy,C0026848
ace arb users,C1452534;C1706077;C4284014
ertugliflozin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
beta blocker users,C0001645;C1706077
medical history of cv disease or heart failure n,C0262926;C0018801;C0018802;C4554158
thiazide users,C0541746;C1706077
currently on aha therapy,C0050451;C0039798;C0087111;C1363945;C0772110
c peptide nmol l,C0607868
glp $nmbr$ receptor agonists,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
overall n n loopy,C0282416;C1561607
insulins and analogs,C0021641;C3537244;C4049919;C0243071
glargine n n loopy,C0907402
overall cohort primary analysis,C0086027;C0205225;C0439612;C0439631
std n n loopy,
difference in ls means $nmbr$ ci versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408
person years,C0027361;C0439234;C2347489
stage $nmbr$ a ckd cohort secondary analysis,C0205390;C1300072;C1306673;C0086027;C0027627;C0175668;C0205436
first co primary,C0205225;C0439612;C0439631
overall cohort post hoc analysis excluding metformin users,C0086027;C0025598
anti gad positive,C0439178;C1446409;C1514241;C2825490;C3812269
stage $nmbr$ a ckd cohort post hoc analysis excluding metformin users,C0205390;C1300072;C1306673;C0086027;C0025598
anti gad negative,C0205160;C1513916;C2825415;C2825491;C3853545
week $nmbr$ a,C0332174;C0439230
second co primary,C0205225;C0439612;C0439631
table $nmbr$ baseline characteristics in america between patients w wo resistant htn,C4684572;C0002454;C0030705;C1980014
microvascular outcome,C0443258;C1274040
non severe hypoglycaemia,C0020615;C4553659
hbalc $nmbr$ $nmbr$ mmol mol,C3829066
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker bb beta blocker bmi body mass index bnp brain natriuretic peptide ccb calcium channel blocker dbp diastolic blood pressure egfr estimated glomerular ltration rate hr heart rate sbp systolic blood pressure w wo with or without,C4528226;C1980014
iglarlixi n $nmbr$,
america all patients,C0002454;C0030705
iglar n $nmbr$,
america rhtn only,C0002454
beam values mg dl mean sd,C0439269;C2699239
no resistant htn n $nmbr$ $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
beam $nmbr$ mg dl at week $nmbr$ n,C0439269;C0332174;C0439230
resistant htn n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
sample statistics,C2348149
resistant htn placebo n $nmbr$,C0020538;C0032042;C1696465;C1706408
nilvadipine,C0132512
resistant htn spiro n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
years since diagnosis,C0439234;C0011900;C1704338;C1704656
race_white,C0007457;C0043157;C0220938
years since symptom onset,C0439234;C4086878
nyha_class,C1882083
apoe $nmbr$ carrier,C0007294;C0560175;C1325398;C1706209;C3273162
eligibility strata,C0013893;C1548635
smmse,
elevated bnp,C0054015;C1095989;C1417808;C2982014
smmse $nmbr$,
ace or arb,C1452534;C4284014;C3888198
baseline adas cog $nmbr$,C0168634;C3539026;C1442488
bb,C0004739;C0332297
baseline cdr sb n $nmbr$ $nmbr$,C0168634;C0038111;C3811240;C1442488
hb g dl,C0439267
baseline dad n $nmbr$ $nmbr$,C0168634;C1442488
table $nmbr$ outcomes in americas according to the presence absence of rhtn,C1274040;C0002454;C0596070;C0332197;C1689985
d $nmbr$ ci,C0008107;C3259781
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker ci con dence interval cvd cardiovascular death hf heart failure hr hazard ratio rhtn resistant hypertension afrom unadjusted model bstrati ed by eligibility strata cfurther adjusted for age ace arb diabetes,C0596525;C3538926;C0013893;C1548635;C4300468
group difference,C1705241;C1705242
rhtn,
non carrier n $nmbr$,C2986416
no rhtn,
carrier n $nmbr$,C0007294;C0560175;C1325398;C1706209;C3273162
number and of participants with events and incidence rate per $nmbr$ person year,C0237753;C0449788;C0679646;C0441471;C3541888;C1708485;C0027361;C2347489
mild n $nmbr$,C2945599
unadjusted model hr $nmbr$ ci p value,C0008107;C1709380;C3259781
moderate n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
strata modelb hr $nmbr$ ci p value,C0008107;C1709380;C3259781
ease $nmbr$,C1331418
adjusted modelc hr $nmbr$ ci p value,C0008107;C1709380;C3259781
empaglifiozin $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p for interaction between rhtn and no rhtn and treatmenta,C0369773;C2603361
placebo w $nmbr$,C0032042;C1696465;C1706408
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr,
empaglifiozin $nmbr$ $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
femaie,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per pyr $nmbr$ pyr,
pacific,
recurrent hf,C0018488;C1313497;C1538440;C3273279
egfr ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
$nmbr$ $nmbr$ per $nmbr$ pyr,
total daily insulin dose units kgt,C2348070
$nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr pyr,
basal insulin doset,C0650607
itca $nmbr$ $nmbr$ mg day n $nmbr$,C0165330;C0439422
bolus insulin doseh,C1186706;C0021641;C1533581;C1579433;C3714501;C1511237;C1705509;C3812160
femalesex,
type of insulin,C0457592
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
figure $nmbr$ hba $nmbr$ c ef cacy analysis data are from patients treated with $nmbr$ dose of study drug who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement c placebo corrected change from baseline in hba $nmbr$ c with empagli ozin at week $nmbr$ in subgroups by baseline hba $nmbr$ c $nmbr$ and $nmbr$ data are based on mixed model repeated measures analysis p $nmbr$ $nmbr$ for difference vs placebo p $nmbr$ $nmbr$ for difference vs placebo,C1511726;C3245479;C3714741;C0030705;C0332293;C0013175;C0168634;C1442488;C1299575;C0019016;C1825777;C3538758;C0332174;C0439230;C1079232;C1527178;C1705938;C1705241;C1705242;C0032042;C1696465;C1706408
egfr ml min bsa,C1739039;C0439445;C3811844;C3812682
permanent users,C0205355;C1706077
medications at baselinet,C0013227;C0802604;C2598133;C4284232
fp,C0016704;C1419068;C1419906;C3541238;C3541412
metforminmonotherapy,
other ics,C0815320;C4551720
metformin su tzd,C0025598;C0038642;C1705534
no ics,C0815320;C4551720
tah n $nmbr$,C0404079
non inhaled steroid use n,C1518422;C0586793
ta n $nmbr$,C0039297;C1506978;C1705538;C3272501;C4553364
anticholinergic use n,C0242896;C0042153;C0457083;C1947944;C3537004
anthropometrics mean sd,C0444504;C2699239;C2347634;C2348143
fvc l mean sd,C0444504;C2699239;C2347634;C2348143
vital signs mean sd,C0150404;C2699239;C0518766
fvc predicted mean sd,C0444504;C2699239;C2347634;C2348143
baseline sitting sbp $nmbr$ mm hg,C0085805;C0439475
fev $nmbr$ fvc mean sd,C0444504;C2699239;C2347634;C2348143
baseline sitting dbp mm hg,C0168634;C0439475;C1442488
post bronchodilator fev $nmbr$ l mean sd,C2599594;C2699239
comorbidity no,C0009488
post bronchodilator fev $nmbr$ predicted mean sd,C2599594;C2699239
dm or ckd,C0011816;C3250443;C1561643
treatment throughout study,C1521826;C3161471
female gender n,C0086287
fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
crcl ml min mean sd,C0439445;C2699239
fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
prespecified medical conditions n f,C0199168;C0016327;C0205476
other ics versus no ics,C0815320;C4551720
cardiovascular disease n,C0007222
hr or rr $nmbr$ ci,C0008107;C3259781
cancer n,C0006826;C0998265;C1306459
permanent users n,C0205355;C1706077
number of medications n,C1718138
patients with pneumonia events n,C0030705;C0032285
aspirin use n,C0004057;C0042153;C0457083;C1947944
pneumonia events n,C0032285;C0441471;C3541888
dose adjustment n,C2826232
adjusted rate of pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
dose adjustment reason $nmbr$ kg,C0022718;C0439209;C4054209
patients with hospitalized pneumonia events n,C0870668;C0032285
crcl $nmbr$ $nmbr$ ml min,C1846718;C0439445
hospitalized pneumonia events n,C0032285;C0441471;C3541888
p gp use,C0042153;C0457083;C1947944
adjusted rate of hospitalized pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
two or more,C0205448
patients with pneumonia resulting in death n,C0030705;C0032285;C0332294;C0011065;C1306577;C4082313;C4552775
treatment duration mean sd,C0444921;C2699239;C3259042
treatment at baseline,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
unprovoked vte n,C0630906
hr or rr,
index events dvt n,C0441471;C0149871;C2926618;C3899446;C3541888
use at baseline n,C0042153;C0457083;C1947944
extent of index dvt n of dvt patients,C0439792;C0030705
patients with pneumonia event n,C0030705;C0032285
index events pe dvt n,C0070939;C0149871;C2926618;C3899446;C1880476;C4284304
albiglutide n $nmbr$,C2607479
extent of index pe n of pe patients,C0439792;C0030705
race or ethnicity,C0034510;C1706779;C3853635;C0015031;C0243103
nt probnp $nmbr$ ng ml n,C4284038;C0439275
non hispanic black or african american,C0005680;C0027567;C0085756;C0439541
edoxaban n n rate,C0871208;C1521828
eastern and central europe,C1707877;C0682369
warfarin n n rate,C0871208;C1521828
diabetic eye disease,C0342245
primary efficacy outcome recurrent vte during overall study period,C0543472;C0630906
peripheral sensory neuropathy,C0151313;C4554142
primary safety outcome major or clinically relevant non major bleeding,C0205082;C0205164;C4318856;C4521762;C0019080
autonomic neuropathy,C0259749
net clinical benefit on treatment vte or major bleeding,C1516635;C0630906;C0205082;C0019080;C0205164;C4318856;C4521762
glucose lowering medications,C0017725;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
diabetes absent $nmbr$ $nmbr$ $nmbr$,C0011847;C0011849;C0332197;C4285062
none or diet,C0012155;C0012159;C1519433;C2983588;C3668949
diabetes present $nmbr$ $nmbr$ $nmbr$,C0150312;C0449450
sodium glucose cotransporter $nmbr$ inhibitor,C0017725;C1999216
median weight kg iqr,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
glucosidase inhibitor,C1512211
median body mass index kg m $nmbr$ iqr,C0022718;C0439209;C4054209
albiglutide events patients,C0441471;C0030705;C3541888
medications before admission,C0013227;C0802604;C2598133;C4284232
$nmbr$ $nmbr$ o $nmbr$ s i $nmbr$,C0021966;C0221138
at index event,C0441471;C4019010
$nmbr$ $nmbr$ o $nmbr$ o i i $nmbr$,C0021966;C0221138
diagnostic angiography,C0002978
$nmbr$ o $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
laboratory values at admission median and iqr,C0022877;C0042295;C3244292;C4283904
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$ ^,
no prior statin use,C0042153;C0457083;C1947944
number of arterial beds involved,C0237753;C0449788;C1314939
high density lipoprotein cholesterol mg l,C0023822;C0439268
heart failure history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
triglycerides mg l,C0041004;C0439268
baseline egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
creatine clearance ml min,C0373595;C0439445
baseline dipeptidyl peptidase a,C0168634;C0022709;C1442488
laboratory values at randomization median and iqr,C0022877;C0042295;C3244292;C4283904
baseline antiplatelet,C0168634;C1442488
statin during admission,C0360714;C0184666;C0809949
normoalbuminuria uacr,
no statin during admission,C0360714;C0184666;C0809949
lixisenatide n $nmbr$ o,C2973895
km event at $nmbr$ y,C0441471;C4019010
$nmbr$ tq fi i,C0021966;C0221138
primary end points,C0205225;C2349179;C0439612;C0439631
$nmbr$ f $nmbr$ q,C0016327
secondary end points $nmbr$,C0027627;C2349179;C0175668;C0205436
$nmbr$ f $nmbr$ l $nmbr$,C0016327
secondary end points ii,C1710602;C4082587
egfr ml min per $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
secondary end points iii,C0439070;C1705160
$nmbr$ ^ f $nmbr$ $nmbr$,C0016327
tertiary end points,C0205372;C2349179
therapies,C0087111
alanine aminotransferase or aspartate aminotransferase $nmbr$ x upper limit of normal n $nmbr$,C0001899;C0057041;C1415274;C3887708;C0004002;C1519815
angiotensin converting enzyme inhibitors,C0003015;C2757044
dm absent,C0011816;C3250443;C0332197;C4285062
other blood pressure lowering drugs,C0003364
dm present,C0150312;C0449450
amann whitney u test wilcoxon sum rank test,C0439148;C0683443
cholecystectomy n $nmbr$,C0008320
age group $nmbr$ no,C0027362;C2348001
gall bladder adverse event n $nmbr$,C0016976;C0877248
bpearson s chi square test,C0008041
rhabdomyolysis n $nmbr$,C0035410;C4552660
body mass index group kg m $nmbr$ $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
rhabdomyolysis myopathy or elevated creatine phosphokinase $nmbr$ x upper limit of normal n $nmbr$,C0035410;C0026848;C4552660;C1519815
dyslipidaemia including hypercholesterol no,C0242339
hemorrhagic stroke n $nmbr$,C0553692
cancer n $nmbr$,C0006826;C0998265;C1306459
chronic renal disease no,C0022661;C1561643
e $nmbr$ n $nmbr$,
cfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
s $nmbr$ n $nmbr$,C2986823
mi no,C3810814
e $nmbr$ s $nmbr$ n $nmbr$,C3846405
coronary artery bypass graft no,C0010055;C1260596
testing order,C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
chronic obstructive pulmonary disease no,C0024117
hba $nmbr$ c change from baseline,C0392747;C0443172;C1705241;C4319952
transient ischaemic attack no,C0007787;C0917805
e $nmbr$ s $nmbr$ vs s $nmbr$,C3846405
haemorrhagic stroke no,C0553692
e $nmbr$ s $nmbr$ vs e $nmbr$,C3846405
non haemorrhagic stroke no,C1518422;C0553692
body weight change from baseline,C0005911
timi risk score category no,C0683312;C3889287
fasting plasma glucose change from baseline,C0392747;C0443172;C1705241;C4319952
gp iib iiia inhibitor before pci no,C0016011;C1999216
systolic blood pressure change from baseline,C1268766
ticagrelor in hosp n $nmbr$,C1999375
hba $nmbr$ c patients,C0019016;C0030705;C1825777;C3538758
ticagrelor pre hosp n $nmbr$,C0332152;C0740175;C2257086;C3669034
atwo sample t test,C0370003;C0871472;C2347026
dynamic measure of cell function s change from baseline assessed for mmtt subset only,C0079809;C0242485;C0392747;C0443172;C1705241;C4319952;C1516048;C1515021
liraglutide $nmbr$,C1456408
age group $nmbr$ years no,C1510829
hbaie mean sd,C0444504;C2699239;C2347634;C2348143
cmann whitney u test wilcoxon sum rank test,C0439148;C0683443
hbajc mmol mol mean sd,C3829066;C2699239
body mass index group $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
diabetes duration mean sd,C0011847;C2699239;C0011849
dyslipidaemia no,C0242339
$nmbr$ $nmbr$ d,
caleitonin ng l males mean sd,C0439297;C2699239
dfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
$nmbr$ $nmbr$ lo $nmbr$ $nmbr$,C0206579;C1232424
univariate logistic modela,C0242415
caleitonin ng l females mean sd,C0439297;C2699239
multivariate logistic modelb,C0242415
lo lo lo,C0206579;C1232424
aunivariate logistic regression,C0206031
egfr n normal egfr $nmbr$ ml min em^,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828;C0441722;C0443221
mild impairment egfr $nmbr$ $nmbr$ ml min m^,C0221099;C0439445;C0684336
mi previous pci and chronic obstructive pulmonary disease,C0205156;C4049621;C1552607;C0024117
moderate impairment egfr $nmbr$ $nmbr$ ml min m^,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335
pre hospital ticagrelor,C0019994;C1999375;C1510665
patients with established cv disease aged $nmbr$ years,C0683521
in hospital ticagrelor,C0019994;C1999375;C1510665
n patients with risk faetors for cv disease aged $nmbr$,C0030705;C0035647;C4552904;C0007222;C0001779;C0001792;C1999167
the p value is from the test statistic for testing the interaction between the treatment group and diabetes group,C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675;C0374505;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
years n smoking n current,C0521116;C1705970
$nmbr$ days composite of death new mi urgent revascularization and definite st,C0205199;C1547335;C0036056;C3272372
use of proton inhibitors n,C1524063;C0033727
$nmbr$ days new mi or definite acute st,C0205314;C3810814;C0036056;C3272372
use of h $nmbr$ bloekers n,C1524063;C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ days new mi,C0205314;C3810814
history of thyroid disease n,C0683519;C0730226;C0850708;C0944983
$nmbr$ days definite st,C0036056;C3272372
ct calcitonin cv cardiovascular egfr estimated glomerular filtration rate hbalc glycated hemoglobin h $nmbr$ histamine $nmbr$ iqr interquartile range n number of patients sd standard deviation,C2986735;C0030705;C0871420
$nmbr$ days urgent revascularization,C0439228;C0581603
high uln,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
$nmbr$ days stroke ischemic,C0038454;C0475224;C4554100
$nmbr$ ng l,C0439297
timi flow grade $nmbr$ of mi culprit vessel pre pci,C0441800;C0919553;C3244287;C3810814;C0005847;C0332152;C0740175;C2257086;C3669034
ulnand,
st str $nmbr$ pre ci,C0008107;C3259781
cdmard,
timi flow grade $nmbr$ of mi culprit vessel post pci,C0441800;C0919553;C3244287;C0856742;C4049621
none cdmard naive or past use at baseline,C0042153;C0457083;C1947944;C0168634;C1442488
st str $nmbr$ post pci,C0036056;C4049621;C3272372
ixeq $nmbr$ w n $nmbr$,C0369718;C0441922
bail out use of glycoprotein iib iiia inhibitors,C1524063;C0016011
time since psa diagnosis years mean sd,C0556970;C0011900;C1704338;C1704656
timi minor bleeding,C0026193;C0019080;C0205165
tender joint count $nmbr$ joints mean sd,C0451530;C2699239
antiplatelet use,C0042153;C0457083;C1947944
swollen joint count $nmbr$ joints mean sd,C0451521;C2699239
high intensity statin use,C0042153;C0457083;C1947944
haq di total score mean sd,C2964552;C2699239
moderate intensity statin use,C0042153;C0457083;C1947944
van der heijde mtss mean sd,C0444504;C2699239;C2347634;C2348143
imaged artery,C0003842;C0226004
figure $nmbr$ acr response rates at $nmbr$ weeks in patients treated with pbo ixeq $nmbr$ w or ixeq $nmbr$ w alone or in combination with cdmards or mtx the proportions of patients achieving acr $nmbr$ a acr $nmbr$ b and acr $nmbr$ c are shown,C0237629;C0439230;C0030705;C0332293;C0031962;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910;C0025677;C1417487;C1709707;C1412134;C1515941;C1547282
ramus,C3538818
overallb,
p value between groups,C1709380
who fc ii symptoms at baseline,C0683368;C1457887
normalized volume measures,C0079809;C1879489
who fc iii symptoms at baseline,C0683368;C1457887
necrotic core mm^,C4330985;C4554674
time since pah diagnosisc years,C0556970;C0030123;C3203102;C4284467
nominal change,C0392747;C0443172;C1705241;C4319952
pah classification,C0008902;C0008903;C0678229
fibrofatty mm^,C4330985;C4554674
associated with ctd,C0332281;C1335071;C1442905
fibrous mm,C4330985;C4554674
associated with corrected,C0332281;C0205202
dense calcium mm,C4330985;C4554674
congenital shunts,C0232180;C0542331;C1442858
necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
associated with drug toxin,C0332281;C0013227;C1254351
volume change mm^,C4330985;C4554674
exposure,C0274281;C0332157
fibrofatty,
p value for interaction $nmbr$,C1709380;C1704675
fibrous,C0016059;C0439709
patients events n,C0030705;C0441471;C3541888
dense calcium,C0006675;C0006726;C2936886;C3540037;C3714611
selexipag vs placebo hazard ratio $nmbr$ cl,C2000145;C2985465;C0596019
fig $nmbr$ proportion of patients achieving das de ned remission over time by symptom duration in each treatment arm a abatacept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci das de ned remission is de ned as das $nmbr$ crp $nmbr$ $nmbr$ das $nmbr$ crp disease activity score in $nmbr$ joints with c reactive pro tein das $nmbr$ crp mtx methotrexate,C1709707;C0030705;C0544452;C0687702;C0444921;C3259042;C0743559;C1608199;C1882932;C1518340;C4706353;C0022417;C0392905
time to first morbidity mortality event up to the end of the treatment periodd,C0040223;C3541383;C0444930;C2746065
fig $nmbr$ proportion of patients achieving haq response over time by baseline symptom duration in each treatment arm a abata cept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci haq response is de ned as a reduction of at least $nmbr$ $nmbr$ units from baseline haq h ealth assessment question naire mtx methotrexate,C1709707;C0030705;C0102923;C0034746;C0451208;C0444921;C3259042;C0743559;C1608199;C1882932;C0871261;C1704632;C1706817;C2911692;C0011198;C1518340;C0017480;C3541240;C4684571;C0025677
time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931;C0030123;C3203102;C4284467;C0019993;C0678226;C0444930;C2746065
dapaglifloiin n,
time to all cause death up to end of the study,C1301931;C0444930;C2746065
[ ifrerence vs placebo $nmbr$ cl,C0032042;C0596019;C1696465;C1706408
open label population,C0032659;C1257890
baseline hbalc^,C0168634;C1442488
randomize,
s $nmbr$ $nmbr$ s $nmbr$ $nmbr$,C0565930;C2603362
d population,C0032659;C1257890
s $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
demographic disease characteristics at baseline,C0599878
insulin administration,C0199782
etn $nmbr$ mg mtx n $nmbr$,C0014758;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0717758
cgm use,C0042153;C0457083;C1947944
prior tobacco use n,C0040335;C0543414;C0841002;C3853727
dapaglifloz in n,
acpa positive n,C0439178;C1446409;C1514241;C2825490;C3812269
difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
clinical and patient reported characteristics at baseline and randomization,C0205210;C0815172;C4684572;C0034656
baseline hba $nmbr$ c^,C0168634;C0019016;C1825777;C3538758;C1442488
tjc $nmbr$ $nmbr$,
dapagliflozin n,C2353951
sjc $nmbr$ $nmbr$,
difference vs placebo kg $nmbr$ cl,C1705241;C1705242;C0022718;C0596019;C0439209;C4054209
esr $nmbr$ $nmbr$ mm hour,C0439227;C0564385
pga $nmbr$ $nmbr$,C0016410;C3541266;C4050369
n liraglutide $nmbr$ placebo,C0032042;C1696465;C1706408
ptga $nmbr$ $nmbr$,
ldl c $nmbr$ mg dl,C0439269
general health vas $nmbr$ $nmbr$ mm,C4330985;C4554674
ldl c $nmbr$ $nmbr$ mg dl,C0439269
pain vas $nmbr$ $nmbr$ mm,C4330985;C4554674
non fatal ml,C0439526;C1705224;C3887665
total haq $nmbr$ $nmbr$,C0102923;C0451208
expanded mace,C0349381;C0949745;C1445339
radiographic characteristics at baseline and randomization,C0444708;C4684572;C0034656
pci indication,C0392360;C3146298
mtss $nmbr$ $nmbr$,
thienopyridine at discharge,C1120149;C0012621;C0030685;C2926602
vein bypass stented,C0042449;C0741847;C0038257
fig $nmbr$ continuous and categorical baseline predictors of disease activity score based on $nmbr$ joints das $nmbr$ a simplified disease activity index sdai b and clinical disease activity index cdai c remission using univariate logistic regression unadjusted if the $nmbr$ ci does not contain the value $nmbr$ $nmbr$ the predictor is statistically significant at $nmbr$ $nmbr$ non significant predictors black significant predictors gray,C0349966;C1337208;C0549178;C0035648;C1527178;C1705938;C3869582;C3871128;C0544452;C1524063;C0206031;C1439367;C0008107;C3259781;C1518422;C0332256;C2700400;C1522609;C2698872;C0237881;C0005680;C0027567;C0085756;C0439541
stent thrombosis or mi,C3897493;C3810814
mvd n $nmbr$ $nmbr$,C1417507;C3272839
definite probable stent thrombosis,C0033204;C3897493;C0332148
no mvd n $nmbr$ $nmbr$,C1417507;C3272839
definite stent thrombosis,C0439544;C3897493;C1704787
qualifying mi stemi,C1514624;C1536220;C3538872
probable stent thrombosis,C0033204;C3897493;C0332148
figure $nmbr$ ef cacy of ticagrelor,C1419788;C3274822
noncardiac death,C0011065;C1306577;C4082313;C4552775
supplementary figure s $nmbr$ mda response through $nmbr$ weeks by disease duration,C0871261;C1704632;C1706817;C2911692;C0872146
genetic subgroup,C1079230;C1515021
met atopy and ige $nmbr$ $nmbr$ ku l criteria n $nmbr$,C0392707;C3539705;C0439340;C0243161
total aim high study,C0557651;C2603343
did not meet atopy and ige $nmbr$ $nmbr$ ku lcriteriaa n $nmbr$ $nmbr$,C0392707;C3539705;C0022804;C1337080;C1532717;C1881335
statin placebo n $nmbr$,C0360714;C0032042;C1696465;C1706408
ige high $nmbr$ ku l n $nmbr$ $nmbr$,C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
statin er niacin n $nmbr$,C0360714;C0027996;C1142562
igelow n $nmbr$ $nmbr$,
baseline tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
atopy n $nmbr$ $nmbr$,C0392707;C3539705
baseline tg mg dl median iqr,C0168634;C0439269;C1442488
no atopy n $nmbr$,C0392707;C3539705
baseline lipoprotein a nmol l median iqr,C0065058;C0125953;C1096202;C1439335
body mass index kg m $nmbr$ mean sd c,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
change in ldl c,C0392747;C0443172;C1705241;C4319952
eosinophil count cells pl median range c,C0200638;C0750879
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
fev $nmbr$ pre bronchodilator l mean sd c,C2599602;C0444504;C2347634;C2348143
change in hdl c,C0392747;C0443172;C1705241;C4319952
fev $nmbr$ pre bronchodilator predicted normal mean sd c d,C0520835;C2599602
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ b,
reversibility median range c,C0449261;C0549183;C0876920;C2347635;C2348144;C2939193
change in tc,C0392747;C0443172;C1705241;C4319952
exacerbations in previous $nmbr$ mo n mean sd,C4086268;C0026544;C0332177
change in tg,C0392747;C0443172;C1705241;C4319952
acq $nmbr$ score mean sd e,C0449820;C0444504;C2347634;C2348143;C4050231
change in lp a,C0392747;C0443172;C1705241;C4319952
aqlq s $nmbr$ score mean sd c f,C0444504;C0016327;C2347634;C2348143
gene chr snp,C0752046;C1527094
atopy by phadiatop test n,C0392707;C3539705
alleles,C0002085
ige ku l median range c,C0439340;C0549183;C0876920;C2347635;C2348144;C2939193
placebo statin,C0032042;C0360714;C1696465;C1706408
nasal polyps n,C0027430
niacin statin,C0027996;C0360714;C1142562
maintenance ocs use n,C0024501;C0042153;C0457083;C1947944
maf,
ige low $nmbr$ ku l n $nmbr$ $nmbr$,C0205251;C0439340;C1550472;C3890211;C4048187;C4321351;C4522223
minor major,C0205082;C0205164;C4318856;C4521762
annual asthma exacerbation rates,C0871208;C1521828
trait,C0599883
patients analyzed n,C0030705;C0936012
frequency of events,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
rate estimate $nmbr$ ci,C0008107;C3259781
freqency of events,C0441471;C3541888
absolute difference estimate vs placebo $nmbr$ ci,C1549031;C0750572;C0008107;C3259781
lipc,C1416867
rate ratio vs placebo $nmbr$ ci,C0871208;C0456603;C1547037;C1521828;C0008107;C3259781
aa g,C0282379;C0439267;C1235746;C1882141;C4554792
nominal p vs placebo,C0032042;C1696465;C1706408
cad death,C0011065;C1306577;C4082313;C4552775
pre bronchodilator fevi change,C2599602;C3481639
p value by gt,C1709380;C1435727;C1704693;C2697657
ampd $nmbr$,
patients in analysis n,C0030705;C0002778;C0936012;C1524024
ga a,C0016993
patients with eot data n,C2707520
cyp $nmbr$ a $nmbr$,C1418793;C2634343
ls mean difference vs placebo $nmbr$ ci,C0444504;C1705241;C1705242;C2347634;C2348143;C0008107;C3259781
a ga,C0016993
igelow,
ga,C0016993
absolutedifferenceestimate vs placebo $nmbr$ ci,C0008107;C3259781
male sex^,C0086582
montelukast n $nmbr$,C0298130
diabetes duration years^,C0011847;C0439234;C0011849
lebrikizumab n $nmbr$,C2981360
geographic region^,C0017446
pre bronchodilator fev $nmbr$,C2599602;C3714541
hbau,
absolute litres,C0205344;C0475211
body weight kg^,C0022718;C0439209;C4054209
aqlq s score,C0449820;C4050231
systolic blood pressure mm hg^,C0488055;C0439475;C0871470;C1306620
median serum periostin ng mla,C0017887;C0599973;C0028074
median feno ppba,C0549183;C0876920;C2347635;C2348144;C2939193
diastolic blood pressure mm hg^,C0428883;C0439475;C1305849
median blood eosinophil count cells per pla,C0200638;C0456170
established cvd chronic kidney disease age $nmbr$ ^,C1561643;C0001779;C4553188
cvd risk factors age $nmbr$ ^ ^,C0001783
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl na,C0005516;C0439275;C0005773
antihyperglycaemic medication at baseline,C0013227;C3244316;C4284232
biomarker low periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl na,C0005516;C0439275;C0005773
$nmbr$ oad,
saba puffs per day at baseline,C1533107;C0332173;C0439228;C0439505;C0168634;C1442488
$nmbr$ oads,
fig $nmbr$ absolute change in fev $nmbr$ from baseline at week $nmbr$ mitt patients top biomarker high group middle biomarker low group bottom,C0349966;C1549031;C1337208;C0168634;C1442488
insulin dose u,C0366513;C0439148
ltg subgroup n $nmbr$,C1420817;C1079230;C1515021;C4521367;C4521846
per body weight u kg,C0005910;C1300561;C1305866
tpm subgroup n $nmbr$,C0076829;C1079230;C1515021
fig s $nmbr$ change in hba $nmbr$ c from baseline stratified by hba $nmbr$ c at baseline i first quartile hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205363;C0019016;C1825777;C3538758;C0021966;C0221138
brv overalla n $nmbr$,C0155502
table $nmbr$ baseline characteristics of the liraglutide and placebo groups including concomitant antihyperglycaemic treatment,C0039224;C4684572;C1706074;C0032042;C0374505;C1696465;C1706408
whiteb,
regions n,C0017446;C0205147
age at time of first seizure,C0001779;C0036572;C1959629;C4553401
full analysis set data are the mean standard deviation or the number of patients percentage of either liraglutide or placebo group percentage data refer to the proportion of patients a data rst published in the leader primary publication marso et al [ $nmbr$ ] b established cvd was de ned as prior myocardial infarction or prior stroke or transient ischaemic attack or prior revascularisation or [ $nmbr$ stenosis of coronary carotid or lower extremity arteries or documented symptomatic coronary heart disease or documented asymptomatic cardiac ischaemia or heart failure or chronic kidney disease c cvd risk factors included microalbuminuria or proteinuria hypertension and left ventricular hypertrophy left ven tricular systolic or diastolic dysfunction or ankle brachial index \ $nmbr$ $nmbr$ bmi body mass index cvd cardiovascular disease hba $nmbr$ c glycated haemoglobin oad oral antihyperglycaemic drug,C1511726;C3245479;C3714741;C1828170;C2360800;C0439165;C1549488;C1561533;C0205543;C0030705;C1425219;C0034037;C1704324;C0443211;C0007222;C1272684;C1518340;C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0007787;C0917805;C0332152;C0581603;C2826257;C0007282;C0242231;C0226415;C0010054;C0010068;C1956346;C1279369;C2062869;C0018801;C0018802;C4554158;C0679238;C0730345;C0020538;C1963138;C0149721;C0039155;C3484363;C0520863;C0007220
lev status,C0023556;C0449438
age years^,C1510829
previous lev only,C0205156;C0023556;C1552607
diabetes duration ycars,C0011847;C0011849
number of concomitant aedsc,C0237753;C0449788
no polyvascular disease n $nmbr$ $nmbr$,C0012634
aed inducer status,C0887457;C0449438
polyvascular disease n $nmbr$,C0012634
no inducer at core study entry,C3898767;C0444669;C1167518;C1706352;C1882467;C3274653
cardiac catheterisation or pci for index event,C0018795;C4049621;C0441471;C4019010
no of prior aedsd,C0332152;C2826257
medications at enrolment,C0013227;C0802604;C2598133;C4284232
seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
aspirin any dose,C0004057;C0178602;C0869039;C1114758
type ia,C0020980;C0694634;C1947960
polyvascular disease status,C3176928
type ib,C2744579;C3890035;C4283819
polyvascular disease and type $nmbr$ diabetes status,C0012634;C1317301
type ic,C0020750;C4554818
polyvascular disease and type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
baseline weight kg,C0022718;C0439209;C4054209
polyvascular disease and no type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
region pooled,C0017446;C0205147;C1709595;C2349200;C4522255
cardiovascular death myocardial infarction or stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
usa and canada,C0041703;C0006823
cardiovascular hospitalisation,C0007226;C0019993;C3887460
seropositivity,
peripheral revascularisation,C0205100;C0581603
rf or acpa positive,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
central and eastern europe,C0205099;C1879652;C0015177
rf and acpa negative,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
canada or united states,C0006823;C0041703
no of prior bdmards,C0332152;C2826257
rest ofworld,C0035253;C1622890
no of prior tnfi,C0332152;C2826257
prior tnfi treatment,C1514463
medical history before index acute coronary syndrome no,C0262926;C1704706
etn yes,C1549445;C1705108;C1710701
family history of premature coronary heart disease,C0260520;C1313980;C2317524
etn no,C0014758;C0717758
index acute coronary syndrome no,C0600653;C0948089;C0918012;C1552854;C1637833;C2986546
ada yes,C1549445;C1705108;C1710701
percutaneous coronary intervention or coronary artery bypass grafting for index acute coronary syndrome no,C1532338;C0010055
ada no,C1060325;C3811629
median time from index acute coronary syndrome to randomization iqr mo,C0040223;C3541383;C0026544;C0332177
inflix yes,C1549445;C1705108;C1710701
median duration oftype $nmbr$ diabetes iqr yr,C0011847;C0439234;C0011849
inflix no,C0666743
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m^,C3811844;C0439445
no of non tnfi,C1518422
established atherosclerotic cardiovascular disease no,C0443211;C0004153;C1272684
no of tnfi among non tnfi naive,C1518422
history of coronary artery disease no,C1881055
bdp ff g n $nmbr$,C0004906;C0439267;C1422585;C1538710
history of peripheral artery disease no,C0683519;C0730226;C0850708;C0944983
blood leukocyte count $nmbr$ cells per l,C0005771;C0009555
history of cerebrovascular disease no,C0585890
blood eosinophil count $nmbr$ cells per l,C0200638
glucose lowering therapies no,C0017725;C0441994;C2003888;C0087111
blood eosinophil,C0014467
dpp $nmbr$,C1414174
fev_ l,C3714541
cardiovascular therapies no,C0587038
proportion of predicted normal fev $nmbr$ value,C1709707;C0086715
dapagliflozin placebo no of events no of patients,C0032042;C1696465;C1706408;C0441471;C3541888;C0030705
clinical copd phenotype^,C0031437;C1285572
hazard ratio $nmbr$ c,C2985465
mixed chronic bronchitis and emphysema,C0205430;C0008677;C3160715;C0013990;C0034067
a cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
moderate or severe exacerbations in the previous year range,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
[,
copd medication taken for at least $nmbr$ months before st,C0013227;C3244316;C4284232;C1883727;C0439231;C0036056;C3272372
mrf,C0312443;C1412879
udy entry,C1705654
$nmbr$ em,
benign prostatic hyperplasia,C1704272
i h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
overall pp n $nmbr$,C0030375;C0063017;C4319755
$nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
sensitivity analyses,C0020517;C0036667;C0312418;C0427965;C1511883;C1522640;C2346484;C2349185
b mace,C0349381;C0949745;C1445339
mar itt n $nmbr$,C3829202;C4255469
$nmbr$ ml min $nmbr$ $nmbr$,C0439445
cr itt n $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
icosapent ethyl events n,C0058978;C0441471;C3541888
post bronchodilator fev $nmbr$ at screening,C2599594;C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
risk stratum,C0035647;C4552904
males n $nmbr$,C0086582
secondary prevention cohort,C0009247;C0599755
females n $nmbr$,C0086287
primary prevention cohort,C0009247;C0599755
ex smokers n $nmbr$,C0337671;C4555205
the netherlands australia new zealand and south africa,C0027978;C0324547;C0037712
current smokers n $nmbr$,C3173209;C3241966
$nmbr$ yr from the united states,C0439234;C0041703
reversibility $nmbr$ n $nmbr$,C0449261
baseline estimated gfr,C0017654;C1424601
chronic bronchitis n $nmbr$,C0008677
$nmbr$ to $nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
emphysema n $nmbr$,C0013990;C0034067
baseline triglycerides $nmbr$ mg dl and,C0041004;C0439269
mixed n $nmbr$,C0205430;C3160715
h dl cholesterol $nmbr$ mg dl,C3539687
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ l n $nmbr$,C0014467;C0200638
baseline statin intensity,C0168634;C0522510;C1442488
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
baseline ldl cholesterol derived,C0023824;C0202117;C1441547;C3245521
prediabetese,
in thirds,C0205437
prior admb,C0332152;C2826257
$nmbr$ to $nmbr$ mg dl,C0439269
no prior admc,C0332152;C2826257
$nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all diabetesd,
black af rican american,C0085756;C0344434;C4049859
dmab n $nmbr$,C0012411
europe plus south africa,C0015176;C0037712
white or caucasian n,C0007457;C0043157;C0220938
ischemic heart disease no,C0010054;C0151744
serum ctx i ng ml,C0631180;C0439275
egfr mdrd ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
$nmbr$ oh vitamin d ng ml,C0014695;C0439275;C0042866;C2936842;C3537249;C3714503
uacr median iqr mg g,C0549183;C1300563;C0876920;C2347635;C2348144;C2939193
baseline use of adm n,C0168634;C1524063;C1442488
hemoglobin a^c,C0019020;C3889898
insulins,C0021641;C3537244;C4049919
heart rate min,C0702093;C1524029;C3813700
a glucosidase inhibitors,C1512211
$nmbr$ glucose lowering medication no,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
meglitinides glinides,C0065880;C3537178;C1579432
no of background glucose lowering therapies no,C1706907;C0017725;C0441994;C2003888;C0087111
baseline numberf of adm classes n,C0168634;C0215825;C4521767;C1442488
$nmbr$ antihypertensive medication no,C0003364
all dulaglutide $nmbr$ $nmbr$ mg insulin lispro insulin glargine n $nmbr$,C0907402
incidence rate difference linagliptin placebo $nmbr$ cl,C1708485;C0596019
insulin glargine insulin lispro award $nmbr$ n $nmbr$,C0293359
primary outcome $nmbr$ point mace,C0349381;C0949745;C1445339
placebo insulin glargine award $nmbr$ n $nmbr$,C0907402;C0004446
cardiovascular death nonfatal myocardial infarction or nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
ef $nmbr$ $nmbr$ hfmref n $nmbr$ $nmbr$,
secondary kidney composite outcome,C0022646;C1274040;C0227665
ef $nmbr$ hfpef n $nmbr$ $nmbr$,
physical exam oedema,C0013604;C1717255
sustained esrd death due to kidney failure or sustained decrease of $nmbr$ in egfr from baseline,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047;C1739039;C3811844;C3812682
creatinine mg dl_,C0010294;C0439269;C1561535
death due to renal failure,C0011065;C1306577;C4082313;C4552775
hf cause,C0015127;C1524003
sustained decrease of $nmbr$ in egfr,C0392756;C0547047;C1739039;C3811844;C3812682
previous hf,C0018488;C1313497;C1538440;C3273279
exploratory cardiovascular and death outcomes,C0007226;C3887460;C0011065;C1274040;C1306577;C4082313;C4552775
af,C0344434;C4049859
noncardiovascular death,C0011065;C1306577;C4082313;C4552775
other vasodilator,C0042402;C3537240
fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
anti arrhythmic,C0003195;C3537142
fatal or nonfatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
ef $nmbr$ $nmbr$,
fatal or nonfatal stroke,C1302234;C1705232;C0038454;C4554100
ef $nmbr$,
$nmbr$ point mace $nmbr$ point mace plus hospitalization for unstable angina,C0349381;C0019993;C0949745;C1445339;C0002965
cv death hf hospitalization,C0011065;C0019993;C1306577;C4082313;C4552775
exploratory kidney and microvascular outcomes,C0022646;C0227665;C0443258;C1274040
incidence rate,C1708485
death due to renal failure or sustained esrd,C0011065;C1306577;C4082313;C4552775;C0022661;C0035078;C2316810
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$ $nmbr$,
albuminuria progression,C0242656;C0449258
unadjusted irr,C1439367;C4082285
composite microvascular end point,C2349179;C2826544
azl m $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
composite ocular end point,C2349179;C2826544
age mean sd yearsa,C0001779;C0444504;C2347634;C2348143
severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
weight mean sd kgb,C0005910;C0043100;C1305866;C1705104
no severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
bmi mean sd kg m $nmbr$ c,C0444504;C1532718;C2347634;C2348143
previous cvd^,C0205156;C0007222;C1552607
concomitant medication n d,C0521115;C0013227;C3244316;C4284232
alcohol^,C0001962;C0001975
medication continued into double blind treatment period,C0013227;C3244316;C4284232;C0549178;C0013072
previous dm,C0011816;C3250443
initiated use during double blind treatment period,C0042153;C0457083;C1947944
dm duration years,C0011816;C0439234;C3250443
smoking classification n,C0008902;C0008903;C0678229
mean alc,C1424945;C3811058
scsbp mean sd mmhge,C0444504;C2347634;C2348143
mean fpg mmol l,C0444504;C1532563;C2347634;C2348143
scdbp mean sd mmhgf,C0444504;C2347634;C2348143
glargine allocation,C0907402;C1706778
prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
standard allocation,C1442989;C1706778;C2828392
no prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
n $nmbr$ allocation,C0369718;C1706778;C0441922
age median $nmbr$ th $nmbr$ th y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
other glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
history of diabetes mellitus no,C0455488
mean mmse score,C3533236;C0451306
prior mi within $nmbr$ y no,C0332152;C3810814;C2826257
nonsevere hypoglycemia,C0020615;C4553659
history of pvd no,C4534349
no nonsevere hypoglycemia,C0020615;C4553659
history of hf or lvef b $nmbr$ with index event no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0428772;C0441471;C4019010;C0488728
a severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
history of impaired renal function no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
b nonsevere hypoglycemia,C0020615;C4553659
no revascularization for index acs event no,C0581603;C0441471;C4019010
no prior dm,C0011816;C3250443
hf,C0018488;C1313497;C1538440;C3273279
no prior cvd,C0332152;C0007222;C2826257
revascularization history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
educ ssy,
pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
educ $nmbr$ $nmbr$ y,
cabg history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
educ $nmbr$ y,
giargine,
acs management no,C0001554;C0376636;C1273870;C3273539
standard,C1442989;C2828392
dual antiplatelet therapy,C0205173;C1096021;C1554184
itch nrs $nmbr$ v $nmbr$,C2240043;C4050142
cardiovascular death mi or stroke,C0007226;C3810814;C3887460;C0038454;C4554100
itch nrs $nmbr$ $nmbr$ at $nmbr$,C2240043;C4050142
timi major minor bleeding,C4441842;C0019080
itch nrs $nmbr$ $nmbr$ v $nmbr$,C2240043;C4050142
any bleeding,C0019080
itch nrs $nmbr$ $nmbr$ \ $nmbr$,C2240043;C4050142
all death,C0011065;C1306577;C4082313;C4552775
itch nrs $nmbr$ $nmbr$ a $nmbr$,C2240043;C4050142
six study placebo controlled set,C0036849;C1442518;C1705195
geographic region n,C0017446
ra beam,C0338248;C2347880;C4521565
baseline pssi score mean sd,C0168634;C2699239;C1442488
all baricitinib ra n $nmbr$,C4044947;C3538806;C4048756
baseline ppasi score mean sd,C0168634;C2699239;C1442488
$nmbr$ years of age n,C1510829
tobacco use yes n,C0040335;C0543414;C0841002;C3853727
baseline skin pain vas mean sd,C0042815;C2699239
baseline bsa mean sd,C0168634;C2699239;C1442488
duration of rat years,C0449238;C2926735
baseline spga mean sd,C0168634;C2699239;C1442488
central south america and mexico,C0007674;C0025885
asia excluding japan,C0003980;C0022341
baseline pasi mean sd,C0168634;C2699239;C1442488
hscrp mg l median first third quartiles,C0439268;C2828255
baseline dlqi mean sd,C0168634;C2699239;C1442488
baricitinib $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age at enrollment years mean sd,C1510829;C0444504;C2347634;C2348143
non statin n $nmbr$,C1518422;C0360714
duration of psoriasis years mean sd,C0449238;C2926735
patients with draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
previous use of nonbiologic systemic therapy n,C1524063;C1515119
patients without draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
previous use of biologic systemic therapy n,C1524063;C1515119
vdz pbo [n $nmbr$ ],C0031962;C0369718;C0441922
facial psoriasis n,C1276112
vdz vdz [n $nmbr$ ],C0369718;C0441922
scalp psoriasis n,C0406326
age [year] mean sda,C0001779;C0439234;C0439508;C0276477;C1428349;C1553165
fig $nmbr$ impact of baseline psoriasis associated itch severity on the itch numeric rating scale changes from baseline during the induction period pooled data from uncover $nmbr$ and $nmbr$ lsm in patients with psoriasis associated itch nrs c $nmbr$ at baseline the lsm difference $nmbr$ con dence interval and p values were derived from a mixed effects model for repeated measures analysis including the xed effects treatment study visit and treatment $nmbr$ visit with the variance covariance structure set to unstructured intent to treat population itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs scores at baseline etn etanercept ixe ixekizumab lsm least squares mean nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks,C1825598;C4049986;C0392747;C0443172;C1511726;C3245479;C3714741;C0030705;C0033860;C0033774;C1422257;C0168634;C1442488;C1272706;C1552654;C1552713;C1709380;C1441547;C3245521;C0002778;C0936012;C1524024;C2359836;C0036849;C1442518;C1705195;C2240043;C4050142;C0449820;C0023189;C0439230
male sex n [ ],C0086582
current smoker n [ ],C3173209;C3241966
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for a clinically meaningful improvement in itch i e c $nmbr$ point reduction in itch nrs at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treat ment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033774;C1422257;C0301630;C0392756;C1293152;C4551656;C0332174;C0439230;C0030705;C0332281;C0032659;C1257890;C4049715;C0014758;C0717758;C0031962
disease duration [year] mean sda,C0872146;C0439234;C0439508;C0276477;C1428349;C1553165
cdai score mean sda,C0276477;C1428349;C1553165
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for complete itch resolution i e itch nrs $nmbr$ at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2240043;C4050142;C0332174;C0439230;C0030705;C0332281;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C0449820;C4050231;C0014758;C0717758;C0031962
crp [mg l] median,C3890735;C4048285;C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for c $nmbr$ improvement in psoriasis area and severity index from baseline at the end of the induction period week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population pooled data from uncover $nmbr$ and $nmbr$ nri treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pasi $nmbr$ c $nmbr$ improvement in pasi from baseline pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033860;C0017446;C0205146;C0444930;C2746065;C0336604;C1511726;C3245479;C3714741;C0039798;C0033774;C1422257;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0449820;C4050231;C4050142;C4528685;C0031962;C0439230;C0014758;C0717758
disease site n [ ],C0012634;C0205145;C1515974;C2825164
prior surgery for cd n [ ],C0455610;C0007928;C0034283;C4552032
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for absolute psoriasis area and severity index score b $nmbr$ at week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C0457451;C0332174;C0439230;C0336604;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C2240043;C4050142;C0449820;C4050231;C0014758;C0717758;C0031962
prior tnf antagonist failure n [ ],C0231491;C0231174;C0680095
baseline crp,C3890735;C4048285
concomitant medication n [ ],C0521115;C0013227;C3244316;C4284232
normal uln n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
cs,C0010182;C0271160;C3540510;C4085345
high uln and $nmbr$ xuln n $nmbr$,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
imm,C0205470
very high $nmbr$ xuln n $nmbr$,C0442804;C4321397
cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
age at disease onset years,C0206132;C3870509
neither cs nor imm,C0010182;C0271160;C3540510;C4085345;C0205470
age at disease onset n,C0206132;C3870509
history of fistulising disease n [ ],C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
duration of as years,C0449238;C2926735;C0439234
concomitant antibiotic use n [ ],C0003232;C0042153;C0457083;C1947944
duration of as n,C0449238;C2926735;C0369718;C0441922
number of draining fistulae per patient n,C0237753;C0449788;C0013103;C0180499;C4265177;C0016169;C0030705
prior nsaid n a,C0332152;C0003211;C3536840;C2826257
[ ],
hla b $nmbr$ n,C1426226
patients with perianal fistulae n [ ],C0030705;C0267561
ptga,
psa ng ml,C3810537;C0439275;C3813209
asdas crp,C3890735;C4048285
drinker n,C0556338
basdai,C1998004
ex drinker,C0337679
basfi,
underlying disease,C4067746;C0012634
nbp,
erectile dysfunction,C0242350;C1961100
tbp,
pde $nmbr$ inhibitors,C0031638
comparison cat $nmbr$ vs cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
irritative subscore,
week $nmbr$ outcomes,C0332174;C1274040;C0439230
obstructive subscore,C0549186
asdas crp $nmbr$ $nmbr$,C3890735;C4048285
qol,C0518214
cat $nmbr$ n n,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
voided volume ml,C0439526;C1705224;C3887665
or $nmbr$ ci a,C0008107;C3259781
pvr ml,C0439526;C1705224;C3887665
pb,C1415801;C3819255
tamsulosin $nmbr$ $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
high vs normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
tamsulosin $nmbr$ $nmbr$ mg vs $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
very high vs normal,C0442804;C4321397;C0205307;C0231683;C0439166;C2347086;C4553972
t $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ crp,C3890735;C4048285
week $nmbr$ baseline,C0168634;C1442488
elevated vs normalc,C0205250;C3163633
ancova result,C1274040;C1546471;C2825142
baseline asdas crp,C3890735;C4048285
ls mean difference se,C0023668;C0036919
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ and $nmbr$ $nmbr$,
participants with heart failure,C0679646;C0018801;C0018802;C4554158
male vs female,C0086582;C1706180;C1706428;C1706429;C0043210;C0086287;C1705497;C1705498
participants without heart failure,C0679646;C0018801;C0018802;C4554158
$nmbr$ years vs $nmbr$ years,C0439234
p value heart failure vs no heart failure,C0018801;C0018802;C4554158
$nmbr$ to $nmbr$ years vs $nmbr$ years,C0439234
duration of diabetes mellitus y mean sd,C0449238;C2926735
prior nsaid use,C0042153;C0457083;C1947944
microvascular disease history n,C0443258;C0683519
yes vs no,C1549445;C1705108;C1710701
atherosclerotic vascular disease history n t,C0004153
hla b $nmbr$,C0019737;C0550853;C1415561
cardiovascular disease history n,C1880008
positive vs negative,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
history of amputation n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline ptga,C0168634;C1442488
ldl hdl cholesterol ratio mean sd,C0428621;C2699239
$nmbr$ and $nmbr$ vs $nmbr$,
$nmbr$ vs $nmbr$,
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C3811844;C0439445;C0444504;C2699239;C2347634;C2348143
baseline basdai,C0168634;C1998004;C1442488
micro or macroalbuminuria n,C0085672;C1553035;C3811161;C4049106
baseline basfi,C0168634;C1442488
concomitant drug therapies n,C0013216
$nmbr$ to $nmbr$ vs $nmbr$,
renin angiotensin aldosterone system blocker,C0086907
baseline nbp,C0168634;C1442488
glucagon like peptide $nmbr$ receptor agonist,C0014361;C4543206
baseline tbp,C0168634;C1442488
patients per $nmbr$ patient years,C0030705;C0439234
week $nmbr$ outcome,C0332174;C1274040;C0439230
ard $nmbr$ cl per $nmbr$ patient years,C0596019;C0030705
potential predictor,C3245505;C2698872
cardiovascular death or hospitalized hf,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
high vs normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
no history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
very high vs normalb,C0442804;C4321397
fatal or nonlatal myocardial inlarctlon,C1302234;C1705232;C0027061;C1522564
elevated vs normalb,C0205250;C3163633
fatal or nonlatal stroke,C1302234;C1705232;C0038454;C4554100
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
serious decline in kidney function $nmbr$,C0205404;C0232804
boost intensify premix i global patient population,C1511253;C1874596;C0032659;C1257890
number of previous anti tnf treatments for psa n,C0237753;C0449788;C1448177;C0087111
boost intensify all pan asian patient population,C1511253;C1874596;C0032659;C1257890
time since diagnosis of psa years mean sd,C0556970;C0011900;C1704338;C1704656
total included in combined analysis,C0439175;C0439810;C0332257;C0002778;C0936012;C1524024
mtx use at randomization n,C0042153;C0457083;C1947944
idegasp bid,
systemic glucocorticoid use at randomization n,C0042153;C0457083;C1947944
biasp $nmbr$ bid,
patients with specific disease characteristics n,C0683521;C0815172
full analysis set n,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
psoriasis $nmbr$ of bsa,C0033860
idegasp biasp $nmbr$,
presence of dactylitis,C0150312;C0392148;C3854307
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C1180255;C0008107;C3259781
presence of enthesitis,C0150312;C0392148;C3854307
end of trial,C0444930;C2746065
disease and quality of life scores mean sd,C0012634;C3476431;C2699239
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p,C1180255;C0008107;C3259781
pasia,
etr $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C0008107;C3259781
psa pain vas,C3810537;C0042815;C3813209
subpopulation,C1257890
all doses n $nmbr$,C0178602
week $nmbr$ before ee,C0332174;C0439230
alcohol use $nmbr$ day,C0332173;C0439228;C0439505
week $nmbr$ non ee responders,C0332174;C0439230
daily exercise,C0015259;C1522704
adjusted mean difference $nmbr$ ci,C0008107;C3259781
impaired fasting glucose $nmbr$ mg dl,C1272092;C0439269
crp uln,C3890735;C1519815;C4048285
canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
facit f,C3272505
all canakinumab,C2718773
tnfi na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
n events n at risk,C0369718;C0441471;C3541888;C0441922;C1444641
lev n $nmbr$,C0023556
hazard ratio $nmbr$ ci vs placebo,C0008107;C3259781;C0032042;C1696465;C1706408
duration of epilepsy mean sd years,C0449238;C2926735
p value vs placebo,C1709380;C0032042;C1696465;C1706408
seizure history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline prediabetes,C0168634;C0362046;C1442488
focal,C0205234
baseline normoglycemia,C0168634;C1442488
generalized,C0205246
hazard ratio vs placebo,C2985465;C0032042;C1696465;C1706408
absence,C0332197;C1689985
p heterogeneity,C0019409;C0242960
atypical absence,C0595948
myoclonic,
hazard ratio $nmbr$ ci for adjudicated type $nmbr$ diabetes,C0008107;C3259781
clonic,
risk marker and model,C1519104;C3161035;C3274659;C3714583;C3853906
tonic,C3543842
hscrp range mg l,C1514721;C0439268;C2348147;C3542016
tonic clonic,C3543842
model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
atonic,
il $nmbr$ range ng l,C0020898;C0439297;C0021764;C0022271
cluster seizures,C1555715;C0036572;C1704332
czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
classification of epilepsy type n,C0008902;C0008903;C0678229
week $nmbr$ czp $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
idiopathica,
pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
juvenile myoclonic epilepsy,C0270853
demographic characteristics mean sd unless otherwise indicated,C0683970;C2699239;C1444656
epilepsy with grand mal seizures on awakening,C0014549;C1720052
mean sd unless otherwise indicated,C0444504;C2699239;C2347634;C2348143;C1444656
symptomaticb,
time from psoriatic arthritis diagnosis [a] years,C0040223;C3541383;C0439234
specific syndromes,C0039082;C1558916
crp mg l [b] median min max,C3890735;C0439268;C4048285;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
undeterminedc,
tender joint count $nmbr$ $nmbr$ joints,C0451530
seizure frequency during $nmbr$ week baseline median range,C0149775;C0168634;C1442488
swollen joint count $nmbr$ $nmbr$ joints,C0451521
prior aeds $nmbr$ n,C0332152;C0180309;C2826257
psoriasis bsa $nmbr$ n,C0033860
concomitant aeds n,C0521115;C0180309
pasi [c] median min max,C4528685;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
phenobarbital,C0031412
prior use of synthetic dmards n,C1524063;C0242708
freedom from gtc seizures n,C0016694;C0036572
concomitant use of nsaids to week $nmbr$,C1524063;C0003211;C0332174;C0439230
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week treatment period full analysis set p values versus placebo calculated using ancova b median percent reduction from combined baseline in generalized tonic clonic seizures week for patients with idiopathic and symptomatic generalized epilepsy during the $nmbr$ week treatment period ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0332174;C0439230;C0332240;C0270854;C0377265;C3693636
prior anti tnf exposure,C0332152;C2826257
concomitant use of mtx to week $nmbr$,C1524063;C0025677;C1417487;C0332174;C0439230
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week evaluation period p values versus placebo calculated using ancova b generalized tonic clonic seizure $nmbr$ responder rates during the $nmbr$ week treatment and $nmbr$ week evaluation periods full analysis set p values versus placebo calculated using logistic regression ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0042295;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0871208;C1521828;C0814908
week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
faster aspart mealtime,C0123677;C0587119
week $nmbr$ czp dose combined,C0178602;C0869039;C1114758;C0205195
pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C1861828;C1872109;C0205195
insulin aspart mealtime,C0123677;C0587119;C1708521
faster aspart,C0015663;C0123677;C0456962;C2985769
mtss at baseline observed case,C0168634;C0868928;C1706255;C1706256;C1442488
n observed,C0369718;C0441922;C1441672
insulin aspart,C0123677;C1708521
[min max],C0702093;C1524029;C3813700
faster aspart basal,C0123677;C0205112
basal insulin,C0650607
mmrm estimates ls mean se [ $nmbr$ ci],C0008107;C3259781
mtss at,
gender n men,C0079399;C0025266;C1522384
lb,
czp baseline,C0168634;C1442488
$nmbr$ mmol mol $nmbr$ $nmbr$ n,C3829066
cfb at week $nmbr$,C0009002;C1824728
observed case,C0868928;C1706255;C1706256
change in hbalc after $nmbr$ weeks etd $nmbr$ cl,C0392747;C0443172;C1705241;C4319952;C0439230;C0596019
all participants n $nmbr$ $nmbr$,C0679646
rate of non progression defined as cfb in mtss $nmbr$ $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
bmi $nmbr$ kg m^ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
rate of non progression defined as cfb in mtss $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
hbalc $nmbr$ $nmbr$ $nmbr$,
blisibimod n $nmbr$,C3713826
hbalc $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
gender female male,C0086582;C1706180;C1706428;C1706429
all participantst n $nmbr$ $nmbr$,
central and south america,C0205099;C1879652;C0037713
bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
selena sledai mean score sd,C3533236;C2699239
bmi $nmbr$ kg m n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
selena sledai activity n,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
hbalc a $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
total score $nmbr$,C2964552
all participants^^ n $nmbr$ $nmbr$,C0679646
dermal,C0221928;C1522447
dose ratio at week $nmbr$ $nmbr$ cl,C0178602;C0456603;C1547037;C0869039;C1114758
bilag a b or c domain score n,C1880389;C0449820;C4050231;C1883221;C3541951
hbalc $nmbr$ mmol mol,C3829066
haematological,
normal baseline crp,C3890735;C4048285
pga score mean sd,C0016410;C2699239;C3541266;C4050369
elevated baseline crp,C0742906;C0168634;C1442488
pga score range,C1514721;C2348147;C3542016
pooled secukinumab,C1709595;C3179547;C2349200;C4522255
corticosteroid dose prednisone,C0001617;C0032952;C3536709
pooled placebo,C0032042;C1696465;C1706408
dose equivalent mg sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
positive for hla b $nmbr$ n,C0439178;C1446409;C1514241;C2825490;C3812269
smedian prednisone dose n,C0032952;C0178602;C0869039;C1114758
concomitant methotrexate use n,C0025677;C0042153;C0457083;C1947944
systemic sle medications n,C0024141;C0013227;C0802604;C2598133;C4284232
hscrp mg l median minimum maximum,C0806909;C1552615;C2826546
any including corticosteroid,C0001617;C3536709
antimalarial,C0003374;C3536844;C4552582
ptga of disease activity $nmbr$ $nmbr$ mm mean sd,C1292728;C0444504;C2347634;C2348143
mycophenolate any derivative,C0883242;C1527240
week,C0332174;C0439230
sle markers n,C0024141;C0005516
baseline crp levels,C3890735;C0441889;C4048285
anti dsdna positive,C0439178;C1446409;C1514241;C2825490;C3812269
baseline crp levels $nmbr$ mg l,C0168634;C0439268;C1442488
low c $nmbr$ c $nmbr$ and anti dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0012854;C0311474
basdai mean change from baseline,C0392747;C0443172;C1705241;C4319952
upcr n,
basdai $nmbr$,C1998004
s $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
asdas inactive disease,C0544452
s $nmbr$ mg mmol,C0567349;C2348885
asas partial remission,C1521726;C4552913;C4552914
patients without diabetes,C0030705;C0011847;C0011849
with prior mi stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
patients with diabetes,C0030705;C0011847;C0011849
cvd without mi or stroke n $nmbr$,C0007222;C3810814;C0038454;C4554100
previous hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
cardiovascular risk factors alone n $nmbr$,C0850624;C0205171;C0439044;C0679994
ntprobnp pg ml,C0669479;C0439297;C0754710
age sd y,C0001779;C2699239
treatments at randomisation,C0087111;C0034656
bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
difference $nmbr$ ci p value,C0008107;C1709380;C3259781
diabetes mellitus duration sd y,C0011849;C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p,C0369773;C2603361
hba $nmbr$ c sd mmol mol,C0019016;C3829066;C1825777;C3538758
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
sbp sd mm hg,C0085805;C0439475
characteristic outcome,C1521970;C1274040
dbp sd mm hg,C0536221;C0439475;C3813197;C4281799
nonblack n $nmbr$,
heart rate sd bpm,C0018810;C2699239
standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
egfr from the mdrd equation sd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
bnp nt probnp,C0669479;C0754710
moderate $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
qrs duration ms,C2349943;C3539704;C3713294
mild $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C2945599;C0439445;C0369718;C0441922
egfr ml kg per $nmbr$ $nmbr$ m $nmbr$,C1739039;C1300574;C3811844;C3812682
normal $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0369718;C0441922
hf signs and symptoms,C0220912;C0220913;C0311392;C0683368;C1457887
total cholesterol sd mg dl,C0201950;C0439269;C0543421
paroxysmal nocturnal dyspnea,C1956415
ldl cholesterol sd mg dl,C0023824;C0439269;C0202117
not present at screening but within previous year,C0150312;C0449450;C0205156;C0439234;C0439508;C1552607
hdl cholesterol sd mg dl,C0023822;C0439269;C0392885
present at screening,C0150312;C0449450
triglycerides sd mg dl,C0041004;C0439269
chest x ray,C0039985
lipid lowering drugs n,C0086440
comorbid illnesses,C0221423
platelet aggregation inhibitors n,C0032177
any cvd history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
antithrombotic medications n,C0013227;C0802604;C2598133;C4284232
insulin treated dm,C0011816;C3250443
blood glucose lowering drugs excluding insulin n,C0005802;C0441994;C2003888;C0013227;C3687832
non insulin treated dm,C0011816;C3250443
insulin treatment n,C0745343
adjusted hazard ratio or interaction p value,C0456081;C2985465;C1704675;C1709380
insulin naive n,C0021641;C1533581;C1579433;C3714501
black n $nmbr$ adjusted hazard ratio,C0456081;C2985465
rate $nmbr$ pyo,C0871208;C0033809;C1521828
nonblack n $nmbr$ adjusted hazard ratio,C0456081;C2985465
hzard ratio,C0456603;C1547037
sc belimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior ml stroke,C0038454;C4554100
sri $nmbr$ response rate,C1420401;C0237629
cvd without ml stroke,C0007222;C0038454;C4554100
$nmbr$ point reduction in selena sledai score,C0301630;C0392756;C1293152;C4551656
all mis,C0687670;C1333208;C1412384;C3538735
no worsening in pga,C0332271;C0016410;C3541266;C4050369;C1457868;C1546960
all strokes,C0038454
no new a or and no more than $nmbr$ new bilag b domain score,C0205314;C0449820;C4050231
cvd without miatroke,C0007222
baricitinib $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cvd without ml^troke,C0007222;C0439526;C1705224;C3887665
us w $nmbr$,C0815353;C3889164
micro macroalbuminuria,C0085672;C1553035;C3811161;C4049106
row n $nmbr$,C1552840;C1552846
smoking n,C0037369;C0453996;C1881674
body mass index kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
prior stroke mi n,C0332152;C0038454;C4554100;C2826257
time from symptom onset of ra years median,C1320528
diabetes mellitus duration y sd,C0011849;C2699239
time from ra diagnosis years median,C0556970;C0011900;C1704338;C1704656
body weight kg sd,C0005910;C2699239;C1305866
seropositivity status n,C0449438
creatinine mg dl sd,C0439269;C2699239
rf and acpa positive n,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
egfr ml min $nmbr$ $nmbr$ m $nmbr$ sd,C1739039;C0439445;C3811844;C3812682;C2699239
rf negative and acpa positive n,C0205160;C1513916;C2825415;C2825491;C3853545;C0439178;C1446409;C1514241;C2825490;C3812269
normal egfr $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972
rf positive and acpa negative n,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
mild impairment egfr $nmbr$ $nmbr$ n,C0221099;C0684336
rf and acpa negative n,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
moderate impairment egfr $nmbr$ $nmbr$ n,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
no of previous csdmards n,C0205156;C1552607
uacr mg g q $nmbr$ q $nmbr$,C1300563
current corticosteroid use n,C0521116;C0239126;C1705970
total cholesterol mmol l sd,C0201950;C2699239;C0543421
mtx average weekly dose mg week mean sd,C0366550;C2699239
ldl c mmol l sd,C1532563;C2699239
tender joint count $nmbr$ mean sd,C0451530;C2699239
sbp mm hg sd,C0439475;C2699239
swollen joint count $nmbr$ mean sd,C0451521;C2699239
dbp mm hg sd,C0439475;C2699239
patient global assessment of disease activity mean sd,C4054228;C0444504;C2347634;C2348143
hr bpm sd,C2699239
patient assessment of pain $nmbr$ $nmbr$ mm mean sd,C0679830
liraglutide n,C1456408
physician global assessment of disease activity mean sd,C4050369;C0444504;C2347634;C2348143
hazard ratio [ $nmbr$ ci],C2985465;C0008107;C3259781
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
hscrp mean sd,C0444504;C2699239;C2347634;C2348143
egfr $nmbr$ ml min $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682
das $nmbr$ hscrp mean sd,C0051767;C2699239;C0057671
outcome_subgroup,C1079230;C1515021
esr mm h mean sd,C0456680;C2699239
egfr_p_interaction,C1739039;C1704675;C3811844;C3812682
bone erosion score mean sd,C0587240;C2699239
albuminuria_p_interaction,C0001925;C1704675
joint space narrowing score mean sd,C1859695;C2699239
primary cv endpoint,C2986535;C3538987;C4048877;C4318503
table baseline characteristics by study and blood pressure intervention in participants with baseline egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ or higher,C4684572;C0184661;C0886296;C1273869;C0168634;C0439445;C1442488;C0205250
egfr s $nmbr$ ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
micro macroaibuminuria,C0085672;C1553035;C3811161;C4049106
expanded cv endpoint,C2349179;C2826544
data are number of patients mean sd or median iqr accord action to control cardiovascular risk in diabetes acr albumin creatinine ratio egfr estimated glomerular filtration rate mdrd modification of diet in renal disease n a not applicable n r not reported sprint systolic blood pressure intervention trial defined in the accord trial as one or more of myocardial infarction stroke angina coronary artery bypass graft percutaneous transluminal coronary intervention or other revascularisation procedure defined in sprint as one or more of myocardial infarction acute coronary syndrome coronary revascularisation carotid revascularisation peripheral arterial disease with revascularisation greater than $nmbr$ stenosis of coronary carotid or lower extremity artery or abdominal aortic aneurysm $nmbr$ mm or larger $nmbr$ participants assigned the standard intervention and $nmbr$ allocated the intensive intervention had a fasting plasma glucose greater than $nmbr$ $nmbr$ mmol l at baseline estimated by four variable mdrd equation,C1511726;C3245479;C3714741;C2360800;C0444504;C2347634;C2348143;C0441472;C3266814;C0086153;C3671772;C0022658;C0205090;C0684010;C2603358;C0814861;C1704788;C3539106;C0205447;C0010055;C1260596;C0184661;C2700391;C3274430;C3539779;C0948089;C0085096;C1704436;C0581603;C0439093;C0007282;C0226415;C4330985;C4554674;C0549177;C0679646;C1704243;C1516050;C1552601;C0886296;C1273869;C0202042;C0455280;C1532563;C0168634;C1442488;C0750572;C0205450
egfr s $nmbr$ o ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
accord trial,C0680240;C0008976
egfr $nmbr$ ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
sprint,
hospitalization for unstable ap,C0019993;C0002680;C3887950
intensive n $nmbr$,
clinical atherosclerotic disease,C0205210;C0012634
acute increase in serum creatinine,C0442805;C0201976;C0600061
demographic factors,C0011292;C0011298
antihypertensive agents n per patient,C0003364
residence in asia n,C0237096;C0003980
n r,C0205090;C0684010;C2603358
medical and lifestyle history,C0199168;C0205476;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
urinary acr mg mmol,C0567349;C2348885
sprint acr,C1412134;C1515941
history of macrovascular disease at baseline n,C0683519;C0730226;C0850708;C0944983;C0168634;C1442488
sprint acr $nmbr$ $nmbr$,C1412134;C1515941
current alcohol drinking n,C0001962;C0001975;C0001948;C0684271;C0369718;C0441922
accord acr,C1412134;C1515941
hemoglobin a,C0019016
accord acr $nmbr$ $nmbr$,C1412134;C1515941
ecfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
absolute risk difference $nmbr$ cl,C1549031;C0596019
uacr pg mg,C1627892
sustain $nmbr$,C0443318;C2732140
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
pooled analysis of sustain $nmbr$ $nmbr$ trials,C0002778;C0936012;C1524024;C0443318;C2732140;C0008976
randomized treatments n,C0034656;C0087111;C3815594
semaglutide,C3885068
perindopril indapamide,C1273169
semaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
intensive blood glucose control,C3267174
exenatide er,C3810541;C3811131
blood glucose lowering treatments n,C0005802;C0441994;C2003888;C0087111
placebo add on to basal insulin,C1883712;C0650607
oral hypoglycemic agentsj,C0359086
elderly,C0001792;C1999167
bp lowering treatments n,C0037623;C0087111;C1415692;C1708288;C4318478
bw kg,C0022718;C0439209;C4054209
diuretics^,C0012798
mdrd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
angiotensin converting enzyme inhibitors^,C0003015;C2757044
blood pressure mmhg systolic,C0005823;C0039155;C1271104;C1272641
angiotensin ii receptor blockers,C0521942;C2757003
dyspnea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
any bp lowering agents^,C0450442;C1254351;C1521826
number of patients with exacerbations in the previous $nmbr$ months n,C2360800;C4086268;C0205156;C1552607
changes in serum creatinine pmol l,C0392747;C0443172
ccq total score,C2964552
first serum creatinine,C0201976;C0600061
tofacitinib $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
second serum creatinine,C0201976;C0600061
induction study treatment,C4049995
increase in serum creatinine,C0442805;C0201976;C0600061
in remission at maintenance study baseline,C0544452;C0687702
n events n subjects,C0681850;C1550501;C1706203;C2349001;C2697811
ibdq total score,C2964552
combined major macrovascular events neohrodathv and all cause mortalitv,C0205082;C0205164;C4318856;C4521762;C0015127;C1524003
baseline crp category mg l,C0168634;C0439268;C1442488
major macrovascular events,C0441471;C3541888
prior anti tnf treatment,C1514463;C1448177
new or worsenina neohrodathv,C0205314
prior anti tnf failure,C0332152;C2826257
all cause mortalitv,C0015127;C1524003
prior immunosuppressant failure,C0231174;C0680095
n events,C0441471;C3541888
prior corticosteroid treatment,C1514463;C0001617;C3536709
combined major macrovascular events,C0441471;C3541888
steroid use at baseline mg day,C0281991;C0439422
neohrodathv and all cause mortalitv,C0015127;C1524003
subsets,C1515021
new or worsentna neohrodathv,C0205314
dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
golden $nmbr$ and $nmbr$,
semaglutide exposure nmol l,C0274281;C0439282;C0332157
golden $nmbr$,
mean change from baseline points,C0392747;C0443172;C1705241;C4319952
glycopyrrolate glycopyrrolate eflow cs $nmbr$ meg eflow cs $nmbr$ meg n $nmbr$ n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg points,C0392747;C0443172;C1705241;C4319952;C1552961;C2347617;C3714763
tiotropium $nmbr$ meg n $nmbr$,C0024489;C0025175;C0072225
mean change from baseline,C0392747;C0443172;C1705241;C4319952
glycopyrrolate eflow cs $nmbr$ meg n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg,C0392747;C0443172;C1705241;C4319952;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
black or african heritage,C0005680;C0027567;C0085756;C0439541;C2986513
$nmbr$ participants with highest body weight,C0679646;C0948775
body mass index kg rn \ mean sd,C0005893;C2699239;C0578022;C1305855
$nmbr$ participants with lowest body weight,C0679646;C0041667
number of copd exacerbations within $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
$nmbr$ participants with highest hba $nmbr$ c,C0679646;C0019016;C1825777;C3538758
history of oxygen use yes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ participants with lowest hba $nmbr$ c,C0679646;C0019016;C1825777;C3538758
high cardiovascular risk n ^,C0332167;C3272283;C4050568;C4319571
sustain $nmbr$ semaglutide vs placebo,C0443318;C2732140;C3885068;C0032042;C1696465;C1706408
background laba use yes n,C0042153;C0457083;C1947944
sustain $nmbr$ semaglutide vs sitagliptin $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
inhaled corticosteroid yes n,C0004048;C0001617;C3536709
sustain $nmbr$ semaglutide vs exenatide er $nmbr$ $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pulmonary function tests post bronchodilator mean sd,C0024119;C2699239;C2598152
sustain $nmbr$ semaglutide vs iglar,C0443318;C2732140;C3885068
fevi fvc,C0802741;C3815113
sustain $nmbr$ semaglutide add on to insulin vs placebo,C0443318;C2732140;C1883712;C0021641;C1533581;C1579433;C3714501;C0032042;C1696465;C1706408
fevi percent predicted,C0429706;C0439165;C0849974;C1561566;C4528367;C0681842;C1882327
$nmbr$ wk,C0332174;C0439230
post bronchodilator fevi n,C2599594;C0429706;C0849974;C1561566;C4528367
baseline characteristics mean sd a,C4684572;C2699239
$nmbr$ predicted to,C0681842;C1882327
subject disposition n,C0681850;C0743223;C1705555;C1550501;C1706203;C2349001;C2697811
$nmbr$ predicted,C0681842;C1882327
exposed,C0332157
baseline in check pifr l min,C0702093;C1524029;C3813700
trial completers,C0008976
sgrq scores mean sd,C0444504;C2699239;C2347634;C2348143
premature treatment discontinuation,C0457454;C1444662;C4552847
activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
subjects with imputed value for end of treatment body weight,C0681850;C1550501;C1706203;C2349001;C2697811;C2983672;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
impacts,C1825598;C4049986
adverse events any grade,C0877248;C1705413;C0441800;C0919553;C3244287
sgrq responder,
gastrointestinal disorders,C0017178
odds ratio and $nmbr$ cl,C0028873;C0596019
adverse events leading to premature treatment discontinuation,C0877248;C1705413;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
sun $nmbr$ $nmbr$,C0038817;C0376223
nausea and or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767;C0877248;C1705413
lcl,C3658298
ucl,
participants with a history of cabg,C0679646;C0010055
background laba use,C0042153;C0457083;C1947944
participants without a history of cabg,C0679646;C0010055
fev predicted,C3714541;C0681842;C1882327
time since cabg,C0040223;C3541383
pifr l min,C0702093;C1524029;C3813700
cv disease,C0007222
$nmbr$ l min,C0439393
history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ l_ min,C0439393
peripheral artery diseaseb,C0489868
participants with hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
single vessel coronary artery diseasea,C0265903;C0005847
participants without hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
cardiac failurec,C0018787;C1522601
total carmelina population,C3258257
hba $nmbr$ c mmol mold,C0019016;C0369241;C1825777;C3538758
europe including south africa,C0015176;C0037712
hba $nmbr$ c d,C0019016;C1825777;C3538758
egfr mdrd n,C1739039;C3811844;C3812682
angiotensin converting enzyme inhibitor angiotensin receptor blocker,C0034787;C1622222
uacr mg g median $nmbr$ th $nmbr$ th percentile,C1300563;C1264641
renin inhibitor,C1960108;C3537174;C4521920
uacr n,
total cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
diabetes mellitus duration y,C0011849;C0449238;C2926735
ldl cholesterol mmol lf,C1416933;C2986618;C4554443
heart rate bpm mean sd,C0018810;C2699239
hdl cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
glucose lowering therapy n,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
triacylglycerol mmol le,C0023190;C0439090;C1423767;C2697858
antihypertensives n,C0003364
egfr mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
asa n,C0004057;C3853627
empagliflozin n with event n,C3490348;C0441471;C4019010
patients with event patients analysed,C0030705;C0441471;C4019010
placebo analysed,C0032042;C1696465;C1706408
p for interaetion,C0369773;C2603361
all participants history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
plaeebo,
three point mace,C0349381;C0949745;C1445339
blaek afriean ameriean,
fatal or non fatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
hispanie latino,C0086528
fatal or non fatal stroke,C1302234;C1705232;C0038454;C4554100
not hispanie latino,C1518422;C0086528
hospitalisation for heart failure,C3898876
enrope sonth afriea,
heart failure hospitalisation or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
north ameriea,C1709269
incident or worsening nephropathy,C1551358;C0332271;C1457868;C1546960;C0022658
latin ameriea,
placebo $nmbr$ $nmbr$ ml n $nmbr$,C0032042;C0439526;C1705224;C3887665;C1696465;C1706408
$nmbr$ ky nr,C0027496;C3844738
dupiiumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ ml niin l $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
prebronchodilator fevi liters,C0429706;C0475211;C0849974;C1561566;C4528367
$nmbr$ to $nmbr$ ml min l $nmbr$ nr,C0027496;C3844738
percent of predicted normal value,C1882327
$nmbr$ ml min $nmbr$ $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
fevi reversibility,C3830088
not on metformin,C1518422;C0025598
no of exacerbations in past year,C4086268;C0439234;C0439508
angiotensin eonverting enzyme inhibitors angiotensin reeeptor bloekers,C0014432;C1152555;C2756995
use of high dose inhaled glucocorticoid no,C1524063;C0444956
angiotensin eonverting enzyme inhibitors,C0014432;C1152555;C2756995
ongoing atopic or allergic condition no,C0549178;C0392707;C0851444
calcium channel blocker ccb,C0006684;C3536851;C4521885
nasal polyposis or chronic rhinosinusitis no,C0027430;C0149516
duration of type $nmbr$ diabetes,C0449238;C2926735
no of pack yr,C1968515;C0439234;C2825051;C2828395
ckd prognosis by kdigo,C0033325;C3854082
biomarker levels,C0005516;C0441889
cardio renal risk,C0035647;C4552904
blood eosinophil count cells mm,C4330985;C4554674
albuminuria and previous maerovaseular disease without established renal disease,C0001925;C0012634;C0022658
feno ppb,C1415800
established renal disease egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m^ with any uacr mg g or egfr $nmbr$ $nmbr$ ml inin l $nmbr$ m $nmbr$ with an uacr $nmbr$ mg g without previous maerovaseular and albuminuria disease,C0022658;C0439445;C1300563;C0439268;C0439294;C0456615;C0205156;C1552607;C0001925;C0012634
total ige lu ml,C0439175;C2697941;C0439810
albuminuria and previous maerovaseular disease plus established renal disease egfr $nmbr$ $nmbr$ ml min l $nmbr$ in with an uacr $nmbr$ mg g or egfr $nmbr$ $nmbr$ ml inin l $nmbr$ in with any uacr mg g,C0001925;C0022658;C0439445;C1300563;C1739039;C1635169;C3811844;C3812682
relative risk vs placebo $nmbr$ cl,C0242492;C0032042;C0596019;C1696465;C1706408
established renal disease,C0443211;C0022658;C1272684
dupilumab $nmbr$,C3660996
established macrovascular disease and albuminuria,C0443211;C0012634;C1272684;C0001925
$nmbr$ cells mm^,C4330985;C4554674
prevalent kidney disease egfr $nmbr$ ml min usm^ or maeroalbuminuria uacr $nmbr$ mg g,C0022658;C0439445;C1300563
$nmbr$ to $nmbr$ cells mm,C4330985;C4554674
patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
fraction of exhaled nitric oxide,C1264633;C0028128;C3810607
$nmbr$ ppb,C1415800
patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
$nmbr$ to $nmbr$ ppb,C1415800
empagliflozin pooled n $nmbr$,C1709595;C2349200;C4522255
$nmbr$ to $nmbr$ cells mm^,C4330985;C4554674
north america plus america and new zealand,C0028405;C0027978;C0324547
gene,C0017337
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
snp,C0752046;C1527094
time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
short term n $nmbr$,C0443303
ldl cholesterol lowering therapy,C0023824;C0202117;C0441994;C2003888;C0039798;C0087111;C1363945
long term n $nmbr$,C0443252
glucose lowering medication,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
p $nmbr$ cl,C0369773;C0596019;C2603361
highest,C1522410
octi,
empagllflozin,
rs $nmbr$,C0035970;C3714753;C3813325
randomized group by subgroup interaction,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mate,C0682323;C1260875
rvw,
atm locus,C3711796;C1708726
prior mi or stroke at baseline,C0332152;C3810814;C2826257;C0038454;C4554100
atm locm,C3711796
all causa mortality,C0026565;C0026566
ocn,C1412791;C2347392
hospitalization for heart failure or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
octi mate $nmbr$,C0682323;C1260875
empagllflozln,
short term^,C0443303
history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
long term,C0443252
history of stroke at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
rs $nmbr$ rs $nmbr$,C0035970;C3714753;C3813325
$nmbr$ n n,C0369718;C0441922
rs $nmbr$ aa rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C4554792;C3714753;C3813325
estimated cv risk at baseline,C1519101;C0168634;C1442488
rs $nmbr$ ac rs $nmbr$,C0001246;C0003354;C1412573;C2000891;C3539770
lowest,C1708760
rs $nmbr$ cc rs $nmbr$,C0035970;C0008318;C3538933;C3714753;C3813325
$nmbr$ polnt mace,C0349381;C0949745;C1445339
active canakinumab n $nmbr$ $nmbr$,C0205177;C2718773;C3853793;C3888249
hospitalization for heart failure or cv,C3898876;C3538987;C4048877;C4318503
serum creatinine mol l,C0201976;C0347982;C0600061
gly $nmbr$ g bid,C0017890;C0439267;C0523677
serum albumin g l,C0439294;C0456615
baseline fev $nmbr$ median range l,C0168634;C0549183;C0876920;C2347635;C2348144;C2939193;C1442488
serum calcium mmol l,C0036785;C1532563;C0728876
high cv risk,C0332167;C3272283;C4050568;C4319571
$nmbr$ yearsa,
serum phosphate mmol l,C0036820;C1532563
$nmbr$ a n $nmbr$,C0369718;C0441922
protein in urine $nmbr$,C0033687
post bronchodilator fev $nmbr$ predictedb,C2599594;C3714541
glucose in urine $nmbr$,C0004076
preferred term,C1709637;C2347664
urine albumin creatinine ratio mg mmol,C0567349;C2348885
fev $nmbr$ predicted $nmbr$,C0681842;C1882327
canakinumab dose,C0178602;C0869039;C1114758
gly,C0017890;C0523677
ptrend across doses,C0178602
$nmbr$ g bid n $nmbr$,C0439267
all doses,C0178602
any teae,
incidence rate n,C1708485
copd worsening,C0024117;C1412502;C3714496;C0332271;C1457868;C1546960
uacr $nmbr$ mg mmol,C0567349;C2348885
chest discomfort,C0235710
figure $nmbr$ clinical remission from week $nmbr$ through week $nmbr$ of treatment among a all randomised patients entering the long term extension and b by induction study subgroups sc subcutaneous tnf tumour necrosis factor q $nmbr$ w every $nmbr$ weeks q $nmbr$ w every $nmbr$ weeks,C0205210;C0544452;C0687702;C0332174;C0439230;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0030705;C1522196;C0443252;C0231448;C1880641;C0033453;C0046774;C1824728
any serious teaes,C0205404
tnf antagonist naive,C1448177;C0231491
age $nmbr$ yearsa,C0001779
tnf antagonist exposed,C1448177;C0231491;C0332157
any teaes,
vedolizumab n $nmbr$,C2742797
notes,C1317574
age y median min max,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
^ $nmbr$ incidence in any treatment group in the overall safety population,C0021149;C0220856;C0032659;C1257890
weight kg median min max,C0005910;C1532757;C0043100;C1305866;C1705104
asubset of the $nmbr$ years subgroup,C0439234;C1079230;C1515021
duration of disease y median min max,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
abbreviations teae treatment emergent adverse event gly glycopyrrolate inhalation solution bid twice daily,C4684800;C0585361
complete mayo clinic score median min max,C0205197;C0002424;C0442592;C0725685;C3853530;C4283785
mace category n [ir],C0349381;C0683312;C3889287;C0949745;C1445339;C0022065;C0022071;C1448132
history of elms n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
chlorthalidone n $nmbr$,C0008294
elms n,C0330531;C2980688
lisinopril n $nmbr$,C0065374
concomitant medications yes n,C0521115;C0013227;C0802604;C2598133;C4284232
incident dm or change in,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
imm only,C0205470
no incident dm or change in fg $nmbr$,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
no cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
fg $nmbr$,C0016703;C0439214;C2348814
type of tnf antagonist failure n o,C0332307;C1547052
lvh by ecg echo,C0232306;C0058928;C1655045
weight kg median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
visit $nmbr$ sbp mm hg,C0085805;C0439475
visit $nmbr$ dbp mm hg,C0536221;C0439475;C3813197;C4281799
disease duration y median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
cdai score median min max,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
serum fg mg dl,C0439269
quintile range mg dl,C1508496;C0439269
prior surgery for cd n,C0455610;C0007928;C0034283;C4552032
serum cholesterol mg dl,C0587184;C0439269
history of fistullzing disease n,C0683519;C0730226;C0850708;C0944983
draining fistulae n,C0013103;C0180499;C4265177;C0016169
mean score min max range,C1514721;C2348147;C3542016
grs,C1412761;C3539564
type of tnf antagonist failure n,C0332307;C1547052
q $nmbr$ n $nmbr$,
inadequate response ^,C0871261;C1704632;C1706817;C2911692
test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
loss of response s,C1517945;C0871261;C1704632;C1706817;C2911692
with cerebrovascular disease,C0007820
without cerebrovascular disease,C0007820
figure $nmbr$ rbs and sfs in patients with uc percentage change from baseline in rbs in the overall itt a tnf antagonist naive b and tnf antagonist exposed c populations and in sfs in the overall itt d tnf antagonist naive e and tnf antagonist exposed f populations after vdz or pbo administration adata points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se bdifference adjusted o f c $nmbr$ h $nmbr$ a ngcei[vd $nmbr$ z i npdibcoat]e s asdtajutisstteicdalmseiagnni change from bl for vdz adjusted mean change from bl for pbo upper limit cance at a nominal signi cance level of $nmbr$ $nmbr$ statistical signi cance and non signi cance patients with baseline rbs $nmbr$ or sfs $nmbr$ were excluded from this analysis of note the number of patients varies per study population at weeks $nmbr$ $nmbr$ and $nmbr$ and is reported below the x axis bl baseline ci con dence interval itt intent to treat ns nonsigni cance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C0392475;C0030705;C0392747;C0443172;C1705241;C4319952;C0282416;C1561607;C3887647;C0231491;C2348484;C1448177;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0033727;C0369286;C0441932;C0564385;C4528284;C0036916;C0021966;C0221138;C0031962;C0557837;C0038215;C1829939;C0168634;C1442488;C0332196;C1554077;C2828389;C2360800;C1548673;C2348561;C0439230;C0684224;C0700287;C4319718;C0018932;C2742797;C0267596
p value w,C1709380
figure $nmbr$ proportion of patients with uc who achieved the composite score rbs $nmbr$ and sfs $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance cl confidence interval ns nonsignificance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C1709707;C0030705;C3272598;C4055211;C0392475;C0814896;C0237881;C1709380;C0009667;C2742797
ith vs without,
age y meantsd,C0001779
figure $nmbr$ abdominal pain subscores in patients with cd percentage change from baseline in aps in overall itt a tnf antagonist naive s and tnf antagonist exposed c populations and percentage change from baseline in lsfs in overall itt d tnf antagonist naive and tnf antagonist exposed f populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0000737;C4554323;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C1448177;C0231491;C2348484;C0243902;C1456377;C3538776;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
other region no,C0017446;C0205147
duration of diabetes microvascular disease no,C0011847;C0872146;C0011849
figure $nmbr$ combined score of abdominal pain and loose stool frequency in patients with cd percentage change from baseline in aps and lsfs in the overall itt a tnf antagonist naive s and tnf antagonist exposed c populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0582148;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C0243902;C1456377;C3538776;C1448177;C0231491;C2348484;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
atherosclerotic vascular disease no,C0004153
figure $nmbr$ proportion of patients with cd gemini $nmbr$ and $nmbr$ who achieved the average daily composite score of aps $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance aps abdominal pain subscore cl confidence interval lsfs loose stool frequency subscore ns nonsignificance pbo placebo vdz vedolizumab,C1709707;C0030705;C0007928;C0034283;C4552032;C3272598;C4055211;C0001468;C1706670;C0814896;C0237881;C1709380;C0518090;C2742797;C4082250
amputation no,C0002688;C0332840;C1546539
tnf na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
body mass index blood pressure mmhg,C0005893;C0439475;C0578022;C1305855
pain vas mean change from baselinea,C0392747;C0443172;C1705241;C4319952
hba $nmbr$ c cholesterol mmol l,C0008377;C1532563
sf $nmbr$ bodily pain mean change from baselineb,C0392747;C0443172;C1705241;C4319952
microalbuminuria no,C0730345
eq $nmbr$ d $nmbr$ l no pain or discomfortc,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
macroalbuminuria no drug therapy no,C0013216;C0013217
tnf ir,C0022065;C0022071;C1448132
antithrombotic i,C0021966;C0221138
pain vas mean change from baselined,C0392747;C0443172;C1705241;C4319952
participants with an event per $nmbr$ patient years,C0679646;C0441471;C4019010;C0030705;C0439234
sf $nmbr$ bodily pain mean change from baselinee,C0392747;C0443172;C1705241;C4319952
rvalue,
eq $nmbr$ d $nmbr$ l no pain or discomfortf,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
$nmbr$ kg m^,C0022718;C0439209;C4054209
low nfs nfs,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
bp control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
indeterminate nfs $nmbr$ $nmbr$ nfs,C0205258;C1555018
sbp $nmbr$ mmhg or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
high nfs nfs $nmbr$ $nmbr$ n $nmbr$,C0205250;C1513839;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
duration of diabetes mellitus,C0449238;C2926735
p value low vs high nfs^,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205250;C1555018;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
$nmbr$ ml min per $nmbr$ $nmbr$ m^,C0439445
p j $nmbr$ trend,C1521798;C4554533
history of pvd,C4534349
hospitalized heart failure,C0018801;C0018802;C4554158
body mass index kg m^^,C0022718;C0439209;C4054209
progression of albuminuria,C0242656;C0449258
ezetimibe simvastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
serious decline in kidney function,C0205404;C0232804
past cardiovascular history no,C1880008
duration of t $nmbr$ d y,C0449238;C2926735
any lipid lowering agent use,C0042153;C0457083;C1947944
baseline hba $nmbr$ c $nmbr$ mmol mol $nmbr$ $nmbr$ n,C0019016;C3829066;C1825777;C3538758
at index event no,C0441471;C4019010
diagnostic catheterization,C0596429
fpg mmol la,C0023031;C0023749;C0230347;C2346906;C4553351
prerandomization pci,C4049621
aha status at screeningb n,C0050451;C0449438;C0772110
laboratory parameters median iqr,C0022877;C0449381;C3244292;C4283904
not on an aha,C0050451;C0772110
alanine aminotransferase u l,C0001899;C0439339;C0057041;C1415274;C3887708
on non metformin aha,C0050451;C0772110
aspartate aminotransferase u l,C0004002;C0439339
on metformin ir or metformin xr $nmbr$ mg d,C0022065;C0022071;C1448132;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gamma glutamyltransferase u l,C0017040;C0439339
supplemental figure $nmbr$ point estimates and $nmbr$ confidence intervals for differences in hba $nmbr$ c mean response variable in selected subgroups at week $nmbr$ for each subgroup n is given for sitagliptin placebo treatment groups,C1552961;C0750572;C2347617;C3714763;C0009667;C0439828;C4553760;C0332174;C0439230;C1079230;C1515021;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
c reactive protein u l,C0006560;C0439339;C1413716;C4048285
$nmbr$ parameter,C0549193;C1704769;C2350001
platelets xlooo mm^,C4330985;C4554674
baseline hbalc $nmbr$ mmol mol $nmbr$ $nmbr$,C0168634;C3829066;C1442488
total cholesterol mg dl ^,C0201950;C0439269;C0543421
glimepiride,C0061323
hemoglobin ale,C0678386;C2632076
stratification factor menopausal status n,C1514984;C1513126
outcome n,C1274040
female premenopausal,C0043210;C0086287;C1705497;C1705498;C0279752
high nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
female perimenopausal or,C0043210;C0086287;C1705497;C1705498;C0849668;C3839366
female $nmbr$ years postmenopausal,C0043210;C0232970;C0086287;C1705497;C1705498
low nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
placebo simva,C0032042;C1696465;C1706408
dipeptidyl peptidase $nmbr$ inhibitors,C0003015
other blood glucose lowering agents,C0005802;C0441994;C2003888;C0450442;C1254351;C1521826
death from cv causes major coronary event or nonfatal stroke,C0376297;C0038454;C4554100
sulphonamides urea derivatives,C0038760;C0243072
secondary endpoints,C4528314
ertugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
$nmbr$ death from any cause major coronary event or nonfatal stroke,C0007465;C0376297;C0038454;C4554100
female participants who are $nmbr$ years postmenopausal,C0043210;C3272598;C0086287;C1705497;C1705498;C0439234;C0232970
ii death from coronary heart disease nonfatal mi coronary revascularization $nmbr$ days,C0376297
ertugliflozin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
iii death from cv causes nonfatal mi hospitalization for ua all revascularization $nmbr$ days nonfatal stroke,C0007465;C0019993;C0041580;C0042014;C0038454;C4554100
ertugliflozin $nmbr$ mg vs placebo glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
tertiary endpoints,C0205372;C2349179
eduglinozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
death from coronary heart disease,C0376297
ertuglifldzin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
urgent coronaiy revascularization $nmbr$ days,C0439609;C0439228;C3272275
erlugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
clinical endpoint,C2347784
distal forearm,C0588203
km rates p s,C0234833;C0722388
ertugliflozin $nmbr$ mg vs placebo giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
km rates e s,C3887676;C0871208;C1521828
ertuglrflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
hr $nmbr$ c,
rivaroxaban $nmbr$ $nmbr$ mg bid aspirin $nmbr$ mg od,C0229089;C0439164;C1512019;C3273373;C3665488
primary endpoint^,C2986535
peri operative cabg participants,C0010055;C0679646
nfs,C1555018
teriparatide n $nmbr$,C0070093
nfs $nmbr$ $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
number of patients with available data,C2360800;C1511726;C3245479;C3714741
secondary p,C0027627;C0175668;C0205436
secondary ip,C1308226;C4049997
daily dose of vitamin d iu day,C2348070;C0014695;C0042866;C2936842;C3537249;C3714503
secondary iii,C0439070;C1705160
number of patients with dose available,C2360800;C0178602;C0869039;C1114758;C0470187
p inte faction,C0369773;C2603361
patients with supplemental vitamin d dose of $nmbr$ iu day starting at screeningc n,C0030705;C0014695;C0042866;C2936842;C3537249;C3714503;C0439659
upa $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum $nmbr$ oh d concentrations ng ml mean sd,C0229671;C0220853;C1546774;C1550100;C0439275;C2699239
characteristic_name,C0027365;C1547383;C4522128
patients with serum $nmbr$ oh d $nmbr$ $nmbr$ and,C0030705;C0220853
characteristic_level,C0441889;C0456079;C1547707;C2946261
teriparatide n n,C0070093
n america,C0369718;C0002454;C0441922
risedronate n n,C0246719
placebo n l $nmbr$,C0032042;C1696465;C1706408
risk ratio [ $nmbr$ cl],C0028873;C0242492;C0596019
upadacitinib $nmbr$ mg n l $nmbr$,C0439268
a new vertebral fractures mfas,C1549796;C1549980
time since rheumatoid arthritis diagnosis years,C0556970;C0003873
baseline vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
u $nmbr$ $nmbr$ $nmbr$,C0439148
sufficient,C0205410
tj $nmbr$,C0039247
insufficient,C0205412;C0231180;C0439856
age years geographical distribution of patients,C0001782
overall vero population,C0032659;C1257890
previous bdmard received,C0205156;C1552607;C1514756
b pooled new and worsened vertebral fractures mfas,C1709595;C0205314;C2349200;C4522255;C1549796;C1549980
stratum $nmbr$ inadequate response or intolerance to $nmbr$ $nmbr$ bdmards of same moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
hazard ratio [ $nmbr$ cl],C2985465;C0596019
stratum $nmbr$ inadequate response or intolerance to $nmbr$ bdmards of same moa or $nmbr$ of multiple moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652;C0439064;C4551881
c clinical fractures fas,C0205210;C0016658
inadequate response or intolerance to $nmbr$ anti tnfdrug,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
d non vertebral fragility fractures fas,C0080179;C0302113
lack of efficacy with $nmbr$ bdmard,C0235828
hazard ratio $nmbr$ cl],C2985465;C0596019
lack of efficacy with $nmbr$ anti interleukin $nmbr$,C0235828;C0021764;C1527200
e major non vertebral fragility fractures fas,C0205082;C0080179;C0205164;C4318856;C4521762
t] $nmbr$,C2603360
rivaroxaban plus aspirin,C1739768;C0004057
csdmard use at baseline^,C0042153;C0457083;C1947944
hazard ratio with rivaroxaban plus aspirin $nmbr$ cl,C2985465;C1739768;C0004057;C0596019
methotrexate alone^,C0025677;C0205171;C0439044;C0679994
no of events patients yr,C0030705;C0439234
methotrexate plus other csdmardfl,C0025677
$nmbr$ to $nmbr$ yr,C0439234
methotrexate dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lei $nmbr$ n $nmbr$,C0023401;C0428209
csdmard otherthan methotrexate,C0025677
ldi b $nmbr$ n $nmbr$,
chloroquine,C0008269
integrated analysis set n $nmbr$,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
oral glucocorticoid use,C1527415;C0017710
other multiple,C0439064
oral glucocorticoid dose mg prednisone equivalent,C0205163;C0439185
cdmard experience n,C0237607;C0596545
rheumatoid factor and acpa positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
mtx at baseline n,C0025677;C1417487
rheumatoid factor or acpa positive or both,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
time since psa onset mean years sd,C0449244
patient s ga $nmbr$ $nmbr$ mm vas,C0030705;C0042815;C3536884;C3827561
active pso wi $nmbr$ bsa $nmbr$ n y,C0205177;C0043193;C1520135;C3853793;C3888249
physician s ga $nmbr$ $nmbr$ mmvas,C0031831;C0804815;C0016993
current enthesitis n,C0521116;C1282952;C1705970
clinical disease activity index,C3869583
current dactylitis n,C0521116;C0239161;C1705970
morning stiffness severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
leeds enthesitis index mean sd,C0451148;C2699239
morning stiffness duration min,C0702093;C1524029;C3813700
leeds dactylitis index basic mean sd ^,C0239161;C2699239
uniti $nmbr$ and uniti $nmbr$ im uniti,
ustekinumab n $nmbr$,C1608841
fig $nmbr$ patients reporting no enthesitis a and no dactylitis b at week $nmbr$ integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders $nmbr$ cl nri p vs pbo $nmbr$ $nmbr$ p vs pbo $nmbr$ $nmbr$ abbreviations achill tend insert achilles tendon insertion cl confidence interval ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks lat epicond lateral epicondyle lei leeds enthesitis index ldi b leeds dactylitis index basic med fern cond medial femoral condyle nri nonresponder imputation pbo placebo,C0030705;C0700287;C1282952;C0002778;C0036849;C1442518;C1705195;C0936012;C1524024;C0168634;C1442488;C0239161;C1547282;C0596019;C0031962;C0000723;C0001074;C0009667;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230;C0064678;C0331729;C1856054;C2826243;C0032042;C1696465;C1706408
cd duration y,C0007928;C0034283;C4552032
currently smoker,C0521116;C0337664
involved gl areas,C1879646;C0018229;C1423073;C1427674
time since ipf diagnosisa mean years sd,C0556970;C0034069;C1800706
ileum only n,C0020885;C0369718;C0441922
mean ml sd,C0439526;C2699239;C1705224;C3887665
colon only n,C0009368;C3888384;C0369718;C0441922
median ml,C0439526;C1705224;C3887665
ileum and colon n,C0020885;C0009368;C3888384
predicted value sd,C0681842;C2699239;C1882327
proximal gl tract n,C0205107;C0018229;C1423073;C1427674;C4489236
total sgrq mean total score sd,C2964552;C2699239
perianal n,C0442158
any aes,C1412268;C2699274
cd complications,C0009566;C1171258
most frequent aesa,C0332183
intra abdominal abscess past,C0243001
lung infection,C0876973;C4552950
sinus tracts perforation ^ n,C0854572
ipf,C0034069;C1800706
fistula n,C0016169
upper abdominal pain,C0232492
bowel stricturing n,C0021853;C4083257;C1261287;C0369718;C0441922
alt increased,C1266129;C4553172;C0205217;C0442805
patients with evaluable endoscopy,C2986511;C0014245
ast increased,C1415181;C3891303;C0205217;C0442805
data n,C1511726;C3245479;C3714741
ggt increased,C1415053;C0205217;C0442805
patients with eligible ses cd score,C0030705;C0007928;C0034283;C4552032
aes leading to dose reduction of study drugb,C1412268;C2699274;C0861063;C0178602;C0869039;C1114758
or ulcerations n,C0041582
transaminases increased,C0002594;C0919834;C0205217;C0442805
ses cd mean sd,C0007928;C2699239;C0034283;C4552032
aes leading to discontinuation of study drugb,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
endoscopic disease severity,C0014245;C0521117;C0442418
blood bilirubin increased,C0005767;C0005437;C0005768;C0229664;C0205217;C0442805
total ses cd score at,C2964552;C0007928;C0034283;C4552032
liver disorder,C0023895
baseline of induction n,C0168634;C1442488
lung neoplasm malignant,C0024121;C0205282
mild $nmbr$ $nmbr$,C2945599
investigator defined drug related aes,C1412268;C2699274
patients who had ulcerations at,C0030705;C3272598;C0041582
severe aes,C1412268;C2699274
baseline of induction,C0168634;C1442488
fatal aes,C1412268;C2699274
lieum only n,C0369718;C0441922
risk factor,C0035648
ileum ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
pioglitazone group n $nmbr$,C0071097;C0441848
colon ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
fasting glucose level mg dl,C0202045;C0439269
hemoglobin level,C0019029;C1314664
figure $nmbr$ endoscopy as sessments at week $nmbr$ pooled ustekinumab vs placebo a by induction study b randomized pa tients with eligible ses cd score or ulcerations at in duction baseline note $nmbr$ pooled ustekinumab group comprises patients receiving ustekinumab $nmbr$ mg and tiered ustekinu mab doses approximating $nmbr$ mg kg combined for analyses patients who prior to the designated analysis timepoint had a cd related surgery due to lack of ef cacy or had an initiation of speci ed prohibited medication had their baseline value carried forward or were considered to not have mucosal healing patients with missing segments at the designated analysis timepoint had their base line score or ulceration status at baseline for the missing segment s carried forward $nmbr$ clinically meaningful endoscopic improvement ses cd reduction $nmbr$ from induction baseline endoscopic response ses cd reduc tion $nmbr$ from induction baseline endoscopic remission ses cd total score $nmbr$ mucosal healing complete absence of ul cers in patients with ulcers at baseline cd crohn s disease ses simpli ed endoscopic disease severity score,C0014245;C0332174;C1608841;C0439230;C0032042;C1696465;C1706408;C0034656;C0030428;C3541314;C3815594;C0449820;C4050231;C0041582;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2700400;C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0003250;C0178602;C0369637;C0332232;C0439272;C0205195;C0002778;C2348792;C0936012;C1524024;C0038894;C0038895;C0543467;C1274039;C0138547;C4288398;C0168634;C0439780;C1442488;C0750591;C1518422;C0026724;C0449438;C1963256;C3887532;C1551393;C0441635;C1705492;C3272743;C0301630;C0392756;C1293152;C4551656;C0007928;C0034283;C4552032;C0442418;C0332197;C1689985;C0010346;C0521117
homa ir score,C0449820;C4050231
sex women men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
diastolic pressure mm hg,C0428883;C0439475
race or ethnic origin,C0034510;C1706779;C3853635;C0015031
total cholesterol level mg dl,C0878805;C0439269;C1445957
native american or alaskan native,C0282204;C1515945;C0238611;C0302891
triglycerides level mg dl,C0428475;C0439269
hba $nmbr$ c mmol mol [se],C0019016;C3829066;C1825777;C3538758;C0036919
hdl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
sitting systolic blood pressure mm hg,C1319893;C0439475
ldl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
sitting diastolic blood pressure mm hg,C1319894;C0439475
categorical variables no,C0439828
total daily insulin dose u day,C2348070;C0456683
adherence $nmbr$,C1510802
stroke m $nmbr$,C0038454;C4554100
duration of chronic kidney disease years,C0872146
stroke m l hf hospitalization,C0456616;C0019993
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
no previous copd medication,C0013227;C3244316;C4284232
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
previous ics only,C0815320;C4551720
baseline egfr $nmbr$ to,C1739039;C3811844;C3812682
previous labd only,C0205156;C0396059;C1552607
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ mean [se],C1739039;C3811844;C3812682;C0444504;C2347634;C2348143;C0036919
previous ics labd,C0205156;C0396059;C1552607
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
subjects,C0681850;C1550501;C1706203;C2349001;C2697811
uacr mg g median [iqr],C0549183;C0876920;C2347635;C2348144;C2939193
former smokers,C0337671
normal albuminuria uacr,C0205307;C0001925;C0231683;C0439166;C2347086;C4553972
screening fev $nmbr$ predicted,C0681842;C1882327
microalbuminuria uacr $nmbr$ $nmbr$,C0730345
one or more exacerbations,C0205447;C4086268
macroalbuminuria uacr $nmbr$,
ff $nmbr$ g,C4554348;C0439267
angiotensin converting enzyme inhibitor or angiotensin receptor blocker use mitt population,C0003015;C2757044;C3536837;C4541021;C0032659;C1257890
vi $nmbr$ g,C0205999;C0439267
indacaterol glycopyrronium $nmbr$ $nmbr$ g o d,C1722260;C0439267
ff vi $nmbr$ $nmbr$ g,C0205999;C0439267
salmeterol fluticasone $nmbr$ $nmbr$ g b i d,C0439417
total subjects,C0681850;C1550501;C1706203;C2349001;C2697811
copd severitya n,C0024117;C1412502;C3714496
subjects who did not receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1518422;C1514756;C0396059;C0332152
sgrq c total scoreb,C3826872;C0439175;C0439810
active versus placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
data presented as mean sd unless otherwise specified acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ] gold $nmbr$ [ $nmbr$ ] bon a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status the mcid is a change of $nmbr$ units on a scale of $nmbr$ $nmbr$ with higher scores indicating more severe dyspnea on a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status,C1511726;C3245479;C3714741;C0449450;C0444504;C2347634;C2348143;C0439793;C0522510;C1527178;C1705938;C0018026;C1304897;C1552041;C2986536;C0175659;C0349674;C1947916;C0205250;C0449820;C0332271;C0018759;C1279889;C1457868;C0392747;C0443172;C1705241;C4319952;C2080700
reduction in risk $nmbr$ ci,C0520870;C1137094
subjects who did receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1514756;C0396059;C0332152
b i d twice daily cat copd assessment test copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s fvc forced vital capacity gold global initiative for chronic obstructive lung disease ics inhaled corticosteroid mcid minimum clinically important difference mmrc modified medical research council o d once daily sd standard deviation sgrq c st george s respiratory questionnaire for copd,C0016529;C1306036;C0205246;C0424093;C2348867;C0024117;C0079816;C0871420;C1553316;C0034394;C1412502;C3714496
labd alone,C0396059;C0205171;C0439044;C0679994
baseline eosinophil $nmbr$ cells l,C0014467;C0347983
ics labd,C0815320;C0396059;C4551720
very severe copd,C0024117;C1412502;C3714496
a those receiving no inhaled pre treatment maintenance medication,C1514756;C2347660
severe copd,C0024117;C1412502;C3714496
b those on inhaled corticosteroids and long acting bronchodilators as previous treatment use,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727;C0006280;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
moderate copd,C0024117;C1412502;C3714496
previous ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
previous labd alone,C0205156;C0396059;C1552607;C0205171;C0439044;C0679994
drug therapy,C0013216;C0013217
overall mortality,C0026565;C0026566
renin angiotensin system inhibitor,C1960108;C3537174;C4521920
ff vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
microvascular disease history,C0443258;C0683519
ff vi $nmbr$ $nmbr$ $nmbr$,C4554348;C0205999
atherosclerotic vascular disease history,C0683519
ff $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
ratio of ldl to hdl cholesterol,C0456603;C1547037;C0023822;C0392885
ff $nmbr$ $nmbr$ $nmbr$,C4554348
urinary albumin to creatinine ratio,C0486293;C1318293
vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
mg g,C1300563
vi $nmbr$ $nmbr$ $nmbr$,C0205999
mg mmol,C0567349;C2348885
risk of moderate severe exacerbations,C0332166
normoalbuminuria,
distribution of metformin dose at randomization n,C0520511;C1704711;C0034656
composite of doubling of serum creatinine end stage kidney disease or death from renal causes,C0205199;C1547335;C0007465;C0022646
background aha therapy at screening a n,C0039798;C0087111;C1363945;C0369718;C0441922
number of agents,C0237753;C0449788
composite of $nmbr$ reduction in egfr end stage kidney disease or death from renal causes,C0205199;C1547335;C0022661;C2316810;C0007465;C0022646
hong kong,C0019907;C2987742
pvaluefor interaction $nmbr$ $nmbr$,C1704675
baseline fpg mg dl,C0168634;C0439269;C1442488
$nmbr$ $nmbr$ o $nmbr$ s o $nmbr$,C0483204
baseline egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
central or south america,C0205099;C1879652;C0037713
ertugliflozin,C4079805
rest ofthe world,C0035253;C2700280;C1622890
background aha therapy at screening a,C0039798;C0087111;C1363945
$nmbr$ $nmbr$ o $nmbr$ i $nmbr$,C0021966;C0221138
ls mean $nmbr$ ci a,C0008107;C3259781
$nmbr$ $nmbr$ o $nmbr$ i o $nmbr$,C0021966;C0221138
pairwise comparison,C1707455
systolic blood pressure $nmbr$ mm hg or diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
difference in ls means $nmbr$ ci a,C1705241;C1705242
blood pressure $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
systolic blood pressure $nmbr$ mm hg and diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
$nmbr$ ci a,C0008107;C3259781
$nmbr$ o $nmbr$ o $nmbr$,C0483204
$nmbr$ ae,C3887670
hbai,
drug relateda,C0013227;C1254351
ecfr ml min per $nmbr$ $nmbr$ m,C0439445
$nmbr$ sae,C1519255;C1622657;C4553214
baseline albuminuria,C0168634;C0001925;C1442488
because of ae,C3887670
renin angiotensin system inhibitor use,C0042153;C0457083;C1947944
because of drug relateda ae,C0013227;C3887670;C1254351
loop diuretic use,C0042153;C0457083;C1947944
because of sae,C1519255;C1622657;C4553214
sotagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
because of drug relateda sae,C1519255;C1622657;C4553214
race or ethnic group n,C0034510;C1706779;C3853635;C0441848
deathsb,
hispanic latino ethnicity,C0015031;C0243103
tier $nmbr$ aes,C1412268;C2699274
alc mmol mol,C1424945;C3829066;C3811058
gmi women,C0043210
mg dl sd,C0439269;C2699239
gmi men,C0025266
symptomatic hypoglycaemia,C0020615;C4553659
body mass index $nmbr$ kg m n,C0022718;C0439209;C4054209;C0369718;C0441922
hypovolaemia,C0546884
systolic blood pressure $nmbr$ mm hg n,C0488055;C0871470;C1306620
other selected aes,C1412268;C2699274
total daily insulin dose lu kg,C0022718;C0439209;C4054209
documented hypoglycaemiac,C1301725;C1609436
mdi,C0993596;C1839839;C4049613
due to ae,C3887670
csii,
due to drug relateda ae,C0013227;C3887670;C1254351
figure $nmbr$ lsm percent a and absolute b change from baseline in insulin dose at $nmbr$ and $nmbr$ weeks baseline values are iu day,C0439165;C1549031;C0168634;C1442488;C0366513;C0042295;C0439465
due to sae,C1519255;C1622657;C4553214
drug therapy no,C0013216;C0013217
due to drug relateda sae,C1519255;C1622657;C4553214
glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
characteristic a,C1521970
microvascular disease history no,C0443258;C0683519
leader,
atherosclerotic vascular disease history no,C0683519
cv historya,C3538987;C4048877;C4318503
cv disease history no,C0683519
heart failure nyha ii iii n,C0018801;C0018802;C4554158
systolic bp mm hg mean sd,C0488053;C2699239
coronary artery bypass graft n,C0010055;C1260596
diastolic bp mm hg mean sd,C0488053;C2699239
ischaemic stroke n,C0948008
glycohemoglobin mean sd,C0202054;C2699239;C0696092
carotid artery stenosis n,C0007282
hdl c mmol l mean sd,C1532563;C2699239
$nmbr$ stenosis of major artery n,C0038449
ldl c mmol l mean sd,C1532563;C2699239
lv systolic dysfunction n,C0023128;C0749225;C0731033;C1881413
ldl c hdl c ratio mean sd,C0428621;C2699239
lv diastolic dysfunction n,C0023128;C0520863;C0731033;C1881413
uacr mg g median iqr,C1300563;C0549183;C0876920;C2347635;C2348144;C2939193
diabetes medication,C0013227;C3244316;C4284232
normoalbuminuria no,
oral antihyperglycaemic n,C0359086
micro or macroalbuminuria no,C0085672;C1553035;C3811161;C4049106
metformin n,C0025598
patients with an event per $nmbr$ patient years,C0030705;C0441471;C4019010;C0439234
su n,C0038642;C1705534
number of participants with an event,C0237753;C0449788;C0441471;C4019010
moderate or severe renal disease n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
canagiiflozin,
cv medication,C0013227;C3244316;C4284232
interaction p vaiue,C1704675
acei n,
fatal nonfatal ml,C0439526;C1705224;C3887665
lipid lowering therapies n,C0585943
fatal nonfatal stroke,C0038454;C4554100
anti platelet agents n,C0432633
renal composite,C0205199;C1547335
sustain,C0443318;C2732140
geometric mean uacr,C2986759
moderate or severe renal disease b n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
dabigatran $nmbr$ mg b i d,C0439422
diabetes duration at baseline,C0449238;C2926735
nsaid at least once,C0003211;C3536840
hazard ratio glp $nmbr$ analogue vs placebo [ $nmbr$ cl],C2985465;C0243071;C0032042;C1696465;C1706408;C0596019
never nsaid,C0003211;C3536840
glp $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
hr vs warfarin $nmbr$ ci,C0008107;C3259781
bempedoic acid n $nmbr$,C3659310
gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
cardiovascular risk factor no,C0850624
stroke se,C0038454;C0036919;C4554100
lipid measures at baseline mg dl,C0079809;C1879489
duration of disease y,C0872146
total cholesterol^,C0201950;C0543421
daily bowel movements,C0332173;C0011135
ldl cholesterol^,C0023824;C0202117
$nmbr$ mg l,C0439268
non hdl cholesterol j,C0729627;C1535899
oral corticosteroid use at baseline,C0239126
hdl cholesterol^,C0023822;C0392885
mean dose,C0444504;C0178602;C0869039;C1114758;C2347634;C2348143
apolipoprotein,C0003591
median dose range,C0178602;C0869039;C1114758
high sensitivity c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
dapagliflozin $nmbr$ mg insulin n $nmbr$,C0024671;C0021641;C1533581;C1579433;C3714501;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concomitant lipid modifying therapy no,C1707479;C0023779
placebo insulin n $nmbr$,C0032042;C0021641;C1533581;C1579433;C3714501;C1696465;C1706408
intensity of statin therapy at baseline no,C0522510;C1278454;C0168634;C1442488
total baseline insulin dose,C2986497
bempedoic acid,C3659310
dose iu,C0049272;C0439453;C0694756
least squares mean difference $nmbr$ cl,C0023189;C0596019
dose weight iu kg,C0005910;C0439463;C0043100;C1305866;C1705104
age $nmbr$ yr or $nmbr$ yr,C0001779;C0439234
method of insulin administration,C0087111;C1547585
cardiovascular disease risk category atherosclerotic cardiovascular disease,C1113685;C0004153
use of cgm yes,C1524063;C1549445;C1705108;C1710701
cardiovascular disease risk category heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
hba $nmbr$ c at randomization,C0019016;C0034656;C1825777;C3538758
background lipid lowering therapy intensity of statin therapy,C0585943;C0522510
subgroup statistics,C0038215;C0600673
low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
for patients using personal cgm,C0030705;C1524063;C1519021
background lipid lowering therapy ezetimibe,C0585943;C1142985
adjusted mean change from baseline,C0392747;C0443172;C1705241;C4319952
background lipid lowering therapy fibrate,C1706907;C0585943
difference from placebo $nmbr$ cl,C1705241;C1705242
el n,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
for patients not using personal cgm,C0030705;C1518422;C1524063;C1519021
ll n,C0369718;C0441922
use of cgm interaction test p value^,C1524063;C1709380
age y median q $nmbr$ q $nmbr$,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
adjusted mean change from baseline se,C0392747;C0443172;C1705241;C4319952
acs presentation,C0742343;C0449450;C4318612
patients n n a,C0030705
$nmbr$ mg ld,C0024671;C0694649;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
overall pea population,C0032659;C1257890
us site,C0205145;C1515974;C2825164
ics subset,C0815320;C1515021;C4551720
time from ld to pci min median q $nmbr$ q $nmbr$,C0040223;C3541383;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
ics laba subset,C0815320;C1515021;C4551720
catheter site femoral,C0449652;C0015811
ff vi n $nmbr$,C4554348;C0205999
bivalirudin used,C0168273;C1273517
uc n $nmbr$,
gp iib iiia inhibitor used,C0016011;C1999216;C1273517
adjusted or $nmbr$ ci b,C0456081;C0008107;C3259781
no of vessels with $nmbr$ stenosis,C0005847;C0678234;C1261287;C2632116
adjusted or $nmbr$ ci c,C0456081;C0008107;C3259781
no of vessels treated,C0005847;C1522326
act total score $nmbr$ and or improvement from baseline $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375;C2986411;C0168634;C1442488
received drug eluting stent,C1514756;C1322815
act total score $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375
improvement from baseline $nmbr$,C2986411;C0168634;C1442488
left main coronary artery bifurcation,C3898614
difference ff vi versus uc $nmbr$ ci b,C1705241;C0205999;C1705242;C0008107;C3259781
pci duration,C0449238;C2926735
difference ff vi versus uc $nmbr$ ci c,C1705241;C0205999;C1705242;C0008107;C3259781
dosing,
percent work time missed due to asthma,C0043227;C0040223;C3541383;C1705492;C0678226
cangrelor n n,C1121991
percent impairment while working due to asthma,C0221099;C0684336;C0043227;C0678226
clopidogrel n n,C0070166
adjusted $nmbr$ or $nmbr$ cl,C0456081;C0596019
percent overall work impairment due to asthma,C0221099;C0684336
d mi idfvst,C3810814
percent activity impairment due to asthma,C0221099;C0684336
early load,C1550025;C1704782;C1708715
proportion of responders n n,C1709707
late load,C1550025;C1704782;C1708715
ffa i,C0021966;C0221138
adjusted or $nmbr$ cl,C0456081;C0596019
uc,
environmental stimuli,C0450025
severe lite threatening,C0205082;C4050465;C4050466
activity limitation,C0443288;C0449295
transfusions,C0005841;C0199960;C1879316
hfref n $nmbr$,
emotional function,C0031843;C0542341;C0700205;C1705273
hf without known reduced ef n $nmbr$,C0018488;C1313497;C1538440;C3273279
secukinumab $nmbr$ mg no load n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1550025;C1704782;C1708715
no hx of hf n $nmbr$,C0262926;C3814444
time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
age yrs median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
hla b $nmbr$ positive at baseline n,C0439178;C1446409;C1514241;C2825490;C3812269
hemoglobin ale median iqr,C0019046;C0549183;C0876920;C2347635;C2348144;C2939193
tnfi na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
duration of diabetes years median iqr,C0449238;C2926735
total basdai score mean sd,C2964552;C2699239
history of dyslipidemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
total back pain score $nmbr$ $nmbr$ mm scale mean sd,C1504479;C2699239
main etiology of heart failure,C0015127;C1314792;C1524003
previous systemic treatment n,C0205156;C0678812;C1552607
non ischemic,C1518422;C0475224
methotrexate use at randomization,C0042153;C0457083;C1947944
history of coronary arteiy disease,C0683519;C0730226;C0850708;C0944983
sulfasalazine use at randomization,C0042153;C0457083;C1947944
cgfrby ckd epi ml min $nmbr$ $nmbr$ m $nmbr$ median iqr,C0162734;C0439445;C4281721;C0549183;C0876920;C2347635;C2348144;C2939193
corticosteroid use at randomization,C0239126;C0034656
mineralcorticoid receptor antagonist,C4543207
cumulative nsaid score mean sd,C0003211;C2699239;C3536840
km rate,C0871208;C1521828
uveitis,C0042164;C1963266
cardiovascular death hospitalization for heart failure,C3898876
tnf alpha inhibitor naive,C1448177;C1456820;C1522669
hfref,
tnf alpha inhibitor inadequate response,C0871261;C1704632;C1706817;C2911692
nothfref,
asas $nmbr$,C0004057;C3853627
hf without known reduced ef,C0018488;C1313497;C1538440;C3273279
hscrp post baseline baseline ratio ls mean se,C0023668;C0036919
without hx of hf,C0262926;C3814444
asas $nmbr$ $nmbr$,C0004057;C3853627
age in years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
basdai ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
raee,
sf $nmbr$ pcs ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
blaek,
asqol ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
duration of diabetes in years median iqr,C0449238;C2926735;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hbalc in median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
a $nmbr$ $nmbr$ $nmbr$ a $nmbr$,
egfr in ml min $nmbr$ $nmbr$ m^ median iqr,C1739039;C3811844;C3812682;C0549183;C0876920;C2347635;C2348144;C2939193
a $nmbr$ $nmbr$,
prior cad,C1504769;C2239547;C3813548;C4284121
$nmbr$ nil,C0442734
prior pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
other^,
insulin at baseline,C0021641;C1533581;C1579433;C3714501
bmp kg m $nmbr$,C0022718;C0439209;C4054209
betablocker,C0001645
eosinophil counf cells pl,C3897966;C4049765
cv death or hhf hr $nmbr$ cl or absolute risk reductions,C0011065;C1306577;C4082313;C4552775;C0596019;C3179139
pre bronchodilator fevr l,C2599602;C1708033
patients with prior ml,C0030705;C0332152;C2826257
pre bronchodilator fevr pred,C0032952;C0044955
patients with ascvd but no ml,C0030705;C3665365;C0439526;C1705224;C3887665
$nmbr$ $nmbr$ $nmbr$ a $nmbr$,
patients with only mrf,C0030705;C0312443;C1412879
pre bronchodilator fevi fvc,C0802741;C3815113
cv death or hhf,C0011065;C1306577;C4082313;C4552775
$nmbr$ i $nmbr$ $nmbr$ ai,C0003504;C4551710
patients with prior ml hr $nmbr$ cl,C0030705;C0332152;C2826257
pre bronchodilator fvc pred,C0032952;C0044955
patients with ascvd but no prior ml hr $nmbr$ cl,C0030705;C3665365;C0332152;C0596019;C2826257
age at asthma diagnosis years,C1828181;C3173302
patients with only mrf hr $nmbr$ cl,C0030705;C0312443;C0596019;C1412879
exacerbations in the past $nmbr$ months n,C4086268;C0439231
tass,C0559483
absolute risk reductions,C3179139
aqlq si $nmbr$ score,C0449820;C4050231
ascvd no prior ml,C3665365;C0439526;C1705224;C3887665
atopic,C0392707
cv death ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
ocs use,C0042153;C0457083;C1947944
tanezumab all doses combined,C2346819;C0178602;C0205195
subgroup name level,C0441889;C0456079;C1547707;C2946261
tanezumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fas,
tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
no ocs,
tanezumab all doses combined nsaida,C2346819;C0178602;C0205195
no nasal polyps,C0027430
tanezumab $nmbr$ $nmbr$ mg nsaid,C0003211;C3536840
pre bd fvc,C0005126;C3714541;C2344255;C4050145
tanezumab $nmbr$ mg nsaid,C0003211;C3536840
pre bd fvc s $nmbr$ of predicted,C0005126;C3714541;C2344255;C4050145;C0681842;C1882327
active comparatorb,C0205177;C3853793;C3888249
s $nmbr$ exacerbations,C4086268
diabetesc,
age at diagnosis s $nmbr$ years,C1828181;C3173302;C0439234
severe oa symptoms at baselined,C0436345;C0029408;C3887876
age at diagnosis,C1828181;C3173302
less severe oa symptoms at baseline,C0436345;C0029408;C3887876
either ocs use nasal polyps pre bd fvc,C0027430;C3714541
figure $nmbr$ least squares mean change in womac pain from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
no ocs use no nasal polyps pre bd fvc s $nmbr$ of predicted and age at diagnosis,C0042153;C0457083;C1947944;C0027430;C3714541;C0681842;C1882327;C1828181;C3173302
figure $nmbr$ least squares mean change in womac physical function from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
aspirin group n $nmbr$,C0004057;C0441848
white race no i,C0007457;C0043157;C0021966;C0221138
figure $nmbr$ least squares mean change in pga from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis pga patient s global assessment sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C0030705;C1710181;C3472647
participant reported hypertension no,C0020538;C1963138
figure $nmbr$ percentage of patients with $nmbr$ $nmbr$ $nmbr$ and $nmbr$ improvement on the womac pain subscale at week $nmbr$ in the subgroups notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily oa osteoarthritis womac western ontario and mcmaster universities osteoarthritis index,C0439165;C1549488;C1561533;C2986411;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132;C0332174;C0439230;C1079230;C1317574;C0032042;C1696465;C1706408;C3472647
aspirin use before screening no,C0042153;C0457083;C1947944
ethnicity not hispanic latino n,C0015031;C0243103;C1518424;C0086528
statin use no,C0042153;C0457083;C1947944
background lipid therapy per acc aha definition n a,C0039798;C0087111;C1363945
median interquartile range yr,C1711350;C0439234
moderate intensity statin,C4081855;C0360714
vascular risk score no ^,C0449820;C4050231
coronary artery stenosis $nmbr$,C0242231
aspirin n $nmbr$ no of participants with events,C0004057;C0679646;C0441471;C3541888
coronary artery bypass,C0010055
placebo n $nmbr$ no of participants with events,C0032042;C1696465;C1706408;C0679646;C0441471;C3541888
copd n,C0024117;C1412502;C3714496
heterogeneity or trend p vaiue,C0019409;C0242960;C1521798;C4554533
diabetes related medication use n,C0011847;C0240320;C0011849
body mass index kg m ^,C0022718;C0439209;C4054209
insulin use n,C0240016
weight at randomization kg,C2985844;C0022718;C0439209;C4054209
lipid values mean sd,C0023779;C2699239
prior aspirin use,C0042153;C0457083;C1947944
non hdl c mmol l mean sd,C1532563;C2699239
vascular risk score,C0449820;C4050231
apob g l mean sd,C0439294;C2699239;C0456615
low $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
lp a nmol l mean sd,C0065058;C2699239;C1439335;C4553379
other treatment assignment,C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
triacylglycerol mmol l mean sd,C1532563;C2699239
omega $nmbr$ fatty acids,C1719844;C0015684
hba $nmbr$ c mmol mol median q $nmbr$ q $nmbr$,C0019016;C3829066;C1825777;C3538758
moderate s $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
fasting serum glucose mmol l median q $nmbr$ q $nmbr$,C0202041;C1532563;C3534430
fatty acid group n $nmbr$,C0015684;C0441848
percent change from baseline to week $nmbr$ in auc mean sem,C3272907;C0332174;C0439230;C0376690;C0444504;C2347634;C2348143
unknown no,C0439673;C3541433;C4050014
baseline tg $nmbr$ $nmbr$ mmol l,C0168634;C1532563;C1442488
patient reported hypertension no,C0020538;C1963138
chylomicron triglycerides,C0008731;C0041004;C1325761
medication use no,C0240320
chylomicron cholesterol,C0008731;C0008377;C1325761
median iqr yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
apob $nmbr$,C0003593;C3252643
systolic blood pressure^,C0488055;C0871470;C1306620
age s $nmbr$ yr,C0001779;C0439234
$nmbr$ mm hg no,C0439475
major coronary event,C0205082;C0741923;C0205164;C4318856;C4521762
omega $nmbr$ fa n $nmbr$,C1719844
age $nmbr$ $nmbr$ yr,C0001779;C0439234
heterogeneity or trend p value,C0019409;C0242960;C1521798;C1709380;C4554533
c $nmbr$ e $nmbr$ fab bolus n $nmbr$,C1186706;C1511237;C1705509;C3812160
percentage,C0439165;C1549488;C1561533
c $nmbr$ e $nmbr$ fab bolus and infusion n $nmbr$,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
body mass index kg m^ ^,C0022718;C0439209;C4054209
risk factors of group,C0035648;C1553898
canakinumab $nmbr$ month on treatment il $nmbr$ above the median value $nmbr$ $nmbr$ ng l n $nmbr$,C0020898;C0021764;C0022271;C0549183;C0439297;C0876920;C2347635;C2348144;C2939193
elevated cholesterol,C0020443
canakinumab $nmbr$ month on treatment il $nmbr$ below the median value,C0020898;C0021764;C0022271;C0549183;C0876920;C2347635;C2348144;C2939193
history of smoking,C1519384
unknown missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
vascular disease of group,C0042373
randomized to canakinumab $nmbr$ mg,C0034656;C3815594
cerebral,
treatment group on treatment il $nmbr$ threshold,C0020898;C0449864;C0021764;C0022271
previous infarction of group,C0205156;C0021308;C1552607
incidence rate n a,C1708485
previous coronary procedure of group,C0018821;C1279986
hradjusted $nmbr$ ci b,C0008107;C3259781
angioplasty,C0162577;C1548817
$nmbr$ ref,C1425988
no of diseased vessels of group,C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
canakinumab il $nmbr$ top tertilec,C0020898;C0021764;C0022271
coronary procedure of group,C0018821;C1279986
canakinumab il $nmbr$ middle tertile,C0020898;C0021764;C0022271
atherectomy,C0162513
canakinumab il $nmbr$ lowest tertile,C0020898;C0021764;C0022271
duration of procedure min,C2346509;C0702093;C1524029;C3813700
p value for trend across categories,C1709380;C1521798;C4554533;C0683312
contrast used ml,C0439526;C1705224;C3887665
experimental intervention group n $nmbr$,C0441848
thrombolytic agents of group,C0016018;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
mean body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
lowest activated clotting time sec,C0427611;C0565930
insulin dependent diabetes mellitus,C0011854
subgroup $nmbr$,C1079230;C1515021
stable coronary artery disease,C0010054;C0010068;C1956346
transfusion,C0005841;C0199960;C1879316
percutaneous coronary intervention done,C1532338;C1272695
c $nmbr$ e $nmbr$ fab bolus and infusion,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
vascular access site,C0589360
harzard ratio $nmbr$ ci,C0008107;C3259781
lesions treated per patient,C0221198;C1522326;C0030705
harzar ratio $nmbr$ ci,C0008107;C3259781
one lesion,C0221198;C1546698
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l l,C3539687
two lesions,C0205448;C0221198
entry category,C0683312;C3889287
three or more lesions,C0205449;C0221198
unstable,C0443343;C1883468
treated lesions,C1522326;C0221198
angina or acute mi,C0002962;C0155626
n lesions,C0369718;C0221198;C0441922
anatomy,C0002808;C0700276;C1384516
stented lesions,C0038257;C0221198
dalteparin n $nmbr$,C0206461
index percutaneous coronary intervention,C0600653;C1532338;C0918012;C1552854;C1637833;C2986546
ulcer,C0041582;C3887532
n stented lesions,C0038257;C0221198
inclusion findings,C2607943;C2926606;C3539655
mean stents per lesion sd,C0038257;C0221198;C1546698
unstable but no rest angina,C0002965
biolimus a $nmbr$ eluting stent,C0038257
rest angina but not past $nmbr$ h,C0002965;C0152172;C1414318;C4284302
other stent,C0038257
rest angina past $nmbr$ h,C0002965;C0152172
mean total stent length per lesion mm sd,C1444754;C1706316
non q wave myocardial infarction,C0542269;C3537181
mean stent diameter per lesion mm sd,C0038257;C0552409
ecg changes t,C0855329
direct stenting per lesion,C0038257;C2348535
t wave inversion only,C0520888
bifurcation per lesion,C0184906;C3146289
st depression only,C0520887
thrombus aspiration done per lesion,C0220787;C0349707;C0700198;C2712334;C2827071;C1272695;C0221198;C1546698
st depression and t wave inversion,C0520887;C0520888
timi flow,C3272266
medication at entry,C0013227;C3244316;C4284232
pre procedure,C3272300
oral fi blockers,C0442027;C4050619;C4521986
post procedure,C3272301
annanginal drugs $nmbr$ l s $nmbr$ ^,C0013227;C3687832
experimental treatment group,C0949266;C2585119
glyceryl trinitrate infusion,C0574032;C1827465
control group,C0009932
median delay h,C0033727;C0369286;C0441932;C0564385;C4528284
indication,C0392360;C3146298
age distribution,C0001782
s $nmbr$ years,C0439234
mean sd age in years,C0444504;C1510829;C2347634;C2348143
renal failure,C0035078;C1963154
mean sd bmd in g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
left main treated,C0205091;C1522326;C0443246;C1552822
post erior anterior spine,C0037949;C2752558
type of reference treatment strategy,C0455708;C0679199
vertebral fractures at baseline,C0080179;C0168634;C1442488
use of ticagrelor,C1524063;C1999375
history of postmenopausal fracture,C1272071;C0232970
use of clopidogrel,C1524063;C0070166
self rated health status,C0036588;C0018759;C1551994
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ o $nmbr$,C0483204
very g ood ex cellent,C0439267;C4267693
cld $nmbr$ mg n l $nmbr$,C0439268
fair poor,C0032854;C0542537;C2700379
azl m $nmbr$ mg $nmbr$ cld $nmbr$ mg n l $nmbr$,C2827881
mean sd anthropometry,C0444504;C0003188;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ l l,C3539687
baseline height cm,C0168634;C0489786;C1442488
non hispanic and latino,C1518424;C0086528
body mass index kg cm $nmbr$,C0005893;C4054689;C0578022;C1305855
not collected^,C1516695;C1516698
mean sd calcium intake in mg daily,C0489458;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bmi kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
ever,
anti hypertensive treatment history n,C0432633
digoxin n $nmbr$,C0012265
raas inhibitors,C0243077
$nmbr$ $nmbr$ $nmbr$ s,
change from baseline to final apbm,C0392747;C0443172;C1705241;C4319952;C0205088;C1546485;C3853528
$nmbr$ s $nmbr$ s $nmbr$,C0565930;C2603362
cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
median duration of chf mo,C0449238;C2926735
azl m $nmbr$ mg cld $nmbr$ mg,C1319635
of patients $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705
p value overall,C1709380;C0282416;C1561607
method of assessing ejection fraction,C0025663;C0449851;C0871511;C1516048;C0489482;C2700378
baseline $nmbr$ hour mean sbp mm hg,C0085805;C0439475
radionuclide ventriculography,C0017200;C0034610
cgfr ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
two dimensional echocardiography,C0013524
people with diabetes n $nmbr$,C0027361;C0011847;C0011849
contrast angiography,C0009924;C0002978;C1979874
people without diabetes n $nmbr$,C0027361;C0011847;C0011849
cardiothoracic ratio $nmbr$ $nmbr$,C0456603;C1547037
atherosclerotic coronary heart disease ischaemic stroke or peripheral arterial disease n n number of people in phase $nmbr$ studies only high intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily,C0010054;C0948008;C0237753;C0449788;C0205390;C0947630;C1710475;C4081854;C0360714;C1704788;C3539106;C0024671;C0965129;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
no of signs or symptoms of chff,C0220912;C0220913;C0311392;C0683368;C1457887
heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
primary cause of chf,C0205225;C0015127;C1524003;C0439612;C0439631
high intensity statins,C4081854;C0360714
other vasodilators,C0042402
any other lipid lowering therapy n,C0585943
daily dose of study medication prescribed,C2348070;C0278329
anti hyperglycaemic agent n,C0432633;C1321567
anthropometry mean sd,C0003188;C2699239
injectable anti hyperglycaemic n,C1272883;C0432633
w eight k g,C0205454;C0439267
insulin n,C0021641;C1533581;C1579433;C3714501
number of patients with,C2360800
triglycerides median q $nmbr$ q $nmbr$,C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
a ngina $nmbr$ day s previously,C0332173;C0439228;C0439505
duration of total exposure to study treatment weeks,C0439175;C2826870;C0439810;C1521826;C0439230
infarct ion w ithin previous $nmbr$ day s,C0022023;C1700702
teaes of special interest,C0205555;C0543488
$nmbr$ l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
study population,C2348561
infarction $nmbr$ $nmbr$ days,C0021308;C0439228
proportion of individuals a alirocumab placebo,C1709707;C0027361;C0237401;C0032042;C1696465;C1706408
infarction $nmbr$ days previously,C0021308;C0439228
rate per $nmbr$ patient years control vs alirocumab i,C0489879;C0030705;C0021966;C0221138
infarction date not reported,C0011008;C2348077;C0684224;C0700287;C4319718
hr vs control $nmbr$ cl,C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389
medication within $nmbr$ days before enrolment,C0013227;C3244316;C4284232;C1516879;C1696073;C3888021
lisrs,
intravenous heparin,C0354566
neurocognitive disorders,C0029227;C4041080
medication after enrolment,C0013227;C3244316;C4284232
neurologicai events,C0441471;C3541888
ticlopidin,
hepatic disorders,C0023895
tertile of total cholesterol at baseline mean sd mmol l,C0201950;C0543421;C0168634;C1532563;C1442488
general allergic events,C0441471;C3541888
cwt mean se mm,C4330985;C4554674
ophthalmologic events,C0441471;C3541888
difference $nmbr$ years baseline,C0168634;C1442488
dm or diabetic complications,C0011816;C3250443;C0342257
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
adjudicated mace $nmbr$,C0349381;C0949745;C1445339
p for heterogeneity of treatment effect between tertiles $nmbr$ $nmbr$,C0369773;C2603361
teaes in a $nmbr$ of individuals,C0027361;C0237401
$nmbr$ $nmbr$ yr no,C0439234
proportion of individuals control alirocumab,C1709707;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
$nmbr$ $nmbr$ vr no,C3476815
rate per $nmbr$ patient years control vs alirocumab,C0489879;C0030705;C3491162
median vr,C0549183;C3476815;C0876920;C2347635;C2348144;C2939193
k,C0597277;C1708601
time from qualifying event to randomization,C0040223;C3541383;C1514624;C0441471;C4019010
diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
coronary risk factors no,C2024776
at,
history of systemic hypertension,C0455527
ta,C0039297;C1506978;C1705538;C3272501;C4553364
obesityj,
tk,C0041405;C0220928;C4050092
other vascular disease no,C0042373
week $nmbr$ czp dose combined n $nmbr$,C0054841;C0178602;C0869039;C1114758;C1861828;C1872109
claudication,C0021775;C0311395;C1456822
dmard n $nmbr$,C0242708
ptca only,C2936173
demographic characteristics mean sd unless otherwise stated,C0683970;C2699239;C1301808;C1442792
cabg only,C0010055
disease characteristics n unless otherwise stated,C0599878;C1301808;C1442792
both ptca and cabg,C2936173;C0010055
prior use of synthetic dmards,C1524063;C0242708
oral hypoglycemic drug,C0359086
concomitant use of corticosteroids,C1524063
lipid levels mg dlj total cholesterol,C0201950;C0543421
tender joint count $nmbr$ $nmbr$ joints mean sd,C0451530;C2699239
totalhdl cholesterol ratio,C0456603;C1547037
swollen joint count $nmbr$ $nmbr$ joints mean sd,C0451521;C2699239
unstable angina age,C0002965;C0001779
patients with psoriasis bsa $nmbr$,C0030705;C0033860
baseline abi affected limb,C0168634;C0015385;C1442488
pasi mean sd,C0444504;C2699239;C2347634;C2348143
baseline pfd m,C0016065;C1839454;C2827389;C3889643
patients with enthesitis lei $nmbr$,C0030705;C1282952
baseline mwd m,C0168634;C1442488
lei mean sd,C0444504;C2699239;C2347634;C2348143
plasma creatine mg dl,C0010286;C0439269
patients with dactylitisa,C0030705
concurrent illness,C0205420;C0221423
ldi mean sd a,C0444504;C2699239;C2347634;C2348143
concurrent medications,C0013227;C0802604;C2598133;C4284232
patients with nail psoriasis mnapsi $nmbr$,C0030705;C0406322
plasma lipoproteins mmol l,C0023820;C1532563
mnapsi mean sd,C0444504;C2699239;C2347634;C2348143
hdl $nmbr$,C3715113
observed,C1441672
lpa mg dl,C1096202;C0439269;C1439335;C3539666;C4049711;C4553379
imputed,C2699638
week $nmbr$ mean sem,C0332174;C0439230
clinical and patient reported outcomes observed n unless otherwise indicated,C0205210;C2987124;C1441672;C1444656
weeko mean sem,C0444504;C2347634;C2348143
pasi $nmbr$ a,C4528685
pretreatment hdl c,C1550147;C3715113;C2709094;C3539075;C3539076
ldi mean [sd]b,C0444504;C2347634;C2348143;C2699239
pretreatment triglycerides,C1550147;C0041004;C2709094;C3539075;C3539076
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ] n $nmbr$,C0369718;C0441922
no of patients with stroke,C0030705;C0038454;C4554100
total resolution of dactylitisb,C1514893;C1706463;C2699488
ldl hdl ratio,C0428621
lei mean [sd]c,C0444504;C2347634;C2348143;C2699239
table $nmbr$ relationship of baseline serum lipids to stroke or tia reduction,C0439849;C1705630;C1706279;C3540605;C0038454;C4554100;C0301630;C0392756;C1293152;C4551656
total resolution of enthesitisc,C1514893;C1706463;C2699488
mnapsi mean [sd]d,C0444504;C2347634;C2348143;C2699239
total resolution of nail psoriasisd,C1514893;C1706463;C2699488
haq di mean [sd],C0444504;C2347634;C2348143;C2699239
haq di mcide,C3826998;C4321476
uc [gemini $nmbr$ ],
cd [gemini $nmbr$ ],C0007928;C0034283;C4552032
vdz n \ $nmbr$,
vdz pla n $nmbr$,C0456170
pla n $nmbr$,C0456170
vdz n $nmbr$,
pla $nmbr$,C0456170
disease duration mean [sd] years,C0444504;C2347634;C2348143;C2699239;C0439234
disease duration $nmbr$ years $nmbr$ [ ] disease activity s,C0872146;C0439234;C1292728
cdai mean [sd],C0444504;C2347634;C2348143;C2699239
cdai $nmbr$ n [ ],C0683448;C1413248;C3273706
ms mean [sd],C0444504;C2347634;C2348143;C2699239
ms,C2349943;C3539704;C3713294
ms $nmbr$ $nmbr$ n [ ],C2349943;C3539704;C3713294
crp mean [sd] mg $nmbr$,C0444504;C2347634;C2348143;C2699239;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crp $nmbr$ mg $nmbr$ n [ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concomitant therapy n [ ],C1707479
cs and im,C0010182;C0271160;C3540510;C4085345
im on]y,
prior tnf antagonist n [ ],C0332152;C0231491;C2826257
smoking status n [ ],C1519386
supplementary figure $nmbr$ incidence of arthritis arthralgia in patients receiving corticosteroids at baseline according to tapering of corticosteroids in the previous $nmbr$ weeks in a patients with crohn s disease n $nmbr$ and b patients with ulcerative colitis n $nmbr$ this analysis includes patients who received $nmbr$ mg prednisone equivalent per day at baseline,C0021149;C0220856;C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727;C0441640;C1548969;C0439230;C0010346;C0012634;C0009324;C0002778;C0936012;C1524024;C0332257;C1552866;C2700399;C0205163;C0439185;C0168634;C1442488
aii participants n $nmbr$,C1424250;C0679646;C2698414
anti gad positive n $nmbr$,C0270549;C0439178;C1446409;C1514241;C2825490;C3812269;C1414925
anti gad negative n $nmbr$,C0270549;C0205160;C1513916;C2825415;C2825491;C3853545;C1414925
prior cvd,C0332152;C0007222;C2826257
thyroid disease,C0040128
ethnic background,C0015031
prior gestational diabetes,C0332152;C0085207;C2826257
alcohol $nmbr$ drinks per week,C0556297;C0332174;C0439230
education level,C0013621;C0013658
education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
education $nmbr$ y,C0013621;C0013622;C0013658;C0039401
creatinine pmol l,C0010294;C0439284;C1561535
acr $nmbr$ mg g,C1412134;C1300563;C1515941
f plasma glucose mmol l,C0202042;C1532563;C0455280
statin users,C0360714;C1706077
ace arb users,C1452534;C1706077;C4284014
beta blocker users,C0001645;C1706077
thiazide users,C0541746;C1706077
c peptide nmol l,C0607868
overall n n loopy,C0282416;C1561607
glargine n n loopy,C0907402
std n n loopy,
person years,C0027361;C0439234;C2347489
first co primary,C0205225;C0439612;C0439631
anti gad positive,C0439178;C1446409;C1514241;C2825490;C3812269
anti gad negative,C0205160;C1513916;C2825415;C2825491;C3853545
second co primary,C0205225;C0439612;C0439631
microvascular outcome,C0443258;C1274040
non severe hypoglycaemia,C0020615;C4553659
hbalc $nmbr$ $nmbr$ mmol mol,C3829066
iglarlixi n $nmbr$,
iglar n $nmbr$,
beam values mg dl mean sd,C0439269;C2699239
beam $nmbr$ mg dl at week $nmbr$ n,C0439269;C0332174;C0439230
sample statistics,C2348149
nilvadipine,C0132512
years since diagnosis,C0439234;C0011900;C1704338;C1704656
years since symptom onset,C0439234;C4086878
apoe $nmbr$ carrier,C0007294;C0560175;C1325398;C1706209;C3273162
smmse,
smmse $nmbr$,
baseline adas cog $nmbr$,C0168634;C3539026;C1442488
baseline cdr sb n $nmbr$ $nmbr$,C0168634;C0038111;C3811240;C1442488
baseline dad n $nmbr$ $nmbr$,C0168634;C1442488
d $nmbr$ ci,C0008107;C3259781
group difference,C1705241;C1705242
non carrier n $nmbr$,C2986416
carrier n $nmbr$,C0007294;C0560175;C1325398;C1706209;C3273162
mild n $nmbr$,C2945599
moderate n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ease $nmbr$,C1331418
empaglifiozin $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo w $nmbr$,C0032042;C1696465;C1706408
empaglifiozin $nmbr$ $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
femaie,
pacific,
egfr ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
total daily insulin dose units kgt,C2348070
basal insulin doset,C0650607
bolus insulin doseh,C1186706;C0021641;C1533581;C1579433;C3714501;C1511237;C1705509;C3812160
type of insulin,C0457592
figure $nmbr$ hba $nmbr$ c ef cacy analysis data are from patients treated with $nmbr$ dose of study drug who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement c placebo corrected change from baseline in hba $nmbr$ c with empagli ozin at week $nmbr$ in subgroups by baseline hba $nmbr$ c $nmbr$ and $nmbr$ data are based on mixed model repeated measures analysis p $nmbr$ $nmbr$ for difference vs placebo p $nmbr$ $nmbr$ for difference vs placebo,C1511726;C3245479;C3714741;C0030705;C0332293;C0013175;C0168634;C1442488;C1299575;C0019016;C1825777;C3538758;C0332174;C0439230;C1079232;C1527178;C1705938;C1705241;C1705242;C0032042;C1696465;C1706408
permanent users,C0205355;C1706077
fp,C0016704;C1419068;C1419906;C3541238;C3541412
other ics,C0815320;C4551720
no ics,C0815320;C4551720
non inhaled steroid use n,C1518422;C0586793
anticholinergic use n,C0242896;C0042153;C0457083;C1947944;C3537004
fvc l mean sd,C0444504;C2699239;C2347634;C2348143
fvc predicted mean sd,C0444504;C2699239;C2347634;C2348143
fev $nmbr$ fvc mean sd,C0444504;C2699239;C2347634;C2348143
post bronchodilator fev $nmbr$ l mean sd,C2599594;C2699239
post bronchodilator fev $nmbr$ predicted mean sd,C2599594;C2699239
treatment throughout study,C1521826;C3161471
fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
other ics versus no ics,C0815320;C4551720
hr or rr $nmbr$ ci,C0008107;C3259781
permanent users n,C0205355;C1706077
patients with pneumonia events n,C0030705;C0032285
pneumonia events n,C0032285;C0441471;C3541888
adjusted rate of pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
patients with hospitalized pneumonia events n,C0870668;C0032285
hospitalized pneumonia events n,C0032285;C0441471;C3541888
adjusted rate of hospitalized pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
patients with pneumonia resulting in death n,C0030705;C0032285;C0332294;C0011065;C1306577;C4082313;C4552775
treatment at baseline,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hr or rr,
use at baseline n,C0042153;C0457083;C1947944
patients with pneumonia event n,C0030705;C0032285
albiglutide n $nmbr$,C2607479
race or ethnicity,C0034510;C1706779;C3853635;C0015031;C0243103
non hispanic black or african american,C0005680;C0027567;C0085756;C0439541
eastern and central europe,C1707877;C0682369
diabetic eye disease,C0342245
peripheral sensory neuropathy,C0151313;C4554142
autonomic neuropathy,C0259749
glucose lowering medications,C0017725;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
none or diet,C0012155;C0012159;C1519433;C2983588;C3668949
sodium glucose cotransporter $nmbr$ inhibitor,C0017725;C1999216
glucosidase inhibitor,C1512211
albiglutide events patients,C0441471;C0030705;C3541888
$nmbr$ $nmbr$ o $nmbr$ s i $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ o $nmbr$ o i i $nmbr$,C0021966;C0221138
$nmbr$ o $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$ ^,
number of arterial beds involved,C0237753;C0449788;C1314939
heart failure history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
baseline dipeptidyl peptidase a,C0168634;C0022709;C1442488
baseline antiplatelet,C0168634;C1442488
normoalbuminuria uacr,
lixisenatide n $nmbr$ o,C2973895
$nmbr$ tq fi i,C0021966;C0221138
$nmbr$ f $nmbr$ q,C0016327
$nmbr$ f $nmbr$ l $nmbr$,C0016327
egfr ml min per $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
$nmbr$ ^ f $nmbr$ $nmbr$,C0016327
therapies,C0087111
angiotensin converting enzyme inhibitors,C0003015;C2757044
other blood pressure lowering drugs,C0003364
amann whitney u test wilcoxon sum rank test,C0439148;C0683443
age group $nmbr$ no,C0027362;C2348001
bpearson s chi square test,C0008041
body mass index group kg m $nmbr$ $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
dyslipidaemia including hypercholesterol no,C0242339
chronic renal disease no,C0022661;C1561643
cfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
mi no,C3810814
coronary artery bypass graft no,C0010055;C1260596
chronic obstructive pulmonary disease no,C0024117
transient ischaemic attack no,C0007787;C0917805
haemorrhagic stroke no,C0553692
non haemorrhagic stroke no,C1518422;C0553692
timi risk score category no,C0683312;C3889287
gp iib iiia inhibitor before pci no,C0016011;C1999216
ticagrelor in hosp n $nmbr$,C1999375
ticagrelor pre hosp n $nmbr$,C0332152;C0740175;C2257086;C3669034
atwo sample t test,C0370003;C0871472;C2347026
age group $nmbr$ years no,C1510829
cmann whitney u test wilcoxon sum rank test,C0439148;C0683443
body mass index group $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
dyslipidaemia no,C0242339
$nmbr$ $nmbr$ d,
dfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
univariate logistic modela,C0242415
multivariate logistic modelb,C0242415
aunivariate logistic regression,C0206031
bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828;C0441722;C0443221
mi previous pci and chronic obstructive pulmonary disease,C0205156;C4049621;C1552607;C0024117
pre hospital ticagrelor,C0019994;C1999375;C1510665
in hospital ticagrelor,C0019994;C1999375;C1510665
the p value is from the test statistic for testing the interaction between the treatment group and diabetes group,C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675;C0374505;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ days composite of death new mi urgent revascularization and definite st,C0205199;C1547335;C0036056;C3272372
$nmbr$ days new mi or definite acute st,C0205314;C3810814;C0036056;C3272372
$nmbr$ days new mi,C0205314;C3810814
$nmbr$ days definite st,C0036056;C3272372
$nmbr$ days urgent revascularization,C0439228;C0581603
$nmbr$ days stroke ischemic,C0038454;C0475224;C4554100
timi flow grade $nmbr$ of mi culprit vessel pre pci,C0441800;C0919553;C3244287;C3810814;C0005847;C0332152;C0740175;C2257086;C3669034
st str $nmbr$ pre ci,C0008107;C3259781
timi flow grade $nmbr$ of mi culprit vessel post pci,C0441800;C0919553;C3244287;C0856742;C4049621
st str $nmbr$ post pci,C0036056;C4049621;C3272372
bail out use of glycoprotein iib iiia inhibitors,C1524063;C0016011
timi minor bleeding,C0026193;C0019080;C0205165
antiplatelet use,C0042153;C0457083;C1947944
high intensity statin use,C0042153;C0457083;C1947944
moderate intensity statin use,C0042153;C0457083;C1947944
imaged artery,C0003842;C0226004
ramus,C3538818
p value between groups,C1709380
normalized volume measures,C0079809;C1879489
necrotic core mm^,C4330985;C4554674
nominal change,C0392747;C0443172;C1705241;C4319952
fibrofatty mm^,C4330985;C4554674
fibrous mm,C4330985;C4554674
dense calcium mm,C4330985;C4554674
necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
volume change mm^,C4330985;C4554674
fibrofatty,
fibrous,C0016059;C0439709
dense calcium,C0006675;C0006726;C2936886;C3540037;C3714611
fig $nmbr$ proportion of patients achieving das de ned remission over time by symptom duration in each treatment arm a abatacept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci das de ned remission is de ned as das $nmbr$ crp $nmbr$ $nmbr$ das $nmbr$ crp disease activity score in $nmbr$ joints with c reactive pro tein das $nmbr$ crp mtx methotrexate,C1709707;C0030705;C0544452;C0687702;C0444921;C3259042;C0743559;C1608199;C1882932;C1518340;C4706353;C0022417;C0392905
fig $nmbr$ proportion of patients achieving haq response over time by baseline symptom duration in each treatment arm a abata cept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci haq response is de ned as a reduction of at least $nmbr$ $nmbr$ units from baseline haq h ealth assessment question naire mtx methotrexate,C1709707;C0030705;C0102923;C0034746;C0451208;C0444921;C3259042;C0743559;C1608199;C1882932;C0871261;C1704632;C1706817;C2911692;C0011198;C1518340;C0017480;C3541240;C4684571;C0025677
dapaglifloiin n,
[ ifrerence vs placebo $nmbr$ cl,C0032042;C0596019;C1696465;C1706408
baseline hbalc^,C0168634;C1442488
s $nmbr$ $nmbr$ s $nmbr$ $nmbr$,C0565930;C2603362
s $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
insulin administration,C0199782
cgm use,C0042153;C0457083;C1947944
dapaglifloz in n,
difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
baseline hba $nmbr$ c^,C0168634;C0019016;C1825777;C3538758;C1442488
dapagliflozin n,C2353951
difference vs placebo kg $nmbr$ cl,C1705241;C1705242;C0022718;C0596019;C0439209;C4054209
n liraglutide $nmbr$ placebo,C0032042;C1696465;C1706408
ldl c $nmbr$ mg dl,C0439269
ldl c $nmbr$ $nmbr$ mg dl,C0439269
non fatal ml,C0439526;C1705224;C3887665
expanded mace,C0349381;C0949745;C1445339
pci indication,C0392360;C3146298
thienopyridine at discharge,C1120149;C0012621;C0030685;C2926602
vein bypass stented,C0042449;C0741847;C0038257
stent thrombosis or mi,C3897493;C3810814
definite probable stent thrombosis,C0033204;C3897493;C0332148
definite stent thrombosis,C0439544;C3897493;C1704787
probable stent thrombosis,C0033204;C3897493;C0332148
noncardiac death,C0011065;C1306577;C4082313;C4552775
genetic subgroup,C1079230;C1515021
total aim high study,C0557651;C2603343
statin placebo n $nmbr$,C0360714;C0032042;C1696465;C1706408
statin er niacin n $nmbr$,C0360714;C0027996;C1142562
baseline tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
baseline tg mg dl median iqr,C0168634;C0439269;C1442488
baseline lipoprotein a nmol l median iqr,C0065058;C0125953;C1096202;C1439335
change in ldl c,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
change in hdl c,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ b,
change in tc,C0392747;C0443172;C1705241;C4319952
change in tg,C0392747;C0443172;C1705241;C4319952
change in lp a,C0392747;C0443172;C1705241;C4319952
gene chr snp,C0752046;C1527094
alleles,C0002085
placebo statin,C0032042;C0360714;C1696465;C1706408
niacin statin,C0027996;C0360714;C1142562
maf,
minor major,C0205082;C0205164;C4318856;C4521762
trait,C0599883
frequency of events,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
freqency of events,C0441471;C3541888
lipc,C1416867
aa g,C0282379;C0439267;C1235746;C1882141;C4554792
cad death,C0011065;C1306577;C4082313;C4552775
p value by gt,C1709380;C1435727;C1704693;C2697657
ampd $nmbr$,
ga a,C0016993
cyp $nmbr$ a $nmbr$,C1418793;C2634343
a ga,C0016993
ga,C0016993
male sex^,C0086582
diabetes duration years^,C0011847;C0439234;C0011849
geographic region^,C0017446
hbau,
body weight kg^,C0022718;C0439209;C4054209
systolic blood pressure mm hg^,C0488055;C0439475;C0871470;C1306620
diastolic blood pressure mm hg^,C0428883;C0439475;C1305849
established cvd chronic kidney disease age $nmbr$ ^,C1561643;C0001779;C4553188
cvd risk factors age $nmbr$ ^ ^,C0001783
antihyperglycaemic medication at baseline,C0013227;C3244316;C4284232
$nmbr$ oad,
$nmbr$ oads,
insulin dose u,C0366513;C0439148
per body weight u kg,C0005910;C1300561;C1305866
fig s $nmbr$ change in hba $nmbr$ c from baseline stratified by hba $nmbr$ c at baseline i first quartile hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205363;C0019016;C1825777;C3538758;C0021966;C0221138
table $nmbr$ baseline characteristics of the liraglutide and placebo groups including concomitant antihyperglycaemic treatment,C0039224;C4684572;C1706074;C0032042;C0374505;C1696465;C1706408
full analysis set data are the mean standard deviation or the number of patients percentage of either liraglutide or placebo group percentage data refer to the proportion of patients a data rst published in the leader primary publication marso et al [ $nmbr$ ] b established cvd was de ned as prior myocardial infarction or prior stroke or transient ischaemic attack or prior revascularisation or [ $nmbr$ stenosis of coronary carotid or lower extremity arteries or documented symptomatic coronary heart disease or documented asymptomatic cardiac ischaemia or heart failure or chronic kidney disease c cvd risk factors included microalbuminuria or proteinuria hypertension and left ventricular hypertrophy left ven tricular systolic or diastolic dysfunction or ankle brachial index \ $nmbr$ $nmbr$ bmi body mass index cvd cardiovascular disease hba $nmbr$ c glycated haemoglobin oad oral antihyperglycaemic drug,C1511726;C3245479;C3714741;C1828170;C2360800;C0439165;C1549488;C1561533;C0205543;C0030705;C1425219;C0034037;C1704324;C0443211;C0007222;C1272684;C1518340;C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0007787;C0917805;C0332152;C0581603;C2826257;C0007282;C0242231;C0226415;C0010054;C0010068;C1956346;C1279369;C2062869;C0018801;C0018802;C4554158;C0679238;C0730345;C0020538;C1963138;C0149721;C0039155;C3484363;C0520863;C0007220
age years^,C1510829
diabetes duration ycars,C0011847;C0011849
no polyvascular disease n $nmbr$ $nmbr$,C0012634
polyvascular disease n $nmbr$,C0012634
cardiac catheterisation or pci for index event,C0018795;C4049621;C0441471;C4019010
medications at enrolment,C0013227;C0802604;C2598133;C4284232
aspirin any dose,C0004057;C0178602;C0869039;C1114758
polyvascular disease status,C3176928
polyvascular disease and type $nmbr$ diabetes status,C0012634;C1317301
polyvascular disease and type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
polyvascular disease and no type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
cardiovascular death myocardial infarction or stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
cardiovascular hospitalisation,C0007226;C0019993;C3887460
peripheral revascularisation,C0205100;C0581603
central and eastern europe,C0205099;C1879652;C0015177
canada or united states,C0006823;C0041703
rest ofworld,C0035253;C1622890
medical history before index acute coronary syndrome no,C0262926;C1704706
family history of premature coronary heart disease,C0260520;C1313980;C2317524
index acute coronary syndrome no,C0600653;C0948089;C0918012;C1552854;C1637833;C2986546
percutaneous coronary intervention or coronary artery bypass grafting for index acute coronary syndrome no,C1532338;C0010055
median time from index acute coronary syndrome to randomization iqr mo,C0040223;C3541383;C0026544;C0332177
median duration oftype $nmbr$ diabetes iqr yr,C0011847;C0439234;C0011849
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m^,C3811844;C0439445
established atherosclerotic cardiovascular disease no,C0443211;C0004153;C1272684
history of coronary artery disease no,C1881055
history of peripheral artery disease no,C0683519;C0730226;C0850708;C0944983
history of cerebrovascular disease no,C0585890
glucose lowering therapies no,C0017725;C0441994;C2003888;C0087111
dpp $nmbr$,C1414174
cardiovascular therapies no,C0587038
dapagliflozin placebo no of events no of patients,C0032042;C1696465;C1706408;C0441471;C3541888;C0030705
hazard ratio $nmbr$ c,C2985465
a cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
[,
mrf,C0312443;C1412879
$nmbr$ em,
i h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
$nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
b mace,C0349381;C0949745;C1445339
$nmbr$ ml min $nmbr$ $nmbr$,C0439445
icosapent ethyl events n,C0058978;C0441471;C3541888
risk stratum,C0035647;C4552904
secondary prevention cohort,C0009247;C0599755
primary prevention cohort,C0009247;C0599755
the netherlands australia new zealand and south africa,C0027978;C0324547;C0037712
$nmbr$ yr from the united states,C0439234;C0041703
baseline estimated gfr,C0017654;C1424601
$nmbr$ to $nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
baseline triglycerides $nmbr$ mg dl and,C0041004;C0439269
h dl cholesterol $nmbr$ mg dl,C3539687
baseline statin intensity,C0168634;C0522510;C1442488
baseline ldl cholesterol derived,C0023824;C0202117;C1441547;C3245521
in thirds,C0205437
$nmbr$ to $nmbr$ mg dl,C0439269
$nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
black af rican american,C0085756;C0344434;C4049859
europe plus south africa,C0015176;C0037712
ischemic heart disease no,C0010054;C0151744
egfr mdrd ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
uacr median iqr mg g,C0549183;C1300563;C0876920;C2347635;C2348144;C2939193
hemoglobin a^c,C0019020;C3889898
heart rate min,C0702093;C1524029;C3813700
$nmbr$ glucose lowering medication no,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
no of background glucose lowering therapies no,C1706907;C0017725;C0441994;C2003888;C0087111
$nmbr$ antihypertensive medication no,C0003364
incidence rate difference linagliptin placebo $nmbr$ cl,C1708485;C0596019
primary outcome $nmbr$ point mace,C0349381;C0949745;C1445339
cardiovascular death nonfatal myocardial infarction or nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
secondary kidney composite outcome,C0022646;C1274040;C0227665
sustained esrd death due to kidney failure or sustained decrease of $nmbr$ in egfr from baseline,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047;C1739039;C3811844;C3812682
death due to renal failure,C0011065;C1306577;C4082313;C4552775
sustained decrease of $nmbr$ in egfr,C0392756;C0547047;C1739039;C3811844;C3812682
exploratory cardiovascular and death outcomes,C0007226;C3887460;C0011065;C1274040;C1306577;C4082313;C4552775
noncardiovascular death,C0011065;C1306577;C4082313;C4552775
fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
fatal or nonfatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
fatal or nonfatal stroke,C1302234;C1705232;C0038454;C4554100
$nmbr$ point mace $nmbr$ point mace plus hospitalization for unstable angina,C0349381;C0019993;C0949745;C1445339;C0002965
exploratory kidney and microvascular outcomes,C0022646;C0227665;C0443258;C1274040
death due to renal failure or sustained esrd,C0011065;C1306577;C4082313;C4552775;C0022661;C0035078;C2316810
albuminuria progression,C0242656;C0449258
composite microvascular end point,C2349179;C2826544
composite ocular end point,C2349179;C2826544
severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
no severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
previous cvd^,C0205156;C0007222;C1552607
alcohol^,C0001962;C0001975
previous dm,C0011816;C3250443
dm duration years,C0011816;C0439234;C3250443
mean alc,C1424945;C3811058
mean fpg mmol l,C0444504;C1532563;C2347634;C2348143
glargine allocation,C0907402;C1706778
standard allocation,C1442989;C1706778;C2828392
n $nmbr$ allocation,C0369718;C1706778;C0441922
other glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
mean mmse score,C3533236;C0451306
nonsevere hypoglycemia,C0020615;C4553659
no nonsevere hypoglycemia,C0020615;C4553659
a severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
b nonsevere hypoglycemia,C0020615;C4553659
no prior dm,C0011816;C3250443
no prior cvd,C0332152;C0007222;C2826257
educ ssy,
educ $nmbr$ $nmbr$ y,
educ $nmbr$ y,
giargine,
standard,C1442989;C2828392
itch nrs $nmbr$ v $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ at $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ v $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ \ $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ a $nmbr$,C2240043;C4050142
geographic region n,C0017446
baseline pssi score mean sd,C0168634;C2699239;C1442488
baseline ppasi score mean sd,C0168634;C2699239;C1442488
baseline skin pain vas mean sd,C0042815;C2699239
baseline bsa mean sd,C0168634;C2699239;C1442488
baseline spga mean sd,C0168634;C2699239;C1442488
baseline pasi mean sd,C0168634;C2699239;C1442488
baseline dlqi mean sd,C0168634;C2699239;C1442488
age at enrollment years mean sd,C1510829;C0444504;C2347634;C2348143
duration of psoriasis years mean sd,C0449238;C2926735
previous use of nonbiologic systemic therapy n,C1524063;C1515119
previous use of biologic systemic therapy n,C1524063;C1515119
facial psoriasis n,C1276112
scalp psoriasis n,C0406326
fig $nmbr$ impact of baseline psoriasis associated itch severity on the itch numeric rating scale changes from baseline during the induction period pooled data from uncover $nmbr$ and $nmbr$ lsm in patients with psoriasis associated itch nrs c $nmbr$ at baseline the lsm difference $nmbr$ con dence interval and p values were derived from a mixed effects model for repeated measures analysis including the xed effects treatment study visit and treatment $nmbr$ visit with the variance covariance structure set to unstructured intent to treat population itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs scores at baseline etn etanercept ixe ixekizumab lsm least squares mean nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks,C1825598;C4049986;C0392747;C0443172;C1511726;C3245479;C3714741;C0030705;C0033860;C0033774;C1422257;C0168634;C1442488;C1272706;C1552654;C1552713;C1709380;C1441547;C3245521;C0002778;C0936012;C1524024;C2359836;C0036849;C1442518;C1705195;C2240043;C4050142;C0449820;C0023189;C0439230
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for a clinically meaningful improvement in itch i e c $nmbr$ point reduction in itch nrs at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treat ment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033774;C1422257;C0301630;C0392756;C1293152;C4551656;C0332174;C0439230;C0030705;C0332281;C0032659;C1257890;C4049715;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for complete itch resolution i e itch nrs $nmbr$ at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2240043;C4050142;C0332174;C0439230;C0030705;C0332281;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C0449820;C4050231;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for c $nmbr$ improvement in psoriasis area and severity index from baseline at the end of the induction period week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population pooled data from uncover $nmbr$ and $nmbr$ nri treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pasi $nmbr$ c $nmbr$ improvement in pasi from baseline pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033860;C0017446;C0205146;C0444930;C2746065;C0336604;C1511726;C3245479;C3714741;C0039798;C0033774;C1422257;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0449820;C4050231;C4050142;C4528685;C0031962;C0439230;C0014758;C0717758
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for absolute psoriasis area and severity index score b $nmbr$ at week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C0457451;C0332174;C0439230;C0336604;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C2240043;C4050142;C0449820;C4050231;C0014758;C0717758;C0031962
baseline crp,C3890735;C4048285
normal uln n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
high uln and $nmbr$ xuln n $nmbr$,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
very high $nmbr$ xuln n $nmbr$,C0442804;C4321397
age at disease onset years,C0206132;C3870509
age at disease onset n,C0206132;C3870509
duration of as years,C0449238;C2926735;C0439234
duration of as n,C0449238;C2926735;C0369718;C0441922
prior nsaid n a,C0332152;C0003211;C3536840;C2826257
hla b $nmbr$ n,C1426226
ptga,
asdas crp,C3890735;C4048285
basdai,C1998004
basfi,
nbp,
tbp,
comparison cat $nmbr$ vs cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
week $nmbr$ outcomes,C0332174;C1274040;C0439230
asdas crp $nmbr$ $nmbr$,C3890735;C4048285
cat $nmbr$ n n,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
or $nmbr$ ci a,C0008107;C3259781
pb,C1415801;C3819255
high vs normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
very high vs normal,C0442804;C4321397;C0205307;C0231683;C0439166;C2347086;C4553972
week $nmbr$ crp,C3890735;C4048285
elevated vs normalc,C0205250;C3163633
baseline asdas crp,C3890735;C4048285
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ and $nmbr$ $nmbr$,
male vs female,C0086582;C1706180;C1706428;C1706429;C0043210;C0086287;C1705497;C1705498
$nmbr$ years vs $nmbr$ years,C0439234
$nmbr$ to $nmbr$ years vs $nmbr$ years,C0439234
prior nsaid use,C0042153;C0457083;C1947944
yes vs no,C1549445;C1705108;C1710701
hla b $nmbr$,C0019737;C0550853;C1415561
positive vs negative,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
baseline ptga,C0168634;C1442488
$nmbr$ and $nmbr$ vs $nmbr$,
$nmbr$ vs $nmbr$,
baseline basdai,C0168634;C1998004;C1442488
baseline basfi,C0168634;C1442488
$nmbr$ to $nmbr$ vs $nmbr$,
baseline nbp,C0168634;C1442488
baseline tbp,C0168634;C1442488
week $nmbr$ outcome,C0332174;C1274040;C0439230
potential predictor,C3245505;C2698872
high vs normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
very high vs normalb,C0442804;C4321397
elevated vs normalb,C0205250;C3163633
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
boost intensify premix i global patient population,C1511253;C1874596;C0032659;C1257890
boost intensify all pan asian patient population,C1511253;C1874596;C0032659;C1257890
total included in combined analysis,C0439175;C0439810;C0332257;C0002778;C0936012;C1524024
idegasp bid,
biasp $nmbr$ bid,
full analysis set n,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
idegasp biasp $nmbr$,
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C1180255;C0008107;C3259781
end of trial,C0444930;C2746065
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p,C1180255;C0008107;C3259781
etr $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C0008107;C3259781
subpopulation,C1257890
week $nmbr$ before ee,C0332174;C0439230
week $nmbr$ non ee responders,C0332174;C0439230
adjusted mean difference $nmbr$ ci,C0008107;C3259781
crp uln,C3890735;C1519815;C4048285
facit f,C3272505
tnfi na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
lev n $nmbr$,C0023556
duration of epilepsy mean sd years,C0449238;C2926735
seizure history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
focal,C0205234
generalized,C0205246
absence,C0332197;C1689985
atypical absence,C0595948
myoclonic,
clonic,
tonic,C3543842
tonic clonic,C3543842
atonic,
cluster seizures,C1555715;C0036572;C1704332
classification of epilepsy type n,C0008902;C0008903;C0678229
idiopathica,
juvenile myoclonic epilepsy,C0270853
epilepsy with grand mal seizures on awakening,C0014549;C1720052
symptomaticb,
specific syndromes,C0039082;C1558916
undeterminedc,
seizure frequency during $nmbr$ week baseline median range,C0149775;C0168634;C1442488
prior aeds $nmbr$ n,C0332152;C0180309;C2826257
concomitant aeds n,C0521115;C0180309
phenobarbital,C0031412
freedom from gtc seizures n,C0016694;C0036572
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week treatment period full analysis set p values versus placebo calculated using ancova b median percent reduction from combined baseline in generalized tonic clonic seizures week for patients with idiopathic and symptomatic generalized epilepsy during the $nmbr$ week treatment period ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0332174;C0439230;C0332240;C0270854;C0377265;C3693636
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week evaluation period p values versus placebo calculated using ancova b generalized tonic clonic seizure $nmbr$ responder rates during the $nmbr$ week treatment and $nmbr$ week evaluation periods full analysis set p values versus placebo calculated using logistic regression ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0042295;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0871208;C1521828;C0814908
onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
faster aspart mealtime,C0123677;C0587119
insulin aspart mealtime,C0123677;C0587119;C1708521
faster aspart,C0015663;C0123677;C0456962;C2985769
insulin aspart,C0123677;C1708521
faster aspart basal,C0123677;C0205112
basal insulin,C0650607
gender n men,C0079399;C0025266;C1522384
lb,
$nmbr$ mmol mol $nmbr$ $nmbr$ n,C3829066
change in hbalc after $nmbr$ weeks etd $nmbr$ cl,C0392747;C0443172;C1705241;C4319952;C0439230;C0596019
all participants n $nmbr$ $nmbr$,C0679646
bmi $nmbr$ kg m^ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc $nmbr$ $nmbr$ $nmbr$,
hbalc $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
all participantst n $nmbr$ $nmbr$,
bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
bmi $nmbr$ kg m n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc a $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
all participants^^ n $nmbr$ $nmbr$,C0679646
dose ratio at week $nmbr$ $nmbr$ cl,C0178602;C0456603;C1547037;C0869039;C1114758
hbalc $nmbr$ mmol mol,C3829066
normal baseline crp,C3890735;C4048285
elevated baseline crp,C0742906;C0168634;C1442488
pooled secukinumab,C1709595;C3179547;C2349200;C4522255
pooled placebo,C0032042;C1696465;C1706408
positive for hla b $nmbr$ n,C0439178;C1446409;C1514241;C2825490;C3812269
concomitant methotrexate use n,C0025677;C0042153;C0457083;C1947944
hscrp mg l median minimum maximum,C0806909;C1552615;C2826546
ptga of disease activity $nmbr$ $nmbr$ mm mean sd,C1292728;C0444504;C2347634;C2348143
week,C0332174;C0439230
baseline crp levels,C3890735;C0441889;C4048285
baseline crp levels $nmbr$ mg l,C0168634;C0439268;C1442488
basdai mean change from baseline,C0392747;C0443172;C1705241;C4319952
basdai $nmbr$,C1998004
asdas inactive disease,C0544452
asas partial remission,C1521726;C4552913;C4552914
with prior mi stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
cvd without mi or stroke n $nmbr$,C0007222;C3810814;C0038454;C4554100
cardiovascular risk factors alone n $nmbr$,C0850624;C0205171;C0439044;C0679994
age sd y,C0001779;C2699239
bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
diabetes mellitus duration sd y,C0011849;C0449238;C2926735
hba $nmbr$ c sd mmol mol,C0019016;C3829066;C1825777;C3538758
sbp sd mm hg,C0085805;C0439475
dbp sd mm hg,C0536221;C0439475;C3813197;C4281799
heart rate sd bpm,C0018810;C2699239
egfr from the mdrd equation sd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
moderate $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
mild $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C2945599;C0439445;C0369718;C0441922
normal $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0369718;C0441922
total cholesterol sd mg dl,C0201950;C0439269;C0543421
ldl cholesterol sd mg dl,C0023824;C0439269;C0202117
hdl cholesterol sd mg dl,C0023822;C0439269;C0392885
triglycerides sd mg dl,C0041004;C0439269
lipid lowering drugs n,C0086440
platelet aggregation inhibitors n,C0032177
antithrombotic medications n,C0013227;C0802604;C2598133;C4284232
blood glucose lowering drugs excluding insulin n,C0005802;C0441994;C2003888;C0013227;C3687832
insulin treatment n,C0745343
insulin naive n,C0021641;C1533581;C1579433;C3714501
rate $nmbr$ pyo,C0871208;C0033809;C1521828
hzard ratio,C0456603;C1547037
prior ml stroke,C0038454;C4554100
cvd without ml stroke,C0007222;C0038454;C4554100
all mis,C0687670;C1333208;C1412384;C3538735
all strokes,C0038454
cvd without miatroke,C0007222
cvd without ml^troke,C0007222;C0439526;C1705224;C3887665
micro macroalbuminuria,C0085672;C1553035;C3811161;C4049106
smoking n,C0037369;C0453996;C1881674
prior stroke mi n,C0332152;C0038454;C4554100;C2826257
diabetes mellitus duration y sd,C0011849;C2699239
body weight kg sd,C0005910;C2699239;C1305866
creatinine mg dl sd,C0439269;C2699239
egfr ml min $nmbr$ $nmbr$ m $nmbr$ sd,C1739039;C0439445;C3811844;C3812682;C2699239
normal egfr $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972
mild impairment egfr $nmbr$ $nmbr$ n,C0221099;C0684336
moderate impairment egfr $nmbr$ $nmbr$ n,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
uacr mg g q $nmbr$ q $nmbr$,C1300563
total cholesterol mmol l sd,C0201950;C2699239;C0543421
ldl c mmol l sd,C1532563;C2699239
sbp mm hg sd,C0439475;C2699239
dbp mm hg sd,C0439475;C2699239
hr bpm sd,C2699239
liraglutide n,C1456408
hazard ratio [ $nmbr$ ci],C2985465;C0008107;C3259781
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
egfr $nmbr$ ml min $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682
outcome_subgroup,C1079230;C1515021
egfr_p_interaction,C1739039;C1704675;C3811844;C3812682
albuminuria_p_interaction,C0001925;C1704675
primary cv endpoint,C2986535;C3538987;C4048877;C4318503
egfr s $nmbr$ ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
micro macroaibuminuria,C0085672;C1553035;C3811161;C4049106
expanded cv endpoint,C2349179;C2826544
egfr s $nmbr$ o ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
egfr $nmbr$ ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
hospitalization for unstable ap,C0019993;C0002680;C3887950
acute increase in serum creatinine,C0442805;C0201976;C0600061
demographic factors,C0011292;C0011298
residence in asia n,C0237096;C0003980
medical and lifestyle history,C0199168;C0205476;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of macrovascular disease at baseline n,C0683519;C0730226;C0850708;C0944983;C0168634;C1442488
current alcohol drinking n,C0001962;C0001975;C0001948;C0684271;C0369718;C0441922
hemoglobin a,C0019016
ecfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
uacr pg mg,C1627892
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
randomized treatments n,C0034656;C0087111;C3815594
perindopril indapamide,C1273169
intensive blood glucose control,C3267174
blood glucose lowering treatments n,C0005802;C0441994;C2003888;C0087111
oral hypoglycemic agentsj,C0359086
bp lowering treatments n,C0037623;C0087111;C1415692;C1708288;C4318478
diuretics^,C0012798
angiotensin converting enzyme inhibitors^,C0003015;C2757044
angiotensin ii receptor blockers,C0521942;C2757003
any bp lowering agents^,C0450442;C1254351;C1521826
changes in serum creatinine pmol l,C0392747;C0443172
first serum creatinine,C0201976;C0600061
second serum creatinine,C0201976;C0600061
increase in serum creatinine,C0442805;C0201976;C0600061
n events n subjects,C0681850;C1550501;C1706203;C2349001;C2697811
combined major macrovascular events neohrodathv and all cause mortalitv,C0205082;C0205164;C4318856;C4521762;C0015127;C1524003
major macrovascular events,C0441471;C3541888
new or worsenina neohrodathv,C0205314
all cause mortalitv,C0015127;C1524003
n events,C0441471;C3541888
combined major macrovascular events,C0441471;C3541888
neohrodathv and all cause mortalitv,C0015127;C1524003
new or worsentna neohrodathv,C0205314
golden $nmbr$ and $nmbr$,
golden $nmbr$,
glycopyrrolate glycopyrrolate eflow cs $nmbr$ meg eflow cs $nmbr$ meg n $nmbr$ n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
tiotropium $nmbr$ meg n $nmbr$,C0024489;C0025175;C0072225
glycopyrrolate eflow cs $nmbr$ meg n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
black or african heritage,C0005680;C0027567;C0085756;C0439541;C2986513
body mass index kg rn \ mean sd,C0005893;C2699239;C0578022;C1305855
number of copd exacerbations within $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
history of oxygen use yes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
high cardiovascular risk n ^,C0332167;C3272283;C4050568;C4319571
background laba use yes n,C0042153;C0457083;C1947944
inhaled corticosteroid yes n,C0004048;C0001617;C3536709
pulmonary function tests post bronchodilator mean sd,C0024119;C2699239;C2598152
fevi fvc,C0802741;C3815113
fevi percent predicted,C0429706;C0439165;C0849974;C1561566;C4528367;C0681842;C1882327
post bronchodilator fevi n,C2599594;C0429706;C0849974;C1561566;C4528367
$nmbr$ predicted to,C0681842;C1882327
$nmbr$ predicted,C0681842;C1882327
baseline in check pifr l min,C0702093;C1524029;C3813700
sgrq scores mean sd,C0444504;C2699239;C2347634;C2348143
activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
impacts,C1825598;C4049986
sgrq responder,
odds ratio and $nmbr$ cl,C0028873;C0596019
sun $nmbr$ $nmbr$,C0038817;C0376223
lcl,C3658298
ucl,
background laba use,C0042153;C0457083;C1947944
fev predicted,C3714541;C0681842;C1882327
pifr l min,C0702093;C1524029;C3813700
$nmbr$ l min,C0439393
$nmbr$ l_ min,C0439393
participants with hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
participants without hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
total carmelina population,C3258257
europe including south africa,C0015176;C0037712
egfr mdrd n,C1739039;C3811844;C3812682
uacr mg g median $nmbr$ th $nmbr$ th percentile,C1300563;C1264641
uacr n,
diabetes mellitus duration y,C0011849;C0449238;C2926735
heart rate bpm mean sd,C0018810;C2699239
glucose lowering therapy n,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
antihypertensives n,C0003364
asa n,C0004057;C3853627
patients with event patients analysed,C0030705;C0441471;C4019010
p for interaetion,C0369773;C2603361
plaeebo,
blaek afriean ameriean,
hispanie latino,C0086528
not hispanie latino,C1518422;C0086528
enrope sonth afriea,
north ameriea,C1709269
latin ameriea,
$nmbr$ ky nr,C0027496;C3844738
$nmbr$ ml niin l $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
$nmbr$ to $nmbr$ ml min l $nmbr$ nr,C0027496;C3844738
$nmbr$ ml min $nmbr$ $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
not on metformin,C1518422;C0025598
angiotensin eonverting enzyme inhibitors angiotensin reeeptor bloekers,C0014432;C1152555;C2756995
angiotensin eonverting enzyme inhibitors,C0014432;C1152555;C2756995
calcium channel blocker ccb,C0006684;C3536851;C4521885
duration of type $nmbr$ diabetes,C0449238;C2926735
ckd prognosis by kdigo,C0033325;C3854082
cardio renal risk,C0035647;C4552904
albuminuria and previous maerovaseular disease without established renal disease,C0001925;C0012634;C0022658
established renal disease egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m^ with any uacr mg g or egfr $nmbr$ $nmbr$ ml inin l $nmbr$ m $nmbr$ with an uacr $nmbr$ mg g without previous maerovaseular and albuminuria disease,C0022658;C0439445;C1300563;C0439268;C0439294;C0456615;C0205156;C1552607;C0001925;C0012634
albuminuria and previous maerovaseular disease plus established renal disease egfr $nmbr$ $nmbr$ ml min l $nmbr$ in with an uacr $nmbr$ mg g or egfr $nmbr$ $nmbr$ ml inin l $nmbr$ in with any uacr mg g,C0001925;C0022658;C0439445;C1300563;C1739039;C1635169;C3811844;C3812682
established renal disease,C0443211;C0022658;C1272684
established macrovascular disease and albuminuria,C0443211;C0012634;C1272684;C0001925
prevalent kidney disease egfr $nmbr$ ml min usm^ or maeroalbuminuria uacr $nmbr$ mg g,C0022658;C0439445;C1300563
patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
empagliflozin pooled n $nmbr$,C1709595;C2349200;C4522255
north america plus america and new zealand,C0028405;C0027978;C0324547
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
ldl cholesterol lowering therapy,C0023824;C0202117;C0441994;C2003888;C0039798;C0087111;C1363945
glucose lowering medication,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
highest,C1522410
empagllflozin,
randomized group by subgroup interaction,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
rvw,
prior mi or stroke at baseline,C0332152;C3810814;C2826257;C0038454;C4554100
all causa mortality,C0026565;C0026566
hospitalization for heart failure or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
empagllflozln,
history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
history of stroke at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
$nmbr$ n n,C0369718;C0441922
estimated cv risk at baseline,C1519101;C0168634;C1442488
lowest,C1708760
$nmbr$ polnt mace,C0349381;C0949745;C1445339
hospitalization for heart failure or cv,C3898876;C3538987;C4048877;C4318503
gly $nmbr$ g bid,C0017890;C0439267;C0523677
baseline fev $nmbr$ median range l,C0168634;C0549183;C0876920;C2347635;C2348144;C2939193;C1442488
high cv risk,C0332167;C3272283;C4050568;C4319571
$nmbr$ yearsa,
$nmbr$ a n $nmbr$,C0369718;C0441922
post bronchodilator fev $nmbr$ predictedb,C2599594;C3714541
preferred term,C1709637;C2347664
fev $nmbr$ predicted $nmbr$,C0681842;C1882327
gly,C0017890;C0523677
$nmbr$ g bid n $nmbr$,C0439267
any teae,
copd worsening,C0024117;C1412502;C3714496;C0332271;C1457868;C1546960
chest discomfort,C0235710
any serious teaes,C0205404
age $nmbr$ yearsa,C0001779
any teaes,
notes,C1317574
^ $nmbr$ incidence in any treatment group in the overall safety population,C0021149;C0220856;C0032659;C1257890
asubset of the $nmbr$ years subgroup,C0439234;C1079230;C1515021
abbreviations teae treatment emergent adverse event gly glycopyrrolate inhalation solution bid twice daily,C4684800;C0585361
mace category n [ir],C0349381;C0683312;C3889287;C0949745;C1445339;C0022065;C0022071;C1448132
chlorthalidone n $nmbr$,C0008294
lisinopril n $nmbr$,C0065374
incident dm or change in,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
no incident dm or change in fg $nmbr$,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
fg $nmbr$,C0016703;C0439214;C2348814
lvh by ecg echo,C0232306;C0058928;C1655045
visit $nmbr$ sbp mm hg,C0085805;C0439475
visit $nmbr$ dbp mm hg,C0536221;C0439475;C3813197;C4281799
serum fg mg dl,C0439269
quintile range mg dl,C1508496;C0439269
serum cholesterol mg dl,C0587184;C0439269
mean score min max range,C1514721;C2348147;C3542016
grs,C1412761;C3539564
q $nmbr$ n $nmbr$,
test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
with cerebrovascular disease,C0007820
without cerebrovascular disease,C0007820
p value w,C1709380
ith vs without,
age y meantsd,C0001779
other region no,C0017446;C0205147
duration of diabetes microvascular disease no,C0011847;C0872146;C0011849
atherosclerotic vascular disease no,C0004153
amputation no,C0002688;C0332840;C1546539
body mass index blood pressure mmhg,C0005893;C0439475;C0578022;C1305855
hba $nmbr$ c cholesterol mmol l,C0008377;C1532563
microalbuminuria no,C0730345
macroalbuminuria no drug therapy no,C0013216;C0013217
antithrombotic i,C0021966;C0221138
participants with an event per $nmbr$ patient years,C0679646;C0441471;C4019010;C0030705;C0439234
rvalue,
$nmbr$ kg m^,C0022718;C0439209;C4054209
bp control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
sbp $nmbr$ mmhg or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
duration of diabetes mellitus,C0449238;C2926735
$nmbr$ ml min per $nmbr$ $nmbr$ m^,C0439445
history of pvd,C4534349
hospitalized heart failure,C0018801;C0018802;C4554158
progression of albuminuria,C0242656;C0449258
serious decline in kidney function,C0205404;C0232804
duration of t $nmbr$ d y,C0449238;C2926735
baseline hba $nmbr$ c $nmbr$ mmol mol $nmbr$ $nmbr$ n,C0019016;C3829066;C1825777;C3538758
fpg mmol la,C0023031;C0023749;C0230347;C2346906;C4553351
aha status at screeningb n,C0050451;C0449438;C0772110
not on an aha,C0050451;C0772110
on non metformin aha,C0050451;C0772110
on metformin ir or metformin xr $nmbr$ mg d,C0022065;C0022071;C1448132;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
supplemental figure $nmbr$ point estimates and $nmbr$ confidence intervals for differences in hba $nmbr$ c mean response variable in selected subgroups at week $nmbr$ for each subgroup n is given for sitagliptin placebo treatment groups,C1552961;C0750572;C2347617;C3714763;C0009667;C0439828;C4553760;C0332174;C0439230;C1079230;C1515021;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ parameter,C0549193;C1704769;C2350001
baseline hbalc $nmbr$ mmol mol $nmbr$ $nmbr$,C0168634;C3829066;C1442488
glimepiride,C0061323
stratification factor menopausal status n,C1514984;C1513126
female premenopausal,C0043210;C0086287;C1705497;C1705498;C0279752
female perimenopausal or,C0043210;C0086287;C1705497;C1705498;C0849668;C3839366
female $nmbr$ years postmenopausal,C0043210;C0232970;C0086287;C1705497;C1705498
dipeptidyl peptidase $nmbr$ inhibitors,C0003015
other blood glucose lowering agents,C0005802;C0441994;C2003888;C0450442;C1254351;C1521826
sulphonamides urea derivatives,C0038760;C0243072
ertugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
female participants who are $nmbr$ years postmenopausal,C0043210;C3272598;C0086287;C1705497;C1705498;C0439234;C0232970
ertugliflozin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertugliflozin $nmbr$ mg vs placebo glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
eduglinozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
ertuglifldzin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
erlugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
distal forearm,C0588203
ertugliflozin $nmbr$ mg vs placebo giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertuglrflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
rivaroxaban $nmbr$ $nmbr$ mg bid aspirin $nmbr$ mg od,C0229089;C0439164;C1512019;C3273373;C3665488
peri operative cabg participants,C0010055;C0679646
teriparatide n $nmbr$,C0070093
number of patients with available data,C2360800;C1511726;C3245479;C3714741
daily dose of vitamin d iu day,C2348070;C0014695;C0042866;C2936842;C3537249;C3714503
number of patients with dose available,C2360800;C0178602;C0869039;C1114758;C0470187
patients with supplemental vitamin d dose of $nmbr$ iu day starting at screeningc n,C0030705;C0014695;C0042866;C2936842;C3537249;C3714503;C0439659
serum $nmbr$ oh d concentrations ng ml mean sd,C0229671;C0220853;C1546774;C1550100;C0439275;C2699239
patients with serum $nmbr$ oh d $nmbr$ $nmbr$ and,C0030705;C0220853
teriparatide n n,C0070093
risedronate n n,C0246719
risk ratio [ $nmbr$ cl],C0028873;C0242492;C0596019
a new vertebral fractures mfas,C1549796;C1549980
baseline vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
sufficient,C0205410
insufficient,C0205412;C0231180;C0439856
overall vero population,C0032659;C1257890
b pooled new and worsened vertebral fractures mfas,C1709595;C0205314;C2349200;C4522255;C1549796;C1549980
hazard ratio [ $nmbr$ cl],C2985465;C0596019
c clinical fractures fas,C0205210;C0016658
d non vertebral fragility fractures fas,C0080179;C0302113
hazard ratio $nmbr$ cl],C2985465;C0596019
e major non vertebral fragility fractures fas,C0205082;C0080179;C0205164;C4318856;C4521762
rivaroxaban plus aspirin,C1739768;C0004057
hazard ratio with rivaroxaban plus aspirin $nmbr$ cl,C2985465;C1739768;C0004057;C0596019
no of events patients yr,C0030705;C0439234
$nmbr$ to $nmbr$ yr,C0439234
lei $nmbr$ n $nmbr$,C0023401;C0428209
ldi b $nmbr$ n $nmbr$,
integrated analysis set n $nmbr$,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
other multiple,C0439064
cdmard experience n,C0237607;C0596545
mtx at baseline n,C0025677;C1417487
time since psa onset mean years sd,C0449244
active pso wi $nmbr$ bsa $nmbr$ n y,C0205177;C0043193;C1520135;C3853793;C3888249
current enthesitis n,C0521116;C1282952;C1705970
current dactylitis n,C0521116;C0239161;C1705970
leeds enthesitis index mean sd,C0451148;C2699239
leeds dactylitis index basic mean sd ^,C0239161;C2699239
fig $nmbr$ patients reporting no enthesitis a and no dactylitis b at week $nmbr$ integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders $nmbr$ cl nri p vs pbo $nmbr$ $nmbr$ p vs pbo $nmbr$ $nmbr$ abbreviations achill tend insert achilles tendon insertion cl confidence interval ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks lat epicond lateral epicondyle lei leeds enthesitis index ldi b leeds dactylitis index basic med fern cond medial femoral condyle nri nonresponder imputation pbo placebo,C0030705;C0700287;C1282952;C0002778;C0036849;C1442518;C1705195;C0936012;C1524024;C0168634;C1442488;C0239161;C1547282;C0596019;C0031962;C0000723;C0001074;C0009667;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230;C0064678;C0331729;C1856054;C2826243;C0032042;C1696465;C1706408
currently smoker,C0521116;C0337664
time since ipf diagnosisa mean years sd,C0556970;C0034069;C1800706
mean ml sd,C0439526;C2699239;C1705224;C3887665
median ml,C0439526;C1705224;C3887665
predicted value sd,C0681842;C2699239;C1882327
total sgrq mean total score sd,C2964552;C2699239
any aes,C1412268;C2699274
most frequent aesa,C0332183
lung infection,C0876973;C4552950
ipf,C0034069;C1800706
upper abdominal pain,C0232492
alt increased,C1266129;C4553172;C0205217;C0442805
ast increased,C1415181;C3891303;C0205217;C0442805
ggt increased,C1415053;C0205217;C0442805
aes leading to dose reduction of study drugb,C1412268;C2699274;C0861063;C0178602;C0869039;C1114758
transaminases increased,C0002594;C0919834;C0205217;C0442805
aes leading to discontinuation of study drugb,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
blood bilirubin increased,C0005767;C0005437;C0005768;C0229664;C0205217;C0442805
liver disorder,C0023895
lung neoplasm malignant,C0024121;C0205282
investigator defined drug related aes,C1412268;C2699274
severe aes,C1412268;C2699274
fatal aes,C1412268;C2699274
risk factor,C0035648
pioglitazone group n $nmbr$,C0071097;C0441848
fasting glucose level mg dl,C0202045;C0439269
hemoglobin level,C0019029;C1314664
homa ir score,C0449820;C4050231
diastolic pressure mm hg,C0428883;C0439475
total cholesterol level mg dl,C0878805;C0439269;C1445957
triglycerides level mg dl,C0428475;C0439269
hdl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
ldl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
categorical variables no,C0439828
adherence $nmbr$,C1510802
stroke m $nmbr$,C0038454;C4554100
stroke m l hf hospitalization,C0456616;C0019993
no previous copd medication,C0013227;C3244316;C4284232
previous ics only,C0815320;C4551720
previous labd only,C0205156;C0396059;C1552607
previous ics labd,C0205156;C0396059;C1552607
subjects,C0681850;C1550501;C1706203;C2349001;C2697811
former smokers,C0337671
screening fev $nmbr$ predicted,C0681842;C1882327
one or more exacerbations,C0205447;C4086268
ff $nmbr$ g,C4554348;C0439267
vi $nmbr$ g,C0205999;C0439267
ff vi $nmbr$ $nmbr$ g,C0205999;C0439267
total subjects,C0681850;C1550501;C1706203;C2349001;C2697811
subjects who did not receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1518422;C1514756;C0396059;C0332152
active versus placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
reduction in risk $nmbr$ ci,C0520870;C1137094
subjects who did receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1514756;C0396059;C0332152
labd alone,C0396059;C0205171;C0439044;C0679994
ics labd,C0815320;C0396059;C4551720
a those receiving no inhaled pre treatment maintenance medication,C1514756;C2347660
b those on inhaled corticosteroids and long acting bronchodilators as previous treatment use,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727;C0006280;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
previous labd alone,C0205156;C0396059;C1552607;C0205171;C0439044;C0679994
overall mortality,C0026565;C0026566
ff vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
ff vi $nmbr$ $nmbr$ $nmbr$,C4554348;C0205999
ff $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
ff $nmbr$ $nmbr$ $nmbr$,C4554348
vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
vi $nmbr$ $nmbr$ $nmbr$,C0205999
risk of moderate severe exacerbations,C0332166
distribution of metformin dose at randomization n,C0520511;C1704711;C0034656
background aha therapy at screening a n,C0039798;C0087111;C1363945;C0369718;C0441922
number of agents,C0237753;C0449788
hong kong,C0019907;C2987742
baseline fpg mg dl,C0168634;C0439269;C1442488
baseline egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
ertugliflozin,C4079805
background aha therapy at screening a,C0039798;C0087111;C1363945
ls mean $nmbr$ ci a,C0008107;C3259781
pairwise comparison,C1707455
difference in ls means $nmbr$ ci a,C1705241;C1705242
week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
$nmbr$ ci a,C0008107;C3259781
$nmbr$ ae,C3887670
drug relateda,C0013227;C1254351
$nmbr$ sae,C1519255;C1622657;C4553214
because of ae,C3887670
because of drug relateda ae,C0013227;C3887670;C1254351
because of sae,C1519255;C1622657;C4553214
because of drug relateda sae,C1519255;C1622657;C4553214
deathsb,
tier $nmbr$ aes,C1412268;C2699274
gmi women,C0043210
gmi men,C0025266
symptomatic hypoglycaemia,C0020615;C4553659
hypovolaemia,C0546884
other selected aes,C1412268;C2699274
documented hypoglycaemiac,C1301725;C1609436
due to ae,C3887670
due to drug relateda ae,C0013227;C3887670;C1254351
due to sae,C1519255;C1622657;C4553214
due to drug relateda sae,C1519255;C1622657;C4553214
characteristic a,C1521970
leader,
cv historya,C3538987;C4048877;C4318503
heart failure nyha ii iii n,C0018801;C0018802;C4554158
coronary artery bypass graft n,C0010055;C1260596
ischaemic stroke n,C0948008
carotid artery stenosis n,C0007282
$nmbr$ stenosis of major artery n,C0038449
lv systolic dysfunction n,C0023128;C0749225;C0731033;C1881413
lv diastolic dysfunction n,C0023128;C0520863;C0731033;C1881413
diabetes medication,C0013227;C3244316;C4284232
oral antihyperglycaemic n,C0359086
metformin n,C0025598
su n,C0038642;C1705534
moderate or severe renal disease n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
cv medication,C0013227;C3244316;C4284232
acei n,
lipid lowering therapies n,C0585943
anti platelet agents n,C0432633
sustain,C0443318;C2732140
moderate or severe renal disease b n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
diabetes duration at baseline,C0449238;C2926735
hazard ratio glp $nmbr$ analogue vs placebo [ $nmbr$ cl],C2985465;C0243071;C0032042;C1696465;C1706408;C0596019
glp $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
bempedoic acid n $nmbr$,C3659310
cardiovascular risk factor no,C0850624
lipid measures at baseline mg dl,C0079809;C1879489
total cholesterol^,C0201950;C0543421
ldl cholesterol^,C0023824;C0202117
non hdl cholesterol j,C0729627;C1535899
hdl cholesterol^,C0023822;C0392885
apolipoprotein,C0003591
high sensitivity c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
concomitant lipid modifying therapy no,C1707479;C0023779
intensity of statin therapy at baseline no,C0522510;C1278454;C0168634;C1442488
bempedoic acid,C3659310
least squares mean difference $nmbr$ cl,C0023189;C0596019
age $nmbr$ yr or $nmbr$ yr,C0001779;C0439234
cardiovascular disease risk category atherosclerotic cardiovascular disease,C1113685;C0004153
cardiovascular disease risk category heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
background lipid lowering therapy intensity of statin therapy,C0585943;C0522510
low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
background lipid lowering therapy ezetimibe,C0585943;C1142985
background lipid lowering therapy fibrate,C1706907;C0585943
el n,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
ll n,C0369718;C0441922
age y median q $nmbr$ q $nmbr$,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
acs presentation,C0742343;C0449450;C4318612
$nmbr$ mg ld,C0024671;C0694649;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
us site,C0205145;C1515974;C2825164
time from ld to pci min median q $nmbr$ q $nmbr$,C0040223;C3541383;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
catheter site femoral,C0449652;C0015811
bivalirudin used,C0168273;C1273517
gp iib iiia inhibitor used,C0016011;C1999216;C1273517
no of vessels with $nmbr$ stenosis,C0005847;C0678234;C1261287;C2632116
no of vessels treated,C0005847;C1522326
received drug eluting stent,C1514756;C1322815
left main coronary artery bifurcation,C3898614
pci duration,C0449238;C2926735
dosing,
cangrelor n n,C1121991
clopidogrel n n,C0070166
adjusted $nmbr$ or $nmbr$ cl,C0456081;C0596019
d mi idfvst,C3810814
early load,C1550025;C1704782;C1708715
late load,C1550025;C1704782;C1708715
adjusted or $nmbr$ cl,C0456081;C0596019
severe lite threatening,C0205082;C4050465;C4050466
transfusions,C0005841;C0199960;C1879316
hfref n $nmbr$,
hf without known reduced ef n $nmbr$,C0018488;C1313497;C1538440;C3273279
no hx of hf n $nmbr$,C0262926;C3814444
age yrs median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
hemoglobin ale median iqr,C0019046;C0549183;C0876920;C2347635;C2348144;C2939193
duration of diabetes years median iqr,C0449238;C2926735
history of dyslipidemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
main etiology of heart failure,C0015127;C1314792;C1524003
non ischemic,C1518422;C0475224
history of coronary arteiy disease,C0683519;C0730226;C0850708;C0944983
cgfrby ckd epi ml min $nmbr$ $nmbr$ m $nmbr$ median iqr,C0162734;C0439445;C4281721;C0549183;C0876920;C2347635;C2348144;C2939193
mineralcorticoid receptor antagonist,C4543207
km rate,C0871208;C1521828
cardiovascular death hospitalization for heart failure,C3898876
hfref,
nothfref,
hf without known reduced ef,C0018488;C1313497;C1538440;C3273279
without hx of hf,C0262926;C3814444
age in years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
raee,
blaek,
duration of diabetes in years median iqr,C0449238;C2926735;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
hbalc in median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
egfr in ml min $nmbr$ $nmbr$ m^ median iqr,C1739039;C3811844;C3812682;C0549183;C0876920;C2347635;C2348144;C2939193
prior cad,C1504769;C2239547;C3813548;C4284121
prior pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
insulin at baseline,C0021641;C1533581;C1579433;C3714501
betablocker,C0001645
cv death or hhf hr $nmbr$ cl or absolute risk reductions,C0011065;C1306577;C4082313;C4552775;C0596019;C3179139
patients with prior ml,C0030705;C0332152;C2826257
patients with ascvd but no ml,C0030705;C3665365;C0439526;C1705224;C3887665
patients with only mrf,C0030705;C0312443;C1412879
cv death or hhf,C0011065;C1306577;C4082313;C4552775
patients with prior ml hr $nmbr$ cl,C0030705;C0332152;C2826257
patients with ascvd but no prior ml hr $nmbr$ cl,C0030705;C3665365;C0332152;C0596019;C2826257
patients with only mrf hr $nmbr$ cl,C0030705;C0312443;C0596019;C1412879
absolute risk reductions,C3179139
ascvd no prior ml,C3665365;C0439526;C1705224;C3887665
cv death ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
tanezumab all doses combined,C2346819;C0178602;C0205195
tanezumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tanezumab all doses combined nsaida,C2346819;C0178602;C0205195
tanezumab $nmbr$ $nmbr$ mg nsaid,C0003211;C3536840
tanezumab $nmbr$ mg nsaid,C0003211;C3536840
active comparatorb,C0205177;C3853793;C3888249
diabetesc,
severe oa symptoms at baselined,C0436345;C0029408;C3887876
less severe oa symptoms at baseline,C0436345;C0029408;C3887876
figure $nmbr$ least squares mean change in womac pain from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
figure $nmbr$ least squares mean change in womac physical function from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
figure $nmbr$ least squares mean change in pga from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis pga patient s global assessment sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C0030705;C1710181;C3472647
figure $nmbr$ percentage of patients with $nmbr$ $nmbr$ $nmbr$ and $nmbr$ improvement on the womac pain subscale at week $nmbr$ in the subgroups notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily oa osteoarthritis womac western ontario and mcmaster universities osteoarthritis index,C0439165;C1549488;C1561533;C2986411;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132;C0332174;C0439230;C1079230;C1317574;C0032042;C1696465;C1706408;C3472647
ethnicity not hispanic latino n,C0015031;C0243103;C1518424;C0086528
background lipid therapy per acc aha definition n a,C0039798;C0087111;C1363945
moderate intensity statin,C4081855;C0360714
coronary artery stenosis $nmbr$,C0242231
coronary artery bypass,C0010055
copd n,C0024117;C1412502;C3714496
diabetes related medication use n,C0011847;C0240320;C0011849
insulin use n,C0240016
lipid values mean sd,C0023779;C2699239
non hdl c mmol l mean sd,C1532563;C2699239
apob g l mean sd,C0439294;C2699239;C0456615
lp a nmol l mean sd,C0065058;C2699239;C1439335;C4553379
triacylglycerol mmol l mean sd,C1532563;C2699239
hba $nmbr$ c mmol mol median q $nmbr$ q $nmbr$,C0019016;C3829066;C1825777;C3538758
fasting serum glucose mmol l median q $nmbr$ q $nmbr$,C0202041;C1532563;C3534430
percent change from baseline to week $nmbr$ in auc mean sem,C3272907;C0332174;C0439230;C0376690;C0444504;C2347634;C2348143
baseline tg $nmbr$ $nmbr$ mmol l,C0168634;C1532563;C1442488
chylomicron triglycerides,C0008731;C0041004;C1325761
chylomicron cholesterol,C0008731;C0008377;C1325761
apob $nmbr$,C0003593;C3252643
age s $nmbr$ yr,C0001779;C0439234
major coronary event,C0205082;C0741923;C0205164;C4318856;C4521762
age $nmbr$ $nmbr$ yr,C0001779;C0439234
c $nmbr$ e $nmbr$ fab bolus n $nmbr$,C1186706;C1511237;C1705509;C3812160
c $nmbr$ e $nmbr$ fab bolus and infusion n $nmbr$,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
risk factors of group,C0035648;C1553898
elevated cholesterol,C0020443
history of smoking,C1519384
vascular disease of group,C0042373
cerebral,
previous infarction of group,C0205156;C0021308;C1552607
previous coronary procedure of group,C0018821;C1279986
angioplasty,C0162577;C1548817
no of diseased vessels of group,C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
coronary procedure of group,C0018821;C1279986
atherectomy,C0162513
duration of procedure min,C2346509;C0702093;C1524029;C3813700
contrast used ml,C0439526;C1705224;C3887665
thrombolytic agents of group,C0016018;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
lowest activated clotting time sec,C0427611;C0565930
subgroup $nmbr$,C1079230;C1515021
transfusion,C0005841;C0199960;C1879316
c $nmbr$ e $nmbr$ fab bolus and infusion,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
harzard ratio $nmbr$ ci,C0008107;C3259781
harzar ratio $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l l,C3539687
entry category,C0683312;C3889287
unstable,C0443343;C1883468
angina or acute mi,C0002962;C0155626
anatomy,C0002808;C0700276;C1384516
dalteparin n $nmbr$,C0206461
ulcer,C0041582;C3887532
inclusion findings,C2607943;C2926606;C3539655
unstable but no rest angina,C0002965
rest angina but not past $nmbr$ h,C0002965;C0152172;C1414318;C4284302
rest angina past $nmbr$ h,C0002965;C0152172
non q wave myocardial infarction,C0542269;C3537181
ecg changes t,C0855329
t wave inversion only,C0520888
st depression only,C0520887
st depression and t wave inversion,C0520887;C0520888
medication at entry,C0013227;C3244316;C4284232
oral fi blockers,C0442027;C4050619;C4521986
annanginal drugs $nmbr$ l s $nmbr$ ^,C0013227;C3687832
glyceryl trinitrate infusion,C0574032;C1827465
median delay h,C0033727;C0369286;C0441932;C0564385;C4528284
age distribution,C0001782
mean sd age in years,C0444504;C1510829;C2347634;C2348143
mean sd bmd in g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
post erior anterior spine,C0037949;C2752558
vertebral fractures at baseline,C0080179;C0168634;C1442488
history of postmenopausal fracture,C1272071;C0232970
self rated health status,C0036588;C0018759;C1551994
very g ood ex cellent,C0439267;C4267693
fair poor,C0032854;C0542537;C2700379
mean sd anthropometry,C0444504;C0003188;C2347634;C2348143
baseline height cm,C0168634;C0489786;C1442488
body mass index kg cm $nmbr$,C0005893;C4054689;C0578022;C1305855
mean sd calcium intake in mg daily,C0489458;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ever,
digoxin n $nmbr$,C0012265
$nmbr$ $nmbr$ $nmbr$ s,
$nmbr$ s $nmbr$ s $nmbr$,C0565930;C2603362
median duration of chf mo,C0449238;C2926735
of patients $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705
method of assessing ejection fraction,C0025663;C0449851;C0871511;C1516048;C0489482;C2700378
radionuclide ventriculography,C0017200;C0034610
two dimensional echocardiography,C0013524
contrast angiography,C0009924;C0002978;C1979874
cardiothoracic ratio $nmbr$ $nmbr$,C0456603;C1547037
no of signs or symptoms of chff,C0220912;C0220913;C0311392;C0683368;C1457887
primary cause of chf,C0205225;C0015127;C1524003;C0439612;C0439631
other vasodilators,C0042402
daily dose of study medication prescribed,C2348070;C0278329
anthropometry mean sd,C0003188;C2699239
w eight k g,C0205454;C0439267
number of patients with,C2360800
a ngina $nmbr$ day s previously,C0332173;C0439228;C0439505
infarct ion w ithin previous $nmbr$ day s,C0022023;C1700702
$nmbr$ l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
infarction $nmbr$ $nmbr$ days,C0021308;C0439228
infarction $nmbr$ days previously,C0021308;C0439228
infarction date not reported,C0011008;C2348077;C0684224;C0700287;C4319718
medication within $nmbr$ days before enrolment,C0013227;C3244316;C4284232;C1516879;C1696073;C3888021
intravenous heparin,C0354566
medication after enrolment,C0013227;C3244316;C4284232
ticlopidin,
tertile of total cholesterol at baseline mean sd mmol l,C0201950;C0543421;C0168634;C1532563;C1442488
cwt mean se mm,C4330985;C4554674
difference $nmbr$ years baseline,C0168634;C1442488
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
p for heterogeneity of treatment effect between tertiles $nmbr$ $nmbr$,C0369773;C2603361
$nmbr$ $nmbr$ yr no,C0439234
$nmbr$ $nmbr$ vr no,C3476815
median vr,C0549183;C3476815;C0876920;C2347635;C2348144;C2939193
time from qualifying event to randomization,C0040223;C3541383;C1514624;C0441471;C4019010
coronary risk factors no,C2024776
history of systemic hypertension,C0455527
obesityj,
other vascular disease no,C0042373
claudication,C0021775;C0311395;C1456822
ptca only,C2936173
cabg only,C0010055
both ptca and cabg,C2936173;C0010055
oral hypoglycemic drug,C0359086
lipid levels mg dlj total cholesterol,C0201950;C0543421
totalhdl cholesterol ratio,C0456603;C1547037
unstable angina age,C0002965;C0001779
baseline abi affected limb,C0168634;C0015385;C1442488
baseline pfd m,C0016065;C1839454;C2827389;C3889643
baseline mwd m,C0168634;C1442488
plasma creatine mg dl,C0010286;C0439269
concurrent illness,C0205420;C0221423
concurrent medications,C0013227;C0802604;C2598133;C4284232
plasma lipoproteins mmol l,C0023820;C1532563
hdl $nmbr$,C3715113
lpa mg dl,C1096202;C0439269;C1439335;C3539666;C4049711;C4553379
week $nmbr$ mean sem,C0332174;C0439230
weeko mean sem,C0444504;C2347634;C2348143
pretreatment hdl c,C1550147;C3715113;C2709094;C3539075;C3539076
pretreatment triglycerides,C1550147;C0041004;C2709094;C3539075;C3539076
no of patients with stroke,C0030705;C0038454;C4554100
ldl hdl ratio,C0428621
table $nmbr$ relationship of baseline serum lipids to stroke or tia reduction,C0439849;C1705630;C1706279;C3540605;C0038454;C4554100;C0301630;C0392756;C1293152;C4551656
